candidate_gene	treatment	dose	name	moa	drug_category	target	disease.area	indication	cellLines_TRUE	tissueType_TRUE	diseases_TRUE	avg_log2fc_TRUE	median_log2fc_TRUE	avg_log2fc_FALSE	median_log2fc_FALSE	t_test_statistic	df	p_value	p_adj	conf_low	conf_high
ADAMTS9	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	0.0273454467081	0.0273454467081	0.15170881216861	0.1647699361925	5.19513401754778	70.4266812448436	1.90303997729902e-06	7.4321547976407e-05	0.0766247520022676	0.172101978918752
ADAMTS9	BRD-A18696154-003-22-6::2.5::HTS002	2.5	idazoxan	adrenergic receptor antagonist	noncancer	ADRA2A	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.9649450063715	-0.9649450063715	-0.651830874171877	-0.5933012129785	6.04695584001734	51.1615738446004	1.71321267152592e-07	7.8059344956522e-06	0.209168499118614	0.417059765280632
ADAMTS9	BRD-A43671941-003-11-9::2.5::HTS002	2.5	oxprenolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	angina pectoris, hypertension, cardiac arrythmia	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.765130909436	-0.765130909436	-0.403210279379903	-0.38193178245	10.3535894873537	191.021879120311	3.1792614147932e-20	5.39942884129328e-18	0.292971193182239	0.430870066929955
ADAMTS9	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	0.242710071694	0.242710071694	0.358763774831476	0.3667280736395	4.8022309358683	58.6103152217021	1.1252018572288e-05	0.000383597011580136	0.067689674735819	0.164417731539133
ADAMTS9	BRD-K03273112-001-01-8::2.5::HTS002	2.5	1-azakenpaullone	glycogen synthase kinase inhibitor	noncancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-1.447556064	-1.447556064	-0.707516688359918	-0.635465288366	9.08750125313151	17.279406582013	5.38518514961995e-08	2.62080233408922e-06	0.568438232108975	0.911640519171189
ADAMTS9	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-2.296208538965	-2.296208538965	-0.271180848521877	-0.201937004263	39.7499292391945	142.084390703155	7.37088844213023e-79	7.89897574456665e-74	1.92432118242765	2.12573419845859
ADAMTS9	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-1.25117030053	-1.25117030053	-1.68578291424047	-1.35955217781	-3.56811136551028	75.1750989406628	0.000630231833427682	0.0146934579165367	-0.67725068815193	-0.191974539269004
ADAMTS9	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-1.29990816602	-1.29990816602	0.0301681459594522	0.2036144024465	19.0034821739038	14.4688848473886	1.2305245171076e-11	9.11953973814506e-10	1.18041525213474	1.47973737182416
ADAMTS9	BRD-K16505263-003-02-9::2.5::MTS006	2.5	forodesine	purinergic receptor antagonist	targeted cancer	PNP	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	0.3404385968635	0.3404385968635	0.221814755776849	0.234801911362	-5.84651520651957	172.399269907764	2.45760407741306e-08	1.25145123380343e-06	-0.158671985307638	-0.0785756968656639
ADAMTS9	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.467794731076	-0.467794731076	-0.0898744519383583	-0.0178822580687	8.351876827278	14.9558061914607	5.15626007257464e-07	2.19577998230648e-05	0.281447906738445	0.474392651536839
ADAMTS9	BRD-K16803204-001-01-6::2.5::HTS002	2.5	filgotinib	JAK inhibitor	noncancer	JAK1, JAK2, JAK3, TYK2	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	0.0934421654141	0.0934421654141	0.244968588905767	0.2325578097185	5.19555672155378	163.697425852472	6.00433611929693e-07	2.53477123520345e-05	0.093939087033863	0.209113759949471
ADAMTS9	BRD-K17472821-001-01-2::2.5::MTS006	2.5	GSK2830371	protein phosphatase inhibitor	targeted cancer	PPM1D	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.008237274535685	-0.008237274535685	0.216306776053537	0.228521183111	9.99137972558215	11.2431226256774	6.23100158363702e-07	2.62322596428863e-05	0.175209786935408	0.273878314243035
ADAMTS9	BRD-K17743125-001-08-4::2.5::MTS010::PROS003_PR500	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-1.15372711657	-1.15372711657	-0.67228626648872	-0.579023272912	5.2068297749625	23.7963058838812	2.52671709985863e-05	0.000808643794677617	0.290519422508579	0.67236227765398
ADAMTS9	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.2341531794705	-0.2341531794705	-0.0244704005306878	-0.0049429262928	8.62954407865194	175.620117173394	3.59628653553241e-15	3.78952063359944e-13	0.161728638157541	0.257636919722083
ADAMTS9	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-4.184614336755	-4.184614336755	-3.02674007047064	-3.15858467957	9.32865713855504	7.80757006932811	1.67171130628766e-05	0.000554209145499346	0.870420129035895	1.44532840353282
ADAMTS9	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.6994464842475	-0.6994464842475	-0.235648538956606	-0.109165735913	10.5205372078757	15.5069895364067	1.8417604247553e-08	9.54406842546856e-07	0.370099845293454	0.557496045288335
ADAMTS9	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-3.43825976302	-3.43825976302	-2.29564104967088	-2.022141704435	10.9916471665452	141.830711716723	1.03117380979734e-20	1.82051442734805e-18	0.937120450006342	1.3481169766919
ADAMTS9	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	0.3617877562845	0.3617877562845	0.239990329675052	0.2536769304835	-4.11383225783066	20.0921799887828	0.000534738070574512	0.0127174740266494	-0.183537979062964	-0.060056874155932
ADAMTS9	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.445015169732	-0.445015169732	-0.17521207046761	-0.120119113317	7.77418414035153	187.997925285507	4.83910076287946e-13	4.14863850962877e-11	0.201341825817609	0.33826437271117
ADAMTS9	BRD-K38548312-001-01-0::2.5::HTS002	2.5	VER-49009	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-3.21760673736	-3.21760673736	-2.72925740519883	-2.656179650135	5.52491181614928	187.01748357871	1.09364174412593e-07	5.12908405638439e-06	0.313978893651047	0.662719770671294
ADAMTS9	BRD-K40331046-305-01-5::2.5::HTS002	2.5	CR8-(R)	CDK inhibitor	targeted cancer	CCNA2	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-6.35404008258	-6.35404008258	-5.25423683809264	-5.161930725595	8.53418883443353	5.26553484099297	0.000280635361971811	0.00712826457644658	0.773493832262969	1.42611265671175
ADAMTS9	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-2.59145838814	-2.59145838814	-1.23504207361314	-0.855735961913	14.4935498161708	32.7178905619702	8.5394573980548e-16	9.54748755695194e-14	1.16594855382632	1.54688407522741
ADAMTS9	BRD-K50018155-003-02-1::2.5::HTS002	2.5	RS-67506	serotonin receptor partial agonist	noncancer	HTR4	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.2560255209725	-0.2560255209725	0.306433435450157	0.3592817861405	12.2198979798768	8.41787387235717	1.19986017316496e-06	4.84029420392007e-05	0.457228096228138	0.667689816617175
ADAMTS9	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	0.0149120014503	0.0149120014503	0.203906914993064	0.242605983944	5.49936374062396	60.1161406940726	8.23465647502412e-07	3.4058774365794e-05	0.120254035445216	0.257735791640313
ADAMTS9	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.151699545009	-0.151699545009	0.118453393660134	0.150496276102	9.4557995271846	96.6409658117254	2.07356015784852e-15	2.23985023111678e-13	0.213446580080424	0.326859297257844
ADAMTS9	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-1.428240532245	-1.428240532245	-0.377239484080941	-0.1848985030465	15.4868878766622	40.0745588704007	1.6402877621825e-18	2.35788890530392e-16	0.913850881430589	1.18815121489753
ADAMTS9	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.904468146723	-0.904468146723	-1.1865084598103	-1.12103485225	-4.70264253977576	52.088286896933	1.92567811334914e-05	0.00062985284946247	-0.402383812759192	-0.16169681341541
ADAMTS9	BRD-K59058747-001-18-3::2.5::HTS002	2.5	acetylcysteine	mucolytic agent	noncancer	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	0.5917245064825	0.5917245064825	0.389338510586322	0.3974557070265	-7.98256156507645	181.985317588404	1.56395373094294e-13	1.40781452834637e-11	-0.252410640035472	-0.152361351756883
ADAMTS9	BRD-K63932022-001-01-5::2.5::HTS002	2.5	2'-MeCCPA	adenosine receptor agonist	noncancer	ADORA1	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.2858981956595	-0.2858981956595	0.201821523105549	0.269128450915	8.47787882622483	30.1507281420425	1.77097745252839e-09	1.02809270428754e-07	0.370255456274965	0.605183981255132
ADAMTS9	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-3.838149752165	-3.838149752165	-2.11004886702742	-1.97310817512	18.7214454113636	151.340320238994	3.11709809468825e-41	3.69107468252175e-38	1.54572619270097	1.91047557757418
ADAMTS9	BRD-K66911501-003-01-2::2.5::HTS002	2.5	MK-3207	calcitonin antagonist	noncancer	CALCA	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	0.6794421490235	0.6794421490235	0.192296891097287	0.213447590059	-12.0256358721875	3.79064513867152	0.0003708187108184	0.00919130374361013	-0.602108624859746	-0.372181890992681
ADAMTS9	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.519928823218	-0.519928823218	-0.00221569661226314	0.0201994348842	9.35407407756777	27.9290118715428	4.21664897032359e-10	2.60747304431761e-08	0.404328444591135	0.631097808620339
ADAMTS9	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-0.255472363905	-0.255472363905	-1.03732719965179	-0.659178147727	-6.48551522613604	8.07307279222986	0.000183555908606429	0.00490051748078069	-1.05941548660557	-0.504294184888012
ADAMTS9	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	0.12308661251	0.12308661251	-0.214578793017719	-0.195517916983	-13.1385471377345	142.462851849061	2.49623901687427e-26	7.09570838524729e-24	-0.388468743351988	-0.286862067703449
ADAMTS9	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-3.54681505566	-3.54681505566	-3.05703860618417	-2.99006854464	5.1732192312577	175.891622968769	6.22313206305237e-07	2.62042764625138e-05	0.302930552329194	0.676622346622456
ADAMTS9	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	NUGC4, OAW42	STOMACH, OVARY	carcinoma (signet_ring_adenocarcinoma), carcinoma	-3.871776208795	-3.871776208795	-2.90023372616551	-2.82333441128	11.2147138304541	138.053256620314	3.74806595613335e-21	6.8484162686454e-19	0.800247176640188	1.1428377886188
ADIPOR2	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.3066445061845	-0.3066445061845	-0.0478123160324612	0.112237719657	4.35158358444214	25.6137422991787	0.000191214609045084	0.00508030692227889	0.136479502795236	0.381184877508841
ADIPOR2	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.05727369603425	-0.05727369603425	-0.34410174416185	-0.266254262221	-6.55860430661518	10.4281886254392	5.26086894803704e-05	0.0015796536575565	-0.383731821245266	-0.189924275009935
ADIPOR2	BRD-A57382968-001-29-0::2.5::HTS002	2.5	piroxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.3505796870945	-0.3505796870945	0.0238090111360826	0.0121600555155	11.6253905515885	5.27390531030204	5.86059481904001e-05	0.00174312437825427	0.292881277654834	0.455896118806331
ADIPOR2	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.05385023571975	0.05385023571975	0.186758991553949	0.190024427126	4.4913442844495	43.4225653187865	5.1710865333341e-05	0.00155487346465062	0.0732471883594092	0.192570323308988
ADIPOR2	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.709399021198	0.709399021198	0.40986998684019	0.462027349437	-6.9031583738833	5.02104340496834	0.000960956931582857	0.0213674590921488	-0.410926494969862	-0.188131573745759
ADIPOR2	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.297026737711	-0.297026737711	0.0367038884616282	0.01565074111015	7.04471576556083	12.1553901383523	1.25739882984194e-05	0.000425544029371851	0.230659476237566	0.43680177610769
ADIPOR2	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.1321778394625	-0.1321778394625	0.225995589919544	0.2226649685355	11.5383620819557	14.7989391683971	8.5370789390532e-09	4.5927298994185e-07	0.291930668277497	0.42441619048659
ADIPOR2	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-5.34463699593	-5.34463699593	-3.69955446870562	-3.617290410825	15.8817544044839	181.413160045344	3.6209955263765e-36	2.60430989990855e-33	1.44069979113153	1.84946526331724
ADIPOR2	BRD-K00259736-001-16-4::0.15625::HTS002	0.15625	colchicine	microtubule inhibitor	noncancer	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-4.170660924915	-4.170660924915	-3.03906401029328	-2.79751437588	7.86026117945601	6.07475938222894	0.000210947461537431	0.00554614309173896	0.780377190241126	1.48281663900232
ADIPOR2	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-3.642633155745	-3.642633155745	-2.75183633432511	-2.614624073445	6.92769599704576	6.44048652676489	0.000328347360110712	0.00822034357495255	0.581304379114036	1.20028926372574
ADIPOR2	BRD-K02407574-001-09-7::2.5::HTS002	2.5	parbendazole	tubulin polymerization inhibitor	noncancer	TUBB	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-4.157983227285	-4.157983227285	-3.03879633037964	-2.97464571571	11.1173415451426	41.5183265299205	5.05581338734144e-14	4.78836689127487e-12	0.915956012006508	1.3224177818042
ADIPOR2	BRD-K03601870-001-01-2::2.5::HTS002	2.5	ixabepilone	microtubule stabilizing agent	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-4.04138807181	-4.04138807181	-3.62089954228589	-3.52276573862	4.5347051393692	188.120665006758	1.02512585678494e-05	0.000352331943166868	0.237570663299849	0.603406395748372
ADIPOR2	BRD-K06854232-001-19-9::2.5::HTS002	2.5	AM-580	retinoid receptor agonist	targeted cancer	RARA	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.03336758272985	-0.03336758272985	0.121050454736135	0.154475017862	5.2579841151812	165.140655094891	4.45692137899216e-07	1.91624373568307e-05	0.0964322972717394	0.21240377766023
ADIPOR2	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.2410560154165	-0.2410560154165	-0.423707717393868	-0.399128631959	-3.47186173203693	105.260162111189	0.000750991292728396	0.0172020105567152	-0.28696292720788	-0.0783404767468565
ADIPOR2	BRD-K11267252-001-04-4::2.5::HTS002	2.5	alectinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.1530795052495	0.1530795052495	-0.159162524306196	-0.125024480839	-6.19025169920008	97.2435503602719	1.4310014635547e-08	7.53390107300945e-07	-0.412350139072925	-0.212133920038467
ADIPOR2	BRD-K11630072-001-13-2::0.625::HTS002	0.625	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.774660725228	-0.774660725228	-0.266619841738642	-0.1902642862985	10.2936164015378	154.499789396583	2.99944524962157e-19	4.61830532260159e-17	0.41054327439832	0.605538492580397
ADIPOR2	BRD-K13249881-001-02-3::2.5::HTS002	2.5	piperazine	benzodiazepine receptor agonist	noncancer	GABRB3	infectious disease	gastrointestinal roundworms	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.1005014348018	-0.1005014348018	0.0387159266472227	0.0803711832404	3.48284591876473	160.811765911597	0.00063912852618742	0.0148798368335024	0.060279040536668	0.218155682361378
ADIPOR2	BRD-K13533483-001-16-2::2.5::MTS005	2.5	cyclosporine	calcineurin inhibitor	noncancer	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	transplant, rheumatology, dermatology	organ rejection, rheumatoid arthritis, psoriasis	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.1439273694765	0.1439273694765	0.22499437026987	0.2295047390715	3.19180009419286	45.60908860322	0.00256088990787244	0.0496089093514454	0.0299306029590047	0.132203398627736
ADIPOR2	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-1.040848243345	-1.040848243345	-0.467127844376209	-0.349104647656	6.14952404202964	52.7657198939235	1.06191222764934e-07	4.99091045357646e-06	0.386574748856104	0.760866049081478
ADIPOR2	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-2.92149984277	-2.92149984277	-2.05014986973293	-1.99105481758	9.55685228174424	72.00336136117	1.93440683627535e-14	1.91147756022157e-12	0.689595249990149	1.05310469608399
ADIPOR2	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.2033569922025	-0.2033569922025	-0.0310912393368919	-0.0206189181826	5.47270067095855	5.28646470012198	0.0023311699835827	0.0457543343783238	0.0926520027442657	0.25187950298695
ADIPOR2	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-1.47279769575	-1.47279769575	-1.97950489939576	-1.88069436606	-4.56764567636012	26.0545375984962	0.000104777912977741	0.00295719585338507	-0.734712077203383	-0.278702330088132
ADIPOR2	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-4.153756067045	-4.153756067045	-3.69235049659338	-3.84343615246	4.6101337087787	72.3481263464743	1.69178817265444e-05	0.00056008536802109	0.261906023836324	0.660905117066914
ADIPOR2	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.06147452998185	0.06147452998185	-0.0727941422331927	0.0269217911151	-3.88264753834253	19.2170084401271	0.000984198989825031	0.0218276474845001	-0.206593785474735	-0.0619435589553499
ADIPOR2	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-3.999806844455	-3.999806844455	-3.11072709241813	-3.10613635441	7.70505856413283	23.9394166673196	6.20093863581965e-08	2.99603466383361e-06	0.650896462515723	1.12726304155801
ADIPOR2	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.183676711513	0.183676711513	0.0362139676077881	0.0389416186426	-5.84628571732354	6.30682184215981	0.000924786191083491	0.0206639386518696	-0.208461406880179	-0.0864640809302445
ADIPOR2	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-3.380588236555	-3.380588236555	-2.60988054828841	-2.424137198535	8.11477445800665	66.1539616378013	1.62470073851434e-11	1.18442341695592e-09	0.581090501204614	0.96032487532856
ADIPOR2	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-3.089521070805	-3.089521070805	-1.9242919759673	-1.73054296956	13.234404972705	160.07293671185	1.75683720882182e-27	5.57013553446112e-25	0.991348608947076	1.33910958072832
ADIPOR2	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.3920159930655	-0.3920159930655	-0.141816142905198	-0.03734266076635	5.03341227247967	23.2627022190198	4.16109160869015e-05	0.0012753361981967	0.147435648644853	0.352964051675751
ADIPOR2	BRD-K40175214-001-11-6::2.5::HTS002	2.5	torin-1	mTOR inhibitor	targeted cancer	MTOR	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-3.36040140695	-3.36040140695	-3.73311530388543	-3.718490926125	-4.69381937739098	23.992929871589	9.05170741828596e-05	0.00258706947493507	-0.536600831993379	-0.208826961877472
ADIPOR2	BRD-K40718343-001-02-6::2.5::HTS002	2.5	AEE788	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.0831038928698	0.0831038928698	-0.397440839593189	-0.1963749895675	-7.39205840017848	157.890826080108	7.94320615653316e-12	6.02001213692926e-10	-0.608942684018655	-0.352146780907322
ADIPOR2	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.980987317694	-0.980987317694	-0.098839563261081	-0.110521384274	17.1805199125624	55.7818288695074	6.09418685683946e-24	1.42593992886413e-21	0.7792808537327	0.985014655133138
ADIPOR2	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.08253107574535	-0.08253107574535	0.0294896260487459	0.0483026079462	4.26323305221799	79.1320953609236	5.522657621349e-05	0.00165201072620532	0.0597209941528572	0.164320409435335
ADIPOR2	BRD-K50071428-001-03-3::2.5::HTS002	2.5	abiraterone	androgen biosynthesis inhibitor	targeted cancer	CYP11B1, CYP17A1	oncology	prostate cancer	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.2066060202665	0.2066060202665	0.525526722040389	0.541027308905	10.3339190443274	9.57524959329179	1.668685918884e-06	6.58166699132295e-05	0.249741179588069	0.388100223959709
ADIPOR2	BRD-K52075715-001-06-7::2.5::HTS002	2.5	oxibendazole	tubulin polymerization inhibitor	noncancer	TUBB, TUBB4B	infectious disease	strongyles	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-3.48022139479	-3.48022139479	-2.86579980271134	-2.67119320704	4.90468654258573	8.48749134226103	0.000999269651984326	0.0221115491678865	0.328405807776393	0.900437376380919
ADIPOR2	BRD-K56483981-342-06-4::2.5::HTS002	2.5	chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	noncancer	MIF	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.1671002456905	0.1671002456905	0.264930602391449	0.2788714906115	3.40040513790836	177.598636242986	0.000831035551863603	0.0188202682581756	0.041054903568136	0.154605809833761
ADIPOR2	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.794541285774	-0.794541285774	-1.1876595264171	-1.12103485225	-6.3755128355277	30.2918826740519	4.69643516134567e-07	2.01155525918477e-05	-0.518995217194425	-0.267241264091769
ADIPOR2	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-4.04634708425	-4.04634708425	-4.65441110257817	-4.74198978259	-5.86163607531399	18.8897025173236	1.23435191661969e-05	0.000418008235008978	-0.825272278578171	-0.390855758078165
ADIPOR2	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.630483857437	-0.630483857437	-0.202604539317272	-0.243848377549	11.266301867239	4.70470672047868	0.000139577981197039	0.00382259252900336	0.328379843648426	0.52737879259103
ADIPOR2	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-1.97981729586	-1.97981729586	-1.18780150456849	-1.16994261629	10.4000035357209	63.4966419238611	2.41502322040396e-15	2.59193546222314e-13	0.639854782108246	0.944176800474769
ADIPOR2	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.02901213531035	0.02901213531035	-0.211354557742389	-0.1382371077965	-5.97430051437784	34.7679264423581	8.55574710930279e-07	3.53050581861717e-05	-0.322064423039156	-0.158668963066322
ADIPOR2	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-2.105710077125	-2.105710077125	-0.697843447944347	-0.527733859615	14.2015162145388	187.560812436399	1.47774494980812e-31	6.7966437199018e-29	1.21230384119514	1.60342941716617
ADIPOR2	BRD-K66715657-050-01-0::2.5::HTS002	2.5	UH-232-(+)	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4, HTR1A	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.545589109675	-0.545589109675	0.00369198979869843	0.0198593711464	18.2710725457295	188.465063420881	1.39369229749833e-43	1.978203155169e-40	0.489978121574287	0.60858407737311
ADIPOR2	BRD-K67977190-066-02-3::2.5::HTS002	2.5	eprosartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.298261682191	0.298261682191	0.422816192808001	0.410651476159	4.0017900435965	188.992784117112	9.01977764527871e-05	0.00257966362814911	0.0631580674019145	0.185950953832087
ADIPOR2	BRD-K69280563-001-01-8::2.5::HTS002	2.5	vinorelbine	tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-4.21071102279	-4.21071102279	-3.35646965282187	-3.520745955955	6.59844914194898	4.22100822433845	0.00225684136281872	0.0445072237293682	0.502102162257049	1.20638057767922
ADIPOR2	BRD-K69650333-003-14-0::2.5::HTS002	2.5	idarubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-7.121400513655	-7.121400513655	-6.61988645657639	-6.534390959045	4.73154524790292	165.78496968143	4.74640054292498e-06	0.000173806813935515	0.292242550479873	0.710785563677357
ADIPOR2	BRD-K70511574-001-06-9::2.5::HTS002	2.5	HMN-214	PLK inhibitor	targeted cancer	PLK1	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-3.392491895845	-3.392491895845	-2.8257571900709	-2.78074740787	5.76640455561996	105.423876816791	8.15912828081055e-08	3.87948725404508e-06	0.37186846660851	0.761600944939688
ADIPOR2	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.229560509421	-0.229560509421	-0.613502646710357	-0.443084865138	-7.45502640083153	183.730144128861	3.42740304182302e-12	2.7053366593113e-10	-0.485551753827969	-0.282332520750744
ADIPOR2	BRD-K71035033-001-07-1::2.5::HTS002	2.5	masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor	noncancer	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.120713439085	0.120713439085	0.280086978197264	0.3182262126035	4.0322915565789	54.0397521263069	0.000174586697341645	0.00468733461788016	0.0801334047647301	0.238613673459799
ADIPOR2	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.579888059544	-0.579888059544	-0.192440634208361	-0.111990350412	9.54533155643592	13.5770598514672	2.14548404075127e-07	9.65643529966775e-06	0.300134877753308	0.474759972917971
ADIPOR2	BRD-K76011241-001-01-8::2.5::HTS002	2.5	oseltamivir-phosphate	neuraminidase inhibitor	noncancer	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.13406420026	0.13406420026	0.327283299996851	0.306165315644	8.14702554525501	191.830712981349	4.6897077133119e-14	4.45540941704976e-12	0.146440455758811	0.23999774371489
ADIPOR2	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.248432058263	0.248432058263	0.0937546009554321	0.1896034324075	-3.59033907813233	193.689311284118	0.000418503772628073	0.0102231017875088	-0.239646701686585	-0.0697082129285507
ADIPOR2	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-2.43494399756	-2.43494399756	-0.828714124917462	-0.670558533384	17.0943995877525	62.8103181653411	2.61854602520015e-25	6.84427257359905e-23	1.41845001105865	1.79400973422643
ADIPOR2	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-3.369695411835	-3.369695411835	-2.76871274575886	-2.642391718485	5.33477787775127	8.05848924215014	0.000681861603730884	0.0157804465679772	0.341530513867994	0.860434818284285
ADIPOR2	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-5.24011475949	-5.24011475949	-4.83773870746251	-4.95161811894	4.38127059415498	183.602772204626	1.98073178005468e-05	0.000646260103040552	0.221178525092065	0.583573578962908
ADIPOR2	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.3244153246825	-0.3244153246825	-0.0468823984844018	-0.0538286289263	5.96690970953772	51.1688397166268	2.28658296917432e-07	1.02398880317627e-05	0.184163662916954	0.370902189479243
ADIPOR2	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.1407800049205	-0.1407800049205	0.00700771410503973	0.0499653436317	4.53179520960672	171.053212401011	1.09460023274255e-05	0.00037416997333888	0.0834153155208024	0.212160122530277
ADIPOR2	BRD-K89053832-001-01-0::2.5::HTS002	2.5	VLX600	ubiquitin C-terminal hydrolase inhibitor	targeted cancer	USP14	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-3.202695860855	-3.202695860855	-2.05397397093747	-1.884641143255	10.690491707074	96.6725795122535	4.53612184754271e-18	6.28726104424332e-16	0.935448959805467	1.3619948200296
ADIPOR2	BRD-K90647725-001-07-3::2.50156::HTS002	2.50156	oleanolic-acid	G protein-coupled receptor agonist	noncancer	GPBAR1	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.2666610457825	0.2666610457825	0.118800470473352	0.139454786175	-5.74012884243556	187.230528745628	3.75744296306727e-08	1.86418748340566e-06	-0.198675951483138	-0.0970451991351585
ADIPOR2	BRD-K92213669-001-01-3::2.5::HTS002	2.5	lomitapide	microsomal trigylceride transfer protein inhibitor	noncancer	MTTP	endocrinology	hypercholesterolemia	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.4174140840535	0.4174140840535	0.224987207721912	0.227576049132	-4.16817518349465	12.1239832871536	0.00127582015271127	0.0273609423164353	-0.292899409054947	-0.0919543436082294
ADIPOR2	BRD-K92441787-001-04-1::2.5::HTS002	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.063558528197	-0.063558528197	0.157828316987307	0.1923821643865	5.90346393013777	5.07752867406543	0.00188357822162314	0.038103391851087	0.125428045372752	0.317345644995862
ADIPOR2	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	-0.5052689970215	-0.5052689970215	-0.237883568149685	-0.175986017994	5.54320582966171	25.3981955673794	8.7252653643658e-06	0.000303534718435182	0.168119198282673	0.366651659460956
ADIPOR2	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.213107031707	0.213107031707	-0.227008601449761	-0.0281474951666	-6.4322340343695	14.824324331385	1.19405551868614e-05	0.000405451085653489	-0.586107434356022	-0.2941238319575
ADIPOR2	BRD-K99616396-001-05-1::2.5::MTS006	2.5	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.1967916447705	0.1967916447705	-0.0189519572064201	-0.0209452377113	-7.69104478697171	125.009959513488	3.76219816473564e-12	2.95907585486101e-10	-0.271260510729154	-0.160226693224686
ADIPOR2	BRD-M80207679-001-01-5::2.5::HTS002	2.5	nemonapride	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	ABC1, NCIH460	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (large_cell_carcinoma)	0.033415420173615	0.033415420173615	0.37612270633863	0.391465254449	7.8666440188608	6.60972884123851	0.000136858798729564	0.00376013453056131	0.238447406872847	0.446967165457183
ADK	BRD-A20644369-001-08-6::2.5::HTS002	2.5	canrenone	mineralocorticoid receptor antagonist	noncancer	NR3C2	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.150339542928	0.150339542928	0.513006068070291	0.523877694724	9.27225403090202	5.98894733604478	8.99234874484328e-05	0.00257250549136881	0.266917405604004	0.458415644680578
ADK	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.728373532162	-0.728373532162	-0.528354617316486	-0.5103777767265	5.06168465211856	6.83585346693597	0.00156820552023557	0.032660763866152	0.106120995192855	0.293916834498172
ADK	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.4549816712575	-0.4549816712575	0.192476203991895	0.190024427126	20.3057073437292	12.1591932497046	9.45027084365269e-11	6.28636592069906e-09	0.578086057717264	0.716829692781526
ADK	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.510464608093	-0.510464608093	-1.19561584372043	-1.043529721605	-9.15701226909049	18.6082600748209	2.55440995447202e-08	1.29735576097638e-06	-0.84198012359971	-0.528322347655155
ADK	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.0460712384835	-0.0460712384835	0.225079562249554	0.2226649685355	8.17506217426352	8.29316487220378	3.02876253194152e-05	0.000951835256170814	0.195133243567715	0.347168357898394
ADK	BRD-K02389548-001-02-5::2.5::HTS002	2.5	RG2833	HDAC inhibitor	noncancer	HDAC1, HDAC3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5197588060765	0.5197588060765	0.314991062497163	0.3525103772395	-5.02059525479949	27.078894672418	2.85968843420934e-05	0.000902804775984171	-0.288441374686493	-0.121094112472181
ADK	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.275723436423	0.275723436423	0.428601641962737	0.408179294611	4.62473464830959	175.97171982158	7.24201483611258e-06	0.000255754456715962	0.0876397098467629	0.218116701232711
ADK	BRD-K13646352-001-03-8::2.5::HTS002	2.5	midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	targeted cancer	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.43121225627	-2.43121225627	-2.96001557292995	-2.8725192622	-4.6283159937676	12.0051066287839	0.000581140475758534	0.0137054640216605	-0.777729513203039	-0.279877120116851
ADK	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.4524933585085	-0.4524933585085	-0.326283782793969	-0.309372115648	3.73256541401086	181.43336430576	0.000253466565818971	0.00652555382407378	0.0594921087311594	0.192927042697902
ADK	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.156185329235	-2.156185329235	-3.53441388813905	-3.39005054237	-8.59339405958924	6.00098521071787	0.000136391107120598	0.00375058868054005	-1.77065436481733	-0.985802752990771
ADK	BRD-K15519488-050-01-3::2.5::HTS002	2.5	CS-110266	dopamine receptor agonist	noncancer	SLC6A3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.150274402084	0.150274402084	-0.119055940703602	-0.154725041554	-5.11985378491248	159.266716314045	8.7214651414294e-07	3.59335429122918e-05	-0.373223851944974	-0.16543683363023
ADK	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.14040758377	-2.14040758377	-2.86961627120601	-2.63264407289	-5.6603204723296	152.287740465086	7.29808811547609e-08	3.49618222552945e-06	-0.983729847520195	-0.474687527351822
ADK	BRD-K18424115-003-01-3::2.5::HTS002	2.5	TG-100572	src inhibitor, VEGFR inhibitor	targeted cancer	KDR, SRC	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.81100585992	-1.81100585992	-1.19719993556998	-1.10820806652	6.90321008975057	4.00505791097502	0.00229873963203818	0.0452171959063061	0.367058399238933	0.860553449461105
ADK	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.107847973205	-2.107847973205	-2.99814983274765	-2.880185474935	-11.2222129336286	82.3865055725903	2.83505272885947e-18	3.99233913484705e-16	-1.04811116426028	-0.732492554825022
ADK	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.1834604458345	-0.1834604458345	-0.824353493594833	-0.81565114113	-7.17649576838524	3.75816209057934	0.00252392340529541	0.0489680437705766	-0.895263067319532	-0.386523028201134
ADK	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.742024718159	-0.742024718159	-0.18983341064568	-0.144534319806	9.50445273689042	12.9100388979604	3.42377811847577e-07	1.49391318735309e-05	0.426588877424025	0.677793737602615
ADK	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.6981539783495	0.6981539783495	0.380979825512721	0.383188744526	-11.7446764580929	29.2360557885817	1.36341261904096e-12	1.11918369676917e-10	-0.372387810797515	-0.261960494876043
ADK	BRD-K24603946-001-02-1::2.5::HTS002	2.5	5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	noncancer	CHRM3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.99303535069	-2.99303535069	-2.41455937071632	-2.16827680102	5.16393167484563	27.0914854622697	1.94241775265216e-05	0.000634919100973286	0.348661329908978	0.808290630038374
ADK	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.3973049412205	0.3973049412205	-0.478959953687527	-0.387317230447	-14.773013159291	8.7348808573025	1.76643656953593e-07	8.02966242867584e-06	-1.01106868582039	-0.741461103995666
ADK	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.998704963675	-3.998704963675	-3.62487388588051	-3.57671972887	5.1150120693605	174.474579601942	8.20487212306499e-07	3.39421354422775e-05	0.229586424211703	0.518075731377287
ADK	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.047014047645	-2.047014047645	-1.33302528977707	-1.36979496737	8.60453088394908	7.26365743524752	4.59930787550439e-05	0.00139666344240434	0.519211016285415	0.90876649945044
ADK	BRD-K31309378-001-01-5::2.5::HTS002	2.5	lucitanib	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.131458713665	-1.131458713665	-0.757837640762479	-0.624049076154	5.42173657218744	13.969784671732	9.07028653718954e-05	0.00259168836585695	0.225790183761226	0.521451962043816
ADK	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.509965387454	-0.509965387454	-0.8765594141752	-0.7074523288895	-4.04446531829024	188.696217339309	7.63759424472132e-05	0.0022168986144053	-0.545393699364415	-0.187794354077986
ADK	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.03655212631	-3.03655212631	-3.66715324094024	-3.65355610334	-6.33353363682255	183.482801036813	1.79771336993346e-09	1.04220207969832e-07	-0.827041489431468	-0.434160739829009
ADK	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.04385059635595	-0.04385059635595	0.173176284804097	0.1694730901705	8.90094734025795	193.443033389893	3.99555259835684e-16	4.63901837948659e-14	0.168937302534128	0.265116459785966
ADK	BRD-K36788280-001-01-2::2.5::HTS002	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.389760806555	-2.389760806555	-1.05134444070428	-0.990767487764	18.7504949621984	142.454242957957	2.6820564717001e-40	2.91798213971071e-37	1.1973148275383	1.47951790416314
ADK	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.01093238688676	0.01093238688676	-0.1798884556637	-0.13613940777	-5.53702953888316	194.894112822093	9.8585929581598e-08	4.65107279359329e-06	-0.258788497924456	-0.122853187176464
ADK	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.10925911272165	0.10925911272165	-0.239969928521116	-0.026104548309	-5.4103079212586	7.44032284358178	0.000814306906303179	0.0184902622016161	-0.500050573530785	-0.198407508954747
ADK	BRD-K38305202-001-17-4::2.5::HTS002	2.5	domperidone	dopamine receptor antagonist	noncancer	DRD2, DRD3	infectious disease	fescue toxicosis	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.11207742446795	0.11207742446795	-0.362541215520721	-0.225769257521	-7.79362479871889	87.9631037583748	1.22324842416736e-11	9.06875169503171e-10	-0.595641957301199	-0.353595322676142
ADK	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.01275359930315	0.01275359930315	-1.38266989334107	-1.00119520354	-13.7886040420532	190.091979216561	1.97154419080917e-30	8.20503096838716e-28	-1.59504512367123	-1.19580186161721
ADK	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.1878845530565	0.1878845530565	-0.148802896472933	-0.07517274316945	-6.53478851705138	14.6649296078789	1.05494942864797e-05	0.000361943742744821	-0.446723613853841	-0.226651285205025
ADK	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-6.34333013234	-6.34333013234	-6.60290973755505	-6.671127343215	-3.21722839065685	96.1234258471959	0.00176444296503904	0.0360609608328266	-0.419733917554897	-0.0994252928752087
ADK	BRD-K43389675-003-20-9::2.5::HTS002	2.5	daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-5.67939367279	-5.67939367279	-5.05850320529024	-5.07769741889	6.8869383375063	5.73752526953972	0.000559857363945205	0.013256039434049	0.397820112599497	0.843960822400017
ADK	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.152411997098	-0.152411997098	0.0302063534472346	0.0483026079462	6.54172967120687	23.8304245755989	9.45856736498865e-07	3.88063798769267e-05	0.124981035812545	0.240255665277924
ADK	BRD-K50018155-003-02-1::2.5::HTS002	2.5	RS-67506	serotonin receptor partial agonist	noncancer	HTR4	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.428197151223	0.428197151223	0.298189788797199	0.322728889347	-3.43839551890382	165.890606078055	0.000739951312223081	0.0169817994215077	-0.204659125670485	-0.0553555991811167
ADK	BRD-K50071428-001-03-3::2.5::HTS002	2.5	abiraterone	androgen biosynthesis inhibitor	targeted cancer	CYP11B1, CYP17A1	oncology	prostate cancer	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.305035787517	0.305035787517	0.524517185966025	0.541027308905	7.02230308715524	8.80421923192444	6.88636408977943e-05	0.00201797583948364	0.14853750358913	0.290425293308919
ADK	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.082047590415	0.082047590415	-0.103376344764489	-0.112273492753	-3.68543787705785	18.5914615168508	0.00161850909137462	0.0335389572701567	-0.290886241848439	-0.0799616285105387
ADK	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.62068012957	-1.62068012957	-1.10220250955454	-0.990481977481	8.99186547023179	169.944427656862	4.62414301362e-16	5.31414449311614e-14	0.404654088388538	0.632301151642376
ADK	BRD-K53734668-003-02-0::2.65747::HTS002	2.65747	PRT062607	syk inhibitor	targeted cancer	FGR, MAP3K9, SYK	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.272484124011	-0.272484124011	-0.0620636512380068	-0.0448082329464	4.65615108929417	52.8106801283146	2.21093659750405e-05	0.000714517234629742	0.119769346014301	0.301071599531686
ADK	BRD-K53972329-001-07-0::2.5::MTS010::PROS003_PR500	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.280709344177	0.280709344177	-0.0165234840433447	-0.0154250985054	-9.34103361481337	4.27179901067817	0.000531770496628628	0.0126525131851596	-0.383406315534655	-0.211059340906035
ADK	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-6.822758870105	-6.822758870105	-5.57202829692421	-5.500812389495	11.2739707494118	3.81497979189817	0.000455278047044257	0.0110333885736034	0.936730884326623	1.56473026203495
ADK	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.7998087717825	-0.7998087717825	-0.367122963198903	-0.394478559639	9.33911207712613	180.168315924964	3.68063458733507e-17	4.67061415316127e-15	0.341265599802078	0.524106017365116
ADK	BRD-K61314889-001-04-4::2.5::HTS002	2.5	endo-IWR-1	PARP inhibitor	targeted cancer	TNKS, TNKS2	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.20617918985	-2.20617918985	-1.43477466531465	-1.402650367965	12.0454292354177	160.71118191182	3.2075043290754e-24	7.68113067426147e-22	0.644933595291578	0.897875453779116
ADK	BRD-K62627508-001-01-5::2.5::HTS002	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.513104495735	-0.513104495735	-1.10706316219073	-0.7188580200695	-5.87997173990222	122.191078416984	3.65626010615327e-08	1.81693153788946e-06	-0.793922567540373	-0.393994765371086
ADK	BRD-K63126190-003-01-6::2.5::HTS002	2.5	epinephrine	adrenergic receptor agonist, neurotransmitter	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.11074821806595	-0.11074821806595	-0.441819705035654	-0.3976462300305	-4.07397081702703	11.1692292412811	0.00178276620231916	0.0363839196131574	-0.509604595637624	-0.152538378301784
ADK	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.4449802534405	-0.4449802534405	-0.168032060931459	-0.0695637223616	5.48382163864444	132.131020280117	2.04113789241024e-07	9.21388044107823e-06	0.177049634582995	0.376846750435088
ADK	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.07531388258829	-0.07531388258829	-0.719443407460695	-0.5340799664045	-5.00586084829015	6.10955604332302	0.00231405554303766	0.0454517238346517	-0.957622543564959	-0.330636506179851
ADK	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.817186050995	-0.817186050995	-1.18039606035039	-1.01733335597	-6.51834374294715	190.805561655337	6.1855163639225e-10	3.75668896787517e-08	-0.473118694870396	-0.253301323840386
ADK	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.0620527548579	-0.0620527548579	0.126987272528522	0.138278646354	6.87343896471805	152.349581453728	1.50773195164831e-10	9.78058963271277e-09	0.13470356503676	0.243376489736084
ADK	BRD-K69694239-001-02-2::2.5::HTS002	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-6.516188822885	-6.516188822885	-5.68213887380186	-5.73883515181	9.82924613294962	21.6326658124162	1.95087409329244e-09	1.1255151912282e-07	0.657900300695143	1.01019959747114
ADK	BRD-K72951360-001-01-4::2.5::HTS002	2.5	valrubicin	DNA inhibitor, topoisomerase inhibitor	chemo	TOP2A	oncology	bladder cancer	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.57841775593	-2.57841775593	-3.29460451844559	-3.181546610205	-6.4349985373719	67.758789101955	1.47319730030392e-08	7.7389437298245e-07	-0.938287909829418	-0.494085615201763
ADK	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.522508091665	-1.522508091665	-0.88161773649292	-0.689609968602	10.2516626635941	112.901104896071	7.90924731501761e-18	1.07357889029792e-15	0.517034209820868	0.764746500523292
ADK	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.374749837658	-0.374749837658	-0.191917825020543	-0.131154903569	4.06362560477767	85.3046590947648	0.000107046515046793	0.00301289199257572	0.0933798048634477	0.272284220411465
ADK	BRD-K76674262-001-03-3::2.5::HTS002	2.5	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-5.24672671058	-5.24672671058	-4.74904779197691	-4.86837811059	5.02775959020122	105.854151636989	2.03326334439161e-06	7.91477114675097e-05	0.301425987456594	0.693931849749577
ADK	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.233141548021	0.233141548021	0.0312558446149016	0.114428305936	-3.74867583699909	16.8189727738648	0.00162530279168943	0.0336439561560754	-0.315603485432906	-0.0881679213792906
ADK	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.4770366235135	0.4770366235135	0.327541216827979	0.364286574892	-4.4596254482709	8.64859982297969	0.00174149989541234	0.0357078284783155	-0.225799640175069	-0.0731911731959729
ADK	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5029356219475	0.5029356219475	0.185331153901482	0.18484230673	-9.08526397071627	157.235782417517	4.18952598030436e-16	4.85371304774407e-14	-0.386652720158464	-0.248556215933573
ADK	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.297652255741	0.297652255741	-0.123562024659339	-0.0479466221371	-10.098709956269	5.76513464882953	7.01667039700609e-05	0.00205279272388741	-0.524290656567997	-0.318137904232681
ADK	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.874511831255	-3.874511831255	-5.23228186156627	-5.37506459637	-15.3738414909829	182.398288276296	9.46331443531055e-35	5.84513752047745e-32	-1.53202415380604	-1.1835159068165
ADK	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.895069532035	-1.895069532035	-0.9495476209308	-0.823450093444	8.36774087226809	5.59707613987726	0.000227353115546304	0.00592082210229935	0.664133214614195	1.2269106075942
ADK	BRD-K97010173-001-04-1::2.5::HTS002	2.5	deferasirox	chelating agent	noncancer	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.257160568911	0.257160568911	0.0476750607844885	0.106077867549	-4.47882527465394	15.3147857195423	0.000420566917352575	0.0102699882453298	-0.309000390272154	-0.109970625980869
ADK	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.79836326692	-3.79836326692	-3.15960332140149	-3.187890366305	6.9722019525105	5.26573797158391	0.000754540165781748	0.0172685359521448	0.40678566717385	0.870734223863162
ADK	BRD-K99383816-001-03-5::2.5::HTS002	2.5	ftorafur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.3554866483185	-0.3554866483185	0.03211015106134	0.0749758772654	8.88787775395298	3.82814440224357	0.00108020763787883	0.0236317059119049	0.264343025442068	0.510850573317612
ADK	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	HDQP1, PC3	BREAST, PROSTATE	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.30255059084	-1.30255059084	-0.611319862671781	-0.6000769492995	12.5444534767877	22.3580045111011	1.3485209147352e-11	9.93561839581577e-10	0.577061139391431	0.805400316945007
AFF3	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.3107950370755	0.3107950370755	0.175682336411185	0.21394626854	-4.41296639759555	19.7855853995764	0.00027414200524988	0.00698507459900965	-0.199023471560276	-0.0712019297683537
AFF3	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.332120739486	0.332120739486	-0.054571736621567	0.106263594851	-5.67810875095203	6.75894313935377	0.000851090937196965	0.0192196259064891	-0.548900540973345	-0.22448441124179
AFF3	BRD-A17883755-001-06-1::2.5::HTS002	2.5	lenalidomide	anticancer agent	targeted cancer	CDH5, CRBN, PTGS2, TNF, TNFSF11	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.2515466631475	-0.2515466631475	-0.0483385224554024	0.0255769508677	3.25372038903482	81.8814002308375	0.00165628037205303	0.0342059082541678	0.0789643694288647	0.32745191195533
AFF3	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-4.16967178113	-4.16967178113	-3.80253377077647	-3.74224322709	3.6887297019261	191.209883112263	0.000293681455138288	0.00743058111183262	0.170820914523927	0.563455106183125
AFF3	BRD-A36267905-003-18-4::2.5::HTS002	2.5	buphenine	adrenergic receptor agonist	noncancer	ADRB2	rheumatology	Raynaud's disease	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.0997002760274	-0.0997002760274	-0.444558251161835	-0.393531150995	-5.3073425946368	5.36145135406341	0.0025705651063029	0.0497828362400646	-0.508557238965047	-0.181158711303822
AFF3	BRD-A64553394-001-04-4::2.6791::HTS002	2.6791	DPI-201106	sodium channel activator	noncancer	ADRB2	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.9931221983615	-0.9931221983615	-1.65522518657209	-1.51643544753	-6.12832741130427	12.1005455907522	4.93024704917365e-05	0.00148851235357422	-0.897284639154616	-0.426921337266572
AFF3	BRD-A88138582-001-04-8::2.5::HTS002	2.5	halcinonide	glucocorticoid receptor agonist	noncancer	NR3C1	dermatology	corticosteroid-responsive dermatoses	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.799060764679	0.799060764679	0.278695836268534	0.260075782914	-12.8071657893303	13.6297248788881	5.5287959179849e-09	3.04075263101305e-07	-0.607731877529981	-0.432997979290952
AFF3	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.021589835532705	0.021589835532705	0.224359763589807	0.2226649685355	6.33705885314752	11.2781323113374	4.95238688629549e-05	0.00149477556534689	0.132555264992045	0.27298459112216
AFF3	BRD-K00317371-001-06-1::2.40436::HTS002	2.40436	RITA	MDM inhibitor	targeted cancer	MDM2	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.1925544402275	-0.1925544402275	-2.21065437422858	-1.66399627555	-15.0632787622541	188.567315536181	3.52320181023473e-34	2.06883375557753e-31	-2.28238189564944	-1.75381797235272
AFF3	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-2.820385836995	-2.820385836995	-1.88671004450827	-1.71824464082	7.37244148447078	8.30986278279564	6.42899297314473e-05	0.00189796092967099	0.643518810960708	1.22383277401275
AFF3	BRD-K02130563-001-11-4::0.15625::HTS002	0.15625	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-1.598758850835	-1.598758850835	-3.03753036859127	-3.136612886985	-8.40269239936893	6.12718206272347	0.000138430468957121	0.00379407467789141	-1.85565086106572	-1.02189217444683
AFF3	BRD-K03109492-001-02-2::2.5::HTS002	2.5	NSC-663284	CDC inhibitor	targeted cancer	CDC25A, CDC25B, CDC25C	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.2273274735175	-0.2273274735175	-1.22050637504839	-0.957814328752	-9.74911566021797	10.9428090737774	9.92730313343778e-07	4.05355106360561e-05	-1.21754455541498	-0.768813247646797
AFF3	BRD-K03765900-001-01-9::2.49999::MTS010::PROS002_PR500	2.49999	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.417717768616	0.417717768616	-0.565862846469815	-0.353034364185	-12.4396280818662	61.988772104065	1.68104976212532e-18	2.41324658048598e-16	-1.1416365236212	-0.825524706550431
AFF3	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.1296111386117	0.1296111386117	-1.70055063016712	-1.35955217781	-15.2308875311146	89.0871501258522	1.56160134211187e-26	4.57235592969255e-24	-2.06891630143825	-1.59140723611938
AFF3	BRD-K07955840-001-02-3::2.5::HTS002	2.5	PF-05212384	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-4.1855995331	-4.1855995331	-4.70793514652969	-4.691855544975	-5.21301428989496	51.5600028488227	3.31563788594215e-06	0.000124760771147488	-0.723439231712399	-0.321231995146983
AFF3	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.02562629476855	-0.02562629476855	0.339565613628574	0.348412196747	12.4266842533113	101.64832780033	4.08069752284031e-22	8.09825758678557e-20	0.306899085889101	0.423484730905148
AFF3	BRD-K12502280-001-08-0::2.5::HTS002	2.5	TG-101348	FLT3 inhibitor, JAK inhibitor	targeted cancer	BRD4, JAK1, JAK2, JAK3, TYK2	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.1954853577145	0.1954853577145	-0.399044967365202	-0.2460199545545	-7.4687608398213	9.5229765412819	2.80355006610359e-05	0.000887041750986	-0.773106932323079	-0.415953717836324
AFF3	BRD-K13514097-001-05-3::2.5::HTS002	2.5	everolimus	mTOR inhibitor	targeted cancer	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.419308498702	-0.419308498702	-0.749606430033491	-0.7206768922275	-5.78466606781325	161.396785759718	3.67015144953414e-08	1.82341189157905e-06	-0.443055154810931	-0.217540707852051
AFF3	BRD-K13571841-001-14-4::2.5::HTS002	2.5	pepstatin	aspartic protease inhibitor	noncancer	CTSB, CTSD, CTSL, REN	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.511898180524	-0.511898180524	-0.720934223425574	-0.751877550498	-3.2887642378217	162.46122188144	0.0012337214499804	0.0265804467885855	-0.334547610510922	-0.0835244752922253
AFF3	BRD-K13662825-001-07-5::2.5::HTS002	2.5	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-5.91728005878	-5.91728005878	-4.91532902341121	-4.867325233515	13.094903789039	189.111959370388	2.62165182221662e-28	9.18130740855989e-26	0.85101933141153	1.15288273932605
AFF3	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-2.157130026815	-2.157130026815	-3.69453239689105	-3.60112771075	-10.8578101535251	3.10395954188682	0.00143217379286197	0.0302178164238595	-1.97959928230306	-1.09520545784904
AFF3	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.5815926227725	-0.5815926227725	-1.10777291775772	-0.898661589303	-4.45155263968	11.3794123608083	0.000899004492211564	0.020152989625689	-0.785285681805123	-0.267074908165313
AFF3	BRD-K16136380-001-01-7::2.5::HTS002	2.5	pyrithione-zinc	ATP synthase inhibitor	noncancer	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-4.9444366706	-4.9444366706	-6.35590696858255	-6.34443535145	-11.7641442615059	14.5000055700448	8.23669660712985e-09	4.44004765369601e-07	-1.66797330439118	-1.15496729157392
AFF3	BRD-K17555800-003-01-5::2.5::HTS002	2.5	talmapimod	p38 MAPK inhibitor	targeted cancer	MAPK11, MAPK14	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.5558156351255	0.5558156351255	0.41072977341957	0.416811773993	-5.61720579060593	155.35279090133	8.73973587365991e-08	4.14420099572048e-06	-0.196106891408291	-0.0940648320035691
AFF3	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.667595860393	-0.667595860393	-0.94004964544468	-0.8887322701185	-4.1523822023375	159.49969513556	5.34495054168966e-05	0.00160355249811003	-0.402037778118355	-0.142869791985004
AFF3	BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500	2.5	sonidegib	smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.06991577978255	-0.06991577978255	0.0012289895853275	0.01374069413735	3.53499877995713	34.3155843769737	0.00118980771462392	0.0257692660533308	0.0302580209522518	0.112031517783503
AFF3	BRD-K21680192-300-14-4::2.5::HTS002	2.5	mitoxantrone	topoisomerase inhibitor	chemo	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-5.62891226914	-5.62891226914	-4.71194691428741	-4.740808103055	7.32412015404442	161.997631304785	1.06948788967941e-11	7.97572268291922e-10	0.669734817595736	1.16419589210945
AFF3	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-1.13804485586	-1.13804485586	-0.493762043925307	-0.427199621459	9.33417985647577	3.25097129222353	0.00186482800473984	0.0377775729137887	0.433906198402935	0.854659425466451
AFF3	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.203297448816	-0.203297448816	-1.04502571760028	-0.8676646214495	-9.47865634705994	10.2494571205053	2.15532731591599e-06	8.36409828522466e-05	-1.03894171602378	-0.644514821544769
AFF3	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.266591323856	0.266591323856	-0.0555154630837916	-0.030411088067	-14.0611583517291	6.48563310370616	4.23197568985247e-06	0.000156304517944234	-0.377157712236592	-0.267055861642991
AFF3	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.263048206614	-0.263048206614	-0.533919185211668	-0.4752073320215	-5.53453505238247	33.151153406265	3.75292154299679e-06	0.000139791435764505	-0.370426895121219	-0.171315062074116
AFF3	BRD-K27182532-001-02-3::2.5::HTS002	2.5	metatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-1.313499244655	-1.313499244655	-0.968612341582679	-0.9486901264415	6.95901357732916	189.97661490391	5.400815280179e-11	3.68177906547546e-09	0.247128842234802	0.44264496390984
AFF3	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-5.60664254568	-5.60664254568	-4.67129572427709	-4.90330008871	7.21018673254148	3.75683398116716	0.00248560445511166	0.0483208269623244	0.565787326219016	1.3049063165868
AFF3	BRD-K29582115-066-01-2::2.5::HTS002	2.5	ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.7097607342235	0.7097607342235	0.259699187924969	0.262353751493	-11.5525156444324	18.6373734288305	6.16888444478622e-10	3.74764975670801e-08	-0.531708844234583	-0.368414248362479
AFF3	BRD-K30519779-001-03-1::2.5::HTS002	2.5	homoquinolinic-acid	glutamate receptor agonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.226274492002	0.226274492002	0.429271201153387	0.45172565456	5.35784428587307	8.03160567274493	0.000670559750695954	0.0155339819289789	0.115687190921617	0.290306227381156
AFF3	BRD-K32285926-001-02-1::2.5::HTS002	2.5	AMG-208	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.6020127646615	0.6020127646615	0.405285170177975	0.412883434958	-4.51694232635482	11.0597209328337	0.000864639438799036	0.0194620149420667	-0.292524572131922	-0.100930616835129
AFF3	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-2.1351767131	-2.1351767131	-3.67669160510119	-3.65355610334	-12.6343136162247	7.86694405563879	1.67560621217479e-06	6.60653060796927e-05	-1.8237013383891	-1.25932844561328
AFF3	BRD-K36627727-001-05-4::2.5::HTS002	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.2795806369095	-0.2795806369095	0.141406385988452	0.154182848854	14.2920109533349	32.3241191867663	1.59314467206099e-15	1.73769518787867e-13	0.361010480113526	0.480963565682378
AFF3	BRD-K36627727-001-05-4::2.5::MTS010::PROS005_PR500	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.279019402327	0.279019402327	-0.0816101353450517	-0.032678012842	-12.7509933665495	32.3103701209823	3.73435760871021e-14	3.58754429366764e-12	-0.418217340339324	-0.30304173500478
AFF3	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-2.222268375425	-2.222268375425	-3.78595596734025	-3.70292092273	-14.4231305527969	24.7904501052346	1.46467335049953e-13	1.32400664082334e-11	-1.78706876072623	-1.34030642310426
AFF3	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.559970203758	-0.559970203758	-1.37667278545562	-1.00119520354	-7.6613358949037	77.2391921182221	4.47858202794582e-11	3.09442297700709e-09	-1.02896089554429	-0.604444267850936
AFF3	BRD-K39160765-003-02-9::2.5::HTS002	2.5	4-chlorophenylguanidine	urokinase inhibitor	noncancer	PLAUR	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.363040108136	0.363040108136	0.0510917527341404	0.07182611721785	-8.16599946741201	6.88389734621987	8.7588817121485e-05	0.00251343199689795	-0.402588840656262	-0.221307870147457
AFF3	BRD-K39171998-001-01-1::2.5::HTS002	2.5	STF-118804	NAMPT inhibitor	targeted cancer	NAMPT	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-5.840003990935	-5.840003990935	-4.6538800235833	-4.65401991694	9.70320649761143	6.30176447940348	5.09000528648318e-05	0.00153156779874583	0.890450357369667	1.48179757733372
AFF3	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.4993440451265	0.4993440451265	0.08516460577198	0.1179670530315	-13.7021506857217	31.2173609290559	9.5031369445775e-15	9.61207096835466e-13	-0.475811093401178	-0.352547785307862
AFF3	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-6.293596338785	-6.293596338785	-6.60343325117142	-6.671127343215	-3.53614648667938	19.8077365384754	0.00209807879770513	0.0418072825058891	-0.492722684125319	-0.126951140647524
AFF3	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.032235307153902	-0.032235307153902	-1.02434188929064	-1.03228700688	-14.070567340833	23.5444300976755	5.93089355035009e-13	5.03430686634845e-11	-1.13777988583228	-0.8464332784412
AFF3	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.0476490783695	0.0476490783695	-0.207490518629798	-0.158031671069	-6.13448236188703	8.6004656312727	0.000207397099111522	0.00545882510812642	-0.349895591374457	-0.160383602624139
AFF3	BRD-K44827188-001-06-0::2.5::MTS010::PROS003_PR500	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.1826951077315	0.1826951077315	0.0355190687809853	0.0567242940999	-6.24810469825343	21.1610578643702	3.26771381393759e-06	0.000123043892134123	-0.196139294472707	-0.0982127834283227
AFF3	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.4040599221745	0.4040599221745	-0.269316074877765	-0.234942866008	-11.7881117325458	2.68295066981373	0.00218554906809885	0.0432506341404404	-0.867946565025074	-0.478805429079457
AFF3	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-2.350474500305	-2.350474500305	-3.15954661400161	-3.19197499768	-7.87448456497363	70.3818507809625	3.01078815745723e-11	2.12409221527206e-09	-1.01397308648253	-0.604171140910696
AFF3	BRD-K58466253-003-14-0::2.5::HTS002	2.5	palmatine-chloride	dopamine synthesis inhibitor	noncancer	CYP3A4	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.349345955643	-0.349345955643	-0.0524730920202989	-0.0597563096057	6.61731601715886	5.2764885785982	0.0009617855427998	0.0213770127141697	0.1833428760215	0.410402851223902
AFF3	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.1969894884955	-0.1969894884955	0.0398354782426792	0.0957301689988	6.36960005071305	8.1479769380073	0.000199757443932201	0.00527862821745752	0.15135684256755	0.322293090908809
AFF3	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.0967310876442	0.0967310876442	-0.173794947538743	-0.07625513394025	-4.82157949572088	17.4972351656693	0.000147550312984532	0.00402293741657064	-0.388646451230929	-0.152405619134956
AFF3	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-3.21616775157	-3.21616775157	-2.11666569682099	-1.97310817512	9.42384913472325	6.40964563030932	5.46290517587086e-05	0.00163642068964252	0.818380263668017	1.38062384583001
AFF3	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.377051662622	-0.377051662622	0.150797577154184	0.1059379473725	13.9319385148832	4.94556041273752	3.70464398886787e-05	0.00114543081576755	0.430132438067906	0.625566041484463
AFF3	BRD-K67844266-003-01-9::2.5::MTS010::PROS003_PR500	2.5	pevonedistat	nedd activating enzyme inhibitor	targeted cancer	NAE1, UBA3	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-2.24514735442	-2.24514735442	-0.929459468610943	-0.949123876335	14.4964953465478	186.512718731845	2.19169352215919e-32	1.07987007105944e-29	1.13664168006751	1.49473409155061
AFF3	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-3.807154780595	-3.807154780595	-3.09755632020171	-3.15624915805	7.60731064572576	184.613858468412	1.38404921286449e-12	1.13568868202157e-10	0.525569593874515	0.893627326912059
AFF3	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.6925856300115	-0.6925856300115	-1.21999254020409	-1.04907947641	-6.49254179429156	56.198580518504	2.34399365305035e-08	1.19729698680798e-06	-0.690122939411535	-0.364690880973641
AFF3	BRD-K69280563-001-01-8::2.5::HTS002	2.5	vinorelbine	tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-2.907545160305	-2.907545160305	-3.37094927351614	-3.5318421653	-4.97225837491692	179.782534492808	1.53701249948264e-06	6.10677925956218e-05	-0.64730661720238	-0.279501609219908
AFF3	BRD-K73197500-001-02-2::2.5::HTS002	2.5	SNX-5422	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-4.27733442087	-4.27733442087	-3.60801772931259	-3.686768984175	6.06642108802971	7.4197723636947	0.000404628596657156	0.009910140840239	0.411386899291309	0.927246483823509
AFF3	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.6294729783575	-0.6294729783575	-0.891708528733683	-0.708568317551	-4.31714343229469	176.228448097251	2.63179590555867e-05	0.000839015595184418	-0.382112557030341	-0.142358543722025
AFF3	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.6890622996005	-0.6890622996005	-0.147841136395872	-0.1187166368295	12.158508202878	37.2291735981008	1.57012482264563e-14	1.56522457261774e-12	0.451046414229444	0.631395912179812
AFF3	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.04559388855345	0.04559388855345	-0.215210880118872	-0.189464823924	-8.01058907029899	21.876434844624	6.01355828356183e-08	2.90877890624582e-06	-0.328347013699359	-0.193262523645285
AFF3	BRD-K77625799-001-07-7::2.5::HTS002	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.3427205938875	-0.3427205938875	0.11321441902898	0.1701419093195	6.47033482490311	4.25792799684989	0.00236237350308601	0.04624818693304	0.264878015547644	0.646992010285315
AFF3	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-1.565670368225	-1.565670368225	-1.10457718225098	-1.10749370834	9.48307984691934	188.074261670155	1.10819444685732e-17	1.48263550312411e-15	0.365177195207991	0.557009176740042
AFF3	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.4797596622465	0.4797596622465	-0.4703734361536	-0.217946401079	-11.1763373740131	194.625446587734	1.00920329380002e-22	2.12476947698295e-20	-1.11779794257991	-0.782468254220292
AFF3	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.0653147343492	0.0653147343492	0.284895027870717	0.278924535231	6.3947260836962	65.6277574707837	1.93926571676705e-08	1.00057987917421e-06	0.151015570930637	0.288145016112397
AFF3	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-2.268320409255	-2.268320409255	-0.830477337492118	-0.670558533384	10.6424428031343	3.10013663042485	0.0015305777103166	0.0319880059183444	1.01563092337449	1.86005522015127
AFF3	BRD-K83029223-001-01-3::2.5::MTS006	2.5	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-3.634493347415	-3.634493347415	-2.40722614867008	-2.23881824047	8.6315633662983	4.06518264213449	0.000921240195538553	0.0205938379795053	0.834985959261351	1.6195484382285
AFF3	BRD-K84466663-001-05-4::2.5::HTS002	2.5	nelarabine	DNA synthesis inhibitor, T cell inhibitor	chemo	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.1047847401584	0.1047847401584	0.613728792302869	0.607124565028	14.5193346763243	3.30022412724575	0.000418950864412045	0.0102328569593811	0.402917192656068	0.61497091163287
AFF3	BRD-K85606544-001-09-1::2.5::HTS002	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-0.35857392575	-0.35857392575	-1.60211563941584	-1.5159358626	-14.5681252143517	168.560116997008	1.21204795540037e-31	5.59864280674583e-29	-1.4120549861684	-1.07502844116329
AFF3	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.3788448669745	0.3788448669745	0.150643964681401	0.185599499868	-10.7846671763549	48.3036299966051	1.85851875050414e-14	1.83903261900647e-12	-0.270738531042897	-0.185663273543301
AFF3	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-3.93927161762	-3.93927161762	-5.2316107756972	-5.37506459637	-11.9991138401002	8.39108674126878	1.42720242427921e-06	5.69205188673873e-05	-1.53870192240543	-1.04597639374897
AFF3	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.08401139764785	0.08401139764785	-0.301450988043221	-0.183745665678	-5.60610295603577	10.6610163220766	0.000178352381586142	0.00477766374115438	-0.537386081744346	-0.233538689637796
AFF3	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	0.2516103686495	0.2516103686495	-0.0922912360714137	0.0692106615383	-6.06393617972181	29.79564822219	1.19867221594407e-06	4.83732286520573e-05	-0.459757511275385	-0.228045698166443
AFF3	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	HCC44, GAMG	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma	-5.922306242945	-5.922306242945	-5.64382827903412	-5.72114668903	3.0891079576057	143.533066840187	0.00241115854744687	0.0470828353057344	0.100288084785599	0.456667843036166
AGO2	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.176103238997333	0.17927924313	-0.0103581048836088	0.062505767768	-4.56765747645831	13.1356436366638	0.00051429922802056	0.0122883443081196	-0.274559631569255	-0.0983630561926291
AGO2	BRD-A31095847-001-02-3::2.5::HTS002	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	-0.259698996526667	-0.270872360905	0.0322358511656673	0.08711680237565	6.95947110403428	13.5198459107716	8.04247017612926e-06	0.000282116954235615	0.201664967123515	0.382204728261153
AGO2	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	-0.560115953316333	-0.588045198551	-0.33767175087912	-0.255739101173	4.56356913601267	10.3877809552542	0.000940020190567701	0.0209671752965121	0.114384041946009	0.330504362928417
AGO2	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.2042221441583	0.207621172144	-0.455711699139969	-0.338375716384	-6.74934402687946	10.1428098036029	4.70960752297201e-05	0.00142793248096063	-0.877380566455525	-0.442487120141013
AGO2	BRD-A55484088-050-02-5::2.5::HTS002	2.5	BNTX	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	-0.363233829678	-0.356277072241	-1.40040167299704	-1.329869990725	-11.0935740515477	7.53482560179086	6.191884411375e-06	0.000222034531371188	-1.25510124373547	-0.819234442902616
AGO2	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.663071848628333	0.664933597398	0.149515236274348	0.162524596038	-18.9297056936512	53.98485483669	1.6976323127771e-25	4.51989858341867e-23	-0.567948669342996	-0.459164555364974
AGO2	BRD-K13390322-001-06-3::2.5::HTS002	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.2822073780997	0.369761475542	-0.342457040587956	-0.1920820036935	-5.07502787122668	5.77497983207126	0.00254607062061547	0.0493619873401983	-0.928712481869295	-0.320616355506017
AGO2	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.2218324722176	0.245174046767	-0.349149913101635	-0.225709542629	-6.26252271104602	5.16274550328188	0.00135482184182811	0.0287958756978558	-0.803149065448571	-0.338815705189899
AGO2	BRD-K24869513-001-02-1::2.5::HTS002	2.5	CNX-2006	EGFR inhibitor	targeted cancer	EGFR	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.1428220893554	0.153185204115	-0.127838421184467	-0.0301351279742	-4.96118258297598	15.5419416608588	0.000153979158927747	0.00418490985972928	-0.386590952018882	-0.154730069060852
AGO2	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	-2.97496914326667	-2.89914003216	-1.95845328287521	-1.761878546985	7.39068933876017	8.9628660473221	4.23660352164157e-05	0.00129644059992849	0.705182016025586	1.32784970475733
AGO2	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.0408354931173333	0.111672544241	-0.78361234090448	-0.716748306674	-7.98764852630978	3.89649204548047	0.00148535442337474	0.0311714998734442	-1.11404692275726	-0.534848745286365
AGO2	BRD-K31627533-001-09-5::2.5::HTS002	2.5	rimexolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	ophthalmology	anterior uveitis	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.846733735311333	0.808812084053	0.251670212247852	0.237225072	-10.2154493822896	3.72973096848783	0.000733941337819591	0.0168565058930063	-0.761523657528135	-0.428603388598828
AGO2	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	-0.398767800642	-0.393054092081	-0.941279876361269	-0.800050374419	-7.57440110373729	138.325494009533	4.66008620414118e-12	3.623012226734e-10	-0.684132344771804	-0.400891806666734
AGO2	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	-0.129294270632633	-0.0906009316028	-0.514018657307129	-0.415072163515	-5.52213962691762	7.67915538062619	0.000644377287345941	0.0149890101605783	-0.54655834163306	-0.22289043171593
AGO2	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.119549397199267	0.103900311895	-0.360194171351184	-0.283169297694	-7.83770739036829	8.75731102315044	3.04727005360533e-05	0.000957370775900288	-0.618796636144632	-0.340690500956271
AGO2	BRD-K48141473-001-01-7::2.5::HTS002	2.5	cebranopadol	opioid receptor agonist	noncancer	OPRL1, OPRM1	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.735503087862	0.731659267909	0.337404476623964	0.352622628431	-11.1104890459773	22.185869227492	1.55561486953665e-10	1.00729117635323e-08	-0.472371232272447	-0.323825990203625
AGO2	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.0543214690192167	0.0716190743943	-0.229413415831742	-0.187647312675	-6.42362115403933	10.8019549583701	5.34590888240678e-05	0.00160361554213767	-0.381171521740521	-0.186298247961396
AGO2	BRD-K55966568-001-05-4::2.5::HTS002	2.5	orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.763850593817667	0.797696324785	0.312396513865571	0.333980144611	-8.62481744867789	3.33670110115179	0.00215318579578733	0.0427147499468071	-0.608917579833664	-0.293990580070528
AGO2	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	-5.28198674779	-5.33428480517	-4.83490004070484	-4.94763308684	3.87664238332849	14.2065276883132	0.00163534816213482	0.0338257610733635	0.200068963193592	0.694104450976731
AGO2	BRD-K89053832-001-01-0::2.5::HTS002	2.5	VLX600	ubiquitin C-terminal hydrolase inhibitor	targeted cancer	USP14	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	-0.0930846931047333	-0.0523413514254	-2.09592326126225	-1.92427650365	-16.7703818817613	26.8348637858122	9.54775269103805e-16	1.06029030389507e-13	-2.24795337478013	-1.75772376153491
AGO2	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	0.46883729894	0.474129579166	0.092818463459878	0.163098987383	-6.37236395091362	4.56385706040046	0.00196270656036838	0.0394508988443397	-0.532168484747054	-0.21986918621319
AGO2	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	JHH1, NCIN87, U2OS	LIVER, STOMACH, BONE	carcinoma (hepatocellular_carcinoma), carcinoma, osteosarcoma	-2.56447147829667	-2.62054484365	-3.07832064888251	-3.087127735	-4.38752815776277	14.8243126626889	0.000544212171014959	0.0129188276740294	-0.763733650066167	-0.263964691105527
AHCTF1	BRD-A14886633-001-01-6::2.5::HTS002	2.5	norgestrel	progesterone receptor agonist	noncancer	PGR	endocrinology	contraceptive	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.66097207153	-0.66097207153	-0.128111122114372	-0.0685599407545	9.749728909356	13.0184823400293	2.38358180012327e-07	1.06364918517306e-05	0.414805361196942	0.650916537634314
AHCTF1	BRD-A67748489-001-10-0::2.5::HTS002	2.5	K-858	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.039019721103	-1.039019721103	-2.66147857493958	-2.53659706209	-14.0769524785603	12.4482463720633	5.146542853239e-09	2.8392622475981e-07	-1.87258172267647	-1.37233598499669
AHCTF1	BRD-A73427433-240-01-3::2.5::HTS002	2.5	adaprev	TGF beta receptor inhibitor	noncancer	IGF2R, M6PR	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.63860552864	-0.63860552864	-0.392445359950405	-0.3772229678335	5.13983671651817	6.88326175104616	0.00140982894702015	0.0298083484646229	0.132521636711295	0.359798700667894
AHCTF1	BRD-A73556557-001-06-4::2.5::HTS002	2.5	tagatose	phosphorylase inhibitor	noncancer	PYGL	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.530850624712	0.530850624712	0.110593959282809	0.1416103571295	-12.2622172153578	10.5753712583128	1.38020836729067e-07	6.38365729721712e-06	-0.496061086756042	-0.344452244102339
AHCTF1	BRD-A74914197-001-02-9::0.15625::MTS010::PROS005_PR500	0.15625	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.812902442267	0.812902442267	-0.412086833997013	-0.2745905537905	-13.2394951418673	4.19775274711501	0.00013963477574402	0.00382365936507476	-1.47717780315351	-0.972800749374511
AHCTF1	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-2.72252416397	-2.72252416397	-4.29035457686859	-4.26036322773	-19.2035720700915	6.0980208174276	1.09783736189524e-06	4.45219269513047e-05	-1.76682694514038	-1.36883388065679
AHCTF1	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.707061486115	-0.707061486115	-1.02982651373087	-1.0089298839585	-6.11095678850181	185.591825803703	5.69840500433596e-09	3.13001908296853e-07	-0.426964758654193	-0.218565296577556
AHCTF1	BRD-K07359318-001-03-9::2.44929::HTS002	2.44929	benfotiamine	antioxidant	noncancer	AGER	rheumatology	lumbago	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.146353514704	0.146353514704	0.336771961099663	0.3600151541855	7.07846372646976	48.9025339224802	5.06623985487624e-09	2.79784107667037e-07	0.136355940524935	0.244480952266392
AHCTF1	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.7100487869095	-0.7100487869095	-2.52852207743854	-2.34739362698	-11.9865328627013	3.64357009143834	0.000465690343846338	0.0112539120200972	-2.25644579290445	-1.38050078815363
AHCTF1	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.303810460358	-0.303810460358	-2.11525585728369	-1.95679219665	-17.0143465180646	190.879966543355	4.12895221242304e-40	4.46946565018393e-37	-2.02144591113072	-1.60144488272065
AHCTF1	BRD-K12539581-001-23-7::2.5::HTS002	2.5	nocodazole	tubulin polymerization inhibitor	targeted cancer	HPGDS	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.568729867135	-1.568729867135	-3.5186147144406	-3.357933574425	-12.4750385592427	3.15555556678902	0.00086344077855832	0.0194370757932598	-2.43372209251768	-1.46604760209351
AHCTF1	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.0251875420631	0.0251875420631	-0.424193814795633	-0.390164965854	-8.82902347997716	3.13735483676945	0.00256562276197268	0.0496916104238968	-0.607423238353996	-0.291339475363469
AHCTF1	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.570785096599	-0.570785096599	-0.0482971776194948	0.2281371067585	7.51661669435805	50.1800980496437	9.16582871012216e-10	5.47825683661955e-08	0.382883280459349	0.662092557499662
AHCTF1	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.2275596734075	0.2275596734075	-0.0730486561776539	0.0407112965926	-7.32086934523042	188.623773357493	6.91927941766576e-12	5.27758803668642e-10	-0.381607744424417	-0.219608914745891
AHCTF1	BRD-K18961567-001-01-1::2.5::MTS010::PROS002_PR500	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.582246861029	0.582246861029	-0.424432044057838	-0.32717924466	-17.2574499230488	179.712236800243	5.47001408196093e-40	5.86191324086302e-37	-1.12178463511734	-0.891573175056336
AHCTF1	BRD-K19687926-379-07-4::2.5::HTS002	2.5	lapatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2	oncology	breast cancer	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.991129724845	-1.991129724845	-0.645110678718999	-0.498501703786	21.2660952377632	14.3168529780335	3.09895089914332e-12	2.45816079667834e-10	1.21054795509638	1.48149013715562
AHCTF1	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-3.67160999593	-3.67160999593	-5.26689699453356	-5.45683590772	-19.743456327774	17.5344144613887	2.0220765140452e-13	1.80053858404152e-11	-1.76536684424398	-1.42520715296314
AHCTF1	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.31333970651	-1.31333970651	-2.82102915281049	-2.6496200301	-10.9660401400642	5.15891882570474	9.05139681200752e-05	0.00258706947493507	-1.85786177190304	-1.15751712069793
AHCTF1	BRD-K24593301-001-02-3::2.54476::HTS002	2.54476	AZD3463	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.69232673038	-1.69232673038	-3.51645898869918	-3.310368963095	-14.2262776573665	14.2870456051584	7.83954617753378e-10	4.72110731296611e-08	-2.09862521453034	-1.54963930210802
AHCTF1	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.309617618176	0.309617618176	-0.478041761823187	-0.387317230447	-16.2249872281651	190.906806730086	8.92419386949849e-38	7.44246516675386e-35	-0.883414957595142	-0.691903802403232
AHCTF1	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.146416742373	0.146416742373	-0.185757256255591	-0.06456986921455	-6.40212310896267	9.72458271935584	8.85574198359963e-05	0.00253816839208736	-0.44822628014684	-0.216121717110341
AHCTF1	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.4504956368965	0.4504956368965	-0.408670073651455	-0.2809944464045	-10.3145953055087	4.36256332313813	0.000315852739289967	0.00793348198280549	-1.0830464499277	-0.635284971168209
AHCTF1	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.360493659915	-0.360493659915	-2.24471767833244	-2.28506663454	-12.969824116686	4.5695661771925	8.86972101986938e-05	0.00254183505343974	-2.26850447779357	-1.4999435590413
AHCTF1	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.12775942814995	-0.12775942814995	-0.695797327253597	-0.621232482709	-9.99892667669291	12.7525145033052	2.12923467473805e-07	9.59135642290736e-06	-0.691010756963127	-0.445065041244166
AHCTF1	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.0843865470985	-0.0843865470985	0.166176581294383	0.1606220898175	9.88054361217809	41.226352617565	1.96416449382926e-12	1.58739597208873e-10	0.199357631836948	0.301768624948818
AHCTF1	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.06764240594545	0.06764240594545	0.41508853121207	0.43502168689	13.1128306588913	21.2521501441975	1.17487428899341e-11	8.72823679326405e-10	0.292383099886495	0.402509150646745
AHCTF1	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.02422107247055	-0.02422107247055	-0.276336675177262	-0.153671266635	-4.70523647426778	124.314319490629	6.64132356753092e-06	0.000236449873572315	-0.358166588803407	-0.146064616610016
AHCTF1	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.363438224465	-1.363438224465	-2.63133959097022	-2.459947367395	-12.750846910578	25.6310067076207	1.33617529721671e-12	1.10130478937683e-10	-1.4724396147534	-1.06336311825705
AHCTF1	BRD-K39160765-003-02-9::2.5::HTS002	2.5	4-chlorophenylguanidine	urokinase inhibitor	noncancer	PLAUR	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.1618944801285	-0.1618944801285	0.0566761632475925	0.0820318935995	7.17809553148325	181.897346632645	1.73902377460548e-11	1.26218498675049e-09	0.158490656517412	0.278650630234772
AHCTF1	BRD-K39624409-003-02-6::2.5::HTS002	2.5	ADL5859	opioid receptor agonist	noncancer	OPRD1	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.0701367954387	0.0701367954387	0.240892669130375	0.2967828750075	4.26683542568087	10.6340894960622	0.00143229706222671	0.0302178164238595	0.0823027379334716	0.259209009449879
AHCTF1	BRD-K42673188-001-01-1::2.5::MTS006	2.5	verubulin	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.036466885253	-1.036466885253	-2.47889337194466	-2.30487473877	-13.5620917775848	32.7181238273984	5.55042883356682e-15	5.75250416571345e-13	-1.65888273640277	-1.22597023698054
AHCTF1	BRD-K44827188-001-06-0::2.5::HTS002	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.2809443649755	0.2809443649755	-0.116242032660995	-0.06245449085225	-6.67279705490077	10.2503894877407	4.92860735228885e-05	0.00148830594280562	-0.529374579617748	-0.264998215655241
AHCTF1	BRD-K45551181-001-02-1::2.49051::HTS002	2.49051	MPI-0479605	mitotic kinase inhibitor	targeted cancer	TTK	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.06236000716	-1.06236000716	-2.31878933834582	-2.31598955621	-14.4704312856316	145.396327983231	5.85937645853504e-30	2.35616190803256e-27	-1.42803615882721	-1.08482250354442
AHCTF1	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.0830772835744	0.0830772835744	0.155312557040299	0.14294893902	3.72199100402643	190.814189978061	0.000259993438255858	0.00666955519185395	0.03395409124437	0.110516455687427
AHCTF1	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.66455111046	-1.66455111046	-2.24629540290023	-2.140330076935	-9.33598449809459	185.999284907505	3.07385972340232e-17	3.93793951379017e-15	-0.70467350634046	-0.458815078540004
AHCTF1	BRD-K50140147-001-10-1::2.5::HTS002	2.5	NVP-TAE684	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, INSR	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.365859514494	-0.365859514494	-1.82229580542139	-1.65535849639	-15.4795543855605	21.0272937040183	5.72555597291072e-13	4.86579177683577e-11	-1.65208699452108	-1.2607855873337
AHCTF1	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.109466624429	0.109466624429	-0.218023045965677	-0.1500661795165	-9.46855363010149	115.744016953353	4.25503185245619e-16	4.91896829506517e-14	-0.395995347389956	-0.258983993399399
AHCTF1	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-4.80212350271	-4.80212350271	-5.59329814289679	-5.54901350857	-9.7160651115318	86.9622748074893	1.54292596009698e-15	1.68549326249555e-13	-0.95302564342608	-0.6293236369475
AHCTF1	BRD-K59753975-001-02-6::2.5::MTS006	2.5	vindesine	tubulin polymerization inhibitor	chemo	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.7299054370725	-0.7299054370725	-2.4302217592944	-2.28041477314	-17.922899196205	183.629384821075	3.45617243505501e-42	4.35739989313474e-39	-1.88748848625544	-1.51314415818836
AHCTF1	BRD-K60341624-001-02-2::2.5::HTS002	2.5	GSK1292263	glucose dependent insulinotropic receptor agonist	noncancer	GRPR	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.902271446695	-0.902271446695	-1.01462548723234	-0.9579958637765	-3.0695387974468	187.758809349104	0.00246157899633924	0.0479189613720611	-0.184559828818848	-0.0401482522558337
AHCTF1	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-5.71866999345	-5.71866999345	-7.22912410174968	-7.25572463628	-12.0350730837036	7.78656249417761	2.63094731234613e-06	0.000100730148202582	-1.8012543724358	-1.21965384416356
AHCTF1	BRD-K61443650-236-13-1::2.5::HTS002	2.5	thiomersal	other antibiotic	noncancer	OXCT1	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.08683882102385	0.08683882102385	-0.172359505396034	-0.0402678564845	-5.0209137393798	191.987147443931	1.17029168664779e-06	4.73080812726394e-05	-0.36102084582423	-0.157375807015537
AHCTF1	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.3834699771255	0.3834699771255	0.143164003238846	0.15713254048	-6.72278520253511	4.38516066207841	0.0018220545642546	0.0370551783421118	-0.336204987813918	-0.144406959959391
AHCTF1	BRD-K64800655-001-07-4::2.5::HTS002	2.5	PHA-793887	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.0385930028505	-0.0385930028505	-1.63954083800161	-1.592670797355	-14.3464297334608	7.08234570446638	1.71166435368745e-06	6.73259881191921e-05	-1.86420048496567	-1.33769518533654
AHCTF1	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.9774740031885	0.9774740031885	-0.73064327858598	-0.5340799664045	-15.3655505028461	21.0011109907364	6.75049147891594e-13	5.71190717798884e-11	-1.93929760327845	-1.47693696027051
AHCTF1	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.1301574272401	0.1301574272401	-1.09068095523268	-0.4202572111255	-10.2601077995446	78.6433680613936	3.6490661431778e-16	4.24362830928462e-14	-1.45769645606666	-0.983980308878903
AHCTF1	BRD-K68870568-066-01-5::2.5::HTS002	2.5	flumatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, PDGFRB	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.3833993139265	0.3833993139265	0.156724423066478	0.180263859869	-5.6401557434997	12.8739114011336	8.36341312100505e-05	0.00241059974557812	-0.31358549160784	-0.139764290112203
AHCTF1	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.08156103805855	0.08156103805855	-0.1537821355251	0.0566391407425	-3.76420852710041	191.003750965371	0.000222266755175514	0.0058017551297056	-0.3586640265544	-0.1120223206129
AHCTF1	BRD-K71164191-001-01-0::2.5::HTS002	2.5	KD-023	ACAT inhibitor	noncancer	ACACA, ACACB	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.313496005595	-1.313496005595	-0.943611543162855	-0.959659141772	5.80381569460678	11.1258109583383	0.000113449284381317	0.00317890857264523	0.229806197215947	0.509962727648343
AHCTF1	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.215909778524	-0.215909778524	-1.34324257448829	-1.10972386317	-11.8425432050983	23.0732841890472	2.75826539783088e-11	1.95430170066676e-09	-1.3242208915777	-0.93044470035088
AHCTF1	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.14609858303035	-0.14609858303035	-0.951677355231615	-0.8151847008705	-9.34376481813649	4.38044502365466	0.000468861042773921	0.0113215996436111	-1.03697149540822	-0.574186048994308
AHCTF1	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.1686372982205	0.1686372982205	0.0153729368805246	0.0495734767378	-4.78310682144414	12.591286154728	0.000390491593854109	0.00960560918388125	-0.222717836562605	-0.0838108861173452
AHCTF1	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.7620820214155	0.7620820214155	-0.862545088081224	-0.774088070041	-15.939159949891	16.1806791248546	2.57146072229231e-11	1.82980944604312e-09	-1.84050628533231	-1.40874793366114
AHCTF1	BRD-K86797399-001-05-1::2.54945::HTS002	2.54945	SB-939	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-3.886492504985	-3.886492504985	-5.48105676566279	-5.519676819535	-19.6841098710974	118.823389672779	3.32030758021509e-39	3.26439542825652e-36	-1.75497002550646	-1.43415849584912
AHCTF1	BRD-K87696786-003-04-4::2.5::HTS002	2.5	LY456236	glutamate receptor antagonist	noncancer	GRM1	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-1.223519630915	-1.223519630915	-2.19827047393631	-2.03818987744	-10.1581079687325	112.932298301165	1.30204266845238e-17	1.72903037848036e-15	-1.16486200945503	-0.78463967658759
AHCTF1	BRD-K89015388-001-01-7::2.5::HTS002	2.5	GSK923295	centromere associated protein inhibitor	targeted cancer	CENPE	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.2614025366515	-0.2614025366515	-1.65488971485262	-1.4981509162	-12.5220624752138	6.99276757795639	4.81566120138844e-06	0.000175982242051557	-1.65668380187962	-1.13029055452261
AHCTF1	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.0834073933841	-0.0834073933841	0.0257664679020493	0.0455215007673	4.53439491766276	24.4370425626199	0.00013064140320235	0.0036087435632113	0.0595287115400077	0.158819011032291
AHCTF1	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	0.4070755204685	0.4070755204685	0.599077183656152	0.600417589144	5.30804650350787	185.544619295945	3.1411611842111e-07	1.38044276286812e-05	0.120640760370325	0.263362566004979
AHCTF1	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	SUIT2, BT474	PANCREAS, BREAST	carcinoma (ductal_carcinoma)	-0.2361428693495	-0.2361428693495	-1.09770730350105	-1.03443241086	-11.941775040968	16.4417855549604	1.60711240498676e-09	9.35245166028803e-08	-1.01417613485426	-0.708952733448837
ANKS1A	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.413708757072	0.413708757072	0.174581654913897	0.21394626854	-7.47224143238441	11.8446023150037	8.10145019106114e-06	0.000284046412236209	-0.308955190288409	-0.169299014027798
ANKS1A	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.09434821959055	-0.09434821959055	0.152976454525887	0.1647699361925	10.6596384199681	144.798723401149	6.05135370372675e-20	9.90817867048166e-18	0.201466370502172	0.293182977730702
ANKS1A	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.61261705531	-1.61261705531	-2.10107889275475	-2.089022441025	-6.67265602161308	111.792089971067	1.00519656532809e-09	5.97953856925354e-08	-0.633508153337906	-0.343415521551589
ANKS1A	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.298372495062	-0.298372495062	-0.493274361181695	-0.379151386241	-3.27243588042359	80.5287241418014	0.00157166420510015	0.0327105474281327	-0.313415413277559	-0.0763883189618308
ANKS1A	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.167405370292	-0.167405370292	-0.514198059029031	-0.46624794895	-6.89012368408313	175.342043032592	9.62620226492215e-11	6.39743970616589e-09	-0.44612691081881	-0.247458466655253
ANKS1A	BRD-A26503646-001-16-6::2.5::HTS002	2.5	formestane	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.434803939401	-0.434803939401	0.147730062476679	0.129884484973	15.1282560832787	36.0116048149864	3.52235297958944e-17	4.47505863522481e-15	0.504440367772471	0.660627635982887
ANKS1A	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.28362717345	-1.28362717345	-0.989697997972043	-0.915436263548	4.24830483546376	20.2373064747437	0.000384880858367331	0.00948173902218525	0.149715198658428	0.438143152297485
ANKS1A	BRD-A48300215-001-04-8::2.5::HTS002	2.5	ajmaline	sodium channel blocker	noncancer	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.2363926922915	0.2363926922915	0.0792604364296303	0.10011510474205	-3.26573327467095	162.684413179214	0.00133140824696593	0.0283883205495384	-0.252143604519238	-0.0621209072045016
ANKS1A	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.280169770038	-0.280169770038	-0.0792131875175211	-0.05385103964535	4.75065631144354	103.04194972869	6.58408698503852e-06	0.000234528964503294	0.117063320144932	0.284849844896026
ANKS1A	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.3560888817395	0.3560888817395	-0.0161853694409129	0.03331372318045	-7.81059192829269	177.037773805919	4.82551112681881e-13	4.13864335454161e-11	-0.46633450035261	-0.278214002008216
ANKS1A	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.417048109114	0.417048109114	0.150536438480876	0.162581247373	-8.02730498885528	11.090950988696	6.00391480834324e-06	0.00021579960706983	-0.339512743889561	-0.193510597376687
ANKS1A	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.0477270414288	-0.0477270414288	-0.186517769741311	-0.0590439534084	-3.32833765008018	181.038399858809	0.00105833936318739	0.0232030296003058	-0.221070695310829	-0.0565107613141932
ANKS1A	BRD-A93477898-001-04-2::2.5::HTS002	2.5	PETCM	caspase activator	noncancer	CASP3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.192507718277	-0.192507718277	0.183825623800701	0.198279920588	8.41913229164586	12.8755080580081	1.36191668833739e-06	5.44687893067111e-05	0.279670343373587	0.472996340781814
ANKS1A	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.334318881045	-1.334318881045	-1.90227095504178	-1.73380354334	-5.52377356916333	190.441710342437	1.0784664544803e-07	5.06345315930578e-06	-0.770763576551443	-0.365140571442116
ANKS1A	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.1178236520995	-0.1178236520995	0.160324338429607	0.166606190016	9.95038734979236	21.6618909242067	1.54594624775589e-09	9.0062819607304e-08	0.220123505799791	0.336172475258423
ANKS1A	BRD-K03243820-001-23-8::2.37329::HTS002	2.37329	trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	chemo	TYMS	infectious disease	virus herpes simplex (HSV)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.7504007240475	-0.7504007240475	-2.2693806247443	-2.05370099582	-16.8312828927256	133.1340454901	8.99276183291291e-35	5.60293503164649e-32	-1.69748415684823	-1.34047564454537
ANKS1A	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.12381312489525	0.12381312489525	-0.343203540139094	-0.229059189804	-8.11958231614335	4.62050253551871	0.000663134490255587	0.0153785925299707	-0.618597942786002	-0.315435387282687
ANKS1A	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.400161777715	-1.400161777715	-2.03305520612256	-1.93975006052	-6.99168566938094	51.9101636950936	5.14514773103269e-09	2.83922339867277e-07	-0.814544313955279	-0.451242542859846
ANKS1A	BRD-K03549949-001-01-0::2.5::HTS002	2.5	XL388	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.06921080231	-1.06921080231	-1.33280355573024	-1.14186011868	-3.71224298206449	175.000348323712	0.000275879206331804	0.00701826877316194	-0.403731730942686	-0.123453775897795
ANKS1A	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.096617887575	-1.096617887575	-0.639021203056875	-0.586240520956	6.80487962224392	12.2055687250328	1.73274144108027e-05	0.000572405580032819	0.311354814422311	0.60383855461394
ANKS1A	BRD-K07442505-001-03-6::2.5::HTS002	2.5	BAM7	BAX activator	targeted cancer	BAX	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.08609668902745	-0.08609668902745	-0.299859590379354	-0.257563051703	-3.52261414075141	183.286808364795	0.000539399915584557	0.0128141259706631	-0.33348999651512	-0.0940358061886877
ANKS1A	BRD-K07572174-001-39-4::2.48092::HTS002	2.48092	curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	targeted cancer	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.77942567642	-1.77942567642	-1.16885610660217	-1.01297286124	6.15604197553691	7.1130189620387	0.000436292258280854	0.0106128797440787	0.376794321963211	0.844344817672445
ANKS1A	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.608170051394	-0.608170051394	-2.05074564771727	-1.66463476506	-10.9747243024335	56.1022363258412	1.37737372551714e-15	1.5123521168871e-13	-1.70588152439444	-1.17926966825209
ANKS1A	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.67927013622	-1.67927013622	-2.20343116123629	-2.14710453103	-7.01481586704221	191.78083818134	3.84717549061878e-11	2.67107637100367e-09	-0.671543490871766	-0.37677855916081
ANKS1A	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.243010286445	-1.243010286445	-2.52249991360198	-2.34739362698	-12.0319381908723	171.545540988479	1.43834630149192e-24	3.58464330758676e-22	-1.48939519181435	-1.0695840624996
ANKS1A	BRD-K11071038-001-01-7::2.5::HTS002	2.5	ICI-162846	histamine receptor antagonist	noncancer	HRH2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.2549257862365	-0.2549257862365	0.0995546921237439	0.0637321133413	9.45276901141234	8.53344105608678	8.29043350006487e-06	0.000290055553646001	0.268936891437881	0.440024065282607
ANKS1A	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.45344091988	-1.45344091988	-2.10321784200074	-1.95679219665	-6.03143445028074	186.210478838645	8.57077853361795e-09	4.60738999832406e-07	-0.862308536038862	-0.437245308202608
ANKS1A	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-6.98699575826	-6.98699575826	-4.24036561076991	-4.34713599697	13.9367024339735	2.9317241405886	0.000901062644659119	0.0201864592418882	2.11109238629832	3.38216790868187
ANKS1A	BRD-K12251893-065-04-7::2.5::HTS002	2.5	vincristine	tubulin polymerization inhibitor	chemo	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.34804694656	-3.34804694656	-2.69867724520622	-2.57343902316	4.98237476047766	7.80456684695843	0.00115835009312774	0.0251665501378586	0.347505349773012	0.951234052934541
ANKS1A	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.032981910065	-3.032981910065	-1.92038914495819	-2.01595157397	13.7678258396636	74.7746094455682	3.39506114562745e-22	6.78787369665285e-20	0.951600900517209	1.27358462969642
ANKS1A	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.0924810524818	-0.0924810524818	-0.571077061137012	-0.549657042838	-13.349240809205	67.4370348584643	1.32948633406758e-20	2.32420453910579e-18	-0.550148230929521	-0.407043786380902
ANKS1A	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.24076834143	-1.24076834143	-0.0421127381915273	-0.0356049990197	18.4140566468788	3.52841440928544	0.000123974361890153	0.00344098692172425	1.00798714204372	1.38932406443323
ANKS1A	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.1799088851445	0.1799088851445	-0.0725444150320137	0.0407112965926	-6.14485122480142	188.665153685978	4.65199686084082e-09	2.58104539266672e-07	-0.333495755834373	-0.171410844518655
ANKS1A	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.452252246567	-0.452252246567	0.0924078189374393	0.105022107206	13.6720423433958	5.45453979839529	1.98675024437146e-05	0.000648026469526542	0.444768777528395	0.644551353480484
ANKS1A	BRD-K18163608-001-05-6::2.48005::HTS002	2.48005	HA14-1	BCL inhibitor	targeted cancer	BCL2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.657077284487	-0.657077284487	-0.0362767696770346	0.0501858788395	10.1613354150827	6.87019768334891	2.18526055258902e-05	0.000706795916564841	0.475780099318682	0.765820930301249
ANKS1A	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.9557952393205	-0.9557952393205	-0.438904180312184	-0.343450980127	9.58739609560236	5.50790755728078	0.000121613963014904	0.00338511676350926	0.382058832995014	0.651723285021618
ANKS1A	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.535211645675	-1.535211645675	-3.05462851985043	-3.177325410155	-12.1443229931186	7.25514032894331	4.40514605416282e-06	0.000162364668726167	-1.81316686048931	-1.22566688786156
ANKS1A	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.95216316463	-1.95216316463	-3.10205745120386	-2.8622910827	-10.9188851262662	118.067504507482	1.30294411767468e-19	2.07011645513044e-17	-1.35844032695439	-0.941348246193329
ANKS1A	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.6726007906115	-0.6726007906115	-1.87726651219135	-1.673362994515	-13.0486546626953	187.823555883566	4.02981082680639e-28	1.37532695015698e-25	-1.38678515453217	-1.02254628862753
ANKS1A	BRD-K22064724-001-01-8::2.49999::MTS010::PROS004_PR500	2.49999	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.98341173128	-2.98341173128	-2.28112345914741	-2.41370110422	9.44907615282209	127.603880101801	2.1774361595869e-16	2.59559351862125e-14	0.55522220187391	0.849354342391265
ANKS1A	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-5.52586347153	-5.52586347153	-5.24748072777335	-5.41033082	3.75875935299022	118.611343815923	0.000266458731873729	0.00681501593601007	0.131726856117316	0.425038631395983
ANKS1A	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.6659369722555	-0.6659369722555	-0.257980699815613	-0.291499790384	6.31375787055902	10.2800402480651	7.74463063009831e-05	0.00224644598500249	0.264517456319024	0.551395088560749
ANKS1A	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.018685819523514	0.018685819523514	0.388405707029945	0.399212772621	11.9618947273132	7.11219716526276	5.73161134164686e-06	0.000206635917114185	0.296866832776839	0.442572942236023
ANKS1A	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.46929257747	-2.46929257747	-3.0903796562442	-2.9100349769	-4.96652101494651	6.43803984056092	0.00207200896439499	0.0413454621850678	-0.922108406103186	-0.32006575144522
ANKS1A	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.4370274278	0.4370274278	-0.117812715265127	0.0546590882103	-8.35849196162516	15.8983696507909	3.27499553785878e-07	1.43455245990953e-05	-0.695633475568632	-0.414046810561622
ANKS1A	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.07668047743535	0.07668047743535	-0.0729550517300551	0.0269217911151	-4.07518554236101	10.1919727679407	0.00214567606965694	0.0426131028848687	-0.231241494825932	-0.0680295635048784
ANKS1A	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.485781634985	-1.485781634985	-2.31757900616565	-2.045349051995	-6.66769833278325	8.80389170794406	0.000101778385785531	0.00287974384779237	-1.11496330475003	-0.548631437611279
ANKS1A	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.38846571671	-3.38846571671	-2.56739768960362	-2.525806741025	8.6382917233313	51.4384745146572	1.38200868528856e-11	1.01718591864427e-09	0.630287047899239	1.01184900631351
ANKS1A	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.3496087393665	0.3496087393665	0.209500373983771	0.239322143773	-7.14343903827349	190.645366866858	1.87202154785516e-11	1.35230369508004e-09	-0.178795852093281	-0.101420878672177
ANKS1A	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.5081069068575	-0.5081069068575	0.0321633769182979	0.056211415311	16.045762223703	169.365465254046	7.954980417868e-36	5.46468909609369e-33	0.47380219100167	0.606738376549925
ANKS1A	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.2016673585305	0.2016673585305	0.428517265830854	0.4313451016155	4.28495141607462	134.993462764192	3.45047207383319e-05	0.00107334721206472	0.122148718727725	0.331551095872982
ANKS1A	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.7409425113565	-0.7409425113565	-1.94045648319962	-1.836818850415	-14.2221808278802	185.6302472126	1.58060294592719e-31	7.20785210207723e-29	-1.3659042178565	-1.03312372582973
ANKS1A	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.06924123895445	-0.06924123895445	-1.03982298636822	-1.017015264785	-13.373324127298	149.559196698062	2.50581896254106e-27	7.76112243385063e-25	-1.11398839764806	-0.827175097179476
ANKS1A	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.338843400219	0.338843400219	-0.0238640700535921	-0.0227579244188	-10.8651348639444	9.95035574647809	7.71498162126361e-07	3.20951920788783e-05	-0.437139080412099	-0.288275860133085
ANKS1A	BRD-K36740062-001-06-6::2.5::HTS002	2.5	GSK1070916	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC, CYP2D6, CYP3A4	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.450906979565	-1.450906979565	-2.26752991021409	-1.977136981175	-7.30124818832172	39.920759612575	7.24596826192674e-09	3.91781314735241e-07	-1.04268818993866	-0.590557671359526
ANKS1A	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.95024569574	-3.95024569574	-2.98086826740419	-3.07991378512	10.2799180273637	190.106486960283	5.41246609305269e-20	8.96482569751074e-18	0.783372303954513	1.15538255271711
ANKS1A	BRD-K38332599-001-01-3::2.5::MTS010::PROS002_PR500	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.16550722196	-1.16550722196	-0.563470832938963	-0.5253626676245	7.30685067733589	84.6726638572861	1.39979267899855e-10	9.12735519005415e-09	0.43820706067644	0.765865717365634
ANKS1A	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.28585956032	0.28585956032	-0.359411600913371	-0.2780855887145	-14.4847651497753	179.750823299691	5.21152868615635e-32	2.47119852162656e-29	-0.733175996236546	-0.557366326230195
ANKS1A	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.69088529434	-1.69088529434	-1.00724240488666	-1.02230629729	10.2904770185837	80.4672953898094	2.4657147554267e-16	2.91813460969547e-14	0.551445769064629	0.815840009842046
ANKS1A	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.3049496810245	0.3049496810245	-0.706115433578876	-0.5759216002185	-14.8756334991922	32.4991300573572	4.63831871250366e-16	5.32187479299891e-14	-1.14942779129003	-0.872702437916726
ANKS1A	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.0947376850343	-0.0947376850343	-0.49763646088397	-0.332266676493	-7.66528285775662	192.197160446793	8.61065549888686e-13	7.21185299890943e-11	-0.506570222328716	-0.299227329370624
ANKS1A	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.589365107145	-0.589365107145	-1.3981239226857	-1.273586296615	-9.44533384314704	6.09037484596251	7.33187980447639e-05	0.0021371337775243	-1.01752485618975	-0.599992774891661
ANKS1A	BRD-K47337578-034-02-5::2.5::HTS002	2.5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	noncancer	HTR2A	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.916070796371	-0.916070796371	-0.116579008514171	-0.0894405664739	14.4960924202239	3.52109969149865	0.00028927625324304	0.00732950586136984	0.637790729910957	0.961192845802702
ANKS1A	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.1803234146565	0.1803234146565	0.0267936825574449	0.0405492292056	-6.13221384800707	194.115171167553	4.7584767694531e-09	2.6367103607035e-07	-0.202908404430614	-0.104151059767496
ANKS1A	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.698970549855	-1.698970549855	-0.769777998575964	-0.611397713918	10.306693747742	8.40118119075954	4.7062168957999e-06	0.000172394250736609	0.723011840322957	1.13537326223512
ANKS1A	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.5186105892545	-0.5186105892545	-1.25674728616691	-0.921278111753	-8.20384392474613	83.931632647252	2.38044621562908e-12	1.91300583783114e-10	-0.917062972675122	-0.559210421149701
ANKS1A	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.5296861135965	0.5296861135965	-0.116702546021729	0.03876057814515	-8.74425915728499	3.25688567923346	0.00227378387797071	0.0447797321309919	-0.871483218315004	-0.421294100921455
ANKS1A	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.576840537851	0.576840537851	0.197593111213281	0.2395368500345	-11.1182940804315	66.255089066941	8.55609129891326e-17	1.0527086636078e-14	-0.447345778959673	-0.311149074315765
ANKS1A	BRD-K51350053-048-16-5::2.5::HTS002	2.5	toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	ESR1	oncology	breast cancer	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.751613011015	-1.751613011015	-0.490331843746172	-0.414253606169	15.3060422937806	6.48148283323049	2.49048043579833e-06	9.5642748848633e-05	1.06322132965342	1.45934100488424
ANKS1A	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.258874687125	-2.258874687125	-3.67560082949245	-3.70951336465	-16.7603461745759	12.6926398799921	4.92260937555788e-10	3.0248220896042e-08	-1.599789301632	-1.2336629831029
ANKS1A	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.04448549930465	0.04448549930465	0.138859597688552	0.155273340434	3.83647066638646	155.481229302479	0.000181059087965702	0.00484230262847528	0.0457823441391593	0.142965852628645
ANKS1A	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.59915890857	-0.59915890857	-0.289641134132124	-0.3736278329815	4.36010457034524	63.4443907994528	4.86415592146594e-05	0.00147083757687905	0.1676777951796	0.451357753696153
ANKS1A	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.666350846465	-1.666350846465	-3.16671021247114	-3.19197499768	-15.4259734423787	190.981282354563	2.14233680388465e-35	1.39563800863159e-32	-1.69220487130092	-1.30851386071137
ANKS1A	BRD-K58435339-001-03-0::2.5::HTS002	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.46877980879	-3.46877980879	-4.69280729202672	-4.73299399791	-12.2909651100491	51.5787735328884	6.00954668740342e-17	7.50594482496788e-15	-1.42390343784037	-1.02415152863306
ANKS1A	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.2995598828105	0.2995598828105	-0.341232337187243	-0.3277516003215	-14.2370093076574	171.22011221667	7.50178023731523e-31	3.20288656670027e-28	-0.729636014711154	-0.551948425284331
ANKS1A	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.38423472216	0.38423472216	0.142698785826716	0.0968721731692	-6.25839429399473	4.70038567681893	0.00190675143174748	0.0384922414632199	-0.342677326473109	-0.140394546193458
ANKS1A	BRD-K67578145-001-09-7::2.38272::HTS002	2.38272	GDC-0879	RAF inhibitor	targeted cancer	BRAF	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.00198504312085	-0.00198504312085	0.591430638197294	0.662966427996	9.76168287878884	7.46228824519959	1.63814436883175e-05	0.000544090879323324	0.451455121519541	0.735376241116746
ANKS1A	BRD-K72420232-001-12-3::2.5::HTS002	2.5	WZ-4002	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.529747165835	-0.529747165835	-0.0676715062318375	0.037173334974	7.29227280191925	4.88246101392201	0.000839555163157708	0.0189891323938823	0.298003942333665	0.62614737687266
ANKS1A	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.750913100925	-1.750913100925	-2.53028808581848	-2.26266997363	-5.76292333808323	6.59684220037398	0.000852582347012626	0.0192453084542582	-1.10317045647935	-0.455579513307602
ANKS1A	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.465495121652	-0.465495121652	-1.3406153603501	-1.10972386317	-8.01727987091596	6.51871712302999	0.000131220442787145	0.00362147132141721	-1.13714283621747	-0.613097641178727
ANKS1A	BRD-K77245796-003-01-6::2.5::HTS002	2.5	gamma-aminobutyric-acid	benzodiazepine receptor agonist	noncancer	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.00253382359985	-0.00253382359985	0.511131589746618	0.500110131001	11.47310212968	3.58225462156097	0.000594673638932398	0.0139861523492529	0.383429438567088	0.643901388125849
ANKS1A	BRD-K78789465-001-01-6::2.5::HTS002	2.5	pentagastrin	CCK receptor agonist	noncancer	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.223041878602	-0.223041878602	0.150492728479463	0.184916881491	7.39173513222641	126.933526255326	1.71925232491106e-11	1.24910383574868e-09	0.273536259284973	0.473532954877953
ANKS1A	BRD-K86727142-001-12-4::2.5::HTS002	2.5	embelin	HCV inhibitor, XIAP inhibitor	targeted cancer	XIAP	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.9152665468305	-0.9152665468305	-0.161417717563078	-0.181229635182	13.9427705882325	4.67702776457786	5.4695750644787e-05	0.00163750321831912	0.611927299168258	0.895770359366586
ANKS1A	BRD-K88677950-001-03-9::2.5::HTS002	2.5	PD-198306	MAP kinase inhibitor, MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.67881619663	-1.67881619663	-0.654977262355428	-0.550135683891	16.7658926513564	5.63810155275146	5.01323129448276e-06	0.00018264165393765	0.872057886661947	1.1756199818872
ANKS1A	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.185202823185	-2.185202823185	-2.91753191473587	-2.87877770547	-8.42443356532819	131.645844063097	5.45519018844807e-14	5.14615078301006e-12	-0.904287878930582	-0.560370304171149
ANKS1A	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.286734548444	0.286734548444	-0.0115345859375225	0.0437990200838	-7.08046866884358	174.81784801143	3.36030285460507e-11	2.34978907185856e-09	-0.38140938665043	-0.215128882112615
ANKS1A	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.128512885065	-2.128512885065	-3.08020521738713	-3.084015642295	-8.09830098716096	7.03047359611393	8.23330918706328e-05	0.00237533574472215	-1.22933314879987	-0.674051515844394
ANKS1A	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.04801902618135	0.04801902618135	0.24906601191215	0.266502193274	6.96149629831239	191.659424539003	5.21540130379986e-11	3.56217892301504e-09	0.144083824146825	0.258010147314776
ANKS1A	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.2836739342455	0.2836739342455	0.0666654430613692	0.0390021562258	-7.97460064909665	6.20033253579262	0.000175352145570452	0.0047055277335632	-0.283076932921984	-0.150940049446278
ANKS1A	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.4505611844115	0.4505611844115	0.0905455723538333	0.162270559212	-9.17585418677561	4.94569654556566	0.000273057966201399	0.00696219852938135	-0.461206656958882	-0.258824567156451
ANKS1A	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.02910449940045	0.02910449940045	-0.0775590310212116	-0.07508781022425	-3.42895523188355	34.8604268576517	0.00157306032762405	0.0327332472776053	-0.169822557021834	-0.0435045038214896
ANKS1B	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	RVH421, SKOV3, MKN1, NCIH1299	SKIN, OVARY, STOMACH, LUNG	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.34177505285925	0.327527860673	0.149322139442932	0.161370874991	-5.11117387312741	15.02569807983	0.000127096974694199	0.0035199079324503	-0.27269721532896	-0.112208611503676
ANKS1B	BRD-A69815203-001-07-6::2.5::HTS002	2.5	cyclosporin-a	calcineurin inhibitor	noncancer	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	RVH421, SKOV3, MKN1	SKIN, OVARY, STOMACH	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.137158537218	0.138142958791	-0.075989535920334	-0.00309315861126	-4.68573535709844	51.7589186012512	2.06137602861804e-05	0.000670225520081426	-0.304437975792293	-0.121858170484375
ANKS1B	BRD-K02130563-001-11-4::0.15625::HTS002	0.15625	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	RVH421, SKOV3, MKN1	SKIN, OVARY, STOMACH	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-3.60070284550667	-3.66069913342	-3.01018270112865	-3.05581238871	3.87755119366725	33.4752672749156	0.000467710662202519	0.0112963667477128	0.280846705908956	0.900193582847082
ANKS1B	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	RVH421, SKOV3, MKN1	SKIN, OVARY, STOMACH	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.177214392369333	-0.19271863904	-0.505667408704761	-0.4446499038335	-5.48225159043546	12.3676369741044	0.000125848078760791	0.0034889267717917	-0.458561126553493	-0.198344906117362
ANKS1B	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	RVH421, SKOV3, MKN1	SKIN, OVARY, STOMACH	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.154356072344	-0.120357577278	-0.537111417197805	-0.476930130125	-6.23926289060577	9.17741255354752	0.000139468546986779	0.00382008360474496	-0.521122323741072	-0.244388365966539
ANKS1B	BRD-K33610132-001-02-9::2.5::HTS002	2.5	rociletinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	RVH421, SKOV3, MKN1	SKIN, OVARY, STOMACH	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.390184834725333	0.40947405904	0.194858159425298	0.2373061414675	-4.17973100353035	29.694036414481	0.000236208025190311	0.00612834158467668	-0.29080715491095	-0.0998461956891216
ANKS1B	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	RVH421, SKOV3, MKN1	SKIN, OVARY, STOMACH	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-2.98783426723333	-2.87527794397	-1.75447199998618	-1.62422248514	8.13312696317122	5.35952272268314	0.000326686259347172	0.00818162412708812	0.851277312723184	1.61544722177113
ANKS1B	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	RVH421, SKOV3, MKN1	SKIN, OVARY, STOMACH	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-3.09363778316667	-3.14815442306	-3.66978498379321	-3.73065713946	-5.67973170954432	8.45744172880754	0.000379702554573487	0.00938761896633764	-0.807882241057038	-0.344412160196047
ANKS1B	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	RVH421, SKOV3, MKN1, NCIH1299	SKIN, OVARY, STOMACH, LUNG	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.799690298863	-0.7854961981535	-2.10382859521358	-1.79709860457	-7.80004455701344	13.4874074455215	2.3322732256049e-06	9.01109723873597e-05	-1.66402143558408	-0.944255157117072
ANKS1B	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	RVH421, SKOV3, MKN1	SKIN, OVARY, STOMACH	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.658360368916333	0.688597210644	0.180338295882676	0.178883281648	-8.74137843612037	5.56755596230173	0.00018591280895333	0.00495480060061654	-0.614391585915497	-0.341652560151817
ANKS1B	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	RVH421, SKOV3, MKN1	SKIN, OVARY, STOMACH	malignant_melanoma, carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.281824854181	0.295278301963	-0.0947053753009438	0.0687690203107	-6.09133742847132	21.3094726453684	4.51625791996457e-06	0.000166244697019691	-0.504966001358857	-0.24809445760503
AP3D1	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.4787374273995	-0.4787374273995	-1.21977173361865	-1.12011346307	-8.5865179434625	6.83152638350555	6.65709714488311e-05	0.00195748247217129	-0.946130939615783	-0.535937672822526
AP3D1	BRD-A19585813-003-03-3::2.5::HTS002	2.5	methylphenidate	dopamine-norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD), narcolepsy	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.5767288466085	0.5767288466085	0.254393765063651	0.248593111525	-9.38502557937384	11.6287640557547	9.05118303378274e-07	3.72276148234048e-05	-0.397433707085832	-0.247236456003867
AP3D1	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.2101433607765	0.2101433607765	0.0740331268745689	0.128125201883	-4.6330116333998	164.762594362864	7.2854583549874e-06	0.000257215567733585	-0.194116804689836	-0.0781036631140265
AP3D1	BRD-A74765037-001-01-1::2.5::HTS002	2.5	estradiol-benzoate	contraceptive agent	noncancer	ESR1	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.265365671881	0.265365671881	0.0272597758855268	0.0102513278737	-7.80033893913122	26.682437077664	2.36752753793254e-08	1.20816621351796e-06	-0.300773064710633	-0.175438727280313
AP3D1	BRD-K00312224-001-09-5::2.5::HTS002	2.5	PPT	estrogen receptor agonist	noncancer	ESR1	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.8102960897045	-0.8102960897045	0.173163893566845	0.257314113773	19.4229959925512	11.7187203722093	2.8288052914537e-10	1.7853209932626e-08	0.872844017808226	1.09407594873446
AP3D1	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-1.04509104604	-1.04509104604	-1.90529951875911	-1.73380354334	-8.19877856558744	149.997836974448	1.00254505708136e-13	9.18267006577735e-12	-1.06751870712185	-0.652898238316373
AP3D1	BRD-K07359318-001-03-9::2.44929::HTS002	2.44929	benfotiamine	antioxidant	noncancer	AGER	rheumatology	lumbago	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.000161471722249999	0.000161471722249999	0.338414568324177	0.3600151541855	9.58363896444246	4.02747599609463	0.00064073577243113	0.0149140157872928	0.240521976675054	0.4359842165288
AP3D1	BRD-K10670311-001-15-5::0.625::HTS002	0.625	sulfasalazine	cyclooxygenase inhibitor	noncancer	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.4262874054595	0.4262874054595	0.275677538274381	0.3245071237905	-3.75757094396804	15.9512239942624	0.00172813136737434	0.0355016455322511	-0.235600416936914	-0.0656193174333244
AP3D1	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.4628629986395	0.4628629986395	0.182089080555341	0.22754908413	-7.92862914139362	175.680702954533	2.47105252266961e-13	2.17949883181586e-11	-0.350662917140918	-0.2108849190274
AP3D1	BRD-K11071038-001-01-7::2.5::HTS002	2.5	ICI-162846	histamine receptor antagonist	noncancer	HRH2	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.06192789648465	-0.06192789648465	0.0975853259017862	0.0637321133413	4.59148091308581	18.5325373324012	0.000211314163668485	0.00555374045185808	0.086674868983566	0.232351575789306
AP3D1	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-1.51113090173	-1.51113090173	-0.500415712011874	-0.370831351035	14.0492362234683	14.2574767091236	9.52478403999789e-10	5.68487173073992e-08	0.856678238035686	1.16475214140057
AP3D1	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.5181650645025	0.5181650645025	0.305896558057081	0.3131581681635	-5.78608173287251	8.95885617206799	0.000268687060470417	0.00686627268195589	-0.295316260566049	-0.12922075232479
AP3D1	BRD-K21396683-001-04-8::2.5::HTS002	2.5	marimastat	matrix metalloprotease inhibitor	targeted cancer	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.920520813077	-0.920520813077	-1.80387223216109	-1.72083973318	-10.2284175169266	14.5278557614352	5.0074496736271e-08	2.44418510840087e-06	-1.0679510892172	-0.698751748950975
AP3D1	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.6561168751755	0.6561168751755	0.0850860172717714	0.0863678330512	-23.2001012872935	191.765999079183	1.44464812980607e-57	6.73108671767837e-54	-0.6195784036	-0.522483312207458
AP3D1	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.2613891620155	-0.2613891620155	-0.979080428730322	-0.82417204092	-6.64887331830252	23.7915294527542	7.38890393272369e-07	3.08104356225046e-05	-0.940575513461872	-0.494807019967773
AP3D1	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.826125560798	0.826125560798	0.379581228983229	0.383188744526	-13.8856217080064	5.51770223917531	1.67583671117355e-05	0.00055540498912806	-0.52693172986125	-0.366156933768292
AP3D1	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.2291404495265	-0.2291404495265	-0.426519507232065	-0.326694667694	-5.03126255804219	190.848387263596	1.12093260017299e-06	4.5415569614835e-05	-0.274760163613473	-0.119997951797657
AP3D1	BRD-K27184429-300-01-3::2.5::HTS002	2.5	levocetirizine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.2233681222325	0.2233681222325	-0.359557616877013	-0.252619761318	-10.8298813762863	12.6780907707918	8.98827839584339e-08	4.25640459633831e-06	-0.699509902742616	-0.466341575476409
AP3D1	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.0990483040847	-0.0990483040847	-0.473762537506321	-0.387317230447	-7.04829847673028	34.130253198975	3.80079282942816e-08	1.88438613541177e-06	-0.482740860462909	-0.266687606380333
AP3D1	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.551218568511	0.551218568511	0.267992739641774	0.2845478404215	-7.77343722875041	3.80078381730917	0.00181543009836676	0.036944485145542	-0.386511645574758	-0.179940012163694
AP3D1	BRD-K32107296-001-16-9::2.5::HTS002	2.5	temozolomide	DNA alkylating agent	chemo	MGMT	oncology	glioblastoma, astrocytoma	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.01799954236571	0.01799954236571	0.227915961485348	0.232952381397	7.09566097257503	76.5909570766151	5.60334381046919e-10	3.41861393553672e-08	0.151002581162664	0.268830257076612
AP3D1	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-4.532307382025	-4.532307382025	-3.10515117055876	-3.10613635441	10.0262758771427	4.40482934203462	0.000338247130348293	0.00844648365378298	1.04587304668893	1.80843937624355
AP3D1	BRD-K33610132-001-02-9::2.5::HTS002	2.5	rociletinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.124692023727	-0.124692023727	0.20162655938223	0.245890456129	8.05634165826909	180.17544303262	1.04419498606645e-13	9.54783563006131e-12	0.246394261350641	0.406242904867819
AP3D1	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-1.066886697365	-1.066886697365	-0.685859472552908	-0.601202853428	7.30790868133701	44.7058096631617	3.7037245339249e-09	2.07479240886458e-07	0.275994763507092	0.486059686117092
AP3D1	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.580144860786	-0.580144860786	-0.0898818991257611	-0.0710979031402	11.8304980735937	68.0822603715276	3.57220602324748e-18	4.99756752452095e-16	0.407571337052505	0.572954586267973
AP3D1	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-1.74511922069	-1.74511922069	-2.59595365701641	-2.52528636523	-7.33323877790266	12.4374162635671	7.38176896650298e-06	0.00026030390931583	-1.10264728525734	-0.59902158739547
AP3D1	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.169203301253	0.169203301253	-0.240597616359141	-0.026104548309	-7.72515886073836	123.270160417316	3.33742041672289e-12	2.63755892513201e-10	-0.514803046856735	-0.304798788367546
AP3D1	BRD-K38305202-001-17-4::2.5::HTS002	2.5	domperidone	dopamine receptor antagonist	noncancer	DRD2, DRD3	infectious disease	fescue toxicosis	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.1501567487635	-0.1501567487635	-0.359795307947617	-0.225769257521	-3.58529343024508	190.780198968618	0.00042763171600311	0.0104258762437983	-0.324972808703999	-0.0943043096642344
AP3D1	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.148741188632	0.148741188632	-0.148331289672638	-0.07517274316945	-5.92952792816867	20.7119523093701	7.33514909935345e-06	0.00025883028832982	-0.401350529294745	-0.192794427314531
AP3D1	BRD-K47049295-300-01-5::2.5::HTS002	2.5	BAN-ORL-24	nociceptin/orphanin FQ receptor antagonist	noncancer	OPRL1	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.02545590814297	0.02545590814297	0.367463537025259	0.375415378686	10.8949618667152	6.54635678899967	1.95369796585355e-05	0.000638216935411409	0.266723277960176	0.417291979804401
AP3D1	BRD-K47557313-001-02-7::2.5::HTS002	2.5	LY2109761	TGF beta receptor inhibitor	targeted cancer	TGFBR1, TGFBR2	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.4316933554655	0.4316933554655	0.254844823399394	0.273399788387	-4.65722826333734	108.925747372219	9.10390224397615e-06	0.000315835264494847	-0.252110190524771	-0.10158687360744
AP3D1	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.5559257059435	0.5559257059435	0.343563804990659	0.381901791063	-6.58138299148757	165.990341935162	5.84220589603758e-10	3.55624580372576e-08	-0.276068654917059	-0.148655146988623
AP3D1	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.022507381794295	0.022507381794295	0.374794143865378	0.3764822376655	9.01604276110418	22.9419833249723	5.31426360753488e-09	2.92802263429137e-07	0.271446120539767	0.433127403602398
AP3D1	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.6291177893175	0.6291177893175	0.400128931736824	0.450986520291	-6.03992755074532	6.73926895444852	0.000602596655660803	0.0141321740465176	-0.319345630499822	-0.138632084661529
AP3D1	BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500	2.49998	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-1.00746988649	-1.00746988649	-0.187562863297762	-0.0644082695915	14.4250247941594	8.28819400488664	3.67588846858591e-07	1.59548298822104e-05	0.689624652717213	0.950189393667263
AP3D1	BRD-K56301217-001-07-4::2.5::HTS002	2.5	ABT-737	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.462727214366	0.462727214366	-0.140765090260113	-0.0916218688464	-13.5475891859517	3.53773375584949	0.000356151978022351	0.00885541731990169	-0.733813956362089	-0.473170652890136
AP3D1	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-6.15514973669	-6.15514973669	-4.63232939941126	-4.72849824175	11.0922316807893	3.15519250745236	0.00124328218104	0.0267568457254867	1.09782078194894	1.94781989260855
AP3D1	BRD-K60866521-001-07-1::2.5::MTS010::PROS003_PR500	2.5	idelalisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.1956462377735	0.1956462377735	-0.0136357757095107	0.000732567672741	-8.15335007702346	6.53945265872694	0.000116634663775353	0.00325582063718516	-0.270855093058309	-0.147708933907713
AP3D1	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.5904714039315	0.5904714039315	-0.259316451767335	-0.132231172134	-14.2953031140923	19.1159427241483	1.16632845351285e-11	8.6707600108552e-10	-0.974157135786327	-0.725418575611343
AP3D1	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.2862443562175	-0.2862443562175	-1.08625114902569	-0.4202572111255	-6.85775541774624	135.029393599163	2.2855167522123e-10	1.45356830856056e-08	-1.03071845352282	-0.56929513209355
AP3D1	BRD-K66956375-001-11-3::2.5::HTS002	2.5	oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	noncancer	CNR1, GPR119, GPR55, PPARA	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.1107583497435	0.1107583497435	0.333732616484728	0.335539254934	9.76657756717283	188.923531827669	1.69240689306447e-18	2.42792421006436e-16	0.177939136934574	0.268009396547882
AP3D1	BRD-K67537649-001-04-5::2.5::HTS002	2.5	PQ-401	IGF-1 inhibitor	targeted cancer	IGF1R	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.07440578771595	-0.07440578771595	0.17960347741518	0.20362806034	7.82191535010794	127.425472361748	1.72065865652142e-12	1.39957134418816e-10	0.189751045596108	0.318267484666152
AP3D1	BRD-K67868012-001-07-6::2.5::HTS002	2.5	PI-103	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.3228857571055	-0.3228857571055	-0.524865044551258	-0.5017718155375	-4.83788771819454	64.2420787127525	8.56753074725781e-06	0.000298776548928777	-0.285377405495178	-0.118581169396337
AP3D1	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-2.68848799287	-2.68848799287	-3.68163629978576	-3.50719189578	-8.73157548223944	132.997976317221	9.25184733325192e-15	9.37116818094778e-13	-1.21812593656135	-0.768170677270163
AP3D1	BRD-K69694239-001-02-2::2.5::MTS010::PROS002_PR500	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-2.945737958795	-2.945737958795	-2.52181411895487	-2.6020166043	6.56085518265411	5.97005495414652	0.000612874037742801	0.0143324254921306	0.265626367486223	0.582221312194044
AP3D1	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.694636136821	-0.694636136821	-1.19533507973363	-1.12346956245	-6.80646549957295	101.638424375851	7.10994910227063e-10	4.29985406642371e-08	-0.646615555191993	-0.354782330633262
AP3D1	BRD-K76908866-001-07-6::2.5::HTS002	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-1.424602945425	-1.424602945425	-0.687944823084246	-0.619490026625	8.30120019970735	4.4932616440706	0.000684871346915671	0.0158449687945908	0.500582271509689	0.97273397317182
AP3D1	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.74363606404	-0.74363606404	-0.958728262195888	-0.892479910689	-3.69177320007621	27.7862309645716	0.00096230399527719	0.021386318229341	-0.334479043214022	-0.0957053530977533
AP3D1	BRD-K81528515-001-13-8::2.5::HTS002	2.5	nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	targeted cancer	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.7225578014565	0.7225578014565	0.184649217249726	0.2214201178065	-10.1251278085665	73.5278654197417	1.38253126570679e-15	1.5172378066957e-13	-0.643775950687407	-0.432041217726142
AP3D1	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-0.08657866028985	-0.08657866028985	-0.16350350123342	-0.121855279851	-3.48516813868935	135.066303796606	0.000663696603679722	0.0153899631472543	-0.120576390143849	-0.0332732917432908
AP3D1	BRD-K89299012-001-06-0::2.5::HTS002	2.5	DCEBIO	potassium channel activator	noncancer	KCNN2, KCNN3, KCNN4	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-1.290795020855	-1.290795020855	-2.05089993456723	-1.8672769967	-8.34257797723532	135.86729431485	7.26330755364031e-14	6.76254320010501e-12	-0.94028505066972	-0.579924776754739
AP3D1	BRD-K91701654-001-03-1::2.66738::HTS002	2.66738	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.2395970422845	0.2395970422845	-0.0804074591572888	-0.00292791542841	-6.32799153238598	11.8623150198758	3.99041427443291e-05	0.00122704404206753	-0.430328373204964	-0.209680629678614
AP3D1	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	-2.254522774	-2.254522774	-1.82249466320579	-1.68862958657	5.18006073041948	99.2187335215159	1.16596804940398e-06	4.71421931825513e-05	0.266544698996601	0.597511522591816
AP3D1	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	PANC1, DETROIT562	PANCREAS, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma	0.25278833856	0.25278833856	0.0669922747617448	0.0390021562258	-8.09594769831278	36.3727694208538	1.17616019090128e-09	6.94832518069683e-08	-0.23232277711395	-0.13926935048256
ARFGEF2	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	-1.73368073713667	-1.78131124582	-2.10178663734212	-2.08990729669	-4.18975335145589	16.4102492627066	0.000659260485434144	0.0153053120215137	-0.553980122456113	-0.182231677954791
ARFGEF2	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	-0.0841186831128	-0.06690152321	-0.45046913864413	-0.338375716384	-4.66051965649552	78.1701748035232	1.27560798099124e-05	0.000430754345293636	-0.522840026661986	-0.209860884400675
ARFGEF2	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5255211731385	0.5255211731385	0.070449288097728	0.128125201883	-14.6105704142927	39.5310061827728	1.58892441605162e-17	2.09313202930502e-15	-0.518045101378343	-0.392098668703201
ARFGEF2	BRD-K00673382-001-18-9::0.15625::HTS002	0.15625	famotidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	heartburn	KYSE520, MCF7	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma	0.731917852682	0.731917852682	0.499686450464742	0.4883209569055	-5.35764296954867	7.75323894177432	0.000754160874515591	0.017261698640971	-0.332743491394918	-0.131719313039599
ARFGEF2	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	-2.00536647018667	-1.97571405907	-3.08979781383359	-3.13127399588	-6.96865109264484	4.98946323169911	0.000943940350302522	0.0210371000665477	-1.48470839227975	-0.6841542950141
ARFGEF2	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	-0.472796441788667	-0.578617415305	-1.26958403357091	-0.953793919557	-5.33134329987002	5.70692568648134	0.00207660187079774	0.0414255400564229	-1.16708795534059	-0.426487228223895
ARFGEF2	BRD-K11073688-001-01-6::2.5::HTS002	2.5	CPI-1189	tumor necrosis factor release inhibitor	noncancer	TNF	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	0.0976777746819667	0.065808136473	-0.265923339213006	-0.245576538446	-5.93978219775536	10.1870714483362	0.000132886997699485	0.00366133658952731	-0.499656891667142	-0.227545336122804
ARFGEF2	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	0.471358368881333	0.452607985962	0.166292346904865	0.158690789127	-8.34638272756284	6.45641539579908	0.000108581691576967	0.00305329380398841	-0.392991888744472	-0.217140155208465
ARFGEF2	BRD-K45662124-050-01-5::2.5::HTS002	2.5	3'-fluorobenzylspiperone	dopamine receptor ligand	noncancer	DRD2	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	0.725642627584667	0.726079680707	0.505400360883538	0.521961606456	-6.57595326969063	56.3564742496811	1.68894513843601e-08	8.79470171467086e-07	-0.287325575025838	-0.153158958376419
ARFGEF2	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.595547963555	-0.595547963555	-1.59731338818541	-1.48697544025	-10.3280361474235	12.6137457981484	1.62151855738851e-07	7.42762237415091e-06	-1.21196401179281	-0.791566837468005
ARFGEF2	BRD-K61443650-236-13-1::2.5::HTS002	2.5	thiomersal	other antibiotic	noncancer	OXCT1	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	0.163116038021067	0.194585488636	-0.174901328195052	-0.0429652749088	-5.39513525314043	18.3732841184211	3.71222765073061e-05	0.0011476100391655	-0.469453434258722	-0.206581298173516
ARFGEF2	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3439496201855	0.3439496201855	-0.341736766021049	-0.3277516003215	-10.1855339917334	3.15486743139023	0.00161828759747927	0.033537609986476	-0.894099099049735	-0.477273673363364
ARFGEF2	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	-2.50296591914333	-2.39021985371	-3.6897926920389	-3.54895693019	-7.0181705405353	6.1348983797679	0.000378548968820525	0.00936125786758212	-1.59842285908669	-0.775230686704431
ARFGEF2	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	-1.79642189505	-1.79002707394	-2.53370749327868	-2.26335819526	-6.80092053460442	177.677552629047	1.52634993177374e-10	9.8923814492632e-09	-0.951221840276916	-0.523349356180451
ARFGEF2	BRD-K78789465-001-01-6::2.5::HTS002	2.5	pentagastrin	CCK receptor agonist	noncancer	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	-0.235058118255	-0.22921148489	0.152975051667587	0.188126620199	7.48431887837212	112.017656278136	1.7538600815635e-11	1.27252226615241e-09	0.285306832992436	0.490759506852739
ARFGEF2	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	0.300700664932667	0.335435075823	-0.128323375561845	-0.1270249092555	-8.25743470188234	4.11078208505501	0.00104221688413774	0.0229151931227285	-0.571756984069601	-0.286291096919422
ARFGEF2	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	0.0672392310608667	0.0620920284115	0.311205804510993	0.3323056757265	6.25533689410452	6.33940087306154	0.000625352950091262	0.0145971762622642	0.149758647009783	0.33817449989047
ARFGEF2	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	KYSE520, MCF7, BT474	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma, carcinoma (ductal_carcinoma)	-1.66960090872333	-1.6554657127	-1.95857701116646	-1.89912472252	-4.4841760366276	118.364658321197	1.70410031118148e-05	0.000563987207528127	-0.416587750378319	-0.161364454507932
ARFGEF2	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.309252990853	0.309252990853	-0.0117904773285339	0.0437990200838	-7.04937099632954	35.5785186522915	3.01626148107094e-08	1.5161170426277e-06	-0.413445224847016	-0.228641711516052
ARHGAP42	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.0752077261185	0.0752077261185	-0.497227591035457	-0.379151386241	-7.793622792524	6.04728677906408	0.000226239954262224	0.00589684824967388	-0.751818910416748	-0.393051723891166
ARHGAP42	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.00745418520452	0.00745418520452	0.254948984937039	0.256070233499	8.8162828115695	55.0378898924137	4.13839470656278e-12	3.24187865154566e-10	0.191237191161505	0.303752408303532
ARHGAP42	BRD-A43671941-003-11-9::2.5::HTS002	2.5	oxprenolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	angina pectoris, hypertension, cardiac arrythmia	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.6343308082615	-0.6343308082615	-0.404572780433804	-0.38193178245	6.02524684933142	35.3179974385783	6.91128135298287e-07	2.89540269957675e-05	0.152369743981514	0.307146311673878
ARHGAP42	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.489651527988	0.489651527988	0.20706371683214	0.236646785158	-6.63075385142719	117.917015288993	1.05863172990044e-09	6.2782368577153e-08	-0.366983174439944	-0.198192447871775
ARHGAP42	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.4690349861715	0.4690349861715	0.259971620465672	0.303778240807	-5.39249484750433	109.507095896358	4.04233724249968e-07	1.74851684933948e-05	-0.285898906809554	-0.132227824602101
ARHGAP42	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.1733880518125	-0.1733880518125	0.069625726572828	0.07956967035945	8.67750037747729	147.894240452473	6.76245419235099e-15	6.93820030920247e-13	0.187672055130705	0.298355501639951
ARHGAP42	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.67434906738	-1.67434906738	-0.345148585876216	-0.221401224326	14.7745326073832	3.24567352978033	0.000435310054740722	0.0105913916134095	1.0547676757213	1.60363328728627
ARHGAP42	BRD-K03601870-001-01-2::2.5::HTS002	2.5	ixabepilone	microtubule stabilizing agent	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.970670336515	-2.970670336515	-3.63222988869113	-3.58404887743	-7.07290095402709	182.315799661734	3.14053108023787e-11	2.20763163626206e-09	-0.846108649356641	-0.477010454995613
ARHGAP42	BRD-K05638300-001-01-2::2.5::HTS002	2.5	sevoflurane	membrane integrity inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.053378329646	0.053378329646	-0.582060502884384	-0.439418069219	-10.734958716651	68.8888825824582	2.35870613639896e-16	2.79767087719011e-14	-0.753529856294139	-0.517347808766629
ARHGAP42	BRD-K06234293-001-04-2::2.5::HTS002	2.5	LY364947	TGF beta receptor inhibitor, p38 MAPK inhibitor	targeted cancer	TGFBR1	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	1.114396175855	1.114396175855	0.782400621773071	0.806042544038	-7.42553429989703	4.24166624952222	0.00138980447301422	0.0294139827092589	-0.453390264529803	-0.210600843634055
ARHGAP42	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.314983120249	0.314983120249	0.199921772250869	0.204355413473	-4.01474431818416	82.460029809368	0.000130506656308977	0.00360548609693822	-0.17206984961835	-0.0580528463779126
ARHGAP42	BRD-K13049116-001-05-7::2.5::HTS002	2.5	BMS-754807	IGF-1 inhibitor	targeted cancer	AKT1, IGF1R	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.9775231118865	-0.9775231118865	-1.54407093082335	-1.37567614357	-6.41408232799512	43.2661734751878	8.89809833546502e-08	4.2164946233515e-06	-0.744648016793683	-0.388447621080017
ARHGAP42	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.03490233929625	-0.03490233929625	-0.330656463623417	-0.31281935927	-7.70568918481294	16.0549039854288	8.79001314787668e-07	3.61881430651414e-05	-0.377096170363782	-0.214412078290552
ARHGAP42	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.356182709435	-2.356182709435	-3.69242601929719	-3.60112771075	-11.6827189243851	8.80420828759779	1.17094792734989e-06	4.73256832587165e-05	-1.59586356907334	-1.07662305065104
ARHGAP42	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.4699621159735	0.4699621159735	0.306470402682426	0.3131581681635	-4.9702087809065	31.6889066499361	2.21825551733045e-05	0.000716774441088372	-0.230521088304305	-0.0964623382778427
ARHGAP42	BRD-K18779551-003-07-8::2.5::HTS002	2.5	bifemelane	acetylcholine release enhancer	noncancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.470819958349	-0.470819958349	0.0243720591492044	0.0610865008582	12.1671321404535	6.91490430441429	6.38349667146071e-06	0.000228142147423295	0.398713200374977	0.591670834621432
ARHGAP42	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.151159801765	-1.151159801765	-0.938613350227203	-0.89400890482	4.07884283833309	75.3404299440652	0.00011130328573904	0.0031220418700645	0.108746696635232	0.316346206440363
ARHGAP42	BRD-K24844714-001-24-5::2.5::HTS002	2.5	5-fluorouracil	thymidylate synthase inhibitor	chemo	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.309639036455	-1.309639036455	-1.04655086107455	-0.9725872071865	4.51736292145887	19.007432615018	0.000235505762269164	0.00611234130799076	0.141195089599197	0.384981261161705
ARHGAP42	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.0811670194305	-0.0811670194305	-0.24212266947825	-0.125640191534	-4.1510631797853	182.249537986398	5.07490124641905e-05	0.00152751706096692	-0.237460416691135	-0.0844508834043645
ARHGAP42	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.584761899045	-1.584761899045	-1.96584743593138	-1.89093805071	-5.05757449724343	91.9237454525901	2.1595142161624e-06	8.37579664198102e-05	-0.53073773407494	-0.231433339697819
ARHGAP42	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.5306252827505	-0.5306252827505	-0.178554681520235	-0.04268072142135	7.10585396464755	15.1456148430648	3.39899807806797e-06	0.000127539191014396	0.246552977511288	0.457588224949243
ARHGAP42	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.148001128659	0.148001128659	0.765102484836788	0.7663988354595	20.7384324444008	195.999230822384	2.55317163059827e-51	7.20024634755916e-48	0.558417506499453	0.675785205856124
ARHGAP42	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.2752881073165	0.2752881073165	-0.279440397247594	-0.153671266635	-10.6139192956488	189.277217175785	6.01673587021896e-21	1.08457609951906e-18	-0.657823728945789	-0.451633280182399
ARHGAP42	BRD-K36529613-001-02-6::2.5::HTS002	2.5	PU-H71	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-3.799630413465	-3.799630413465	-3.4765325163542	-3.273820150365	3.21835337992791	185.484607564166	0.00152188875436125	0.031832233320337	0.125040353068093	0.521155441153503
ARHGAP42	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.541065937799	0.541065937799	0.2530785801731	0.2832758926905	-7.1731060982714	6.98360532517784	0.000183695295709866	0.00490254962802911	-0.382967983004022	-0.193006732247779
ARHGAP42	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.8954348921005	-0.8954348921005	-0.0998401764259172	-0.110521384274	16.2086649479359	157.750768748504	2.09111594299222e-35	1.37060180105682e-32	0.69864706572834	0.892542365620825
ARHGAP42	BRD-K43236057-001-07-1::2.59978::HTS002	2.59978	polydatin	ICAM1 expression inhibitor	noncancer	ICAM1	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.844714399504	-0.844714399504	-1.31845657184898	-1.21412289307	-6.19513295900248	99.9191845400627	1.30657170218089e-08	6.90594836884657e-07	-0.625458090691855	-0.322026253998105
ARHGAP42	BRD-K44084986-300-08-4::2.5::HTS002	2.5	Y-27632	rho associated kinase inhibitor	targeted cancer	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.18396648576	-1.18396648576	-0.933808354771045	-0.842583812381	4.15162640102544	147.108653622889	5.5685287597261e-05	0.00166442927903466	0.131080026945987	0.369236235031924
ARHGAP42	BRD-K44827188-001-06-0::2.5::HTS002	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.363239595317	0.363239595317	-0.11716669817045	-0.06245449085225	-9.26707504665763	78.9456453491851	2.94764851032346e-14	2.86126158319346e-12	-0.583592578258058	-0.377220008716842
ARHGAP42	BRD-K47557313-001-02-7::2.5::HTS002	2.5	LY2109761	TGF beta receptor inhibitor	targeted cancer	TGFBR1, TGFBR2	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.1234250835215	-0.1234250835215	0.260627307138842	0.276216738452	10.0295440841146	82.8575732540979	5.85152818302142e-16	6.6568587257898e-14	0.307888990717884	0.460215790602801
ARHGAP42	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.4128169122175	0.4128169122175	-0.0723579054442113	0.318163539168	-5.30413256583102	34.2583883733812	6.7755346285308e-06	0.000240748269462596	-0.671014819981997	-0.299334815341425
ARHGAP42	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.1282109984441	0.1282109984441	-0.26920091866136	-0.2054130743915	-7.23983463104307	13.4499644537452	5.39939850968724e-06	0.000195580139121642	-0.515597712465845	-0.279226121745075
ARHGAP42	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.5150914897045	0.5150914897045	-0.116547284065431	0.03876057814515	-11.9840692414898	53.5394915543249	8.83312911565201e-17	1.08430454194077e-14	-0.737329835456341	-0.525947712083522
ARHGAP42	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.310279251917	-0.310279251917	-0.0993317381425096	-0.09755826700195	4.55749141442801	86.8845773485355	1.68210140710287e-05	0.000557222739540882	0.118947586406457	0.302947441142524
ARHGAP42	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.4144235752985	-0.4144235752985	-0.212449745968576	-0.1324820733985	5.89494305307956	150.305520754356	2.3764982006675e-08	1.21245532694802e-06	0.134276047380251	0.269671611279597
ARHGAP42	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-5.061813758215	-5.061813758215	-5.93228820632576	-5.96310429975	-8.98859087420637	3.68754369658225	0.00122499185758938	0.0264178963696087	-1.14857920752377	-0.592369688697747
ARHGAP42	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.8624586422175	-0.8624586422175	-0.286898428573296	-0.3736278329815	8.0163261726748	47.8429209113023	2.12839407297325e-10	1.35969172359548e-08	0.4311874037011	0.719933023587309
ARHGAP42	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.02076845766	-1.02076845766	-0.611318071333758	-0.573831164789	4.79028861219733	10.619254686055	0.000620352166070462	0.0144914942127211	0.220494721713909	0.598406050938575
ARHGAP42	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.9912932108	-1.9912932108	-0.567465325250878	-0.45596991553	18.3910268393057	68.9471896208641	2.70281740114525e-28	9.43472558257426e-26	1.26937768809476	1.57827808300348
ARHGAP42	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.74314797869	-1.74314797869	-0.11754739475733	0.0301334081165	17.3626966766229	2.96015749986213	0.000450124694004907	0.0109196123985713	1.3253590534417	1.92584211442364
ARHGAP42	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.05746955436	-2.05746955436	-1.17443514664133	-1.09615123005	15.0279544313854	72.5033409960887	5.71984693767402e-24	1.34274816462731e-21	0.765913467098452	1.00015534833889
ARHGAP42	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-3.383381609275	-3.383381609275	-4.66135314943654	-4.74198978259	-13.7390327074784	152.2318841926	1.8937472010737e-28	6.753493242245e-26	-1.46174355706184	-1.09419952326125
ARHGAP42	BRD-K66911501-003-01-2::2.5::HTS002	2.5	MK-3207	calcitonin antagonist	noncancer	CALCA	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.2912924204005	0.2912924204005	0.196361286161402	0.213447590059	-3.32995638572246	190.040304786874	0.00104336770986268	0.0229334384050003	-0.151164328129717	-0.0386979403484791
ARHGAP42	BRD-K68870568-066-01-5::2.5::HTS002	2.5	flumatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, PDGFRB	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.263685225596	-0.263685225596	0.163500177407028	0.184523838067	12.3751089433591	181.795249698189	6.54745524197721e-26	1.79451347130145e-23	0.359074562568489	0.495296243437567
ARHGAP42	BRD-K69172251-001-08-9::2.5::HTS002	2.5	cisplatin	DNA alkylating agent, DNA synthesis inhibitor	chemo	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.09524708859785	0.09524708859785	0.38430089952092	0.3712286324115	8.19703148282378	4.09248831325804	0.00109355183651047	0.0238894986818318	0.192013864689889	0.386093757156251
ARHGAP42	BRD-K73293050-001-03-1::2.5::HTS002	2.5	WZ-3146	EGFR inhibitor	targeted cancer	EGFR	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.006260228635	-2.006260228635	-2.5794080209099	-2.4237476511	-5.56436737564259	52.4921162105199	9.07282207453583e-07	3.73022996818183e-05	-0.779792773817487	-0.366502810732307
ARHGAP42	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.40294739295	0.40294739295	0.239560696903542	0.2560401890915	-3.86852611501158	11.8254527489209	0.00229333625361633	0.0451191909217306	-0.25555944254912	-0.0712139495437966
ARHGAP42	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.322089984241	-0.322089984241	-1.06344220268589	-0.7851415156885	-7.20484885926301	25.5977883320704	1.3034556076476e-07	6.05742274352778e-06	-0.953020436386576	-0.529684000503212
ARHGAP42	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.407269727086	-0.407269727086	-0.118457253505525	-0.0981289252682	7.3603257461541	4.5560264111613	0.00107611788369793	0.0235518502905233	0.184915826871098	0.392709120289852
ARHGAP42	BRD-K82967180-001-01-6::2.5::MTS006	2.5	LY3023414	PI3K inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-3.60992343736	-3.60992343736	-3.37456575074168	-3.47125881494	3.7245530147611	124.844950735776	0.000294951581029881	0.00745920588120699	0.11029362545458	0.360421747782069
ARHGAP42	BRD-K88677950-001-03-9::2.5::HTS002	2.5	PD-198306	MAP kinase inhibitor, MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.024291573715	-2.024291573715	-0.65141566052981	-0.550135683891	17.4300370923641	2.30675753674931	0.00168659627716736	0.0347650022589925	1.07370445177033	1.67204737460005
ARHGAP42	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.1689935570675	-0.1689935570675	0.171039773183762	0.182655209923	11.3757464119905	3.28334433299012	0.000948776298586833	0.0211338885158821	0.249386204343968	0.430680456158555
ARHGAP42	BRD-K92441787-001-04-1::2.5::HTS002	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.492747641625	0.492747641625	0.152093201834503	0.1701725882685	-9.72149706360896	7.43991923359244	1.72035041224519e-05	0.000568575148043328	-0.422531141256593	-0.258777738324401
ARHGAP42	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.306287777753	0.306287777753	0.096508557553847	0.163411081458	-5.95351327884622	134.451786012658	2.16044268249319e-08	1.1077644011868e-06	-0.279468162351383	-0.140090278046922
ARHGAP42	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.3526444212305	0.3526444212305	-0.247363274428713	-0.195507988981	-13.85281216293	180.859451162793	3.24900333376166e-30	1.32639168670819e-27	-0.685471613622279	-0.514543777696147
ARHGAP42	BRD-K99616396-001-05-1::2.5::MTS006	2.5	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.201455774484	-0.201455774484	-0.0147818271618703	-0.0150428280254	6.06916783283424	20.1212878594716	6.06638888473755e-06	0.000217832315682229	0.122539188998094	0.250808705646165
ARHGAP42	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	RVH421, ES2	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.1861697129845	-0.1861697129845	0.0973193053048546	0.1722526996835	6.88101538966505	4.01683230866987	0.00230169935530565	0.0452667246014411	0.169291826724325	0.397686209854385
ARL15	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.1860382967605	-0.1860382967605	0.176825070439992	0.161263687573	14.5458536214512	187.993995471788	1.31987198390126e-32	6.59409889131872e-30	0.313652974077646	0.412073760323339
ARL15	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.46224127567	-0.46224127567	0.000803251892680741	0.008505826587825	10.0308800063214	2.87947881175337	0.00250709102269637	0.0486811298970366	0.312596198095259	0.613492857030102
ARL15	BRD-A45498368-001-07-1::2.5::HTS002	2.5	WYE-125132	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-2.959398336435	-2.959398336435	-2.33541779627858	-2.38754178221	8.0894548794741	13.903624870806	1.26053225679674e-06	5.07073232107712e-05	0.458434653202204	0.789526427110637
ARL15	BRD-A57382968-001-29-0::2.5::HTS002	2.5	piroxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.1546893233915	-0.1546893233915	0.0217360972344636	0.0121600555155	6.33717176735575	17.2688091609239	6.90947983200421e-06	0.000245223034097306	0.117758206070983	0.235092635180944
ARL15	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.0541698482058	-0.0541698482058	0.0770366860675496	0.1349064957195	4.23975325671542	52.1449864962873	9.16706599522091e-05	0.0026165509224793	0.0691114704411336	0.193301598105566
ARL15	BRD-A74765037-001-01-1::2.5::HTS002	2.5	estradiol-benzoate	contraceptive agent	noncancer	ESR1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.1006206977288	-0.1006206977288	0.0311326475216094	0.0157796912763	4.75312330984375	188.764207469762	3.96161725126726e-06	0.000147003023519193	0.0770739112233068	0.186432779277512
ARL15	BRD-A94756469-001-04-7::2.5::HTS002	2.5	digoxin	ATPase inhibitor	noncancer	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-6.16790246981	-6.16790246981	-5.6656180775567	-5.6162004602	5.45592800268794	12.8030437536986	0.000116231008965002	0.00324709018775547	0.303084770319027	0.701484014187565
ARL15	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.170173508398	-0.170173508398	0.069591529302461	0.07956967035945	6.7392801400191	5.9663765794725	0.00053233538374494	0.0126631421157236	0.152591589512477	0.326938485888445
ARL15	BRD-K01773560-001-02-4::2.59308::HTS002	2.59308	UNC2250	MER tyrosine kinase inhibitor	targeted cancer	MERTK	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.6537258115425	-0.6537258115425	-0.123573197074012	-0.110029885293	9.57283288033997	6.61004025948317	4.10317981940072e-05	0.00125830652097916	0.397614930684931	0.662690298252046
ARL15	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.189853166635	-0.189853166635	-1.1439485091498	-1.07388474495	-12.0292227925084	13.6527912577204	1.19479075723651e-08	6.33543563106737e-07	-1.12461542563957	-0.783575259390034
ARL15	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-2.079978256335	-2.079978256335	-1.01567273259459	-0.9876270936225	15.7219371043084	5.73193126734564	6.22391681869157e-06	0.000222959362833586	0.896764328503501	1.23184671897733
ARL15	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-5.633339300335	-5.633339300335	-3.00205782423262	-2.91986435367	26.8499132158667	85.204510540379	2.4095148494875e-43	3.33179940758585e-40	2.43643871443438	2.82612423777038
ARL15	BRD-K08303368-001-10-0::2.5::HTS002	2.5	chlorpyrifos	acetylcholinesterase inhibitor	noncancer	ACHE	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.05655413144145	0.05655413144145	0.293249862354541	0.280025726935	9.66362609340267	169.261336253872	7.21621132860554e-18	9.81995782761078e-16	0.188343700204672	0.285047761621509
ARL15	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.0624663536772	-0.0624663536772	0.33994153259703	0.348412196747	13.3745986393264	55.8497092834367	4.68507927917129e-19	7.07645071758635e-17	0.342131854240536	0.462683918307924
ARL15	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-3.15030802403	-3.15030802403	-4.28550311352555	-4.413620661915	-7.6856157799855	16.6317672704647	7.23232998132661e-07	3.01927941676617e-05	-1.44734939742375	-0.82304078156735
ARL15	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-3.16844062734	-3.16844062734	-1.9189403886237	-2.01595157397	13.1619087470601	8.19287824937613	8.4962008635989e-07	3.50660934892026e-05	1.03147806101855	1.46752241641406
ARL15	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.626045813278	0.626045813278	-0.0605097379243621	0.1891566141585	-10.2470960868745	119.442184697382	4.59922691211611e-18	6.36376826886335e-16	-0.819217220328733	-0.553893882075991
ARL15	BRD-K17075857-001-18-4::2.5::HTS002	2.5	chloroxine	opioid receptor antagonist	noncancer	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.12956982377285	-0.12956982377285	-0.680111856318617	-0.656068942946	-8.7903477257824	10.6500301193711	3.31017647879203e-06	0.000124599019059188	-0.688945059313323	-0.412139005778211
ARL15	BRD-K17979676-001-01-2::2.5::HTS002	2.5	eprobemide	monoamine oxidase inhibitor	noncancer	MAOA	neurology/psychiatry	depression	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.3854025012595	0.3854025012595	-0.0500644804353822	-0.01607222471295	-8.31775096448756	24.7153523660311	1.25315509582216e-08	6.63178959339425e-07	-0.543354928774824	-0.32757903461494
ARL15	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.1868134311445	0.1868134311445	-0.199409061669428	-0.14719250083	-5.967167527722	5.81388989509287	0.00111254317580149	0.0242722176635135	-0.545834956609646	-0.226610029018209
ARL15	BRD-K25596805-001-01-8::2.5::HTS002	2.5	JNJ-16259685	glutamate receptor antagonist	noncancer	GRM1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.032274698906575	0.032274698906575	0.395957739403469	0.392933353126	8.71949945044992	5.54265715551752	0.000192896581422015	0.00511738227498442	0.259547889678023	0.467818191315764
ARL15	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.457077936662	-0.457077936662	-1.67690935595981	-1.54523819361	-10.4810885645921	3.32489043498354	0.00116421702184625	0.0252735207206812	-1.57056118439262	-0.869101654203003
ARL15	BRD-K29968218-001-03-2::2.5::HTS002	2.5	KX2-391	src inhibitor, tubulin polymerization inhibitor	targeted cancer	SRC	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-3.608013226805	-3.608013226805	-2.73842594301838	-2.69887921665	8.04961399050844	141.893989882014	3.0274653071205e-13	2.64846372167277e-11	0.656034094552282	1.08314047302096
ARL15	BRD-K31627533-001-09-5::2.5::HTS002	2.5	rimexolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	ophthalmology	anterior uveitis	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.08971475234775	-0.08971475234775	0.264728204302781	0.264424524013	11.5309612697877	178.753982090686	2.35543691065766e-23	5.21527311595399e-21	0.293786195462808	0.415099717838255
ARL15	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.586105519364	0.586105519364	0.0368231664839823	0.143970790547	-13.1248037851631	191.986251692605	1.66626868020576e-28	5.97206856120099e-26	-0.631828583312427	-0.466736122447608
ARL15	BRD-K41599323-001-02-3::2.5::HTS002	2.5	lonafarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, HRAS, KRAS, NRAS	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.832031427288	-0.832031427288	-1.29027625402836	-1.19482949475	-6.03228279623925	190.134889579276	8.2760342582642e-09	4.46013112029044e-07	-0.608088054469655	-0.308401599011058
ARL15	BRD-K42673188-001-01-1::2.5::MTS006	2.5	verubulin	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-4.002833066635	-4.002833066635	-2.4478319459616	-2.27910783508	12.7374299690343	7.32142393556412	2.92718847578633e-06	0.000111257559642988	1.26887425291613	1.84112798843067
ARL15	BRD-K42756753-001-01-9::2.5::HTS002	2.5	epiandrosterone	steroid	noncancer	G6PD	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.0579222407495	-0.0579222407495	0.22533908770295	0.2373509608245	9.81331489463017	109.308688069895	1.11029991446438e-16	1.3459811672355e-14	0.226053651314991	0.340469005589909
ARL15	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.222367921315	-0.222367921315	-0.6341469430647	-0.4291875223905	-5.18953163818648	7.5796930300148	0.000987926220724057	0.0219035108059963	-0.596537118342017	-0.227020925157384
ARL15	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.0974489679596	0.0974489679596	-0.111452853151766	-0.11764531931	-3.72847190781859	16.2410608873394	0.00178843183440348	0.0364712470633553	-0.327534460457786	-0.0902691817649467
ARL15	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.639378067853	0.639378067853	0.36555648991139	0.394038132066	-6.54200035448573	186.637964531306	5.67382989151459e-10	3.45866406944946e-08	-0.356393134005261	-0.191250021877959
ARL15	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.281330273935	0.281330273935	-0.127896013197763	-0.075355311638	-8.7822809405293	6.01892809995885	0.000118743052117375	0.00330993362170177	-0.523157717140216	-0.295294857125309
ARL15	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.1707693140525	0.1707693140525	-0.266834259897744	-0.234942866008	-10.5811618984667	15.6161698147924	1.58728464560498e-08	8.29556524769248e-07	-0.525451650765032	-0.349755497135456
ARL15	BRD-K47337578-034-02-5::2.5::HTS002	2.5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	noncancer	HTR2A	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.4250305399825	-0.4250305399825	-0.121641279198588	-0.0894405664739	7.74760710175577	135.080750231412	1.99647903796416e-12	1.6122959899315e-10	0.225945045241049	0.380833476326775
ARL15	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.5587174500905	0.5587174500905	-0.371793723233947	-0.243490121847	-9.96852855384665	3.14812150668054	0.00174545100781013	0.0357648918788658	-1.21982352693996	-0.641198819708932
ARL15	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.01276186709725	-0.01276186709725	-0.955831760046295	-0.580280097075	-8.08050170900303	4.15482274912019	0.00108352805929724	0.0236922551949723	-1.26239999855086	-0.623739787347231
ARL15	BRD-K51143828-003-03-1::2.5::HTS002	2.5	lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.235077976325	0.235077976325	-0.0227086542284447	0.03172783000245	-8.32498880793736	22.5926386572237	2.46908831326539e-08	1.25700054416593e-06	-0.321907416924912	-0.193665844181978
ARL15	BRD-K52172416-001-11-4::2.5::HTS002	2.5	anastrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.128028809935	0.128028809935	0.30626462222478	0.301007029734	6.81351464748523	162.003909357307	1.77722589589303e-10	1.14490847322169e-08	0.126578917656196	0.229892706923365
ARL15	BRD-K55187425-236-05-2::2.5::MTS010::PROS004_PR500	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.856288696785	-1.856288696785	-0.78971817752611	-0.7051188233505	11.847037179239	36.7921351953017	4.04693908241613e-14	3.86531375488042e-12	0.88412073727393	1.24902030124385
ARL15	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.267480638189	-0.267480638189	-0.708217703202251	-0.5410189846345	-6.32503126131525	159.10615175245	2.45150683394958e-09	1.39778932751684e-07	-0.578356871915376	-0.303117258111127
ARL15	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-2.631726819095	-2.631726819095	-2.00151293509662	-2.19151625043	6.40248641531935	16.3046468111115	8.00113988017005e-06	0.000280805028553621	0.421862353511121	0.838565414485634
ARL15	BRD-K59632282-052-03-1::2.5::HTS002	2.5	quinidine	sodium channel blocker	noncancer	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.310435886753	0.310435886753	0.441531952034051	0.447983088223	5.23288109686313	188.934507049397	4.41259397718576e-07	1.89985306254771e-05	0.0816777761769863	0.180514354385115
ARL15	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.916281784533	-0.916281784533	-0.684026318913516	-0.630554296997	3.76393694930423	14.4900821404049	0.0019824293969734	0.0398062685238816	0.100329121240596	0.364181809998373
ARL15	BRD-K66956375-001-11-3::2.5::HTS002	2.5	oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	noncancer	CNR1, GPR119, GPR55, PPARA	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.0828296474555	0.0828296474555	0.334028158307881	0.335539254934	10.7564060797384	138.117739179808	5.59248426640111e-20	9.24870031121514e-18	0.205022124758774	0.297374896945989
ARL15	BRD-K69116396-001-04-1::2.5::HTS002	2.5	sertindole	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.3283399805885	-0.3283399805885	0.0186469067343944	0.0375517717561	9.64415842374637	3.87761533033903	0.000751443852613417	0.0172105374531717	0.245837469356142	0.448136305289647
ARL15	BRD-K69280563-001-01-8::2.5::HTS002	2.5	vinorelbine	tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-5.37039513043	-5.37039513043	-3.34358427384809	-3.520745955955	16.48382590324	5.05034899926007	1.38363089606393e-05	0.000464669737264943	1.71168382913012	2.3419378840337
ARL15	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.632329772235	-1.632329772235	-1.02290984459074	-0.654329018583	5.22421523594888	10.5626173712188	0.000323983940909934	0.00812248848652301	0.351365484882286	0.867474370406225
ARL15	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.0626449640511	0.0626449640511	-0.532999425374713	-0.376499820922	-11.4755145231031	190.457187488276	1.64534859939034e-23	3.69262743412286e-21	-0.698028231560879	-0.493260547290746
ARL15	BRD-K72414522-001-06-7::2.5::HTS002	2.5	AZD5438	CDK inhibitor	targeted cancer	KCNH2	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.4654107166	-1.4654107166	-2.42742254741535	-2.22027282363	-9.41442858119128	134.645984654764	1.75739411601587e-16	2.10778132899589e-14	-1.16410679506559	-0.759916866565097
ARL15	BRD-K73197500-001-02-2::2.5::HTS002	2.5	SNX-5422	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-3.902465194145	-3.902465194145	-3.61253422602012	-3.686768984175	3.26162181744404	163.024838303337	0.00134911725087385	0.0286973949248254	0.11440351346393	0.465458422785829
ARL15	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.410441032917	0.410441032917	0.239481816482837	0.2560401890915	-4.44407791481974	42.7269793934677	6.16298735064201e-05	0.00182597030118296	-0.248553679437288	-0.0933647534310392
ARL15	BRD-K76210423-001-01-6::2.5::MTS010::PROS001_PR500	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.3186693571945	-0.3186693571945	0.110521655601157	0.094360121778	16.9738865831825	7.23460620711786	4.30826787947924e-07	1.85680021383653e-05	0.369791426581044	0.488590599010269
ARL15	BRD-K76973696-001-12-6::2.01421::HTS002	2.01421	tryptanthrin	cyclooxygenase inhibitor	targeted cancer	IDO1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.117749038065	-1.117749038065	-1.38928165616751	-1.35544849592	-5.25196736319482	13.5484413274352	0.000136382578636361	0.00375058868054005	-0.382768233150923	-0.160297003054099
ARL15	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.653503845245	-0.653503845245	-0.959662274825888	-0.892479910689	-4.78673771854584	9.51766232015547	0.000847973724976877	0.0191532680472725	-0.449654630818604	-0.162662228343172
ARL15	BRD-K77841042-001-14-1::2.5::HTS002	2.5	brefeldin-a	protein synthesis inhibitor	targeted cancer	ARF1, CYTH2	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-6.5044777159	-6.5044777159	-4.71913669813584	-4.786446704285	14.0614683220334	15.5243149640946	3.03086184631379e-10	1.9055488080334e-08	1.51551137521162	2.05517066031669
ARL15	BRD-K81839095-001-30-1::2.5::HTS002	2.5	estrone	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.169711565873	0.169711565873	0.408795975971366	0.408585546428	7.5109653199873	4.37876903142441	0.00116506476998621	0.025289362678385	0.153641163762777	0.324527656433955
ARL15	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.210610736285	-1.210610736285	-1.69219077177243	-1.42296021894	-5.32242662165443	64.29164786341	1.38965691406564e-06	5.55160814044313e-05	-0.662321404357028	-0.300838666617835
ARL15	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.1974291304645	-0.1974291304645	-0.503821111279612	-0.3823931691785	-4.5027721802716	22.7811226247833	0.000164032474105743	0.00443844415384545	-0.447229049774813	-0.165554911855411
ARL15	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.2218027059415	0.2218027059415	0.347280770506662	0.388891879995	4.28464925311522	189.04842054196	2.91151261783581e-05	0.000917678805688427	0.0677097410531028	0.183246388077221
ARL15	BRD-K82850175-001-01-1::2.5::HTS002	2.5	navarixin	CC chemokine receptor antagonist	targeted cancer	CXCR1, CXCR2	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.310351710175	-1.310351710175	-0.877009027143921	-0.790872902529	7.04358831437527	60.2494558932283	2.06709531024331e-09	1.18777069905935e-07	0.310288839528696	0.556396526533462
ARL15	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.3216337531205	0.3216337531205	-0.328430530411489	-0.193950713334	-12.5792373392663	190.978528400523	7.97031181103444e-27	2.3825229569696e-24	-0.751996378040779	-0.548132189023199
ARL15	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-6.18981064024	-6.18981064024	-4.82758153226733	-4.95161811894	11.8093978439407	6.72181986087584	9.66112741583345e-06	0.000333869683635628	1.08716159744462	1.63729661850073
ARL15	BRD-K87024524-065-17-7::2.5::HTS002	2.5	phenelzine	monoamine oxidase inhibitor	noncancer	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.206364669373	0.206364669373	0.354350066336316	0.37808925029	4.82989675676699	160.52469635273	3.16461568609939e-06	0.000119413541441196	0.087476999615984	0.208493794310647
ARL15	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.009724297095555	-0.009724297095555	0.104156977508685	0.135507608915	4.82518831935957	189.599307175678	2.86806694310542e-06	0.000109126561308156	0.0673261866801045	0.160436362528375
ARL15	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.259301963488	-0.259301963488	0.102462133777437	0.1765205692495	10.5314910167387	189.96036708545	1.01281000411803e-20	1.78956764528123e-18	0.294006281184739	0.429521913346134
ARL15	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	CAL120, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-3.321202551175	-3.321202551175	-0.933523654423609	-0.823450093444	21.6775373867517	5.74409331866896	9.92370845647333e-07	4.05285539208741e-05	2.11522552428992	2.66013226921286
ASAP1	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2022637485195	0.2022637485195	-0.00966307729378182	0.0633629143304	-6.60303838609531	189.388164285299	3.94971363392327e-10	2.45231220580863e-08	-0.275237118481134	-0.14861653314543
ASAP1	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.254643933575	-4.254643933575	-3.7127864883611	-3.697322932235	5.89246219760342	7.35378121989697	0.000502302175559742	0.0120395798462921	0.326514743154497	0.757200147273312
ASAP1	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.03998974744415	-0.03998974744415	-1.03604614500264	-0.797857785181	-12.4678090661008	191.479036315335	1.66010970269094e-26	4.83437027809846e-24	-1.15363436779142	-0.838478427325556
ASAP1	BRD-A70858459-001-01-7::2.5::HTS002	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.7375415831965	0.7375415831965	0.093392766418643	0.09357088918285	-21.1501681477163	56.6459089490573	1.45576253749504e-28	5.24228974097299e-26	-0.705144101318451	-0.583153532237263
ASAP1	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.5822404821965	0.5822404821965	0.355151749187833	0.3602013274625	-9.79944070307161	153.547622094388	6.52958015426924e-18	8.92524480155849e-16	-0.272869054650084	-0.181308411367251
ASAP1	BRD-A74391928-051-01-3::2.5::HTS002	2.5	ibutilide	potassium channel blocker	noncancer	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.6405506036025	0.6405506036025	0.161257425033899	0.15975952739	-10.2892740149758	11.1119979937124	5.09929384539291e-07	2.17324826126311e-05	-0.581693152297458	-0.376893204839744
ASAP1	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.572959366511	-0.572959366511	-1.19496485665358	-1.043529721605	-8.27519404193844	17.6853888175406	1.71835187506883e-07	7.82602292884887e-06	-0.780123034174014	-0.463887946111142
ASAP1	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0923205120271	-0.0923205120271	-0.849505715370872	-0.797149374107	-12.0565625783805	32.4371520211417	1.58633901556993e-13	1.42736546963932e-11	-0.88504262454116	-0.629327782146384
ASAP1	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.400535099105	-1.400535099105	-3.04141448862602	-2.92318120426	-13.8273436000836	42.5255727539259	2.46067621521246e-17	3.17707393090525e-15	-1.88027581393496	-1.40148296510709
ASAP1	BRD-K03294269-001-08-0::2.5::HTS002	2.5	NU6027	CDK inhibitor	targeted cancer	CCNA2, CDK2	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.5302166801055	0.5302166801055	-0.0547508542320244	0.0643359918563	-10.0799698169763	7.45522881270356	1.3176388506389e-05	0.000443968271055784	-0.720512500290151	-0.449422568384898
ASAP1	BRD-K07487750-001-03-3::2.5::HTS002	2.5	WHI-P154	JAK inhibitor	targeted cancer	EGFR, JAK1, JAK2, JAK3	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.260329230629	0.260329230629	-0.648203422656142	-0.57901895305	-13.2867676610766	13.8349839749452	2.89349471576237e-09	1.64106861321681e-07	-1.05535477895107	-0.761710527619211
ASAP1	BRD-K08586861-001-01-1::2.5::HTS002	2.5	ramatroban	prostanoid receptor antagonist	noncancer	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.3385621557605	-0.3385621557605	-0.0402951258468544	-0.0764489475894	6.90009932271004	9.22900697182867	6.2472279980909e-05	0.00184939520663374	0.200850556662302	0.39568350316499
ASAP1	BRD-K09397065-003-06-1::2.5::HTS002	2.5	SR-57227A	serotonin receptor agonist	noncancer	HTR3A	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.5682068811295	0.5682068811295	0.241760383106131	0.2348348168625	-10.229539952371	186.560990935191	8.82783388263874e-20	1.42474458451211e-17	-0.389401529293686	-0.263491466753052
ASAP1	BRD-K10845183-304-01-6::2.5::HTS002	2.5	tiludronate	bone resorption inhibitor, osteoclast inhibitor	noncancer	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.7938741216825	0.7938741216825	0.208937523237891	0.2055339429765	-16.1897124921493	134.539367558305	2.17927802992567e-33	1.18548853014198e-30	-0.656393112184426	-0.513480084704791
ASAP1	BRD-K11590034-002-03-4::2.48778::HTS002	2.48778	morin	cytochrome P450 inhibitor	noncancer	ADORA2A, ESR2, FASN, MCL1, SLC22A12	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.871611032369	0.871611032369	0.584257249020916	0.559642670397	-7.70722835348867	5.59372584077489	0.000349861115636296	0.0087141642130403	-0.380214149049184	-0.194493417646984
ASAP1	BRD-K11630072-001-13-2::0.625::HTS002	0.625	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.09230727561025	0.09230727561025	-0.277594120230265	-0.1988130745045	-6.75943441376063	23.0456161561243	6.72348874938446e-07	2.81838181139609e-05	-0.483093637892157	-0.256709153788874
ASAP1	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.255073680135	-1.255073680135	-2.42785834760324	-2.32972185313	-11.4902052140061	3.56511220468323	0.000606456189464161	0.0142040376605468	-1.47033941133098	-0.875229923605496
ASAP1	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.03837267383226	-0.03837267383226	-0.515837264136458	-0.419130200084	-6.59443351359101	14.1345164214039	1.14470573088517e-05	0.000389558009836276	-0.632617588618905	-0.322311591989491
ASAP1	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.594591170498	-0.594591170498	-1.65483263946518	-1.461946185705	-12.6215328411008	179.053287167501	1.55348600281679e-26	4.55481670995511e-24	-1.22600390372816	-0.894479034206205
ASAP1	BRD-K13249881-001-02-3::2.5::HTS002	2.5	piperazine	benzodiazepine receptor agonist	noncancer	GABRB3	infectious disease	gastrointestinal roundworms	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.3442504148695	0.3442504148695	0.0332251630710338	0.0696303010169	-6.92701756854834	19.0682091975471	1.30108134763009e-06	5.22208734374923e-05	-0.404979937765089	-0.217070565831844
ASAP1	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.2060509434	-2.2060509434	-2.60775841208723	-2.686193418095	-5.54171352699264	128.098166066022	1.63436232229527e-07	7.47686749573582e-06	-0.545136219031255	-0.258278718343204
ASAP1	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.4514670892225	0.4514670892225	-0.0481519417360916	0.0935597000564	-8.31090890452077	186.763559521868	1.91329595907886e-14	1.89236183485654e-12	-0.618212809990675	-0.381025251926509
ASAP1	BRD-K21361524-001-01-1::0.625::MTS006	0.625	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.03834349606	-2.03834349606	-2.75492862862185	-2.60110257698	-7.98316402397901	37.2146882483651	1.39110534430268e-09	8.14629009123087e-08	-0.898424903033302	-0.534745362090393
ASAP1	BRD-K21680192-300-14-4::2.5::HTS002	2.5	mitoxantrone	topoisomerase inhibitor	chemo	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.362738844545	-5.362738844545	-4.71523300594907	-4.740808103055	4.49959349712448	15.6140823194734	0.000385307589030499	0.00948647544894524	0.341830776546829	0.953180900645024
ASAP1	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.04593870976158	-0.04593870976158	-0.843523171022365	-0.742464669951	-10.5622653494468	6.56326236722622	2.32914170637832e-05	0.000749215987972923	-0.978580592637555	-0.616588329884016
ASAP1	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1002512659829	0.1002512659829	-0.506865706590312	-0.436225052339	-11.0141714809854	10.8514973826756	3.15876285002812e-07	1.38789356884723e-05	-0.728641312665832	-0.485592632480591
ASAP1	BRD-K28192623-066-08-1::2.5::HTS002	2.5	spiradoline	opioid receptor agonist	noncancer	OPRK1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.661265481385	-1.661265481385	-2.32880439238404	-2.17007557799	-6.7028827816717	7.60133656108722	0.000191896665785091	0.0050965328972804	-0.899306965399424	-0.435770856598655
ASAP1	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.4935866987125	-0.4935866987125	-1.67652505320139	-1.54523819361	-15.0494551065138	189.895447708265	3.29212273095127e-34	1.94379441543266e-31	-1.3379863253148	-1.02789038366298
ASAP1	BRD-K29950728-048-17-4::2.5::HTS002	2.5	clomifene	estrogen receptor antagonist	noncancer	ESR1	obstetrics/gynecology	infertility	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.6957063438125	-0.6957063438125	-0.132076683874501	-0.112752624282	17.3241021765283	188.975832785918	6.99946016751251e-41	8.1091205310421e-38	0.499452365293913	0.627806954582084
ASAP1	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.15383955071	-2.15383955071	-3.71351363433238	-3.85009077555	-15.5450212845357	58.1306552618764	2.27490083439093e-22	4.6303629718345e-20	-1.76050220917947	-1.35884595806528
ASAP1	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.466886915197	0.466886915197	0.160434149395471	0.154760250633	-11.7630188263344	25.2147746353311	9.81827303191782e-12	7.36813949810194e-10	-0.360085154905172	-0.252820376697886
ASAP1	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.398653112426	0.398653112426	0.762544811533043	0.7663988354595	9.65425639692421	7.16005922784542	2.32681153301294e-05	0.000748578788740813	0.275165744717893	0.452617653496194
ASAP1	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.2466811544645	-0.2466811544645	0.136010833751839	0.1319992768505	11.7966567378198	80.8767933266047	2.92198383573372e-19	4.51200197066983e-17	0.318143649088688	0.447240327343989
ASAP1	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.371117889041	0.371117889041	-0.0782167399856035	-0.0620606581655	-14.3201819602726	159.628022252347	1.92166226173328e-30	8.01299515359983e-28	-0.511303633336752	-0.387365624716455
ASAP1	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.954051312551	-0.954051312551	-0.169991186951518	-0.120119113317	21.9379118055908	73.3458524421019	5.97305754359428e-34	3.45067237267121e-31	0.712836142884626	0.855284108314338
ASAP1	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.637249016096	-0.637249016096	-1.78781207172506	-1.67706700871	-10.1846289372837	10.8254270578628	7.03305623471088e-07	2.94181871531879e-05	-1.39969963016892	-0.901426481089211
ASAP1	BRD-K42205652-001-02-7::2.5::HTS002	2.5	MNS-(3,4-Methylenedioxy-nitrostyrene)	src inhibitor, syk inhibitor	noncancer	SRC, SYK	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.451482129946	0.451482129946	0.238139415341877	0.255658141899	-5.56236152166203	131.449279157647	1.43031159086291e-07	6.60683734823399e-06	-0.289215045410863	-0.137470383797383
ASAP1	BRD-K42673188-001-01-1::2.5::MTS006	2.5	verubulin	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.7839001259775	-0.7839001259775	-2.48153805005225	-2.30487473877	-11.7494576295121	3.30472890119647	0.00082770073096782	0.0187526712439325	-2.13437809433553	-1.26089775381398
ASAP1	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.8980392538	0.8980392538	0.468685283029636	0.492327571576	-10.2608567312597	3.47125695097739	0.00102052621684423	0.0225098655480093	-0.552854309725857	-0.305853631814872
ASAP1	BRD-K44067360-001-30-3::2.5::HTS002	2.5	flufenamic-acid	chloride channel blocker	noncancer	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.52654444087	0.52654444087	0.0676451622749161	0.08403527726685	-15.7187426834256	131.882635777708	5.06051256631819e-32	2.41025466183647e-29	-0.516649165013402	-0.401149392176766
ASAP1	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.307782822457	0.307782822457	-0.731502331500243	-0.623158972273	-10.6464050100607	47.4380393991027	3.63135418579201e-14	3.49642637595066e-12	-1.23562021171545	-0.842950096199034
ASAP1	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.3429585756715	-0.3429585756715	-1.40066419620605	-1.273586296615	-10.7915112348394	3.33175694401754	0.00104857954568218	0.0230291019004526	-1.35277043450659	-0.762640806562512
ASAP1	BRD-K48684885-001-04-2::2.5::HTS002	2.5	BAY-11-7085	NFkB pathway inhibitor	targeted cancer	NFKBIA	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.746144331649	-0.746144331649	-1.44981179427784	-1.33433747778	-10.0225463327338	127.497569147553	8.63017027215485e-18	1.16773722491204e-15	-0.842592104099304	-0.56474282115837
ASAP1	BRD-K49371609-003-03-8::2.5::HTS002	2.5	PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.00169964346	-5.00169964346	-5.34480391611053	-5.36758305195	-4.22618583165034	34.343758599035	0.000166057065595133	0.00448473346924638	-0.50803189752422	-0.178176647776849
ASAP1	BRD-K54095730-001-03-1::2.5::HTS002	2.5	CMPD-1	p38 MAPK inhibitor	noncancer	GNRHR, MAPK14	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.4119942811655	-0.4119942811655	-1.52399577302833	-1.5570935433	-10.9135481711234	2.93290285931593	0.00182207972111808	0.0370551783421118	-1.44050417574164	-0.783498807984022
ASAP1	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1454026938793	0.1454026938793	-0.514341335478133	-0.339269333107	-8.84886246966831	6.76035422167633	5.85216854509193e-05	0.00174110137715298	-0.837318004808837	-0.482170053906029
ASAP1	BRD-K55187425-236-05-2::2.5::MTS010::PROS004_PR500	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	1.08007086073	1.08007086073	-0.820305256250224	-0.733552010026	-21.8104679420518	58.9274358866795	6.62380176532464e-30	2.65359403469208e-27	-2.07473009304161	-1.72602214091884
ASAP1	BRD-K56981171-001-01-0::2.5::MTS006	2.5	brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	targeted cancer	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.296746535299	-0.296746535299	-0.0682161109265646	-0.00661629893245	6.93348384602768	190.681678592692	6.18475638800697e-11	4.1961780686456e-09	0.163516589553299	0.293544259191572
ASAP1	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.266244475287	0.266244475287	-0.5905014240885	-0.48109263675	-10.1224383890876	16.6222257302596	1.60906348005702e-08	8.40323992731823e-07	-1.03562674136818	-0.677865057382819
ASAP1	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.07711683509	-1.07711683509	-2.01805133918178	-2.23082742718	-8.45429474293254	5.91686657112045	0.000161081889060472	0.00436466753482198	-1.21419775517372	-0.667671253009844
ASAP1	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.81820457711	-4.81820457711	-5.59312886842942	-5.54901350857	-7.55471813526985	5.54373730331578	0.000404335792319512	0.009905233287467	-1.03100941431639	-0.518839168322453
ASAP1	BRD-K59632282-052-03-1::2.5::HTS002	2.5	quinidine	sodium channel blocker	noncancer	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.811957210121	0.811957210121	0.436224848083067	0.439082857511	-12.8382337027237	12.4720278247202	1.48008617594388e-08	7.77322690526526e-07	-0.439232320803045	-0.312232403272822
ASAP1	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.474293017401	0.474293017401	-0.214295299897568	-0.255561480265	-18.9314680881364	5.53925526028554	3.01401406079941e-06	0.000114273946512839	-0.779414735400836	-0.597761899196301
ASAP1	BRD-K61936403-001-01-7::2.5::HTS002	2.5	AS-1949490	SHIP2 phosphatase inhibitor	noncancer	INPP5D	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.0738636754889	0.0738636754889	0.243329194390662	0.276762978408	4.56597067528505	146.10636249048	1.04752936595751e-05	0.000359570662197801	0.0961141051037653	0.242816932699758
ASAP1	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1203539954125	0.1203539954125	-0.212326279658369	-0.1382371077965	-8.48727096241743	57.5239929592821	1.00011070561379e-11	7.48961311752265e-10	-0.411156533546923	-0.254204016594816
ASAP1	BRD-K63923597-001-10-0::2.5::HTS002	2.5	barasertib-HQPA	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.8126075135935	-0.8126075135935	-1.17206564667329	-1.00704468422	-4.09669755510171	11.7637693507562	0.00154211806575229	0.0321923370508759	-0.551061213578572	-0.167855052581003
ASAP1	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.882482779152	-0.882482779152	-1.84913410238622	-1.7566794361	-9.73175603846817	48.637923296089	5.32616216529917e-13	4.54077569899127e-11	-1.16629919820193	-0.767003448266508
ASAP1	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.784653481147	-0.784653481147	-2.14253286991059	-2.025815521035	-13.8355516947873	40.0439840749621	7.60849444581482e-17	9.42068749900083e-15	-1.55622946394642	-1.15952931358077
ASAP1	BRD-K66030860-001-03-6::2.5::HTS002	2.5	salidroside	beta amyloid protein neurotoxicity inhibitor	noncancer	APP	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.2337855319875	-0.2337855319875	0.137016032693819	0.138943386396	13.1762878552675	81.3311322198257	7.05693656661207e-22	1.37500559762309e-19	0.314812102603533	0.426791026759105
ASAP1	BRD-K68747584-001-02-0::2.5::HTS002	2.5	PF-03814735	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.7092687375415	-0.7092687375415	-1.27556621124309	-1.09893939309	-6.76509413370544	45.4081252853685	2.18038869279696e-08	1.116655981215e-06	-0.73485370647747	-0.397741240925712
ASAP1	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.4386138832	-1.4386138832	-2.59423060657068	-2.40345273405	-8.94024593548117	23.1250776406583	5.77669743015953e-09	3.16977415132786e-07	-1.42293152457164	-0.888301922169724
ASAP1	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.76290958309	-1.76290958309	-0.948165842309359	-0.855208083422	10.4016319303132	3.27237796122236	0.00128440486087417	0.0275120137343895	0.576804227784098	1.05268325377718
ASAP1	BRD-K77791657-003-01-7::2.66704::HTS002	2.66704	3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.116450692025	-1.116450692025	-1.5229518600418	-1.46906470598	-4.77933856993867	8.8470904257288	0.00105134792640921	0.0230793455013954	-0.599414466985948	-0.213587869047646
ASAP1	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1474014411905	0.1474014411905	0.0155941437245871	0.0495734767378	-4.64774994573075	96.9826155710539	1.05797672798195e-05	0.000362866209204104	-0.188092939900565	-0.0755216550312609
ASAP1	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.9396123990135	-0.9396123990135	-1.69523569691031	-1.42296021894	-7.75183814649582	17.6200781094962	4.41038742047403e-07	1.89928455986092e-05	-0.960731135565567	-0.550515460228061
ASAP1	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.1835150301425	-0.1835150301425	-0.503977449485477	-0.3823931691785	-4.40024885257908	10.6184299466039	0.00115602546650117	0.0251313299736008	-0.481461893661346	-0.159462945024609
ASAP1	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.72955045221	-0.72955045221	-0.377949144921321	-0.338570487031	6.85632873274292	7.58138015406671	0.000167167106211173	0.00451073381683677	0.232200190537467	0.471002424039892
ASAP1	BRD-K88677950-001-03-9::2.5::HTS002	2.5	PD-198306	MAP kinase inhibitor, MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.4091061293085	-0.4091061293085	-0.668067056863897	-0.5546333344115	-5.31733503331266	114.687455445223	5.26244703071536e-07	2.23877532680864e-05	-0.355431550152492	-0.162490304958302
ASAP1	BRD-K89015388-001-01-7::2.5::HTS002	2.5	GSK923295	centromere associated protein inhibitor	targeted cancer	CENPE	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.252905486387	-0.252905486387	-1.6549851873275	-1.4981509162	-11.6058631859995	4.49495679971967	0.000160618378687968	0.0043559631134776	-1.72342037047964	-1.08073903140136
ASAP1	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.76042989726	-1.76042989726	-2.92188856012997	-2.87877770547	-12.9481559650521	56.127599196161	1.6949308046675e-18	2.42991855808415e-16	-1.34114174474728	-0.981775580992658
ASAP1	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.7353484636535	0.7353484636535	0.305796839033204	0.328628776305	-9.0670122229273	3.48491730600659	0.0015220561767173	0.0318326286396997	-0.569120025446491	-0.289983223794102
ASAP1	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.25224935719	-5.25224935719	-4.6224071614568	-4.61970061714	6.04292555840602	18.2686271041721	9.69050367013871e-06	0.000334776911849961	0.411097811704165	0.848586579762229
ASAP1	BRD-K97472745-001-01-8::2.5::HTS002	2.5	gestrinone	progesterone receptor antagonist	noncancer	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.4256483935785	0.4256483935785	-0.166999741606525	-0.1123477003	-15.1966163124304	106.102583259794	2.18248818552505e-28	7.74454487277151e-26	-0.669965969031956	-0.515330301338095
ASAP1	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.10117347908595	0.10117347908595	-0.244584589985127	-0.195507988981	-7.17301118394165	25.3714716193148	1.48349331945616e-07	6.83187880674085e-06	-0.44495961290374	-0.246556525238413
ASAP1	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	HCC1419, NCIH1650	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.824021637835	-4.824021637835	-5.65557463844706	-5.73830939241	-9.14576656999503	110.713574870278	3.36991127237511e-15	3.55622704626728e-13	-1.01172649906531	-0.651379502158811
ASCC1	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.5945909484485	0.5945909484485	-0.0573491991502707	0.106263594851	-11.374359440552	46.5655912971132	4.87449742609781e-15	5.0839229140541e-13	-0.767274770936214	-0.536605524261328
ASCC1	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.3781327119745	-0.3781327119745	-0.0489481176131291	0.009756743375275	9.50312259373334	190.776310927168	8.86831987820635e-18	1.19844774979577e-15	0.260858741706339	0.397510447016403
ASCC1	BRD-A36267905-003-18-4::2.5::HTS002	2.5	buphenine	adrenergic receptor agonist	noncancer	ADRB2	rheumatology	Raynaud's disease	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.5781926944165	0.5781926944165	-0.452725636347906	-0.393531150995	-19.5760152045017	34.8536332253743	2.19742391076138e-20	3.77683776559404e-18	-1.13784457086971	-0.9239920906591
ASCC1	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-2.147276373265	-2.147276373265	-0.980654550853562	-0.915436263548	18.1380039268196	62.8231036647717	1.16684857752399e-26	3.4542747067975e-24	1.0380830829064	1.29516056191648
ASCC1	BRD-A50049929-001-01-9::2.5::HTS002	2.5	oxazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3	neurology/psychiatry	anxiety	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.01549780975098	-0.01549780975098	-0.258968768669615	-0.09984291970545	-3.84169807485196	91.9649246472887	0.000224470693069257	0.00585358062718587	-0.36934154738393	-0.11760037045334
ASCC1	BRD-A55913614-316-09-6::2.5::HTS002	2.5	primaquine	antimalarial agent, DNA inhibitor	noncancer	KRT7, NQO2	infectious disease	malaria	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.673555726971	0.673555726971	0.0916472959953774	0.121843056182	-15.9346315623917	21.3627894792004	2.45756892817764e-13	2.16939164253453e-11	-0.6577743018271	-0.506042560124145
ASCC1	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.682769811068	0.682769811068	0.138361717514338	0.135666555282	-19.5941302043382	51.3178678459703	1.76746763551583e-25	4.69417064253373e-23	-0.600178903201946	-0.488637283905378
ASCC1	BRD-A74391928-051-01-3::2.5::HTS002	2.5	ibutilide	potassium channel blocker	noncancer	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	1.0107177435295	1.0107177435295	0.157050980262001	0.15975952739	-15.8679566635384	4.26387418205489	5.92321066145181e-05	0.00176101514476114	-0.999458507489962	-0.707875019045035
ASCC1	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.348338588093	0.348338588093	-0.190665053820073	-0.0590439534084	-13.0775904252388	190.763348397577	2.56610637171881e-28	9.0014895670069e-26	-0.620300927626531	-0.457706356199616
ASCC1	BRD-A90547603-001-02-5::2.5::HTS002	2.5	eptifibatide	platelet aggregation inhibitor	noncancer	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.636752209663	0.636752209663	0.0382441679998655	0.04269931862485	-18.148688665741	5.2766356181765	5.86046219900387e-06	0.000211139183501479	-0.681961298472142	-0.515054784854127
ASCC1	BRD-K00312224-001-09-5::2.5::HTS002	2.5	PPT	estrogen receptor agonist	noncancer	ESR1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	1.174887690395	1.174887690395	0.15193198148022	0.22700730099	-21.9412724636476	33.4604763048388	1.94299882482317e-21	3.63386557701156e-19	-1.11776021616852	-0.928151201661035
ASCC1	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.5105176442225	0.5105176442225	-0.0901051504819825	-0.0325205860223	-12.8150839945847	6.29059479860434	9.64114445054664e-06	0.000333340353111988	-0.714033658638834	-0.48721193077013
ASCC1	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.6241795112005	0.6241795112005	-0.31558150348581	-0.199486634258	-12.0902659454378	3.72236845042186	0.000401864230419392	0.00984918909566129	-1.16206919687424	-0.717452832498379
ASCC1	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.575231568445	0.575231568445	0.18088727766972	0.22754908413	-8.93311559464575	7.04020169304875	4.32571346032423e-05	0.00132219885943786	-0.498607773283017	-0.290080808267542
ASCC1	BRD-K11073688-001-01-6::2.5::HTS002	2.5	CPI-1189	tumor necrosis factor release inhibitor	noncancer	TNF	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.003472640433525	-0.003472640433525	-0.26300631888246	-0.2451174209795	-5.67606224077831	193.655027245989	4.97541794741755e-08	2.43021046775765e-06	-0.349715136867021	-0.169352220030849
ASCC1	BRD-K13044802-213-20-7::2.5::HTS002	2.5	ciclopirox	membrane integrity inhibitor	noncancer	ATP1A1	infectious disease	onychomycosis	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.9633453266	-0.9633453266	-1.62494318688452	-1.66652193871	-10.1100616064079	77.393535129586	8.43911064000881e-16	9.44514957891618e-14	-0.791894074325903	-0.531301646243128
ASCC1	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.2212397909705	-0.2212397909705	-1.30585500307231	-1.26174940362	-13.6861851968473	2.78142895011651	0.001235465300029	0.0266153424756171	-1.3484118461656	-0.820818578038029
ASCC1	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.9881168879675	0.9881168879675	-0.0707956392171207	-0.0626502991923	-27.5865882603132	9.38239420950755	2.66427063412422e-10	1.68594762545383e-08	-1.14520905000011	-0.972616004369132
ASCC1	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.2507165241755	0.2507165241755	-0.346490771747213	-0.216806871006	-10.6802883903095	192.299545122389	3.33021722692261e-21	6.11097712353678e-19	-0.707496259538674	-0.486918332306752
ASCC1	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-1.473028572745	-1.473028572745	-0.767585074385508	-0.7406610501725	10.1442636767173	21.3883494260665	1.2465614227796e-09	7.35004850572018e-08	0.560984534831189	0.849902461887795
ASCC1	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-2.379347561195	-2.379347561195	-3.27645820980985	-3.04327234152	-7.92071649130578	189.066593491093	1.96654941444504e-13	1.7518228156633e-11	-1.12052882503925	-0.673692472190459
ASCC1	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.477708670566	-0.477708670566	0.38192687972803	0.395322173914	28.6967519114536	70.0485977296761	1.85277315565469e-40	2.03642573168366e-37	0.799891223213138	0.919379877374921
ASCC1	BRD-K24844714-001-24-5::2.5::HTS002	2.5	5-fluorouracil	thymidylate synthase inhibitor	chemo	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.6512367546675	-0.6512367546675	-1.05403270518577	-0.97521082715	-7.80946487645699	175.446683504122	5.020892169548e-13	4.29418514687571e-11	-0.504588970685697	-0.301002930350845
ASCC1	BRD-K25244359-066-03-4::2.68145::HTS002	2.68145	apatinib	RET tyrosine kinase inhibitor	targeted cancer	CSK, KDR, KIT, RET	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.4699315095865	0.4699315095865	0.133237792674517	0.183294433483	-8.99413985235223	186.645567434584	2.6756250043361e-16	3.15263348847911e-14	-0.410543397933314	-0.262844035890653
ASCC1	BRD-K28192623-066-08-1::2.5::HTS002	2.5	spiradoline	opioid receptor agonist	noncancer	OPRK1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-1.5327156482	-1.5327156482	-2.33015046393572	-2.17007557799	-9.50993435699033	71.7313691709625	2.44892466729453e-14	2.39583553758784e-12	-0.964603053470784	-0.630266578000647
ASCC1	BRD-K31309378-001-01-5::2.5::HTS002	2.5	lucitanib	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.518583464655	-0.518583464655	-0.764357590220032	-0.647544423054	-4.07079533692159	157.42864896716	7.39733331150783e-05	0.00215357654349655	-0.365023580094095	-0.126524671035969
ASCC1	BRD-K32107296-001-16-9::2.5::HTS002	2.5	temozolomide	DNA alkylating agent	chemo	MGMT	oncology	glioblastoma, astrocytoma	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.995702015325	0.995702015325	0.217731560725355	0.214329388476	-27.2412461125505	114.458413526312	7.55237276547632e-52	2.2798485950025e-48	-0.834542289345249	-0.72139861985404
ASCC1	BRD-K33882852-003-02-8::2.5::HTS002	2.5	ZK-93423	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.531824112168	-0.531824112168	-0.886819412833571	-0.832624878756	-5.88259334741583	147.973796899227	2.58952424828825e-08	1.31208071539331e-06	-0.474248014784185	-0.235742586546957
ASCC1	BRD-K34332569-001-01-3::2.5::HTS002	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-2.83571331321	-2.83571331321	-0.975492579925417	-0.8949729778575	13.8530706299266	2.92064107845565	0.00093484402139298	0.0208734435109007	1.42623015936908	2.29421130720009
ASCC1	BRD-K38852836-001-02-1::2.5::HTS002	2.5	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-5.53100788043	-5.53100788043	-4.84689849751539	-4.86851000212	8.58037115620813	190.860985104574	3.2529903985246e-15	3.43792001541113e-13	0.526845087877058	0.841373677952156
ASCC1	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-2.36257647458	-2.36257647458	-3.04465672957307	-2.95683473862	-6.04885928743674	10.3100350538236	0.000109070792330796	0.0030662426350298	-0.932308838831045	-0.431851671155103
ASCC1	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.3421885135915	-0.3421885135915	-1.79112735827006	-1.67706700871	-11.116920810019	4.37463007342374	0.00022652783356716	0.00590219840026937	-1.79891048471165	-1.09896720464547
ASCC1	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.2497892665925	0.2497892665925	-0.519399224196573	-0.465030888818	-15.2662949577167	67.8386639739668	1.24286312482029e-23	2.80993260210557e-21	-0.869734028461919	-0.668642953116228
ASCC1	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	1.19548640477	1.19548640477	0.465144245518088	0.492327571576	-21.2830058228829	8.94948882626868	5.66523322843323e-09	3.11339428876119e-07	-0.808036601502845	-0.652647717000979
ASCC1	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.6184286609345	0.6184286609345	-0.131501343540003	-0.075355311638	-13.0191328932658	2.61627416033676	0.00188796432668845	0.0381812767603477	-0.949435917941027	-0.55042409100798
ASCC1	BRD-K47557313-001-02-7::2.5::HTS002	2.5	LY2109761	TGF beta receptor inhibitor	targeted cancer	TGFBR1, TGFBR2	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	1.45317187789	1.45317187789	0.244204422124139	0.273399788387	-30.0107219042591	19.4611991334907	9.12987029336909e-18	1.23301573415722e-15	-1.2931488825023	-1.12478602902942
ASCC1	BRD-K49027941-001-01-1::2.5::HTS002	2.5	PSB-1115	adenosine receptor antagonist	noncancer	ADORA1, ADORA2B, ADORA3	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.1276847283645	-0.1276847283645	0.119112105695756	0.179780985377	4.44291495920087	36.5875739242373	7.90946504831624e-05	0.00229183565575167	0.134202236070029	0.359391432050483
ASCC1	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.186262545951	0.186262545951	-0.104450725749396	-0.112273492753	-5.12773315898728	6.47342551313489	0.00172131472868912	0.0353853505165174	-0.427016654311696	-0.154409889089096
ASCC1	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-6.8581952061	-6.8581952061	-6.17431480005026	-6.268105536705	7.63493089412092	139.111416482782	3.27611661361332e-12	2.59389286176258e-10	0.506780755205403	0.86098005689407
ASCC1	BRD-K54247840-004-01-3::2.5::HTS002	2.5	halofuginone	collagenase inhibitor	noncancer	COL1A1, MMP2	rheumatology	scleroderma	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-6.126945181315	-6.126945181315	-5.70842731704977	-5.53178334297	3.63942026696625	173.025025371008	0.000360554358190787	0.00895345325416212	0.191542779688065	0.645492948842394
ASCC1	BRD-K55187425-236-05-2::2.5::HTS002	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-2.40686587271	-2.40686587271	-2.92710473006658	-2.897999861155	-5.51920460826555	165.596616391913	1.29142303102319e-07	6.00671455764258e-06	-0.706344659234566	-0.33413305547859
ASCC1	BRD-K55187425-236-05-2::2.5::MTS010::PROS004_PR500	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-1.123425455275	-1.123425455275	-0.797352169625172	-0.7051188233505	3.83718814429924	152.82802854685	0.000181679787300303	0.00485587319270315	0.1581917590526	0.493954812247056
ASCC1	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-1.894341483885	-1.894341483885	-1.03012917095373	-1.108311362665	7.62488929406371	3.58085877021566	0.00245193728226854	0.0477703177685059	0.534454597474012	1.19397002838853
ASCC1	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-2.75857664725	-2.75857664725	-2.00016346883965	-2.19151625043	7.71554481725912	16.439466178969	7.41284915703744e-07	3.08862470252465e-05	0.550485136146582	0.966341220674108
ASCC1	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.272204789316	0.272204789316	-0.378968416912699	-0.400498604256	-14.0468374602876	180.740394967982	8.87836188640593e-31	3.76065301334288e-28	-0.742644288046366	-0.559702124411031
ASCC1	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.9128538700445	-0.9128538700445	-0.68406165823814	-0.630554296997	4.09047619848512	74.4153671076207	0.000107898807446286	0.00303448937162511	0.117353803515377	0.340230620097345
ASCC1	BRD-K61936403-001-01-7::2.5::HTS002	2.5	AS-1949490	SHIP2 phosphatase inhibitor	noncancer	INPP5D	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.217948894326	-0.217948894326	0.246450184442158	0.276762978408	10.7757700080203	11.0297536993117	3.40444396048465e-07	1.48669737083683e-05	0.369575305310814	0.559222852225501
ASCC1	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-2.33748989436	-2.33748989436	-1.47098571213034	-1.34809352963	13.1006319015237	140.57760635739	3.96297323592962e-26	1.1146720350178e-23	0.735742248938643	0.997266115520674
ASCC1	BRD-K65877271-001-01-8::2.5::HTS002	2.5	halobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.0472412867953	0.0472412867953	-0.286100059737332	-0.253825714787	-6.79892411423284	91.8192159670564	1.04269879438119e-09	6.18888368598519e-08	-0.430718820434301	-0.235963872630963
ASCC1	BRD-K68488863-001-04-9::0.15625::HTS002	0.15625	ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	targeted cancer	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.14475170173	0.14475170173	0.516992604648161	0.524698126717	12.7845381222725	7.07216996184261	3.81400708187502e-06	0.000141820319890908	0.303533512544957	0.440948293291366
ASCC1	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.537094453949	0.537094453949	-0.158527275273959	0.0566391407425	-10.569568854825	67.5566832611088	5.85744512525214e-16	6.66005494031919e-14	-0.826966396191532	-0.564277062254386
ASCC1	BRD-K70511574-001-06-9::2.5::HTS002	2.5	HMN-214	PLK inhibitor	targeted cancer	PLK1	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-3.37333316746	-3.37333316746	-2.82595886089601	-2.78074740787	5.38736789305186	47.9739923462926	2.13307739728809e-06	8.28225263556809e-05	0.343084337520874	0.751664275607114
ASCC1	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	1.272536430845	1.272536430845	0.0893815939620041	0.129185439077	-19.8894363377387	2.4797319202112	0.000847487883913087	0.0191483481626827	-1.39704755764188	-0.96926211612411
ASCC1	BRD-K72420232-001-12-3::2.5::HTS002	2.5	WZ-4002	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.57247903154	0.57247903154	-0.079460021711784	0.0237239176578	-13.2206798272739	71.5078392591512	6.94836817823532e-21	1.24518127363963e-18	-0.750252423226865	-0.553625683276703
ASCC1	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.08063394359065	0.08063394359065	-0.196736701012593	-0.145323520972	-6.35258383729628	169.37927131371	1.88220008955373e-09	1.0876518279697e-07	-0.363563709630393	-0.191177579576092
ASCC1	BRD-K78809024-001-05-7::2.5::HTS002	2.5	SB-590885	RAF inhibitor	targeted cancer	BRAF	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.6152835051785	0.6152835051785	0.0879727034145937	0.1598746623085	-8.34321521834106	4.24645632487164	0.000866379797624165	0.0194938871392883	-0.698844188775466	-0.355777414752346
ASCC1	BRD-K80608265-001-01-6::2.5::HTS002	2.5	erteberel	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.692111140426	0.692111140426	-0.00220672696344505	0.05335983697175	-14.8936214566711	27.2283703993963	1.30911832001456e-14	1.3105185446539e-12	-0.789933545123026	-0.598702189655864
ASCC1	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.3013086151705	-0.3013086151705	-0.778445941695755	-0.670066066219	-7.911939872118	8.33315465138118	3.7598196422381e-05	0.00116148513130765	-0.615241341963425	-0.339033311087085
ASCC1	BRD-K84810405-003-01-1::2.5::HTS002	2.5	almorexant	orexin receptor antagonist	noncancer	HCRTR1, HCRTR2	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.509836201468	0.509836201468	0.255320724156233	0.26116496822	-7.32148662956121	7.42770067544748	0.000119355959092958	0.00332610137593534	-0.335766611019408	-0.173264343604126
ASCC1	BRD-K84868168-001-01-0::2.5::MTS006	2.5	erdafitinib	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.5606530249635	0.5606530249635	0.0839484284328707	0.13174233615	-8.35956437942218	3.27175292315453	0.00257290030199744	0.0498129990682224	-0.649947217447885	-0.303461975613373
ASCC1	BRD-K86797399-001-05-1::2.54945::HTS002	2.54945	SB-939	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-7.090225189875	-7.090225189875	-5.44733326371658	-5.51001928833	20.9251118646394	189.627167139531	3.66884621787331e-51	1.00812838593663e-47	1.48802099954148	1.79776285277536
ASCC1	BRD-K92213669-001-01-3::2.5::HTS002	2.5	lomitapide	microsomal trigylceride transfer protein inhibitor	noncancer	MTTP	endocrinology	hypercholesterolemia	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.610958526218	0.610958526218	0.222812551068378	0.227576049132	-9.05404228759784	30.0926552845548	4.26942410518046e-10	2.63706455054531e-08	-0.475686708132436	-0.300605242166808
ASCC1	BRD-K97810537-001-13-6::2.5::HTS002	2.5	beclomethasone-dipropionate	glucocorticoid receptor agonist	noncancer	GPR97, NR3C1	allergy	allergic rhinitis	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	0.300279789481	0.300279789481	0.0717915610854242	0.0633860344485	-5.34986751681204	59.659916534578	1.46767140446619e-06	5.84475184778584e-05	-0.313929240950861	-0.14304721584029
ASCC1	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-0.01404362338015	-0.01404362338015	0.249709148177036	0.266502193274	9.11433483472646	187.881727881976	1.19855162700424e-16	1.451324133696e-14	0.206667160407235	0.320838382707137
ASCC1	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	GCIY, BFTC909	STOMACH, KIDNEY	carcinoma (adenocarcinoma), carcinoma	-4.09930982563	-4.09930982563	-3.15640176226628	-3.187890366305	13.3229820758765	125.583139846902	8.69523968332729e-26	2.356058187216e-23	0.802845772349098	1.08297035437834
ASIC2	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.312104621848	0.312104621848	0.0728744761805745	0.128125201883	-6.51020878100425	6.86094430369028	0.000360179606731083	0.00894725717791682	-0.326481100587986	-0.151979190746865
ASIC2	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.11054806118025	-0.11054806118025	-0.849300911447803	-0.797149374107	-10.809092845158	11.2263331945419	2.81721769236845e-07	1.24728661596289e-05	-0.888811091892207	-0.588694608642898
ASIC2	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.1109480398116	-0.1109480398116	0.160252717468275	0.166606190016	7.81119388717764	4.21181192894681	0.00116944960921416	0.0253716940270535	0.176686068787228	0.365715445772522
ASIC2	BRD-K03109492-001-02-2::2.5::HTS002	2.5	NSC-663284	CDC inhibitor	targeted cancer	CDC25A, CDC25B, CDC25C	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.988449862945	-1.988449862945	-1.20167084147163	-0.927441060587	8.75046083789764	73.4245477336628	5.23269012146187e-13	4.46463869841879e-11	0.607600390019851	0.965957652926899
ASIC2	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.06314491981055	-0.06314491981055	-0.341256060506742	-0.229059189804	-6.58606026491886	191.183700163565	4.25512165738771e-10	2.62898809370496e-08	-0.36140225423867	-0.194820027153714
ASIC2	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.52406746602	-1.52406746602	-2.03175776436021	-1.93975006052	-5.19875595100752	15.748343647662	9.24095672428755e-05	0.00263448392359647	-0.714981199980241	-0.300399396700173
ASIC2	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.0207325176695355	-0.0207325176695355	0.243154495789656	0.240200693149	8.0423643158011	6.48420723390482	0.000132423875734606	0.0036499841643933	0.185029829267766	0.342744197650617
ASIC2	BRD-K06749501-001-02-1::2.5::HTS002	2.5	GSK1838705A	insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R, INSR, RPS6KA1	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.3004768448675	0.3004768448675	-0.239581292560206	-0.164638438825	-9.22406013234804	37.9389483808107	3.11462721322164e-11	2.19229864033688e-09	-0.658590356922399	-0.421525917933013
ASIC2	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-2.474016384295	-2.474016384295	-1.93550922322972	-1.85386313087	4.85783122747574	44.4920276133246	1.50705475321274e-05	0.00050343755954073	0.315166552094002	0.76184777003655
ASIC2	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.740164647469	-0.740164647469	-0.418535607217159	-0.37916191768	5.75507313764545	28.4853653068546	3.33200018936455e-06	0.000125332444469343	0.20723920793053	0.436018872573153
ASIC2	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.802590263936	-0.802590263936	-0.415434261292997	-0.389042162364	8.0049688230005	3.74528856295566	0.00173346176791329	0.0355804565461682	0.249195319350221	0.525116685935785
ASIC2	BRD-K15071410-001-01-1::2.5::HTS002	2.5	tiotidine	histamine receptor antagonist	noncancer	HRH2	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.00716598315942	0.00716598315942	0.382365670101253	0.366990824591	11.7716308014647	24.3949471077774	1.49882323439388e-11	1.0993883812608e-09	0.309472923372345	0.440926450511321
ASIC2	BRD-K15916496-001-27-9::2.5::HTS002	2.5	clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	noncancer	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.1527509621095	0.1527509621095	0.334015950930173	0.346280454324	7.17414191728429	172.754153928745	2.05083210328344e-11	1.47402010014969e-09	0.131394324179045	0.231135653462302
ASIC2	BRD-K17472821-001-01-2::2.5::MTS006	2.5	GSK2830371	protein phosphatase inhibitor	targeted cancer	PPM1D	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.02768552240345	0.02768552240345	0.215930621111766	0.228521183111	9.88237287906908	187.755369753629	8.27984914543041e-19	1.21966445875667e-16	0.150668372735451	0.225821824681181
ASIC2	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.4455080549	-1.4455080549	-0.935531169566103	-0.89400890482	9.7506067659746	65.1037589214628	2.36986154902552e-14	2.32249682643389e-12	0.405525601108463	0.61442816955933
ASIC2	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-2.414867754725	-2.414867754725	-3.09710873901033	-2.8622910827	-5.74419727530944	14.3460476337746	4.61481970266489e-05	0.00140077849037312	-0.936403034816897	-0.42807893375376
ASIC2	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.477281266296	-0.477281266296	0.0968922479120995	0.09201913789375	16.8079593199061	4.27052575203658	4.59670759293841e-05	0.00139626947517984	0.481651067601227	0.666695960814972
ASIC2	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.181960489332	0.181960489332	0.375195561769887	0.395322173914	5.60206697118922	11.4478729991111	0.000137867693573778	0.00378058404503253	0.11767613616197	0.268794008713804
ASIC2	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.0608374259053	0.0608374259053	-0.243609627021033	-0.125640191534	-7.0876989907314	22.1911545821416	3.94254474363292e-07	1.70707408557192e-05	-0.393484321400742	-0.215409784451924
ASIC2	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.443399827062	-0.443399827062	-0.774370493098396	-0.707312470978	-5.00762456456428	10.6048928076764	0.000444487935291569	0.0107938652484825	-0.477105131761841	-0.184836200310951
ASIC2	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.1533337110315	-0.1533337110315	0.275487976658184	0.290224760638	10.7924413350767	2.83559921106901	0.00218032739953905	0.0431652864599856	0.298121564933033	0.559521810446334
ASIC2	BRD-K32285926-001-02-1::2.5::HTS002	2.5	AMG-208	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.1525121663015	0.1525121663015	0.409871910977567	0.419799796324	7.04670351457987	195.191648974724	3.0727444907811e-11	2.164951525196e-09	0.185331339026023	0.32938815032611
ASIC2	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.427846534905	-1.427846534905	-0.603803154517577	-0.471294403844	11.5066099493849	14.7346836239978	9.28316116727575e-09	4.97039882543354e-07	0.671160344564008	0.976926416210838
ASIC2	BRD-K33610132-001-02-9::2.5::MTS010::PROS002_PR500	2.5	rociletinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.3379437609785	-0.3379437609785	-0.0776273076369155	-0.04459956876075	5.44974664570539	23.2771963354402	1.4793209964438e-05	0.000494558399386684	0.161568562054111	0.359064344629058
ASIC2	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.0055769836325	-0.0055769836325	-0.276529878170402	-0.153671266635	-4.50910331505093	15.1018082033632	0.000409041530566022	0.0100125013938654	-0.398956949854322	-0.142948839221483
ASIC2	BRD-K36363294-001-04-2::2.5::HTS002	2.5	I-BET151	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.151923029519	-0.151923029519	0.118226225040523	0.175731719762	4.60777425362805	191.455286285806	7.41657968978493e-06	0.000261371619519877	0.15450750915466	0.385790999964386
ASIC2	BRD-K37590257-001-02-8::2.5::HTS002	2.5	GSK256066	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.3292099812405	-0.3292099812405	-0.0807545096762652	-0.072384668123	3.94331589560622	162.000543663758	0.000119369622326865	0.00332610137593534	0.124035074518956	0.372875868609513
ASIC2	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.3595403567315	0.3595403567315	0.475095984185213	0.4963205206125	3.82655769968512	71.845341751403	0.000274696062906625	0.00699647444643067	0.0553541556375641	0.175757099269862
ASIC2	BRD-K44827188-001-06-0::2.5::MTS010::PROS003_PR500	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.09970193907485	-0.09970193907485	0.0385073973186186	0.0592458296823	6.58300078383351	188.988486277339	4.42647931324065e-10	2.73013779777714e-08	0.0967949157007216	0.179623757086216
ASIC2	BRD-K45662124-050-01-5::2.5::HTS002	2.5	3'-fluorobenzylspiperone	dopamine receptor ligand	noncancer	DRD2	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.2870167635765	0.2870167635765	0.511300866231481	0.5308791065105	7.33047011480858	184.74319462287	6.94518298647729e-12	5.29546113236816e-10	0.163921341699488	0.284646863610474
ASIC2	BRD-K48684885-001-04-2::2.5::HTS002	2.5	BAY-11-7085	NFkB pathway inhibitor	targeted cancer	NFKBIA	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.66536859621	-1.66536859621	-1.44028615423057	-1.32973039145	3.28202814837084	192.955955084518	0.0012233226123955	0.0263882359291582	0.0898191690051298	0.360345714953724
ASIC2	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.2306861874055	0.2306861874055	0.1368787393045	0.1526722270265	-3.77999477770548	127.600486720623	0.000239711189233415	0.00621246184730455	-0.142913232583023	-0.0447016636189763
ASIC2	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.8068750111885	-0.8068750111885	-1.11072402911875	-1.00700802709	-4.83395698048967	27.3250930697935	4.62548569243374e-05	0.00140341976638396	-0.432749587699133	-0.174948448161361
ASIC2	BRD-K54256913-001-08-7::2.5::MTS010::PROS004_PR500	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-3.457946145465	-3.457946145465	-1.1872566173988	-1.175511705255	17.4745678151001	6.3342142082838	1.34444502120298e-06	5.39007775812597e-05	1.9567543490541	2.58462470707831
ASIC2	BRD-K55966568-001-05-4::2.5::HTS002	2.5	orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.425053366807	0.425053366807	0.31840209117394	0.334471064367	-4.04171828356239	74.1740814751875	0.000128331393632867	0.00355180000851481	-0.159227681001478	-0.0540748702646416
ASIC2	BRD-K56334280-001-05-1::2.5::HTS002	2.5	amonafide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.983356397237	-0.983356397237	-0.398765152859315	-0.351314644036	8.65080071298085	58.7988441297025	4.50236836468678e-12	3.51160156199037e-10	0.449361205557102	0.719821283198268
ASIC2	BRD-K56751279-300-01-4::0.15625::HTS002	0.15625	Y-39983	rho associated kinase inhibitor	noncancer	ROCK1, ROCK2	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.9568594615375	0.9568594615375	0.778589846840916	0.797329257919	-5.57867714604905	8.65167737503858	0.00039583813023627	0.00971705309992092	-0.251004145686265	-0.105535083706902
ASIC2	BRD-K66030860-001-03-6::2.5::HTS002	2.5	salidroside	beta amyloid protein neurotoxicity inhibitor	noncancer	APP	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.1297305323405	-0.1297305323405	0.135920716908061	0.138943386396	7.02530888112842	4.09447571333735	0.00198110226368611	0.0397833474256141	0.161612753677679	0.369689744819442
ASIC2	BRD-K66715657-050-01-0::2.5::HTS002	2.5	UH-232-(+)	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4, HTR1A	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.154473292472	0.154473292472	-0.00371607794888885	0.0059117559481	-5.23375284368343	188.790965933524	4.39742825834482e-07	1.8944651280056e-05	-0.217811177051424	-0.0985675637903535
ASIC2	BRD-K67844266-003-01-9::2.5::HTS002	2.5	pevonedistat	nedd activating enzyme inhibitor	targeted cancer	NAE1, UBA3	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-3.38784590211	-3.38784590211	-2.6032573349392	-2.60596765275	7.8633725072675	41.6615762071716	9.18174798974159e-10	5.48624160828917e-08	0.583180714503571	0.985996419838026
ASIC2	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.351262558428	-0.351262558428	-0.528665315191685	-0.376499820922	-3.34452959193404	159.233047916852	0.00102782155182857	0.0226544596238035	-0.282160640005761	-0.0726448735216099
ASIC2	BRD-K72414522-001-06-7::2.5::HTS002	2.5	AZD5438	CDK inhibitor	targeted cancer	KCNH2	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-2.784293226085	-2.784293226085	-2.41300853091824	-2.18452453626	3.67657520915862	173.861209363928	0.000314779690752568	0.0079093102390747	0.171967265356022	0.570602124977494
ASIC2	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.05011085887205	-0.05011085887205	-0.197988039450999	-0.124222212564	-4.11023699610621	120.454366353439	7.24849318521255e-05	0.00211541706957165	-0.219107934016774	-0.0766464271411241
ASIC2	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.4008181922205	-0.4008181922205	-0.210536408068883	-0.185900015084	5.63636458633513	14.1958574879633	5.82511056903918e-05	0.00173449586433954	0.117968112022563	0.262595456280671
ASIC2	BRD-K77625799-001-07-7::2.5::HTS002	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.3096093853355	0.3096093853355	0.105884868700631	0.160912505802	-3.97473828035541	172.549202679799	0.000103421693374557	0.00292161171995194	-0.304891683613823	-0.102557349655915
ASIC2	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.3571930408	-1.3571930408	-0.767389560275551	-0.659860660516	10.5313734448571	16.4369677435855	1.01486165726924e-08	5.41484401645158e-07	0.471335408231278	0.708271552817621
ASIC2	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.5905504489685	0.5905504489685	0.326148409153684	0.364286574892	-8.51348037228799	17.6663265866609	1.15411087762362e-07	5.39804580184964e-06	-0.329738547475372	-0.19906553215426
ASIC2	BRD-K84783599-001-01-0::2.5::HTS002	2.5	riociguat	guanylate cyclase stimulant	noncancer	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.4643930680735	0.4643930680735	-0.00757899286812644	0.04755872580485	-9.28458535510564	105.660448425108	2.34730901896617e-15	2.52052301966934e-13	-0.572759031750372	-0.371185090132881
ASIC2	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-2.56099035504	-2.56099035504	-2.22949985789532	-2.16824610201	4.9563903355077	184.031675826492	1.62254703078398e-06	6.41384881152525e-05	0.199537553215699	0.46344344107366
ASIC2	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.01347957185815	0.01347957185815	-0.495845719863022	-0.41754362105	-8.98170149179893	9.82581261711657	4.76386903435114e-06	0.000174386897739273	-0.635980621139721	-0.382669962302623
ASIC2	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.323450211173	0.323450211173	0.16588329393517	0.180090535551	-6.01120233345601	5.91907437053169	0.0010038062363425	0.022201387789345	-0.221919058221569	-0.0932147762540909
ASIC2	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.08069480257	-1.08069480257	-1.60085560276251	-1.38505413113	-6.64795526802529	45.5683181185168	3.21077397094442e-08	1.60823083528522e-06	-0.677697527484634	-0.362624072900395
ASIC2	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.6102467038905	-0.6102467038905	-0.360187741922984	-0.28708101882	4.20628486790326	194.486055066558	3.95972979068968e-05	0.00121797492294594	0.13281168765761	0.367306236277421
ASIC2	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	SH10TC, NCIH838	STOMACH, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.885314464848	-0.885314464848	-0.291300979011851	-0.17409866014	8.3017205587467	7.68507843674544	4.22600200823714e-05	0.00129356581608606	0.427827469268928	0.76019950240337
BCAR3	BRD-A08545410-311-03-4::2.5::HTS002	2.5	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.661957487755667	-0.680764769906	-0.49293823347895	-0.4877850808235	4.24779557299663	29.2403437023028	0.000200647863396762	0.00529719161009922	0.0876688679906688	0.250369640562766
BCAR3	BRD-A75726477-003-21-3::2.5::HTS002	2.5	clenbuterol	adrenergic receptor agonist	noncancer	ADRB1, ADRB2, ADRB3, NGF, TNF	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.600262181498667	0.60454107353	0.359785317002268	0.363988651487	-6.03529526297809	11.4525058864573	7.16777739717952e-05	0.00209442748706215	-0.327754393274442	-0.153199335718355
BCAR3	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.165631307564667	-0.177037426307	0.0347216913875535	0.0756101147754	3.45536867664638	61.8916613722179	0.000998188406678356	0.022103597790574	0.0844423909523847	0.316263606952056
BCAR3	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.252044434568	0.225595727133	-0.202424167903026	-0.14794699035	-6.52431766910587	8.25820867506548	0.000159335718106501	0.00432336563185824	-0.614229382884589	-0.294707822057463
BCAR3	BRD-K19761926-001-03-6::2.44857::HTS002	2.44857	eplerenone	cytochrome P450 inhibitor	noncancer	NR3C2	cardiology	congestive heart failure, hypertension	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.13011697157	-1.1084153149	-0.864186859897498	-0.7641372569925	3.36506753757477	99.9294705248842	0.00108667675669374	0.0237538340219698	0.10914207649124	0.422718146853763
BCAR3	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.215380844259667	0.231508314571	0.416350715396857	0.442538388669	6.18902248479664	15.3828153211027	1.54872063697467e-05	0.000516069255911295	0.131907180144702	0.270032562129678
BCAR3	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-6.23063239302333	-6.25852142864	-5.23488762509842	-5.409599745625	8.95823852282406	5.80657365261486	0.000129786309508712	0.0035874348633857	0.721549135310319	1.26994040053951
BCAR3	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0413109747253	0.0612255860006	-0.409562538678323	-0.317592260671	-5.42276324465351	7.46581913037293	0.000793823496256933	0.0180691797078645	-0.645019655260796	-0.25672737154645
BCAR3	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.354106700653	-0.346982305281	-0.0277515875817202	-0.018353672615	12.0620802441835	32.6812517714868	1.40294570279058e-13	1.27196256147801e-11	0.271288279000971	0.381421947141588
BCAR3	BRD-K41876534-001-13-7::2.5::HTS002	2.5	tioxolone	carbonic anhydrase inhibitor	noncancer	CA2	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.535307264107	0.568953173137	0.211059785420209	0.271068765033	-5.5125858223987	9.98758142445926	0.000258354918164901	0.00663228545399031	-0.455327558420397	-0.193167398953185
BCAR3	BRD-K52172416-001-11-4::2.5::HTS002	2.5	anastrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	JHH1, NCIH226	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.490913710429	0.490913710429	0.301812046758596	0.296380524619	-6.61990863315752	32.7773343093878	1.62697197093408e-07	7.4510101615028e-06	-0.247233816405488	-0.130969510935319
BCAR3	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.303469313167	-0.329684083601	-0.692348505175063	-0.647957316617	-5.4041941102732	9.72739921285798	0.00032965226356368	0.00825204858646811	-0.549824475450796	-0.227933908565329
BCAR3	BRD-K61642990-001-01-0::2.5::HTS002	2.5	FERb-033	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.122465969612633	-0.106717765528	0.186981249674579	0.264303650452	5.96401754902125	9.2946303072695	0.000186102517768547	0.00495910644758063	0.192638328226188	0.426256110348237
BCAR3	BRD-K66175015-001-09-0::2.5::HTS002	2.5	afatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.72926292528667	-1.73153059105	-0.895171327692827	-0.708848942726	5.56777719375424	5.55843334821598	0.00183007173351869	0.0371824290997562	0.46035136866962	1.20783182651806
BCAR3	BRD-K79930101-300-03-7::2.5::HTS002	2.5	GW-583340	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.64780319006	-1.57858828656	-0.510087709402434	-0.357711899162	9.98916535867731	4.36499132743552	0.00036047175072578	0.00895276163125629	0.83165250691449	1.44377845440064
BCAR3	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.48544979900667	-1.47795077755	-1.28053169531777	-1.21290029961	3.2022210676347	119.772177147684	0.00174691542527217	0.0357859485848486	0.0782149699152045	0.331621237462579
BCAR3	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.415144977645	0.409644718316	0.0936707225280526	0.163098987383	-8.05704099243703	27.9027609677442	9.212250848449e-09	4.9348975558541e-07	-0.403218106650221	-0.239730403583674
BCAR3	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.00221343697846667	-0.018111096879	0.303673624393443	0.280568538636	6.29372542473959	9.29958619878036	0.000123300970026312	0.00342628984892641	0.196479455770028	0.415294666973791
BCAR3	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	JHH1, MIAPACA2, NCIH226	LIVER, PANCREAS, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.93168153393667	-3.95282494547	-3.15404869708829	-3.18250469697	7.57049388778424	6.62344768812728	0.000170693236956773	0.00459662153332179	0.531913710473877	1.02335196322287
BCAS3	BRD-A03623303-045-09-5::2.5::HTS002	2.5	metoprolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.0641289734617	0.0641289734617	0.241128752484176	0.21036832824	6.10387135245621	144.34031494638	9.07059175152863e-09	4.86265847802246e-07	0.119684291817863	0.234315266227089
BCAS3	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.695407670057	-0.695407670057	-0.489072930758467	-0.37614168814	3.54300754267885	140.742934781942	0.000537176503209079	0.0127655508101007	0.0912020202155584	0.321467458381507
BCAS3	BRD-A16997652-001-02-3::2.5::HTS002	2.5	protirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	radiology	thyroid function diagnostic	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.20173494162	0.20173494162	0.336509185744021	0.3577439342815	6.12408813830578	186.454988819454	5.28256943435611e-09	2.91205716125543e-07	0.0913590630177695	0.178189425230273
BCAS3	BRD-A28329383-001-02-1::2.5::HTS002	2.5	MTPG	glutamate receptor antagonist	noncancer	GRM2, GRM3	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.160252182976	0.160252182976	0.0212061142569722	0.0389518722109	-4.09009990027351	193.440192026612	6.3222395310975e-05	0.00186927752305228	-0.20609602714854	-0.071996110289516
BCAS3	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.1204162384845	-1.1204162384845	-3.8342968493457	-3.817245684415	-17.1861791209512	2.60764762488738	0.000935345798063284	0.0208768904199976	-3.26202889185998	-2.16573232986242
BCAS3	BRD-A48300215-001-04-8::2.5::HTS002	2.5	ajmaline	sodium channel blocker	noncancer	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.279516882576	-0.279516882576	0.0854762144400821	0.1404901413085	7.56948943453876	156.903826121292	2.99800090636829e-12	2.38072818177477e-10	0.269751027099267	0.460235166932897
BCAS3	BRD-A51964809-003-12-6::2.5::HTS002	2.5	halofantrine	antimalarial agent	noncancer	KCNH2, KCNN4	infectious disease	malaria	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.24641155365	-0.24641155365	-0.128758754736604	-0.125815846573	3.98865368709159	130.45953796995	0.000110122474136183	0.00309377896960729	0.0592987004929666	0.176006897333826
BCAS3	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.4907415339845	0.4907415339845	0.0708445112699325	0.128125201883	-11.4039184231643	6.58275889018756	1.41016671935548e-05	0.000473062486762782	-0.508094785674347	-0.331699259754788
BCAS3	BRD-A67748489-001-10-0::2.5::HTS002	2.5	K-858	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.203024305825	-1.203024305825	-2.65966636958353	-2.53659706209	-10.231411813805	3.60506354444187	0.000860796748241412	0.0193836631911992	-1.86960133206571	-1.04368279545135
BCAS3	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.4246978508525	-0.4246978508525	0.150206291438622	0.138064341376	19.0918031021395	14.5609504331858	1.03449962247234e-11	7.72824223021518e-10	0.510551649522551	0.639256635059692
BCAS3	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.6403884317425	0.6403884317425	0.354533153979896	0.3602013274625	-8.9585385259631	4.05481874635205	0.000806533697930733	0.0183273495487485	-0.373977654916547	-0.19773290060866
BCAS3	BRD-A79981887-003-16-4::2.5::HTS002	2.5	midodrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.03528747486315	0.03528747486315	-1.04836653870281	-1.024762922465	-9.89197720154417	4.17572596727714	0.000472060757785841	0.0113873168436108	-1.38282812097562	-0.784479906156303
BCAS3	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.617914123758	0.617914123758	0.410897907036145	0.462027349437	-5.98150621193419	50.6768406994873	2.2382985857421e-07	1.00404415567919e-05	-0.276508204139507	-0.137524229304204
BCAS3	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.6155698335495	0.6155698335495	0.205745200543538	0.236646785158	-9.88913136236508	189.844550927205	7.30109764000687e-19	1.08293214953982e-16	-0.491570425572218	-0.328078840439706
BCAS3	BRD-K01773560-001-02-4::2.59308::HTS002	2.59308	UNC2250	MER tyrosine kinase inhibitor	targeted cancer	MERTK	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.5975122077365	0.5975122077365	-0.137711479777729	-0.120206350846	-16.5255447552453	120.177152426046	1.00224410024122e-32	5.12672973175659e-30	-0.823309732499771	-0.647137642528688
BCAS3	BRD-K03549949-001-01-0::2.5::HTS002	2.5	XL388	mTOR inhibitor	targeted cancer	MTOR	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.895203090439	-0.895203090439	-1.33478091609241	-1.14186011868	-6.08116569452939	150.539524926768	9.4077985679587e-09	5.0346168770837e-07	-0.58240222792016	-0.296753423386662
BCAS3	BRD-K04430056-236-02-1::2.5::HTS002	2.5	7-nitroindazole	nitric oxide synthase inhibitor	noncancer	NOS1, NOS2, NOS3	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.4346519443675	0.4346519443675	0.307113442508023	0.309926543901	-4.67900197651058	54.452050522547	1.94921838002812e-05	0.000636947745346924	-0.182176370125981	-0.072900633592973
BCAS3	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.3709109516145	-0.3709109516145	-1.23014281089399	-1.264129385735	-8.71269937246938	4.68721623041902	0.000454184141641425	0.0110118589246454	-1.11791203373517	-0.600551684823824
BCAS3	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.7145116018805	-0.7145116018805	-1.0297497084137	-1.0089298839585	-5.79632034105723	98.0390162308269	8.24963492543291e-08	3.91874114346877e-06	-0.423164621015211	-0.207311592051199
BCAS3	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.96805651157	-1.96805651157	-3.08445489623352	-3.12584681211	-11.8289279521915	188.94006341811	1.612832519703e-24	3.97429114611292e-22	-1.30256964805823	-0.930227121268806
BCAS3	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.1791011368295	0.1791011368295	-0.289235576612194	-0.2721742756055	-12.0744185987943	8.83492465129774	8.6235333225076e-07	3.55573927179633e-05	-0.556330717350799	-0.380342709532588
BCAS3	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.771763753166	0.771763753166	0.396645037187495	0.431459247123	-11.4883198669536	38.2733969835664	5.69397089014542e-14	5.357256746769e-12	-0.441204100926798	-0.309033331030212
BCAS3	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.06351417871	-2.06351417871	-2.36007991637229	-2.30540806626	-3.34214862760545	192.052352174511	0.000999170238770388	0.0221115491678865	-0.47158614347696	-0.121545331847622
BCAS3	BRD-K17979676-001-01-2::2.5::HTS002	2.5	eprobemide	monoamine oxidase inhibitor	noncancer	MAOA	neurology/psychiatry	depression	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.1362389273675	0.1362389273675	-0.0470982474128584	-0.01607222471295	-3.85373768895599	165.405384957678	0.000166184437053683	0.00448760793867694	-0.277267472773845	-0.0894068767868715
BCAS3	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.10903352006	0.10903352006	-0.0616859670108253	-0.0626502991923	-5.17950529999352	175.542093047801	6.05492292809771e-07	2.55461727609499e-05	-0.235769495371547	-0.105669478770104
BCAS3	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.6925812503895	-0.6925812503895	-0.190343137117531	-0.144534319806	8.82296587160053	16.2233812149077	1.36388908189114e-07	6.31635659102519e-06	0.381699618136384	0.622776608407555
BCAS3	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.376223421413	-0.376223421413	-0.779010128045216	-0.759682041762	-6.0969405213909	54.9845946479758	1.12239454867667e-07	5.25932884178668e-06	-0.535182238258698	-0.270391175005734
BCAS3	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.8027078707235	-0.8027078707235	-0.397874499310557	-0.300509996498	6.7767298159087	105.867055318629	7.17738138270019e-10	4.33696355898717e-08	0.286393771228013	0.523272971597874
BCAS3	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.1051261983265	0.1051261983265	-0.0538068374168128	-0.030411088067	-8.81775580251979	188.462584324725	7.7659717130797e-16	8.71908303453462e-14	-0.194488146593595	-0.12337792489303
BCAS3	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.80715765596	-2.80715765596	-3.6382620578773	-3.592577528105	-9.2429132072627	7.81567162702198	1.77496670691746e-05	0.000585182032497941	-1.03931002370196	-0.622898780132646
BCAS3	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.182251386306	0.182251386306	-0.944665265968792	-0.797793160199	-13.8669408809962	11.288835155146	1.93469519499467e-08	9.98462042976194e-07	-1.30522606418524	-0.948607240364347
BCAS3	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.129054283126	-0.129054283126	-1.34825349158943	-1.265409369745	-20.8223927143529	191.999176950303	3.91497033290921e-51	1.04886459560262e-47	-1.33468758385611	-1.10371083307075
BCAS3	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.0435797647955	-0.0435797647955	-0.696688117342003	-0.621232482709	-8.9778205021948	3.1899477927889	0.00227900498816089	0.0448743096102466	-0.877014616967152	-0.429202088125855
BCAS3	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.0687750143847	0.0687750143847	0.415076545937581	0.43502168689	13.3197373039807	28.2118750931259	1.08191405191839e-13	9.88429483519252e-12	0.293062748999647	0.399540314106114
BCAS3	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.0412630613737	-0.0412630613737	-0.276160074255985	-0.153671266635	-4.50393720223718	192.967647975139	1.15332865171722e-05	0.000392430189861726	-0.337761526379689	-0.132032499384882
BCAS3	BRD-K36529613-001-02-6::2.5::HTS002	2.5	PU-H71	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.384220335855	-2.384220335855	-3.49159007037133	-3.372344193665	-8.63173493294171	6.17760886619893	0.000113499448022898	0.00317908646491918	-1.41911051163152	-0.795628957401142
BCAS3	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.6400318575035	0.6400318575035	0.252025751240073	0.2832758926905	-12.0805528832822	171.232916183758	1.07133438675827e-24	2.70775976155086e-22	-0.451404777706622	-0.324607434820232
BCAS3	BRD-K41599323-001-02-3::2.5::HTS002	2.5	lonafarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, HRAS, KRAS, NRAS	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.225052713221	-0.225052713221	-1.29663205208141	-1.19482949475	-13.3301136057925	51.539169696991	2.48053908156432e-18	3.51175377776081e-16	-1.23292372467395	-0.910234953046882
BCAS3	BRD-K41783120-001-02-8::2.5::HTS002	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.5014750766465	0.5014750766465	-0.286489078808219	-0.180532347642	-10.4483008619839	8.97645789377058	2.53265191431496e-06	9.71578221126204e-05	-0.958634167032429	-0.617294143877009
BCAS3	BRD-K44067360-001-30-3::2.5::HTS002	2.5	flufenamic-acid	chloride channel blocker	noncancer	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.532767811588	0.532767811588	0.067578956203448	0.08403527726685	-16.3221637669588	187.952379252305	7.1153138079906e-38	6.00400824075913e-35	-0.521410703127595	-0.408967007641509
BCAS3	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	1.493953251425	1.493953251425	-0.74405439953165	-0.623158972273	-21.7903580245979	17.0920106210275	6.55591640273987e-14	6.12520927063135e-12	-2.45461023513102	-2.02140506678229
BCAS3	BRD-K45662124-050-01-5::2.5::HTS002	2.5	3'-fluorobenzylspiperone	dopamine receptor ligand	noncancer	DRD2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.7597641984735	0.7597641984735	0.506217560479901	0.5255641700865	-7.87158572630782	62.0001324004292	6.61042913501077e-11	4.46660361310758e-09	-0.317934234556905	-0.189159041430294
BCAS3	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.267395087167	0.267395087167	-0.684654537740279	-0.588520646364	-13.0681401079471	4.12709199366086	0.000163617270973228	0.00442776844323497	-1.15188820099386	-0.752211048820697
BCAS3	BRD-K48195801-001-01-6::2.5::HTS002	2.5	tecastemizole	histamine receptor antagonist	noncancer	KCNH2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.08418974798725	-0.08418974798725	0.345368348211047	0.312371086483	9.11073083920379	3.4471416163645	0.0015698592322012	0.0326829876718156	0.289942045485187	0.569174146911406
BCAS3	BRD-K49027941-001-01-1::2.5::HTS002	2.5	PSB-1115	adenosine receptor antagonist	noncancer	ADORA1, ADORA2B, ADORA3	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.49900369432	0.49900369432	0.112409555720521	0.170361291898	-6.49303942097781	13.7355595540416	1.55467224043694e-05	0.000517569659242945	-0.514525300779666	-0.258662976419292
BCAS3	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.6429318022415	0.6429318022415	0.399971057303407	0.450986520291	-6.6963171179857	9.18738588215552	8.06931337997172e-05	0.00233367678776948	-0.324783532228211	-0.161137957647974
BCAS3	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-3.494067597315	-3.494067597315	-1.22559066828146	-0.855735961913	16.1015973948119	2.43583787624578	0.00155758503853933	0.0324806035926343	1.75524182120164	2.78171203686543
BCAS3	BRD-K50853363-001-02-3::2.5::HTS002	2.5	dienogest	progesterone receptor agonist	noncancer	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.03810786426187	0.03810786426187	-0.280478585040957	-0.2219400984365	-5.47432266963118	9.38979762798662	0.00033878909728288	0.00845804641019712	-0.449407697417917	-0.187765201187737
BCAS3	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.441230413747	0.441230413747	-0.107079260468943	-0.112273492753	-12.423817726283	193.063548953224	2.00476270626295e-26	5.76750048416955e-24	-0.635355887906521	-0.461263460525364
BCAS3	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-4.378846817895	-4.378846817895	-6.20041320413663	-6.32403693229	-21.0357286460708	189.877587538138	1.7091968112528e-51	4.93249218436077e-48	-1.9923760567885	-1.65075671569476
BCAS3	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.02671467216725	-0.02671467216725	0.260623942772847	0.257282112096	8.51971402645396	18.5300616009227	7.89751848082637e-08	3.76148275217119e-06	0.216627249552599	0.358049980327595
BCAS3	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.09646039468375	0.09646039468375	-0.217884681819451	-0.1500661795165	-7.8800141400824	11.1376493123063	6.98350577465826e-06	0.000247522376248839	-0.40201332438567	-0.226676828620732
BCAS3	BRD-K54247840-004-01-3::2.5::HTS002	2.5	halofuginone	collagenase inhibitor	noncancer	COL1A1, MMP2	rheumatology	scleroderma	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-3.683521626515	-3.683521626515	-5.73651264526586	-5.5836707127	-11.82302189834	3.06465718764845	0.0011750300187438	0.025474432900234	-2.59906471763154	-1.50691731987019
BCAS3	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.398661963642	0.398661963642	-0.141345283005464	0.01900224238145	-7.33016162359859	11.0926534557056	1.41710016636394e-05	0.00047509097693824	-0.701987008368694	-0.378027484926234
BCAS3	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-4.86701395616	-4.86701395616	-5.59261508549205	-5.54901350857	-8.22445292646609	19.5364022965494	9.02286858150048e-08	4.2699545157969e-06	-0.90991530781276	-0.541286950851347
BCAS3	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.5654412076475	0.5654412076475	0.0319753679731638	0.07942712884705	-12.0431727432587	3.33963838120217	0.000724098791541613	0.016662590712081	-0.666662435837163	-0.400269243511509
BCAS3	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.67925962052	-1.67925962052	-3.66108748198413	-3.579783032275	-11.8323307393164	3.54291443886092	0.000565711141017131	0.0133724829759635	-2.4715061414136	-1.49214958151465
BCAS3	BRD-K60184833-001-05-6::2.5::HTS002	2.5	tyrphostin-AG-99	tyrosine kinase inhibitor	targeted cancer	EGFR	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.2798482008	-1.2798482008	-1.68985971741466	-1.52742041275	-4.80343109621495	29.5913355292511	4.18379182912828e-05	0.00128192697490384	-0.584436922933753	-0.235586110295569
BCAS3	BRD-K60997853-001-02-3::2.5::MTS010::PROS004_PR500	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.459981085356	0.459981085356	-0.737147016078533	-0.7041999710785	-18.1257204387549	53.0668953023808	2.16281174045395e-24	5.2497539922962e-22	-1.32959534584693	-1.06466085702214
BCAS3	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.346168651049	-0.346168651049	-0.207363272781119	-0.128286851934	3.43295280180942	32.3075135513127	0.00165531548681827	0.0341892756070417	0.0564763129359412	0.22113444359982
BCAS3	BRD-K62965247-001-04-9::2.5::HTS002	2.5	tipifarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, FNTB	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.525133949379	-0.525133949379	-1.47962343302132	-1.40587252118	-16.1163192769198	94.1409146404555	8.13695949309514e-29	2.97608599180135e-26	-1.0720798732476	-0.836899094037048
BCAS3	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.0728226261495	-1.0728226261495	-1.8471410149831	-1.7566794361	-6.26516355779161	5.21386004722165	0.00130403625620476	0.0278767989982157	-1.0881395936983	-0.460497183968905
BCAS3	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.9858987273095	0.9858987273095	-0.730732903310671	-0.5340799664045	-15.9606353593465	35.2783975770738	1.0309217329167e-17	1.38704597673762e-15	-1.93491646576811	-1.49834679547223
BCAS3	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.0560405234456	0.0560405234456	-1.08989247753274	-0.4202572111255	-7.24976340978503	4.23333671060898	0.00154077250203314	0.0321706994240877	-1.57541430698697	-0.716451694969707
BCAS3	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.528525892807	-0.528525892807	-2.64836097110781	-2.62453052692	-11.1880179035852	3.60992562786885	0.000624433049686246	0.0145804674916879	-2.66909318868805	-1.57057696791357
BCAS3	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.02206705550825	-0.02206705550825	-0.79241489467606	-0.692855994301	-9.31489895115566	4.85099590712799	0.000281716160274625	0.00715414788045953	-0.984915673300704	-0.555780005034915
BCAS3	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.94488759767	-1.94488759767	-3.11715913265355	-3.18680355288	-8.71804814973125	3.54600794270691	0.0016142456772242	0.0334862235534054	-1.56523346411342	-0.779309605853694
BCAS3	BRD-K69172251-001-08-9::2.5::HTS002	2.5	cisplatin	DNA alkylating agent, DNA synthesis inhibitor	chemo	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.589427887137	0.589427887137	0.37904365698327	0.369534361464	-7.803429154781	48.0632021535837	4.33198618766886e-10	2.67416551732972e-08	-0.264590075765006	-0.156178384542455
BCAS3	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.934833973213	-0.934833973213	-2.59973639793666	-2.40345273405	-11.1016082343852	5.91074134123604	3.52177339681875e-05	0.00109409794226231	-2.03321200124972	-1.2965928481976
BCAS3	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	1.13234253907	1.13234253907	-0.742413067196513	-0.60872932846	-17.6127800359758	15.2828793165591	1.45060372540693e-11	1.06474810226966e-09	-2.1012680952365	-1.64824311729653
BCAS3	BRD-K69932463-001-10-6::2.5::HTS002	2.5	AZD8055	mTOR inhibitor	targeted cancer	MTOR	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.784354694405	-1.784354694405	-2.75216048360106	-2.74184167239	-15.365200691505	156.404965405614	4.61665849506931e-33	2.46140248405401e-30	-1.09222043446541	-0.843391143926707
BCAS3	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-3.14526287698	-3.14526287698	-0.505355117108314	-0.39621393329	25.2924829716128	2.5431250954022	0.000401119891997273	0.00983431998763253	2.27129044539585	3.00852507434752
BCAS3	BRD-K71847383-001-12-5::2.5::HTS002	2.5	cytarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.607888489793	0.607888489793	0.326525855940167	0.311150220691	-9.72172042470873	52.283732976887	2.57845443118845e-13	2.27329312950304e-11	-0.339430803329324	-0.223294464376341
BCAS3	BRD-K72420232-001-12-3::2.5::HTS002	2.5	WZ-4002	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.397356620626	-0.397356620626	-0.0690874478918267	0.037173334974	6.42371459210675	36.5848977733132	1.76458628791263e-07	8.02295321387413e-06	0.224685592046829	0.431852753421517
BCAS3	BRD-K72827473-001-01-0::2.5::HTS002	2.5	CEP-37440	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.2581172877795	0.2581172877795	-0.236297639173442	-0.1997036713495	-10.8081951919755	28.5357519809077	1.33847988272821e-11	9.86502939426599e-10	-0.588038988232221	-0.400790865673663
BCAS3	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.661799897335	-1.661799897335	-2.33017532009343	-2.24109191203	-7.45617823374061	91.2286214420352	4.98202929006766e-11	3.4137391501731e-09	-0.846429220109823	-0.490321625407044
BCAS3	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.08127100497715	0.08127100497715	-0.149911932145583	-0.132191437107	-5.49528725870745	151.448663946821	1.6148725271537e-07	7.40350831812458e-06	-0.314301443283193	-0.148064430962273
BCAS3	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.0892579693385	0.0892579693385	-0.215668095624475	-0.189464823924	-9.855350682792	52.7169343645072	1.47987722115534e-13	1.3366228610746e-11	-0.366991934002695	-0.242860195923254
BCAS3	BRD-K80608265-001-01-6::2.5::HTS002	2.5	erteberel	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.4542744574155	0.4542744574155	0.000245197603673487	0.05335983697175	-9.99629316242512	47.1240480665145	3.14742101239246e-13	2.74891441795054e-11	-0.545395687015242	-0.362662832608411
BCAS3	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.139263975295	0.139263975295	0.015678908994332	0.0495734767378	-4.12085452039087	29.5306703934752	0.000280146774000025	0.00711725492976384	-0.184873978816887	-0.0622961537844487
BCAS3	BRD-K81548480-001-01-2::2.5::HTS002	2.5	AC-264613	PAR agonist	noncancer	F2RL1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.0063283960547	-0.0063283960547	-0.373249283296972	-0.2564995934565	-6.27814982261217	10.2549204868368	8.20603175418645e-05	0.00236810364863744	-0.496705029796471	-0.237136744688073
BCAS3	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.681875234349	0.681875234349	-0.513700935603359	-0.3823931691785	-15.5988099123916	6.67401811615073	1.68696906955901e-06	6.64766305772223e-05	-1.37862365946018	-1.01252868044454
BCAS3	BRD-K84163249-001-01-9::2.5::HTS002	2.5	ercalcitriol	vitamin D receptor agonist	noncancer	VDR	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.04304070888364	-0.04304070888364	-0.523498640076298	-0.512270344083	-8.24573774608762	5.45163174920373	0.000280168711851488	0.00711725492976384	-0.626582804916922	-0.334333057468394
BCAS3	BRD-K87696786-003-04-4::2.5::HTS002	2.5	LY456236	glutamate receptor antagonist	noncancer	GRM1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.290906999655	-1.290906999655	-2.19754975341502	-2.03818987744	-8.85891999886799	28.6488498773836	1.06435669120325e-09	6.30869760146297e-08	-1.11606787274856	-0.69721763477149
BCAS3	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.23951801558	-1.23951801558	-0.773940085880323	-0.768623385632	9.6692955917831	188.000091373601	3.30898099032585e-18	4.6455895751695e-16	0.370593946564093	0.560561912835262
BCAS3	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.107330250375	-1.107330250375	-2.07029615551076	-1.887176140495	-9.1925981631688	127.910934754725	9.01455323457638e-16	1.00629176052788e-13	-1.17024193228494	-0.755689877986575
BCAS3	BRD-K89299012-001-06-0::2.5::HTS002	2.5	DCEBIO	potassium channel activator	noncancer	KCNN2, KCNN3, KCNN4	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.0533051275285	-1.0533051275285	-2.05356836033494	-1.8672769967	-8.75868430388961	6.30570125030591	9.298197574589e-05	0.00264974523063966	-1.27645525179458	-0.724071213818307
BCAS3	BRD-K89714990-001-01-5::2.5::HTS002	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.386544068755	0.386544068755	-0.0101833698448802	-0.02895586832955	-9.86676380348555	7.05133226810832	2.22644857834451e-05	0.000718988243706493	-0.491665221760737	-0.301789655439024
BCAS3	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.400856176821	-0.400856176821	-1.42810917205096	-1.12582537284	-11.308393561835	164.543905853378	2.65226386834802e-22	5.36786650273053e-20	-1.2066150514604	-0.847890938999531
BCAS3	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.235216171405	-1.235216171405	-2.2547741731459	-2.18755983006	-10.2014630138591	12.4706145941573	2.06262554833697e-07	9.30304021779279e-06	-1.23640570642033	-0.802710297061465
BCAS3	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.644368139135	-1.644368139135	-1.24655343353336	-1.23927241763	5.35101972856321	50.201758434729	2.16759371723475e-06	8.40561233618973e-05	0.248505819707398	0.547123591495884
BCAS3	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.420618734277	0.420618734277	0.598932336449644	0.600417589144	4.790258145017	109.522815720719	5.26082226152659e-06	0.000190980144730815	0.104540369515109	0.252086834830179
BCAS3	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.6059044378455	0.6059044378455	-0.0832097136142507	-0.0625986180944	-10.4974548509105	4.16663055719199	0.000375662451252973	0.00929953309246923	-0.868537252382857	-0.509691050536645
BCAS3	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-3.445839016195	-3.445839016195	-4.64152261480067	-4.64147020308	-12.5888103320247	97.4745277839563	3.74825284349843e-22	7.45923197487628e-20	-1.38418076463449	-1.00718643257684
BCAS3	BRD-K98157055-001-10-9::0.625::HTS002	0.625	SIB-1757	glutamate receptor antagonist	noncancer	GRM5	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.1530778629805	-0.1530778629805	0.227341322994445	0.266385718245	8.15060153054184	9.33372098802116	1.52919313829773e-05	0.000510276251188253	0.275408476498248	0.485429895451641
BCAS3	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	OE19, BT474	OESOPHAGUS, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.304496030405	-2.304496030405	-3.07835276322566	-3.084015642295	-6.24963136003973	5.22854023181978	0.00130571827624647	0.0279099723177052	-1.08801790710069	-0.459695558540631
BCAS4	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.410334305883	0.410334305883	0.174617745300945	0.21394626854	-6.94767909852764	7.40608003219369	0.00017080088407515	0.00459894254810839	-0.315058904994096	-0.156374216170015
BCAS4	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.3612928295015	-0.3612928295015	-0.833590048345413	-0.720201208535	-6.21033595301326	6.58662154407095	0.000560727818492392	0.0132707854030097	-0.654440749274203	-0.290153688413623
BCAS4	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.175014663678	-0.175014663678	0.256879872226801	0.256070233499	16.2145219553685	168.379979455522	3.19239305863363e-36	2.31939800631826e-33	0.379310448609003	0.484478623200599
BCAS4	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.149986274013	-0.149986274013	-0.514378567798762	-0.46624794895	-7.22621818679149	169.567456850249	1.61360246163631e-11	1.17753422540024e-09	-0.463936704384418	-0.264847883187105
BCAS4	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.2930710746105	-0.2930710746105	-0.0790682290391784	-0.05385103964535	5.23987667723494	177.550624404313	4.51950029226279e-07	1.94120236100279e-05	0.13340620799877	0.294599483143873
BCAS4	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.10197136601015	0.10197136601015	-0.224924616659087	-0.09818472346655	-5.80251662386959	180.771783890167	2.87277496750557e-08	1.44704814573561e-06	-0.438058540691276	-0.215733424647198
BCAS4	BRD-A72703248-003-04-9::2.5::HTS002	2.5	SKF-96365	calcium channel blocker	noncancer	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.989428133805	-1.989428133805	-3.55903104415324	-3.55274052264	-10.1449297804964	4.12331550528738	0.000455116073633251	0.0110315400581953	-1.9941493872645	-1.14505643343198
BCAS4	BRD-A74391928-051-01-3::2.5::HTS002	2.5	ibutilide	potassium channel blocker	noncancer	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.361417100726	0.361417100726	0.164429396657496	0.15975952739	-4.71433121870183	55.0630382025568	1.69399198636967e-05	0.000560728352813321	-0.280724294505492	-0.113251113631516
BCAS4	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.7162471870425	0.7162471870425	0.257409836000688	0.303778240807	-10.2299927973068	10.2713043716307	1.03821961903519e-06	4.22400479742206e-05	-0.558417551835881	-0.359257150247743
BCAS4	BRD-K00673382-001-18-9::0.15625::HTS002	0.15625	famotidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	heartburn	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.6872793164725	0.6872793164725	0.500251495226887	0.4883209569055	-4.72633522572232	18.2723116429446	0.00016214614276729	0.00439017441045611	-0.270075580200199	-0.103980062291026
BCAS4	BRD-K02389548-001-02-5::2.5::HTS002	2.5	RG2833	HDAC inhibitor	noncancer	HDAC1, HDAC3	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.0102238254283555	-0.0102238254283555	0.320945923525307	0.362491356389	8.60941831216646	85.5492632060077	3.18615456545695e-13	2.77821530455583e-11	0.254696155084635	0.407643342822691
BCAS4	BRD-K03273112-001-01-8::2.5::HTS002	2.5	1-azakenpaullone	glycogen synthase kinase inhibitor	noncancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.006761694933	-1.006761694933	-0.712084505655949	-0.635465288366	4.01301327433071	132.864899887409	9.96106955841453e-05	0.00282400274786432	0.149433337063678	0.439921041490424
BCAS4	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.1686118006265	0.1686118006265	-0.297263603438189	-0.208078798615	-8.69275010698846	114.879408509402	2.86255083607755e-14	2.78243835893726e-12	-0.572035112062625	-0.359715696066753
BCAS4	BRD-K06234293-001-04-2::2.5::HTS002	2.5	LY364947	TGF beta receptor inhibitor, p38 MAPK inhibitor	targeted cancer	TGFBR1	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.3676527157445	0.3676527157445	0.790387182843772	0.824104228749	8.82932097833953	3.27258364802192	0.00216255548256061	0.0428688821699717	0.277297924322682	0.568171009875862
BCAS4	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.333612607935	-1.333612607935	-2.50201198308241	-2.37307934162	-9.79919629113426	18.4725110216469	9.537340538098e-09	5.10139421060646e-07	-1.41844263702757	-0.918356113267242
BCAS4	BRD-K07572174-001-39-4::2.48092::HTS002	2.48092	curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	targeted cancer	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.70948883872	-1.70948883872	-1.16958842951003	-1.01297286124	6.81860380830231	188.10857209575	1.21579258530656e-10	7.97611291754422e-09	0.383704589284384	0.696096229135565
BCAS4	BRD-K07955840-001-02-3::2.5::HTS002	2.5	PF-05212384	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-5.87717158476	-5.87717158476	-4.69049625939918	-4.630205698585	12.0944798080682	77.5968141179349	1.55515573358741e-19	2.45445488382957e-17	0.991323189979004	1.38202746074265
BCAS4	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.763238938825	-1.763238938825	-1.48885322357328	-1.38645123972	3.54009125662693	16.9741817707107	0.00252048307365373	0.0489057230393925	0.110838988056675	0.437932442446774
BCAS4	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.140691993273	-0.140691993273	-0.422438475797367	-0.390164965854	-7.31733129448013	17.4280684857649	1.03547636545249e-06	4.21444386500318e-05	-0.362831078563999	-0.200661886484735
BCAS4	BRD-K16180792-001-01-7::2.5::MTS006	2.5	bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	noncancer	PTPN1	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.170950635412	0.170950635412	-0.238067826127273	-0.0973395896878	-7.14935283336758	114.410330810804	8.78074774474908e-11	5.86465840880126e-09	-0.522347775557368	-0.295689147521178
BCAS4	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.4961268588315	-0.4961268588315	0.0928624781318901	0.105022107206	16.8125478911648	14.1795021105984	9.18666495277615e-11	6.12241515131704e-09	0.513940757652657	0.664037916274123
BCAS4	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-3.48356005845	-3.48356005845	-2.85452467036691	-2.57172187262	4.95568098109994	177.955943861998	1.6699143279056e-06	6.58530023892694e-05	0.378549426372667	0.879521349793518
BCAS4	BRD-K18518344-001-15-9::2.5::HTS002	2.5	digitoxigenin	ATPase inhibitor	noncancer	ATP1A1	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-2.830321676505	-2.830321676505	-4.14749725217942	-4.343421581	-10.1505148047504	172.947083110773	2.7617314707881e-19	4.27687243065421e-17	-1.57330140278342	-1.06104974856543
BCAS4	BRD-K21528677-001-02-8::2.43672::HTS002	2.43672	desonide	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.1711880273675	-0.1711880273675	0.0891854724172513	0.124628316908	5.67532491280496	9.47054491760237	0.000251360658720309	0.00647973932206756	0.157370618582031	0.363376380987471
BCAS4	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-2.80843825177	-2.80843825177	-3.27194146569854	-3.04327234152	-3.90919334399999	85.3812113276014	0.000185035468679064	0.00493510041892921	-0.69923194062749	-0.227774487229584
BCAS4	BRD-K24556098-001-16-7::2.45349::HTS002	2.45349	deoxycorticosterone-acetate	progestogen hormone	noncancer	NR3C2	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-3.520216614665	-3.520216614665	-2.65436814277277	-2.47219740762	7.35918036913026	188.19835281313	5.57448880510191e-12	4.28541826079156e-10	0.633755326980967	1.0979416168035
BCAS4	BRD-K24696047-001-02-3::2.5::HTS002	2.5	NVP-AEW541	IGF-1 inhibitor	targeted cancer	IGF1R, INSR	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.0640825168053	-0.0640825168053	0.167230247871587	0.195838010554	6.37427467802569	17.7747079737346	5.60864690585862e-06	0.000202645934370494	0.155004164276376	0.307621365077399
BCAS4	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.11642289296665	0.11642289296665	-0.507036834918182	-0.436225052339	-10.6414744105477	6.82731487564487	1.69098580465745e-05	0.000559906220495021	-0.762711187225242	-0.484208268544421
BCAS4	BRD-K27184429-300-01-3::2.5::HTS002	2.5	levocetirizine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.0182929347875	-1.0182929347875	-0.346690662918256	-0.229917154619	12.883449517733	17.8277008291172	1.81110075900385e-10	1.1653299747119e-08	0.562007235090771	0.781197308647716
BCAS4	BRD-K27316855-001-13-3::2.43597::HTS002	2.43597	calcitriol	vitamin D receptor agonist	noncancer	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.226566539588	-0.226566539588	-0.0342314438708124	0.01343134409051	4.06667881223985	13.4275281293826	0.00125220695438804	0.0269326908506807	0.09048936993867	0.294180821495705
BCAS4	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-2.323184334425	-2.323184334425	-1.32997368439829	-1.36979496737	14.4506328179337	84.2090366897937	1.61323633158286e-24	3.97429114611292e-22	0.856535897183496	1.12988540286993
BCAS4	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.800404048467	-0.800404048467	-0.505024157607424	-0.3949049279025	5.75093809405631	69.2854091285546	2.19819975145144e-07	9.8708978531078e-06	0.192922961625723	0.397836820093428
BCAS4	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-5.936010257275	-5.936010257275	-4.65207902314533	-5.03947371329	9.42718624297109	21.271231449618	4.78179701172233e-09	2.64894745858215e-07	1.00091893993685	1.56694352832249
BCAS4	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.646393536965	-1.646393536965	-1.00770108279775	-1.02230629729	9.39598869569137	47.8497683876885	1.92826121460003e-12	1.56191344619807e-10	0.502008443865623	0.775376464468886
BCAS4	BRD-K40797222-001-01-8::2.5::HTS002	2.5	SC-12267	dihydroorotate dehydrogenase inhibitor	noncancer	IL17A	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.263588931654	-0.263588931654	0.19190561945423	0.185775968658	12.6644310715683	2.54295370063483	0.00230305171015359	0.0452794332388632	0.328467437816853	0.582521664399606
BCAS4	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.0446549102027	0.0446549102027	-0.110835378792037	-0.11764531931	-3.15829353560027	167.609099485747	0.00188266452102418	0.0380920989452082	-0.25268575747075	-0.0582948205187236
BCAS4	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.520641055855	-0.520641055855	0.380451940090891	0.3764822376655	22.337660626212	12.9529742405324	1.00070788729623e-11	7.49146771834835e-10	0.813912347481754	0.988273644410029
BCAS4	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.03414390608295	-0.03414390608295	0.407709065398544	0.468890554884	14.4762061763745	119.64123997519	4.59333997576225e-28	1.55281697738982e-25	0.381418293970282	0.502287648992706
BCAS4	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.594073988909	0.594073988909	0.19739947693173	0.2395368500345	-9.25671935308741	5.30780938496687	0.000179218961008384	0.0047996777076054	-0.504936673033343	-0.288412350921196
BCAS4	BRD-K51471001-303-04-7::2.5::HTS002	2.5	demecarium	acetylcholinesterase inhibitor	noncancer	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.0203424488502	0.0203424488502	0.281593430620299	0.276786886739	9.69524523465173	17.7102093318295	1.6682801354699e-08	8.68920566598124e-07	0.204572434691954	0.317929528848243
BCAS4	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.237852757038	-0.237852757038	-0.100078403038169	-0.09755826700195	3.08105311232277	187.377620783076	0.00237344956803628	0.0464353329500362	0.0495616012791244	0.225987106720537
BCAS4	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.470946775996	0.470946775996	0.224523531133877	0.2005091684065	-6.63408329586123	5.46896726254053	0.00082425698052808	0.0186924319521324	-0.339496651305852	-0.153349838418395
BCAS4	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.654358710718	-0.654358710718	-0.289066136193082	-0.3736278329815	4.91991156919562	26.6090282646302	3.91695535574348e-05	0.00120533686208348	0.212843881133444	0.517741267916392
BCAS4	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.229282239625	-1.229282239625	-0.609168444715562	-0.573831164789	6.853634330625	6.86125781716206	0.000263890453045914	0.00675658546301252	0.405283488841028	0.834944100977848
BCAS4	BRD-K55044200-001-15-3::2.5::HTS002	2.5	amoxicillin	penicillin binding protein inhibitor	noncancer	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.535084240338	0.535084240338	0.0927988799100963	0.127274405853	-11.6435674764596	2.96013458983999	0.00144861245099061	0.0305169705138948	-0.564098049724352	-0.320472671131455
BCAS4	BRD-K58466253-003-14-0::2.5::HTS002	2.5	palmatine-chloride	dopamine synthesis inhibitor	noncancer	CYP3A4	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.584523451359	-0.584523451359	-0.049957824686438	-0.0597563096057	10.7909727100908	3.41788158144771	0.000927833898534688	0.0207233963775574	0.387275647502393	0.681855605842731
BCAS4	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-4.363501525775	-4.363501525775	-5.59791521633821	-5.54901350857	-15.7386701053984	181.718795724068	9.00734050607554e-36	6.16784116078806e-33	-1.38916801276884	-1.07965936835758
BCAS4	BRD-K61443650-236-13-1::2.5::HTS002	2.5	thiomersal	other antibiotic	noncancer	OXCT1	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.1830801577595	0.1830801577595	-0.173356824947698	-0.0402678564845	-6.77671913952794	142.625956774513	2.99769768635521e-10	1.88635803704882e-08	-0.460407939205859	-0.252466026208538
BCAS4	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-2.9182711901	-2.9182711901	-4.00271216005125	-4.1239035813	-10.2630892713327	178.522854130033	1.02194778990043e-19	1.64192689551402e-17	-1.29295247462779	-0.875929465274722
BCAS4	BRD-K62696033-001-01-4::2.5::HTS002	2.5	G-1	G protein-coupled receptor agonist	targeted cancer	GPER1	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.927299508328	-0.927299508328	-1.2505965753496	-1.18405970294	-4.28005435991425	174.531393249994	3.07570084741628e-05	0.000965322737298799	-0.472378128878495	-0.174216005164708
BCAS4	BRD-K64800655-001-07-4::2.5::HTS002	2.5	PHA-793887	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-2.52424045717	-2.52424045717	-1.61417708846774	-1.563662443425	7.31553161403356	4.14637795058865	0.00161388252334422	0.0334819308243	0.569425394682626	1.2507013427219
BCAS4	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-3.6812058847	-3.6812058847	-2.9330207447224	-2.87845710522	6.88253729236373	6.41186051732291	0.000347712372185973	0.00866467213326909	0.486274208005664	1.01009607194954
BCAS4	BRD-K66094457-001-01-5::2.5::HTS002	2.5	CPP	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.340258042305	-1.340258042305	-0.908657240724882	-0.85122207753	6.73097731466026	33.3255864221704	1.08682813997603e-07	5.09936051692038e-06	0.301192897499403	0.562008705660833
BCAS4	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.4173211434945	0.4173211434945	0.14234680262103	0.0968721731692	-9.42049876225625	126.130745686539	2.79695050301835e-16	3.29016248277399e-14	-0.33273780772511	-0.217210874021829
BCAS4	BRD-K68507560-003-24-6::2.5::HTS002	2.5	dicycloverine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.097605526491	0.097605526491	0.232767349617233	0.2203060574785	3.82772319910588	19.3850508699229	0.00110199202396155	0.0240591676177706	0.0613536909712495	0.208969955281218
BCAS4	BRD-K69650333-003-14-0::2.5::HTS002	2.5	idarubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-5.750918948235	-5.750918948235	-6.63639828266578	-6.575075579375	-7.80551232425293	45.0385665703114	6.58718697012163e-10	3.99384779665968e-08	-1.11395950387602	-0.656999164985547
BCAS4	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.77831254637	-1.77831254637	-2.59051805287484	-2.40345273405	-5.85349175051982	10.5801660208807	0.000128749570129962	0.00356153415286327	-1.11908987947505	-0.505321133534624
BCAS4	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.12253057742575	-0.12253057742575	-0.729063353191239	-0.60872932846	-5.02866362853987	6.06781858080353	0.00230698277093814	0.045333575713982	-0.900869537952516	-0.312196013578462
BCAS4	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.870988441825	-1.870988441825	-2.52901744729044	-2.26266997363	-5.88095216970664	66.8639387787171	1.43486600128316e-07	6.62501928455448e-06	-0.881373879756877	-0.434684131173995
BCAS4	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.08756387835	-1.08756387835	-0.770212902290734	-0.659860660516	6.21841222190653	92.032285035079	1.45491199251001e-08	7.65602338430339e-07	0.215993352479846	0.418708599638686
BCAS4	BRD-K81528515-001-13-8::2.5::HTS002	2.5	nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	targeted cancer	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.3320169450025	-0.3320169450025	0.195750004054557	0.2381526124685	9.63156625720448	37.8390002725753	1.00208045960719e-11	7.49727838162755e-10	0.416823660121743	0.638710237992372
BCAS4	BRD-K81801188-001-02-8::2.5::HTS002	2.5	PP-121	protein tyrosine kinase inhibitor	noncancer	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-3.974375141215	-3.974375141215	-4.63118104484745	-4.63633744063	-6.50050144394399	180.761347094434	7.56094533093379e-10	4.56101844028626e-08	-0.856174017198047	-0.457437790066846
BCAS4	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-2.086407834685	-2.086407834685	-2.78194251459546	-2.665674709255	-7.2499702040893	67.4659108400144	5.21769008383256e-10	3.19606258353172e-08	-0.886999855690209	-0.504069504130709
BCAS4	BRD-K89391146-001-08-0::2.5::HTS002	2.5	RG108	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3B	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.6828286217315	0.6828286217315	0.377108208661037	0.397149460871	-9.80219357966521	8.23416121098529	8.03894985525273e-06	0.000282039627357417	-0.377287867118752	-0.234152959022174
BCAS4	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-2.305057386115	-2.305057386115	-3.11571625766961	-3.009227373135	-7.09442039697765	52.269202633419	3.40857650685275e-09	1.91948711018719e-07	-1.03992448411059	-0.581393258998629
BCAS4	BRD-K93869735-001-01-1::2.5::HTS002	2.5	taltirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	neurology/psychiatry	spinocerebellar ataxia	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.1909382105995	0.1909382105995	-0.18491432637862	-0.1119517959605	-8.15885701919546	112.034312705264	5.4836109968158e-13	4.66572791320577e-11	-0.467127715713097	-0.284577358243144
BCAS4	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.9117399269545	-0.9117399269545	-1.41253822662862	-1.39259151278	-5.50023603282677	11.8658158107305	0.000141826264472665	0.0038782191168872	-0.699429023159366	-0.302167576188864
BCAS4	BRD-K97010173-001-04-1::2.5::HTS002	2.5	deferasirox	chelating agent	noncancer	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	MFE280, MCF7	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.725182820488	-0.725182820488	0.0579613789980906	0.111819102778	18.8808373210436	114.944567698481	5.05594692303488e-37	3.99865700393779e-34	0.70098333639973	0.865305062572452
BID	BRD-A23072235-050-18-5::2.5::HTS002	2.5	pheniramine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-1.16467369983	-1.16467369983	-1.71563989030123	-1.478667912985	-4.91045047239898	6.96927830168431	0.00175434503430034	0.0358990850540919	-0.816520878853627	-0.285411502088831
BID	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-4.02308317451	-4.02308317451	-3.71524990069157	-3.697322932235	3.94033902141807	54.27510163637	0.000234480631427799	0.006090159870733	0.151223165795491	0.46444338184136
BID	BRD-A93093700-001-02-9::2.5::HTS002	2.5	temazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.11044314363095	0.11044314363095	0.298384960239858	0.2970613680105	6.19563372888564	9.33540513795985	0.000136824425121382	0.00376013453056131	0.11969426732792	0.256189365889897
BID	BRD-K01507359-001-22-9::2.5::HTS002	2.5	rifampin	RNA polymerase inhibitor	noncancer	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.125174274296	0.125174274296	-0.0961113892873408	-0.0621919503453	-7.34572110728184	56.7858742212493	8.61360984586469e-10	5.16549072371106e-08	-0.281613724845366	-0.160957602321315
BID	BRD-K08303368-001-10-0::2.5::HTS002	2.5	chlorpyrifos	acetylcholinesterase inhibitor	noncancer	ACHE	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.507762182915	0.507762182915	0.28812249813325	0.2721196218245	-8.21077482223403	28.0629183952337	6.05506302469767e-09	3.30622012979009e-07	-0.274429405415398	-0.164849964148101
BID	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-3.03762539491	-3.03762539491	-2.40929010057433	-2.32376274045	7.74948139386762	15.8989946487948	8.7113025292638e-07	3.58985725782461e-05	0.456362574063544	0.800308014607795
BID	BRD-K12502280-001-08-0::2.5::HTS002	2.5	TG-101348	FLT3 inhibitor, JAK inhibitor	targeted cancer	BRD4, JAK1, JAK2, JAK3, TYK2	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.01086706930525	-0.01086706930525	-0.396872836554467	-0.2460199545545	-4.74317942415403	8.10903723368443	0.0014047586460239	0.029721669875978	-0.573232886640365	-0.198778647858069
BID	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.675167503716	-0.675167503716	-0.257881977554004	-0.291499790384	7.65196436048743	170.198263024898	1.40383075489319e-12	1.14971968615018e-10	0.309637125983296	0.524933926340697
BID	BRD-K27182532-001-02-3::2.5::HTS002	2.5	metatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-1.253245509275	-1.253245509275	-0.969246591428784	-0.9486901264415	5.30402264807873	39.5530782948018	4.60660709402186e-06	0.000169353257607995	0.1757442290616	0.392253606630832
BID	BRD-K28392481-001-05-1::2.5::HTS002	2.5	AZD4547	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.519603435484	0.519603435484	0.370817519215767	0.402350667123	-3.46889576655871	77.4557645691233	0.000856697955825732	0.0193035340805481	-0.234185654755479	-0.0633861777809879
BID	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.314885708441	-0.314885708441	-0.510081640316029	-0.4097580139535	-3.73774090468404	48.26264823645	0.000491878366850344	0.0118108669604154	-0.300182490693051	-0.0902093730570063
BID	BRD-K36627727-001-05-4::2.5::MTS010::PROS005_PR500	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.04084062352955	0.04084062352955	-0.0790897249874068	-0.032678012842	-4.01685780822769	16.0348882628704	0.00099219468619865	0.0219822301941565	-0.18321265604429	-0.0566480409896232
BID	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.4169438768145	0.4169438768145	0.0860140920432378	0.1179670530315	-9.76870416493771	8.71791522854996	5.48352310663474e-06	0.000198426139443173	-0.407943472360813	-0.253916097181711
BID	BRD-K40331046-305-01-5::2.5::HTS002	2.5	CR8-(R)	CDK inhibitor	targeted cancer	CCNA2	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-5.77551973356	-5.77551973356	-5.26032652597706	-5.161930725595	4.91294419485104	42.4323896532025	1.38236080304125e-05	0.000464388728142677	0.303632042787943	0.726754372377931
BID	BRD-K41599323-001-02-3::2.5::HTS002	2.5	lonafarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, HRAS, KRAS, NRAS	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-1.691371532895	-1.691371532895	-1.28127792831519	-1.15325467398	4.89742970430012	26.5116690174888	4.19710758435117e-05	0.00128563937608461	0.238132304624776	0.582054904534836
BID	BRD-K45462423-001-03-7::2.5::HTS002	2.5	VU0361737	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.1887976047535	-0.1887976047535	0.0847918244176117	0.109184936724	7.44860099652135	177.557705466591	3.95365851319906e-12	3.10283293839415e-10	0.201105300096608	0.346073558245615
BID	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.01069940897766	-0.01069940897766	-0.21674468390816	-0.1500661795165	-6.05687531525106	171.28634573281	8.55037973718158e-09	4.59873108830713e-07	-0.273194571811747	-0.138895978049252
BID	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	0.172009879435	0.172009879435	0.304550015320108	0.306467449749	5.23104815784638	12.642587211567	0.000177639672732085	0.0047633345948949	0.077644712529716	0.187435559240501
BID	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.180594688067	-0.180594688067	0.118759162369743	0.150496276102	9.89264333538989	28.4740526462928	1.022624725109e-10	6.76267000024336e-09	0.237414998885475	0.36129270198801
BID	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.4182190481385	-0.4182190481385	-0.132268827319014	0.0301334081165	4.32662908733507	52.2189620341429	6.85740151834133e-05	0.0020108633329109	0.153342636306447	0.418557805332525
BID	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.0381106652814	-0.0381106652814	-0.392685371491648	-0.201440599557	-5.44316419026192	121.296020038891	2.77352065408815e-07	1.22844783688791e-05	-0.483535881665781	-0.225613530754715
BID	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.594473740313	-0.594473740313	-1.18975447453711	-1.12103485225	-9.70152205273178	31.9665361743992	4.78489111242861e-11	3.29120965094901e-09	-0.720271117574047	-0.470290350874167
BID	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.0761672001798	-0.0761672001798	-0.197715198180761	-0.124222212564	-3.47314477328245	190.919158526998	0.000636339408487082	0.0148229528400856	-0.190577499764144	-0.0525184962377774
BID	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.597513973482	-0.597513973482	-0.892069647432841	-0.708568317551	-4.30264636113982	20.3634556381136	0.00033462446210784	0.00836381648269518	-0.437195815078907	-0.151915532822775
BID	BRD-K76908866-001-07-6::2.5::HTS002	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-1.1036159584	-1.1036159584	-0.691341510777632	-0.619490026625	6.01035431145757	62.2759514882723	1.05508650985227e-07	4.96237956045925e-06	0.275169012548619	0.549379882696117
BID	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.629615397556	-0.629615397556	-1.11448252585595	-1.11451105929	-7.01886224681842	3.82556830008678	0.00255909368356633	0.0495785944233108	-0.68016428227766	-0.289569974322234
BID	BRD-K85606544-001-09-1::2.5::HTS002	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.9736984393805	-0.9736984393805	-1.59564064453552	-1.5159358626	-6.03028335549886	8.9712640728817	0.000197670272957076	0.0052278469808264	-0.855367102383493	-0.388517307926554
BID	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.00174044474925	-0.00174044474925	-0.325044413156308	-0.193950713334	-5.84836930707784	51.2812728841246	3.4821635602054e-07	1.5169281172668e-05	-0.434270519807759	-0.212337417006358
BID	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.00208505696221	-0.00208505696221	-0.164397613437945	-0.121855279851	-7.55773406509797	188.084209250847	1.74617419603586e-12	1.41871027013711e-10	-0.204678031792202	-0.119947081159268
BID	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	1.061597428485	1.061597428485	0.592076949345815	0.574544422816	-10.9000618468422	10.2111962305674	5.98971190863586e-07	2.5305912944333e-05	-0.565229229632474	-0.373811728645897
BID	BRD-K99616396-001-05-1::2.5::MTS006	2.5	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	NCIH1437, NCIH596	LUNG	carcinoma (adenocarcinoma), carcinoma (mixed_adenosquamous_carcinoma)	-0.1796634571035	-0.1796634571035	-0.0150100189669017	-0.0150428280254	5.98374377705115	184.007109940004	1.11542131602792e-08	5.9307153372103e-07	0.110364455761506	0.218942420511691
BLTP3A	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.413708757072	0.413708757072	0.174581654913897	0.21394626854	-7.47224143238441	11.8446023150037	8.10145019106114e-06	0.000284046412236209	-0.308955190288409	-0.169299014027798
BLTP3A	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.09434821959055	-0.09434821959055	0.152976454525887	0.1647699361925	10.6596384199681	144.798723401149	6.05135370372675e-20	9.90817867048166e-18	0.201466370502172	0.293182977730702
BLTP3A	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.61261705531	-1.61261705531	-2.10107889275475	-2.089022441025	-6.67265602161308	111.792089971067	1.00519656532809e-09	5.97953856925354e-08	-0.633508153337906	-0.343415521551589
BLTP3A	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.298372495062	-0.298372495062	-0.493274361181695	-0.379151386241	-3.27243588042359	80.5287241418014	0.00157166420510015	0.0327105474281327	-0.313415413277559	-0.0763883189618308
BLTP3A	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.167405370292	-0.167405370292	-0.514198059029031	-0.46624794895	-6.89012368408313	175.342043032592	9.62620226492215e-11	6.39743970616589e-09	-0.44612691081881	-0.247458466655253
BLTP3A	BRD-A26503646-001-16-6::2.5::HTS002	2.5	formestane	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.434803939401	-0.434803939401	0.147730062476679	0.129884484973	15.1282560832787	36.0116048149864	3.52235297958944e-17	4.47505863522481e-15	0.504440367772471	0.660627635982887
BLTP3A	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.28362717345	-1.28362717345	-0.989697997972043	-0.915436263548	4.24830483546376	20.2373064747437	0.000384880858367331	0.00948173902218525	0.149715198658428	0.438143152297485
BLTP3A	BRD-A48300215-001-04-8::2.5::HTS002	2.5	ajmaline	sodium channel blocker	noncancer	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.2363926922915	0.2363926922915	0.0792604364296303	0.10011510474205	-3.26573327467095	162.684413179214	0.00133140824696593	0.0283883205495384	-0.252143604519238	-0.0621209072045016
BLTP3A	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.280169770038	-0.280169770038	-0.0792131875175211	-0.05385103964535	4.75065631144354	103.04194972869	6.58408698503852e-06	0.000234528964503294	0.117063320144932	0.284849844896026
BLTP3A	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.3560888817395	0.3560888817395	-0.0161853694409129	0.03331372318045	-7.81059192829269	177.037773805919	4.82551112681881e-13	4.13864335454161e-11	-0.46633450035261	-0.278214002008216
BLTP3A	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.417048109114	0.417048109114	0.150536438480876	0.162581247373	-8.02730498885528	11.090950988696	6.00391480834324e-06	0.00021579960706983	-0.339512743889561	-0.193510597376687
BLTP3A	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.0477270414288	-0.0477270414288	-0.186517769741311	-0.0590439534084	-3.32833765008018	181.038399858809	0.00105833936318739	0.0232030296003058	-0.221070695310829	-0.0565107613141932
BLTP3A	BRD-A93477898-001-04-2::2.5::HTS002	2.5	PETCM	caspase activator	noncancer	CASP3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.192507718277	-0.192507718277	0.183825623800701	0.198279920588	8.41913229164586	12.8755080580081	1.36191668833739e-06	5.44687893067111e-05	0.279670343373587	0.472996340781814
BLTP3A	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.334318881045	-1.334318881045	-1.90227095504178	-1.73380354334	-5.52377356916333	190.441710342437	1.0784664544803e-07	5.06345315930578e-06	-0.770763576551443	-0.365140571442116
BLTP3A	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.1178236520995	-0.1178236520995	0.160324338429607	0.166606190016	9.95038734979236	21.6618909242067	1.54594624775589e-09	9.0062819607304e-08	0.220123505799791	0.336172475258423
BLTP3A	BRD-K03243820-001-23-8::2.37329::HTS002	2.37329	trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	chemo	TYMS	infectious disease	virus herpes simplex (HSV)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.7504007240475	-0.7504007240475	-2.2693806247443	-2.05370099582	-16.8312828927256	133.1340454901	8.99276183291291e-35	5.60293503164649e-32	-1.69748415684823	-1.34047564454537
BLTP3A	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.12381312489525	0.12381312489525	-0.343203540139094	-0.229059189804	-8.11958231614335	4.62050253551871	0.000663134490255587	0.0153785925299707	-0.618597942786002	-0.315435387282687
BLTP3A	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.400161777715	-1.400161777715	-2.03305520612256	-1.93975006052	-6.99168566938094	51.9101636950936	5.14514773103269e-09	2.83922339867277e-07	-0.814544313955279	-0.451242542859846
BLTP3A	BRD-K03549949-001-01-0::2.5::HTS002	2.5	XL388	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.06921080231	-1.06921080231	-1.33280355573024	-1.14186011868	-3.71224298206449	175.000348323712	0.000275879206331804	0.00701826877316194	-0.403731730942686	-0.123453775897795
BLTP3A	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.096617887575	-1.096617887575	-0.639021203056875	-0.586240520956	6.80487962224392	12.2055687250328	1.73274144108027e-05	0.000572405580032819	0.311354814422311	0.60383855461394
BLTP3A	BRD-K07442505-001-03-6::2.5::HTS002	2.5	BAM7	BAX activator	targeted cancer	BAX	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.08609668902745	-0.08609668902745	-0.299859590379354	-0.257563051703	-3.52261414075141	183.286808364795	0.000539399915584557	0.0128141259706631	-0.33348999651512	-0.0940358061886877
BLTP3A	BRD-K07572174-001-39-4::2.48092::HTS002	2.48092	curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	targeted cancer	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.77942567642	-1.77942567642	-1.16885610660217	-1.01297286124	6.15604197553691	7.1130189620387	0.000436292258280854	0.0106128797440787	0.376794321963211	0.844344817672445
BLTP3A	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.608170051394	-0.608170051394	-2.05074564771727	-1.66463476506	-10.9747243024335	56.1022363258412	1.37737372551714e-15	1.5123521168871e-13	-1.70588152439444	-1.17926966825209
BLTP3A	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.67927013622	-1.67927013622	-2.20343116123629	-2.14710453103	-7.01481586704221	191.78083818134	3.84717549061878e-11	2.67107637100367e-09	-0.671543490871766	-0.37677855916081
BLTP3A	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.243010286445	-1.243010286445	-2.52249991360198	-2.34739362698	-12.0319381908723	171.545540988479	1.43834630149192e-24	3.58464330758676e-22	-1.48939519181435	-1.0695840624996
BLTP3A	BRD-K11071038-001-01-7::2.5::HTS002	2.5	ICI-162846	histamine receptor antagonist	noncancer	HRH2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.2549257862365	-0.2549257862365	0.0995546921237439	0.0637321133413	9.45276901141234	8.53344105608678	8.29043350006487e-06	0.000290055553646001	0.268936891437881	0.440024065282607
BLTP3A	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.45344091988	-1.45344091988	-2.10321784200074	-1.95679219665	-6.03143445028074	186.210478838645	8.57077853361795e-09	4.60738999832406e-07	-0.862308536038862	-0.437245308202608
BLTP3A	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-6.98699575826	-6.98699575826	-4.24036561076991	-4.34713599697	13.9367024339735	2.9317241405886	0.000901062644659119	0.0201864592418882	2.11109238629832	3.38216790868187
BLTP3A	BRD-K12251893-065-04-7::2.5::HTS002	2.5	vincristine	tubulin polymerization inhibitor	chemo	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.34804694656	-3.34804694656	-2.69867724520622	-2.57343902316	4.98237476047766	7.80456684695843	0.00115835009312774	0.0251665501378586	0.347505349773012	0.951234052934541
BLTP3A	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.032981910065	-3.032981910065	-1.92038914495819	-2.01595157397	13.7678258396636	74.7746094455682	3.39506114562745e-22	6.78787369665285e-20	0.951600900517209	1.27358462969642
BLTP3A	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.0924810524818	-0.0924810524818	-0.571077061137012	-0.549657042838	-13.349240809205	67.4370348584643	1.32948633406758e-20	2.32420453910579e-18	-0.550148230929521	-0.407043786380902
BLTP3A	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.24076834143	-1.24076834143	-0.0421127381915273	-0.0356049990197	18.4140566468788	3.52841440928544	0.000123974361890153	0.00344098692172425	1.00798714204372	1.38932406443323
BLTP3A	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.1799088851445	0.1799088851445	-0.0725444150320137	0.0407112965926	-6.14485122480142	188.665153685978	4.65199686084082e-09	2.58104539266672e-07	-0.333495755834373	-0.171410844518655
BLTP3A	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.452252246567	-0.452252246567	0.0924078189374393	0.105022107206	13.6720423433958	5.45453979839529	1.98675024437146e-05	0.000648026469526542	0.444768777528395	0.644551353480484
BLTP3A	BRD-K18163608-001-05-6::2.48005::HTS002	2.48005	HA14-1	BCL inhibitor	targeted cancer	BCL2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.657077284487	-0.657077284487	-0.0362767696770346	0.0501858788395	10.1613354150827	6.87019768334891	2.18526055258902e-05	0.000706795916564841	0.475780099318682	0.765820930301249
BLTP3A	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.9557952393205	-0.9557952393205	-0.438904180312184	-0.343450980127	9.58739609560236	5.50790755728078	0.000121613963014904	0.00338511676350926	0.382058832995014	0.651723285021618
BLTP3A	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.535211645675	-1.535211645675	-3.05462851985043	-3.177325410155	-12.1443229931186	7.25514032894331	4.40514605416282e-06	0.000162364668726167	-1.81316686048931	-1.22566688786156
BLTP3A	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.95216316463	-1.95216316463	-3.10205745120386	-2.8622910827	-10.9188851262662	118.067504507482	1.30294411767468e-19	2.07011645513044e-17	-1.35844032695439	-0.941348246193329
BLTP3A	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.6726007906115	-0.6726007906115	-1.87726651219135	-1.673362994515	-13.0486546626953	187.823555883566	4.02981082680639e-28	1.37532695015698e-25	-1.38678515453217	-1.02254628862753
BLTP3A	BRD-K22064724-001-01-8::2.49999::MTS010::PROS004_PR500	2.49999	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.98341173128	-2.98341173128	-2.28112345914741	-2.41370110422	9.44907615282209	127.603880101801	2.1774361595869e-16	2.59559351862125e-14	0.55522220187391	0.849354342391265
BLTP3A	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-5.52586347153	-5.52586347153	-5.24748072777335	-5.41033082	3.75875935299022	118.611343815923	0.000266458731873729	0.00681501593601007	0.131726856117316	0.425038631395983
BLTP3A	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.6659369722555	-0.6659369722555	-0.257980699815613	-0.291499790384	6.31375787055902	10.2800402480651	7.74463063009831e-05	0.00224644598500249	0.264517456319024	0.551395088560749
BLTP3A	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.018685819523514	0.018685819523514	0.388405707029945	0.399212772621	11.9618947273132	7.11219716526276	5.73161134164686e-06	0.000206635917114185	0.296866832776839	0.442572942236023
BLTP3A	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.46929257747	-2.46929257747	-3.0903796562442	-2.9100349769	-4.96652101494651	6.43803984056092	0.00207200896439499	0.0413454621850678	-0.922108406103186	-0.32006575144522
BLTP3A	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.4370274278	0.4370274278	-0.117812715265127	0.0546590882103	-8.35849196162516	15.8983696507909	3.27499553785878e-07	1.43455245990953e-05	-0.695633475568632	-0.414046810561622
BLTP3A	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.07668047743535	0.07668047743535	-0.0729550517300551	0.0269217911151	-4.07518554236101	10.1919727679407	0.00214567606965694	0.0426131028848687	-0.231241494825932	-0.0680295635048784
BLTP3A	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.485781634985	-1.485781634985	-2.31757900616565	-2.045349051995	-6.66769833278325	8.80389170794406	0.000101778385785531	0.00287974384779237	-1.11496330475003	-0.548631437611279
BLTP3A	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.38846571671	-3.38846571671	-2.56739768960362	-2.525806741025	8.6382917233313	51.4384745146572	1.38200868528856e-11	1.01718591864427e-09	0.630287047899239	1.01184900631351
BLTP3A	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.3496087393665	0.3496087393665	0.209500373983771	0.239322143773	-7.14343903827349	190.645366866858	1.87202154785516e-11	1.35230369508004e-09	-0.178795852093281	-0.101420878672177
BLTP3A	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.5081069068575	-0.5081069068575	0.0321633769182979	0.056211415311	16.045762223703	169.365465254046	7.954980417868e-36	5.46468909609369e-33	0.47380219100167	0.606738376549925
BLTP3A	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.2016673585305	0.2016673585305	0.428517265830854	0.4313451016155	4.28495141607462	134.993462764192	3.45047207383319e-05	0.00107334721206472	0.122148718727725	0.331551095872982
BLTP3A	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.7409425113565	-0.7409425113565	-1.94045648319962	-1.836818850415	-14.2221808278802	185.6302472126	1.58060294592719e-31	7.20785210207723e-29	-1.3659042178565	-1.03312372582973
BLTP3A	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.06924123895445	-0.06924123895445	-1.03982298636822	-1.017015264785	-13.373324127298	149.559196698062	2.50581896254106e-27	7.76112243385063e-25	-1.11398839764806	-0.827175097179476
BLTP3A	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.338843400219	0.338843400219	-0.0238640700535921	-0.0227579244188	-10.8651348639444	9.95035574647809	7.71498162126361e-07	3.20951920788783e-05	-0.437139080412099	-0.288275860133085
BLTP3A	BRD-K36740062-001-06-6::2.5::HTS002	2.5	GSK1070916	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC, CYP2D6, CYP3A4	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.450906979565	-1.450906979565	-2.26752991021409	-1.977136981175	-7.30124818832172	39.920759612575	7.24596826192674e-09	3.91781314735241e-07	-1.04268818993866	-0.590557671359526
BLTP3A	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.95024569574	-3.95024569574	-2.98086826740419	-3.07991378512	10.2799180273637	190.106486960283	5.41246609305269e-20	8.96482569751074e-18	0.783372303954513	1.15538255271711
BLTP3A	BRD-K38332599-001-01-3::2.5::MTS010::PROS002_PR500	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.16550722196	-1.16550722196	-0.563470832938963	-0.5253626676245	7.30685067733589	84.6726638572861	1.39979267899855e-10	9.12735519005415e-09	0.43820706067644	0.765865717365634
BLTP3A	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.28585956032	0.28585956032	-0.359411600913371	-0.2780855887145	-14.4847651497753	179.750823299691	5.21152868615635e-32	2.47119852162656e-29	-0.733175996236546	-0.557366326230195
BLTP3A	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.69088529434	-1.69088529434	-1.00724240488666	-1.02230629729	10.2904770185837	80.4672953898094	2.4657147554267e-16	2.91813460969547e-14	0.551445769064629	0.815840009842046
BLTP3A	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.3049496810245	0.3049496810245	-0.706115433578876	-0.5759216002185	-14.8756334991922	32.4991300573572	4.63831871250366e-16	5.32187479299891e-14	-1.14942779129003	-0.872702437916726
BLTP3A	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.0947376850343	-0.0947376850343	-0.49763646088397	-0.332266676493	-7.66528285775662	192.197160446793	8.61065549888686e-13	7.21185299890943e-11	-0.506570222328716	-0.299227329370624
BLTP3A	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.589365107145	-0.589365107145	-1.3981239226857	-1.273586296615	-9.44533384314704	6.09037484596251	7.33187980447639e-05	0.0021371337775243	-1.01752485618975	-0.599992774891661
BLTP3A	BRD-K47337578-034-02-5::2.5::HTS002	2.5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	noncancer	HTR2A	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.916070796371	-0.916070796371	-0.116579008514171	-0.0894405664739	14.4960924202239	3.52109969149865	0.00028927625324304	0.00732950586136984	0.637790729910957	0.961192845802702
BLTP3A	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.1803234146565	0.1803234146565	0.0267936825574449	0.0405492292056	-6.13221384800707	194.115171167553	4.7584767694531e-09	2.6367103607035e-07	-0.202908404430614	-0.104151059767496
BLTP3A	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.698970549855	-1.698970549855	-0.769777998575964	-0.611397713918	10.306693747742	8.40118119075954	4.7062168957999e-06	0.000172394250736609	0.723011840322957	1.13537326223512
BLTP3A	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.5186105892545	-0.5186105892545	-1.25674728616691	-0.921278111753	-8.20384392474613	83.931632647252	2.38044621562908e-12	1.91300583783114e-10	-0.917062972675122	-0.559210421149701
BLTP3A	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.5296861135965	0.5296861135965	-0.116702546021729	0.03876057814515	-8.74425915728499	3.25688567923346	0.00227378387797071	0.0447797321309919	-0.871483218315004	-0.421294100921455
BLTP3A	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.576840537851	0.576840537851	0.197593111213281	0.2395368500345	-11.1182940804315	66.255089066941	8.55609129891326e-17	1.0527086636078e-14	-0.447345778959673	-0.311149074315765
BLTP3A	BRD-K51350053-048-16-5::2.5::HTS002	2.5	toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	ESR1	oncology	breast cancer	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.751613011015	-1.751613011015	-0.490331843746172	-0.414253606169	15.3060422937806	6.48148283323049	2.49048043579833e-06	9.5642748848633e-05	1.06322132965342	1.45934100488424
BLTP3A	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.258874687125	-2.258874687125	-3.67560082949245	-3.70951336465	-16.7603461745759	12.6926398799921	4.92260937555788e-10	3.0248220896042e-08	-1.599789301632	-1.2336629831029
BLTP3A	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.04448549930465	0.04448549930465	0.138859597688552	0.155273340434	3.83647066638646	155.481229302479	0.000181059087965702	0.00484230262847528	0.0457823441391593	0.142965852628645
BLTP3A	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.59915890857	-0.59915890857	-0.289641134132124	-0.3736278329815	4.36010457034524	63.4443907994528	4.86415592146594e-05	0.00147083757687905	0.1676777951796	0.451357753696153
BLTP3A	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.666350846465	-1.666350846465	-3.16671021247114	-3.19197499768	-15.4259734423787	190.981282354563	2.14233680388465e-35	1.39563800863159e-32	-1.69220487130092	-1.30851386071137
BLTP3A	BRD-K58435339-001-03-0::2.5::HTS002	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-3.46877980879	-3.46877980879	-4.69280729202672	-4.73299399791	-12.2909651100491	51.5787735328884	6.00954668740342e-17	7.50594482496788e-15	-1.42390343784037	-1.02415152863306
BLTP3A	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.2995598828105	0.2995598828105	-0.341232337187243	-0.3277516003215	-14.2370093076574	171.22011221667	7.50178023731523e-31	3.20288656670027e-28	-0.729636014711154	-0.551948425284331
BLTP3A	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.38423472216	0.38423472216	0.142698785826716	0.0968721731692	-6.25839429399473	4.70038567681893	0.00190675143174748	0.0384922414632199	-0.342677326473109	-0.140394546193458
BLTP3A	BRD-K67578145-001-09-7::2.38272::HTS002	2.38272	GDC-0879	RAF inhibitor	targeted cancer	BRAF	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.00198504312085	-0.00198504312085	0.591430638197294	0.662966427996	9.76168287878884	7.46228824519959	1.63814436883175e-05	0.000544090879323324	0.451455121519541	0.735376241116746
BLTP3A	BRD-K72420232-001-12-3::2.5::HTS002	2.5	WZ-4002	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.529747165835	-0.529747165835	-0.0676715062318375	0.037173334974	7.29227280191925	4.88246101392201	0.000839555163157708	0.0189891323938823	0.298003942333665	0.62614737687266
BLTP3A	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.750913100925	-1.750913100925	-2.53028808581848	-2.26266997363	-5.76292333808323	6.59684220037398	0.000852582347012626	0.0192453084542582	-1.10317045647935	-0.455579513307602
BLTP3A	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.465495121652	-0.465495121652	-1.3406153603501	-1.10972386317	-8.01727987091596	6.51871712302999	0.000131220442787145	0.00362147132141721	-1.13714283621747	-0.613097641178727
BLTP3A	BRD-K77245796-003-01-6::2.5::HTS002	2.5	gamma-aminobutyric-acid	benzodiazepine receptor agonist	noncancer	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.00253382359985	-0.00253382359985	0.511131589746618	0.500110131001	11.47310212968	3.58225462156097	0.000594673638932398	0.0139861523492529	0.383429438567088	0.643901388125849
BLTP3A	BRD-K78789465-001-01-6::2.5::HTS002	2.5	pentagastrin	CCK receptor agonist	noncancer	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.223041878602	-0.223041878602	0.150492728479463	0.184916881491	7.39173513222641	126.933526255326	1.71925232491106e-11	1.24910383574868e-09	0.273536259284973	0.473532954877953
BLTP3A	BRD-K86727142-001-12-4::2.5::HTS002	2.5	embelin	HCV inhibitor, XIAP inhibitor	targeted cancer	XIAP	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-0.9152665468305	-0.9152665468305	-0.161417717563078	-0.181229635182	13.9427705882325	4.67702776457786	5.4695750644787e-05	0.00163750321831912	0.611927299168258	0.895770359366586
BLTP3A	BRD-K88677950-001-03-9::2.5::HTS002	2.5	PD-198306	MAP kinase inhibitor, MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-1.67881619663	-1.67881619663	-0.654977262355428	-0.550135683891	16.7658926513564	5.63810155275146	5.01323129448276e-06	0.00018264165393765	0.872057886661947	1.1756199818872
BLTP3A	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.185202823185	-2.185202823185	-2.91753191473587	-2.87877770547	-8.42443356532819	131.645844063097	5.45519018844807e-14	5.14615078301006e-12	-0.904287878930582	-0.560370304171149
BLTP3A	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.286734548444	0.286734548444	-0.0115345859375225	0.0437990200838	-7.08046866884358	174.81784801143	3.36030285460507e-11	2.34978907185856e-09	-0.38140938665043	-0.215128882112615
BLTP3A	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	-2.128512885065	-2.128512885065	-3.08020521738713	-3.084015642295	-8.09830098716096	7.03047359611393	8.23330918706328e-05	0.00237533574472215	-1.22933314879987	-0.674051515844394
BLTP3A	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.04801902618135	0.04801902618135	0.24906601191215	0.266502193274	6.96149629831239	191.659424539003	5.21540130379986e-11	3.56217892301504e-09	0.144083824146825	0.258010147314776
BLTP3A	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.2836739342455	0.2836739342455	0.0666654430613692	0.0390021562258	-7.97460064909665	6.20033253579262	0.000175352145570452	0.0047055277335632	-0.283076932921984	-0.150940049446278
BLTP3A	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.4505611844115	0.4505611844115	0.0905455723538333	0.162270559212	-9.17585418677561	4.94569654556566	0.000273057966201399	0.00696219852938135	-0.461206656958882	-0.258824567156451
BLTP3A	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	MCF7, COLO741	BREAST, SKIN	carcinoma, malignant_melanoma	0.02910449940045	0.02910449940045	-0.0775590310212116	-0.07508781022425	-3.42895523188355	34.8604268576517	0.00157306032762405	0.0327332472776053	-0.169822557021834	-0.0435045038214896
BLTP3B	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.121129484268	-0.121129484268	0.180301850008442	0.215520353965	8.83177247999558	7.05230324811805	4.61257968661258e-05	0.00140029687202831	0.220847099986905	0.38201556856598
BLTP3B	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.7083952349465	-0.7083952349465	-0.99572136905585	-0.927705434	-4.22607080855253	26.0339936693881	0.000258148266880911	0.00662856833500883	-0.427070549891015	-0.147581718327685
BLTP3B	BRD-A50157456-065-20-6::2.5::HTS002	2.5	terbutaline	adrenergic receptor agonist	noncancer	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.690642387614	-0.690642387614	0.160539675161418	0.167154929659	29.3364575824193	57.3607172595645	3.13853687761229e-36	2.29583437010841e-33	0.793089486081249	0.909274639469588
BLTP3B	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.46198102997	-0.46198102997	-0.21892512308483	-0.08022384013305	4.35502773179215	187.150646851544	2.18851821946983e-05	0.000707592278565017	0.132957545607604	0.353154268162736
BLTP3B	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.07326784563525	0.07326784563525	-0.701108391728225	-0.633794699256	-14.5465599777782	96.2059373485242	4.92976453233217e-26	1.36687128389421e-23	-0.880042641949298	-0.668709832777653
BLTP3B	BRD-K00662280-001-09-4::2.5::HTS002	2.5	CL-218872	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.650915246831	0.650915246831	0.182283845974275	0.188771787503	-17.3384908335757	133.467314418689	5.43830827095201e-36	3.80910840981985e-33	-0.522090780446182	-0.415172021267268
BLTP3B	BRD-K06152156-001-01-8::2.5::HTS002	2.5	methoxyflurane	membrane permeability inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-3.68050023837	-3.68050023837	-1.84500869545459	-1.70603192552	15.173163355232	3.9318332233496	0.000123143507275299	0.00342235798376655	1.49731711518268	2.17366597064813
BLTP3B	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-4.626537508535	-4.626537508535	-3.69574304312524	-3.52000958617	7.22334039788196	10.1877896448286	2.57682363547027e-05	0.000822959369641941	0.644393847866182	1.21719508295333
BLTP3B	BRD-K08303368-001-10-0::2.5::HTS002	2.5	chlorpyrifos	acetylcholinesterase inhibitor	noncancer	ACHE	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.0951078555505	0.0951078555505	0.292811751853301	0.280025726935	7.44877232018239	32.217367196765	1.70177042545605e-08	8.85718196982928e-07	0.143654301442068	0.251753491163534
BLTP3B	BRD-K09090949-001-01-9::2.5::HTS002	2.5	CP-945,598	cannabinoid receptor antagonist	noncancer	CNR1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.0244480514636	0.0244480514636	-0.69967905960499	-0.6321793589915	-10.8822242093036	10.1903455088862	6.1920503140333e-07	2.6093903888251e-05	-0.872017827864428	-0.576236394272752
BLTP3B	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.293001313456	-0.293001313456	0.190173190845132	0.239804537816	13.7494164075852	183.195555986617	5.1387997785044e-30	2.07028913106592e-27	0.41384048661149	0.552508521990774
BLTP3B	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.369727246388	-0.369727246388	-0.0503487883359336	0.2281371067585	4.38635221804812	22.6333303385697	0.000221867454873554	0.00579274329828163	0.168620514465824	0.470136401638308
BLTP3B	BRD-K17555800-003-01-5::2.5::HTS002	2.5	talmapimod	p38 MAPK inhibitor	targeted cancer	MAPK11, MAPK14	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.162295388337	0.162295388337	0.414872091806817	0.422256044569	9.47592822825762	68.757279029293	4.22988733935371e-14	4.03286264927198e-12	0.199398960952296	0.305754445987338
BLTP3B	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.512251998462	0.512251998462	0.321209935259198	0.339932692016	-6.30606298434311	187.820558380502	1.99790084054198e-09	1.15016945810508e-07	-0.250804213403792	-0.131279913001811
BLTP3B	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.00211050831585	-0.00211050831585	-0.782907137556645	-0.759682041762	-11.9802871366051	69.9576351553728	1.29697895694116e-18	1.88205959960894e-16	-0.910782357969831	-0.650810900511758
BLTP3B	BRD-K27182532-001-02-3::2.5::HTS002	2.5	metatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.2550069256075	-0.2550069256075	-0.979754365993705	-0.968618770448	-13.4713604746465	33.0567212451341	5.6000095851453e-15	5.79828238828313e-13	-0.834195454016024	-0.615299426756386
BLTP3B	BRD-K38305202-001-17-4::2.5::HTS002	2.5	domperidone	dopamine receptor antagonist	noncancer	DRD2, DRD3	infectious disease	fescue toxicosis	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.7729953724635	-0.7729953724635	-0.353273437542381	-0.215692294583	5.72065423913373	7.271275701775	0.000628017479369133	0.0146513941804405	0.247534001470738	0.5919098683715
BLTP3B	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.0231559390032	0.0231559390032	-0.796153670764131	-0.4002530483955	-5.7717531328814	6.88654762774862	0.000724512148342442	0.0166703128547598	-1.15609607597223	-0.482523143562437
BLTP3B	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.561865932687	0.561865932687	-0.544297324046246	-0.407422571936	-14.5556505275939	16.7142893727242	6.38642484467149e-11	4.32479004907929e-09	-1.26670868241043	-0.945617831056058
BLTP3B	BRD-K41859756-001-06-8::2.5::HTS002	2.5	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-3.372021136965	-3.372021136965	-3.99358272892371	-3.99973792001	-5.90438274937876	13.8851064027714	3.97057243118654e-05	0.00122113476625596	-0.847521309743	-0.395601874174426
BLTP3B	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.476921674915	-2.476921674915	-3.24402762597307	-3.15387343916	-10.1234305890052	26.6262395102024	1.26868413346946e-10	8.31292576100201e-09	-0.92268620099361	-0.611525701122538
BLTP3B	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.32154406465	-1.32154406465	-1.83487475030702	-1.58248812639	-5.05222830142792	41.0475501984445	9.45525908306293e-06	0.000327177304490441	-0.718518539283264	-0.308142832030783
BLTP3B	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.4961676458215	-0.4961676458215	-1.25698229081019	-0.921278111753	-8.81821372462138	190.879309522568	7.25151936399607e-16	8.17145580318566e-14	-0.930994691102741	-0.590634598874637
BLTP3B	BRD-K50853363-001-02-3::2.5::HTS002	2.5	dienogest	progesterone receptor agonist	noncancer	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.1537813931945	0.1537813931945	-0.281709154497687	-0.2219400984365	-6.95851918719787	5.73212947561124	0.00053268225177002	0.0126699871645341	-0.590379132245008	-0.280601963139366
BLTP3B	BRD-K54247840-004-01-3::2.5::HTS002	2.5	halofuginone	collagenase inhibitor	noncancer	COL1A1, MMP2	rheumatology	scleroderma	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-6.205651695335	-6.205651695335	-5.70752264447483	-5.53178334297	3.78449426394304	16.7908548217255	0.00150813091542368	0.0315814549068727	0.220163637322079	0.776094464398267
BLTP3B	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.835445981304	-0.835445981304	-0.579259684735531	-0.45596991553	3.33875499828903	109.594967333302	0.00115051671246112	0.0250242638994397	0.104117044633329	0.40825554850361
BLTP3B	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.004225688853609	0.004225688853609	-0.207695080036183	-0.0810605722641	-4.39915586258434	190.674300685538	1.80533327160063e-05	0.000594001896605938	-0.306941319883404	-0.116900217896179
BLTP3B	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.4511146472825	-0.4511146472825	-0.167966801422501	-0.0695637223616	5.03197394632826	16.877803144955	0.000104702104903117	0.00295544546842882	0.164363570259402	0.401932121460596
BLTP3B	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.4962850326645	0.4962850326645	0.141944381016802	0.15713254048	-12.8501059388736	50.7941779848261	1.3839930072115e-17	1.83558067600639e-15	-0.409705061805832	-0.298976241489564
BLTP3B	BRD-K65928735-001-04-3::2.5::HTS002	2.5	AZD1480	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.1794378612945	-0.1794378612945	-0.0221752152139491	-0.05528360346055	4.84439055211215	79.0689927497167	6.20590342312275e-06	0.000222388409091201	0.0926478680664911	0.221877424094611
BLTP3B	BRD-K67772619-001-05-1::2.5::HTS002	2.5	rheochrysidin	protein tyrosine kinase inhibitor	targeted cancer	PTPN1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.180605636727	0.180605636727	0.0191114449936468	0.07194686545995	-3.64212149850858	24.852426368378	0.00124270446017075	0.0267497844977339	-0.252843062522203	-0.0701453209445034
BLTP3B	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.0010760953905	-1.0010760953905	-1.1784705101473	-1.01733335597	-3.15663996955537	185.190649017125	0.00186335975210043	0.0377513973256388	-0.288263484640024	-0.0665253448735697
BLTP3B	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.63850025556	-2.63850025556	-1.19950922835621	-0.979171957663	13.5541387307512	4.11154393815527	0.000144520952265632	0.00394586384434913	1.14735363030023	1.73062842410735
BLTP3B	BRD-K70511574-001-06-9::2.5::HTS002	2.5	HMN-214	PLK inhibitor	targeted cancer	PLK1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-3.75966257175	-3.75966257175	-2.82189223558769	-2.78074740787	9.75469828151377	168.070240390344	4.2863796111159e-18	5.9501001014952e-16	0.747982129105277	1.12755854321934
BLTP3B	BRD-K76703230-004-04-1::2.5::HTS002	2.5	YM-155	survivin inhibitor	targeted cancer	BIRC5	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-4.469466022075	-4.469466022075	-5.49888430898337	-5.55235554655	-8.6245009623172	3.85450593746879	0.00117083927021973	0.0253967017454634	-1.36580617223298	-0.693030401583762
BLTP3B	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.05813407672015	0.05813407672015	-0.427935061576704	-0.2959843885325	-7.63275726635473	13.9790145632992	2.37838656322722e-06	9.17159434526677e-05	-0.622672652033124	-0.349465624560584
BLTP3B	BRD-K86797399-001-05-1::2.54945::HTS002	2.54945	SB-939	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-5.85194379436	-5.85194379436	-5.460367804722	-5.51001928833	4.89149300743605	184.135834758048	2.17424743978078e-06	8.42836461422999e-05	0.233638040736208	0.549513938539793
BLTP3B	BRD-K87696786-003-04-4::2.5::HTS002	2.5	LY456236	glutamate receptor antagonist	noncancer	GRM1	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-3.52112477387	-3.52112477387	-2.17369715689936	-2.00238452918	12.6755883943734	16.2213869690992	7.81443042727972e-10	4.70730483150207e-08	1.12232927850187	1.57252595543941
BLTP3B	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.1410865553875	0.1410865553875	-0.315850549776474	-0.108614953002	-5.94109445701295	110.390494457419	3.35380395404785e-08	1.67556514607721e-06	-0.609351189282739	-0.304523021045209
BLTP3B	BRD-K98572433-001-02-9::2.5::HTS002	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	-3.48221510249	-3.48221510249	-2.70103591985055	-2.69732165055	6.61191216645544	5.9943235802358	0.000578328560720727	0.0136421507914058	0.492016923494335	1.07034144178457
BLTP3B	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MKN1, NCIH1299	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (non_small_cell_carcinoma)	0.290259479611	0.290259479611	-0.621883400387809	-0.542183140466	-10.075111382671	3.14360174508995	0.00170007470727328	0.0349923472520096	-1.19295882161153	-0.631326938386091
BMPR1B	BRD-A14344385-001-03-2::2.5::HTS002	2.5	IDRA-21	glutamate receptor positive allosteric modulator	noncancer	GRIA1, GRIA2, GRIA3, GRIA4	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	0.337327255713333	0.343490576742	0.13856223687891	0.112477706002	-5.6797949740923	10.2459359866152	0.000186120647529446	0.00495910644758063	-0.276486017262324	-0.121044020406522
BMPR1B	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	0.616528038112333	0.6073134397	0.0203261206082222	0.0487695697886	-6.85475692543642	5.04260316748443	0.000975701322034986	0.0216638442608968	-0.819214850897794	-0.373188984110428
BMPR1B	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-0.608567295680667	-0.673474842836	-1.91671941204225	-1.744671566725	-7.01700224683186	4.11263228576734	0.00195713732486907	0.039364797832382	-1.82021095728236	-0.796093275440812
BMPR1B	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-1.00838205336533	-0.963845036124	-1.96008499285854	-1.89330602941	-5.94932825642907	5.86976674795271	0.00109149057735047	0.0238517622301131	-1.34524571641651	-0.558160162569899
BMPR1B	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-0.829611588871333	-0.82507603073	-2.11648765734361	-1.965037814515	-8.7107810361338	8.68377438586678	1.40373476985231e-05	0.000471126009219661	-1.62293733100247	-0.950814805942084
BMPR1B	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	0.465937572921667	0.415367371252	-0.487790865579514	-0.383523896219	-9.2225543007032	23.3509749611202	2.99633044401458e-09	1.69535508905808e-07	-1.16747594768627	-0.739980929316096
BMPR1B	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	0.472945439619667	0.451815406448	0.237631415288446	0.252871815613	-6.508731912321	8.88087531858974	0.000117154113045345	0.00326776729501506	-0.317266659526671	-0.153361389135771
BMPR1B	BRD-K44827188-001-06-0::2.5::MTS010::PROS003_PR500	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-0.276848986128667	-0.282475971966	0.0420693679439107	0.0596417519595	10.912672705795	8.24511152921506	3.48097983682121e-06	0.000130501124269031	0.251873473008459	0.385963235136696
BMPR1B	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-2.05431466068333	-2.04919182971	-2.49269958631894	-2.4206862555	-4.12744363446583	14.9290018648532	0.000903427184190514	0.0202373165719449	-0.664864707588363	-0.211905143682854
BMPR1B	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-0.246240145259333	-0.251431750469	-1.04158799697644	-0.663483610975	-7.0135200113665	27.6874332020901	1.33681046745582e-07	6.1989885478005e-06	-1.02775971015564	-0.562935993278577
BMPR1B	BRD-K82967180-001-01-6::2.5::MTS006	2.5	LY3023414	PI3K inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-4.26625001077333	-4.18433749055	-3.36296397491611	-3.46992091637	7.6593945264905	3.73396469362093	0.00205313671250462	0.0410223490681833	0.566446147757787	1.24012592395667
BMPR1B	BRD-K86118762-001-01-8::2.5::HTS002	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	MFE280, HCC1428	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma	0.5149819110515	0.5149819110515	0.059713613635723	0.0670772689305	-13.7876503932524	92.5109463873753	3.69744306985296e-24	8.78569041816536e-22	-0.520844053656899	-0.389692541174655
BMPR1B	BRD-K86797399-001-05-1::2.54945::HTS002	2.54945	SB-939	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-6.60172653995	-6.5758069397	-5.44639466066693	-5.50767878864	12.1479062190131	19.9661244510485	1.11874735328496e-10	7.36198960645418e-09	0.956923842455639	1.3537399161105
BMPR1B	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-5.65746241149	-5.69444213978	-6.22330262991324	-6.20807518194	-7.00818431564341	9.16533791785612	5.72255419346404e-05	0.00170609169248985	-0.74798557967169	-0.383694857174799
BMPR1B	BRD-K89053832-001-01-0::2.5::HTS002	2.5	VLX600	ubiquitin C-terminal hydrolase inhibitor	targeted cancer	USP14	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-0.809935676118333	-0.875832936587	-2.0848947846005	-1.92427650365	-6.99592114661748	4.34351377624297	0.0016077149555008	0.0333733596801482	-1.76554957417794	-0.784368642786405
BMPR1B	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-0.7277632565	-0.678761564663	-1.8443275602674	-1.731193314785	-10.439719546722	10.1795193752027	9.23608546457384e-07	3.79662631671777e-05	-1.35430306732483	-0.878825540209974
BMPR1B	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-1.85439067196	-1.81238790704	-0.944895161434308	-0.808966842152	6.8240084062648	5.91036931055958	0.000518148816563089	0.012369605447221	0.58217149282657	1.23681952822481
BMPR1B	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	MFE280, HCC1428, JHH7	ENDOMETRIUM, BREAST, LIVER	carcinoma (adenocarcinoma), carcinoma, carcinoma (hepatocellular_carcinoma)	-5.53539182682667	-5.61271849195	-4.61453870611296	-4.61794794805	6.06238271487104	4.95178651718427	0.00182326616960058	0.0370757888865581	0.529245153987537	1.31246108743988
C1orf159	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.414457240042	-0.414457240042	0.183439045257362	0.215520353965	20.4773173017664	33.2874246438476	1.94299914625692e-20	3.36110624711945e-18	0.538512029517786	0.657280541080938
C1orf159	BRD-A03932035-004-04-3::2.5::HTS002	2.5	methscopolamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.170918218711	-0.170918218711	0.245274083351017	0.2387115992065	15.1109462467264	177.993863693001	9.90625230191983e-34	5.61692367623856e-31	0.361840568210315	0.470544035913719
C1orf159	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.294537988865	-0.294537988865	-1.03339460082117	-0.797857785181	-7.06864871280531	5.76030096276153	0.000480462365455505	0.0115641550460427	-0.997224361263524	-0.480488862648814
C1orf159	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.472863183049	-0.472863183049	-0.230791655988283	-0.218507717473	4.76015302492875	21.4866423348679	9.99601331630075e-05	0.00283278532073175	0.136461065601242	0.347681988520193
C1orf159	BRD-A91452556-001-04-0::2.5::HTS002	2.5	estradiol-cypionate	estrogen receptor agonist	noncancer	ESR1	endocrinology	hypoestrogenism, menopause	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	1.108448867445	1.108448867445	0.587833351229855	0.60273481392	-18.9956238378288	12.8606884298758	8.63427800971343e-11	5.77042772542522e-09	-0.57989028323535	-0.46134074919494
C1orf159	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.289167332662	-0.289167332662	-1.91321495031281	-1.73380354334	-15.5006774845348	138.412599319128	4.75835833354273e-32	2.27646023051312e-29	-1.83120955887565	-1.41688567642596
C1orf159	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.10459600292905	0.10459600292905	-0.0858096833783481	-0.0325205860223	-5.14514008123482	183.021330971114	6.84628444195222e-07	2.86873372074131e-05	-0.26342068500899	-0.117390687605806
C1orf159	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.564294431864	-0.564294431864	-0.356957677743408	-0.221401224326	3.40219447071414	187.62668831375	0.000817010510726017	0.0185477222490622	0.0871170679640568	0.327556440277128
C1orf159	BRD-K03243820-001-23-8::2.37329::HTS002	2.37329	trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	chemo	TYMS	infectious disease	virus herpes simplex (HSV)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.7639750705925	-0.7639750705925	-2.26923698086552	-2.05370099582	-11.6165733476334	3.41383088514533	0.000729500566502521	0.01676709135849	-1.89075268324011	-1.11977113730593
C1orf159	BRD-K03765900-001-01-9::2.49999::MTS010::PROS002_PR500	2.49999	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.254937319405	-0.254937319405	-0.558388901047359	-0.353034364185	-3.93757657880495	129.298005785242	0.000133824315562759	0.00368432006811183	-0.455924371212346	-0.150978792072373
C1orf159	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.1261741492994	0.1261741492994	-0.652532717276481	-0.593822379071	-10.3536027327889	5.36461408684771	9.53060709286336e-05	0.0027105699145519	-0.968157133548037	-0.589256599603725
C1orf159	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-3.24695142494	-3.24695142494	-3.71003927197079	-3.60790168659	-3.99398524871135	40.5935685732837	0.000266250547328434	0.00681131696805394	-0.69731738784669	-0.228858306214886
C1orf159	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.66123340178	-1.66123340178	-3.04365055615466	-2.93942386342	-12.9306785705334	21.5129466206019	1.28815995172423e-11	9.51378477922476e-10	-1.60442605236099	-1.16040825638834
C1orf159	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.709369554487	-0.709369554487	-1.26244957392384	-0.9430769633885	-5.03729954118987	15.6867396165922	0.000128793405947617	0.00356228699230181	-0.786217449937104	-0.319942588936568
C1orf159	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.8507752525035	0.8507752525035	0.00627166353141335	0.1859491052615	-11.4217025543956	9.39307767367384	8.09195776510757e-07	3.35138399195699e-05	-1.01070319391688	-0.678303984027292
C1orf159	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.03699754023435	0.03699754023435	0.280024418210144	0.26768413301	7.13286890269094	7.01831577057252	0.000185849272004764	0.00495372324580388	0.162503405892453	0.323550350059135
C1orf159	BRD-K11663430-001-02-3::2.5::HTS002	2.5	pyroxamide	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.41133594275	-1.41133594275	-0.629852089263419	-0.605158922275	12.471831281819	177.182455988319	4.95169306812525e-26	1.37078540179704e-23	0.657828074956897	0.905139632016265
C1orf159	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.14326883203	-1.14326883203	-2.42902298143766	-2.32972185313	-14.1324251245551	5.93106592033464	8.60878885458754e-06	0.000299925670100696	-1.50900048023903	-1.0625078185763
C1orf159	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.272180671904	-0.272180671904	-1.81981779189141	-1.56065418801	-12.5698435108541	12.0437832235372	2.76823129702908e-08	1.39833194829353e-06	-1.81579101874054	-1.27948322123428
C1orf159	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.6170375892585	0.6170375892585	0.504458884845167	0.505306635797	-4.10444001021604	10.3142950597646	0.00199596074962536	0.0400329657033927	-0.173441759908008	-0.051715648918658
C1orf159	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.37110147309	0.37110147309	-0.481835653922407	-0.373418715101	-9.05344748817932	41.8502503224249	2.06931340171806e-11	1.48630654181243e-09	-1.04308340053629	-0.662790853488524
C1orf159	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.6632455291475	0.6632455291475	-0.0624765229035861	-0.0387919597267	-10.4179496422712	2.96400431163195	0.00198951401209542	0.0399186059444298	-0.948944499405027	-0.502499604697145
C1orf159	BRD-K15071410-001-01-1::2.5::HTS002	2.5	tiotidine	histamine receptor antagonist	noncancer	HRH2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.137566103912	0.137566103912	0.381035056624186	0.366990824591	8.48431451267602	195.222297064902	5.35948707189632e-15	5.57618206132265e-13	0.186874275551256	0.300063629873116
C1orf159	BRD-K15409150-001-05-8::2.5::HTS002	2.5	penfluridol	T-type calcium channel blocker	noncancer	CACNA1G	neurology/psychiatry	schizophrenia	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.6878078055555	-0.6878078055555	-2.87499807180099	-2.6535756676	-15.3371830608886	2.83227783706758	0.000820975192982249	0.018623919574163	-2.65661895753028	-1.71776157496071
C1orf159	BRD-K18424115-003-01-3::2.5::HTS002	2.5	TG-100572	src inhibitor, VEGFR inhibitor	targeted cancer	KDR, SRC	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.7215734257905	-0.7215734257905	-1.20848939084593	-1.11267387683	-6.70484065473236	15.6855409962007	5.6011274372803e-06	0.000202408370005876	-0.641118005827281	-0.332713924283587
C1orf159	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.1887936473215	0.1887936473215	-0.378561432600538	-0.173057746988	-6.83982557889462	21.1705244713032	8.82333495797563e-07	3.63044069535028e-05	-0.73977191346468	-0.394938246379396
C1orf159	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.0919804394245	-1.0919804394245	-3.1112572664467	-2.8622910827	-13.856489465831	3.72293765499802	0.000243906382433063	0.00631202741372808	-2.43603862042049	-1.60251503362391
C1orf159	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.547003517124	-0.547003517124	-1.91693334204811	-1.67956785013	-13.8822253975837	44.6748719674998	8.20389691617185e-18	1.11216509939671e-15	-1.56872609578931	-1.17113355405891
C1orf159	BRD-K22064724-001-01-8::2.49999::MTS010::PROS004_PR500	2.49999	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-2.86102623962	-2.86102623962	-2.28240498262029	-2.41370110422	7.11773274214582	21.1566909860922	4.86905289278863e-07	2.07967165695196e-05	0.40963958774941	0.747602926250005
C1orf159	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.028146293221255	0.028146293221255	-0.864571807717817	-0.55802362728	-9.2583594102314	99.9600815345569	4.19476501230751e-15	4.39853126381045e-13	-1.08401937464051	-0.701416827237636
C1orf159	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.3948836024565	0.3948836024565	-0.410962930711431	-0.310618907363	-11.6778561663752	10.263944808195	2.96341793143345e-07	1.30634800869231e-05	-0.959068051028636	-0.652625015307225
C1orf159	BRD-K25835157-001-01-4::2.5::HTS002	2.5	PRT062070	JAK inhibitor, syk inhibitor	targeted cancer	SYK	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.215332068487	0.215332068487	-0.0854890301793523	-0.0811687124677	-6.57764736646491	173.659588088575	5.41286164351488e-10	3.30993786930927e-08	-0.391086834222016	-0.210555363110688
C1orf159	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.5714403702065	-0.5714403702065	-1.98894319599831	-1.88069436606	-14.1288298254752	187.380516946773	2.48311249357268e-31	1.11339543438272e-28	-1.61541835483684	-1.21958729674677
C1orf159	BRD-K27182532-001-02-3::2.5::HTS002	2.5	metatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.01695265689283	0.01695265689283	-0.982617098441077	-0.968618770448	-18.6183499588209	31.2026573047407	1.8653330723501e-18	2.66352413100416e-16	-1.10903699809085	-0.890102512576965
C1orf159	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.309715543575	-1.309715543575	-1.96916124744307	-1.89093805071	-6.92208324105176	5.50137903899956	0.000651201325151152	0.0151313235926194	-0.897774081307923	-0.421117326428209
C1orf159	BRD-K31491153-003-05-9::2.5::HTS002	2.5	1-phenylbiguanide	serotonin receptor agonist	noncancer	HTR3A, HTR3B	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.09070565343785	0.09070565343785	-0.0999922117121276	0.0097375334851	-3.71822100519685	131.664004553387	0.00029576472776866	0.00747623049155906	-0.292151794608369	-0.0892439356915867
C1orf159	BRD-K35960502-001-20-0::2.5::HTS002	2.5	niclosamide	DNA replication inhibitor, STAT inhibitor	noncancer	STAT3	infectious disease	tapeworm	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.11223974013145	-0.11223974013145	-0.70915149648441	-0.681426229631	-9.80286078647907	35.4636641442881	1.23760399511572e-11	9.1629402474294e-10	-0.720470502379292	-0.473353010326628
C1orf159	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.012749904107	-1.012749904107	-1.97880258983133	-2.04775511057	-13.6058835688899	50.9574282510315	1.35471737245688e-18	1.96318606978574e-16	-1.1085991822002	-0.823506189248454
C1orf159	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.169192871497	0.169192871497	-0.515124125523716	-0.4097580139535	-13.6018614893001	104.382080921282	7.46531520291755e-25	1.91391572024655e-22	-0.784080388013192	-0.58455360602824
C1orf159	BRD-K37237504-001-02-7::2.5::HTS002	2.5	CEP-33779	JAK inhibitor	targeted cancer	JAK2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.03781224943425	-0.03781224943425	0.192329642504184	0.159444358103	5.95697508327774	23.7772615804796	3.93280937140246e-06	0.000145984603353536	0.150365648134028	0.309918135742839
C1orf159	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.203156705	-0.203156705	-1.95483551422979	-1.74375486562	-14.6930841771687	4.29535925857518	7.78443035309152e-05	0.00225768494336638	-2.07389486733606	-1.42946275112351
C1orf159	BRD-K37865504-001-04-1::2.5::HTS002	2.5	LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	noncancer	FAAH	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.8851972733445	-0.8851972733445	-1.29424504257351	-1.08170547456	-4.33757118953103	12.409769028528	0.000894604033022216	0.020065361616163	-0.613767300077322	-0.204328238380691
C1orf159	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.2487387261835	-0.2487387261835	-0.496040595172579	-0.332266676493	-4.50847357353118	91.8800121786827	1.92228157175927e-05	0.000628912665232166	-0.356245926549826	-0.138357811428333
C1orf159	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.51860977029	0.51860977029	-0.215719811642904	-0.158274399371	-10.9665182749156	2.94787169317525	0.00175648646136888	0.0359351066372907	-0.949577293250085	-0.519081870615724
C1orf159	BRD-K44084986-300-08-4::2.5::HTS002	2.5	Y-27632	rho associated kinase inhibitor	targeted cancer	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.5784779888	-0.5784779888	-0.941103396903093	-0.864137598244	-6.01513557161495	144.233031987176	1.40973135309298e-08	7.42921837170063e-07	-0.481782577318226	-0.24346823888796
C1orf159	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.319887405322	-0.319887405322	-1.75457808404619	-1.65992199057	-14.5216905470323	5.54412228778114	1.26770048875963e-05	0.000428574061875704	-1.68133800741329	-1.18804335003508
C1orf159	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.6357254614255	0.6357254614255	-0.7349726239761	-0.623158972273	-10.0456847524832	3.20754774580751	0.00156952437764825	0.0326829876718156	-1.78946099436277	-0.95193517644043
C1orf159	BRD-K45446451-001-05-0::2.5::HTS002	2.5	JZL-184	monoacylglucerol lipase inhibitor	targeted cancer	MGLL	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.4372828301155	0.4372828301155	-0.0547039032100567	-0.08025310757335	-12.105442919519	11.4449588371437	7.13399460206525e-08	3.41938362183949e-06	-0.581016205468701	-0.402957261182413
C1orf159	BRD-K45462423-001-03-7::2.5::HTS002	2.5	VU0361737	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.5079128851105	0.5079128851105	0.0773003137739127	0.1040664300715	-10.0179256761343	11.605726049792	4.65596199511452e-07	1.99541627364707e-05	-0.524621204932532	-0.336603937740643
C1orf159	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.2007090285985	0.2007090285985	-0.267152767499297	-0.234942866008	-10.0089798703108	5.84787008353488	6.75390171487887e-05	0.00198268319497093	-0.582965903419634	-0.35275768877596
C1orf159	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.016705023972045	0.016705023972045	0.156007554523046	0.14294893902	5.67809947351565	6.92278315450392	0.000782280750538377	0.0178424445016643	0.0811590588051779	0.197446002296824
C1orf159	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.3701766446235	0.3701766446235	-0.369777244031091	-0.243490121847	-9.02375948845678	5.34270714336201	0.000196724336880917	0.00520411384835226	-0.946740571300946	-0.533167206008236
C1orf159	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.900058721425	-1.900058721425	-0.0476212676512433	0.365958476092	18.9164399313273	11.8681523328406	3.15733566293189e-10	1.98215757264361e-08	1.63880882480817	2.06606608273935
C1orf159	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.251208309767	-0.251208309767	-0.784780716089829	-0.640313618355	-7.09801543796648	142.917752764926	5.44547122322318e-11	3.7098614170445e-09	-0.682165150506315	-0.384979662139343
C1orf159	BRD-K49669041-001-08-4::2.5::HTS002	2.5	BX-912	pyruvate dehydrogenase kinase inhibitor	targeted cancer	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.516952476835	-1.516952476835	-1.94129225464517	-1.738347180205	-4.60699503348047	192.541776580726	7.41813966360105e-06	0.000261371619519877	-0.606009466229157	-0.242670089391179
C1orf159	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.36740086818	-1.36740086818	-0.445297420490003	-0.3126477114325	14.6358367500734	7.56549363114914	8.02777186152975e-07	3.32865992514957e-05	0.775352677284794	1.0688542180952
C1orf159	BRD-K50168500-001-07-9::2.5::HTS002	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.186259492002	-0.186259492002	-0.473781274565921	-0.3595601778475	-4.79274409531713	26.7610006690697	5.42764511695404e-05	0.00162654047856773	-0.410664721859137	-0.164378843268705
C1orf159	BRD-K51318897-001-15-3::2.5::HTS002	2.5	fenbendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.7613035716675	-0.7613035716675	-2.77861824039109	-2.716477305745	-17.6629521485903	17.7967242494642	9.98670642346263e-13	8.318852705147e-11	-2.25746101774185	-1.77716831970533
C1orf159	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.2082671093285	0.2082671093285	-0.104677576918236	-0.112273492753	-6.50705129750395	36.7063300412347	1.34447901982975e-07	6.23050473169926e-06	-0.410417015709188	-0.215472356784285
C1orf159	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.344088595945	-1.344088595945	-2.7542632876944	-2.66953815971	-16.348968368513	89.1450127227219	1.44283577681934e-28	5.21486592259549e-26	-1.58155702052812	-1.23879236297068
C1orf159	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-6.778397285765	-6.778397285765	-5.57249526096989	-5.500812389495	14.9883967494966	107.328020088599	4.48460805970579e-28	1.52085690004538e-25	1.04641354770756	1.36539050188265
C1orf159	BRD-K61036791-001-01-6::2.5::HTS002	2.5	rucinol	tyrosinase inhibitor	noncancer	TYR	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.2618592240035	0.2618592240035	0.405098367195603	0.443703234986	5.71898960080663	189.924251232034	4.10558390268547e-08	2.02565767099142e-06	0.0938346174409129	0.192643668943294
C1orf159	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.45739553089	0.45739553089	-0.381014723449428	-0.400498604256	-12.4467805547562	3.49098243914941	0.000513828396141884	0.012282882703178	-1.03669184556608	-0.640128663112777
C1orf159	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-8.29175971791	-8.29175971791	-7.20175080680862	-7.241239224365	8.51191681634462	6.93651888534582	6.44904457428619e-05	0.00190257023339599	0.786639994836467	1.3933778273663
C1orf159	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.4120114417845	0.4120114417845	-0.257366069667368	-0.132231172134	-11.2508364148799	19.6460497653079	5.18545691731843e-10	3.17722640260704e-08	-0.793627071270373	-0.545127951633362
C1orf159	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.1551484585045	0.1551484585045	-0.234609287505856	-0.1756829862115	-5.78929062873163	10.2354559907524	0.000160379755584075	0.00435004209498598	-0.53929835874052	-0.240217133280192
C1orf159	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.033397725808245	0.033397725808245	-0.211401212960452	-0.1382371077965	-5.50079617011519	10.0196866940349	0.000259671276572464	0.00666288579390633	-0.34393018778216	-0.145667689755234
C1orf159	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.03187724189535	-0.03187724189535	-0.493395316742897	0.00515603334304	-5.14063353403518	184.524888934178	6.94254860706245e-07	2.90736518249919e-05	-0.63864226954915	-0.284393880145943
C1orf159	BRD-K63784565-001-06-2::2.50835::HTS002	2.50835	10-hydroxycamptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-6.33277393905	-6.33277393905	-5.71266022271497	-5.76312410001	6.49494588135654	161.440580229178	9.80367244329413e-10	5.83831984189716e-08	0.431570147181375	0.808657285488678
C1orf159	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.6155616105115	-0.6155616105115	-1.08274777398001	-0.4089077458395	-4.00922127657821	141.493230663213	9.81808154420386e-05	0.00278678267684766	-0.697546901350155	-0.236825425586856
C1orf159	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.2571775831485	0.2571775831485	-0.795759141845602	-0.692855994301	-11.4881418777799	3.19672662271028	0.00104730771445227	0.023010601243551	-1.33472483467475	-0.771148615313452
C1orf159	BRD-K68202742-001-16-5::2.63491::HTS002	2.63491	trichostatin-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-6.00986496916	-6.00986496916	-5.50343841881757	-5.50871409078	5.51452010536657	8.42977062931536	0.000469817836178346	0.0113421476695504	0.296519079667103	0.71633402101776
C1orf159	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.328257265505	-1.328257265505	-3.15527730479596	-3.04544241525	-17.1588891759918	136.453431473612	6.9876990345709e-36	4.83118240767918e-33	-2.03757769032761	-1.61646238825431
C1orf159	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.431613174197	0.431613174197	0.309072704554303	0.289065772439	-4.93142934247654	187.145627701904	1.79455379671014e-06	7.02896419398917e-05	-0.171560367395685	-0.0735205718897096
C1orf159	BRD-K71847383-001-12-5::2.5::HTS002	2.5	cytarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.06129254480575	0.06129254480575	0.332340706418755	0.318284588664	7.14293919799478	4.15173504725105	0.00176216977898411	0.0360179369215989	0.167193640516947	0.374902682709063
C1orf159	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.1152832877305	0.1152832877305	-0.199719915331654	-0.124222212564	-8.94412648116875	180.15251432291	4.46380461910114e-16	5.14367086132973e-14	-0.384498023998833	-0.245508382125474
C1orf159	BRD-K73197500-001-02-2::2.5::HTS002	2.5	SNX-5422	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.889064841325	-1.889064841325	-3.63679206159627	-3.70624580332	-16.9061014547965	11.2595196630994	2.35403686825944e-09	1.34471846465132e-07	-1.97462352107571	-1.52083091946682
C1orf159	BRD-K76674262-001-03-3::0.625::MTS010::PROS003_PR500	0.625	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-2.23211581019	-2.23211581019	-1.59347339494449	-1.84636117372	5.83145348563895	35.3840868007027	1.23947845386015e-06	4.98884840445806e-05	0.416397628670732	0.860887201820292
C1orf159	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.340983297053	-0.340983297053	-0.962900829729432	-0.892479910689	-11.0046609332035	45.5102932701874	2.04941330591298e-14	2.02046322190903e-12	-0.735707378639145	-0.508127686713719
C1orf159	BRD-K77625799-001-07-7::2.5::MTS010::PROS002_PR500	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.3735115646385	0.3735115646385	-0.126943610445062	-0.08759243402935	-11.8376997186492	91.3211109158407	3.84233041384124e-20	6.45900262955435e-18	-0.584428046517398	-0.416482303649726
C1orf159	BRD-K77638923-001-02-0::2.5::HTS002	2.5	CUDC-907	PI3K inhibitor	targeted cancer	HDAC2, PIK3R1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-5.206855096125	-5.206855096125	-5.89813227574005	-5.8647928098	-8.97961338638482	31.2253662943018	3.67612000197573e-10	2.29708199388763e-08	-0.848239036559643	-0.534315322670462
C1orf159	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-4.857148726455	-4.857148726455	-3.96181759242175	-3.94724012749	7.19861356371084	35.5747064385357	1.93199589591131e-08	9.97309124216704e-07	0.642981186437172	1.14768108162933
C1orf159	BRD-K80480517-001-02-4::2.5::HTS002	2.5	repsox	TGF beta receptor inhibitor	noncancer	TGFBR1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.3248032467835	-0.3248032467835	-0.89759712483323	-0.828383638665	-7.31171258727264	3.96097287176734	0.00193304662266809	0.0389496991247372	-0.791146218761794	-0.354441537337665
C1orf159	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.8429103219185	-0.8429103219185	-1.69632223710239	-1.42296021894	-7.23849725504438	4.39908995990841	0.00133087842040873	0.0283873449330558	-1.1693665061872	-0.537457324180582
C1orf159	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.376787207794	0.376787207794	-0.107912143386448	-0.0756772814281	-12.9266578137759	7.89548643533435	1.3653645798442e-06	5.45964972077288e-05	-0.571365162600563	-0.398033539760333
C1orf159	BRD-K85090592-008-22-7::2.5::HTS002	2.5	pilocarpine	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.771571394707	0.771571394707	0.468897075220467	0.471563787015	-8.36076411933245	145.48880335548	4.59930723439369e-14	4.37534363178147e-12	-0.374223598043295	-0.23112504092977
C1orf159	BRD-K85849709-001-01-5::2.5::HTS002	2.5	AZD2858	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.183092745695	-1.183092745695	-1.74520211630566	-1.58142257926	-4.86088455881862	11.7716271082482	0.000413106945677185	0.0100981750182533	-0.814608994645324	-0.309609746576002
C1orf159	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.59115980493	-1.59115980493	-2.23976261503934	-2.18551801488	-7.66703097251695	6.55061273404489	0.000167164147101397	0.00451073381683677	-0.851457216343205	-0.445748403875479
C1orf159	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.7729185688705	-0.7729185688705	-0.487696516332155	-0.397290410403	5.50940217993597	29.3347594845782	5.94103485496986e-06	0.000213754584426865	0.17939286139607	0.39105124368062
C1orf159	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.262375153839	0.262375153839	-0.123186736341232	-0.0479466221371	-11.4382848866769	68.1960381781136	1.62313503750054e-17	2.13295468701689e-15	-0.452821687960254	-0.31830209240021
C1orf159	BRD-K89053832-001-01-0::2.5::HTS002	2.5	VLX600	ubiquitin C-terminal hydrolase inhibitor	targeted cancer	USP14	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.6083712652895	-0.6083712652895	-2.08044667089222	-1.90794289133	-11.0278065618649	6.04112385862212	3.15772719815502e-05	0.000987729878361598	-1.79816956671478	-1.14598124449065
C1orf159	BRD-K89162000-001-06-4::2.5::HTS002	2.5	tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFD, PDGFRB	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.299543245474	-0.299543245474	0.0593953271740926	0.145916428293	6.8254984183535	4.50812095859379	0.00154225940884525	0.0321923370508759	0.219197952057048	0.498679193239137
C1orf159	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-1.95154554995	-1.95154554995	-2.91992839958956	-2.87877770547	-9.90347687317453	14.7211961073468	6.72476371780374e-08	3.23890310758013e-06	-1.17714479767868	-0.759620901600437
C1orf159	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.582339255635	-0.582339255635	-1.01805936674057	-0.966558687453	-7.25957521007956	15.7183037740081	2.11944318658503e-06	8.23378899288712e-05	-0.563142522360126	-0.308297699851006
C1orf159	BRD-K93869735-001-01-1::2.5::HTS002	2.5	taltirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	neurology/psychiatry	spinocerebellar ataxia	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.6638014513205	-0.6638014513205	-0.175201375674984	-0.1008749924888	8.88148367932021	8.2460321865804	1.68401525873161e-05	0.000557684342380544	0.362394921454928	0.614805229836105
C1orf159	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.08303816330285	0.08303816330285	0.301230597409163	0.276885156297	5.98778108701243	146.314299440041	1.57339574923209e-08	8.22899798772976e-07	0.146176453239998	0.290208414972629
C1orf159	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.185040811817	-0.185040811817	-1.42014764144681	-1.39259151278	-13.162086551284	8.71174032629321	4.77506861986526e-07	2.04400975080308e-05	-1.44845918075128	-1.02175447850834
C1orf159	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.6156120436925	0.6156120436925	-0.302382564693788	-0.214794605924	-12.1512734085218	38.1031897800663	1.11823684466451e-14	1.12468599099062e-12	-1.07091830649496	-0.765070910277613
C1orf159	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.26708804828	0.26708804828	-0.03758400320041	0.00448333894144	-5.85009813149971	168.065123993254	2.50319041926583e-08	1.27345430660058e-06	-0.40748696976188	-0.20185713319894
C1orf159	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.5638256059	0.5638256059	-0.0827421710370785	-0.0625986180944	-12.8077169565691	45.4148094179408	1.11262592614827e-16	1.34803845181138e-14	-0.748219471674641	-0.544916082199516
C1orf159	BRD-K96344439-002-02-7::2.5::MTS006	2.5	tofogliflozin	sodium/glucose cotransporter inhibitor	noncancer	GCK	endocrinology	diabetes mellitus, diabetes mellitus	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	0.4257352262135	0.4257352262135	0.135329606966537	0.243893587025	-8.15866083423666	189.31350775789	4.60356414452989e-14	4.3774503084869e-12	-0.360618929283519	-0.220192309210406
C1orf159	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	SNUC2A, HCC1428	LARGE_INTESTINE, BREAST	carcinoma (adenocarcinoma), carcinoma	-6.615680027575	-6.615680027575	-5.63641251663166	-5.72114668903	8.01632892708155	4.25031828871936	0.00101391909401987	0.0223871706502714	0.647833818766739	1.31070120311994
C5orf24	BRD-A02180903-001-04-5::2.5::HTS002	2.5	betamethasone	glucocorticoid receptor agonist	noncancer	NR3C1	dermatology	corticosteroid-responsive dermatoses	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.114489070116	0.114489070116	-0.0733930767920429	-0.04557426840735	-3.8812066892749	137.086968064014	0.000160863773312102	0.00436041123943462	-0.283605449262241	-0.0921588445538446
C5orf24	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.2326465784385	0.2326465784385	-0.181346629636354	-0.1596607583295	-9.34003612923956	114.934506404573	8.98752888691559e-16	1.00379785242508e-13	-0.501792208581876	-0.326194207567832
C5orf24	BRD-A16997652-001-02-3::2.5::HTS002	2.5	protirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	radiology	thyroid function diagnostic	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.493494359793	0.493494359793	0.333470025138053	0.352492434088	-7.33832446408063	191.1151585275	6.02390147624421e-12	4.61105992679266e-10	-0.203036974181868	-0.117011695128027
C5orf24	BRD-A43885598-001-08-1::2.5::HTS002	2.5	SID-7969543	steroidogenic factor antagonist	noncancer	NR5A1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.7078124392485	0.7078124392485	0.405399290607383	0.415971610724	-7.1714797958337	5.96560168103789	0.000380982003139472	0.00940623105067158	-0.40574103253694	-0.199085264745295
C5orf24	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.588161454212	0.588161454212	0.20377763147152	0.2241591843385	-8.7640068363796	4.28882873006747	0.000677604963154677	0.015687016002158	-0.502989940794251	-0.265777704686709
C5orf24	BRD-A50157456-065-20-6::2.5::HTS002	2.5	terbutaline	adrenergic receptor agonist	noncancer	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.6180407283145	0.6180407283145	0.145668276116776	0.1597653685015	-16.5871872942845	145.072549914507	2.5578631519328e-35	1.65127786593556e-32	-0.528658132515331	-0.416086771880117
C5orf24	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.583606911593	0.583606911593	-0.227304614917989	-0.093015492892	-12.6078162009053	177.423238008063	1.95467206863285e-26	5.63095308868293e-24	-0.937838576314269	-0.683984476707708
C5orf24	BRD-A81370665-001-03-6::2.5::HTS002	2.5	BI-D1870	ribosomal protein inhibitor	noncancer	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.545750471497	-0.545750471497	0.368492326764804	0.3647781877755	28.3178976134485	153.321395981182	8.68462320493752e-63	7.75569419537939e-59	0.850461967427148	0.97802362909646
C5orf24	BRD-A98299281-050-09-6::2.5::HTS002	2.5	hydroxytacrine-maleate-(r,s)	cholinesterase inhibitor	noncancer	ACHE	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.07753227549005	0.07753227549005	-0.25293690356925	-0.147378080883	-5.98118450261846	8.61285512587551	0.000246909169249916	0.0063820303106808	-0.456318336285264	-0.204620021833336
C5orf24	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.04831333393815	0.04831333393815	0.224075471053579	0.2226649685355	5.63231980322479	14.5617081024882	5.33219148418552e-05	0.00160039667919619	0.109073342172856	0.242450932058003
C5orf24	BRD-K03243820-001-23-8::2.37329::HTS002	2.37329	trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	chemo	TYMS	infectious disease	virus herpes simplex (HSV)	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.73654267036	-1.73654267036	-2.25894526023306	-2.05370099582	-5.64502420657927	85.0743141294845	2.13015923107078e-07	9.59249846805365e-06	-0.706398825914474	-0.338406353831642
C5orf24	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.1059180096995	-0.1059180096995	-0.340810507487066	-0.229059189804	-4.76305434386041	13.5237144782964	0.000332764918771215	0.00832316166125753	-0.34101431331838	-0.128770682256752
C5orf24	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.28186227719	-0.28186227719	-0.685164752844993	-0.506361258966	-4.96384229446044	9.17942794007886	0.000732036284506952	0.0168163563582091	-0.58655213318314	-0.220052818126845
C5orf24	BRD-K06234293-001-04-2::2.5::HTS002	2.5	LY364947	TGF beta receptor inhibitor, p38 MAPK inhibitor	targeted cancer	TGFBR1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.5573201332065	0.5573201332065	0.788358654314767	0.824104228749	6.42792499810521	23.1959026314978	1.41179318850346e-06	5.6347899869415e-05	0.156719617202064	0.305357425014469
C5orf24	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.1131868893	-1.1131868893	-2.50432010579063	-2.37307934162	-12.1597398272476	33.6067419126149	7.42971088575619e-14	6.90547486744682e-12	-1.62373209945435	-1.1585343335269
C5orf24	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.236843114565	-1.236843114565	-1.80971661448135	-1.56065418801	-5.2170884266655	80.5683041550553	1.38061258491044e-06	5.51753337145756e-05	-0.791372989673948	-0.354374010158754
C5orf24	BRD-K12502280-001-08-0::2.5::HTS002	2.5	TG-101348	FLT3 inhibitor, JAK inhibitor	targeted cancer	BRD4, JAK1, JAK2, JAK3, TYK2	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.0508324158441	0.0508324158441	-0.397522304819197	-0.2460199545545	-6.59420672554319	110.76752841773	1.51121895897758e-09	8.81595123186463e-08	-0.583088949375154	-0.313620491951441
C5orf24	BRD-K13167095-001-02-9::2.5::HTS002	2.5	AR-42	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.998387013994	-0.998387013994	-3.27604142019292	-3.28129580755	-16.1923826618214	7.74934407545502	2.97565013099802e-07	1.31120089828675e-05	-2.60385711677171	-1.95145169562612
C5orf24	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-2.758862415685	-2.758862415685	-2.05891561686413	-2.351388502545	6.9617410979975	65.383014519248	1.97463193327941e-09	1.13799647116925e-07	0.499173020812577	0.900720576829161
C5orf24	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.46498948255	-1.46498948255	-3.54231326924402	-3.39005054237	-16.8677059087431	174.666907914459	1.66708645624478e-38	1.51400412322241e-35	-2.32038508815046	-1.83426248523758
C5orf24	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.563243649619	0.563243649619	0.398923945422982	0.431459247123	-4.52605424875728	10.361249713375	0.00100384758509834	0.022201387789345	-0.244832254108784	-0.0838071542832528
C5orf24	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.7136855193135	0.7136855193135	-0.0509564169242306	0.0935597000564	-12.5351760869322	158.050684295019	1.82539232169797e-25	4.83602609291969e-23	-0.885121654965706	-0.644162217509755
C5orf24	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.325731886604	0.325731886604	-0.0983162244668689	-0.0311349339001	-7.70027300246373	4.03961192404715	0.00147024915452232	0.0308998853735648	-0.576355330102415	-0.271740892039323
C5orf24	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-3.37929553174	-3.37929553174	-2.44045482614335	-2.31886428958	10.3306978271797	183.722279450881	5.14375057378387e-20	8.54616214518235e-18	0.75954057915143	1.11814083204187
C5orf24	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.05232147151825	0.05232147151825	-0.376946377265588	-0.173057746988	-4.84985099923495	10.5116487798513	0.000581929082455607	0.0137225523504927	-0.625190410049369	-0.233345287518307
C5orf24	BRD-K24048528-001-02-5::2.5::HTS002	2.5	abiraterone-acetate	androgen biosynthesis inhibitor	targeted cancer	CYP17A1	oncology	prostate cancer	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.26284341362	0.26284341362	0.403434608307085	0.3679428252945	4.54409818770695	131.13323366483	1.23800242998315e-05	0.000419178235096142	0.0793864684846377	0.201795920889532
C5orf24	BRD-K24844714-001-24-5::2.5::HTS002	2.5	5-fluorouracil	thymidylate synthase inhibitor	chemo	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.5586048023	-0.5586048023	-1.05508534100813	-0.97521082715	-7.70607763511725	7.30917739655477	9.23909783361112e-05	0.00263430437618736	-0.647529839001317	-0.345431238414941
C5orf24	BRD-K25244359-066-03-4::2.68145::HTS002	2.68145	apatinib	RET tyrosine kinase inhibitor	targeted cancer	CSK, KDR, KIT, RET	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.4999200029165	0.4999200029165	0.132923777037554	0.183294433483	-8.55107846340871	15.0249292934603	3.70923336126113e-07	1.60963004066762e-05	-0.45846081902892	-0.275531632728973
C5orf24	BRD-K25433859-003-25-4::2.5::HTS002	2.5	maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2	neurology/psychiatry	depression, dysthymic disorder	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.0595106948076	0.0595106948076	0.173946364340847	0.1863876312595	3.96429448292111	32.3351501858738	0.000382031390591739	0.00942671032859047	0.0556602393494125	0.173211099717082
C5orf24	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.1071430390386	0.1071430390386	-0.506938635405716	-0.436225052339	-13.0492106886778	155.87319473221	8.97263105015096e-27	2.6746801673822e-24	-0.707037149142263	-0.521126199746369
C5orf24	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.40663170769	-1.40663170769	-1.98019773696707	-1.88069436606	-4.64036402811443	8.23365940198571	0.00154313811168686	0.0322012704059714	-0.857194768338934	-0.289937290215199
C5orf24	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.5812101679795	0.5812101679795	0.144106189899926	0.195908235522	-9.780882586404	30.0555764672295	7.4990243545774e-11	5.04633717705563e-09	-0.528365292482394	-0.345842663676753
C5orf24	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.0412949861099775	0.0412949861099775	-0.697586262854231	-0.621232482709	-11.6129240950896	5.48074044445636	4.56820241262055e-05	0.00138800433072661	-0.89821426130964	-0.579548236618777
C5orf24	BRD-K33882852-003-02-8::2.5::HTS002	2.5	ZK-93423	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.238451497494	-0.238451497494	-0.889813010942489	-0.832624878756	-7.6620895672996	3.66433989878433	0.00220654640050501	0.0436198933290756	-0.896165957346234	-0.406557069550744
C5orf24	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.5244475224265	0.5244475224265	0.0849058070369285	0.1179670530315	-15.8610331348778	192.033341518442	9.2796614726363e-37	7.18014643959807e-34	-0.49420080191736	-0.384882628861783
C5orf24	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.344314231513	-0.344314231513	-1.0211245807921	-1.03228700688	-10.6641387081148	193.822984777895	3.45677006958894e-21	6.3269519406057e-19	-0.801983020605785	-0.551637677952408
C5orf24	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.35896939078	-1.35896939078	-0.688600495980934	-0.55798899715	10.7128230590705	189.960126289863	2.99375013264302e-21	5.50298003584259e-19	0.546935201447836	0.793802588150296
C5orf24	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.12106880591195	-0.12106880591195	-0.515515893594432	-0.465030888818	-6.13595218704981	5.05552314251947	0.00160532623157755	0.033330230154779	-0.55915146903417	-0.229742706330795
C5orf24	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.763902175356	0.763902175356	0.470282153011112	0.492327571576	-8.89132416377555	15.4246770246967	1.83728666892137e-07	8.33581317661408e-06	-0.363838905813267	-0.223401138876509
C5orf24	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.30312645054	0.30312645054	-0.731453057723344	-0.623158972273	-9.94222288722414	17.1604486465639	1.54173511596368e-08	8.07326033885607e-07	-1.25396891076695	-0.815190105759739
C5orf24	BRD-K45462423-001-03-7::2.5::HTS002	2.5	VU0361737	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.417880372804	0.417880372804	0.0782684053040901	0.1040664300715	-9.02720527794469	106.208768961806	8.53310519399972e-15	8.68832258016516e-13	-0.41419745180482	-0.265026483195
C5orf24	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.544280873775	-0.544280873775	0.356819305951123	0.3889604534415	24.1237648640912	10.9279501411812	7.92997997237776e-11	5.32297111650408e-09	0.81882012558096	0.983380233871285
C5orf24	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.33912776683	-1.33912776683	-1.83469158674265	-1.58248812639	-4.7068037877926	22.649157317433	0.000100234164938805	0.00284017561305779	-0.713552783459638	-0.277574856365659
C5orf24	BRD-K50168500-001-07-9::2.5::HTS002	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.0287363003485	-1.0287363003485	-0.464818755328192	-0.351276488642	7.68356723838717	4.74847970114368	0.000748422201575325	0.0171541634094148	0.372209964658699	0.755625125381917
C5orf24	BRD-K51471001-303-04-7::2.5::HTS002	2.5	demecarium	acetylcholinesterase inhibitor	noncancer	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.492095184886	0.492095184886	0.276601338175476	0.268075360474	-8.43424264886885	41.2111411206288	1.6242321511291e-10	1.04981921809213e-08	-0.267084839095345	-0.163902854325704
C5orf24	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.07198900921605	0.07198900921605	-0.326166188415973	-0.2394985033815	-7.64206476597776	28.3911393895855	2.30018453023462e-08	1.17547985260052e-06	-0.504811980603985	-0.291498414660061
C5orf24	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-5.23989452359	-5.23989452359	-4.58322247672602	-4.6036621232	5.38028285394758	7.20166805857562	0.000938195891086484	0.0209330196898475	0.369696188817988	0.94364790490997
C5orf24	BRD-K52313696-001-12-3::0.15625::HTS002	0.15625	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.1593532349735	0.1593532349735	0.419218605535089	0.39525647476	6.19395226320206	4.70659246003284	0.00198362075613673	0.0398239329896465	0.149963489655304	0.369767251467874
C5orf24	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.05623788753843	0.05623788753843	-0.588358499723719	-0.48109263675	-7.13234952226325	8.95668926139996	5.60668721029973e-05	0.00167504274197983	-0.849192906365522	-0.439999868158775
C5orf24	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.4771762619035	-0.4771762619035	-1.19098272038433	-1.12103485225	-12.4212442416057	134.575828627765	4.45668420398098e-24	1.05313855430545e-21	-0.827460914773026	-0.600152002188628
C5orf24	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.661865351395	-0.661865351395	-0.368647199888268	-0.394478559639	5.6122164162457	20.7018964636571	1.51037034666097e-05	0.000504466520226741	0.184470451494236	0.401965851519229
C5orf24	BRD-K62696033-001-01-4::2.5::HTS002	2.5	G-1	G protein-coupled receptor agonist	targeted cancer	GPER1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.9065308318	-1.9065308318	-1.24012351306648	-1.15205900339	8.73660766370325	140.942912006838	6.34777709244915e-15	6.53464321060295e-13	0.5156112337839	0.817203403683143
C5orf24	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.2983223148515	0.2983223148515	0.144084518506673	0.15713254048	-5.70132986823286	87.987476623175	1.56274994476726e-07	7.1783676149169e-06	-0.20799995790793	-0.100475634781724
C5orf24	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.15197154402	-0.15197154402	-0.607649109416319	-0.456560974373	-5.93402442277163	8.14922608311575	0.00032410010043968	0.00812445034235512	-0.632194273446808	-0.279160857345829
C5orf24	BRD-K69650333-003-14-0::2.5::HTS002	2.5	idarubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-7.93719191078	-7.93719191078	-6.61005764456283	-6.534390959045	10.0835642050831	7.57750326656705	1.17304730467314e-05	0.00039869656797223	1.02066181044217	1.63360672199217
C5orf24	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.01765751880062	0.01765751880062	0.223480940146079	0.235603358555	7.25586156301825	16.9337450855356	1.37449257436946e-06	5.49512439791144e-05	0.145957488182652	0.265689354508266
C5orf24	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.56601173562	-1.56601173562	-2.64162503145656	-2.52531204565	-10.0112498988588	4.53172933094393	0.000292558333736968	0.00740653615774989	-1.36060633533217	-0.790620256340959
C5orf24	BRD-K76037122-001-02-5::2.5::HTS002	2.5	guanidine	HSP inhibitor	noncancer	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.3453182557145	0.3453182557145	0.21177150981818	0.2145436511	-4.50175405364454	31.4041771889738	8.69605027698733e-05	0.00249740822700847	-0.194018369251683	-0.0730751225409568
C5orf24	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2925649709245	-0.2925649709245	-0.168863398332196	-0.1689019992055	3.8972877345558	107.04644315772	0.000169876453409204	0.00457692650945835	0.0607801922905823	0.186622952894026
C5orf24	BRD-K77638923-001-02-0::2.5::HTS002	2.5	CUDC-907	PI3K inhibitor	targeted cancer	HDAC2, PIK3R1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-5.46547117129	-5.46547117129	-5.89543835829042	-5.8647928098	-5.73263108517759	53.343113108757	4.71936654411501e-07	2.02056954061851e-05	-0.580382498523926	-0.279551875476907
C5orf24	BRD-K78809024-001-05-7::2.5::HTS002	2.5	SB-590885	RAF inhibitor	targeted cancer	BRAF	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.182868908311	-0.182868908311	0.096841063564477	0.1634753207025	4.85957309470491	7.04580903053413	0.00180255981829528	0.0367279060077392	0.143784812115648	0.415635131635306
C5orf24	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.72541803638	-1.72541803638	-2.51214260608851	-2.254263331985	-6.54218673742478	21.4132960355987	1.60064125409164e-06	6.33777645202674e-05	-1.03651301691797	-0.536936122499045
C5orf24	BRD-K81528515-001-13-8::2.5::HTS002	2.5	nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	targeted cancer	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.7424413191185	0.7424413191185	0.18443991706381	0.2214201178065	-8.70430118944521	6.83968084967513	6.06545327916995e-05	0.0018005575289075	-0.71031221659816	-0.40569058751122
C5orf24	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.30234793945	-1.30234793945	-1.69116001668069	-1.42296021894	-4.10431314689038	26.8426008031675	0.000338709549971808	0.00845704556569288	-0.583240572710377	-0.194383581751004
C5orf24	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.294764029621	0.294764029621	0.457507017997639	0.487412056788	5.06023245878437	133.564918190118	1.35762376557415e-06	5.43275100918112e-05	0.0991319130454711	0.226354063707807
C5orf24	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.295982100153	0.295982100153	0.0326334702651521	0.0430886024597	-10.1668214610719	192.97713704019	1.02036819059366e-19	1.6406188591279e-17	-0.314437481477839	-0.212259778297857
C5orf24	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.404992276803	-0.404992276803	-0.148411674605986	-0.137644446714	6.18076782529533	16.7357675462257	1.07930963707082e-05	0.000369532516299924	0.168890921831827	0.344270282562202
C5orf24	BRD-K86118762-001-01-8::2.5::HTS002	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.186686654569	0.186686654569	0.0636689781716567	0.0670772689305	-3.67122391957677	76.7908599596003	0.000443826119835486	0.0107790151204782	-0.189744779251543	-0.0562905735431438
C5orf24	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.356949151091	0.356949151091	0.100376838867586	0.1180798290625	-8.76179989768604	7.42518314548761	3.56843308361445e-05	0.00110666863605557	-0.325020011189766	-0.188124613257062
C5orf24	BRD-K92150287-066-01-2::0.625::HTS002	0.625	exatecan-mesylate	topoisomerase inhibitor	chemo	TOP1	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-4.724233867775	-4.724233867775	-4.10413750896254	-4.11703772867	4.5986353445652	67.0513676659466	1.93963059601178e-05	0.000634297352366773	0.350951277684834	0.889241439940092
C5orf24	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.219130451789	-0.219130451789	0.0272026907423128	0.0455215007673	11.3655463513301	188.004943699882	4.02350454322056e-23	8.77267248467874e-21	0.203578302388157	0.289087982674468
C5orf24	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2257304999755	-0.2257304999755	-0.968304239268548	-0.879578497328	-8.41330509520779	135.789185588128	4.90318607839555e-14	4.64792113664945e-12	-0.917119313122183	-0.568028165463912
C5orf24	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.4903333717325	0.4903333717325	-0.0949290593098999	0.0692106615383	-9.9611906338098	17.3790127388615	1.32848336169072e-08	7.01657246002491e-07	-0.709017477587305	-0.461507384497495
C5orf24	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	TE5, CAOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2941583134075	-0.2941583134075	-0.621823948895036	-0.6228392960495	-6.30766236477469	73.7373196664353	1.88387114057194e-08	9.74579333062137e-07	-0.431178892962993	-0.224152378012079
CABLES1	BRD-A03932035-004-04-3::2.5::HTS002	2.5	methscopolamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.54625846193	0.54625846193	0.237215918399994	0.224710721764	-10.9263223659838	129.416269621064	4.2934717422016e-20	7.1835714678714e-18	-0.365001868220906	-0.253083218839106
CABLES1	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.2000162203875	-0.2000162203875	-0.835244167413249	-0.720201208535	-10.2971991072916	105.285527764063	1.28101090322167e-17	1.70532786258756e-15	-0.757542748286408	-0.51291314576509
CABLES1	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.0757026376132	-0.0757026376132	-1.2239267314515	-1.12011346307	-11.8770147583787	3.82232415425756	0.00037095815578728	0.00919369687462211	-1.4216331317125	-0.874815055964106
CABLES1	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1110103563469	0.1110103563469	-0.497606454847398	-0.379151386241	-8.77021482893209	8.81976498651711	1.20313625369812e-05	0.000408146549729131	-0.766091588861105	-0.45114203352749
CABLES1	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.05910508140615	0.05910508140615	0.405373579919937	0.4132826179685	6.89927684055481	150.703316857204	1.35198988665622e-10	8.83177812914173e-09	0.247103350843622	0.445433646183953
CABLES1	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-5.011199249745	-5.011199249745	-3.70473802755078	-3.697322932235	12.4218736337434	3.64791974425088	0.000407286533335713	0.0099718203567866	1.00299267408334	1.6099297703051
CABLES1	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.03625965445555	-0.03625965445555	0.0912056534034588	0.131172819567	4.86768747035638	191.386691341198	2.3555422849049e-06	9.09168057592982e-05	0.075815065832192	0.179115549885826
CABLES1	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1886712094615	0.1886712094615	-0.0844810636916728	-0.0709548517643	-6.34299303730742	65.8107750210297	2.36583014016073e-08	1.20787519797644e-06	-0.359136189041013	-0.187168357265332
CABLES1	BRD-A72703248-003-04-9::2.5::HTS002	2.5	SKF-96365	calcium channel blocker	noncancer	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-3.023673332995	-3.023673332995	-3.54618327770368	-3.55274052264	-4.65710365869975	157.268667567865	6.78121692050603e-06	0.000240910233939191	-0.744115981952508	-0.300903907464843
CABLES1	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.49817012221	-1.49817012221	-2.36533121903532	-2.31691828506	-8.18185345629679	4.69525301983884	0.000595700186328547	0.0140018345088575	-1.14501211522481	-0.589310078425827
CABLES1	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1073489142981	0.1073489142981	-0.188310052544062	-0.138056758361	-5.27488389211615	8.40625579974478	0.000638805639389662	0.0148739352400594	-0.423831998842731	-0.167485934841592
CABLES1	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.0906368397101	-0.0906368397101	0.265771328505896	0.320326091732	7.08325299944466	4.93465825538981	0.000916597809009282	0.0205066275372808	0.226547314732482	0.48626902169951
CABLES1	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-2.456237995285	-2.456237995285	-3.73129511706435	-3.62613694573	-11.4220577948713	44.7758421081539	7.38120816191998e-15	7.54774314950452e-13	-1.49992481286768	-1.05018943069103
CABLES1	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.946260216436	-0.946260216436	-3.20293415854349	-3.102963726805	-16.369772467384	5.71063889350797	5.12309647406482e-06	0.000186295918593457	-2.5981826671865	-1.91516521702848
CABLES1	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.65077518133	-1.65077518133	-2.45615720896888	-2.47219362388	-6.37528752921633	4.94309381132441	0.00146556331515029	0.0308286112251296	-1.13124806245363	-0.479515992824131
CABLES1	BRD-K12251893-065-04-7::2.5::HTS002	2.5	vincristine	tubulin polymerization inhibitor	chemo	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.6164914819085	-0.6164914819085	-2.72655026015165	-2.6144312066	-19.6198931367523	106.082463495624	4.39682544988774e-37	3.50322379869513e-34	-2.32327906356693	-1.89683849291936
CABLES1	BRD-K13094524-001-07-5::2.63083::HTS002	2.63083	PFI-1	bromodomain inhibitor	targeted cancer	BRD4	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.50823043136	-1.50823043136	-2.23725180008604	-2.09295317057	-6.48849342245585	24.3069727178608	9.76450746168409e-07	3.99392580105971e-05	-0.960757941876516	-0.497284795575568
CABLES1	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.125808581899	0.125808581899	-0.485834691429423	-0.4134526693685	-13.34731038837	187.013855330651	5.5512888477297e-29	2.05138308180183e-26	-0.702044039425189	-0.521242507231657
CABLES1	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.968504712455	0.968504712455	-0.383816044024095	-0.1455477562875	-16.5768411115804	187.664341586844	1.32787303207697e-38	1.22673146160356e-35	-1.51325030856806	-1.19139120439013
CABLES1	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-3.677727982745	-3.677727982745	-4.18254078459059	-4.20452435995	-5.6736262880255	184.192095620276	5.34380194357784e-08	2.60184399537732e-06	-0.68035463636558	-0.329270967325609
CABLES1	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.479963998082	0.479963998082	0.297228057489186	0.330939410236	-7.390368573073	104.230344845962	3.80037856581748e-11	2.64115219725387e-09	-0.231767703901526	-0.133704177284103
CABLES1	BRD-K21782625-001-02-4::2.5::HTS002	2.5	AMG458	MET inhibitor	targeted cancer	MET	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.5563760920075	0.5563760920075	0.0221611165776784	0.00058782327668	-10.1143726988721	7.89934467632676	8.54074304187592e-06	0.000297942207816165	-0.656282813085768	-0.412147137773875
CABLES1	BRD-K25596805-001-01-8::2.5::HTS002	2.5	JNJ-16259685	glutamate receptor antagonist	noncancer	GRM1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.047833587062	-0.047833587062	0.396857832504239	0.392933353126	11.3208649320522	7.93747763164169	3.5539953601753e-06	0.000133075519138891	0.353985635002252	0.535397204130227
CABLES1	BRD-K26619122-001-02-1::2.5::HTS002	2.5	thiocolchicoside	GABA receptor antagonist	noncancer	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.6376203589455	0.6376203589455	0.153321123562099	0.1631740037055	-13.0923621007921	3.1017755744573	0.000812184832806308	0.0184440308360398	-0.599865703622626	-0.368732767144176
CABLES1	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.7504904709565	-0.7504904709565	-0.528733629208024	-0.447815997104	4.75089459446599	93.2488981426768	7.32326321459116e-06	0.000258453430186087	0.129069108974039	0.314444574522912
CABLES1	BRD-K31309378-001-01-5::2.5::HTS002	2.5	lucitanib	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.946023830487	-0.946023830487	-0.759810352285649	-0.624049076154	3.11621336515849	183.327582012201	0.00212689019720503	0.0422988075602446	0.0683149268587381	0.304112029543963
CABLES1	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.3243077892505	-0.3243077892505	-1.34621960090063	-1.265409369745	-11.4032364381057	3.04398509236059	0.00135230442093103	0.028750922947498	-1.30479248750018	-0.739031135800086
CABLES1	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.739370709511	0.739370709511	0.0191688184144593	0.046531478462	-17.1273555894357	6.62438304508573	9.86250235337731e-07	4.02939433262868e-05	-0.820788294155296	-0.619615488037785
CABLES1	BRD-K37249724-001-25-7::2.5::HTS002	2.5	astemizole	histamine receptor antagonist	noncancer	HRH1, KCNH1, KCNH2	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.2352036902945	0.2352036902945	0.0607318992020611	0.100436576625	-4.66999841562374	138.914947263277	7.02845758316833e-06	0.000248868707309249	-0.248339823335824	-0.100603758849054
CABLES1	BRD-K38305202-001-17-4::2.5::HTS002	2.5	domperidone	dopamine receptor antagonist	noncancer	DRD2, DRD3	infectious disease	fescue toxicosis	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.02990000383795	0.02990000383795	-0.361680718969621	-0.225769257521	-5.46308376980736	8.60130926715483	0.000466826926327346	0.0112777646594175	-0.554879661211408	-0.228281784403734
CABLES1	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.430812368133	0.430812368133	-1.02911557666474	-1.03228700688	-16.6569913596186	4.16230796266515	5.74665289882716e-05	0.00171279984585277	-1.69957674570499	-1.22027914389048
CABLES1	BRD-K42981054-001-01-9::2.5::HTS002	2.5	mibampator	glutamate receptor modulator	noncancer	GRIA1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.7720298767625	-0.7720298767625	-1.056157797457	-1.074754636055	-5.50270117307298	157.873410937274	1.48058805252356e-07	6.81996468320055e-06	-0.386110975703377	-0.182144865685624
CABLES1	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-3.81051430436	-3.81051430436	-3.22998980882102	-3.119370710775	6.55225804297368	6.12435993335483	0.000556208359834467	0.0131769184873396	0.364792826005361	0.796256165072597
CABLES1	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.145069941451	0.145069941451	-0.126438683438576	-0.075355311638	-7.17508156500756	75.0493946614567	4.34239661213089e-10	2.67982010792226e-08	-0.34688993962328	-0.196127310155871
CABLES1	BRD-K45462423-001-03-7::2.5::HTS002	2.5	VU0361737	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.482570547853	-0.482570547853	0.0879506732681439	0.109184936724	12.7835059110898	8.27082879567926	9.80691443501773e-07	4.00897608991592e-05	0.468189106297958	0.672853335944329
CABLES1	BRD-K49371609-003-03-8::2.5::HTS002	2.5	PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-5.966097686035	-5.966097686035	-5.33448949854289	-5.33091328007	8.43294776559691	183.88502533124	9.66739334531916e-15	9.76898985529896e-13	0.483838914806922	0.779377460177303
CABLES1	BRD-K50853363-001-02-3::2.5::HTS002	2.5	dienogest	progesterone receptor agonist	noncancer	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.0828400144959	-0.0828400144959	-0.279191905479704	-0.2219400984365	-4.01104818734895	151.437998712704	9.46763358251108e-05	0.00269408980099046	-0.293070447617287	-0.0996333343503214
CABLES1	BRD-K51143828-003-03-1::2.5::HTS002	2.5	lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1712172452835	0.1712172452835	-0.0220434382800958	0.03172783000245	-5.64709672575303	8.21750808321646	0.0004384601637141	0.010661984164815	-0.271816977265992	-0.1147043898612
CABLES1	BRD-K51471001-303-04-7::2.5::HTS002	2.5	demecarium	acetylcholinesterase inhibitor	noncancer	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.09524779347655	0.09524779347655	0.280800781470814	0.276786886739	5.93671736908782	5.44681108705502	0.00143896059128787	0.0303464513008106	0.10715152140219	0.263954454586338
CABLES1	BRD-K52313696-001-12-3::2.5::MTS010::PROS004_PR500	2.5	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.136279797181	0.136279797181	-0.0126288560425489	-0.0070642593788	-4.39886090955288	10.6799613440947	0.00114277568531416	0.0248659867875836	-0.223688919575714	-0.0741283868713841
CABLES1	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.003068272198	-0.003068272198	-0.295850411594332	-0.406253558846	-4.20547552732154	103.014082164535	5.56883219720967e-05	0.00166442927903466	-0.430855318547611	-0.154708960245053
CABLES1	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.4834821739785	-0.4834821739785	-0.739272182922971	-0.696454065727	-4.5037274726991	121.218175735577	1.54703503948334e-05	0.00051558773593131	-0.368229002670415	-0.143351015218528
CABLES1	BRD-K55966568-001-05-4::2.5::HTS002	2.5	orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.158072972089	0.158072972089	0.321242308139025	0.338245080864	6.06672161102251	47.4675424427028	2.06092914018339e-07	9.29930277234453e-06	0.109076028615712	0.217262643484339
CABLES1	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.040060802907095	-0.040060802907095	-0.710538313766352	-0.5410189846345	-8.0403628907536	8.9308004653141	2.22551966527351e-05	0.000718811035372937	-0.859339490241659	-0.481615531476856
CABLES1	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.5644560352765	0.5644560352765	-0.143187439356958	0.01900224238145	-8.79801856668732	5.85087878172586	0.000137396299819673	0.00377200096631877	-0.905676169881307	-0.509610779385609
CABLES1	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.996021227567	-0.996021227567	-0.382041920799586	-0.1848985030465	7.8515759267555	8.08302363401729	4.71805688884383e-05	0.00142988746454894	0.433975764713606	0.793982848821222
CABLES1	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.8623830076185	-0.8623830076185	-2.02033574160169	-2.23082742718	-11.4501687127407	11.7931935542368	9.648696688892e-08	4.55806813452399e-06	-1.37872484898666	-0.937180618979719
CABLES1	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.632013839105	-1.632013839105	-1.32629191747777	-1.441894150425	5.22805467038056	191.303799248814	4.46499212784129e-07	1.91932871594083e-05	0.19037906425108	0.421064779003379
CABLES1	BRD-K59753975-001-02-6::2.5::MTS006	2.5	vindesine	tubulin polymerization inhibitor	chemo	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.901040593513	-0.901040593513	-2.42842976812748	-2.28041477314	-16.2310694147132	190.089140771069	9.64180729018678e-38	8.00976323526528e-35	-1.7130090533254	-1.34176929590356
CABLES1	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.199736046555	-0.199736046555	-1.20924826660831	-1.18840349692	-10.2093902094106	4.46146765892643	0.000292350135099052	0.00740301419017541	-1.27320478243455	-0.745819657672069
CABLES1	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-2.55560845381	-2.55560845381	-4.00654986096438	-4.1239035813	-10.3600850289381	4.97629850558012	0.000148279573421878	0.00404179227927479	-1.81147059995245	-1.0904122143563
CABLES1	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.5364781573475	0.5364781573475	0.150752942017138	0.163841475196	-10.3980783929292	6.27717462072344	3.45475315423089e-05	0.00107436707602025	-0.475532645304605	-0.29591778535612
CABLES1	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.09827664564975	0.09827664564975	-0.173811389645185	-0.07625513394025	-5.13303766371078	42.4649953355002	6.73103249670089e-06	0.000239206676170686	-0.379026235370337	-0.165149835219533
CABLES1	BRD-K64800655-001-07-4::2.5::HTS002	2.5	PHA-793887	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.05122965611855	-0.05122965611855	-1.6394118925601	-1.592670797355	-17.8296089551971	191.707684366647	1.45344111668252e-42	1.87659386203282e-39	-1.76387623922872	-1.41248823365437
CABLES1	BRD-K67173685-001-06-9::2.38783::HTS002	2.38783	4E1RCat	protein synthesis inhibitor	noncancer	EIF4E, EIF4G1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.6671405440915	0.6671405440915	0.464745789140157	0.4775114804595	-5.02743406008813	6.5749756452342	0.00182658969138769	0.0371288124461216	-0.298851728744477	-0.105937781158209
CABLES1	BRD-K67977190-066-02-3::2.5::HTS002	2.5	eprosartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.201136755633	0.201136755633	0.423843969808615	0.410651476159	5.68011540439122	7.03906990386629	0.000735989158285127	0.0168999164673337	0.130098722316433	0.315315706034796
CABLES1	BRD-K68336408-001-10-9::2.5::HTS002	2.5	tyrphostin-AG-1478	EGFR inhibitor	targeted cancer	EGFR, MAPK14	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.8508070724225	-0.8508070724225	-2.66018501762239	-2.59421184968	-11.6199705038448	2.69761089597559	0.00221657667583481	0.0438100942784027	-2.33788188280861	-1.28087400759118
CABLES1	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.59341896135	0.59341896135	-0.0143834319627331	-0.0198550434605	-10.4216121883874	13.9034506609745	5.96335864280183e-08	2.8851482947022e-06	-0.732970769578358	-0.482634017047108
CABLES1	BRD-K69116396-001-04-1::2.5::HTS002	2.5	sertindole	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.16513136902	0.16513136902	0.0135065801759725	0.0316933159242	-5.16695029000389	15.0379190758132	0.000113878194082884	0.003186935141944	-0.214158702751298	-0.0890908749367566
CABLES1	BRD-K74671368-001-01-8::2.5::MTS006	2.5	idronoxil	XIAP inhibitor	targeted cancer	ENOX2, SPHK1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.3929597206785	-0.3929597206785	-0.249970095062235	-0.186172390275	3.56303658494156	62.9852461021944	0.000705275057127067	0.0162783650354283	0.06279306598594	0.223186185246589
CABLES1	BRD-K76011241-001-01-8::2.5::HTS002	2.5	oseltamivir-phosphate	neuraminidase inhibitor	noncancer	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.2174786081355	0.2174786081355	0.326414399914814	0.306165315644	4.58697623386628	191.872425974507	8.10397126673125e-06	0.000284088331309657	0.062093281894487	0.155778301664142
CABLES1	BRD-K76180386-001-01-6::2.5::HTS002	2.5	JIB04	histone lysine demethylase inhibitor	noncancer	KDM4E	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.16065510185	-1.16065510185	-1.70154496418558	-1.602559897845	-5.90975179259225	12.4638293047891	6.12085025339789e-05	0.00181549365341893	-0.739485679740339	-0.342294044930812
CABLES1	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.887442791775	-1.887442791775	-1.10168002310282	-0.895557196833	9.62636860499593	186.371128914323	4.64512229951178e-18	6.41898399311451e-16	0.624732921429107	0.946792615915262
CABLES1	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.611802714439	-0.611802714439	-0.203232062962428	-0.177852990832	8.86569201259047	190.175084668819	5.468614165974e-16	6.24777508304393e-14	0.317668286772444	0.4994730161807
CABLES1	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.1770160016805	-0.1770160016805	-1.06493781075353	-0.7851415156885	-7.49977823678129	6.55148277772314	0.000190514355563183	0.00506295738543105	-1.17180947019697	-0.604034147949092
CABLES1	BRD-K78318619-001-02-7::2.5::HTS002	2.5	PF-4981517	cytochrome P450 inhibitor	noncancer	CYP3A4	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1958800246825	0.1958800246825	-0.596116066388632	-0.549021652731	-7.37608067995023	3.8553704037992	0.00207683492190792	0.041426333362271	-1.09457567510166	-0.489416507040599
CABLES1	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-2.04075471566	-2.04075471566	-3.99085258222376	-3.95467393468	-17.1735213700243	193.02714030393	9.87061568035762e-41	1.13131507387988e-37	-2.174061042093	-1.72613469103452
CABLES1	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.517280675071	-0.517280675071	-2.52499513120882	-2.254263331985	-16.8319793348851	21.3180289705506	8.61685570299745e-14	7.95024565633982e-12	-2.25554516234009	-1.75988374993554
CABLES1	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.9721155539165	-0.9721155539165	-1.28688007982226	-1.24885809452	-4.56655124576033	18.7625301217335	0.000217092225804537	0.00568399214078435	-0.459156760303979	-0.170372291507532
CABLES1	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.0381481781065	-0.0381481781065	0.123427867915977	0.135109067247	4.16838358527606	48.8873568869907	0.000124736840438999	0.00345946199203548	0.0836757905660619	0.239476301478892
CABLES1	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.767393342527	-0.767393342527	-3.08741479977033	-2.99864068297	-24.1756314542625	90.9626881201626	2.24284304915262e-41	2.6855100998985e-38	-2.51064576818131	-2.12939714630534
CABLES1	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.00243010260135	0.00243010260135	-0.854506443437688	-0.774088070041	-7.86207566530291	9.06277163440014	2.44273634233011e-05	0.000783873689946506	-1.10324304701748	-0.610630045060597
CABLES1	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-3.076678957055	-3.076678957055	-4.38914416875749	-4.37968901574	-15.0631951118665	149.027758811831	9.54787409617638e-32	4.45835796766751e-29	-1.48463616078459	-1.14029426262039
CABLES1	BRD-K85402309-001-06-6::2.5::HTS002	2.5	dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.5810393700565	0.5810393700565	-0.174030289991034	-0.192386953034	-19.7089266896886	141.944190740624	1.82786860894253e-42	2.33193601836931e-39	-0.830803619183257	-0.679335700911811
CABLES1	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.4035381398775	-0.4035381398775	-0.148427742417317	-0.137644446714	5.79948160554291	9.46274454333645	0.000214231636648653	0.00561801694007942	0.156338394572687	0.353882400347679
CABLES1	BRD-K86118762-001-01-8::2.5::HTS002	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.4454998063905	0.4454998063905	0.0605507474268194	0.0670772689305	-12.0670108540946	165.955888670107	1.79486626217024e-24	4.39647875548212e-22	-0.447933061857018	-0.321965056070343
CABLES1	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.271885810946	-0.271885810946	-0.492888565637072	-0.41754362105	-4.39321223713076	50.7850613838154	5.69179209334214e-05	0.00169833789165241	-0.322005646694498	-0.119999862687646
CABLES1	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.723519984605	0.723519984605	-0.0580306464555454	-0.06359011505395	-11.6974443180052	2.94046113296819	0.00147437346042847	0.0309713799274893	-0.996638463601398	-0.566462798519692
CABLES1	BRD-K88789588-001-14-9::2.5::HTS002	2.5	letrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.6575705453825	0.6575705453825	0.16838350607708	0.134941484208	-12.4267780280914	32.9345738683633	5.57180035617807e-14	5.24691739252763e-12	-0.569282911896058	-0.409091166714783
CABLES1	BRD-K89704198-001-12-3::2.5::HTS002	2.5	vincamine	adrenergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.386258886568	0.386258886568	-0.199447307212076	-0.1128406004625	-12.2767635574094	39.3705636521886	4.88382689433892e-15	5.09117575115159e-13	-0.68217674816962	-0.489235639390531
CABLES1	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.965152697935	-1.965152697935	-3.11925693150482	-3.009227373135	-7.52166535840936	3.75107980662577	0.00215131564628646	0.042681600588071	-1.59149862663094	-0.716709840508692
CABLES1	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.336179839343	-0.336179839343	-0.0909711376771886	-0.0408206395104	7.46705775461888	26.4616161447187	5.61886183839476e-08	2.72833040090918e-06	0.177764987448504	0.312652415883119
CABLES1	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.407349249203	0.407349249203	-0.232960021388117	-0.164801274437	-7.677928879629	4.38653020504037	0.00105629454018819	0.0231700493812296	-0.864025110045793	-0.416593431136441
CABLES1	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.2459061904545	0.2459061904545	-0.303146221475751	-0.183745665678	-6.79481387659186	4.04373272341412	0.00235533729784757	0.0461357236072357	-0.772448364356205	-0.325656459504298
CABLES1	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.581029486087	-0.581029486087	-1.25830303190958	-1.28599874522	-9.62315138668215	166.349355538796	1.05487182213985e-17	1.41837906378552e-15	-0.816225912819684	-0.538321178825476
CABLES1	BRD-K95785537-001-23-1::2.5::HTS002	2.5	PP-2	src inhibitor	targeted cancer	ABL1, LCK, LYN, RIPK2, SRC	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1216444925826	0.1216444925826	-0.277419568482382	-0.127481786851	-4.07862583634179	9.47808322507243	0.00248051587540709	0.0482481610908545	-0.618709574889767	-0.179418547240197
CABLES1	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.184804334505	-1.184804334505	-0.211476252936294	0.00102328451077	15.5956673226036	56.9726635186585	3.20960147765976e-22	6.45925516530835e-20	0.848352593720971	1.09830356941644
CABLES1	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	EFM192A, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.3369092402515	0.3369092402515	-1.10370784915132	-1.03443241086	-18.3640248039938	7.2204623664847	2.51903496366682e-07	1.12059411525061e-05	-1.62497461306618	-1.25625956573945
CARM1	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.00344975813925	-0.00344975813925	-0.178431860048974	-0.1596607583295	-3.80081074087687	51.9262710562925	0.00038041002828639	0.00939821942284239	-0.267367428909289	-0.0825967749101592
CARM1	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.14781335103	-0.14781335103	0.176418422081157	0.161263687573	12.0873520453638	43.4448641355708	1.72409637300544e-15	1.87766184720469e-13	0.270151928848546	0.378311617373769
CARM1	BRD-A14344385-001-03-2::2.5::HTS002	2.5	IDRA-21	glutamate receptor positive allosteric modulator	noncancer	GRIA1, GRIA2, GRIA3, GRIA4	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.241517291946	0.241517291946	0.140957236549886	0.114657353	-3.54971252203199	38.2152466816147	0.00104162681741801	0.0229053001402171	-0.157898653966721	-0.0432214568255061
CARM1	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.190664136993	-0.190664136993	-0.513957035539902	-0.46624794895	-5.49091982320539	11.5739285081813	0.000157385890335944	0.0042720821289023	-0.452102185961633	-0.194483611132171
CARM1	BRD-A25234499-001-18-3::2.5::HTS002	2.5	aminoglutethimide	glucocorticoid receptor antagonist	targeted cancer	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.372683394118	0.372683394118	0.213566817249632	0.202759398616	-5.1674938729599	14.0316345844445	0.000141812221845462	0.0038782191168872	-0.225144511471469	-0.0930886422652671
CARM1	BRD-A27883417-300-01-6::2.5::HTS002	2.5	alexidine	phosphatidylglycerophosphatase inhibitor	targeted cancer	PTPMT1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.3267668555235	0.3267668555235	-0.239842481475651	-0.2582141227055	-12.7910662062196	54.6143469245687	4.60623497175348e-18	6.36935313071581e-16	-0.655397145850041	-0.477821528148262
CARM1	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.0373026488636	0.0373026488636	0.405636259830089	0.4132826179685	7.20999152596027	105.171170971857	8.90707073856005e-11	5.94532408696617e-09	0.267040335895724	0.469626886037253
CARM1	BRD-A28329383-001-02-1::2.5::HTS002	2.5	MTPG	glutamate receptor antagonist	noncancer	GRM2, GRM3	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.459346664776	0.459346664776	0.0181226659909928	0.0389518722109	-9.48514782942308	4.40382135056326	0.000428451666101566	0.0104434910888073	-0.565837652792892	-0.316610344777122
CARM1	BRD-A55484088-050-02-5::2.5::HTS002	2.5	BNTX	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.731877124937	-0.731877124937	-1.39091261185353	-1.31545762585	-7.35378711582045	4.55388678950798	0.00108229297428346	0.0236749102760971	-0.896363506769603	-0.421707467063459
CARM1	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1285784494455	0.1285784494455	-0.225207670738187	-0.09818472346655	-6.01609874317016	69.0745287649767	7.62055126167459e-08	3.64008275320582e-06	-0.471099755362212	-0.236472485005162
CARM1	BRD-A69651145-003-07-2::2.5::HTS002	2.5	minocycline	bacterial 30S ribosomal subunit inhibitor	noncancer	ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA	endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.490672485136	0.490672485136	0.0825873214506767	0.0503507635315	-8.13400371443648	6.68790668811682	0.000104940372363951	0.00296100119383798	-0.527850545502632	-0.288319781868015
CARM1	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1239303353165	0.1239303353165	-0.188480995028788	-0.138056758361	-6.47265765194841	59.8468428238908	1.98887470920539e-08	1.02444971773439e-06	-0.408963416401844	-0.215859244288732
CARM1	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.35748069479	-1.35748069479	-1.90202842296068	-1.73380354334	-5.20719265380726	164.0814495731	5.67720833600586e-07	2.40567494157335e-05	-0.75103602650917	-0.338059429832191
CARM1	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.820703391379	-0.820703391379	-2.21830320265527	-2.04082568027	-8.66181510420877	3.73552533851392	0.00132129250708239	0.0282006872884348	-1.85837455874513	-0.936825063807406
CARM1	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1553512275565	0.1553512275565	-0.343532062041816	-0.229059189804	-11.6584889359403	169.027242344026	2.00219196619104e-23	4.46542978066346e-21	-0.583357751591215	-0.414408827605417
CARM1	BRD-K03601870-001-01-2::2.5::HTS002	2.5	ixabepilone	microtubule stabilizing agent	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-2.923014450105	-2.923014450105	-3.63273418378541	-3.58404887743	-6.58903298481012	14.1075167396889	1.16593726969181e-05	0.00039640572505675	-0.940574518222231	-0.478864949138596
CARM1	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.166615760571	0.166615760571	-0.2972424813212	-0.208078798615	-8.73121021087874	142.07031270276	6.24713533786182e-15	6.44341804537337e-13	-0.568878754491138	-0.358837729293262
CARM1	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.31062641195	-1.31062641195	-2.52173588958497	-2.34739362698	-10.2695417128239	22.5901164322205	5.59867329287044e-10	3.41673703925862e-08	-1.45531595642993	-0.966902998840013
CARM1	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-2.046112103225	-2.046112103225	-2.41961836402938	-2.32972185313	-4.71739431451557	21.9038345658094	0.000105773545960883	0.00298137011207918	-0.537749855002013	-0.209262666606753
CARM1	BRD-K13662825-001-07-5::2.5::HTS002	2.5	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-4.097053016095	-4.097053016095	-4.93448930807105	-4.88144799249	-9.60272067696969	18.0979341731981	1.57969377588563e-08	8.25790700711687e-07	-1.02058294743172	-0.654289636520384
CARM1	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.1956992378315	0.1956992378315	-0.0727115087112412	0.0407112965926	-6.00475906518642	35.0347860060197	7.58201813608546e-07	3.15604265894166e-05	-0.359152679557409	-0.177668813528074
CARM1	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.3412488242905	-0.3412488242905	-0.0570198287274005	-0.0602706039178	7.30799941897298	10.5588580693395	1.91495198759978e-05	0.000626897425615202	0.19818801432833	0.370269976797869
CARM1	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.620269946495	-1.620269946495	-2.4589708849354	-2.36107459971	-7.49343471498526	7.91807457910691	7.35625119142785e-05	0.00214278059473708	-1.09726548353406	-0.580136393346743
CARM1	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-3.652553463745	-3.652553463745	-4.18280577952744	-4.20452435995	-5.94850323732525	180.428151079908	1.37468218135067e-08	7.24985869209417e-07	-0.706144194459082	-0.354360437105791
CARM1	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.19136718655	-1.19136718655	-1.91015056658047	-1.67956785013	-7.50327430231226	98.870508840544	2.75259693117444e-11	1.95093038247912e-09	-0.908866431479785	-0.528700328581153
CARM1	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.5616953862175	0.5616953862175	0.411330496548245	0.440703373362	-5.78160708254531	177.189732176326	3.27612651012358e-08	1.63866725504849e-06	-0.201689111980807	-0.0990406673577025
CARM1	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.383274908541	-0.383274908541	-0.977584898098107	-0.82417204092	-5.93281709405011	105.085236348179	3.86136449494491e-08	1.91220515442941e-06	-0.792933302050955	-0.395686677063259
CARM1	BRD-K27316855-001-13-3::2.43597::HTS002	2.43597	calcitriol	vitamin D receptor agonist	noncancer	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.260185739935	-0.260185739935	-0.0338537000466888	0.01343134409051	5.45392020972068	133.449338548881	2.31058654490756e-07	1.03409000539464e-05	0.144251233381712	0.308412846394911
CARM1	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.2309178697335	-0.2309178697335	-0.472381704358166	-0.387317230447	-4.30819411292259	16.1425246678514	0.000531259792941914	0.0126417653115852	-0.360194185559542	-0.12273348368979
CARM1	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-3.965804046365	-3.965804046365	-3.62524355910871	-3.57671972887	4.59236710216292	140.500689909918	9.64499898052619e-06	0.000333419836531806	0.193950809463721	0.487170165048863
CARM1	BRD-K30867024-003-03-3::2.5::HTS002	2.5	SB-216641	serotonin receptor antagonist	noncancer	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.2840672663135	0.2840672663135	-0.0516822939788612	-0.02368862812505	-8.06881832825586	13.6422186132323	1.47541516294624e-06	5.87449854094567e-05	-0.42521582172523	-0.246283298859493
CARM1	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.29375676115	0.29375676115	-0.62164360318136	-0.480230640816	-13.7129522118946	40.567739765916	8.01418982424955e-17	9.8887351228646e-15	-1.05025731706553	-0.780543411597185
CARM1	BRD-K32744045-001-31-2::2.5::HTS002	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.820523207928	-0.820523207928	-1.28035639908688	-1.09614559515	-4.6000829837542	127.748549944643	1.0033809893933e-05	0.000345856616397036	-0.657628671016642	-0.26203771130111
CARM1	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.0575872156962	-0.0575872156962	-0.881271686797678	-0.7074523288895	-7.15603459586922	6.45061865289792	0.000270210931175965	0.00690110088989675	-1.10063131778463	-0.546737624418327
CARM1	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-2.85683198301	-2.85683198301	-3.66905504139844	-3.65355610334	-6.52398288851287	7.08798431654529	0.000309799829681888	0.007798812273419	-1.1058749542446	-0.518571162532274
CARM1	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.5382850577595	0.5382850577595	0.159690418743779	0.154760250633	-15.4895831499456	86.6354301307685	1.08215773302049e-26	3.20799149046401e-24	-0.427178418422859	-0.330010859608584
CARM1	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.2170257572905	0.2170257572905	0.428332224881938	0.4313451016155	3.63634223224423	21.6886808548512	0.00148376648400164	0.0311412247110838	0.0906941171796908	0.331918818003185
CARM1	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.321968809145	-1.321968809145	-1.94299623270444	-1.74375486562	-7.13673660702025	188.976953784382	1.99015288104543e-11	1.43232866635859e-09	-0.792679632380449	-0.449375214738441
CARM1	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-6.055005421545	-6.055005421545	-4.65083949018419	-5.03947371329	10.5044624845353	27.841050626787	3.43086719793367e-11	2.39756875013344e-09	1.13027818938823	1.6780536733334
CARM1	BRD-K38548312-001-01-0::2.5::HTS002	2.5	VER-49009	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-2.065364035205	-2.065364035205	-2.74151530628558	-2.671842712285	-7.64153303842085	187.909961294911	1.06730856396839e-12	8.87335830902956e-11	-0.850700346570018	-0.501602195591151
CARM1	BRD-K38852836-001-02-1::2.5::HTS002	2.5	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-4.60893383361	-4.60893383361	-4.85655372313654	-4.89533061736	-3.07521235622107	179.868193599675	0.00243177271774255	0.0474162495288431	-0.406507655679286	-0.088732123373802
CARM1	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.7196808816695	-0.7196808816695	-1.29100003224066	-1.33795379646	-7.16459116547031	178.258662579633	1.98409943101914e-11	1.42845161891468e-09	-0.728679015169874	-0.413959285972443
CARM1	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-4.597124029665	-4.597124029665	-5.4560457643683	-5.49470441072	-9.37257188513398	13.7940924019518	2.34096547399709e-07	1.04703002728782e-05	-1.05575000401254	-0.662093465394056
CARM1	BRD-K43621685-001-02-5::2.5::HTS002	2.5	CP-673451	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	KIT, PDGFRA, PDGFRB	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.5475129699685	-0.5475129699685	0.00245012181013401	0.03337894475615	9.59351807110607	19.7960853761812	6.96776712768525e-09	3.78170311650963e-07	0.430303032859597	0.669623150697671
CARM1	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.231637785356	-0.231637785356	-0.89606707701771	-0.852653660565	-8.36477034980056	5.17798099188845	0.000336787822415539	0.00841396400402146	-0.866522364199077	-0.462336219124343
CARM1	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.913847350825	-1.913847350825	-1.32375014788546	-1.04970341453	6.04585719516735	25.6920293534023	2.29730205699937e-06	8.8812852195999e-05	0.389353094149765	0.790841311729321
CARM1	BRD-K47598052-001-15-8::2.5::HTS002	2.5	PP-1	src inhibitor	targeted cancer	HCK, RET	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.2183805689845	0.2183805689845	-0.296585916764257	-0.119341908815	-6.15830498743469	5.42783741898235	0.00122092022448665	0.026344368347327	-0.724924711764655	-0.30500825973286
CARM1	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.606248345675	-0.606248345675	-1.59719109810404	-1.48697544025	-9.61824391748582	7.64737371715059	1.54131890424868e-05	0.000514082383175716	-1.23044483859072	-0.751440666267355
CARM1	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.9614518605895	-0.9614518605895	-0.277391928662256	-0.2569086069275	16.8320240392756	12.6063455344455	5.15364643925637e-10	3.16135056576811e-08	0.595982205877713	0.772137657976774
CARM1	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.481420484871	0.481420484871	0.37786771623434	0.393436647762	-3.78134368909347	14.7164616697847	0.00186711950570084	0.0378204192928226	-0.162020995398676	-0.0450845418746451
CARM1	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.2539974011695	-0.2539974011695	-0.510159135529978	-0.339269333107	-4.23993637454045	132.343599907318	4.16734511034636e-05	0.00127707021755137	-0.375668494726935	-0.13665497399402
CARM1	BRD-K60369935-001-18-3::2.5::HTS002	2.5	ribavirin	antiviral	noncancer	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.479225379757	0.479225379757	0.371121128955688	0.414452156411	-3.75059030025581	188.064770274207	0.000234795090050477	0.00609684963113989	-0.164962699626166	-0.0512458019764587
CARM1	BRD-K60997853-001-02-3::2.5::MTS010::PROS004_PR500	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.3042631506955	-0.3042631506955	-0.729186138619664	-0.7041999710785	-6.74504555125921	186.4849261847	1.86497757271328e-10	1.19819777632513e-08	-0.549202926226958	-0.300643049621369
CARM1	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.07710549944	-1.07710549944	-0.458206925538617	-0.469747665561	6.91732499940342	3.94207345389939	0.00241796937930002	0.0471955846147375	0.369041588460359	0.868755559342407
CARM1	BRD-K63126190-003-01-6::2.5::HTS002	2.5	epinephrine	adrenergic receptor agonist, neurotransmitter	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.1512130469815	-0.1512130469815	-0.441320139246573	-0.3976462300305	-4.0513712620087	75.2046136280043	0.000122750160383028	0.00341275381044675	-0.43274946058132	-0.147464723948826
CARM1	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.725350327724	-0.725350327724	-0.210330772090655	-0.1907303952045	9.44527500915003	47.3960305213624	1.79831523145151e-12	1.45886110992343e-10	0.405350199901955	0.624688911364735
CARM1	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.308500686295	-1.308500686295	-2.49830194282501	-2.41136656484	-9.5733685735934	3.39596001685886	0.00142213025896117	0.0300328856313812	-1.56047181493951	-0.819130698120509
CARM1	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.77819054039	-1.77819054039	-2.59051938627352	-2.40345273405	-5.85154856056439	10.5351006015411	0.000131302836343318	0.00362281225677483	-1.11952908934269	-0.505128602424357
CARM1	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.417949825816	-0.417949825816	-1.19835897384297	-1.12346956245	-10.9558639239004	180.652494543735	9.6101235392046e-22	1.84398224533051e-19	-0.92096307907834	-0.639855216975603
CARM1	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.01238725940778	0.01238725940778	-0.196014513878382	-0.145323520972	-4.81229428064765	186.917473772106	3.0668059301396e-06	0.000116029205331137	-0.293833337489067	-0.122970209083257
CARM1	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.04196424820225	0.04196424820225	-0.428551362801065	-0.2512002355925	-6.81236053455869	42.0906991388681	2.66978694977726e-08	1.35083278366102e-06	-0.609891430229661	-0.331139791776969
CARM1	BRD-K77638923-001-02-0::2.5::HTS002	2.5	CUDC-907	PI3K inhibitor	targeted cancer	HDAC2, PIK3R1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-5.641479976535	-5.641479976535	-5.89360493323578	-5.8647928098	-3.55553484786796	188.093328493647	0.00047717402708575	0.0114990141726177	-0.392007117471077	-0.112242795930485
CARM1	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.807054891398	-0.807054891398	-0.319987873020125	-0.3195858510195	5.78271201811529	5.21345525784954	0.0018927452457445	0.0382671630766128	0.27319107866717	0.700942958088581
CARM1	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-3.147037376245	-3.147037376245	-4.38842254394528	-4.37968901574	-10.0868116573563	3.67329479943011	0.000827169049692853	0.0187426065389174	-1.59540841364434	-0.887361921756228
CARM1	BRD-K85406984-001-01-0::0.15625::HTS002	0.15625	sobetirome	thyroid hormone receptor agonist	noncancer	THRA, THRB	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.0749919929365	-0.0749919929365	0.243060873307381	0.243956318012	7.727298936376	3.50480585522147	0.00254418929554531	0.0493299753505455	0.197117078375034	0.438988654112728
CARM1	BRD-K85606544-001-09-1::2.5::HTS002	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.657019981006	-0.657019981006	-1.5989741019921	-1.5159358626	-11.1803319576018	189.096789109849	1.32812112199275e-22	2.7744139566821e-20	-1.10814667613176	-0.77576156584043
CARM1	BRD-K86816506-001-01-8::2.5::HTS002	2.5	PF-04457845	FAAH inhibitor	noncancer	FAAH	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.8461539981965	-0.8461539981965	-0.402552819783204	-0.352413552775	15.0530978361181	165.534176392745	8.11481056686675e-33	4.20106095165696e-30	0.385417438574408	0.501784918252184
CARM1	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.0631283331555	-0.0631283331555	0.155271956305799	0.189344687703	10.0016967865545	27.3152201223288	1.24987397188655e-10	8.19468456777218e-09	0.173620034651687	0.263180544270911
CARM1	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-2.139177300565	-2.139177300565	-2.91800397137812	-2.87877770547	-8.81835749247331	87.0550071572238	1.05259666880365e-13	9.6205540054592e-12	-0.954368266936533	-0.603285074689711
CARM1	BRD-K92428232-001-10-6::2.5::HTS002	2.5	GSK461364	PLK inhibitor	targeted cancer	PLK1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-1.23787548619	-1.23787548619	-2.71370185964719	-2.38486964806	-12.3989151851416	193.442500304324	2.31902195624486e-26	6.60071257450206e-24	-1.71058699972612	-1.24106574718826
CARM1	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.3523978916875	-0.3523978916875	-0.0908030749585927	-0.0408206395104	8.80601645119533	192.997321649196	7.40655453740935e-16	8.3373919508845e-14	0.203003989503644	0.32018564395417
CARM1	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.3638592844515	0.3638592844515	0.0959025416938628	0.163411081458	-7.25166374413876	43.0884226308019	5.50667223384541e-09	3.0293623028949e-07	-0.342471257570397	-0.193442227944878
CARM1	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.11055181169895	-0.11055181169895	-1.43118117591469	-1.12582537284	-11.108940441782	5.1612533359287	8.46241829948184e-05	0.00243651484646647	-1.62337030363147	-1.01788842480001
CARM1	BRD-K94455792-001-01-8::2.5::HTS002	2.5	ICG-001	beta-catenin inhibitor	targeted cancer	CTNNB1	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.06061956213155	-0.06061956213155	-0.674648744640919	-0.6952871935485	-10.8817426671006	17.6399079388385	2.98063404685982e-09	1.68736480356423e-07	-0.732752596559974	-0.495305768458764
CARM1	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-0.6407704563125	-0.6407704563125	-1.25764291069162	-1.28599874522	-7.30457664928465	9.30462808452546	3.80918319940833e-05	0.0011757177793001	-0.806962748937636	-0.426782159820602
CARM1	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	-3.62795338901	-3.62795338901	-3.13694849886941	-3.215000704775	8.18942960463402	85.3104827555312	2.29956231531221e-12	1.84939171286511e-10	0.371802696164928	0.610207084116257
CARM1	BRD-K99964838-001-11-9::2.5::HTS002	2.5	bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	targeted cancer	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	MCF7, MKN7	BREAST, STOMACH	carcinoma, carcinoma (tubular_adenocarcinoma)	0.3595322045715	0.3595322045715	-0.401333782455317	-0.289629896197	-11.9370553356654	21.34486041801	6.50686644633386e-11	4.40295712857152e-09	-0.893289956768191	-0.628442017285444
CAVIN1	BRD-A14240607-003-26-1::2.5::HTS002	2.5	octopamine	trace amine associated receptor agonist	noncancer	F10, TAAR1	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.482659600544	0.482659600544	0.692751427023957	0.680383035614	7.0221460185275	17.5699187421343	1.7061702886407e-06	6.71222048080163e-05	0.147124996150884	0.27305865680903
CAVIN1	BRD-A54927599-001-16-9::2.5::HTS002	2.5	KF-38789	P selectin inhibitor	noncancer	SELP	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.42683011285	-4.42683011285	-2.92547170545631	-2.70844162047	12.0671561541696	5.58990608465372	3.25150546573608e-05	0.00101543335999672	1.19142437605241	1.81129243873496
CAVIN1	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.3871121856575	0.3871121856575	-0.225096809008601	-0.093015492892	-8.90534222343385	51.9045794287463	4.94195847642194e-12	3.8266077250471e-10	-0.750164499514197	-0.474253489818005
CAVIN1	BRD-A64553394-001-04-4::2.6791::HTS002	2.6791	DPI-201106	sodium channel activator	noncancer	ADRB2	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.2801719608795	0.2801719608795	-1.66877086911721	-1.51643544753	-19.7015760032442	32.7627134315291	9.85373672126542e-20	1.58673293593696e-17	-2.15025897132477	-1.74762668866865
CAVIN1	BRD-K01773560-001-02-4::2.59308::HTS002	2.59308	UNC2250	MER tyrosine kinase inhibitor	targeted cancer	MERTK	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5835441267855	0.5835441267855	-0.137553648354554	-0.120206350846	-14.4224225043365	14.888506968758	3.73736726299747e-10	2.33059699770435e-08	-0.827736351067523	-0.614459199212585
CAVIN1	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.58133283914	-4.58133283914	-3.00626755227205	-2.85234115214	13.5038540071646	62.0927778336777	3.87235282516343e-20	6.50436919016028e-18	1.34191576776901	1.8082148059669
CAVIN1	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.723061400595	-3.723061400595	-2.18623294840978	-2.01441788744	12.2816290299971	23.5818944833681	9.84969948217263e-12	7.38913629791592e-10	1.27832555583189	1.79533134853854
CAVIN1	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.007463472288095	0.007463472288095	0.242856125525554	0.240200693149	9.1806168673504	188.029700911006	7.80477762760923e-17	9.65256886409613e-15	0.184813281867669	0.28597202460725
CAVIN1	BRD-K05638300-001-01-2::2.5::HTS002	2.5	sevoflurane	membrane integrity inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.0012170000469	0.0012170000469	-0.581505595122691	-0.439418069219	-8.26333694343455	7.35342213151466	5.61796860814389e-05	0.00167817922482909	-0.747862632180339	-0.417582558158844
CAVIN1	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.23734703224	0.23734703224	-0.69071779358756	-0.506361258966	-11.6939895053195	10.7771185374048	1.84532520695354e-07	8.37051230224646e-06	-1.10318237671208	-0.752947274943038
CAVIN1	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.668066997244	0.668066997244	-0.31604592132754	-0.199486634258	-17.7988188107927	141.76989465625	5.83199248089753e-38	5.01994022665979e-35	-1.09341412522536	-0.874811711917725
CAVIN1	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.5613028621435	-0.5613028621435	-1.50324766760539	-1.38879124785	-13.9557909103002	166.922897562537	7.84323671774221e-30	3.11879978196098e-27	-1.07519848874171	-0.808691122182067
CAVIN1	BRD-K10845183-304-01-6::2.5::HTS002	2.5	tiludronate	bone resorption inhibitor, osteoclast inhibitor	noncancer	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.53764590004	0.53764590004	0.212180918448556	0.2055339429765	-7.61626486434615	10.5323810560788	1.3393514956445e-05	0.000450929730929926	-0.420031428303244	-0.230898534879644
CAVIN1	BRD-K13533483-001-16-2::2.5::MTS005	2.5	cyclosporine	calcineurin inhibitor	noncancer	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	transplant, rheumatology, dermatology	organ rejection, rheumatoid arthritis, psoriasis	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.0028474849966	-0.0028474849966	0.226625201986238	0.2295047390715	7.19188075794344	4.82255711702889	0.00094092329018753	0.0209851350533406	0.146536576985822	0.312408796979853
CAVIN1	BRD-K18779551-003-07-8::2.5::HTS002	2.5	bifemelane	acetylcholine release enhancer	noncancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.3615660281185	0.3615660281185	0.0157462976314065	0.0566081056954	-10.4832884048712	145.100864712612	1.71337288432377e-19	2.69820350421917e-17	-0.411018233935747	-0.28062122703844
CAVIN1	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.194028428822	0.194028428822	-0.199483443088783	-0.14719250083	-6.62249371260506	10.5953259363122	4.48728605080119e-05	0.00136613001702012	-0.524907528909606	-0.262116214911961
CAVIN1	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.801767419488	0.801767419488	0.408633057972172	0.440703373362	-10.7402669683085	3.95138814060857	0.000454313244567597	0.0110137431732755	-0.495257735321125	-0.291010987710531
CAVIN1	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.4353230106215	0.4353230106215	0.269225671108684	0.2845478404215	-5.16374830082627	7.17053710708001	0.00121038622577084	0.0261565708190401	-0.241792764849335	-0.0904019141762975
CAVIN1	BRD-K29582115-066-01-2::2.5::HTS002	2.5	ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.020269358514485	0.020269358514485	0.266918992906215	0.27385544783	6.60970781623618	38.2579722003876	8.07827907670227e-08	3.84415958310506e-06	0.171123521726334	0.322175747057126
CAVIN1	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.1696682449315	-0.1696682449315	-0.748332401146581	-0.6332790164525	-10.4694335364859	177.950244745446	2.73406203462941e-20	4.65070461761974e-18	-0.687736625909397	-0.469591686520766
CAVIN1	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.873898025225	-4.873898025225	-3.68472994677137	-3.84343615246	12.25159277967	141.344154155214	5.70830001700902e-24	1.34150683590518e-21	0.99728655597213	1.38104960093513
CAVIN1	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.11850545555	-1.11850545555	-1.93643985613373	-1.836818850415	-8.45787553120516	15.8468838272779	2.87237964025447e-07	1.26934898127031e-05	-1.0231048460021	-0.612763955165359
CAVIN1	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.4791985709345	0.4791985709345	-0.0793665344738323	-0.0620606581655	-11.6713791816669	2.88147665770561	0.00162930308984029	0.0337169935253819	-0.71447575208857	-0.402654458728094
CAVIN1	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.384907591435	-2.384907591435	-4.6890696759145	-5.08551792173	-14.7144573077111	5.89013913368114	7.21834558090699e-06	0.000255039970605025	-2.68906726495315	-1.91925690400585
CAVIN1	BRD-K40175214-001-11-6::2.5::HTS002	2.5	torin-1	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.528218030215	-4.528218030215	-3.72069172278686	-3.70757684528	11.3045645058682	186.623463316267	6.59631141885969e-23	1.41378083009278e-20	0.666605076859733	0.948447537996544
CAVIN1	BRD-K42205652-001-02-7::2.5::HTS002	2.5	MNS-(3,4-Methylenedioxy-nitrostyrene)	src inhibitor, syk inhibitor	noncancer	SRC, SYK	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.594694129246	0.594694129246	0.236556962310938	0.255658141899	-6.96761324136068	4.42916321687573	0.00151569872487556	0.0317089499271698	-0.495555720512512	-0.220718613357613
CAVIN1	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.23388256126	-1.23388256126	0.385591362950032	0.396546401632	26.6132989362212	3.09999719338859	9.18812388429219e-05	0.00262116518567345	1.4293019973633	1.80964585105676
CAVIN1	BRD-K43236057-001-07-1::2.59978::HTS002	2.59978	polydatin	ICAM1 expression inhibitor	noncancer	ICAM1	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.0846835830427	0.0846835830427	-1.32829147113519	-1.21412289307	-16.7685497158469	15.1430131651407	3.43284765447451e-11	2.39817081139462e-09	-1.59243062373617	-1.23351948461961
CAVIN1	BRD-K44067360-001-30-3::2.5::HTS002	2.5	flufenamic-acid	chloride channel blocker	noncancer	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.115128093995	-0.115128093995	0.0744714658373097	0.0872280051655	6.09034959670764	35.2170640628772	5.7321164551023e-07	2.42606395676465e-05	0.126413896292875	0.252785223371745
CAVIN1	BRD-K44084986-300-08-4::2.5::HTS002	2.5	Y-27632	rho associated kinase inhibitor	targeted cancer	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.72735161177	-1.72735161177	-0.927261546023936	-0.842583812381	12.9295794796436	71.736398518338	2.02592552636349e-20	3.49890888106334e-18	0.676725610237205	0.923454521254922
CAVIN1	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.783778037047	0.783778037047	0.221195538995036	0.2005091684065	-20.059196693196	187.01445549003	1.70451838380215e-48	3.84555495454664e-45	-0.617909907768812	-0.507255088335115
CAVIN1	BRD-K53561341-001-07-5::2.5::HTS002	2.5	aurora-a-inhibitor-i	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.992973942327	-0.992973942327	-0.61387247045996	-0.5126874975615	6.36895613816736	102.956372261998	5.40512761262439e-09	2.97579141044483e-07	0.261050393067868	0.497152550666212
CAVIN1	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.361378931965	-1.361378931965	-0.377982390750719	-0.1848985030465	14.9339616988954	79.2601067459509	9.45989298840187e-25	2.40799216664036e-22	0.852332727193144	1.11446035523542
CAVIN1	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.830682925865	-1.830682925865	-1.18959830420699	-1.16994261629	8.74816204573051	151.657236194291	3.87617606538547e-15	4.0784336765734e-13	0.496298784505384	0.785870458810644
CAVIN1	BRD-K61443650-236-13-1::2.5::HTS002	2.5	thiomersal	other antibiotic	noncancer	OXCT1	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.3295164820785	0.3295164820785	-0.174874299811108	-0.0402678564845	-8.9376590328353	29.2459572851818	7.33755399689964e-10	4.43124995942942e-08	-0.619769793602532	-0.389011770176683
CAVIN1	BRD-K65781196-001-03-0::2.5::HTS002	2.5	avanafil	phosphodiesterase inhibitor	noncancer	PDE5A	urology	erectile dysfunction	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.375676692252	0.375676692252	0.519401903149601	0.5001680411375	4.66782105660314	12.7385384232948	0.000464229569685126	0.0112211412474392	0.0770670152756489	0.210383406519553
CAVIN1	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.0173660321975	0.0173660321975	-2.65432700307508	-2.62453052692	-13.6511051551031	3.18883766685591	0.000616918308095524	0.0144191367563583	-3.27418295367906	-2.06920311686609
CAVIN1	BRD-K67578145-001-09-7::2.38272::HTS002	2.38272	GDC-0879	RAF inhibitor	targeted cancer	BRAF	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	1.545776863825	1.545776863825	0.57432829668408	0.659791110046	-14.4377817016474	4.17416123406073	0.000101402379067981	0.00287137937683463	-1.15522791791156	-0.787669216370281
CAVIN1	BRD-K67868012-001-07-6::2.5::HTS002	2.5	PI-103	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.888843480839	-0.888843480839	-0.518844217703029	-0.4812241803595	9.02972923198404	97.4656783577542	1.60822304280692e-14	1.60171392445057e-12	0.288678794906263	0.45131973136568
CAVIN1	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.86788303568	-3.86788303568	-3.09691707541134	-3.15624915805	6.15643028902678	4.78764787240552	0.00191761970550368	0.0386715763888688	0.4447112661218	1.09722065441551
CAVIN1	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.13647986612465	0.13647986612465	-0.66750732694869	-0.50591048476	-10.8089583385769	10.0428951410288	7.47881798461309e-07	3.11490007738853e-05	-0.969623737493142	-0.638350648653538
CAVIN1	BRD-K76011241-001-01-8::2.5::HTS002	2.5	oseltamivir-phosphate	neuraminidase inhibitor	noncancer	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.4563163520045	0.4563163520045	0.323926506749512	0.301103308343	-4.96253877633505	20.9981401510759	6.5500192862415e-05	0.00192970320769877	-0.187869762359433	-0.0769099281505427
CAVIN1	BRD-K77677632-003-02-6::2.5::HTS002	2.5	SB-200646	serotonin receptor antagonist	noncancer	HTR2B, HTR2C	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.008748120461	-0.008748120461	-0.617403491172701	-0.496261939988	-8.81649039306687	189.961570371301	7.51498067844385e-16	8.4461368318311e-14	-0.744831034168326	-0.472479707255077
CAVIN1	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-5.02251205775	-5.02251205775	-4.12343449899175	-4.24145212342	7.50558930559796	36.1075544748444	7.07714316862276e-09	3.83330052612521e-07	0.656161892202297	1.14199322531419
CAVIN1	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.8132575942565	-0.8132575942565	-0.418951642288285	-0.2916892525045	5.62060083752443	6.45549725868101	0.00105667440265043	0.0231760098286597	0.225539760146512	0.563072143789918
CAVIN1	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.469616639145	-0.469616639145	0.197641942016577	0.205191667076	14.0425280495368	4.35541685421893	8.59614063544165e-05	0.00247169603736728	0.539469542580067	0.795047619743086
CAVIN1	BRD-K84091759-001-07-1::2.5::HTS002	2.5	candesartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension, congestive heart failure	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.8231888899135	0.8231888899135	0.328026321096498	0.339578920682	-12.8706661135409	5.45299826728306	2.74398737465424e-05	0.000869994186423474	-0.591637738570455	-0.39868739906355
CAVIN1	BRD-K84466663-001-05-4::2.5::HTS002	2.5	nelarabine	DNA synthesis inhibitor, T cell inhibitor	chemo	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.708627390306	0.708627390306	0.607338922989137	0.593873040614	-3.87457399238652	30.8100110225112	0.000520934331357142	0.0124291811538957	-0.154618416544651	-0.0479585180890738
CAVIN1	BRD-K84810405-003-01-1::2.5::HTS002	2.5	almorexant	orexin receptor antagonist	noncancer	HCRTR1, HCRTR2	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.534016435793	0.534016435793	0.255067527985291	0.26116496822	-9.99976333218684	188.693363842834	3.68319171002459e-19	5.64136445779024e-17	-0.333976110607863	-0.223921705007555
CAVIN1	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.8841830539695	-0.8841830539695	-1.96518453491421	-1.89031364576	-14.8758113626141	10.602044568135	1.92630895449547e-08	9.95332381649132e-07	-1.24167908981285	-0.920323872076578
CAVIN1	BRD-K90647725-001-07-3::2.50156::HTS002	2.50156	oleanolic-acid	G protein-coupled receptor agonist	noncancer	GPBAR1	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.6297141097185	0.6297141097185	0.114938203835735	0.139454786175	-13.5980267987924	3.33127363739755	0.000492664819208986	0.011825776462789	-0.628750591718532	-0.400801220046999
CAVIN1	BRD-K91623615-001-05-0::2.46068::HTS002	2.46068	ABT-751	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.22389234053	-2.22389234053	-3.50441970178914	-3.442891314055	-11.0055097015888	8.3313424231881	3.00061341152927e-06	0.000113806135529934	-1.5469924362788	-1.01406228623948
CAVIN1	BRD-K92213669-001-01-3::2.5::HTS002	2.5	lomitapide	microsomal trigylceride transfer protein inhibitor	noncancer	MTTP	endocrinology	hypercholesterolemia	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.6332987165425	0.6332987165425	0.222561537693945	0.227576049132	-7.34335625511376	3.772054538117	0.00229385352473613	0.0451252255257613	-0.569804559514841	-0.251669798182268
CAVIN1	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.0501557204469	-0.0501557204469	-1.43182028799143	-1.12582537284	-15.4795742840147	188.984810404112	1.92115934791328e-35	1.26306798122363e-32	-1.55773311364616	-1.20559602144291
CAVIN1	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	HCC38, GCIY	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.894190794729	0.894190794729	-0.0445907377976056	0.00448333894144	-15.0956580622981	9.04835499991738	1.00715661477521e-07	4.74423890303639e-06	-1.07934795375976	-0.798215111293448
CBFB	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-2.73473855873	-2.73473855873	-2.08847078597475	-2.05580997476	8.98748712262203	159.289142975233	6.9754071102802e-16	7.87273317819508e-14	0.504252700075465	0.788282845435041
CBFB	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.1249741633755	0.1249741633755	-0.0523797093611385	0.106263594851	-3.21922239250256	131.194609466937	0.00162012997612759	0.0335692998504882	-0.28633777377478	-0.0683699716984966
CBFB	BRD-A23072235-050-18-5::2.5::HTS002	2.5	pheniramine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.8481397266515	-0.8481397266515	-1.71900727299462	-1.478667912985	-9.31846541845994	66.6098829569645	1.08989574441371e-13	9.95297251829769e-12	-1.05742681082995	-0.684308281856286
CBFB	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.772560108936	0.772560108936	-0.0208648214318848	0.03331372318045	-13.1864054442196	6.783332652483	4.38615333914476e-06	0.000161775917918698	-0.936630645821036	-0.650219214914733
CBFB	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.4380473842685	-0.4380473842685	-1.03189971128572	-0.797857785181	-6.08400790520817	9.12377430384538	0.000172791148535421	0.00464494595189368	-0.814202854246542	-0.373501799787889
CBFB	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.01686406363237	-0.01686406363237	0.249896591347974	0.2649123832205	7.56731443897136	29.5474021847123	2.14557338773644e-08	1.10040344249859e-06	0.194720818992471	0.338800490968217
CBFB	BRD-A90547603-001-02-5::2.5::HTS002	2.5	eptifibatide	platelet aggregation inhibitor	noncancer	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.206263610552	0.206263610552	0.0427284242406051	0.04269931862485	-5.11182140903081	6.81487179419365	0.00149844856219808	0.031413158741766	-0.239601812321858	-0.0874685603009317
CBFB	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.4111853464865	0.4111853464865	-0.191309454447888	-0.136086260588	-9.37448517845873	3.72381056068623	0.00100848745924428	0.0222925029550709	-0.786278611607382	-0.418710990261393
CBFB	BRD-K00662280-001-09-4::2.5::HTS002	2.5	CL-218872	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.308504120115	-0.308504120115	0.192174767282997	0.1913856373495	12.4598909728369	3.0394220158575	0.00104498870366637	0.0229643580301558	0.373731088742638	0.627626686053356
CBFB	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.5933634699295	0.5933634699295	-0.369273187336956	-0.264963110089	-13.9054118201432	16.8626107646044	1.14699430056838e-10	7.54323846107763e-09	-1.10878458198653	-0.816488732546378
CBFB	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-1.127044994495	-1.127044994495	-2.21491821256559	-2.04082568027	-7.08270507007027	4.60960261066437	0.00120910841666634	0.0261342272928278	-1.49297647395214	-0.682769962189029
CBFB	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.2198062168715	0.2198062168715	-0.385911190732684	-0.278845004201	-8.59056063184093	8.3510548869566	1.9999419041477e-05	0.000651720351111287	-0.767130861739494	-0.444303953468874
CBFB	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.297856341082	0.297856341082	-0.36239360052322	-0.164030729397	-9.71604331683394	25.8811589430728	4.03166265154884e-10	2.49957253238013e-08	-0.799963867704645	-0.520536015505795
CBFB	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-1.855683745025	-1.855683745025	-1.21434735564495	-1.22574357102	7.30160268476185	9.70266896772037	3.05549852250618e-05	0.00095981524670999	0.444811792227401	0.837860986532704
CBFB	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-3.061038011215	-3.061038011215	-3.71196583584359	-3.60790168659	-5.1881358004841	13.2214566704404	0.000165388665569026	0.00446780782741918	-0.921517012360207	-0.380338636896964
CBFB	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.925668371851	-0.925668371851	-1.9551085651594	-1.885064313955	-7.07665330028268	3.98315214362926	0.00213805817260744	0.0424972521632922	-1.43400407931602	-0.624876307300769
CBFB	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.1658741274115	-0.1658741274115	0.2614814863257	0.2294815220965	10.711481909471	3.22054384090634	0.00125985416510783	0.0270618644371013	0.305165618163767	0.549545609310634
CBFB	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.6608932613185	-0.6608932613185	-1.50205496821407	-1.38879124785	-9.45590370594252	5.47055299859626	0.000135867904590015	0.00373770146616266	-1.06403974641021	-0.618283667380938
CBFB	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.683608485283	0.683608485283	0.179728166259688	0.22754908413	-9.85298418766814	3.46972677256207	0.00117270452717292	0.0254345869868898	-0.654848698766052	-0.352911939280571
CBFB	BRD-K11071038-001-01-7::2.5::HTS002	2.5	ICI-162846	histamine receptor antagonist	noncancer	HRH2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.2902121960975	-0.2902121960975	0.0999147575304888	0.0637321133413	8.94608320047807	3.79739126359242	0.00109343318678659	0.0238893416402428	0.266459061793911	0.513794845462066
CBFB	BRD-K13094524-001-07-5::2.63083::HTS002	2.63083	PFI-1	bromodomain inhibitor	targeted cancer	BRD4	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.7996462851125	-0.7996462851125	-2.2445946409798	-2.09295317057	-13.3722430562867	44.6577368273954	3.20179674063157e-17	4.09694264849447e-15	-1.66262994593036	-1.22726676580424
CBFB	BRD-K13390322-001-06-3::2.5::HTS002	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.846742462051	0.846742462051	-0.345551554386821	-0.191679875324	-11.7796995012903	6.0973350882909	2.01500338060248e-05	0.00065634294766132	-1.43900541396585	-0.945582618909789
CBFB	BRD-K13949769-001-01-7::2.5::HTS002	2.5	tenovin-6	SIRT inhibitor	targeted cancer	SIRT1, SIRT2, SIRT3	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.7443368819095	-0.7443368819095	-1.27112099372519	-1.229883421555	-7.63889025540955	179.3373206645	1.26566880748719e-12	1.04616093266457e-10	-0.662863124376709	-0.390705099254663
CBFB	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.3383959041685	0.3383959041685	-0.0575745347701836	0.1891566141585	-5.45747123109646	23.7048944851689	1.36622823649517e-05	0.000459185089696996	-0.545816680337898	-0.246124197539469
CBFB	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.655097635163	0.655097635163	0.397920076728512	0.431459247123	-8.39987573450379	168.422555458805	1.77906017732851e-14	1.7636641477643e-12	-0.317619748575324	-0.196735368293652
CBFB	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-2.089973719465	-2.089973719465	-1.2862871085331	-1.25961873039	13.5031546429019	12.2692829683634	9.93545825521337e-09	5.30375300717715e-07	0.674322049159569	0.933051172704223
CBFB	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.766654727021	-0.766654727021	-0.564090805442305	-0.546522000374	4.90469906664784	9.64108460238202	0.00068866648684239	0.015926487162569	0.110075376443285	0.295052466714104
CBFB	BRD-K15567136-003-27-2::2.5::HTS002	2.5	papaverine	phosphodiesterase inhibitor	noncancer	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-1.17381906241	-1.17381906241	-0.514488549900792	-0.4889366454155	17.4404677599947	12.9753974396562	2.18294590272103e-10	1.39163775248155e-08	0.577642820114776	0.741018204903639
CBFB	BRD-K15916496-001-27-9::2.5::HTS002	2.5	clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	noncancer	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.0104144113833	-0.0104144113833	0.335742568639092	0.346280454324	13.1126545992344	56.68812190078	8.24947737667714e-19	1.21602629756935e-16	0.293288199760674	0.39902576028411
CBFB	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-1.85042441419	-1.85042441419	-0.865112599680209	-0.775615128041	13.5440527896053	153.841211674275	5.17336196830244e-28	1.73793338135469e-25	0.841596512748548	1.12902711627103
CBFB	BRD-K19284129-001-02-6::2.5::HTS002	2.5	salvinorin-a	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.5646182199125	0.5646182199125	0.00745545391772021	0.0190895048791	-13.8559098895935	19.2583198489934	1.80629898294063e-11	1.30702989437773e-09	-0.641249432336407	-0.473076099653153
CBFB	BRD-K19761926-001-03-6::2.44857::HTS002	2.44857	eplerenone	cytochrome P450 inhibitor	noncancer	NR3C2	cardiology	congestive heart failure, hypertension	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.345093553229	0.345093553229	-0.881204590909512	-0.799528598077	-11.259939561861	3.39787891550589	0.000828692776569732	0.0187691951927945	-1.55102625306708	-0.901570035209941
CBFB	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-5.8209497622	-5.8209497622	-5.24439081897052	-5.41033082	6.49881609227081	8.11605456871127	0.000176807289085229	0.00474279467613868	0.372484031097868	0.780633855361085
CBFB	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.05656439602025	0.05656439602025	0.376475113742456	0.395322173914	10.2699195691134	45.7036394331136	1.8694718220446e-13	1.66950844227916e-11	0.257197512276545	0.382623923167866
CBFB	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.7182620687315	-0.7182620687315	-0.421424490365346	-0.310239188826	7.60808634973078	191.52868506796	1.22396389528652e-12	1.01286084059021e-10	0.219881230976222	0.373793925756086
CBFB	BRD-K28392481-001-05-1::2.5::HTS002	2.5	AZD4547	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.0770056285068	0.0770056285068	0.375452051225999	0.422629133595	7.30687257427121	190.509729655089	7.29825802287158e-12	5.54887670728642e-10	0.217880643318239	0.379012202120159
CBFB	BRD-K30519779-001-03-1::2.5::HTS002	2.5	homoquinolinic-acid	glutamate receptor agonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.537882915478	0.537882915478	0.425828014153652	0.440439645693	-3.55524657838422	120.193546473362	0.000540959892889536	0.0128483369772962	-0.174457680617734	-0.0496521220309626
CBFB	BRD-K31627533-001-09-5::2.5::HTS002	2.5	rimexolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	ophthalmology	anterior uveitis	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.7933431417395	0.7933431417395	0.255383676323022	0.238873966221	-14.4730997383956	8.5669431268373	2.56223446607567e-07	1.13886592882524e-05	-0.622695358042188	-0.453223572790767
CBFB	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.3920794316215	0.3920794316215	-0.0452327009135472	-0.03775802467905	-8.49136295223908	9.11161080249342	1.26783554466741e-05	0.000428574061875704	-0.553597900358261	-0.321026364711833
CBFB	BRD-K38332599-001-01-3::2.5::MTS010::PROS002_PR500	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-1.112294952275	-1.112294952275	-0.564062080379908	-0.5253626676245	6.90484997885566	178.000374692223	8.55339183111807e-11	5.71815320577575e-09	0.391549923011693	0.704915820778492
CBFB	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.3391025310615	0.3391025310615	-0.359978015495727	-0.2780855887145	-12.6635447206769	7.43562653226901	2.67593912092312e-06	0.000102233753270647	-0.828083235462634	-0.57007785765182
CBFB	BRD-K43389675-003-20-9::2.5::HTS002	2.5	daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-4.181031512745	-4.181031512745	-5.07677591455908	-5.1170914027	-9.90757354448088	5.55069250718996	9.77816677707266e-05	0.00277729221728493	-1.12138403515507	-0.670104768473104
CBFB	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-4.15615418804	-4.15615418804	-5.46073693289622	-5.49470441072	-16.5950775181255	187.681446593689	1.17094841674394e-38	1.09593101839437e-35	-1.45966065904076	-1.14950483067169
CBFB	BRD-K45462423-001-03-7::2.5::HTS002	2.5	VU0361737	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.4144514771245	0.4144514771245	0.0783052751501063	0.1040664300715	-7.00971123484728	5.43628063687423	0.000643043571995624	0.0149644827081705	-0.456499846929689	-0.215792557019098
CBFB	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.1785622444295	0.1785622444295	-0.299080412187354	-0.290098649131	-9.86844055012485	29.9885091593493	6.24788340238154e-11	4.23766646123112e-09	-0.576492329036708	-0.378792984197001
CBFB	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.9053571865255	0.9053571865255	0.365597791732761	0.3732554744945	-14.0423606010881	27.8211984279436	3.75058174274655e-14	3.60151628289035e-12	-0.618518746308714	-0.461000043276764
CBFB	BRD-K49071277-001-04-7::2.5::HTS002	2.5	securinine	GABA receptor antagonist, TP53 activator	noncancer	GABRA1	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.1107291273175	0.1107291273175	0.293385547555462	0.294659751206	7.26889274147242	71.3039221238003	3.68689349782007e-10	2.30314251382768e-08	0.132555301547144	0.23275753892878
CBFB	BRD-K49328571-001-15-0::2.5::MTS010::PROS005_PR500	2.5	dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor	targeted cancer	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.6569640351965	0.6569640351965	-0.478523681097372	-0.286018332538	-13.5954427968116	66.3473921867746	7.47823499373766e-21	1.33789868779032e-18	-1.30222394289951	-0.968751489688234
CBFB	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-3.581920262955	-3.581920262955	-4.60058346374838	-4.62878838486	-9.62833507021367	32.6172727145983	4.67017994423112e-11	3.21540313930971e-09	-1.23400781396616	-0.803318587620591
CBFB	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.3839530270715	0.3839530270715	0.225448996547967	0.2005091684065	-5.40923964406167	98.6773574081684	4.42783996252454e-07	1.90565162917253e-05	-0.216648821050722	-0.100359239996344
CBFB	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.11805672329205	-0.11805672329205	-0.743139118909071	-0.696454065727	-8.11445407477003	4.11016407060575	0.00111663616484926	0.0243491212306418	-0.836718913011799	-0.413445878222243
CBFB	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-1.05401264242	-1.05401264242	-0.228246039756616	-0.09048394609	14.1266826586502	54.9106751032149	6.251147242138e-20	1.02196959363859e-17	0.708617105961941	0.942916099364827
CBFB	BRD-K56483981-342-06-4::2.5::HTS002	2.5	chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	noncancer	MIF	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.697530801091	0.697530801091	0.259347122860917	0.2726437247965	-12.5745968927967	8.32531085874653	1.05340632612957e-06	4.2809162774559e-05	-0.517997118611181	-0.358370237848985
CBFB	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-4.67525691386	-4.67525691386	-5.59463358067416	-5.54901350857	-11.7528507908902	189.371443341817	2.63975867209444e-24	6.35704310597e-22	-1.07368263050289	-0.765070703125427
CBFB	BRD-K62200014-003-10-5::2.5::HTS002	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.3134999440565	0.3134999440565	-0.0841570181825348	0.0371962455536	-5.86619199496793	6.99927971508903	0.000620565375887964	0.0144948949922288	-0.557953269289152	-0.237360655188918
CBFB	BRD-K64800655-001-07-4::2.5::HTS002	2.5	PHA-793887	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-1.1304063038	-1.1304063038	-1.6283998859511	-1.592670797355	-5.58521909141414	195.807431221035	7.72893430165689e-08	3.68938699318445e-06	-0.673836222456981	-0.322150941845225
CBFB	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-1.73252865508	-1.73252865508	-2.1324490914645	-2.025815521035	-4.20958730000031	95.1795027212193	5.79980792045968e-05	0.00172744167841051	-0.588519241682796	-0.2113216310862
CBFB	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-3.558242213515	-3.558242213515	-2.93437945932113	-2.87845710522	7.16052193006137	129.048727266224	5.44234046662137e-11	3.70890743996976e-09	0.451483793850653	0.796241714537094
CBFB	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-2.58912133843	-2.58912133843	-1.74910860522436	-1.67073793274	13.1135724825976	179.373894745147	5.51339952982965e-28	1.8492666789184e-25	0.713611008785072	0.966414457626211
CBFB	BRD-K69650333-003-14-0::2.5::HTS002	2.5	idarubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-7.57788711984	-7.57788711984	-6.61438661794765	-6.534390959045	9.03228290476861	160.62180251601	5.05768304442331e-16	5.79683502261071e-14	0.752838088635887	1.17416291514881
CBFB	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.222268195879	-0.222268195879	-1.0376748872751	-0.659178147727	-6.53232906387456	6.40164356504233	0.00047147860282458	0.0113783962914975	-1.11626004828814	-0.514553334504064
CBFB	BRD-K72280606-001-01-2::2.5::MTS006	2.5	gilteritinib	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.5236952040975	-0.5236952040975	0.0281914959066166	0.043697431473	21.2660842974028	121.67170837741	8.44407585176148e-43	1.11716687236555e-39	0.500511733370458	0.603261666637775
CBFB	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-3.66068888549	-3.66068888549	-2.62003042166409	-2.476182958975	13.2673973272424	193.497925853624	5.41650812804579e-29	2.00503414607241e-26	0.885956657785587	1.19536026986623
CBFB	BRD-K75911534-001-01-6::2.5::HTS002	2.5	SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.1370958195015	-0.1370958195015	-0.526013721047099	-0.4139887396705	-6.27281964327139	25.6782203384058	1.29232636665804e-06	5.18986355329681e-05	-0.516439509429655	-0.261396293661544
CBFB	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.664720561522	-0.664720561522	-0.142221297439406	-0.1170838755295	8.69100849735813	3.4842122744881	0.00175660835556035	0.0359351066372907	0.34536907732711	0.699629450838077
CBFB	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.2476331197915	-0.2476331197915	0.00516489584031735	0.03806515271055	8.12271202271462	14.2872059327047	9.97934886858215e-07	4.07092475000827e-05	0.186172847422074	0.319423183841561
CBFB	BRD-K77677632-003-02-6::2.5::HTS002	2.5	SB-200646	serotonin receptor antagonist	noncancer	HTR2B, HTR2C	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.32241813648	0.32241813648	-0.62088945177208	-0.496261939988	-12.2085127232071	20.8199548066095	5.93195768621369e-11	4.02848719559092e-09	-1.10407647436649	-0.782538702137666
CBFB	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.5292892842055	0.5292892842055	0.279985244274354	0.273644438403	-6.53066689894737	12.6457796138044	2.18267987324097e-05	0.000706237310615737	-0.332010177845198	-0.166597902017094
CBFB	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.766180634173	-0.766180634173	0.0422980786722939	0.129465498685	13.7254629216536	7.07598054291646	2.33743142662532e-06	9.02828149643498e-05	0.669496526987276	0.947460898703312
CBFB	BRD-K82967180-001-01-6::2.5::MTS006	2.5	LY3023414	PI3K inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-4.532391950995	-4.532391950995	-3.36490639457796	-3.47125881494	13.0624475374129	3.44197452418734	0.00047067385769311	0.011361533646301	0.902633692814013	1.43233742002007
CBFB	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.1630285017205	-0.1630285017205	0.0452140144233874	0.06241133456585	7.54921317321551	176.256069807372	2.26130705223308e-12	1.81999128500963e-10	0.153803778787704	0.262681253500071
CBFB	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-2.93446830733	-2.93446830733	-1.94404757353936	-1.864714539655	14.2657857203634	17.2595137428292	5.50183190702048e-11	3.74468761765574e-09	0.844111634931359	1.13672983264991
CBFB	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.2796696880035	-0.2796696880035	-2.07959571239134	-1.887176140495	-12.9409992731654	4.49457955370981	9.97017155928357e-05	0.00282620936401228	-2.16989878303363	-1.42995326574204
CBFB	BRD-K89015388-001-01-7::2.5::HTS002	2.5	GSK923295	centromere associated protein inhibitor	targeted cancer	CENPE	NA	NA	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-1.1452054976	-1.1452054976	-1.64495934450488	-1.4981509162	-4.90195568320195	15.7656988933068	0.000166358700968969	0.00449174779793122	-0.716139296063498	-0.283368397746265
CBFB	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.64631224429	-0.64631224429	-0.267951295458145	-0.201241346164	8.12755007055	186.542516134464	5.9065851078978e-14	5.5426991225509e-12	0.286523150042441	0.470198747621269
CBFB	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	-0.308152375142	-0.308152375142	-0.0912615777207223	-0.0408206395104	5.8852885372192	7.90405100714161	0.000385140259877297	0.00948601974775504	0.131727621114117	0.302053973728438
CBFB	BRD-K95785345-300-14-8::2.5::HTS002	2.5	thiamine	vitamin B	noncancer	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	T47D, JHH7	BREAST, LIVER	carcinoma (ductal_carcinoma), carcinoma (hepatocellular_carcinoma)	0.599562251802	0.599562251802	0.170002489521822	0.1869116591445	-15.8538401913553	24.2782357372533	2.60223937186991e-14	2.53400891564519e-12	-0.485447194003406	-0.37367233055695
CCDC170	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.151631603499	-0.158988528494	-0.516250736055677	-0.4692197687775	-6.92039442841339	102.831390942709	3.95806536555417e-10	2.45536379662477e-08	-0.469114642430285	-0.260123622683069
CCDC170	BRD-A44090213-001-25-6::2.5::HTS002	2.5	indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	CXCR1, CXCR2, PTGS1, PTGS2	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.03330113088833	-0.982752666678	-1.91722472122926	-1.83417815232	-8.72560542493199	19.1630673364962	4.20754535110852e-08	2.07167238124911e-06	-1.09582961689381	-0.672017563788054
CCDC170	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.641504018374667	-0.603387381028	-1.19714481233186	-1.04762820909	-6.99158938833836	20.2974162689256	8.05267391923783e-07	3.33769396332687e-05	-0.721262446588131	-0.390019141326253
CCDC170	BRD-K02389548-001-02-5::2.5::HTS002	2.5	RG2833	HDAC inhibitor	noncancer	HDAC1, HDAC3	NA	NA	MCF7, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.0094164000796555	-0.0094164000796555	0.320936851330378	0.362491356389	8.63867461150997	98.8695887452748	1.01775355927006e-13	9.31400950490151e-12	0.254473183345848	0.40623331947422
CCDC170	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.125869245304433	0.155325578918	-0.345680948653554	-0.229610255998	-8.75728993083104	13.22548981562	7.21394644130337e-07	3.01219155818841e-05	-0.587677384481722	-0.355423003434254
CCDC170	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.47446611131	-1.41296766119	-2.20933050372202	-2.17094660797	-5.87917213994045	4.78531921818267	0.00234257909091712	0.0459235922415782	-1.06055746976562	-0.409171315058421
CCDC170	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.180857022738667	-0.185337291627	-0.423296195978896	-0.3914859259735	-5.14761815982303	8.50012500491916	0.00072477701972857	0.0166728275047123	-0.349943557441414	-0.134934789039045
CCDC170	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.01728248142667	-2.02627642065	-1.28320493539196	-1.25454191877	10.9563247551677	10.6981942435035	3.78185565500879e-07	1.64014840283768e-05	0.586101620829046	0.882053471240361
CCDC170	BRD-K18849474-001-04-4::2.60504::HTS002	2.60504	dalcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.0472576101263	0.0432090714792	0.304491286172577	0.28793221443	5.78526541735454	5.03834444844908	0.00211741138350359	0.0421376661480911	0.143197516334002	0.371269835758552
CCDC170	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1469819083448	0.174918444136	-0.310877914548571	-0.199338421936	-7.33812252667699	40.1115331689347	6.26685546562596e-09	3.41686305034889e-07	-0.583953257807166	-0.331766387979576
CCDC170	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.425074256984667	0.430379139046	0.0943184398354135	0.136288783323	-7.70684354892009	3.73809216628272	0.00199990422018612	0.0400970506649458	-0.453278841307792	-0.208232792990715
CCDC170	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.54367998010333	-3.57415868795	-4.1873394978698	-4.22504454942	-5.83514171977821	15.2428738096744	3.07772114680279e-05	0.000965381085428209	-0.878448385819891	-0.408870649713051
CCDC170	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.00243717839220333	0.00199046724481	-0.868933255613281	-0.560893595726	-9.31299932873439	187.848409726815	3.35237890893808e-17	4.27685725698684e-15	-1.0559435099776	-0.686797358033368
CCDC170	BRD-K30867024-003-03-3::2.5::HTS002	2.5	SB-216641	serotonin receptor antagonist	noncancer	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.241682780105	0.220144798778	-0.0527977811535503	-0.0253006385055	-6.08938157203509	9.6901162228232	0.000133786608061913	0.00368375512837894	-0.402701559805586	-0.186259562711515
CCDC170	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.019084949473	0.0902486237933	-0.88678844578516	-0.713479277931	-7.75394773333827	11.9167336813681	5.39556658745162e-06	0.000195474373076727	-1.16061579124074	-0.651130999275576
CCDC170	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.722655836858	-0.750755696512	-1.94716436552763	-1.84222232008	-10.4895129251156	8.47036687235296	3.8495705624907e-06	0.000143018652988051	-1.49112332560156	-0.957893731737698
CCDC170	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.15939009935	-1.10608028394	-1.9816312570356	-2.048574796455	-7.3569182034202	4.81686829931816	0.000854285387968798	0.0192762769076621	-1.11285717638272	-0.531625138988487
CCDC170	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.477705613985	-2.477705613985	-0.769262686323398	-0.3920750884915	10.5050266526146	3.52821664130546	0.000871445822339226	0.0195884752654582	1.23206848680536	2.18481736851785
CCDC170	BRD-K45551181-001-02-1::2.49051::HTS002	2.49051	MPI-0479605	mitotic kinase inhibitor	targeted cancer	TTK	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.54662628101	-1.61445505441	-2.31769839673268	-2.317347513715	-6.08969566277142	6.75355530120066	0.000569868728752423	0.0134633371654297	-1.07270797460383	-0.469436256841531
CCDC170	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.93437867437333	-2.8841509626	-0.914664494104825	-0.5694567555345	11.2109311126667	3.1836756048677	0.0011528584536935	0.025067566148085	1.46464391165935	2.57478444887767
CCDC170	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.657383947515333	-0.640236329584	-0.258833866170498	-0.187054055963	5.51996827377776	6.05589575513709	0.00144224192187298	0.0304036853420984	0.222273860429706	0.574826302259964
CCDC170	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.632410883193333	-0.637826217209	-1.25883536940426	-0.927896185514	-6.30809859121414	30.7988593086383	5.26974974480284e-07	2.24099244653541e-05	-0.829011590597118	-0.423837381824732
CCDC170	BRD-K51313569-003-03-3::2.5::HTS002	2.5	palbociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.26896307626	-1.29666102163	-0.749498064655102	-0.726050674211	7.13404284041016	37.8480118585361	1.65744650889777e-08	8.64959466290603e-07	0.372039399000057	0.666890624209739
CCDC170	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.53449937189667	-1.54772106844	-2.75867877382016	-2.680907482985	-8.36334455361632	4.33109718609589	0.000784902845763279	0.0178946327017975	-1.61861567768143	-0.829743126165556
CCDC170	BRD-K61443650-236-13-1::2.5::HTS002	2.5	thiomersal	other antibiotic	noncancer	OXCT1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.176016228059967	0.194585488636	-0.17510289366441	-0.0429652749088	-4.75550637394593	7.5460056914224	0.00168541819523854	0.0347474024978146	-0.523180766945256	-0.179057476503497
CCDC170	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.192301044802667	0.165256919355	-0.0829139282925187	0.0393108833872	-5.23150047460282	16.9296590095375	6.86134642886466e-05	0.00201146972883618	-0.38624175667969	-0.164188189510681
CCDC170	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.125278110071333	0.120618047906	-0.201535639911047	-0.1246715830005	-6.38270209492399	6.95235763100667	0.000384047507356302	0.00946516077436488	-0.448058097435241	-0.205569402529519
CCDC170	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.47202638188	-1.46180668388	-0.878836797709868	-0.6850177992955	6.22498991526098	5.6636532139348	0.000988739692033622	0.0219147455484875	0.356621200750296	0.829757967589967
CCDC170	BRD-K75009076-001-02-1::2.429::HTS002	2.429	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.371949340460667	-0.391911824099	-1.9402790887545	-1.72733383121	-15.6465119847243	47.6154175993949	2.14156012031757e-20	3.68377559412154e-18	-1.769907991967	-1.36675150462067
CCDC170	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.631398840431333	0.567602054345	-0.701199122363802	-0.483058782813	-13.1107664039144	10.2513193508402	9.80083245260116e-08	4.6248406401003e-06	-1.55831900628948	-1.10687691930079
CCDC170	BRD-K76674262-001-03-3::0.625::MTS010::PROS003_PR500	0.625	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.08516076708333	-2.07118984664	-1.5923746322449	-1.83860859946	4.25587886136779	32.0838323282055	0.000169093866595333	0.00455698721658633	0.256954784906344	0.728617484770519
CCDC170	BRD-K78789465-001-01-6::2.5::HTS002	2.5	pentagastrin	CCK receptor agonist	noncancer	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.197794591374	-0.211861069409	0.152297532997024	0.188126620199	5.50512594866092	12.5829950770657	0.000113897846957279	0.003186935141944	0.212241708427716	0.487942540314331
CCDC170	BRD-K85402309-001-06-6::2.5::HTS002	2.5	dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB	NA	NA	HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.331536269349	-0.331536269349	-0.163035402769281	-0.1901331802295	4.29177354196177	113.65751467874	3.74447623492595e-05	0.00115724563367764	0.0907219006019351	0.246279832557503
CCDC170	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.06567741561333	-3.02790000969	-4.87064696541737	-5.03472792017	-13.5555450268077	6.76078160876045	3.7639978046845e-06	0.000140082286070537	-2.12210033058426	-1.4878387690238
CCDC170	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.00670457833916667	0.0791220741041	-0.791350138284886	-0.784000908404	-8.58074275329137	3.7070001323221	0.00141230140679064	0.0298517897648945	-1.06453079612175	-0.531578637126358
CCDC170	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.531436246525	0.531122434913	-0.305922283932532	-0.2165693192205	-8.74537446385149	9.0714978575684	1.02469958993654e-05	0.000352241922071384	-1.05369726408825	-0.621019796826809
CCDC171	BRD-A54927599-001-16-9::2.5::HTS002	2.5	KF-38789	P selectin inhibitor	noncancer	SELP	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.01672624822	-2.01672624822	-2.95084121982084	-2.73649504122	-8.68950391963746	19.7643036329332	3.49606311898978e-08	1.74176595125514e-06	-1.15852598896254	-0.709703954239133
CCDC171	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.67050067016	-0.67050067016	-0.213213518493798	-0.0782038921815	7.07298883915445	177.984781499915	3.3417929452062e-11	2.34142902959496e-09	0.329702862432913	0.584871440899492
CCDC171	BRD-A74914197-001-02-9::0.15625::MTS010::PROS005_PR500	0.15625	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.03135260989662	0.03135260989662	-0.403683072358621	-0.2745905537905	-5.6147003061789	14.6654851250817	5.3618355760413e-05	0.0016081680061256	-0.60051239482946	-0.269558969681023
CCDC171	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.407106619787	0.407106619787	0.260613365195046	0.303778240807	-3.90119171224943	192.99481783047	0.000132117077070264	0.00364246475577471	-0.220556093996792	-0.0724304151871172
CCDC171	BRD-K00317371-001-06-1::2.40436::HTS002	2.40436	RITA	MDM inhibitor	targeted cancer	MDM2	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.7182736271455	-0.7182736271455	-2.20509120822945	-1.66399627555	-9.98433841022991	25.8879664415363	2.29255022809768e-10	1.45717674329166e-08	-1.79298119683815	-1.18065396532974
CCDC171	BRD-K00673382-001-18-9::0.15625::HTS002	0.15625	famotidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	heartburn	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.03081258884038	0.03081258884038	0.508561200639952	0.491238275219	10.0037153297515	4.39592040462905	0.000345174388199908	0.00860643106660051	0.349733151610866	0.605764071988278
CCDC171	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-3.202291222935	-3.202291222935	-2.30795660284888	-2.417981872085	12.564786628895	96.8479885572229	4.70002518296613e-22	9.23328778588403e-20	0.753063471273159	1.03560576889908
CCDC171	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.02380482860085	0.02380482860085	-0.342161787052694	-0.229059189804	-8.66252458221251	191.844072026836	1.89328621080649e-15	2.05878305568718e-13	-0.449295093730356	-0.282638137576733
CCDC171	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.71333938559	-2.71333938559	-3.18433332518398	-3.102963726805	-4.27073954568385	111.683536688835	4.10991508116498e-05	0.00126019168731189	-0.68951417098587	-0.252473708202083
CCDC171	BRD-K09426783-300-01-0::2.5::HTS002	2.5	TAS-103	topoisomerase inhibitor	chemo	TOP1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.18198430911	-2.18198430911	-2.71574583404011	-2.622314881585	-5.47303420813046	100.540038037662	3.25727734187787e-07	1.42766665727473e-05	-0.727237021877049	-0.340286027983182
CCDC171	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.91040821767	-2.91040821767	-2.41061527950391	-2.32376274045	7.02182976110787	185.752272937572	3.99856311311529e-11	2.76990314631832e-09	0.35937367284981	0.640212203482361
CCDC171	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-3.130986778245	-3.130986778245	-4.28573042229949	-4.413620661915	-7.93908050390945	20.1444857783915	1.24693761171299e-07	5.80358070316686e-06	-1.45800873220612	-0.851478555902867
CCDC171	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.98794369277	-2.98794369277	-2.05652935356116	-2.351388502545	9.8041832194205	191.090565350932	1.21894675275896e-18	1.77362958976289e-16	0.744027609667913	1.11880106874976
CCDC171	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-3.367427117945	-3.367427117945	-2.59499603654278	-2.674840125005	10.9157974287863	180.624855229985	1.25552083812018e-21	2.38347675565509e-19	0.632803249070482	0.912058913733958
CCDC171	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.1137664075625	0.1137664075625	-0.0960612725621721	-0.0311349339001	-5.21693054978529	135.280460718887	6.67083042052355e-07	2.79794992798511e-05	-0.289370008404198	-0.130285351845146
CCDC171	BRD-K17743125-001-08-4::2.5::HTS002	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-1.189966781685	-1.189966781685	-2.62352537667651	-2.55701566981	-11.8968920430418	16.2383557195179	1.96441599167588e-09	1.13241343485718e-07	-1.68869977338376	-1.17841741659927
CCDC171	BRD-K17743125-001-08-4::2.5::MTS010::PROS003_PR500	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.239720761501	-0.239720761501	-0.681958291410085	-0.635077786673	-5.30832352208886	188.251480051918	3.09441141729972e-07	1.36073472437101e-05	-0.606579044356394	-0.277896015461777
CCDC171	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.3037638787925	0.3037638787925	0.548098156775752	0.548346398175	9.61042823482167	177.386279818639	7.23983322020966e-18	9.84585161328881e-16	0.194162110720571	0.294506445245932
CCDC171	BRD-K25279140-001-01-5::2.5::HTS002	2.5	MK-8745	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.24120011912	-2.24120011912	-1.56502524590068	-1.481480616365	7.61481718445323	26.6027091515489	3.78690284905849e-08	1.87836866636394e-06	0.493850551315969	0.858499195122675
CCDC171	BRD-K25433859-003-25-4::2.5::HTS002	2.5	maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2	neurology/psychiatry	depression, dysthymic disorder	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.0808203207544	0.0808203207544	0.173706930341445	0.1863876312595	3.49791702106622	176.711786202267	0.000593202699131	0.0139638156290003	0.0404811907326567	0.145292028441433
CCDC171	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.05762221479735	0.05762221479735	-0.137263215524186	-0.1059972226705	-5.24628494717813	188.239242708269	4.15528891490244e-07	1.79375411448565e-05	-0.268163960990343	-0.12160689965273
CCDC171	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.0527103278392	0.0527103278392	-0.429455452829624	-0.326694667694	-9.54100732569033	5.94181948843531	8.01854644640102e-05	0.00232024711936099	-0.606117384989728	-0.358214176347921
CCDC171	BRD-K28360340-001-08-3::2.30697::HTS002	2.30697	TW-37	BCL inhibitor	targeted cancer	BCL2, BCL2L1, MCL1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.26804380804	-2.26804380804	-2.77418780579675	-2.74381570724	-5.84215086361941	188.82208506669	2.22003823384029e-08	1.13641885507704e-06	-0.677043935902394	-0.335244059611109
CCDC171	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-1.93255837658	-1.93255837658	-2.31255904277695	-2.045349051995	-3.68485101823465	170.696469150535	0.000307007401369733	0.00773305785969839	-0.583565401815919	-0.176435930577976
CCDC171	BRD-K34332569-001-01-3::2.5::HTS002	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-1.3016339923	-1.3016339923	-0.992729426227776	-0.8949729778575	3.49756734393224	176.750958987439	0.000593900446572579	0.0139784311006543	0.134607463802013	0.483201668342434
CCDC171	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.421858658867	0.421858658867	0.576421231933084	0.571651612309	4.86160522148763	180.388772617752	2.52262310117328e-06	9.67904200951251e-05	0.0918295516094967	0.217295594522672
CCDC171	BRD-K37237504-001-02-7::2.5::HTS002	2.5	CEP-33779	JAK inhibitor	targeted cancer	JAK2	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.296065229117	-0.296065229117	0.195231361377023	0.159444358103	13.4759756042775	63.5013813472301	2.74024026349405e-20	4.65751748956713e-18	0.418453907933207	0.56413927305484
CCDC171	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.258884930335	0.258884930335	-0.0987137916638769	-0.09070553113985	-8.56356383972515	59.7148356372491	5.59186582401069e-12	4.29569537704081e-10	-0.441135695909687	-0.274061748088066
CCDC171	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.1573683002935	0.1573683002935	-0.240473689647523	-0.026104548309	-6.33387236234516	9.06679552262802	0.000131148603528125	0.00362042105172329	-0.539772769468113	-0.255911210413932
CCDC171	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-4.60784573399	-4.60784573399	-3.7614885072524	-3.68976707366	8.12800877503699	57.1453627133004	4.1405180178375e-11	2.86638593748415e-09	0.637855029934413	1.05485942354079
CCDC171	BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500	0.625	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.8576831086695	-0.8576831086695	-1.73085457939881	-1.77978641517	-10.0029484906725	186.969278772552	3.8684513989485e-19	5.90542250630508e-17	-1.0453741270574	-0.700968814401218
CCDC171	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.8187792872385	-0.8187792872385	-1.78577240575717	-1.67706700871	-8.5640792245811	11.009950475973	3.37699936696875e-06	0.000126846985160015	-1.21548484646103	-0.718501390576307
CCDC171	BRD-K41312087-001-02-7::2.5::HTS002	2.5	GW-441756	growth factor receptor inhibitor	targeted cancer	NTRK1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.1956476894985	0.1956476894985	-0.00976822404764072	0.0262867427605	-6.44525891013686	192.053561746565	9.0915842508941e-10	5.43539793838182e-08	-0.268277765354284	-0.142554061737997
CCDC171	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.1290375647029	-0.1290375647029	-0.63511913427941	-0.4291875223905	-5.9187663393006	4.90601579829627	0.00209270814109162	0.0417080196366027	-0.727150582365313	-0.285012556787707
CCDC171	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.372284236208	0.372284236208	0.474944271334302	0.4963205206125	3.3212069707206	43.5628202616092	0.00182044526823396	0.0370324804380521	0.040346433797154	0.164973636455451
CCDC171	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.659120015167	0.659120015167	0.36534534608985	0.394038132066	-5.61598606033467	7.53034074053379	0.000620981014650646	0.014503022762238	-0.41572493736863	-0.171824400785669
CCDC171	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-1.61680182722	-1.61680182722	-0.770629487929694	-0.611397713918	10.5596184236004	32.2276044229986	5.40546193025145e-12	4.16144845563529e-10	0.68299225949003	1.00935241909058
CCDC171	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.2268148785825	0.2268148785825	-0.290033064185363	-0.277245593931	-10.8031930052991	4.43837087514962	0.000235872428345434	0.00612037550785091	-0.644661546341297	-0.389034339194428
CCDC171	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.02064603447279	-0.02064603447279	0.139552486345759	0.155273340434	5.73404964189251	14.6129597637453	4.37438212978268e-05	0.00133517081671061	0.100512179597035	0.219884862040063
CCDC171	BRD-K54256913-001-08-7::2.5::HTS002	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.01080883519	-2.01080883519	-3.35934569022632	-3.39786885204	-10.2096656128698	11.8095543506011	3.28506024524554e-07	1.43837319163071e-05	-1.6368394607436	-1.06023424932903
CCDC171	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.504632428385	-0.504632428385	-0.203936300471261	-0.243848377549	9.12859192447715	12.6188621344519	6.4607704968549e-07	2.71356159086893e-05	0.229314401005063	0.372077854822414
CCDC171	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.038446078746	0.038446078746	-0.144101224618457	-0.139438991422	-9.41383599395671	161.934316087015	4.66820414520317e-17	5.87511172188638e-15	-0.220839891233623	-0.144254715495291
CCDC171	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-3.090568492775	-3.090568492775	-4.0008889081711	-4.1239035813	-8.44660825673713	121.962390281048	7.4291850964604e-14	6.90547486744682e-12	-1.12366945386212	-0.696971376930066
CCDC171	BRD-K66911501-003-01-2::2.5::HTS002	2.5	MK-3207	calcitonin antagonist	noncancer	CALCA	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.147015518381	-0.147015518381	0.200950898085815	0.229755723799	11.720691353208	86.0319574474691	1.61632858519669e-19	2.54725065688693e-17	0.288948509126455	0.406984323807175
CCDC171	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.67570573018	-2.67570573018	-3.13904298594446	-3.04544241525	-3.75087072271239	12.8206119464007	0.00247928401079305	0.0482329547743726	-0.730583173540467	-0.196091337988445
CCDC171	BRD-K69694239-001-02-2::2.5::MTS010::PROS002_PR500	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.910161134035	-2.910161134035	-2.52220941700776	-2.6020166043	6.61012494328569	12.2543153977995	2.2572579355171e-05	0.000728279145057119	0.260369757738449	0.51553367631604
CCDC171	BRD-K70511574-001-06-9::2.5::HTS002	2.5	HMN-214	PLK inhibitor	targeted cancer	PLK1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.22108009064	-2.22108009064	-2.83808784065201	-2.842294760615	-6.50587035162959	189.534080457712	6.7044684181542e-10	4.06380659387605e-08	-0.804082543453483	-0.42993295657053
CCDC171	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.2399567991445	-0.2399567991445	-1.0374896662985	-0.659178147727	-8.01964146346077	149.761703394023	2.81260570252997e-13	2.46856252095637e-11	-0.994034149922629	-0.601031584385368
CCDC171	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.1161101394865	-0.1161101394865	0.245024460402873	0.276258886308	9.65039657527566	75.1159998970145	8.57699454173751e-15	8.7288635476546e-13	0.286588564471204	0.435680635307543
CCDC171	BRD-K73319509-001-08-0::2.5::HTS002	2.5	PF-04217903	c-Met inhibitor	targeted cancer	MET	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.166732442788	-0.166732442788	0.0485842948382231	0.0909616793379	5.48372726012294	10.6917206674645	0.000211204529560094	0.00555153981065557	0.128590791535008	0.302042683717438
CCDC171	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-1.189960887105	-1.189960887105	-0.885375332024671	-0.689609968602	4.7632529484981	69.702058515116	1.00354389388322e-05	0.000345857146216588	0.177041963210872	0.432129146949785
CCDC171	BRD-K76703230-004-04-1::2.5::HTS002	2.5	YM-155	survivin inhibitor	targeted cancer	BIRC5	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-6.209580025475	-6.209580025475	-5.480173405721	-5.502396220135	7.55658902272634	15.9062450391639	1.19603805055766e-06	4.828510818195e-05	0.524682767447429	0.93413047206056
CCDC171	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.385876342156	-0.385876342156	0.00670093164436733	0.03806515271055	12.3291189785326	10.9739235538577	9.01862130029153e-08	4.26983009646606e-06	0.322474347305969	0.462680200294766
CCDC171	BRD-K77677632-003-02-6::2.5::HTS002	2.5	SB-200646	serotonin receptor antagonist	noncancer	HTR2B, HTR2C	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.3345586816395	0.3345586816395	-0.621017246984285	-0.496261939988	-11.788688094988	12.013156466656	5.82811922358663e-08	2.82226607562607e-06	-1.13216625083704	-0.778985606410531
CCDC171	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-5.90950231483	-5.90950231483	-4.11414664289668	-4.24145212342	15.7350586171395	94.1502101551862	4.22539776671522e-28	1.43750044117826e-25	1.56881399090526	2.02189735296139
CCDC171	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-5.50006529734	-5.50006529734	-4.83495848780636	-4.95161811894	5.75273785237873	6.83284654395117	0.000759616698724592	0.0173717336129901	0.390357495933857	0.939856123133416
CCDC171	BRD-K86972824-001-01-4::2.5::HTS002	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.352017861549	-0.352017861549	0.0117921817682373	0.002128528664087	9.7524286000828	7.95822672123679	1.06116928927986e-05	0.000363902964163302	0.27770691566859	0.449913170965884
CCDC171	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-1.933781497495	-1.933781497495	-0.294237340892281	-0.0918736144378	19.7038431073021	19.0152456161869	4.1080369171093e-14	3.92192180136802e-12	1.46539441677155	1.81369389643388
CCDC171	BRD-K89162000-001-06-4::2.5::HTS002	2.5	tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFD, PDGFRB	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.377866165822	-0.377866165822	0.0602513153746172	0.145916428293	9.74879776064057	12.7188452055099	2.90425173188295e-07	1.28316918046329e-05	0.340810454044225	0.53542450834901
CCDC171	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-6.231925566395	-6.231925566395	-5.20785270368917	-5.34898111958	8.4789886650481	4.41447584697746	0.000679331568163394	0.0157252895207789	0.700799412770245	1.34734631264141
CCDC171	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-2.49518448577	-2.49518448577	-3.1137357670482	-3.009227373135	-5.10628558742201	19.6252331405617	5.69651564644112e-05	0.00169951072102739	-0.871544719301964	-0.365557843254443
CCDC171	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.7399755264025	-0.7399755264025	-1.02606000543873	-0.948156981669	-6.66979963519796	51.7019100493922	1.70520648853696e-08	8.87291093667486e-07	-0.372166420131598	-0.200002537940858
CCDC171	BRD-K92213669-001-01-3::2.5::HTS002	2.5	lomitapide	microsomal trigylceride transfer protein inhibitor	noncancer	MTTP	endocrinology	hypercholesterolemia	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.05321523629605	-0.05321523629605	0.23027517761348	0.233495634758	7.10904972469491	147.661172350089	4.6445094750158e-11	3.20349215473987e-09	0.204686297804861	0.362294530014198
CCDC171	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.2728487447265	-0.2728487447265	-0.0315511898707285	0.0202365059018	4.36773397514072	45.9140479774051	7.09085232747866e-05	0.00207336328580651	0.130088555670131	0.352506554041412
CCDC171	BRD-K95785537-001-23-1::2.5::HTS002	2.5	PP-2	src inhibitor	targeted cancer	ABL1, LCK, LYN, RIPK2, SRC	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.1145203766805	0.1145203766805	-0.277334757578785	-0.127481786851	-4.59582542674472	63.0671886585712	2.12116772988551e-05	0.000687683797275197	-0.562236644189786	-0.221473624328785
CCDC171	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-5.75071827633	-5.75071827633	-4.61713235807966	-4.61970061714	8.64899918002379	3.76569850056202	0.00128282433738621	0.0274836522798529	0.760583877995367	1.50658795850531
CCDC171	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-1.379201293035	-1.379201293035	-0.604123179402214	-0.5106967244835	12.732509645984	168.5163661605	1.89404305687833e-26	5.47838534868658e-24	0.654904340987827	0.895251886277746
CCDC171	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	0.309161905564	0.309161905564	0.0920498200011471	0.162270559212	-6.95609182558391	52.1706709113589	5.72362275883355e-09	3.14226009804825e-07	-0.279738250041169	-0.154485921084536
CCDC171	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	NCIH358, ONS76	LUNG, CENTRAL_NERVOUS_SYSTEM	carcinoma (bronchioloalveolar_adenocarcinoma), primitive_neuroectodermal_tumour-medulloblastoma	-0.2969193980865	-0.2969193980865	-0.0195704111137844	0.015242959648	7.9119761577513	7.55706830537395	6.47576413989762e-05	0.00190966435379763	0.195681399881892	0.35901657406354
CCDC26	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4914954077455	0.4914954077455	-0.0126602965603725	0.0633629143304	-14.7889968166649	44.3604424987361	9.26941222037723e-19	1.36075606286386e-16	-0.572843658146668	-0.435467750465077
CCDC26	BRD-A69651145-003-07-2::2.5::HTS002	2.5	minocycline	bacterial 30S ribosomal subunit inhibitor	noncancer	ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA	endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.2292628515185	0.2292628515185	0.0858146008780532	0.0503507635315	-3.49065302885137	91.720063634415	0.000742795362515752	0.0170379481220718	-0.225069709872199	-0.0618267914086948
CCDC26	BRD-A90547603-001-02-5::2.5::HTS002	2.5	eptifibatide	platelet aggregation inhibitor	noncancer	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.3890810619395	-0.3890810619395	0.0489299312457249	0.04774642890375	12.1306779652866	3.6750108414112	0.000425848865320393	0.010388317943917	0.334164890327244	0.541857096043206
CCDC26	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.72943766678	-3.72943766678	-2.75094144245877	-2.614624073445	9.25795222880248	70.196455934488	8.69226477160012e-14	8.0129222203539e-12	0.767709527951916	1.18928292069054
CCDC26	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.8311233946405	0.8311233946405	0.250875129708126	0.2240846909	-15.9458971444414	4.43766986372896	4.35487811514468e-05	0.0013305440791744	-0.677468157958129	-0.483028371906619
CCDC26	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.616940688695	-0.616940688695	0.0225796184336189	0.2036144024465	9.19059864143021	17.6480112306105	3.81733105932824e-08	1.89127311284041e-06	0.493120079785386	0.785920534471852
CCDC26	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.551987603395	0.551987603395	0.274574787912147	0.25640594941	-9.79725209706534	73.868603359726	5.36749527122163e-15	5.58180443467084e-13	-0.333834088841615	-0.22099154212409
CCDC26	BRD-K13044802-213-20-7::2.5::HTS002	2.5	ciclopirox	membrane integrity inhibitor	noncancer	ATP1A1	infectious disease	onychomycosis	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.038556522345	-3.038556522345	-1.60321322671965	-1.63543004783	15.6410404166879	3.30430957697285	0.000326259054826341	0.00817283508203305	1.1579387236045	1.71274786764621
CCDC26	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.53786629707	-3.53786629707	-2.0508009930997	-2.351388502545	15.4295942888896	161.659488008045	1.34301082533693e-33	7.4571545902497e-31	1.29674417020011	1.67738643774048
CCDC26	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.115762663955	-1.115762663955	-0.814435384891424	-0.7654167490095	4.28339394101422	20.3494687736578	0.000350624724151854	0.00873115446761272	0.154745756804207	0.447908801322946
CCDC26	BRD-K19687926-379-07-4::2.5::HTS002	2.5	lapatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2	oncology	breast cancer	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.49139216237	-2.49139216237	-0.639926612008895	-0.498501703786	32.7025011003799	69.8075047804915	4.60523531319338e-44	6.80714123752706e-41	1.73854419855227	1.96438690216994
CCDC26	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.99460978122	-3.99460978122	-3.1223906694569	-3.13313730075	7.43972230550164	190.996697022169	3.3354435619209e-12	2.63696895309091e-10	0.640971336140853	1.10346688738534
CCDC26	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.03134006434596	0.03134006434596	-0.21317448842916	-0.0984348398408	-4.00842533828243	11.2884234713449	0.0019544860533754	0.0393151610824867	-0.378357634223764	-0.110671471326476
CCDC26	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.962903739675	-1.962903739675	-0.676377810729522	-0.601202853428	26.2200547749617	122.230413580692	5.09598825149494e-52	1.58292473326762e-48	1.18939575482372	1.38365610306723
CCDC26	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.1895503072085	0.1895503072085	-0.208992118934973	-0.158031671069	-8.17057398131506	3.67337065327385	0.00174483498833742	0.0357556877536447	-0.538855197459116	-0.258229654827829
CCDC26	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.6059659839325	-0.6059659839325	-1.75164394477839	-1.65992199057	-11.3743251575555	5.10593276182654	8.05520105187324e-05	0.00233022430320818	-1.40299218678282	-0.88836373490896
CCDC26	BRD-K46937689-001-15-0::0.625::HTS002	0.625	phenazone	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.295212732859	0.295212732859	0.0912265419309256	0.0795356739513	-5.57623902858996	13.4710446303741	7.87207630000567e-05	0.00228217806209105	-0.282735336693604	-0.125237045162545
CCDC26	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.47569610606	-1.47569610606	-0.666209128288141	-0.568122839674	12.1781800452009	6.64980866228826	8.61141214854443e-06	0.000299963490067508	0.650616136695634	0.968357818848083
CCDC26	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.6427995359095	0.6427995359095	0.222695310283733	0.2005091684065	-12.7527072270132	12.6960502758229	1.31130147153932e-08	6.92753101044001e-07	-0.491445443541086	-0.348763007710448
CCDC26	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.289927754845	-1.289927754845	-2.01578739322694	-2.23082742718	-7.16892656308961	12.0135167445785	1.1272077532047e-05	0.000384030059667158	-0.946438681692026	-0.505280595071859
CCDC26	BRD-K59753975-001-02-6::2.5::MTS006	2.5	vindesine	tubulin polymerization inhibitor	chemo	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.393051954535	-3.393051954535	-2.40233540832621	-2.27131346061	8.92346500803982	12.6864903867424	7.97601275161233e-07	3.31040053648396e-05	0.75026039883682	1.23117269358077
CCDC26	BRD-K60866521-001-07-1::2.5::MTS010::PROS003_PR500	2.5	idelalisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.4549162540905	-0.4549162540905	-0.00675151653634667	0.00998791590484	14.9360843067939	3.15330044905753	0.000494943866201046	0.0118764917038742	0.355247148047633	0.541082327060674
CCDC26	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.10977218903505	0.10977218903505	0.256801817809719	0.250852150231	5.91476808148875	8.95539084279568	0.000229357792740238	0.00597012707799642	0.0907540744142888	0.203305183135048
CCDC26	BRD-K68336408-001-10-9::2.5::HTS002	2.5	tyrphostin-AG-1478	EGFR inhibitor	targeted cancer	EGFR, MAPK14	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-5.009521213585	-5.009521213585	-2.61731167596092	-2.53878806693	16.6387471366098	3.33422706794865	0.000252161433816251	0.00649351290981657	1.95954216891098	2.82487690633717
CCDC26	BRD-K71035033-001-07-1::2.5::HTS002	2.5	masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor	noncancer	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.570244800283	0.570244800283	0.275304729673881	0.3093136114795	-7.82066120765283	160.082344841083	6.65775976567575e-13	5.63789408462077e-11	-0.369419108497753	-0.220461032720484
CCDC26	BRD-K72951360-001-01-4::2.5::HTS002	2.5	valrubicin	DNA inhibitor, topoisomerase inhibitor	chemo	TOP2A	oncology	bladder cancer	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-4.039041840815	-4.039041840815	-3.27906596435107	-3.154872737575	6.67770747871676	41.6353147018038	4.38296544238553e-08	2.1511257162836e-06	0.530242617603614	0.989709135324247
CCDC26	BRD-K80608265-001-01-6::2.5::HTS002	2.5	erteberel	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.372709466372	-0.372709466372	0.00877080506540031	0.0577771714578	7.64728632113201	12.4348215587308	4.79236375907183e-06	0.000175314072934073	0.273211539092738	0.489749003782063
CCDC26	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.3232202643615	-0.3232202643615	-0.619626019579781	-0.529789535968	-5.45983244948324	103.380732846058	3.29425287965114e-07	1.44210360588797e-05	-0.40406934799566	-0.188742162440902
CCDC26	BRD-K81528515-001-13-8::2.5::HTS002	2.5	nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	targeted cancer	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.706839838007	0.706839838007	0.184814669496563	0.2214201178065	-10.0811389927612	140.053890791323	2.62441442457958e-18	3.70301592630491e-16	-0.624401332535796	-0.419649004485079
CCDC26	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.158683802639	0.158683802639	-0.105604170845125	-0.0756772814281	-8.6423591532148	184.175620249357	2.62143731862307e-15	2.80364290949683e-13	-0.324621171523425	-0.203954775444825
CCDC26	BRD-K88677950-001-03-9::2.5::HTS002	2.5	PD-198306	MAP kinase inhibitor, MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.12647322372	0.12647322372	-0.673588493493057	-0.5546333344115	-16.7309111306614	151.403574899603	3.04896623778993e-36	2.23795166020301e-33	-0.8945411529889	-0.705582281437214
CCDC26	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.484371663206	0.484371663206	-0.371414596970128	-0.291376214184	-12.3318478354815	12.3438343567576	2.64013284277718e-08	1.33709128558504e-06	-1.00652230303394	-0.705050217318317
CCDC26	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	NCIH2122, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.06402694039245	-0.06402694039245	-0.219302375656778	-0.147984722712	-3.17077771381019	144.34272927992	0.00185704734714059	0.0376412994954886	-0.252067896412759	-0.0584829741158966
CCPG1	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.752034607568	0.752034607568	0.247069827028431	0.251620004261	-18.6070610937494	103.268750004876	9.28489587662018e-35	5.75150996630094e-32	-0.55878561576317	-0.451143945315969
CCPG1	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.1881641924635	0.1881641924635	-0.222861438298556	-0.093015492892	-5.42635862275191	12.7559644597513	0.000123773419957078	0.00343674482782493	-0.574983987668748	-0.247067273855364
CCPG1	BRD-A64092382-003-18-3::2.5::HTS002	2.5	mexiletine	sodium channel blocker	noncancer	AHR, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.90040651698	-1.90040651698	-3.10108296380631	-3.114732961095	-12.4782212045383	173.812460068432	6.29355370852079e-26	1.72713325581761e-23	-1.39058995231079	-1.01076294134184
CCPG1	BRD-A73556557-001-06-4::2.5::HTS002	2.5	tagatose	phosphorylase inhibitor	noncancer	PYGL	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.213402480184	-0.213402480184	0.118266671704417	0.145010239158	10.7687248034118	45.950599646769	3.7147808576233e-14	3.57033751763921e-12	0.269671584174007	0.393666719602827
CCPG1	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.55233611668	-1.55233611668	-1.12054881449749	-1.02154011458	7.6885421820052	193.518782951198	7.32781186459136e-13	6.1857526156991e-11	0.321023343442014	0.542551260923014
CCPG1	BRD-K00312224-001-09-5::2.5::HTS002	2.5	PPT	estrogen receptor agonist	noncancer	ESR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.2518782555175	-0.2518782555175	0.167191510313509	0.257314113773	8.59077794088581	20.4764298389234	3.15817547904847e-08	1.58336512806779e-06	0.31746521413111	0.520674317530907
CCPG1	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.73694744356	-2.73694744356	-2.3134964097462	-2.417981872085	6.13212400156808	167.959547937914	6.00457394087142e-09	3.28271221614575e-07	0.287124335171196	0.559777732456398
CCPG1	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.354827132855	0.354827132855	-0.36673556672978	-0.264963110089	-10.7406140567884	26.5268536317323	3.70086061677425e-11	2.57784125814952e-09	-0.859521383229461	-0.5836040159401
CCPG1	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.818229562975	-1.818229562975	-1.44975669905641	-1.361653967605	4.41733732861778	14.930544198866	0.000504588393182718	0.0120862679618304	0.19060561226576	0.546340115571419
CCPG1	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.5982153058795	-0.5982153058795	-1.22772467946564	-1.264129385735	-8.03220845727025	41.4266796550689	5.56453264620742e-10	3.39686903312159e-08	-0.787737641557368	-0.47128110561492
CCPG1	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.36679873139	-1.36679873139	-2.50166448440748	-2.37307934162	-8.70914094206716	7.94959230580477	2.45198251913656e-05	0.000786487520718379	-1.43568719995464	-0.834044306080328
CCPG1	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.402724862035	-2.402724862035	-3.18760295174771	-3.102963726805	-6.50441944156635	19.1766068836925	2.98943256375855e-06	0.000113442296734739	-1.03728268294481	-0.532473496480616
CCPG1	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.9710596117505	0.9710596117505	0.00493517065089117	0.1859491052615	-15.7622646429956	175.508174067339	1.9121722195959e-35	1.26102756816545e-32	-1.08709162700268	-0.845157255196538
CCPG1	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.1948325447345	-0.1948325447345	-0.475669037619292	-0.33490377325	-3.68472708644214	17.2933349928331	0.00179358360432198	0.0365589139639302	-0.441431434294903	-0.12024155147468
CCPG1	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.6230032959255	0.6230032959255	0.504395080495788	0.505306635797	-5.1654827915795	185.65167427383	6.15063253731896e-07	2.5929561783852e-05	-0.163907596966398	-0.0733088338930268
CCPG1	BRD-K16551357-001-03-2::2.5::HTS002	2.5	evacetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.5101636149645	-0.5101636149645	0.0659444332821947	0.05179178276535	14.5380329969509	6.74882700356203	2.41597906137169e-06	9.30316881503293e-05	0.481691930814003	0.670524165679386
CCPG1	BRD-K16803204-001-01-6::2.5::HTS002	2.5	filgotinib	JAK inhibitor	noncancer	JAK1, JAK2, JAK3, TYK2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.06944217738815	0.06944217738815	0.245257745388007	0.2325578097185	4.98213569765337	9.07226664476397	0.000739273680973183	0.0169686567594481	0.0960826864754883	0.255548449524226
CCPG1	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-3.556163996675	-3.556163996675	-2.344612042611	-2.27083369545	10.0868527072805	4.70372601630784	0.000230991583527658	0.00600973477857482	0.896852100399542	1.52625180772847
CCPG1	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.619033997475	-2.619033997475	-0.857229424467029	-0.775615128041	23.7661379719147	72.6924180923471	5.25480792328937e-36	3.70479515589042e-33	1.61405142223601	1.90955772377994
CCPG1	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-3.96816086171	-3.96816086171	-3.08049597850782	-2.85883819524	6.51293514099468	5.17158073616775	0.0011211310210728	0.0244342571645098	0.540781074426257	1.23454869197811
CCPG1	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.137386287504	0.137386287504	-0.115305339616559	-0.0402228786984	-4.49895914304978	100.594145278705	1.83636024494645e-05	0.000603380737297451	-0.364116674089461	-0.141266580151657
CCPG1	BRD-K21728777-001-02-3::2.5::HTS002	2.5	AMG900	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.98684763157	-1.98684763157	-1.53850066454733	-1.382083596445	4.8405737557101	23.6774024233777	6.4428698084745e-05	0.00190106919691949	0.257045204044959	0.639648730000372
CCPG1	BRD-K21782625-001-02-4::2.5::HTS002	2.5	AMG458	MET inhibitor	targeted cancer	MET	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.134510480732	-0.134510480732	0.0293578517103815	0.0127189864736	3.77817505837613	167.64859646491	0.000219210447098499	0.00573112088016382	0.0782419785284181	0.249494686356345
CCPG1	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.20876706436	-2.20876706436	-3.09316602536837	-2.9100349769	-8.51708310907579	54.1237848112552	1.43093698407531e-11	1.05139284490873e-09	-1.09257120348291	-0.676226718533835
CCPG1	BRD-K33610132-001-02-9::2.5::HTS002	2.5	rociletinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.3134878385965	-0.3134878385965	0.203712700982998	0.245890456129	12.8511148758779	180.901939104138	2.82287231009317e-27	8.65555649999942e-25	0.437789405221553	0.596611673937443
CCPG1	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.646415451826	0.646415451826	0.0361949380208365	0.143970790547	-11.0792902836604	5.44430897331837	6.11501780708601e-05	0.00181426585212478	-0.748396219075751	-0.472044808534576
CCPG1	BRD-K35960502-001-20-0::2.5::HTS002	2.5	niclosamide	DNA replication inhibitor, STAT inhibitor	noncancer	STAT3	infectious disease	tapeworm	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.482809568515	-0.482809568515	-0.705311394635876	-0.681426229631	-3.91693983005007	178.447701747253	0.000127560394380041	0.00353137325847066	-0.334597832336571	-0.11040581990518
CCPG1	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.0909006111634	-0.0909006111634	-0.51241481841267	-0.4097580139535	-8.66420473436366	191.014443037922	1.91308170467729e-15	2.07820014537141e-13	-0.517474584065765	-0.325553830432775
CCPG1	BRD-K37764012-001-04-1::2.5::HTS002	2.5	PF-03758309	p21 activated kinase inhibitor	targeted cancer	PAK4	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.236855646645	-4.236855646645	-3.18731041598534	-3.08603561013	11.070925336085	180.800467023623	4.4370979408292e-22	8.74883868040461e-20	0.862484720148546	1.23660574117077
CCPG1	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2375681340715	0.2375681340715	0.0878633265045058	0.1179670530315	-5.31413638858304	168.606676903784	3.35533339689859e-07	1.46794295085503e-05	-0.205318227663006	-0.0940913874709828
CCPG1	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.10129969818835	0.10129969818835	0.257756944424277	0.300751796019	4.55904414672915	41.1787835306681	4.541321529809e-05	0.00138042391456876	0.0871597899303719	0.225754702541482
CCPG1	BRD-K40718343-001-02-6::2.5::HTS002	2.5	AEE788	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.03516244558671	0.03516244558671	-0.396936192779682	-0.1963749895675	-5.69294919868405	11.2404712783533	0.000128619083297385	0.00355884320992064	-0.59871987508682	-0.265477401645965
CCPG1	BRD-K41859756-001-06-8::2.5::HTS002	2.5	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.691470365085	-4.691470365085	-3.97954603500754	-3.96236214096	6.40982588089279	8.55856485623293	0.000154461882374685	0.00419682644912016	0.458682458962241	0.965166201192672
CCPG1	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.48463033503	-1.48463033503	-2.29643302808746	-2.14029239454	-9.01767118181558	61.9988968698844	6.93212321201876e-13	5.85935361269501e-11	-0.991757251446996	-0.631848134667924
CCPG1	BRD-K42673188-001-01-1::2.5::MTS006	2.5	verubulin	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.613521058825	-1.613521058825	-2.47285091986537	-2.30487473877	-8.77986664967907	190.999591884793	9.21717119414938e-16	1.02623744668615e-13	-1.0523846736357	-0.666275048445037
CCPG1	BRD-K42898655-001-01-8::2.5::HTS002	2.5	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.797140436264	-0.797140436264	-1.35067642251555	-1.32952488095	-8.41123265637793	5.27650295009832	0.000298434133850403	0.0075365959083331	-0.720071877241574	-0.38700009526153
CCPG1	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.272262358322	-0.272262358322	-0.895632589606309	-0.852653660565	-9.53416390859855	30.9549773626576	1.00335878300134e-10	6.64756984859027e-09	-0.756727170929767	-0.490013291638851
CCPG1	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.216693619585	-2.216693619585	-1.57878600925935	-1.40747957336	7.16147042336738	43.4683373497683	7.08623772024472e-09	3.8362875583287e-07	0.458326810263278	0.817488410388017
CCPG1	BRD-K51350053-048-16-5::2.5::HTS002	2.5	toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	ESR1	oncology	breast cancer	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.05916247877855	-0.05916247877855	-0.507870191230488	-0.436805913717	-6.75031857782082	145.485706130323	3.26777261472305e-10	2.04908846325622e-08	-0.580083398691723	-0.317332026212152
CCPG1	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.0483718683154	0.0483718683154	0.259853824408923	0.257282112096	5.57807014056352	6.63227667064329	0.00100482306970659	0.0222183765301913	0.120814166170792	0.302149746016253
CCPG1	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.532742231906	-0.532742231906	-0.764955680192532	-0.6098527820225	-3.38585782648481	161.659262761285	0.000890807906160095	0.0199922479287316	-0.367648206364339	-0.0967786902087248
CCPG1	BRD-K53972329-001-07-0::2.5::HTS002	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.3255873032235	0.3255873032235	0.558033725757516	0.4808891597695	4.68455575439414	161.205572654157	5.92772032113062e-06	0.000213387732965374	0.1344579114588	0.330434933609233
CCPG1	BRD-K54247840-004-01-3::2.5::HTS002	2.5	halofuginone	collagenase inhibitor	noncancer	COL1A1, MMP2	rheumatology	scleroderma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.539290434325	-4.539290434325	-5.72667622218759	-5.5836707127	-7.98789665818678	6.01371931637543	0.00020283221467053	0.00534984318706866	-1.55091357612472	-0.823857999600455
CCPG1	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.6674830612795	-0.6674830612795	-1.30175969454069	-1.05786698502	-7.46110043283624	63.9144505033215	2.89500695299259e-10	1.8249527800822e-08	-0.804110281209185	-0.464442985313197
CCPG1	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.6372946129855	0.6372946129855	0.230332775355032	0.271076937361	-8.32365714578142	5.6250665666288	0.000227860673162409	0.00593187783532442	-0.528556522465541	-0.285367152795396
CCPG1	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.266695130595	-2.266695130595	-1.02589787951385	-1.108311362665	13.9665934142775	16.8158603611245	1.11364036262151e-10	7.33063345455485e-09	1.053203992283	1.42839050987931
CCPG1	BRD-K60866521-001-07-1::2.5::MTS010::PROS003_PR500	2.5	idelalisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.349497515691	0.349497515691	-0.0152638315604895	0.000732567672741	-16.8426838591384	37.3097346002703	5.04062237574812e-19	7.57078873981583e-17	-0.408630225194083	-0.320892469308896
CCPG1	BRD-K63923597-001-10-0::2.5::HTS002	2.5	barasertib-HQPA	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.740718539835	-1.740718539835	-1.16192235676901	-0.996883336969	7.38876401670639	63.1119537251173	4.14781047596828e-10	2.56786849076778e-08	0.422262326558733	0.73533003957325
CCPG1	BRD-K66030860-001-03-6::2.5::HTS002	2.5	salidroside	beta amyloid protein neurotoxicity inhibitor	noncancer	APP	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.4095146623045	0.4095146623045	0.130244451701271	0.132086067756	-9.17914164191187	19.8740619500735	1.38395024169536e-08	7.29514686060809e-07	-0.342760264020745	-0.215780157185712
CCPG1	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.37911854124	-4.37911854124	-2.60627799134352	-2.56925440076	13.5303716378792	182.659135790291	2.40354567288194e-29	9.33241921237524e-27	1.51432001023383	2.03136108955914
CCPG1	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.054043908735	-1.054043908735	-1.76501614335591	-1.7012260142	-10.4612288738239	47.1171036108037	7.10549134336301e-14	6.621360235355e-12	-0.847686365858882	-0.574258103382944
CCPG1	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.185502657631	0.185502657631	-0.0813776955933777	0.0411624842104	-6.25142698667273	187.65469465316	2.67486730356782e-09	1.52029073006202e-07	-0.351096515890513	-0.182664190558242
CCPG1	BRD-K70401845-003-09-6::2.5::HTS002	2.5	erlotinib	EGFR inhibitor	targeted cancer	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.5005911987575	-0.5005911987575	-1.09473065455635	-1.05295046381	-8.99438023501981	89.0160054847061	3.85311936649346e-14	3.69501217315963e-12	-0.725392470188348	-0.46288644140936
CCPG1	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.3045933160685	0.3045933160685	0.102806574857888	0.0827932765815	-5.46488539676306	180.118026286638	1.52528502297733e-07	7.01529643110962e-06	-0.274646467023353	-0.12892701539787
CCPG1	BRD-K70821460-300-02-4::2.5::HTS002	2.5	4-methylhistamine	histamine receptor agonist	noncancer	HRH4	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2343700832395	0.2343700832395	0.479435235220047	0.473971299308	7.87333498512574	53.8166817587548	1.61497820310885e-10	1.04446790372395e-08	0.182656480036986	0.307473823924109
CCPG1	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.1963797639	-1.1963797639	-0.885302802343372	-0.689609968602	4.94337277495894	102.779575446062	2.99653361287993e-06	0.000113671513754857	0.186270773989489	0.435883149123768
CCPG1	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.33779420376	-2.33779420376	-2.63366851116646	-2.52531204565	-3.75888932982745	193.000479725543	0.000226074794985593	0.00589397697779676	-0.451122895006364	-0.140625719806557
CCPG1	BRD-K76180386-001-01-6::2.5::HTS002	2.5	JIB04	histone lysine demethylase inhibitor	noncancer	KDM4E	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.687915479236	-0.687915479236	-1.70673990509342	-1.602559897845	-12.1439307937401	38.9258970499101	8.18944888126813e-15	8.35031583859809e-13	-1.18852996755471	-0.849118884160138
CCPG1	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2930648267905	0.2930648267905	0.093294469321128	0.1896034324075	-4.48730558434046	112.50154297707	1.75094486618288e-05	0.000577973605766381	-0.287974755370919	-0.111565959567825
CCPG1	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.352625072191	0.352625072191	0.500205198196242	0.518013519807	5.10631652389758	186.079021318962	8.08548748799247e-07	3.34935146465778e-05	0.0905634333628976	0.204596818647586
CCPG1	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2471770773005	0.2471770773005	0.0197384590600814	0.0259313359155	-7.7898617161781	38.9811521277255	1.81543621645452e-09	1.05133917545658e-07	-0.286495525367542	-0.168381711113296
CCPG1	BRD-K79930101-300-03-7::2.5::HTS002	2.5	GW-583340	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.0609331315514	-0.0609331315514	-0.532311707328592	-0.365507892562	-5.70323454120012	6.90757599091719	0.000768349366767157	0.0175471019104782	-0.667348714647498	-0.275408436906886
CCPG1	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.5506207716705	-0.5506207716705	-1.71193391757385	-1.55120007366	-15.6679318377617	21.0132996549835	4.57971355629527e-13	3.93728610833217e-11	-1.31544898539118	-1.00717730641553
CCPG1	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.06642317582	-4.06642317582	-2.76152998530541	-2.642391718485	11.4554555028085	7.23901025555516	6.7181680679656e-06	0.000238789095164013	1.03733076280283	1.57245561822636
CCPG1	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-5.394262055845	-5.394262055845	-4.8360900732769	-4.95161811894	5.1179652901546	10.6289238235951	0.000372847800765165	0.00923625708393402	0.317103240675362	0.79924072446084
CCPG1	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.235464308741	0.235464308741	0.00310880930025736	0.041364371782	-7.10146985320958	158.134447473453	3.95157396797555e-11	2.74089610673862e-09	-0.296978810296176	-0.167732188585309
CCPG1	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.01755169112	-1.01755169112	-0.776288935874609	-0.768623385632	4.99248618433449	188.878327634394	1.34986801860624e-06	5.40718543272844e-05	0.145936362403078	0.336589148087704
CCPG1	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-6.000781723495	-6.000781723495	-6.21667575773106	-6.19873542132	-3.3677919888223	36.9259497488865	0.00178279152040732	0.0363839196131574	-0.345792935136705	-0.0859951333354109
CCPG1	BRD-K89162000-001-06-4::2.5::HTS002	2.5	tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFD, PDGFRB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2733417700495	0.2733417700495	0.0531342887530708	0.117993019303	-4.5850768865964	7.51599527866561	0.00210428609080813	0.0419153841595554	-0.332211720489044	-0.108203242103814
CCPG1	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.283191638327	0.283191638327	0.101137225597112	0.1180798290625	-6.76428777445779	15.8962740004939	4.70374714902445e-06	0.000172362698359251	-0.239139932827704	-0.124968892632072
CCPG1	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.8426320976815	-0.8426320976815	-1.02500711752817	-0.948156981669	-4.26767197132123	57.0911584753794	7.52863426754541e-05	0.00218942286828866	-0.267945570517126	-0.0968044691762229
CCPG1	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.32071283012	0.32071283012	-0.369736044835912	-0.291376214184	-9.95191158450815	12.6133174622219	2.46918904255657e-07	1.09956122647436e-05	-0.840800480519685	-0.54009726939214
CCPG1	BRD-K95523387-001-09-6::2.5::HTS002	2.5	OLDA	TRPV agonist	noncancer	GPR119	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.770468781433	0.770468781433	0.270618345302184	0.3623330707505	-8.28876150865786	8.17926460548985	2.96564159210891e-05	0.000933230064300558	-0.638384356159777	-0.361316516101856
CCPG1	BRD-K95763993-001-19-3::2.5::HTS002	2.5	trapidil	PDGFR tyrosine kinase receptor inhibitor	noncancer	PDGFRA	cardiology	coronary artery disease (CAD)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.204510328808	0.204510328808	0.395517182531919	0.422554855711	7.12511321877837	74.5550214328849	5.55266385824252e-10	3.39155569128886e-08	0.137598243831937	0.244415463615901
CCS	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.80707022783	-1.80707022783	-1.2060775810369	-1.08580167806	8.62413058907161	144.583099519784	1.04674919794563e-14	1.05476590901029e-12	0.463255112129858	0.738730181456349
CCS	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-5.17686418634	-5.17686418634	-3.7920421832222	-3.74224322709	13.9076847008211	190.702088864991	8.12850376707784e-31	3.46356676718494e-28	1.18841720755316	1.58122679868243
CCS	BRD-A45498368-001-07-1::2.5::HTS002	2.5	WYE-125132	mTOR inhibitor	targeted cancer	MTOR	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-2.954568866115	-2.954568866115	-2.33546944836756	-2.38754178221	8.73829486627443	50.0674788251064	1.21239293659451e-11	8.99449517851733e-10	0.476799773159302	0.761399062335571
CCS	BRD-A58193911-003-18-7::2.5::HTS002	2.5	oxyphencyclimine	cholinergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.32700699304	-4.32700699304	-2.2800712355236	-2.128802868855	15.8870432434749	13.6057650764627	3.5758014510332e-10	2.23635234665449e-08	1.7698417186322	2.32402979640059
CCS	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.00014968509915	-0.00014968509915	0.145665669345003	0.138064341376	4.88474732806016	18.7997951904922	0.000105889623857401	0.00298424946636857	0.0832911029525942	0.208339605935711
CCS	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.440064014178	0.440064014178	-0.191611848873977	-0.136086260588	-14.0440050872196	187.708130063029	4.2995508602441e-31	1.88064987005155e-28	-0.72040382583683	-0.542947900267124
CCS	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.733774456378	0.733774456378	-0.194768047823236	-0.138056758361	-20.2226219600671	159.695831181747	6.75934571798449e-46	1.13181547530461e-42	-1.0192234584055	-0.837861549996974
CCS	BRD-K00317371-001-06-1::2.40436::HTS002	2.40436	RITA	MDM inhibitor	targeted cancer	MDM2	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-5.52065971628	-5.52065971628	-2.15427230781533	-1.66153106221	24.1543488699546	71.3743499270139	4.43144024725112e-36	3.14498727401684e-33	3.08851712327806	3.64425769365129
CCS	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-5.45718553444	-5.45718553444	-2.73312960877156	-2.614624073445	23.9055103944276	15.0291933057472	2.25416939552501e-13	2.00138306699867e-11	2.48121628207792	2.96689556925896
CCS	BRD-K02389548-001-02-5::2.5::HTS002	2.5	RG2833	HDAC inhibitor	noncancer	HDAC1, HDAC3	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.608801758934	0.608801758934	0.313990579880787	0.3525103772395	-7.62718133768955	77.0241288741462	5.28642475438615e-11	3.60609207887597e-09	-0.371778160081513	-0.217844198024914
CCS	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.789611622966	-0.789611622966	-0.375229520469853	-0.261056095384	7.20195675719232	188.335663575302	1.38109844576633e-11	1.01718591864427e-09	0.300881465984814	0.527882739007479
CCS	BRD-K05638300-001-01-2::2.5::HTS002	2.5	sevoflurane	membrane integrity inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.724793507471	0.724793507471	-0.589203217542097	-0.439418069219	-19.2765967883493	8.57266137452637	2.33242933220024e-08	1.19167400796459e-06	-1.46937727682814	-1.15861617319805
CCS	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.26563749887	-4.26563749887	-3.01637930906471	-2.91986435367	13.1139621979208	190.037924446181	2.12192669869571e-28	7.55465826253742e-26	1.06135206373881	1.43716431587176
CCS	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.59443519845	-1.59443519845	-0.292104099150884	-0.169768923228	15.1027022555369	2.6491405741917	0.00120778175277772	0.0261081851024807	1.00615077257038	1.59851142602786
CCS	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.7830698072455	-0.7830698072455	-0.41809099416248	-0.37916191768	5.55674924682292	6.02639300812536	0.00141630078058662	0.0299304210217264	0.2044310362082	0.52552658995784
CCS	BRD-K13044802-213-20-7::2.5::HTS002	2.5	ciclopirox	membrane integrity inhibitor	noncancer	ATP1A1	infectious disease	onychomycosis	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-2.53644498012	-2.53644498012	-1.60847093920368	-1.63543004783	12.1906324066065	8.80802081867101	8.17961304378644e-07	3.38441753679866e-05	0.755200519460075	1.10074756237257
CCS	BRD-K15071410-001-01-1::2.5::HTS002	2.5	tiotidine	histamine receptor antagonist	noncancer	HRH2	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	1.09098130602	1.09098130602	0.371306330072063	0.358823468762	-17.3053868903635	3.44310090583518	0.000180535411446631	0.0048322377599339	-0.842889988261754	-0.59645996363412
CCS	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-5.419540773365	-5.419540773365	-3.6600095318482	-3.56303502077	17.9541138445224	70.1530368500421	6.14779157529537e-28	2.04604040456752e-25	1.56408078078493	1.95498170224868
CCS	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-2.980816531605	-2.980816531605	-2.73823000000926	-2.77483229013	4.61811461495196	16.5900959237796	0.00026055467111052	0.00668235277066492	0.131550342879834	0.353622720311647
CCS	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.08660757432525	0.08660757432525	-0.0715570995736089	0.0407112965926	-3.83126227476846	188.007070882451	0.000173672408319858	0.00466687983986796	-0.239601404944283	-0.0767279428534349
CCS	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-3.831259955635	-3.831259955635	-1.10180539473508	-0.868089738117	20.6936658002146	3.56188467191094	7.6980389495723e-05	0.00223353592801256	2.34477964537969	3.11412947642014
CCS	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.4211457158335	0.4211457158335	-0.0649202902830896	-0.0626502991923	-9.80872392885534	3.0218834605233	0.00218437995640591	0.0432375297078429	-0.643126297635845	-0.329005714597334
CCS	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.776685646075	-4.776685646075	-2.96975794261073	-2.85647744883	22.6095000290384	52.1135082006565	1.3316486763496e-28	4.82113056002252e-26	1.64656689379015	1.96728851313838
CCS	BRD-K19412355-001-01-0::2.5::HTS002	2.5	SB-242235	p38 MAPK inhibitor	noncancer	HSPB1, MAPK14	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.4521069872505	0.4521069872505	0.110048294251388	0.111624443211	-7.5326760179079	3.85782524142632	0.00191885874272003	0.0386929227084807	-0.469990794970244	-0.214126591027981
CCS	BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500	2.5	sonidegib	smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.3255805913655	-0.3255805913655	0.00389216470598323	0.01374069413735	14.1137668565992	6.63927650680089	3.38158908882245e-06	0.000126974878734798	0.273658970416674	0.385286541726293
CCS	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.0667479327987	-0.0667479327987	-0.448022614225228	-0.359947291571	-8.29475464069845	22.148547725705	3.05963772594879e-08	1.53683874892167e-06	-0.47656477290232	-0.285984589950737
CCS	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-6.180776691555	-6.180776691555	-4.15619290344523	-4.1358778776	17.0318784235066	4.5945494423708	2.5021745933443e-05	0.00080162717252151	1.71072671317421	2.33844086304533
CCS	BRD-K22064724-001-01-8::2.49999::MTS010::PROS004_PR500	2.49999	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-2.706276693045	-2.706276693045	-2.28402539672055	-2.41370110422	5.77865477365761	183.08022560877	3.18553045091095e-08	1.59670616467094e-06	0.278082031771061	0.56642056087783
CCS	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-5.479284978545	-5.479284978545	-2.7764735884037	-2.61952250038	15.9393944777381	2.43168399488068	0.00160949256825498	0.0334070242747939	2.08430519024942	3.32131759003318
CCS	BRD-K24556098-001-16-7::2.45349::HTS002	2.45349	deoxycorticosterone-acetate	progestogen hormone	noncancer	NR3C2	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.38236244411	-4.38236244411	-2.64524490648234	-2.47219740762	12.0102431215545	8.25692962847138	1.6276834798152e-06	6.43098509568652e-05	1.40538345769214	2.06885161756317
CCS	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.631004224975	-1.631004224975	-0.388822080138409	-0.300509996498	15.5035692390736	4.05969340755065	9.14598110136999e-05	0.00261122816501336	1.02101096851506	1.46335332115812
CCS	BRD-K27316855-001-13-3::2.43597::HTS002	2.43597	calcitriol	vitamin D receptor agonist	noncancer	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.0147886286045	-1.0147886286045	-0.0253750159043349	0.01343134409051	22.8227270918095	34.0201429416497	3.32298019257498e-22	6.65617777284488e-20	0.901313425435104	1.07751379996523
CCS	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.4153314827495	-0.4153314827495	0.278275186995609	0.290224760638	24.1787459478878	16.5207950279971	2.4990125146471e-14	2.44125274955241e-12	0.632949168724784	0.754264170765435
CCS	BRD-K29582115-066-01-2::2.5::HTS002	2.5	ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.4818593720375	0.4818593720375	0.262085589623251	0.262353751493	-5.9782619974389	52.0861991706636	2.07269985158572e-07	9.346511392605e-06	-0.293539533565018	-0.14600803126348
CCS	BRD-K29968218-001-03-2::2.5::HTS002	2.5	KX2-391	src inhibitor, tubulin polymerization inhibitor	targeted cancer	SRC	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.94912981854	-4.94912981854	-2.72376893108685	-2.69887921665	18.236736381263	13.3372551861558	8.1261296616468e-11	5.44781121129527e-09	1.9624151933499	2.4883065815564
CCS	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.72745631101	-4.72745631101	-3.68627959454084	-3.84343615246	8.619152743605	6.69877795714555	7.27198641007728e-05	0.00212082946698252	0.752910223083723	1.32944320985459
CCS	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.611034281485	-0.611034281485	-0.301830121216671	-0.250836974988	7.23631260311586	39.6043683637712	9.32181729322525e-09	4.98984959700218e-07	0.222817698642858	0.3955906218938
CCS	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.3070166595425	0.3070166595425	-0.116451345964001	0.0546590882103	-6.63103922765146	27.2195043869724	3.92408490654355e-07	1.69942451795226e-05	-0.554451521873128	-0.292484489139875
CCS	BRD-K33277808-331-01-3::2.5::HTS002	2.5	ouabain	ATPase inhibitor	noncancer	ATP1A1	cardiology	hypertension, cardiac arrythmia	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.369735947885	-4.369735947885	-5.38487765178298	-5.29484648824	-11.604676740477	160.94366668469	5.21271997605573e-23	1.1273835113502e-20	-1.18789234654801	-0.842391061247952
CCS	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.09421328687955	-0.09421328687955	-0.51238031137396	-0.4097580139535	-7.65206604258636	21.5881664361887	1.3886379548688e-07	6.41849006316744e-06	-0.531624688505345	-0.304709360483476
CCS	BRD-K37723606-001-01-5::2.5::HTS002	2.5	dioscin	apoptosis stimulant	targeted cancer	CXCR3	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.44019865177	-1.44019865177	-1.00165248741981	-0.8388253651295	5.22975371418225	19.0709243044226	4.71556393423873e-05	0.00142933404392795	0.263077732444196	0.614014596256178
CCS	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.5340401683615	-0.5340401683615	-0.140105008263078	-0.03734266076635	8.40217346767925	66.0505420402313	5.02475143835073e-12	3.88510083344254e-10	0.300327750823842	0.487542569373003
CCS	BRD-K39171998-001-01-1::2.5::HTS002	2.5	STF-118804	NAMPT inhibitor	targeted cancer	NAMPT	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-5.98457703597	-5.98457703597	-4.65233378780753	-4.65401991694	9.25658425847279	3.12012310006545	0.00227283437677731	0.0447692600992835	0.884029388496893	1.78045710782805
CCS	BRD-K40331046-305-01-5::2.5::HTS002	2.5	CR8-(R)	CDK inhibitor	targeted cancer	CCNA2	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-6.487760527475	-6.487760527475	-5.25282925446217	-5.161930725595	9.74377893139166	5.72602754604737	8.89136524263208e-05	0.00254667569302164	0.921175845746418	1.54868670027924
CCS	BRD-K42981054-001-01-9::2.5::HTS002	2.5	mibampator	glutamate receptor modulator	noncancer	GRIA1	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-2.214427765455	-2.214427765455	-1.03877950964143	-1.06430669766	18.4741443266759	6.80138710394914	4.58048770582436e-07	1.96542812713039e-05	1.02427409963067	1.32702241199648
CCS	BRD-K43621685-001-02-5::2.5::HTS002	2.5	CP-673451	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	KIT, PDGFRA, PDGFRB	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.5492077350465	-0.5492077350465	0.00246777561302987	0.03337894475615	9.53200440587266	17.5247070606571	2.36728639482605e-08	1.20816621351796e-06	0.429845463202498	0.673505558116562
CCS	BRD-K44827188-001-06-0::2.5::MTS010::PROS003_PR500	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.284118839788	-0.284118839788	0.0404588989134668	0.0592458296823	10.0652584945287	2.93636864185119	0.00228731489787592	0.0450172557159639	0.220682682795434	0.4284727946075
CCS	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-6.10305882859	-6.10305882859	-5.27176923375676	-5.30447708423	8.12906445102863	6.50437773369519	0.000122188137270998	0.00339800976685554	0.585693984375231	1.07688520529126
CCS	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.1412161335075	0.1412161335075	-0.266519864360031	-0.234942866008	-10.0186550214078	19.1130167757532	4.81644646539557e-09	2.66676350938198e-07	-0.492883139387876	-0.322588856347186
CCS	BRD-K47598052-001-15-8::2.5::HTS002	2.5	PP-1	src inhibitor	targeted cancer	HCK, RET	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.6617907608275	-0.6617907608275	-0.287172319653969	-0.114957705133	5.75373353040952	130.413172179704	5.91454472606729e-08	2.86217759447567e-06	0.245812384795723	0.50342449755134
CCS	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.17247165528	-1.17247165528	-0.255509522306369	-0.192385634515	19.6726785332665	189.423293122632	1.18067557783441e-47	2.32158730203369e-44	0.825018936579541	1.00890532936772
CCS	BRD-K53523901-001-04-4::2.5::HTS002	2.5	arctigenin	MEK inhibitor	targeted cancer	CHUK, MAP2K1	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.8835784291235	-0.8835784291235	-0.429292700561096	-0.429548063404	12.0774534990948	85.5619227653498	3.50613307297143e-20	5.92171785182738e-18	0.37950538619333	0.529066070931478
CCS	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.100271533065	-1.100271533065	-0.732745311398246	-0.670954227568	5.24932025320422	6.76051849741396	0.00132499055408668	0.0282739845148192	0.200772963580626	0.534279479752881
CCS	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-2.06850338268	-2.06850338268	-0.60051668035417	-0.573831164789	20.7771452597093	193.200107072075	3.90271942765155e-51	1.04886459560262e-47	1.32863465392836	1.6073387507233
CCS	BRD-K59058747-001-18-3::2.5::HTS002	2.5	acetylcysteine	mucolytic agent	noncancer	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.8726063313565	0.8726063313565	0.386350406066386	0.3974557070265	-19.3909038619701	185.215643717127	1.84759216123334e-46	3.32766874222673e-43	-0.535728211591085	-0.436783638989143
CCS	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.0105475439215	-1.0105475439215	-1.33276552471927	-1.45938861893	-4.6280675359732	11.1369149982134	0.000707381108843513	0.0163164319497763	-0.475226704091515	-0.169209257504016
CCS	BRD-K59753975-001-02-6::2.5::MTS006	2.5	vindesine	tubulin polymerization inhibitor	chemo	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.350726473165	-4.350726473165	-2.39230740289553	-2.27131346061	14.2500506703076	3.47169866770433	0.000333380729252825	0.0083366186349351	1.55281760106713	2.36402053947182
CCS	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-3.69301281709	-3.69301281709	-1.51218367260615	-1.40779088077	36.7359606149264	106.919563253523	1.8471149052516e-62	1.52265496356796e-58	2.06314400569452	2.29851428327318
CCS	BRD-K61642990-001-01-0::2.5::HTS002	2.5	FERb-033	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.0192081072579	0.0192081072579	0.183877608978096	0.261629731323	4.31447864455445	190.484162962923	2.56701584536965e-05	0.000820560684746057	0.0893857958687946	0.239953207571597
CCS	BRD-K64800655-001-07-4::2.5::HTS002	2.5	PHA-793887	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.174279448285	-4.174279448285	-1.59733995590534	-1.563662443425	23.1697293356419	6.62749119160033	1.36480561831437e-07	6.31923576080578e-06	2.31091930330047	2.84295968145885
CCS	BRD-K66715657-050-01-0::2.5::HTS002	2.5	UH-232-(+)	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4, HTR1A	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.458089859156	0.458089859156	-0.00692895167041271	0.0059117559481	-14.0965907199911	29.8744849313478	9.73194911177749e-15	9.82495959104172e-13	-0.532401234979561	-0.397636386673264
CCS	BRD-K68507560-003-24-6::2.5::HTS002	2.5	dicycloverine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.4095500803665	0.4095500803665	0.229222525141375	0.216100311033	-5.59690993246837	111.062064145667	1.59269257108893e-07	7.30494770102544e-06	-0.24417151425573	-0.116483596194519
CCS	BRD-K69932463-001-10-6::2.5::HTS002	2.5	AZD8055	mTOR inhibitor	targeted cancer	MTOR	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-3.07530316982	-3.07530316982	-2.73805175709379	-2.73243511548	5.0136064021743	40.4462338146955	1.10621477785716e-05	0.000377959360949064	0.201345978360777	0.473156847091641
CCS	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-2.144056784155	-2.144056784155	-0.643627362024296	-0.503206841324	14.5261422271361	2.35430351628705	0.00233551098458275	0.0458195072111674	1.1143245617714	1.88653428249001
CCS	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.486436526532	0.486436526532	0.21859782548221	0.2281967000125	-10.5382732155586	135.727463988365	2.41998198964208e-19	3.76122059360404e-17	-0.318100906810546	-0.217576495289033
CCS	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.5775047621945	0.5775047621945	0.0968150877443624	0.129185439077	-9.41290112092452	4.34014016245956	0.000476120158565562	0.0114749080698525	-0.618198132402986	-0.343181216497289
CCS	BRD-K76973696-001-12-6::2.01421::HTS002	2.01421	tryptanthrin	cyclooxygenase inhibitor	targeted cancer	IDO1	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.78434803002	-1.78434803002	-1.38240950161127	-1.323892199525	8.61519482666635	69.1696652729104	1.4726274659048e-12	1.2033045068239e-10	0.308869206881084	0.495007849936368
CCS	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.77438110427	-1.77438110427	-0.948046966442209	-0.855208083422	15.7425172244335	192.706927147378	1.92018228814703e-36	1.44743837677303e-33	0.722804275962289	0.929863999693293
CCS	BRD-K77791657-003-01-7::2.66704::HTS002	2.66704	3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-3.730496522115	-3.730496522115	-1.49614113357934	-1.42535569611	30.5796059961006	41.1742991655411	6.23133310188746e-30	2.50104006066374e-27	2.08681286574204	2.38189791132928
CCS	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-1.342557488025	-1.342557488025	-0.609117388407993	-0.517259346977	11.5186512506427	8.91493258514812	1.18335115205527e-06	4.78030717369972e-05	0.589189421400437	0.877690777833577
CCS	BRD-K81473043-001-14-6::2.5::HTS002	2.5	tanespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-5.458117228685	-5.458117228685	-4.82314190660793	-4.73895662772	5.97012715341424	62.4005569653876	1.22700409525165e-07	5.72198783140102e-06	0.42239433434135	0.847556309812795
CCS	BRD-K85402309-001-06-6::2.5::HTS002	2.5	dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.6976363003155	-0.6976363003155	-0.158624559022697	-0.1901331802295	11.810012518589	9.9536027138618	3.54382266262066e-07	1.54159522520159e-05	0.437254671318067	0.640768811267539
CCS	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.213742888335	-4.213742888335	-2.76001122538257	-2.642391718485	15.3919849651323	87.2242386052316	1.36066603020262e-26	4.0059091976277e-24	1.26601420059432	1.64144912531053
CCS	BRD-K88789588-001-14-9::2.5::HTS002	2.5	letrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.3732912424955	0.3732912424955	0.171299191234895	0.134941484208	-5.55809486236943	193.806875254591	8.93847147968057e-08	4.234689774024e-06	-0.273668563830025	-0.130315538691185
CCS	BRD-K89714990-001-01-5::2.5::HTS002	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.5175004726185	0.5175004726185	-0.0115474990517917	-0.02895586832955	-16.1511556445189	117.28222230448	1.3518321073677e-31	6.23089943526909e-29	-0.593917970140477	-0.464177973200107
CCS	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-4.650305811805	-4.650305811805	-3.09128658656867	-2.979502562735	13.8846756926928	70.9541926871068	6.48533722094024e-22	1.26940259472776e-19	1.33512988913642	1.78290856133623
CCS	BRD-K92000912-001-12-6::2.5::HTS002	2.5	AM-251	cannabinoid receptor antagonist	targeted cancer	CNR1, GPR18, GPR55	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.0471104537392	0.0471104537392	-0.128357974121539	-0.0852704438558	-4.22769623441679	13.482225823204	0.00091372343801407	0.0204487241042203	-0.264808530903445	-0.0861283248180339
CCS	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-0.1472683365655	-0.1472683365655	0.10128283244141	0.1765205692495	6.97522352277141	100.469486771731	3.30280062283912e-10	2.06984197278505e-08	0.177859495468824	0.319242842544997
CCS	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.5188566916575	0.5188566916575	0.304689968471173	0.301488629615	-7.55364862266036	21.6684852877296	1.6667468824485e-07	7.6152673751504e-06	-0.273018933390942	-0.155314512981711
CCS	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.6941217015905	0.6941217015905	0.294963073939546	0.274833859863	-10.7352807976142	82.8159275884242	2.37064675693794e-17	3.07008065720696e-15	-0.473114453178557	-0.32520280212335
CCS	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	-2.55008189325	-2.55008189325	-1.23654554674756	-1.23927241763	13.0053242001089	3.47444685039014	0.000453715458345752	0.0110017400692145	1.01556831472389	1.61150437828099
CCS	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.0534893299308	0.0534893299308	0.249009324826664	0.266502193274	6.00355216330044	19.0181053707769	8.8762090899817e-06	0.000308635466912181	0.127360066490833	0.263679923300894
CCS	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	G401, HGC27	SOFT_TISSUE, STOMACH	rhabdoid_tumour, carcinoma (undifferentiated_adenocarcinoma)	0.050753329241189	0.050753329241189	-0.619335462617918	-0.542183140466	-8.48855208221843	5.56298450951829	0.000217676993401097	0.00569791063979772	-0.866987318474625	-0.473190265243588
CCSER1	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.2101608905405	-0.2101608905405	-0.835140119514244	-0.720201208535	-9.59486943266783	31.9003922601837	6.37366974227535e-11	4.31751663145428e-09	-0.757674827778095	-0.492283630169392
CCSER1	BRD-A10977446-001-12-1::2.5::HTS002	2.5	carvedilol	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA	cardiology	myocardial infarction, hypertension	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.5724395655695	0.5724395655695	-0.225847799887565	-0.214242337971	-15.3889146680397	145.918919762531	2.32773352639761e-32	1.14426788756714e-29	-0.900809156356404	-0.695765574557726
CCSER1	BRD-A55913614-316-09-6::2.5::HTS002	2.5	primaquine	antimalarial agent, DNA inhibitor	noncancer	KRT7, NQO2	infectious disease	malaria	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.5726357100285	0.5726357100285	0.0927152326825996	0.121843056182	-13.8686971390206	58.6086657543508	3.65069596634744e-20	6.15133660197548e-18	-0.549173762528893	-0.410667192162908
CCSER1	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.0631525040014	0.0631525040014	0.417131183662623	0.4743784763675	9.31884623247718	12.5964531237664	5.21175719133877e-07	2.21809115778881e-05	0.271648494400024	0.436308864922422
CCSER1	BRD-A95696066-003-13-8::2.5::HTS002	2.5	nisoxetine	norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.2389443258835	-0.2389443258835	0.344624531276226	0.338484825644	19.8669428676563	4.05683350185985	3.39758515229223e-05	0.00105735592871445	0.502462559906464	0.664675154412988
CCSER1	BRD-A98299281-050-09-6::2.5::HTS002	2.5	hydroxytacrine-maleate-(r,s)	cholinesterase inhibitor	noncancer	ACHE	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.0874622591622	-0.0874622591622	-0.251172256139815	-0.147378080883	-3.54118699686667	134.097112208271	0.00054836704106678	0.0130055283329426	-0.255144793456669	-0.0722752004985606
CCSER1	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.0875832777846	-0.0875832777846	0.265739685377135	0.320326091732	7.31111364257044	6.11807625675823	0.000305440738741374	0.00769902482579089	0.235622479468199	0.47102344685527
CCSER1	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.444904941595	-2.444904941595	-3.73141965611589	-3.62613694573	-11.0654049508082	22.4384485659224	1.46940417223266e-10	9.55219674948298e-09	-1.52735983148555	-1.04566959755623
CCSER1	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.3487164409715	0.3487164409715	-0.366670559369317	-0.264963110089	-11.7929954640616	187.003981101353	2.34076486545646e-24	5.66885641636629e-22	-0.835056845469642	-0.595717155211993
CCSER1	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.2894184938085	-0.2894184938085	-1.46602064660074	-1.380035679485	-15.5485513955218	65.7122917451026	1.05490492641242e-23	2.39763221604505e-21	-1.32770008646509	-1.02550421911938
CCSER1	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.107834812786	0.107834812786	-0.689332636160244	-0.506361258966	-8.24571449166789	3.58379339296031	0.00186953121558471	0.0378585370280665	-1.07833710144804	-0.515997796444446
CCSER1	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.8579008509585	0.8579008509585	0.250590263151551	0.2240846909	-18.9502438466255	9.39387375987878	8.38610724906756e-09	4.5183156877461e-07	-0.679346661712533	-0.535274513901364
CCSER1	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.991194548375	-1.991194548375	-2.4201904218924	-2.32972185313	-5.87202021487068	109.583943140366	4.67857330507736e-08	2.29224123531974e-06	-0.573785059206742	-0.284206687828065
CCSER1	BRD-K12502280-001-08-0::2.5::HTS002	2.5	TG-101348	FLT3 inhibitor, JAK inhibitor	targeted cancer	BRD4, JAK1, JAK2, JAK3, TYK2	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.464735380646	0.464735380646	-0.401879178132902	-0.2460199545545	-10.9928828882853	10.110428502568	6.02783196740619e-07	2.54368812313881e-05	-1.04200828058127	-0.691220836976538
CCSER1	BRD-K12885236-001-02-7::2.5::HTS002	2.5	dapivirine	non-nucleoside reverse transcriptase inhibitor	noncancer	CYP3A4, CYP3A5	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.9999023291615	-0.9999023291615	-1.34364965091482	-1.23896057589	-6.55662068884058	35.0200371233115	1.43371381546764e-07	6.62112579951225e-06	-0.450178656355423	-0.237315987151211
CCSER1	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.24818390156	-0.24818390156	-1.65868160912005	-1.461946185705	-16.1550183992745	77.0721222449362	1.85333978424473e-26	5.36789814347821e-24	-1.58435190860341	-1.23664350651669
CCSER1	BRD-K14175878-001-01-6::2.5::HTS002	2.5	MK-0812	CC chemokine receptor antagonist	noncancer	CCR2	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.490487279973	0.490487279973	0.328305365753246	0.3144400388815	-5.41932296528759	13.3533160587542	0.000106691178013083	0.00300328519731626	-0.226660941875285	-0.0977028865642223
CCSER1	BRD-K17472821-001-01-2::2.5::MTS006	2.5	GSK2830371	protein phosphatase inhibitor	targeted cancer	PPM1D	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.291854883678	0.291854883678	0.213164449789519	0.222894017996	-3.9372325940853	69.1681422305047	0.000194016616425913	0.00514454872967332	-0.11856014155995	-0.0388207262170118
CCSER1	BRD-K17743125-001-08-4::2.5::HTS002	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.515020000455	-1.515020000455	-2.62004887166293	-2.55701566981	-9.63096623936505	33.9530743397348	3.07168573005436e-11	2.16491723392575e-09	-1.33821452756843	-0.871843214847426
CCSER1	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.026025486975	-2.026025486975	-0.804751737838019	-0.7654167490095	13.8148968512028	3.78973483681422	0.000221653816683026	0.00578787047707802	0.970363507241956	1.47218399103201
CCSER1	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.6277475662	-1.6277475662	-2.45889217314904	-2.36107459971	-7.72018522425391	10.8123253090966	1.01386798682533e-05	0.000348910262922745	-1.06860243792235	-0.593686775975722
CCSER1	BRD-K19540840-001-09-4::2.5::MTS010::PROS004_PR500	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.04529236873793	0.04529236873793	-0.40696675663108	-0.3364454572695	-6.78106100444302	8.84012011712082	8.79595592319231e-05	0.00252271970702781	-0.603549419911261	-0.300968830826759
CCSER1	BRD-K19687926-379-07-4::2.5::HTS002	2.5	lapatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2	oncology	breast cancer	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.36727381816	-1.36727381816	-0.651575506767548	-0.498501703786	12.4125380846886	85.1514188505587	8.48203988632736e-21	1.51117799401218e-18	0.601059109840667	0.830337512944237
CCSER1	BRD-K20755323-001-05-9::2.5::HTS002	2.5	SKI-II	sphingosine kinase inhibitor	targeted cancer	SPHK1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.6662312891575	-0.6662312891575	0.0632719692460283	0.07792704644355	21.120352957549	189.844590939288	1.00924150888467e-51	2.96314689531153e-48	0.661371192181866	0.797635324625191
CCSER1	BRD-K24869513-001-02-1::2.5::HTS002	2.5	CNX-2006	EGFR inhibitor	targeted cancer	EGFR	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.9075008448445	-0.9075008448445	-0.114516475235368	-0.012076776291505	12.8351194672922	3.84051453938258	0.00026989092623667	0.00689374953275882	0.618602782946795	0.96736595627147
CCSER1	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.6693302750855	-0.6693302750855	-0.129611084051735	-0.0959676428829	14.2193566117305	115.106348550955	4.18557985401387e-27	1.26887007713004e-24	0.464535104220701	0.614903277846829
CCSER1	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.27221792491	-1.27221792491	-0.735944202495137	-0.611167140032	8.22992093640453	11.9070358298687	2.95930217552477e-06	0.000112398418567792	0.394176045159935	0.67837139966979
CCSER1	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.20273976701	-1.20273976701	-2.32075925187324	-2.045349051995	-10.9864194078149	177.438294761111	9.43662323088229e-22	1.81231363839764e-19	-1.31884251990088	-0.917196449825603
CCSER1	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.2463408028345	0.2463408028345	-0.62115224610037	-0.480230640816	-13.223235654108	59.2829375279289	2.46799009146849e-19	3.83028130567958e-17	-0.998752621217222	-0.736233476652518
CCSER1	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.3077910288685	-0.3077910288685	-1.34639165048795	-1.265409369745	-13.3389683495786	5.26819506866635	2.92000385915697e-05	0.000920084544441715	-1.23572538261237	-0.84147586062652
CCSER1	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.8487682011705	-0.8487682011705	-0.171071013734908	-0.120119113317	15.9448475593904	7.7134988206015	3.50632869966272e-07	1.52621430517874e-05	0.579048765087104	0.776345609784081
CCSER1	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.01338281601978	0.01338281601978	-0.516923763981152	-0.465030888818	-10.3815570002555	53.91693040716	1.81979332077797e-14	1.80321073809071e-12	-0.632722642964363	-0.427890517037501
CCSER1	BRD-K40797222-001-01-8::2.5::HTS002	2.5	SC-12267	dihydroorotate dehydrogenase inhibitor	noncancer	IL17A	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.2758187636845	0.2758187636845	0.186167239716586	0.184399160559	-3.67335756682193	30.7102552761437	0.000906202031605537	0.0202931120292533	-0.139446685780483	-0.039856362155344
CCSER1	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.400252169575	-1.400252169575	-0.621877315478659	-0.4180119465525	9.92148001863842	8.04457980246292	8.65442905893734e-06	0.000301314997688918	0.597635112957684	0.959114595234998
CCSER1	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-3.77916013373	-3.77916013373	-3.23031985272239	-3.119370710775	7.52928643903308	57.0151569596693	4.16637586172306e-10	2.57861730311072e-08	0.402873278379702	0.69480728363552
CCSER1	BRD-K44827188-001-06-0::2.5::HTS002	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.9116085231625	-0.9116085231625	-0.102842562007759	-0.054617955294	11.8218789872791	4.26229273476952	0.000203350344687917	0.00536021104742548	0.623344208578825	0.994187713730657
CCSER1	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.70003888412	-0.70003888412	-0.35833108864346	-0.229271162585	5.09598119067962	40.9803825191516	8.24125051778878e-06	0.000288476070917386	0.20628678435186	0.47712880660122
CCSER1	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.7274575954575	-0.7274575954575	-1.5958058495351	-1.48697544025	-8.52692392731857	8.38124313452029	2.06927296152048e-05	0.000672385088795821	-1.10133617879008	-0.635360329365106
CCSER1	BRD-K49371609-003-03-8::2.5::HTS002	2.5	PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-5.91013335908	-5.91013335908	-5.33508804749428	-5.33091328007	6.54297667725092	11.9850175604528	2.77411811676659e-05	0.000878377842884425	0.383528529562302	0.766562093609142
CCSER1	BRD-K50388907-001-30-4::2.5::HTS002	2.5	fenofibrate	PPAR receptor agonist	noncancer	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.340217843582	-0.340217843582	0.203412551483343	0.198833641083	16.703629555536	6.05525214039358	2.70312106699913e-06	0.000103217038155862	0.464169882771408	0.623090907359277
CCSER1	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-5.712122450035	-5.712122450035	-6.18637872379832	-6.32403693229	-4.93369693946472	29.8592428915719	2.84123096735115e-05	0.000897638844341693	-0.670610454904736	-0.277902092621895
CCSER1	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.213179053225	-2.213179053225	-2.74516286405796	-2.66953815971	-5.460805918198	13.1306409701885	0.000105378448646257	0.00297062442718712	-0.742231142569891	-0.321736479096027
CCSER1	BRD-K58049875-001-04-7::2.5::HTS002	2.5	thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	noncancer	FOXM1	obstetrics/gynecology	mastitis	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.0412493618603	-0.0412493618603	-0.813650087921805	-0.698370160758	-8.87234323986269	4.13785940822164	0.000762425978198872	0.0174284280334378	-1.01096703240071	-0.533834419722303
CCSER1	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.176224431385	-2.176224431385	-3.65580062229407	-3.579783032275	-9.99630127181101	6.36547189651735	3.99721141674674e-05	0.00122862229419176	-1.83676808126113	-1.12238430055702
CCSER1	BRD-K60341624-001-02-2::2.5::HTS002	2.5	GSK1292263	glucose dependent insulinotropic receptor agonist	noncancer	GRPR	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.671894321818	-0.671894321818	-1.01707630770976	-0.9579958637765	-8.13634255304879	13.6901179971978	1.30965161446329e-06	5.25451742561404e-05	-0.436367550788504	-0.253996420995008
CCSER1	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.233344546214	-0.233344546214	-1.20884334492567	-1.18840349692	-12.2440597099924	26.0599946031106	2.59295185630524e-12	2.07135586436841e-10	-1.13924692620887	-0.811750671214473
CCSER1	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.36676182738	-1.36676182738	-0.776310765671608	-0.683338343709	7.60264668529896	6.96687033855994	0.000129074958322778	0.00356961377320809	0.406627979984429	0.774274143432355
CCSER1	BRD-K68633617-003-02-9::2.5::HTS002	2.5	ACDPP	glutamate receptor antagonist	noncancer	GRM5	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.5258413799935	0.5258413799935	0.234072342670571	0.319454889976	-5.8194058771109	157.603376529465	3.20231132068748e-08	1.6047420693281e-06	-0.390796655784908	-0.192741418860949
CCSER1	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.1837195622885	-0.1837195622885	0.346978815024393	0.3666851523545	17.6706251971234	189.019397429804	6.8150048627714e-42	8.49216963507518e-39	0.471455860217471	0.589940894408314
CCSER1	BRD-K72414522-001-06-7::2.5::HTS002	2.5	AZD5438	CDK inhibitor	targeted cancer	KCNH2	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.01850177484865	0.01850177484865	-2.44364017027271	-2.22027282363	-19.4360690907235	6.15369796619397	9.31540446016769e-07	3.82776327174709e-05	-2.77024725886967	-2.15403663137305
CCSER1	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.13853704434	-2.13853704434	-2.93337989374959	-2.86819814614	-7.56614597434006	46.9159684724095	1.15162194365409e-09	6.80899253962588e-08	-1.00619129195979	-0.583494406859394
CCSER1	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.85282236584	-1.85282236584	-1.10204254065187	-0.895557196833	8.88767115454973	90.3602002971714	5.72179971037998e-14	5.38107771007473e-12	0.582965991960726	0.918593658415528
CCSER1	BRD-K76674262-001-03-3::2.5::HTS002	2.5	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-4.268509822075	-4.268509822075	-4.76022741355983	-4.89137011484	-4.90896190669124	79.341116439956	4.80358949582769e-06	0.000175660899684568	-0.691082340653293	-0.292352842316364
CCSER1	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.2677104047395	0.2677104047395	-0.000561143321138224	0.03094358609725	-8.53535370345597	12.8467839619141	1.18930322626413e-06	4.8031311698128e-05	-0.336255709972275	-0.200287386149001
CCSER1	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.6643549383365	0.6643549383365	0.496871188932653	0.515272690573	-5.73138169714792	177.239100943727	4.2070689145375e-08	2.07167238124911e-06	-0.22515203249374	-0.109815466313952
CCSER1	BRD-K79612754-001-19-1::2.62081::HTS002	2.62081	inosine	neurotrophic agent	noncancer	PARP1, PNP	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.000410848289	-1.000410848289	-1.40272957823286	-1.36932187497	-5.55389705067495	29.2991141947773	5.26925676369685e-06	0.000191221559923194	-0.550407442549489	-0.254230017338236
CCSER1	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.5039860985575	-0.5039860985575	-0.947870041236646	-0.8151847008705	-5.71188535406693	7.96473700802149	0.000455507452859928	0.011037700041155	-0.623227104013381	-0.26454078134491
CCSER1	BRD-K81839095-001-30-1::2.5::HTS002	2.5	estrone	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.587837567307	0.587837567307	0.404440496789762	0.3953780325455	-7.92442395266643	191.877153418796	1.82226575886287e-13	1.62803000346528e-11	-0.229044957283433	-0.137749183751043
CCSER1	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.89562369436	0.89562369436	0.45108071142289	0.472553592618	-11.4923007117572	7.97755073258257	3.04701942400775e-06	0.000115402831971754	-0.533787106218535	-0.355298859655684
CCSER1	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.206689694577	-0.206689694577	0.0378425044074319	0.0524875741405	7.70826250417502	8.69413941784372	3.60979336791784e-05	0.00111836282560344	0.172382215850458	0.316682182118405
CCSER1	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.692335180715	-2.692335180715	-1.94654379133952	-1.864714539655	10.3467899472005	11.8968572277788	2.6698444741428e-07	1.18522182331929e-05	0.588592518869266	0.902990259881697
CCSER1	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.27819056781	-0.27819056781	0.00843165776192575	0.0499653436317	7.87730923948556	18.7613326090408	2.29803978323034e-07	1.02868957539677e-05	0.210400239330757	0.362844211813094
CCSER1	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.09284654727605	-0.09284654727605	0.155583141793973	0.189344687703	8.75231406266308	3.72710936747485	0.00128547951510595	0.0275322813024027	0.167293170608702	0.329566207531343
CCSER1	BRD-K92049597-001-20-8::2.5::HTS002	2.5	triamterene	sodium channel blocker	noncancer	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.463467040738	-0.463467040738	-0.0518730047330435	-0.0499338044925	11.6558350183092	10.7296226574411	1.98869899550707e-07	8.98473581382871e-06	0.333632624479589	0.489555447530324
CCSER1	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.116242798008	-0.116242798008	0.311410597991443	0.317996860903	14.4027590731846	11.8722105450247	7.04031765055363e-09	3.81624744998864e-07	0.362881759431993	0.492425032566893
CCSER1	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.471888194123	0.471888194123	-0.233635821858483	-0.164801274437	-11.6157008945193	188.644036039921	7.05525917675999e-24	1.63475312875221e-21	-0.825338578777752	-0.585709453185214
CCSER1	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.27130359329	-2.27130359329	-3.07870215730055	-3.084015642295	-8.64027248228429	189.514008224083	2.31039144195677e-15	2.48212474868748e-13	-0.991726385028936	-0.623070742992169
CCSER1	BRD-K99107520-001-24-1::2.5::MTS006	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	NCIH1355, MKN7	LUNG, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.4212440361175	-0.4212440361175	0.072813081481561	0.0963924251422	19.678844933124	5.37170444710034	3.25748323543314e-06	0.000122680218655272	0.430840428893687	0.557273806304435
CDC42	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.412980634473	0.412980634473	0.174589442321373	0.21394626854	-6.69891712591231	5.5481604401173	0.000741122892210684	0.0170014051551561	-0.327216524231872	-0.149565860071382
CDC42	BRD-A03623303-045-09-5::2.5::HTS002	2.5	metoprolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.01991737258635	-0.01991737258635	0.242018131807436	0.21036832824	9.2087999220536	187.963813574423	6.52739502938357e-17	8.11961723303977e-15	0.205824931232267	0.318046077555305
CDC42	BRD-A20239487-001-24-9::2.5::HTS002	2.5	atenolol-(+/-)	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.3973038878305	0.3973038878305	0.197101298605169	0.207866793196	-6.38362167023486	6.38315099546037	0.000543255895952641	0.0129014396591284	-0.275839548122703	-0.12456563032796
CDC42	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.129196433019	-0.129196433019	-0.514594006565539	-0.46624794895	-7.55843436798928	132.930614517589	5.93285183763441e-12	4.54948909305311e-10	-0.486252471220507	-0.284542675872571
CDC42	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-3.15872368245	-3.15872368245	-0.970063479553195	-0.915436263548	25.9942056835358	3.88519136346272	1.67295518455257e-05	0.000554535743504435	1.95213932231443	2.42518108347918
CDC42	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.9388279367145	-0.9388279367145	-0.4379645063385	-0.316823475009	5.47026441609601	7.36119677985557	0.000789505783777584	0.0179842687991568	0.2864909103524	0.715235950399601
CDC42	BRD-A69651145-003-07-2::2.5::HTS002	2.5	minocycline	bacterial 30S ribosomal subunit inhibitor	noncancer	ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA	endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.542831155063	-0.542831155063	0.0953466256506643	0.0643379541356	10.5316602926127	2.93815838774142	0.00200288069999109	0.0401454612876078	0.443017191694042	0.833338369733286
CDC42	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.00627913547	-2.00627913547	-1.18003444239359	-1.01823698977	10.4660892636883	10.4247306433988	7.39148426001575e-07	3.08151999604146e-05	0.651311030053857	1.00117835609897
CDC42	BRD-K04430056-236-02-1::2.5::HTS002	2.5	7-nitroindazole	nitric oxide synthase inhibitor	noncancer	NOS1, NOS2, NOS3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.472254834499	0.472254834499	0.306715528326737	0.309926543901	-6.47386428218507	188.079492162734	8.09240278480789e-10	4.86791073944735e-08	-0.215980944282713	-0.115097668061812
CDC42	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.9405221384325	-0.9405221384325	-0.67812026235042	-0.479061239467	3.91848156405406	186.890401682462	0.000124905930259383	0.0034637033415142	0.130297056176826	0.394506695987333
CDC42	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.9245607122095	-0.9245607122095	-1.68927606491769	-1.35955217781	-5.33943273366558	8.19477216390924	0.000641313666918819	0.0149258461197789	-1.09362066583688	-0.435810039579505
CDC42	BRD-K07487750-001-03-3::2.5::HTS002	2.5	WHI-P154	JAK inhibitor	targeted cancer	EGFR, JAK1, JAK2, JAK3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.4167583455825	-0.4167583455825	-0.640961844300938	-0.57901895305	-3.55796422919471	52.8778008214044	0.000798691214986823	0.0181684026127054	-0.350601489722908	-0.0978055077139679
CDC42	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.748784488258	0.748784488258	0.331663462781365	0.3338165124735	-13.1689320863518	22.1364699614425	5.96921072373433e-12	4.57321253893626e-10	-0.482786711581785	-0.351455339371485
CDC42	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-5.04728084695	-5.04728084695	-4.1274561419935	-4.11179699224	6.51143627933996	11.3087792338559	3.82605827909275e-05	0.00118058630132403	0.609939676453	1.22970973346
CDC42	BRD-K13044802-213-20-7::2.5::HTS002	2.5	ciclopirox	membrane integrity inhibitor	noncancer	ATP1A1	infectious disease	onychomycosis	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-1.322444827725	-1.322444827725	-1.62118298268425	-1.66652193871	-4.46733607067963	49.7303575596931	4.57598227060598e-05	0.00139017109011582	-0.433071872891603	-0.164404437026905
CDC42	BRD-K13566078-001-02-3::2.5::HTS002	2.5	BMS-345541	IKK inhibitor	targeted cancer	CHUK, IKBKB	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.99838414467	-2.99838414467	-1.46925846667672	-1.48395465403	25.928724741824	152.372623016979	9.55958887149468e-58	4.65658437099678e-54	1.41261300470522	1.64563835128134
CDC42	BRD-K13949769-001-01-7::2.5::HTS002	2.5	tenovin-6	SIRT inhibitor	targeted cancer	SIRT1, SIRT2, SIRT3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.060848534825	-2.060848534825	-1.25711555060906	-1.214888952245	10.4375675843979	19.5903713553618	1.9069404488006e-09	1.10105775714166e-07	0.642890161591745	0.964575806840126
CDC42	BRD-K16505263-003-02-9::2.5::MTS006	2.5	forodesine	purinergic receptor antagonist	targeted cancer	PNP	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.3247285908155	0.3247285908155	0.22197925845798	0.234801911362	-5.13252835006895	190.628388259543	7.01579314788599e-07	2.9363169880751e-05	-0.142237019078566	-0.063261645636475
CDC42	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.4515999197955	-0.4515999197955	-0.184632461604519	-0.102291191228	6.42717566692588	103.170647219926	4.09169026993096e-09	2.28080073826796e-07	0.184589660067789	0.349345256314173
CDC42	BRD-K17743125-001-08-4::2.5::MTS010::PROS003_PR500	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.00725755053	-2.00725755053	-0.663254198404488	-0.579023272912	11.2490713310107	3.61381719386393	0.000609179186051967	0.0142617088524267	0.997823487587683	1.69018321666334
CDC42	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.6444867853005	0.6444867853005	0.304392728047581	0.3131581681635	-7.99477318964113	3.90631882534797	0.00146507680145042	0.0308214022161432	-0.459328287512687	-0.220859826993152
CDC42	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.46636044296	-2.46636044296	-3.13839328032873	-3.22475555586	-5.56748945759764	120.968553917029	1.58396796716115e-07	7.2680426125815e-06	-0.911004058045308	-0.433061616692158
CDC42	BRD-K21528677-001-02-8::2.43672::HTS002	2.43672	desonide	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.22855488008	-0.22855488008	0.0897738503937898	0.124628316908	6.48377457610005	5.94090998178812	0.000665607989633398	0.0154309458961749	0.197904403382897	0.438753057564683
CDC42	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-1.00740122747	-1.00740122747	-0.395637413444475	-0.300509996498	10.4760292725067	166.419145811158	4.82892286033772e-20	8.05430511854726e-18	0.496470293238388	0.727057334812663
CDC42	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.223242018315	-2.223242018315	-1.02353694558433	-0.8397340938795	15.3283601511611	56.5911999332466	8.38097697940633e-22	1.61827604956683e-19	1.04295352803605	1.35645661742529
CDC42	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-1.15599388072	-1.15599388072	-0.46269504455726	-0.381757809721	10.2529219497221	4.22935920686161	0.000381992816411934	0.00942671032859047	0.509504569830929	0.87709310249455
CDC42	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.6416214438655	-0.6416214438655	-0.301495835289015	-0.250836974988	6.66358451091559	6.11925739288873	0.000509080553503667	0.0121829752067762	0.215816921946592	0.464434295206377
CDC42	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.013510215725	-2.013510215725	-2.58142784777694	-2.555934411265	-5.13896009548523	7.98117566660649	0.000892808803963486	0.0200329583484809	-0.82286381492865	-0.312971449175232
CDC42	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.01268068940829	-0.01268068940829	0.133521467102304	0.1319992768505	4.65694739873233	180.49438184099	6.20492934269625e-06	0.000222388409091201	0.0842548702248156	0.208149442796373
CDC42	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.510656160301	-0.510656160301	-1.29323559075797	-1.33795379646	-9.27312970205638	48.4656335341481	2.57390879322044e-12	2.05691013326675e-10	-0.952219132237386	-0.612939728676551
CDC42	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.438069775945	-2.438069775945	-0.611066715412305	-0.4180119465525	22.5772409083924	5.8560939093539	6.41760151247426e-07	2.69701591091588e-05	1.62780774398422	2.02619837708117
CDC42	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-5.882859913525	-5.882859913525	-5.44236772305064	-5.470053491025	4.70228703845832	11.3744921185186	0.000591731969474608	0.0139307250972675	0.235137543314879	0.645846837633844
CDC42	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-3.538375862955	-3.538375862955	-1.30664984775777	-1.04970341453	18.1483165203986	3.89339956676578	6.59118905078447e-05	0.00193996561118592	1.88658385239696	2.57686817799749
CDC42	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.886411600812	-0.886411600812	-0.67244494315849	-0.568122839674	3.71259359580142	30.1120255503061	0.000832290734989359	0.018846702687748	0.0962834156246711	0.331649899682348
CDC42	BRD-K49328571-001-15-0::2.5::MTS010::PROS005_PR500	2.5	dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor	targeted cancer	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-1.91169449592	-1.91169449592	-0.451342109339526	-0.279272959842	12.1896502338378	3.09221564153181	0.00102568719001607	0.0226190461723381	1.08543914890277	1.83526562425818
CDC42	BRD-K55044200-001-15-3::2.5::HTS002	2.5	amoxicillin	penicillin binding protein inhibitor	noncancer	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.558109770834	0.558109770834	0.0925552235027312	0.127274405853	-18.4134550470427	129.098342488411	6.32797248093599e-38	5.40345822257582e-35	-0.515577990968359	-0.415531103694178
CDC42	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-4.87420740429	-4.87420740429	-3.1331200914468	-3.15598793833	17.2600892592073	93.778373100433	7.27979245677405e-31	3.12054127493585e-28	1.54079424742302	1.94138037826338
CDC42	BRD-K56957086-001-06-3::2.5::HTS002	2.5	dacinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-6.08236068833	-6.08236068833	-5.58139052038601	-5.599173214095	6.15129764889798	187.998671500556	4.52223034238049e-09	2.51295075720007e-07	0.340313789087637	0.661626546800343
CDC42	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-1.92514450922	-1.92514450922	-0.371718328781219	-0.1848985030465	15.3036838654131	2.55149353639151	0.00140674357260746	0.0297607287704457	1.1957608585665	1.91109150231106
CDC42	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-3.959639433455	-3.959639433455	-4.65531903609435	-4.74198978259	-6.04073307543651	7.19095676334604	0.000469370812620194	0.0113326322967302	-0.966541871725997	-0.424817333552694
CDC42	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.4035474143255	-0.4035474143255	-0.203425204610224	-0.0713354708951	4.06445115963798	137.04432438031	8.07247389540133e-05	0.00233427584663717	0.102759306881546	0.297485112549007
CDC42	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.2980584690865	0.2980584690865	-0.212430384042388	-0.255561480265	-17.7277547482574	113.104877283043	1.95060091474383e-34	1.18462086774699e-31	-0.567538398025842	-0.453439308231935
CDC42	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.9403098583405	-0.9403098583405	-2.08885701121536	-1.79411655002	-9.33786432808654	175.715117895173	4.35276429490771e-17	5.48778599154867e-15	-1.39129245990904	-0.905801845840681
CDC42	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-8.37424017249	-8.37424017249	-7.20087335516415	-7.241239224365	11.481333996574	177.802312466897	3.48840407827167e-23	7.66837084812193e-21	0.97169014156495	1.37504349308675
CDC42	BRD-K62196610-001-01-6::2.5::HTS002	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.92777264997	-2.92777264997	-1.65572024373235	-1.61645478176	18.9580439677214	136.061733865546	5.22875198265671e-40	5.63152353613483e-37	1.13936199243257	1.40474282004273
CDC42	BRD-K62398570-300-01-2::2.5::HTS002	2.5	lerisetron	serotonin receptor antagonist	noncancer	HTR3A	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.614898160769	0.614898160769	0.497145613207713	0.5032243317015	-4.50589989793611	8.64565324583984	0.00163363156893599	0.0337969466721806	-0.177240844644388	-0.0582642504781853
CDC42	BRD-K64800655-001-07-4::2.5::HTS002	2.5	PHA-793887	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.53835408799	-2.53835408799	-1.61403307182672	-1.563662443425	8.04021672280686	6.10085428021472	0.000181783616230056	0.0048574368137354	0.644142041238044	1.20449999108853
CDC42	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.1100789238908	0.1100789238908	-1.09046735413322	-0.4202572111255	-9.74783886480866	37.3346096124611	8.32937530687713e-12	6.29709587353675e-10	-1.45001717742122	-0.951075378626824
CDC42	BRD-K67578145-001-09-7::2.38272::HTS002	2.38272	GDC-0879	RAF inhibitor	targeted cancer	BRAF	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	1.12408862708	1.12408862708	0.578987835211649	0.659791110046	-11.2112476179568	180.744854658519	1.74910995141826e-22	3.6220771669326e-20	-0.641038346874826	-0.449163236861875
CDC42	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-5.000250290495	-5.000250290495	-3.84620856552659	-3.68860468998	16.1118681794899	78.2171816265088	1.44897849182594e-26	4.26005639471278e-24	1.01144993599429	1.29663351394252
CDC42	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.5100649997675	0.5100649997675	-0.0134724597050009	-0.0198550434605	-8.16351075953769	6.5280407115707	0.000116847421193781	0.00326087134096545	-0.677435239524912	-0.36963967942009
CDC42	BRD-K68870568-066-01-5::2.5::HTS002	2.5	flumatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, PDGFRB	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.2109885283895	-0.2109885283895	0.16294837953052	0.184523838067	8.34400738413848	5.65786150415318	0.0002183565523236	0.00571360535990292	0.262650834349813	0.485222981490227
CDC42	BRD-K69694239-001-02-2::2.5::HTS002	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-6.579829774545	-6.579829774545	-5.68144334427552	-5.73883515181	10.7657587393	27.4868620865192	2.30051621112701e-11	1.64520299971518e-09	0.72730604384145	1.06946681669751
CDC42	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.774723648715	-2.774723648715	-0.509276167142864	-0.39621393329	34.90859786076	188.39091534688	3.46716490205908e-84	7.4311398629342e-79	2.13743020418805	2.39346475895622
CDC42	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.32247844297	-0.32247844297	-1.03662556531603	-0.659178147727	-7.17677318645686	148.954970712899	3.13383982157789e-11	2.20365077138769e-09	-0.910776941975922	-0.517517302716142
CDC42	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-1.44424715113	-1.44424715113	-0.650955211584767	-0.503206841324	11.6973086843049	30.2293863300668	9.48177148232717e-13	7.92596957892238e-11	0.654832490789239	0.931751388301227
CDC42	BRD-K76703230-004-04-1::2.5::HTS002	2.5	YM-155	survivin inhibitor	targeted cancer	BIRC5	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-5.10718595791	-5.10718595791	-5.49202710537224	-5.55235554655	-4.48509903317429	150.49806408791	1.43751202826859e-05	0.000481482287086699	-0.554377919113684	-0.215304375810801
CDC42	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.511456065134	-0.511456065134	0.00809626189967843	0.03806515271055	19.5403495098823	179.635727038367	2.53206639083285e-46	4.52246047900678e-43	0.467085981136032	0.572018672931325
CDC42	BRD-K77841042-001-14-1::2.5::HTS002	2.5	brefeldin-a	protein synthesis inhibitor	targeted cancer	ARF1, CYTH2	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-5.68572043928	-5.68572043928	-4.72775519578447	-4.786446704285	8.57203935853141	183.305039040258	4.15259744694798e-15	4.3585801087508e-13	0.737474433228766	1.17845605376229
CDC42	BRD-K80700417-001-04-2::2.5::HTS002	2.5	SGI-1776	Pim kinase inhibitor	targeted cancer	FLT3, PIM1, PIM2, PIM3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-1.03195867502	-1.03195867502	-0.34194470223834	-0.3090790625965	9.61636132334037	30.4699392969394	9.63984196488114e-11	6.40451856320834e-09	0.543567135278889	0.83646081028443
CDC42	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.30241514939	-0.30241514939	-0.502641493089438	-0.3823931691785	-3.24723084064542	165.989628222389	0.00141010064017212	0.0298111521116048	-0.321966570048747	-0.0784861173501291
CDC42	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.454450871033	0.454450871033	0.305873920461808	0.320041105609	-5.5611853344657	110.909438189886	1.87391334091638e-07	8.49659345134901e-06	-0.201518504845426	-0.0956353962969579
CDC42	BRD-K85849709-001-01-5::2.5::HTS002	2.5	AZD2858	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.833150455295	-2.833150455295	-1.72783308778356	-1.560521012105	11.2199051446959	179.885165752269	1.73895418186232e-22	3.60452911841749e-20	0.910925731037659	1.29970900398523
CDC42	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.3363291904725	0.3363291904725	0.039665595621243	0.0562766217073	-8.31289417316498	5.75607159490951	0.000203898797269439	0.00537202523908564	-0.384891849337338	-0.208435340365176
CDC42	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.353302202835	-2.353302202835	-3.11521370749544	-3.009227373135	-5.49096995110435	6.02885537590901	0.00150390861409892	0.031511774908466	-1.10104456568737	-0.422778443633516
CDC42	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-1.4670767075	-1.4670767075	-1.01860255742747	-0.939851070617	8.26417461421237	4.79676427933076	0.000515470765581275	0.0123111582032838	0.30717908959255	0.589769210552506
CDC42	BRD-K92150287-066-01-2::0.625::HTS002	0.625	exatecan-mesylate	topoisomerase inhibitor	chemo	TOP1	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-5.86001938692	-5.86001938692	-4.08994018997323	-4.11703772867	11.2942259691831	8.36650484888791	2.36534070401761e-06	9.12621256078112e-05	1.41140969903461	2.12874869485894
CDC42	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.901447720094	-0.901447720094	-1.83666298837758	-1.72447120363	-10.7623586266531	36.9654990830317	6.03487906188927e-13	5.12054471280945e-11	-1.11129059653882	-0.759139940028346
CDC42	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-0.9056547534975	-0.9056547534975	-1.60268848285751	-1.38505413113	-8.08367038927177	11.6294394744968	4.14196881963542e-06	0.00015319137793678	-0.885573153526717	-0.508494305193312
CDC42	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.158409028859	0.158409028859	-0.0960964109228052	-0.0469105128274	-6.23860836192046	4.45467115038903	0.00233274320203694	0.0457801008360926	-0.363354363099375	-0.145656516464236
CDC42	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-2.346853763045	-2.346853763045	-0.198564592619183	0.00102328451077	22.1699580326944	2.31447004459511	0.000953337886492238	0.021217856269366	1.78120491659001	2.51537342426162
CDC42	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	-4.33623767494	-4.33623767494	-3.15388125323107	-3.187890366305	11.6193944615681	3.33668616790092	0.000817882101787556	0.0185647655700135	0.876243185154779	1.48846965826308
CDC42	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	MFE280, NUGC3	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma	0.1051481702256	0.1051481702256	-0.078342986390543	-0.07508781022425	-5.63596999628494	17.4948095993178	2.66291251741876e-05	0.000847706612177166	-0.252033057691539	-0.114949255540747
CDH1	BRD-A20239487-001-24-9::2.5::HTS002	2.5	atenolol-(+/-)	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.341109721891667	0.343118397748	0.196920612368547	0.206837465744	-4.32244866202683	9.42452230563863	0.00172992375463835	0.035531655812926	-0.21913561957067	-0.06924259947557
CDH1	BRD-A74765037-001-01-1::2.5::HTS002	2.5	estradiol-benzoate	contraceptive agent	noncancer	ESR1	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-0.108027462494733	-0.103077422539	0.0319516562426105	0.0185873487963	4.00629013619715	14.2077953633203	0.00126480524160728	0.0271491680148669	0.0651433176724124	0.214814919802275
CDH1	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-0.675097612785667	-0.671957270129	-1.91566893335112	-1.744671566725	-10.7966312273611	42.7085041294788	8.74160021816675e-14	8.05147586230968e-12	-1.47234217173968	-1.00880046939123
CDH1	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	LN18, NCIH1693	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.4174239553645	0.4174239553645	0.198837742249646	0.204355413473	-7.02929591763311	18.2613521465463	1.35412813413407e-06	5.42179953037217e-05	-0.283850493164342	-0.153321933065365
CDH1	BRD-K11630072-001-13-2::0.625::HTS002	0.625	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.1111675427908	0.135469402469	-0.280310567347349	-0.202592948555	-6.66671711486145	21.1594218087466	1.29086608571254e-06	5.18497071373093e-05	-0.513539681908824	-0.269416538367474
CDH1	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-1.66360442329667	-1.59127853712	-2.46019349476751	-2.47957916758	-6.58931253630526	12.6921023327859	1.96127941695909e-05	0.000640498333319252	-1.05840386709104	-0.534774275850638
CDH1	BRD-K16136380-001-01-7::2.5::HTS002	2.5	pyrithione-zinc	ATP synthase inhibitor	noncancer	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	LN18, NCIH1693	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-5.27828682204	-5.27828682204	-6.35186030008024	-6.34443535145	-8.99471727003783	15.8683151758196	1.25595825386125e-07	5.84429606148126e-06	-1.32676765466565	-0.820379301414836
CDH1	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-0.223290454711667	-0.238746757787	-1.14440778390282	-0.8933435345705	-9.49179698934357	125.498462432511	1.95347471001216e-16	2.33902950347595e-14	-1.11317103090219	-0.72906362748012
CDH1	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.493730712050667	0.460225837662	-0.387383850898809	-0.1974546788955	-8.89977452652678	9.96281291577244	4.69536482041574e-06	0.000172173284276285	-1.10182120401604	-0.660407921882912
CDH1	BRD-K20755323-001-05-9::2.5::HTS002	2.5	SKI-II	sphingosine kinase inhibitor	targeted cancer	SPHK1	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.425272264226667	0.422553105431	0.0500854023975881	0.0641912137013	-6.45095740602489	4.80326338362241	0.00154639882654761	0.0322661715435284	-0.52655231052615	-0.223821413132007
CDH1	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.0479832857982667	0.0563388713157	-0.075435621372226	-0.0633939045143	-3.54320288401266	42.33064107561	0.000978319868920232	0.0217129873859174	-0.193697641558301	-0.053140172782684
CDH1	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-2.11243464849667	-2.06703060926	-3.00478435010626	-3.129070651175	-6.38255137095649	6.77678732861643	0.000426623909750621	0.0104036723123155	-1.22517005075249	-0.559529352466707
CDH1	BRD-K44827188-001-06-0::2.5::HTS002	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.249200471897333	0.246777630758	-0.117947991522023	-0.0656373257446	-4.88295737783403	6.28950876623199	0.00241803355894178	0.0471955846147375	-0.549097721512317	-0.185199205326395
CDH1	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.230180997233667	0.226308857767	-0.270127514568833	-0.237001689988	-11.6324565836762	20.7499923922909	1.49569867066446e-10	9.70546776823627e-09	-0.589817751624997	-0.410799271980003
CDH1	BRD-K49371609-003-03-8::2.5::HTS002	2.5	PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-4.17307247977667	-4.23036648012	-5.36001351699065	-5.36977024652	-9.93271035297123	5.25248541189898	0.000133331380752794	0.00367263610144784	-1.48973234262373	-0.884149731804232
CDH1	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-0.548694514841	-0.608052769445	-1.11639976862913	-1.02042464103	-6.0184804033846	4.93711025217268	0.00190254333908632	0.0384398766330158	-0.811112508937399	-0.324297998638861
CDH1	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-2.69665558407333	-2.68008518692	-1.99710116943388	-2.18307290243	7.79954618779085	130.411272211067	1.75169528210891e-12	1.42265668101221e-10	0.52211540584897	0.876993423429941
CDH1	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.193486242485667	0.194046714045	-0.237252068123416	-0.176604083321	-7.58835255018129	190.584838947564	1.39768106665108e-12	1.14555864372565e-10	-0.542702895796875	-0.31877372542129
CDH1	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.152284373839567	0.106771043643	-0.498788949307005	-0.003081886328155	-6.35240784632897	31.438121869262	4.24768270490528e-07	1.83179393653852e-05	-0.859989878846228	-0.442156767446915
CDH1	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-1.00650248961533	-0.988563830231	-1.85226353497487	-1.767693319835	-8.79167814531866	151.967789322709	2.96418445368073e-15	3.14531953439952e-13	-1.03582348578087	-0.655698604938208
CDH1	BRD-K79612754-001-19-1::2.62081::HTS002	2.62081	inosine	neurotrophic agent	noncancer	PARP1, PNP	NA	NA	LN18, NCIH1693	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-2.012427894695	-2.012427894695	-1.39202040313862	-1.34952956082	9.44000565450157	188.064869371996	1.46544597558183e-17	1.93761610425958e-15	0.490762232568561	0.7500527505442
CDH1	BRD-K81016934-001-02-0::2.5::HTS002	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.291640475473	0.279869623049	0.141478826284137	0.199846390298	-4.27970222142143	43.6030685034262	0.000100765753673958	0.00285486096750639	-0.220892913614366	-0.0794303847633607
CDH1	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	LN18, NCIH1693	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.632916453189	0.632916453189	0.278888660475587	0.273644438403	-8.41091070566158	5.97948398326799	0.000156756620752233	0.00425607927149803	-0.45710768773914	-0.250947897687686
CDH1	BRD-K81528515-001-13-8::2.5::HTS002	2.5	nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	targeted cancer	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.686140525626	0.694999277845	0.18238119208192	0.219640118402	-5.94326073278145	4.83611546773161	0.00215767595539041	0.0427879838862761	-0.72388522469823	-0.28363344238993
CDH1	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	-1.05585511080933	-1.09018564289	-1.71009770062301	-1.55245273459	-7.324607659638	9.89193472181375	2.68110120457661e-05	0.000852325333841147	-0.853557683443323	-0.454927496184025
CDH1	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	CAL120, LN18, NCIH1693	BREAST, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma, glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (adenocarcinoma)	0.284294574279667	0.283107666528	0.0912877339492228	0.155322247219	-6.38546565045244	158.392052470227	1.80819917165667e-09	1.04782640086172e-07	-0.252704757369644	-0.133308923291243
CDH12	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.345147529012	0.345147529012	0.151281522212503	0.162581247373	-5.75148891985801	9.81360926258931	0.00019856670835049	0.00524961194449884	-0.26916390792076	-0.118568105678235
CDH12	BRD-A75726477-003-21-3::2.5::HTS002	2.5	clenbuterol	adrenergic receptor agonist	noncancer	ADRB1, ADRB2, ADRB3, NGF, TNF	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.0192333803969	0.0192333803969	0.36766472411856	0.3771474213795	11.3948753670533	173.953656764337	7.96200070723005e-23	1.68959173225734e-20	0.28807989438093	0.40878279306239
CDH12	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.219876953065	-0.219876953065	-1.19864279846031	-1.043529721605	-14.5934155547685	153.567371663984	8.20043481526544e-31	3.48728371730363e-28	-1.11126281779402	-0.846268872996589
CDH12	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.3970967030025	0.3970967030025	0.260717094902657	0.303778240807	-3.44582534959137	66.0384331405949	0.000994432643810261	0.0220249823411398	-0.215399200667227	-0.0573600155324596
CDH12	BRD-K03273112-001-01-8::2.5::HTS002	2.5	1-azakenpaullone	glycogen synthase kinase inhibitor	noncancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.131359498962	-0.131359498962	-0.721156031002799	-0.657905942127	-7.89617393800898	83.1112175824495	1.03896806082427e-11	7.75891935569354e-10	-0.738356882264118	-0.44123618181748
CDH12	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.1018309362277	-0.1018309362277	-0.382507622975021	-0.278845004201	-4.88227691477311	188.958963222817	2.22529520246677e-06	8.62001256912165e-05	-0.394079149483006	-0.167274224011635
CDH12	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-4.626429350585	-4.626429350585	-4.27041839690403	-4.2400927308	4.51100154036924	8.46827118948583	0.00170921552477996	0.0351568574098429	0.175756634229601	0.536265273132336
CDH12	BRD-K07310275-001-02-5::2.5::HTS002	2.5	PF-04691502	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-3.502546666235	-3.502546666235	-3.92850547128394	-3.94541046238	-4.42121597489663	177.634657656139	1.70538803402548e-05	0.000564326249721548	-0.616085413463116	-0.235832196634771
CDH12	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-5.463104935795	-5.463104935795	-3.00384038302361	-2.91986435367	19.641349434508	5.19484459718342	4.47923013359541e-06	0.000164953421873431	2.14100309936335	2.77752600617942
CDH12	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.0083940323209	-0.0083940323209	-0.308887603554366	-0.199486634258	-4.42584471702295	7.69182236265328	0.00243161632920516	0.0474162495288431	-0.458158801407913	-0.14282834105902
CDH12	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.315121600775	-1.315121600775	-2.20718526984912	-2.14710453103	-11.9080593704766	182.914206195955	1.41543386889588e-24	3.54500306841025e-22	-1.03986757972243	-0.744259758425812
CDH12	BRD-K11630072-001-13-2::2.5::MTS010::PROS004_PR500	2.5	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.7038768108365	-0.7038768108365	-0.234067343569039	-0.1778523821605	9.46753829998399	191.612469376123	1.08735509550587e-17	1.45930951950331e-15	0.371931602703174	0.567687331831748
CDH12	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-2.90858857591	-2.90858857591	-2.41063423410558	-2.32376274045	7.01801314812332	190.204428202927	3.85443239140307e-11	2.67524818658364e-09	0.357997036885033	0.637911646723806
CDH12	BRD-K12251893-065-04-7::2.5::HTS002	2.5	vincristine	tubulin polymerization inhibitor	chemo	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.95062371818	-1.95062371818	-2.71293666590398	-2.6144312066	-5.86616798653383	7.94852288608401	0.000385173567642072	0.00948601974775504	-1.06231806939643	-0.462307826051525
CDH12	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-3.346930651375	-3.346930651375	-2.59522127243915	-2.674840125005	10.5133398828475	161.457322527769	5.0655244993766e-20	8.42272149283853e-18	0.610512581252501	0.892906176619192
CDH12	BRD-K17979676-001-01-2::2.5::HTS002	2.5	eprobemide	monoamine oxidase inhibitor	noncancer	MAOA	neurology/psychiatry	depression	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.207559560541	0.207559560541	-0.0479473025696858	-0.01607222471295	-4.58106692457031	11.9020995593505	0.000644607087127113	0.0149927284185423	-0.377140083810483	-0.133873642410889
CDH12	BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500	2.5	sonidegib	smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.09659821418875	0.09659821418875	-0.00050553118520688	0.0115719304002	-5.2389440501992	191.250266535583	4.24173162519618e-07	1.82959568826056e-05	-0.133662992231478	-0.0605444985164361
CDH12	BRD-K21782625-001-02-4::2.5::HTS002	2.5	AMG458	MET inhibitor	targeted cancer	MET	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.1266757248125	-0.1266757248125	0.0292762396695534	0.0127189864736	3.65567418775226	191.000000366016	0.000331479058985822	0.00829390324928465	0.0718062484340499	0.240097680530057
CDH12	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.767378426645	-1.767378426645	-0.960602032845298	-0.757900155601	7.23397439673428	15.5309723872651	2.37405126287341e-06	9.15817194241173e-05	0.569770178003006	1.0437826095964
CDH12	BRD-K24603946-001-02-1::2.5::HTS002	2.5	5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	noncancer	CHRM3	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.997426004435	-1.997426004435	-2.4265546640447	-2.202066494735	-4.21998665127714	165.986809147578	4.01179328561294e-05	0.00123239736722393	-0.62990038357909	-0.228356935640304
CDH12	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.686246199887	-0.686246199887	-0.399147304456311	-0.300509996498	4.93828307902608	180.034177837636	1.7904655730591e-06	7.01423315313806e-05	0.172380550453484	0.401817240407894
CDH12	BRD-K25690923-001-02-4::2.5::HTS002	2.5	4-iodo-6-phenylpyrimidine	macrophage migration inhibiting factor inhibitor	targeted cancer	MIF	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.1305517828795	0.1305517828795	0.240897322088047	0.240167075909	3.75426500414713	24.8036122958847	0.000937912967551942	0.020928885832633	0.0497871700825786	0.170903908334515
CDH12	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-2.16914251327	-2.16914251327	-3.09358981735864	-2.9100349769	-9.48347822532509	186.467205795605	1.16881175170787e-17	1.55983968824282e-15	-1.11675225606539	-0.732142352111891
CDH12	BRD-K26619122-001-02-1::2.5::HTS002	2.5	thiocolchicoside	GABA receptor antagonist	noncancer	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.0566348982271	-0.0566348982271	0.160552949157647	0.1742741148005	7.03457206639217	7.28312431630055	0.000170431899112206	0.00459016065654939	0.144753010530428	0.289622684239065
CDH12	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.164547571385	-1.164547571385	-1.9709102591562	-1.89093805071	-10.8509054156433	116.982371936009	2.1049917908977e-19	3.29074241831738e-17	-0.953535803923303	-0.659189571619094
CDH12	BRD-K33588785-001-01-9::2.5::HTS002	2.5	obidoxime	cholinesterase reactivator	noncancer	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.2781326917685	0.2781326917685	0.172148052731851	0.177010520924	-3.8944584921778	32.3961480839964	0.000463709130897263	0.0112110901653784	-0.16139161279301	-0.0505776652802885
CDH12	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.125320590673	-0.125320590673	0.166602977581617	0.1606220898175	10.6037035073883	12.8182656902478	1.03480128885081e-07	4.87124808781253e-06	0.232362052599682	0.351485083909552
CDH12	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-2.647079172145	-2.647079172145	-1.92017843361676	-1.7784006568	8.22704290196596	75.0315572917189	4.39905649976554e-12	3.43978613841025e-10	0.550889678212509	0.902911798843973
CDH12	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.140243634739	-0.140243634739	0.134878519712206	0.1319992768505	7.80883048014652	18.6562155728223	2.71123942586269e-07	1.20309986522924e-05	0.2012882655438	0.348956043358611
CDH12	BRD-K36740062-001-06-6::2.5::HTS002	2.5	GSK1070916	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC, CYP2D6, CYP3A4	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-3.591532100355	-3.591532100355	-2.24347794256477	-1.941905488655	10.2341941101231	6.56886779923623	2.81916580587773e-05	0.000891456164071949	1.0323920487918	1.66371626678866
CDH12	BRD-K37249724-001-25-7::2.5::HTS002	2.5	astemizole	histamine receptor antagonist	noncancer	HRH1, KCNH1, KCNH2	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.5121883661305	0.5121883661305	0.0578008444313097	0.100436576625	-12.3471789768667	173.514915684404	1.53610307492822e-25	4.11025513041561e-23	-0.527022600659109	-0.381752442739272
CDH12	BRD-K39171998-001-01-1::2.5::HTS002	2.5	STF-118804	NAMPT inhibitor	targeted cancer	NAMPT	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-5.84482420678	-5.84482420678	-4.65382847047266	-4.65401991694	10.7723865335095	14.0188346619755	3.64066465797467e-08	1.8104408711811e-06	0.953897869675942	1.42809360293873
CDH12	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.054040733701005	0.054040733701005	-0.499178206155838	-0.332266676493	-7.6975782433417	4.55574673939576	0.000889070888046285	0.0199595343421046	-0.743517068311107	-0.36292081140258
CDH12	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.434025559085	-1.434025559085	-2.29700483346537	-2.14029239454	-9.85432047205037	119.239575620936	4.04570591889672e-17	5.11570562767679e-15	-1.03638036233426	-0.689578186426474
CDH12	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.91038842299	-1.91038842299	-0.708029619908211	-0.576037096811	9.98586822194878	5.35895186984402	0.000115469344696292	0.00322707382701937	0.898978139151905	1.50573946701167
CDH12	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.0400775773075	-0.0400775773075	-0.95554573166713	-0.580280097075	-10.4167366796954	71.280394492882	5.75180740940296e-16	6.55384970893103e-14	-1.09069263065533	-0.740243678063933
CDH12	BRD-K49328571-001-15-0::2.5::MTS010::PROS005_PR500	2.5	dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor	targeted cancer	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.931181728064	-0.931181728064	-0.461717905824774	-0.279272959842	4.77343326575135	8.12218069345366	0.00134463855925336	0.0286220118945489	0.243262397845743	0.695665246632708
CDH12	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.858680088013	-0.858680088013	-0.450709343683269	-0.3126477114325	7.7899308039656	119.311910756144	2.74698130395699e-12	2.18869054236356e-10	0.304272630720147	0.511668857939314
CDH12	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.3939205530415	0.3939205530415	-0.11525823154774	0.03876057814515	-9.47915245203083	37.6816726908467	1.60800711817418e-11	1.1746508440053e-09	-0.617950597527407	-0.400406971651072
CDH12	BRD-K51318897-001-15-3::2.5::HTS002	2.5	fenbendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-2.292915732	-2.292915732	-2.76016508183286	-2.716477305745	-4.52531598384893	150.382013778004	1.21726196294711e-05	0.0004124814849905	-0.671261934282772	-0.263236765382958
CDH12	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.128188188549	0.128188188549	0.381490611581232	0.394227062385	8.06323320185804	5.19669559835218	0.000395694648380047	0.00971464356158616	0.173459617695462	0.333145228369002
CDH12	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-6.78807066578	-6.78807066578	-5.91421221776487	-5.9507974936	11.6930269384723	24.513398350492	1.61766870998826e-11	1.18009978537466e-09	0.719787273561538	1.02792962246872
CDH12	BRD-K53972329-001-07-0::2.5::HTS002	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.3351808306025	0.3351808306025	0.557915287147899	0.4808891597695	4.38575599430241	128.832660765262	2.37898292546397e-05	0.0007641016505796	0.122252122949893	0.323216790140905
CDH12	BRD-K54095730-001-03-1::2.5::HTS002	2.5	CMPD-1	p38 MAPK inhibitor	noncancer	GNRHR, MAPK14	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.928241815555	-1.928241815555	-1.50828336334554	-1.52656619113	5.75583941104698	28.8761465935572	3.1664826073204e-06	0.000119462955596616	0.270706281961938	0.569210622456983
CDH12	BRD-K56483981-342-06-4::2.5::HTS002	2.5	chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	noncancer	MIF	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.163421178996	0.163421178996	0.264969329409286	0.2788714906115	3.56767188166975	189.85859323499	0.000455988057540764	0.0110455995009781	0.045402980283348	0.157693320543223
CDH12	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.127734683804	0.127734683804	-0.394528097592597	-0.201440599557	-7.75544407454151	53.4967982725372	2.5980917712996e-10	1.64552722000849e-08	-0.657303332845797	-0.387222229947397
CDH12	BRD-K58049875-001-04-7::2.5::HTS002	2.5	thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	noncancer	FOXM1	obstetrics/gynecology	mastitis	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.613773898513	-0.613773898513	-0.806625246981281	-0.698370160758	-3.07310861193714	162.931650053828	0.00248387235537192	0.0483002974101351	-0.316768288517573	-0.0689344084189891
CDH12	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.5692705408215	-0.5692705408215	-1.19001838238519	-1.12103485225	-11.0741149350101	190.467822126493	2.53348935391923e-22	5.13232740771412e-20	-0.73131408928153	-0.510181593845842
CDH12	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.527312689805	0.527312689805	0.0323684454766947	0.07942712884705	-14.1116840215418	12.8099977811949	3.51317453289165e-09	1.97320541001084e-07	-0.570830045923915	-0.419058442732696
CDH12	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.6766886973215	-0.6766886973215	-1.4884678299939	-1.417507299725	-9.51422094084985	5.42442487301311	0.000138070240738404	0.00378565391163124	-1.02604564519009	-0.597512620154714
CDH12	BRD-K65928735-001-04-3::2.5::HTS002	2.5	AZD1480	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.6582744322275	-0.6582744322275	-0.0172891277554491	-0.05528360346055	13.2022123039492	2.74895451190041	0.00144300735956808	0.0304148683270771	0.478175518802171	0.80379509014193
CDH12	BRD-K66808046-065-03-7::2.5::HTS002	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.05524546943815	0.05524546943815	-0.459812577247672	-0.3317635225235	-6.17393139362785	156.816285005323	5.4712349867429e-09	3.01131594784458e-07	-0.679839004595714	-0.35027708877593
CDH12	BRD-K68633617-003-02-9::2.5::HTS002	2.5	ACDPP	glutamate receptor antagonist	noncancer	GRM5	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.508055863258	0.508055863258	0.23429056986978	0.319454889976	-5.24920808302673	71.4000335716816	1.50321673885255e-06	5.97742004492632e-05	-0.377746596465571	-0.169783990310869
CDH12	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.193083415013	-0.193083415013	-0.613890700906186	-0.443084865138	-6.94073993491443	11.4652823438692	1.97847619026686e-05	0.000645622447295533	-0.553592174701705	-0.288022397084668
CDH12	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.194926684665	-1.194926684665	-0.885319221317779	-0.689609968602	4.9488390864222	118.380237370314	2.49788068089429e-06	9.58925789818004e-05	0.185722516323295	0.433492410371147
CDH12	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-2.339797018755	-2.339797018755	-2.63364786358919	-2.52531204565	-3.73206155210342	193.215484227176	0.000249673789972313	0.00644261181446856	-0.449144974627865	-0.138556715040518
CDH12	BRD-K74501079-001-18-1::2.5::HTS002	2.5	azithromycin	bacterial 50S ribosomal subunit inhibitor	noncancer	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.437441987875	-0.437441987875	-0.784368937372745	-0.6289149698795	-5.03947898444192	136.58475013608	1.45354012762092e-06	5.79278174066313e-05	-0.483060618283988	-0.210793280711502
CDH12	BRD-K74671368-001-01-8::2.5::MTS006	2.5	idronoxil	XIAP inhibitor	targeted cancer	ENOX2, SPHK1	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.54938016585	-0.54938016585	-0.248332184641592	-0.186172390275	6.99525719061334	18.3615962360806	1.40255214722399e-06	5.60103594489231e-05	0.210760132967256	0.391335829449561
CDH12	BRD-K76674262-001-03-3::2.5::HTS002	2.5	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-6.12510958627	-6.12510958627	-4.73900913054046	-4.86837811059	11.9839786486986	9.26457640908308	5.9981228515202e-07	2.5326471092267e-05	1.12558763191189	1.6466132795472
CDH12	BRD-K77625799-001-07-7::2.5::HTS002	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.7504291246085	0.7504291246085	0.100931837922283	0.160912505802	-10.2643507278916	7.4883212449994	1.12461571968957e-05	0.000383512748743589	-0.797168166193102	-0.501826407179332
CDH12	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.596172271755	-1.596172271755	-2.21374796034828	-2.0670113581	-5.71776583734037	56.705157335392	4.20893616323091e-07	1.81618095214238e-05	-0.833886288360204	-0.401265088826358
CDH12	BRD-K79612754-001-19-1::2.62081::HTS002	2.62081	inosine	neurotrophic agent	noncancer	PARP1, PNP	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.868782909015	-0.868782909015	-1.40412246647915	-1.36932187497	-7.34671536305173	26.3179255593864	7.80275408544711e-08	3.72048160262468e-06	-0.685033611705642	-0.385645503222655
CDH12	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.980580067986	-0.980580067986	-0.318015996013443	-0.3195858510195	7.85365367537822	5.12903040754538	0.000477912362819871	0.0115116294460351	0.447330717809741	0.877797426135373
CDH12	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.1808772241265	0.1808772241265	0.308738565979153	0.330760339171	4.11868051329604	10.246096645572	0.0019775533851941	0.0397195238960985	0.0589149838185796	0.196807699886727
CDH12	BRD-K83988098-001-02-0::0.039::MTS010::PROS005_PR500	0.039	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.579549550892	0.579549550892	-0.991526749371505	-0.942675371448	-12.7902729174509	7.19452984270505	3.29480000195994e-06	0.000124042014688226	-1.85994731163874	-1.28220528888827
CDH12	BRD-K84163249-001-01-9::2.5::HTS002	2.5	ercalcitriol	vitamin D receptor agonist	noncancer	VDR	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.727644148909	-0.727644148909	-0.515806466592867	-0.503488543469	3.99705063946853	10.6323457871504	0.00224136892575531	0.0442368645721143	0.0946947583940658	0.328980606238199
CDH12	BRD-K85606544-001-09-1::2.5::HTS002	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.667570486826	-0.667570486826	-1.5988630440361	-1.5159358626	-8.6615064969347	6.6198164418776	7.5483645580924e-05	0.00219486287799672	-1.18852915466459	-0.67405595975561
CDH12	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.040572932563	0.040572932563	-0.325487485170049	-0.193950713334	-6.54166020591103	39.780922705524	8.39955493173074e-08	3.98818832291298e-06	-0.479175837463611	-0.252944998002487
CDH12	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-5.381547045535	-5.381547045535	-4.83622606269198	-4.95161811894	5.31377199243093	20.6945890908221	3.00602146027195e-05	0.000945520360373683	0.331710573838612	0.758931391847431
CDH12	BRD-K87696786-003-04-4::2.5::HTS002	2.5	LY456236	glutamate receptor antagonist	noncancer	GRM1	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.35437359029	-1.35437359029	-2.19687096634941	-2.03818987744	-8.42920736681137	44.2774052662768	9.36712258343406e-11	6.23298980498242e-09	-1.04389727171179	-0.641097480407031
CDH12	BRD-K88568253-011-19-9::2.5::HTS002	2.5	iproniazid	monoamine oxidase inhibitor	noncancer	MAOA, MAOB	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.315199808697	0.315199808697	0.475089330612778	0.497154810155	5.04863325566027	107.788036835353	1.82101491953815e-06	7.12739785773724e-05	0.0971129613733624	0.222666082458193
CDH12	BRD-K89299012-001-06-0::2.5::HTS002	2.5	DCEBIO	potassium channel activator	noncancer	KCNN2, KCNN3, KCNN4	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.15541386867	-1.15541386867	-2.05242107110863	-1.8672769967	-10.0938407367756	177.103234565431	3.27531461365907e-19	5.03583146220182e-17	-1.07238130105197	-0.721633103825296
CDH12	BRD-K89391146-001-08-0::2.5::HTS002	2.5	RG108	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3B	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.0967310624651	0.0967310624651	0.383277656653315	0.404681325209	8.81154215434583	6.26474252078622	9.31206484513185e-05	0.00265334425178445	0.207782393389829	0.3653107949866
CDH12	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	-2.42055569918	-2.42055569918	-3.11451315024185	-3.009227373135	-6.39222414893511	175.206784205208	1.43216107996651e-09	8.37984308239539e-08	-0.908216492499199	-0.479698409624499
CDH12	BRD-K90574421-001-03-5::2.5::HTS002	2.5	ipsapirone	serotonin receptor agonist	noncancer	HTR1A	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.1919606053095	0.1919606053095	-0.0413154777830738	-0.0540308709753	-9.27479164233572	113.947859405718	1.3634924241417e-15	1.49864598858393e-13	-0.283101503427873	-0.183450662757275
CDH12	BRD-K95785537-001-23-1::2.5::HTS002	2.5	PP-2	src inhibitor	targeted cancer	ABL1, LCK, LYN, RIPK2, SRC	NA	NA	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.09303518315865	0.09303518315865	-0.27707898146543	-0.127481786851	-3.91865363870118	13.0826221607475	0.00174283824779961	0.0357250171014386	-0.57402859554724	-0.166199733700919
CDH12	BRD-K96344439-002-02-7::2.5::MTS006	2.5	tofogliflozin	sodium/glucose cotransporter inhibitor	noncancer	GCK	endocrinology	diabetes mellitus, diabetes mellitus	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.4080272364505	0.4080272364505	0.135515030943113	0.243893587025	-7.60760116000886	178.830308814406	1.53439321754152e-12	1.25138875160752e-10	-0.343198520094969	-0.201825890919805
CDH12	BRD-K97472745-001-01-8::2.5::HTS002	2.5	gestrinone	progesterone receptor antagonist	noncancer	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.2371766022955	0.2371766022955	-0.165005331116758	-0.1123477003	-7.64474920514142	4.22866652038161	0.00125319964630865	0.026948633188892	-0.545184771089375	-0.259179095735142
CDH12	BRD-K99964838-001-11-9::2.5::HTS002	2.5	bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	targeted cancer	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	U2OS, ONS76	BONE, CENTRAL_NERVOUS_SYSTEM	osteosarcoma, primitive_neuroectodermal_tumour-medulloblastoma	0.02335726852556	0.02335726852556	-0.397776375724673	-0.289629896197	-6.52746311094559	19.0156815858911	2.97138668089956e-06	0.000112837408917527	-0.556162159430866	-0.286105129069599
CHCHD3	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.143380255987	-0.143380255987	-0.955599366357693	-0.8814928301585	-12.9517853491572	112.674940767027	4.73376237808874e-24	1.1149258865202e-21	-0.936464745051205	-0.687973475690181
CHCHD3	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.2526724489525	0.2526724489525	0.0881959439929583	0.1234730068455	-5.06998202215511	8.02883017809404	0.000954471228179548	0.0212386694211477	-0.239239406515078	-0.0897136034040055
CHCHD3	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.194412562318	0.194412562318	-0.346737202364492	-0.266254262221	-11.7098627529628	6.70942042773848	1.03456823233045e-05	0.000355349318376848	-0.651393285000112	-0.430906244364871
CHCHD3	BRD-A50998626-001-02-1::2.5::HTS002	2.5	palomid-529	AKT inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.228485432004	-0.228485432004	0.0473460705060739	0.0375657070821	7.67592496010205	8.96830654669243	3.1366092652752e-05	0.000981410696667398	0.194497916293926	0.357165088726222
CHCHD3	BRD-A55484088-050-02-5::2.5::HTS002	2.5	BNTX	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.604445367155	-0.604445367155	-1.39227551835387	-1.31545762585	-8.25426421184199	3.52863327614	0.00198401819372388	0.0398239329896465	-1.06739060327806	-0.508269699119689
CHCHD3	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.1699178145235	-0.1699178145235	-0.534053145047492	-0.51783728433	-11.0427298942098	58.8564961961549	5.67552545215661e-16	6.47037071614508e-14	-0.430121757213717	-0.298148903834266
CHCHD3	BRD-A70858459-001-01-7::2.5::MTS010::PROS003_PR500	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.255067084663	0.255067084663	-0.0179468247867451	-0.0158635898493	-10.137714318445	3.69617984034448	0.000788397900651358	0.0179628503931865	-0.350272409141969	-0.195755409757522
CHCHD3	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.2087680364165	0.2087680364165	0.0289341811014892	0.05909936864605	-3.22649587528516	72.068519327812	0.00188600813279375	0.0381453465219923	-0.290940898197947	-0.068726812432075
CHCHD3	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.2129073592455	-0.2129073592455	0.0479777661835675	0.0776480680764	6.75404457826018	6.76792876462507	0.000306297397355637	0.00771789500092128	0.168909207117109	0.352861043741026
CHCHD3	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.64994064077	-1.64994064077	-0.832004365609715	-0.7893202345315	13.9954412884716	152.311423229209	3.86297541791961e-29	1.46799230203421e-26	0.702472590528396	0.933399959792173
CHCHD3	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.99084080388	-0.99084080388	-1.90586758412204	-1.73380354334	-7.16590138354624	7.83254452024293	0.000106125875573398	0.00298894254740748	-1.21058397472886	-0.619469585755222
CHCHD3	BRD-K00673382-001-18-9::0.15625::HTS002	0.15625	famotidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	heartburn	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	1.055950107415	1.055950107415	0.495584776354197	0.4883209569055	-15.2515751236637	52.8492957688045	5.3068200984406e-21	9.60646490606988e-19	-0.634064298692117	-0.486666363429489
CHCHD3	BRD-K03109492-001-02-2::2.5::HTS002	2.5	NSC-663284	CDC inhibitor	targeted cancer	CDC25A, CDC25B, CDC25C	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.6614841494355	-0.6614841494355	-1.21586298814018	-0.957814328752	-5.90013630795567	30.5935481490111	1.71320277473954e-06	6.73617753636305e-05	-0.746115467268156	-0.362642210141196
CHCHD3	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.290136069435	-1.290136069435	-2.03420730777994	-1.93975006052	-8.18187579158172	46.4936192106546	1.4774791361006e-10	9.5959583564032e-09	-0.92707435041766	-0.56106812627223
CHCHD3	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0995569869458	-0.0995569869458	-0.650038450577639	-0.593822379071	-8.89527962975938	36.614769295496	1.10683899456425e-10	7.29482456537398e-09	-0.675916266273898	-0.42504666098978
CHCHD3	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.09314637458545	0.09314637458545	-0.360215834922193	-0.164030729397	-7.02623383997649	74.0571516049097	8.75364796786439e-10	5.23994190819127e-08	-0.581927862008758	-0.324796557006528
CHCHD3	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.2501518460975	-0.2501518460975	-0.685503901840634	-0.506361258966	-5.25343189914792	7.89665753580134	0.000803663235149652	0.018267932710403	-0.626886874554548	-0.24381723693172
CHCHD3	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.8397997371235	-0.8397997371235	-1.02845807815347	-1.0089298839585	-3.48326123802888	110.848928108722	0.000710141498154717	0.01637305477173	-0.295984402970576	-0.0813322790893589
CHCHD3	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-2.99977134539	-2.99977134539	-1.66708129878742	-1.3362918287	8.82863761945716	5.76493636477364	0.000146169025875051	0.00398781328243047	0.959645056615717	1.70573503658945
CHCHD3	BRD-K06753942-001-14-5::2.5::HTS002	2.5	nobiletin	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.5431898261975	0.5431898261975	-0.081081965728957	-0.0747677969197	-9.50771748192462	6.2078415460766	6.29287062360698e-05	0.00186114310840173	-0.7836398161364	-0.464903767716514
CHCHD3	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4690641482045	0.4690641482045	0.198291285182556	0.204355413473	-9.17200280821641	40.5538831527891	1.92997107133892e-11	1.39181954828062e-09	-0.330413014458965	-0.211132711584923
CHCHD3	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.4626422201165	-0.4626422201165	-0.852745410796999	-0.70967469814	-7.45417795059286	188.492878704402	3.18735640869093e-12	2.52454882379275e-10	-0.493337776719601	-0.286868604641396
CHCHD3	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6848375363275	0.6848375363275	0.00811541593336888	0.1859491052615	-11.0033596434448	176.274328037901	9.03641203587009e-22	1.74169528348561e-19	-0.798095958047412	-0.55534828274085
CHCHD3	BRD-K09372874-001-01-0::2.5::HTS002	2.5	merimepodib	inosine monophosphate dehydrogenase inhibitor	noncancer	IMPDH1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.6672050202595	-0.6672050202595	-0.902887357191151	-0.8954429864795	-4.39962508731538	177.808243427521	1.86475830096742e-05	0.000611351498314497	-0.341394629074954	-0.129970044788349
CHCHD3	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.191733275028	0.191733275028	-0.0728992225173221	-0.00556532595827	-5.94450974738381	25.8591792106449	2.90265144036222e-06	0.000110364090928046	-0.356163022331909	-0.173101972758735
CHCHD3	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.5878697530815	0.5878697530815	0.340225381688683	0.3517633375585	-7.95232680360998	165.061911516017	2.74931208698356e-13	2.41399963249119e-11	-0.309130651333977	-0.186158091451657
CHCHD3	BRD-K12244279-001-05-8::2.5::HTS002	2.5	MEK1-2-inhibitor	MEK inhibitor	noncancer	MAP2K2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.3574722436545	-0.3574722436545	-0.15342438186307	-0.1558908725075	6.20191229016429	56.7485600565595	6.80415357988247e-08	3.27125938228495e-06	0.13815882374514	0.269936899837721
CHCHD3	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.8775863055775	-0.8775863055775	-0.414640652386738	-0.389042162364	12.373026567344	24.5604715815534	4.77858531720589e-12	3.71217619590946e-10	0.385816557733298	0.540074748648227
CHCHD3	BRD-K13646352-001-03-8::2.5::HTS002	2.5	midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	targeted cancer	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.611305461695	-1.611305461695	-2.96860098439146	-2.8725192622	-11.1384075430077	6.96428790226796	1.08688431802606e-05	0.00037176959623078	-1.64574189451997	-1.06884915087296
CHCHD3	BRD-K14618467-001-04-6::2.5::HTS002	2.5	IKK-16	IKK inhibitor	noncancer	IKBKB	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4457524525325	0.4457524525325	-0.143897718968006	-0.114726429386	-15.1665890239398	187.628366849601	1.95107132639395e-34	1.18462086774699e-31	-0.66634479402761	-0.512955548973402
CHCHD3	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.3656424524295	0.3656424524295	-0.0472340311821558	0.0935597000564	-6.32411084356667	36.5179780666092	2.4186074749953e-07	1.07860532981329e-05	-0.545217635009174	-0.280535332214138
CHCHD3	BRD-K16338837-001-02-6::2.5::HTS002	2.5	CCMI	acetylcholine receptor allosteric modulator	noncancer	CHRNA7	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0779018371998	-0.0779018371998	0.0896409842706517	0.1287819664105	5.08646732913564	25.9402101993626	2.69222307136183e-05	0.000854973297765461	0.0998282728440002	0.235257370096903
CHCHD3	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.47469877822	-0.47469877822	-0.689479949615301	-0.593823716309	-3.76223870639841	68.5327309151692	0.000351252044390216	0.00874372815587812	-0.328683789341823	-0.100878553448779
CHCHD3	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.489238876245	0.489238876245	0.297123845374995	0.330939410236	-7.25048054543683	25.3202804137076	1.24631206289376e-07	5.80318961824802e-06	-0.246651373584853	-0.137578688155158
CHCHD3	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6294213533085	0.6294213533085	0.0853640956245527	0.0863678330512	-14.6019312131432	3.13775536738165	0.000545805115068394	0.0129476330390143	-0.659741577407699	-0.428372937960196
CHCHD3	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.8680910169	0.8680910169	0.379122590118726	0.383188744526	-15.1893910255649	5.43054663969452	1.17428796770413e-05	0.000398928460659468	-0.569784265032118	-0.408152588530429
CHCHD3	BRD-K25596805-001-01-8::2.5::HTS002	2.5	JNJ-16259685	glutamate receptor antagonist	noncancer	GRM1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6630720400925	0.6630720400925	0.388870128828346	0.376431167142	-7.68619538294887	21.3996593936712	1.37099914848956e-07	6.34243204180054e-06	-0.348307018062945	-0.200096804465363
CHCHD3	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.04655357647645	-0.04655357647645	-0.242485113907088	-0.125640191534	-4.37213212578041	13.4469713283863	0.000699307441137305	0.016147582907942	-0.292419599053024	-0.0994434758082522
CHCHD3	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.245428808051	-0.245428808051	-1.04457751165097	-0.8676646214495	-9.48184270683217	17.6243851026876	2.43291793010853e-08	1.23946961502789e-06	-0.976489511776068	-0.621807895423867
CHCHD3	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0905362223698	-0.0905362223698	-0.778008262218934	-0.707312470978	-9.69521248707589	6.23202583921805	5.47926260428763e-05	0.00163971638468914	-0.85942473096423	-0.515519348734038
CHCHD3	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.5649207158055	0.5649207158055	0.267846972117365	0.2845478404215	-10.4991786637313	25.0485465210944	1.16313169428828e-10	7.63998936270649e-09	-0.355342559451672	-0.238804927924599
CHCHD3	BRD-K30480208-001-18-5::2.5::HTS002	2.5	torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	noncancer	SLC12A1	cardiology	edema, congestive heart failure, hypertension	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.435725489487	0.435725489487	0.0245732586371757	0.129954580002	-8.01026953983568	109.372643372557	1.34097528057613e-12	1.10344573157734e-10	-0.51287904420061	-0.309425417499038
CHCHD3	BRD-K32007074-001-02-9::3.16375::HTS002	3.16375	enocitabine	DNA synthesis inhibitor	chemo	CMPK1, RRM1, TYMS	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.249237472867	-0.249237472867	-0.0446040342104029	0.0407485371646	5.15665157110041	56.2814978507838	3.37417475115006e-06	0.000126763102583566	0.125146820079737	0.284120057233457
CHCHD3	BRD-K33720171-001-01-0::2.5::HTS002	2.5	difluprednate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	endogenous uveitis	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.828699303454	-0.828699303454	-1.4764032163274	-1.46727354757	-7.30188981860736	6.7494039771266	0.000193733061640334	0.00513766559865272	-0.859043688034624	-0.436364137712179
CHCHD3	BRD-K33882852-003-02-8::2.5::HTS002	2.5	ZK-93423	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.3367123001245	-0.3367123001245	-0.888810349691158	-0.832624878756	-8.61867890977714	35.9864052709242	2.82463053491266e-10	1.78321130461648e-08	-0.682016038348046	-0.422180060785269
CHCHD3	BRD-K36627727-001-05-4::2.5::HTS002	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.1041350550375	-0.1041350550375	0.139578827843952	0.154182848854	8.99174486829117	191.999168862792	2.32638525075466e-16	2.76239237899721e-14	0.190253689368477	0.297174076394427
CHCHD3	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.57945679671	-1.57945679671	-3.00569328205372	-3.11792642927	-13.8775533862681	32.6986326861812	2.94620368617874e-15	3.12912234814174e-13	-1.63540276787956	-1.21707020280787
CHCHD3	BRD-K41876534-001-13-7::2.5::HTS002	2.5	tioxolone	carbonic anhydrase inhibitor	noncancer	CA2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.626517852928	0.626517852928	0.211798464071484	0.2726226138565	-9.22230920901656	123.719759142667	9.73850290923515e-16	1.08035382506908e-13	-0.503727916170109	-0.325710861542923
CHCHD3	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.918702307417	-0.918702307417	-2.30282769506614	-2.14029239454	-16.0130871890929	142.054401527307	1.26697275174791e-33	7.05322085478903e-31	-1.55499470506273	-1.21325607023554
CHCHD3	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.0783242178189	0.0783242178189	-0.637279152847345	-0.4291875223905	-9.66210876822811	13.2992762070743	2.21062830844931e-07	9.92254983710224e-06	-0.875241202949741	-0.55596553838275
CHCHD3	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.242029350924	0.242029350924	-0.299362194965745	-0.160539632789	-8.16626421876206	14.6549020312114	7.8527576010413e-07	3.26303544760291e-05	-0.682988729232576	-0.399794362546914
CHCHD3	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.0551122502164	0.0551122502164	-0.21081507598075	-0.158274399371	-5.7581967517394	62.765119802613	2.75084432065086e-07	1.21915986848796e-05	-0.358222241075751	-0.173632411318548
CHCHD3	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6913956392885	0.6913956392885	0.365000152248978	0.394038132066	-7.51743383604044	99.6616456892318	2.47814604863671e-11	1.76399390387997e-09	-0.412540079336825	-0.240250894742218
CHCHD3	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.11214723019195	-0.11214723019195	-0.897345050869732	-0.852653660565	-12.6467388004879	88.9769423275688	1.39023300823931e-21	2.61145705892133e-19	-0.908563768224387	-0.661831873131176
CHCHD3	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.6113551749385	-0.6113551749385	-1.75158867102448	-1.65992199057	-10.6186451259594	3.85856416666313	0.000536675415195617	0.0127564716716715	-1.44272876200895	-0.837738230163006
CHCHD3	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4690836173685	0.4690836173685	-0.129904070346784	-0.075355311638	-15.1693686294034	28.1045061018166	4.5896200405011e-15	4.79614175358635e-13	-0.679858894259545	-0.518116481171023
CHCHD3	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0505247195181	-0.0505247195181	0.15671153089467	0.14294893902	8.99598426674315	11.0657118841979	2.01621313024821e-06	7.85125261615133e-05	0.156569903292958	0.257902597532583
CHCHD3	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.2028895274685	-0.2028895274685	-0.679677980971649	-0.588520646364	-7.4760020102931	9.18525119709015	3.38997917924943e-05	0.00105514209629589	-0.620617144067252	-0.332959762939047
CHCHD3	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.5605778559975	0.5605778559975	0.343507754990008	0.381901791063	-6.59064101928803	131.626832436338	9.63188732424249e-10	5.74399771373836e-08	-0.282222697812425	-0.151917504202559
CHCHD3	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4527206993505	0.4527206993505	-0.370660068145818	-0.243490121847	-9.75401995578877	4.61646318467779	0.000297124489258785	0.00750617570230389	-1.04591131996388	-0.600850215028755
CHCHD3	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.520842990084	0.520842990084	-0.0735132645657781	0.318163539168	-6.77574772559633	83.2798227974295	1.64385737162436e-09	9.55849990783712e-08	-0.768815516390606	-0.41989699290895
CHCHD3	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.300963260223	-0.300963260223	-0.784265120748316	-0.640313618355	-5.739335700772	16.4057589859422	2.76325418238374e-05	0.000875196550400657	-0.661458119486711	-0.305145601563921
CHCHD3	BRD-K49371609-003-03-8::2.5::HTS002	2.5	PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-4.815595787025	-4.815595787025	-5.34679433168738	-5.36758305195	-6.63273403343987	43.7316179494636	4.06737963085467e-08	2.0081949064765e-06	-0.692632112664535	-0.369764976660225
CHCHD3	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.002753569341	-1.002753569341	-1.83819548463316	-1.58248812639	-6.94124018269738	6.45653480372296	0.000321091845289769	0.00805280764206773	-1.12497521229315	-0.545908618291167
CHCHD3	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.391055422803	-0.391055422803	-1.25808294236012	-0.921278111753	-10.072437181819	190.917986435628	2.08085811543192e-19	3.25538860600298e-17	-1.03681597090841	-0.697239068205828
CHCHD3	BRD-K56334280-001-05-1::2.5::HTS002	2.5	amonafide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.6482932430715	-0.6482932430715	-0.402184164636514	-0.351314644036	3.48464660251637	26.3455875254121	0.00174066820566632	0.0356941901886965	0.10102645163471	0.391191705235262
CHCHD3	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.2958358918245	0.2958358918245	-0.759443575079388	-0.674815903064	-10.1086254827451	3.07875621114883	0.00184368414921061	0.0374164359450961	-1.38275119004491	-0.727807743762868
CHCHD3	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.199510238338	0.199510238338	-0.395325603754086	-0.201440599557	-9.4195657914939	179.120832209151	2.28988775660466e-17	2.9690825951925e-15	-0.719447468175092	-0.47022421600908
CHCHD3	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.506553428568	0.506553428568	-0.258399315424564	-0.132231172134	-9.9670047096091	3.52496054314819	0.00104836436893895	0.0230267356866485	-0.989858200098989	-0.54004728788614
CHCHD3	BRD-K62196610-001-01-6::2.5::HTS002	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.306996625025	-1.306996625025	-1.67560706612431	-1.62132235513	-5.48225834827401	157.808249289157	1.6325136048154e-07	7.47000444932706e-06	-0.501410893202179	-0.235809988996447
CHCHD3	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.4420990980235	-0.4420990980235	-0.206342736111178	-0.128286851934	6.38409912803165	187.171676415976	1.3243982956621e-09	7.78970807659064e-08	0.162906441539779	0.308606282284866
CHCHD3	BRD-K65781196-001-03-0::2.5::HTS002	2.5	avanafil	phosphodiesterase inhibitor	noncancer	PDE5A	urology	erectile dysfunction	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.348117068957	0.348117068957	0.519711561838309	0.5001680411375	5.7566642640931	18.236319568327	1.77029192242474e-05	0.000583730611448266	0.109028384927661	0.234160600834957
CHCHD3	BRD-K66094457-001-01-5::2.5::HTS002	2.5	CPP	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.185757102551	-0.185757102551	-0.92074625580084	-0.865994083482	-9.94752220609275	7.09794028211686	2.01811971086446e-05	0.000657158279413352	-0.909215810211422	-0.560762496288259
CHCHD3	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.9987197942175	-0.9987197942175	-0.326479159039197	-0.32021882125	15.0809905765424	175.129709806738	1.7744256114545e-33	9.70180782850593e-31	0.584266596175532	0.760214674181074
CHCHD3	BRD-K66808046-065-03-7::2.5::HTS002	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.145395877329	-0.145395877329	-0.457395211623971	-0.3317635225235	-3.60843550204479	75.7470400091635	0.000550187080778104	0.0130429207870911	-0.484216376681558	-0.139782291908384
CHCHD3	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.870001066847	-0.870001066847	-1.7669233230646	-1.7012260142	-12.4804004575804	18.3909448418811	2.03114069935247e-10	1.30105306321433e-08	-1.047678362953	-0.746166149482197
CHCHD3	BRD-K68507560-003-24-6::2.5::HTS002	2.5	dicycloverine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.09404100553955	0.09404100553955	0.232807855537136	0.2203060574785	4.38911665579649	163.767132354374	2.03316614691146e-05	0.000661655735046139	0.0763390630857194	0.201194636909453
CHCHD3	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-2.61092015841	-2.61092015841	-3.68244852841885	-3.50719189578	-8.7821712957528	28.5090991451893	1.33490644301187e-09	7.84505519671764e-08	-1.32125725986494	-0.821799480152761
CHCHD3	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.0966277635015	0.0966277635015	-0.0804322179962553	0.0411624842104	-3.97564553334852	89.0020708040702	0.000142509937940485	0.00389492635664961	-0.265552352367066	-0.0885676106284446
CHCHD3	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.175854129887	0.175854129887	-0.540499212419076	-0.407441526883	-10.3550424995919	98.9309028941721	1.85480909769186e-17	2.4181227439124e-15	-0.853621028699758	-0.579085655912393
CHCHD3	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.3140525682975	0.3140525682975	0.099632758267325	0.129185439077	-4.99028530857647	14.4253742994018	0.000181182097949911	0.0048443834670043	-0.306321520419927	-0.122518099640423
CHCHD3	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.14561321654	0.14561321654	-0.20003750620924	-0.124222212564	-8.37972570373922	11.6517825719544	2.84842719970162e-06	0.000108417786056624	-0.435822175620144	-0.255479269878336
CHCHD3	BRD-K73838513-003-05-5::2.5::HTS002	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4493704282295	0.4493704282295	0.170843605535307	0.190630234256	-7.56885995474155	136.106891846132	5.1133340448702e-12	3.94221500900355e-10	-0.351298658891573	-0.205754986496812
CHCHD3	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.325397781136	-0.325397781136	-1.48237659100479	-1.368540965995	-12.9725819756448	126.1054482375	5.67548138728839e-25	1.46028841567363e-22	-1.33347478374367	-0.98048283599391
CHCHD3	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.148963458701	0.148963458701	-0.429654447445382	-0.2512002355925	-8.84339350914675	149.155144716091	2.43980414401173e-15	2.61460391190945e-13	-0.707906156135435	-0.449329656157329
CHCHD3	BRD-K76210423-001-01-6::2.5::MTS010::PROS001_PR500	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0219686106064	-0.0219686106064	0.107365264680007	0.094360121778	6.31063430248792	183.348251919275	2.0329493026314e-09	1.1694041628655e-07	0.0888983123058036	0.16976943826701
CHCHD3	BRD-K77625799-001-07-7::2.5::HTS002	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6270149408485	0.6270149408485	0.102318514144306	0.160912505802	-8.41537031835473	8.43179482180799	2.20447495666734e-05	0.000712536439432296	-0.66720366474018	-0.382189188668209
CHCHD3	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.906784975411	0.906784975411	0.45096133943304	0.472553592618	-14.4737488251227	178.556209581835	6.47039292861708e-32	3.03455764988527e-29	-0.517970249443283	-0.393677022512636
CHCHD3	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.3078875120645	0.3078875120645	0.00235830978395167	0.041364371782	-7.15974480631769	5.21157040963295	0.000693642493562057	0.0160288627496132	-0.413898161082993	-0.197160243478103
CHCHD3	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.387210266402	-0.387210266402	-1.02025182729375	-0.966558687453	-9.13470417481697	5.18705309148026	0.000216837928333972	0.00567941541511571	-0.809269732554406	-0.456813389229086
CHCHD3	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.12327000846	-1.12327000846	-1.75633050079539	-1.69551344644	-8.28738452051452	10.6022526588115	5.92884747191842e-06	0.000213387732965374	-0.8019631067566	-0.464157877914186
CHCHD3	BRD-K97472745-001-01-8::2.5::HTS002	2.5	gestrinone	progesterone receptor antagonist	noncancer	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.01165033777969	-0.01165033777969	-0.162372241803793	-0.1123477003	-3.58754767634845	25.7926875581563	0.00136891747063624	0.0290436262684611	-0.237113662397977	-0.0643301456502296
CHCHD3	BRD-K97714174-001-01-3::2.5::HTS002	2.5	P22077	ubiquitin specific protease inhibitor	noncancer	USP7	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.7811672060265	0.7811672060265	0.251649881316252	0.3142607574065	-11.0860985345446	5.04043168556202	9.90302502751882e-05	0.00280977687466651	-0.652003166044318	-0.407031483376177
CHCHD3	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.10486544595965	0.10486544595965	-0.244625385199201	-0.195507988981	-6.52763935741937	8.3398203606784	0.000151974053262602	0.0041335592464112	-0.472084440883697	-0.226897221434004
CHCHD3	BRD-K97810537-001-13-6::2.5::HTS002	2.5	beclomethasone-dipropionate	glucocorticoid receptor agonist	noncancer	GPR97, NR3C1	allergy	allergic rhinitis	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.3108353570785	0.3108353570785	0.0716643855722013	0.0633860344485	-5.73861404669046	105.138829823917	9.29413235631752e-08	4.39347616629285e-06	-0.321808443314311	-0.156533499698286
CHMP4C	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.2936988902725	0.2936988902725	0.148934297131481	0.1611474271015	-6.37335833639678	191.243115891451	1.35059458526858e-09	7.93072840728848e-08	-0.189566772462077	-0.0999624138199616
CHMP4C	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.294933020216	0.294933020216	-0.054178215782731	0.106263594851	-5.24918062563292	7.94299230020349	0.000792685977271236	0.0180490378011863	-0.502670210194414	-0.195552261803048
CHMP4C	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.586461391343	0.586461391343	0.168606988651657	0.1532922606755	-12.5847097057002	5.09860724128657	4.92874985387827e-05	0.00148830594280562	-0.502712192883187	-0.332996612499499
CHMP4C	BRD-A25234499-001-18-3::2.5::HTS002	2.5	aminoglutethimide	glucocorticoid receptor antagonist	targeted cancer	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.048241897522	0.048241897522	0.217000060599854	0.21588142899	5.32933722167806	10.6712628184828	0.000267479627706133	0.00683786272979816	0.0987991764160389	0.238717149739669
CHMP4C	BRD-A50157456-065-20-6::2.5::HTS002	2.5	terbutaline	adrenergic receptor agonist	noncancer	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.408235806011	0.408235806011	0.148052422961134	0.1597653685015	-8.63905891945644	46.5684609331632	3.11002258790851e-11	2.18977671236479e-09	-0.320785993337906	-0.199580772761826
CHMP4C	BRD-A57382968-001-29-0::2.5::HTS002	2.5	piroxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.354256710698	0.354256710698	0.0163504249160562	0.00421329680347	-12.0734679811956	15.4964763226187	2.73410644557686e-09	1.55354798614539e-07	-0.397394218887449	-0.278418352676439
CHMP4C	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.00485336446815	0.00485336446815	-1.03651326075172	-0.797857785181	-11.5599795030258	20.1742288458952	2.36117723385788e-10	1.49946297883119e-08	-1.22917411117707	-0.853559139262677
CHMP4C	BRD-A72703248-003-04-9::2.5::HTS002	2.5	SKF-96365	calcium channel blocker	noncancer	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.886971781495	-2.886971781495	-3.54788143362293	-3.55274052264	-5.58647664368504	53.2415458364731	8.07084350125371e-07	3.34457814536003e-05	-0.898174854529044	-0.423644449726816
CHMP4C	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.940250288697	0.940250288697	0.0200136658297757	0.05909936864605	-15.1685646252238	14.9754642257392	1.69721260309337e-10	1.09599843328834e-08	-1.04956447382773	-0.790908771906715
CHMP4C	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.1441176613765	-0.1441176613765	0.0472758304910267	0.0776480680764	6.0728602795348	107.454859028929	1.93138161278988e-08	9.97309124216704e-07	0.12891932119453	0.253867662540524
CHMP4C	BRD-A90547603-001-02-5::2.5::HTS002	2.5	eptifibatide	platelet aggregation inhibitor	noncancer	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.1996624160965	0.1996624160965	0.0427971866828499	0.04269931862485	-6.14767419509019	177.398190300183	5.05851709364268e-09	2.7942961602148e-07	-0.20721956243155	-0.106510896395751
CHMP4C	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.829504724735	-1.829504724735	-3.7381822958616	-3.62613694573	-13.1159673229296	4.03073124686336	0.000186281405596874	0.00496153937867184	-2.31150277171194	-1.50585237054127
CHMP4C	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.468315582036	-0.468315582036	-1.9113390524136	-1.73380354334	-11.322408126283	7.75934516547774	4.25120641934936e-06	0.000156987736156569	-1.73851434564411	-1.1475325951111
CHMP4C	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.431907905132	0.431907905132	0.238364650045725	0.231867156581	-7.36458705092849	142.471485733416	1.30828567791218e-11	9.65577000899585e-10	-0.245492882506164	-0.141593627666386
CHMP4C	BRD-K06152156-001-01-8::2.5::HTS002	2.5	methoxyflurane	membrane permeability inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.45572744624	-1.45572744624	-1.86867649111555	-1.724302233865	-4.78059979436265	187.369832743008	3.52482736648674e-06	0.000132052565046624	-0.583351705331153	-0.242546384419947
CHMP4C	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.500797700198	-0.500797700198	-1.69380828964509	-1.35955217781	-10.3107428273447	186.491211869418	5.17262704438771e-20	8.5808357724193e-18	-1.42127065493861	-0.964750523955569
CHMP4C	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.003126029642	-1.003126029642	-2.50547257552526	-2.37307934162	-14.1177804585162	167.438635186986	2.5821545686401e-30	1.06428962796551e-27	-1.71243498383776	-1.29225810792877
CHMP4C	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.10733710845	-1.10733710845	-2.04476759912977	-1.66463476506	-6.64043493154608	17.9984664543822	3.12050513160906e-06	0.000117873589064617	-1.23401955867901	-0.640841422680526
CHMP4C	BRD-K08547377-394-03-5::2.5::HTS002	2.5	irinotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	colorectal cancer	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.346660230085	-1.346660230085	-1.96459830941126	-1.95467850154	-7.05754593593853	31.7386413752125	5.53732125909661e-08	2.69117580077305e-06	-0.79634362145298	-0.43953253719955
CHMP4C	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.3067006616905	0.3067006616905	-0.481639671029113	-0.33490377325	-11.8257955744182	167.999842580412	7.28656258100713e-24	1.68652448318e-21	-0.919944994006209	-0.656735671433017
CHMP4C	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.2251014350075	-0.2251014350075	-2.11608003555961	-1.95679219665	-13.1058297404747	4.68864248293612	7.14256766484035e-05	0.00208763041734293	-2.26940781205147	-1.51254938905275
CHMP4C	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.19868707331	-4.19868707331	-2.4294775032937	-2.42612206257	18.7762816989869	180.112535352163	2.84332615086313e-44	4.35290893277389e-41	1.58328116579554	1.95513797423707
CHMP4C	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.03508276633466	-0.03508276633466	-0.515871713429626	-0.419130200084	-6.79268453714468	18.405031320206	2.05870551794653e-06	8.00799083404651e-05	-0.629258833100995	-0.332319061088937
CHMP4C	BRD-K16136380-001-01-7::2.5::HTS002	2.5	pyrithione-zinc	ATP synthase inhibitor	noncancer	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-6.71667659128	-6.71667659128	-6.3344252725743	-6.32859212175	3.36244436520532	33.1120369063408	0.00196228625954788	0.0394501652141701	0.150992115872294	0.613510521539101
CHMP4C	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.61198406928	-1.61198406928	-2.87555361406545	-2.63264407289	-9.99018860904471	177.95340835581	6.16275104561818e-19	9.19176248334238e-17	-1.51316527886679	-1.01397381070411
CHMP4C	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.03869453013103	-0.03869453013103	-1.14151812170371	-0.889953286616	-10.8939889740967	31.7730464042586	2.92976408876541e-12	2.32999409046754e-10	-1.30908482594842	-0.896562357196939
CHMP4C	BRD-K18163608-001-05-6::2.48005::HTS002	2.48005	HA14-1	BCL inhibitor	targeted cancer	BCL2	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.203616138864	0.203616138864	-0.045787194244449	0.0348368088463	-4.96001307689462	96.3493083794333	3.02738996240886e-06	0.000114740488638926	-0.349209279452023	-0.149597386764875
CHMP4C	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.371248599645	-2.371248599645	-2.99534769842382	-2.880185474935	-7.98313478333305	125.316670196733	7.82281568504377e-13	6.58028360659241e-11	-0.778817652499527	-0.469380545058111
CHMP4C	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.9331016424895	-0.9331016424895	-2.89035750881793	-2.75215171608	-12.202854402416	2.84328905271765	0.00152868570172307	0.0319525724365715	-2.48398970615798	-1.43052202649888
CHMP4C	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.22959714056	-2.22959714056	-3.27803453002706	-3.04327234152	-8.7448788418965	62.3118043186458	1.95820217123717e-12	1.58317432349714e-10	-1.28807340098776	-0.808801377946364
CHMP4C	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.6522994239155	0.6522994239155	0.370396184886382	0.3847237758685	-8.7046820539588	23.5405809373349	8.06154356172534e-09	4.3489115782558e-07	-0.348812192166339	-0.214994285891897
CHMP4C	BRD-K25279140-001-01-5::2.5::HTS002	2.5	MK-8745	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.710323843468	-0.710323843468	-1.58222610293048	-1.48579667397	-9.17396917641434	11.520985273476	1.2287488321918e-06	4.94752035421446e-05	-1.07993752690422	-0.663866992020731
CHMP4C	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.08557107075365	-0.08557107075365	-0.843090030465075	-0.742464669951	-12.7141582828224	179.757828904495	7.84813916345309e-27	2.34927907648567e-24	-0.875086584426546	-0.639951334996304
CHMP4C	BRD-K25630527-001-03-8::2.5::HTS002	2.5	LY2784544	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.586973582382	-0.586973582382	-1.0835323062779	-0.892196306228	-6.23618407616953	18.1808520414354	6.66413686455403e-06	0.000237104546819887	-0.663726306316461	-0.329391141475338
CHMP4C	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.146214099832	0.146214099832	-0.138195761682446	-0.1059972226705	-6.00941498926777	6.40794075426887	0.000750001119375881	0.0171848396316777	-0.39845195462286	-0.170367768406032
CHMP4C	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.02094503512975	0.02094503512975	-0.506026487216204	-0.436225052339	-7.81214329783806	3.53223840708136	0.00238010874875906	0.0465316362321245	-0.72445656853104	-0.329486476160868
CHMP4C	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.6023954844	-0.6023954844	-1.98861905867691	-1.88069436606	-12.2887343230015	19.2662361307121	1.44866316835686e-10	9.43166853617126e-09	-1.62210531203858	-1.15034183651523
CHMP4C	BRD-K28907958-001-04-3::2.5::HTS002	2.5	CD-437	retinoid receptor agonist	targeted cancer	RARG	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.32317978105	-3.32317978105	-4.21292313020691	-4.123946828915	-8.61291931127053	21.5858387103423	1.97918895535006e-08	1.01995092476851e-06	-1.10421994415738	-0.675266754156452
CHMP4C	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.5736088421615	-0.5736088421615	-1.67568271484929	-1.54523819361	-10.2580243750859	4.54274832328267	0.000259552605258873	0.00666063821031238	-1.38681931047719	-0.817328434898392
CHMP4C	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.420803716784	0.420803716784	-0.188676266621665	-0.06456986921455	-12.3958794192292	15.8262636238072	1.46437500704742e-09	8.55898638902278e-08	-0.713804453349397	-0.505155513461934
CHMP4C	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.158959009297	0.158959009297	-0.405568620166353	-0.2809944464045	-6.85253781998096	4.64932729271447	0.00134666224112477	0.0286593954401778	-0.781193592315741	-0.347861666610966
CHMP4C	BRD-K33127281-001-05-6::2.5::HTS002	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.551521306014	-0.551521306014	-0.159864519502879	-0.1501441638665	7.81851133790334	4.0739903474428	0.00133911120884457	0.0285258166126853	0.253565411854113	0.529748161168129
CHMP4C	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.221649099616	0.221649099616	-0.0226173221748368	-0.0227579244188	-8.79793431275668	187.495551751701	9.03785419010356e-16	1.00784300245094e-13	-0.299036511985422	-0.189496331596251
CHMP4C	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.3764503353785	0.3764503353785	-0.0782734681381301	-0.0620606581655	-14.759063843256	187.145713479903	3.3710294105268e-33	1.81992282752846e-30	-0.515502943665143	-0.393944663368117
CHMP4C	BRD-K37865504-001-04-1::2.5::HTS002	2.5	LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	noncancer	FAAH	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.629794380535	-0.629794380535	-1.29690548937361	-1.08170547456	-8.31777825268329	191.995510771677	1.62946707465966e-14	1.62061275473193e-12	-0.825303328629837	-0.508918889047374
CHMP4C	BRD-K39171998-001-01-1::2.5::HTS002	2.5	STF-118804	NAMPT inhibitor	targeted cancer	NAMPT	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.445443907695	-3.445443907695	-4.67949029185325	-4.69138817122	-8.81707420936806	3.4219946009365	0.0018055415543827	0.0367851630997423	-1.64994687872912	-0.818145889587387
CHMP4C	BRD-K44067360-001-30-3::2.5::HTS002	2.5	flufenamic-acid	chloride channel blocker	noncancer	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5294721589725	0.5294721589725	0.0676140163376555	0.08403527726685	-15.3952998864348	66.9494147030868	1.10730864509337e-23	2.51141115972715e-21	-0.521739114218684	-0.401977171051005
CHMP4C	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.33154493601	-1.33154493601	-2.24987611445346	-2.140330076935	-14.1655913740273	81.8446948165342	9.96322932747038e-24	2.27171167928447e-21	-1.047298978574	-0.789363378312921
CHMP4C	BRD-K50853363-001-02-3::2.5::HTS002	2.5	dienogest	progesterone receptor agonist	noncancer	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.220726748563	0.220726748563	-0.282421339129267	-0.2219400984365	-10.3223414060938	156.590071161859	2.22159976297831e-19	3.46293276799548e-17	-0.599427877148807	-0.406868298235727
CHMP4C	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.66473952921	-2.66473952921	-3.67128311840644	-3.70951336465	-9.90370737125894	4.08236838211399	0.000526838617936755	0.01255468024725	-1.28649081579026	-0.726596362602614
CHMP4C	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5310167432415	0.5310167432415	0.254903620563527	0.250850268444	-7.77521592682947	10.7237158006486	9.97218780630077e-06	0.000343787846282232	-0.354520801768267	-0.197705443587679
CHMP4C	BRD-K52313696-001-12-3::0.15625::HTS002	0.15625	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.6296382897085	0.6296382897085	0.413448236765334	0.391061862128	-5.74525799609782	9.14949311071322	0.000261211631146965	0.00669759871899723	-0.301101909417163	-0.131278196469169
CHMP4C	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.4958679292905	0.4958679292905	0.224258412481808	0.2005091684065	-7.73215495078757	7.66064254701417	7.04284436110214e-05	0.00205960675272296	-0.353242028135702	-0.189977005481683
CHMP4C	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.356694269374	0.356694269374	-0.59142438117102	-0.48109263675	-10.7019648795204	10.362647802431	6.28101487647741e-07	2.6420896662143e-05	-1.14458366482494	-0.751653636265104
CHMP4C	BRD-K58049875-001-04-7::2.5::HTS002	2.5	thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	noncancer	FOXM1	obstetrics/gynecology	mastitis	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.3653342315335	-0.3653342315335	-0.809673586453422	-0.698370160758	-7.11883900344822	162.020812004311	3.34905399604144e-11	2.34574965332538e-09	-0.56759584236873	-0.321082867471115
CHMP4C	BRD-K58122457-001-02-2::2.5::HTS002	2.5	hesperadin	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.94080451235	-1.94080451235	-2.71332060728278	-2.71475551237	-8.10510165973279	151.989373902849	1.61542891092326e-13	1.45293018484797e-11	-0.960824185097877	-0.584208004767692
CHMP4C	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.0720298734542	0.0720298734542	0.236251777863213	0.281721742376	4.35694530495525	185.264303060968	2.18156201439114e-05	0.000705982190823551	0.0898612241834215	0.238582584634604
CHMP4C	BRD-K58772419-001-07-0::2.5::HTS002	2.5	AZD6482	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.741309036655	-1.741309036655	-2.39730432457047	-2.271239781645	-6.26545605253792	19.6019633098842	4.4526868150677e-06	0.000164032298450781	-0.874680994486379	-0.43730958134456
CHMP4C	BRD-K60369935-001-18-3::2.5::HTS002	2.5	ribavirin	antiviral	noncancer	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5580418461085	0.5580418461085	0.370295825643107	0.414452156411	-6.22601503739115	69.3482747010524	3.20517293820432e-08	1.60580063270779e-06	-0.247898382163845	-0.127593658766941
CHMP4C	BRD-K61036791-001-01-6::2.5::HTS002	2.5	rucinol	tyrosinase inhibitor	noncancer	TYR	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5590058481835	0.5590058481835	0.401970507993709	0.439884501288	-6.17843601567448	165.65670954598	4.84650658035339e-09	2.6818169648921e-07	-0.207217726175657	-0.106852954203926
CHMP4C	BRD-K63126190-003-01-6::2.5::HTS002	2.5	epinephrine	adrenergic receptor agonist, neurotransmitter	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.7182685639135	-0.7182685639135	-0.434319453852351	-0.389178555772	3.62385586242418	16.3141084905626	0.00222014609675466	0.0438725514264549	0.11810237398345	0.449795846138848
CHMP4C	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.7484708698715	-0.7484708698715	-1.85053736845198	-1.7566794361	-8.15588198978575	3.54467724567078	0.00202892731970489	0.0405954036132403	-1.49702645032943	-0.707106546831538
CHMP4C	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.08670041157305	-0.08670041157305	-0.794794452296301	-0.646845557406	-10.6058744266664	149.741675530802	5.9569405486752e-20	9.76909891209966e-18	-0.840015875942948	-0.576172205503554
CHMP4C	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.08612803883255	-0.08612803883255	0.224562039704758	0.235603358555	12.464649498161	187.746154404809	2.24717324169589e-26	6.43036573724217e-24	0.261519654994308	0.359860502080307
CHMP4C	BRD-K72280606-001-01-2::2.5::MTS006	2.5	gilteritinib	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.550055046224	0.550055046224	0.0169480377880669	0.0368466353563	-12.8772249662758	2.51578856528035	0.0023171129992902	0.0454992681653568	-0.6804325455186	-0.385781471353266
CHMP4C	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.08486238988145	-0.08486238988145	0.103899228408276	0.130322249466	4.23428269082731	10.1341153025671	0.00168139853584798	0.0346712013459459	0.0896105049636708	0.287912731615782
CHMP4C	BRD-K73293050-001-03-1::2.5::HTS002	2.5	WZ-3146	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.94731533321	-2.94731533321	-2.56865310542904	-2.38223243926	3.72777427342346	72.9486231036479	0.000378725824279874	0.00936455089894799	0.176213895149322	0.581110560412598
CHMP4C	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.1570754602195	0.1570754602195	-0.197545605950464	-0.145323520972	-8.22149369435948	188.826082595254	3.16466859452526e-14	3.05945085789808e-12	-0.439706325339777	-0.269535807000151
CHMP4C	BRD-K75911534-001-01-6::2.5::HTS002	2.5	SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.1685467503225	-0.1685467503225	-0.525689484646883	-0.4139887396705	-6.36685103558928	193.650450058427	1.36863109932148e-09	8.02784167724338e-08	-0.467776546234692	-0.246508922414074
CHMP4C	BRD-K77908580-001-09-6::2.5::HTS002	2.5	entinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC9	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.628191115895	-2.628191115895	-1.78374242924646	-1.479908957755	6.98297998862306	10.1100521508963	3.58662652677653e-05	0.00111198911739836	0.57539788131969	1.11349949197738
CHMP4C	BRD-K78177893-001-02-4::2.5::HTS002	2.5	A-674563	AKT inhibitor	targeted cancer	AKT1, PKIA, PRKACA	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.955203614985	-1.955203614985	-2.68155512796573	-2.66704888005	-6.73635255758485	5.80619740524944	0.000597685086683779	0.0140400314493476	-0.992340862778433	-0.460362163183023
CHMP4C	BRD-K78431006-001-10-2::2.5::HTS002	2.5	crizotinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.443224747919	-0.443224747919	-1.18250824082398	-1.10147501024	-10.9341356459576	106.218649215459	4.27069354662931e-19	6.49633411749833e-17	-0.873328528080292	-0.60523845772967
CHMP4C	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.612249826375	-2.612249826375	-3.98496088005144	-3.95467393468	-8.8916959734158	4.79891670749659	0.000368765581876834	0.00914570219834297	-1.77461474718402	-0.970807360168856
CHMP4C	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.97059785899	-1.97059785899	-0.932267788466087	-0.8093705059295	16.6052876053631	187.06414987872	1.20369068818476e-38	1.12167748481718e-35	0.914975303855868	1.16168483719196
CHMP4C	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.06323965345605	-0.06323965345605	-0.780938810404807	-0.670066066219	-11.9106271171796	8.18189105318059	1.87780714400726e-06	7.33895928825551e-05	-0.856116285201364	-0.57928202869615
CHMP4C	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.950911405245	-2.950911405245	-2.49910544258994	-2.2273850288	4.15132919718072	166.685127191134	5.26300743607714e-05	0.00158007440925477	0.23693509936641	0.666676825943703
CHMP4C	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5645604592165	0.5645604592165	0.326467304733463	0.364286574892	-8.73112858006897	162.011447357395	2.9643890745009e-15	3.14531953439952e-13	-0.291942557382741	-0.184243751583332
CHMP4C	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.910868327254	-0.910868327254	-1.69555866400874	-1.42296021894	-8.98255699236341	142.366462232074	1.44341883907325e-15	1.58001285168402e-13	-0.957375037948884	-0.612005635560586
CHMP4C	BRD-K83988098-001-02-0::0.039::MTS010::PROS005_PR500	0.039	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.1688274326965	-0.1688274326965	-0.983565292099287	-0.942675371448	-7.5612296276173	29.9285263881805	2.00611312198913e-08	1.03283261907953e-06	-1.03481890676915	-0.594656812036428
CHMP4C	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.23937485833	-3.23937485833	-4.38747549284697	-4.37968901574	-11.0412987229709	9.13177455465563	1.38205872953594e-06	5.5222830992302e-05	-1.38280873690001	-0.913392532133934
CHMP4C	BRD-K84868168-001-01-0::2.5::MTS006	2.5	erdafitinib	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.6159237802075	0.6159237802075	0.0833696770690591	0.13174233615	-11.5994963513335	10.1326882354153	3.55994900335068e-07	1.54798196376374e-05	-0.634670744932443	-0.430437461344439
CHMP4C	BRD-K86118762-001-01-8::2.5::HTS002	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.3225946916585	0.3225946916585	0.0620315319416628	0.0670772689305	-8.14382329430246	165.96848804951	8.73080243335588e-14	8.04498776757838e-12	-0.323733196189548	-0.197393123244127
CHMP4C	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.22269495527	0.22269495527	-0.498013754924284	-0.41754362105	-15.2950455723007	189.87284237914	6.08287189944929e-35	3.84582847002085e-32	-0.813655431894693	-0.627761988493876
CHMP4C	BRD-K92049597-001-20-8::2.5::HTS002	2.5	triamterene	sodium channel blocker	noncancer	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.444951515486	-0.444951515486	-0.0520658747877518	-0.0499338044925	9.85534008575518	4.87638729502188	0.000210668807920955	0.00553949637257886	0.289622458004266	0.49614882339223
CHMP4C	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.037526738222	-0.037526738222	0.0951478276879835	0.110191949027	4.54843196939057	11.8297755369816	0.000692457273014701	0.0160049255761855	0.0690185493717796	0.196330582448187
CHMP4C	BRD-K92213669-001-01-3::2.5::HTS002	2.5	lomitapide	microsomal trigylceride transfer protein inhibitor	noncancer	MTTP	endocrinology	hypercholesterolemia	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.775856885013	0.775856885013	0.22095976052012	0.227576049132	-11.4923031742119	7.96317243852703	3.0918962565533e-06	0.000116895930987972	-0.666330476616166	-0.443463772369595
CHMP4C	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	HCC1419, NCIH1651	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.5895350828035	-0.5895350828035	-0.294398145315981	-0.17409866014	4.96942188097021	115.533368093603	2.34992896356673e-06	9.07328273882712e-05	0.177501367068808	0.412772507906229
CLNS1A	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.279926882187	-0.279926882187	-0.834424570881972	-0.720201208535	-9.22310086417575	186.309409724927	6.27778186134216e-17	7.82273667767211e-15	-0.673102182283094	-0.43589319510685
CLNS1A	BRD-A74765037-001-01-1::2.5::HTS002	2.5	estradiol-benzoate	contraceptive agent	noncancer	ESR1	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.171913964529	0.171913964529	0.0282486828416327	0.0102513278737	-4.91619493124597	63.2838498045008	6.57300876572417e-06	0.000234329074475864	-0.202057384134968	-0.0852731792397666
CLNS1A	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.558421929472	0.558421929472	0.259045330897792	0.303778240807	-7.98901066067878	192.95097314465	1.20569096127379e-13	1.09683589999512e-11	-0.37328698874027	-0.225466208408147
CLNS1A	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.052338844735	-4.052338844735	-3.01211278977928	-2.85234115214	9.40578455491994	180.328454565027	2.39318404609337e-17	3.09552651427367e-15	0.822000685278603	1.25845142463283
CLNS1A	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2052821149215	0.2052821149215	-0.344052175451868	-0.229059189804	-12.1354108114381	44.5533057527153	1.01366182879741e-15	1.12277584550036e-13	-0.640532052726791	-0.458136528019944
CLNS1A	BRD-K03601870-001-01-2::2.5::HTS002	2.5	ixabepilone	microtubule stabilizing agent	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.779550669225	-2.779550669225	-3.63425231903282	-3.58404887743	-8.25746232673813	22.9147099007409	2.55132727247997e-08	1.29609723390225e-06	-1.06886542337082	-0.640537876244825
CLNS1A	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.76902805658	-1.76902805658	-3.04252181631382	-2.93942386342	-12.9738824105399	123.495280887614	8.16466357883261e-25	2.08324307165192e-22	-1.46778428170259	-1.07920323776506
CLNS1A	BRD-K09397065-003-06-1::2.5::HTS002	2.5	SR-57227A	serotonin receptor agonist	noncancer	HTR3A	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.2534926206035	-0.2534926206035	0.250409851545426	0.2503216696235	12.6753174224613	7.1749814292578	3.58763487411854e-06	0.000134241304981661	0.410360478198887	0.597444466098965
CLNS1A	BRD-K12244279-001-05-8::2.5::HTS002	2.5	MEK1-2-inhibitor	MEK inhibitor	noncancer	MAP2K2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.420442888179	-0.420442888179	-0.152754481389405	-0.1558908725075	7.77451773385295	24.2738099931772	4.82488895412211e-08	2.35917407413565e-06	0.196667652666617	0.338709160912573
CLNS1A	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.5767606062165	-0.5767606062165	-1.65503075684609	-1.461946185705	-12.875843210299	179.995198327606	2.58622916119748e-27	7.98708803876505e-25	-1.24351573852753	-0.913024562731648
CLNS1A	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.10632770802315	-0.10632770802315	-0.483365156430251	-0.4134526693685	-6.09377502705428	4.81681697719991	0.00196248599822461	0.0394501652141701	-0.537922535887358	-0.216152360926845
CLNS1A	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.050336141944	0.050336141944	0.242819558060023	0.282942219323	6.227219165919	10.7927720799724	7.02552750751511e-05	0.00205482298738838	0.124291227001503	0.260675605230543
CLNS1A	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.4771232421195	-0.4771232421195	-0.192564353697634	-0.144534319806	5.22726580951417	31.3270762412585	1.08740441139562e-05	0.000371828813162113	0.173579992822812	0.39553778402092
CLNS1A	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.9662431942	-0.9662431942	-1.97329946851987	-1.89093805071	-12.0487343956977	14.3446443606142	6.77359951491086e-09	3.68004768170172e-07	-1.18591842068248	-0.828194127957263
CLNS1A	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.7202004807675	-0.7202004807675	-1.67413964496923	-1.54523819361	-8.66690923824779	4.11869815051295	0.000854447113127577	0.0192762769076621	-1.25609147801773	-0.651786850385729
CLNS1A	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.882078883863	0.882078883863	0.757611895497972	0.759014306598	-3.75206576577501	27.2478880950721	0.000840318208947003	0.0190003757153078	-0.192503241524527	-0.0564307352055297
CLNS1A	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.284212505259	0.284212505259	0.577942183906654	0.571651612309	6.89910888657754	5.0028346473592	0.000977777651157525	0.021703200724414	0.184305761989486	0.403153595305821
CLNS1A	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1128373431895	0.1128373431895	-0.0754690746042046	-0.0620606581655	-5.95375896382908	150.173091763717	1.78079482225151e-08	9.24826686354116e-07	-0.25080007423978	-0.125812761347629
CLNS1A	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2353514253975	0.2353514253975	-0.241290266873743	-0.026104548309	-8.12676596196893	17.716191186535	2.19386585700102e-07	9.85556644865168e-06	-0.600004190964486	-0.353279193577999
CLNS1A	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.855381786515	-5.855381786515	-4.65291890304908	-5.03947371329	8.48698997267762	13.3352389049512	9.70825181050282e-07	3.97546790655953e-05	0.897155564189899	1.50777020274193
CLNS1A	BRD-K39558284-001-01-2::2.5::HTS002	2.5	SDZ-WAG-994	adenosine receptor agonist	noncancer	ADORA1	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.4449691935835	0.4449691935835	0.295095267282032	0.325539232433	-4.47263027679654	11.4443100546954	0.000855594824263522	0.0192847600262463	-0.223279164460728	-0.0764686881422084
CLNS1A	BRD-K40175214-001-11-6::2.5::HTS002	2.5	torin-1	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-3.347468439395	-3.347468439395	-3.73325288864665	-3.718490926125	-5.13054214883671	67.1121817308983	2.66065785183974e-06	0.000101740613153784	-0.535867091938648	-0.23570180656465
CLNS1A	BRD-K41783120-001-02-8::2.5::HTS002	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.7823990552495	0.7823990552495	-0.289355650018454	-0.180532347642	-15.8149581473819	28.8534147714146	9.43529263865435e-16	1.04888840038908e-13	-1.21038727625305	-0.933122134282861
CLNS1A	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.937150276905	0.937150276905	-0.548227003043293	-0.407422571936	-22.5208308613838	190.353864077141	1.41042617733778e-55	5.49627694841142e-52	-1.61547521695278	-1.35527934294381
CLNS1A	BRD-K43644456-001-04-0::2.37833::HTS002	2.37833	WP1130	deubiquitinase inhibitor	targeted cancer	JAK2, UCHL5, USP14, USP9X	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.385821280545	-5.385821280545	-6.30113614543176	-6.296490539345	-10.8723308818905	10.0649003369967	6.95024942337113e-07	2.9094531419174e-05	-1.10273258385859	-0.72789714591492
CLNS1A	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0987665302157	-0.0987665302157	-0.263966857299146	-0.234942866008	-3.87507187778813	11.8103577238666	0.00227174271783302	0.0447518699421354	-0.258252189933119	-0.0721484642337733
CLNS1A	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.13368983964	-2.13368983964	-1.38220304915483	-1.257861831055	8.19312908051804	4.33006988954416	0.000855089024501956	0.0192843636909359	0.504302886193039	0.998670694777305
CLNS1A	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.492348183005	-5.492348183005	-4.58057898291016	-4.6036621232	7.77978005420394	9.64815475355527	1.85260714991298e-05	0.000608066520419141	0.649340764178707	1.17419763601098
CLNS1A	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.0746480436391	0.0746480436391	-0.296659956550968	-0.406253558846	-4.95739650878727	23.3110345073442	5.00199241859013e-05	0.00150783689603939	-0.526135723549981	-0.216480276830156
CLNS1A	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.133377768494	0.133377768494	-0.125379929025564	-0.007473093877485	-5.83192129649499	26.086425670246	3.75466836752804e-06	0.0001398079076692	-0.34994519591858	-0.167570199120549
CLNS1A	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.194688122258	-0.194688122258	-0.708960483977058	-0.5410189846345	-7.48017970334596	192.981337257028	2.54940453667835e-12	2.03884822739453e-10	-0.649872885788046	-0.378671837650069
CLNS1A	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.3198750501165	0.3198750501165	-0.75968887261298	-0.674815903064	-12.1199698543928	5.93130770589158	2.08392248590705e-05	0.000676529873495868	-1.29813141106218	-0.860996434396781
CLNS1A	BRD-K65928735-001-04-3::2.5::HTS002	2.5	AZD1480	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.318593080912	-0.318593080912	-0.0207552639933624	-0.05528360346055	9.60043254172824	195.43250611639	4.00231058173259e-18	5.56658809002053e-16	0.23665423696549	0.359021396871786
CLNS1A	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.7578126859715	-0.7578126859715	-2.64585510451585	-2.62453052692	-14.2694621195955	173.175435201274	4.78835111312602e-31	2.08170893656224e-28	-2.14919714085884	-1.62688769622986
CLNS1A	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.6284764039505	-0.6284764039505	-1.18237207759693	-1.01733335597	-9.03544161440243	28.1617622692392	8.16060908317231e-10	4.90618564989408e-08	-0.679435781555907	-0.428355565736954
CLNS1A	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.05383799316965	-0.05383799316965	-0.262790301912822	-0.236194067289	-4.89905498076304	69.8111025805096	6.00858956458257e-06	0.000215895220919936	-0.29402219807965	-0.123882419406694
CLNS1A	BRD-K69608737-001-10-2::2.5::HTS002	2.5	tacrolimus	calcineurin inhibitor	noncancer	FKBP1A	transplant	organ rejection	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.8718209599455	0.8718209599455	0.298727987012115	0.3216320959495	-18.2029344907623	10.4383141714177	3.02145553988285e-09	1.70866898260568e-07	-0.642845454867384	-0.503340490999386
CLNS1A	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.5091440835275	0.5091440835275	-0.158236125582068	0.0566391407425	-9.29554782014567	15.7771709265415	8.465555654579e-08	4.01774596521316e-06	-0.819755149770326	-0.51500526844881
CLNS1A	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.14218289253	0.14218289253	-0.617457363752389	-0.443084865138	-11.6853708758624	6.54167830022515	1.26664211140232e-05	0.000428334075567606	-0.915569700679459	-0.603710811885318
CLNS1A	BRD-K72726508-001-02-1::2.5::HTS002	2.5	arcyriaflavin-a	CDK inhibitor	targeted cancer	CCND1, CDK4	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.682859472418	-0.682859472418	-0.491798033002488	-0.3795984420275	3.67305492553237	52.3071722347324	0.000564177450404416	0.0133377000626217	0.0866962036500946	0.295426675180929
CLNS1A	BRD-K73589491-001-11-2::2.5::HTS002	2.5	nizatidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.312527914251	0.312527914251	0.0934575302467637	0.09689104741345	-9.03375161357635	149.263614356528	7.91323535178692e-16	8.8704802286252e-14	-0.266988427915088	-0.171152340093384
CLNS1A	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2024203721885	0.2024203721885	0.00016430148498399	0.03094358609725	-7.49371106781124	178.500984232714	2.99513634965594e-12	2.37933498400819e-10	-0.255516810780634	-0.148995330626398
CLNS1A	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2713250077275	0.2713250077275	0.0935185911671383	0.1896034324075	-3.92334013961795	71.7587196159215	0.00019798780626797	0.00523495293974929	-0.268155701480841	-0.0874571316398824
CLNS1A	BRD-K79239947-001-06-8::2.5::HTS002	2.5	PF-573228	focal adhesion kinase inhibitor	targeted cancer	CDK1, CDK2, CDK7, GSK3B, IKBKB	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2115281886145	0.2115281886145	-0.238526404652207	-0.1830123326315	-8.16626021533587	10.5355380917487	7.0751041736799e-06	0.00025035496160486	-0.572009750424392	-0.328099436109022
CLNS1A	BRD-K84892605-001-01-1::2.5::HTS002	2.5	IOWH032	CFTR channel antagonist	noncancer	CFTR	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.00917652106234	-0.00917652106234	0.119121934630372	0.126672721217	4.70127566892627	28.2134248534859	6.17215134649396e-05	0.00182817996951728	0.0724161897451364	0.184180721640287
CLNS1A	BRD-K89704198-001-12-3::2.5::HTS002	2.5	vincamine	adrenergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.177996365936	0.177996365936	-0.1973002709169	-0.1128406004625	-6.41666376458247	5.37470237266816	0.00103835483879453	0.0228513763470574	-0.522545749472829	-0.228047524232972
CLNS1A	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.48412144145	-4.48412144145	-5.62849627874556	-5.62740406384	-8.03306352249047	3.50845788144534	0.00222478277875818	0.043939869903102	-1.56274458385907	-0.726005090732044
CLTC	BRD-K11630072-001-13-2::0.625::HTS002	0.625	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	PATU8988T, RMGI, OVCAR8, KYSE410, ES2, VMCUB1	PANCREAS, OVARY, OESOPHAGUS, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (clear_cell_carcinoma), carcinoma, carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.989726635134333	-0.959649380606	-0.24504478333997	-0.1879124249525	5.26855580115812	6.4407257544294	0.00151232075544479	0.031647548837505	0.404480686697274	1.08488301689145
CLTC	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	PATU8988T, RMGI, U2OS, OVCAR8, NCIH1299, KYSE410, SCABER, VMCUB1	PANCREAS, OVARY, BONE, LUNG, OESOPHAGUS, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (clear_cell_carcinoma), osteosarcoma, carcinoma, carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.22920372968875	-0.2843664294455	-0.709986797102293	-0.631561003742	-4.39450684040444	11.0301066303113	0.00106600485711138	0.0233543652274175	-0.721502708106391	-0.240063426720695
CLTC	BRD-M97302542-001-03-6::2.5::HTS002	2.5	dichloroacetate	pyruvate dehydrogenase kinase inhibitor	targeted cancer	PDK1	NA	NA	PATU8988T, RMGI, U2OS, OVCAR8, NCIH1299, KYSE410, SCABER, ES2, VMCUB1	PANCREAS, OVARY, BONE, LUNG, OESOPHAGUS, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (clear_cell_carcinoma), osteosarcoma, carcinoma, carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.229074391336756	0.141211115086	-0.283917279284276	-0.18532672073	-4.61002082267962	10.9065786860208	0.000769424491271756	0.0175679111313289	-0.758168032738336	-0.267815308503727
CMC1	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7910335484025	0.7910335484025	0.465205732150409	0.473952429855	-6.96829406646525	9.41776472142673	5.22558032981866e-05	0.00156993749160317	-0.430892221337907	-0.220763411166274
CMC1	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.069853026426	0.069853026426	0.151266024879882	0.1647699361925	3.54417786453056	182.70704572329	0.000500121885610669	0.0119913439558171	0.0360906313149847	0.126735365592779
CMC1	BRD-A08545410-311-03-4::2.5::HTS002	2.5	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.04040777548	-1.04040777548	-0.489827750298145	-0.488941484078	15.5948170964833	107.097256409927	2.53745779796158e-29	9.81680130648568e-27	0.48059207056691	0.620567979796799
CMC1	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.79368382803	-1.79368382803	-1.20621558515855	-1.08580167806	8.63194690493637	193.232726466872	2.21802374986005e-15	2.38647998134415e-13	0.453237410355781	0.721699075387127
CMC1	BRD-A13561534-003-02-0::2.5::HTS002	2.5	ornithine	NFkB pathway modulator	noncancer	ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.92686403753	0.92686403753	0.62244858709006	0.6438914807695	-9.23313656069809	7.20094094319041	3.02476430153817e-05	0.000950718152198817	-0.381937987679135	-0.226892913200746
CMC1	BRD-A14240607-003-26-1::2.5::HTS002	2.5	octopamine	trace amine associated receptor agonist	noncancer	F10, TAAR1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7962588116985	0.7962588116985	0.689415265203164	0.666876685048	-4.06051144042338	187.959143856276	7.18080874138837e-05	0.00209680593560358	-0.158749957295252	-0.0549371356954195
CMC1	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.249849590868	0.249849590868	-0.00661436130042342	0.000253415549772	-7.3365291083046	12.6780217627075	6.58116820772033e-06	0.000234528964503294	-0.332179655619519	-0.180748248717328
CMC1	BRD-A27376179-001-01-3::2.5::HTS002	2.5	lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	targeted cancer	FLT3, NTRK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.34042783741	-3.34042783741	-2.90703441751993	-2.875482162025	4.37435346693211	129.647600854672	2.47956464147243e-05	0.000794858824472248	0.237378408482192	0.629408431297952
CMC1	BRD-A68631409-001-05-4::2.5::HTS002	2.5	evodiamine	ATPase inhibitor, TRPV agonist	targeted cancer	TRPV1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.152781087285	-3.152781087285	-2.36887749498975	-2.292575025235	6.45197589545006	4.64411927635444	0.00174898307628119	0.0357996173962632	0.464244737255978	1.10356244733452
CMC1	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.6098860452795	0.6098860452795	0.410988110165117	0.462027349437	-6.03016866476636	153.569261192228	1.1726777553152e-08	6.22588185828468e-07	-0.264058504477138	-0.13373736575163
CMC1	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.5754991009945	-0.5754991009945	0.159032009431474	0.185523876977	16.9253175846282	125.819976232709	3.17593784054545e-34	1.8803745343267e-31	0.648645830476157	0.820416390375791
CMC1	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.657512585485	-5.657512585485	-2.99437606336216	-2.85234115214	23.7837712154736	125.907012725437	2.09707046136261e-48	4.63363932900399e-45	2.44154396741726	2.88472907682843
CMC1	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.6486815978975	0.6486815978975	0.236070748534979	0.231867156581	-12.3716158601649	5.75147653322235	2.31728520492119e-05	0.000745961881474246	-0.495081270249193	-0.33014042847585
CMC1	BRD-K06854232-001-19-9::2.5::HTS002	2.5	AM-580	retinoid receptor agonist	targeted cancer	RARA	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.339070787973	-0.339070787973	0.124733625883642	0.154475017862	12.9257905901172	8.05707560503249	1.13933118281261e-06	4.61174151238986e-05	0.381162076956699	0.546446750756586
CMC1	BRD-K08109215-001-06-4::0.625::HTS002	0.625	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.14712200323	-0.14712200323	0.324366362462662	0.349176591288	7.27384109006744	143.640636463711	2.080837887543e-11	1.49358306630678e-09	0.343364600954021	0.599612130431304
CMC1	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-4.352615654095	-4.352615654095	-1.22151422449004	-0.903447368813	29.7175163446423	17.0925518087049	3.71643846089239e-16	4.3172928936835e-14	2.90889837876902	3.3533044804409
CMC1	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	1.22791306775	1.22791306775	0.00208124336200781	0.1859491052615	-17.8466452798425	18.524193956077	4.01526754875743e-13	3.47151383000255e-11	-1.36984562390648	-1.0818180248695
CMC1	BRD-K09549677-300-03-4::2.5::HTS002	2.5	mibefradil	T-type calcium channel blocker	noncancer	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.3345936209365	0.3345936209365	0.210263076105271	0.2370962732805	-3.61239553004309	18.6301268939311	0.0019033854703717	0.0384460187050509	-0.196464655877903	-0.0521964337845547
CMC1	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-2.03451250065	-2.03451250065	-1.32679175550334	-1.32870952416	10.7975502376057	161.122646495221	8.61142012317585e-21	1.53168221043996e-18	0.578283551763564	0.837157938529752
CMC1	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.278358915365	-5.278358915365	-3.66150351976354	-3.56303502077	11.2042598764156	2.92885674814959	0.00169987268942915	0.0349915495248425	1.15122968016259	2.08248111104033
CMC1	BRD-K15409150-001-05-8::2.5::HTS002	2.5	penfluridol	T-type calcium channel blocker	noncancer	CACNA1G	neurology/psychiatry	schizophrenia	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.959701585595	-3.959701585595	-2.8403748571974	-2.63540745447	9.99862509984235	9.27929041383068	2.84186183553009e-06	0.000108225551767471	0.86723975874622	1.37141369804898
CMC1	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.10086790378345	0.10086790378345	-0.0717080025308386	0.0407112965926	-4.08318341119326	126.678037868321	7.81783229656619e-05	0.00226675889920283	-0.256212835795603	-0.0889389768329738
CMC1	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.562762158271	-0.562762158271	-0.0373045701051451	0.10879840342	8.48128502289504	117.451569465783	7.6893630339209e-14	7.13134352962887e-12	0.402763985413908	0.648151190917802
CMC1	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.490137983133	-0.490137983133	-0.941917623100048	-0.8887322701185	-6.58691893947456	53.975093363344	1.93190833720495e-08	9.97309124216704e-07	-0.589290549648116	-0.31426873028598
CMC1	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7473709444165	0.7473709444165	0.303167916629533	0.3131581681635	-14.3463941895313	98.4007898473993	7.40722716133641e-26	2.01725996221356e-23	-0.505644360554578	-0.382761695019356
CMC1	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.007812916450212	-0.007812916450212	-0.343811710186325	-0.216806871006	-5.92769732051293	181.055790365493	1.52101773715899e-08	7.97451591456822e-07	-0.447842731647975	-0.22415485582425
CMC1	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.4162182990985	0.4162182990985	-0.217121957503545	-0.0984348398408	-12.1384915108201	156.479508525164	2.58547677302254e-24	6.23332566125025e-22	-0.736400766987078	-0.530279746217012
CMC1	BRD-K25244359-066-03-4::2.68145::HTS002	2.68145	apatinib	RET tyrosine kinase inhibitor	targeted cancer	CSK, KDR, KIT, RET	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.5018479362295	-0.5018479362295	0.143413493677826	0.202676632561	16.664585352372	78.605020264969	1.61430899968876e-27	5.13343076549396e-25	0.568184138348987	0.722338721465665
CMC1	BRD-K28578425-001-07-0::2.5::HTS002	2.5	cilostamide	phosphodiesterase inhibitor	targeted cancer	PDE3A, PDE3B	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.05718038723475	0.05718038723475	-0.0883064770758308	-0.0710584788856	-4.24453707272825	177.564340372181	3.52440375283248e-05	0.0010945977857424	-0.213128120377091	-0.0778456082440706
CMC1	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.48636214273	-3.48636214273	-1.64502215379068	-1.528752793545	16.2057430304825	3.50208814722542	0.000203090350800466	0.00535533363640664	1.50737194110782	2.17530803677082
CMC1	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.024774867716895	-0.024774867716895	-0.183936068914209	-0.06456986921455	-3.42271070553308	39.1384809540952	0.00146601028094983	0.0308319612899318	-0.253208735095642	-0.0651136672989863
CMC1	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.0630591410846	-0.0630591410846	0.244370194596383	0.255954419506	11.4835981204496	144.999702230365	4.09471215981945e-22	8.11104956101611e-20	0.254517203571574	0.360341467790392
CMC1	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.405762695615	-3.405762695615	-2.56722118981888	-2.525806741025	8.21896483204265	16.4723640387128	3.16579215005146e-07	1.3901271578127e-05	0.622760725352416	1.05432228623983
CMC1	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.0458771487	-5.0458771487	-3.64589054229061	-3.59749422562	10.6767771023783	5.14827900464242	0.000104680225433531	0.00295521707546672	1.06581959835221	1.73415361446657
CMC1	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.115707645382	-0.115707645382	0.417028743395429	0.43502168689	21.9585939542176	102.336143414694	1.6385251284977e-40	1.82908048055095e-37	0.484616803119783	0.580855974435075
CMC1	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.391381048361	0.391381048361	0.129222937977099	0.121836586496	-7.79572200119136	38.6172759466519	1.89921006831134e-09	1.09688977292132e-07	-0.330199647338024	-0.194116573429777
CMC1	BRD-K36363294-001-04-2::2.5::HTS002	2.5	I-BET151	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.209615904335	-1.209615904335	0.12924385915319	0.175731719762	17.0193270357609	4.68520971451617	2.15631756739816e-05	0.000698339963588517	1.13248401052623	1.54523551645015
CMC1	BRD-K37249724-001-25-7::2.5::HTS002	2.5	astemizole	histamine receptor antagonist	noncancer	HRH1, KCNH1, KCNH2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.1937746806275	0.1937746806275	0.0611703014207595	0.100436576625	-3.61870276458607	187.921972798553	0.000380528809647903	0.00939828984132582	-0.204891171557783	-0.0603175868556984
CMC1	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.592261125765	-3.592261125765	-2.6076287090415	-2.424137198535	10.1880728708246	43.9565140002942	3.79189065974046e-13	3.28634101581687e-11	0.789850565420739	1.17941426802626
CMC1	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.5272317790335	-0.5272317790335	-0.140187037050162	-0.03734266076635	7.82263602523526	24.3215551799364	4.26962356337413e-08	2.09791447026299e-06	0.284999527716743	0.489089956249933
CMC1	BRD-K39171998-001-01-1::2.5::HTS002	2.5	STF-118804	NAMPT inhibitor	targeted cancer	NAMPT	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.84306514094	-5.84306514094	-4.65384728401106	-4.65401991694	11.8118990518423	61.5675036625642	1.81119051869779e-17	2.36990630452979e-15	0.987933978585202	1.39050173527268
CMC1	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.034618135815	-5.034618135815	-3.01638115643831	-2.87565347972	15.2610745512968	3.85720811365602	0.000136423859363363	0.00375058868054005	1.64563608447295	2.39083787428043
CMC1	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.274474435688	0.274474435688	-0.213136368948703	-0.158274399371	-9.54226351914088	12.7391874576044	3.65051824621075e-07	1.58543449886951e-05	-0.598236092227899	-0.376985517045507
CMC1	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.6353123639325	0.6353123639325	0.471812984099487	0.492327571576	-5.59280839596033	146.607217835981	1.06208411268481e-07	4.99091045357646e-06	-0.221273593109859	-0.105725166556168
CMC1	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-4.572373565285	-4.572373565285	-3.74482060748522	-3.638458649165	7.93153858285827	153.685702318812	4.15985983453553e-13	3.58928582317297e-11	0.621433117897052	1.03367279770251
CMC1	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.06603668832	-3.06603668832	-2.23122566550389	-2.12735654465	10.428714576269	6.16065790818348	3.83881027646095e-05	0.00118400973916189	0.640169061756993	1.02945298387523
CMC1	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7573653503995	0.7573653503995	0.375037512485329	0.393436647762	-13.3694140611568	9.22833896494126	2.3812604923583e-07	1.06283461071775e-05	-0.446776024469336	-0.317879651359006
CMC1	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.2444013238885	-0.2444013238885	0.232133617302861	0.2141011890955	16.2535291420211	81.149341516027	3.04299738817181e-27	9.30388854792406e-25	0.418201234349443	0.534868648033279
CMC1	BRD-K53523901-001-04-4::2.5::HTS002	2.5	arctigenin	MEK inhibitor	targeted cancer	CHUK, MAP2K1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.9310450711915	-0.9310450711915	-0.428800818259873	-0.429548063404	9.81128011609699	3.86708411384021	0.000713916553410352	0.016451244057186	0.358169198663395	0.646319307199858
CMC1	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.2140206426765	-0.2140206426765	0.119112876175134	0.150496276102	10.1632655015838	10.787029118194	7.39472715858079e-07	3.08167310358052e-05	0.260815031416938	0.40545200628633
CMC1	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.3681963058635	0.3681963058635	-0.127989023885226	-0.007473093877485	-10.2065554656913	9.15170306011553	2.65251402406284e-06	0.000101465407507293	-0.60588143031921	-0.386489229178242
CMC1	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.04910063126	-1.04910063126	-1.33236393005949	-1.45938861893	-4.84522152456142	191.05715896832	2.6087057233867e-06	9.9947855912563e-05	-0.398577948788525	-0.167948648810454
CMC1	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.03580325248235	0.03580325248235	-0.208025735152714	-0.0810605722641	-5.04953237334293	188.672060481281	1.03966334390317e-06	4.22827333653555e-05	-0.339081619491974	-0.148576355778155
CMC1	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.516966175579	-0.516966175579	-0.203805784627939	-0.243848377549	9.34739968088099	10.7306712509709	1.7423976396775e-06	6.84092954230517e-05	0.239195656210157	0.387125125691965
CMC1	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.4323714347625	0.4323714347625	-0.498308001151974	0.00402399396559	-10.4774429319402	188.006709232387	1.59258532319054e-20	2.77059431602359e-18	-1.10590503144279	-0.755453840386158
CMC1	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.02542677765	-3.02542677765	-2.48003677164038	-2.38802069166	5.68367335129545	18.7003773581795	1.8771716626374e-05	0.000615092990798671	0.344331027210522	0.74644898480871
CMC1	BRD-K65781196-001-03-0::2.5::HTS002	2.5	avanafil	phosphodiesterase inhibitor	noncancer	PDE5A	urology	erectile dysfunction	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.306622124191	0.306622124191	0.520177797172758	0.5001680411375	7.99788215772324	150.029693053086	3.15863076176714e-13	2.75645835724262e-11	0.160796066722515	0.266315279241001
CMC1	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.299599606656	0.299599606656	-0.0825914929234308	0.0411624842104	-7.17666696692973	7.57585233687856	0.00012370276641699	0.0034356732180105	-0.506203739027564	-0.258178460131297
CMC1	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.49705251631	-1.49705251631	-0.780026367429946	-0.642853768929	9.73553135384276	20.4194652291975	4.05700769042965e-09	2.26264481207936e-07	0.563596097441185	0.870456200318924
CMC1	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.8894545495365	-0.8894545495365	-0.523029796960183	-0.364234530081	6.66649243604005	65.1969240697374	6.6298580649839e-09	3.60744059205366e-07	0.256658054403356	0.476191450749279
CMC1	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.8590488914	-3.8590488914	-2.50797977057536	-2.24664413304	8.75417524360783	3.51901704850311	0.00164398733596666	0.0339880545703096	0.898452078380518	1.80368616326877
CMC1	BRD-K76037122-001-02-5::2.5::HTS002	2.5	guanidine	HSP inhibitor	noncancer	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.08236089830095	0.08236089830095	0.214496456527129	0.217996960587	4.13293600513709	12.0246482362913	0.00138234245867782	0.0292733995480643	0.0624917962394067	0.201779320212951
CMC1	BRD-K81548480-001-01-2::2.5::HTS002	2.5	AC-264613	PAR agonist	noncancer	F2RL1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.3254443179745	0.3254443179745	-0.376669620555005	-0.2564995934565	-14.4643465873751	193.99958388509	1.19510444927635e-32	6.02695391785766e-30	-0.797849790502707	-0.606378086556302
CMC1	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.2608545739595	0.2608545739595	-0.327794099216086	-0.193950713334	-10.832846017958	71.8121863496842	9.31163882040345e-17	1.13588744265125e-14	-0.696976818586276	-0.480320527764896
CMC1	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.59460480684	-5.59460480684	-4.8339473700577	-4.95161811894	8.18966894987735	152.642542487723	9.73494869509147e-14	8.92803516846495e-12	0.577160945357834	0.944153928206765
CMC1	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.0818043345879	-0.0818043345879	0.113411070926575	0.0998567885779	7.42702502244734	124.865845439101	1.52096433561826e-11	1.1148658176769e-09	0.143194633873992	0.247236177154957
CMC1	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.157760051922	0.157760051922	-0.122073809725094	-0.0479466221371	-8.61556421843166	170.307068969777	4.57756838948667e-15	4.79055495776508e-13	-0.343949172524387	-0.215718550769801
CMC1	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.7323439264095	-0.7323439264095	-0.267040907287568	-0.201241346164	7.46904021064528	4.8934570369128	0.000745798515793736	0.0170976842540973	0.30410761293846	0.626498425305404
CMC1	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.72660717278	-3.72660717278	-1.80708016688349	-1.68862958657	15.869906832908	3.03579152940021	0.000508901023980432	0.0121800388128087	1.53715243380363	2.3019015779894
CMC1	BRD-K92428232-001-10-6::2.5::HTS002	2.5	GSK461364	PLK inhibitor	targeted cancer	PLK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.991668507425	-3.991668507425	-2.68531224087157	-2.35101835033	7.58471868152343	3.60066551074183	0.0024446220975934	0.0476451222656267	0.806494275250938	1.80621825785592
CMC1	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.532796017447	-0.532796017447	-0.0889336643289606	-0.0408206395104	15.0213426823001	192.653807330464	2.86697202469997e-34	1.71163021471287e-31	0.385581697192	0.502143009044079
CMC1	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.883320284796	-0.883320284796	-0.35738698724703	-0.28708101882	8.47077508492825	76.3367492632495	1.33700762004139e-12	1.10130478937683e-10	0.402283193495674	0.649583401602265
CMC1	BRD-K94176593-001-09-4::2.5::HTS002	2.5	TWS-119	glycogen synthase kinase inhibitor	noncancer	GSK3B, JUN, MYC	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.6430257904935	-0.6430257904935	-0.292458291137632	-0.211299722741	7.84382463748608	23.8182165057705	4.70879258340372e-08	2.30523253907797e-06	0.25828750492241	0.442847493789326
CMC1	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7052893264125	0.7052893264125	0.294848534197782	0.274833859863	-11.5627721839673	194.004525913717	7.32365980349874e-24	1.69145763149147e-21	-0.480449862454973	-0.340431721974463
CMC1	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-2.81932307911	-2.81932307911	-1.39256353393589	-1.36288222555	18.4876258353229	181.254567923181	1.4189940307427e-43	1.98778804977158e-40	1.27448504232301	1.57903404802522
CMC1	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.06517191056135	-0.06517191056135	-0.970108268363088	-0.879578497328	-9.5154174198054	27.2866902098661	3.67401229187354e-10	2.29643447216379e-08	-1.09997390193047	-0.709898813673009
CMC1	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.0793545747386	0.0793545747386	0.312702037863887	0.3392697962385	7.06023380491992	159.073450565762	4.87091237453302e-11	3.34393907213737e-09	0.168072185160893	0.29862274108968
CMC1	BRD-K97752965-001-16-4::2.5::HTS002	2.5	nicorandil	nitric oxide donor, potassium channel activator	noncancer	KCNJ11	cardiology	angina pectoris	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.525267266716	0.525267266716	0.246744382421208	0.245556311183	-9.42972296913283	22.9563432326172	2.32894350115859e-09	1.33073882074065e-07	-0.339630630773473	-0.217415137816112
CMC1	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.3377395552215	0.3377395552215	-0.228393407266589	-0.0281474951666	-9.22041670195334	95.8488473566077	7.12972640881124e-15	7.29755077112752e-13	-0.688013318004734	-0.444252606971443
CMC1	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.90424557582	-1.90424557582	-0.706321377874187	-0.590290062749	12.8611827648096	2.75732637194044	0.00152719237551237	0.0319244723155359	0.886183472155505	1.50966492373612
CMC1	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.063258311678689	0.063258311678689	-0.619468494345976	-0.542183140466	-7.79598614000126	3.54005196360751	0.00237640289645342	0.0464676632053612	-0.938851901030466	-0.426601711018865
CMC1	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.244801260475	-0.244801260475	-0.0747352603008461	-0.0657751951103	4.77667231319084	7.66947185266914	0.00157003504457639	0.0326829876718156	0.0873443174309035	0.252787682917404
COA8	BRD-A12417644-001-07-6::2.3139::HTS002	2.3139	usniacin-(+)	MAP kinase activator	targeted cancer	PTPN1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0039489432524	0.0039489432524	0.172919521609129	0.1617912757505	5.16863884197965	17.7795556590353	6.7059433516921e-05	0.00197022362251517	0.10022718531463	0.237713971398828
COA8	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.04954078852255	-0.04954078852255	0.0913439985499901	0.131172819567	4.77027820819022	20.2237408785926	0.000113529796726021	0.00317908646491918	0.0793218736210324	0.202447700524048
COA8	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.212589484238	-0.212589484238	0.0788369092042791	0.1349064957195	10.07203533199	175.085543559794	4.13599241866298e-19	6.29590283451434e-17	0.234321668698646	0.348531118185912
COA8	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.138060642958	-0.138060642958	-0.534378218226731	-0.51783728433	-12.7097145435698	194.951830690683	2.37384099436299e-27	7.39510125698873e-25	-0.457815442178447	-0.334819708359015
COA8	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2281282911595	0.2281282911595	0.358918900156311	0.3667280736395	5.72826214382995	187.881758006832	3.97093897231384e-08	1.96283989621091e-06	0.08574958253852	0.175831635455103
COA8	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.43867526446	-1.43867526446	-1.12172057586058	-1.02154011458	4.98011111740702	19.1585944482818	8.11818931069535e-05	0.00234591262878795	0.183820651366659	0.450088725832184
COA8	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.8463841380505	-0.8463841380505	-3.0475377036653	-2.92318120426	-19.3066734378221	93.1033595956107	2.57535515800168e-34	1.54614368532029e-31	-2.42755149004014	-1.97475564118946
COA8	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3170590301595	-0.3170590301595	-1.0338471576067	-1.0089298839585	-12.9602700211631	58.8506279663955	6.86816716478104e-19	1.02012986851029e-16	-0.827462203068315	-0.606114051826094
COA8	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.01098666427484	0.01098666427484	-0.478119266297974	-0.33490377325	-7.0447633043752	89.4283778753282	3.69857149942649e-10	2.30841913482988e-08	-0.627049376373432	-0.351162484772197
COA8	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.989337148002	-0.989337148002	-2.46308326167389	-2.47219362388	-13.3494130226538	11.9981815236686	1.46513133953335e-08	7.70223534144821e-07	-1.71428634654616	-1.23320588079761
COA8	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.0554826678688	-0.0554826678688	-0.515658101895237	-0.419130200084	-7.23595660689914	152.917003543607	2.08991826591843e-11	1.49809395323088e-09	-0.585814947005301	-0.334535921047574
COA8	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.020390036649925	0.020390036649925	-0.424143047542583	-0.390164965854	-10.2788160604997	6.31486920976907	3.55932004110303e-05	0.00110400217813252	-0.54908993080033	-0.339976237584686
COA8	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.584835548043	0.584835548043	-0.484062050536501	-0.373418715101	-9.85340469252355	7.82394624145259	1.10746542949433e-05	0.000378205796746478	-1.32003618154615	-0.817759015612855
COA8	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.640673680695	-1.640673680695	-1.29099182098096	-1.25961873039	6.85984612683123	190.644382347607	9.36644574682803e-11	6.23298980498242e-09	0.249134067933508	0.450229651494576
COA8	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1691438889035	-0.1691438889035	-0.570282627598963	-0.549657042838	-11.4869230015469	135.891616059592	9.1732325554601e-22	1.76330920213382e-19	-0.470198304508596	-0.33207917288233
COA8	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.4544780362765	-0.4544780362765	-0.0505222601717786	-0.0356049990197	6.8389491146983	5.88550103720269	0.000521392451565853	0.0124359584633494	0.258739861973213	0.54917169023623
COA8	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.5270677950605	-0.5270677950605	-0.0892438874278849	-0.0178822580687	10.9160816363957	135.546983589343	2.69038686875514e-20	4.58368781552798e-18	0.358505211467761	0.517142603797469
COA8	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.41086727502	0.41086727502	-0.377883730859893	-0.1455477562875	-7.01722277381034	4.5137962912695	0.00136689529879749	0.0290208323423445	-1.08730681568901	-0.490195196070771
COA8	BRD-K19284129-001-02-6::2.5::HTS002	2.5	salvinorin-a	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2309179360235	-0.2309179360235	0.0155731697946181	0.02724514887165	6.5044341712887	58.8863303551889	1.86961175192084e-08	9.6766968649467e-07	0.170658608763502	0.322323602872734
COA8	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.38385573655	0.38385573655	-0.347870452704462	-0.216806871006	-12.9745301622417	184.279541987636	9.10231259652505e-28	2.96487774544167e-25	-0.842993244748135	-0.620459133760788
COA8	BRD-K19412355-001-01-0::2.5::HTS002	2.5	SB-242235	p38 MAPK inhibitor	noncancer	HSPB1, MAPK14	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.06214419600445	-0.06214419600445	0.116358124720773	0.132605896616	4.47942781132184	7.70758320524978	0.00225745479688685	0.0445072237293682	0.0859991471780716	0.271005494272375
COA8	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.930278540383	-0.930278540383	-3.15447790758085	-3.22475555586	-15.0735832766771	6.74796739191329	1.90711516545949e-06	7.44400084315729e-05	-2.57577336789673	-1.87262536649897
COA8	BRD-K24603946-001-02-1::2.5::HTS002	2.5	5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	noncancer	CHRM3	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.4796308109	-1.4796308109	-2.43279316035235	-2.202066494735	-8.85026815244322	53.8156748871119	4.41718026775981e-12	3.45018159478386e-10	-1.16910217565503	-0.737222523249666
COA8	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2659261296915	-0.2659261296915	-0.42613632306368	-0.326694667694	-4.08117944981937	190.492967860319	6.58629885738674e-05	0.0019387925392183	-0.237642191546382	-0.0827781951979775
COA8	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2877489295695	-0.2877489295695	-1.04412729759226	-0.8676646214495	-9.24171243378061	26.612297725672	8.58319364022388e-10	5.14869104314454e-08	-0.924422856565084	-0.588333879480436
COA8	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.5170321910205	-0.5170321910205	-0.773611396562741	-0.707312470978	-4.6454551191237	193.372537717201	6.26193461900421e-06	0.000224121968532334	-0.365514310992782	-0.1476441000917
COA8	BRD-K31491153-003-05-9::2.5::HTS002	2.5	1-phenylbiguanide	serotonin receptor agonist	noncancer	HTR3A, HTR3B	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.462991949891	-0.462991949891	-0.0933211562503342	0.0251960831099	5.93740157688605	7.81174587719924	0.000380249497955924	0.00939668527134459	0.22549130868368	0.513850278597652
COA8	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.3240750248975	0.3240750248975	-0.116629967590755	0.0546590882103	-6.15326639808213	8.01650645626779	0.000270737089471559	0.00691206785578913	-0.605804851227218	-0.275605133749293
COA8	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4551300743225	0.4551300743225	-0.0459833038028448	-0.03775802467905	-11.0433816911238	43.8754706143081	2.97774031204135e-14	2.88654954020583e-12	-0.592571651345104	-0.409655104905586
COA8	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0612295897389	0.0612295897389	-0.207634227744818	-0.158031671069	-7.58173919531589	80.9911094119403	4.98373519257386e-11	3.4137391501731e-09	-0.339422239099626	-0.198305395867811
COA8	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0756204968079	0.0756204968079	-0.111197549395606	-0.11764531931	-3.46719455572425	27.6856873934751	0.00173505980905706	0.0355923759942845	-0.297246012395593	-0.0763900800114196
COA8	BRD-K43236057-001-07-1::2.59978::HTS002	2.59978	polydatin	ICAM1 expression inhibitor	noncancer	ICAM1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.134477238665	-2.134477238665	-1.30480828783669	-1.19469399644	9.67598939514444	13.5005690399474	1.91366626027342e-07	8.65669429924319e-06	0.645123631109192	1.01421427054742
COA8	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.7520461248065	-0.7520461248065	-0.357774861470342	-0.229271162585	5.91523615372723	45.9256128980778	3.8999485237938e-07	1.68931298940218e-05	0.260098838014376	0.528443688657939
COA8	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.228556052504	0.228556052504	-0.789752367512326	-0.640313618355	-11.1374063377994	7.54633496201191	5.94979327610734e-06	0.000213961953536042	-1.23137635801681	-0.80524048201584
COA8	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.542403648252	-0.542403648252	-1.59792075178887	-1.48697544025	-10.0702008251254	6.79220682180654	2.50009409827871e-05	0.00080108038270291	-1.3049127239544	-0.806121483119348
COA8	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.14265112400695	0.14265112400695	-0.589240267442785	-0.48109263675	-8.37386531272647	11.9137122304268	2.46686992772106e-06	9.48209764595638e-05	-0.922476766174213	-0.541306016725258
COA8	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0444406384067	0.0444406384067	0.262850893576132	0.254607479759	7.72391692645745	12.497012605601	4.18834106445455e-06	0.000154746242372605	0.157070332149675	0.279750178189189
COA8	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.033641787862075	0.033641787862075	-0.208003102015329	-0.0810605722641	-4.32345524972465	13.8356144703627	0.000719555758603235	0.016570502437485	-0.36165423727817	-0.121635542476638
COA8	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.316339645834	0.316339645834	-0.236288362373872	-0.1756829862115	-7.81465814362153	7.01061867397787	0.000104995798816945	0.00296139552107343	-0.719795456365182	-0.385460560050561
COA8	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4711857676415	0.4711857676415	-0.498718734833234	0.00402399396559	-10.6421224829224	135.969768181007	1.29380723601256e-19	2.06018136023281e-17	-1.15013630607385	-0.789672698875619
COA8	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.166811084079	-0.166811084079	0.108015463257308	0.101486674715	7.23255749794279	121.292726081961	4.65425269013493e-11	3.20546698208204e-09	0.199600269823638	0.350052824848978
COA8	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.665606404535	-1.665606404535	-0.410947541638825	-0.2259650044755	16.5946139097357	11.1002962341966	3.47752125177702e-09	1.95420464701656e-07	1.08843358087879	1.42088414491356
COA8	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.564564297055	-1.564564297055	-1.10458888670781	-1.10749370834	9.47951295656046	188.964271159541	1.09998218437549e-17	1.47303599635999e-15	0.364258853959488	0.555691966734893
COA8	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4773020832075	0.4773020832075	-0.470348358816467	-0.217946401079	-11.1085567919974	189.883370500343	2.06969647195964e-22	4.22875095461047e-20	-1.11592383682236	-0.779377047225576
COA8	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.425293581735	-3.425293581735	-4.14015929978772	-4.26693586682	-4.99912926140459	5.99719992023252	0.00245776514163003	0.0478664557056269	-1.06480893741168	-0.36492249869376
COA8	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.217987378713	-0.217987378713	-0.425088448634094	-0.2959843885325	-3.77549330261944	193.650194958422	0.000212310267016476	0.00557083807854796	-0.315289143527747	-0.0989129963144415
COA8	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2549019500045	0.2549019500045	-0.508903482970275	-0.3823931691785	-12.5202026397208	175.861945296529	4.00378284416342e-26	1.12173434406105e-23	-0.884203203117576	-0.643407662831975
COA8	BRD-K86816506-001-01-8::2.5::HTS002	2.5	PF-04457845	FAAH inhibitor	noncancer	FAAH	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2392358332045	-0.2392358332045	-0.408842127192448	-0.370640421909	-5.7851903121062	190.157390959272	2.93676996499e-08	1.47754687752662e-06	-0.227435233372847	-0.111777354603048
COA8	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.02947908460285	0.02947908460285	-0.787368626622999	-0.783090045771	-16.8337461660176	174.728372929204	2.05249118264782e-38	1.83295159452385e-35	-0.912617141059297	-0.7210782813924
COA8	BRD-K90647725-001-07-3::2.50156::HTS002	2.50156	oleanolic-acid	G protein-coupled receptor agonist	noncancer	GPBAR1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.251593412205	0.251593412205	0.11896076444758	0.139454786175	-4.4185049174249	13.7917291474982	0.000604286178608369	0.0141624988928325	-0.197105198474372	-0.0681600970404673
COA8	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.93723873221	-2.93723873221	-4.02377781139263	-3.85901121156	-7.89807685551241	10.5110034698835	9.74775644098958e-06	0.000336537836701169	-1.3910563292468	-0.782021829118464
COA8	BRD-K91623615-001-05-0::2.46068::HTS002	2.46068	ABT-751	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.671384272495	-2.671384272495	-3.49965914932143	-3.442891314055	-7.12721444987137	8.59980184118401	6.9268186979155e-05	0.00202872113242079	-1.09304366617407	-0.563506087478786
COA8	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.897679387215	-2.897679387215	-1.58182958616937	-1.34116610852	17.5577542387674	105.181592075293	4.87096249327163e-33	2.577749432643e-30	1.16725251778245	1.46444708430881
COA8	BRD-K92441787-001-04-1::2.5::HTS002	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.25491162119	0.25491162119	0.154545119570946	0.1701725882685	-3.53015047899878	178.108438679587	0.000528664876879457	0.0125856063975005	-0.156471903347915	-0.0442610998901923
COA8	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.8159067202195	0.8159067202195	0.30494885738514	0.328628776305	-15.5412448708021	158.501728007453	1.1101440908538e-33	6.22869300650798e-31	-0.57589244047555	-0.446023285193169
COA8	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.233712847494	0.233712847494	-0.0920934734067121	0.0692106615383	-6.27681788449302	179.679649165613	2.51846303991453e-09	1.4340586208338e-07	-0.428230645491908	-0.223381996309516
CPNE2	BRD-A14240607-003-26-1::2.5::HTS002	2.5	octopamine	trace amine associated receptor agonist	noncancer	F10, TAAR1	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.7935789042075	0.7935789042075	0.689443774857324	0.666876685048	-3.96324084749254	187.441685117654	0.00010504223881252	0.00296231552663796	-0.155968327603457	-0.052301931096895
CPNE2	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.875686492923	0.875686492923	0.395535249660698	0.4040524647295	-7.52561089733288	6.10080069789204	0.000263459878740527	0.00674636706697472	-0.635646689216549	-0.324655797308055
CPNE2	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-4.58262197034	-4.58262197034	-3.79823220630554	-3.74224322709	5.86664294894933	4.95066355706879	0.00211030429778309	0.0420157370961033	0.439661620510489	1.12911790755844
CPNE2	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.00113485842136	-0.00113485842136	0.187376801600478	0.190024427126	6.83470572345966	177.773643380998	1.26528643128582e-10	8.29319802847273e-09	0.134082315982035	0.242941004061641
CPNE2	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.5040357037055	0.5040357037055	0.140273312245488	0.135666555282	-9.98914093825251	4.26020595961818	0.000409252412284178	0.0100165193870567	-0.462479310957186	-0.265045471962838
CPNE2	BRD-A75919782-399-02-6::2.5::HTS002	2.5	leucovorin	folate receptor ligand	targeted cancer	TYMS	oncology	osteosarcoma	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.2194187110305	0.2194187110305	0.588441722437751	0.648962847525	10.2595465332337	157.531495471405	3.10651357986718e-19	4.77972684177569e-17	0.297979798054037	0.440066224760465
CPNE2	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-3.017481311365	-3.017481311365	-2.31015672084376	-2.417981872085	7.21017045166271	3.83468242252881	0.00230217602501639	0.0452681729601594	0.430258673801609	0.984390507240866
CPNE2	BRD-K02389548-001-02-5::2.5::HTS002	2.5	RG2833	HDAC inhibitor	noncancer	HDAC1, HDAC3	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.185163547311	0.185163547311	0.318750559786663	0.362491356389	3.51992186730806	124.979448851074	0.000602993868955489	0.0141383954643213	0.0584757708142028	0.208698254137123
CPNE2	BRD-K03765900-001-01-9::2.5::MTS006	2.5	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.6248247555375	-0.6248247555375	-1.17251711568454	-0.823393929272	-6.14501896554055	71.4856753858517	4.07332812786078e-08	2.01063723723777e-06	-0.725387334597393	-0.369997385696691
CPNE2	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-5.129214118145	-5.129214118145	-3.69053395908783	-3.52000958617	13.3327393098247	184.572291257115	7.69045283090188e-29	2.81758472614422e-26	1.22579276308629	1.65156755502804
CPNE2	BRD-K06753942-001-14-5::2.5::HTS002	2.5	nobiletin	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.475623625558	0.475623625558	-0.080351520316638	-0.0747677969197	-10.5482300527492	110.691747674998	2.00519724452442e-18	2.8556273768882e-16	-0.660422590588144	-0.451527701161132
CPNE2	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.09470804947295	0.09470804947295	0.258709335507781	0.2294815220965	5.90198659299602	99.5642128236278	4.98294280546675e-08	2.43333139337636e-06	0.10886877839685	0.219133793672812
CPNE2	BRD-K10845183-304-01-6::2.5::HTS002	2.5	tiludronate	bone resorption inhibitor, osteoclast inhibitor	noncancer	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.19078179858	-0.19078179858	0.221401522228556	0.2180493051285	11.0659449759173	78.2892781946345	1.12146699793612e-17	1.49852182169982e-15	0.338032744241471	0.486333897375641
CPNE2	BRD-K12251893-065-04-7::2.5::HTS002	2.5	vincristine	tubulin polymerization inhibitor	chemo	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-2.19556053695	-2.19556053695	-2.71043731061041	-2.6144312066	-4.43256033845776	25.9950063232598	0.000150336896094689	0.00409578703483902	-0.753644930175596	-0.276108617145218
CPNE2	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-2.262286814415	-2.262286814415	-1.92863187325391	-2.01595157397	4.26770362712737	177.436298130713	3.20946985252163e-05	0.00100274411664885	0.179369953411367	0.487939928910814
CPNE2	BRD-K13183738-317-10-2::2.5::HTS002	2.5	pentamidine	anti-pneumocystis agent	noncancer	TRDMT1	infectious disease	pneumonia	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.1849921612755	-0.1849921612755	-0.917244900370856	-0.8497746890035	-12.7433542412337	157.923738709242	4.956672621963e-26	1.37078540179704e-23	-0.84574499102922	-0.618760487161492
CPNE2	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.883100787302	0.883100787302	0.501613289144167	0.505306635797	-16.7314139944205	185.484463209834	6.63234014486929e-39	6.34599478084683e-36	-0.426469487006062	-0.336505509309604
CPNE2	BRD-K15567136-003-27-2::2.5::HTS002	2.5	papaverine	phosphodiesterase inhibitor	noncancer	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.2047773547945	-0.2047773547945	-0.526024760705739	-0.5051056770975	-8.5976424765078	16.652398687858	1.5835599914514e-07	7.26772653978133e-06	-0.400205342644203	-0.242289469178274
CPNE2	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-1.66971675796	-1.66971675796	-2.87490493217017	-2.63264407289	-8.89207976233816	45.8570389530867	1.52580438458429e-11	1.11803120664467e-09	-1.47802896533174	-0.932347383088595
CPNE2	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.09222352458125	-0.09222352458125	-0.979071823768647	-0.735958486111	-13.0518835572732	192.183333102887	2.7219484110976e-28	9.48605660166076e-26	-1.0208677211845	-0.752828877190289
CPNE2	BRD-K18961567-001-01-1::2.5::MTS010::PROS002_PR500	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.553684851567	0.553684851567	-0.424114688397149	-0.32717924466	-14.8503922552468	19.1434713590306	5.82864429287321e-12	4.47438217280523e-10	-1.11554137862071	-0.840057701307587
CPNE2	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-2.350219939655	-2.350219939655	-2.99557140757265	-2.880185474935	-8.49659384959785	187.339725923555	5.98627399388259e-15	6.18328731968608e-13	-0.795186784791962	-0.495516151043335
CPNE2	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.4957416707035	-0.4957416707035	-0.68925960519139	-0.593823716309	-3.57459076936295	190.319432884412	0.000444598153711291	0.0107953186458352	-0.300303717159762	-0.0867321518160181
CPNE2	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.1297917369645	-0.1297917369645	0.101860260804249	0.137732029225	9.68692123815013	46.9518296122312	8.94482362218792e-13	7.48588481889853e-11	0.18354214749726	0.279761848040238
CPNE2	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.13102268548775	-0.13102268548775	-0.862878520710274	-0.55802362728	-7.16288616186112	29.6178629769565	6.15632701945069e-08	2.9758218623181e-06	-0.940634539925724	-0.523077130519324
CPNE2	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.1612557748725	0.1612557748725	-0.78460886967319	-0.759682041762	-12.2503324427761	7.52695822199901	3.06420872688627e-06	0.00011595141105664	-1.12588099153177	-0.765848297559609
CPNE2	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-2.821190231355	-2.821190231355	-2.0512461496391	-1.99105481758	6.59915907571269	4.94453018323148	0.00125349737138327	0.0269523312711882	0.469011606617026	1.07087655681477
CPNE2	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.20379859462	0.20379859462	0.386382616591732	0.399212772621	6.5417833939291	19.0003410964227	2.89680739716682e-06	0.000110180981832718	0.124166880560719	0.241001163382745
CPNE2	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.10713239057925	0.10713239057925	-0.619709671880108	-0.480230640816	-8.1109026392534	3.63794642200456	0.00186221814840153	0.0377318352740359	-0.985723936966376	-0.46796018795234
CPNE2	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.1175104928416	-0.1175104928416	-0.88064748599408	-0.7074523288895	-6.90538630862635	8.52147836155709	9.15914870851785e-05	0.00261463929614801	-1.01529187186873	-0.510982114436225
CPNE2	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.250319694158	-0.250319694158	0.0294780934526781	0.056211415311	6.49145969810657	6.09282612403024	0.000597523835083224	0.0140377820946566	0.174718182515267	0.384877392706089
CPNE2	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.933278496235	-0.933278496235	-1.93841035570091	-1.836818850415	-11.6849831230663	139.192675279416	2.0788329931128e-22	4.24337330077023e-20	-1.17520486222665	-0.835058856705164
CPNE2	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.2564347162335	0.2564347162335	-0.279245025319273	-0.153671266635	-8.29885478028124	7.83706803569075	3.7800203173039e-05	0.00116738901237382	-0.685069534128669	-0.386289948976876
CPNE2	BRD-K36740062-001-06-6::2.5::HTS002	2.5	GSK1070916	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC, CYP2D6, CYP3A4	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-1.15161674343	-1.15161674343	-2.27089272185606	-1.977136981175	-9.85050380061821	29.2838777421361	8.37406805561284e-11	5.60526431071656e-09	-1.35156997320687	-0.886981983645254
CPNE2	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.387319962209	0.387319962209	-0.0783891024661141	-0.0620606581655	-14.169173190364	52.4868685475354	1.41500289214706e-19	2.23985343331601e-17	-0.531648502567607	-0.399769626782621
CPNE2	BRD-K37764012-001-04-1::2.5::HTS002	2.5	PF-03758309	p21 activated kinase inhibitor	targeted cancer	PAK4	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-2.26207365465	-2.26207365465	-3.209131211477	-3.15071894959	-8.18684380477629	9.00127853898157	1.83820471158279e-05	0.000603801651538434	-1.20873918907406	-0.685375924579942
CPNE2	BRD-K37865504-001-04-1::2.5::HTS002	2.5	LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	noncancer	FAAH	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.7036434713665	-0.7036434713665	-1.29613622801078	-1.08170547456	-5.64713438275327	5.65356165273016	0.00161525054868133	0.0334941016687616	-0.853082836169489	-0.331902677119066
CPNE2	BRD-K38305202-001-17-4::2.5::HTS002	2.5	domperidone	dopamine receptor antagonist	noncancer	DRD2, DRD3	infectious disease	fescue toxicosis	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.3208703298965	0.3208703298965	-0.364727528666569	-0.225769257521	-11.3391668791853	100.46926234689	1.10541892556495e-19	1.77205185413171e-17	-0.8055474849761	-0.565648232150039
CPNE2	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.93212639507	0.93212639507	-0.805927546635817	-0.4002530483955	-13.0654657489402	10.8126483912812	5.80048374274733e-08	2.80951837310574e-06	-2.03146357396505	-1.44464430944658
CPNE2	BRD-K38904395-001-02-3::2.5::HTS002	2.5	SAR131675	VEGFR inhibitor	targeted cancer	FLT4	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.1657762215045	-0.1657762215045	-0.536853098435904	-0.521573448397	-6.04100176266182	5.27801067409655	0.00148026750073379	0.031076917735799	-0.526509282191744	-0.215644471671065
CPNE2	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.0963556900635	-0.0963556900635	-1.02368085441529	-1.03228700688	-10.7249929725751	4.57974475332288	0.000203858440365165	0.00537162228485682	-1.15586473564657	-0.698785593057005
CPNE2	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-4.23562767081	-4.23562767081	-5.45989147031356	-5.49470441072	-11.3383199872597	4.43308168619828	0.000192868721107355	0.00511727656922732	-1.51284808793316	-0.935679511073964
CPNE2	BRD-K44827188-001-06-0::2.5::MTS010::PROS003_PR500	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.194838858684	0.194838858684	0.0353905634799006	0.0567242940999	-6.89214045197601	27.5266753169919	1.88657735895192e-07	8.54858855743776e-06	-0.206874524302622	-0.112022066105577
CPNE2	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.489524341392	0.489524341392	-0.371053689985834	-0.243490121847	-10.859875411022	6.42291054022554	2.27510458901872e-05	0.000733485095456968	-1.05142748911086	-0.669728573644813
CPNE2	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.8231520888865	0.8231520888865	0.366454094833167	0.3732554744945	-12.0266521995918	35.3240015573943	4.79056563294081e-14	4.54518433617783e-12	-0.533763689799223	-0.379632298307443
CPNE2	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.3481790631075	-0.3481790631075	-1.84501396907309	-1.58248812639	-12.6846403305913	7.10131018667623	3.8887820373368e-06	0.000144400340485163	-1.77506443456507	-1.21860537736611
CPNE2	BRD-K50140147-001-10-1::2.5::HTS002	2.5	NVP-TAE684	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, INSR	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.612419274608	-0.612419274608	-1.81957138818256	-1.65535849639	-10.1669343908134	3.96110745290632	0.000553825719584761	0.0131233734276266	-1.53808862462587	-0.876215602523258
CPNE2	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-2.748190356645	-2.748190356645	-3.67039534364649	-3.70951336465	-12.5659187803117	172.707256614607	3.87525742902565e-26	1.09143239094039e-23	-1.06706057092263	-0.777349403080353
CPNE2	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.5755736269515	-0.5755736269515	-1.30270721448222	-1.05786698502	-8.9585134205607	184.098215292208	3.61701140657959e-16	4.21320890087389e-14	-0.887270230821643	-0.566996944239791
CPNE2	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-8.78887672785	-8.78887672785	-7.19646232797947	-7.241239224365	15.1132384163013	83.7218537601571	1.20700791174893e-25	3.24995978287986e-23	1.38287331412699	1.80195548561407
CPNE2	BRD-K62196610-001-01-6::2.5::HTS002	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-1.46160866152	-1.46160866152	-1.67370998592192	-1.62132235513	-3.09676408559251	117.9323872802	0.00244512536974647	0.0476505978698301	-0.347733503572657	-0.0764691452311835
CPNE2	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.5423535839975	-0.5423535839975	-0.205276199026348	-0.128286851934	8.40213753030337	35.8668729210395	5.38885107856411e-10	3.29713691926225e-08	0.25570371835899	0.418451051583313
CPNE2	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.6947574333205	-0.6947574333205	-1.85109981281377	-1.7566794361	-11.2476468913164	25.5844734778779	2.12639785415467e-11	1.52373361980313e-09	-1.36783337755075	-0.944851381435793
CPNE2	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.33962769506	-0.33962769506	-1.08568324116566	-0.4151365015065	-5.320035150798	8.33724981958854	0.000620335363697791	0.0144914942127211	-1.06717535510212	-0.424935737109194
CPNE2	BRD-K67511046-001-02-3::0.625::HTS002	0.625	naloxone	opioid receptor antagonist	noncancer	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.29009090377	-0.29009090377	0.0736635038284948	0.0434785043643	9.15614452188392	6.05745355520381	9.04312287185009e-05	0.00258530543150695	0.266766798054618	0.460742017142371
CPNE2	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-5.579695955505	-5.579695955505	-3.1040551519044	-3.01726219862	18.0536804947886	5.27511615709489	6.03798995870666e-06	0.000216915244696554	2.12860385495627	2.82267775224494
CPNE2	BRD-K68488863-001-04-9::0.15625::HTS002	0.15625	ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	targeted cancer	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.385712961165	0.385712961165	0.514359148260893	0.524698126717	5.51074897023251	181.773291280049	1.20894622017272e-07	5.6395749468993e-06	0.0825849595454768	0.17470741464631
CPNE2	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.05636318574575	-0.05636318574575	0.103594424085969	0.130322249466	4.29763103939718	186.317520966892	2.77842766622278e-05	0.00087961244205888	0.0865309088218485	0.23338431084159
CPNE2	BRD-K76180386-001-01-6::2.5::HTS002	2.5	JIB04	histone lysine demethylase inhibitor	noncancer	KDM4E	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-1.253756352195	-1.253756352195	-1.70052187352244	-1.602559897845	-5.14428252425448	23.4904506964068	3.06968060365012e-05	0.000963987654358574	-0.62621490514554	-0.267316137509348
CPNE2	BRD-K77625799-001-07-7::2.5::HTS002	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.4062095903675	0.4062095903675	0.104799473138474	0.160912505802	-5.43489744771539	32.7554240854281	5.22481974339341e-06	0.000189769596811009	-0.414272869687309	-0.188547364770744
CPNE2	BRD-K78177893-001-02-4::2.5::HTS002	2.5	A-674563	AKT inhibitor	targeted cancer	AKT1, PKIA, PRKACA	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-1.949317528635	-1.949317528635	-2.6816201675939	-2.66704888005	-7.03191925370554	7.1727241513198	0.000183547675141143	0.00490051748078069	-0.977357112266403	-0.487248165651408
CPNE2	BRD-K80608265-001-01-6::2.5::HTS002	2.5	erteberel	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.622741266345	0.622741266345	-0.0014915736224038	0.05335983697175	-12.1523328590414	9.2755950443084	5.2504824483401e-07	2.23412875257154e-05	-0.739909636476541	-0.508556043458267
CPNE2	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-1.117028736245	-1.117028736245	0.0461748532808243	0.129465498685	19.8159589467946	6.78971608572367	2.91964260915873e-07	1.28943762781451e-05	1.0235230973216	1.30288408173005
CPNE2	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.640096629356	0.640096629356	-0.433934675521403	-0.2959843885325	-19.4947792978676	172.996635077606	1.60357804791269e-45	2.62361282008457e-42	-1.18277285370611	-0.965289756048694
CPNE2	BRD-K81916719-001-13-9::2.5::HTS002	2.5	triclabendazole	microtubule inhibitor	noncancer	DNMT1	infectious disease	tapeworm	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-1.817678119385	-1.817678119385	-2.33771542202199	-2.3242666172	-6.72430174123217	190.864603662697	1.99103351964258e-10	1.2765067999745e-08	-0.67258227929226	-0.367492325981725
CPNE2	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.1239538743704	-0.1239538743704	-0.384224757126912	-0.347155123363	-5.16642092471145	8.68639962869754	0.000660444629515031	0.0153228444467771	-0.374862750702448	-0.145679014810576
CPNE2	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.0319889981562	0.0319889981562	0.191292503569726	0.205191667076	4.48405093851196	135.709799618599	1.54469633400347e-05	0.00051496845632389	0.0890459603082759	0.229561050518776
CPNE2	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	0.242469724739	0.242469724739	-0.327601587705924	-0.193950713334	-11.041190834002	190.245094440169	3.20579556519656e-22	6.45765937681404e-20	-0.671914715123114	-0.468227909766732
CPNE2	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-1.03723895166	-1.03723895166	-2.24562421137024	-2.18551801488	-18.3812912931126	188.069027570993	7.26726243510816e-44	1.05242235841507e-40	-1.33806770769474	-1.07870281172574
CPNE2	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.7482441179865	-0.7482441179865	-1.96658596724394	-1.89031364576	-18.4690142016794	34.9173601543758	1.33943495519762e-19	2.12337096532952e-17	-1.35227291310103	-1.08441078541384
CPNE2	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-2.29284495247	-2.29284495247	-1.64131636779987	-1.710789940465	7.898256396609	3.46879443708371	0.00246110292848732	0.0479140457407356	0.407981144551349	0.89507602478891
CPNE2	BRD-K92049597-001-20-8::2.5::HTS002	2.5	triamterene	sodium channel blocker	noncancer	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.3926852511575	-0.3926852511575	-0.0526103150411737	-0.0499338044925	8.71064969515791	5.45056533736432	0.000211813536630756	0.00556245792577758	0.242160791575931	0.437989080656722
CPNE2	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	KALS1, NCIH1651	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma, carcinoma (adenocarcinoma)	-0.5074831511415	-0.5074831511415	-0.864210522712701	-0.791872957089	-7.52137623270667	43.3455478059795	2.17194725081401e-09	1.2453485348307e-07	-0.452353952410554	-0.261100790731848
CPT1A	BRD-A10977446-001-12-1::2.5::HTS002	2.5	carvedilol	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA	cardiology	myocardial infarction, hypertension	JHH7, KU1919	LIVER, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (transitional_cell_carcinoma)	0.1906767264265	0.1906767264265	-0.221509585806395	-0.214242337971	-7.8468482594492	126.467863112072	1.55736032089835e-12	1.26963666876311e-10	-0.51613573382301	-0.308236890642779
CPT1A	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-3.00652846051	-3.04012950912	-2.30611800205361	-2.41487445029	8.28356578686785	17.1303199010107	2.14111813357207e-07	9.63880925121546e-06	0.522119970115742	0.878700946797047
CPT1A	BRD-K14329163-001-03-9::2.5::HTS002	2.5	BAY-K-8644-(s)-(-)	L-type calcium channel activator	noncancer	CACNA1C	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.0249408456819733	-0.00860900335377	0.29289862861287	0.298498508608	8.70243798652768	8.26159357065962	1.93992373629523e-05	0.000634297352366773	0.23407913930516	0.401599809284527
CPT1A	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.07594524466667	-2.12150611596	-1.28227868123554	-1.25454191877	9.35983390745646	4.8036929271269	0.000290087926949275	0.00734920275355923	0.572987572103725	1.01434555475852
CPT1A	BRD-K17894950-001-14-3::2.5::HTS002	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.375894154922667	-0.39789277332	-0.0937984099149522	-0.0434161099292	5.63607027012117	18.2503264125161	2.27509619269906e-05	0.000733485095456968	0.177044000315756	0.387147489699673
CPT1A	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	JHH7, KU1919	LIVER, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (transitional_cell_carcinoma)	0.0755853813052	0.0755853813052	0.30177163745297	0.3347260991415	6.98380497784471	4.72678387869527	0.00116229486569064	0.0252394626411965	0.14146373085897	0.31090878143657
CPT1A	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.427999241633	0.451815406448	0.238330060853006	0.252871815613	-5.31732292830071	9.48456695820551	0.000405013442837564	0.00991843306557728	-0.269736374207518	-0.10960198735247
CPT1A	BRD-K59058747-001-18-3::2.5::HTS002	2.5	acetylcysteine	mucolytic agent	noncancer	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.115815481873667	0.116912290255	0.395891136671511	0.399628880114	10.8039517671628	155.455654546548	1.19753366570351e-20	2.10554711268719e-18	0.228867995085447	0.331283314510242
CPT1A	BRD-K62304154-001-04-2::2.5::HTS002	2.5	deforolimus	mTOR inhibitor	targeted cancer	MTOR	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-3.27213614585	-3.25723092229	-2.75828987454241	-2.74796355573	5.56175866186091	11.3429694836106	0.000151718868836047	0.00412923853190617	0.311246718272438	0.716445824342741
CPT1A	BRD-K62696033-001-01-4::2.5::HTS002	2.5	G-1	G protein-coupled receptor agonist	targeted cancer	GPER1	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.40763783671667	-2.38091875615	-1.22845830697248	-1.117873749695	12.2833686214423	12.0817085119224	3.46945028489979e-08	1.73051852481333e-06	0.970174510100172	1.3881845493882
CPT1A	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.49812958095	-2.49233943161	-1.7461552851162	-1.668539521375	8.8261698232523	9.97454387533245	5.01637758304439e-06	0.00018272521940794	0.562075056060172	0.94187353560742
CPT1A	BRD-K68507560-003-24-6::2.5::HTS002	2.5	dicycloverine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	JHH7, KU1919	LIVER, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.184363204957	-0.184363204957	0.235971539747324	0.2203060574785	11.874010611506	17.5776577867636	7.95169498960711e-10	4.7859557299284e-08	0.345834735581879	0.49483475382677
CPT1A	BRD-K68747584-001-02-0::2.5::HTS002	2.5	PF-03814735	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.92992974327333	-1.97438702261	-1.2585569500151	-1.07254915068	6.60859539419806	11.7685590453674	2.75549278834088e-05	0.000873254493319994	0.449541599611597	0.893203986904864
CPT1A	BRD-K76011241-001-01-8::2.5::HTS002	2.5	oseltamivir-phosphate	neuraminidase inhibitor	noncancer	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.158924876434333	0.155707527769	0.327904436495353	0.306389581038	5.14397563565399	8.74299363233107	0.000666316667536641	0.0154440342853315	0.0943333903445307	0.243625729777508
CPT1A	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.529890482597	-0.508868776293	-0.141609851702061	-0.112214999812	6.16658933768214	6.10269493587064	0.000782976039955311	0.0178564026034882	0.234836588901086	0.541724672888792
CPT1A	BRD-K81839095-001-30-1::2.5::HTS002	2.5	estrone	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.233505766979333	0.237575443344	0.409045723650839	0.417332498614	6.22297055645299	18.0630134215915	7.04944548143604e-06	0.000249570631085349	0.116291152184391	0.234788761158622
CPT1A	BRD-K84091759-001-07-1::2.5::HTS002	2.5	candesartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension, congestive heart failure	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.53602994935	0.554186994896	0.330219819616698	0.338342322328	-4.81937506212637	7.2817771079523	0.00172227299570923	0.0354016542531278	-0.306004018540306	-0.105616240926298
CPT1A	BRD-K84783599-001-01-0::2.5::HTS002	2.5	riociguat	guanylate cyclase stimulant	noncancer	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.414244894025333	0.412483626124	-0.00950430747170202	0.0406715470457	-7.21983240346144	22.016314493181	3.08996561527557e-07	1.35933752125697e-05	-0.545464533979494	-0.302033869014576
CPT1A	BRD-K84810405-003-01-1::2.5::HTS002	2.5	almorexant	orexin receptor antagonist	noncancer	HCRTR1, HCRTR2	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.497545564278	0.490436508394	0.254175231704961	0.260776909592	-6.3658469559776	8.95066800164998	0.000133585919705665	0.00367917458039005	-0.329926737833502	-0.156813927312576
CPT1A	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.206803740531	-0.21687194746	-0.495056529001322	-0.4216208464325	-5.89474730251343	147.848656941006	2.44318421162945e-08	1.24440406106066e-06	-0.384885874887847	-0.191619702052798
CPT1A	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.83623992412	-1.8190883117	-1.24114548875249	-1.23460644382	6.68441971895314	13.0500063985201	1.47742562079471e-05	0.000494001803243853	0.402837991719545	0.787350879015478
CPT1A	BRD-K96344439-002-02-7::2.5::MTS006	2.5	tofogliflozin	sodium/glucose cotransporter inhibitor	noncancer	GCK	endocrinology	diabetes mellitus, diabetes mellitus	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.273116999822333	0.289680356246	0.136210917808256	0.248241494252	-3.43067794366791	41.4689452470148	0.00137508478079702	0.0291485061797492	-0.217471067916917	-0.0563410961112381
CPT1A	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	JHH7, KYSE410, KU1919	LIVER, OESOPHAGUS, URINARY_TRACT	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-6.84089867192	-6.90491197126	-5.62751507876081	-5.715514625625	10.0142205270739	8.77390836639604	4.27920779363551e-06	0.000157967331588375	0.938206479930411	1.48856070638798
CREB3L2	BRD-A03623303-045-09-5::2.5::HTS002	2.5	metoprolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.4287444649255	0.4287444649255	0.237270387495141	0.206481560524	-6.39354784963199	64.9333100319677	2.02222970275298e-08	1.04063017997922e-06	-0.251285561310081	-0.131662593550637
CREB3L2	BRD-A12417644-001-07-6::2.3139::HTS002	2.3139	usniacin-(+)	MAP kinase activator	targeted cancer	PTPN1	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.5570566527135	0.5570566527135	0.167035397040394	0.15773571254	-13.6509460002311	187.306544864698	6.69277708986025e-30	2.67124063480942e-27	-0.446383564447446	-0.333658946898766
CREB3L2	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.2077915142275	0.2077915142275	-0.00617625633541823	0.000253415549772	-6.70248990538381	47.5295365959308	2.19814896317312e-08	1.12548272605813e-06	-0.27817093700372	-0.149764604122116
CREB3L2	BRD-A19585813-003-03-3::2.5::HTS002	2.5	methylphenidate	dopamine-norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD), narcolepsy	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.01684965682229	0.01684965682229	0.260349926657121	0.25605517774	7.43238386295698	20.0544636272198	3.50422163584422e-07	1.52560698555526e-05	0.175171688556697	0.311828851112965
CREB3L2	BRD-A24514565-001-09-7::2.5::HTS002	2.5	warfarin	vitamin K antagonist	noncancer	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.2652456860675	0.2652456860675	-0.127431848108263	-0.09418085429645	-11.1061986643222	175.930733845463	4.68965108497945e-22	9.22135988433542e-20	-0.462455209926921	-0.322899858424606
CREB3L2	BRD-A95696066-003-13-8::2.5::HTS002	2.5	nisoxetine	norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.4331519338765	0.4331519338765	0.337474571066013	0.334888037039	-4.29540782342449	86.2446233947428	4.55529959960468e-05	0.00138428017564678	-0.13995548822579	-0.0513992373951837
CREB3L2	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.03863121059365	0.03863121059365	-0.0851116432478148	-0.0325205860223	-3.22654026780716	85.347814196023	0.00177755898128624	0.0362915127374836	-0.199991544707023	-0.0474941629759061
CREB3L2	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-3.86632688208	-3.86632688208	-1.65781332513298	-1.3362918287	19.2418833820394	186.081472435464	3.98799276833862e-46	6.83794001636198e-43	1.98208336720022	2.43494374669382
CREB3L2	BRD-K07359318-001-03-9::2.44929::HTS002	2.44929	benfotiamine	antioxidant	noncancer	AGER	rheumatology	lumbago	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.725055545412	0.725055545412	0.330269691091708	0.345721870697	-11.739687036522	4.9391486842077	8.52644482155425e-05	0.00245328702321884	-0.481551496993225	-0.308020211647359
CREB3L2	BRD-K08586861-001-01-1::2.5::HTS002	2.5	ramatroban	prostanoid receptor antagonist	noncancer	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.3709980464715	-0.3709980464715	-0.0399265361796839	-0.0764489475894	9.24897744056442	172.135151408669	8.67205624015956e-17	1.06636439581019e-14	0.260416933836017	0.401726086747615
CREB3L2	BRD-K09549677-300-03-4::2.5::HTS002	2.5	mibefradil	T-type calcium channel blocker	noncancer	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.0824885147677	-0.0824885147677	0.215002645829183	0.2434500151	9.25521319533057	56.5171393314589	6.41932625450448e-13	5.44028381495331e-11	0.233113810887257	0.361868510306509
CREB3L2	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.38940027197	0.38940027197	0.239341977239244	0.274310189966	-5.57299315660648	97.2379300413671	2.2361026062493e-07	1.00326907158218e-05	-0.203497257514876	-0.0966193319466363
CREB3L2	BRD-K16136380-001-01-7::2.5::HTS002	2.5	pyrithione-zinc	ATP synthase inhibitor	noncancer	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-6.89362844278	-6.89362844278	-6.33228040164703	-6.32859212175	5.25817038910864	125.44173605909	6.07470173935442e-07	2.56245768371205e-05	0.350069378807749	0.772626703458192
CREB3L2	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-5.76688569702	-5.76688569702	-5.24495693483628	-5.41033082	6.23123619372436	13.410778087437	2.66340827718183e-05	0.000847706612177166	0.341537955213087	0.702319569154347
CREB3L2	BRD-K24869513-001-02-1::2.5::HTS002	2.5	CNX-2006	EGFR inhibitor	targeted cancer	EGFR	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.0728730378343	0.0728730378343	-0.125531912119399	-0.02986474769355	-4.52597808050911	177.996295076639	1.09668628492247e-05	0.000374823273419148	-0.28491190717869	-0.111897992728708
CREB3L2	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.079686232019	0.079686232019	-0.243806996718559	-0.125640191534	-6.94565223437876	9.34069977139485	5.58780048946947e-05	0.00166986571543154	-0.428270121631541	-0.218716335843576
CREB3L2	BRD-K28578425-001-07-0::2.5::HTS002	2.5	cilostamide	phosphodiesterase inhibitor	targeted cancer	PDE3A, PDE3B	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.30515458621	-0.30515458621	-0.0844312367181329	-0.0458610158792	5.7125770927564	17.6103786479073	2.219115334712e-05	0.000716944182353764	0.139418704845884	0.302027994137851
CREB3L2	BRD-K30480208-001-18-5::2.5::HTS002	2.5	torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	noncancer	SLC12A1	cardiology	edema, congestive heart failure, hypertension	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.8348697890825	-0.8348697890825	0.0390118413481927	0.1423741600205	11.9312085201434	3.32131870752795	0.00076777964140783	0.0175415672916852	0.653040828113378	1.09472243274801
CREB3L2	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.327545400467	0.327545400467	-0.0756097070002313	0.0269217911151	-9.63414766150635	4.4484933617433	0.000380783355938933	0.00940240966532668	-0.51486257335323	-0.291447641581233
CREB3L2	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.1274660590315	-0.1274660590315	-0.512033928330711	-0.4097580139535	-7.56414897874366	87.6555904324371	3.63479577096453e-11	2.53511924111636e-09	-0.485608936226523	-0.283526802371899
CREB3L2	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.332458014581	0.332458014581	-0.799479499533785	-0.4002530483955	-7.34102645257597	4.41050311092854	0.0012428928401792	0.0267511527960201	-1.54478120462359	-0.719093823605985
CREB3L2	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-1.05163092466	-1.05163092466	-1.37152450565559	-0.978492222645	-3.12304540023618	187.902508080514	0.00207322536822779	0.0413620329467462	-0.521954125413835	-0.117833036577354
CREB3L2	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.08977453726875	0.08977453726875	0.257879552519166	0.300751796019	5.2784884998648	187.985375431958	3.57130646547171e-07	1.55260556478314e-05	0.105281224098307	0.230928806402526
CREB3L2	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-1.52371163368	-1.52371163368	-0.882248105377881	-0.834553976767	7.53161900367066	3.81790802239564	0.00199943356156454	0.04009511562655	0.400480357707379	0.882446698896859
CREB3L2	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.6016426068385	-0.6016426068385	-1.40023863863756	-1.171371713075	-9.52581796642875	14.9626952666648	9.63652607036941e-08	4.55332230188758e-06	-0.977324709288876	-0.619867354309251
CREB3L2	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.247355534827	0.247355534827	0.153592365927706	0.139916370482	-4.27701987829867	19.5378179156823	0.00038533239780208	0.00948647544894524	-0.139562248906461	-0.0479640888921271
CREB3L2	BRD-K48684885-001-04-2::2.5::HTS002	2.5	BAY-11-7085	NFkB pathway inhibitor	targeted cancer	NFKBIA	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-1.85974978274	-1.85974978274	-1.43827184141679	-1.32973039145	5.93635116800939	100.329072625353	4.19863199579217e-08	2.06918509318496e-06	0.280622620753255	0.562333261893163
CREB3L2	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.670104188737	0.670104188737	-0.0751096410219599	0.318163539168	-7.17738925989374	8.04875436802473	9.17045227285215e-05	0.00261716892834638	-0.984389371099405	-0.506038288418515
CREB3L2	BRD-K50140147-001-10-1::2.5::HTS002	2.5	NVP-TAE684	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, INSR	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-1.285060724145	-1.285060724145	-1.81213888597774	-1.65535849639	-5.41262860807461	15.1605377061324	6.93371484150845e-05	0.00203046340793232	-0.734446031100477	-0.319710292564995
CREB3L2	BRD-K56981171-001-01-0::2.5::MTS006	2.5	brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	targeted cancer	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.04302830358895	0.04302830358895	-0.0717739626426688	-0.00736994010253	-3.33741320139119	89.3945552864375	0.00123369364156506	0.0265804467885855	-0.183147350345942	-0.0464571821172953
CREB3L2	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.1722673218725	0.1722673218725	0.036028707001772	0.07942712884705	-4.4758870279048	181.739714222677	1.34005623692418e-05	0.000451096141359702	-0.196296613843273	-0.0761806158981831
CREB3L2	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-5.95645192826	-5.95645192826	-3.61558543615711	-3.494830245985	20.3913438441825	187.959345658717	1.64033343572507e-49	3.9951252834718e-46	2.1144102809544	2.56732270325138
CREB3L2	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.365321799017	0.365321799017	-0.497598481196996	0.00402399396559	-8.16475519421747	11.2948057122235	4.5334113167726e-06	0.000166805410148078	-1.09480034930757	-0.631040211120423
CREB3L2	BRD-K69694239-001-02-2::2.5::MTS010::PROS002_PR500	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-2.04968097327	-2.04968097327	-2.53177030768292	-2.614580236685	-9.61154429743429	175.892710751031	7.62645882997783e-18	1.03584999655914e-15	-0.581076954671257	-0.383101714154587
CREB3L2	BRD-K72703948-001-10-1::2.5::HTS002	2.5	ZM-447439	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.986671226094	-0.986671226094	-1.37606369678608	-1.23720066309	-5.57684048169392	147.882363569409	1.13227652261397e-07	5.30099813926015e-06	-0.527372437710975	-0.251412503673182
CREB3L2	BRD-K75009076-001-02-1::2.429::HTS002	2.429	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-1.13118499805	-1.13118499805	-1.92385993416156	-1.72291152257	-7.94831412041094	30.6843828203355	6.09616379064322e-09	3.32718280897574e-07	-0.99615776555658	-0.589192106666546
CREB3L2	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.08557374682785	-0.08557374682785	-1.12054776179336	-0.918129706972	-10.6282147731434	10.0364880974762	8.79597152987643e-07	3.62057188789492e-05	-1.25184297703798	-0.818105052893042
CREB3L2	BRD-K86118762-001-01-8::2.5::HTS002	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.4557075922105	0.4557075922105	0.0604277620554941	0.0670772689305	-12.1335888126923	130.738069770893	3.66640144060334e-23	8.02672272076684e-21	-0.459726747749639	-0.330832912560373
CREB3L2	BRD-K87909389-003-03-4::2.5::HTS002	2.5	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-4.768800184665	-4.768800184665	-5.33690982362806	-5.39635429682	-8.26421743471192	156.111589488491	5.68592565962899e-14	5.35203671806158e-12	-0.703896676441195	-0.43232260148493
CREB3L2	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.05826031684235	0.05826031684235	0.154000870965508	0.189344687703	4.23931359348288	17.7000567605117	0.000509908467942185	0.0121987020901418	0.0482356838523867	0.143245424393929
CREB3L2	BRD-K89714990-001-01-5::2.5::MTS006	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.293974027697	-0.293974027697	0.141874628392276	0.165320273303	10.2096995387157	4.7018380615106	0.000219158626739662	0.00573112088016382	0.323984905749552	0.547712406429
CREB3L2	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.142796576033	-0.142796576033	0.105528856672988	0.135507608915	10.620306788374	193.677248119049	4.68351016211586e-21	8.50688177572992e-19	0.202209127308153	0.294441738103823
CREB3L2	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.0051187051568	-0.0051187051568	-0.300517688537413	-0.183745665678	-4.36348275316753	12.3850313344083	0.000857850924757948	0.0193263856535887	-0.44239323604677	-0.148404730714455
CREB3L2	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-3.149333443585	-3.149333443585	-2.23419226699342	-2.181327009095	10.745732928031	185.956720085742	2.93222781050873e-21	5.39451892187575e-19	0.747130917902581	1.08315143528058
CREB3L2	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-2.427529637065	-2.427529637065	-1.39666608306725	-1.36288222555	9.23832555268803	3.5726552630229	0.00128050557807973	0.0274476927737025	0.705875587813916	1.35585152018159
CREB3L2	BRD-K95581532-001-01-5::2.5::HTS002	2.5	RN-1734	TRPV antagonist	noncancer	TRPV4	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-1.575075352085	-1.575075352085	-2.42634177574937	-2.37248540058	-8.72553066223154	13.2872534404006	7.26373717898884e-07	3.03180043979649e-05	-1.06157064731133	-0.640962200017416
CREB3L2	BRD-K99616396-001-05-1::2.5::MTS006	2.5	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.1487056278455	-0.1487056278455	-0.0153341847182944	-0.0150428280254	4.64671704650569	71.9847274690862	1.48575920102812e-05	0.000496478459303329	0.0761542565046242	0.190588629749787
CREB3L2	BRD-K99964838-001-11-9::2.5::HTS002	2.5	bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	targeted cancer	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	AN3CA, GB1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.06108854189365	-0.06108854189365	-0.39688276926521	-0.289629896197	-5.77575286731803	152.002560465766	4.18487718886527e-08	2.06295965463271e-06	-0.450658305108163	-0.220930149634956
DEPDC1B	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.0701402368368	-0.0701402368368	0.152724288038869	0.1647699361925	7.49900772210115	5.66476859521203	0.000380272389945752	0.00939668527134459	0.149088236937015	0.296640812814323
DEPDC1B	BRD-A08545410-311-03-4::2.5::HTS002	2.5	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.12007477363	-1.12007477363	-0.488984713280685	-0.488941484078	14.6252470601823	6.84794493078157	2.03776762917392e-06	7.93086432164914e-05	0.528593714497051	0.733586406201578
DEPDC1B	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.1715860336135	0.1715860336135	-0.0093451735123725	0.0633629143304	-4.78712328162805	11.5819981383395	0.000489147592033163	0.0117518791898751	-0.263611131637145	-0.0982512826145995
DEPDC1B	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.165393629801	-0.165393629801	-0.514218906080751	-0.46624794895	-6.97176139234364	188.409562353874	5.12573597353304e-11	3.50876354350484e-09	-0.447524138715096	-0.250126413844407
DEPDC1B	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.03583033318	0.03583033318	0.405653998573264	0.4132826179685	7.28992712168728	123.049749755498	3.28398023312826e-11	2.30695575020042e-09	0.269405606676022	0.470241724110507
DEPDC1B	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.289685217939	-0.289685217939	-0.0791062723725661	-0.05385103964535	5.1566067364769	177.483118487979	6.66799353988322e-07	2.79730747193116e-05	0.129990921031831	0.291166970101037
DEPDC1B	BRD-A50049929-001-01-9::2.5::HTS002	2.5	oxazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3	neurology/psychiatry	anxiety	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.207247563375	-1.207247563375	-0.244781271602663	-0.0790763722094	11.8823408907414	5.03396964630655	7.11799631328878e-05	0.00208073244930561	0.754671783105338	1.17026080043934
DEPDC1B	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.06562581232525	0.06562581232525	0.186626681704449	0.190024427126	3.91085787140274	20.9019970268266	0.000809583948001154	0.0183888637124989	0.0566398133139557	0.185361925444441
DEPDC1B	BRD-A69651145-003-07-2::2.5::HTS002	2.5	minocycline	bacterial 30S ribosomal subunit inhibitor	noncancer	ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA	endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.4621885347855	0.4621885347855	0.0829389751587075	0.0503507635315	-9.6021288383834	161.907450996396	1.46346762099505e-17	1.93619476382869e-15	-0.457244067550026	-0.301255051703559
DEPDC1B	BRD-A74914197-001-02-9::0.15625::MTS010::PROS005_PR500	0.15625	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.155408551736	0.155408551736	-0.40501700721711	-0.2745905537905	-6.79330423335131	8.27945929939342	0.000118247063763702	0.00329653680143218	-0.749551503413007	-0.371299614493212
DEPDC1B	BRD-A93477898-001-04-2::2.5::HTS002	2.5	PETCM	caspase activator	noncancer	CASP3	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.225313929688	-0.225313929688	0.184176492371941	0.198279920588	10.4384543981884	123.327122145587	1.14947639365571e-18	1.67368292103149e-16	0.331841012110535	0.487139832009348
DEPDC1B	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.1289660811345	-0.1289660811345	0.160440405398722	0.166606190016	11.6064169041498	191.946054619915	6.13560393091985e-24	1.43406527253012e-21	0.240224610609232	0.338588362457211
DEPDC1B	BRD-K03243820-001-23-8::2.37329::HTS002	2.37329	trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	chemo	TYMS	infectious disease	virus herpes simplex (HSV)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.750332526626	-0.750332526626	-2.26938134641014	-2.05370099582	-16.8349628414273	133.682062262595	7.7625147344493e-35	4.86471351029177e-32	-1.69751544423659	-1.34058219533168
DEPDC1B	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.1781834194785	0.1781834194785	-0.343769897374336	-0.229059189804	-11.6625444224149	57.3738009890165	9.02604377549315e-17	1.10482177975881e-14	-0.611560343378525	-0.432346290327148
DEPDC1B	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.41289028459	-1.41289028459	-2.03292192332806	-1.93975006052	-6.47616550267268	19.9998933200206	2.58360782396299e-06	9.90594063152348e-05	-0.819742992051668	-0.420320285424452
DEPDC1B	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.024069525606875	-0.024069525606875	-0.358968857260572	-0.164030729397	-5.07270977490681	45.0689070050633	7.19440565654799e-06	0.000254366507746994	-0.467864442128627	-0.201934221178768
DEPDC1B	BRD-K06749501-001-02-1::2.5::HTS002	2.5	GSK1838705A	insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R, INSR, RPS6KA1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.026639725503	-1.026639725503	-0.224917021064399	-0.0999889784018	10.9899302775169	4.76803754221421	0.000144425189399741	0.00394425413084317	0.611419549236186	0.992025859641015
DEPDC1B	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-2.152972260055	-2.152972260055	-3.08249811582627	-3.12584681211	-7.52429756272292	5.64326173929383	0.000380288472598869	0.00939668527134459	-1.23650194321094	-0.622549768331604
DEPDC1B	BRD-K08586861-001-01-1::2.5::HTS002	2.5	ramatroban	prostanoid receptor antagonist	noncancer	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.8845311915335	-0.8845311915335	-0.0340909322585248	-0.0764489475894	17.6466356225536	4.4077166956146	2.94352407487207e-05	0.000926814413755334	0.721378387505441	0.979502131044509
DEPDC1B	BRD-K11267252-001-04-4::2.5::HTS002	2.5	alectinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.485144300647	-0.485144300647	-0.151564621855047	-0.10378431841385	5.43067788193097	7.02367051362427	0.000965016175543684	0.0214421471996789	0.188431679147741	0.478727678436165
DEPDC1B	BRD-K11590034-002-03-4::2.48778::HTS002	2.48778	morin	cytochrome P450 inhibitor	noncancer	ADORA2A, ESR2, FASN, MCL1, SLC22A12	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.138997824941	0.138997824941	0.592352422583657	0.572569437985	13.139472683382	8.99184310168524	3.57412344078956e-07	1.55351511446154e-05	0.375292014162908	0.531417181122405
DEPDC1B	BRD-K13390322-001-06-3::2.5::HTS002	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.959965628924	-0.959965628924	-0.323383356951545	-0.176785309489	6.7211105816164	10.1680743638705	4.82066649402307e-05	0.00145871612169627	0.426018543440319	0.847146000504592
DEPDC1B	BRD-K14560436-001-01-4::2.5::HTS002	2.5	TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-2.742815534135	-2.742815534135	-3.74681058444815	-3.62828968956	-8.46499114982339	146.279827444865	2.45805987047331e-14	2.40324249437799e-12	-1.23839689434795	-0.76959320627835
DEPDC1B	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.0833735969497	-0.0833735969497	-0.571171438914547	-0.549657042838	-12.2814147142402	13.2543223416757	1.27872676544377e-08	6.76377662662386e-07	-0.573437109883306	-0.402158574046387
DEPDC1B	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-2.93649097183	-2.93649097183	-3.6862851911237	-3.60112771075	-6.68061059689939	10.6355322430468	4.08290493043472e-05	0.00125316472982263	-0.997857191762788	-0.501731246824609
DEPDC1B	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.247906259349	0.247906259349	-0.191918984303941	-0.123671466435	-10.2179183066129	42.8937142576262	4.59902021828289e-13	3.95229913538233e-11	-0.526638983538027	-0.353011503767855
DEPDC1B	BRD-K17894950-001-14-3::2.5::HTS002	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.444617798205	-0.444617798205	-0.0945597175909682	-0.04443726691935	7.27764354515665	12.7217978791167	7.01774968890116e-06	0.000248530613528172	0.245911859196386	0.454204302031678
DEPDC1B	BRD-K18961567-001-01-1::2.5::MTS010::PROS002_PR500	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.1016370973873	-0.1016370973873	-0.416833333408768	-0.32717924466	-5.33843355224466	176.429434772031	2.85620161674385e-07	1.26324151117435e-05	-0.431717332133307	-0.198675139909628
DEPDC1B	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.655808175205	-1.655808175205	-3.14688073862983	-3.22475555586	-8.72302523374662	3.48413653947559	0.00173520492683808	0.0355923759942845	-1.9947043608035	-0.987440766046166
DEPDC1B	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.6325012268235	-0.6325012268235	-1.87769310329548	-1.673362994515	-12.633933084616	50.1735570031493	3.30870564617229e-17	4.22869154703913e-15	-1.44313713511741	-1.04724661782655
DEPDC1B	BRD-K21728777-001-02-3::2.5::HTS002	2.5	AMG900	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.8907617031565	-0.8907617031565	-1.55016115314748	-1.404443241845	-7.22404673220468	29.2746223329212	5.6037685502108e-08	2.72161819532774e-06	-0.846008705522431	-0.472790194459525
DEPDC1B	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.595582855565	-1.595582855565	-2.06464076576796	-1.99815705335	-5.32263140818394	165.715032054958	3.28265954463042e-07	1.43761572852696e-05	-0.643050762487468	-0.295065057918443
DEPDC1B	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-2.244881816695	-2.244881816695	-2.81106613558926	-2.6496200301	-5.34192158334641	144.37535313018	3.50132527591869e-07	1.52465571934656e-05	-0.775674693513271	-0.356693944275242
DEPDC1B	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.4293089476495	-0.4293089476495	-0.97702006326242	-0.82417204092	-4.54966121571754	7.91711022400846	0.00192588899158888	0.0388200753953026	-0.825826225481978	-0.269596005743862
DEPDC1B	BRD-K28143534-001-02-2::2.5::HTS002	2.5	cyproheptadine	histamine receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.1665943112795	-0.1665943112795	-0.00316046661035073	0.0299978587143	5.56919482652806	169.159698828144	9.8895643573101e-08	4.66465765655351e-06	0.105502197568758	0.221365491769541
DEPDC1B	BRD-K28307902-001-21-7::2.5::HTS002	2.5	flutamide	androgen receptor antagonist	targeted cancer	AHR, AR	oncology	prostate cancer	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.4241604919775	0.4241604919775	0.241131047458172	0.2782830589715	-6.51001382941957	23.4388665721349	1.10597752611686e-06	4.48265993182869e-05	-0.241129683289616	-0.12492920574904
DEPDC1B	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.472611740381	0.472611740381	0.268828982494221	0.2845478404215	-5.9370331846794	4.94402081296386	0.00201109364761871	0.0402806957406063	-0.292316754106756	-0.115248761666802
DEPDC1B	BRD-K31812033-003-11-0::2.5::HTS002	2.5	levobunolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.3733937264335	0.3733937264335	0.17116121864409	0.2093635994345	-5.02372020306151	17.7887027343626	9.128976032304e-05	0.00260741511730768	-0.28687829857026	-0.11758671700856
DEPDC1B	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.60124628983	-1.60124628983	-2.31628165049324	-2.045349051995	-6.45380907794259	36.112288521483	1.70356955493939e-07	7.76529900341567e-06	-0.939709247841517	-0.490361473484961
DEPDC1B	BRD-K33277808-331-01-3::2.5::HTS002	2.5	ouabain	ATPase inhibitor	noncancer	ATP1A1	cardiology	hypertension, cardiac arrythmia	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-4.58119629261	-4.58119629261	-5.38225081520255	-5.29484648824	-9.03626189353959	150.380360462949	7.43692811707069e-16	8.36279835468858e-14	-0.9762127201316	-0.625896325053492
DEPDC1B	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.138130032655	-0.138130032655	-0.880432699121023	-0.7074523288895	-8.22485945419599	191.47876497362	2.92681790649232e-14	2.84361720344783e-12	-0.920316705672913	-0.564288627259134
DEPDC1B	BRD-K34073885-001-09-3::2.54435::HTS002	2.54435	tanshinone-i	AP inhibitor	targeted cancer	IFNG	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.7996722963015	-0.7996722963015	-0.149298460235205	-0.126283883542	12.3682685547113	2.74482605676929	0.0017344125490701	0.0355923759942845	0.473873014460919	0.826874657671671
DEPDC1B	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.541366140769	0.541366140769	0.167143122565696	0.159843684784	-12.7858596135771	9.97882122005745	1.63976909314258e-07	7.50000149304645e-06	-0.439456081205391	-0.308989955201218
DEPDC1B	BRD-K36363294-001-04-2::2.5::HTS002	2.5	I-BET151	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.5640123387235	-0.5640123387235	0.122518822011403	0.175731719762	8.90167067820427	5.44500746639818	0.00019050231549671	0.00506295738543105	0.493053682918507	0.8800086385513
DEPDC1B	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.309917081175	-1.309917081175	-1.94312376421736	-1.74375486562	-7.28599731650553	188.904849343688	8.43399059051312e-12	6.3739378324192e-10	-0.804640240704951	-0.461773125379759
DEPDC1B	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.535269246457	-0.535269246457	0.0958307221800574	0.1259414280465	16.0602947244727	3.74041556210996	0.000137585919306855	0.00377527237218267	0.518945720354193	0.743254216919921
DEPDC1B	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-5.555965487385	-5.555965487385	-6.61119778644932	-6.671127343215	-9.17138318406281	3.28962647570226	0.00187558815612432	0.0379701999671813	-1.4038162473443	-0.706648350784328
DEPDC1B	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.76128865805	-0.76128865805	-1.29055502928472	-1.33795379646	-5.55878930868369	9.92684215777827	0.000247622853648059	0.00639816257981132	-0.741625214876046	-0.316907527593388
DEPDC1B	BRD-K43644456-001-04-0::2.37833::HTS002	2.37833	WP1130	deubiquitinase inhibitor	targeted cancer	JAK2, UCHL5, USP14, USP9X	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-5.92779639405	-5.92779639405	-6.29537045273489	-6.296490539345	-4.61853868294077	18.8897031138157	0.000190051220081376	0.00505190226327933	-0.534216703849454	-0.200931413520332
DEPDC1B	BRD-K44067360-001-30-3::2.5::HTS002	2.5	flufenamic-acid	chloride channel blocker	noncancer	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.341896336384	-0.341896336384	0.076883893947831	0.0872280051655	10.9658703841204	5.00603509637309	0.000108883559418305	0.00306138061216921	0.320646786861218	0.516913673802445
DEPDC1B	BRD-K44827188-001-06-0::2.5::HTS002	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.3236128611515	-0.3236128611515	-0.109449254839343	-0.054617955294	4.15682657944121	97.3511525914141	6.94545495688836e-05	0.00203306803531129	0.111913463056919	0.316413749567395
DEPDC1B	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-2.39526691682	-2.39526691682	-0.0423249233154679	0.365958476092	24.3816171082146	12.5599921985274	5.90000410050899e-12	4.52591975253397e-10	2.14371125429413	2.56217273271494
DEPDC1B	BRD-K49669041-001-08-4::2.5::HTS002	2.5	BX-912	pyruvate dehydrogenase kinase inhibitor	targeted cancer	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.173336961255	-1.173336961255	-1.94483468264084	-1.738347180205	-6.75860173224991	7.67321341572733	0.000174051552795203	0.00467589562033632	-1.03669339527895	-0.506302047492725
DEPDC1B	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.48327339176	-1.48327339176	-1.83319006981629	-1.58248812639	-3.69897734327529	190.860327316349	0.000282971877529717	0.00718165536282614	-0.53650894488891	-0.163324411223679
DEPDC1B	BRD-K50140147-001-10-1::2.5::HTS002	2.5	NVP-TAE684	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, INSR	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-3.022486750175	-3.022486750175	-1.79294080834205	-1.63753619039	14.2773067251756	129.919019878208	2.14443475954477e-28	7.62213196647548e-26	1.05916900101367	1.39992288265224
DEPDC1B	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.471730008817	-0.471730008817	-0.222419500436332	-0.176181988507	6.28963028009816	11.3100658247828	5.23110503646235e-05	0.00157137703063762	0.162358035063971	0.336262981697366
DEPDC1B	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.511250896401	0.511250896401	0.224094763895526	0.2005091684065	-8.86287719875581	15.7220208914123	1.64707641053707e-07	7.53020989748292e-06	-0.355939634084125	-0.218372630926824
DEPDC1B	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.589433484861	-0.589433484861	-0.289742440629092	-0.3736278329815	4.00932407378029	24.1152786981818	0.000510877074754092	0.0122191465857571	0.145456696559758	0.453925391904057
DEPDC1B	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.168477066555	-1.168477066555	-0.732023559721103	-0.670954227568	7.05091620012716	21.0710240552683	5.7483164089975e-07	2.43147998346956e-05	0.307751296003321	0.565155717664472
DEPDC1B	BRD-K55187425-236-05-2::2.5::MTS010::PROS004_PR500	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.491002290068	0.491002290068	-0.814169125305829	-0.733552010026	-10.2811358889266	3.00590342315902	0.00194557059758124	0.0391541972402807	-1.70872866136839	-0.901614169379267
DEPDC1B	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.64249295274	-1.64249295274	-3.16696003334784	-3.19197499768	-14.9940390102358	80.9411711796638	4.47930213362986e-25	1.15807520747739e-22	-1.72676378790859	-1.3221703733071
DEPDC1B	BRD-K58435339-001-03-0::2.5::HTS002	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-3.515472555485	-3.515472555485	-4.69231578942993	-4.73299399791	-9.49065882220596	5.25090561255778	0.000167792786512337	0.00452533788101203	-1.49106866993754	-0.862617797952311
DEPDC1B	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.882651018422	-0.882651018422	-1.18673691141555	-1.12103485225	-5.29734114228598	149.981222136811	4.11490733521385e-07	1.77775443307609e-05	-0.417509879221932	-0.190661906765162
DEPDC1B	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-2.60408187693	-2.60408187693	-2.00180703022604	-2.19151625043	6.87997751961579	152.269667856527	1.45791170264447e-10	9.48323997924388e-09	0.429324594383676	0.775225099024249
DEPDC1B	BRD-K59369769-001-20-3::2.5::HTS002	2.5	tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, AURKC, LCK	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.318140643525	-1.318140643525	-1.78905945593662	-1.696260218435	-6.779045823061	70.1206700208594	3.12834895069043e-09	1.76585699829478e-07	-0.60946184123735	-0.332375783585887
DEPDC1B	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.535109700915	-0.535109700915	-0.202047589043841	-0.0713354708951	6.09401310551308	17.749724583824	9.88413404738791e-06	0.000340861877110636	0.218122184166857	0.44800203957546
DEPDC1B	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.336789281675	-1.336789281675	-1.53793474949593	-1.43484346641	-3.34207280717936	179.6183700869	0.00101174094035039	0.0223527977161975	-0.319907735261805	-0.0823832003800632
DEPDC1B	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.48072654422	-1.48072654422	-2.08325683830469	-1.79411655002	-4.50994910277264	29.8497153598641	9.34642373596957e-05	0.00266195722764907	-0.875436005949314	-0.329624582220068
DEPDC1B	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-2.858694887125	-2.858694887125	-4.00334259711977	-4.1239035813	-8.8814367570875	8.30565070724393	1.60795061794786e-05	0.000534393623808571	-1.43995461445624	-0.849340805533305
DEPDC1B	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.326005088692	0.326005088692	-0.723712758218996	-0.5340799664045	-8.51687581720791	7.97219475091483	2.83408713858053e-05	0.000895645919087033	-1.33410899002158	-0.765326703800408
DEPDC1B	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.3457169894115	0.3457169894115	-0.341756849762254	-0.3277516003215	-10.013699737838	2.97481782584526	0.00219719299845692	0.0434550316661689	-0.907009417580454	-0.467938260767054
DEPDC1B	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.64350225247	-1.64350225247	-1.1717435346805	-1.00861942347	8.17887754207483	104.354081242716	7.33621823563071e-13	6.19041070167124e-11	0.35738142355862	0.586136012020388
DEPDC1B	BRD-K69116396-001-04-1::2.5::HTS002	2.5	sertindole	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.07484591853065	-0.07484591853065	0.0160063435879584	0.0375517717561	3.40328284960583	74.9332316643717	0.00107184323473107	0.0234678811581036	0.0376713663817267	0.14403315785549
DEPDC1B	BRD-K71035033-001-07-1::2.5::HTS002	2.5	masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor	noncancer	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.0920847994541	0.0920847994541	0.280391538193338	0.3182262126035	4.67539351739574	36.8051917128246	3.86621610512375e-05	0.00119194797410108	0.106684972994461	0.269928504484015
DEPDC1B	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.494977601074	-0.494977601074	-1.19751714023359	-1.12346956245	-7.12528818539547	4.23147947297399	0.00165305672582024	0.034145913163871	-0.970485574543276	-0.434593503775914
DEPDC1B	BRD-K71847383-001-12-5::2.5::HTS002	2.5	cytarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.0972848256571	0.0972848256571	0.331957809813954	0.318284588664	8.46267437330327	149.207396504651	2.24533490707261e-14	2.20550130750671e-12	0.179878056260671	0.289467912053037
DEPDC1B	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.06544392854365	0.06544392854365	0.222983165044589	0.235603358555	4.93945192133948	6.32365248270357	0.00224433022059824	0.0442769745812408	0.0804553290262746	0.234623143975603
DEPDC1B	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.839644526535	-1.839644526535	-2.52934912893372	-2.26266997363	-6.5040358385869	188.588573451883	6.83611992034827e-10	4.1365859582392e-08	-0.898886572542277	-0.480522632255157
DEPDC1B	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-3.823005861375	-3.823005861375	-2.61835705077868	-2.476182958975	10.5512233961749	3.54227354512555	0.000841971863134363	0.0190337503906471	0.870831482344957	1.53846613884769
DEPDC1B	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.01216642737065	0.01216642737065	-0.209765771253628	-0.20601445055	-4.62210480636358	96.7331757867972	1.17389410306567e-05	0.000398921118148031	-0.31723279070926	-0.126631606539297
DEPDC1B	BRD-K77908580-001-09-6::2.5::HTS002	2.5	entinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC9	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.9458405839785	-0.9458405839785	-1.80145138221401	-1.534233909595	-6.84729647529868	7.83010372628917	0.00014520224451955	0.00396345540825658	-1.14485177502408	-0.566369821446927
DEPDC1B	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.993139160908	-0.993139160908	0.106554304245855	0.2180824951125	24.2153949311961	46.6110218847644	4.76607941804735e-28	1.60867564659948e-25	1.00831418537376	1.19107274493395
DEPDC1B	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.41889886724	-1.41889886724	-1.05213489461374	-0.7722654685825	3.7223509643084	59.3006768838339	0.000441146455045908	0.0107175786174943	0.169626418713515	0.563901526539005
DEPDC1B	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.241581637685	-1.241581637685	-2.21773212477603	-2.0670113581	-9.13843937828309	70.2231397045636	1.43423289652131e-13	1.29703671931864e-11	-1.18918051566074	-0.763120458521323
DEPDC1B	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-3.29394184054	-3.29394184054	-4.38691583149097	-4.37968901574	-10.5883799250856	9.72776713759152	1.1808899715483e-06	4.77185080527857e-05	-1.32384664932579	-0.862101332576157
DEPDC1B	BRD-K84564571-001-02-4::2.5::HTS002	2.5	telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.01227201084414	0.01227201084414	-0.186510914567591	-0.150870587106	-4.84308528066147	187.980575920283	2.66282314369932e-06	0.000101805248227958	-0.279750304800943	-0.117815546022519
DEPDC1B	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.99517271912	-1.99517271912	-2.78288308279716	-2.665674709255	-7.22215977165547	10.3505569508378	2.36979909539685e-05	0.000761265992681823	-1.02961914505114	-0.545801582303179
DEPDC1B	BRD-K86816506-001-01-8::2.5::HTS002	2.5	PF-04457845	FAAH inhibitor	noncancer	FAAH	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.877665547996	-0.877665547996	-0.402226275225696	-0.352413552775	12.2140129099478	4.95108047940479	6.94017008448993e-05	0.00203207611207465	0.375079417267559	0.575799128273048
DEPDC1B	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-1.661656680565	-1.661656680565	-1.95716934288746	-1.89031364576	-4.80889030596122	193.06065018685	3.04819852439768e-06	0.000115427092144104	-0.416714809211598	-0.174310515433315
DEPDC1B	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.1354542450225	0.1354542450225	-0.0517746279493486	-0.06359011505395	-4.21964048669419	158.814907438244	4.10217759516687e-05	0.00125817919547012	-0.274861841000132	-0.0995959049435648
DEPDC1B	BRD-K89714990-001-01-5::2.5::MTS006	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.356513121022	0.356513121022	0.135063244636056	0.163955716777	-6.53067256847488	44.2623283612023	5.44933471140951e-08	2.65021660849033e-06	-0.289777938873621	-0.153121813898268
DEPDC1B	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-2.084554373605	-2.084554373605	-2.91856420652643	-2.87877770547	-7.15516588956327	4.40709855081459	0.00138567940227411	0.0293382673723213	-1.14617817856348	-0.521841487279381
DEPDC1B	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.4970271577035	-0.4970271577035	-0.26953103182414	-0.201241346164	4.46210816823677	29.0058287810609	0.000112696021665802	0.00315862764843855	0.123223046586658	0.331769205172063
DEPDC1B	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	0.5795175112225	0.5795175112225	-0.302000611969238	-0.214794605924	-10.3896110430124	9.23636625268722	2.12098960988093e-06	8.23681069208497e-05	-1.07270724051313	-0.690329005870346
DEPDC1B	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	RMGI, MCF7	OVARY, BREAST	carcinoma (clear_cell_carcinoma), carcinoma	-0.742452239888	-0.742452239888	-0.0813071188500048	0.0900706694704	8.97708355822393	3.78221610986587	0.00109926586917867	0.0240069853755039	0.451936963625974	0.870353278450016
DHX34	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.117631469325	-1.117631469325	-1.62649717770206	-1.545847432105	-5.21789787253726	10.9971871383265	0.00028667539075381	0.00726790274720527	-0.723519358700344	-0.29421205805378
DHX34	BRD-A44090213-001-25-6::2.5::HTS002	2.5	indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	CXCR1, CXCR2, PTGS1, PTGS2	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.9504141627125	-0.9504141627125	-1.91319017261135	-1.821377260325	-11.0855580347088	94.2893856843503	8.92684812452778e-19	1.31316570465471e-16	-1.1352109785852	-0.790341041212487
DHX34	BRD-A74765037-001-01-1::2.5::HTS002	2.5	estradiol-benzoate	contraceptive agent	noncancer	ESR1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.08029144365675	-0.08029144365675	0.0309175231398946	0.0157796912763	3.90678655824238	122.320445860109	0.000153799778957241	0.00418056472087843	0.0548599758061246	0.167557957787165
DHX34	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.049293748967	0.049293748967	0.224065041106464	0.2226649685355	5.51086650373718	12.3224929642724	0.000121674928637607	0.00338637394883388	0.105872587024394	0.243669997254534
DHX34	BRD-K01669786-001-02-2::2.5::HTS002	2.5	triapine	ribonucleotide reductase inhibitor	chemo	RRM1, RRM2	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.9701119923	-1.9701119923	-3.20248727988509	-3.10063742322	-9.95200334562904	9.05638167266142	3.55394342659542e-06	0.000133075519138891	-1.51223684532169	-0.95251372984849
DHX34	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.9992855602275	-0.9992855602275	-2.21632991902158	-2.04082568027	-9.91209571041571	33.0082056317521	2.01323456913337e-11	1.44845435370186e-09	-1.46684743316853	-0.967241284419631
DHX34	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.595451820931	-0.595451820931	-1.22775407824169	-1.264129385735	-8.17219521631712	54.0441128967823	5.17756187126861e-11	3.54084766530673e-09	-0.787421655294287	-0.477182859327095
DHX34	BRD-K06234293-001-04-2::2.5::HTS002	2.5	LY364947	TGF beta receptor inhibitor, p38 MAPK inhibitor	targeted cancer	TGFBR1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.54936947207	0.54936947207	0.788443688123713	0.824104228749	5.95838489444138	7.69053962118392	0.00039472583667023	0.00969418973847756	0.145896022396892	0.332252409710534
DHX34	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.224344631425	-1.224344631425	-2.5031561503757	-2.37307934162	-10.3581344721148	12.4235679031017	1.79751717232566e-07	8.15710476450109e-06	-1.54679331057851	-1.0108297273229
DHX34	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-2.494120571785	-2.494120571785	-3.18664089164508	-3.102963726805	-6.18239598402595	74.2195186500865	3.1199833285067e-08	1.56678281821817e-06	-0.915703864249281	-0.469336775470881
DHX34	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.8092332018975	-0.8092332018975	-1.26132751046979	-0.9430769633885	-4.3107597844972	29.5803394175427	0.000165415738137449	0.00446797602259121	-0.666406727011829	-0.237781890132742
DHX34	BRD-K11630072-001-13-2::2.5::MTS010::PROS004_PR500	2.5	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.4565195452575	0.4565195452575	-0.246154805611685	-0.182730639513	-9.49863151739657	3.21769583991064	0.00184439643426315	0.037427347411398	-0.929340985301294	-0.476007716437076
DHX34	BRD-K13390322-001-06-3::2.5::HTS002	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.9050361292555	-0.9050361292555	-0.324057338542569	-0.176785309489	7.37396715368187	162.115722593611	8.06741355240665e-12	6.10766753540715e-10	0.425396076214388	0.736561505211474
DHX34	BRD-K13646352-001-03-8::2.5::HTS002	2.5	midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	targeted cancer	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.425317966265	-1.425317966265	-2.97054849743262	-2.8725192622	-13.0865584126805	8.59088299570162	5.71718386467961e-07	2.42069992203263e-05	-1.8142924863849	-1.27616857595033
DHX34	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.711271535154	-0.711271535154	-2.62418455943059	-2.686193418095	-27.3315272702994	167.143688901902	1.45484733715872e-63	1.48483797583758e-59	-2.05108989577664	-1.77473615277655
DHX34	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.589678983991	0.589678983991	-0.0601386478295969	0.1891566141585	-8.85957416223386	19.9149427894951	2.41066759659555e-08	1.22871813391374e-06	-0.802857387248804	-0.49677787639239
DHX34	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	1.088551951893	1.088551951893	-0.489309096409939	-0.373418715101	-11.3262735865238	2.66150213773183	0.00251406853633924	0.0488033507223126	-2.05487743934453	-1.10084465726135
DHX34	BRD-K17555800-003-01-5::2.5::HTS002	2.5	talmapimod	p38 MAPK inhibitor	targeted cancer	MAPK11, MAPK14	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.2631986711345	0.2631986711345	0.413809951987896	0.422256044569	5.81143311871869	144.190884565573	3.81652815826215e-08	1.89127311284041e-06	0.0993861945701055	0.201836367136687
DHX34	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.2798707516205	-0.2798707516205	-1.13899271624309	-0.889953286616	-7.47502549460192	7.9456379321977	7.35047274764964e-05	0.00214167954531131	-1.12447231308893	-0.593771616156251
DHX34	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.538987339534	-0.538987339534	-0.974442146929758	-0.735958486111	-5.39062346330137	11.6878631623818	0.000178098361817175	0.00477212814793093	-0.611982139241331	-0.258927475550185
DHX34	BRD-K17894950-001-14-3::2.5::MTS010::PROS002_PR500	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.21335192107	0.21335192107	0.0174017893967317	0.01698904715675	-6.5026596065473	9.30630195327548	9.54927058498569e-05	0.00271551760011861	-0.263777143337141	-0.128123120009396
DHX34	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-2.11986688588	-2.11986688588	-3.04847425416407	-3.177325410155	-8.93371390486111	95.097298515251	3.11529850429393e-14	3.01308128667335e-12	-1.13495988881391	-0.722254847754217
DHX34	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-2.43518989494	-2.43518989494	-3.27587039577043	-3.04327234152	-7.20477958876811	124.776992112884	4.85560100993986e-11	3.33556445147244e-09	-1.07161610283191	-0.60974489882895
DHX34	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.472017983485	0.472017983485	-0.243932471227339	-0.0866927101235	-11.4778440044548	129.070545324453	1.88497531676814e-21	3.52842685299213e-19	-0.839363717564468	-0.592537191860211
DHX34	BRD-K25433859-003-25-4::2.5::HTS002	2.5	maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2	neurology/psychiatry	depression, dysthymic disorder	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.08028526529895	0.08028526529895	0.173712942200495	0.1863876312595	3.34728823199374	63.7130106449246	0.00137300053412327	0.0291187246663474	0.0376633027003828	0.149192051102707
DHX34	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-2.220573796845	-2.220573796845	-3.09303975015463	-2.9100349769	-8.69213981244561	123.437752275764	1.82195843601738e-14	1.80452185597583e-12	-1.0711433856853	-0.673788520933958
DHX34	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.2918978042145	0.2918978042145	-0.0557832565267387	-0.030411088067	-13.7639785832837	3.97953887088422	0.000166684670873268	0.00449998221735692	-0.417957103259259	-0.277405018223218
DHX34	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.39902271355	-1.39902271355	-1.96808525744337	-1.89093805071	-7.7148261810396	142.257286948137	1.93143085166989e-12	1.56388984891408e-10	-0.714874203379412	-0.423250884407323
DHX34	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-3.24381923771	-3.24381923771	-2.56887367408322	-2.525806741025	7.57965015254261	195.382067482197	1.36168044808152e-12	1.11819007186538e-10	0.499328735084939	0.85056239216863
DHX34	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.02573095701	-1.02573095701	-1.33891310956981	-1.265409369745	-4.90889555094836	40.8964163581066	1.5107796652887e-05	0.000504524610286166	-0.442036563107723	-0.184327742011889
DHX34	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.4804239274085	0.4804239274085	0.167771392806526	0.159843684784	-12.8080398209634	193.669547302028	1.31940064534967e-27	4.25882260417395e-25	-0.360797376093654	-0.264507693110295
DHX34	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.2567424358145	0.2567424358145	0.130655263642488	0.121836586496	-4.01448489562286	179.963439639227	8.73417074836208e-05	0.00250701229720865	-0.188062604407838	-0.0641117399361864
DHX34	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.400082567956	-0.400082567956	-1.02054964948856	-1.03228700688	-7.54948354958164	6.03175805613346	0.000273299138402155	0.00696669018013744	-0.821314286311784	-0.419619876753336
DHX34	BRD-K40331046-305-01-5::2.5::HTS002	2.5	CR8-(R)	CDK inhibitor	targeted cancer	CCNA2	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-4.16872296125	-4.16872296125	-5.27724017621191	-5.186080091785	-8.48843457566512	4.92690687926846	0.000400890551506459	0.00982982164670265	-1.44571677699637	-0.771317652927438
DHX34	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.74895935118	-1.74895935118	-1.27999170636354	-1.26660735332	5.8527101851795	167.872803309202	2.47483656476161e-08	1.25932869441783e-06	0.310778696539049	0.627156593093869
DHX34	BRD-K41859756-001-06-8::2.5::HTS002	2.5	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-4.556001850675	-4.556001850675	-3.98098718941616	-3.96236214096	5.0062332342402	6.80706552107983	0.001687730327191	0.034781687816973	0.30184617835568	0.848183144162001
DHX34	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.3146977170505	0.3146977170505	-0.213562012137724	-0.158274399371	-10.8407262611047	22.2581054105471	2.38322842513954e-10	1.51212245450483e-08	-0.62924996740852	-0.427269490967929
DHX34	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.0482089898	-1.0482089898	-1.74710811907718	-1.65992199057	-8.65108344519983	51.7424749894316	1.25847186721786e-11	9.31056323192741e-10	-0.861030251535976	-0.536768007018389
DHX34	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.911203383882	-0.911203383882	-1.39694543888178	-1.171371713075	-6.56429959071667	158.621380252752	7.06723855040782e-10	4.27523051445204e-08	-0.631889601423641	-0.339594508575922
DHX34	BRD-K47869605-001-32-0::0.625::HTS002	0.625	podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	noncancer	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-2.432195156375	-2.432195156375	-3.27806326803868	-3.15922322391	-8.06337436091028	189.001135428825	8.29100481161223e-14	7.66279762944388e-12	-1.05279825472299	-0.638937968604376
DHX34	BRD-K51143828-003-03-1::2.5::HTS002	2.5	lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.3175182066605	0.3175182066605	-0.0235674066277728	0.03172783000245	-8.2912911341526	3.29838619732405	0.00255785780484624	0.049559130849294	-0.465552869221697	-0.216618357354849
DHX34	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.190510093135	0.190510093135	-0.229353951765672	-0.187297921894	-11.376728218537	25.5565911826705	1.68761493334728e-11	1.2273662064791e-09	-0.495788532955741	-0.343939556845604
DHX34	BRD-K54256913-001-08-7::2.5::MTS010::PROS004_PR500	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.2804237579005	0.2804237579005	-1.22619797055885	-1.224724300865	-10.8776574384154	4.7060069205921	0.00016352481282464	0.00442582518094358	-1.86945816778001	-1.14378528913869
DHX34	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.513723999478	0.513723999478	-0.518198103076025	-0.339269333107	-16.1720345036629	32.4802400903241	4.25519415713064e-17	5.37109251180007e-15	-1.16182154971601	-0.902022655392045
DHX34	BRD-K55187425-236-05-2::2.5::HTS002	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-2.5787525718	-2.5787525718	-2.92503380598116	-2.897999861155	-3.52974193376776	89.2942793968902	0.000659977356784929	0.0153154570412522	-0.541202621127526	-0.151359847234787
DHX34	BRD-K56032964-001-02-1::2.5::HTS002	2.5	AP26113	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, EGFR	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.04435580675225	-0.04435580675225	-0.551288527732064	-0.449925278333	-7.53126821630524	25.6537681253005	5.87114193886675e-08	2.8424576024743e-06	-0.64538218156314	-0.368483260396488
DHX34	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.160893856204	0.160893856204	-0.24117057697602	-0.10314419939105	-6.288035892043	14.5790583899257	1.65703777684191e-05	0.000549684645833077	-0.538695362857025	-0.265433503503014
DHX34	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.0035310528085	-1.0035310528085	-0.700706984685726	-0.536026797501	4.02293262335768	29.0427605200356	0.000375117867926853	0.00928712458298422	0.148880362938919	0.456767773306629
DHX34	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.2024714054135	0.2024714054135	0.0357173246972256	0.07942712884705	-5.54285899803065	193.407872042488	9.65762241302489e-08	4.56127931723493e-06	-0.226089881876907	-0.107418279555642
DHX34	BRD-K59753975-001-02-6::2.5::MTS006	2.5	vindesine	tubulin polymerization inhibitor	chemo	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.454606128585	-1.454606128585	-2.42263327037804	-2.28041477314	-10.0023447529554	143.662050574908	3.34450279327688e-18	4.68818796062943e-16	-1.15932393267635	-0.776730350909724
DHX34	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-3.09475663128	-3.09475663128	-3.64602900314626	-3.579783032275	-4.70375977390836	174.592408623792	5.17158418067624e-06	0.000187931581190261	-0.782580040740989	-0.319964702991521
DHX34	BRD-K60997853-001-02-3::2.5::MTS010::PROS004_PR500	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.5589902453025	0.5589902453025	-0.738178361494643	-0.7041999710785	-13.6400067432851	2.98603203351204	0.000873201708534845	0.0196238281418229	-1.60062266473749	-0.993714548856798
DHX34	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.2868643224105	0.2868643224105	0.144208388695224	0.15713254048	-4.42084584244654	7.79972684482872	0.00236574050762458	0.0462971874779646	-0.21740209849376	-0.0679097689367921
DHX34	BRD-K67173685-001-06-9::2.38783::HTS002	2.38783	4E1RCat	protein synthesis inhibitor	noncancer	EIF4E, EIF4G1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.239436769089	0.239436769089	0.469898846670308	0.4806347706055	6.71078187281745	34.0306046855814	1.03936479962102e-07	4.89058217646483e-06	0.160672925371978	0.300251229790638
DHX34	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-3.34716448081	-3.34716448081	-3.86457618563421	-3.711772040445	-7.46428915893125	177.052203925814	3.64368146156343e-12	2.86901764869739e-10	-0.654208091049141	-0.38061531859927
DHX34	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.05367451468	-1.05367451468	-1.33442399831823	-1.10972386317	-3.27349061667424	189.999801891616	0.00126206924450955	0.0271026277572352	-0.449922497129978	-0.111576470146474
DHX34	BRD-K73319509-001-08-0::2.5::HTS002	2.5	PF-04217903	c-Met inhibitor	targeted cancer	MET	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.531666674543	0.531666674543	0.0412327251821074	0.085387538628	-13.7425938399105	33.0569165990929	3.19224868799608e-15	3.37538958583874e-13	-0.563035244538745	-0.41783265418304
DHX34	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.466376392782	0.466376392782	-0.692539524144564	-0.481859441946	-15.1923291735269	191.091584740833	1.06010451173088e-34	6.52905574410253e-32	-1.30938070637186	-1.00845112748127
DHX34	BRD-K75911534-001-01-6::2.5::HTS002	2.5	SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.276568469179	-0.276568469179	-0.52457585867929	-0.4139887396705	-4.07099428750028	34.847422336303	0.00025557460964516	0.00657114329542196	-0.371702130234488	-0.124312648766092
DHX34	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.877834207813	-0.877834207813	-0.418285904004197	-0.2916892525045	8.06395161828907	95.0913125953857	2.19509921108616e-12	1.76803238937575e-10	0.346414262941383	0.572682344676222
DHX34	BRD-K81801188-001-02-8::2.5::HTS002	2.5	PP-121	protein tyrosine kinase inhibitor	noncancer	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-3.177396858475	-3.177396858475	-4.63965953721702	-4.63633744063	-9.52875513228784	2.97231980741479	0.00254649651064371	0.0493657788196234	-1.9532172098327	-0.97130814765134
DHX34	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.04132908494065	-0.04132908494065	0.123461528305756	0.135109067247	3.89037868039849	13.2122115405228	0.00180707486121369	0.036808211128567	0.0734298197364806	0.256151406756332
DHX34	BRD-K83029223-001-01-3::2.5::MTS006	2.5	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-1.211230225555	-1.211230225555	-2.43260063162149	-2.31559247235	-11.6603432912364	107.745285303118	8.16530982029061e-21	1.45960190865143e-18	-1.42900004535613	-1.01374076677685
DHX34	BRD-K84892605-001-01-1::2.5::HTS002	2.5	IOWH032	CFTR channel antagonist	noncancer	CFTR	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.2903924255765	0.2903924255765	0.115968577297332	0.1106185229635	-6.3001006547373	22.4658714592512	2.21098470011501e-06	8.56767564257728e-05	-0.231771900455192	-0.117075796103144
DHX34	BRD-K89391146-001-08-0::2.5::HTS002	2.5	RG108	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3B	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.672808127369	0.672808127369	0.377213687549063	0.397149460871	-10.7410621711082	34.6267978357479	1.44432114655896e-12	1.18107557047247e-10	-0.351484620130367	-0.239704259509506
DHX34	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.889281317879	-0.889281317879	-1.83679038525941	-1.72447120363	-9.61493735682333	8.4244465910452	7.93934681889073e-06	0.000278727643627524	-1.17277789653799	-0.72224023822284
DHX34	BRD-K93123848-001-04-1::2.5::HTS002	2.5	RAF265	RAF inhibitor, VEGFR inhibitor	targeted cancer	BRAF	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-0.477228508242	-0.477228508242	-1.29578966194159	-1.194488826315	-9.99064866731299	5.64308383092668	8.47355127824932e-05	0.00243939257476951	-1.02215753030527	-0.614964777093923
DHX34	BRD-K97010173-001-04-1::2.5::HTS002	2.5	deferasirox	chelating agent	noncancer	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.365925774136	0.365925774136	0.0465361581119754	0.106077867549	-7.29702412246039	40.2788821806169	6.97425185568632e-09	3.78272438030877e-07	-0.407832697522253	-0.230946534525796
DHX34	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	-3.4201518513	-3.4201518513	-3.13909078276332	-3.215000704775	4.88169039908107	193.957115547396	2.19145427076092e-06	8.49352988061335e-05	0.167508519292406	0.394613617780944
DHX34	BRD-K99383816-001-03-5::2.5::HTS002	2.5	ftorafur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.1556851014305	0.1556851014305	0.0268673638844271	0.0625789324056	-3.97053407860271	63.6171251984661	0.000185146879372616	0.00493684318351	-0.193638449593774	-0.0639970254983722
DHX34	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	TE5, HCC15	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma)	0.1398384351045	0.1398384351045	-0.221437091630568	-0.147984722712	-6.25314792415494	9.74080366345394	0.000106096276303139	0.00298894254740748	-0.490472042453171	-0.232079011016965
DLG2	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	-1.387638452445	-1.388810653	-0.938137936331179	-0.8610860266675	6.52828933303359	57.2926947718226	1.89721550013585e-08	9.81245899924269e-07	0.311637507470861	0.587363524756781
DLG2	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	0.26989347408975	0.273273494693	-0.00973595833844367	-0.003707708051943	-6.47842320251855	11.0377925431	4.488180152632e-05	0.00136620815783761	-0.374591309316558	-0.18466755553983
DLG2	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	0.59653332480725	0.622482994431	-0.0258804050922301	0.0311708165355	-6.62313786590365	5.44132125523552	0.000847958375355702	0.0191532680472725	-0.858210043299559	-0.386617416499401
DLG2	BRD-A69815203-001-07-6::2.5::HTS002	2.5	cyclosporin-a	calcineurin inhibitor	noncancer	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	0.144655868779075	0.1525451546495	-0.0772692064434005	-0.00711196934273	-3.9899355694878	14.8013138836334	0.00121224741550806	0.0261835912847351	-0.340617652485324	-0.103232497959627
DLG2	BRD-K12885236-001-02-7::2.5::HTS002	2.5	dapivirine	non-nucleoside reverse transcriptase inhibitor	noncancer	CYP3A4, CYP3A5	NA	NA	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	-2.0753123704325	-2.150216871335	-1.32452718783769	-1.22268830223	6.67667644375923	4.48394113636942	0.00172481663367374	0.035447140116853	0.451427268725483	1.05014309646414
DLG2	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	-0.130736239529625	-0.130831403515	-0.33175790620395	-0.317030058783	-4.34722944848574	13.4408700727187	0.000733642864957268	0.0168514566073761	-0.300587914030682	-0.101455419317968
DLG2	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	-2.172683327845	-2.33151960496	-0.805336377929481	-0.728179465488	7.35030885374949	3.68200898230803	0.00250417065104165	0.0486420510664407	0.832780208696771	1.90191369113427
DLG2	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	-0.041238056431225	-0.04565971083725	-0.228892234789674	-0.187996703456	-3.95683290398253	12.0041671736183	0.00190292829738604	0.0384440304506036	-0.290981157279394	-0.0843271994375051
DLG2	BRD-K56957086-001-06-3::2.5::HTS002	2.5	dacinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	-6.787791378285	-6.795653541415	-5.56083319191446	-5.590369010985	6.44878235312098	4.47572825747155	0.00200365585458578	0.0401572429079405	0.720129945508272	1.7337864272328
DLG2	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	-0.077019427350125	-0.0775415369749	-0.472823577075954	-0.508975147277	-4.3975607127401	11.9310873953313	0.000880949067737374	0.0197917120271576	-0.592034737961764	-0.199573561489894
DLG2	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	0.192278569155075	0.2205834261045	-0.332571841687691	-0.216747892199	-7.3138060987908	13.0842716428955	5.66909396699137e-06	0.000204691920628587	-0.679780476923716	-0.369920344761817
DLG2	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	LU99, RVH421, CALU6, HGC27	LUNG, SKIN, STOMACH	carcinoma (large_cell_carcinoma), malignant_melanoma, carcinoma (undifferentiated_carcinoma), carcinoma (undifferentiated_adenocarcinoma)	0.31763413065875	0.3238911259795	0.0985232735409307	0.10349917696965	-5.14767514703284	6.2131452219937	0.00190893590003954	0.0385327107289107	-0.322403682434869	-0.115818031800769
DMD	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.269787509468	0.269787509468	-0.0556277075249074	0.002007296385155	-9.45297389545069	193.625354986764	1.11897176553799e-17	1.49612039635678e-15	-0.393310640041962	-0.257519793943853
DMD	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.7217234705175	-0.7217234705175	-0.179460215510016	-0.0542138701025	13.0950653059567	185.922920653018	3.45784659127459e-28	1.19342480203106e-25	0.460569892621289	0.623956617393679
DMD	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.09012715458465	-0.09012715458465	0.153840865619604	0.185523876977	5.0896219873292	20.2726941722343	5.37744514328977e-05	0.00161239848925035	0.144064749420069	0.343871290988439
DMD	BRD-A98299281-050-09-6::2.5::HTS002	2.5	hydroxytacrine-maleate-(r,s)	cholinesterase inhibitor	noncancer	ACHE	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.5567046654685	-0.5567046654685	-0.24615362077825	-0.13432560034	6.23755629903531	26.841280542015	1.16366372378178e-06	4.70667828372194e-05	0.208367684587398	0.412734404793102
DMD	BRD-K03549949-001-01-0::2.5::HTS002	2.5	XL388	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.728785771254	-0.728785771254	-1.33667202199224	-1.14186011868	-6.95458344964777	8.34304015638573	9.63291948919975e-05	0.00273821485570384	-0.8080159596587	-0.407756541817781
DMD	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.6180122315785	-0.6180122315785	-1.0307445472828	-1.0089298839585	-6.63239518503031	11.1434830529223	3.47336384517165e-05	0.00107968469843625	-0.549484218617783	-0.275980412790812
DMD	BRD-K11663430-001-02-3::2.5::HTS002	2.5	pyroxamide	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.24973832952	-1.24973832952	-0.631667792782857	-0.605158922275	7.1210611810174	4.36141894129331	0.00147236536878359	0.0309382938358842	0.384764634974496	0.85137643849979
DMD	BRD-K16478699-001-09-2::2.5::HTS002	2.5	PLX-4720	RAF inhibitor	targeted cancer	BRAF, KDR	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.4054378963115	-0.4054378963115	-1.52124520764728	-1.41373612569	-13.3109933502971	187.553792737334	6.78312461853665e-29	2.49368836426474e-26	-1.28117028024778	-0.950444342423767
DMD	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.562416448234	-0.562416448234	-1.13603412256127	-0.889953286616	-5.20936119438904	11.392313410565	0.000258886150742577	0.00664512692245578	-0.814960071481591	-0.332275277172954
DMD	BRD-K17979676-001-01-2::2.5::HTS002	2.5	eprobemide	monoamine oxidase inhibitor	noncancer	MAOA	neurology/psychiatry	depression	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.6831551957835	-0.6831551957835	-0.0373435554705846	-0.00773751956823	11.4443707026829	10.1785420954049	3.88155935284369e-07	1.68236751169997e-05	0.520374950245713	0.771248330380118
DMD	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.24916579687	-4.24916579687	-3.11972516143962	-3.13313730075	7.45588036081144	6.02152818118826	0.000295126658104236	0.00746274203690688	0.759095588219052	1.4997856826417
DMD	BRD-K23984367-075-15-2::2.5::HTS002	2.5	sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.2767277459395	-0.2767277459395	-0.85801986376082	-0.738304903661	-6.25887081972379	8.41443039062206	0.000196964042216446	0.00520981194671215	-0.793639795997332	-0.368944439645308
DMD	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.1711623774445	-0.1711623774445	-0.473007416319307	-0.387317230447	-6.06451520823444	154.217704634922	9.80078969587384e-09	5.23577630789368e-07	-0.400168578864844	-0.20352149888477
DMD	BRD-K32821942-001-21-3::2.5::HTS002	2.5	azathioprine	dehydrogenase inhibitor	noncancer	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.9316145076955	-0.9316145076955	-0.634934903868467	-0.563960443725	5.89951630709161	11.7474646587404	7.91207732551034e-05	0.00229222441348919	0.186847908821079	0.406511298832988
DMD	BRD-K33720171-001-01-0::2.5::HTS002	2.5	difluprednate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	endogenous uveitis	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.3392637706595	-0.3392637706595	-1.48150150312734	-1.46727354757	-16.2390594126275	175.48386715036	8.52219171306477e-37	6.6420102824344e-34	-1.28105681596866	-1.00341864896702
DMD	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.238187624275	0.238187624275	-0.241319965291308	-0.026104548309	-8.38472578764716	25.0137846074333	9.83189384830562e-09	5.25108391879765e-07	-0.59728565379762	-0.361729525334996
DMD	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	1.0826519219685	1.0826519219685	-0.80754610068849	-0.4002530483955	-11.2986511406981	3.19651816708337	0.001103701593595	0.0240866774110196	-2.40455621952595	-1.37583982578802
DMD	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.3511775310525	-0.3511775310525	-1.37885909616457	-1.00119520354	-9.97941285566907	171.010698741828	9.0391072839504e-19	1.32785663129664e-16	-1.23095751533758	-0.82440561488657
DMD	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.366545933665	-1.366545933665	-1.01058610963589	-1.02230629729	5.30230896189268	65.8505944104261	1.4296645907529e-06	5.70081082923681e-05	0.221918819862473	0.490000828195747
DMD	BRD-K43389675-003-20-9::2.5::HTS002	2.5	daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.323240613245	-4.323240613245	-5.07504165723591	-5.1170914027	-8.98212959746367	9.32662674763559	6.81766875315967e-06	0.000242074454547104	-0.940136808633882	-0.563465279347947
DMD	BRD-K43621685-001-02-5::2.5::HTS002	2.5	CP-673451	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	KIT, PDGFRA, PDGFRB	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.4879846375295	-0.4879846375295	0.00183003501389443	0.03337894475615	8.12314558970363	11.3914529710162	4.51055991671145e-06	0.000166078645660341	0.357652559762615	0.621976785324174
DMD	BRD-K45662124-050-01-5::2.5::HTS002	2.5	3'-fluorobenzylspiperone	dopamine receptor ligand	noncancer	DRD2	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.796136942483	0.796136942483	0.505826455705605	0.5255641700865	-9.4622759567302	179.818990966152	1.6999452725268e-17	2.23115474779789e-15	-0.350851260067275	-0.229769713487516
DMD	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.156629755382	-0.156629755382	-0.954325290011899	-0.580280097075	-8.13421652790088	12.7506897344684	2.12071664016328e-06	8.23681069208497e-05	-1.00997755904292	-0.585413510216881
DMD	BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500	2.49998	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.848300126056	-0.848300126056	-0.189256158621528	-0.0644082695915	10.8968214254053	5.69193171260493	5.01364538634903e-05	0.0015111371143451	0.509090346143103	0.808997588725841
DMD	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.591910956875	-3.591910956875	-3.14654727937784	-3.15598793833	4.56093479635547	190.223625588988	9.10767214652337e-06	0.000315914915599969	0.252752770993176	0.637974584001134
DMD	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.27701755634	-1.27701755634	-2.08536781227236	-1.79411655002	-5.56350965316136	10.6988847605931	0.000187353420996182	0.00498451729998643	-1.12924398389017	-0.487456527974546
DMD	BRD-K66956375-001-11-3::2.5::HTS002	2.5	oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	noncancer	CNR1, GPR119, GPR55, PPARA	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.140936144316	0.140936144316	0.33341327474322	0.335539254934	8.14079809803181	105.375751465518	8.42314515551918e-13	7.06861502755392e-11	0.145598344391709	0.239355916462731
DMD	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.385314180602	-0.385314180602	-1.18491827888854	-1.01733335597	-11.024182637859	5.69666964087855	4.6793989420351e-05	0.00141897410278359	-0.979399208200013	-0.619808988373062
DMD	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.4357143332285	0.4357143332285	0.309029306046033	0.289065772439	-4.87045821813637	70.9556422413984	6.53574618713395e-06	0.000233116981950779	-0.178549861048287	-0.0748201933166469
DMD	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.01423495655975	-0.01423495655975	-0.532194400028002	-0.376499820922	-7.88170309125645	6.97432057732671	0.000102197887802983	0.00289055458722137	-0.673470787175692	-0.362448099760812
DMD	BRD-K72726508-001-02-1::2.5::HTS002	2.5	arcyriaflavin-a	CDK inhibitor	targeted cancer	CCND1, CDK4	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.3382236749905	-0.3382236749905	-0.49535097936772	-0.4023952462985	-3.21423316675224	193.901919470629	0.001532057897592	0.0320136918331867	-0.253541611840653	-0.0607129969137878
DMD	BRD-K73589491-001-11-2::2.5::HTS002	2.5	nizatidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.311492781427	0.311492781427	0.0934683128803471	0.09689104741345	-8.71506628116914	68.912738310466	9.95843089923466e-13	8.29852463531129e-11	-0.267933066561037	-0.168115870532268
DMD	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.28163372135	-1.28163372135	-0.674331085455689	-0.4541784692175	7.70413051313652	129.348589554875	3.03303554303714e-12	2.40676591967274e-10	0.451343117963515	0.763262153825108
DMD	BRD-K78431006-001-10-2::2.5::HTS002	2.5	crizotinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.545149821195	-1.545149821195	-1.17108932814755	-1.07734518699	4.8710963005362	12.7227531214645	0.000324867228783599	0.0081427281344825	0.207793545509956	0.540327440584953
DMD	BRD-K79259477-001-04-9::2.5::HTS002	2.5	NVP-BHG712	ephrin inhibitor	targeted cancer	EPHB4	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5778505270555	0.5778505270555	0.146704758233365	0.138812266601	-11.8310030593648	27.0428545879085	3.35707602388912e-12	2.65211480694483e-10	-0.505913094165874	-0.356378443478396
DMD	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.2736232868235	0.2736232868235	0.120128698974919	0.120954188254	-3.91523966909865	38.9982216234638	0.000352554259384506	0.00877308740968557	-0.232793069685145	-0.0741961060120181
DMD	BRD-K84163249-001-01-9::2.5::HTS002	2.5	ercalcitriol	vitamin D receptor agonist	noncancer	VDR	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.010303890003625	-0.010303890003625	-0.523866469501917	-0.512270344083	-11.6312622186201	177.4860672732	1.31565977223862e-23	2.97138085694553e-21	-0.600696258258364	-0.426428900738219
DMD	BRD-K84937637-001-09-9::2.5::HTS002	2.5	sirolimus	mTOR inhibitor	noncancer	FGF2, FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.65110176861	-1.65110176861	-1.34538972097959	-1.32265051102	4.86519046839312	7.29318147224315	0.00162409522977288	0.0336254546466375	0.158329397888956	0.453094697371857
DMD	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.99438723406	-1.99438723406	-1.69704972723994	-1.533280492745	4.45563828559272	192.62898483424	1.41680277248126e-05	0.00047509097693824	0.165716564486478	0.428958449153641
DMD	BRD-K86972824-001-01-4::2.5::HTS002	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.09351970489215	-0.09351970489215	0.00915444547582043	0.002128528664087	3.33991831996224	161.15611491933	0.0010412743254609	0.0229053001402171	0.0419660023942598	0.163382298341681
DMD	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.512627808035	-1.512627808035	-1.95870572301663	-1.89031364576	-6.95915207332257	78.8542993490596	9.01156579387963e-10	5.39056624347314e-08	-0.573668371403146	-0.318487458560118
DMD	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.0537017414572	0.0537017414572	-0.0950113613124238	-0.0469105128274	-4.89433646521035	145.553182568632	2.58681723715134e-06	9.91647203758556e-05	-0.208765376748728	-0.0886608287905195
DMD	BRD-K95785345-300-14-8::2.5::HTS002	2.5	thiamine	vitamin B	noncancer	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.024024734110855	-0.024024734110855	0.176931233809743	0.197775982352	6.76021924571444	9.51375290269198	6.3391968513234e-05	0.00187377426830409	0.134260012434145	0.267651923407051
DMD	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	SW1990, NCIH1792	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.516791457412	-0.516791457412	-0.0707353147780563	-0.0594618685141	6.84802524926279	4.37696288601654	0.00170246207971959	0.0350347570892195	0.271188410211447	0.62092387505644
DNER	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.030802402893315	-0.030802402893315	-0.344378930477462	-0.266254262221	-6.86745072622759	7.45282395825228	0.000178968416573774	0.0047935668277731	-0.420232526170016	-0.206920528998278
DNER	BRD-A43885598-001-08-1::2.5::HTS002	2.5	SID-7969543	steroidogenic factor antagonist	noncancer	NR5A1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3004926202785	0.3004926202785	0.409900062087714	0.426109956866	3.26720765740915	124.684485247491	0.00140326133152232	0.0296929211100649	0.0431318070749895	0.175683076543439
DNER	BRD-A50998626-001-02-1::2.5::HTS002	2.5	palomid-529	AKT inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0801470944207	-0.0801470944207	0.0457927894842593	0.0375657070821	4.07784129775786	80.2909037281634	0.000106348241166241	0.0029948117436499	0.0644822648831187	0.1873975029268
DNER	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2146081553885	0.2146081553885	0.359062731387918	0.3667280736395	6.34617728518904	187.464450942496	1.61814502797105e-09	9.41409896036933e-08	0.0995510988566791	0.189358053142156
DNER	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.6477216782135	-0.6477216782135	-0.180221422775636	-0.133134130631	10.2877569119227	170.810897811015	1.27259111326157e-19	2.03092465163245e-17	0.377799272362515	0.557201238513212
DNER	BRD-K03406345-001-27-8::2.5::HTS002	2.5	azacitidine	DNA methyltransferase inhibitor	chemo	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.14275625385	-1.14275625385	-0.577493935177629	-0.551785683571	9.95266956658278	4.51976848003226	0.000304419669483956	0.00767509273506962	0.414474554966846	0.716050082377895
DNER	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.342451135497	-0.342451135497	-0.684516743665239	-0.506361258966	-4.7274530494115	37.8545402111538	3.12185394463762e-05	0.000978221979678707	-0.488563734600648	-0.195567481735829
DNER	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.22349740809	-3.22349740809	-3.71028231877752	-3.60790168659	-3.93979782245881	15.6896272883032	0.00121165734068911	0.0261754578758477	-0.749133268143786	-0.22443655323126
DNER	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.454716531765	-2.454716531765	-1.93575352516048	-1.85386313087	4.92528139532688	133.620432951385	2.4451403052007e-06	9.41207752286928e-05	0.310559691812383	0.727366321396651
DNER	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0090508500236	-0.0090508500236	0.280511702763138	0.26768413301	8.54263553830496	7.21554991575185	5.01739202539798e-05	0.00151205373370574	0.209893704534142	0.369231401039334
DNER	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.7118746755765	-0.7118746755765	-0.418828767547651	-0.37916191768	5.7564737122015	192.554769405501	3.34306978892113e-08	1.67059175749517e-06	0.19263857744333	0.393453238614368
DNER	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.831363306704	-0.831363306704	-0.415129784649949	-0.389042162364	12.1818859457939	168.857261628465	6.69206548870133e-25	1.71978861406219e-22	0.348781586051577	0.483685458056524
DNER	BRD-K15916496-001-27-9::2.5::HTS002	2.5	clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	noncancer	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1595696959265	0.1595696959265	0.333943795016766	0.346280454324	6.95914378928428	187.843935286148	5.54405415783687e-11	3.772227249508e-09	0.124945154724674	0.223803043455858
DNER	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.191977628586	0.191977628586	-0.0289325032328501	-0.00807522835948	-6.8236085789206	4.85823132516494	0.00115510840127507	0.0251139408132364	-0.304866902318949	-0.136953361318751
DNER	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3071288504045	0.3071288504045	-0.200649426816438	-0.14719250083	-8.59020765412244	10.9927325746187	3.31421835563705e-06	0.0001247292547753	-0.637891849640272	-0.377664704801604
DNER	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.455613388728	-0.455613388728	-0.109254322512151	-0.02484856783435	6.4123941070214	195.090452760559	1.05634430083759e-09	6.26640513850593e-08	0.239832741639781	0.452885390791916
DNER	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.073436731625	-4.073436731625	-2.85747441887934	-2.68228454863	10.9423105390966	42.4626361531011	6.17325598600299e-14	5.7853422921908e-12	0.991775706812247	1.44014891867907
DNER	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.947723528378	-0.947723528378	-0.495776026226704	-0.427199621459	9.53499935144309	140.038589859741	6.48862113001019e-17	8.07607246326337e-15	0.358237758632386	0.545657245670205
DNER	BRD-K26997899-001-02-2::2.5::HTS002	2.5	D-64131	microtubule inhibitor	chemo	TUBB	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.908918580875	-3.908918580875	-3.00833185284392	-2.8512516893	8.70339719019425	39.5543944971971	9.9333389075529e-11	6.58929927179481e-09	0.691381909146764	1.10979154691541
DNER	BRD-K28360340-001-08-3::2.30697::HTS002	2.30697	TW-37	BCL inhibitor	targeted cancer	BCL2, BCL2L1, MCL1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.89967015613	-1.89967015613	-2.7780859396794	-2.74381570724	-10.0024372678705	164.208535537145	1.08390898072901e-18	1.58251449544052e-16	-1.05181811718883	-0.705013449909963
DNER	BRD-K31309378-001-01-5::2.5::HTS002	2.5	lucitanib	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.463953367674	-0.463953367674	-0.764938761464511	-0.647544423054	-4.68250557163299	37.4481507957125	3.66052425502908e-05	0.00113309720256517	-0.431173830530093	-0.170796957050929
DNER	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2118307113655	-0.2118307113655	-0.694907684044966	-0.621232482709	-7.01777117316587	3.89878049313024	0.00238816481150862	0.0466635952124925	-0.676169851527294	-0.289984093831639
DNER	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.05790097565995	-0.05790097565995	0.165900689925231	0.1606220898175	7.99050791151473	11.0509806578561	6.4177322892517e-06	0.000229136455742633	0.162190182930502	0.28541314823986
DNER	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.80906541925	-2.80906541925	-1.91845517566883	-1.7784006568	8.1539050487327	5.91790487580083	0.000196420263145167	0.00519799463879991	0.622445003887156	1.15877548327518
DNER	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.003603405829	-0.003603405829	-0.276550329753858	-0.153671266635	-4.61647889867729	18.3069354056536	0.000205795883477408	0.00541867640169893	-0.397013738854025	-0.148880108995691
DNER	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.152961737222	0.152961737222	-0.14838213965565	-0.07517274316945	-5.64958609503256	10.4908377035161	0.000177809075634681	0.00476608821557098	-0.419441386766438	-0.183246366988862
DNER	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2962080253635	0.2962080253635	0.0872587915427326	0.1179670530315	-6.55786316165043	15.8595137836376	6.8864387715902e-06	0.000244445766060973	-0.276543156530321	-0.141355311111213
DNER	BRD-K39624409-003-02-6::2.5::HTS002	2.5	ADL5859	opioid receptor agonist	noncancer	OPRD1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1282217019375	0.1282217019375	0.240240029731512	0.2967828750075	3.33419317984086	177.663735787124	0.00104124454285275	0.0229053001402171	0.0457181229041324	0.178318532683892
DNER	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.22682332901	-1.22682332901	-1.01202654885914	-1.02230629729	3.29946782770598	144.112502111603	0.00122068510844147	0.026341947101002	0.0861217411565951	0.34347181914513
DNER	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.85167699949	-3.85167699949	-2.73430482574708	-2.72063669108	12.657267563298	142.439160478453	4.46001505688374e-25	1.15448136126429e-22	0.942865704569156	1.29187864291668
DNER	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.387229067054	-0.387229067054	-0.206134215480534	-0.155158212647	3.69813572868866	21.8546850059172	0.00126648525611864	0.0271797855671024	0.0794997231175438	0.282689980029389
DNER	BRD-K43471985-001-03-0::2.69009::HTS002	2.69009	OTX015	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.489110897549	-0.489110897549	-0.808544840417431	-0.721568534239	-3.40824301500735	24.7978170600809	0.0022381062811414	0.0441867244962008	-0.512541830205007	-0.126326055531856
DNER	BRD-K47598052-001-15-8::2.5::HTS002	2.5	PP-1	src inhibitor	targeted cancer	HCK, RET	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.006202676819685	0.006202676819685	-0.294316634495115	-0.119341908815	-4.64700449650475	152.878018442011	7.21940335493885e-06	0.000255039970605025	-0.428280499750687	-0.172758122878913
DNER	BRD-K51791723-003-01-7::2.5::MTS010::PROS004_PR500	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.8973147209005	-0.8973147209005	-2.24787928409143	-2.452542786	-18.2019692761478	128.503629060018	2.1996480097727e-37	1.78578923593399e-34	-1.4973741063132	-1.20375502006866
DNER	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.214471686994	0.214471686994	0.380605652622822	0.394227062385	5.76690991770228	9.09999262489189	0.000259383463306309	0.00665709475595472	0.101074412293792	0.231193518963851
DNER	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0432735386716	-0.0432735386716	0.117306028513707	0.150496276102	4.76256263426948	8.75684816914388	0.00110705010099158	0.0241572939417047	0.0839822340266121	0.237176900344001
DNER	BRD-K55044200-001-15-3::2.5::HTS002	2.5	amoxicillin	penicillin binding protein inhibitor	noncancer	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0159680545523	0.0159680545523	0.0982921728813735	0.129657009362	3.29558157353435	186.956847976354	0.00117513597359487	0.025474432900234	0.0330449293472293	0.131603307310918
DNER	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.199387038515	-0.199387038515	-0.585750082110929	-0.48109263675	-4.6066283302268	19.2710318976664	0.000186219193736422	0.0049610233477653	-0.561740347749648	-0.21098573944221
DNER	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.08823888997845	0.08823888997845	0.236082049941493	0.281721742376	3.88857081517853	163.853296337079	0.000146265160965209	0.00398942042307359	0.0727710093499084	0.222915310576177
DNER	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.437115226583	0.437115226583	0.0332983162315607	0.07942712884705	-9.15126508653844	3.42351896591511	0.0015934000337917	0.0331114830175046	-0.534914049673401	-0.272719771029478
DNER	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-6.56032506571	-6.56032506571	-7.22017032438521	-7.25572463628	-6.01271545271345	38.7438869517472	5.0934943779315e-07	2.17135604395413e-05	-0.881865603037218	-0.437824914313207
DNER	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.657241409735	-4.657241409735	-3.98431035878528	-4.06345371982	6.13697688082102	80.7382255997638	2.97017344165779e-08	1.49400212057515e-06	0.454747481673794	0.891114620225656
DNER	BRD-K69280563-001-01-8::2.5::HTS002	2.5	vinorelbine	tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.044583313085	-4.044583313085	-3.35831551626303	-3.520745955955	7.19293746910168	132.012744078599	4.25266367333918e-11	2.94117183750601e-09	0.497540405869313	0.87499518777462
DNER	BRD-K72703948-001-10-1::2.5::HTS002	2.5	ZM-447439	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.06372001286	-1.06372001286	-1.3752652637626	-1.23720066309	-4.41855155969785	117.50328507931	2.22556445032394e-05	0.000718811035372937	-0.451177305477858	-0.171913196327335
DNER	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.1054369006631	-0.1054369006631	0.244912110520522	0.276258886308	7.14287769969531	4.44228209944898	0.00135217971706838	0.028750922947498	0.219352016399164	0.48134600596808
DNER	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.617258289545	-3.617258289545	-2.91756469326612	-2.84610122618	7.07581394496102	180.840911714695	3.15496440110024e-11	2.21705037745381e-09	0.504576323279916	0.89481086927785
DNER	BRD-K77638923-001-02-0::2.5::HTS002	2.5	CUDC-907	PI3K inhibitor	targeted cancer	HDAC2, PIK3R1	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.262175127795	-5.262175127795	-5.89755602541016	-5.8647928098	-8.83047987704603	142.81290253455	3.41568153278586e-15	3.60098183590979e-13	-0.777611730103921	-0.493150065126391
DNER	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.67876789797	-1.67876789797	-1.10338038299442	-1.10749370834	11.6468384546195	146.955242599424	1.27858492582019e-22	2.6787666526502e-20	0.477755625316381	0.673019404634773
DNER	BRD-K84783599-001-01-0::2.5::HTS002	2.5	riociguat	guanylate cyclase stimulant	noncancer	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.40585981993	0.40585981993	-0.00688216848546573	0.04755872580485	-6.15542570360587	4.65021224841035	0.00212438805800818	0.0422608101062592	-0.589081794429054	-0.236402182401878
DNER	BRD-K84810405-003-01-1::2.5::HTS002	2.5	almorexant	orexin receptor antagonist	noncancer	HCRTR1, HCRTR2	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.467624758958	0.467624758958	0.255762728789846	0.26116496822	-5.89867586629893	6.07559033778196	0.00100818069329741	0.0222880206099784	-0.29948309490988	-0.124240965426428
DNER	BRD-K87024524-065-17-7::2.5::HTS002	2.5	phenelzine	monoamine oxidase inhibitor	noncancer	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0958618583868	0.0958618583868	0.355665575990913	0.37808925029	6.57418579056854	5.75084471569803	0.000705429758450258	0.0162791802561401	0.162080099730661	0.357527335477565
DNER	BRD-K89714990-001-01-5::2.5::MTS006	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.06414177418365	-0.06414177418365	0.139468007936639	0.165320273303	6.27573887888925	126.95412881772	5.04628307502987e-09	2.78825678058282e-07	0.139408829478773	0.267810734761804
DNER	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.339236794719	0.339236794719	0.165717989395421	0.180090535551	-8.60222457433799	190.689742245341	2.84816222930589e-15	3.03401472388123e-13	-0.213306513209887	-0.133731097437271
DNER	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.215974582455	-1.215974582455	-1.83336951337904	-1.72447120363	-7.21642541878898	52.752512842243	2.07267118876719e-09	1.19033639661651e-07	-0.789013560878251	-0.445776300969823
DNER	BRD-K93123848-001-04-1::2.5::HTS002	2.5	RAF265	RAF inhibitor, VEGFR inhibitor	targeted cancer	BRAF	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.66998337206	-1.66998337206	-1.28310078041162	-1.18097328249	4.86173925244066	6.85403471761485	0.00194362752639507	0.0391224402803089	0.197897493964685	0.575867689332084
DNER	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.187547882176	0.187547882176	0.30819588179902	0.317996860903	4.54186000547511	75.7713044393615	2.06653317224126e-05	0.000671698496016527	0.0677394896152909	0.173556509630749
DNER	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.555749258444	-0.555749258444	-0.342770965764569	-0.279710660695	5.54700941963152	174.90893714173	1.05859653809956e-07	4.9777959064138e-06	0.137200859386417	0.288755725972446
DNER	BRD-K97472745-001-01-8::2.5::HTS002	2.5	gestrinone	progesterone receptor antagonist	noncancer	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.4769852858385	-0.4769852858385	-0.157448062459256	-0.109259098298	6.20574789091652	4.67220386193916	0.00201895350956427	0.0404184837242107	0.184334143453015	0.454740303305474
DNER	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.4211515812205	-0.4211515812205	-0.721851157922349	-0.596555071115	-4.42490497906854	17.0846878590254	0.000366768958270075	0.00910223985782991	-0.444020434588653	-0.157378718815045
DNER	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0831741242616	0.0831741242616	0.24870171037764	0.266502193274	4.6975355306531	8.71886301041847	0.00122506740579922	0.0264178963696087	0.0854221720337053	0.245633000198375
DNER	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	NCIH838, KYSE410	LUNG, OESOPHAGUS	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.543820243065	-1.543820243065	-1.08401434670821	-1.01891124495	7.17110529578736	169.1008674948	2.21616877679873e-11	1.58541134099631e-09	0.333228599877041	0.586383192836529
DOCK4	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-2.860014430785	-2.83848518007	-3.82624089383265	-3.857943636075	-5.59524356516352	6.76977986583419	0.000920451337196425	0.0205799514552444	-1.3773985675565	-0.55505435853879
DOCK4	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.5673738381485	-0.549323219696	-0.0704022248045498	-0.0503674228669	5.67632872683795	4.9013295870613	0.00252001149334184	0.0489054276853009	0.270543489649127	0.723399737038773
DOCK4	BRD-A74391928-051-01-3::2.5::HTS002	2.5	ibutilide	potassium channel blocker	noncancer	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.282792036971	-0.295677931613	0.17434733785191	0.166211801936	7.03438058515871	4.9396654940482	0.00094203733747323	0.0210012399108904	0.289470818693552	0.624807930952268
DOCK4	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-2.9783652130775	-2.97995102798	-2.30257729441068	-2.410134775015	5.50386424762081	6.43734105421453	0.00119635540241655	0.0258820689456483	0.380224768675822	0.971351068657827
DOCK4	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.557647091542	-0.568667553202	-1.23174186672018	-1.26677083286	-6.67932345886715	8.61609558814603	0.000111031246239616	0.00311504950932164	-0.903957673209499	-0.444231877146865
DOCK4	BRD-K11590034-002-03-4::2.48778::HTS002	2.48778	morin	cytochrome P450 inhibitor	noncancer	ADORA2A, ESR2, FASN, MCL1, SLC22A12	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	0.33658408072725	0.325553169468	0.593002501757625	0.585017286812	7.66583422993834	37.4237117116691	3.477491495777e-09	1.95420464701656e-07	0.18866916234951	0.324167679711239
DOCK4	BRD-K13183738-317-10-2::2.5::HTS002	2.5	pentamidine	anti-pneumocystis agent	noncancer	TRDMT1	infectious disease	pneumonia	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.65183593104	-1.644016550665	-0.889021377288374	-0.8084046081105	6.25322152434858	4.95910383588351	0.0015794249994917	0.0328433667135012	0.448456424225138	1.07717268327811
DOCK4	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-2.66073088093667	-2.74304793907	-3.69467388522994	-3.61087064154	-6.74529644757676	5.10736539957127	0.000999210826865408	0.0221115491678865	-1.42549253030684	-0.642393478279712
DOCK4	BRD-K16136380-001-01-7::2.5::HTS002	2.5	pyrithione-zinc	ATP synthase inhibitor	noncancer	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-5.22574744439	-5.13435504725	-6.35936756600091	-6.344923432095	-6.61237977872569	5.00015313718864	0.00118993895427038	0.0257692660533308	-1.57431417537192	-0.692926067849914
DOCK4	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-4.57607147568	-4.56110541818	-4.17095233127335	-4.12140382517	4.33288806602937	106.067704774358	3.35465571908254e-05	0.00104521006776456	0.219750361443062	0.59048792737024
DOCK4	BRD-K21782625-001-02-4::2.5::HTS002	2.5	AMG458	MET inhibitor	targeted cancer	MET	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.147787968078	-0.142346557161	0.0304243480165616	0.013560290369	3.95103577277715	111.492468614445	0.00013681278162438	0.00376013453056131	0.088837672592322	0.267586959596801
DOCK4	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.206858891575667	-0.19003424642	-0.86557556465123	-0.560893595726	-5.77348415916167	17.5253634646584	1.99588880195019e-05	0.000650589625554459	-0.898884274152723	-0.418549071998404
DOCK4	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.726663592636	-0.7205465712815	-0.395081738921187	-0.296942194087	4.27552440010573	15.3793415296774	0.000629587754070199	0.0146816357025472	0.166634905591017	0.496528801838609
DOCK4	BRD-K28907958-001-04-3::2.5::HTS002	2.5	CD-437	retinoid receptor agonist	targeted cancer	RARG	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-3.1496414139125	-3.163530335015	-4.22622227088898	-4.12804770498	-5.85320209977448	5.36156289323844	0.00162631989448838	0.0336617592144665	-1.5399575737972	-0.613204140155754
DOCK4	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-4.6660221682	-4.67128885545	-3.61145138479932	-3.57314682257	11.3143231364585	12.2205995348951	7.77996162913396e-08	3.71043924345939e-06	0.851896654664126	1.25724491213723
DOCK4	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-0.9063156253265	-0.863103563961	-1.68032803725735	-1.558472176555	-5.41832110978987	6.23546425536857	0.00144451591477669	0.0304396471829881	-1.12038133707509	-0.42764348678662
DOCK4	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	0.067697223142025	0.070788619812	-0.0743632765490793	0.0269217911151	-3.9171173073172	35.1421029901271	0.000394639658726835	0.00969318398066284	-0.215674956978998	-0.0684460424032105
DOCK4	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-1.17084932964667	-1.11884341717	-0.683959763509597	-0.628462635581	5.91748519290765	5.11849404902267	0.00181286754553086	0.0369063533592405	0.276846859760081	0.696932272514058
DOCK4	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.605894802792667	-0.572094840877	-0.288483076113628	-0.267330713915	4.9444099106596	7.25210988212521	0.00150406831233108	0.031511774908466	0.166675365134959	0.468148088223119
DOCK4	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-1.03553691860433	-1.0816579985	-0.281166517354423	-0.359027987102	7.48084545994915	6.39793232915553	0.000216963710287562	0.00568132132708892	0.511295998527222	0.997444803972599
DOCK4	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	0.120521488831375	0.11713477849975	-0.244625627496824	-0.1080101224105	-4.20845802339225	8.60082748153628	0.00251998941654959	0.0489054276853009	-0.562820726980721	-0.167473505675677
DOCK4	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-4.62652217672	-4.596764616465	-5.60545109281346	-5.560736120845	-6.05269846793761	5.10754001759156	0.00164755606713297	0.0340552651473183	-1.39206098603173	-0.565796846155184
DOCK4	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	0.02209272032755	0.0304886152042	-0.145703797736399	-0.155177124635	-6.19902582925898	11.996817355226	4.59864896905605e-05	0.00139666123691202	-0.226774811384522	-0.108818224743375
DOCK4	BRD-K63923597-001-10-0::2.5::HTS002	2.5	barasertib-HQPA	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.859909936405	-1.86305655595	-1.15289275482198	-0.983257102006	7.12956754619822	15.447431457485	2.92049536629179e-06	0.000111022854090449	0.496179900733678	0.91785446243236
DOCK4	BRD-K71035033-001-07-1::2.5::HTS002	2.5	masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor	noncancer	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.481257478988	0.473879720543	0.275155114129902	0.308896006376	-5.05305972464407	57.1086146197847	4.77129912446787e-06	0.000174599243648297	-0.287774832313394	-0.124429897402802
DOCK4	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-1.17173050724333	-1.21004445459	-0.883955477391175	-0.6850177992955	3.95007008645084	21.1670579738351	0.000723012047310978	0.0166429437319423	0.136341395843432	0.439208663860884
DOCK4	BRD-K81801188-001-02-8::2.5::HTS002	2.5	PP-121	protein tyrosine kinase inhibitor	noncancer	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-3.73082951686	-3.848722596225	-4.64348101422747	-4.64267510651	-5.07116387782324	6.33927916805307	0.00194324253812813	0.0391183647933187	-1.34736891750599	-0.477934077228954
DOCK4	BRD-K83029223-001-01-3::2.5::MTS006	2.5	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.4294374369825	-1.43971488406	-2.44090704414225	-2.33695006246	-6.22888434741255	8.12634672441784	0.000235596202989578	0.00611394824924969	-1.38491623060077	-0.638022983718727
DOCK4	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	HCC95, RVH421, ONS76, HCC15	LUNG, SKIN, CENTRAL_NERVOUS_SYSTEM	carcinoma (squamous_cell_carcinoma), malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	0.251310609832	0.247930548563	-0.0562793763643039	-0.06793161332675	-4.47419062362854	8.49468339801868	0.00178427903414581	0.0364004132028781	-0.464529620380213	-0.150650352012395
DOCK4	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-3.66327383868	-3.7150951904	-2.87094775860566	-2.81855044317	5.14185356812443	7.62067109540697	0.00102750517943932	0.022650362265324	0.433883467277918	1.15076869287076
DOCK4	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.333538609863667	0.338194810245	-0.0140413363297541	0.0436894050189	-6.43228064654109	12.5012848236707	2.67796644151694e-05	0.000851455080023563	-0.464794563320148	-0.230365329066693
DOCK9	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.123399526684	-0.123399526684	0.180326128536955	0.215520353965	9.26256680006195	9.4426754415628	4.81522916895697e-06	0.000175982242051557	0.230074755746256	0.377376554695655
DOCK9	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.115267479635	-1.115267479635	-0.82585697501071	-0.696430068405	4.50698195743976	43.4070721822179	4.9212227290271e-05	0.00148704461622677	0.159946116547878	0.418874892700702
DOCK9	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.51649691064	0.51649691064	-0.0565228072157892	0.106263594851	-9.84227899691717	35.0577329911885	1.26058295889628e-11	9.31974767151708e-10	-0.691206104925329	-0.45483333078625
DOCK9	BRD-A26503646-001-16-6::2.5::HTS002	2.5	formestane	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.114496628476	-0.114496628476	0.144410815731342	0.129884484973	6.76956824451924	45.9672781560157	2.02770508602517e-08	1.04294697236066e-06	0.181921195227924	0.335893693186761
DOCK9	BRD-A31095847-001-02-3::2.5::HTS002	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.547701597143	0.547701597143	0.0221473007157643	0.0703858703435	-13.3712587577548	10.4132013196897	6.85650193446357e-08	3.29421027373154e-06	-0.612662024621949	-0.438446568232522
DOCK9	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3902233663985	0.3902233663985	0.205883355809962	0.2241591843385	-5.79508346249779	187.804074964661	2.83797920977486e-08	1.43052974142012e-06	-0.247090292198879	-0.121589728978197
DOCK9	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.1841590673045	0.1841590673045	0.0743284029367507	0.128125201883	-3.76075416788314	174.265696403978	0.000231067676729915	0.00601025535022403	-0.167470573261344	-0.0521907554741542
DOCK9	BRD-A68631409-001-05-4::2.5::HTS002	2.5	evodiamine	ATPase inhibitor, TRPV agonist	targeted cancer	TRPV1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.66018967167	-1.66018967167	-2.38458898357517	-2.305746334225	-6.10064705274485	5.19614369800594	0.00149475864457525	0.0313473704044196	-1.02620056792457	-0.422598055885772
DOCK9	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3048733406005	0.3048733406005	0.142403390995274	0.135666555282	-5.05607852857046	8.97425118069789	0.000690728852172265	0.0159684202521011	-0.235192983339005	-0.0897469158714468
DOCK9	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.793150961636	0.793150961636	0.40892895380156	0.462027349437	-9.83920838808531	9.73813732850446	2.26164115564428e-06	8.7497344268607e-05	-0.4715492278038	-0.296894787865079
DOCK9	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.2004909839285	0.2004909839285	-0.0524816047020122	-0.0230394948173	-7.18145298483155	13.7919577888127	5.11522704024839e-06	0.00018604131958415	-0.328631521645429	-0.177313655615595
DOCK9	BRD-A95696066-003-13-8::2.5::HTS002	2.5	nisoxetine	norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.66863368187	0.66863368187	0.334969446087359	0.334888037039	-13.6766892667013	15.688806270936	3.9336526470448e-10	2.44304792288747e-08	-0.385466142185677	-0.281862329379605
DOCK9	BRD-K09900591-001-26-7::2.5::HTS002	2.5	caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	noncancer	ALOX5, MIF	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.6121011005765	0.6121011005765	-0.0605430210047226	-0.0732110977947	-20.9067216232174	142.152033868065	3.31849461934522e-45	5.34774160353115e-42	-0.736244627515413	-0.609043615647033
DOCK9	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.917727531067	0.917727531067	0.33342964571326	0.34680571662	-12.0604321655199	2.88374402252426	0.00147919596530643	0.0310605067157991	-0.74205618791181	-0.42653958279567
DOCK9	BRD-K14880289-001-02-2::2.5::HTS002	2.5	GW-501516	PPAR receptor agonist	noncancer	PPARA, PPARD	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.588118630109	0.588118630109	0.296605993019644	0.308945987709	-11.5713961099758	41.1111013108809	1.64411827837066e-14	1.63366818027308e-12	-0.342385789712507	-0.240639484466205
DOCK9	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.1171222948269	0.1171222948269	0.310670876743695	0.322928237233	5.11350875009118	7.16987969628439	0.00128135891087993	0.0274589722021867	0.104474600403147	0.282622563430443
DOCK9	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.439528649245	-1.439528649245	-0.869326915218106	-0.775615128041	6.75344666745198	11.997027779991	2.03638945544161e-05	0.000662302451586259	0.386236856167307	0.754166611886481
DOCK9	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.278003891995	0.278003891995	-0.829262688678126	-0.81565114113	-14.7622016575062	9.53156787304875	6.96125363881334e-08	3.34154206305313e-06	-1.2755123480477	-0.939020813298555
DOCK9	BRD-K19412355-001-01-0::2.5::HTS002	2.5	SB-242235	p38 MAPK inhibitor	noncancer	HSPB1, MAPK14	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3741130590575	0.3741130590575	0.111005274965412	0.111624443211	-6.87281844171261	10.4298140968591	3.51148320017046e-05	0.00109121746093858	-0.347932139284484	-0.178283428899691
DOCK9	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.1903268538125	-0.1903268538125	0.102494136373338	0.137732029225	11.0779461655599	11.3934191950689	1.90655769436602e-07	8.63000219801004e-06	0.234886982256357	0.350754998115319
DOCK9	BRD-K25412176-001-01-9::2.5::MTS006	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.0453878977614	-0.0453878977614	-0.669027038708254	-0.516853765181	-11.4591972538036	188.845895292889	2.02479962046267e-23	4.50647225186026e-21	-0.730993429563428	-0.51628485233028
DOCK9	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.00349556442315	-0.00349556442315	-1.0471512695619	-0.8676646214495	-13.3675630512232	62.3759777546483	5.67856215290538e-20	9.36936526304894e-18	-1.19970418658714	-0.887607223690363
DOCK9	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.1647204994705	-0.1647204994705	-0.74838799379221	-0.6332790164525	-8.48499306509574	7.62549090549249	3.79775907642615e-05	0.0011725293936781	-0.743659732292107	-0.423675256351314
DOCK9	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.5740823357875	-0.5740823357875	-0.93639932365083	-0.797793160199	-5.07298205668123	101.756089625903	1.76751351501157e-06	6.93318821667121e-05	-0.503984097324041	-0.220649878402619
DOCK9	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.2681502925255	-0.2681502925255	-0.615820732158815	-0.480230640816	-4.87757562475836	16.2446652854119	0.000160714026609025	0.00435690318860179	-0.498591167060635	-0.196749712205996
DOCK9	BRD-K32821942-001-21-3::2.5::HTS002	2.5	azathioprine	dehydrogenase inhibitor	noncancer	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.3577110034275	-0.3577110034275	-0.641007956823684	-0.577859685861	-6.65854417312266	188.915557706355	2.92593213585013e-10	1.84336304745627e-08	-0.367223975765748	-0.199369931026619
DOCK9	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.519740267715	-1.519740267715	-1.97338023300129	-2.04775511057	-5.8010833416521	13.0625091575044	6.04813271250436e-05	0.00179616216729714	-0.622496881061781	-0.284783049510808
DOCK9	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	1.02400808102	1.02400808102	0.569767647157913	0.566004994618	-14.1165588198133	155.283636733318	1.22749979396857e-29	4.81847625167565e-27	-0.517803220221098	-0.390677647503075
DOCK9	BRD-K36788280-001-01-2::2.5::HTS002	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.34070887873	-1.34070887873	-1.06262456896046	-0.990767487764	3.92407582268852	184.355483537813	0.000122798852645102	0.00341322205791364	0.138271311642366	0.417897307896707
DOCK9	BRD-K37723606-001-01-5::2.5::HTS002	2.5	dioscin	apoptosis stimulant	targeted cancer	CXCR3	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.4131107839755	-0.4131107839755	-1.01235131937601	-0.8558575413485	-7.67710433860076	67.0250427860598	9.17508682090107e-11	6.1171487140526e-09	-0.755038978042207	-0.443442092758805
DOCK9	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.164187483785	-0.164187483785	-1.0229815575728	-1.03228700688	-9.78290484479939	4.29949438374634	0.000425428002827549	0.0103792326030763	-1.09597291641896	-0.621615231156638
DOCK9	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.1027252863026	0.1027252863026	-0.517859287230187	-0.465030888818	-8.81622129461415	3.44265557603679	0.00176106574512733	0.0359988040140577	-0.82915547860352	-0.412013668462054
DOCK9	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.02293944221852	0.02293944221852	-1.29894249559775	-1.33795379646	-15.6063470766056	40.5230897799115	9.79826951295518e-19	1.43544313495706e-16	-1.49300136695866	-1.15076250867388
DOCK9	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.428141358405	-1.428141358405	-2.29707132160865	-2.14029239454	-8.2013819336055	7.7306633029248	4.44737947661283e-05	0.0013545579022921	-1.11473889274021	-0.623121033667087
DOCK9	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-2.48709019855	-2.48709019855	-3.24392058888218	-3.15387343916	-10.5112633340322	73.2571181769381	2.79674342715797e-16	3.29016248277399e-14	-0.900321382881534	-0.613339397782824
DOCK9	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.0107673580525	-1.0107673580525	-1.74749213581305	-1.65992199057	-7.3709835457484	5.40975074057074	0.000511519009179965	0.0122304058142049	-0.98790829060174	-0.485541264919368
DOCK9	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-5.05272315566	-5.05272315566	-3.73903326302287	-3.638458649165	9.43751878025476	4.73187923309802	0.000302337942104414	0.00762799161781012	0.949683218052797	1.67769656722147
DOCK9	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.1863125274575	-0.1863125274575	-0.698754722368124	-0.636668754802	-8.14062135388222	7.45015182986067	5.7729687499019e-05	0.00171992579816197	-0.659488463725187	-0.36539592609606
DOCK9	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-6.085802445425	-6.085802445425	-5.27195281230106	-5.30447708423	9.8964914277315	126.912257114092	1.8338763764981e-17	2.39520347287302e-15	0.651117995000752	0.976581271247121
DOCK9	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.08806370842815	0.08806370842815	-0.298063574704193	-0.290098649131	-7.37272683085872	11.4462425000222	1.12420433223293e-05	0.000383433466459504	-0.500852199001524	-0.271402367263162
DOCK9	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.06293933119585	-0.06293933119585	-0.324760684870016	-0.2394985033815	-5.2578730919735	71.9386044925861	1.43300106539007e-06	5.71198968465667e-05	-0.361089428565103	-0.162553278783228
DOCK9	BRD-K51967704-001-03-6::2.5::MTS010::PROS004_PR500	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.6084228348865	-0.6084228348865	-1.39309187673078	-1.39474896106	-8.36918260371273	18.1606337530653	1.19864869539796e-07	5.59462491803025e-06	-0.981520274356427	-0.587817809332134
DOCK9	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3873759696045	0.3873759696045	0.256376859267496	0.250850268444	-4.05434846092767	36.9205014848054	0.000249065835341361	0.00642847199215781	-0.196471702511558	-0.06552651816245
DOCK9	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.5738631282255	0.5738631282255	0.300274980758507	0.2999355775105	-11.9929344608399	58.6606448496082	2.02241742136576e-17	2.62704668790244e-15	-0.319241268711898	-0.227935026222087
DOCK9	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.02139093394145	0.02139093394145	-0.51304278301805	-0.339269333107	-8.98349126318908	175.109307683839	4.09666800023617e-16	4.74870068049009e-14	-0.651844691012087	-0.417022742906914
DOCK9	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-2.696876691325	-2.696876691325	-3.15591936592811	-3.19197499768	-4.23681790490548	25.6870589808324	0.000256808141309668	0.00659652829802971	-0.681883388655055	-0.236201960551159
DOCK9	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.0941765702112	-0.0941765702112	0.0387755512500576	0.0957301689988	3.96878655415656	24.3927206347483	0.000556547983911576	0.0131820502645358	0.0638715368418811	0.202032706080634
DOCK9	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.7855472069235	-0.7855472069235	-0.244277997003892	-0.116969809946	9.51225414986764	41.1746784738644	5.97232380894913e-12	4.57321253893626e-10	0.426367472517582	0.656170947321634
DOCK9	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-4.83730182247	-4.83730182247	-3.98240495759231	-4.06345371982	7.02261266735354	13.9610808434167	6.12126408920048e-06	0.000219575633635857	0.593733227680101	1.11606050207527
DOCK9	BRD-K62814476-001-03-3::2.5::HTS002	2.5	BMS-265246	CDK inhibitor	targeted cancer	CDK1, CDK2	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.3394504488	-1.3394504488	-2.54936547927998	-2.46335728498	-9.93774977810741	3.73996504574331	0.000800346120316489	0.0181963916008606	-1.55741943490828	-0.862410626051688
DOCK9	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.470673992847	-0.470673992847	-0.167758723278198	-0.0695637223616	6.08661828789712	175.472446670431	7.06136995424707e-09	3.8257238648226e-07	0.204695516738639	0.401135022398965
DOCK9	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.380364175145	0.380364175145	-0.222754530549857	-0.209793035138	-11.0251743294025	43.33127949206	3.71148347684475e-14	3.57033751763921e-12	-0.713415005240282	-0.492822406149432
DOCK9	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.06745134554505	0.06745134554505	-1.0900138692572	-0.4202572111255	-9.7610189164071	86.3765177628954	1.3334136538592e-15	1.46709042617038e-13	-1.39318052621651	-0.921749903387999
DOCK9	BRD-K66175015-001-09-0::2.5::HTS002	2.5	afatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.4301082427465	-0.4301082427465	-0.916358987956248	-0.7732511578805	-4.30691955676563	11.0082662884928	0.00123938808628835	0.026686438531856	-0.734718964228814	-0.237782526190682
DOCK9	BRD-K67868012-001-07-6::2.5::HTS002	2.5	PI-103	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.022597475050585	0.022597475050585	-0.528540398084833	-0.5017718155375	-12.9738982680515	40.1160288170791	6.12162702502445e-16	6.94569718711734e-14	-0.63698646076382	-0.465289285507016
DOCK9	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.271899590666	0.271899590666	-0.0108695590590828	-0.0198550434605	-4.50514723946191	7.6279877656428	0.002241677916277	0.0442368645721143	-0.428745266183003	-0.136793033267163
DOCK9	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.0487002966688	0.0487002966688	-0.153439836135623	0.0599731342785	-3.17907645169179	167.119950134276	0.0017608009116073	0.0359988040140577	-0.32767259763756	-0.0766076679712871
DOCK9	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.505440780336	-0.505440780336	-0.207927709495539	-0.182274470613	11.3754963160322	95.0055818447618	1.97701228004705e-19	3.10198437020647e-17	0.245591145110696	0.349434996570226
DOCK9	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.07439316121525	0.07439316121525	-0.196670660987456	-0.145323520972	-5.3999325837359	13.5787736839827	0.000104114090984201	0.00294000909177245	-0.37904120666051	-0.163086437744902
DOCK9	BRD-K77677632-003-02-6::2.5::HTS002	2.5	SB-200646	serotonin receptor antagonist	noncancer	HTR2B, HTR2C	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.376382296715	0.376382296715	-0.621457495564027	-0.496261939988	-11.0202747665141	5.44372454996912	6.2929907322795e-05	0.00186114310840173	-1.22500294952216	-0.770676635035893
DOCK9	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.7172932354625	-0.7172932354625	-1.6977336650401	-1.42296021894	-10.2285128520096	21.4533832320978	1.04141981460239e-09	6.1830046383356e-08	-1.17952283583476	-0.781358023320442
DOCK9	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.0078645672389	-0.0078645672389	-0.324980286219244	-0.193950713334	-4.79202113808146	6.52668525174241	0.0024058607104965	0.0469836647125289	-0.475926662748247	-0.158304775212441
DOCK9	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3550504730495	0.3550504730495	0.00186957443695684	0.041364371782	-8.45315851069369	5.80815085536059	0.000177765208572361	0.0047655083662421	-0.456239349445454	-0.250122447779632
DOCK9	BRD-K90647725-001-07-3::2.50156::HTS002	2.50156	oleanolic-acid	G protein-coupled receptor agonist	noncancer	GPBAR1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.2958097614715	-0.2958097614715	0.124784202465415	0.1471527723635	14.4272482465231	17.8258956620168	2.85306464052645e-11	2.0154729444278e-09	0.359303401584867	0.481884526288964
DOCK9	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-3.45864257724	-3.45864257724	-4.01823096197742	-3.85901121156	-4.11824281519867	11.9777712594767	0.00143054836985866	0.0301868663545768	-0.855707241403342	-0.263469528071499
DOCK9	BRD-K91701654-001-03-1::2.66738::HTS002	2.66738	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.1345498597825	0.1345498597825	-0.0792899359391825	-0.00292791542841	-4.38823474766305	17.9343951588694	0.000357360107748276	0.00888236513203992	-0.31624511220535	-0.111434479238015
DOCK9	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3221674417145	0.3221674417145	-0.303944768609364	-0.183745665678	-10.7060852870865	156.539238415066	2.05113668177383e-20	3.53675039314484e-18	-0.741627666473495	-0.510596754174233
DOCK9	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.674085839199	-0.674085839199	-1.42521785287236	-1.12582537284	-8.07900134165213	99.6895343925328	1.5634535078846e-12	1.27363522193614e-10	-0.935595574611489	-0.566668452735233
DOCK9	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.827623597297	0.827623597297	-0.30462607319754	-0.214794605924	-11.7794362841281	4.36013270152397	0.00018059256776764	0.0048322377599339	-1.39065147648067	-0.873847864508413
DPP3	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.757381823675	-1.757381823675	-1.22952077871366	-1.016750192265	4.96617098825151	11.4726192945124	0.000374406201103189	0.00927057609476034	0.295085826888179	0.760636263034505
DPP3	BRD-A31095847-001-02-3::2.5::HTS002	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.335767767969	-0.335767767969	0.0314961828862616	0.0832482326418	10.8830701742404	134.876289297449	3.45056646969889e-20	5.83246420255594e-18	0.300523491355435	0.434004410355088
DPP3	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.012517359777925	-0.012517359777925	0.210167831620349	0.242459349924	5.78502691384877	9.36717215413016	0.000226966468875216	0.00591218963387898	0.136124670955022	0.309245711841527
DPP3	BRD-A70858459-001-01-7::2.5::HTS002	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.219491814146	-0.219491814146	0.10357397277335	0.0978091979841	8.72334200432496	6.5062260140843	7.97686573063026e-05	0.00230942352748458	0.234127313831693	0.412004260007008
DPP3	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.06864828440965	-0.06864828440965	0.212909788166147	0.255620963174	5.935203033125	16.1125000670379	2.03426286336789e-05	0.00066181166551727	0.181049644660483	0.382066500491112
DPP3	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.407415329459	0.407415329459	0.260610166131087	0.303778240807	-3.9069801035204	192.897362402443	0.000129240536960844	0.00357327077480401	-0.22091596967486	-0.0726943569809655
DPP3	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.12619200223	-3.12619200223	-2.30886254595251	-2.417981872085	9.1598309187144	5.9243199986003	0.000102509795567437	0.00289852532640807	0.598314233733769	1.03634467882121
DPP3	BRD-K04430056-236-02-1::2.5::HTS002	2.5	7-nitroindazole	nitric oxide synthase inhibitor	noncancer	NOS1, NOS2, NOS3	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.565834685198	0.565834685198	0.305725265356378	0.309926543901	-9.8596017479195	114.267265334908	5.78229595959754e-17	7.24321280376728e-15	-0.312369322758436	-0.207849516924809
DPP3	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.8247403751575	-0.8247403751575	-0.415199868581658	-0.389042162364	12.1680383968925	188.143803199222	1.66909627851732e-25	4.44944945619823e-23	0.343146791188916	0.475934221962767
DPP3	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.3936300720135	0.3936300720135	0.506848270056344	0.511327989939	4.81576597363996	124.539107390838	4.1729702160093e-06	0.000154284721998802	0.0666874962397497	0.159748899845938
DPP3	BRD-K13566078-001-02-3::2.5::HTS002	2.5	BMS-345541	IKK inhibitor	targeted cancer	CHUK, IKBKB	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.764206799075	-1.764206799075	-1.48245822438362	-1.48395465403	4.29187674078792	23.9757179116102	0.000251904356023051	0.00648923181755584	0.146252687845262	0.417244461537503
DPP3	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.648450081199	0.648450081199	-0.0607383529031479	0.1891566141585	-9.20053794837147	11.4070303158659	1.28599855554722e-06	5.16735628818672e-05	-0.878107322749801	-0.540269545454494
DPP3	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.246391274277	0.246391274277	-0.191903203209441	-0.123671466435	-10.1904320966653	43.598949942543	4.1372485657803e-13	3.57265248934378e-11	-0.524998752919576	-0.351590202053305
DPP3	BRD-K18849474-001-04-4::2.60504::HTS002	2.60504	dalcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.17735082919	0.17735082919	0.301782280339207	0.287686302566	4.51753731776454	160.328516958082	1.20791688620056e-05	0.000409703463051876	0.0700354356210035	0.178827466677411
DPP3	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.64993252645	-1.64993252645	-0.867168926733952	-0.775615128041	10.5101056821522	89.5389586207642	2.6569790699033e-17	3.41817327174853e-15	0.634791194943979	0.930736004488117
DPP3	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.65430347639	-1.65430347639	-0.677128067959071	-0.587603052309	13.2822211357273	4.52944111708726	8.45232902521894e-05	0.00243459108674392	0.781992175031843	1.17235864183001
DPP3	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-4.967942212085	-4.967942212085	-4.16895958217649	-4.1358778776	6.90077203226436	5.56684796027657	0.000629366017116517	0.0146780619241095	0.510244900118191	1.08772035969883
DPP3	BRD-K25596805-001-01-8::2.5::HTS002	2.5	JNJ-16259685	glutamate receptor antagonist	noncancer	GRM1	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.137694026938	0.137694026938	0.394773252571655	0.392933353126	6.27388285905324	6.19546704810684	0.000672995585905937	0.0155853561244337	0.157576168037598	0.356582283229712
DPP3	BRD-K28453807-003-11-2::2.5::HTS002	2.5	nitrocaramiphen	cholinergic receptor antagonist	noncancer	CHRM1	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4792118130285	0.4792118130285	0.355830165348081	0.3384293751915	-4.59035487002967	142.66090853051	9.62072579760524e-06	0.000332741736239298	-0.176513158023329	-0.0702501373375097
DPP3	BRD-K28907958-001-04-3::2.5::HTS002	2.5	CD-437	retinoid receptor agonist	targeted cancer	RARG	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.76595403213	-3.76595403213	-4.20821276583372	-4.123946828915	-4.00176244774517	10.4833216316596	0.00228661643844315	0.0450076420823842	-0.686973480683498	-0.197543986723949
DPP3	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.16768886375	-0.16768886375	-0.880124794630451	-0.7074523288895	-6.57109975610263	9.95016440673632	6.45207679655836e-05	0.0019029409216039	-0.954173932441998	-0.470697929318903
DPP3	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.137203135305	-3.137203135305	-3.66608815089796	-3.65355610334	-4.89396473705076	32.0624643947813	2.69176395835414e-05	0.000854973297765461	-0.748997189225002	-0.308772841960925
DPP3	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.2408186106875	-0.2408186106875	0.0406589448036049	0.0420255810144	12.2008728062044	12.0283322033377	3.9204088373328e-08	1.93965213688066e-06	0.231224861194135	0.331730249788074
DPP3	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.687515205928	0.687515205928	0.408529030683154	0.431801339153	-10.2064123195653	14.8583547344204	4.17232273411567e-08	2.05763865457956e-06	-0.337296485663521	-0.220675864826171
DPP3	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.250690893954	-0.250690893954	-0.700266585421208	-0.5759216002185	-7.1379465972105	186.130466474672	2.05624640210603e-11	1.47741614186049e-09	-0.573829759826506	-0.325321623107909
DPP3	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.2036156867745	0.2036156867745	-0.540546012570723	-0.407422571936	-7.70115398369001	3.61298771534897	0.00228978752840324	0.0450576451684849	-1.02417214133402	-0.464151257356427
DPP3	BRD-K42205652-001-02-7::2.5::HTS002	2.5	MNS-(3,4-Methylenedioxy-nitrostyrene)	src inhibitor, syk inhibitor	noncancer	SRC, SYK	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.04436527686945	-0.04436527686945	0.243618392212766	0.262709081551	6.73346075164061	16.6936065125593	3.85248153328173e-06	0.000143077198847122	0.197622551569284	0.378344786595148
DPP3	BRD-K51313569-003-03-3::2.5::HTS002	2.5	palbociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.23259898182	-1.23259898182	-0.753065493573685	-0.730954040019	7.36677343545231	157.619822165392	9.19891230887105e-12	6.92759548927626e-10	0.350964253729541	0.608102722763087
DPP3	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.03689423667255	-0.03689423667255	-0.226972754594912	-0.187297921894	-5.28669959553802	42.8424611445706	3.97507980858677e-06	0.000147477043499151	-0.262594579155623	-0.117562456689101
DPP3	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.2172322910165	0.2172322910165	0.380577338735411	0.394227062385	5.9785084429112	14.9730750885889	2.54816393565336e-05	0.000815020785203177	0.105100375490533	0.221589719947289
DPP3	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.52622556016	-0.52622556016	-1.11366276682585	-1.00700802709	-7.2976298748699	3.9277390322868	0.00201113113540505	0.0402806957406063	-0.812563649386465	-0.362310763945239
DPP3	BRD-K53972329-001-07-0::2.5::MTS010::PROS003_PR500	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.190566698026	-0.190566698026	-0.0115364359777045	-0.0140997876931	6.85966457575528	18.4428763834308	1.78439457798566e-06	6.99428503118306e-05	0.124292563978721	0.23376796011787
DPP3	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.6472821379	-3.6472821379	-2.93339559275334	-2.87845710522	7.6730377372936	30.5526881158171	1.30220694163301e-08	6.88457601364729e-07	0.524020975903159	0.903752114390167
DPP3	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-4.06186737835	-4.06186737835	-3.66725536381215	-3.47824152187	3.54459216136311	190.775164528815	0.000494566589499431	0.0118687675020517	0.175020306184733	0.614203722890973
DPP3	BRD-K69694239-001-02-2::2.5::MTS010::PROS002_PR500	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.90808039266	-2.90808039266	-2.52223253635637	-2.6020166043	6.45020693307726	10.2888078480134	6.45013100953537e-05	0.00190262885926604	0.253067205364124	0.518628507243141
DPP3	BRD-K70821460-300-02-4::2.5::HTS002	2.5	4-methylhistamine	histamine receptor agonist	noncancer	HRH4	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.200656259478	-0.200656259478	0.484242156134053	0.473971299308	19.7079437173695	9.86647694274645	2.98909770606382e-09	1.69170932728533e-07	0.60732295774581	0.762473873478297
DPP3	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.3113246189095	0.3113246189095	-0.535603400818256	-0.376499820922	-14.6120682809283	22.0438512194163	8.04308340029036e-13	6.76025891019935e-11	-0.967117620490602	-0.72673841896491
DPP3	BRD-K71847383-001-12-5::2.5::HTS002	2.5	cytarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.6263632775445	0.6263632775445	0.326329315644939	0.311150220691	-8.31404495405966	5.2112913056715	0.000336146101280582	0.008398910904799	-0.391680153932745	-0.208387769866377
DPP3	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.0881492101136	-0.0881492101136	0.244730134830527	0.276258886308	8.48496522826897	29.0291594604222	2.36550024343706e-09	1.35054688778802e-07	0.252645073937173	0.413113615951081
DPP3	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.6969081165445	-0.6969081165445	-0.188508742704284	-0.131154903569	10.7595399211875	28.8384688174025	1.30763380156394e-11	9.65428332950042e-10	0.411736643129996	0.605062104550436
DPP3	BRD-K76973696-001-12-6::2.01421::HTS002	2.01421	tryptanthrin	cyclooxygenase inhibitor	targeted cancer	IDO1	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.76728003703	-1.76728003703	-1.38258546030189	-1.323892199525	6.6707282939929	5.83948516144519	0.00061445152843732	0.0143677483786212	0.242637894483104	0.526751258973111
DPP3	BRD-K78789465-001-01-6::2.5::HTS002	2.5	pentagastrin	CCK receptor agonist	noncancer	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.449723907409	0.449723907409	0.142387116599813	0.1708900100665	-5.61270431429535	25.2021147022104	7.49368251534677e-06	0.00026398318972514	-0.420065813646298	-0.194607767972076
DPP3	BRD-K82850175-001-01-1::2.5::HTS002	2.5	navarixin	CC chemokine receptor antagonist	targeted cancer	CXCR1, CXCR2	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.575536919921	-0.575536919921	-0.885312019124192	-0.794282488065	-4.53044319094951	12.4428494330111	0.000629708558405904	0.0146828552670343	-0.458168382196903	-0.161381816209481
DPP3	BRD-K83003151-057-02-4::2.34747::HTS002	2.34747	alogliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.555231883387	0.555231883387	0.243048412323971	0.320568591806	-7.46370539145633	103.431423938796	2.73521806729641e-11	1.94118063955487e-09	-0.395133100078918	-0.22923384204714
DPP3	BRD-K83029223-001-01-3::2.5::MTS006	2.5	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.1303439824	-1.1303439824	-2.43344760798961	-2.31559247235	-12.6717052154604	163.521528371249	4.5039661853485e-26	1.25367606303839e-23	-1.50616067935562	-1.10004657182359
DPP3	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-5.639420589045	-5.639420589045	-4.83346805687904	-4.95161811894	7.09180643227549	7.62542360863572	0.000129811083713583	0.00358765696469999	0.541627561164279	1.07027750316765
DPP3	BRD-K86972824-001-01-4::2.5::HTS002	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.30879458462	-0.30879458462	0.011351127922023	0.002128528664087	8.71421137573383	8.98574955115953	1.12237109104592e-05	0.000382930075728719	0.237017704618653	0.403273720465393
DPP3	BRD-K89391146-001-08-0::2.5::HTS002	2.5	RG108	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3B	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.605477087282	0.605477087282	0.377922435339453	0.397149460871	-8.97997457885404	189.977379740217	2.65692784069423e-16	3.13404891121714e-14	-0.277539014650985	-0.17757028923411
DPP3	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.234797024801	0.234797024801	-0.277275203067573	-0.208293631699	-7.99950450461852	4.31393319293133	0.000958731630056246	0.0213224023594817	-0.684814394711335	-0.339330061025811
DPP3	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.4696605177945	-0.4696605177945	-1.41716733038945	-1.39259151278	-11.9691898123052	120.26245712008	3.19354987625837e-22	6.43904375755955e-20	-1.10423887878896	-0.790774746400942
DPP3	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.853304337005	-1.853304337005	-1.24424474626408	-1.23927241763	7.86754125075746	23.9467326958522	4.30210938176895e-08	2.11289367938854e-06	0.449265678044791	0.768853503437054
DPP3	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.3569311529215	-0.3569311529215	-0.0725115403835063	-0.0594618685141	5.20531684446085	14.8498748348809	0.000110176366468752	0.0030940763166773	0.16785412834006	0.400985096735927
DPP3	BRD-K97010173-001-04-1::2.5::HTS002	2.5	deferasirox	chelating agent	noncancer	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	NCIH358, KYSE410	LUNG, OESOPHAGUS	carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.20447011055	-0.20447011055	0.0525088898887921	0.111819102778	6.17503984699987	133.023447722501	7.48579660625144e-09	4.04544453056295e-07	0.174664764641612	0.339293236235973
EHMT1	BRD-K03406345-001-27-8::2.5::HTS002	2.5	azacitidine	DNA methyltransferase inhibitor	chemo	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.187115850445	0.187115850445	-0.591274993253225	-0.567938192977	-15.5737185397941	9.5293338138627	4.2696522259177e-08	2.09791447026299e-06	-0.890505668562195	-0.666276018834255
EHMT1	BRD-K09372874-001-01-0::2.5::HTS002	2.5	merimepodib	inosine monophosphate dehydrogenase inhibitor	noncancer	IMPDH1	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.161084439375	-1.161084439375	-0.897338150234797	-0.886556137179	4.9440503592109	177.030993404202	1.76699340128189e-06	6.93318821667121e-05	0.158469977486711	0.369022600793695
EHMT1	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.647486355165	-1.647486355165	-2.51792956254299	-2.34739362698	-7.26662255379594	18.8116282975173	7.19666437637861e-07	3.00673270784571e-05	-1.12132924193447	-0.619557172821517
EHMT1	BRD-K11071038-001-01-7::2.5::HTS002	2.5	ICI-162846	histamine receptor antagonist	noncancer	HRH2	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.05479560598955	-0.05479560598955	0.0975125474273464	0.0637321133413	4.38759934234837	18.7378001052367	0.00032595229513156	0.00816705979229041	0.0795834601958956	0.225032846637897
EHMT1	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.01150598422955	-0.01150598422955	-0.516118590729156	-0.419130200084	-5.94517845319456	4.64965289207153	0.00245947610830302	0.0478921151029896	-0.72783622707825	-0.281388985920962
EHMT1	BRD-K13167095-001-02-9::2.5::HTS002	2.5	AR-42	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.781399379525	-1.781399379525	-3.26779918476627	-3.28129580755	-11.4003781507198	16.3640576485705	3.36037266662191e-09	1.89383463913859e-07	-1.76229758527274	-1.21050202520981
EHMT1	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.3487253928705	-0.3487253928705	-0.056942351332789	-0.0602706039178	6.72446379083538	5.10712257274943	0.00101391426539254	0.0223871706502714	0.180942257943524	0.402623825131898
EHMT1	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.627605198725	-0.627605198725	-0.442270232010599	-0.343450980127	4.10247158780085	29.6563296019661	0.000292822726046049	0.00741235408653875	0.093027559461427	0.277642373967374
EHMT1	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.278601943075	-1.278601943075	-3.05732967461464	-3.177325410155	-13.9155258469175	6.24394671777726	6.20185662798592e-06	0.000222317733604214	-2.08856158974025	-1.46889387333904
EHMT1	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.25109670079	0.25109670079	0.0978719001994899	0.13724327771	-6.86331898164466	190.126723248491	9.24227028275318e-11	6.15755843155799e-09	-0.197261650247368	-0.109187950933652
EHMT1	BRD-K27184429-300-01-3::2.5::HTS002	2.5	levocetirizine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.10980806104595	0.10980806104595	-0.358380828678188	-0.252619761318	-9.60169485646252	57.7867590876111	1.42117306011612e-13	1.28631165879066e-11	-0.565802440073322	-0.370575339374954
EHMT1	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.483300396401	0.483300396401	0.167741738487015	0.159843684784	-10.4321022993504	7.83731743689756	7.1993426051362e-06	0.000254499076565436	-0.385565367804905	-0.245551948023064
EHMT1	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.43466303432	-1.43466303432	-2.63058188022708	-2.459947367395	-11.1883049737516	11.0233486568065	2.33536619941279e-07	1.04474369057387e-05	-1.43112154900974	-0.960716142804422
EHMT1	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.06019368403465	-0.06019368403465	-0.795257438258348	-0.4002530483955	-6.5612926717173	185.409641976259	5.1751770119929e-10	3.17364953877948e-08	-0.956081801587899	-0.514045706859498
EHMT1	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-6.164941183685	-6.164941183685	-5.92073713380775	-5.9507974936	3.50429046107007	114.322390549883	0.000654652867839923	0.0152049300510688	0.106158498441892	0.382249601312611
EHMT1	BRD-K53734668-003-02-0::2.65747::HTS002	2.65747	PRT062607	syk inhibitor	targeted cancer	FGR, MAP3K9, SYK	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.3417175191005	0.3417175191005	-0.0684284351044472	-0.0530930824029	-9.67742133436325	192.994607981821	2.62167234140681e-18	3.70158373689974e-16	-0.493736817083121	-0.326555091326773
EHMT1	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.2667092970955	0.2667092970955	-0.515611561689821	-0.339269333107	-12.4123638617804	43.7646315354682	6.22091184987488e-16	7.05461278239065e-14	-0.90936383295644	-0.655277884614202
EHMT1	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.1273782085955	0.1273782085955	-0.394524136756947	-0.201440599557	-8.2358292806817	179.991821210912	3.54721214931449e-14	3.41694576517045e-12	-0.646945504468202	-0.396859186236692
EHMT1	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.615293440562	0.615293440562	0.230563154123864	0.271076937361	-8.29185757623941	7.79924973639473	3.91153138339849e-05	0.00120384062302185	-0.492206843504001	-0.277253729372271
EHMT1	BRD-K60184833-001-05-6::2.5::HTS002	2.5	tyrphostin-AG-99	tyrosine kinase inhibitor	targeted cancer	EGFR	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.22174992739	-1.22174992739	-1.69045866868693	-1.52742041275	-5.09076557083088	11.5071309994582	0.000303121066698886	0.00764594975926863	-0.670269986203817	-0.267147496390042
EHMT1	BRD-K69172251-001-08-9::2.5::HTS002	2.5	cisplatin	DNA alkylating agent, DNA synthesis inhibitor	chemo	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.5167176420455	0.5167176420455	0.379817170228924	0.369534361464	-5.06969102624983	47.5963989162123	6.46919884610821e-06	0.000230897072354293	-0.191206968456517	-0.0825939751766352
EHMT1	BRD-K70177501-003-01-4::2.5::HTS002	2.5	INH1	Hec1 inhibitor	targeted cancer	NDC80	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.1107966928919	-0.1107966928919	0.164524374030912	0.175739960051	9.49620476527825	8.18759260027016	1.06459584793786e-05	0.000364902868211535	0.208729369721763	0.34191276412386
EHMT1	BRD-K70511574-001-06-9::2.5::HTS002	2.5	HMN-214	PLK inhibitor	targeted cancer	PLK1	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-3.75900462081	-3.75900462081	-2.82189916138706	-2.78074740787	9.75935933866399	171.412443508724	3.59279680383188e-18	5.02309553925951e-16	0.747569189506528	1.12664172933935
EHMT1	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-3.41658975033	-3.41658975033	-2.9197108808513	-2.84610122618	4.24912853662113	10.9794213415097	0.00137343237388786	0.029119281385044	0.239444163673818	0.754313575283571
EHMT1	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-2.938259040055	-2.938259040055	-2.31659596751131	-2.223018080895	7.01042144278683	120.584475942658	1.47819799312929e-10	9.59771880246616e-09	0.446097470777729	0.797228674309659
EHMT1	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.954103515001	-0.954103515001	-0.418282622974227	-0.2259650044755	8.14230753676875	131.071024385499	2.64690284087349e-13	2.33172231393989e-11	0.405639591510555	0.66600219254299
EHMT1	BRD-K80431395-001-07-3::2.48737::HTS002	2.48737	triciribine	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.58864282556	-0.58864282556	-0.940833587796343	-0.783018318744	-5.27855359502867	67.7300464525932	1.48204903400265e-06	5.89872028614213e-05	-0.485340200705451	-0.219041323767235
EHMT1	BRD-K84564571-001-02-4::2.5::HTS002	2.5	telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.169195999184	0.169195999184	-0.188180318698866	-0.150870587106	-7.88295323713402	26.093320766927	2.27128767743769e-08	1.16209791505739e-06	-0.450548213519419	-0.264204422246314
EHMT1	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.110734698965	-1.110734698965	-1.70615954718937	-1.55120007366	-8.26063662192544	36.0022175965358	7.86485693967697e-10	4.7350194466967e-08	-0.741609099543851	-0.449240596904894
EHMT1	BRD-K92000912-001-12-6::2.5::HTS002	2.5	AM-251	cannabinoid receptor antagonist	targeted cancer	CNR1, GPR18, GPR55	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.03007670383795	0.03007670383795	-0.128181458578521	-0.0852704438558	-3.94589378753409	20.2275424383828	0.00078417857342941	0.0178819246158689	-0.241859712363826	-0.0746566124691162
EHMT1	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.501170693728	0.501170693728	0.304877121888417	0.301488629615	-7.67805122399097	177.33872574014	1.04542612497421e-12	8.69480543032971e-11	-0.246745419397599	-0.145841724281567
EHMT1	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.926404552251	-0.926404552251	-2.25809472819056	-2.18755983006	-14.1358677682642	24.6809707811221	2.46516895993631e-13	2.17520460277558e-11	-1.52583927537355	-1.13754107650557
EHMT1	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.09574498980105	-0.09574498980105	-1.42108267623232	-1.39259151278	-16.1006037699307	43.5095651596215	6.08426664243e-20	9.95446400920137e-18	-1.49128756448772	-1.15938780837481
EHMT1	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.7708061057325	0.7708061057325	-0.0850419543685507	-0.0625986180944	-14.3274887827217	6.59919005234357	3.2353480843881e-06	0.000121889421616948	-0.998856017760334	-0.712840102441768
EHMT1	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	CAMA1, NCIH1299	BREAST, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.4967635407705	-0.4967635407705	-0.72105940965481	-0.596555071115	-3.44585469761095	31.9688792753702	0.00161307153303944	0.0334683454602914	-0.356887988302642	-0.0917037494659772
EML4	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.3870042438945	-0.3870042438945	-0.833326341531126	-0.720201208535	-6.19020173858738	9.66336146565373	0.000118955974402525	0.00331543758617928	-0.607735834281134	-0.284908360992118
EML4	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.247430371835	0.247430371835	-0.0536755422548897	0.106263594851	-5.40025467061725	95.634972454828	4.84638934020885e-07	2.07164296150304e-05	-0.411789514700755	-0.190422313479025
EML4	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.377690011215	-3.377690011215	-3.72211578540748	-3.729909299115	-4.47011679150318	74.5719007739224	2.74337260637958e-05	0.000869927958799716	-0.497933149202244	-0.190918399182713
EML4	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.180653316198	-0.180653316198	0.0927097540466093	0.131172819567	7.28715266379205	3.74506029229456	0.00242204632714179	0.0472696018257123	0.166353582543343	0.380372557945876
EML4	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.7886101709595	-0.7886101709595	-0.994881422081892	-0.927705434	-3.34778256950648	190.377609090105	0.000981723825108453	0.0217772599577385	-0.32780563242133	-0.084736869823453
EML4	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.448120350505	-1.448120350505	-0.208434279249352	-0.08022384013305	17.366764128649	6.01781222763711	2.2725797068737e-06	8.78888011538313e-05	1.06514420469905	1.41422793781224
EML4	BRD-A73427433-240-01-3::2.5::HTS002	2.5	adaprev	TGF beta receptor inhibitor	noncancer	IGF2R, M6PR	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.07038493306355	-0.07038493306355	-0.398426629377526	-0.383170209678	-8.5443094921498	163.226635337007	8.73715033059653e-15	8.88341884822781e-13	-0.403852677226017	-0.252230715401935
EML4	BRD-A95696066-003-13-8::2.5::HTS002	2.5	nisoxetine	norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.0113836846547	0.0113836846547	0.34196146733433	0.338484825644	15.6046054517059	187.09378445413	1.0525799394404e-35	7.07205033982197e-33	0.288786343366594	0.372369221992667
EML4	BRD-K00317371-001-06-1::2.40436::HTS002	2.40436	RITA	MDM inhibitor	targeted cancer	MDM2	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.87762182652	-4.87762182652	-2.1610769415694	-1.66153106221	19.749675435663	116.13704341315	6.28781236795941e-39	6.04332079377745e-36	2.44411547020145	2.98897429969975
EML4	BRD-K01669786-001-02-2::2.5::HTS002	2.5	triapine	ribonucleotide reductase inhibitor	chemo	RRM1, RRM2	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.71645413845	-1.71645413845	-3.20514338306676	-3.10063742322	-14.1341840897924	98.0698322777554	2.15055252110814e-25	5.65553093615443e-23	-1.69770230438165	-1.27967618485188
EML4	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.1371818115135	0.1371818115135	-0.364420190970828	-0.264963110089	-7.33195912583094	20.9618528183851	3.2727987121232e-07	1.43417639576907e-05	-0.643890584960591	-0.359313420008065
EML4	BRD-K03601870-001-01-2::2.5::HTS002	2.5	ixabepilone	microtubule stabilizing agent	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.257067044735	-3.257067044735	-3.62919923569409	-3.58404887743	-3.58748925920208	22.8357882630172	0.00157001718676285	0.0326829876718156	-0.586800573628024	-0.157463808290156
EML4	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.5965110821995	-0.5965110821995	-1.13932739647293	-1.07388474495	-6.88633581507107	15.2919582375115	4.66989115838933e-06	0.000171356463291633	-0.710549148786709	-0.37508347976016
EML4	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.4038198453	-2.4038198453	-3.07984364402474	-3.12584681211	-7.16123220450513	188.637020102385	1.73763020507758e-11	1.26160075956665e-09	-0.8622400413221	-0.489807556127371
EML4	BRD-K07310275-001-02-5::2.5::HTS002	2.5	PF-04691502	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.283046678335	-2.283046678335	-3.942207718339	-3.94541046238	-12.1503801564392	3.79523348497554	0.000354489239758141	0.00881612024461853	-2.0464957850691	-1.2718262949389
EML4	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.636727669525	-1.636727669525	-0.840386616592699	-0.6898846907305	14.793149299564	98.2990628866575	9.57191179150638e-27	2.841465765044e-24	0.689517767310528	0.903164338554075
EML4	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.455888439639	0.455888439639	-0.313800645585688	-0.199486634258	-9.32885195120667	3.07881742878606	0.00234560837742599	0.0459745677115075	-1.0284989490403	-0.510879221409075
EML4	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.6066392015045	-0.6066392015045	-2.05076398124888	-1.66463476506	-8.49706530098378	4.48606716551928	0.000624692789502728	0.0145849434511253	-1.89650182236711	-0.991747737121644
EML4	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.676847292694	-0.676847292694	0.0232452473669411	0.2036144024465	10.1505834373865	19.5811876442038	3.04985498381943e-09	1.72336506413666e-07	0.556024719487446	0.844160360634436
EML4	BRD-K12539581-001-23-7::2.5::HTS002	2.5	nocodazole	tubulin polymerization inhibitor	targeted cancer	HPGDS	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.78749648966	-2.78749648966	-3.50564911207331	-3.357933574425	-6.50151127618731	62.9576009096856	1.46889358880912e-08	7.72012000970743e-07	-0.93889090231418	-0.49741434251244
EML4	BRD-K14329163-001-03-9::2.5::HTS002	2.5	BAY-K-8644-(s)-(-)	L-type calcium channel activator	noncancer	CACNA1C	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.03400845331195	-0.03400845331195	0.291304457022259	0.2983677815075	12.5035567655456	187.055748365525	1.8145650009551e-26	5.26270503504338e-24	0.273987224362435	0.376638596305983
EML4	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.0010121850238	0.0010121850238	0.405068551593421	0.440216058218	11.639847651811	15.4759717028097	4.63763546917711e-09	2.57441018511593e-07	0.330264635397595	0.477848097741648
EML4	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.312928515085	0.312928515085	-0.0587298168708321	-0.0387919597267	-7.29876201190792	21.9273569670511	2.66744205507987e-07	1.18440063853991e-05	-0.47728176236232	-0.266034901549345
EML4	BRD-K15409150-001-05-8::2.5::HTS002	2.5	penfluridol	T-type calcium channel blocker	noncancer	CACNA1G	neurology/psychiatry	schizophrenia	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.271962816435	-2.271962816435	-2.85823452671232	-2.6535756676	-5.43122118380659	13.280212596268	0.000106541480295468	0.00299985929194	-0.818972923139903	-0.353570497414743
EML4	BRD-K17743125-001-08-4::2.5::HTS002	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.9312535229405	-0.9312535229405	-2.62629236340105	-2.55701566981	-10.5203346102953	2.98709017170477	0.00186924273744889	0.0378562720093246	-2.20905131366887	-1.18102636725223
EML4	BRD-K18910433-001-36-6::2.58082::HTS002	2.58082	estradiol	estrogen receptor agonist	noncancer	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.019136289195	0.019136289195	0.3103225803941	0.326005969483	9.80974058814459	175.030411903709	2.23116402339273e-18	3.1711084480752e-16	0.232602866627151	0.349769715771049
EML4	BRD-K21396683-001-04-8::2.5::HTS002	2.5	marimastat	matrix metalloprotease inhibitor	targeted cancer	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.796358824876	-0.796358824876	-1.80517235769199	-1.72083973318	-13.3466263130642	167.96292766635	3.64618999424841e-28	1.25037480844363e-25	-1.15803385857021	-0.859593207061761
EML4	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.6355939127695	-0.6355939127695	-0.107417786552544	-0.02484856783435	9.45294044657415	109.625853182057	7.22506642236056e-16	8.14592983292012e-14	0.417442239292244	0.638910013141668
EML4	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.596850397935	0.596850397935	0.410935496416588	0.440703373362	-7.00022927759907	142.891768901454	9.17590858711566e-11	6.1171487140526e-09	-0.238413026376133	-0.133416776660691
EML4	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.2948308129535	-0.2948308129535	-0.167642533244047	-0.149311762512	5.13540240456795	5.8988211983635	0.00225718691679484	0.0445072237293682	0.066332858036079	0.188043701382826
EML4	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.510709315395	-1.510709315395	-0.76719256664957	-0.7406610501725	11.0734276663463	37.3635189251646	2.32976239509823e-13	2.0659315034299e-11	0.607514285594789	0.87951921189607
EML4	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.141962219683	0.141962219683	0.37560370737855	0.395322173914	8.04278234938454	195.540550585323	8.2571951990223e-14	7.63484206130824e-12	0.176350277423423	0.290932697967677
EML4	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.79678838212	-1.79678838212	-2.81585857873979	-2.6496200301	-7.35129526921701	5.03322294320993	0.00071063338658763	0.0163808714899914	-1.37470970597398	-0.663430687265599
EML4	BRD-K24696047-001-02-3::2.5::HTS002	2.5	NVP-AEW541	IGF-1 inhibitor	targeted cancer	IGF1R, INSR	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.146952971688	-0.146952971688	0.168116562897071	0.195838010554	9.90753369930251	186.146474275397	7.48260732205114e-19	1.10602741015717e-16	0.252332830390163	0.377806238779978
EML4	BRD-K25224017-001-25-0::2.5::HTS002	2.5	pirenperone	serotonin receptor antagonist	noncancer	HTR2A, HTR7	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.86216606928	-1.86216606928	-2.55795565311424	-2.47770840728	-6.0383433262597	7.61299769093041	0.00037679369118596	0.00932430608915779	-0.963876754629493	-0.427702413038988
EML4	BRD-K27184429-300-01-3::2.5::HTS002	2.5	levocetirizine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.2455365267525	0.2455365267525	-0.359787341276184	-0.252619761318	-10.3444297569973	6.56396354043704	2.65038563879637e-05	0.000844314065959553	-0.745579656938904	-0.465068079118463
EML4	BRD-K28578425-001-07-0::2.5::HTS002	2.5	cilostamide	phosphodiesterase inhibitor	targeted cancer	PDE3A, PDE3B	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.4130302765285	-0.4130302765285	-0.0832774860195393	-0.0458610158792	7.71725970046199	7.06052370406586	0.000109615527039487	0.00308034434179182	0.228889460269888	0.430616120748033
EML4	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.95753963031	-3.95753963031	-3.62533641771607	-3.57671972887	4.19505327740979	33.1775711078357	0.000191254612775201	0.00508073994812791	0.171124179899027	0.493282245288838
EML4	BRD-K31627533-001-09-5::2.5::HTS002	2.5	rimexolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	ophthalmology	anterior uveitis	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.500445630831	-0.500445630831	0.26907456280525	0.264424524013	18.575815793297	4.36589636450554	2.53712907169657e-05	0.000811733597264747	0.658207023677201	0.880833363595299
EML4	BRD-K31812033-003-11-0::2.5::HTS002	2.5	levobunolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.3553695409535	0.3553695409535	0.171366038933636	0.2093635994345	-4.54766929715057	16.7596586180799	0.000294952012295253	0.00745920588120699	-0.269462216899488	-0.098544787140241
EML4	BRD-K32744045-001-31-2::2.5::HTS002	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.279815014176	0.279815014176	-1.29271974989703	-1.09614559515	-15.9092603018259	138.596566285168	4.52776510338098e-33	2.42002834624075e-30	-1.76797189448282	-1.37709763366325
EML4	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.0740085879224	-0.0740085879224	0.43183866277607	0.4313451016155	9.06108434367096	39.629909805401	3.33642488424421e-11	2.33843233817913e-09	0.392985160468376	0.618709340928563
EML4	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.924577607339	-0.924577607339	-0.0295582123544936	-0.03550064325705	18.8792864713186	18.432908789166	1.64228700567379e-13	1.47584793140066e-11	0.795587380704298	0.994451409264715
EML4	BRD-K37865504-001-04-1::2.5::HTS002	2.5	LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	noncancer	FAAH	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.1728233897975	0.1728233897975	-1.3052660911479	-1.08170547456	-18.3082911468249	167.113413211133	8.70492544304895e-42	1.07844969091517e-38	-1.6374781784783	-1.3187007834125
EML4	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.170907272819	-0.170907272819	-1.79305186659335	-1.67706700871	-15.1710496535268	18.5095904211018	6.85449341170776e-12	5.23189714543416e-10	-1.84634044195329	-1.3979487455954
EML4	BRD-K41312087-001-02-7::2.5::HTS002	2.5	GW-441756	growth factor receptor inhibitor	targeted cancer	NTRK1	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.1294314252435	-0.1294314252435	-0.00639952855808631	0.0338208037479	3.76303543730442	141.394311952811	0.000245247558182635	0.0063429062263456	0.0583979691296854	0.187665824241142
EML4	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.130086904665	-2.130086904665	-2.75271755403398	-2.75783530181	-6.50177829388317	26.6936693272163	6.02358835212632e-07	2.54239792816637e-05	-0.8192259265137	-0.426035372224257
EML4	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.550528953525	-1.550528953525	-0.711837656622127	-0.576037096811	9.19246015841205	188.660295840718	7.09261943666654e-17	8.80738140927754e-15	0.658715806959009	1.01866678684674
EML4	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.06127122380825	0.06127122380825	-0.125542440469134	-0.075355311638	-5.18159580030766	186.247555718642	5.68812922308314e-07	2.40982614796241e-05	-0.25793901342475	-0.115688315130019
EML4	BRD-K48578705-001-17-6::2.5::HTS002	2.5	methyldopa	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.0175169289827	0.0175169289827	0.256746780163776	0.2888342624615	8.4943979395011	191.101688688917	5.54008549804834e-15	5.74734261718878e-13	0.183679099883864	0.294780602478287
EML4	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.53717130895	-2.53717130895	-1.82221196651223	-1.55587758491	7.52139116513219	181.392660050398	2.42309392888282e-12	1.94436278054484e-10	0.527400089431094	0.902518595444443
EML4	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.136730876782	0.136730876782	-0.103940089984767	-0.112273492753	-4.46176008054751	9.18993693861931	0.00149403264933294	0.031338277911419	-0.362310208026457	-0.119031725507078
EML4	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.666012536185	-1.666012536185	-1.10172782466852	-0.990481977481	8.44763907436927	12.4687243370993	1.64332306160338e-06	6.4840167244181e-05	0.4193490399623	0.709220383070655
EML4	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.05090017035835	0.05090017035835	0.228992112044916	0.2141011890955	6.25770598534963	181.255351939249	2.74366256375793e-09	1.55856467963868e-07	0.121937172217609	0.234246711155522
EML4	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.307279732185	-1.307279732185	-0.5744450546245	-0.45596991553	8.94734687204878	26.320133794985	1.82901919197574e-09	1.05834733908469e-07	0.564575634094238	0.901093721026762
EML4	BRD-K58049875-001-04-7::2.5::HTS002	2.5	thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	noncancer	FOXM1	obstetrics/gynecology	mastitis	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.4341824521315	-0.4341824521315	-0.808828823010502	-0.698370160758	-5.82836022371356	115.592440978867	5.16010702080546e-08	2.51468980823605e-06	-0.501965529458797	-0.247327212299206
EML4	BRD-K58122457-001-02-2::2.5::HTS002	2.5	hesperadin	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.59449651822	-3.59449651822	-2.69302990782426	-2.67816134682	7.81843142497564	8.62684904363195	3.38155471105324e-05	0.00105282574036219	0.638909518061856	1.16402370272963
EML4	BRD-K60184833-001-05-6::2.5::HTS002	2.5	tyrphostin-AG-99	tyrosine kinase inhibitor	targeted cancer	EGFR	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.6927814135035	-0.6927814135035	-1.69591195233524	-1.52742041275	-8.64006921978939	3.21476999658153	0.00248752900558914	0.0483538549101139	-1.35903985327372	-0.647221224389765
EML4	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.384253225595	-0.384253225595	-2.09461925611428	-1.79411655002	-13.3561789168001	63.0586723017643	4.78365603520322e-20	7.98501724586504e-18	-1.96626493445252	-1.45446712658603
EML4	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.5370660128245	-0.5370660128245	-1.20518405014723	-1.18840349692	-9.16659854224858	160.951791633408	2.20771323013594e-16	2.63022217288386e-14	-0.812054514178583	-0.524181560466883
EML4	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.9437739944515	-0.9437739944515	-0.223162178620898	-0.157800770878	10.8139267552528	10.8948583050212	3.66419548554335e-07	1.59105217629866e-05	0.573771040984753	0.867452590676451
EML4	BRD-K62696033-001-01-4::2.5::HTS002	2.5	G-1	G protein-coupled receptor agonist	targeted cancer	GPER1	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.649485240568	-0.649485240568	-1.25356785094062	-1.18405970294	-6.97495736425914	14.1533114033972	6.12747903915432e-06	0.000219761789655774	-0.789648319926372	-0.418516900818864
EML4	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.33882282721	-1.33882282721	-2.13663745133546	-2.025815521035	-6.6098858283896	5.35446321273359	0.000912693131741574	0.0204277993142272	-1.10200712484713	-0.493622123403783
EML4	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.0900039670523	-0.0900039670523	-1.08833881274021	-0.4202572111255	-8.74373865162396	186.963895467114	1.28978487483625e-15	1.42127661922252e-13	-1.22357586527243	-0.773093826103393
EML4	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.989174700268	-0.989174700268	-2.64332655791152	-2.62453052692	-8.97160486265457	4.05073434118054	0.000805734985090603	0.0183111413020341	-2.16354400489606	-1.14475971039097
EML4	BRD-K66715657-050-01-0::2.5::HTS002	2.5	UH-232-(+)	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4, HTR1A	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.331661225216	0.331661225216	-0.00559108252819044	0.0059117559481	-10.5583402735585	59.7118187414771	2.78535748571118e-15	2.96858719321229e-13	-0.401151747441049	-0.273352868047332
EML4	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.01955107479175	0.01955107479175	-0.338050418914302	-0.3277516003215	-6.01398096055249	5.29663158069927	0.00149308428073883	0.0313214506025714	-0.507913451544365	-0.20728953586774
EML4	BRD-K66808046-065-03-7::2.5::HTS002	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.425197909652	0.425197909652	-0.464269835563501	-0.3317635225235	-9.2783274790196	13.548850069331	3.05688242755697e-07	1.34533583945762e-05	-1.09572208985233	-0.683213400578668
EML4	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.0707619134116	-0.0707619134116	0.127079923151434	0.138278646354	7.29424193936055	185.540682251333	8.45688213357501e-12	6.38898516322523e-10	0.144332681236127	0.251350991889941
EML4	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.4676605335	0.4676605335	-0.157804005269282	0.0566391407425	-9.16100286829275	32.2735641691921	1.70749198630331e-10	1.10230436726627e-08	-0.764489293374565	-0.486439784163999
EML4	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.284631557615	-1.284631557615	-0.782250670662354	-0.642853768929	7.67771212919348	190.224866904938	8.26999694103307e-13	6.94553359864685e-11	0.373312105443596	0.631449668461696
EML4	BRD-K70463136-001-01-5::2.5::HTS002	2.5	BAY-87-2243	hypoxia inducible factor inhibitor	targeted cancer	HIF1A	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.10357445164	-1.10357445164	-1.63168529958594	-1.609919901395	-9.31443817995644	149.53478124921	1.47775784345821e-16	1.78236556460638e-14	-0.640143739318097	-0.416077956573774
EML4	BRD-K71847383-001-12-5::2.5::HTS002	2.5	cytarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.7294573314195	0.7294573314195	0.325232570390949	0.311150220691	-14.8951356711027	187.657153937557	1.24794113674419e-33	6.98355028452339e-31	-0.457759590171203	-0.350689931885899
EML4	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.0394465311635	-0.0394465311635	0.224075773999872	0.235603358555	9.96052196760798	51.2194454988591	1.4076206081445e-13	1.27566138402961e-11	0.210413835939376	0.316630774387368
EML4	BRD-K73319509-001-08-0::2.5::HTS002	2.5	PF-04217903	c-Met inhibitor	targeted cancer	MET	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.09573785051235	-0.09573785051235	0.0478369833405847	0.0909616793379	4.25649521322339	133.4836515628	3.88577170899745e-05	0.00119728804574139	0.0768589092828739	0.210290758422996
EML4	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.475162163605	-1.475162163605	-2.2151076244848	-2.0670113581	-5.51877331585368	5.44852030277823	0.0020364755948894	0.0407274216457077	-1.07624227749794	-0.403648644261654
EML4	BRD-K79239947-001-06-8::2.5::HTS002	2.5	PF-573228	focal adhesion kinase inhibitor	targeted cancer	CDK1, CDK2, CDK7, GSK3B, IKBKB	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.1064570483485	0.1064570483485	-0.237420392649407	-0.1830123326315	-7.46885377181644	189.148814656828	2.89421339757968e-12	2.30343061006259e-10	-0.434698272380434	-0.253056609615379
EML4	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.0642964424995	-1.0642964424995	-2.51917581453404	-2.254263331985	-9.89997239787331	4.42660499459902	0.000347826122316634	0.00866649906649637	-1.84785028111862	-1.06190846295047
EML4	BRD-K84783599-001-01-0::2.5::HTS002	2.5	riociguat	guanylate cyclase stimulant	noncancer	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.316290846124	0.316290846124	-0.00581587117825143	0.04755872580485	-6.01155685465568	35.1321517427361	7.35001715463631e-07	3.06661831173067e-05	-0.430867808570254	-0.213345626034249
EML4	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.4806289336265	-0.4806289336265	0.0487429081112319	0.06241133456585	18.7105472192173	86.1050939849416	4.39423951412756e-32	2.10696411817326e-29	0.473128801051244	0.58561488242422
EML4	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.461641827355	-3.461641827355	-2.04384321644357	-1.827878240625	10.1338204980946	4.45231991741942	0.00030520211745633	0.00769391491793669	1.04443204576838	1.79116517605448
EML4	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.3576238929785	-0.3576238929785	-1.42856665653607	-1.12582537284	-9.07944566735872	5.43252236644927	0.000174230529177549	0.00468011719364517	-1.36703014473822	-0.774855382376925
EML4	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.383810203527	-0.383810203527	-0.865505527399764	-0.791872957089	-8.36367050968503	5.67973646715244	0.000211417792755598	0.00555578274932743	-0.624571044245833	-0.338819603499695
EML4	BRD-M97302542-001-03-6::2.5::HTS002	2.5	dichloroacetate	pyruvate dehydrogenase kinase inhibitor	targeted cancer	PDK1	NA	NA	HDQP1, NCIH2228	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.085074779032	0.085074779032	-0.26328461482174	-0.170283353784	-6.24559185826131	5.05009279150385	0.00148689027227319	0.0312006760491521	-0.491311620398852	-0.205407167308629
ENDOV	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-1.48890145119	-1.48890145119	-0.82202483171271	-0.696430068405	11.113611104219	188.120400056449	2.20305439532244e-22	4.4883882651622e-20	0.548506707035785	0.785246531918794
ENDOV	BRD-A26032986-050-02-1::2.5::HTS002	2.5	zaldaride	calmodulin antagonist	noncancer	CALM1	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.316185943703	-0.316185943703	-0.165496702359717	-0.153177968043	4.3357155110475	26.525505008296	0.000187031508231676	0.00497780654759553	0.0793174496804906	0.222061033006075
ENDOV	BRD-A43885598-001-08-1::2.5::HTS002	2.5	SID-7969543	steroidogenic factor antagonist	noncancer	NR5A1	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.7775497356675	0.7775497356675	0.404628712746399	0.415971610724	-10.3238655196227	24.2251206757836	2.37290122340193e-10	1.50646192627521e-08	-0.44743699159226	-0.298405054249942
ENDOV	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.472667985863	-0.472667985863	0.215063051046786	0.242459349924	17.118506902901	6.3861679930897	1.41295443137267e-06	5.6373252107534e-05	0.590850177622956	0.784611896196616
ENDOV	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.426200032125	-0.426200032125	-0.0775723980558694	-0.05385103964535	6.98452113931262	8.78346017626084	7.25807387900034e-05	0.00211763642310409	0.235287833549909	0.461967434588352
ENDOV	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.3231341890085	-0.3231341890085	0.149120049065958	0.138064341376	17.8447435744624	169.981238445909	8.296279132043e-41	9.55985596823464e-38	0.42001260792951	0.524495868219407
ENDOV	BRD-A97701745-001-16-0::2.5::HTS002	2.5	pindolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B	cardiology	hypertension	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.2859132359195	0.2859132359195	0.155893717670816	0.160676381126	-3.40608182527358	78.2327269224746	0.00104298961299692	0.0229274790527198	-0.206012069789557	-0.0540269667078117
ENDOV	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.4301294320465	0.4301294320465	0.260374786829662	0.303778240807	-3.88058798814897	13.4555630115406	0.00178313237577191	0.0363874111174728	-0.263934815559748	-0.0755744748739276
ENDOV	BRD-K01507359-001-22-9::2.5::HTS002	2.5	rifampin	RNA polymerase inhibitor	noncancer	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.05794258631375	0.05794258631375	-0.0954146878574729	-0.0621919503453	-4.84902124689687	23.7238401628446	6.27612403878634e-05	0.00185743632851289	-0.218671268603262	-0.0880432797391839
ENDOV	BRD-K07359318-001-03-9::2.44929::HTS002	2.44929	benfotiamine	antioxidant	noncancer	AGER	rheumatology	lumbago	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.1162565618028	0.1162565618028	0.337110129109789	0.3600151541855	6.810845289567	6.17207997484786	0.000435282839462722	0.0105913916134095	0.142041337819392	0.299665796794586
ENDOV	BRD-K11663430-001-02-3::2.5::HTS002	2.5	pyroxamide	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.2567282899325	-0.2567282899325	-0.642825208957998	-0.612220843488	-5.92698818179294	104.31704448864	4.02749990318364e-08	1.98988019075483e-06	-0.51527168194416	-0.256922156106835
ENDOV	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.819910653259	0.819910653259	0.502289119454787	0.505306635797	-10.4973423494891	5.2093742936741	0.00010607441693742	0.00298894254740748	-0.394469558181436	-0.240773509426989
ENDOV	BRD-K14618467-001-04-6::2.5::HTS002	2.5	IKK-16	IKK inhibitor	noncancer	IKBKB	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.214455441129	0.214455441129	-0.141437112463714	-0.114726429386	-7.6311542603822	10.7423966073808	1.17262452891079e-05	0.000398616086688218	-0.458840556701728	-0.2529445504837
ENDOV	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.0317954321181	-0.0317954321181	0.0922517704727464	0.09201913789375	4.49006694412274	26.1581696336775	0.000127587744445562	0.00353167424503072	0.0672757419384068	0.180818663243286
ENDOV	BRD-K25412176-001-01-9::2.5::MTS006	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.03083746670245	-0.03083746670245	-0.669179399242903	-0.516853765181	-9.01550514513158	5.69000817479952	0.000140280370017998	0.00383937574072118	-0.813909209365089	-0.462774655715816
ENDOV	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-3.11602777164	-3.11602777164	-3.63479160713933	-3.592577528105	-5.69878281387268	7.30627762626959	0.00063184985562096	0.0147279769119505	-0.7322013269284	-0.305326344070252
ENDOV	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.1200793925965	0.1200793925965	-0.185477071683501	-0.06456986921455	-7.10687071920494	187.972407290352	2.39340392872532e-11	1.70707444472469e-09	-0.390370221911017	-0.220742706648984
ENDOV	BRD-K30519779-001-03-1::2.5::HTS002	2.5	homoquinolinic-acid	glutamate receptor agonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.2719026752615	0.2719026752615	0.42876702233284	0.45172565456	4.68153439705553	31.378073743264	5.2080416629173e-05	0.00156532654827009	0.088559651934528	0.225169042208151
ENDOV	BRD-K30867024-003-03-3::2.5::HTS002	2.5	SB-216641	serotonin receptor antagonist	noncancer	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.38974300473	-0.38974300473	-0.044514099606058	-0.01731915547495	7.2383221898951	5.09811096997809	0.000723308673132438	0.0166479837418172	0.223332302813697	0.467125507434187
ENDOV	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-2.58197318039	-2.58197318039	-3.24292182065228	-3.15387343916	-9.60154877562567	189.168620708493	4.935561342207e-18	6.80716812685897e-16	-0.796736790398918	-0.525160490125651
ENDOV	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.779199679154	-0.779199679154	-1.39616686524231	-1.273586296615	-7.1103074944369	5.70213229361949	0.000487076128457269	0.0117034237148114	-0.832005462570618	-0.401928909606007
ENDOV	BRD-K48141473-001-01-7::2.5::HTS002	2.5	cebranopadol	opioid receptor agonist	noncancer	OPRL1, OPRM1	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.151700270731	0.151700270731	0.345645025284491	0.370996268268	5.74849478553237	23.1941518974389	7.20571578455595e-06	0.000254640372364071	0.12418396379225	0.263705545314731
ENDOV	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.0111862413536	-0.0111862413536	-0.267733579295068	-0.2054130743915	-4.60975460084919	11.8616343137079	0.000619005721999791	0.0144663479871871	-0.377962186370434	-0.135132489512502
ENDOV	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.013104545925325	-0.013104545925325	-0.239319530144857	-0.10314419939105	-4.08296602939486	187.863889397233	6.57341195836593e-05	0.00193579666340287	-0.33551002883047	-0.116919939608593
ENDOV	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.09610755124255	0.09610755124255	-1.34429318196056	-1.45938861893	-17.1557892356837	3.53845626350525	0.00015587168721051	0.0042331250441132	-1.68600661226979	-1.19479485413642
ENDOV	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.1892421593705	0.1892421593705	0.0358537086770503	0.07942712884705	-4.93689530043689	116.904634833549	2.66330840019047e-06	0.000101805640468062	-0.214921126521039	-0.0918557748658608
ENDOV	BRD-K61688984-001-02-9::2.5::HTS002	2.5	RGFP966	HDAC inhibitor	targeted cancer	HDAC3	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.03957805187265	-0.03957805187265	0.146627424799045	0.1540824495245	4.73225211361271	16.5060479700594	0.000207873321273483	0.00547001609272245	0.102998436023625	0.269412517319765
ENDOV	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.160014376712	-0.160014376712	-1.18727743913869	-1.01733335597	-13.3363036159589	4.19615994604563	0.000135833775250294	0.00373724226131198	-1.23724016432912	-0.817285960524271
ENDOV	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.2673659653865	-0.2673659653865	-1.03720265932214	-0.659178147727	-6.75651404413108	13.1280522407943	1.28298450433502e-05	0.000432972422972162	-1.015745088072	-0.523928299799281
ENDOV	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.145062951705	0.145062951705	-0.214811346871634	-0.195517916983	-9.66365730126047	3.33431848038775	0.00149562466002731	0.03136246333617	-0.471941613439329	-0.247806983713939
ENDOV	BRD-K77245796-003-01-6::2.5::HTS002	2.5	gamma-aminobutyric-acid	benzodiazepine receptor agonist	noncancer	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.1214520339383	-0.1214520339383	0.512445603120524	0.500110131001	15.911926003855	5.93560552126336	4.29959485825159e-06	0.00015869258935323	0.536160893561126	0.731634380556522
ENDOV	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-2.41585388573	-2.41585388573	-0.440826359133432	-0.176655264129	23.5955534736356	195.645451320988	3.94711500648806e-59	2.22626634796205e-55	1.80995078646174	2.14010426673139
ENDOV	BRD-K82850175-001-01-1::2.5::HTS002	2.5	navarixin	CC chemokine receptor antagonist	targeted cancer	CXCR1, CXCR2	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-1.43478972019	-1.43478972019	-0.875602947934712	-0.790872902529	8.14446993175182	11.7244381372609	3.6438827981035e-06	0.000136155815243153	0.409201954385775	0.709171590124801
ENDOV	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.3630843779375	0.3630843779375	-0.124258111065685	-0.0479466221371	-14.0887006218189	37.4390432822835	1.52176481700705e-16	1.83235017676576e-14	-0.557402814838407	-0.417282163167962
ENDOV	BRD-K88172511-003-20-3::2.41866::HTS002	2.41866	naltrexone	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.1019648546998	0.1019648546998	0.311069692831961	0.3037924157915	9.07620974649074	82.5019583104501	4.82826481804627e-14	4.57892553180106e-12	0.163277531584228	0.254932144680095
ENDOV	BRD-K89714990-001-01-5::2.5::MTS006	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.0410030643851	-0.0410030643851	0.13922571778168	0.165320273303	5.64622946698057	177.929594971266	6.38206831320641e-08	3.08007727876878e-06	0.117237896015503	0.243219668318057
ENDOV	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-3.47600407232	-3.47600407232	-4.01804626522125	-3.85901121156	-4.54060344841289	101.512458058952	1.5468230466096e-05	0.00051558773593131	-0.778838934423661	-0.305245451378839
ENDOV	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.3497548608645	-0.3497548608645	-1.60850942414163	-1.38505413113	-12.840018029467	4.77492879464489	6.95533520192084e-05	0.00203540420329395	-1.51437325727227	-1.00313586928199
ENDOV	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.649025633846	-0.649025633846	0.106564488202258	0.1765205692495	19.6283075700377	18.5673630174406	7.15164411343724e-14	6.6614721042542e-12	0.674892074753616	0.836288169342899
ENDOV	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	-2.36683738396	-2.36683738396	-3.14994969479776	-3.23564927932	-11.1811798291848	8.77166117540593	1.73795063391185e-06	6.82597070580343e-05	-0.942181187122944	-0.624043434552571
ENDOV	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NUGC4, SUIT2	STOMACH, PANCREAS	carcinoma (signet_ring_adenocarcinoma), carcinoma (ductal_carcinoma)	0.331172897613	0.331172897613	-0.62231864951549	-0.542183140466	-15.9190898178436	187.802634864034	1.12256757022588e-36	8.56223433305842e-34	-1.07164717220218	-0.835335922054804
ENSG00000256500	BRD-A12417644-001-07-6::2.3139::HTS002	2.3139	usniacin-(+)	MAP kinase activator	targeted cancer	PTPN1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0039489432524	0.0039489432524	0.172919521609129	0.1617912757505	5.16863884197965	17.7795556590353	6.7059433516921e-05	0.00197022362251517	0.10022718531463	0.237713971398828
ENSG00000256500	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.04954078852255	-0.04954078852255	0.0913439985499901	0.131172819567	4.77027820819022	20.2237408785926	0.000113529796726021	0.00317908646491918	0.0793218736210324	0.202447700524048
ENSG00000256500	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.212589484238	-0.212589484238	0.0788369092042791	0.1349064957195	10.07203533199	175.085543559794	4.13599241866298e-19	6.29590283451434e-17	0.234321668698646	0.348531118185912
ENSG00000256500	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.138060642958	-0.138060642958	-0.534378218226731	-0.51783728433	-12.7097145435698	194.951830690683	2.37384099436299e-27	7.39510125698873e-25	-0.457815442178447	-0.334819708359015
ENSG00000256500	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2281282911595	0.2281282911595	0.358918900156311	0.3667280736395	5.72826214382995	187.881758006832	3.97093897231384e-08	1.96283989621091e-06	0.08574958253852	0.175831635455103
ENSG00000256500	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.43867526446	-1.43867526446	-1.12172057586058	-1.02154011458	4.98011111740702	19.1585944482818	8.11818931069535e-05	0.00234591262878795	0.183820651366659	0.450088725832184
ENSG00000256500	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.8463841380505	-0.8463841380505	-3.0475377036653	-2.92318120426	-19.3066734378221	93.1033595956107	2.57535515800168e-34	1.54614368532029e-31	-2.42755149004014	-1.97475564118946
ENSG00000256500	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3170590301595	-0.3170590301595	-1.0338471576067	-1.0089298839585	-12.9602700211631	58.8506279663955	6.86816716478104e-19	1.02012986851029e-16	-0.827462203068315	-0.606114051826094
ENSG00000256500	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.01098666427484	0.01098666427484	-0.478119266297974	-0.33490377325	-7.0447633043752	89.4283778753282	3.69857149942649e-10	2.30841913482988e-08	-0.627049376373432	-0.351162484772197
ENSG00000256500	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.989337148002	-0.989337148002	-2.46308326167389	-2.47219362388	-13.3494130226538	11.9981815236686	1.46513133953335e-08	7.70223534144821e-07	-1.71428634654616	-1.23320588079761
ENSG00000256500	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.0554826678688	-0.0554826678688	-0.515658101895237	-0.419130200084	-7.23595660689914	152.917003543607	2.08991826591843e-11	1.49809395323088e-09	-0.585814947005301	-0.334535921047574
ENSG00000256500	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.020390036649925	0.020390036649925	-0.424143047542583	-0.390164965854	-10.2788160604997	6.31486920976907	3.55932004110303e-05	0.00110400217813252	-0.54908993080033	-0.339976237584686
ENSG00000256500	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.584835548043	0.584835548043	-0.484062050536501	-0.373418715101	-9.85340469252355	7.82394624145259	1.10746542949433e-05	0.000378205796746478	-1.32003618154615	-0.817759015612855
ENSG00000256500	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.640673680695	-1.640673680695	-1.29099182098096	-1.25961873039	6.85984612683123	190.644382347607	9.36644574682803e-11	6.23298980498242e-09	0.249134067933508	0.450229651494576
ENSG00000256500	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1691438889035	-0.1691438889035	-0.570282627598963	-0.549657042838	-11.4869230015469	135.891616059592	9.1732325554601e-22	1.76330920213382e-19	-0.470198304508596	-0.33207917288233
ENSG00000256500	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.4544780362765	-0.4544780362765	-0.0505222601717786	-0.0356049990197	6.8389491146983	5.88550103720269	0.000521392451565853	0.0124359584633494	0.258739861973213	0.54917169023623
ENSG00000256500	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.5270677950605	-0.5270677950605	-0.0892438874278849	-0.0178822580687	10.9160816363957	135.546983589343	2.69038686875514e-20	4.58368781552798e-18	0.358505211467761	0.517142603797469
ENSG00000256500	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.41086727502	0.41086727502	-0.377883730859893	-0.1455477562875	-7.01722277381034	4.5137962912695	0.00136689529879749	0.0290208323423445	-1.08730681568901	-0.490195196070771
ENSG00000256500	BRD-K19284129-001-02-6::2.5::HTS002	2.5	salvinorin-a	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2309179360235	-0.2309179360235	0.0155731697946181	0.02724514887165	6.5044341712887	58.8863303551889	1.86961175192084e-08	9.6766968649467e-07	0.170658608763502	0.322323602872734
ENSG00000256500	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.38385573655	0.38385573655	-0.347870452704462	-0.216806871006	-12.9745301622417	184.279541987636	9.10231259652505e-28	2.96487774544167e-25	-0.842993244748135	-0.620459133760788
ENSG00000256500	BRD-K19412355-001-01-0::2.5::HTS002	2.5	SB-242235	p38 MAPK inhibitor	noncancer	HSPB1, MAPK14	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.06214419600445	-0.06214419600445	0.116358124720773	0.132605896616	4.47942781132184	7.70758320524978	0.00225745479688685	0.0445072237293682	0.0859991471780716	0.271005494272375
ENSG00000256500	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.930278540383	-0.930278540383	-3.15447790758085	-3.22475555586	-15.0735832766771	6.74796739191329	1.90711516545949e-06	7.44400084315729e-05	-2.57577336789673	-1.87262536649897
ENSG00000256500	BRD-K24603946-001-02-1::2.5::HTS002	2.5	5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	noncancer	CHRM3	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.4796308109	-1.4796308109	-2.43279316035235	-2.202066494735	-8.85026815244322	53.8156748871119	4.41718026775981e-12	3.45018159478386e-10	-1.16910217565503	-0.737222523249666
ENSG00000256500	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2659261296915	-0.2659261296915	-0.42613632306368	-0.326694667694	-4.08117944981937	190.492967860319	6.58629885738674e-05	0.0019387925392183	-0.237642191546382	-0.0827781951979775
ENSG00000256500	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2877489295695	-0.2877489295695	-1.04412729759226	-0.8676646214495	-9.24171243378061	26.612297725672	8.58319364022388e-10	5.14869104314454e-08	-0.924422856565084	-0.588333879480436
ENSG00000256500	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.5170321910205	-0.5170321910205	-0.773611396562741	-0.707312470978	-4.6454551191237	193.372537717201	6.26193461900421e-06	0.000224121968532334	-0.365514310992782	-0.1476441000917
ENSG00000256500	BRD-K31491153-003-05-9::2.5::HTS002	2.5	1-phenylbiguanide	serotonin receptor agonist	noncancer	HTR3A, HTR3B	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.462991949891	-0.462991949891	-0.0933211562503342	0.0251960831099	5.93740157688605	7.81174587719924	0.000380249497955924	0.00939668527134459	0.22549130868368	0.513850278597652
ENSG00000256500	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.3240750248975	0.3240750248975	-0.116629967590755	0.0546590882103	-6.15326639808213	8.01650645626779	0.000270737089471559	0.00691206785578913	-0.605804851227218	-0.275605133749293
ENSG00000256500	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4551300743225	0.4551300743225	-0.0459833038028448	-0.03775802467905	-11.0433816911238	43.8754706143081	2.97774031204135e-14	2.88654954020583e-12	-0.592571651345104	-0.409655104905586
ENSG00000256500	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0612295897389	0.0612295897389	-0.207634227744818	-0.158031671069	-7.58173919531589	80.9911094119403	4.98373519257386e-11	3.4137391501731e-09	-0.339422239099626	-0.198305395867811
ENSG00000256500	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0756204968079	0.0756204968079	-0.111197549395606	-0.11764531931	-3.46719455572425	27.6856873934751	0.00173505980905706	0.0355923759942845	-0.297246012395593	-0.0763900800114196
ENSG00000256500	BRD-K43236057-001-07-1::2.59978::HTS002	2.59978	polydatin	ICAM1 expression inhibitor	noncancer	ICAM1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.134477238665	-2.134477238665	-1.30480828783669	-1.19469399644	9.67598939514444	13.5005690399474	1.91366626027342e-07	8.65669429924319e-06	0.645123631109192	1.01421427054742
ENSG00000256500	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.7520461248065	-0.7520461248065	-0.357774861470342	-0.229271162585	5.91523615372723	45.9256128980778	3.8999485237938e-07	1.68931298940218e-05	0.260098838014376	0.528443688657939
ENSG00000256500	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.228556052504	0.228556052504	-0.789752367512326	-0.640313618355	-11.1374063377994	7.54633496201191	5.94979327610734e-06	0.000213961953536042	-1.23137635801681	-0.80524048201584
ENSG00000256500	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.542403648252	-0.542403648252	-1.59792075178887	-1.48697544025	-10.0702008251254	6.79220682180654	2.50009409827871e-05	0.00080108038270291	-1.3049127239544	-0.806121483119348
ENSG00000256500	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.14265112400695	0.14265112400695	-0.589240267442785	-0.48109263675	-8.37386531272647	11.9137122304268	2.46686992772106e-06	9.48209764595638e-05	-0.922476766174213	-0.541306016725258
ENSG00000256500	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0444406384067	0.0444406384067	0.262850893576132	0.254607479759	7.72391692645745	12.497012605601	4.18834106445455e-06	0.000154746242372605	0.157070332149675	0.279750178189189
ENSG00000256500	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.033641787862075	0.033641787862075	-0.208003102015329	-0.0810605722641	-4.32345524972465	13.8356144703627	0.000719555758603235	0.016570502437485	-0.36165423727817	-0.121635542476638
ENSG00000256500	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.316339645834	0.316339645834	-0.236288362373872	-0.1756829862115	-7.81465814362153	7.01061867397787	0.000104995798816945	0.00296139552107343	-0.719795456365182	-0.385460560050561
ENSG00000256500	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4711857676415	0.4711857676415	-0.498718734833234	0.00402399396559	-10.6421224829224	135.969768181007	1.29380723601256e-19	2.06018136023281e-17	-1.15013630607385	-0.789672698875619
ENSG00000256500	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.166811084079	-0.166811084079	0.108015463257308	0.101486674715	7.23255749794279	121.292726081961	4.65425269013493e-11	3.20546698208204e-09	0.199600269823638	0.350052824848978
ENSG00000256500	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.665606404535	-1.665606404535	-0.410947541638825	-0.2259650044755	16.5946139097357	11.1002962341966	3.47752125177702e-09	1.95420464701656e-07	1.08843358087879	1.42088414491356
ENSG00000256500	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.564564297055	-1.564564297055	-1.10458888670781	-1.10749370834	9.47951295656046	188.964271159541	1.09998218437549e-17	1.47303599635999e-15	0.364258853959488	0.555691966734893
ENSG00000256500	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4773020832075	0.4773020832075	-0.470348358816467	-0.217946401079	-11.1085567919974	189.883370500343	2.06969647195964e-22	4.22875095461047e-20	-1.11592383682236	-0.779377047225576
ENSG00000256500	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.425293581735	-3.425293581735	-4.14015929978772	-4.26693586682	-4.99912926140459	5.99719992023252	0.00245776514163003	0.0478664557056269	-1.06480893741168	-0.36492249869376
ENSG00000256500	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.217987378713	-0.217987378713	-0.425088448634094	-0.2959843885325	-3.77549330261944	193.650194958422	0.000212310267016476	0.00557083807854796	-0.315289143527747	-0.0989129963144415
ENSG00000256500	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2549019500045	0.2549019500045	-0.508903482970275	-0.3823931691785	-12.5202026397208	175.861945296529	4.00378284416342e-26	1.12173434406105e-23	-0.884203203117576	-0.643407662831975
ENSG00000256500	BRD-K86816506-001-01-8::2.5::HTS002	2.5	PF-04457845	FAAH inhibitor	noncancer	FAAH	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2392358332045	-0.2392358332045	-0.408842127192448	-0.370640421909	-5.7851903121062	190.157390959272	2.93676996499e-08	1.47754687752662e-06	-0.227435233372847	-0.111777354603048
ENSG00000256500	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.02947908460285	0.02947908460285	-0.787368626622999	-0.783090045771	-16.8337461660176	174.728372929204	2.05249118264782e-38	1.83295159452385e-35	-0.912617141059297	-0.7210782813924
ENSG00000256500	BRD-K90647725-001-07-3::2.50156::HTS002	2.50156	oleanolic-acid	G protein-coupled receptor agonist	noncancer	GPBAR1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.251593412205	0.251593412205	0.11896076444758	0.139454786175	-4.4185049174249	13.7917291474982	0.000604286178608369	0.0141624988928325	-0.197105198474372	-0.0681600970404673
ENSG00000256500	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.93723873221	-2.93723873221	-4.02377781139263	-3.85901121156	-7.89807685551241	10.5110034698835	9.74775644098958e-06	0.000336537836701169	-1.3910563292468	-0.782021829118464
ENSG00000256500	BRD-K91623615-001-05-0::2.46068::HTS002	2.46068	ABT-751	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.671384272495	-2.671384272495	-3.49965914932143	-3.442891314055	-7.12721444987137	8.59980184118401	6.9268186979155e-05	0.00202872113242079	-1.09304366617407	-0.563506087478786
ENSG00000256500	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.897679387215	-2.897679387215	-1.58182958616937	-1.34116610852	17.5577542387674	105.181592075293	4.87096249327163e-33	2.577749432643e-30	1.16725251778245	1.46444708430881
ENSG00000256500	BRD-K92441787-001-04-1::2.5::HTS002	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.25491162119	0.25491162119	0.154545119570946	0.1701725882685	-3.53015047899878	178.108438679587	0.000528664876879457	0.0125856063975005	-0.156471903347915	-0.0442610998901923
ENSG00000256500	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.8159067202195	0.8159067202195	0.30494885738514	0.328628776305	-15.5412448708021	158.501728007453	1.1101440908538e-33	6.22869300650798e-31	-0.57589244047555	-0.446023285193169
ENSG00000256500	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.233712847494	0.233712847494	-0.0920934734067121	0.0692106615383	-6.27681788449302	179.679649165613	2.51846303991453e-09	1.4340586208338e-07	-0.428230645491908	-0.223381996309516
ENSG00000268750	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.2330801241395	0.2330801241395	0.149565742612033	0.1611474271015	-3.33617672112342	28.9438595305281	0.00234142247713782	0.0459093164488585	-0.134716849126715	-0.0323119139282201
ENSG00000268750	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.310991516881	0.310991516881	-0.182313851098607	-0.1596607583295	-9.11003506750554	7.19169730880696	3.33563542121273e-05	0.00104003986644327	-0.620660335960645	-0.365950399998569
ENSG00000268750	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.674232153666	-0.674232153666	-1.6315358062891	-1.545847432105	-8.92254926223242	5.53754744111253	0.000171901687678592	0.00462567693891588	-1.22524100363878	-0.689366301607411
ENSG00000268750	BRD-A20239487-001-24-9::2.5::HTS002	2.5	atenolol-(+/-)	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.616307388263	0.616307388263	0.19461262246389	0.207866793196	-15.1467310462815	16.2545602035942	5.22069403778202e-11	3.56238819619161e-09	-0.480639266215117	-0.362750265383103
ENSG00000268750	BRD-A27883417-300-01-6::2.5::HTS002	2.5	alexidine	phosphatidylglycerophosphatase inhibitor	targeted cancer	PTPMT1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.5134868837045	-0.5134868837045	-0.231180071792889	-0.2422575452235	6.18666812105119	32.712102084501	5.78017673616089e-07	2.4435098613109e-05	0.189437821866794	0.375175801956429
ENSG00000268750	BRD-A28329383-001-02-1::2.5::HTS002	2.5	MTPG	glutamate receptor antagonist	noncancer	GRM2, GRM3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.3727590918325	0.3727590918325	0.0190153213821629	0.0389518722109	-9.65780306855997	37.8986983000442	9.15555890632058e-12	6.89737006971101e-10	-0.427899319555793	-0.279588221344882
ENSG00000268750	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.2552180427405	0.2552180427405	-0.452350602476512	-0.3315553181695	-8.13302342129865	10.803449208515	6.2636908281599e-06	0.000224121968532334	-0.899479062620544	-0.51565822781348
ENSG00000268750	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.702529764981	0.702529764981	0.138150381108851	0.135666555282	-21.3183919706576	157.591065179994	2.72064422412726e-48	5.71679368542129e-45	-0.61666867341394	-0.512090094330358
ENSG00000268750	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.273317883122	0.273317883122	-0.0532441900338813	-0.0230394948173	-9.90537877576565	33.4747738707756	1.75977908596055e-11	1.27509023568235e-09	-0.393600169936838	-0.259523976374924
ENSG00000268750	BRD-A91452556-001-04-0::2.5::HTS002	2.5	estradiol-cypionate	estrogen receptor agonist	noncancer	ESR1	endocrinology	hypoestrogenism, menopause	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7603131101175	0.7603131101175	0.59151732749787	0.60273481392	-7.10956793733329	188.683332754924	2.33410849160994e-11	1.66644616555052e-09	-0.215629758186559	-0.1219618070527
ENSG00000268750	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-3.068995121165	-3.068995121165	-3.72456152227446	-3.62613694573	-4.97337587414864	6.98775854315918	0.00162128059408165	0.0335801554357292	-0.967370481713718	-0.343762320505205
ENSG00000268750	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.672091678384	0.672091678384	0.152096053737071	0.1638819685105	-19.6582846297449	48.3095883610749	1.07978884483028e-24	2.71950720709317e-22	-0.573171587446672	-0.466819661847187
ENSG00000268750	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-2.25691771672	-2.25691771672	-3.03741302406105	-2.93942386342	-7.97072553770843	140.93467509816	4.85348222715385e-13	4.1559807921041e-11	-0.97407767733705	-0.586912937345047
ENSG00000268750	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-2.495633797245	-2.495633797245	-2.06165758163955	-2.351388502545	3.85227680732202	11.8280248133205	0.00236042797862666	0.046214320656899	0.188126805878961	0.679825625331943
ENSG00000268750	BRD-K14175878-001-01-6::2.5::HTS002	2.5	MK-0812	CC chemokine receptor antagonist	noncancer	CCR2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.5356511904315	0.5356511904315	0.327844509524078	0.3144400388815	-6.66197749755229	9.11640630568862	8.70790594646823e-05	0.00249980816180095	-0.278232911040271	-0.137380450774573
ENSG00000268750	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.493138206298	-0.493138206298	-0.184199771120118	-0.102291191228	6.07030628402322	6.74779198439717	0.000582459066717831	0.0137305179620068	0.187676842487418	0.430200027868347
ENSG00000268750	BRD-K18910433-001-36-6::2.58082::HTS002	2.58082	estradiol	estrogen receptor agonist	noncancer	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.414173617467	0.414173617467	0.305833519845555	0.322506570142	-3.62518855337234	175.785560393375	0.000377955370280685	0.00934981493038885	-0.167320399133328	-0.0493597961095623
ENSG00000268750	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-5.601385709225	-5.601385709225	-5.24668991900168	-5.41033082	4.46109499854106	26.2099426664694	0.000137212994363701	0.0037674511746064	0.191327040759105	0.518064539687544
ENSG00000268750	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-1.327976173415	-1.327976173415	-2.06756542896085	-1.99815705335	-8.33909125461168	143.638135495613	5.55591737106075e-14	5.23426028229485e-12	-0.914894315126109	-0.564284195965594
ENSG00000268750	BRD-K24696047-001-02-3::2.5::HTS002	2.5	NVP-AEW541	IGF-1 inhibitor	targeted cancer	IGF1R, INSR	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.770158192953	0.770158192953	0.158307887339413	0.182728129692	-17.3542328198931	23.154872052458	9.07932082072812e-15	9.21383405391021e-13	-0.684757044098179	-0.538943567128995
ENSG00000268750	BRD-K25224017-001-25-0::2.5::HTS002	2.5	pirenperone	serotonin receptor antagonist	noncancer	HTR2A, HTR7	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.07119575101035	-0.07119575101035	-2.57651493102377	-2.47770840728	-19.4570643981402	3.89085076711138	5.06297251419517e-05	0.00152450384376923	-2.8668083103993	-2.14383004962754
ENSG00000268750	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-6.100611857945	-6.100611857945	-4.66612327074552	-4.90330008871	15.7521471259839	180.117413153895	1.03691694546885e-35	6.98872239010673e-33	1.25479469627058	1.61418247812838
ENSG00000268750	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.148876515952	0.148876515952	-0.310135157254234	-0.26288025127	-11.1812966035498	92.3065307974303	7.43457564847707e-19	1.09968610363178e-16	-0.540540363600037	-0.377482982812431
ENSG00000268750	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.3641693234005	-0.3641693234005	-0.938693454933748	-0.797793160199	-7.70527632547068	37.7493643612816	2.91453375517086e-09	1.6516898604231e-07	-0.725500799244968	-0.423547463821528
ENSG00000268750	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.655447238788	-0.655447238788	-0.0327621453134341	-0.03550064325705	12.96975202765	17.4652785145012	2.13289033864649e-10	1.36134679390043e-08	0.521596830596902	0.723773356352229
ENSG00000268750	BRD-K36788280-001-01-2::2.5::HTS002	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4742160534055	0.4742160534055	-1.08213989081138	-1.010750177675	-17.9491901208066	7.66083742128252	1.55141918647186e-07	7.1278482919041e-06	-1.75785859976864	-1.35485328866513
ENSG00000268750	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4754664269035	0.4754664269035	-0.24380456008323	-0.026104548309	-13.6686128357417	137.369389706033	2.16513895284365e-27	6.77448272443834e-25	-0.823325058816449	-0.61521691515701
ENSG00000268750	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-1.376637532085	-1.376637532085	-3.05508994589577	-2.95683473862	-12.3823245720317	3.57447379175713	0.000460432514260627	0.0111390765154639	-2.07315135619675	-1.28375347142479
ENSG00000268750	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-1.603717490405	-1.603717490405	-0.686024200195408	-0.55798899715	13.776528875223	49.0164783277755	1.76901183706966e-18	2.53104498015557e-16	0.78383097654258	1.0515556038766
ENSG00000268750	BRD-K43471985-001-03-0::2.69009::HTS002	2.69009	OTX015	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4502311682355	0.4502311682355	-0.820000231463584	-0.721568534239	-11.689241093895	5.94968154031261	2.50824415715855e-05	0.000803211507484888	-1.5366753305329	-1.00378746886527
ENSG00000268750	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.5796315248635	0.5796315248635	0.150113036189104	0.139916370482	-13.6517092925713	2.51064502918645	0.00202262877656684	0.0404769377266848	-0.541646039496237	-0.317390937852555
ENSG00000268750	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.2298520782105	0.2298520782105	-0.270270824764164	-0.2054130743915	-8.89051370801817	10.5256305386526	3.23040173624929e-06	0.000121724467955094	-0.624620331000267	-0.375625474949061
ENSG00000268750	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.3561874601045	-0.3561874601045	-1.60004893679627	-1.48697544025	-14.1764471950036	53.0402806193593	1.11201394711668e-19	1.77863311396695e-17	-1.41984534011975	-1.0678776132638
ENSG00000268750	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.000921624061542	-0.000921624061542	-0.227349431166755	-0.187297921894	-6.78786799238255	190.343698549324	1.40607954458412e-10	9.15998853225438e-09	-0.292226090463125	-0.160629523747302
ENSG00000268750	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-2.58490429018	-2.58490429018	-4.61102342157848	-4.62878838486	-17.9184007104899	12.2050047948396	3.90776988549333e-10	2.42978941626893e-08	-2.27202971890644	-1.78020854389052
ENSG00000268750	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7607714495385	0.7607714495385	0.252547162037404	0.250850268444	-12.6427194938718	4.68094592613697	8.51191965111603e-05	0.00244945116394206	-0.613713863645149	-0.402734711357044
ENSG00000268750	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.836938156552	-0.836938156552	-1.1104092317851	-1.00700802709	-4.57738485704858	75.9073065056866	1.80615332511275e-05	0.000594001896605938	-0.392463824018759	-0.154478326447437
ENSG00000268750	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4887808304365	0.4887808304365	-0.775596545425266	-0.6098527820225	-11.9952543594015	2.77510071699709	0.00179278877561021	0.0365496647472426	-1.61574415681982	-0.913010594903716
ENSG00000268750	BRD-K56981171-001-01-0::2.5::MTS006	2.5	brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	targeted cancer	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.245600643759	0.245600643759	-0.073895138979528	-0.00736994010253	-9.69693785152234	190.948206018377	2.48067000710584e-18	3.51175377776081e-16	-0.384484791316828	-0.254506774160228
ENSG00000268750	BRD-K58529924-001-01-5::2.64858::MTS010::PROS001_PR500	2.64858	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.815010641956	0.815010641956	-0.126446608950122	-0.0782443732808	-14.3627957369575	2.43853603096737	0.002042411248234	0.040830888949048	-1.1800498705187	-0.702864631293547
ENSG00000268750	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.343705806496	-0.343705806496	-1.33971179281745	-1.45938861893	-16.4333786390468	88.4216558241761	1.29260817997407e-28	4.68770589857299e-26	-1.11644506938941	-0.875566903253483
ENSG00000268750	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.6883166767505	-0.6883166767505	-1.54502188179019	-1.43484346641	-10.7443572704364	4.99316858627648	0.000122031320273836	0.00339433447080631	-1.06175584972568	-0.651654560353697
ENSG00000268750	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7342591783135	0.7342591783135	-0.2406416908372	-0.1756829862115	-14.3052671568619	8.75698130486072	2.2569961589238e-07	1.01158454568377e-05	-1.12972102968991	-0.820080708611494
ENSG00000268750	BRD-K62965247-001-04-9::2.5::HTS002	2.5	tipifarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, FNTB	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.774919814399	-0.774919814399	-1.4770078742253	-1.40587252118	-12.1850364021178	183.84648858365	2.0298487239247e-25	5.35782570381844e-23	-0.815767297921957	-0.588408821730649
ENSG00000268750	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.435790297551	-0.435790297551	-0.213584255575745	-0.1907303952045	4.2324319835638	121.925475282939	4.50427414648246e-05	0.00137032870623341	0.11827483918367	0.326137244766841
ENSG00000268750	BRD-K66808046-065-03-7::2.5::HTS002	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.3472872615145	0.3472872615145	-0.46333115305582	-0.3317635225235	-8.89800408192247	25.9963231175994	2.27685204205786e-09	1.30236301393707e-07	-0.997880801674897	-0.623356027465744
ENSG00000268750	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.1356853459595	0.1356853459595	-0.275429124988974	-0.224936831672	-12.8442667810432	173.710875221413	5.61728949755727e-27	1.68856667702939e-24	-0.474288382205209	-0.34794055969174
ENSG00000268750	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.575945079264	-0.575945079264	-1.19663224976157	-1.12346956245	-7.92071162511724	26.9102690375721	1.66826187408064e-08	8.68920566598124e-07	-0.781498934480709	-0.459875406514437
ENSG00000268750	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.1439750335985	0.1439750335985	-0.214799834510719	-0.195517916983	-13.5760810788193	70.2342717291201	2.55248455054033e-21	4.72020242651216e-19	-0.411478733668675	-0.306071002549762
ENSG00000268750	BRD-K74671368-001-01-8::2.5::MTS006	2.5	idronoxil	XIAP inhibitor	targeted cancer	ENOX2, SPHK1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.0145559052907	-0.0145559052907	-0.253932438678862	-0.195737211392	-6.28616515974368	189.864953707315	2.1809271052242e-09	1.24949458844052e-07	-0.31449054946663	-0.164262517309693
ENSG00000268750	BRD-K75478907-001-02-3::2.5::HTS002	2.5	GS-39783	GABA receptor modulator	noncancer	GABBR1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.8519708019005	0.8519708019005	0.474817749367266	0.475315506582	-14.9058668484461	78.2062994082519	1.45839274417765e-24	3.62196823252435e-22	-0.427524014547112	-0.326782090519355
ENSG00000268750	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.764599669687	-0.764599669687	-2.33972000336628	-2.24109191203	-13.0265825205823	3.94181004205801	0.000218815497185018	0.00572351802491673	-1.91280014078369	-1.23744052657488
ENSG00000268750	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.332480066815	0.332480066815	0.0136662413743319	0.0495734767378	-9.32798287180384	7.26943471007979	2.65900710011651e-05	0.000846683008113016	-0.399029178298012	-0.238598472583325
ENSG00000268750	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.993874354388	-0.993874354388	-2.51992498568417	-2.254263331985	-9.92945207889272	3.69077784686294	0.000855307313737462	0.0192843636909359	-1.96723660432324	-1.08486465826909
ENSG00000268750	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.5063939413715	-0.5063939413715	-1.29168133355983	-1.24885809452	-12.8648212747601	188.083764669231	1.39738929125384e-27	4.47016491649468e-25	-0.905701243179515	-0.664873541197151
ENSG00000268750	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.5630083434675	-0.5630083434675	-0.0979672169180723	-0.0599890522741	10.7295231279824	3.75219989832718	0.000595728203066079	0.0140018345088575	0.341503921615808	0.588578331483048
ENSG00000268750	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.05585838322755	-0.05585838322755	-0.384930409884869	-0.347155123363	-7.68144800576544	88.9882964484269	1.94842902036347e-11	1.40371375968229e-09	-0.414194036464246	-0.243950016850393
ENSG00000268750	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	1.96833510959	1.96833510959	-0.87530967102487	-0.774088070041	-32.0256957208521	153.57105920707	7.26027484734001e-70	1.29673953979628e-65	-3.01905738103913	-2.66823218019061
ENSG00000268750	BRD-K84564571-001-02-4::2.5::HTS002	2.5	telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4166957067675	0.4166957067675	-0.190813294311457	-0.150870587106	-11.9712256481756	7.75231059259001	2.83881597527736e-06	0.000108167215851595	-0.7251868185341	-0.489831183623813
ENSG00000268750	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.4070182346315	-0.4070182346315	-3.1354874988309	-3.009227373135	-20.9455042895148	8.16718252685762	2.17813217158082e-08	1.11576694599127e-06	-3.02779427571971	-2.42914425267908
ENSG00000268750	BRD-K90574421-001-03-5::2.5::HTS002	2.5	ipsapirone	serotonin receptor agonist	noncancer	HTR1A	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.4184682851415	-0.4184682851415	-0.033960912837881	-0.0431604898369	14.9379099979931	58.3803947931755	1.32283300980376e-21	2.49359257834855e-19	0.332989565090773	0.436025179516465
ENSG00000268750	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7956042498315	0.7956042498315	0.0858908167096112	0.09873309755385	-25.676176684431	15.9792722268249	2.03049534475314e-14	2.00273371719096e-12	-0.768315767700651	-0.651111098543126
ENSG00000275778	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.865519408062	0.865519408062	-0.78891584062831	-0.4776049590865	-14.6785709197688	19.1675651464492	7.01988760285059e-12	5.34861532183208e-10	-1.89020241145747	-1.41866808592315
ENSG00000275778	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.2809430433395	0.2809430433395	-0.0557427130287373	0.002007296385155	-9.18560987603	54.3154262956976	1.19946220845298e-12	9.93736125533509e-11	-0.410162046243276	-0.263209466493199
ENSG00000275778	BRD-A50998626-001-02-1::2.5::HTS002	2.5	palomid-529	AKT inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.4673420469725	0.4673420469725	0.0400599188937545	0.0209581438432	-13.7592367905384	61.980278995506	1.67270507792965e-20	2.9005599243332e-18	-0.489358987631125	-0.365205268526366
ENSG00000275778	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.398082042309	0.398082042309	0.150732978033259	0.162581247373	-8.24649255500427	44.2658957437192	1.71134586423712e-10	1.10412717560529e-08	-0.307788665704962	-0.186909462846519
ENSG00000275778	BRD-K00317371-001-06-1::2.40436::HTS002	2.40436	RITA	MDM inhibitor	targeted cancer	MDM2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-1.03517946231	-1.03517946231	-2.20173770732824	-1.66399627555	-8.66017740888398	188.962238001447	2.0680136309968e-15	2.23517545899099e-13	-1.43227451249955	-0.90084197753692
ENSG00000275778	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.6294611623465	-0.6294611623465	-1.03062651706869	-1.0089298839585	-5.80344719953072	5.39064439195617	0.00166240582423206	0.0343125749135047	-0.575053646481984	-0.227277062962405
ENSG00000275778	BRD-K06593056-001-04-8::2.5::HTS002	2.5	LE-135	retinoid receptor agonist	noncancer	RARB	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.5809775877845	0.5809775877845	-0.149124982901514	-0.158245986785	-23.5841978085243	101.997061436797	4.31424003572984e-43	5.81551416740844e-40	-0.791506206279387	-0.668698935092641
ENSG00000275778	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-1.896460828845	-1.896460828845	-2.51511629165395	-2.34739362698	-4.68218620802315	7.5784698840221	0.00182402678524159	0.0370842190148023	-0.926322216627655	-0.310988708990254
ENSG00000275778	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.155413273279	-0.155413273279	-0.514611708121309	-0.419130200084	-5.35266104884995	43.5899189713526	3.05730960081355e-06	0.000115731209719669	-0.494478677024386	-0.223918192660231
ENSG00000275778	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.429837703445	0.429837703445	-0.0585076143546377	0.1891566141585	-5.6294138795235	5.14643290700628	0.00223302085468712	0.0440903847779122	-0.709445431113792	-0.267245204485483
ENSG00000275778	BRD-K15567136-003-27-2::2.5::HTS002	2.5	papaverine	phosphodiesterase inhibitor	noncancer	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.013601548103395	-0.013601548103395	-0.528300663166347	-0.5051056770975	-14.2168095641825	23.4627432420033	5.04641545831321e-13	4.30913617037774e-11	-0.589510236984481	-0.439887993141423
ENSG00000275778	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.08149404150175	0.08149404150175	0.311095022616614	0.322928237233	7.39899877335967	106.81021827007	3.28678774823078e-11	2.30741543167558e-09	0.168083682718252	0.291118279511475
ENSG00000275778	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.371410827026	0.371410827026	-0.347741489911467	-0.216806871006	-12.7899115454978	189.738312099434	2.04633684300459e-27	6.44037194162012e-25	-0.830064792568303	-0.608239841306631
ENSG00000275778	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-3.33730244187	-3.33730244187	-4.18612421133665	-4.20452435995	-8.69527119998788	25.9980979260643	3.5821244249523e-09	2.00877327544637e-07	-1.04948076077008	-0.648162778163214
ENSG00000275778	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.0860782864604	-0.0860782864604	-0.428009738097337	-0.326694667694	-8.01263931834835	31.9474003947064	3.83920840324591e-09	2.14620161152658e-07	-0.428861179010759	-0.255001724263115
ENSG00000275778	BRD-K28307902-001-21-7::2.5::HTS002	2.5	flutamide	androgen receptor antagonist	targeted cancer	AHR, AR	oncology	prostate cancer	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.4317378052925	0.4317378052925	0.241049570970914	0.2782830589715	-6.70048086443257	19.7691791837827	1.70538927595648e-06	6.71037962413212e-05	-0.250096900040793	-0.131279568602378
ENSG00000275778	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.143126380435	0.143126380435	-0.500101373479507	-0.332266676493	-11.1515044175126	29.5235285502657	4.1864689154971e-12	3.27714279105032e-10	-0.761107446834662	-0.525348060994351
ENSG00000275778	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.00580283388185	0.00580283388185	-0.636523721764668	-0.4291875223905	-7.34236090347349	4.39622693565664	0.001258429211932	0.0270339655772451	-0.876821683156577	-0.407831428136458
ENSG00000275778	BRD-K46937689-001-15-0::0.625::HTS002	0.625	phenazone	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.7058886602945	0.7058886602945	0.0861564687527096	0.0795356739513	-17.1285824819248	13.1449107324923	2.2556502781192e-10	1.43627827825018e-08	-0.697809358219202	-0.541655024864379
ENSG00000275778	BRD-K47557313-001-02-7::2.5::HTS002	2.5	LY2109761	TGF beta receptor inhibitor	targeted cancer	TGFBR1, TGFBR2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.7852863729475	0.7852863729475	0.251161562800624	0.273399788387	-11.5297088223005	6.82120509278186	1.01038086422394e-05	0.000348045516310276	-0.644253058043089	-0.423996562250664
ENSG00000275778	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.8208696954395	0.8208696954395	-0.276492062840259	-0.2054130743915	-15.1947824595231	2.8862452279822	0.000762583682551498	0.0174284280334378	-1.33240739503688	-0.862316121522638
ENSG00000275778	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.0921811666449	-0.0921811666449	-0.458863587527611	-0.3435721987365	-7.20252917557553	187.998344718348	1.38319535507549e-11	1.01736059457095e-09	-0.467111139080629	-0.266253702684792
ENSG00000275778	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.524745903191	0.524745903191	-0.116649990591884	0.03876057814515	-11.9080664293109	34.713246653488	8.2130416310583e-14	7.59729391343588e-12	-0.750774482538241	-0.532017305027526
ENSG00000275778	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-4.43880153777	-4.43880153777	-3.63173065307721	-3.494830245985	6.64988405512429	77.0626265737522	3.7846924996651e-09	2.11738282109298e-07	0.565403121623022	1.04873864776255
ENSG00000275778	BRD-K66175015-001-09-0::2.5::HTS002	2.5	afatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.17178159291	-0.17178159291	-0.919548205855464	-0.7732511578805	-6.91501401493148	16.9932584727454	2.50581927886336e-06	9.61628899229195e-05	-0.975921946225626	-0.519611279665302
ENSG00000275778	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	1.0015083399985	1.0015083399985	-0.0188434251720063	-0.0198550434605	-18.2731207060483	21.3481252665601	1.61992206047539e-14	1.61186757335019e-12	-1.13636001140595	-0.904343518935067
ENSG00000275778	BRD-K71164191-001-01-0::2.5::HTS002	2.5	KD-023	ACAT inhibitor	noncancer	ACACA, ACACB	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.08834252942765	-0.08834252942765	-0.956507895543564	-0.979843337188	-13.928964409505	13.0178147211051	3.37322198262627e-09	1.90007698899949e-07	-1.00279822993284	-0.733532502298987
ENSG00000275778	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-2.742078632405	-2.742078632405	-4.37413888178058	-4.09603677997	-12.0931838782959	13.9416575608301	8.87065132508419e-09	4.76023492201795e-07	-1.92162798368247	-1.34249251506869
ENSG00000275778	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.4824373693625	-0.4824373693625	-1.11639212176682	-0.918129706972	-6.94534729071942	20.7098182436818	7.93368924137052e-07	3.29347217008271e-05	-0.823939031398031	-0.44397047341061
ENSG00000275778	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.824999563451	0.824999563451	-0.21827711299269	-0.20601445055	-16.5049162617543	4.29026626244956	4.79995811970527e-05	0.00145286008168099	-1.21419089190338	-0.872362460984
ENSG00000275778	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.740974608174	0.740974608174	0.088676842708927	0.1896034324075	-11.4811399896275	5.28850920875147	6.13478940480545e-05	0.00181877488386486	-0.795980457899755	-0.508615073030391
ENSG00000275778	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.9568169615765	0.9568169615765	0.49374325285522	0.515272690573	-13.5328044067403	11.0650291145033	3.13907975929349e-08	1.57452802651443e-06	-0.538334386169241	-0.387813031273319
ENSG00000275778	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.1599334023125	0.1599334023125	-0.42898453916013	-0.2959843885325	-9.80752666760004	30.2620820157504	6.55387173843971e-11	4.43118225813263e-09	-0.711506877141557	-0.466329005803703
ENSG00000275778	BRD-K87024524-065-17-7::2.5::HTS002	2.5	phenelzine	monoamine oxidase inhibitor	noncancer	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.6536770119495	0.6536770119495	0.349024919400881	0.3670145193675	-8.42976739862167	10.6722766437936	4.84294414233406e-06	0.000176916005008949	-0.384494806746298	-0.22480937835094
ENSG00000275778	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-1.513196958135	-1.513196958135	-1.95869985548983	-1.89031364576	-6.93127643533586	73.7278806501339	1.34021372593452e-09	7.8719284095867e-08	-0.573580077712046	-0.317425716997609
ENSG00000275778	BRD-K88568253-011-19-9::2.5::HTS002	2.5	iproniazid	monoamine oxidase inhibitor	noncancer	MAOA, MAOB	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.82076809628	0.82076809628	0.468998146425031	0.4917980145095	-7.87737294537669	3.51343394605898	0.00236282624969486	0.0462486015772466	-0.482828412987589	-0.22071148672235
ENSG00000275778	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-5.35409940563	-5.35409940563	-3.99806652763285	-3.812026280445	8.70800565949046	4.72126707832103	0.000439451828388414	0.0106824623938596	0.948521616522332	1.76354413947198
ENSG00000275778	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.571626496651	0.571626496651	-0.234680201989666	-0.164801274437	-8.89510786656732	3.20081137732585	0.00231296764580501	0.0454345195268757	-1.08480981481896	-0.527803582462377
ENSG00000275778	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.494557315426	0.494557315426	0.308331482698756	0.328628776305	-5.69683142778769	186.803565116865	4.68011685108369e-08	2.29224123531974e-06	-0.25071360987399	-0.121738055580498
ENSG00000275778	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.1515231210325	0.1515231210325	-0.0242661442982765	0.013127326234	-5.29117511010921	11.8283277783731	0.00020054451680135	0.00529602091443032	-0.248292885319512	-0.103285645342041
ENSG00000285188	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.3018927754415	-0.3018927754415	-0.0789691088051222	-0.05385103964535	5.38375028536389	162.030413784945	2.52307827685826e-07	1.12192706224223e-05	0.141157195606015	0.30469013766674
ENSG00000285188	BRD-A70858459-001-01-7::2.5::HTS002	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.3737539983275	0.3737539983275	0.0972628471087387	0.09357088918285	-7.21702268959975	5.39673436074623	0.000574164444748618	0.013551381045978	-0.372834418287632	-0.18014788414989
ENSG00000285188	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.00400443722574	-0.00400443722574	0.417885756035962	0.4743784763675	12.744733908105	131.135138226347	1.04871075396495e-24	2.65370870350121e-22	0.356404995374167	0.487375391149237
ENSG00000285188	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.772994663504	-0.772994663504	0.0536929427576339	0.0776480680764	19.5934984656117	3.98258917809077	4.13602688556215e-05	0.00126783539238508	0.709341769031184	0.944033443492084
ENSG00000285188	BRD-K00259736-001-16-4::0.15625::HTS002	0.15625	colchicine	microtubule inhibitor	noncancer	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-2.52994403818	-2.52994403818	-3.0598325784798	-2.82813961253	-4.73399535913217	157.995070262711	4.85984508734067e-06	0.000177354969815195	-0.750965839279264	-0.308811241320331
ENSG00000285188	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-2.3939081845	-2.3939081845	-1.11890242940134	-1.061699565275	17.5078604107803	43.6038242780584	2.41522649721639e-21	4.48961907998171e-19	1.1281994190759	1.42181209112143
ENSG00000285188	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.151439007215	-1.151439007215	-1.95225070901555	-1.885064313955	-5.93684395610518	5.70667195464271	0.00122024271812891	0.0263350520122699	-1.13502826245619	-0.4665951411449
ENSG00000285188	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.0473581851098	0.0473581851098	0.202753782146521	0.216719294223	5.30651279416039	49.5820309075192	2.60911147735859e-06	9.9947855912563e-05	0.0965647868681421	0.214226407205301
ENSG00000285188	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.210257124557	0.210257124557	0.344774931429942	0.3629794578985	4.31319188132363	165.145753089073	2.76115188618776e-05	0.000874789242593846	0.0729401234452275	0.196095490300656
ENSG00000285188	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.5736008147415	-0.5736008147415	-0.250934802082996	-0.133670857256	5.03403392927859	9.95367174491065	0.000518412657444641	0.0123717700097375	0.179759046556528	0.46557297876048
ENSG00000285188	BRD-K13049116-001-05-7::2.5::HTS002	2.5	BMS-754807	IGF-1 inhibitor	targeted cancer	AKT1, IGF1R	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.241877680785	-1.241877680785	-1.54130282015426	-1.37567614357	-3.36927806158117	39.117457265494	0.00170454990595933	0.0350709875006582	-0.479162863813195	-0.119687414925316
ENSG00000285188	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.244930697194	0.244930697194	0.508438637701472	0.511327989939	11.0871691770078	87.65910048286	2.290856323015e-18	3.25163539639392e-16	0.216273607161598	0.310742273853346
ENSG00000285188	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.1375624649065	-0.1375624649065	-0.329581488486137	-0.31281935927	-5.09875290014951	20.6955852298722	4.95582359197049e-05	0.0014951811861535	-0.270407480817085	-0.113630566342188
ENSG00000285188	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.4954586684045	0.4954586684045	-0.4831310413736	-0.373418715101	-8.24785820559139	4.69915174862714	0.000572629930440745	0.0135181408042113	-1.28955111374317	-0.667628305813032
ENSG00000285188	BRD-K16180792-001-01-7::2.5::MTS006	2.5	bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	noncancer	PTPN1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.150791951474	0.150791951474	-0.237856740431587	-0.0973395896878	-6.98540027048496	190.054629173544	4.6469013101756e-11	3.20349215473987e-09	-0.498394598453317	-0.278902785357858
ENSG00000285188	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.480818950848	-0.480818950848	0.0927038469610766	0.105022107206	12.7937284023892	3.32183455284897	0.000610865349025532	0.0142979315705246	0.438368093093542	0.708677502524611
ENSG00000285188	BRD-K17472821-001-01-2::2.5::MTS006	2.5	GSK2830371	protein phosphatase inhibitor	targeted cancer	PPM1D	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.625401352211	0.625401352211	0.209671816611163	0.222894017996	-21.7798427960689	156.135444452913	3.48474451815916e-49	8.11828051991886e-46	-0.453433195696504	-0.37802587550317
ENSG00000285188	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.4885678698325	0.4885678698325	-0.378710332932367	-0.1455477562875	-8.6932683386784	9.15733258107728	1.01208573103212e-05	0.000348352854739656	-1.09237114279437	-0.642185262735359
ENSG00000285188	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.1377509454054	0.1377509454054	-1.14336571830619	-0.889953286616	-10.0099799054021	4.31107717498069	0.000381409829178533	0.00941354068148384	-1.62656980114306	-0.935663526280119
ENSG00000285188	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.29808499838	-1.29808499838	-1.90902722119278	-1.67956785013	-5.22057352753434	6.84908246600724	0.00131167278268099	0.0280288649889565	-0.888905344997051	-0.332979100628518
ENSG00000285188	BRD-K22503835-001-11-0::2.5::HTS002	2.5	scriptaid	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.93954978287	-1.93954978287	-1.33672441039527	-1.30328750996	8.02859998826556	14.5467899638355	1.01483591098564e-06	4.13436164162024e-05	0.442350660669607	0.76330008427986
ENSG00000285188	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.36381782702	-1.36381782702	-0.965553696644377	-0.757900155601	4.07621827871161	161.07272754879	7.17293644635365e-05	0.00209509788360687	0.205317510636246	0.591210750114999
ENSG00000285188	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.0564755754764	0.0564755754764	-0.137251145636597	-0.1059972226705	-4.8638237378576	42.1241156390048	1.64480312341311e-05	0.000546078333467061	-0.274100157299978	-0.113353284926017
ENSG00000285188	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.03005021987	-0.03005021987	-0.403557883685853	-0.2809944464045	-5.97805305534566	116.647215835225	2.52270372736609e-08	1.28246813847876e-06	-0.497249578635555	-0.249765748996152
ENSG00000285188	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.505161632415	-1.505161632415	-0.340358183969381	-0.263302729629	16.525898845833	2.59984751754796	0.00105140568693749	0.0230793455013954	0.919639147085392	1.40996774980585
ENSG00000285188	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.565585739425	-1.565585739425	-1.00853415287548	-1.02230629729	6.56953986032142	5.11339884529452	0.00112466367000987	0.0245017320318708	0.3405299200722	0.773573253026845
ENSG00000285188	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-3.11257415653	-3.11257415653	-3.76240855216901	-3.649368876965	-5.8865123089679	46.4737868983736	4.143278733222e-07	1.78929032362026e-05	-0.871984450664224	-0.427684340613801
ENSG00000285188	BRD-K45551181-001-02-1::2.49051::HTS002	2.49051	MPI-0479605	mitotic kinase inhibitor	targeted cancer	TTK	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-2.66671288076	-2.66671288076	-2.30106168228394	-2.3121762476	3.9119856089936	32.6725165473427	0.000436911160964578	0.0106255227752612	0.175413707749496	0.55588868920263
ENSG00000285188	BRD-K48578705-001-17-6::2.5::HTS002	2.5	methyldopa	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.1303671962155	-0.1303671962155	0.258287239801257	0.2888342624615	13.8462200296409	191.000323209421	1.20922948488153e-30	5.07187761771379e-28	0.333288704987975	0.444020167045539
ENSG00000285188	BRD-K51747290-001-13-1::2.5::HTS002	2.5	hydroxyurea	ribonucleotide reductase inhibitor	chemo	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.387265008824	-0.387265008824	-0.21477038170872	-0.221646260579	3.57113597696425	20.5454696687305	0.00185065719254979	0.0375366239634715	0.0719086910021682	0.273080563228392
ENSG00000285188	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-6.47437412156	-6.47437412156	-5.91749699833262	-5.9507974936	6.50499901440986	6.7642262847894	0.00038411959378071	0.00946516077436488	0.353008223549271	0.760746022905493
ENSG00000285188	BRD-K59632282-052-03-1::2.5::HTS002	2.5	quinidine	sodium channel blocker	noncancer	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.2064923222175	0.2064923222175	0.442631883933897	0.447983088223	8.82492813243505	47.8444497129448	1.32165929437887e-11	9.74776032019717e-10	0.182333991329947	0.289945132102847
ENSG00000285188	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.166249114065	-1.166249114065	-0.681449336134835	-0.630554296997	8.52989235178029	49.5587187477522	2.73374895733285e-11	1.94118063955487e-09	0.370617342314003	0.598982213546326
ENSG00000285188	BRD-K61642990-001-01-0::2.5::HTS002	2.5	FERb-033	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.907483770185	0.907483770185	0.174576293135927	0.239686907074	-16.8174254488833	14.7649262742557	4.89876142030927e-11	3.35982923665109e-09	-0.825925538263017	-0.639889415835129
ENSG00000285188	BRD-K61734568-003-02-1::2.5::HTS002	2.5	2,3-DCPE	Bcl-XL downregulator	targeted cancer	BCL2L1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.10114597305335	0.10114597305335	-0.36167616420136	-0.146091240972	-5.886033793711	18.3718529509532	1.31123530123653e-05	0.000442088643823698	-0.627779470414182	-0.297864804095239
ENSG00000285188	BRD-K63126190-003-01-6::2.5::HTS002	2.5	epinephrine	adrenergic receptor agonist, neurotransmitter	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.745075140069	-0.745075140069	-0.433988508467715	-0.389178555772	4.38801689784967	94.7879075773846	2.96777104086406e-05	0.000933626008245052	0.170339026046059	0.451834237156511
ENSG00000285188	BRD-K67772619-001-05-1::2.5::HTS002	2.5	rheochrysidin	protein tyrosine kinase inhibitor	targeted cancer	PTPN1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.7209769456495	0.7209769456495	0.0134825771923707	0.07194686545995	-17.5756602403419	163.482943362446	1.64763845926865e-39	1.67363366510232e-36	-0.786979572167475	-0.628009164746784
ENSG00000285188	BRD-K68103045-001-02-9::2.5::HTS002	2.5	CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.5377340275125	0.5377340275125	0.446027174471436	0.4684149214555	-3.1951163041941	106.659356139914	0.00183861694038819	0.0373249127888064	-0.148607686426193	-0.0348060196559357
ENSG00000285188	BRD-K68488863-001-04-9::0.15625::HTS002	0.15625	ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	targeted cancer	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.301974811915	0.301974811915	0.515274319290948	0.524698126717	7.93350781577751	14.4583019126595	1.21929638612437e-06	4.91038284745679e-05	0.155805996931564	0.270793017820332
ENSG00000285188	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-2.885834246395	-2.885834246395	-3.67956984686927	-3.50719189578	-6.5695797436992	34.3748680770143	1.5041919235747e-07	6.9212527004689e-06	-1.03917247501531	-0.54829872593322
ENSG00000285188	BRD-K68938568-001-01-7::2.5::HTS002	2.5	GDC-0152	XIAP inhibitor	targeted cancer	BIRC2, BIRC3, BIRC7, XIAP	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.918957959273	0.918957959273	-0.451318574840284	-0.296863885148	-19.1013642207903	102.465227607466	1.5261484426772e-35	1.01268690269523e-32	-1.51255898400447	-1.2279940842221
ENSG00000285188	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.215948908072	-0.215948908072	-0.0771069342561117	0.061565492344	3.25303584518723	187.040221482316	0.00135477607162382	0.0287958756978558	0.0546444734179043	0.223039474213872
ENSG00000285188	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.6151947882235	-0.6151947882235	-0.206766291422655	-0.182274470613	13.4832027516316	9.70905666248106	1.31790968505882e-07	6.11928650106093e-06	0.34065932914812	0.476197664453569
ENSG00000285188	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.219097134347	0.219097134347	-0.689963698535866	-0.481859441946	-10.2380838813933	14.3394226879617	5.58700252728971e-08	2.71409035510307e-06	-1.09907887769444	-0.719042788071296
ENSG00000285188	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.954830904892	-0.954830904892	-0.418275124109372	-0.2259650044755	6.76652332814885	8.06370739963428	0.000137487034041996	0.0037730420639164	0.353950869716099	0.719160691849158
ENSG00000285188	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.5050395884005	-0.5050395884005	-0.166603030061175	-0.1689019992055	9.62259729338762	15.7410201654744	5.40909972883307e-08	2.63124588239007e-06	0.263777506751382	0.413095609927269
ENSG00000285188	BRD-K77245796-003-01-6::2.5::HTS002	2.5	gamma-aminobutyric-acid	benzodiazepine receptor agonist	noncancer	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.8959843304305	0.8959843304305	0.501203212354018	0.490985614625	-8.59372606144886	3.31997607682967	0.00222313822153783	0.0439195310059897	-0.5333205309939	-0.256241705159064
ENSG00000285188	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-5.25109899848	-5.25109899848	-4.12104091846055	-4.24145212342	8.8793593115533	14.9667174008509	2.37126338081631e-07	1.05925491693826e-05	0.858740263045656	1.40137589699324
ENSG00000285188	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.037146786865	-1.037146786865	-0.612265952337477	-0.517259346977	7.692166205811	65.5905643550205	9.75971081360836e-11	6.4781327314025e-09	0.314586700966792	0.535174968088253
ENSG00000285188	BRD-K81801188-001-02-8::2.5::HTS002	2.5	PP-121	protein tyrosine kinase inhibitor	noncancer	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-3.93736760044	-3.93736760044	-4.63157474208973	-4.63633744063	-6.17718582518636	21.4543231144574	3.60737712948399e-06	0.00013490935836419	-0.927618208250054	-0.460796075049414
ENSG00000285188	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.7686543898295	-0.7686543898295	-0.377543922769823	-0.338570487031	6.90238935923701	4.37692337590786	0.00164869078124737	0.0340688629438842	0.238990270968106	0.543230663151248
ENSG00000285188	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.4434994905425	0.4434994905425	0.30598859460307	0.320041105609	-4.38179745673368	9.35081849398131	0.00161204802559042	0.0334503476887181	-0.208098663817551	-0.0669231280613101
ENSG00000285188	BRD-K86797399-001-05-1::2.54945::HTS002	2.54945	SB-939	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-6.695615353295	-6.695615353295	-5.45148705147005	-5.51001928833	15.705655383106	189.331668910115	3.89792779082788e-36	2.77554473581511e-33	1.08787034227473	1.40038626137516
ENSG00000285188	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.4169719090085	-0.4169719090085	-0.115959639927961	-0.0422450278637	8.83770936915383	55.7276991178416	3.44131059534773e-12	2.71365952387889e-10	0.232774557713477	0.369249980447601
ENSG00000285188	BRD-K88172511-003-20-3::2.41866::HTS002	2.41866	naltrexone	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.4906500048045	0.4906500048045	0.307020889185037	0.300369801672	-8.25281882521404	182.881548767984	2.98832409684362e-14	2.89419121261815e-12	-0.227529751601892	-0.139728479637033
ENSG00000285188	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.170736012747	0.170736012747	0.0230771196890218	0.0377701807511	-6.65609264473286	135.003297380349	6.46564805838856e-10	3.92126735344188e-08	-0.191532048608876	-0.103785737507081
ENSG00000285188	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.669492813661	-0.669492813661	-0.359580089515082	-0.28708101882	4.39459681782104	11.0910558585114	0.00105201100791048	0.0230879036774979	0.154851698801191	0.464973749490645
ENSG00000285188	BRD-K97810537-001-13-6::2.5::HTS002	2.5	beclomethasone-dipropionate	glucocorticoid receptor agonist	noncancer	GPR97, NR3C1	allergy	allergic rhinitis	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.320203782177	-0.320203782177	0.0792672667680507	0.06870536578965	8.45520425061643	12.6324452371644	1.48552789652838e-06	5.91037142259201e-05	0.297100463415464	0.501841634474637
ENSG00000285188	BRD-K99383816-001-03-5::2.5::HTS002	2.5	ftorafur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.2221751801575	-0.2221751801575	0.0307428539519964	0.0749758772654	7.52213982726173	30.3534452904757	2.03206956524728e-08	1.04469042420217e-06	0.18428391540494	0.321552152814053
ENSG00000285188	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-7.398788163695	-7.398788163695	-5.62803702854481	-5.72114668903	18.8713605884324	43.03766673089	1.95361643900845e-22	4.01454130159389e-20	1.58152420562555	1.95997806467482
ENSG00000285188	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.42909508038	-1.42909508038	-0.854560136019104	-0.7866589985	13.0873395655574	190.038923779184	2.55116028746301e-28	8.96373169265015e-26	0.487940959706881	0.66112892901491
ENSG00000289720	BRD-A06352418-001-25-9::2.5::HTS002	2.5	terfenadine	histamine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.675657580607	0.675657580607	0.0543636814265476	0.03270660508035	-10.1315268402578	4.0118852986027	0.000526294206657563	0.0125431014142899	-0.791354630729662	-0.451233167631243
ENSG00000289720	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.3038350788195	-0.3038350788195	-0.047842045422567	0.112237719657	4.76683393566556	188.977347808483	3.7258692746513e-06	0.000138904476564053	0.150058781267867	0.361927285525999
ENSG00000289720	BRD-A17883755-001-06-1::2.5::HTS002	2.5	lenalidomide	anticancer agent	targeted cancer	CDH5, CRBN, PTGS2, TNF, TNFSF11	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	1.107329311875	1.107329311875	-0.0624201387768791	0.0179498928779	-13.0051546858774	3.07434965075177	0.000867418636788242	0.019510228670814	-1.45211813926735	-0.887380762036408
ENSG00000289720	BRD-A27883417-300-01-6::2.5::HTS002	2.5	alexidine	phosphatidylglycerophosphatase inhibitor	targeted cancer	PTPMT1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.0290660584029	-0.0290660584029	-0.236174100919709	-0.2582141227055	-4.94625416189114	193.958596603571	1.63500260923111e-06	6.45475178179951e-05	-0.289690336494162	-0.124525748539456
ENSG00000289720	BRD-A51964809-003-12-6::2.5::HTS002	2.5	halofantrine	antimalarial agent	noncancer	KCNH2, KCNN4	infectious disease	malaria	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.004539684495205	0.004539684495205	-0.131332613589375	-0.13262425304	-4.73917654693517	194.144323350529	4.14040391737657e-06	0.00015315992944553	-0.192416988723489	-0.0793276074456712
ENSG00000289720	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.3359810786075	-0.3359810786075	0.191139118681221	0.190024427126	13.8959101630806	4.20199628045838	0.000113656077324291	0.00318179119603421	0.42376695119806	0.630473443379381
ENSG00000289720	BRD-A67748489-001-10-0::2.5::HTS002	2.5	K-858	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-5.00454829389	-5.00454829389	-2.61766057966016	-2.49115990214	16.1334963388158	3.06275312449511	0.000460470668584325	0.0111390765154639	1.92146791142037	2.85230751703931
ENSG00000289720	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.879252822055	0.879252822055	0.202984122129868	0.236646785158	-13.9168985475731	11.7365343750928	1.18574119890002e-08	6.29056251037235e-07	-0.782408714500901	-0.570128685349363
ENSG00000289720	BRD-A93477898-001-04-2::2.5::HTS002	2.5	PETCM	caspase activator	noncancer	CASP3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.512357718441	0.512357718441	0.176286956028316	0.179996842636	-7.91163774574847	24.166525013967	3.65608363181873e-08	1.81693153788946e-06	-0.423709143474478	-0.24843238135089
ENSG00000289720	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.1175686163418	-0.1175686163418	0.0690319027912248	0.07956967035945	5.22986115683995	5.89788581634748	0.00206284620263284	0.0411894693277523	0.0989274149734989	0.274273623292551
ENSG00000289720	BRD-K02594908-001-16-4::2.5::HTS002	2.5	sulfanilamide	carbonic anhydrase inhibitor	noncancer	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.3693718125795	0.3693718125795	-0.369395925662871	-0.3369002650265	-8.93169071248848	15.8600572934931	1.38579051082367e-07	6.40671040539963e-06	-0.914237482399229	-0.563297994085514
ENSG00000289720	BRD-K03109492-001-02-2::2.5::HTS002	2.5	NSC-663284	CDC inhibitor	targeted cancer	CDC25A, CDC25B, CDC25C	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.674502653479	-0.674502653479	-1.21572375280281	-0.957814328752	-5.40998863369305	13.3881296805829	0.000107459202487039	0.00302252275719745	-0.756711516514136	-0.325730682133489
ENSG00000289720	BRD-K03601870-001-01-2::2.5::HTS002	2.5	ixabepilone	microtubule stabilizing agent	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-4.71939199142	-4.71939199142	-3.61372489763393	-3.52276573862	11.8560030348962	183.036787249883	1.9946892918421e-24	4.85817910490029e-22	0.921668200957743	1.2896659866144
ENSG00000289720	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-3.0759988757	-3.0759988757	-1.66626603108357	-1.3362918287	12.0121401477289	165.251597217175	2.71180833517241e-24	6.51590996265883e-22	1.17801647156672	1.64144921766615
ENSG00000289720	BRD-K06753942-001-14-5::2.5::HTS002	2.5	nobiletin	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.53005199681	0.53005199681	-0.080939935140984	-0.0747677969197	-8.18352864659377	3.48008719470321	0.00215914825136073	0.0428092586092408	-0.831088357927001	-0.390895505974967
ENSG00000289720	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.491008765938	-0.491008765938	-0.852446815577825	-0.70967469814	-6.36653315312502	34.1461253084498	2.83647594679651e-07	1.25503520479139e-05	-0.476793567160602	-0.246082532119047
ENSG00000289720	BRD-K08109215-001-06-4::0.625::HTS002	0.625	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.778479117805	0.778479117805	0.313281319096974	0.333968556929	-7.3037991662492	166.680877195224	1.09747110494625e-11	8.17019397193553e-10	-0.590945962949212	-0.33944963446684
ENSG00000289720	BRD-K09372874-001-01-0::2.5::HTS002	2.5	merimepodib	inosine monophosphate dehydrogenase inhibitor	noncancer	IMPDH1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.6560862939665	-0.6560862939665	-0.903012286700061	-0.8954429864795	-4.43498717410179	87.2091227166559	2.67332845627436e-05	0.000850358882019632	-0.357585964301769	-0.136266021165354
ENSG00000289720	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.55114537361	-1.55114537361	-2.51901816120463	-2.34739362698	-9.09853542740211	173.847249345205	2.08716909447786e-16	2.49214966490443e-14	-1.17782899485199	-0.757916580337272
ENSG00000289720	BRD-K11073688-001-01-6::2.5::HTS002	2.5	CPI-1189	tumor necrosis factor release inhibitor	noncancer	TNF	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.06355799914	-0.06355799914	-0.262386882194765	-0.2451174209795	-3.91698526598271	25.3732174521261	0.000600357374335002	0.0140950811352664	-0.30329456836423	-0.0943631977452996
ENSG00000289720	BRD-K12244279-001-05-8::2.5::HTS002	2.5	MEK1-2-inhibitor	MEK inhibitor	noncancer	MAP2K2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.353871593207	-0.353871593207	-0.153462686655065	-0.1558908725075	6.29097972326234	125.019234367405	4.84863958631678e-09	2.6818169648921e-07	0.137360936326224	0.263456876777647
ENSG00000289720	BRD-K12885236-001-02-7::2.5::HTS002	2.5	dapivirine	non-nucleoside reverse transcriptase inhibitor	noncancer	CYP3A4, CYP3A5	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.5201407355635	-0.5201407355635	-1.34867333252317	-1.23896057589	-12.4367354833101	4.22172786573173	0.000174480193729402	0.00468506206988586	-1.00972981603149	-0.647335377887852
ENSG00000289720	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.9335243595815	0.9335243595815	0.501073999601071	0.505306635797	-18.1280639628184	68.27246939233	8.47271319933847e-28	2.77667912431348e-25	-0.480049425439725	-0.384851294521133
ENSG00000289720	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.04996424851555	0.04996424851555	-0.980545272194521	-0.735958486111	-14.4257683857966	71.667515764641	6.9197916360045e-23	1.47762770970752e-20	-1.17292453572944	-0.888094505690697
ENSG00000289720	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.11684970262355	-0.11684970262355	-0.374944351536099	-0.173057746988	-3.36367730446047	96.9071682023692	0.00110275994704148	0.024071029299262	-0.410384118036863	-0.105805179788235
ENSG00000289720	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.7677697811315	0.7677697811315	0.543188041407085	0.547894384564	-8.59005113735735	96.7036778923684	1.50351897316833e-13	1.35569086243246e-11	-0.276473146232666	-0.172690333216164
ENSG00000289720	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.36931848776	-1.36931848776	-1.90827739498878	-1.67956785013	-5.62191557464226	98.8380446202571	1.75245596513811e-07	7.96949150333303e-06	-0.729184652140343	-0.348733162317227
ENSG00000289720	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.0160902383524535	0.0160902383524535	-0.170950204002621	-0.1612454874865	-7.32244249849951	4.97626490405156	0.000759920206534055	0.0173749667107145	-0.252796280721788	-0.121284603988362
ENSG00000289720	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-4.374135570175	-4.374135570175	-3.25546044129427	-2.99271378173	8.52661361850103	14.57201437405	4.82339263910109e-07	2.06304713818778e-05	0.838316045588834	1.39903421217262
ENSG00000289720	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.597179250001	0.597179250001	0.0856999508673391	0.0863678330512	-20.4446894437828	172.919510383698	5.19114227321264e-48	1.05963079264323e-44	-0.560858698746399	-0.462099899520923
ENSG00000289720	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.283671216125	0.283671216125	-0.40974749479524	-0.310618907363	-11.7608534759148	135.634949323315	1.8852738000454e-22	3.88527738740318e-20	-0.810018307813116	-0.576819114027363
ENSG00000289720	BRD-K25412176-001-01-9::2.5::MTS006	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.0191581087858	-0.0191581087858	-0.669301696184438	-0.516853765181	-9.86294512576491	9.11419444761393	3.65384557769425e-06	0.000136432938819099	-0.798975684237435	-0.501311490559842
ENSG00000289720	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.813754849754	-0.813754849754	-0.497193684201561	-0.427199621459	5.5949729896355	8.97406323015734	0.000339960248637221	0.0084843199965262	0.188512874834184	0.444609456270693
ENSG00000289720	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.0649781643109	0.0649781643109	-0.0339458686615025	-0.0304287468122	-3.99687527122157	90.3310204489514	0.000130849224750955	0.00361262185902967	-0.14809245409803	-0.0497556118467751
ENSG00000289720	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.5342290593705	0.5342290593705	0.268173479100716	0.2845478404215	-8.4780695851184	8.4217121431497	2.09855217361492e-05	0.00068076371850872	-0.337795805201011	-0.194315355338558
ENSG00000289720	BRD-K28907958-001-04-3::2.5::HTS002	2.5	CD-437	retinoid receptor agonist	targeted cancer	RARG	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-3.38889595929	-3.38889595929	-4.21222402192777	-4.123946828915	-8.94221115910861	187.433648957334	3.63527137188766e-16	4.22988098732524e-14	-1.00495879317893	-0.6416973320966
ENSG00000289720	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-3.09018738329	-3.09018738329	-3.63508194858146	-3.592577528105	-5.97239872286469	7.18939750432399	0.000503643315044533	0.0120690259470237	-0.759485358055594	-0.330303772527327
ENSG00000289720	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.2074268339545	0.2074268339545	-0.0224660214763102	-0.0227579244188	-6.33358280193321	5.7301468182606	0.00086641923812858	0.0194938871392883	-0.319733314197788	-0.140052396663832
ENSG00000289720	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.367378840693	0.367378840693	0.577023218874234	0.571651612309	6.32533482954736	87.5615362170796	1.03697162975903e-08	5.52593467017958e-07	0.143773837209728	0.27551491915274
ENSG00000289720	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.06938104792635	0.06938104792635	-0.18048792911026	-0.13613940777	-6.92900860152441	79.8418233391721	9.78765654725818e-10	5.83040200143774e-08	-0.321635410525188	-0.178102543548032
ENSG00000289720	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.802736793219	0.802736793219	-0.804536260594409	-0.4002530483955	-13.3095215885937	38.4996565821343	5.52791900897914e-16	6.30880379805906e-14	-1.85163705960271	-1.36290904802411
ENSG00000289720	BRD-K41783120-001-02-8::2.5::HTS002	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.674369596468	-0.674369596468	-0.274490663776438	-0.1460716862095	5.71034170484287	19.6726173746402	1.46315354155076e-05	0.000489382389836193	0.253648870706479	0.546108994676644
ENSG00000289720	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.4484967680645	-0.4484967680645	-1.33917489086188	-1.07204580455	-7.37895831087845	4.47907151527476	0.00114216362628863	0.0248551921879193	-1.21213525859145	-0.569220987003321
ENSG00000289720	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-5.851199623325	-5.851199623325	-5.27444858700426	-5.30447708423	7.04049890223999	143.721037989246	7.27887980005959e-11	4.9028127865084e-09	0.414829206113	0.738672866528489
ENSG00000289720	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.257020519367	-0.257020519367	-0.679105166242565	-0.588520646364	-7.63470391318098	67.5882622261917	1.04391204104794e-10	6.89705992126273e-09	-0.532416327550463	-0.311752966200666
ENSG00000289720	BRD-K48195801-001-01-6::2.5::HTS002	2.5	tecastemizole	histamine receptor antagonist	noncancer	KCNH2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.1973674662565	-0.1973674662565	0.346523222887263	0.312371086483	15.9226693792612	51.8523302874964	1.30639681866179e-21	2.47348695889542e-19	0.475342478061934	0.612438900225593
ENSG00000289720	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.3739891121635	0.3739891121635	-0.12805338839967	-0.007473093877485	-12.5516455026368	179.999979507585	2.29769896611232e-26	6.54871704398786e-24	-0.580968067506433	-0.423116933619907
ENSG00000289720	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.563420675169	0.563420675169	-0.143175935355764	0.01900224238145	-11.2272512335582	151.130830360589	1.1870886322472e-21	2.25956944459068e-19	-0.83094432761621	-0.582248893433317
ENSG00000289720	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.817423623665	-1.817423623665	-0.450454903295423	-0.469747665561	21.7077895377291	187.000406599771	5.44564435676724e-53	1.85263414181201e-49	1.24274319415943	1.49119424657972
ENSG00000289720	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.378662391561	-0.378662391561	-0.689568786882299	-0.642732938193	-4.64160428042089	7.19102000044171	0.00220348771649683	0.043563446064851	-0.468445974503977	-0.153366816138622
ENSG00000289720	BRD-K65877271-001-01-8::2.5::HTS002	2.5	halobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.4547013178635	0.4547013178635	-0.290411806097842	-0.253825714787	-11.9447505925906	5.16711125614759	5.84636228928661e-05	0.0017396154145502	-0.903918575013663	-0.586307672909021
ENSG00000289720	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-3.97011639722	-3.97011639722	-2.56656391242839	-2.37614016574	12.0123354345365	173.395171036391	1.41747856315645e-24	3.54500306841025e-22	1.17293561521201	1.63416935437121
ENSG00000289720	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.784013472565	-1.784013472565	-0.71138800324295	-0.5475428257095	7.85111721221345	3.44720900789439	0.00257146436771417	0.0497912536333734	0.66806888707005	1.47718205157405
ENSG00000289720	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.4032547053895	-0.4032547053895	-0.791479747649008	-0.646845557406	-5.69818405235244	96.0183451251065	1.32607884213627e-07	6.15321827573553e-06	-0.523464397841899	-0.252985686677118
ENSG00000289720	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.3378693969305	0.3378693969305	-0.535881356609052	-0.376499820922	-13.599336143978	7.85720616914477	9.7181892271677e-07	3.97801714833771e-05	-1.02238039482638	-0.725121112252723
ENSG00000289720	BRD-K72414522-001-06-7::2.5::HTS002	2.5	AZD5438	CDK inhibitor	targeted cancer	KCNH2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.753067210015	-1.753067210015	-2.42427876060207	-2.22027282363	-5.42377011998466	8.00151007549124	0.000627573563524851	0.0146426316456257	-0.956578690573708	-0.385844410600427
ENSG00000289720	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.09520035517265	-0.09520035517265	0.244804357410096	0.276258886308	9.54470180297866	189.122066129205	7.16041942505914e-18	9.75022576209339e-16	0.269736531622077	0.410272893543415
ENSG00000289720	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-2.09420509255	-2.09420509255	-0.665866800339022	-0.4541784692175	15.8482001044517	11.6493546867248	3.05523677990462e-09	1.72549629459862e-07	1.23131258213058	1.62536400229138
ENSG00000289720	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.4561864962525	0.4561864962525	-0.153777040303061	-0.132191437107	-9.89011082559472	3.18735375170623	0.00169427377011863	0.0348897005068943	-0.799869937233651	-0.42005713587747
ENSG00000289720	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.3764372006365	-0.3764372006365	-0.962533431764836	-0.892479910689	-8.41604537526821	5.37114925165642	0.000272142561661705	0.00694216175891354	-0.761454982301177	-0.410737479955495
ENSG00000289720	BRD-K81332461-001-01-4::2.5::HTS002	2.5	maxacalcitol	vitamin D receptor agonist	noncancer	VDR	endocrinology	hyperparathyroidism	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.2329574671655	0.2329574671655	-0.144581550202861	-0.1171657345245	-9.6886257062182	13.2660014414229	2.18645941201641e-07	9.83053617197535e-06	-0.461551355986132	-0.293526678750589
ENSG00000289720	BRD-K81839095-001-30-1::2.5::HTS002	2.5	estrone	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.6835048739255	0.6835048739255	0.40344396234582	0.3953780325455	-10.4359373150863	13.7000255580531	6.73170621312083e-08	3.24006256670104e-06	-0.337737298343546	-0.222384524815815
ENSG00000289720	BRD-K82135108-001-04-3::0.15625::MTS010::PROS001_PR500	0.15625	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.832107207005	-1.832107207005	-0.967303981010736	-0.893367929172	10.6939991762879	20.002117195714	1.01075961751922e-09	6.00929536930036e-08	0.696116502921153	1.03348994906737
ENSG00000289720	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.037817978498	-1.037817978498	-1.69413226343296	-1.42296021894	-6.60144138657898	14.1467744129341	1.12669269760237e-05	0.000383976656359387	-0.869341280668142	-0.443287289201778
ENSG00000289720	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.9096407562895	0.9096407562895	0.45093079632204	0.472553592618	-14.7008168376439	186.818708896212	5.22128661216583e-33	2.73612014254008e-30	-0.520265525400541	-0.397154394534378
ENSG00000289720	BRD-K85406984-001-01-0::0.15625::HTS002	0.15625	sobetirome	thyroid hormone receptor agonist	noncancer	THRA, THRB	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.5527198042005	0.5527198042005	0.235358888066436	0.238622249408	-8.43863030464742	5.10350444306791	0.00034670106488827	0.00864047587633	-0.41344887681935	-0.221272955448778
ENSG00000289720	BRD-K86816506-001-01-8::2.5::HTS002	2.5	PF-04457845	FAAH inhibitor	noncancer	FAAH	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.111601803281	-0.111601803281	-0.410164759626888	-0.370640421909	-10.2534604602808	192.966456658582	5.71735756401999e-20	9.41887416863059e-18	-0.355993891408702	-0.241132021283074
ENSG00000289720	BRD-K87909389-003-03-4::2.5::HTS002	2.5	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-5.05345113796	-5.05345113796	-5.33392918537367	-5.39635429682	-3.93843621774493	68.0216419653382	0.000195683039295046	0.00518232424676484	-0.422585720183951	-0.138370374643379
ENSG00000289720	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.76481388551	-1.76481388551	-1.4036055150207	-1.36288222555	4.51998086952484	103.462029799951	1.64975355701037e-05	0.000547522499412319	0.202726816776318	0.519689924202274
ENSG00000289720	BRD-K96344439-002-02-7::2.5::MTS006	2.5	tofogliflozin	sodium/glucose cotransporter inhibitor	noncancer	GCK	endocrinology	diabetes mellitus, diabetes mellitus	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.032749878861	-0.032749878861	0.14013049811915	0.25364293864	4.85903479663205	190.526260446808	2.45650218596503e-06	9.44902471313172e-05	0.102700723461171	0.243060030499128
ENSG00000289720	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.086042163274	0.086042163274	-0.244417393125326	-0.195507988981	-7.31363955441118	94.0147244909985	8.54700806486848e-11	5.71627290688602e-09	-0.420173282544182	-0.24074583025447
ENSG00000289720	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.164556788883	0.164556788883	-0.727984229860606	-0.596555071115	-14.6676472374755	126.242673688874	4.76580900647909e-29	1.78263713533971e-26	-1.01296111678789	-0.772120920699321
ENSG00000289720	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.477425829173	-0.477425829173	-1.09518078036153	-1.03443241086	-9.42247736086157	98.0070437777722	2.16932060210421e-15	2.33759836766412e-13	-0.747860171646656	-0.487649730730413
ENSG00000289720	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.55413111178	-0.55413111178	-0.863722062391879	-0.791872957089	-6.05716577185864	14.4515204901618	2.57515413304835e-05	0.000822548748408523	-0.41889380237665	-0.200288098847108
ERBB2	BRD-A55484088-050-02-5::2.5::HTS002	2.5	BNTX	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.6208998296222	-0.744387133965	-1.40467344303464	-1.34698387815	-5.66204424313086	6.68212224424438	0.000900219506296616	0.0201760061241292	-1.1142820688484	-0.453265157976475
ERBB2	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.09658525435776	-0.0369436572238	-1.05035932837887	-0.807833132642	-5.18239194177869	6.11484720423336	0.00193519739154917	0.0389820415162915	-1.40206455583435	-0.505483592207858
ERBB2	BRD-A98299281-050-09-6::2.5::HTS002	2.5	hydroxytacrine-maleate-(r,s)	cholinesterase inhibitor	noncancer	ACHE	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.13991819063788	0.200121277163	-0.2600202574438	-0.148647992452	-5.42627235494997	10.3628623382642	0.000256485985552415	0.00659062280271712	-0.563385259745918	-0.236491636417441
ERBB2	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.22932787816984	0.291072057344	-0.375044711731556	-0.301432715387	-5.15020296095765	7.56397996068353	0.00104134328185843	0.0229053001402171	-0.877719919319112	-0.33102526048368
ERBB2	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.041272274087746	0.0221689946497	-0.30135461730647	-0.219975302496	-4.50252457274698	14.4512375552502	0.00046034232945097	0.0111390765154639	-0.505361086442378	-0.179892696346055
ERBB2	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.6953343059796	0.633992184565	-0.398362585846043	-0.152257865386	-7.09089759536764	7.80016160346385	0.000116427145728241	0.00325087463741378	-1.45096633439407	-0.736427449257214
ERBB2	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.07017876931452	0.0232020141775	-1.16201193698002	-0.90366074847	-8.14432702444638	10.2747256866667	8.49490711642441e-06	0.000296483463174748	-1.56807775444455	-0.896303658144529
ERBB2	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.2893158836785	-0.33344602652	-0.850055768323464	-0.748477383955	-4.81729256259682	7.38896948223477	0.00165739135936232	0.0342189608574094	-0.83307538282409	-0.288404386465838
ERBB2	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.2974968983782	-0.393054092081	-0.950120868932144	-0.8036444409985	-4.61095704855612	6.93069347028408	0.00251641361390675	0.0488444496880112	-0.987986958411486	-0.317260982696402
ERBB2	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.725246475752	-1.85946916855	-0.255210557892031	-0.1361289826035	6.43251559208308	4.51326654582444	0.00196466139701254	0.0394790842452936	0.862998716457224	2.07707311926271
ERBB2	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.7242050123848	-0.675706153165	-1.76646602155066	-1.666963154235	-6.53471445597788	6.6785813973793	0.000394416731513862	0.00969104019816971	-1.42312009263048	-0.661401925701241
ERBB2	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4216499751634	0.446647413346	-0.283422472858755	-0.228373945443	-9.96707098528551	12.7196471009928	2.25785954224757e-07	1.01175993692323e-05	-0.858240442575318	-0.551904453468992
ERBB2	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.1973331757482	-1.34385919366	-2.03006064625737	-2.27655784807	-5.52799670448582	8.88491240686731	0.000383803115636243	0.00946389070078238	-1.17416879268868	-0.491286148329664
ERBB2	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.89765401496	-1.80121484936	-3.68732267988787	-3.59913816567	-6.52264108707781	5.90386646809741	0.000661306664777454	0.0153411836946733	-2.46370614677354	-1.1156311830822
ERBB2	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.4442025411876	-0.304050673627	-1.2203292738905	-1.19478399038	-4.8443501980764	6.3474641790855	0.00245515391629636	0.0478286387680314	-1.1630096284024	-0.389243837003398
ERBB2	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.1693250829504	0.182836878937	-0.506247821306184	-0.003081886328155	-4.32124290627849	8.92567739568573	0.00196738443853804	0.0395300964964302	-1.02968262141338	-0.321463187099791
ERBB2	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.803199738926	-2.8760480509	-0.471971205337641	-0.38697038764	12.2250707775658	4.99120050618066	6.55309955320494e-05	0.00193034534653499	1.84077797222698	2.82167909494973
ERBB2	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.426679096674	-3.46992408001	-4.38201684128209	-4.11283332285	-5.79289595438067	16.3177372846484	2.54210807243007e-05	0.000813205195605768	-1.30439032521629	-0.606285163999881
ERBB2	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	OE19, HCC1419, MKN7	OESOPHAGUS, BREAST, STOMACH	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.983953314186333	-1.00898440678	-1.66024784947722	-1.74344352007	-9.40486453679711	13.0832558871799	3.46487109022813e-07	1.51093053081893e-05	-0.831544083168852	-0.521044987412914
ERBB2	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.491764746585	-0.417422824778	-1.44223398999112	-1.17040496281	-5.19870669905889	6.98283024362015	0.00126444669194361	0.0271441902080912	-1.38300439401339	-0.517934092798863
ERBB2	BRD-K95785537-001-23-1::2.5::HTS002	2.5	PP-2	src inhibitor	targeted cancer	ABL1, LCK, LYN, RIPK2, SRC	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.17892491332236	0.193018605756	-0.28641104900901	-0.15060797847	-3.81281794442272	13.0361820400733	0.00214411386035426	0.0425944455556042	-0.728924122735589	-0.201747801927152
ERBB2	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	OE19, NCIN87, HCC1419, MKN7, NCIH2170	OESOPHAGUS, STOMACH, BREAST, LUNG	carcinoma (adenocarcinoma), carcinoma, carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.0723012275289	0.0802118926619	-0.249600954869553	-0.2009376415855	-5.94677362831611	32.1913427051394	1.23819971119575e-06	4.98463760144393e-05	-0.432136825987911	-0.211667538808996
ERC1	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.637462866711	-0.637462866711	-0.95050573119559	-0.8814928301585	-4.69369682271958	31.5794803421902	4.96338607709581e-05	0.00149725204013775	-0.448965709432009	-0.177120019537171
ERC1	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.458450444875	-3.458450444875	-2.0803391917484	-2.05580997476	19.4897165268762	174.147910641705	1.25678329672549e-45	2.07203928618368e-42	1.23855303011987	1.51766947613334
ERC1	BRD-A18696154-003-22-6::2.5::HTS002	2.5	idazoxan	adrenergic receptor antagonist	noncancer	ADRA2A	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.23080187727	-1.23080187727	-0.64900260958785	-0.5933012129785	9.22502048988942	5.79723741963123	0.000111544780238412	0.00312799701736474	0.426160723870831	0.737437811493468
ERC1	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.192936361728	0.192936361728	-0.0548354276512992	0.002007296385155	-7.18067377273493	193.99193447879	1.44407586884242e-11	1.06068312848913e-09	-0.315825623695369	-0.179717955063229
ERC1	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.26672373766	0.26672373766	-0.183102525900433	-0.008049193223815	-8.30192067101754	113.92405243531	2.36903894321143e-13	2.09815598206431e-11	-0.557163923239069	-0.342488603881796
ERC1	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.9401733617265	-0.9401733617265	-0.526193394565828	-0.5103777767265	9.62688998594885	4.31349790846708	0.000447277795323458	0.0108530060674608	0.297931528987997	0.530028405333347
ERC1	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.125940916665	0.125940916665	-0.188336282391508	-0.0590439534084	-6.95711465826492	31.0907970976243	8.20425613123364e-08	3.89804924041493e-06	-0.406398249829612	-0.222156148283403
ERC1	BRD-K01507359-001-22-9::2.5::HTS002	2.5	rifampin	RNA polymerase inhibitor	noncancer	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.2263674430635	-0.2263674430635	-0.0924684699364651	-0.0471468975624	4.06398830221908	14.2144253427517	0.00112764889926454	0.0245617744848039	0.0633331116387016	0.204464834615368
ERC1	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.6244507443035	-0.6244507443035	-0.0780949029843528	-0.0155909227599	11.0930049707253	4.85939348162674	0.000123425566200759	0.00342886301727057	0.418638978033242	0.674072704605052
ERC1	BRD-K03243820-001-23-8::2.37329::HTS002	2.37329	trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	chemo	TYMS	infectious disease	virus herpes simplex (HSV)	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.96851713457	-1.96851713457	-2.25649050399803	-2.05370099582	-3.23869119449861	188.730821140442	0.00141885543021054	0.02997554120272	-0.463371404634778	-0.112575334221286
ERC1	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.93132240429	-0.93132240429	-0.373729935482298	-0.261056095384	9.01553539265196	40.1950120056708	3.35991617437328e-11	2.34978907185856e-09	0.432611968183178	0.682572969432226
ERC1	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-4.054960091395	-4.054960091395	-1.65579585765368	-1.3362918287	19.9541296863445	77.1337130504176	3.444401448369e-32	1.6626917072691e-29	2.15975443535321	2.63857403212944
ERC1	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.9237457197	-3.9237457197	-3.17159220587756	-3.022544850085	6.93871596572334	163.010662271333	8.86016886383827e-11	5.91586022559997e-09	0.538105247842018	0.966201779802872
ERC1	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.786512671275	-1.786512671275	-0.838809932363751	-0.6898846907305	12.1783574900771	3.1799506357312	0.00089533623933617	0.0200791588197847	0.707791800735026	1.18761367708747
ERC1	BRD-K08109215-001-06-4::2.5::MTS010::PROS002_PR500	2.5	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.7789008815755	-0.7789008815755	-0.166717585794966	-0.03477254501165	11.9270074357254	105.317505161302	2.88497363036483e-21	5.31214358438543e-19	0.510413950639753	0.713952640921315
ERC1	BRD-K09372874-001-01-0::2.5::HTS002	2.5	merimepodib	inosine monophosphate dehydrogenase inhibitor	noncancer	IMPDH1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.57583871826	-1.57583871826	-0.892677989797887	-0.886556137179	9.77788666414531	5.55104249459045	0.000104800644851843	0.00295744798030951	0.50879175615093	0.857529700773295
ERC1	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.2949296976405	0.2949296976405	-0.429261973487723	-0.399128631959	-13.3132788849781	42.8113076614228	8.11838459110292e-17	1.00115376929028e-14	-0.833906030931689	-0.614477311324758
ERC1	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.0956486665386	-0.0956486665386	-0.42291512475752	-0.390164965854	-9.47603042594681	140.670305421992	8.85116557131728e-17	1.08527543806342e-14	-0.395543623070387	-0.258989293367452
ERC1	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.1273457174695	-0.1273457174695	-0.0255888032741538	-0.0049429262928	3.96130732146559	50.0913392114689	0.00023624824390003	0.00612864316955331	0.0501639608966902	0.153349867494002
ERC1	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.230496521715	-1.230496521715	-0.937782599232962	-0.89400890482	5.78652123202242	154.79278955592	3.86483554181359e-08	1.9134819515855e-06	0.192786974606577	0.392640870357499
ERC1	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.0846042738262	0.0846042738262	0.550417306034655	0.548346398175	14.3750041760843	5.95564737320904	7.5419961765938e-06	0.000265560785039128	0.386379025472107	0.545247038944802
ERC1	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.64539099939	-1.64539099939	-0.22176064941713	-0.0566869180409	15.9329445576917	3.29495688950835	0.000312370708504474	0.00785608736306371	1.15314619876298	1.69411450118276
ERC1	BRD-K25630527-001-03-8::2.5::HTS002	2.5	LY2784544	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.68941913293	-1.68941913293	-1.07192761627213	-0.867561627106	8.55183486920353	117.282153862589	5.32418229289556e-14	5.0358634892057e-12	0.474495437983218	0.76048759533252
ERC1	BRD-K26756394-001-02-2::2.5::HTS002	2.5	VE-821	ATR kinase inhibitor	targeted cancer	ATR	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.0938542263945	0.0938542263945	-0.117332926607335	-0.0693224120433	-5.40742790186476	192.525805994245	1.88068735084164e-07	8.52550421359005e-06	-0.28821778419544	-0.134156521808231
ERC1	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.07693976790495	-0.07693976790495	0.150997812265208	0.201815706844	4.58868326077934	9.15063830552923	0.00125604741619306	0.0269909150456428	0.115848867122195	0.340026293218122
ERC1	BRD-K28578425-001-07-0::2.5::HTS002	2.5	cilostamide	phosphodiesterase inhibitor	targeted cancer	PDE3A, PDE3B	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.3642475949575	-0.3642475949575	-0.0837992259293896	-0.0458610158792	6.81795273187623	9.36554257408515	6.39117847623189e-05	0.00188809771417272	0.187947917300941	0.37294882075528
ERC1	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-4.072686128385	-4.072686128385	-3.69320837954216	-3.84343615246	3.59995964491599	26.2367108672243	0.00130176388448823	0.0278365510923355	0.16289606744886	0.596059430236811
ERC1	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.1408695296275	0.1408695296275	-0.0736343009596017	0.0269217911151	-6.7885583801462	107.601607889686	6.43469406582519e-10	3.90470425944011e-08	-0.277138872679619	-0.151868788494584
ERC1	BRD-K32821942-001-21-3::2.5::HTS002	2.5	azathioprine	dehydrogenase inhibitor	noncancer	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.07485036606	-1.07485036606	-0.63341918049953	-0.563960443725	10.3996409767268	188.743916143728	2.58724247737756e-20	4.42908221193175e-18	0.357700160685059	0.525162210435881
ERC1	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.193439556515	-1.193439556515	-0.684520288858199	-0.601202853428	8.27177347977898	6.7961099077786	8.66699568881242e-05	0.00249006503885721	0.362546732490394	0.655291802823207
ERC1	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.419378661096	-0.419378661096	-0.175475009017723	-0.120119113317	6.11374382931564	14.5019877656957	2.29755107523377e-05	0.000740276344563708	0.158615881671291	0.329191422485263
ERC1	BRD-K37764012-001-04-1::2.5::HTS002	2.5	PF-03758309	p21 activated kinase inhibitor	targeted cancer	PAK4	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.736477926545	-3.736477926545	-3.19283945156656	-3.08603561013	5.72485300617907	180.320565427245	4.25142445027905e-08	2.09135540739926e-06	0.356260513031778	0.731016436925106
ERC1	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.395702454114	-0.395702454114	-0.698740147945839	-0.5759216002185	-4.12941911017676	12.8581626614694	0.00121271048500341	0.0261909538029319	-0.461754447544797	-0.144320940118881
ERC1	BRD-K42981054-001-01-9::2.5::HTS002	2.5	mibampator	glutamate receptor modulator	noncancer	GRIA1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.51231796044	-1.51231796044	-1.04723866391872	-1.06430669766	8.0704733272062	19.3473301366604	1.29184051050525e-07	6.00735267468172e-06	0.344610435102781	0.585548157939785
ERC1	BRD-K43644456-001-04-0::2.37833::HTS002	2.37833	WP1130	deubiquitinase inhibitor	targeted cancer	JAK2, UCHL5, USP14, USP9X	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-5.16220589279	-5.16220589279	-6.30351503253553	-6.296490539345	-15.0669821332846	36.4339189924475	3.13996565416338e-17	4.02022520126155e-15	-1.29487176934698	-0.987746510144078
ERC1	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.9646378382555	-0.9646378382555	-0.611896737513186	-0.573831164789	4.90287857910207	190.126845106949	2.01907684376712e-06	7.8609758555452e-05	0.210826758875412	0.494655442609217
ERC1	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.86137642501	-1.86137642501	-1.32390272387459	-1.441894150425	7.47066497318752	8.3885195624882	5.55142921005493e-05	0.00165992225329501	0.372897278999536	0.702050123271276
ERC1	BRD-K60866521-001-07-1::2.5::MTS010::PROS003_PR500	2.5	idelalisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.1700925027745	-0.1700925027745	-0.00976552448678053	0.00998791590484	6.85801341242438	14.083179963403	7.59129763207026e-06	0.000267077352295467	0.110213817930816	0.210440138644623
ERC1	BRD-K61936403-001-01-7::2.5::HTS002	2.5	AS-1949490	SHIP2 phosphatase inhibitor	noncancer	INPP5D	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.1570374877605	-0.1570374877605	0.245798725548409	0.276762978408	8.49446534271315	5.66955201746703	0.000196519166826068	0.00519932804674292	0.285136041758896	0.520536384858922
ERC1	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.603331054465	-0.603331054465	-1.08287788627837	-0.4089077458395	-4.16706878077523	177.578512156654	4.81184300139173e-05	0.00145625176312523	-0.706647457432269	-0.252446206194475
ERC1	BRD-K66911501-003-01-2::2.5::HTS002	2.5	MK-3207	calcitonin antagonist	noncancer	CALCA	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.2879752437605	-0.2879752437605	0.202426916152617	0.229755723799	17.2232555077633	188.688494581188	1.44669478011542e-40	1.6405748440601e-37	0.434235358122061	0.546568961704172
ERC1	BRD-K67868012-001-07-6::2.5::HTS002	2.5	PI-103	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.858732910368	-0.858732910368	-0.519164542920805	-0.4812241803595	8.17426262068719	70.0352852069912	8.69487316938797e-12	6.56646748245861e-10	0.256717866227174	0.422418868667215
ERC1	BRD-K68103045-001-02-9::2.5::HTS002	2.5	CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.675571692438	0.675571692438	0.444576251682746	0.4684149214555	-8.30395978507923	188.23196773448	1.93092791044635e-14	1.90891996364417e-12	-0.285869556484372	-0.176121325026136
ERC1	BRD-K68336408-001-10-9::2.5::HTS002	2.5	tyrphostin-AG-1478	EGFR inhibitor	targeted cancer	EGFR, MAPK14	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-2.03628433702	-2.03628433702	-2.64796360252345	-2.59421184968	-5.285095149144	12.3915590993366	0.000173308684674592	0.0046576899156891	-0.862966864297953	-0.360391666708943
ERC1	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.08516037483	-3.08516037483	-3.67748266227832	-3.50719189578	-5.34299166443927	190.066788182004	2.59788017805104e-07	1.15375271587547e-05	-0.810995616303503	-0.373648958593146
ERC1	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.1334826906101	-0.1334826906101	-0.728946841348853	-0.60872932846	-5.83835129001659	32.0281231851203	1.72852978840531e-06	6.79270372238945e-05	-0.803207562349656	-0.387720739127849
ERC1	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.62323439192	-0.62323439192	-0.189288358837877	-0.131154903569	10.103331949787	188.317230242406	1.88690421244693e-19	2.96494349669749e-17	0.349219547546102	0.518672518618145
ERC1	BRD-K79259477-001-04-9::2.5::HTS002	2.5	NVP-BHG712	ephrin inhibitor	targeted cancer	EPHB4	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.1698352760775	-0.1698352760775	0.154831777832637	0.151755478673	7.6713109085121	6.44573291846321	0.000180577748289243	0.0048322377599339	0.222819651679341	0.426514456140933
ERC1	BRD-K79612754-001-19-1::2.62081::HTS002	2.62081	inosine	neurotrophic agent	noncancer	PARP1, PNP	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-2.05807226557	-2.05807226557	-1.39153739392301	-1.34952956082	10.0730205720265	186.028165286844	2.53674753647382e-19	3.93414300104847e-17	0.535994210314429	0.797075532979549
ERC1	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.2148672719195	-0.2148672719195	0.0245264834043301	0.0294162092714	7.61739505593533	13.7048886945573	2.75172762229644e-06	0.000105035624142328	0.171852590396919	0.306934920250741
ERC1	BRD-K80700417-001-04-2::2.5::HTS002	2.5	SGI-1776	Pim kinase inhibitor	targeted cancer	FLT3, PIM1, PIM2, PIM3	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.191630961965	-1.191630961965	-0.340150631598509	-0.3090790625965	13.0486516924304	177.059325728226	1.05705409210758e-27	3.43268706829281e-25	0.722704104742818	0.980256555990165
ERC1	BRD-K89015388-001-01-7::2.5::HTS002	2.5	GSK923295	centromere associated protein inhibitor	targeted cancer	CENPE	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-2.328546468315	-2.328546468315	-1.63166337854179	-1.457033289835	6.39074338768661	8.39124362217699	0.000171946100163903	0.00462629120035515	0.447449494670143	0.946316684876274
ERC1	BRD-K89085489-001-23-2::2.5::MTS006	2.5	fenretinide	apoptosis stimulant, retinoid receptor agonist	targeted cancer	RARA	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.0375335505129	0.0375335505129	0.321436629862322	0.367607553977	8.22961597549607	12.8346077877989	1.78738193976431e-06	7.00343297564435e-05	0.209277517172492	0.358528641526353
ERC1	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-5.65493482216	-5.65493482216	-5.21383188238591	-5.34898111958	5.02267888714614	192.009842016257	1.16072046534548e-06	4.69565980779599e-05	0.267882706623307	0.61432317292488
ERC1	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.433994110695	-3.433994110695	-4.01849317970662	-3.85901121156	-4.86874845035165	87.7811307598272	4.92209079389594e-06	0.000179504304537166	-0.823083882948216	-0.345914255075029
ERC1	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.7778224041755	-0.7778224041755	-0.266559653554595	-0.201241346164	10.2239542286558	38.900900992268	1.40218285808445e-12	1.14880905883174e-10	0.410107098307168	0.612418402934643
ERC1	BRD-K94455792-001-01-8::2.5::HTS002	2.5	ICG-001	beta-catenin inhibitor	targeted cancer	CTNNB1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.021218010385	-1.021218010385	-0.664642510804946	-0.6707896523965	7.15588587264847	191.444715062998	1.72403592980992e-11	1.25215485191539e-09	0.258289806484389	0.45486119267572
ERC1	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.3806242694925	0.3806242694925	0.599360084736109	0.600417589144	5.56883922830032	33.1862579082681	3.37913650653735e-06	0.000126905019854502	0.138840081403728	0.29863154908349
ERC1	BRD-K97010173-001-04-1::2.5::HTS002	2.5	deferasirox	chelating agent	noncancer	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.435894676431	-0.435894676431	0.0549321837723628	0.111819102778	8.52310503892141	3.85153242957108	0.00122724209529766	0.0264594679653006	0.328477210118534	0.653176510288192
ERC1	BRD-K97752965-001-16-4::2.5::HTS002	2.5	nicorandil	nitric oxide donor, potassium channel activator	noncancer	KCNJ11	cardiology	angina pectoris	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.5978887886025	0.5978887886025	0.245999546299295	0.245556311183	-11.3446481728367	12.5289785210396	5.90629187046499e-08	2.85882933673191e-06	-0.419156727787212	-0.284621756819198
ERC1	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	GI1, KYSE30	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.0574902074656	0.0574902074656	-0.244101901900924	-0.195507988981	-6.59153051466757	69.7173790572045	6.98227431790076e-09	3.78574215097737e-07	-0.39285306410362	-0.210331154629428
ERC2	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.7447225511145	-0.7447225511145	-1.63073477904536	-1.545847432105	-7.79659960347909	4.22785051864535	0.00115948864164562	0.025183627997088	-1.19493555426725	-0.577088901594481
ERC2	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.13974197996625	-0.13974197996625	-0.776804257640017	-0.4776049590865	-5.21110767729938	9.17687963395378	0.000521858902282011	0.0124443142709392	-0.912802476209335	-0.3613220791382
ERC2	BRD-A43671941-003-11-9::2.5::HTS002	2.5	oxprenolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	angina pectoris, hypertension, cardiac arrythmia	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.2490096440625	-0.2490096440625	-0.408586542560877	-0.3932406545145	-4.05787263436352	21.8183545795204	0.00053095709959246	0.0126362102296166	-0.241171881872762	-0.0779819151239916
ERC2	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.451239543322	0.451239543322	0.205234247544818	0.2241591843385	-7.68085157127659	177.923860488845	1.01679866111052e-12	8.46327923251091e-11	-0.309209690054327	-0.182800901500037
ERC2	BRD-A54927599-001-16-9::2.5::HTS002	2.5	KF-38789	P selectin inhibitor	noncancer	SELP	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.30178088417	-2.30178088417	-2.94784064470557	-2.73649504122	-5.28703673985739	6.39903531591836	0.00151481744631926	0.03169360683836	-0.940602822669275	-0.351516698401871
ERC2	BRD-A57382968-001-29-0::2.5::HTS002	2.5	piroxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.2716584278725	0.2716584278725	0.0172244808189715	0.00421329680347	-9.53835868703979	31.2356814143243	9.07059539862937e-11	6.05258916934257e-09	-0.308820956911064	-0.200046937195993
ERC2	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.0951641640338	0.0951641640338	-0.18800033211854	-0.136086260588	-5.27485881394328	10.6412446017487	0.00029300258861486	0.00741603115437345	-0.401805402242439	-0.164523590062242
ERC2	BRD-A94756469-001-04-7::2.5::HTS002	2.5	digoxin	ATPase inhibitor	noncancer	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-4.89035872392	-4.89035872392	-5.68013562012364	-5.6771282936	-9.63134949315249	79.5102166482979	5.37997284827803e-15	5.59206692821814e-13	-0.952978818865701	-0.626574973541571
ERC2	BRD-A95696066-003-13-8::2.5::HTS002	2.5	nisoxetine	norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.1338481456255	0.1338481456255	0.340658653919747	0.338484825644	8.60464377721394	19.881637646745	3.89486186662601e-08	1.92790265360759e-06	0.15665574581655	0.256965270771945
ERC2	BRD-K03601870-001-01-2::2.5::HTS002	2.5	ixabepilone	microtubule stabilizing agent	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.71024932219	-2.71024932219	-3.63498566662049	-3.58404887743	-8.75953557583389	17.5336559380345	8.12178336082262e-08	3.86400378677414e-06	-1.1469524036157	-0.702520285245285
ERC2	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.2120698841885	0.2120698841885	-0.297723477338316	-0.208078798615	-9.12881477422023	43.3340728721836	1.18487896061792e-11	8.79951222280937e-10	-0.622389264038561	-0.397197459015072
ERC2	BRD-K04623885-001-07-5::2.5::HTS002	2.5	BIBR-1532	telomerase inhibitor	targeted cancer	TERT	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.66369998715	-1.66369998715	-0.901577096215614	-0.830912857483	11.4737499055474	4.49943833519827	0.000167865784828918	0.00452673701517327	0.585501963315139	0.938743818553633
ERC2	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.3595990662605	-0.3595990662605	-0.64716505743604	-0.593822379071	-4.65366385281043	39.1092060523638	3.69223319788116e-05	0.00114225266897903	-0.412543903767946	-0.162588078583135
ERC2	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.31573979831	-1.31573979831	-1.02355147958453	-0.9876270936225	5.26569916731414	60.028011159306	1.98219606009008e-06	7.72861741610054e-05	0.181194881853454	0.403181755597477
ERC2	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.784351539815	-2.784351539815	-3.18358582882371	-3.102963726805	-3.38278892838354	26.7388688486141	0.00222432548029471	0.0439389360245239	-0.641500537741972	-0.156968040275454
ERC2	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.0449016709917	0.0449016709917	0.202779777004914	0.216719294223	4.8771206675684	11.8665714029045	0.000392836909528471	0.00965665121944347	0.0872593264762355	0.228496885550192
ERC2	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.0082662243515	-0.0082662243515	-0.308888956019651	-0.199486634258	-4.95356636455987	23.928292358237	4.71311184658375e-05	0.00142879285568097	-0.425896764159543	-0.175348699176759
ERC2	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.550028713777	0.550028713777	0.181156826917507	0.22754908413	-7.77383491207322	4.73602602920201	0.000718833203393358	0.0165609805062985	-0.492920630421717	-0.24482314329727
ERC2	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4353702250145	0.4353702250145	0.334861567508339	0.3338165124735	-3.30647263557529	49.6902077654554	0.00175997711856556	0.0359902810652646	-0.161573360273764	-0.039443954738557
ERC2	BRD-K12885236-001-02-7::2.5::HTS002	2.5	dapivirine	non-nucleoside reverse transcriptase inhibitor	noncancer	CYP3A4, CYP3A5	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.579313321975	-1.579313321975	-1.33758252010002	-1.23321321289	4.8965545430872	140.46109552839	2.64409393991579e-06	0.000101179434038245	0.144131336763021	0.339330266986948
ERC2	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.0674400453875	0.0674400453875	0.342333179594721	0.357900779497	7.2587043982473	9.78672053420856	3.0647779764459e-05	0.000962589095711715	0.190261748495277	0.359524519919165
ERC2	BRD-K15409150-001-05-8::2.5::HTS002	2.5	penfluridol	T-type calcium channel blocker	noncancer	CACNA1G	neurology/psychiatry	schizophrenia	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.507966986835	-2.507966986835	-2.85573712808375	-2.6535756676	-3.60152722882483	85.1814195195574	0.000530967388117926	0.0126362102296166	-0.539755070961711	-0.155785211535791
ERC2	BRD-K16338837-001-02-6::2.5::HTS002	2.5	CCMI	acetylcholine receptor allosteric modulator	noncancer	CHRNA7	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.19889437805	0.19889437805	0.0867874150412724	0.1218664316535	-3.74383418461765	189.760799855933	0.000240166189328481	0.00622350129278008	-0.17117366300232	-0.0530402630151353
ERC2	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.5015283699975	0.5015283699975	0.306094613944045	0.3131581681635	-5.15276350279844	7.07262109893256	0.00127862108577211	0.0274155240788766	-0.284932764137017	-0.105934747969893
ERC2	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.9304413715435	-0.9304413715435	-0.439164219981692	-0.343450980127	8.24358910206898	3.56842968301607	0.00190418531538544	0.0384549264544658	0.317615887078274	0.664938416045343
ERC2	BRD-K21283037-001-21-5::2.5::HTS002	2.5	riluzole	glutamate inhibitor	noncancer	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.09824263211985	-0.09824263211985	0.0469318887882533	0.027710059388	4.2029409804892	9.76863689977689	0.00191630749079686	0.0386487501830245	0.0679641912982722	0.222384850517934
ERC2	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.426789228805	-1.426789228805	-1.86924323093397	-1.673362994515	-4.64197902482664	124.97397534499	8.59264397134635e-06	0.000299551706795412	-0.631096208499457	-0.253811795758491
ERC2	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.17426362261	0.17426362261	0.415683662431475	0.442474468431	9.25276626153599	177.305925577515	7.03440859022399e-17	8.74016092019778e-15	0.189929875226672	0.292910204416279
ERC2	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.614584656424	0.614584656424	0.370781029452621	0.3847237758685	-7.27429287725874	15.2690176535231	2.45192410164378e-06	9.434801450291e-05	-0.315131363128288	-0.172475890814469
ERC2	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.494815891928	-0.494815891928	-0.773840430574004	-0.707312470978	-4.59767416852474	29.9381395244921	7.26768301323439e-05	0.00211986286410386	-0.402977104248754	-0.155071973043254
ERC2	BRD-K26997899-001-02-2::2.5::HTS002	2.5	D-64131	microtubule inhibitor	chemo	TUBB	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.66135369624	-2.66135369624	-3.02153359765487	-2.92524371085	-3.63842067813873	115.169202119598	0.00041195225233018	0.0100746942128415	-0.556263857561193	-0.164095945268542
ERC2	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.5767477939445	0.5767477939445	0.409701172608905	0.431801339153	-5.42179849534494	5.89444255487793	0.00172548586978031	0.0354574938623341	-0.242764906056875	-0.0913283366143145
ERC2	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.366546272395	-2.366546272395	-2.99745150743921	-3.11792642927	-6.284474223772	57.6244505888953	4.71419014418826e-08	2.30734793197928e-06	-0.831887728854073	-0.429922741234356
ERC2	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.334731030432	0.334731030432	0.0868616471605831	0.1179670530315	-7.88550584731046	18.5528941158948	2.44406621994211e-07	1.08905253399994e-05	-0.313768019660247	-0.181970746882587
ERC2	BRD-K43236057-001-07-1::2.59978::HTS002	2.59978	polydatin	ICAM1 expression inhibitor	noncancer	ICAM1	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.4605781713235	-0.4605781713235	-1.32252150548052	-1.21412289307	-11.4416860303154	135.760250471611	1.21120305303802e-21	2.30342448229446e-19	-1.01092245715494	-0.712964211159097
ERC2	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-4.7774568411	-4.7774568411	-5.4541273302041	-5.49470441072	-6.37744653713723	4.91136567247281	0.00149848193653596	0.031413158741766	-0.950905822373026	-0.402435155835166
ERC2	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.6165948827315	-0.6165948827315	-0.891949888810485	-0.852653660565	-4.60822845286968	186.05445906436	7.5231952805573e-06	0.000264942313717806	-0.393235304709171	-0.157474707448799
ERC2	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.75696715646	-2.75696715646	-0.699071114792127	-0.576037096811	21.2253709007338	43.8099301989717	1.10719262527557e-24	2.785252208717e-22	1.86247306170832	2.25331902162743
ERC2	BRD-K45551181-001-02-1::2.49051::HTS002	2.49051	MPI-0479605	mitotic kinase inhibitor	targeted cancer	TTK	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.64918787061	-1.64918787061	-2.31230505256184	-2.31598955621	-6.74079414971604	15.6198838939597	5.37252212624775e-06	0.000194771193301176	-0.872073429137899	-0.454160934765776
ERC2	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.245182080021	-0.245182080021	-0.679230440732998	-0.588520646364	-6.5728615762613	7.15139099033321	0.000284687944236554	0.00722093282843507	-0.589532101671551	-0.278564619752445
ERC2	BRD-K48195801-001-01-6::2.5::HTS002	2.5	tecastemizole	histamine receptor antagonist	noncancer	KCNH2	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.153382608139	0.153382608139	0.342944140495473	0.312371086483	5.35015139073702	29.316241555847	9.28138793296461e-06	0.000321784308360461	0.117130818296354	0.261992246416591
ERC2	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4226045066925	0.4226045066925	-0.0724625855990241	0.318163539168	-4.89186915598187	9.93125641978742	0.000643514632797804	0.0149721936314503	-0.720771017879859	-0.269363166703189
ERC2	BRD-K51471001-303-04-7::2.5::HTS002	2.5	demecarium	acetylcholinesterase inhibitor	noncancer	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.484430050848	0.484430050848	0.276682450704978	0.268075360474	-8.44312799014011	97.8677371768975	2.87455513355871e-13	2.52086958764527e-11	-0.256577289265598	-0.158917911020446
ERC2	BRD-K52075715-001-06-7::2.5::HTS002	2.5	oxibendazole	tubulin polymerization inhibitor	noncancer	TUBB, TUBB4B	infectious disease	strongyles	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.027027097295	-2.027027097295	-2.88101649692595	-2.70188227417	-8.23438077471624	157.306480587241	6.52935551591143e-14	6.10571657229398e-12	-1.05883359243973	-0.649145206822177
ERC2	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.1072915075405	-0.1072915075405	0.140474246697543	0.155273340434	8.94950714842884	15.876463910457	1.33813649037131e-07	6.20379528109005e-06	0.189039359722679	0.306492148753407
ERC2	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.330932911335	-1.330932911335	-0.742843893414495	-0.6455499330205	8.36153519915481	153.597671732728	3.48785308553715e-14	3.36278931160635e-12	0.449144804450048	0.727033231390963
ERC2	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.72867509633	-0.72867509633	-2.09105011755744	-1.79411655002	-7.7023459546955	3.53522742097225	0.00248837387223049	0.0483658913268603	-1.88000801224967	-0.844742030205203
ERC2	BRD-K61936403-001-01-7::2.5::HTS002	2.5	AS-1949490	SHIP2 phosphatase inhibitor	noncancer	INPP5D	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.462710826977	0.462710826977	0.239170401326618	0.265760037454	-4.99067937943728	8.27984258035076	0.000961207016595968	0.02136858610725	-0.326225489691952	-0.120855361608813
ERC2	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.9132315795525	-0.9132315795525	-0.223480328776096	-0.157800770878	10.3337990881121	10.7714617462507	6.35250759222654e-07	2.67018356488394e-05	0.542460659301017	0.837041842251791
ERC2	BRD-K62814476-001-03-3::2.5::HTS002	2.5	BMS-265246	CDK inhibitor	targeted cancer	CDK1, CDK2	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.909952701365	-1.909952701365	-2.54336019241088	-2.46335728498	-6.53095102326044	17.7241406759816	4.17711817059964e-06	0.000154411445392627	-0.837394002589605	-0.429420979502153
ERC2	BRD-K63932022-001-01-5::2.5::HTS002	2.5	2'-MeCCPA	adenosine receptor agonist	noncancer	ADORA1	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.632882974633	0.632882974633	0.19166924498077	0.258471111718	-8.13073436569582	106.173431507774	8.50218025830139e-13	7.12656938827329e-11	-0.54879720206762	-0.333630257236841
ERC2	BRD-K68336408-001-10-9::2.5::HTS002	2.5	tyrphostin-AG-1478	EGFR inhibitor	targeted cancer	EGFR, MAPK14	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.81160504851	-1.81160504851	-2.65027988384829	-2.59421184968	-7.45449564114121	16.6737399878484	1.06177010038021e-06	4.31163554081832e-05	-1.07639586595122	-0.600953804725368
ERC2	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.05344999404355	0.05344999404355	0.344482293378792	0.3666851523545	7.77336137142369	8.06884588602673	5.12128301499066e-05	0.00154076286822001	0.204824257024302	0.377240341646182
ERC2	BRD-K69608737-001-10-2::2.5::HTS002	2.5	tacrolimus	calcineurin inhibitor	noncancer	FKBP1A	transplant	organ rejection	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4874914969905	0.4874914969905	0.302731418917896	0.3216320959495	-6.51654999311921	51.7228412865203	2.98207884008899e-08	1.49963861031777e-06	-0.241660664225606	-0.127859491919601
ERC2	BRD-K71035033-001-07-1::2.5::HTS002	2.5	masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor	noncancer	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.0398407294309	-0.0398407294309	0.281795001266583	0.3182262126035	6.88010951405779	7.08498888749624	0.000222961044161991	0.00581775232946133	0.21136101725732	0.431910444137646
ERC2	BRD-K73319509-001-08-0::2.5::HTS002	2.5	PF-04217903	c-Met inhibitor	targeted cancer	MET	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.382766765872	0.382766765872	0.0428000926418021	0.085387538628	-7.5773672281399	4.55404825489181	0.000952465359933249	0.021200638501312	-0.458779709824865	-0.221153636635531
ERC2	BRD-K74671368-001-01-8::2.5::MTS006	2.5	idronoxil	XIAP inhibitor	targeted cancer	ENOX2, SPHK1	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.136388715157	0.136388715157	-0.255513010620722	-0.195737211392	-8.87923443574844	13.5506697904766	5.12039735740028e-07	2.18137476687387e-05	-0.486861261610273	-0.296942189945172
ERC2	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.426718257055	-1.426718257055	-2.21565193804154	-2.0670113581	-7.25639855779984	48.4853299067823	2.81824995639087e-09	1.59923932990018e-07	-1.00747837254834	-0.570388989424737
ERC2	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.3792036694005	-0.3792036694005	-0.619048871074225	-0.529789535968	-4.58527317464669	193.005433453698	8.13740898590382e-06	0.000285167222128806	-0.34301336341822	-0.136677039929229
ERC2	BRD-K82818427-001-02-2::2.39189::HTS002	2.39189	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.710826628665	-0.710826628665	-1.62269454628779	-1.52596467706	-15.0596095465806	185.881219059573	5.04612291386888e-34	2.93894151632229e-31	-1.03132258567955	-0.79241324956603
ERC2	BRD-K87024524-065-17-7::2.5::HTS002	2.5	phenelzine	monoamine oxidase inhibitor	noncancer	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.07724084694625	0.07724084694625	0.355887254698539	0.37808925029	7.47561705024196	8.34557565982281	5.6765419272374e-05	0.00169402332877035	0.193307934841468	0.36398488066311
ERC2	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.5773376934735	-0.5773376934735	-0.114253620944291	-0.0422450278637	10.1180722393587	3.75914284256648	0.000731306055996466	0.0168013823213278	0.332735404635406	0.593432740423012
ERC2	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-6.635431879825	-6.635431879825	-6.2099598830609	-6.171939349	7.08923519184038	161.581750716037	3.97384745654684e-11	2.75456258575106e-09	0.306953903867207	0.543990089660994
ERC2	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.1090931341455	-0.1090931341455	-0.273636153766552	-0.208293631699	-3.55348276166155	188.000011723521	0.000480727984992683	0.0115689552862337	-0.255886610609887	-0.0731994286322174
ERC2	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4575305972065	0.4575305972065	-0.233485480529515	-0.164801274437	-8.71445716213132	5.58844647032544	0.000185223237301747	0.00493826486225228	-0.888561746839691	-0.493470408632338
ERC2	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.0755234160833	0.0755234160833	0.30130767173962	0.276885156297	5.88492384245018	42.7891243054186	5.46322904684353e-07	2.31867013540778e-05	0.148399694252984	0.303168817059656
ERC2	BRD-K98157055-001-10-9::0.625::HTS002	0.625	SIB-1757	glutamate receptor antagonist	noncancer	GRM5	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.345426529773	0.345426529773	0.221148721842227	0.259105939105	-3.18328577287846	151.637827368476	0.00176710725483721	0.0361050839677793	-0.201411824116418	-0.0471437917451272
ERC2	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-4.102205635395	-4.102205635395	-3.15637095577942	-3.187890366305	11.0712857783358	7.89987596040692	4.36073154334109e-06	0.000160865960577066	0.748394216558705	1.14327514267245
ERC2	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.312350446692	-0.312350446692	-0.866253797104843	-0.791872957089	-8.85724267418306	3.87154038364053	0.00104019137387174	0.0228870934165441	-0.729829105652927	-0.377977595172759
ERC2	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.2593468057175	0.2593468057175	0.0925797678718546	0.162270559212	-5.6356343276121	177.807957914293	6.72957386706556e-08	3.24006256670104e-06	-0.225162827749132	-0.108371247942159
ERC2	BRD-M80207679-001-01-5::2.5::HTS002	2.5	nemonapride	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.558387996788	0.558387996788	0.370224138062064	0.3843772363715	-5.17873784313053	57.5946247728053	2.97225239210462e-06	0.000112850289273231	-0.260905007111836	-0.115422710340035
ERC2	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	SKOV3, NCIH226	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.2288902441345	-0.2288902441345	-0.0748992913971399	-0.0657751951103	4.49820006125821	10.4352421086463	0.00103058147607684	0.0227082859243419	0.0781421108911941	0.229839794583526
ERICH5	BRD-A08187463-001-12-9::2.5::HTS002	2.5	racecadotril	enkephalinase inhibitor	noncancer	MME	gastroenterology	diarrhea	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.476944630464	0.476944630464	-0.261482680993142	-0.255018062044	-15.4894231475935	7.86193678999846	3.59120853058082e-07	1.56030839884625e-05	-0.848698399245136	-0.628156223669148
ERICH5	BRD-A10977446-001-12-1::2.5::HTS002	2.5	carvedilol	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA	cardiology	myocardial infarction, hypertension	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1649755801795	0.1649755801795	-0.221217527326315	-0.214242337971	-7.38548736835479	140.314666062028	1.23237187943962e-11	9.13007371408273e-10	-0.489572824335846	-0.282813390675785
ERICH5	BRD-A20644369-001-08-6::2.5::HTS002	2.5	canrenone	mineralocorticoid receptor antagonist	noncancer	NR3C2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.699207381796	0.699207381796	0.507197942791265	0.518391273844	-5.40950952037884	12.7586740471114	0.000127248535494903	0.00352365004703967	-0.268838984518374	-0.115179893491097
ERICH5	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.2763962949775	-0.2763962949775	-1.00024491816547	-0.927705434	-10.8780387302315	35.3787688565421	7.81190026462238e-13	6.57468572345525e-11	-0.858884789124714	-0.588812457251231
ERICH5	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.607941265181	0.607941265181	-0.227578034621225	-0.093015492892	-9.14437828627777	3.89258094290416	0.000900853954310014	0.020186003886389	-1.0919872079882	-0.579051391616245
ERICH5	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.022092888606	0.022092888606	-1.03669283912816	-0.797857785181	-10.2800853308818	6.181069419356	4.08781347842387e-05	0.00125431206158498	-1.30902384085986	-0.808547614608459
ERICH5	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.1083282217861	-0.1083282217861	-0.849325853463467	-0.797149374107	-10.4625445924759	8.35983927120612	4.34331989514117e-06	0.000160251232536704	-0.903102111895724	-0.57889315145901
ERICH5	BRD-K01669786-001-02-2::2.5::HTS002	2.5	triapine	ribonucleotide reductase inhibitor	chemo	RRM1, RRM2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.13616301206	-2.13616301206	-3.20074852575148	-3.10063742322	-10.4648543320777	190.857416151754	1.51964801093657e-20	2.64800519134979e-18	-1.26524425160193	-0.863926775781026
ERICH5	BRD-K04623885-001-07-5::2.5::HTS002	2.5	BIBR-1532	telomerase inhibitor	targeted cancer	TERT	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.32113929116	-1.32113929116	-0.905126947987531	-0.830912857483	6.50848093993799	5.55625708396625	0.000851260694282752	0.0192214341914168	0.256531089643368	0.57549359670157
ERICH5	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.769724177725	-1.769724177725	-3.72534732634607	-3.60790168659	-15.4833115599264	11.4551153730548	4.90825118749036e-09	2.7133881061739e-07	-2.23227745252263	-1.67896884471951
ERICH5	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.483799035415	-2.483799035415	-3.03503730344644	-2.93942386342	-5.7602182360363	190.543114111875	3.32316086956259e-08	1.66103019126045e-06	-0.740000760933544	-0.362475775129339
ERICH5	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.44440121145	-2.44440121145	-2.02875485538127	-1.59680097986	3.19604137580829	79.1029567550142	0.00200272555665719	0.0401454612876078	0.156792812917302	0.674499899220165
ERICH5	BRD-K09090949-001-01-9::2.5::HTS002	2.5	CP-945,598	cannabinoid receptor antagonist	noncancer	CNR1	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.353883378669	-0.353883378669	-0.695696623498331	-0.6321793589915	-4.89181507336137	7.2351780111207	0.00161023073172444	0.0334191093734646	-0.505957713663272	-0.17766877599539
ERICH5	BRD-K13044802-213-20-7::2.5::HTS002	2.5	ciclopirox	membrane integrity inhibitor	noncancer	ATP1A1	infectious disease	onychomycosis	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.3971688360595	-0.3971688360595	-1.63087173652368	-1.66652193871	-19.6411944487059	170.646070911614	1.16586535258926e-45	1.93704461360546e-42	-1.3576914922415	-1.10971430868686
ERICH5	BRD-K13094524-001-07-5::2.63083::HTS002	2.63083	PFI-1	bromodomain inhibitor	targeted cancer	BRD4	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.517456885865	-1.517456885865	-2.23715618915853	-2.09295317057	-7.02587532363018	171.461117288797	4.79853819795604e-11	3.29953767542419e-09	-0.921896410225937	-0.51750219636112
ERICH5	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.272824637402	0.272824637402	-0.480811936883991	-0.373418715101	-8.37828880216821	126.105153738943	8.9143103533048e-14	8.19997950091615e-12	-0.931645783901662	-0.575627364670319
ERICH5	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.4140654827935	0.4140654827935	-0.0477519245550328	0.0935597000564	-6.3732458670477	9.93466850390031	8.34706518328335e-05	0.0024062113431983	-0.623416582001466	-0.3002182326956
ERICH5	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.81806683236	-0.81806683236	-2.37298610648991	-2.30540806626	-13.262348810501	5.20704773678284	3.27053146203606e-05	0.00102107754949268	-1.85273327299763	-1.25710527526218
ERICH5	BRD-K19412355-001-01-0::2.5::HTS002	2.5	SB-242235	p38 MAPK inhibitor	noncancer	HSPB1, MAPK14	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.5426669802615	0.5426669802615	0.10893712869297	0.111624443211	-12.2409152758734	23.6785666130582	9.96628206805044e-12	7.47136505548507e-10	-0.506912117694689	-0.360547585442371
ERICH5	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.07367394072335	-0.07367394072335	-0.447951578246514	-0.359947291571	-8.04691092216284	18.9071874278456	1.59089696287673e-07	7.29827386892993e-06	-0.471660653011183	-0.276894622035145
ERICH5	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.09598477068525	-0.09598477068525	0.101506261157346	0.137732029225	7.66465928971432	15.1822721095753	1.34573690956675e-06	5.39424810343244e-05	0.142628522931972	0.25235354075322
ERICH5	BRD-K24556098-001-16-7::2.45349::HTS002	2.45349	deoxycorticosterone-acetate	progestogen hormone	noncancer	NR3C2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.9564426888335	-0.9564426888335	-2.6814980255858	-2.51583725089	-11.0470248308614	5.17342175751857	8.57459677164768e-05	0.00246583221718835	-2.12245253139704	-1.32765814210756
ERICH5	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.05452747885728	-0.05452747885728	-0.843429304693451	-0.742464669951	-9.72225203908722	4.50286362623908	0.000343746312893598	0.00857481418717085	-1.00460959851505	-0.57319405315729
ERICH5	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.387192739909	0.387192739909	0.146137786005377	0.195908235522	-5.87249254091921	187.875390281212	1.91501201050688e-08	9.89733805642462e-07	-0.3220294556597	-0.160080452147547
ERICH5	BRD-K26838195-075-04-9::2.5::HTS002	2.5	AST-1306	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2091976642485	0.2091976642485	-0.663582907279961	-0.557623655143	-12.4198698502879	162.127826977033	2.58496663997793e-25	6.77685257092415e-23	-1.0115488007526	-0.734012342304326
ERICH5	BRD-K26997899-001-02-2::2.5::HTS002	2.5	D-64131	microtubule inhibitor	chemo	TUBB	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.03798870182	-2.03798870182	-3.02813005262227	-2.92524371085	-7.9738736376651	5.94615627692268	0.000216781797986856	0.00567933333097724	-1.29465038943602	-0.685632312168527
ERICH5	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.152118500557	0.152118500557	-0.476392556403093	-0.387317230447	-12.7111711870341	163.971123161905	3.3459420164e-26	9.48587839197085e-24	-0.726143164932909	-0.530878948987276
ERICH5	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-3.083111189905	-3.083111189905	-3.6351614563723	-3.592577528105	-6.83176611809556	23.5858678630752	5.02546215434455e-07	2.14348712055425e-05	-0.718981532254857	-0.38511900067975
ERICH5	BRD-K29582115-066-01-2::2.5::HTS002	2.5	ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	1.015253150105	1.015253150105	0.256500314460241	0.262353751493	-21.8641464926222	155.32307123456	2.88318928991788e-49	6.86612308132011e-46	-0.827303696280871	-0.690201975008647
ERICH5	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.02699502035	-2.02699502035	-3.71485590449492	-3.85009077555	-12.7469464479651	4.09577066193008	0.000189450433791893	0.0050378067027522	-2.05213263588197	-1.32358913240786
ERICH5	BRD-K32285926-001-02-1::2.5::HTS002	2.5	AMG-208	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	1.021590644585	1.021590644585	0.40100376323998	0.412883434958	-11.6831052426577	3.50115459608053	0.000628700649439758	0.0146641398948497	-0.776735466740565	-0.464438295949476
ERICH5	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.06370274745	-1.06370274745	-2.59111976071852	-2.555934411265	-15.4746002116702	23.7442609229454	6.68614501664843e-14	6.24416024084201e-12	-1.73124984174811	-1.32358418478893
ERICH5	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.4420548631475	0.4420548631475	0.16069281660432	0.154760250633	-10.4018129606393	15.5308853676589	2.11932326549728e-08	1.08746094366954e-06	-0.338845148943936	-0.223878944142424
ERICH5	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.3814955489145	0.3814955489145	-0.0783271406225556	-0.0620606581655	-13.1903992178794	19.4517592200147	3.71772695183721e-11	2.5887482126716e-09	-0.53267183790419	-0.386973541169921
ERICH5	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.5680655272315	-0.5680655272315	-2.6088176318083	-2.52528636523	-17.0166246867436	8.52970341878628	7.02112691628329e-08	3.36877347400959e-06	-2.31434310567898	-1.76716110347462
ERICH5	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.189786339495	-1.189786339495	-1.94439498899704	-1.74375486562	-7.82828266398932	24.9855805685089	3.49593169386827e-08	1.74176595125514e-06	-0.953144031070095	-0.55607326793398
ERICH5	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.790966717032	0.790966717032	-0.804409700635409	-0.4002530483955	-14.1008516934536	167.387249465422	2.89946791276116e-30	1.19049819592756e-27	-1.81874251023715	-1.37201032509767
ERICH5	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.39793300305	-0.39793300305	-1.37836951007036	-1.00119520354	-7.83197243225053	8.32914205940395	4.06590202242326e-05	0.00124848239908876	-1.26713736481508	-0.693735649225638
ERICH5	BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500	0.625	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.0004664590235	-1.0004664590235	-1.72932748474262	-1.77978641517	-7.80794240306316	48.8923861654083	3.81489817064671e-10	2.37617933744998e-08	-0.916462642516283	-0.541259408921952
ERICH5	BRD-K38904395-001-02-3::2.5::HTS002	2.5	SAR131675	VEGFR inhibitor	targeted cancer	FLT4	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.334774266548	-0.334774266548	-0.534985716722717	-0.521573448397	-3.92192900603056	28.4762635212602	0.00050635719138998	0.0121232160939927	-0.304702319444648	-0.0957205809047849
ERICH5	BRD-K40175214-001-11-6::2.5::HTS002	2.5	torin-1	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.38506350893	-4.38506350893	-3.72221464322606	-3.70757684528	8.30003712783119	21.5823280754709	3.68803999267055e-08	1.83091944673454e-06	0.497041356424171	0.828656374983702
ERICH5	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.79624481715	-1.79624481715	-2.29291196049288	-2.14029239454	-5.16842701684186	20.2617572608028	4.49144158493281e-05	0.00136700679275357	-0.696954802415579	-0.296379484270189
ERICH5	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.663391797725	-1.663391797725	-0.664222930492745	-0.568122839674	13.6311331728898	4.0106128315636	0.000164994298697153	0.00446052762934688	0.795866267749704	1.20247146671481
ERICH5	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1499684385805	0.1499684385805	-0.367422076052022	-0.243490121847	-8.27384630144932	182.496596746358	2.65245389110552e-14	2.58056191569113e-12	-0.640771631051684	-0.394009398213359
ERICH5	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.990299999215	-2.990299999215	-4.60677844033204	-4.62878838486	-16.6838626116719	189.014207592941	5.21795678504181e-39	5.03765522423976e-36	-1.80760060198567	-1.42535628024841
ERICH5	BRD-K52172416-001-11-4::2.5::HTS002	2.5	anastrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.571569742228	0.571569742228	0.300822402196645	0.296380524619	-7.94012750103295	5.75842778529358	0.000260132752609864	0.00667233038943509	-0.355039500091079	-0.186455179971631
ERICH5	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.62343598131	0.62343598131	-0.302376497568374	-0.406253558846	-9.10841263085917	3.0821094051865	0.00250871149390384	0.0487081824238534	-1.24446706717596	-0.607157890580792
ERICH5	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1314502773823	0.1314502773823	-0.51419523687607	-0.339269333107	-7.69488959679974	3.79802604240636	0.00188869014770137	0.0381887802515743	-0.883573295078525	-0.407717733438215
ERICH5	BRD-K61036791-001-01-6::2.5::HTS002	2.5	rucinol	tyrosinase inhibitor	noncancer	TYR	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.11127771848885	0.11127771848885	0.406683435674705	0.443703234986	10.2946209475406	15.79702394219	2.07253790644995e-08	1.06421891938551e-06	0.234511125440636	0.356300308931074
ERICH5	BRD-K62627508-001-01-5::2.5::HTS002	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.4229229732175	-0.4229229732175	-1.10802254008985	-0.7188580200695	-6.89332119434465	170.97211695198	1.00627728538252e-10	6.66278666353878e-09	-0.881281179570466	-0.488917954174238
ERICH5	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.8926407545835	-0.8926407545835	-1.84902773615133	-1.7566794361	-9.94580766249143	105.51397013395	7.73935776733361e-17	9.57718712999333e-15	-1.14704329778483	-0.765730665350834
ERICH5	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.7264237727635	-0.7264237727635	-2.1431523348934	-2.025815521035	-15.2244382598308	136.239314958838	3.41981026067976e-31	1.50771592475455e-28	-1.60074997640094	-1.23270714785885
ERICH5	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.5694311651245	0.5694311651245	-0.72630239732998	-0.5340799664045	-10.525127108841	7.9442073263395	6.09632771705266e-06	0.000218754365188043	-1.57996989820188	-1.01149722670708
ERICH5	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.13752060997455	0.13752060997455	-1.0907592869639	-0.4202572111255	-10.1135967041641	49.13250656964	1.33994426991447e-13	1.21587178419348e-11	-1.47232289831602	-0.984236895560881
ERICH5	BRD-K65877271-001-01-8::2.5::HTS002	2.5	halobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2955200720555	0.2955200720555	-0.288727348470244	-0.253825714787	-11.8644740104422	76.541002626839	5.08762403055153e-19	7.63603200871204e-17	-0.682313006046599	-0.486181835004889
ERICH5	BRD-K68747584-001-02-0::2.5::HTS002	2.5	PF-03814735	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.780488391097	-0.780488391097	-1.27478785437363	-1.09893939309	-5.62481151627832	20.4232895463491	1.54168344512062e-05	0.000514123963138723	-0.67736734690204	-0.311231579651224
ERICH5	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.399277815455	-1.399277815455	-2.59466050895041	-2.40345273405	-10.2090090712169	171.434615503187	2.04305564651279e-19	3.20326315772817e-17	-1.42650834335672	-0.964257043634104
ERICH5	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.2733238390925	-0.2733238390925	0.109192399776794	0.101486674715	10.3854861982215	180.014562690614	4.27656518542873e-20	7.16087452834184e-18	0.30983861885255	0.455193858886039
ERICH5	BRD-K70463136-001-01-5::2.5::HTS002	2.5	BAY-87-2243	hypoxia inducible factor inhibitor	targeted cancer	HIF1A	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.0035287452705	-1.0035287452705	-1.63274961561114	-1.609919901395	-10.4064360191306	34.1786047982418	3.91530718582585e-12	3.07498671246196e-10	-0.752076050567579	-0.506365690113707
ERICH5	BRD-K71106091-001-06-1::2.5::HTS002	2.5	fludarabine-phosphate	ribonucleotide reductase inhibitor	chemo	DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.6591580697765	-0.6591580697765	-0.197345781070617	-0.21623153212	14.0465807606686	6.09074320041741	7.18882466698411e-06	0.000254211120615416	0.381654311718878	0.541970265692888
ERICH5	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-3.213069356735	-3.213069356735	-4.36918108468237	-4.09603677997	-9.93848875518853	189.561417817022	5.33107363447843e-19	7.98465185886882e-17	-1.38557285027444	-0.926650605620292
ERICH5	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.305756876282	-0.305756876282	-0.895366337796683	-0.708568317551	-6.90361543553127	4.02554387354114	0.00225545652126613	0.0444882883072381	-0.82614201139657	-0.353076911632796
ERICH5	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.11597181574395	0.11597181574395	-0.215947821764846	-0.189464823924	-8.03160279110368	3.84828750605513	0.00153248175117904	0.0320163058045084	-0.448467132842491	-0.215372142175101
ERICH5	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2639888851385	0.2639888851385	-0.212402655628161	-0.20601445055	-8.191701224128	7.06982060197084	7.41583912607767e-05	0.00215837776215793	-0.613632345059322	-0.339150736474
ERICH5	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.279373101527	0.279373101527	-0.468328675329932	-0.217946401079	-6.5569556896703	4.9218723593911	0.00131299886431179	0.0280467348679898	-1.0422350320593	-0.453168521654567
ERICH5	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.126726422758	-0.126726422758	0.0236131067290813	0.0294162092714	5.52745227570669	188.724698161431	1.06953912301498e-07	5.02373987939245e-06	0.0966869986494758	0.203992060324687
ERICH5	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.7231582105225	0.7231582105225	0.342003344142651	0.3852845671545	-11.7705451530555	25.5013334293175	8.32753449578542e-12	6.29709587353675e-10	-0.447780613914397	-0.3145291188453
ERICH5	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.983497894881	0.983497894881	-0.864888113197261	-0.774088070041	-20.7519904383155	186.70968318133	2.27758745628626e-50	5.74297696374563e-47	-2.02409953198077	-1.67267248417575
ERICH5	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.76837351841	0.76837351841	-0.322384788974625	-0.108614953002	-10.7811154246596	4.5720860337142	0.000201112780407026	0.00530841146697751	-1.35832648286051	-0.823190131908744
ERICH5	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.3659096113995	0.3659096113995	0.0958809593049365	0.163411081458	-7.08695941022203	25.2327824350521	1.88470539592035e-07	8.54191209139802e-06	-0.348464883256274	-0.191592420932853
ERICH5	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.555050557258	0.555050557258	0.304306964602385	0.301488629615	-7.28948786123342	4.65188234780836	0.00102925076078941	0.0226812961453046	-0.341194194086736	-0.160292991224494
ERICH5	BRD-K95763993-001-19-3::2.5::HTS002	2.5	trapidil	PDGFR tyrosine kinase receptor inhibitor	noncancer	PDGFRA	cardiology	coronary artery disease (CAD)	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.961259717456	0.961259717456	0.387675219955256	0.400240695615	-22.4249773453674	171.628863404929	6.90361496204017e-53	2.24188619878653e-49	-0.624072323341903	-0.523096671659585
ERICH5	BRD-K99616396-001-05-1::2.5::MTS006	2.5	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1039087545273	0.1039087545273	-0.0179793614970672	-0.0209452377113	-4.21263184262722	59.7270482077009	8.64743279200991e-05	0.00248511078422994	-0.179770091321831	-0.0640061407269037
ESR1	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.151631603499	-0.158988528494	-0.516250736055677	-0.4692197687775	-6.92039442841339	102.831390942709	3.95806536555417e-10	2.45536379662477e-08	-0.469114642430285	-0.260123622683069
ESR1	BRD-A44090213-001-25-6::2.5::HTS002	2.5	indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	CXCR1, CXCR2, PTGS1, PTGS2	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.03330113088833	-0.982752666678	-1.91722472122926	-1.83417815232	-8.72560542493199	19.1630673364962	4.20754535110852e-08	2.07167238124911e-06	-1.09582961689381	-0.672017563788054
ESR1	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.641504018374667	-0.603387381028	-1.19714481233186	-1.04762820909	-6.99158938833836	20.2974162689256	8.05267391923783e-07	3.33769396332687e-05	-0.721262446588131	-0.390019141326253
ESR1	BRD-K02389548-001-02-5::2.5::HTS002	2.5	RG2833	HDAC inhibitor	noncancer	HDAC1, HDAC3	NA	NA	MCF7, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.0094164000796555	-0.0094164000796555	0.320936851330378	0.362491356389	8.63867461150997	98.8695887452748	1.01775355927006e-13	9.31400950490151e-12	0.254473183345848	0.40623331947422
ESR1	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.125869245304433	0.155325578918	-0.345680948653554	-0.229610255998	-8.75728993083104	13.22548981562	7.21394644130337e-07	3.01219155818841e-05	-0.587677384481722	-0.355423003434254
ESR1	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.47446611131	-1.41296766119	-2.20933050372202	-2.17094660797	-5.87917213994045	4.78531921818267	0.00234257909091712	0.0459235922415782	-1.06055746976562	-0.409171315058421
ESR1	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.180857022738667	-0.185337291627	-0.423296195978896	-0.3914859259735	-5.14761815982303	8.50012500491916	0.00072477701972857	0.0166728275047123	-0.349943557441414	-0.134934789039045
ESR1	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.01728248142667	-2.02627642065	-1.28320493539196	-1.25454191877	10.9563247551677	10.6981942435035	3.78185565500879e-07	1.64014840283768e-05	0.586101620829046	0.882053471240361
ESR1	BRD-K18849474-001-04-4::2.60504::HTS002	2.60504	dalcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.0472576101263	0.0432090714792	0.304491286172577	0.28793221443	5.78526541735454	5.03834444844908	0.00211741138350359	0.0421376661480911	0.143197516334002	0.371269835758552
ESR1	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1469819083448	0.174918444136	-0.310877914548571	-0.199338421936	-7.33812252667699	40.1115331689347	6.26685546562596e-09	3.41686305034889e-07	-0.583953257807166	-0.331766387979576
ESR1	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.425074256984667	0.430379139046	0.0943184398354135	0.136288783323	-7.70684354892009	3.73809216628272	0.00199990422018612	0.0400970506649458	-0.453278841307792	-0.208232792990715
ESR1	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.54367998010333	-3.57415868795	-4.1873394978698	-4.22504454942	-5.83514171977821	15.2428738096744	3.07772114680279e-05	0.000965381085428209	-0.878448385819891	-0.408870649713051
ESR1	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.00243717839220333	0.00199046724481	-0.868933255613281	-0.560893595726	-9.31299932873439	187.848409726815	3.35237890893808e-17	4.27685725698684e-15	-1.0559435099776	-0.686797358033368
ESR1	BRD-K30867024-003-03-3::2.5::HTS002	2.5	SB-216641	serotonin receptor antagonist	noncancer	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.241682780105	0.220144798778	-0.0527977811535503	-0.0253006385055	-6.08938157203509	9.6901162228232	0.000133786608061913	0.00368375512837894	-0.402701559805586	-0.186259562711515
ESR1	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.019084949473	0.0902486237933	-0.88678844578516	-0.713479277931	-7.75394773333827	11.9167336813681	5.39556658745162e-06	0.000195474373076727	-1.16061579124074	-0.651130999275576
ESR1	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.722655836858	-0.750755696512	-1.94716436552763	-1.84222232008	-10.4895129251156	8.47036687235296	3.8495705624907e-06	0.000143018652988051	-1.49112332560156	-0.957893731737698
ESR1	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.15939009935	-1.10608028394	-1.9816312570356	-2.048574796455	-7.3569182034202	4.81686829931816	0.000854285387968798	0.0192762769076621	-1.11285717638272	-0.531625138988487
ESR1	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.477705613985	-2.477705613985	-0.769262686323398	-0.3920750884915	10.5050266526146	3.52821664130546	0.000871445822339226	0.0195884752654582	1.23206848680536	2.18481736851785
ESR1	BRD-K45551181-001-02-1::2.49051::HTS002	2.49051	MPI-0479605	mitotic kinase inhibitor	targeted cancer	TTK	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.54662628101	-1.61445505441	-2.31769839673268	-2.317347513715	-6.08969566277142	6.75355530120066	0.000569868728752423	0.0134633371654297	-1.07270797460383	-0.469436256841531
ESR1	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.93437867437333	-2.8841509626	-0.914664494104825	-0.5694567555345	11.2109311126667	3.1836756048677	0.0011528584536935	0.025067566148085	1.46464391165935	2.57478444887767
ESR1	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.657383947515333	-0.640236329584	-0.258833866170498	-0.187054055963	5.51996827377776	6.05589575513709	0.00144224192187298	0.0304036853420984	0.222273860429706	0.574826302259964
ESR1	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.632410883193333	-0.637826217209	-1.25883536940426	-0.927896185514	-6.30809859121414	30.7988593086383	5.26974974480284e-07	2.24099244653541e-05	-0.829011590597118	-0.423837381824732
ESR1	BRD-K51313569-003-03-3::2.5::HTS002	2.5	palbociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.26896307626	-1.29666102163	-0.749498064655102	-0.726050674211	7.13404284041016	37.8480118585361	1.65744650889777e-08	8.64959466290603e-07	0.372039399000057	0.666890624209739
ESR1	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.53449937189667	-1.54772106844	-2.75867877382016	-2.680907482985	-8.36334455361632	4.33109718609589	0.000784902845763279	0.0178946327017975	-1.61861567768143	-0.829743126165556
ESR1	BRD-K61443650-236-13-1::2.5::HTS002	2.5	thiomersal	other antibiotic	noncancer	OXCT1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.176016228059967	0.194585488636	-0.17510289366441	-0.0429652749088	-4.75550637394593	7.5460056914224	0.00168541819523854	0.0347474024978146	-0.523180766945256	-0.179057476503497
ESR1	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.192301044802667	0.165256919355	-0.0829139282925187	0.0393108833872	-5.23150047460282	16.9296590095375	6.86134642886466e-05	0.00201146972883618	-0.38624175667969	-0.164188189510681
ESR1	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.125278110071333	0.120618047906	-0.201535639911047	-0.1246715830005	-6.38270209492399	6.95235763100667	0.000384047507356302	0.00946516077436488	-0.448058097435241	-0.205569402529519
ESR1	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.47202638188	-1.46180668388	-0.878836797709868	-0.6850177992955	6.22498991526098	5.6636532139348	0.000988739692033622	0.0219147455484875	0.356621200750296	0.829757967589967
ESR1	BRD-K75009076-001-02-1::2.429::HTS002	2.429	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.371949340460667	-0.391911824099	-1.9402790887545	-1.72733383121	-15.6465119847243	47.6154175993949	2.14156012031757e-20	3.68377559412154e-18	-1.769907991967	-1.36675150462067
ESR1	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.631398840431333	0.567602054345	-0.701199122363802	-0.483058782813	-13.1107664039144	10.2513193508402	9.80083245260116e-08	4.6248406401003e-06	-1.55831900628948	-1.10687691930079
ESR1	BRD-K76674262-001-03-3::0.625::MTS010::PROS003_PR500	0.625	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.08516076708333	-2.07118984664	-1.5923746322449	-1.83860859946	4.25587886136779	32.0838323282055	0.000169093866595333	0.00455698721658633	0.256954784906344	0.728617484770519
ESR1	BRD-K78789465-001-01-6::2.5::HTS002	2.5	pentagastrin	CCK receptor agonist	noncancer	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.197794591374	-0.211861069409	0.152297532997024	0.188126620199	5.50512594866092	12.5829950770657	0.000113897846957279	0.003186935141944	0.212241708427716	0.487942540314331
ESR1	BRD-K85402309-001-06-6::2.5::HTS002	2.5	dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB	NA	NA	HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.331536269349	-0.331536269349	-0.163035402769281	-0.1901331802295	4.29177354196177	113.65751467874	3.74447623492595e-05	0.00115724563367764	0.0907219006019351	0.246279832557503
ESR1	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.06567741561333	-3.02790000969	-4.87064696541737	-5.03472792017	-13.5555450268077	6.76078160876045	3.7639978046845e-06	0.000140082286070537	-2.12210033058426	-1.4878387690238
ESR1	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.00670457833916667	0.0791220741041	-0.791350138284886	-0.784000908404	-8.58074275329137	3.7070001323221	0.00141230140679064	0.0298517897648945	-1.06453079612175	-0.531578637126358
ESR1	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MCF7, HCC1428, ZR751	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.531436246525	0.531122434913	-0.305922283932532	-0.2165693192205	-8.74537446385149	9.0714978575684	1.02469958993654e-05	0.000352241922071384	-1.05369726408825	-0.621019796826809
EXD3	BRD-A14344385-001-03-2::2.5::HTS002	2.5	IDRA-21	glutamate receptor positive allosteric modulator	noncancer	GRIA1, GRIA2, GRIA3, GRIA4	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.024593184533	0.024593184533	0.143618882039617	0.119694147136	4.41527908623447	112.200873056613	2.33314991921178e-05	0.000750280103578006	0.0656135468336494	0.172437848179584
EXD3	BRD-A14886633-001-01-6::2.5::HTS002	2.5	norgestrel	progesterone receptor agonist	noncancer	PGR	endocrinology	contraceptive	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.293568532093	0.293568532093	-0.138836297435979	-0.0793835829582	-8.05134880977696	15.9762794013564	5.15593277609033e-07	2.19577998230648e-05	-0.546269963866065	-0.318539695191893
EXD3	BRD-A23072235-050-18-5::2.5::HTS002	2.5	pheniramine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.28562130653667	-1.24812832971	-1.71664589762931	-1.4857082858	-3.91090451349783	16.0670124786411	0.00123608879014314	0.0266260979198582	-0.664582244853619	-0.197466937331668
EXD3	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.690001828563	-0.690001828563	-1.24087588504464	-1.05465528871	-4.92601178823535	7.61742008976983	0.00133257095397784	0.0284074597170397	-0.811025568686071	-0.290722544277202
EXD3	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.745325780544	-0.745325780544	-0.0739867154893638	-0.05385103964535	16.5787941233036	177.056128541021	7.20746505200813e-38	6.05791677306608e-35	0.591426375881723	0.75125175422755
EXD3	BRD-A50998626-001-02-1::2.5::HTS002	2.5	palomid-529	AKT inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.369424123577	0.369424123577	0.0410852374633409	0.0209581438432	-11.1165224983456	189.882792214138	1.96084052093663e-22	4.02552670509412e-20	-0.386599935701589	-0.270077836525729
EXD3	BRD-A59303141-001-10-4::2.5::HTS002	2.5	quinethazone	thiazide diuretic	noncancer	CA1, CA2, SLC12A1, SLC12A2, SLC12A3	cardiology	hypertension	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.8050743094825	0.8050743094825	0.358430142769648	0.3935946417985	-10.3717159229578	4.03909282800188	0.000463961497054131	0.0112159264270375	-0.565753084466407	-0.327535248959297
EXD3	BRD-A64553394-001-04-4::2.6791::HTS002	2.6791	DPI-201106	sodium channel activator	noncancer	ADRB2	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.815226830438	-0.815226830438	-1.65711769048617	-1.51643544753	-8.15032252925379	19.9114685405105	9.02095793497697e-08	4.2699545157969e-06	-1.0574227310927	-0.626358989003652
EXD3	BRD-A74914197-001-02-9::0.15625::MTS010::PROS005_PR500	0.15625	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.460017448365667	0.44810494878	-0.412985938291932	-0.279633863157	-6.97253809346488	3.90154215281365	0.00243899759603458	0.0475441487731236	-1.22411810628519	-0.52188866703001
EXD3	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.563902283661	0.563902283661	0.14684589836564	0.177485579355	-8.26791862725086	11.2770136740289	4.05064820509039e-06	0.000150150705490975	-0.527748250253308	-0.306364520337412
EXD3	BRD-K00494077-066-01-9::2.5::HTS002	2.5	trovafloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.10916133684504	0.0859684935528	-0.530838753319914	-0.326551927722	-6.22420565543225	7.00918329277146	0.000432621046740349	0.0105307480212166	-0.883076551131088	-0.396923629198821
EXD3	BRD-K06593056-001-04-8::2.5::HTS002	2.5	LE-135	retinoid receptor agonist	noncancer	RARB	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.308705142799333	-0.297162807117	-0.138700544078581	-0.151587118479	5.21578405669854	81.8729330630197	1.35124908030625e-06	5.41128296212551e-05	0.105162734507859	0.234846462933646
EXD3	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.08101498374755	0.08101498374755	-0.478952936767888	-0.33490377325	-7.24162847671605	14.3498772183314	3.7113468360068e-06	0.000138507619016977	-0.725437652760193	-0.394498188270682
EXD3	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.8878715990835	-0.8878715990835	-1.65157396803646	-1.461946185705	-8.87202682358899	126.895060513662	5.67926247758008e-15	5.87466528743852e-13	-0.934040130227601	-0.593364607678311
EXD3	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.72122064138333	-2.77452122148	-2.05584220599546	-2.34587178742	5.84232098547978	21.516498901949	7.68876485520214e-06	0.000270373303142021	0.428878169046155	0.901878701729589
EXD3	BRD-K15567136-003-27-2::2.5::HTS002	2.5	papaverine	phosphodiesterase inhibitor	noncancer	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.09936189061235	-0.09936189061235	-0.527279706707907	-0.5051056770975	-10.0660104700741	5.7557403646668	7.21454525420536e-05	0.00210608317868235	-0.533018377348571	-0.322817254842544
EXD3	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.266246454425833	-0.211717868579	-1.14372953127576	-0.8933435345705	-5.75688887925633	5.04409821480915	0.00215628908126979	0.0427649691891993	-1.26827116627096	-0.486694987428883
EXD3	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.688042231011	-0.688042231011	-0.943462748873841	-0.900132875838	-5.01248693482349	131.719356099356	1.69785587796907e-06	6.68687527506861e-05	-0.356220179943996	-0.154620855781687
EXD3	BRD-K28360340-001-08-3::2.30697::HTS002	2.30697	TW-37	BCL inhibitor	targeted cancer	BCL2, BCL2L1, MCL1	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.571988830925	-1.571988830925	-2.78155346693024	-2.74381570724	-9.89452286261625	3.91967822245309	0.000647368892571235	0.0150536972307584	-1.55173425197043	-0.867395020040053
EXD3	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.192109521238	0.192109521238	-0.042852106742315	-0.03775802467905	-4.91796273743323	20.2104144363025	8.06902710744451e-05	0.00233367678776948	-0.334554584671814	-0.135368671288816
EXD3	BRD-K37764012-001-04-1::2.5::HTS002	2.5	PF-03758309	p21 activated kinase inhibitor	targeted cancer	PAK4	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.07353976192	-2.07353976192	-3.21121445891048	-3.15071894959	-10.5578616005929	17.8850966430894	4.11415974065155e-09	2.29213346257891e-07	-1.36416630105208	-0.91118309292888
EXD3	BRD-K41783120-001-02-8::2.5::HTS002	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.235695171872667	0.262094993769	-0.286440999019158	-0.184923947897	-7.19909072953822	26.1465333381297	1.1657374828967e-07	5.44932058826101e-06	-0.671179104423965	-0.373093237359686
EXD3	BRD-K44408410-001-17-6::2.5::HTS002	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.553667079766	-0.553667079766	-1.12315421090645	-1.07322078363	-6.68543989521613	4.98548230190405	0.00114477341962237	0.024904399335591	-0.788649432089737	-0.35032483019117
EXD3	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.033563292769265	0.033563292769265	-0.701403828635916	-0.636668754802	-11.8199536715882	7.89398967725441	2.68687482718352e-06	0.000102614967005598	-0.878690794472425	-0.591243448337937
EXD3	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.33540746780667	-1.33668102766	-1.83734459573209	-1.59172250832	-5.06454850696912	118.151911930356	1.52509985895011e-06	6.06218708584787e-05	-0.698195279106845	-0.305678976743995
EXD3	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.05007431622895	0.05007431622895	0.229000897727143	0.2141011890955	6.0703991293685	84.5352823966643	3.49751654615173e-08	1.74208511229411e-06	0.120317220377468	0.237535942618918
EXD3	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.1006444823988	-0.1006444823988	-1.551444528723	-1.43484346641	-23.2728632809892	57.8024940530879	4.81627478610916e-31	2.08961003771658e-28	-1.57559359117182	-1.32600650147658
EXD3	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.01399253316033	-0.993648704795	-0.455946085143552	-0.462750367244	7.72416601617675	33.9039911883739	5.63702191668688e-09	3.09868497148392e-07	0.411207924400124	0.704884971633439
EXD3	BRD-K62814476-001-03-3::2.5::HTS002	2.5	BMS-265246	CDK inhibitor	targeted cancer	CDK1, CDK2	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.03290073032	-2.04456506899	-2.54475999878221	-2.46690436697	-4.39907972238033	9.31669668032217	0.00158490804208665	0.0329445985600222	-0.773717203508262	-0.250001333416151
EXD3	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.71137415017	-2.7129517048	-1.19073879073169	-0.954970062426	20.106235210266	188.449402562131	9.0179441090671e-49	2.05617759888536e-45	1.37144510727691	1.66982561159971
EXD3	BRD-K68747584-001-02-0::2.5::HTS002	2.5	PF-03814735	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.07455169192665	-0.07455169192665	-1.28250300955582	-1.09893939309	-12.0064313386284	5.96566096592996	2.1099632759731e-05	0.000684154794214884	-1.45447581478453	-0.961426820473814
EXD3	BRD-K69608737-001-10-2::2.5::HTS002	2.5	tacrolimus	calcineurin inhibitor	noncancer	FKBP1A	transplant	organ rejection	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4406208652845	0.4406208652845	0.303219654664834	0.3216320959495	-4.64091174566358	24.0389943579451	0.00010311036600153	0.00291473775187839	-0.198500803849942	-0.0763016173893907
EXD3	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.63846642459	0.63846642459	-0.159583233301469	0.0566391407425	-9.90078809756655	6.08082900832404	5.6437551486831e-05	0.0016847080741812	-0.994648388546741	-0.601450927236198
EXD3	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.0270876336649	-0.0270876336649	-1.20263069178998	-1.12346956245	-13.4794135771577	8.09346981448547	7.89741831870321e-07	3.2809571056975e-05	-1.37624670653759	-0.974839409712564
EXD3	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.317109783330333	-0.319737870029	-0.898522876094238	-0.709867744389	-6.09045042006221	5.63889586100325	0.00112122446898438	0.0244342571645098	-0.818677191403053	-0.344148994124756
EXD3	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.1055921935411	0.1055921935411	-0.156769838566003	-0.1366984748555	-5.28558372162044	10.0297725642049	0.000351295085525681	0.00874378404199672	-0.37291631318667	-0.151807751027535
EXD3	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.532914829285667	-0.524942313928	-1.06400633576004	-0.791129598907	-5.49567438494371	143.725102547812	1.7242690341541e-07	7.85130354410908e-06	-0.722107052453633	-0.340075960495121
EXD3	BRD-K78177893-001-02-4::2.5::HTS002	2.5	A-674563	AKT inhibitor	targeted cancer	AKT1, PKIA, PRKACA	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.81415185832	-1.81415185832	-2.6831137109123	-2.66704888005	-9.07784494979161	14.5442030539445	2.25255045399134e-07	1.0102257506874e-05	-1.07354968735527	-0.664374017829338
EXD3	BRD-K78318619-001-02-7::2.5::HTS002	2.5	PF-4981517	cytochrome P450 inhibitor	noncancer	CYP3A4	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.14650822048895	-0.14650822048895	-0.592454160023162	-0.549021652731	-4.73396931149286	7.66827234789324	0.00165644471127178	0.0342060062166075	-0.664821107801171	-0.227070771267252
EXD3	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.0960943533379667	-0.0692865712404	0.125211987978301	0.141810912898	4.70624875635242	12.0618392375073	0.000501835819361023	0.0120297471566747	0.118908213712452	0.323704468920082
EXD3	BRD-K86118762-001-01-8::2.5::HTS002	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.1805366502795	0.1805366502795	0.0637430746088796	0.0670772689305	-3.6259555425066	164.059593594724	0.000383882388237916	0.00946475651543131	-0.180394005418356	-0.0531931459228849
EXD3	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.28217861652	-1.30104018771	-2.07277310922093	-1.89760523602	-5.53854590874226	8.42987529049194	0.000456162420146412	0.011048574454465	-1.1168638548072	-0.464325130594663
EXD3	BRD-K89053832-001-01-0::2.5::HTS002	2.5	VLX600	ubiquitin C-terminal hydrolase inhibitor	targeted cancer	USP14	NA	NA	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.711897691870667	-0.711830948515	-2.08640306128124	-1.92427650365	-13.2961507344058	194.069111795021	4.21634199430633e-29	1.59379958253559e-26	-1.57839041163954	-1.1706203271816
EXD3	BRD-K89162000-001-06-4::2.5::HTS002	2.5	tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFD, PDGFRB	NA	NA	MFE319, TE5	ENDOMETRIUM, OESOPHAGUS	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.565564234017	0.565564234017	0.0499406006222784	0.117993019303	-13.4703664431595	182.919908300535	3.52300101757935e-29	1.34356100551026e-26	-0.591147528139284	-0.440099738650159
EXD3	BRD-K93869735-001-01-1::2.5::HTS002	2.5	taltirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	neurology/psychiatry	spinocerebellar ataxia	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.760796938917333	-0.725181458966	-0.170746595455349	-0.0988352539386	8.0718472964738	5.04911086010045	0.000451393174591821	0.0109479062710298	0.402689759539897	0.777410927384071
EXD3	BRD-K97752965-001-16-4::2.5::HTS002	2.5	nicorandil	nitric oxide donor, potassium channel activator	noncancer	KCNJ11	cardiology	angina pectoris	MFE319, TE5, NCIH1299	ENDOMETRIUM, OESOPHAGUS, LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.027343476701449	0.000806732914053	0.25385422441068	0.2754870353435	6.58390549697773	5.26626995781135	0.000992851039249585	0.0219944982316614	0.173057322003212	0.389338080221045
EXOC4	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.143380255987	-0.143380255987	-0.955599366357693	-0.8814928301585	-12.9517853491572	112.674940767027	4.73376237808874e-24	1.1149258865202e-21	-0.936464745051205	-0.687973475690181
EXOC4	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.2526724489525	0.2526724489525	0.0881959439929583	0.1234730068455	-5.06998202215511	8.02883017809404	0.000954471228179548	0.0212386694211477	-0.239239406515078	-0.0897136034040055
EXOC4	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.194412562318	0.194412562318	-0.346737202364492	-0.266254262221	-11.7098627529628	6.70942042773848	1.03456823233045e-05	0.000355349318376848	-0.651393285000112	-0.430906244364871
EXOC4	BRD-A50998626-001-02-1::2.5::HTS002	2.5	palomid-529	AKT inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.228485432004	-0.228485432004	0.0473460705060739	0.0375657070821	7.67592496010205	8.96830654669243	3.1366092652752e-05	0.000981410696667398	0.194497916293926	0.357165088726222
EXOC4	BRD-A55484088-050-02-5::2.5::HTS002	2.5	BNTX	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.604445367155	-0.604445367155	-1.39227551835387	-1.31545762585	-8.25426421184199	3.52863327614	0.00198401819372388	0.0398239329896465	-1.06739060327806	-0.508269699119689
EXOC4	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.1699178145235	-0.1699178145235	-0.534053145047492	-0.51783728433	-11.0427298942098	58.8564961961549	5.67552545215661e-16	6.47037071614508e-14	-0.430121757213717	-0.298148903834266
EXOC4	BRD-A70858459-001-01-7::2.5::MTS010::PROS003_PR500	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.255067084663	0.255067084663	-0.0179468247867451	-0.0158635898493	-10.137714318445	3.69617984034448	0.000788397900651358	0.0179628503931865	-0.350272409141969	-0.195755409757522
EXOC4	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.2087680364165	0.2087680364165	0.0289341811014892	0.05909936864605	-3.22649587528516	72.068519327812	0.00188600813279375	0.0381453465219923	-0.290940898197947	-0.068726812432075
EXOC4	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.2129073592455	-0.2129073592455	0.0479777661835675	0.0776480680764	6.75404457826018	6.76792876462507	0.000306297397355637	0.00771789500092128	0.168909207117109	0.352861043741026
EXOC4	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.64994064077	-1.64994064077	-0.832004365609715	-0.7893202345315	13.9954412884716	152.311423229209	3.86297541791961e-29	1.46799230203421e-26	0.702472590528396	0.933399959792173
EXOC4	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.99084080388	-0.99084080388	-1.90586758412204	-1.73380354334	-7.16590138354624	7.83254452024293	0.000106125875573398	0.00298894254740748	-1.21058397472886	-0.619469585755222
EXOC4	BRD-K00673382-001-18-9::0.15625::HTS002	0.15625	famotidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	heartburn	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	1.055950107415	1.055950107415	0.495584776354197	0.4883209569055	-15.2515751236637	52.8492957688045	5.3068200984406e-21	9.60646490606988e-19	-0.634064298692117	-0.486666363429489
EXOC4	BRD-K03109492-001-02-2::2.5::HTS002	2.5	NSC-663284	CDC inhibitor	targeted cancer	CDC25A, CDC25B, CDC25C	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.6614841494355	-0.6614841494355	-1.21586298814018	-0.957814328752	-5.90013630795567	30.5935481490111	1.71320277473954e-06	6.73617753636305e-05	-0.746115467268156	-0.362642210141196
EXOC4	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.290136069435	-1.290136069435	-2.03420730777994	-1.93975006052	-8.18187579158172	46.4936192106546	1.4774791361006e-10	9.5959583564032e-09	-0.92707435041766	-0.56106812627223
EXOC4	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0995569869458	-0.0995569869458	-0.650038450577639	-0.593822379071	-8.89527962975938	36.614769295496	1.10683899456425e-10	7.29482456537398e-09	-0.675916266273898	-0.42504666098978
EXOC4	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.09314637458545	0.09314637458545	-0.360215834922193	-0.164030729397	-7.02623383997649	74.0571516049097	8.75364796786439e-10	5.23994190819127e-08	-0.581927862008758	-0.324796557006528
EXOC4	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.2501518460975	-0.2501518460975	-0.685503901840634	-0.506361258966	-5.25343189914792	7.89665753580134	0.000803663235149652	0.018267932710403	-0.626886874554548	-0.24381723693172
EXOC4	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.8397997371235	-0.8397997371235	-1.02845807815347	-1.0089298839585	-3.48326123802888	110.848928108722	0.000710141498154717	0.01637305477173	-0.295984402970576	-0.0813322790893589
EXOC4	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-2.99977134539	-2.99977134539	-1.66708129878742	-1.3362918287	8.82863761945716	5.76493636477364	0.000146169025875051	0.00398781328243047	0.959645056615717	1.70573503658945
EXOC4	BRD-K06753942-001-14-5::2.5::HTS002	2.5	nobiletin	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.5431898261975	0.5431898261975	-0.081081965728957	-0.0747677969197	-9.50771748192462	6.2078415460766	6.29287062360698e-05	0.00186114310840173	-0.7836398161364	-0.464903767716514
EXOC4	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4690641482045	0.4690641482045	0.198291285182556	0.204355413473	-9.17200280821641	40.5538831527891	1.92997107133892e-11	1.39181954828062e-09	-0.330413014458965	-0.211132711584923
EXOC4	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.4626422201165	-0.4626422201165	-0.852745410796999	-0.70967469814	-7.45417795059286	188.492878704402	3.18735640869093e-12	2.52454882379275e-10	-0.493337776719601	-0.286868604641396
EXOC4	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6848375363275	0.6848375363275	0.00811541593336888	0.1859491052615	-11.0033596434448	176.274328037901	9.03641203587009e-22	1.74169528348561e-19	-0.798095958047412	-0.55534828274085
EXOC4	BRD-K09372874-001-01-0::2.5::HTS002	2.5	merimepodib	inosine monophosphate dehydrogenase inhibitor	noncancer	IMPDH1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.6672050202595	-0.6672050202595	-0.902887357191151	-0.8954429864795	-4.39962508731538	177.808243427521	1.86475830096742e-05	0.000611351498314497	-0.341394629074954	-0.129970044788349
EXOC4	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.191733275028	0.191733275028	-0.0728992225173221	-0.00556532595827	-5.94450974738381	25.8591792106449	2.90265144036222e-06	0.000110364090928046	-0.356163022331909	-0.173101972758735
EXOC4	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.5878697530815	0.5878697530815	0.340225381688683	0.3517633375585	-7.95232680360998	165.061911516017	2.74931208698356e-13	2.41399963249119e-11	-0.309130651333977	-0.186158091451657
EXOC4	BRD-K12244279-001-05-8::2.5::HTS002	2.5	MEK1-2-inhibitor	MEK inhibitor	noncancer	MAP2K2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.3574722436545	-0.3574722436545	-0.15342438186307	-0.1558908725075	6.20191229016429	56.7485600565595	6.80415357988247e-08	3.27125938228495e-06	0.13815882374514	0.269936899837721
EXOC4	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.8775863055775	-0.8775863055775	-0.414640652386738	-0.389042162364	12.373026567344	24.5604715815534	4.77858531720589e-12	3.71217619590946e-10	0.385816557733298	0.540074748648227
EXOC4	BRD-K13646352-001-03-8::2.5::HTS002	2.5	midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	targeted cancer	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.611305461695	-1.611305461695	-2.96860098439146	-2.8725192622	-11.1384075430077	6.96428790226796	1.08688431802606e-05	0.00037176959623078	-1.64574189451997	-1.06884915087296
EXOC4	BRD-K14618467-001-04-6::2.5::HTS002	2.5	IKK-16	IKK inhibitor	noncancer	IKBKB	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4457524525325	0.4457524525325	-0.143897718968006	-0.114726429386	-15.1665890239398	187.628366849601	1.95107132639395e-34	1.18462086774699e-31	-0.66634479402761	-0.512955548973402
EXOC4	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.3656424524295	0.3656424524295	-0.0472340311821558	0.0935597000564	-6.32411084356667	36.5179780666092	2.4186074749953e-07	1.07860532981329e-05	-0.545217635009174	-0.280535332214138
EXOC4	BRD-K16338837-001-02-6::2.5::HTS002	2.5	CCMI	acetylcholine receptor allosteric modulator	noncancer	CHRNA7	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0779018371998	-0.0779018371998	0.0896409842706517	0.1287819664105	5.08646732913564	25.9402101993626	2.69222307136183e-05	0.000854973297765461	0.0998282728440002	0.235257370096903
EXOC4	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.47469877822	-0.47469877822	-0.689479949615301	-0.593823716309	-3.76223870639841	68.5327309151692	0.000351252044390216	0.00874372815587812	-0.328683789341823	-0.100878553448779
EXOC4	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.489238876245	0.489238876245	0.297123845374995	0.330939410236	-7.25048054543683	25.3202804137076	1.24631206289376e-07	5.80318961824802e-06	-0.246651373584853	-0.137578688155158
EXOC4	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6294213533085	0.6294213533085	0.0853640956245527	0.0863678330512	-14.6019312131432	3.13775536738165	0.000545805115068394	0.0129476330390143	-0.659741577407699	-0.428372937960196
EXOC4	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.8680910169	0.8680910169	0.379122590118726	0.383188744526	-15.1893910255649	5.43054663969452	1.17428796770413e-05	0.000398928460659468	-0.569784265032118	-0.408152588530429
EXOC4	BRD-K25596805-001-01-8::2.5::HTS002	2.5	JNJ-16259685	glutamate receptor antagonist	noncancer	GRM1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6630720400925	0.6630720400925	0.388870128828346	0.376431167142	-7.68619538294887	21.3996593936712	1.37099914848956e-07	6.34243204180054e-06	-0.348307018062945	-0.200096804465363
EXOC4	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.04655357647645	-0.04655357647645	-0.242485113907088	-0.125640191534	-4.37213212578041	13.4469713283863	0.000699307441137305	0.016147582907942	-0.292419599053024	-0.0994434758082522
EXOC4	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.245428808051	-0.245428808051	-1.04457751165097	-0.8676646214495	-9.48184270683217	17.6243851026876	2.43291793010853e-08	1.23946961502789e-06	-0.976489511776068	-0.621807895423867
EXOC4	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0905362223698	-0.0905362223698	-0.778008262218934	-0.707312470978	-9.69521248707589	6.23202583921805	5.47926260428763e-05	0.00163971638468914	-0.85942473096423	-0.515519348734038
EXOC4	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.5649207158055	0.5649207158055	0.267846972117365	0.2845478404215	-10.4991786637313	25.0485465210944	1.16313169428828e-10	7.63998936270649e-09	-0.355342559451672	-0.238804927924599
EXOC4	BRD-K30480208-001-18-5::2.5::HTS002	2.5	torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	noncancer	SLC12A1	cardiology	edema, congestive heart failure, hypertension	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.435725489487	0.435725489487	0.0245732586371757	0.129954580002	-8.01026953983568	109.372643372557	1.34097528057613e-12	1.10344573157734e-10	-0.51287904420061	-0.309425417499038
EXOC4	BRD-K32007074-001-02-9::3.16375::HTS002	3.16375	enocitabine	DNA synthesis inhibitor	chemo	CMPK1, RRM1, TYMS	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.249237472867	-0.249237472867	-0.0446040342104029	0.0407485371646	5.15665157110041	56.2814978507838	3.37417475115006e-06	0.000126763102583566	0.125146820079737	0.284120057233457
EXOC4	BRD-K33720171-001-01-0::2.5::HTS002	2.5	difluprednate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	endogenous uveitis	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.828699303454	-0.828699303454	-1.4764032163274	-1.46727354757	-7.30188981860736	6.7494039771266	0.000193733061640334	0.00513766559865272	-0.859043688034624	-0.436364137712179
EXOC4	BRD-K33882852-003-02-8::2.5::HTS002	2.5	ZK-93423	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.3367123001245	-0.3367123001245	-0.888810349691158	-0.832624878756	-8.61867890977714	35.9864052709242	2.82463053491266e-10	1.78321130461648e-08	-0.682016038348046	-0.422180060785269
EXOC4	BRD-K36627727-001-05-4::2.5::HTS002	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.1041350550375	-0.1041350550375	0.139578827843952	0.154182848854	8.99174486829117	191.999168862792	2.32638525075466e-16	2.76239237899721e-14	0.190253689368477	0.297174076394427
EXOC4	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.57945679671	-1.57945679671	-3.00569328205372	-3.11792642927	-13.8775533862681	32.6986326861812	2.94620368617874e-15	3.12912234814174e-13	-1.63540276787956	-1.21707020280787
EXOC4	BRD-K41876534-001-13-7::2.5::HTS002	2.5	tioxolone	carbonic anhydrase inhibitor	noncancer	CA2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.626517852928	0.626517852928	0.211798464071484	0.2726226138565	-9.22230920901656	123.719759142667	9.73850290923515e-16	1.08035382506908e-13	-0.503727916170109	-0.325710861542923
EXOC4	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.918702307417	-0.918702307417	-2.30282769506614	-2.14029239454	-16.0130871890929	142.054401527307	1.26697275174791e-33	7.05322085478903e-31	-1.55499470506273	-1.21325607023554
EXOC4	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.0783242178189	0.0783242178189	-0.637279152847345	-0.4291875223905	-9.66210876822811	13.2992762070743	2.21062830844931e-07	9.92254983710224e-06	-0.875241202949741	-0.55596553838275
EXOC4	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.242029350924	0.242029350924	-0.299362194965745	-0.160539632789	-8.16626421876206	14.6549020312114	7.8527576010413e-07	3.26303544760291e-05	-0.682988729232576	-0.399794362546914
EXOC4	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.0551122502164	0.0551122502164	-0.21081507598075	-0.158274399371	-5.7581967517394	62.765119802613	2.75084432065086e-07	1.21915986848796e-05	-0.358222241075751	-0.173632411318548
EXOC4	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6913956392885	0.6913956392885	0.365000152248978	0.394038132066	-7.51743383604044	99.6616456892318	2.47814604863671e-11	1.76399390387997e-09	-0.412540079336825	-0.240250894742218
EXOC4	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.11214723019195	-0.11214723019195	-0.897345050869732	-0.852653660565	-12.6467388004879	88.9769423275688	1.39023300823931e-21	2.61145705892133e-19	-0.908563768224387	-0.661831873131176
EXOC4	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.6113551749385	-0.6113551749385	-1.75158867102448	-1.65992199057	-10.6186451259594	3.85856416666313	0.000536675415195617	0.0127564716716715	-1.44272876200895	-0.837738230163006
EXOC4	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4690836173685	0.4690836173685	-0.129904070346784	-0.075355311638	-15.1693686294034	28.1045061018166	4.5896200405011e-15	4.79614175358635e-13	-0.679858894259545	-0.518116481171023
EXOC4	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0505247195181	-0.0505247195181	0.15671153089467	0.14294893902	8.99598426674315	11.0657118841979	2.01621313024821e-06	7.85125261615133e-05	0.156569903292958	0.257902597532583
EXOC4	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.2028895274685	-0.2028895274685	-0.679677980971649	-0.588520646364	-7.4760020102931	9.18525119709015	3.38997917924943e-05	0.00105514209629589	-0.620617144067252	-0.332959762939047
EXOC4	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.5605778559975	0.5605778559975	0.343507754990008	0.381901791063	-6.59064101928803	131.626832436338	9.63188732424249e-10	5.74399771373836e-08	-0.282222697812425	-0.151917504202559
EXOC4	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4527206993505	0.4527206993505	-0.370660068145818	-0.243490121847	-9.75401995578877	4.61646318467779	0.000297124489258785	0.00750617570230389	-1.04591131996388	-0.600850215028755
EXOC4	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.520842990084	0.520842990084	-0.0735132645657781	0.318163539168	-6.77574772559633	83.2798227974295	1.64385737162436e-09	9.55849990783712e-08	-0.768815516390606	-0.41989699290895
EXOC4	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.300963260223	-0.300963260223	-0.784265120748316	-0.640313618355	-5.739335700772	16.4057589859422	2.76325418238374e-05	0.000875196550400657	-0.661458119486711	-0.305145601563921
EXOC4	BRD-K49371609-003-03-8::2.5::HTS002	2.5	PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-4.815595787025	-4.815595787025	-5.34679433168738	-5.36758305195	-6.63273403343987	43.7316179494636	4.06737963085467e-08	2.0081949064765e-06	-0.692632112664535	-0.369764976660225
EXOC4	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.002753569341	-1.002753569341	-1.83819548463316	-1.58248812639	-6.94124018269738	6.45653480372296	0.000321091845289769	0.00805280764206773	-1.12497521229315	-0.545908618291167
EXOC4	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.391055422803	-0.391055422803	-1.25808294236012	-0.921278111753	-10.072437181819	190.917986435628	2.08085811543192e-19	3.25538860600298e-17	-1.03681597090841	-0.697239068205828
EXOC4	BRD-K56334280-001-05-1::2.5::HTS002	2.5	amonafide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.6482932430715	-0.6482932430715	-0.402184164636514	-0.351314644036	3.48464660251637	26.3455875254121	0.00174066820566632	0.0356941901886965	0.10102645163471	0.391191705235262
EXOC4	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.2958358918245	0.2958358918245	-0.759443575079388	-0.674815903064	-10.1086254827451	3.07875621114883	0.00184368414921061	0.0374164359450961	-1.38275119004491	-0.727807743762868
EXOC4	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.199510238338	0.199510238338	-0.395325603754086	-0.201440599557	-9.4195657914939	179.120832209151	2.28988775660466e-17	2.9690825951925e-15	-0.719447468175092	-0.47022421600908
EXOC4	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.506553428568	0.506553428568	-0.258399315424564	-0.132231172134	-9.9670047096091	3.52496054314819	0.00104836436893895	0.0230267356866485	-0.989858200098989	-0.54004728788614
EXOC4	BRD-K62196610-001-01-6::2.5::HTS002	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.306996625025	-1.306996625025	-1.67560706612431	-1.62132235513	-5.48225834827401	157.808249289157	1.6325136048154e-07	7.47000444932706e-06	-0.501410893202179	-0.235809988996447
EXOC4	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.4420990980235	-0.4420990980235	-0.206342736111178	-0.128286851934	6.38409912803165	187.171676415976	1.3243982956621e-09	7.78970807659064e-08	0.162906441539779	0.308606282284866
EXOC4	BRD-K65781196-001-03-0::2.5::HTS002	2.5	avanafil	phosphodiesterase inhibitor	noncancer	PDE5A	urology	erectile dysfunction	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.348117068957	0.348117068957	0.519711561838309	0.5001680411375	5.7566642640931	18.236319568327	1.77029192242474e-05	0.000583730611448266	0.109028384927661	0.234160600834957
EXOC4	BRD-K66094457-001-01-5::2.5::HTS002	2.5	CPP	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.185757102551	-0.185757102551	-0.92074625580084	-0.865994083482	-9.94752220609275	7.09794028211686	2.01811971086446e-05	0.000657158279413352	-0.909215810211422	-0.560762496288259
EXOC4	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.9987197942175	-0.9987197942175	-0.326479159039197	-0.32021882125	15.0809905765424	175.129709806738	1.7744256114545e-33	9.70180782850593e-31	0.584266596175532	0.760214674181074
EXOC4	BRD-K66808046-065-03-7::2.5::HTS002	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.145395877329	-0.145395877329	-0.457395211623971	-0.3317635225235	-3.60843550204479	75.7470400091635	0.000550187080778104	0.0130429207870911	-0.484216376681558	-0.139782291908384
EXOC4	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.870001066847	-0.870001066847	-1.7669233230646	-1.7012260142	-12.4804004575804	18.3909448418811	2.03114069935247e-10	1.30105306321433e-08	-1.047678362953	-0.746166149482197
EXOC4	BRD-K68507560-003-24-6::2.5::HTS002	2.5	dicycloverine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.09404100553955	0.09404100553955	0.232807855537136	0.2203060574785	4.38911665579649	163.767132354374	2.03316614691146e-05	0.000661655735046139	0.0763390630857194	0.201194636909453
EXOC4	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-2.61092015841	-2.61092015841	-3.68244852841885	-3.50719189578	-8.7821712957528	28.5090991451893	1.33490644301187e-09	7.84505519671764e-08	-1.32125725986494	-0.821799480152761
EXOC4	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.0966277635015	0.0966277635015	-0.0804322179962553	0.0411624842104	-3.97564553334852	89.0020708040702	0.000142509937940485	0.00389492635664961	-0.265552352367066	-0.0885676106284446
EXOC4	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.175854129887	0.175854129887	-0.540499212419076	-0.407441526883	-10.3550424995919	98.9309028941721	1.85480909769186e-17	2.4181227439124e-15	-0.853621028699758	-0.579085655912393
EXOC4	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.3140525682975	0.3140525682975	0.099632758267325	0.129185439077	-4.99028530857647	14.4253742994018	0.000181182097949911	0.0048443834670043	-0.306321520419927	-0.122518099640423
EXOC4	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.14561321654	0.14561321654	-0.20003750620924	-0.124222212564	-8.37972570373922	11.6517825719544	2.84842719970162e-06	0.000108417786056624	-0.435822175620144	-0.255479269878336
EXOC4	BRD-K73838513-003-05-5::2.5::HTS002	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.4493704282295	0.4493704282295	0.170843605535307	0.190630234256	-7.56885995474155	136.106891846132	5.1133340448702e-12	3.94221500900355e-10	-0.351298658891573	-0.205754986496812
EXOC4	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.325397781136	-0.325397781136	-1.48237659100479	-1.368540965995	-12.9725819756448	126.1054482375	5.67548138728839e-25	1.46028841567363e-22	-1.33347478374367	-0.98048283599391
EXOC4	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.148963458701	0.148963458701	-0.429654447445382	-0.2512002355925	-8.84339350914675	149.155144716091	2.43980414401173e-15	2.61460391190945e-13	-0.707906156135435	-0.449329656157329
EXOC4	BRD-K76210423-001-01-6::2.5::MTS010::PROS001_PR500	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.0219686106064	-0.0219686106064	0.107365264680007	0.094360121778	6.31063430248792	183.348251919275	2.0329493026314e-09	1.1694041628655e-07	0.0888983123058036	0.16976943826701
EXOC4	BRD-K77625799-001-07-7::2.5::HTS002	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.6270149408485	0.6270149408485	0.102318514144306	0.160912505802	-8.41537031835473	8.43179482180799	2.20447495666734e-05	0.000712536439432296	-0.66720366474018	-0.382189188668209
EXOC4	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.906784975411	0.906784975411	0.45096133943304	0.472553592618	-14.4737488251227	178.556209581835	6.47039292861708e-32	3.03455764988527e-29	-0.517970249443283	-0.393677022512636
EXOC4	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.3078875120645	0.3078875120645	0.00235830978395167	0.041364371782	-7.15974480631769	5.21157040963295	0.000693642493562057	0.0160288627496132	-0.413898161082993	-0.197160243478103
EXOC4	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.387210266402	-0.387210266402	-1.02025182729375	-0.966558687453	-9.13470417481697	5.18705309148026	0.000216837928333972	0.00567941541511571	-0.809269732554406	-0.456813389229086
EXOC4	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.12327000846	-1.12327000846	-1.75633050079539	-1.69551344644	-8.28738452051452	10.6022526588115	5.92884747191842e-06	0.000213387732965374	-0.8019631067566	-0.464157877914186
EXOC4	BRD-K97472745-001-01-8::2.5::HTS002	2.5	gestrinone	progesterone receptor antagonist	noncancer	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.01165033777969	-0.01165033777969	-0.162372241803793	-0.1123477003	-3.58754767634845	25.7926875581563	0.00136891747063624	0.0290436262684611	-0.237113662397977	-0.0643301456502296
EXOC4	BRD-K97714174-001-01-3::2.5::HTS002	2.5	P22077	ubiquitin specific protease inhibitor	noncancer	USP7	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.7811672060265	0.7811672060265	0.251649881316252	0.3142607574065	-11.0860985345446	5.04043168556202	9.90302502751882e-05	0.00280977687466651	-0.652003166044318	-0.407031483376177
EXOC4	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.10486544595965	0.10486544595965	-0.244625385199201	-0.195507988981	-6.52763935741937	8.3398203606784	0.000151974053262602	0.0041335592464112	-0.472084440883697	-0.226897221434004
EXOC4	BRD-K97810537-001-13-6::2.5::HTS002	2.5	beclomethasone-dipropionate	glucocorticoid receptor agonist	noncancer	GPR97, NR3C1	allergy	allergic rhinitis	PANC1, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.3108353570785	0.3108353570785	0.0716643855722013	0.0633860344485	-5.73861404669046	105.138829823917	9.29413235631752e-08	4.39347616629285e-06	-0.321808443314311	-0.156533499698286
EYA2	BRD-A57382968-001-29-0::2.5::HTS002	2.5	piroxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.274759379191	0.274759379191	0.0171916665193049	0.00421329680347	-8.52735766944875	7.95080504426594	2.85493574388658e-05	0.000901437128832451	-0.327295350522684	-0.187840074820706
EYA2	BRD-A83937277-001-10-5::2.5::HTS002	2.5	mephenytoin	hydantoin antiepileptic	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.422575484291	0.422575484291	-0.0749810774286595	-0.0963568398651	-10.6532212143832	5.73587238192025	5.40023184169547e-05	0.00161883313046445	-0.61312694287199	-0.381986180567329
EYA2	BRD-K02594908-001-16-4::2.5::HTS002	2.5	sulfanilamide	carbonic anhydrase inhibitor	noncancer	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.07990434700085	0.07990434700085	-0.365949884405983	-0.3369002650265	-5.97658737281792	103.790154260363	3.24794638868639e-08	1.62571018575611e-06	-0.593792621049901	-0.297915841763765
EYA2	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-2.209040620635	-2.209040620635	-1.44559913461322	-1.361653967605	8.59660892574697	8.28338635043173	2.09240780329957e-05	0.000679078849293449	0.559864652787941	0.967018319255621
EYA2	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-5.73620512476	-5.73620512476	-4.25879770816921	-4.2400927308	23.1751972128187	186.459936061215	8.48108034320515e-57	3.78696139349753e-53	1.3516444116368	1.60317042154477
EYA2	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.98942379816	-0.98942379816	0.0695149526616481	0.0780850986405	17.9346598674737	5.46754950760383	4.55287925817564e-06	0.000167464228338	0.910982608934859	1.20689489270844
EYA2	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.5041173088975	0.5041173088975	0.254353917854328	0.2240846909	-8.18679210323929	17.2948066253487	2.35202076412227e-07	1.05153579130906e-05	-0.314046356523744	-0.1854804255626
EYA2	BRD-K08109215-001-06-4::2.5::MTS010::PROS002_PR500	2.5	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.718820246213	-0.718820246213	-0.167385148410105	-0.03477254501165	8.09677036118569	4.49849613944235	0.00075755249659213	0.0173319245348094	0.370327702156797	0.732542493448993
EYA2	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.560281837982	-0.560281837982	-0.064711708967183	0.051024564158	11.3614797913887	53.8911898585367	6.33959098263788e-16	7.1815972289524e-14	0.408116359679692	0.583023898349942
EYA2	BRD-K19540840-001-09-4::2.5::MTS010::PROS004_PR500	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.1633618369155	-0.1633618369155	-0.40479327532219	-0.3364454572695	-4.09823947975843	41.3379436595358	0.000189741300608011	0.0050442896574069	-0.360375111580518	-0.122487765232862
EYA2	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.5642874439035	-0.5642874439035	-0.191665753679242	-0.144534319806	7.505290118653	193.458658419106	2.18183521634654e-12	1.75800962437721e-10	0.274701082523568	0.470542297924948
EYA2	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-1.661179869625	-1.661179869625	-0.356668254885194	-0.151227527586	17.1185222768359	88.7628657224007	7.27782817653137e-30	2.8993487644011e-27	1.15308895286056	1.45593427661906
EYA2	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-5.2135881415	-5.2135881415	-3.0159087672628	-3.15858467957	15.4627813954147	3.7175155687553	0.000164596656900597	0.00445202383604846	1.79095983871594	2.60439890975845
EYA2	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-5.69592240796	-5.69592240796	-3.24154689563338	-2.99271378173	19.6741908496889	24.2656083267398	2.01089841743674e-16	2.40509959213616e-14	2.19705110528819	2.71169991936505
EYA2	BRD-K24048528-001-02-5::2.5::HTS002	2.5	abiraterone-acetate	androgen biosynthesis inhibitor	targeted cancer	CYP17A1	oncology	prostate cancer	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.213401023862	0.213401023862	0.404023208185156	0.3679428252945	5.89138023997207	46.9228238943234	3.94946217451061e-07	1.70972385053663e-05	0.125527248047198	0.255717120599114
EYA2	BRD-K24869513-001-02-1::2.5::HTS002	2.5	CNX-2006	EGFR inhibitor	targeted cancer	EGFR	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.5009878804225	0.5009878804225	-0.130342191249604	-0.02986474769355	-9.9467316466603	3.52921517821589	0.00104979049553665	0.023053334745684	-0.817223732753401	-0.445436410590806
EYA2	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-1.68438235371	-1.68438235371	-0.825616683110361	-0.73306047453	14.543819245985	182.093618013885	2.65183487775972e-32	1.29468136108283e-29	0.742261813424957	0.975269527774321
EYA2	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.22835561822	0.22835561822	-0.0356839266818121	-0.0304287468122	-9.49107889326029	12.5800960966553	4.29558012861109e-07	1.85170433102391e-05	-0.324345046174565	-0.203734043629059
EYA2	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.790075806791	-0.790075806791	-0.52831250861404	-0.447815997104	5.38824435737171	37.9740019868383	3.93410148608694e-06	0.00014600727920546	0.163415121626416	0.360111474727503
EYA2	BRD-K29950728-048-17-4::2.5::HTS002	2.5	clomifene	estrogen receptor antagonist	noncancer	ESR1	obstetrics/gynecology	infertility	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.403915414292	-0.403915414292	-0.135164418578422	-0.112752624282	7.35684589047221	23.010771954507	1.7463388178029e-07	7.9450446291844e-06	0.193183367927154	0.344318623500001
EYA2	BRD-K32007074-001-02-9::3.16375::HTS002	3.16375	enocitabine	DNA synthesis inhibitor	chemo	CMPK1, RRM1, TYMS	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.544670697538	-0.544670697538	-0.0415104925908113	0.0407485371646	12.7885735317322	62.2243718231781	4.53841238732645e-19	6.87429956581831e-17	0.424517283838832	0.581803126055545
EYA2	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.0901643911952	-0.0901643911952	0.134345761802165	0.1319992768505	6.93413075310517	91.1263488819764	5.73734748774792e-10	3.49539496788381e-08	0.160197332180535	0.288822973814196
EYA2	BRD-K37764012-001-04-1::2.5::HTS002	2.5	PF-03758309	p21 activated kinase inhibitor	targeted cancer	PAK4	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-3.806986612075	-3.806986612075	-3.19206035006899	-3.08603561013	5.12405470586716	7.00890393351522	0.00135731997202887	0.0288375329386377	0.331226095632865	0.898626428379157
EYA2	BRD-K40797222-001-01-8::2.5::HTS002	2.5	SC-12267	dihydroorotate dehydrogenase inhibitor	noncancer	IL17A	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.4545703701475	0.4545703701475	0.184265626881874	0.184399160559	-11.0037182113939	26.042951013481	2.73441356215542e-11	1.94118063955487e-09	-0.320794473318738	-0.219815013212515
EYA2	BRD-K41312087-001-02-7::2.5::HTS002	2.5	GW-441756	growth factor receptor inhibitor	targeted cancer	NTRK1	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.1313437419235	-0.1313437419235	-0.00637971180492571	0.0338208037479	3.91845055802008	192.007530469339	0.000123855780166059	0.00343858620559731	0.0620619851429224	0.187866075094226
EYA2	BRD-K41599323-001-02-3::2.5::HTS002	2.5	lonafarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, HRAS, KRAS, NRAS	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-2.31733584419	-2.31733584419	-1.27472332819692	-1.15325467398	10.0301259471828	4.38959541271994	0.000343948107904451	0.00857884953090341	0.763833065539169	1.32139196644699
EYA2	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-3.637160332765	-3.637160332765	-2.2721106552317	-2.11093641974	12.0634503914796	5.0897580904282	6.14849259771868e-05	0.00182217957684796	1.07570949116403	1.65438986390258
EYA2	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.00508891721615	0.00508891721615	-0.636516285132733	-0.4291875223905	-8.6862544184265	13.7735044035729	5.85950915575768e-07	2.4760700667279e-05	-0.800273397218383	-0.482937007479383
EYA2	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.01750302954805	-0.01750302954805	0.372581956193754	0.396546401632	9.26939319783967	183.540460669127	5.11294003276023e-17	6.42728049431946e-15	0.307056116080415	0.473113855403194
EYA2	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-6.31056982915	-6.31056982915	-5.43781761756527	-5.470053491025	8.98136069144336	8.22460772209928	1.57404442489659e-05	0.000523612242035794	0.649729947557536	1.09577447561193
EYA2	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.3914595799725	0.3914595799725	-0.301472517081096	-0.290098649131	-15.679344295666	175.498857283763	3.29722415326232e-35	2.1095246434166e-32	-0.78015209365554	-0.605712100451652
EYA2	BRD-K47869605-001-32-0::0.625::HTS002	0.625	podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	noncancer	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-4.97774142483	-4.97774142483	-3.25126804416021	-3.14383737587	12.8951810752719	6.39151371372651	8.19013365836936e-06	0.000286874188080511	1.40367167947646	2.04927508186312
EYA2	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.1680003041265	0.1680003041265	-0.367614930228984	-0.243490121847	-8.54952575531764	179.067514202857	5.34200164576876e-15	5.56339101426614e-13	-0.659239604929911	-0.411990863781058
EYA2	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-6.590183767275	-6.590183767275	-6.17713597309053	-6.268105536705	4.20828792915563	21.7894024162409	0.000369145982264635	0.00915301818981918	0.209380889808696	0.616714698560251
EYA2	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.674877236759	0.674877236759	0.299200362582619	0.2999355775105	-12.8313239483726	4.57134032632895	9.28203466962608e-05	0.0026458428098235	-0.453111703921207	-0.298242044431554
EYA2	BRD-K54256913-001-08-7::2.5::MTS010::PROS004_PR500	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-3.549931656135	-3.549931656135	-1.18629843499598	-1.175511705255	23.2887850873823	191.024075030259	1.05404799810803e-57	5.02029007525549e-54	2.16344360529453	2.5638228369835
EYA2	BRD-K55187425-236-05-2::2.5::MTS010::PROS004_PR500	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-2.6796118246	-2.6796118246	-0.781141894944704	-0.7051188233505	22.2959988394684	103.822010325471	2.23366944342859e-41	2.6855100998985e-38	1.72961393430851	2.06732592500208
EYA2	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.232412275248	0.232412275248	0.469906672027555	0.4617368983695	8.54629289096622	50.6416908494213	2.17315240546483e-11	1.55619639796483e-09	0.181695721946111	0.293293071612999
EYA2	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-2.170030347935	-2.170030347935	-1.17325649958819	-1.09615123005	11.8398915858525	3.15576157614246	0.00101507295532943	0.0224080308417759	0.73617883619797	1.25736886049566
EYA2	BRD-K63784565-001-06-2::2.50835::HTS002	2.50835	10-hydroxycamptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-6.40923062413	-6.40923062413	-5.71184250415797	-5.76312410001	7.40631258721492	186.778621856202	4.33182738346696e-12	3.3884533987996e-10	0.51163174110405	0.883144498840015
EYA2	BRD-K66094457-001-01-5::2.5::HTS002	2.5	CPP	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.62759392294	-0.62759392294	-0.916119692236558	-0.865994083482	-4.89601305194686	190.941949260614	2.07646569145938e-06	8.07414396198835e-05	-0.404764678410322	-0.172286860182793
EYA2	BRD-K69694239-001-02-2::2.5::HTS002	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-7.88510538274	-7.88510538274	-5.66717803708213	-5.73883515181	17.0174368168554	2.16894767061761	0.0023848762180264	0.046607835773993	1.69699909839012	2.73885559292562
EYA2	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-1.4429451398	-1.4429451398	-0.882516752898174	-0.689609968602	9.0592051461465	145.358117556394	8.07568599751048e-16	9.04312280125613e-14	0.438161470151818	0.682695303651833
EYA2	BRD-K81801188-001-02-8::2.5::HTS002	2.5	PP-121	protein tyrosine kinase inhibitor	noncancer	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-5.91184426679	-5.91184426679	-4.61056967117112	-4.579711066605	9.39172389353156	4.26889613833003	0.000521841185987698	0.0124443142709392	0.925953548413623	1.67659564282414
EYA2	BRD-K83988098-001-02-0::0.039::MTS010::PROS005_PR500	0.039	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-0.384542917666	-0.384542917666	-0.981270446514505	-0.942675371448	-4.85499916389448	7.47120945916955	0.00153522749545817	0.0320674177832623	-0.883688347307124	-0.309766710389886
EYA2	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-7.182681812405	-7.182681812405	-6.20416887848333	-6.171939349	16.4556655153249	170.237274467082	5.02628710586557e-37	3.9899225522706e-34	0.861131988233668	1.09589387960967
EYA2	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.533869552257	0.533869552257	0.304531102221443	0.301488629615	-7.414438718346	8.77769454397406	4.61893098384857e-05	0.00140182789413379	-0.299581046217333	-0.159095853853781
EYA2	BRD-K97752965-001-16-4::2.5::HTS002	2.5	nicorandil	nitric oxide donor, potassium channel activator	noncancer	KCNJ11	cardiology	angina pectoris	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.5929093277145	0.5929093277145	0.246050617693018	0.245556311183	-12.0810651032302	35.4209075101275	4.04013304995299e-14	3.86225547039863e-12	-0.405120263708934	-0.288597156334029
EYA2	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	-1.34372992253	-1.34372992253	-0.855454012017534	-0.7866589985	10.726536973069	109.329029696591	8.97964445068499e-19	1.32002621088537e-16	0.398059068355931	0.578492752669002
EYA2	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	GI1, SH10TC	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma	0.07477796421095	0.07477796421095	-0.220755830155243	-0.147984722712	-6.18358759081581	190.074048180249	3.75006877567342e-09	2.09999360998203e-07	-0.389807106407972	-0.201260482324414
FBXO42	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.2388061389135	-0.2388061389135	-0.834846322095033	-0.720201208535	-7.10872671302505	4.0301668526446	0.00201097574094733	0.0402806957406063	-0.828149124287847	-0.36393124207522
FBXO42	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.0627487002534	-0.0627487002534	-0.777731887516076	-0.4776049590865	-7.1076239720671	165.977659413759	3.32824543391264e-11	2.33346259602572e-09	-0.913591612157051	-0.516374762368301
FBXO42	BRD-A43671941-003-11-9::2.5::HTS002	2.5	oxprenolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	angina pectoris, hypertension, cardiac arrythmia	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.245973827049	-0.245973827049	-0.408618165654767	-0.3932406545145	-3.98706875767789	13.950133674446	0.00135876212565033	0.0288624507064925	-0.25016588762372	-0.0751227895878152
FBXO42	BRD-A69815203-001-07-6::2.5::HTS002	2.5	cyclosporin-a	calcineurin inhibitor	noncancer	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.146750439192	0.146750439192	-0.0749793053516344	0.001630441296925	-5.28636128491629	152.035055147173	4.26378095191956e-07	1.83836634006029e-05	-0.304597576647891	-0.138861912439378
FBXO42	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.06916596914615	0.06916596914615	0.360609988688368	0.3667280736395	12.8362378045918	187.862130283697	1.73258572682632e-27	5.50138320362901e-25	0.246654924297146	0.33623311478729
FBXO42	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.287663478153	0.287663478153	-0.190029712354733	-0.0590439534084	-10.852638996652	48.8925088715945	1.27770004236517e-14	1.27966435691628e-12	-0.566152208951751	-0.389234172063715
FBXO42	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.296811256991	-0.296811256991	0.15605139077903	0.185523876977	8.02632308231777	5.22132304210561	0.000395615766495638	0.00971381963767253	0.309654604129257	0.596070691410803
FBXO42	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.29479890871	-0.29479890871	-0.847230677205895	-0.797149374107	-6.78136637104081	3.96822813515471	0.00254041700945299	0.0492612898958699	-0.779325836106445	-0.325537700885345
FBXO42	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-3.392724095975	-3.392724095975	-1.88071697373361	-1.71824464082	10.8224652540978	4.60043554497965	0.000190840081444121	0.00507098485195103	1.1432831771467	1.88073106733608
FBXO42	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.1398666244275	-0.1398666244275	0.244415174168047	0.240200693149	10.7911035041917	4.21370225884237	0.000316083429476623	0.00793741597613301	0.287356384240889	0.481207212950205
FBXO42	BRD-K05638300-001-01-2::2.5::HTS002	2.5	sevoflurane	membrane integrity inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-1.49384231415	-1.49384231415	-0.565600708801448	-0.4301086882785	11.1033832029811	3.25873779816313	0.00106339366349432	0.0233043047549155	0.673749570082602	1.1827336406145
FBXO42	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.00594964172675	-0.00594964172675	-0.3089134701215	-0.199486634258	-5.07489619269596	31.0311162585031	1.72837020131662e-05	0.000571137614674669	-0.424714829119733	-0.181212827669768
FBXO42	BRD-K08547377-394-03-5::2.5::HTS002	2.5	irinotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	colorectal cancer	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-2.25560615214	-2.25560615214	-1.95364715372386	-1.92016274671	3.76032963942761	165.910693425289	0.000234885978864905	0.00609847086179723	0.143415065733743	0.460502931098547
FBXO42	BRD-K09090949-001-01-9::2.5::HTS002	2.5	CP-945,598	cannabinoid receptor antagonist	noncancer	CNR1	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-1.12537190928	-1.12537190928	-0.687575691597163	-0.6179289044455	7.72519233278185	151.277079020709	1.42902015326452e-12	1.1690093909505e-10	0.325826902137949	0.549765533227725
FBXO42	BRD-K09900591-001-26-7::2.5::HTS002	2.5	caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	noncancer	ALOX5, MIF	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.2097495295945	0.2097495295945	-0.0562853324229025	-0.0732110977947	-6.19862672706219	4.83786570858901	0.00179415753431612	0.0365671348585432	-0.377481427347967	-0.154588296686838
FBXO42	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-5.22267120936	-5.22267120936	-4.12559028707424	-4.11179699224	6.63317207835682	4.22785674594727	0.00219808464364152	0.0434686550643147	0.647473593722785	1.54668825084873
FBXO42	BRD-K13044802-213-20-7::2.5::HTS002	2.5	ciclopirox	membrane integrity inhibitor	noncancer	ATP1A1	infectious disease	onychomycosis	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-2.381189730165	-2.381189730165	-1.61009664862729	-1.63543004783	12.3693734170392	190.698287343217	3.4735924480354e-26	9.80884842944637e-24	0.648130738546616	0.894055424528803
FBXO42	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.399299784638	0.399299784638	-0.0990988616799966	-0.0311349339001	-9.53269875712061	5.06513538545662	0.000200284792612122	0.00529173987816384	-0.632278354194314	-0.364518938441679
FBXO42	BRD-K17472821-001-01-2::2.5::MTS006	2.5	GSK2830371	protein phosphatase inhibitor	targeted cancer	PPM1D	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.495012678157	0.495012678157	0.211037143041048	0.222894017996	-12.0321501212394	7.48272762650522	3.65949829233164e-06	0.000136620207193372	-0.3390623436982	-0.228888726533704
FBXO42	BRD-K18910433-001-36-6::2.58082::HTS002	2.58082	estradiol	estrogen receptor agonist	noncancer	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.0510260980886	0.0510260980886	0.309960196202127	0.326005969483	8.65096681663065	173.159734461282	3.38824120293651e-15	3.57381077157569e-13	0.19985707341965	0.318011122807404
FBXO42	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.3056478231975	0.3056478231975	-0.347060008006508	-0.216806871006	-10.0938424283359	14.8579912234058	4.82558083181029e-08	2.35917407413565e-06	-0.790650624787967	-0.51476503762005
FBXO42	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-4.514336449525	-4.514336449525	-3.11694850539088	-3.13313730075	9.97066958993524	10.3321174759675	1.2612829891464e-06	5.07280018353834e-05	1.08646986896026	1.70830601930798
FBXO42	BRD-K20755323-001-05-9::2.5::HTS002	2.5	SKI-II	sphingosine kinase inhibitor	targeted cancer	SPHK1	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.144871669665	-0.144871669665	0.0578971278079613	0.07792704644355	4.92788282921268	11.446646271008	0.000401205450122511	0.00983529256768931	0.112633610279807	0.292903984666115
FBXO42	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.172479461998	0.172479461998	0.415703709179925	0.442474468431	9.36547244549848	177.35328233836	3.4434672228141e-17	4.38262996673707e-15	0.191973649458582	0.294474844905267
FBXO42	BRD-K23984367-075-15-2::2.5::HTS002	2.5	sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.052347855674765	0.052347855674765	-0.861717342430643	-0.738304903661	-10.1785395787449	10.8355949649983	7.0198575267469e-07	2.93729091236225e-05	-1.11208716812274	-0.716043228088072
FBXO42	BRD-K33610132-001-02-9::2.5::HTS002	2.5	rociletinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.3865044669525	0.3865044669525	0.195977979374722	0.241806057711	-4.10407733836209	15.8479287237286	0.000844608256935326	0.0190913354883665	-0.289017157304848	-0.0920358178507088
FBXO42	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.5769437018165	0.5769437018165	0.409699099509731	0.431801339153	-5.45034924018988	6.03292862031059	0.00155899870582149	0.0325069202860215	-0.242229148683783	-0.0922600559297548
FBXO42	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.324558285428	0.324558285428	-0.0237121007473048	-0.0227579244188	-12.3854516294709	167.157501018955	2.05435313149779e-25	5.41583582190394e-23	-0.403785146621443	-0.292755625729167
FBXO42	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.758803234475	0.758803234475	0.470342854688267	0.492327571576	-8.0489015108918	7.52198650990558	5.9099262097717e-05	0.00175730934324939	-0.37202721143239	-0.204893548141076
FBXO42	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.11399853085065	0.11399853085065	0.371175522392699	0.396546401632	5.39161072642519	17.623759842111	4.30778221608316e-05	0.00131746954136828	0.156810546206178	0.35754343687792
FBXO42	BRD-K43457670-001-27-8::2.5::HTS002	2.5	acetazolamide	carbonic anhydrase inhibitor	noncancer	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.0980212105482	-0.0980212105482	0.262742489579263	0.242495378939	14.0073024542274	125.348553393654	2.06536730659442e-27	6.49073474274304e-25	0.309791949147456	0.41173545110747
FBXO42	BRD-K44067360-001-30-3::2.5::HTS002	2.5	flufenamic-acid	chloride channel blocker	noncancer	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.2808194271115	-0.2808194271115	0.0762341395938683	0.0872280051655	12.3948316311495	179.181226976785	7.04974045913733e-26	1.92724977406434e-23	0.300209640606413	0.413897492804323
FBXO42	BRD-K44827188-001-06-0::2.5::HTS002	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.354216113887	-0.354216113887	-0.109105398067034	-0.054617955294	4.77259166501577	104.780974014605	5.91874016908127e-06	0.000213167141942366	0.143274827263102	0.34694660437683
FBXO42	BRD-K49328571-001-15-0::2.5::MTS010::PROS005_PR500	2.5	dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor	targeted cancer	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-1.74821468571	-1.74821468571	-0.453072054421113	-0.279272959842	16.3141806248998	187.562436436303	7.96251930618381e-38	6.66640156396512e-35	1.13853543039542	1.45174983218235
FBXO42	BRD-K50018155-003-02-1::2.5::HTS002	2.5	RS-67506	serotonin receptor partial agonist	noncancer	HTR4	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.1293187129665	0.1293187129665	0.301790733836434	0.3592817861405	4.18195618438348	31.2291871803956	0.000217314898960655	0.00568912727242435	0.088383525266763	0.256560516473105
FBXO42	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.331336094828	-0.331336094828	-0.107542735293809	0.0520686308404	3.8702195945507	13.8242396728188	0.00173588494506424	0.0356029171665716	0.0996241342254923	0.347962584842889
FBXO42	BRD-K51313569-003-03-3::2.5::HTS002	2.5	palbociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.003636807066995	-0.003636807066995	-0.767872266763481	-0.762324031266	-11.6611576154338	135.195987197879	3.53299729848427e-22	7.05050072613441e-20	-0.89384546944771	-0.634625449945262
FBXO42	BRD-K51471001-303-04-7::2.5::HTS002	2.5	demecarium	acetylcholinesterase inhibitor	noncancer	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.486813162148	0.486813162148	0.276657232595984	0.268075360474	-8.73471871145998	164.983508394749	2.62717434653445e-15	2.80837730931862e-13	-0.257660809430476	-0.162651049673557
FBXO42	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.6077972321095	-0.6077972321095	-0.289551151595254	-0.3736278329815	4.65743138140069	160.719842888666	6.67220179204385e-06	0.000237352089275845	0.183304053584441	0.453188107444051
FBXO42	BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500	2.49998	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.5696945472535	-0.5696945472535	-0.192220047757725	-0.0644082695915	7.99704739174853	160.547687215385	2.37543190791451e-13	2.1020806993865e-11	0.284258145619394	0.470690853372156
FBXO42	BRD-K56301217-001-07-4::2.5::HTS002	2.5	ABT-737	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.151325602699	0.151325602699	-0.137554764366638	-0.0916218688464	-9.3357902616586	192.438139597041	2.49523912806049e-17	3.21588759517785e-15	-0.349911986097825	-0.227848748033452
FBXO42	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.111155908598	0.111155908598	-0.588918887693714	-0.48109263675	-9.4640314603472	195.524130812735	9.785773485682e-18	1.31910380214638e-15	-0.845960536914495	-0.554189055668934
FBXO42	BRD-K57136142-001-02-4::2.5::HTS002	2.5	CCT129202	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.5988861313235	-0.5988861313235	-0.749298325427702	-0.661176661425	-3.11167739936358	79.8830334897038	0.002580332298648	0.0499494256897513	-0.246609998595129	-0.054214389613275
FBXO42	BRD-K58529924-001-01-5::2.64858::MTS010::PROS001_PR500	2.64858	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.241774141193	0.241774141193	-0.120348348303707	-0.0782443732808	-8.98402978455081	179.386740645396	3.55969331880236e-16	4.14869771248282e-14	-0.441660047626712	-0.282584931366703
FBXO42	BRD-K60369935-001-18-3::2.5::HTS002	2.5	ribavirin	antiviral	noncancer	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.187005989296	0.187005989296	0.374181017861039	0.419717410769	6.42861864691972	162.481197933914	1.37065692348829e-09	8.03752469916064e-08	0.129680679240409	0.244669377889668
FBXO42	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.6193674140815	-0.6193674140815	-0.36911679035582	-0.394478559639	5.01146875716906	43.8717294284958	9.34101473056921e-06	0.000323589840987258	0.149603753674834	0.350897493776525
FBXO42	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.994915594218	-0.994915594218	-0.22262945362333	-0.157800770878	10.7680517186037	6.31951370800635	2.6775526455626e-05	0.000851455080023563	0.598921826194141	0.945650454995199
FBXO42	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.3375479927625	0.3375479927625	-0.497304578485308	0.00402399396559	-8.30885878944997	19.7688966582271	7.05308436557157e-08	3.38334941582048e-06	-1.04460195141356	-0.625103191082056
FBXO42	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.1009252641643	-0.1009252641643	0.158573842894583	0.164761931788	8.58068124462889	80.7135131993916	5.49983912324125e-13	4.67767864859196e-11	0.199323278047735	0.319674936070031
FBXO42	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.1305909022325	-0.1305909022325	-0.607874168803555	-0.456560974373	-7.18030167599502	48.5130420062785	3.67871749564121e-09	2.06132246306741e-07	-0.610896067102692	-0.343670466039419
FBXO42	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.8190438058305	-0.8190438058305	-1.21866140151126	-1.04907947641	-4.94204368316099	63.1872431399177	5.9894350141123e-06	0.000215351386871276	-0.561195636053514	-0.238039555307998
FBXO42	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.02597484480685	0.02597484480685	-0.198784748390045	-0.124222212564	-6.32937440969816	160.302801344324	2.36211930030099e-09	1.34897593262513e-07	-0.29488843270135	-0.15463075369244
FBXO42	BRD-K77625799-001-07-7::2.5::HTS002	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.1417195179985	-0.1417195179985	0.110955979974047	0.1701419093195	4.97147150263789	177.74435924918	1.55624652699023e-06	6.17454205633635e-05	0.152377244822778	0.352973751122316
FBXO42	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.2837061021615	0.2837061021615	-0.46837288962212	-0.217946401079	-6.52473801218276	4.67708641069088	0.00162449809406754	0.0336305468949485	-1.05463912743864	-0.449518856128601
FBXO42	BRD-K80700417-001-04-2::2.5::HTS002	2.5	SGI-1776	Pim kinase inhibitor	targeted cancer	FLT3, PIM1, PIM2, PIM3	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.770599965047	-0.770599965047	-0.344881316957138	-0.3090790625965	6.03555620530431	43.3106025818557	3.16399801015195e-07	1.38990885328522e-05	0.283500527992415	0.567936768187309
FBXO42	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.2280585445545	-0.2280585445545	0.0363519782345204	0.129465498685	5.6123338691675	180.912620969103	7.39286435577682e-08	3.53842167152588e-06	0.171450055147914	0.357370990430127
FBXO42	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.313877678293	0.313877678293	0.0399150568676819	0.0562766217073	-9.38826833561786	51.2436433026403	1.01253223322462e-12	8.43104199746695e-11	-0.332539923059667	-0.21538531979097
FBXO42	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-6.57799005672	-6.57799005672	-6.21056773304085	-6.171939349	4.90513218360976	6.82232738239627	0.00187575399153878	0.0379701999671813	0.189359104091649	0.545485543266657
FBXO42	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.115558483133	-0.115558483133	-0.27356773737515	-0.208293631699	-3.37942410676449	182.327648653883	0.000888347132264128	0.0199453752892351	-0.250262189640048	-0.0657563188442519
FBXO42	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.181003217402	0.181003217402	0.308265137510914	0.317996860903	4.96520430348558	173.518081599357	1.63158825964558e-06	6.44364621524928e-05	0.0766737403841448	0.177850099833683
FBXO42	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.6130633637495	0.6130633637495	-0.0414496491833095	0.00448333894144	-12.5588591731716	156.831699597589	1.77167530863608e-25	4.69952224287949e-23	-0.757452122899573	-0.551573902966046
FBXO42	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	-0.9622388100405	-0.9622388100405	-0.213949203208122	0.00102328451077	12.0781329877819	73.0408003410787	4.40361740201762e-19	6.6795676868863e-17	0.624816467163716	0.87176274650104
FBXO42	BRD-K99383816-001-03-5::2.5::HTS002	2.5	ftorafur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	SKOV3, CAOV3	OVARY	carcinoma (adenocarcinoma)	0.2786282855635	0.2786282855635	0.0256064081497297	0.0625789324056	-7.72013005255744	49.2456833505164	4.97022263597785e-10	3.05145473316098e-08	-0.318875993747174	-0.187167761080366
FBXW7	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-2.58801703958	-2.58801703958	-1.60978825076735	-1.53203888218	10.4451726889141	16.091276608096	1.41162692114061e-08	7.43737921290921e-07	0.779783359737993	1.17667421788732
FBXW7	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-0.4625747129715	-0.4625747129715	0.000806725197904696	0.008505826587825	15.6068958195645	191.998955792965	5.38403277602938e-36	3.78345692083148e-33	0.404819379136055	0.521943497202754
FBXW7	BRD-A31095847-001-02-3::2.5::HTS002	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.205917812141	0.205917812141	0.0257640603454151	0.0703858703435	-5.27024281825319	104.595970382875	7.3622618694866e-07	3.07053166807782e-05	-0.247935770004398	-0.112371733586772
FBXW7	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-0.877270090062	-0.877270090062	-1.90705680625626	-1.73380354334	-9.4284863691143	55.2634876317411	4.19869787038218e-13	3.62133889682553e-11	-1.24864661304492	-0.810926819343605
FBXW7	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-2.078574167805	-2.078574167805	-1.21197618093452	-1.22574357102	11.4566160338557	88.3712435188509	3.68494708644483e-19	5.64136445779024e-17	0.716284791293916	1.01691118244704
FBXW7	BRD-K07955840-001-02-3::2.5::HTS002	2.5	PF-05212384	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-5.909890614095	-5.909890614095	-4.6901589498184	-4.630205698585	10.8448655673574	10.147011154822	6.63599641058934e-07	2.78442927698748e-05	0.969622178150087	1.46984115040311
FBXW7	BRD-K08547377-394-03-5::2.5::HTS002	2.5	irinotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	colorectal cancer	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-3.400055809095	-3.400055809095	-1.93985860364006	-1.92016274671	12.1856390837005	3.1420583385506	0.000948701660184504	0.0211338885158821	1.0884175112005	1.83197689970938
FBXW7	BRD-K10843433-001-22-7::2.5::HTS002	2.5	phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	PTGIS, PTGS1, PTGS2	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.501590966994	0.501590966994	0.122466978131958	0.1301341456285	-8.20336017173275	13.9272139583667	1.05867979796375e-06	4.30071611860827e-05	-0.478295417550321	-0.279952560173762
FBXW7	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.2504095188225	0.2504095188225	-0.28999417642063	-0.2721742756055	-12.3836374437859	4.40128746401796	0.000137785090603158	0.00377928598462813	-0.657328956784787	-0.423478433701473
FBXW7	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-0.5146751628115	-0.5146751628115	-0.251561670720549	-0.133670857256	4.5412920962389	34.5813785186548	6.49763874972623e-05	0.00191585144530207	0.145442130095036	0.380784854086866
FBXW7	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-1.74209390269	-1.74209390269	-2.06950695554116	-2.39516504125	-3.43136250584068	191.977852313684	0.000735341481364275	0.0168868535689836	-0.515614919625446	-0.139211186076879
FBXW7	BRD-K13571841-001-14-4::2.5::HTS002	2.5	pepstatin	aspartic protease inhibitor	noncancer	CTSB, CTSD, CTSL, REN	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-1.3285011865	-1.3285011865	-0.710914554640592	-0.749235782293	7.91920297860797	8.40607890568776	3.55409040809514e-05	0.00110285890122575	0.439251698457302	0.795921565261514
FBXW7	BRD-K16180792-001-01-7::2.5::MTS006	2.5	bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	noncancer	PTPN1	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.1422262209405	0.1422262209405	-0.237767046918147	-0.0973395896878	-6.64908832247724	118.148188416062	9.61684697165697e-10	5.7382215884974e-08	-0.493163722160411	-0.266822813556884
FBXW7	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-1.382850066595	-1.382850066595	-1.90813495731684	-1.67956785013	-5.64295754150672	183.798755825779	6.2378181566124e-08	3.01249510520184e-06	-0.708940954308355	-0.341628827135319
FBXW7	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.0463127343133	0.0463127343133	-0.137144168361196	-0.1059972226705	-4.92755634419146	185.514434911487	1.83798161262864e-06	7.18855403381539e-05	-0.256907103248596	-0.110006702100397
FBXW7	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-2.352058355885	-2.352058355885	-1.3296546344374	-1.36979496737	15.4185555378441	176.200996806432	1.65417230405725e-34	1.01586560388621e-31	0.89153977875902	1.15326766413617
FBXW7	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-2.10562181277	-2.10562181277	-1.6595562625271	-1.528752793545	4.72461546385676	10.5097553648668	0.000707624590890339	0.0163202917185985	0.23707495814504	0.655056142340764
FBXW7	BRD-K33277808-331-01-3::2.5::HTS002	2.5	ouabain	ATPase inhibitor	noncancer	ATP1A1	cardiology	hypertension, cardiac arrythmia	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-5.74605417473	-5.74605417473	-5.36778053095261	-5.28170504445	3.92553709322847	29.3794940175893	0.000481258369713729	0.0115792125193505	0.181301202505038	0.575246085049745
FBXW7	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.5529067617575	0.5529067617575	0.76097079470313	0.7663988354595	5.47935563504822	6.93753229673322	0.000954969393938008	0.021247548555314	0.118109525498451	0.298018540392809
FBXW7	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-2.14450880827	-2.14450880827	-2.59158874349094	-2.52528636523	-3.99180630846877	18.822689654349	0.000793021280726801	0.0180547544164961	-0.681646934073409	-0.212512936368472
FBXW7	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-4.746047528045	-4.746047528045	-3.7600710529544	-3.68976707366	9.07209725346133	25.3930287246812	1.91450937253698e-09	1.10513029708182e-07	0.762316608099656	1.20963634208155
FBXW7	BRD-K43621685-001-02-5::2.5::HTS002	2.5	CP-673451	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	KIT, PDGFRA, PDGFRB	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.1860800473135	0.1860800473135	-0.00519147211988683	0.01840536176465	-3.73211033848559	188.16591411864	0.000251384705116861	0.00647973932206756	-0.29237036191816	-0.0901726769486137
FBXW7	BRD-K44084986-300-08-4::2.5::HTS002	2.5	Y-27632	rho associated kinase inhibitor	targeted cancer	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-1.444410671385	-1.444410671385	-0.930670473016527	-0.842583812381	8.37734488919386	97.321810436304	4.12163473297065e-13	3.56060399307887e-11	0.392032244449303	0.635448152287644
FBXW7	BRD-K46937689-001-15-0::0.625::HTS002	0.625	phenazone	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-0.00253927710522	-0.00253927710522	0.0949024926712246	0.08661449237125	3.08701376844309	161.09631064016	0.00238096981108175	0.0465442246113955	0.0351071192995722	0.159776420253317
FBXW7	BRD-K51747290-001-13-1::2.5::HTS002	2.5	hydroxyurea	ribonucleotide reductase inhibitor	chemo	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-0.429633836191	-0.429633836191	-0.214322034329175	-0.221646260579	4.55110671719069	27.7795348729063	9.60453332498708e-05	0.00273050805545982	0.118367474732807	0.312256128990844
FBXW7	BRD-K52172416-001-11-4::2.5::HTS002	2.5	anastrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.5243754888285	0.5243754888285	0.301401472790504	0.296380524619	-7.55401159978142	19.7948349410346	2.98700303381878e-07	1.31512196638321e-05	-0.284586958801856	-0.161361073274136
FBXW7	BRD-K53523901-001-04-4::2.5::HTS002	2.5	arctigenin	MEK inhibitor	targeted cancer	CHUK, MAP2K1	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.08336114625305	0.08336114625305	-0.439312799787796	-0.434167377237	-10.4292614563778	4.20299005669889	0.000368304794639667	0.00913533136562032	-0.659207891239209	-0.386140000842483
FBXW7	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-1.31253944203	-1.31253944203	-0.608310123041284	-0.573831164789	9.21870348021591	48.0181270720583	3.37696749043193e-12	2.66684622423281e-10	0.550635688361938	0.857822949615495
FBXW7	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.4876910181845	0.4876910181845	0.258209528342857	0.239961209955	-9.27781441520741	126.496502942488	6.07179708813938e-16	6.89646103923595e-14	-0.27842834524073	-0.180534634442556
FBXW7	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.30433549022	0.30433549022	-0.212496807546447	-0.255561480265	-16.6788848901982	24.6305634043728	6.29175453078136e-15	6.48008388672676e-13	-0.580700247023982	-0.452964348508911
FBXW7	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-0.991462293281	-0.991462293281	-2.08832693416934	-1.79411655002	-8.76588326417307	121.717882860498	1.33202248307569e-14	1.33220273810139e-12	-1.34457539122864	-0.849153890548043
FBXW7	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.3319940810835	0.3319940810835	-0.497245806933149	0.00402399396559	-8.26960943029389	20.3140126791692	6.19091773243994e-08	2.99186743331707e-06	-1.0382039958886	-0.620275780144701
FBXW7	BRD-K63932022-001-01-5::2.5::HTS002	2.5	2'-MeCCPA	adenosine receptor agonist	noncancer	ADORA1	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.465621191549	0.465621191549	0.193517441478935	0.258471111718	-4.92556522349094	70.729469999889	5.32701674919091e-06	0.000193252229661026	-0.382262768904053	-0.161944731236076
FBXW7	BRD-K65928735-001-04-3::2.5::HTS002	2.5	AZD1480	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.110747591397	0.110747591397	-0.0251362912618215	-0.0593866490267	-4.38779253894392	195.538116943918	1.87095750814921e-05	0.000613244306108139	-0.196959272252824	-0.0748084930648188
FBXW7	BRD-K66956375-001-11-3::2.5::HTS002	2.5	oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	noncancer	CNR1, GPR119, GPR55, PPARA	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.693295139751	0.693295139751	0.327568206008458	0.332357226456	-10.6930412041149	3.17639370934204	0.00135015185525428	0.0287137028165106	-0.471233103031783	-0.260220764453301
FBXW7	BRD-K67537649-001-04-5::2.5::HTS002	2.5	PQ-401	IGF-1 inhibitor	targeted cancer	IGF1R	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.6370893969145	0.6370893969145	0.17199390324801	0.199537593573	-11.9933548469756	8.32441167362771	1.53468247280736e-06	6.09914629546316e-05	-0.553918028028744	-0.376272959304236
FBXW7	BRD-K68202742-001-16-5::2.63491::HTS002	2.63491	trichostatin-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-6.381828279105	-6.381828279105	-5.49932832699497	-5.50871409078	10.7189433071035	26.4728291177534	3.96119422713102e-11	2.74668003075628e-09	0.71341341156059	1.05158649265947
FBXW7	BRD-K68507560-003-24-6::2.5::HTS002	2.5	dicycloverine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.10153183228415	0.10153183228415	0.232722732505948	0.2203060574785	3.89835109077922	41.7702399261923	0.000344608908887641	0.00859333133600688	0.0632654874905762	0.199116312953019
FBXW7	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-1.042104835975	-1.042104835975	-0.604858558129995	-0.437130502683	8.27549074961693	110.289138968855	3.26893869374329e-13	2.84879246047656e-11	0.332540193655896	0.541952362034114
FBXW7	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-0.7954127797555	-0.7954127797555	-1.19423369565784	-1.12346956245	-4.55029522988412	8.22927660368101	0.00174279239054451	0.0357250171014386	-0.599959869924551	-0.197681961880131
FBXW7	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.497218449982	0.497218449982	0.218485513779606	0.2281967000125	-11.2433315345778	191.911583015103	7.39578337289292e-23	1.57724463137191e-20	-0.327630673511415	-0.229835198893373
FBXW7	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-3.211641733185	-3.211641733185	-2.62465977374971	-2.476182958975	5.9223141550978	7.1701639401175	0.00053558409002392	0.0127347684081137	0.353738329277926	0.82022558959266
FBXW7	BRD-K74501079-001-18-1::2.5::HTS002	2.5	azithromycin	bacterial 50S ribosomal subunit inhibitor	noncancer	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-1.90490792733	-1.90490792733	-0.767693188060756	-0.6097866963755	11.3984163919633	3.25297790361006	0.000986453080853653	0.0218753753094964	0.833225508731251	1.44120396980724
FBXW7	BRD-K76210423-001-01-6::2.5::MTS010::PROS001_PR500	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-0.0255714450079	-0.0255714450079	0.107403592705554	0.094360121778	6.53730629168825	187.638642438477	5.76040597393666e-10	3.50844572886579e-08	0.0928486986902727	0.173101376736636
FBXW7	BRD-K77841042-001-14-1::2.5::HTS002	2.5	brefeldin-a	protein synthesis inhibitor	targeted cancer	ARF1, CYTH2	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-5.660760238665	-5.660760238665	-4.72801793473832	-4.786446704285	8.39528071840892	189.843529831798	1.05786248577764e-14	1.06546338681502e-12	0.713587011508779	1.15189759634459
FBXW7	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.536294299589	0.536294299589	0.0907869489829991	0.1896034324075	-9.76761791146053	58.3758754122161	6.88270021069515e-14	6.419330954996e-12	-0.536794460864908	-0.354220240347094
FBXW7	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.3078652102055	0.3078652102055	-0.468619411132773	-0.217946401079	-9.14340716811571	195.883708360631	7.83508557629321e-17	9.68446399354871e-15	-0.943965184026865	-0.609004058649682
FBXW7	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-2.52732218029	-2.52732218029	-0.926345189303321	-0.8093705059295	15.8030116476436	2.5053855225611	0.00142001926067125	0.0299971720993896	1.23939096420362	1.96256301776973
FBXW7	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.2193352746215	0.2193352746215	0.0314084001220784	0.114428305936	-3.99475392556886	180.00824509727	9.4286385098196e-05	0.00268406250919262	-0.280754366054416	-0.095099382944427
FBXW7	BRD-K88172511-003-20-3::2.41866::HTS002	2.41866	naltrexone	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.4816458265945	0.4816458265945	0.307114682708058	0.300369801672	-7.6693474446872	115.128634620795	6.04421295990227e-12	4.62495579965331e-10	-0.219607795011691	-0.129454492761192
FBXW7	BRD-K89391146-001-08-0::2.5::HTS002	2.5	RG108	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3B	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.708212462798	0.708212462798	0.376841010334021	0.397149460871	-12.6529433976195	101.758313226839	1.30570983526931e-22	2.73025837349695e-20	-0.383319242168026	-0.279423662759932
FBXW7	BRD-K91701654-001-03-1::2.66738::HTS002	2.66738	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.09032405246885	0.09032405246885	-0.0788194486273351	-0.00292791542841	-3.48675467833993	19.056847695778	0.00245975301080913	0.0478921151029896	-0.270656221408087	-0.0676307807842836
FBXW7	BRD-K92441787-001-04-1::2.5::HTS002	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.2559746843875	0.2559746843875	0.154534160156539	0.1701725882685	-3.33326839140681	37.9362950657311	0.0019248329593971	0.0388024382387718	-0.163051803706838	-0.0398292447550836
FBXW7	BRD-K94455792-001-01-8::2.5::HTS002	2.5	ICG-001	beta-catenin inhibitor	targeted cancer	CTNNB1	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-0.915673294009	-0.915673294009	-0.665741934933862	-0.6707896523965	4.7168012417943	52.5692483289559	1.80728349895325e-05	0.000594282394978754	0.143631622771878	0.356231095378398
FBXW7	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-3.183913869995	-3.183913869995	-2.23382043445138	-2.181327009095	9.91559459009533	20.3833389918522	3.02304599600913e-09	1.70911744995685e-07	0.750461081033636	1.14972579005361
FBXW7	BRD-K95763993-001-19-3::2.5::HTS002	2.5	trapidil	PDGFR tyrosine kinase receptor inhibitor	noncancer	PDGFRA	cardiology	coronary artery disease (CAD)	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	0.6979405353975	0.6979405353975	0.390403916142391	0.400240695615	-9.42179972947967	6.39665286526706	5.53802406552127e-05	0.0016563761651397	-0.386220863207102	-0.228852375303116
FBXW7	BRD-K98572433-001-02-9::2.5::HTS002	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	MFE280, OVCAR8	ENDOMETRIUM, OVARY	carcinoma (adenocarcinoma), carcinoma	-4.089898735355	-4.089898735355	-2.69473868013174	-2.69732165055	14.8903507065971	115.626828396822	1.18640563557189e-28	4.32450907255931e-26	1.20957783926593	1.58074227118059
FGD6	BRD-A00758722-001-04-9::2.5::HTS002	2.5	noretynodrel	progestogen hormone	noncancer	PGR	endocrinology	contraceptive	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.341276961286	-0.341276961286	-0.136630281063006	-0.137092082405	4.82254900658487	9.5060922383745	0.000807842425455735	0.018351251638103	0.109424620679667	0.299868739766321
FGD6	BRD-A44090213-001-25-6::2.5::HTS002	2.5	indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	CXCR1, CXCR2, PTGS1, PTGS2	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.368951220755	-3.368951220755	-1.88601559892548	-1.75849184717	15.9034213102323	21.4279387214687	2.4193566928942e-13	2.13830227064462e-11	1.289254807993	1.67661643566605
FGD6	BRD-A70858459-001-01-7::2.5::MTS010::PROS003_PR500	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.112022162941	-0.112022162941	-0.0140622824840573	-0.0140777407944	5.11196355127602	153.735909396225	9.35126300343379e-07	3.84102500625328e-05	0.0601033494512062	0.135816411462679
FGD6	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3501573199575	-0.3501573199575	0.156621936907014	0.185523876977	8.82429662745913	4.76854791412158	0.000394066567308305	0.00968354658388234	0.356969301681575	0.656589212047453
FGD6	BRD-K06152156-001-01-8::2.5::HTS002	2.5	methoxyflurane	membrane permeability inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.82497672709	-2.82497672709	-1.85411000940438	-1.70603192552	7.91437312382908	3.86135048294677	0.0015951147006191	0.033143900985845	0.625398747194707	1.31633468817653
FGD6	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0736334231413	0.0736334231413	0.258933533660245	0.2294815220965	6.31108574683326	30.3884072472062	5.54175142332858e-07	2.34920498578044e-05	0.125368966923305	0.245231254114585
FGD6	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.200938599615	0.200938599615	0.337253726951191	0.348412196747	4.60385558017826	92.1334333595648	1.32417095371725e-05	0.000445888823785175	0.0775104188990053	0.195119835773377
FGD6	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-5.032526190695	-5.032526190695	-4.12761310642174	-4.11179699224	7.59615415996107	187.998931058432	1.39392863265535e-12	1.14292016032283e-10	0.669914121725156	1.13991204682136
FGD6	BRD-K12932420-001-02-3::2.5::HTS002	2.5	YM-976	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.164211706912	0.164211706912	0.314492170488739	0.348254117444	4.49142634098483	189.536528747768	1.22760112828885e-05	0.000415853520191278	0.084279805153429	0.21628112200005
FGD6	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.04277877796005	0.04277877796005	0.3425914127615	0.357900779497	9.45749018416483	178.560773429	1.83597122661201e-17	2.39647915364511e-15	0.237255677854323	0.362369591748578
FGD6	BRD-K13566078-001-02-3::2.5::HTS002	2.5	BMS-345541	IKK inhibitor	targeted cancer	CHUK, IKBKB	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.14513865685	-2.14513865685	-1.47838408686731	-1.48395465403	9.13879605408304	7.89998976963831	1.79694641083608e-05	0.000591609412116875	0.498140077654579	0.835369062310806
FGD6	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.404938306505	-1.404938306505	-0.469550150063423	-0.401202935084	18.4555386396795	22.5853738435153	4.07872608153125e-15	4.28314200062965e-13	0.830435091385479	1.04034122149768
FGD6	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.565120696365	-0.565120696365	-0.0493389162136128	-0.0356049990197	10.1800807309665	22.9636967581155	5.54516146754023e-10	3.38890479662512e-08	0.410962449464424	0.62060111083835
FGD6	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.09200279902745	-0.09200279902745	-1.14095991993516	-0.889953286616	-10.2051374698012	24.997014271416	2.12770845125851e-10	1.35965898822238e-08	-1.26065252641625	-0.837261715399178
FGD6	BRD-K18163608-001-05-6::2.48005::HTS002	2.48005	HA14-1	BCL inhibitor	targeted cancer	BCL2	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.4314512228595	-0.4314512228595	-0.0387698753303772	0.0501858788395	5.98126092180241	4.71591150169984	0.00228611315300414	0.0450018686600133	0.220813527726819	0.564549167331427
FGD6	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.05204160887145	0.05204160887145	0.326105790467608	0.343759219436	8.09853502018583	22.4246670783581	4.18503729236035e-08	2.06295965463271e-06	0.203958797595317	0.344169565597
FGD6	BRD-K19761926-001-03-6::2.44857::HTS002	2.44857	eplerenone	cytochrome P450 inhibitor	noncancer	NR3C2	cardiology	congestive heart failure, hypertension	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.465943117491	-0.465943117491	-0.872622192277554	-0.799528598077	-5.4284979441398	183.714288391948	1.78077613235264e-07	8.091413348972e-06	-0.554484582534783	-0.258873567038325
FGD6	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.4017528602	-1.4017528602	-3.14954100370842	-3.22475555586	-11.0454866474078	4.71641618608424	0.000150528149211277	0.00409943426839947	-2.16201283388465	-1.33356345313219
FGD6	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0206590083528	0.0206590083528	-0.170998807938795	-0.1612454874865	-7.7959872217723	6.09883379853985	0.000216584648109399	0.00567555581912695	-0.251577579809162	-0.131738052774029
FGD6	BRD-K27182532-001-02-3::2.5::HTS002	2.5	metatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.701363282375	-1.701363282375	-0.964529562238258	-0.9486901264415	12.864162823837	13.9991100958919	3.8149518259988e-09	2.13375472315892e-07	0.613983861913364	0.85968357836012
FGD6	BRD-K31812033-003-11-0::2.5::HTS002	2.5	levobunolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.3988703321025	0.3988703321025	0.170871711761488	0.2093635994345	-6.11734972107749	66.5702755946671	5.64879346380954e-08	2.74038083817301e-06	-0.302400310271538	-0.153596930410487
FGD6	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.389958626266	0.389958626266	0.209077862079064	0.239322143773	-8.04990599691147	16.3475405792512	4.40642441443451e-07	1.89795928119239e-05	-0.228432701400625	-0.133328826973247
FGD6	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1676671156355	-0.1676671156355	-0.695375023682321	-0.621232482709	-10.7571913371905	173.918448017412	5.18463206031899e-21	9.40115909353729e-19	-0.624530207501822	-0.43088560859182
FGD6	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.02176198391523	0.02176198391523	0.172499866450786	0.1694730901705	5.20049032836778	11.3970870657907	0.000262198954786414	0.00671728900076706	0.0872117625493261	0.214264002521786
FGD6	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.079654447115	-3.079654447115	-1.35028865725292	-0.978492222645	16.9667299136357	183.414787776437	1.94540708148002e-39	1.96677903003081e-36	1.52826587462223	1.93046570510192
FGD6	BRD-K40331046-305-01-5::2.5::HTS002	2.5	CR8-(R)	CDK inhibitor	targeted cancer	CCNA2	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-4.493912685345	-4.493912685345	-5.27381712648459	-5.186080091785	-7.50034186252906	49.4207243060001	1.06289569847988e-09	6.30178069597496e-08	-0.988820149571465	-0.570988732707713
FGD6	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.945678684064	-0.945678684064	-0.626612455952732	-0.4180119465525	4.95117086227488	172.820087478255	1.7436146162504e-06	6.84445379278997e-05	0.191870376649479	0.446262079573057
FGD6	BRD-K44408410-001-17-6::2.5::HTS002	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.6325315845765	-0.6325315845765	-1.12232840457336	-1.07322078363	-6.89686880400831	22.629271726895	5.41393480454208e-07	2.29911478645274e-05	-0.636840535141133	-0.342753104852585
FGD6	BRD-K45662124-050-01-5::2.5::HTS002	2.5	3'-fluorobenzylspiperone	dopamine receptor ligand	noncancer	DRD2	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.297003502761	0.297003502761	0.511193481939175	0.5308791065105	6.60971075700583	54.8325466466683	1.66240748935998e-08	8.6691516979814e-07	0.149243751898818	0.279136206457532
FGD6	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.216675080283	0.216675080283	0.372771563672787	0.3764822376655	4.30135379476568	107.258895456189	3.75727656048775e-05	0.00116102368652501	0.0841576133894792	0.228035353390095
FGD6	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.07342516890135	0.07342516890135	-0.268624225718805	-0.2054130743915	-7.15021202280778	163.482042207478	2.74330934481598e-11	1.94627854539909e-09	-0.436508728109506	-0.247590061130803
FGD6	BRD-K50018155-003-02-1::2.5::HTS002	2.5	RS-67506	serotonin receptor partial agonist	noncancer	HTR4	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.486791384053	0.486791384053	0.29748383418479	0.322728889347	-4.83726408938168	92.5829962248056	5.22897384872111e-06	0.000189888298207819	-0.267027017938455	-0.111588081797966
FGD6	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.9674129635045	-0.9674129635045	-0.734151222187246	-0.670954227568	4.19324495087398	182.056270318527	4.28787944084383e-05	0.00131174274464994	0.123503289112729	0.343020193521778
FGD6	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0537433028965	0.0537433028965	-0.240030677472749	-0.10314419939105	-5.24657465110354	170.420307561516	4.55566111812709e-07	1.95555836528552e-05	-0.404304094024814	-0.183243866713683
FGD6	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.41147248151	-1.41147248151	-0.454705700595476	-0.469747665561	11.1058117519084	4.55078713143202	0.000181213860766891	0.0048446283602728	0.728571517221501	1.18496204460755
FGD6	BRD-K61734568-003-02-1::2.5::HTS002	2.5	2,3-DCPE	Bcl-XL downregulator	targeted cancer	BCL2L1	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.1239284241042	0.1239284241042	-0.361921136793305	-0.146091240972	-6.27191665694333	22.4006930541677	2.39227279812511e-06	9.22016609511519e-05	-0.646334213417024	-0.325364908377986
FGD6	BRD-K63784565-001-06-2::2.50835::HTS002	2.50835	10-hydroxycamptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-4.82865719211	-4.82865719211	-5.72874703284267	-5.78036148178	-9.58378609462832	186.989423213048	5.98932534046996e-18	8.22875712113837e-16	-1.08536482478244	-0.714814856682908
FGD6	BRD-K71164191-001-01-0::2.5::HTS002	2.5	KD-023	ACAT inhibitor	noncancer	ACACA, ACACB	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.31423719448	-1.31423719448	-0.943603741174592	-0.959659141772	6.38408691798481	37.6190195735177	1.76912789310086e-07	8.04019109839726e-06	0.25306647387245	0.488200432738365
FGD6	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.911881327548	-0.911881327548	-0.522794961588335	-0.364234530081	6.22564958846164	10.2457714720301	8.83194804322175e-05	0.00253168729725247	0.250285129064471	0.52788760285486
FGD6	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.3055641830365	0.3055641830365	0.220481912393622	0.2281967000125	-3.34573083225246	143.181737810168	0.00104812713674256	0.0230262444742616	-0.135349207041173	-0.034815334244583
FGD6	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.5709151182775	-0.5709151182775	-0.192534591708533	-0.111990350412	10.2879092788898	64.8798551655541	2.90819584600838e-15	3.0933533869932e-13	0.30492491936725	0.451836133770683
FGD6	BRD-K75009076-001-02-1::2.429::HTS002	2.429	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.94406991775	-0.94406991775	-1.9258505201222	-1.72291152257	-10.7639645927219	187.224158117187	2.43326941053021e-21	4.51532640250674e-19	-1.16171188538635	-0.801849319358057
FGD6	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.418845141495	-3.418845141495	-2.31148334941088	-2.223018080895	12.5137142345601	117.276950879532	2.43609002082145e-23	5.38828419063613e-21	0.932112633523178	1.28261095064506
FGD6	BRD-K76180386-001-01-6::2.5::HTS002	2.5	JIB04	histone lysine demethylase inhibitor	noncancer	KDM4E	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.41569168685	-2.41569168685	-1.6877533533614	-1.580578387205	9.26236301672661	172.066173491134	7.99639724962943e-17	9.87246443615107e-15	0.572811748488936	0.883064918488263
FGD6	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.177857368303	-0.177857368303	-0.426285160569052	-0.2512002355925	-3.82362150404571	176.79600077212	0.000182077075486673	0.00486406550068344	-0.376647991152103	-0.120207593380001
FGD6	BRD-K81330143-001-04-8::2.38257::HTS002	2.38257	tideglusib	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.863696106136	-0.863696106136	-0.264408873717673	-0.24892468109	9.25743948946962	4.29157931761088	0.000539392707381264	0.0128141259706631	0.424267076192128	0.774307388644526
FGD6	BRD-K81332461-001-01-4::2.5::HTS002	2.5	maxacalcitol	vitamin D receptor agonist	noncancer	VDR	endocrinology	hyperparathyroidism	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.181112076441	0.181112076441	-0.144041494049481	-0.1171657345245	-9.67462554321392	187.691825020571	3.23228820022252e-18	4.54575523402554e-16	-0.39145330866554	-0.258853832315422
FGD6	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.3823151406615	0.3823151406615	0.118978520627427	0.120954188254	-6.88923971390197	65.3850783779385	2.65258901385547e-09	1.50882895634456e-07	-0.33966737010469	-0.187005869963456
FGD6	BRD-K82818427-001-02-2::2.39189::HTS002	2.39189	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.55433244121	-2.55433244121	-1.60359085911116	-1.52191219559	14.820479444115	49.6552702774445	7.3090231369567e-20	1.18644315685743e-17	0.821869286962253	1.07961387723543
FGD6	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.180071198401	0.180071198401	-0.166325192859778	-0.121855279851	-15.0699564206508	43.9366296779467	5.69027779137761e-19	8.50482251567763e-17	-0.392723299963686	-0.30006948255787
FGD6	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1518619903895	-0.1518619903895	0.00712255333269778	0.0499653436317	4.38728443211431	20.1773381763223	0.000279383797179108	0.00709983991766671	0.0834368569805996	0.234532230463796
FGD6	BRD-K89299012-001-06-0::2.5::HTS002	2.5	DCEBIO	potassium channel activator	noncancer	KCNN2, KCNN3, KCNN4	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.89302076798	-2.89302076798	-2.03289739808268	-1.82556226868	7.35655088043755	5.55133570963783	0.000460279848911575	0.0111390765154639	0.568332481790159	1.15191425800448
FGD6	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-4.407243487815	-4.407243487815	-2.866995410775	-2.82062384431	13.3135330737784	38.9912791050807	4.36865006549477e-16	5.04487284422105e-14	1.30624046525225	1.77425568882774
FGD6	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.327278722116	0.327278722116	0.100682719578669	0.1180798290625	-9.43842034123043	134.787841376686	1.51912052162158e-16	1.83019439167302e-14	-0.274076780806121	-0.179115224268542
FGD6	BRD-K92049597-001-20-8::2.5::HTS002	2.5	triamterene	sodium channel blocker	noncancer	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.223714806088	-0.223714806088	-0.054370423843981	-0.0499338044925	4.91145287701965	14.1390096175759	0.000222899735198577	0.00581719314057453	0.0954613866830026	0.243227377805035
FGD6	BRD-K93441486-067-12-8::2.5::HTS002	2.5	diphemanil	acetylcholine receptor antagonist	noncancer	CHRM3	neurology/psychiatry	spasms	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.00312530800029	0.00312530800029	0.134765275362083	0.150302134	4.93024929134896	52.7186560859372	8.56757914102275e-06	0.000298776548928777	0.0780789364449888	0.185200998278597
FGD6	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.94312022837	0.94312022837	-0.305848259769741	-0.214794605924	-16.7114650006299	43.3438591735101	1.65239573311306e-20	2.86998642692374e-18	-1.39965589175179	-1.09828108452769
FGD6	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.503184069972	-0.503184069972	-0.237906606017635	-0.175986017994	5.39406741678457	19.3498710432893	3.12462995598269e-05	0.00097894871193658	0.162469441413943	0.368085486494786
FGD6	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2038000995425	-0.2038000995425	-0.616627447418091	-0.542183140466	-6.55425536984768	82.120070687834	4.60332821277301e-09	2.55669015940769e-07	-0.53812413299126	-0.287530562759922
FGD6	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	AGS, ABC1	STOMACH, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.1163417935935	0.1163417935935	-0.0238977534350409	0.013127326234	-4.92096065492337	172.302633489515	2.00154023216341e-06	7.79836605016093e-05	-0.196490492514517	-0.0839886015425648
FGF12	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	MCF7, T24, NCIH1650	BREAST, URINARY_TRACT, LUNG	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.894052684589	0.901520467269	0.461286687552807	0.471822397403	-8.47721531397139	10.642849502042	4.67975716805558e-06	0.000171630334372379	-0.545589121906985	-0.319942872165401
FGF12	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.0481805813060983	-0.0229582343571965	-0.694577356817131	-0.540248640547	-5.37002476057129	6.29328731802875	0.00147013372080421	0.0308998853735648	-0.937639160115169	-0.355154390906896
FGF12	BRD-K21361524-001-01-1::0.625::MTS006	0.625	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.887496160185	-1.90441928036	-2.76570407628652	-2.61362403643	-6.60286278427997	8.03886555695473	0.000165259513130984	0.00446600758918808	-1.18465803636309	-0.57175779583996
FGF12	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.36341367508975	0.3680441629685	0.144090200563418	0.188754003369	-3.91797977440021	13.8941860277338	0.00156700122691004	0.0326483723109169	-0.339471716585095	-0.0991752324675702
FGF12	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	MCF7, NCIH1650	BREAST, LUNG	carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-0.015012327502985	-0.015012327502985	0.407490418786201	0.468890554884	13.2295083490315	43.1049560606989	8.92988592518034e-17	1.09367629740456e-14	0.358101411254445	0.486904081323928
FGF12	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.766800944599	-0.749249069422	-1.19240660496729	-1.13522122812	-5.40774920655188	12.650107498715	0.000131492932747624	0.00362712339547818	-0.59611228103844	-0.255099039698137
FGF12	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	MCF7, NCIH1650	BREAST, LUNG	carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-1.14767092266	-1.14767092266	-0.778934608841907	-0.683338343709	5.31421637564608	20.0643317658263	3.31759849706519e-05	0.00103501829443593	0.224027790684013	0.513444836952172
FGF12	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.185918128129	-0.1697508970825	-1.04707284311527	-0.667789074223	-5.02006045445177	6.59197377014028	0.00182712765671485	0.0371296523690183	-1.2719344555368	-0.45037497443574
FGF12	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	MCF7, T24, NCIH1650	BREAST, URINARY_TRACT, LUNG	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.28908077459	-1.20810591219	-2.22244202916234	-2.08207952886	-7.06688869031098	11.9143264903467	1.35791089012526e-05	0.000456676107280176	-1.22135822383929	-0.645364285305391
FGF12	BRD-K93869735-001-01-1::2.5::HTS002	2.5	taltirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	neurology/psychiatry	spinocerebellar ataxia	MCF7, NCIH1650	BREAST, LUNG	carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.1901267333825	0.1901267333825	-0.184905105046609	-0.1119517959605	-8.17576603075936	123.870443037992	2.94129968171389e-13	2.57623955652659e-11	-0.465824640958655	-0.284239035899563
FHIT	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	SKNAS, SW1990, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma	-0.103900473737333	-0.0679267523793	0.155374671951122	0.188567655386	4.43412017266479	9.03668107360632	0.00162114808983416	0.0335801554357292	0.127082423716898	0.391467867660012
FHIT	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	SKNAS, SW1990, PC14, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, LUNG, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	0.42563350983275	0.4232243854025	0.236428880372059	0.231529249652	-4.6926462074485	8.61875386643541	0.00127248485487621	0.0273003409870635	-0.281032158076523	-0.0973771008448595
FHIT	BRD-K12539581-001-23-7::2.5::HTS002	2.5	nocodazole	tubulin polymerization inhibitor	targeted cancer	HPGDS	NA	NA	SKNAS, PC14, OVCAR8	AUTONOMIC_GANGLIA, LUNG, OVARY	neuroblastoma, carcinoma (non_small_cell_carcinoma), carcinoma	-5.27150517869333	-5.2130802567	-3.46963909365253	-3.33055310932	8.65207426635489	3.53139536107803	0.00168568416783166	0.0347495433304984	1.19209439198025	2.41163777810137
FHIT	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	SKNAS, SW1990, PC14, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, LUNG, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	0.144325565470308	0.1576052887195	-0.218049986408682	-0.10882519866	-4.93390791272523	11.6140142233375	0.000380610679507628	0.00939922875079967	-0.52299237797915	-0.201758725778828
FHIT	BRD-K31491153-003-05-9::2.5::HTS002	2.5	1-phenylbiguanide	serotonin receptor agonist	noncancer	HTR3A, HTR3B	NA	NA	SW1990, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.3015811124105	0.3015811124105	-0.102532879892521	0.0097375334851	-8.0180529986246	163.66967444705	1.93929364610683e-13	1.7282614048916e-11	-0.503633042755181	-0.304594941850861
FHIT	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	SKNAS, SW1990, PC14, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, LUNG, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	0.20200402427275	0.1939316623565	0.0229007287237221	0.03848964264105	-3.96913608309567	14.8938761166432	0.00125024408200257	0.026898570954781	-0.275342547278727	-0.0828640438193289
FHIT	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	SKNAS, OVCAR8	AUTONOMIC_GANGLIA, OVARY	neuroblastoma, carcinoma	0.676881093126	0.676881093126	0.42279179914898	0.420565301841	-4.37572278305904	21.82422735131	0.000244856853714524	0.0063343300663585	-0.37457113110082	-0.13360745685322
FHIT	BRD-K42981054-001-01-9::2.5::HTS002	2.5	mibampator	glutamate receptor modulator	noncancer	GRIA1	NA	NA	SW1990, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.522500713652	-0.522500713652	-1.05916417291616	-1.074754636055	-8.19370510782816	6.26715486961723	0.000141917345462842	0.00388021466203667	-0.695287390905447	-0.378039527622879
FHIT	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SKNAS, SW1990, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma	0.620611010747333	0.635205142995	-0.0783178899240565	0.3130523972605	-7.53035090705872	51.2970898167378	7.66089305239188e-10	4.61741154956721e-08	-0.885236424836409	-0.512621376506371
FHIT	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	SKNAS, PC14, OVCAR8	AUTONOMIC_GANGLIA, LUNG, OVARY	neuroblastoma, carcinoma (non_small_cell_carcinoma), carcinoma	0.451266040431	0.401357800571	-0.247979031445865	-0.106614148702	-7.46916208265311	4.67502932674852	0.000906774797221007	0.0203038169153344	-0.945016356983332	-0.453473786770398
FHIT	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	SW1990, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-0.785910086317	-0.785910086317	-1.20218592877985	-1.18840349692	-5.74106134565625	165.997798290292	4.37429419008601e-08	2.14736165704752e-06	-0.55943360928507	-0.273118075640637
FHIT	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	SKNAS, SW1990, PC14, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, LUNG, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	0.26722601864325	0.27840266014	-0.504729269640487	-0.0101877666219	-8.50592253268223	188.285906525254	5.51893223007176e-15	5.72817058566126e-13	-0.950982596826735	-0.59292797974074
FHIT	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	SKNAS, SW1990, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma	-0.646275295783333	-0.602318229065	-1.49324571008537	-1.42460554092	-10.3888080156252	14.202426928349	5.07815611231366e-08	2.47644168690802e-06	-1.02159533922821	-0.67234548937586
FHIT	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SKNAS, SW1990, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma	-0.271181475981667	-0.267151962541	-1.34832996974539	-1.13253271131	-9.99386301281339	14.0647950530334	9.03112336176909e-08	4.27291752539648e-06	-1.30821586476462	-0.84608112276282
FHIT	BRD-K79259477-001-04-9::2.5::HTS002	2.5	NVP-BHG712	ephrin inhibitor	targeted cancer	EPHB4	NA	NA	SKNAS, SW1990, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma	0.588657969427	0.562280072093	0.144171599239176	0.13652759306	-8.5298375421035	5.55954556795733	0.000212918183067284	0.00558562316507074	-0.57448315060437	-0.314489589771279
FHIT	BRD-K84163249-001-01-9::2.5::HTS002	2.5	ercalcitriol	vitamin D receptor agonist	noncancer	VDR	NA	NA	SKNAS, SW1990, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma	0.0218591342123	-0.012067836852	-0.527313089005567	-0.513405318355	-9.22739364120954	9.81029761979319	3.79230873055952e-06	0.000141037955563438	-0.682129251509084	-0.41621519492665
FHIT	BRD-K88677950-001-03-9::2.5::HTS002	2.5	PD-198306	MAP kinase inhibitor, MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	SKNAS, SW1990, PC14, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, LUNG, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	-0.395299691805	-0.3902045357885	-0.671052200640589	-0.5600536353885	-4.15837237273178	12.4761723606526	0.00122326612507974	0.0263882359291582	-0.419626029715238	-0.13187898795594
FHIT	BRD-K93123848-001-04-1::2.5::HTS002	2.5	RAF265	RAF inhibitor, VEGFR inhibitor	targeted cancer	BRAF	NA	NA	SKNAS, SW1990, PC14, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, LUNG, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	-0.56587452787125	-0.5326367067205	-1.30268502876354	-1.19686473631	-6.20983127839212	5.79274104556122	0.0009195967636507	0.0205651350956272	-1.02967883464679	-0.443942167137791
FHIT	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	SKNAS, SW1990, PC14, OVCAR8	AUTONOMIC_GANGLIA, PANCREAS, LUNG, OVARY	neuroblastoma, carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	-1.3655829141375	-1.3671910194	-0.269822187075888	-0.190983656017	8.65823754625559	6.17155747499062	0.000112117208230554	0.00314322683098057	0.78816162225289	1.40335983187033
FHOD3	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.3950578709805	0.3950578709805	0.174781129631453	0.21394626854	-8.1288002764312	186.843901682155	5.82393426117203e-14	5.46992991350894e-12	-0.273734707266192	-0.166818775431903
FHOD3	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.548866359594	0.548866359594	-0.0568653410671543	0.106263594851	-10.8587825794689	88.3278848567106	6.03894045264655e-18	8.28630005297877e-16	-0.716582266410973	-0.494881134911336
FHOD3	BRD-A64092382-003-18-3::2.5::HTS002	2.5	mexiletine	sodium channel blocker	noncancer	AHR, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-4.776279429405	-4.776279429405	-3.06802695331867	-3.11121545199	15.7999234655055	18.8243404407886	2.56958822156165e-12	2.05422332688955e-10	1.48181637705692	1.93468857511574
FHOD3	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.018571567922815	-0.018571567922815	-0.186823062657604	-0.0590439534084	-3.56581372841126	16.946610468556	0.00238887047982332	0.0466731286299044	-0.267826195548382	-0.0686767939211963
FHOD3	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.376982938303	0.376982938303	-0.0543296879938918	-0.0230394948173	-11.0210048591894	5.94141991389731	3.54524184941983e-05	0.00110059116504099	-0.527303100161359	-0.335322152432425
FHOD3	BRD-K00662280-001-09-4::2.5::HTS002	2.5	CL-218872	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.0737175282913	0.0737175282913	0.188234337917984	0.1913856373495	4.14373418870749	92.3757925253106	7.5623958726498e-05	0.00219792485552893	0.0596320291226804	0.169401590130687
FHOD3	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.0873307412923	-0.0873307412923	0.160006703942032	0.166606190016	8.08294833174809	8.61269626138757	2.64384422353961e-05	0.000842355416362451	0.177638228090501	0.317036662378163
FHOD3	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.05598510115325	0.05598510115325	-0.342496998225115	-0.229059189804	-7.81559329436018	9.76832700656563	1.65741368060587e-05	0.000549724259904945	-0.512451188787473	-0.284513009969257
FHOD3	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.212876608164	0.212876608164	-0.385837861540012	-0.278845004201	-9.27051644690657	19.9618045592625	1.13232509108232e-08	6.01760735052274e-07	-0.733448032751802	-0.463980906656222
FHOD3	BRD-K04623885-001-07-5::2.5::HTS002	2.5	BIBR-1532	telomerase inhibitor	targeted cancer	TERT	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.11503645630825	-0.11503645630825	-0.917625422960088	-0.834266968334	-15.7411273940457	68.8775664898755	1.64680786612249e-24	4.05233849756794e-22	-0.904307980483963	-0.700869952819713
FHOD3	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.470880960845	-1.470880960845	-1.21844100228516	-1.22574357102	3.42599840573289	173.92206370861	0.000764319472375355	0.0174643740079677	0.107010775652951	0.39786914146673
FHOD3	BRD-K07487750-001-03-3::2.5::HTS002	2.5	WHI-P154	JAK inhibitor	targeted cancer	EGFR, JAK1, JAK2, JAK3	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.229240535017	-0.229240535017	-0.642967382381853	-0.57901895305	-6.75899764535927	103.564068369082	8.3884637979445e-10	5.03893233562121e-08	-0.535117111723365	-0.29233658300634
FHOD3	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.6747993506935	-0.6747993506935	-2.04994769203703	-1.66463476506	-8.26901515320005	4.9742615813748	0.000432553962006992	0.0105303110089728	-1.80330572752403	-0.946990955163035
FHOD3	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.729386252375	-0.729386252375	-0.0631519259310469	-0.00125185876287	11.9495838770462	4.16244985655106	0.000223473393057047	0.00582970166267329	0.513790773510001	0.818677879377905
FHOD3	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.282453046782	0.282453046782	-0.290335065015944	-0.2721742756055	-17.2620245368094	75.6327677770413	5.96073945444334e-28	1.98996779833549e-25	-0.638880937476962	-0.506695286118925
FHOD3	BRD-K13094524-001-07-5::2.63083::HTS002	2.63083	PFI-1	bromodomain inhibitor	targeted cancer	BRD4	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.46491297418	-1.46491297418	-2.23770068565267	-2.09295317057	-7.47099791660103	139.350294018686	7.94945426334274e-12	6.02261782540822e-10	-0.977299202390107	-0.56827622055524
FHOD3	BRD-K13514097-001-05-3::2.5::HTS002	2.5	everolimus	mTOR inhibitor	targeted cancer	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.502361136458	-0.502361136458	-0.748617708155443	-0.7206768922275	-4.26662779808977	138.666697600043	3.65327173431474e-05	0.00113101556773645	-0.360375568683772	-0.132137574711115
FHOD3	BRD-K13533483-001-16-2::2.5::MTS005	2.5	cyclosporine	calcineurin inhibitor	noncancer	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	transplant, rheumatology, dermatology	organ rejection, rheumatoid arthritis, psoriasis	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.3791681253995	0.3791681253995	0.222380584092948	0.221127225806	-5.09120347553694	5.8373480785109	0.00242937390261646	0.0473953467298274	-0.232653986996005	-0.0809210956170987
FHOD3	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.1639123669425	0.1639123669425	-0.0723751397071248	0.0407112965926	-5.27522465110564	33.9270309659993	7.58912052052586e-06	0.000267077352295467	-0.327322877517897	-0.145252135781352
FHOD3	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.5665511398185	0.5665511398185	-0.0493827871970114	0.0935597000564	-7.74716161296452	5.332622259122	0.000426364227404179	0.0103997062131911	-0.816531298392489	-0.415336555638534
FHOD3	BRD-K17979676-001-01-2::2.5::HTS002	2.5	eprobemide	monoamine oxidase inhibitor	noncancer	MAOA	neurology/psychiatry	depression	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.2388065884335	0.2388065884335	-0.0483192909969774	-0.01607222471295	-6.08766065529377	167.000005636184	7.61322868260565e-09	4.11120103379739e-07	-0.380242811652736	-0.194008947208219
FHOD3	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.230961415399	0.230961415399	-0.199864195527721	-0.14719250083	-8.1843059347705	59.6842024748282	2.46572769585478e-11	1.75632087512415e-09	-0.53613366433549	-0.325517557517953
FHOD3	BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500	2.5	sonidegib	smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.2431689984185	0.2431689984185	-0.00203231018760011	0.0115719304002	-10.0107329296764	5.17914623611878	0.00013906682849055	0.00381102854923299	-0.307515275729827	-0.182887341482374
FHOD3	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.920658875542	-0.920658875542	-0.439264553274015	-0.343450980127	11.7591028444684	194.000167284483	1.88842215017857e-24	4.62036108476738e-22	0.40065360593974	0.56213503859623
FHOD3	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.8388994429335	-0.8388994429335	-0.297151233613826	-0.17305387456	7.87036188458688	7.78187145413474	5.72002541320879e-05	0.00170581233725842	0.382238997855864	0.701257420783484
FHOD3	BRD-K23984367-075-15-2::2.5::HTS002	2.5	sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.4399049634335	-0.4399049634335	-0.856186411878865	-0.738304903661	-5.51681742275742	177.014415191349	1.20906862258501e-07	5.6395749468993e-06	-0.565192151640136	-0.267370745250593
FHOD3	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-5.991166061715	-5.991166061715	-3.67290700458629	-3.84343615246	22.4607843289696	28.2657444265887	1.44659725460965e-19	2.28648778011233e-17	2.10692503692643	2.52959307733099
FHOD3	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.04958853954245	0.04958853954245	-0.0726683645565853	0.0269217911151	-3.91246884253529	144.348327874984	0.000140229263688236	0.00383846715926386	-0.184019698090159	-0.060494110107912
FHOD3	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.455824096565	-1.455824096565	-2.31791560772094	-2.045349051995	-7.82360337842843	39.4433813685423	1.50985818274523e-09	8.81041095697255e-08	-1.08489398410709	-0.639289038204782
FHOD3	BRD-K35960502-001-20-0::2.5::HTS002	2.5	niclosamide	DNA replication inhibitor, STAT inhibitor	noncancer	STAT3	infectious disease	tapeworm	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.25144930077	-1.25144930077	-0.697346216063285	-0.652327741583	9.88989760424951	192.792128331798	6.49076147320083e-19	9.6675358984688e-17	0.443598148852508	0.664608020560923
FHOD3	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.12992184577675	-0.12992184577675	-1.0391173979168	-1.017015264785	-8.82639092975145	3.67426212777453	0.00132757209204684	0.0283262517587165	-1.20547612370203	-0.61291498057806
FHOD3	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	1.0027128382475	1.0027128382475	0.570002953707886	0.566004994618	-9.93514078737286	4.43808224738494	0.000337953124853565	0.00844012529675364	-0.549068627560672	-0.316351141518557
FHOD3	BRD-K37249724-001-25-7::2.5::HTS002	2.5	astemizole	histamine receptor antagonist	noncancer	HRH1, KCNH1, KCNH2	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.21395655027	-0.21395655027	0.065484917620733	0.115244087444	6.12912316461718	7.48199600484311	0.00036680078595093	0.00910223985782991	0.173024615541596	0.38585832023987
FHOD3	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.334187488285	-0.334187488285	-0.0924709240994558	-0.0710979031402	5.36158445026119	16.9584247416588	5.22263826830382e-05	0.00156949360264623	0.146581882641825	0.336851245729263
FHOD3	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-7.610790861875	-7.610790861875	-6.58956804566521	-6.64618122736	12.895120135213	136.979388950674	2.09182721505646e-25	5.50785301198816e-23	0.864620895655259	1.17782473676432
FHOD3	BRD-K40530731-001-11-6::2.5::HTS002	2.5	hyoscyamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.1255081015375	0.1255081015375	-0.201415574134045	-0.0978191869653	-5.81490000747113	17.6486026680351	1.78408389234466e-05	0.000587728685427597	-0.445209927126848	-0.208637424216243
FHOD3	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.846538307361	0.846538307361	0.363340872376545	0.394038132066	-9.95417715722124	13.9780908475572	1.00268680631889e-07	4.72422203806378e-06	-0.587325362741697	-0.379069507227212
FHOD3	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.7513704699775	-0.7513704699775	-0.116851085455383	-0.0679983440509	16.4704845200885	42.9505049078248	3.57097895288484e-20	6.0217493941216e-18	0.556824466866262	0.712214302177972
FHOD3	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.11335419888965	0.11335419888965	-0.269044531297629	-0.2054130743915	-6.88016387087267	11.8973836938004	1.77526544999213e-05	0.000585190508507172	-0.503612845571322	-0.261184614803236
FHOD3	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.5044238624605	-0.5044238624605	-0.282253928642352	-0.2569086069275	6.19887415442902	133.918522850631	6.56500991243606e-09	3.57578655533039e-07	0.151283536908389	0.293056330727907
FHOD3	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.619393634694	0.619393634694	0.376452607005386	0.393436647762	-9.93830333356731	107.780994130581	6.56746811772081e-17	8.16472664850919e-15	-0.291396214882291	-0.194485840494938
FHOD3	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.197735097739	-0.197735097739	-0.768445337840105	-0.6098527820225	-8.45368240149093	191.540922029873	7.07012222490518e-15	7.24346188499858e-13	-0.703869250995296	-0.437551229206913
FHOD3	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.195049464779	0.195049464779	0.304304913348364	0.306467449749	4.49591662420586	20.6057414490305	0.000206892741723179	0.00544621891928117	0.058659728139273	0.159851168999454
FHOD3	BRD-K56957086-001-06-3::2.5::HTS002	2.5	dacinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-6.702524161965	-6.702524161965	-5.57479303662394	-5.599173214095	12.6408199876319	28.2898657119719	3.69802881091374e-13	3.21018556911435e-11	0.945069983390548	1.31039226729158
FHOD3	BRD-K57136142-001-02-4::2.5::HTS002	2.5	CCT129202	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.186964901691	-0.186964901691	-0.753703900076178	-0.661176661425	-10.8547362477905	18.4058253318517	1.95672657078832e-09	1.12858786111542e-07	-0.67625759176366	-0.457220405006696
FHOD3	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.256212704265	-0.256212704265	-0.606551834045319	-0.456560974373	-5.634882825584	189.765129041178	6.25500247697076e-08	3.02011359740182e-06	-0.472978643395673	-0.227699616164965
FHOD3	BRD-K66094457-001-01-5::2.5::HTS002	2.5	CPP	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.543291715164	-0.543291715164	-0.91700243786772	-0.865994083482	-6.17668398826659	123.948068291409	8.61866426762194e-09	4.62964835542642e-07	-0.493464502864253	-0.253956942543187
FHOD3	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-4.442805313785	-4.442805313785	-3.09086526195761	-3.15624915805	13.582013162425	40.3163246911952	1.23981380809896e-16	1.50044073221932e-14	1.15081337945478	1.55306672420001
FHOD3	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-4.431893270415	-4.431893270415	-3.85252364352748	-3.68860468998	7.50999307337303	21.83768423402	1.73900134483678e-07	7.91502270625445e-06	0.419308616385533	0.739430637389499
FHOD3	BRD-K69116396-001-04-1::2.5::HTS002	2.5	sertindole	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.294097575091	0.294097575091	0.0121631821960662	0.0316933159242	-11.0031435648795	180.106271185418	7.24365245790015e-22	1.40754740494042e-19	-0.332494435962166	-0.231374349827702
FHOD3	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-6.4007216166	-6.4007216166	-4.335626850368	-4.06811907991	17.8313319345419	189.996075356747	1.95329554115576e-42	2.47720639077144e-39	1.83665091362614	2.29353861883786
FHOD3	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.549988423715	-0.549988423715	-1.33972595717049	-1.10972386317	-9.08568430278923	161.583997305751	3.52516524334177e-16	4.11069173797714e-14	-0.961385296812872	-0.618089770098106
FHOD3	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.503642074403	0.503642074403	-0.201212977529125	-0.145323520972	-11.0707668261287	3.2988246170909	0.00101225567054059	0.0223550484916325	-0.89747756329278	-0.512232540571471
FHOD3	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.07750873601885	-0.07750873601885	-0.464687023926402	-0.217946401079	-4.55185945325863	195.891485179107	9.3222337485417e-06	0.000322991438262398	-0.554927950925303	-0.219428624889802
FHOD3	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.280745566094	0.280745566094	0.0193905990725839	0.0259313359155	-9.22981309397013	75.0524050076723	5.41519824057201e-14	5.11517859719506e-12	-0.317763458594018	-0.204946475448814
FHOD3	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-2.80027433107	-2.80027433107	-4.14670400398317	-4.26693586682	-12.2491427429038	190.234714022205	8.23388832043426e-26	2.23954447948015e-23	-1.56324888446996	-1.12961046135638
FHOD3	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.01187300745485	-0.01187300745485	-0.622835785114902	-0.529789535968	-9.84616565167996	11.2524583149068	7.18344255783268e-07	3.00179383891152e-05	-0.74716282577776	-0.474762729542343
FHOD3	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.810310260307	-0.810310260307	-2.52187779519567	-2.254263331985	-10.3226698977	2.88218717458425	0.00230330865037841	0.0452794332388632	-2.25165286680138	-1.17148220297596
FHOD3	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-2.78568433723	-2.78568433723	-0.825002586931536	-0.670558533384	18.9034985454595	12.7869637008072	1.0047076843193e-10	6.65444973029885e-09	1.73622698839524	2.18513651220169
FHOD3	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-3.950832059985	-3.950832059985	-4.38017849590692	-4.37968901574	-4.77100699933429	75.8874463940496	8.69132833035966e-06	0.00030240319962949	-0.608582820932434	-0.250110050911413
FHOD3	BRD-K84868168-001-01-0::2.5::MTS006	2.5	erdafitinib	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.2812794883855	-0.2812794883855	0.0927644756930696	0.154218588669	8.44282112930571	14.7029723292435	5.10112316703284e-07	2.17359568045125e-05	0.279447512218441	0.468640415938698
FHOD3	BRD-K88789588-001-14-9::2.5::HTS002	2.5	letrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.5919310188095	0.5919310188095	0.169056731990649	0.134941484208	-11.5188117194416	164.447892601943	6.9217801629567e-23	1.47762770970752e-20	-0.49536119062482	-0.350387383012882
FHOD3	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.169290850925	-1.169290850925	-2.06959996898772	-1.887176140495	-7.50262401192354	12.5179506366961	5.6155267964653e-06	0.000202860313965888	-1.16057017373717	-0.640048062388272
FHOD3	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-4.00521439707	-4.00521439707	-3.0980062888055	-2.979502562735	7.70685203885445	29.4938631592533	1.5093913943978e-08	7.9232512409965e-07	0.666629943038847	1.14778627349016
FHOD3	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.3147885311405	0.3147885311405	0.165973992155406	0.180090535551	-6.81595068266892	39.0815405687941	3.79871917717058e-08	1.88379380500646e-06	-0.192973564251069	-0.10465551371912
FHOD3	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.655785618368	-0.655785618368	-1.02692349167498	-0.948156981669	-6.7167958463622	4.43863992272949	0.00174782424724745	0.0357929890204756	-0.518752845010519	-0.22352290160344
FHOD3	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.04552069476285	0.04552069476285	-0.094926583626472	-0.0469105128274	-4.03108296430665	12.8077606881146	0.00146772546659646	0.0308619769969737	-0.215831858120091	-0.0650626986585534
FHOD3	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.967853279545	-1.967853279545	-1.40147944806746	-1.36288222555	6.4311924289687	16.8952644408177	6.3948070596353e-06	0.000228470178743886	0.38048157635258	0.752266086602505
FHOD3	BRD-K95785537-001-23-1::2.5::HTS002	2.5	PP-2	src inhibitor	targeted cancer	ABL1, LCK, LYN, RIPK2, SRC	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.11539787904575	0.11539787904575	-0.277345204035514	-0.127481786851	-4.6665382123724	85.4059343825212	1.12522076424764e-05	0.000383597011580136	-0.560067308430409	-0.225418857732119
FHOD3	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-2.287357252475	-2.287357252475	-3.0785331714144	-3.084015642295	-6.21347412231616	4.56985437326717	0.00217026457680651	0.043005791094893	-1.12798146778964	-0.454370370089151
FHOD3	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.398489366177	0.398489366177	0.0910995278669663	0.162270559212	-7.88857395401748	5.14616426064728	0.000460653726816113	0.0111422472198139	-0.406706636399371	-0.208073040220696
FHOD3	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.368922946273	-0.368922946273	-0.62104515063602	-0.6228392960495	-4.78936598957469	54.7247139803694	1.31555628855185e-05	0.000443336263787782	-0.357631226876935	-0.146613181849106
FHOD3	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.03382641359065	0.03382641359065	-0.0776077105489456	-0.07508781022425	-3.77137407189892	111.09870115224	0.000261995872094232	0.00671449399379226	-0.169983605071972	-0.0528846432072188
FHOD3	BRD-M97302542-001-03-6::2.5::HTS002	2.5	dichloroacetate	pyruvate dehydrogenase kinase inhibitor	targeted cancer	PDK1	NA	NA	COLO741, TE11	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.2568938646715	0.2568938646715	-0.265112477434926	-0.170283353784	-11.3260939625436	25.6344383360472	1.78695623868359e-11	1.29347025896931e-09	-0.616809071484867	-0.427203612727986
FKTN	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.231375820825	-1.231375820825	-0.944382917235652	-0.8676021902365	4.17311813847608	19.9076894208178	0.000473307373098352	0.0114135346499546	0.143494758127542	0.430491049051155
FKTN	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.234126730817	-0.234126730817	-0.834894316024228	-0.720201208535	-7.45233400143973	4.78027201323799	0.000833065745068778	0.018860267040757	-0.810892270604721	-0.390642899809735
FKTN	BRD-A17883755-001-06-1::2.5::HTS002	2.5	lenalidomide	anticancer agent	targeted cancer	CDH5, CRBN, PTGS2, TNF, TNFSF11	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.281492311567	0.281492311567	-0.0538622424006304	0.0179498928779	-4.63937041069291	9.5101262740471	0.00105430090343236	0.0231334212051345	-0.49754611725552	-0.173162990679741
FKTN	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.718287143795	-1.718287143795	-0.682049296095989	-0.624576558799	20.0355919117199	166.494781785729	3.18764535575334e-46	5.55451090612404e-43	0.934126584611408	1.13834911078661
FKTN	BRD-A67748489-001-10-0::2.5::HTS002	2.5	K-858	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.55335605186	-4.55335605186	-2.62264612929585	-2.49115990214	14.0405047957867	4.03341726988426	0.000141654772178361	0.00387501284827262	1.55016519258054	2.31125465254776
FKTN	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.596075042349	0.596075042349	0.243444600758696	0.260666777641	-7.74727822242867	3.88740724729438	0.00167907473580723	0.0346332796699863	-0.4804617250029	-0.224799158177708
FKTN	BRD-K02407574-001-09-7::2.5::HTS002	2.5	parbendazole	tubulin polymerization inhibitor	noncancer	TUBB	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.34957969623	-2.34957969623	-3.05793287568181	-3.07168460551	-6.20946621520325	9.05855108001129	0.00015282493639524	0.00415459358100653	-0.966157751305371	-0.450548607598256
FKTN	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.244795896348	-0.244795896348	-0.648433600749991	-0.593822379071	-5.84727676135651	9.68505539781326	0.000183876059116268	0.00490662000427422	-0.558126869730113	-0.249148539073869
FKTN	BRD-K07972848-001-02-0::2.5::HTS002	2.5	GSK2126458	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.765745939655	-2.765745939655	-3.8788301866459	-3.827765844565	-12.7801509834533	165.000829744061	1.9413062229639e-26	5.59997606274064e-24	-1.28504811882584	-0.941120375155971
FKTN	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.665308366895	-2.665308366895	-2.05989013820569	-2.351388502545	5.35940724336025	11.4683208168032	0.000199762764123371	0.00527862821745752	0.358020051349076	0.852816406029537
FKTN	BRD-K16136380-001-01-7::2.5::HTS002	2.5	pyrithione-zinc	ATP synthase inhibitor	noncancer	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.143386443965	-4.143386443965	-6.36561666829933	-6.34443535145	-13.3387450598782	2.57921546592243	0.00189433539809494	0.0382957000130438	-2.80488190888277	-1.6395785397859
FKTN	BRD-K18518344-001-15-9::2.5::HTS002	2.5	digitoxigenin	ATPase inhibitor	noncancer	ATP1A1	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-6.75790133329	-6.75790133329	-4.10209170701428	-4.32290694066	13.4920299609452	2.98744869400704	0.000899554916431239	0.0201632195862572	2.02787627042743	3.28374298212401
FKTN	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.046960305107315	0.046960305107315	-0.376882931509246	-0.173057746988	-4.62827050762371	8.02024460121158	0.00168062409477457	0.0346619016174883	-0.634927482692854	-0.212758990540267
FKTN	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.4031859717225	-0.4031859717225	-0.778729268146159	-0.759682041762	-5.16921459985899	13.1052669253269	0.000175906451176772	0.0047198114389417	-0.532365962002919	-0.218720630844399
FKTN	BRD-K25835157-001-01-4::2.5::HTS002	2.5	PRT062070	JAK inhibitor, syk inhibitor	targeted cancer	SYK	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.287604375709	0.287604375709	-0.086249791308005	-0.0811687124677	-6.18723983867439	5.03947247329052	0.00156351427883574	0.0325915631072345	-0.528812291045763	-0.218896042988247
FKTN	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.1272492077875	-0.1272492077875	-0.0513478384103154	-0.0260340961769	4.09408908010032	131.982304585367	7.34253512834349e-05	0.00213994861507034	0.039228841215921	0.112573897538448
FKTN	BRD-K36363294-001-04-2::2.5::HTS002	2.5	I-BET151	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.434054512224	-0.434054512224	0.121165094652034	0.175731719762	6.93532330153823	4.56551109998775	0.0013734647741102	0.029119281385044	0.343394590318847	0.76704462343322
FKTN	BRD-K36627727-001-05-4::2.5::HTS002	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.04104433510705	0.04104433510705	0.138066542529947	0.154182848854	3.57691075950752	191.848667197275	0.000440120231125118	0.0106971176737369	0.0435215103753899	0.150522904470403
FKTN	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.5381258373005	0.5381258373005	0.0847647934815264	0.1179670530315	-15.3706315867942	48.6311037594932	2.67091075816837e-20	4.56138352101569e-18	-0.512645398100906	-0.394076689537041
FKTN	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.0187202179357	0.0187202179357	-0.210429975110055	-0.158274399371	-4.3612517179386	10.0976495663669	0.00138624370016866	0.0293473158843786	-0.346068452477488	-0.112231933614021
FKTN	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.3109311089165	-0.3109311089165	-1.34062295043186	-1.07204580455	-9.81280246137703	10.7132066406004	1.10206556580927e-06	4.46849433700973e-05	-1.26140552532192	-0.797978157708803
FKTN	BRD-K51967704-001-03-6::2.5::MTS010::PROS004_PR500	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.112640223275	-2.112640223275	-1.37742294560173	-1.35469471431	8.89097721942132	191.898449605306	4.4410053866452e-16	5.12041997668923e-14	0.572114301450198	0.898320253896336
FKTN	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.233072970185	-0.233072970185	-0.708568801855353	-0.5410189846345	-6.36699834870474	32.7980359246499	3.37918075559372e-07	1.47716996158606e-05	-0.627471667966221	-0.323519995374486
FKTN	BRD-K58466253-003-14-0::2.5::HTS002	2.5	palmatine-chloride	dopamine synthesis inhibitor	noncancer	CYP3A4	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.3416596775615	-0.3416596775615	-0.0525552982029888	-0.0597563096057	8.33298860623114	132.308383937936	8.81463605941062e-14	8.11525829887207e-12	0.220477775559168	0.357730983157855
FKTN	BRD-K59632282-052-03-1::2.5::HTS002	2.5	quinidine	sodium channel blocker	noncancer	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.263001886601	0.263001886601	0.442033899125606	0.447983088223	5.86038886498887	8.93006291223058	0.000248015886170009	0.00640600106856253	0.109841627616964	0.248222397432249
FKTN	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.771741334747	-0.771741334747	-2.64570287884617	-2.62453052692	-14.3118239926865	182.642852452648	1.19664899887754e-31	5.53945104277375e-29	-2.13230713181574	-1.61561595638261
FKTN	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2765190164895	0.2765190164895	-0.535238944248413	-0.376499820922	-14.9283268826097	74.2739281081076	4.6255476242564e-24	1.09183810215776e-21	-0.920099903151332	-0.703416018324494
FKTN	BRD-K78809024-001-05-7::2.5::HTS002	2.5	SB-590885	RAF inhibitor	targeted cancer	BRAF	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.128395991798	-0.128395991798	0.0962358089365548	0.1634753207025	4.54003414051765	36.9262820565501	5.8036234824498e-05	0.00172833794271222	0.124373097761064	0.324890503708045
FKTN	BRD-K79239947-001-06-8::2.5::HTS002	2.5	PF-573228	focal adhesion kinase inhibitor	targeted cancer	CDK1, CDK2, CDK7, GSK3B, IKBKB	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2043072806	0.2043072806	-0.238450395094159	-0.1830123326315	-8.59920382793016	22.5702400196882	1.41678748667584e-08	7.46273396981435e-07	-0.549381502258177	-0.336133849130142
FKTN	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.165837488394	0.165837488394	-0.467170148665309	-0.217946401079	-6.76978612303509	28.0082228432296	2.36513443274549e-07	1.0569576685486e-05	-0.824541046076419	-0.441474228042199
FKTN	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.761699819905	-1.761699819905	-2.51175662966803	-2.254263331985	-5.33555876842355	5.600063268496	0.00219356878922833	0.0433913617929413	-1.10007981718726	-0.400033802338793
FKTN	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	CAOV3, NCIH650	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.382844364403	-0.382844364403	-0.148656402919798	-0.137644446714	6.45089404615837	180.748157144475	9.87275207566313e-10	5.87782522118001e-08	0.162555416374759	0.305820506591645
FUT10	BRD-A03623303-045-09-5::2.5::HTS002	2.5	metoprolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.149128137445	0.149128137445	0.240229290431443	0.21036832824	3.17404108505239	176.857762618226	0.00177333063333882	0.0362184277980632	0.0344587791449298	0.147743526827955
FUT10	BRD-A14344385-001-03-2::2.5::HTS002	2.5	IDRA-21	glutamate receptor positive allosteric modulator	noncancer	GRIA1, GRIA2, GRIA3, GRIA4	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.106274461539	-0.106274461539	0.14522462002823	0.119694147136	6.9480796815503	4.29619486576648	0.00172361887143111	0.0354259214705561	0.153674779593884	0.349323383540576
FUT10	BRD-A24514565-001-09-7::2.5::HTS002	2.5	warfarin	vitamin K antagonist	noncancer	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.298942835631	0.298942835631	-0.127814770262394	-0.09418085429645	-9.11087425487933	5.23039339773392	0.000210092538868917	0.00552569932055911	-0.545586946834385	-0.307928264952403
FUT10	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.8475023809915	-0.8475023809915	-1.23920034725284	-1.05465528871	-4.37339962657306	187.009896129268	2.02859293542062e-05	0.000660368006160034	-0.568383047302297	-0.215012885220391
FUT10	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-1.042984363575	-1.042984363575	-0.689233368225989	-0.624576558799	6.02644905503274	17.4645006718857	1.21377339151692e-05	0.000411429443666661	0.230155810963869	0.477346179734153
FUT10	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.3339817968955	-0.3339817968955	0.19111665484176	0.190024427126	13.3424783849082	3.64335388840006	0.000317526668311612	0.00797085655804164	0.4114799289872	0.638716974487321
FUT10	BRD-A79981887-003-16-4::2.5::HTS002	2.5	midodrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.13960123227205	-0.13960123227205	-1.04640149704961	-1.024762922465	-7.90867080036192	3.53354619877231	0.00228016672052069	0.0448930601729266	-1.24242305164321	-0.571177477911901
FUT10	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.2415757685015	-0.2415757685015	0.161613422975461	0.166606190016	11.5890625046571	4.10971206462075	0.000272090295416705	0.00694216175891354	0.307603818244233	0.498774564709689
FUT10	BRD-K03273112-001-01-8::2.5::HTS002	2.5	1-azakenpaullone	glycogen synthase kinase inhibitor	noncancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.4593931920425	-0.4593931920425	-0.717756718121136	-0.657905942127	-3.60481779219831	192.957305422263	0.000397590603275804	0.00975337031126244	-0.399724145983194	-0.117002906174078
FUT10	BRD-K03294269-001-08-0::2.5::HTS002	2.5	NU6027	CDK inhibitor	targeted cancer	CCNA2, CDK2	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.381915363983	-0.381915363983	-0.0450473218481043	0.0746632768957	7.21977742201172	187.500128333838	1.26157757244252e-11	9.32388481117352e-10	0.244823861651215	0.428912222618577
FUT10	BRD-K10670311-001-15-5::0.625::HTS002	0.625	sulfasalazine	cyclooxygenase inhibitor	noncancer	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.06976968969585	0.06976968969585	0.279972932440208	0.3338993038355	4.81819987413669	7.48369543092313	0.00159754848954834	0.0331816038585529	0.108378345784272	0.312028139704444
FUT10	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.348841521859	-0.348841521859	0.435619225763658	0.408179294611	16.3999798342279	3.35113435524445	0.000256416610797601	0.00658963018892555	0.640872138068173	0.928049357177144
FUT10	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.414319882542	-0.414319882542	-0.282922587044412	-0.2553419121665	3.77841052577196	33.8071404099735	0.000611872047550377	0.0143141929519569	0.0607094884454023	0.202085102549774
FUT10	BRD-K11663430-001-02-3::2.5::HTS002	2.5	pyroxamide	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.140621012836	-0.140621012836	-0.644129785105149	-0.612220843488	-7.8923364433691	160.434678570132	4.36761672638563e-13	3.76097599577945e-11	-0.629499312265132	-0.377518232273166
FUT10	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.868489077661	-0.868489077661	-2.46434868649421	-2.47219362388	-12.3281624465335	4.30547471939337	0.000160688515995493	0.00435690318860179	-1.94542896391311	-1.24629025375332
FUT10	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.876821423551	-0.876821423551	-1.81348647512024	-1.56065418801	-6.57553191285535	4.68007619179121	0.00156766175620079	0.0326557854548313	-1.31049521310417	-0.562834890034315
FUT10	BRD-K14880289-001-02-2::2.5::HTS002	2.5	GW-501516	PPAR receptor agonist	noncancer	PPARA, PPARD	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.818056402121	0.818056402121	0.294093011904759	0.308945987709	-15.4785700943017	3.48097639808828	0.000247044560676586	0.00638399007056329	-0.623741715877883	-0.424185064554598
FUT10	BRD-K15567136-003-27-2::2.5::HTS002	2.5	papaverine	phosphodiesterase inhibitor	noncancer	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.3517848579355	-0.3517848579355	-0.524274671382632	-0.5051056770975	-4.29360913714342	8.58064034467433	0.00224349303811758	0.044268607932858	-0.264050422861829	-0.0809292040324349
FUT10	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.2916840865205	0.2916840865205	-0.0464430326162841	0.0935597000564	-5.51156371682678	151.940869976558	1.48911702233276e-07	6.85630423801413e-06	-0.459333697988691	-0.216920540284877
FUT10	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-1.309849072315	-1.309849072315	-2.87894838931224	-2.63264407289	-8.75975735163797	3.89476505461916	0.00105538067053218	0.0231523729513296	-2.07177718092887	-1.06642145306562
FUT10	BRD-K19540840-001-09-4::2.5::MTS010::PROS004_PR500	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.4243226808805	0.4243226808805	-0.410914989049232	-0.3364454572695	-14.3233748523655	45.1112322178864	2.13479469437055e-18	3.03615402820004e-16	-0.952677907252913	-0.71779743260655
FUT10	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-1.346804354375	-1.346804354375	-1.90851438586652	-1.67956785013	-6.08691895721734	189.515584814914	6.25673493578955e-09	3.41308155269239e-07	-0.743740879600957	-0.379679183382086
FUT10	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.5666880725635	-0.5666880725635	-0.20704086651214	-0.0787988061569	7.01789034827847	194.019239345892	3.6759548102831e-11	2.56299192756398e-09	0.258574087066565	0.460720325036155
FUT10	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.0307245821667	0.0307245821667	-0.86459923632362	-0.55802362728	-8.77838234059925	30.0687434735998	8.50827941238679e-10	5.10804206772394e-08	-1.10359908184416	-0.687048555136479
FUT10	BRD-K24048528-001-02-5::2.5::HTS002	2.5	abiraterone-acetate	androgen biosynthesis inhibitor	targeted cancer	CYP17A1	oncology	prostate cancer	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.7080415114435	0.7080415114435	0.398134630952043	0.363692430058	-10.0537176007833	133.133230585401	4.86643325190963e-18	6.71614792304274e-16	-0.370877180014327	-0.248936580968587
FUT10	BRD-K25224017-001-25-0::2.5::HTS002	2.5	pirenperone	serotonin receptor antagonist	noncancer	HTR2A, HTR7	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-3.19884670044	-3.19884670044	-2.54410404035611	-2.42480640669	5.95185707266854	11.0180123695696	9.50290041637705e-05	0.00270340741085967	0.412668383146876	0.896816937020913
FUT10	BRD-K28143534-001-02-2::2.5::HTS002	2.5	cyproheptadine	histamine receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.185897432157	0.185897432157	-0.00687090601494547	0.02120744072425	-5.28801893416038	7.10904350218193	0.00108308976837032	0.0236875047923513	-0.278700548337631	-0.10683612800626
FUT10	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.18820980336	-0.18820980336	-0.401875334925322	-0.2809944464045	-3.33536437155676	63.9420207973788	0.00142165819626896	0.0300258750047428	-0.341643579887726	-0.0856874832429173
FUT10	BRD-K33610132-001-02-9::2.5::HTS002	2.5	rociletinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.4642927783135	0.4642927783135	0.195118440022666	0.241806057711	-5.56060987224605	10.3585756199953	0.000211644881032626	0.00555970532011787	-0.376528659741441	-0.161820016840226
FUT10	BRD-K36740062-001-06-6::2.5::HTS002	2.5	GSK1070916	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC, CYP2D6, CYP3A4	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-1.718165154845	-1.718165154845	-2.26452700936825	-1.977136981175	-4.60333340411823	16.5897073310052	0.000268786918449798	0.00686800565622636	-0.797244894697879	-0.295478814348625
FUT10	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.3385908258445	-0.3385908258445	-0.0924245731777769	-0.0710979031402	4.93622514697342	6.9718984693121	0.001701996962196	0.0350285487718943	0.128147598038618	0.364184907294828
FUT10	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-1.56378614382	-1.56378614382	-1.94043731911	-1.74375486562	-4.29707886696914	182.791274221724	2.8088315860684e-05	0.000888581645771888	-0.549592591574728	-0.203709759005273
FUT10	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.2116850839325	0.2116850839325	-0.540630508876042	-0.407422571936	-10.8805094598373	102.479156207034	8.70017744066504e-19	1.28070077656614e-16	-0.889453534492086	-0.615177651124998
FUT10	BRD-K46937689-001-15-0::0.625::HTS002	0.625	phenazone	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.127594938104	-0.127594938104	0.0964463897205923	0.08661449237125	5.62218192641692	6.74010667058029	0.000909311248339624	0.0203563579011263	0.129070570203612	0.319012085445573
FUT10	BRD-K49027941-001-01-1::2.5::HTS002	2.5	PSB-1115	adenosine receptor antagonist	noncancer	ADORA1, ADORA2B, ADORA3	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.475564521688	0.475564521688	0.112660242058831	0.170361291898	-5.79713507162631	8.76119799667635	0.000288501315522824	0.00731246433948574	-0.505107307699845	-0.220701251558493
FUT10	BRD-K49669041-001-08-4::2.5::HTS002	2.5	BX-912	pyruvate dehydrogenase kinase inhibitor	targeted cancer	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-1.209062411995	-1.209062411995	-1.94446637902496	-1.738347180205	-6.91006566521984	14.0751616340388	7.00402464166539e-06	0.00024816756446082	-0.96354866076046	-0.507259273299464
FUT10	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.3518066266845	0.3518066266845	-0.127806916338792	-0.007473093877485	-10.8314853661999	25.6450896901727	4.61535349568391e-11	3.18584251006904e-09	-0.570692853189013	-0.388534232857571
FUT10	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.392376542739	0.392376542739	-0.397468562691875	-0.201440599557	-10.44492420426	10.3945550299952	7.72180220951945e-07	3.2117332539571e-05	-0.957474049541483	-0.622216161320266
FUT10	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.4347937724505	-0.4347937724505	-0.139093395505267	-0.134482434125	11.5952869012204	4.97163066171999	8.68059546777519e-05	0.0024936380458555	0.23003331043644	0.361367443454027
FUT10	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.424699094189	-0.424699094189	-0.689094181700567	-0.642732938193	-4.94790599408841	193.193483620158	1.62733024631985e-06	6.43098509568652e-05	-0.369787451785698	-0.159002723237436
FUT10	BRD-K61936403-001-01-7::2.5::HTS002	2.5	AS-1949490	SHIP2 phosphatase inhibitor	noncancer	INPP5D	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.6654905649	0.6654905649	0.237001634076104	0.265760037454	-9.73448172967355	9.26157107489802	3.62312265104956e-06	0.000135450942730996	-0.527636711470411	-0.32934115017738
FUT10	BRD-K67537649-001-04-5::2.5::HTS002	2.5	PQ-401	IGF-1 inhibitor	targeted cancer	IGF1R	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.07050367524215	-0.07050367524215	0.179561743591931	0.20362806034	7.85518785222943	182.534876988117	3.31302888991806e-13	2.88532372591324e-11	0.187254646040325	0.312876191627837
FUT10	BRD-K69694239-001-02-2::2.5::MTS010::PROS002_PR500	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-2.708822150435	-2.708822150435	-2.52444651682553	-2.6020166043	3.65724301482947	171.503087692399	0.00033888506484802	0.00845945691402415	0.0848641399027406	0.283887127316193
FUT10	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.0446170891595	-0.0446170891595	0.103468797384512	0.130322249466	3.66137206010037	33.561949879743	0.000855433446489122	0.0192847600262463	0.0658512832107287	0.230320489877296
FUT10	BRD-K78177893-001-02-4::2.5::HTS002	2.5	A-674563	AKT inhibitor	targeted cancer	AKT1, PKIA, PRKACA	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-2.27464397468	-2.27464397468	-2.67802540023429	-2.66704888005	-4.51773167425538	41.8398921892763	5.0418539989111e-05	0.00151899848992496	-0.58359331790808	-0.223169533200503
FUT10	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.580328181027	0.580328181027	0.0162861160162834	0.0259313359155	-20.2505794719423	89.9358501535352	2.89845136177508e-35	1.85994665244878e-32	-0.619377711153452	-0.508706418867982
FUT10	BRD-K84783599-001-01-0::2.5::HTS002	2.5	riociguat	guanylate cyclase stimulant	noncancer	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.2410114117655	0.2410114117655	-0.00491968743588833	0.04755872580485	-4.32984120497784	15.459468802846	0.000557264223200969	0.0131975562093304	-0.366682887549756	-0.125179310853021
FUT10	BRD-K85849709-001-01-5::2.5::HTS002	2.5	AZD2858	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-0.8283428544865	-0.8283428544865	-1.7489363256868	-1.58142257926	-7.05499209119456	5.08444183319061	0.000825128224947876	0.018710210254428	-1.25435549674764	-0.586831445652965
FUT10	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-2.345428143335	-2.345428143335	-1.64071196330717	-1.710789940465	8.9133490317982	4.05045515007052	0.000826663543029172	0.0187331328519665	0.486276284440953	0.923156075614709
FUT10	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-1.53158863003	-1.53158863003	-2.06552920742475	-1.887176140495	-5.21848072539469	177.756723552648	4.99066652727947e-07	2.12949346232387e-05	-0.735853367095711	-0.332027787693781
FUT10	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.396270111214	0.396270111214	-0.318508711816333	-0.108614953002	-7.30610714851924	5.47960360665994	0.000505076111208405	0.0120952466859426	-0.95978816573715	-0.469769480323517
FUT10	BRD-K89704198-001-12-3::2.5::HTS002	2.5	vincamine	adrenergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.03235611436095	0.03235611436095	-0.195798825024374	-0.1128406004625	-4.73286916287129	34.9258865651559	3.60102524799263e-05	0.00111613035484745	-0.326026710796467	-0.130283167974181
FUT10	BRD-K89714990-001-01-5::2.5::HTS002	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.3372845025855	0.3372845025855	-0.00967024936394792	-0.02895586832955	-10.8472646103524	191.590984314266	1.11348964926697e-21	2.12893062477914e-19	-0.410043615916942	-0.283865887981953
FUT10	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	0.45440740532	0.45440740532	-0.300676695504661	-0.214794605924	-9.61392228843642	20.9447168139951	3.94105172383758e-09	2.20134516845976e-07	-0.91844466410617	-0.591723537543153
FUT10	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-1.554406450015	-1.554406450015	-1.75181598308278	-1.69551344644	-3.08572537466454	190.439099967853	0.0023331319147086	0.0457802645928388	-0.32360031979635	-0.0712187463392013
FUT10	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-1.62522685664	-1.62522685664	-0.0715527031952866	0.0900706694704	22.5621968886488	4.53029256910481	7.90171207464257e-06	0.000277542780604075	1.37099390739663	1.7363543994928
FUT10	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	8305C, ZR751	THYROID, BREAST	carcinoma (anaplastic_carcinoma), carcinoma (ductal_carcinoma)	-5.147652306795	-5.147652306795	-5.65211334786995	-5.73830939241	-4.81847490142984	11.279314621419	0.000500398169368014	0.0119966263134762	-0.734194703651799	-0.274727378498094
FUT8	BRD-A10977446-001-12-1::2.5::HTS002	2.5	carvedilol	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA	cardiology	myocardial infarction, hypertension	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.523844378167	0.523844378167	-0.2252955818489	-0.214242337971	-11.7697141448999	7.53663176421844	4.04438539018154e-06	0.000149944486471583	-0.897502375090351	-0.600777544941449
FUT8	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.0723203905184333	-0.0574886349926	-0.345373786081193	-0.2724473256495	-6.09403370346307	17.3743300390381	1.08449683813746e-05	0.000371130644772735	-0.36743230652869	-0.178674484596829
FUT8	BRD-A54927599-001-16-9::2.5::HTS002	2.5	KF-38789	P selectin inhibitor	noncancer	SELP	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.29607264356	-1.29607264356	-2.95842704723831	-2.73649504122	-15.8599535438364	26.1184120113417	6.35475870434824e-15	6.53868976641504e-13	-1.87775633341373	-1.44695247394289
FUT8	BRD-A57382968-001-29-0::2.5::HTS002	2.5	piroxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.319129684781667	0.32208278027	0.015113588703115	0.002690158672205	-7.99066173976768	5.72063423585776	0.000259792720515858	0.00666520397359868	-0.398225567459716	-0.209806624697388
FUT8	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.0632380568556667	0.0223853580771	-0.226051333531845	-0.0989668093464	-4.12947139715254	14.9572300522483	0.000896407600336475	0.0201010822946763	-0.438644909064132	-0.139933871710892
FUT8	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.104185467464	0.104185467464	-0.701437302598744	-0.633794699256	-15.7493048014359	187.255671705021	3.8459486084352e-36	2.75685056621173e-33	-0.906532805579344	-0.704712734546144
FUT8	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.1004991158641	0.126542265957	-0.18973549073857	-0.139770598556	-5.14622616010224	16.3180279734789	9.17512535964629e-05	0.00261780543557991	-0.40960300199437	-0.17086621121097
FUT8	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.8712027169905	-0.8712027169905	-2.21774519905735	-2.04082568027	-10.3623317952535	14.8509703951502	3.43521210474082e-08	1.71463804191196e-06	-1.62375787791033	-1.06932708622337
FUT8	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.65480542166	-1.65480542166	-1.25182669901178	-0.903447368813	3.69657023266436	17.1636085025393	0.00176664605047209	0.0360991020451552	0.173145719278512	0.632811726017928
FUT8	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.656201837989667	-0.64670305422	0.0268103656683263	0.208078137774	10.4350049561901	82.3280212725283	9.91099533503941e-17	1.20762576416354e-14	0.552811230080704	0.813213177235282
FUT8	BRD-K09602097-001-13-6::2.5::HTS002	2.5	forskolin	adenylyl cyclase activator	targeted cancer	ADCY2, ADCY5, GNAS	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.586517652278333	0.559661109529	0.0318796337754358	0.0389079842969	-11.3716384212965	6.20749345995577	2.18539560165689e-05	0.000706795916564841	-0.673022836778118	-0.436253200227677
FUT8	BRD-K12932420-001-02-3::2.5::HTS002	2.5	YM-976	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.530288891145	0.530288891145	0.310638726444181	0.3289563739625	-5.56523551577545	12.0396911996117	0.000121271984176403	0.00337647481119048	-0.305612685097335	-0.133687644304302
FUT8	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.493648923517	0.540110380864	-0.0636428252431537	-0.04320132136775	-6.87024378819685	4.23457304946786	0.00190367914446876	0.038448327115986	-0.777672009924604	-0.336911487595704
FUT8	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.696655172275	-1.696655172275	-2.87460225335764	-2.63264407289	-7.51010832139328	7.91527797091783	7.25547022980077e-05	0.00211716498146082	-1.54031469367552	-0.815579468489755
FUT8	BRD-K21680192-300-14-4::2.5::HTS002	2.5	mitoxantrone	topoisomerase inhibitor	chemo	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-5.51701869228	-5.51701869228	-4.71332831647086	-4.740808103055	5.3614777038129	10.3557804557645	0.000282516772210259	0.00717265307640992	0.471239218940424	1.13614153267785
FUT8	BRD-K25279140-001-01-5::2.5::HTS002	2.5	MK-8745	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.729337778611	-0.729337778611	-1.58201246320977	-1.48579667397	-9.87812351722557	42.6970497045502	1.35090605647184e-12	1.11061888829135e-10	-1.02679027360626	-0.678559095591274
FUT8	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.337773852593	0.337773852593	-0.150608791648072	-0.07517274316945	-7.86969462304245	4.16134882760009	0.00119456384389506	0.0258511383378618	-0.658082055724272	-0.318683232757871
FUT8	BRD-K48141473-001-01-7::2.5::HTS002	2.5	cebranopadol	opioid receptor agonist	noncancer	OPRL1, OPRM1	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.3436097020155	-0.3436097020155	0.350858814471296	0.370996268268	17.1793749896253	4.7468267481291	1.86222766199576e-05	0.000610756530325769	0.588864563617194	0.800072469356398
FUT8	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.7131324555465	-0.7131324555465	-1.59596956541979	-1.48697544025	-9.37466009250052	17.6903478812008	2.78694968223744e-08	1.40712400104657e-06	-1.08093515366539	-0.684739066081198
FUT8	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.603519181748	0.603519181748	0.400421487251904	0.450986520291	-5.26831265299532	6.10588727784744	0.00178679564881241	0.0364413478555824	-0.297032994582128	-0.109162394410063
FUT8	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.428511443334	-0.428511443334	-0.739853883776352	-0.696454065727	-4.53079749464203	7.67360152314889	0.00213699387068072	0.042480037034792	-0.470984862281933	-0.151700018602771
FUT8	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.190623468273333	-0.130202657038	-0.757371274497903	-0.683798479004	-5.76216363684225	7.73032846228664	0.000480241003884025	0.0115612236461259	-0.794943573215192	-0.338552039233946
FUT8	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.2858472626815	-0.2858472626815	-1.20821078207667	-1.18840349692	-12.4261291843005	111.476244299198	8.93075966661827e-23	1.8839771541207e-20	-1.06944382267347	-0.775283216116865
FUT8	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.516825720695	0.513125316119	0.148735856181503	0.1637586322135	-11.3940040767735	42.3848768237476	1.74227691012946e-14	1.72879846236637e-12	-0.433267621864755	-0.30291210716224
FUT8	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.1390319955275	0.1390319955275	-0.174244957197076	-0.07625513394025	-5.86523543570086	36.5217697272916	1.00027742370351e-06	4.07970428058895e-05	-0.42154883528422	-0.205005070164932
FUT8	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.429942969191333	-0.51170933012	-1.08822393487535	-0.41072646413	-4.2598448337065	9.57993176687499	0.00183274744509259	0.0372297343530708	-1.00465651462541	-0.311905416742619
FUT8	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.599000635955	-1.599000635955	-2.59247774588484	-2.40345273405	-6.42064179493153	5.11114359060667	0.00125287309337122	0.0269443143918483	-1.388640258363	-0.598313961496676
FUT8	BRD-K69932463-001-10-6::2.5::HTS002	2.5	AZD8055	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-3.519834163025	-3.519834163025	-2.73319349487297	-2.73243511548	12.2257280733845	101.504143413496	1.13387733008251e-21	2.16597855863864e-19	0.659009044194361	0.914272292109697
FUT8	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-3.489445496085	-3.489445496085	-4.3662718621629	-4.09603677997	-7.43176260500939	173.769544065598	4.66042612483875e-12	3.623012226734e-10	-1.10969181908983	-0.643960913065964
FUT8	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.9431673578925	-0.9431673578925	-2.53883565981882	-2.26266997363	-14.6438033314395	113.521230348785	6.47840517311419e-28	2.14620169785457e-25	-1.81153774165135	-1.37979886220129
FUT8	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.137035591566	-1.06994601621	-2.34216819891731	-2.24153283646	-8.65151121472925	5.17928273074796	0.000285345828305221	0.00723590700838024	-1.55951166907856	-0.850753545624062
FUT8	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.0389800198214	-0.0485200749739	-0.215248159295439	-0.189984916304	-5.11926525300378	23.6062302320242	3.22210543007943e-05	0.00100654516065223	-0.247395722550742	-0.105140556397337
FUT8	BRD-K77638923-001-02-0::2.5::HTS002	2.5	CUDC-907	PI3K inhibitor	targeted cancer	HDAC2, PIK3R1	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-5.5533232232	-5.55170283244	-5.89630962023424	-5.86512898123	-4.08488153939428	22.1715595658523	0.000484038556619353	0.0116356549799988	-0.51704071474291	-0.168932079325569
FUT8	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.598938083789	0.598938083789	0.279248219940137	0.273644438403	-7.65432128210128	6.27948160524666	0.000208135068202348	0.00547623140593433	-0.420794906255659	-0.218584821442067
FUT8	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	PC14, HCC1419, MKN7	LUNG, BREAST, STOMACH	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.09912765809333	-1.04565023575	-1.65825060651929	-1.74344352007	-6.07854431647766	5.13564469541575	0.00158469774187154	0.0329434221452556	-0.793706738135555	-0.32453915871636
FUT8	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	0.7405705078455	0.7405705078455	0.305741870146972	0.328628776305	-9.95035842679362	4.83256893432199	0.000211766950866092	0.00556223024659052	-0.548343309999492	-0.321313965397564
FUT8	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	HCC1419, MKN7	BREAST, STOMACH	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma)	-2.32221601237	-2.32221601237	-3.07816623709971	-3.084015642295	-7.40219996233271	30.787397627779	2.56506541916028e-08	1.3018420701473e-06	-0.964293999823078	-0.547606449636343
GAB2	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.279926882187	-0.279926882187	-0.834424570881972	-0.720201208535	-9.22310086417575	186.309409724927	6.27778186134216e-17	7.82273667767211e-15	-0.673102182283094	-0.43589319510685
GAB2	BRD-A74765037-001-01-1::2.5::HTS002	2.5	estradiol-benzoate	contraceptive agent	noncancer	ESR1	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.171913964529	0.171913964529	0.0282486828416327	0.0102513278737	-4.91619493124597	63.2838498045008	6.57300876572417e-06	0.000234329074475864	-0.202057384134968	-0.0852731792397666
GAB2	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.558421929472	0.558421929472	0.259045330897792	0.303778240807	-7.98901066067878	192.95097314465	1.20569096127379e-13	1.09683589999512e-11	-0.37328698874027	-0.225466208408147
GAB2	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.052338844735	-4.052338844735	-3.01211278977928	-2.85234115214	9.40578455491994	180.328454565027	2.39318404609337e-17	3.09552651427367e-15	0.822000685278603	1.25845142463283
GAB2	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2052821149215	0.2052821149215	-0.344052175451868	-0.229059189804	-12.1354108114381	44.5533057527153	1.01366182879741e-15	1.12277584550036e-13	-0.640532052726791	-0.458136528019944
GAB2	BRD-K03601870-001-01-2::2.5::HTS002	2.5	ixabepilone	microtubule stabilizing agent	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.779550669225	-2.779550669225	-3.63425231903282	-3.58404887743	-8.25746232673813	22.9147099007409	2.55132727247997e-08	1.29609723390225e-06	-1.06886542337082	-0.640537876244825
GAB2	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.76902805658	-1.76902805658	-3.04252181631382	-2.93942386342	-12.9738824105399	123.495280887614	8.16466357883261e-25	2.08324307165192e-22	-1.46778428170259	-1.07920323776506
GAB2	BRD-K09397065-003-06-1::2.5::HTS002	2.5	SR-57227A	serotonin receptor agonist	noncancer	HTR3A	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.2534926206035	-0.2534926206035	0.250409851545426	0.2503216696235	12.6753174224613	7.1749814292578	3.58763487411854e-06	0.000134241304981661	0.410360478198887	0.597444466098965
GAB2	BRD-K12244279-001-05-8::2.5::HTS002	2.5	MEK1-2-inhibitor	MEK inhibitor	noncancer	MAP2K2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.420442888179	-0.420442888179	-0.152754481389405	-0.1558908725075	7.77451773385295	24.2738099931772	4.82488895412211e-08	2.35917407413565e-06	0.196667652666617	0.338709160912573
GAB2	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.5767606062165	-0.5767606062165	-1.65503075684609	-1.461946185705	-12.875843210299	179.995198327606	2.58622916119748e-27	7.98708803876505e-25	-1.24351573852753	-0.913024562731648
GAB2	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.10632770802315	-0.10632770802315	-0.483365156430251	-0.4134526693685	-6.09377502705428	4.81681697719991	0.00196248599822461	0.0394501652141701	-0.537922535887358	-0.216152360926845
GAB2	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.050336141944	0.050336141944	0.242819558060023	0.282942219323	6.227219165919	10.7927720799724	7.02552750751511e-05	0.00205482298738838	0.124291227001503	0.260675605230543
GAB2	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.4771232421195	-0.4771232421195	-0.192564353697634	-0.144534319806	5.22726580951417	31.3270762412585	1.08740441139562e-05	0.000371828813162113	0.173579992822812	0.39553778402092
GAB2	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.9662431942	-0.9662431942	-1.97329946851987	-1.89093805071	-12.0487343956977	14.3446443606142	6.77359951491086e-09	3.68004768170172e-07	-1.18591842068248	-0.828194127957263
GAB2	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.7202004807675	-0.7202004807675	-1.67413964496923	-1.54523819361	-8.66690923824779	4.11869815051295	0.000854447113127577	0.0192762769076621	-1.25609147801773	-0.651786850385729
GAB2	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.882078883863	0.882078883863	0.757611895497972	0.759014306598	-3.75206576577501	27.2478880950721	0.000840318208947003	0.0190003757153078	-0.192503241524527	-0.0564307352055297
GAB2	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.284212505259	0.284212505259	0.577942183906654	0.571651612309	6.89910888657754	5.0028346473592	0.000977777651157525	0.021703200724414	0.184305761989486	0.403153595305821
GAB2	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1128373431895	0.1128373431895	-0.0754690746042046	-0.0620606581655	-5.95375896382908	150.173091763717	1.78079482225151e-08	9.24826686354116e-07	-0.25080007423978	-0.125812761347629
GAB2	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2353514253975	0.2353514253975	-0.241290266873743	-0.026104548309	-8.12676596196893	17.716191186535	2.19386585700102e-07	9.85556644865168e-06	-0.600004190964486	-0.353279193577999
GAB2	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.855381786515	-5.855381786515	-4.65291890304908	-5.03947371329	8.48698997267762	13.3352389049512	9.70825181050282e-07	3.97546790655953e-05	0.897155564189899	1.50777020274193
GAB2	BRD-K39558284-001-01-2::2.5::HTS002	2.5	SDZ-WAG-994	adenosine receptor agonist	noncancer	ADORA1	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.4449691935835	0.4449691935835	0.295095267282032	0.325539232433	-4.47263027679654	11.4443100546954	0.000855594824263522	0.0192847600262463	-0.223279164460728	-0.0764686881422084
GAB2	BRD-K40175214-001-11-6::2.5::HTS002	2.5	torin-1	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-3.347468439395	-3.347468439395	-3.73325288864665	-3.718490926125	-5.13054214883671	67.1121817308983	2.66065785183974e-06	0.000101740613153784	-0.535867091938648	-0.23570180656465
GAB2	BRD-K41783120-001-02-8::2.5::HTS002	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.7823990552495	0.7823990552495	-0.289355650018454	-0.180532347642	-15.8149581473819	28.8534147714146	9.43529263865435e-16	1.04888840038908e-13	-1.21038727625305	-0.933122134282861
GAB2	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.937150276905	0.937150276905	-0.548227003043293	-0.407422571936	-22.5208308613838	190.353864077141	1.41042617733778e-55	5.49627694841142e-52	-1.61547521695278	-1.35527934294381
GAB2	BRD-K43644456-001-04-0::2.37833::HTS002	2.37833	WP1130	deubiquitinase inhibitor	targeted cancer	JAK2, UCHL5, USP14, USP9X	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.385821280545	-5.385821280545	-6.30113614543176	-6.296490539345	-10.8723308818905	10.0649003369967	6.95024942337113e-07	2.9094531419174e-05	-1.10273258385859	-0.72789714591492
GAB2	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0987665302157	-0.0987665302157	-0.263966857299146	-0.234942866008	-3.87507187778813	11.8103577238666	0.00227174271783302	0.0447518699421354	-0.258252189933119	-0.0721484642337733
GAB2	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.13368983964	-2.13368983964	-1.38220304915483	-1.257861831055	8.19312908051804	4.33006988954416	0.000855089024501956	0.0192843636909359	0.504302886193039	0.998670694777305
GAB2	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.492348183005	-5.492348183005	-4.58057898291016	-4.6036621232	7.77978005420394	9.64815475355527	1.85260714991298e-05	0.000608066520419141	0.649340764178707	1.17419763601098
GAB2	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.0746480436391	0.0746480436391	-0.296659956550968	-0.406253558846	-4.95739650878727	23.3110345073442	5.00199241859013e-05	0.00150783689603939	-0.526135723549981	-0.216480276830156
GAB2	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.133377768494	0.133377768494	-0.125379929025564	-0.007473093877485	-5.83192129649499	26.086425670246	3.75466836752804e-06	0.0001398079076692	-0.34994519591858	-0.167570199120549
GAB2	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.194688122258	-0.194688122258	-0.708960483977058	-0.5410189846345	-7.48017970334596	192.981337257028	2.54940453667835e-12	2.03884822739453e-10	-0.649872885788046	-0.378671837650069
GAB2	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.3198750501165	0.3198750501165	-0.75968887261298	-0.674815903064	-12.1199698543928	5.93130770589158	2.08392248590705e-05	0.000676529873495868	-1.29813141106218	-0.860996434396781
GAB2	BRD-K65928735-001-04-3::2.5::HTS002	2.5	AZD1480	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.318593080912	-0.318593080912	-0.0207552639933624	-0.05528360346055	9.60043254172824	195.43250611639	4.00231058173259e-18	5.56658809002053e-16	0.23665423696549	0.359021396871786
GAB2	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.7578126859715	-0.7578126859715	-2.64585510451585	-2.62453052692	-14.2694621195955	173.175435201274	4.78835111312602e-31	2.08170893656224e-28	-2.14919714085884	-1.62688769622986
GAB2	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.6284764039505	-0.6284764039505	-1.18237207759693	-1.01733335597	-9.03544161440243	28.1617622692392	8.16060908317231e-10	4.90618564989408e-08	-0.679435781555907	-0.428355565736954
GAB2	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.05383799316965	-0.05383799316965	-0.262790301912822	-0.236194067289	-4.89905498076304	69.8111025805096	6.00858956458257e-06	0.000215895220919936	-0.29402219807965	-0.123882419406694
GAB2	BRD-K69608737-001-10-2::2.5::HTS002	2.5	tacrolimus	calcineurin inhibitor	noncancer	FKBP1A	transplant	organ rejection	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.8718209599455	0.8718209599455	0.298727987012115	0.3216320959495	-18.2029344907623	10.4383141714177	3.02145553988285e-09	1.70866898260568e-07	-0.642845454867384	-0.503340490999386
GAB2	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.5091440835275	0.5091440835275	-0.158236125582068	0.0566391407425	-9.29554782014567	15.7771709265415	8.465555654579e-08	4.01774596521316e-06	-0.819755149770326	-0.51500526844881
GAB2	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.14218289253	0.14218289253	-0.617457363752389	-0.443084865138	-11.6853708758624	6.54167830022515	1.26664211140232e-05	0.000428334075567606	-0.915569700679459	-0.603710811885318
GAB2	BRD-K72726508-001-02-1::2.5::HTS002	2.5	arcyriaflavin-a	CDK inhibitor	targeted cancer	CCND1, CDK4	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.682859472418	-0.682859472418	-0.491798033002488	-0.3795984420275	3.67305492553237	52.3071722347324	0.000564177450404416	0.0133377000626217	0.0866962036500946	0.295426675180929
GAB2	BRD-K73589491-001-11-2::2.5::HTS002	2.5	nizatidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.312527914251	0.312527914251	0.0934575302467637	0.09689104741345	-9.03375161357635	149.263614356528	7.91323535178692e-16	8.8704802286252e-14	-0.266988427915088	-0.171152340093384
GAB2	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2024203721885	0.2024203721885	0.00016430148498399	0.03094358609725	-7.49371106781124	178.500984232714	2.99513634965594e-12	2.37933498400819e-10	-0.255516810780634	-0.148995330626398
GAB2	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2713250077275	0.2713250077275	0.0935185911671383	0.1896034324075	-3.92334013961795	71.7587196159215	0.00019798780626797	0.00523495293974929	-0.268155701480841	-0.0874571316398824
GAB2	BRD-K79239947-001-06-8::2.5::HTS002	2.5	PF-573228	focal adhesion kinase inhibitor	targeted cancer	CDK1, CDK2, CDK7, GSK3B, IKBKB	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2115281886145	0.2115281886145	-0.238526404652207	-0.1830123326315	-8.16626021533587	10.5355380917487	7.0751041736799e-06	0.00025035496160486	-0.572009750424392	-0.328099436109022
GAB2	BRD-K84892605-001-01-1::2.5::HTS002	2.5	IOWH032	CFTR channel antagonist	noncancer	CFTR	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.00917652106234	-0.00917652106234	0.119121934630372	0.126672721217	4.70127566892627	28.2134248534859	6.17215134649396e-05	0.00182817996951728	0.0724161897451364	0.184180721640287
GAB2	BRD-K89704198-001-12-3::2.5::HTS002	2.5	vincamine	adrenergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	NA	NA	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.177996365936	0.177996365936	-0.1973002709169	-0.1128406004625	-6.41666376458247	5.37470237266816	0.00103835483879453	0.0228513763470574	-0.522545749472829	-0.228047524232972
GAB2	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	NCIH1435, NCIH650	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.48412144145	-4.48412144145	-5.62849627874556	-5.62740406384	-8.03306352249047	3.50845788144534	0.00222478277875818	0.043939869903102	-1.56274458385907	-0.726005090732044
GATAD2A	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	PLCPRF5, MKN7	LIVER, STOMACH	carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	0.1552200532775	0.1552200532775	-0.0841052080042121	-0.0709548517643	-5.28713236642773	25.6417031562162	1.64489253477754e-05	0.000546078333467061	-0.332433369417962	-0.146217153145462
GATAD2A	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	PLCPRF5, MKN7	LIVER, STOMACH	carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	0.386536551909	0.386536551909	0.18302094305744	0.1739425463755	-6.86013151354963	40.558813934058	2.74116117997926e-08	1.38531085721239e-06	-0.263447977192298	-0.143583240510822
GATAD2A	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.86358592876333	-1.88154327841	-2.32664990382151	-2.47311039932	-4.8227105960133	8.55198315914645	0.00109039888600168	0.0238327659430811	-0.682017336376413	-0.244110613739939
GATAD2A	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-3.55360979719667	-3.57170574901	-2.33834178555043	-2.267592635	8.62841965575011	5.4428476765971	0.000224021071033975	0.00584256657746908	0.861898296946446	1.56863772634603
GATAD2A	BRD-K17979676-001-01-2::2.5::HTS002	2.5	eprobemide	monoamine oxidase inhibitor	noncancer	MAOA	neurology/psychiatry	depression	SKUT1, PLCPRF5	SOFT_TISSUE, LIVER	leiomyosarcoma, carcinoma (hepatocellular_carcinoma)	0.3184271182785	0.3184271182785	-0.0492671544475132	-0.01607222471295	-7.618678248078	131.4103065558	4.49405322066267e-12	3.50639218322319e-10	-0.463165663704468	-0.272222881747558
GATAD2A	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	PLCPRF5, MKN7	LIVER, STOMACH	carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	0.549123489346	0.549123489346	0.411471753816464	0.440703373362	-4.72090319690433	22.0066052287115	0.000103701397665587	0.00292912715607112	-0.198120516047593	-0.0771829550114782
GATAD2A	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.13724536963333	-1.1868117309	-0.769165734652395	-0.736880055036	4.25749938587763	8.55990123961753	0.0023748183176578	0.0464578710483096	0.170962594235845	0.565196675726031
GATAD2A	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.748461122285333	-0.761380150287	-0.232433581801846	-0.1084343968805	11.1749632686667	19.5278529488183	6.24130108775635e-10	3.78949524316638e-08	0.419554251312987	0.612500829653988
GATAD2A	BRD-K32107296-001-16-9::2.5::HTS002	2.5	temozolomide	DNA alkylating agent	chemo	MGMT	oncology	glioblastoma, astrocytoma	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.0793957745904733	-0.115608001969	0.230544769705181	0.242322193572	6.34185941482192	4.48720184903367	0.00212650738358997	0.0422951188768981	0.179867013167205	0.440014075424105
GATAD2A	BRD-K32744045-001-31-2::2.5::HTS002	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.786303472467667	-0.782945082791	-1.28353432223682	-1.11429432905	-5.07504147259814	177.05094898522	9.7365669931705e-07	3.9847788181769e-05	-0.690581359893558	-0.303880339644746
GATAD2A	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	0.0194969295801767	0.0157442345129	0.17331609984737	0.172164765027	5.46723896450488	31.1276397117574	5.55325719621216e-06	0.000200746173318765	0.0964475906920412	0.211190749842346
GATAD2A	BRD-K37720887-001-07-8::2.5::HTS002	2.5	SB-525334	TGF beta receptor inhibitor	noncancer	TGFBR1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.267326564861	0.267326564861	0.0268248048463212	0.0896615671228	-5.3141837089924	34.4408672567969	6.47771927251544e-06	0.000231124204088391	-0.332430842956494	-0.148572677072864
GATAD2A	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.27786831423333	-1.28463895004	-1.74715925905645	-1.663354948005	-4.70967205539684	11.2520055623949	0.000601933116782312	0.0141212481377885	-0.68800829397695	-0.250573595669276
GATAD2A	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.57202862952	-1.57765229068	-1.32563345521142	-1.43413063966	3.59256309588857	26.1646418479182	0.00133064682356749	0.0283873449330558	0.105460288682097	0.387330059935055
GATAD2A	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	0.205696662508667	0.222541885684	-0.499641273062363	-0.003081886328155	-7.41626744285684	90.2322162273309	6.3210667844844e-11	4.28323718890849e-09	-0.894277695479397	-0.516398175662661
GATAD2A	BRD-K63784565-001-06-2::2.50835::HTS002	2.50835	10-hydroxycamptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-6.57001599728667	-6.5529827824	-5.70549979319323	-5.75839630669	7.17445864514991	12.7992088449392	7.86961031737225e-06	0.000276460532652365	0.603777857463425	1.12525455072346
GATAD2A	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.337503576449333	-0.287549693122	-1.08970691978565	-0.419546538883	-4.66559816585139	7.96894948005939	0.00162852566329219	0.033704159606774	-1.12423734742901	-0.380169339243618
GATAD2A	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	0.0610664825963333	0.0738410191856	-0.266145851828223	-0.237535556899	-7.61972338551026	98.1065569993001	1.61956202657899e-11	1.18107897106039e-09	-0.412429786658892	-0.24199488219022
GATAD2A	BRD-K71106091-001-06-1::2.5::HTS002	2.5	fludarabine-phosphate	ribonucleotide reductase inhibitor	chemo	DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.398387567954667	-0.412798322168	-0.199023787441086	-0.205957319551	5.55200251784873	8.31131419483648	0.000471773133583119	0.0113842224665319	0.117095537856262	0.2816320231709
GATAD2A	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-2.00438965286667	-2.10046070672	-2.93981691000674	-2.876359099605	-6.01641313502923	5.51331990885159	0.00129210339778958	0.0276548061858241	-1.32416207715181	-0.546692437128341
GATAD2A	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-2.83107129232667	-2.78985178407	-2.22342680837934	-2.159637620435	6.89978437718154	10.5983196411814	3.12899485585193e-05	0.000979886526095687	0.412909863106679	0.802379104787977
GATAD2A	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	SKUT1, PLCPRF5, MKN7	SOFT_TISSUE, LIVER, STOMACH	leiomyosarcoma, carcinoma (hepatocellular_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.71441976033667	-1.70346314404	-1.0013332571191	-0.950796991811	9.10792822751649	6.38458995160266	6.86344988302913e-05	0.00201181120073817	0.5242734338059	0.901899572629233
GLB1	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.1782425935805	0.1782425935805	-0.180674975502304	-0.1596607583295	-7.14346224729735	13.657802913186	5.730070075385e-06	0.000206635917114185	-0.466934524078874	-0.250900614086735
GLB1	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.213536050195	0.213536050195	0.0886036148133489	0.1234730068455	-4.7653712333302	191.881938508004	3.71395451495795e-06	0.000138580412094124	-0.176642416986017	-0.0732224537772847
GLB1	BRD-A59303141-001-10-4::2.5::HTS002	2.5	quinethazone	thiazide diuretic	noncancer	CA1, CA2, SLC12A1, SLC12A2, SLC12A3	cardiology	hypertension	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.629146923083	0.629146923083	0.360524516417261	0.3935946417985	-7.64148915098112	16.8392771785194	7.20290010133149e-07	3.00875146329814e-05	-0.342843028712777	-0.194401784618701
GLB1	BRD-A64553394-001-04-4::2.6791::HTS002	2.6791	DPI-201106	sodium channel activator	noncancer	ADRB2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.321074182339	-0.321074182339	-1.66237463355106	-1.51643544753	-13.1074428886453	21.5095213746105	9.94955477543379e-12	7.46143500862123e-10	-1.5538033138808	-1.12879758854331
GLB1	BRD-A74765037-001-01-1::2.5::HTS002	2.5	estradiol-benzoate	contraceptive agent	noncancer	ESR1	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.677540088296	0.677540088296	0.0228981418493893	0.0102513278737	-22.687461902648	59.8070342912434	4.49612621595682e-31	1.96262777136418e-28	-0.71236395035095	-0.596919942542272
GLB1	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-1.366576985435	-1.366576985435	-2.36672373900119	-2.31691828506	-12.194437281846	69.9272828369701	5.61880998693906e-19	8.40386549679457e-17	-1.16372677170306	-0.836566735429317
GLB1	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.6974397842475	0.6974397842475	0.145417689803217	0.177485579355	-11.3221108750787	15.6555944123888	6.02262829575542e-09	3.29039994902106e-07	-0.655565536061813	-0.448478652826753
GLB1	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.847796844003	-0.847796844003	-0.178463189056422	-0.1257743846785	11.7384636130699	7.20741321210339	5.87388054492388e-06	0.000211587049296301	0.53528408559392	0.803383224299236
GLB1	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.438702351356	0.438702351356	0.219922396400198	0.209209067771	-7.91988711316451	132.766486394961	8.41210154359327e-13	7.06211246273718e-11	-0.273420287291263	-0.164139622620341
GLB1	BRD-K00662280-001-09-4::2.5::HTS002	2.5	CL-218872	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.625342533582	0.625342533582	0.182547482193337	0.188771787503	-13.5598813991072	8.00517301153195	8.35492498038938e-07	3.45295548808692e-05	-0.518088658147305	-0.367501444630021
GLB1	BRD-K03406345-001-27-8::2.5::HTS002	2.5	azacitidine	DNA methyltransferase inhibitor	chemo	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.347344618772	-0.347344618772	-0.585736542795018	-0.567938192977	-5.50727567537087	95.1142570806761	3.09228320318298e-07	1.36007791228197e-05	-0.324325605510569	-0.152458242535467
GLB1	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.178813767436	-0.178813767436	-1.26841087490194	-0.9430769633885	-9.48378031264178	9.77937626419738	3.04115754674271e-06	0.000115201176358398	-1.34637427758173	-0.832819937350149
GLB1	BRD-K13514097-001-05-3::2.5::HTS002	2.5	everolimus	mTOR inhibitor	targeted cancer	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.1374650667525	-0.1374650667525	-0.752961708985271	-0.7206768922275	-9.40005089071163	14.0710726872528	1.91665554741722e-07	8.66838714543967e-06	-0.755866491443683	-0.475126793021858
GLB1	BRD-K14560436-001-01-4::2.5::HTS002	2.5	TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-1.895453887475	-1.895453887475	-3.75627831234379	-3.62828968956	-13.240193359015	9.26326954495451	2.49882029963309e-07	1.11229419730023e-05	-2.1773840617686	-1.54426478796899
GLB1	BRD-K18518344-001-15-9::2.5::HTS002	2.5	digitoxigenin	ATPase inhibitor	noncancer	ATP1A1	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-5.066580057485	-5.066580057485	-4.12164455413341	-4.32290694066	7.28181754910442	172.883750576441	1.11354932570477e-11	8.28413444737858e-10	0.688805020438476	1.2010659862647
GLB1	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.093265481199	0.093265481199	0.310954886429742	0.322928237233	7.24742185113634	167.236324019963	1.49188196867816e-11	1.09467158666492e-09	0.158389222808722	0.276989587652761
GLB1	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.356673284119	-0.356673284119	-0.94693258077847	-0.900132875838	-9.46962204121613	7.13713004189413	2.70320402876805e-05	0.000858079111791806	-0.737078616546168	-0.443439976772772
GLB1	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.7137582182975	0.7137582182975	0.0844855866142506	0.0863678330512	-25.2339798731876	164.678923182947	1.80372658161504e-58	9.42904669538952e-55	-0.678511099036254	-0.580034164330245
GLB1	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-3.48365200618	-3.48365200618	-3.07953089230078	-2.8750109584	3.90768666501861	61.8100930480501	0.000233727253959982	0.00607353644689489	0.19738090157786	0.610861326180578
GLB1	BRD-K26756394-001-02-2::2.5::HTS002	2.5	VE-821	ATR kinase inhibitor	targeted cancer	ATR	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.3099262987305	-0.3099262987305	-0.113148672460962	-0.0474319307103	4.25880296600094	11.7965025434063	0.00115247594060488	0.0250643344367228	0.095912817159002	0.297642435380074
GLB1	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.1955885641735	-0.1955885641735	-1.34756042616185	-1.265409369745	-12.5558116445289	2.82925159710736	0.00144479077601168	0.0304424461494108	-1.45418174602092	-0.849761977955783
GLB1	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	1.024133954115	1.024133954115	0.569766256294985	0.566004994618	-14.1100308898713	153.159259824292	1.70127728486812e-29	6.62969198524544e-27	-0.517984637412716	-0.390750758227314
GLB1	BRD-K37723606-001-01-5::2.5::HTS002	2.5	dioscin	apoptosis stimulant	targeted cancer	CXCR3	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.378049809066	-0.378049809066	-1.01271653786465	-0.8558575413485	-8.51249869914862	186.291262814252	5.56601487074663e-15	5.76586950813076e-13	-0.781751365214014	-0.487582092383279
GLB1	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-3.309954052215	-3.309954052215	-2.98757289194372	-3.07991378512	3.41033824628516	190.036198880351	0.000792429442905856	0.0180451136919432	0.135917208116598	0.508845112425967
GLB1	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.06485332341475	0.06485332341475	-0.207672574132922	-0.158031671069	-6.61753640528505	9.27523202447453	8.46161333277057e-05	0.00243651484646647	-0.365267210855302	-0.179784584240042
GLB1	BRD-K45662124-050-01-5::2.5::HTS002	2.5	3'-fluorobenzylspiperone	dopamine receptor ligand	noncancer	DRD2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.7349857315235	0.7349857315235	0.506483995608395	0.5255641700865	-6.81058271768785	28.3055321884836	2.01108874091876e-07	9.08206149920727e-06	-0.297194401013466	-0.159809070816743
GLB1	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.549419581054	0.549419581054	0.369305475123089	0.3732554744945	-4.89726344955397	76.0668770765331	5.33449561106412e-06	0.000193490795367027	-0.253363837075412	-0.10686437478641
GLB1	BRD-K52313696-001-12-3::0.15625::HTS002	0.15625	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.04538255665555	-0.04538255665555	0.421730701137899	0.39525647476	12.9036987321359	12.1015884504016	1.95370784678316e-08	1.00754631639362e-06	0.388313712334953	0.545912803251945
GLB1	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.00308734829045	-0.00308734829045	-0.710915593915502	-0.5410189846345	-10.3271732191352	194.864100010677	3.21675841334093e-20	5.45446688269738e-18	-0.843004424359538	-0.572652066890565
GLB1	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.8627110194815	0.8627110194815	-0.241979730849367	-0.1756829862115	-12.4003998461706	2.66100178858471	0.00198405235158772	0.0398239329896465	-1.40976847495814	-0.799613025703595
GLB1	BRD-K62814476-001-03-3::2.5::HTS002	2.5	BMS-265246	CDK inhibitor	targeted cancer	CDK1, CDK2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-1.333016497435	-1.333016497435	-2.54943320508383	-2.46335728498	-9.62003507427774	3.27937882279392	0.0016323536601108	0.0337768611332195	-1.60010907077162	-0.832724344526036
GLB1	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.997250192178	0.997250192178	-0.73085366357523	-0.5340799664045	-16.6843250221079	78.9057526313901	1.34248924801942e-27	4.32033600658791e-25	-1.93427153477506	-1.5219361767314
GLB1	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.133966809734	0.133966809734	-1.09072148057836	-0.4202572111255	-10.3881447800663	99.1815966875148	1.5283119668287e-17	2.0182475387457e-15	-1.45860803994214	-0.990768540682586
GLB1	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.9860642726325	-0.9860642726325	-1.17862770200864	-1.01733335597	-3.42734028890457	185.493431479773	0.000750746084292384	0.0171982318833158	-0.303406216219005	-0.0817206425332688
GLB1	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.1257834134065	-0.1257834134065	-0.272691232220744	-0.224936831672	-3.94062651660995	12.5184437843755	0.00181268872009891	0.0369063533592405	-0.227763128412433	-0.0660525092160544
GLB1	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.2255552192625	0.2255552192625	-0.0103630631967495	-0.0198550434605	-4.62371494567943	165.622145200785	7.5551734867459e-06	0.000265967571156575	-0.336658682995374	-0.135177881923125
GLB1	BRD-K68567222-001-01-2::2.5::HTS002	2.5	BVT-948	tyrosine phosphatase inhibitor	noncancer	PTPN1, PTPN11, PTPN2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.6403597360205	0.6403597360205	0.334347005460727	0.3580438734455	-9.17488998626589	27.4473849226904	7.48115380570517e-10	4.51542724309485e-08	-0.374395864444223	-0.237629596675324
GLB1	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.07080640723805	0.07080640723805	-0.15367010812072	0.0566391407425	-3.54017162666672	174.882268652726	0.000512467194532248	0.0122517101323929	-0.349620652837461	-0.0993323778800782
GLB1	BRD-K72827473-001-01-0::2.5::HTS002	2.5	CEP-37440	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.2921117326595	0.2921117326595	-0.23665928220408	-0.1997036713495	-12.0152021435687	59.5876548833013	1.45775412415843e-17	1.93101967661775e-15	-0.616813651110692	-0.440728378616469
GLB1	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.0780625219863	0.0780625219863	-0.156460516413701	-0.1366984748555	-5.53942965544485	126.87105117371	1.6752893394028e-07	7.64777611980537e-06	-0.31830121330723	-0.150744863492773
GLB1	BRD-K75478907-001-02-3::2.5::HTS002	2.5	GS-39783	GABA receptor modulator	noncancer	GABBR1	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.11230825418375	0.11230825418375	0.482728578754611	0.491150994227	10.1181124584844	3.11401306473945	0.00174924845926654	0.0358016303500896	0.256288565841071	0.484552083300652
GLB1	BRD-K77677632-003-02-6::2.5::HTS002	2.5	SB-200646	serotonin receptor antagonist	noncancer	HTR2B, HTR2C	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.360461915898	0.360461915898	-0.621289912608059	-0.496261939988	-9.6563399396545	3.3541217042221	0.00146054388646107	0.0307441475782081	-1.286815930136	-0.676687726876113
GLB1	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.5638020657255	0.5638020657255	0.279620029655095	0.273644438403	-7.01125802855267	7.64601792208197	0.000138371431973505	0.00379294163492127	-0.37840815461796	-0.18995591752285
GLB1	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.3156265420255	-0.3156265420255	-0.7782960157601	-0.670066066219	-8.53165264307745	25.908949744757	5.33386450206901e-09	2.93806693617052e-07	-0.574159410299309	-0.351179537169892
GLB1	BRD-K81473043-001-14-6::2.5::HTS002	2.5	tanespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-3.932996143785	-3.932996143785	-4.83911176090007	-4.75693780059	-9.01518337112445	190.971475182909	2.06191391090781e-16	2.46474036035114e-14	-1.10436785909579	-0.707863375134353
GLB1	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.09719117656315	0.09719117656315	-0.153960663040971	-0.140788868193	-6.90405004746265	180.907076212978	8.26273108684333e-11	5.53592651176006e-09	-0.322930539174112	-0.17937314003413
GLB1	BRD-K88506063-001-01-8::2.5::HTS002	2.5	KD025	rho associated kinase inhibitor	targeted cancer	ROCK2	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.5074017326385	-0.5074017326385	-1.0201147641634	-0.939621254458	-6.79760947538907	6.01387931617028	0.000491492227541072	0.0118029173822578	-0.697169358905384	-0.328256704144411
GLB1	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.374115538872	0.374115538872	-0.0936448843611651	0.0692106615383	-7.04817087764693	6.26041912286894	0.000337728440104045	0.00843549689302645	-0.628529206165388	-0.306991640300943
GLB1	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	MKN1, BT474	STOMACH, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.2712068284025	0.2712068284025	-0.246463411524536	-0.195507988981	-11.4943449901678	95.6580195366576	1.00935168632958e-19	1.62412415600099e-17	-0.607071957916112	-0.42826852193796
GLCE	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.95633429356	-3.95633429356	-3.71595999516977	-3.697322932235	3.27096197495264	187.975947945231	0.00127506924550766	0.0273475749344952	0.0954084420697591	0.385340154710709
GLCE	BRD-A54927599-001-16-9::2.5::HTS002	2.5	KF-38789	P selectin inhibitor	noncancer	SELP	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.62957958222	-3.62957958222	-2.93386381630505	-2.70844162047	7.30721686961798	189.081761548958	7.43862298575426e-12	5.64558295295229e-10	0.50790668663176	0.883524845198145
GLCE	BRD-A57382968-001-29-0::2.5::HTS002	2.5	piroxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.2369580275325	0.2369580275325	0.0175916808225694	0.00421329680347	-6.97734689492031	6.16395982772438	0.000382915544891217	0.0094452647969835	-0.295803426858067	-0.142929266561794
GLCE	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.6765522237055	-0.6765522237055	0.256840677243481	0.2649123832205	23.6195302012174	7.16149876844427	4.66151550288954e-08	2.28469690422779e-06	0.84037353936056	1.0264122625374
GLCE	BRD-A70858459-001-01-7::2.5::HTS002	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.193833114339	-0.193833114339	0.103301007881787	0.0978091979841	10.223157815053	187.803706583305	8.72260207532469e-20	1.40882183888641e-17	0.239798670983637	0.354469573457936
GLCE	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.4112929767185	0.4112929767185	0.0634057156310088	0.06410268662525	-9.77279157874775	5.86702117306801	7.56247694045181e-05	0.00219792485552893	-0.435472094142573	-0.26030242803241
GLCE	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-5.79667858994	-5.79667858994	-2.99283831745658	-2.85234115214	18.470718732151	4.17987307264638	3.63747314224086e-05	0.00112628717293173	2.3894354828529	3.21824506211395
GLCE	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-4.055268989995	-4.055268989995	-3.06236799169992	-3.06417251019	7.79333400678141	4.81492666637623	0.00066043482785707	0.0153228444467771	0.66157614714367	1.32422584944649
GLCE	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.762976014745	-1.762976014745	-0.839057686643014	-0.6898846907305	14.8491767662223	10.086596192452	3.49243470592312e-08	1.74076753043208e-06	0.785444309573999	1.06239234662997
GLCE	BRD-K07972848-001-02-0::2.5::HTS002	2.5	GSK2126458	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-5.77195804246	-5.77195804246	-3.84261076372054	-3.81318527776	22.3760063274812	165.86327014308	5.69113014671275e-52	1.74253461887828e-48	1.75910935600986	2.09958520146906
GLCE	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.76504877166	-1.76504877166	-1.48883154892854	-1.38645123972	3.71156533701819	30.0769201921649	0.000835676742709692	0.0189113885110575	0.12424621214599	0.428188233316921
GLCE	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.143562643437	0.143562643437	-0.258564200574256	-0.1509093731905	-6.4184224847266	12.176290035623	3.09343242893148e-05	0.000970025280264017	-0.538414895091546	-0.265838792930966
GLCE	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.6736086481715	-0.6736086481715	-0.0481786172638107	-0.0356049990197	10.9931061752447	7.27017270076526	8.64211105134188e-06	0.000300983916074594	0.491906489624304	0.758953572191075
GLCE	BRD-K15071410-001-01-1::2.5::HTS002	2.5	tiotidine	histamine receptor antagonist	noncancer	HRH2	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.498673437998	0.498673437998	0.377350287909023	0.358823468762	-3.92232821790112	44.0577724169855	0.00030321502953986	0.0076474198712931	-0.183659006151358	-0.0589872940265974
GLCE	BRD-K15567136-003-27-2::2.5::HTS002	2.5	papaverine	phosphodiesterase inhibitor	noncancer	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.30955802615	-1.30955802615	-0.512872609856269	-0.4889366454155	20.2591018498963	8.64734080926594	1.37237402461466e-08	7.23946719964647e-07	0.707170393029335	0.886200439558127
GLCE	BRD-K16478699-001-09-2::2.5::HTS002	2.5	PLX-4720	RAF inhibitor	targeted cancer	BRAF, KDR	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.2252292743	-1.2252292743	-1.51274996020698	-1.41373612569	-3.23016367269743	53.758353676254	0.00211272803301214	0.0420561796774829	-0.465995734073652	-0.109045637740308
GLCE	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.274470665901	0.274470665901	0.0976271466381182	0.13724327771	-7.74105069235515	144.578302145787	1.56472106704378e-12	1.27418351663536e-10	-0.221996646078215	-0.131690392447548
GLCE	BRD-K25224017-001-25-0::2.5::HTS002	2.5	pirenperone	serotonin receptor antagonist	noncancer	HTR2A, HTR7	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-2.13757228763	-2.13757228763	-2.55510170266502	-2.47770840728	-4.03281647413899	22.0625270461127	0.000554218975045191	0.0131312401837785	-0.632208350452546	-0.202850479617489
GLCE	BRD-K26997899-001-02-2::2.5::HTS002	2.5	D-64131	microtubule inhibitor	chemo	TUBB	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.95064778039	-3.95064778039	-3.00789027401307	-2.8512516893	7.51277271842669	5.61655642699509	0.000391806455857187	0.00963463582806505	0.630547416919994	1.25496759583387
GLCE	BRD-K30867024-003-03-3::2.5::HTS002	2.5	SB-216641	serotonin receptor antagonist	noncancer	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.2092115822375	-0.2092115822375	-0.0464346466538506	-0.01731915547495	4.33551363945967	75.4276414193826	4.43811644925226e-05	0.00135250541796074	0.087990375137953	0.237563496029346
GLCE	BRD-K32285926-001-02-1::2.5::HTS002	2.5	AMG-208	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.04131339304435	-0.04131339304435	0.411849722807626	0.419799796324	12.2027870089409	160.648613965072	1.18295722520226e-24	2.97235684783558e-22	0.379825360279477	0.526500871424475
GLCE	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.06372632715565	-0.06372632715565	0.165961370669978	0.1606220898175	7.27818563481808	4.98682007127176	0.000774462665720085	0.0176772959191821	0.148499786490239	0.310875609161018
GLCE	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.76305441342	-1.76305441342	-1.9707779426729	-2.04775511057	-3.09929184034727	186.97588260982	0.00223948745116982	0.0442092770248702	-0.339941796487499	-0.0755052620182976
GLCE	BRD-K37249724-001-25-7::2.5::HTS002	2.5	astemizole	histamine receptor antagonist	noncancer	HRH1, KCNH1, KCNH2	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.2087282568805	-0.2087282568805	0.0654295917647595	0.115244087444	7.01398212834973	46.280161529922	8.41835871382354e-09	4.53341307732433e-07	0.195491980835216	0.352823716455303
GLCE	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.319879309099	0.319879309099	-0.541763432699775	-0.407422571936	-10.6347078116606	9.20996510805616	1.77685011901449e-06	6.96624347943778e-05	-1.04429172725575	-0.678993756341799
GLCE	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-4.11410571161	-4.11410571161	-3.22679410979734	-3.119370710775	12.4993062005575	101.281889596692	3.02466781822841e-22	6.1042752242286e-20	0.746493534214142	1.02812966941118
GLCE	BRD-K43644456-001-04-0::2.37833::HTS002	2.37833	WP1130	deubiquitinase inhibitor	targeted cancer	JAK2, UCHL5, USP14, USP9X	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-5.145871225205	-5.145871225205	-6.30368880559495	-6.296490539345	-13.8656901560768	10.5347934403385	4.21174525377713e-08	2.07278794143926e-06	-1.34260004795796	-0.97303511282193
GLCE	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.118544062155	-1.118544062155	-0.687523017130804	-0.630288065045	7.8420142663872	32.5894724272254	5.30949878956047e-09	2.92614956561508e-07	0.31914433592229	0.542897754126101
GLCE	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-6.52789258848	-6.52789258848	-6.17779166970942	-6.268105536705	3.92343315888858	155.422404542276	0.000130736945567211	0.00361045210752156	0.173834359965936	0.526367477575222
GLCE	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-4.983683921395	-4.983683921395	-3.64661349721298	-3.66301517797	18.1799245808412	151.746113709225	6.1804708592685e-40	6.55769375641663e-37	1.19176303458901	1.48237781377503
GLCE	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.196092802821	-0.196092802821	-0.585783696760868	-0.48109263675	-4.73077557259637	24.8012019751808	7.62630238961041e-05	0.00221419218104035	-0.559411425986472	-0.219970361893263
GLCE	BRD-K60369935-001-18-3::2.5::HTS002	2.5	ribavirin	antiviral	noncancer	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.149297986457	0.149297986457	0.374575866058306	0.419717410769	6.78538676461115	14.2928930331495	7.90379679731327e-06	0.000277570516757555	0.154206655378304	0.296349103824307
GLCE	BRD-K62304154-001-04-2::2.5::HTS002	2.5	deforolimus	mTOR inhibitor	targeted cancer	MTOR	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.27420423762	-3.27420423762	-2.76110595237538	-2.75161823552	7.09353731913314	125.117325209809	8.54791216614163e-11	5.71627290688602e-09	0.369943208407618	0.65625336208162
GLCE	BRD-K62696033-001-01-4::2.5::HTS002	2.5	G-1	G protein-coupled receptor agonist	targeted cancer	GPER1	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-2.581057137365	-2.581057137365	-1.23290932798022	-1.15205900339	14.4225207200037	7.02854000837222	1.76905091469452e-06	6.93794901181266e-05	1.12729593199661	1.56899968677295
GLCE	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.622263828345	-0.622263828345	-0.166146065453751	-0.0695637223616	7.66426337756709	9.54371807419334	2.23571158035528e-05	0.000721870785335895	0.322651773765155	0.589583752017343
GLCE	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.899524474593	-0.899524474593	-0.208373759204486	-0.1907303952045	9.88823576287564	4.43651903611761	0.000345501028092441	0.00861357332209198	0.504390947480176	0.877910483296851
GLCE	BRD-K66094457-001-01-5::2.5::HTS002	2.5	CPP	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.6109478622025	-0.6109478622025	-0.916293996537474	-0.865994083482	-5.09528235971916	156.010578006922	9.94310553002875e-07	4.05923021932482e-05	-0.42371957125519	-0.186972697414757
GLCE	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-3.805351297825	-3.805351297825	-3.09757530423087	-3.15624915805	6.1651047115144	7.95156713616928	0.00027625625185048	0.00702619273796863	0.44275755805174	0.972794429136519
GLCE	BRD-K69280563-001-01-8::2.5::HTS002	2.5	vinorelbine	tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-4.017008428435	-4.017008428435	-3.35862190387026	-3.520745955955	6.26431424822947	19.755224084665	4.30782853960145e-06	0.000158969108654311	0.438975128740316	0.877797920389174
GLCE	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.649500206426	-0.649500206426	-0.189010413710829	-0.131154903569	9.02776126216469	11.3612718964943	1.60515606524471e-06	6.35447902304826e-05	0.34865554152044	0.572324043909902
GLCE	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.10605034937	-1.10605034937	-0.611555606332271	-0.517259346977	7.96401746195561	11.3151204403746	5.71333496263567e-06	0.000206150398856354	0.358296034114358	0.630693451961099
GLCE	BRD-K81473043-001-14-6::2.5::HTS002	2.5	tanespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-5.866760594205	-5.866760594205	-4.8188629184873	-4.73895662772	8.60983270108257	9.42309460425772	9.10251090304331e-06	0.000315835264494847	0.774444803298643	1.32135054813676
GLCE	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.08196717069955	0.08196717069955	-0.104792354634126	-0.0756772814281	-6.06196936505077	170.108418217828	8.42336510090577e-09	4.53496965263007e-07	-0.247575526977459	-0.125943523689893
GLCE	BRD-K82967180-001-01-6::2.5::MTS006	2.5	LY3023414	PI3K inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-4.35278183015	-4.35278183015	-3.36678712882764	-3.47125881494	14.3736782771783	20.9084486411803	2.617754905707e-12	2.0896118852338e-10	0.84330088108956	1.12868852155515
GLCE	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.292928453708	0.292928453708	0.0401478260297375	0.0562766217073	-8.12544373754011	18.08103790352	1.89999094130162e-07	8.60573031399481e-06	-0.318118822984301	-0.187442432372224
GLCE	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.41454886493	-0.41454886493	-0.0459235310349603	-0.0538286289263	6.43373720767917	5.51019518419302	0.000931324234824151	0.0207970193712883	0.225350839971845	0.511899827818235
GLCE	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.601643369815	-1.601643369815	-0.770108071549794	-0.768623385632	12.3169885403113	4.02407538403379	0.000241065843200785	0.00624492186957543	0.644535459991756	1.01853513653866
GLCE	BRD-K89391146-001-08-0::2.5::HTS002	2.5	RG108	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3B	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	0.6056665052285	0.6056665052285	0.377920441466331	0.397149460871	-8.98282128654509	189.997537807199	2.60759823374627e-16	3.08094774994821e-14	-0.277756584075904	-0.177735543448433
GLCE	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-5.65027317107	-5.65027317107	-5.21388018965109	-5.34898111958	4.9606617181016	192.877220180515	1.53717294931334e-06	6.10677925956218e-05	0.262884847585427	0.609901115252395
GLCE	BRD-K94455792-001-01-8::2.5::HTS002	2.5	ICG-001	beta-catenin inhibitor	targeted cancer	CTNNB1	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.01042575588	-1.01042575588	-0.664754930122706	-0.6707896523965	6.91706087084031	188.771814907245	6.94628879884518e-11	4.68615401941356e-09	0.247092268506634	0.444249383007954
GLCE	BRD-K95581532-001-01-5::2.5::HTS002	2.5	RN-1734	TRPV antagonist	noncancer	TRPV4	NA	NA	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-1.990131582075	-1.990131582075	-2.42190267168531	-2.37248540058	-4.47340758213575	15.2718366631205	0.00042798932529221	0.0104334081097082	-0.637179064434611	-0.22636311478601
GLCE	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	GI1, KYSE410	CENTRAL_NERVOUS_SYSTEM, OESOPHAGUS	glioma (gliosarcoma), carcinoma (squamous_cell_carcinoma)	-0.5854501442285	-0.5854501442285	-0.342456670676902	-0.279710660695	5.44903124343989	12.468004466296	0.000129165154640258	0.00357164732665359	0.146234705083725	0.339752242019471
GON4L	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.39085304985	-1.39085304985	-0.942738822091064	-0.8676021902365	5.56941121827261	5.38693810563477	0.00202350620787301	0.0404907162755312	0.245675042573727	0.650553412944145
GON4L	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.3656959752085	-0.3656959752085	-0.833544887876623	-0.720201208535	-5.93216266760167	5.35711478813368	0.00153067941668435	0.0319880059183444	-0.666583499985947	-0.2691143253503
GON4L	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.751057307065	-1.751057307065	-1.20665503382829	-1.08580167806	7.18901761916425	24.7591376379607	1.64919762720984e-07	7.53829981322793e-06	0.388362761569911	0.700441784903512
GON4L	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.2017166544725	-0.2017166544725	0.257162432975949	0.256070233499	11.2281464063062	2.87424930697934	0.00183865192869009	0.0373249127888064	0.325537676382282	0.592220498514616
GON4L	BRD-A28329383-001-02-1::2.5::HTS002	2.5	MTPG	glutamate receptor antagonist	noncancer	GRM2, GRM3	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.65499822827	-0.65499822827	0.0296107576718794	0.05552529169545	17.846644521383	16.7828168386119	2.39627211726476e-12	1.9250022736928e-10	0.603595220227706	0.765622751656052
GON4L	BRD-A31095847-001-02-3::2.5::HTS002	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.203858482681	0.203858482681	0.0257858521915527	0.0703858703435	-5.28472030035425	148.237007151697	4.41854565995862e-07	1.90203348614837e-05	-0.244658688605559	-0.111486572373336
GON4L	BRD-A45498368-001-07-1::2.5::HTS002	2.5	WYE-125132	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-3.56157025587	-3.56157025587	-2.32897745489425	-2.38754178221	17.2512588124378	36.5759904485747	3.71796917677301e-19	5.67974779535696e-17	1.08776581126464	1.37741979068687
GON4L	BRD-A57382968-001-29-0::2.5::HTS002	2.5	piroxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.1000267472529	-0.1000267472529	0.021157657275325	0.0121600555155	4.1158638519635	9.88094579481312	0.0021443391586998	0.0425944455556042	0.0554734550773428	0.186895353979107
GON4L	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.000203124772250001	0.000203124772250001	0.212188831001939	0.255620963174	4.48598006737861	16.9801791641102	0.000326234476493025	0.00817283508203305	0.112277167321663	0.311694245137714
GON4L	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.669343188007	-0.669343188007	-0.334941495213029	-0.225332108284	6.41759070056892	8.2787186900661	0.00017699840446643	0.0047473271218728	0.214943154116836	0.453860231471105
GON4L	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.220282066365	-1.220282066365	-1.95137927788707	-1.885064313955	-6.98201211781181	145.003535894651	9.68564387938727e-11	6.43295434467058e-09	-0.938055285218165	-0.524139137825966
GON4L	BRD-K07442505-001-03-6::2.5::HTS002	2.5	BAM7	BAX activator	targeted cancer	BAX	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.687034445238	-0.687034445238	-0.29332765824663	-0.221019719674	5.39028199420527	10.0347949571685	0.000301966712873383	0.00762041959301063	0.231039739144028	0.556373834838711
GON4L	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.5306541254195	0.5306541254195	0.254071611295583	0.2240846909	-7.35164140757805	4.03007636413408	0.00177075472298784	0.0361727114966891	-0.380730857075863	-0.17243417117197
GON4L	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.737876612944	-0.737876612944	-0.0630620808456607	-0.00125185876287	15.7401533515708	44.6995820335788	7.53091115838081e-20	1.22002468455374e-17	0.588449528477297	0.761179535719382
GON4L	BRD-K10843433-001-22-7::2.5::HTS002	2.5	phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	PTGIS, PTGS1, PTGS2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.4888100482275	0.4888100482275	0.122628761913813	0.1301341456285	-8.8915214663359	96.807153715975	3.36050954457465e-14	3.24147007281341e-12	-0.447920590004519	-0.284441982622855
GON4L	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.05542897316	-1.05542897316	-0.415268619386164	-0.37916191768	9.9922738857027	6.89135747979106	2.38707816707457e-05	0.000766586869150322	0.488183949899815	0.792136757647858
GON4L	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.729001017858	-0.729001017858	-2.11080360013709	-1.95679219665	-10.6692747302396	9.28216037062655	1.62179311518613e-06	6.41205121905052e-05	-1.67342783540752	-1.09017732915066
GON4L	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-5.066518450695	-5.066518450695	-4.26295946144714	-4.34713599697	6.20208799919343	169.953724181398	4.10126688971346e-09	2.28554454291575e-07	0.547799643871835	1.05931833462388
GON4L	BRD-K17075857-001-18-4::2.5::HTS002	2.5	chloroxine	opioid receptor antagonist	noncancer	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.607174981955	-1.607174981955	-0.664956931619313	-0.654840996033	16.4396760270939	28.9588941407137	3.18195204121765e-16	3.72669179804447e-14	0.824991220241744	1.05944488042963
GON4L	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-3.48823032439	-3.48823032439	-2.98346491411802	-2.85647744883	6.37710762145904	93.223474984163	6.85938529331477e-09	3.72476612751675e-07	0.347588762012748	0.66194205853121
GON4L	BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500	2.5	sonidegib	smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.244184038244	0.244184038244	-0.00204288351911573	0.0115719304002	-12.3990140557231	40.5401439591352	2.2337332668955e-15	2.40217670527068e-13	-0.286345975720219	-0.206107867806013
GON4L	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.679672181193	0.679672181193	0.544120291141884	0.547894384564	-5.08268480924801	61.5637198254255	3.72359941242313e-06	0.000138868163992559	-0.188870673309705	-0.082233106792527
GON4L	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.33165982314	-1.33165982314	-1.87025524588786	-1.673362994515	-4.77397369424947	9.12756634508285	0.000970867856241812	0.0215632266073006	-0.793267277984454	-0.283923567511261
GON4L	BRD-K22503835-001-11-0::2.5::HTS002	2.5	scriptaid	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.961451273475	-1.961451273475	-1.3364974519434	-1.30328750996	7.08438756001654	4.65874216177226	0.0011575673305233	0.0251571941171902	0.393099869889418	0.856807773173781
GON4L	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-3.319378071625	-3.319378071625	-2.04580147378916	-1.99105481758	14.6519656900572	180.990596999439	1.45899570901021e-32	7.23854378047337e-30	1.10206599205102	1.44508720362067
GON4L	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.385438812524	-0.385438812524	0.154228168753366	0.201815706844	10.6026233618996	7.42752533292549	9.4943791336025e-06	0.000328477931448893	0.420699310003082	0.65863465255165
GON4L	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.00321855562675	0.00321855562675	-0.403911806829436	-0.2809944464045	-5.23607234896348	6.33791733070687	0.001643366239147	0.0339817696739159	-0.594957693068504	-0.219303031843868
GON4L	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.5037541965535	-0.5037541965535	0.437016320711384	0.4313451016155	16.0214862648652	16.4136935737752	1.89740308672681e-11	1.3697154131865e-09	0.816545653038146	1.06499538149162
GON4L	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.679241705224	0.679241705224	-0.283626444894304	-0.153671266635	-13.1207193181534	3.87590392463637	0.000235296699716002	0.00610765488112282	-1.16921717712086	-0.75651912311575
GON4L	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.5659265708965	-0.5659265708965	-0.0142388575949165	-0.01606038970165	19.9753112035288	187.506692081354	2.59775175200728e-48	5.62397510359565e-45	0.497204841553111	0.606170585050056
GON4L	BRD-K36627727-001-05-4::2.5::MTS010::PROS005_PR500	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.1927982684155	0.1927982684155	-0.0806977423936073	-0.032678012842	-10.0775280179465	81.0241300940155	5.96058981089372e-16	6.77373941452302e-14	-0.327494254676714	-0.219497766941501
GON4L	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.607613134585	-1.607613134585	-0.339268274371828	-0.263302729629	19.8513456334297	3.41000377709696	0.00012073092801093	0.00336228418264742	1.07816631992554	1.4585234005008
GON4L	BRD-K40175214-001-11-6::2.5::HTS002	2.5	torin-1	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-4.474938645845	-4.474938645845	-3.72125852474824	-3.70757684528	8.05046030634667	5.50769392345333	0.000301112000105928	0.0076006399565073	0.519545186522127	0.987815055671384
GON4L	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.66042746425	-1.66042746425	-0.481411696332512	-0.306530142238	22.70854571807	192.000062364466	2.75615395030665e-56	1.15828180395152e-52	1.07660997813567	1.2814215576993
GON4L	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-2.25610510141	-2.25610510141	-1.3826379738017	-1.147333132375	8.74049317298524	4.40734991186109	0.000602487252930894	0.0141311545670196	0.605834319539276	1.14109993567733
GON4L	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.9636503673715	-0.9636503673715	-0.25476596541451	-0.219779888934	13.5316749570457	3.45272509723426	0.00041038444636815	0.0100407863020136	0.55387525031556	0.86389355359842
GON4L	BRD-K48684885-001-04-2::2.5::HTS002	2.5	BAY-11-7085	NFkB pathway inhibitor	targeted cancer	NFKBIA	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.2276798924	-1.2276798924	-1.44482178846695	-1.33433747778	-3.17520800938357	192.214099708191	0.00174415456005322	0.035745161857109	-0.352026567239065	-0.0822572248948273
GON4L	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.463541990365	-1.463541990365	-0.0954979917242665	0.0520686308404	28.1110781211976	187.879764226091	3.17282008942516e-69	4.43057634564552e-65	1.27204268078609	1.46404531649538
GON4L	BRD-K51318897-001-15-3::2.5::HTS002	2.5	fenbendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-2.345133334485	-2.345133334485	-2.75953595409208	-2.716477305745	-3.83021325979326	54.1970816599588	0.000334505092873679	0.00836180803015194	-0.631298647501919	-0.197506591712244
GON4L	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-6.45577803134	-6.45577803134	-5.91769172179042	-5.9507974936	7.12203913394049	21.8220784154382	4.02928703448835e-07	1.74322378040947e-05	0.381326364631617	0.694846254467544
GON4L	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-2.25640183052	-2.25640183052	-1.52788433912604	-1.40779088077	11.5365589680123	58.4376407948312	1.06929018243866e-16	1.29920575687016e-14	0.60213199682521	0.854902985962703
GON4L	BRD-K60997853-001-02-3::2.5::MTS010::PROS004_PR500	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.45051144117	-1.45051144117	-0.717246052260554	-0.651377728199	9.8830939812009	11.1405451889082	7.50106929470835e-07	3.12356067780366e-05	0.570216690580105	0.896314087238787
GON4L	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.033791612381	-1.033791612381	-2.08788828837556	-1.79411655002	-7.44407720905136	13.6084378625481	3.71459050096226e-06	0.000138580412094124	-1.35862477370218	-0.749568578286939
GON4L	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.7662654255705	-0.7662654255705	-0.461461795422067	-0.469747665561	4.23655973167595	18.2424404889251	0.000483357799957743	0.0116245055999936	0.153794503609957	0.455812756686908
GON4L	BRD-K61936403-001-01-7::2.5::HTS002	2.5	AS-1949490	SHIP2 phosphatase inhibitor	noncancer	INPP5D	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.174375118062	-0.174375118062	0.245984154749495	0.276762978408	10.1576349793247	17.0073531616264	1.22530212005467e-08	6.49240489713716e-07	0.333050432178821	0.507668113444169
GON4L	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.303701794027	0.303701794027	0.144026361975046	0.15713254048	-6.10895053526699	180.35794068508	6.02226564708523e-09	3.29039994902106e-07	-0.211250944144149	-0.10809991995976
GON4L	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-3.018469536055	-3.018469536055	-3.67818099566864	-3.50719189578	-4.7353903314036	7.30398380627018	0.00188814090665717	0.0381812767603477	-0.986380284727436	-0.333042634499841
GON4L	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.5146078454305	0.5146078454305	0.218304374243684	0.2281967000125	-9.52059032018962	7.25674951548579	2.34152487820082e-05	0.000752618699513233	-0.369371660293251	-0.22323528208038
GON4L	BRD-K72280606-001-01-2::2.5::MTS006	2.5	gilteritinib	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.192497111295	0.192497111295	0.0206920999339203	0.0368466353563	-6.74360597362548	190.411336199272	1.79763946141024e-10	1.15701582019398e-08	-0.222057878404627	-0.121552144317532
GON4L	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.895596956442	-0.895596956442	-1.4765582320731	-1.368540965995	-6.65180745568793	194.633250011159	2.8587502787426e-10	1.80368880922173e-08	-0.753213354572582	-0.408709196689609
GON4L	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-3.45332731349	-3.45332731349	-1.03116140547714	-0.7722654685825	19.2627613080911	4.41118373586152	1.99612622540399e-05	0.000650589625554459	2.08551337774119	2.75881843828453
GON4L	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.2562170004165	-0.2562170004165	-0.851769437056547	-0.774088070041	-6.60508123902892	184.836173122305	4.10163290730517e-10	2.54148273891243e-08	-0.773438872499257	-0.417666000780837
GON4L	BRD-K84810405-003-01-1::2.5::HTS002	2.5	almorexant	orexin receptor antagonist	noncancer	HCRTR1, HCRTR2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.523054851719	0.523054851719	0.255182308970359	0.26116496822	-9.30728251019402	102.067671932469	2.76313528332053e-15	2.9463682693473e-13	-0.324958989801119	-0.210786095696163
GON4L	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.3809407699405	-0.3809407699405	-0.0462810639603805	-0.0538286289263	5.84850823382338	5.55927223594092	0.00144074917082712	0.0303811815263879	0.191908794851171	0.477410617109068
GON4L	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.8842381528945	-0.8842381528945	-1.83684319326972	-1.72447120363	-11.6576881815105	151.780698001434	7.86790221803583e-23	1.67127811148603e-20	-1.11405024163535	-0.791159839115097
GON4L	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-3.13209744783	-3.13209744783	-2.23437760028111	-2.181327009095	10.5213815961115	185.804845037131	1.31885122554311e-20	2.31065881400213e-18	0.729392714625649	1.06604698047213
GON4L	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.9641636981065	-0.9641636981065	-1.41198928661655	-1.39259151278	-5.81092712059387	190.701951026443	2.56847369564922e-08	1.30297684383693e-06	-0.59983708947459	-0.295814087545514
GON4L	BRD-K95581532-001-01-5::2.5::HTS002	2.5	RN-1734	TRPV antagonist	noncancer	TRPV4	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-1.86226445607	-1.86226445607	-2.42327023453028	-2.37248540058	-6.70406170230239	186.827043277189	2.32993203408782e-10	1.4800592855187e-08	-0.726087818459827	-0.395923738460741
GON4L	BRD-K95763993-001-19-3::2.5::HTS002	2.5	trapidil	PDGFR tyrosine kinase receptor inhibitor	noncancer	PDGFRA	cardiology	coronary artery disease (CAD)	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.7213746714945	0.7213746714945	0.390161075353821	0.400240695615	-12.943375138348	190.445486014995	6.6807781559019e-28	2.20969830459305e-25	-0.381688711813285	-0.280738480468073
GON4L	BRD-K97472745-001-01-8::2.5::HTS002	2.5	gestrinone	progesterone receptor antagonist	noncancer	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	-0.3487804220745	-0.3487804220745	-0.158804727684271	-0.109259098298	5.01862491422969	188.01384056654	1.20172664768993e-06	4.84691137886214e-05	0.115302294311764	0.264649094468693
GON4L	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	MFE280, GCIY	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma)	0.08488669584085	0.08488669584085	-0.0235683806837043	0.013127326234	-3.74612412944297	123.423294495481	0.000274311892539041	0.00698835060216332	-0.165760401354907	-0.0511497516942015
GPHN	BRD-A02180903-001-04-5::2.5::HTS002	2.5	betamethasone	glucocorticoid receptor agonist	noncancer	NR3C1	dermatology	corticosteroid-responsive dermatoses	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.128627681844	0.128627681844	-0.073567627554117	-0.04557426840735	-4.24330270947111	161.795358983776	3.69852865916198e-05	0.0011437050194626	-0.29629231286745	-0.108098305928784
GPHN	BRD-A12417644-001-07-6::2.3139::HTS002	2.3139	usniacin-(+)	MAP kinase activator	targeted cancer	PTPN1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.5452261635305	0.5452261635305	0.167161253308298	0.15773571254	-11.7351220920479	20.4144787561401	1.56277719646749e-10	1.01162329731707e-08	-0.445180051355243	-0.310949769089161
GPHN	BRD-A24514565-001-09-7::2.5::HTS002	2.5	warfarin	vitamin K antagonist	noncancer	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.230983810134	0.230983810134	-0.127042508609019	-0.09418085429645	-10.074279140138	172.746678460099	4.54648732405139e-19	6.88166724347889e-17	-0.428172219529126	-0.287880417956913
GPHN	BRD-A50049929-001-01-9::2.5::HTS002	2.5	oxazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3	neurology/psychiatry	anxiety	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.213073940219	0.213073940219	-0.261689860931163	-0.09984291970545	-7.8049365181072	167.012590103826	6.19452014980581e-13	5.25391891249596e-11	-0.594855984626779	-0.354671617673547
GPHN	BRD-A79981887-003-16-4::2.5::HTS002	2.5	midodrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.778430606462	-0.778430606462	-1.03922363891264	-1.024762922465	-3.29569751793648	177.910509968156	0.00118503729956009	0.0256760876847366	-0.416949887001307	-0.104636177899973
GPHN	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.7182705522685	0.7182705522685	0.257388868485393	0.303778240807	-9.23284794351603	5.09083408162379	0.000227473119096572	0.00592322757172265	-0.588513391809712	-0.333249975756503
GPHN	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.2888812108295	0.2888812108295	-0.29853629560965	-0.208078798615	-10.3983855241878	34.2827763498567	3.85496293081489e-12	3.02981426475477e-10	-0.702186612823269	-0.47264840005503
GPHN	BRD-K04623885-001-07-5::2.5::HTS002	2.5	BIBR-1532	telomerase inhibitor	targeted cancer	TERT	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.5791378878865	-0.5791378878865	-0.91281608170021	-0.834266968334	-5.78559532738874	11.5855420023566	9.947408913469e-05	0.00282050298321854	-0.459839349580473	-0.207517038046947
GPHN	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-4.651580665565	-4.651580665565	-4.27015503234927	-4.2400927308	5.84138270421218	160.807619334185	2.78840312314935e-08	1.40752626703127e-06	0.252475128015893	0.510376138415572
GPHN	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.071226308601	-1.071226308601	-2.50475948359899	-2.37307934162	-10.4831292155183	5.78964482614023	5.56049853067643e-05	0.00166240213360489	-1.77110942970379	-1.09595692029219
GPHN	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.0832193739288	-0.0832193739288	-0.308095800997669	-0.199486634258	-3.90154101327347	63.0758443724629	0.000234757699516463	0.00609661734880214	-0.340053764720494	-0.109699089417244
GPHN	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.05845457346	-1.05845457346	-1.33757692596953	-1.3496917977	-4.18224058788644	117.25795993529	5.59575608131891e-05	0.00167201004482504	-0.411294205099931	-0.146950499919129
GPHN	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.11963031858965	-0.11963031858965	-0.483223639296565	-0.4134526693685	-6.01926620746276	5.43557994229914	0.00135624242051524	0.0288232108821628	-0.515200146431433	-0.211986494982397
GPHN	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.340402010551	0.340402010551	0.239844523510208	0.274310189966	-3.87358576300783	194.983880704441	0.000146353286929821	0.00399131615146731	-0.151755523649824	-0.0493594504317603
GPHN	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.5207724862975	0.5207724862975	-0.0594355203021122	0.1891566141585	-7.87810630677536	19.0026556277622	2.10163018609218e-07	9.47298204321665e-06	-0.734353911801917	-0.426062101397308
GPHN	BRD-K14618467-001-04-6::2.5::HTS002	2.5	IKK-16	IKK inhibitor	noncancer	IKBKB	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.1153653283505	0.1153653283505	-0.140382962327772	-0.114726429386	-6.53839325797863	187.91070059626	5.71036670306266e-10	3.47994650298754e-08	-0.33290893931583	-0.178587642040714
GPHN	BRD-K15409150-001-05-8::2.5::HTS002	2.5	penfluridol	T-type calcium channel blocker	noncancer	CACNA1G	neurology/psychiatry	schizophrenia	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-2.488565650105	-2.488565650105	-2.85594243323433	-2.6535756676	-3.65243578406518	35.1190873897004	0.000839337354298455	0.0189882136172085	-0.571548511069103	-0.163205055189564
GPHN	BRD-K15916496-001-27-9::2.5::HTS002	2.5	clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	noncancer	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.1336682092765	0.1336682092765	0.334217884822586	0.346280454324	7.37086070038867	33.3684466793979	1.70663329881916e-08	8.87817981317019e-07	0.145216883822824	0.255882467269348
GPHN	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.179345001645	-1.179345001645	-0.934662812378869	-0.8524847758	3.79879549456567	189.141322288502	0.000195865601707649	0.00518523697485161	0.117627032078998	0.371737346453264
GPHN	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.6791820504665	0.6791820504665	0.303979689176557	0.3131581681635	-12.2312429998334	128.016588446458	2.88611880585812e-23	6.35744046804486e-21	-0.43589946763342	-0.314505254946466
GPHN	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.6397255392125	-0.6397255392125	-0.943968682819376	-0.900132875838	-4.94263755533673	7.93474028174599	0.00115883533163145	0.0251719892361647	-0.446392268667493	-0.162094018546258
GPHN	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.02892180019146	-0.02892180019146	0.32696710332998	0.343759219436	9.83164135186548	10.4191646630573	1.34799659139825e-06	5.40229546443147e-05	0.275671685861815	0.436106121181065
GPHN	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.0550836977367	-0.0550836977367	-0.343321857530506	-0.216806871006	-5.07434833800179	176.333250903893	9.80113959155402e-07	4.00737971674587e-05	-0.400339347951875	-0.176136971635738
GPHN	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.256178791484	0.256178791484	-0.200124168477051	-0.14719250083	-8.51314462150213	40.5396970399157	1.44917482897523e-10	9.43213458607444e-09	-0.564587316915588	-0.348018603006515
GPHN	BRD-K24696047-001-02-3::2.5::HTS002	2.5	NVP-AEW541	IGF-1 inhibitor	targeted cancer	IGF1R, INSR	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.301279153371	0.301279153371	0.163322636425852	0.182728129692	-4.31187128360522	186.751287748911	2.61785137838323e-05	0.000834694239924871	-0.201073768133543	-0.0748392657567542
GPHN	BRD-K24869513-001-02-1::2.5::HTS002	2.5	CNX-2006	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.09637437016445	0.09637437016445	-0.125795972033221	-0.02986474769355	-4.28601585850325	11.5889696257429	0.00114338640039158	0.0248767499552865	-0.335557375553362	-0.10878330884198
GPHN	BRD-K25835157-001-01-4::2.5::HTS002	2.5	PRT062070	JAK inhibitor, syk inhibitor	targeted cancer	SYK	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.147583765242	0.147583765242	-0.0847758901451944	-0.0811687124677	-4.56424675719681	20.3186682425292	0.000181720203311639	0.0048563478124165	-0.338446576239831	-0.126272734534558
GPHN	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-5.73962420698	-5.73962420698	-4.6699032461483	-4.90330008871	11.7753095139062	189.257641548572	2.2802837506373e-24	5.5286304976283e-22	0.890523310788275	1.24891861087513
GPHN	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.348531486855	-1.348531486855	-1.96869358547584	-1.89093805071	-6.38609402951376	4.99666413766099	0.00139757898115674	0.0295756028290227	-0.869844860780168	-0.370479336461507
GPHN	BRD-K28907958-001-04-3::2.5::HTS002	2.5	CD-437	retinoid receptor agonist	targeted cancer	RARG	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-3.80115580519	-3.80115580519	-4.20783827888628	-4.123946828915	-3.85468484542938	16.8903799110215	0.00128390983565697	0.0275041590371338	-0.629385352975395	-0.183979594417158
GPHN	BRD-K32107296-001-16-9::2.5::HTS002	2.5	temozolomide	DNA alkylating agent	chemo	MGMT	oncology	glioblastoma, astrocytoma	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.4193598348005	0.4193598348005	0.223735125105819	0.214329388476	-6.94408586385144	191.000463506141	5.80236938690452e-11	3.94173067615169e-09	-0.251191749867736	-0.140057669521627
GPHN	BRD-K32285926-001-02-1::2.5::HTS002	2.5	AMG-208	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.9278554785505	0.9278554785505	0.401960244526046	0.412883434958	-10.8231320113202	5.12339659008118	0.00010078711385495	0.00285508872923837	-0.649900196063796	-0.401890271985112
GPHN	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-4.0726948857	-4.0726948857	-3.10996386685536	-3.10613635441	6.98866524051591	5.20954618359853	0.00078003335925668	0.0177970408758368	0.612859369607151	1.31260266808213
GPHN	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.339086174435	-1.339086174435	-1.93409325274133	-1.836818850415	-5.39665341392637	5.67123576748337	0.00199589128352637	0.0400329657033927	-0.868627709355384	-0.321386447257283
GPHN	BRD-K36788280-001-01-2::2.5::HTS002	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.428965659425	-0.428965659425	-1.07242825949062	-1.010750177675	-7.86893856601505	14.0604912812118	1.61293949223122e-06	6.38057785955012e-05	-0.818776358777318	-0.468148841353931
GPHN	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-2.2059552937	-2.2059552937	-2.62237664342517	-2.459947367395	-4.25781112796441	36.867214207736	0.000136288896756443	0.00374880171366936	-0.614610599163508	-0.218232100286828
GPHN	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.213661769963	0.213661769963	-0.24106315006291	-0.026104548309	-8.12350942654866	35.8631987271134	1.20458722011755e-09	7.11038210687344e-08	-0.568265386089533	-0.341184453962287
GPHN	BRD-K39624409-003-02-6::2.5::HTS002	2.5	ADL5859	opioid receptor agonist	noncancer	OPRD1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.6233595153485	0.6233595153485	0.234676683513411	0.2809148184015	-9.91282705650551	12.4636310919275	2.85780288005233e-07	1.26361683331621e-05	-0.473763141285012	-0.303602522385165
GPHN	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.3164667969915	-0.3164667969915	-1.02141166774593	-1.03228700688	-9.97480740335107	23.8606564127124	5.48525721539231e-10	3.35325069514495e-08	-0.850850892967401	-0.559038848541451
GPHN	BRD-K40797222-001-01-8::2.5::HTS002	2.5	SC-12267	dihydroorotate dehydrogenase inhibitor	noncancer	IL17A	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.344851340583	0.344851340583	0.185432850600645	0.184399160559	-6.68115570729421	45.9006482361763	2.77118920381319e-08	1.3994962555704e-06	-0.207450826807093	-0.111386153157617
GPHN	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.073438455325	-1.073438455325	-0.487494483989766	-0.306530142238	7.73089651869626	3.66733308184108	0.00213198741912403	0.0423844477834555	0.3677640148187	0.804123927851769
GPHN	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.12199946641415	0.12199946641415	-0.539691392462237	-0.407422571936	-9.34894015604174	58.9496177652262	3.03362703868801e-13	2.65277131609532e-11	-0.803318038616136	-0.520063679136638
GPHN	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.770740859685	-1.770740859685	-2.75656082724232	-2.75783530181	-10.8984242053658	80.1418488638265	1.72417903859583e-17	2.26157631066834e-15	-1.16582681212021	-0.805813122994434
GPHN	BRD-K42756753-001-01-9::2.5::HTS002	2.5	epiandrosterone	steroid	noncancer	G6PD	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.441403074358	0.441403074358	0.220137782337247	0.2292300635955	-7.32631269263265	39.4990560025715	7.11964998992844e-09	3.85340268356407e-07	-0.282328829957754	-0.160201754083752
GPHN	BRD-K43621685-001-02-5::2.5::HTS002	2.5	CP-673451	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	KIT, PDGFRA, PDGFRB	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.6382714169215	0.6382714169215	-0.00990179888663685	0.01840536176465	-10.1191148884855	7.01617478306464	1.94792311004452e-05	0.000636621549638201	-0.799566903080711	-0.496779528535562
GPHN	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.140470265775	-1.140470265775	-1.74616184958	-1.65992199057	-6.11963845046603	5.72794177372429	0.00103331953474362	0.0227569197042812	-0.850690684586541	-0.360692483023465
GPHN	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.11372581923375	0.11372581923375	-0.269048443090725	-0.2054130743915	-6.07779712490786	5.0460578609949	0.00168728441325081	0.0347758420047729	-0.544223778532991	-0.221324746115958
GPHN	BRD-K51040301-001-02-1::2.5::HTS002	2.5	cobicistat	cytochrome P450 inhibitor	noncancer	CYP3A4, CYP3A43, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.3862847533675	0.3862847533675	0.254462238740797	0.226380370277	-3.76220487628968	143.409094590923	0.000244760067702409	0.00633259060243719	-0.201081420457933	-0.0625636087954731
GPHN	BRD-K54256913-001-08-7::2.5::HTS002	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-2.06107554789	-2.06107554789	-3.35881093796355	-3.39786885204	-9.08011702140316	6.48846292989108	6.35616491554754e-05	0.00187827170851288	-1.64116569608172	-0.954305084065383
GPHN	BRD-K54256913-001-08-7::2.5::MTS010::PROS004_PR500	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.2442153180365	0.2442153180365	-1.22582079931027	-1.224724300865	-12.557768996052	16.1638212538925	9.37447153161233e-10	5.59827558901905e-08	-1.71799197542415	-1.22208025926939
GPHN	BRD-K57136142-001-02-4::2.5::HTS002	2.5	CCT129202	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.147772758988	-0.147772758988	-0.754123067377814	-0.661176661425	-11.9371996995033	26.8820222656005	2.97302735402025e-12	2.3635236637975e-10	-0.710594488993696	-0.502106127785933
GPHN	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-5.163290845445	-5.163290845445	-4.64271535638764	-4.72849824175	5.68976753018254	190.207881957562	4.74450507129575e-08	2.32112537645685e-06	0.340103681667722	0.701047296446989
GPHN	BRD-K59632282-052-03-1::2.5::HTS002	2.5	quinidine	sodium channel blocker	noncancer	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.341593133507	0.341593133507	0.441202245719194	0.447983088223	3.59254274128924	26.1577213625771	0.001331097595646	0.0283873449330558	0.0426329234699989	0.156585300954388
GPHN	BRD-K62304154-001-04-2::2.5::HTS002	2.5	deforolimus	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-2.108717167675	-2.108717167675	-2.77398426254052	-2.77605500784	-8.21688977362144	15.5335593610293	4.83013101135649e-07	2.06513341569645e-05	-0.837321594320915	-0.493212595410124
GPHN	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.0841920099567	0.0841920099567	-0.173661553095258	-0.07625513394025	-4.58261434248736	16.9171640925813	0.000267816737676012	0.00684484779028881	-0.37661251061876	-0.139094615485157
GPHN	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.1976465635925	-0.1976465635925	-0.607168319736608	-0.456560974373	-6.59770756774281	189.018550402756	4.08268378897827e-10	2.5304729144243e-08	-0.531961267413875	-0.287082244874341
GPHN	BRD-K68938568-001-01-7::2.5::HTS002	2.5	GDC-0152	XIAP inhibitor	targeted cancer	BIRC2, BIRC3, BIRC7, XIAP	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.1688532500055	0.1688532500055	-0.443120709165229	-0.296863885148	-8.7007758689672	179.754950934063	2.05944967532283e-15	2.22929186597105e-13	-0.750763538277029	-0.473184380064429
GPHN	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.1009030522165	0.1009030522165	-1.04105887940176	-0.659178147727	-10.8729772241617	40.0274208417887	1.62211452027258e-13	1.45833130459523e-11	-1.35422595631752	-0.929697906918986
GPHN	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.01961091628457	0.01961091628457	0.223460592255621	0.235603358555	6.9414326217896	11.7032038094434	1.7757264584024e-05	0.000585252462098919	0.139683848661724	0.268015503280378
GPHN	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.403324210695	-0.403324210695	-0.209008308116078	-0.182274470613	7.62744167718919	177.987020366961	1.38823859273717e-12	1.13869035339749e-10	0.14404223335697	0.244589571800873
GPHN	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.1098347966811	0.1098347966811	-0.156817508264205	-0.1366984748555	-5.11586478156689	6.97794472246334	0.00138833459217874	0.0293857757068021	-0.389981744279646	-0.143322865610964
GPHN	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.462328587421	0.462328587421	-0.692497359505386	-0.481859441946	-15.1042713700482	191.990506992195	1.74640922396612e-34	1.06944612160981e-31	-1.3056293391795	-1.00402255467327
GPHN	BRD-K76674262-001-03-3::2.5::HTS002	2.5	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-5.75131410545	-5.75131410545	-4.74328107889269	-4.86837811059	8.30508229221942	6.72973974392027	8.9215960616389e-05	0.00255431039579883	0.718672583390986	1.29739346972364
GPHN	BRD-K77638923-001-02-0::2.5::HTS002	2.5	CUDC-907	PI3K inhibitor	targeted cancer	HDAC2, PIK3R1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-5.470976753355	-5.470976753355	-5.89538100847724	-5.8647928098	-5.50494272973243	31.3171661745476	4.88926187182232e-06	0.000178367763017159	-0.581576284943261	-0.267232225301218
GPHN	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.5383963070665	-0.5383963070665	-1.06121224059491	-0.7851415156885	-5.57827813919847	185.369265118745	8.49951759036636e-08	4.03297123229053e-06	-0.707717849335915	-0.337914017720904
GPHN	BRD-K78318619-001-02-7::2.5::HTS002	2.5	PF-4981517	cytochrome P450 inhibitor	noncancer	CYP3A4	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.2060550419605	-0.2060550419605	-0.591817295622396	-0.549021652731	-5.10514566170046	186.55142429168	8.11252161049567e-07	3.35925163109723e-05	-0.534830887181471	-0.236693620142322
GPHN	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.416311042877	-0.416311042877	-0.118360554940915	-0.0981289252682	7.92811372918187	5.63754233418307	0.000290928297974682	0.00736875102536229	0.204539481682352	0.391361494189817
GPHN	BRD-K81473043-001-14-6::2.5::HTS002	2.5	tanespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-5.568377842865	-5.568377842865	-4.8219873452029	-4.73895662772	6.14593028372492	9.70988155259603	0.000123343837813897	0.00342703674031823	0.474694972679104	1.0180860226451
GPHN	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.912016612018	-0.912016612018	-0.417933508084558	-0.2916892525045	8.56858839144862	70.3037037580232	1.58743289887619e-12	1.29218726085543e-10	0.379088334805008	0.609077873061876
GPHN	BRD-K81801188-001-02-8::2.5::HTS002	2.5	PP-121	protein tyrosine kinase inhibitor	noncancer	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-2.96599592518	-2.96599592518	-4.6419084833159	-4.63633744063	-12.215458219419	4.39342990166499	0.000147725509252864	0.00402720181539774	-2.04374701342981	-1.308078102842
GPHN	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.5762359503715	0.5762359503715	0.304598684028944	0.320041105609	-8.10709441745228	5.91146322024726	0.000203855759554825	0.00537162228485682	-0.353922358521802	-0.18935217416331
GPHN	BRD-K84466663-001-05-4::2.5::HTS002	2.5	nelarabine	DNA synthesis inhibitor, T cell inhibitor	chemo	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	1.197703658605	1.197703658605	0.602163512742587	0.593873040614	-15.6332743889728	2.57778654992088	0.00126639963696165	0.0271797855671024	-0.728819058572186	-0.46226123315264
GPHN	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.702561881829	-0.702561881829	-0.317705968788981	-0.18498925291	6.05122701945972	8.52896213862416	0.000236447387988727	0.00613306695149895	0.239763132246561	0.529948693833477
GPHN	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.83331530685	-1.83331530685	-2.23720012295553	-2.18551801488	-6.01995426135905	177.213416621945	9.79544531415198e-09	5.23422587568407e-07	-0.536284956887671	-0.271484675323394
GPHN	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.3940423365905	-0.3940423365905	-0.782886918462222	-0.783090045771	-7.22546909902963	23.4123088320418	2.11344653515767e-07	9.52424058944086e-06	-0.500062713711537	-0.277626450031908
GPHN	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-2.0723096183	-2.0723096183	-2.89352875020131	-2.8540109683	-6.63645864522579	15.5724993050993	6.558252537866e-06	0.000233880816670263	-1.08413029373782	-0.558307970064801
GPHN	BRD-K92428232-001-10-6::2.5::HTS002	2.5	GSK461364	PLK inhibitor	targeted cancer	PLK1	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-1.625149616355	-1.625149616355	-2.70970934284137	-2.38486964806	-7.17477034107347	6.71801964624077	0.000220275269421721	0.00575467798877231	-1.4450674305104	-0.724052022462328
GPHN	BRD-K94176593-001-09-4::2.5::HTS002	2.5	TWS-119	glycogen synthase kinase inhibitor	noncancer	GSK3B, JUN, MYC	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.1883763942015	0.1883763942015	-0.30102944768088	-0.2225830716545	-10.130721658765	9.83805245048211	1.60670714420518e-06	6.35944479243496e-05	-0.597285840534849	-0.38152584322991
GPHN	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.5580787258565	-0.5580787258565	-1.41624148527886	-1.39259151278	-8.68852158447092	6.31032770934317	9.70860541095576e-05	0.00275936306739787	-1.09699152955787	-0.61933398928684
GPHN	BRD-K95523387-001-09-6::2.5::HTS002	2.5	OLDA	TRPV agonist	noncancer	GPR119	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.4783528413195	0.4783528413195	0.274137814460178	0.3623330707505	-3.63155966175399	15.9901124698978	0.00224642575196208	0.0443142369988293	-0.323430547260263	-0.0849995064583812
GPHN	BRD-K97472745-001-01-8::2.5::HTS002	2.5	gestrinone	progesterone receptor antagonist	noncancer	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.002399846133735	-0.002399846133735	-0.16247013060428	-0.1123477003	-4.08140264154826	108.069853690803	8.5994362907943e-05	0.00247231197957029	-0.23780942903634	-0.0823311399047486
GPHN	BRD-K97714174-001-01-3::2.5::HTS002	2.5	P22077	ubiquitin specific protease inhibitor	noncancer	USP7	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.6747999539715	0.6747999539715	0.252746450925067	0.3142607574065	-10.6038714883478	24.0976122497331	1.47546169821357e-10	9.58866677733223e-09	-0.504182839874283	-0.339924166218583
GPHN	BRD-K98521173-001-19-4::2.5::HTS002	2.5	desoxycortone	mineralocorticoid receptor agonist	noncancer	NR3C1, NR3C2	NA	NA	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	0.8549115131725	0.8549115131725	0.62452655344122	0.6426158076335	-5.69159602167312	8.56337468020309	0.000357535901873856	0.00888467389133006	-0.322669430261834	-0.138100489200726
GPHN	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.3188447849115	-0.3188447849115	-0.621566798150203	-0.6228392960495	-6.03922817960694	172.851868264235	9.22413882977135e-09	4.94003111255888e-07	-0.401659761867129	-0.203784264610276
GPHN	BRD-K99964838-001-11-9::2.5::HTS002	2.5	bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	targeted cancer	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	CAL27, TE5	UPPER_AERODIGESTIVE_TRACT, OESOPHAGUS	carcinoma (squamous_cell_carcinoma)	-0.06690342232425	-0.06690342232425	-0.39682123613896	-0.289629896197	-5.4531195445539	57.908255878575	1.06890202405954e-06	4.33977461478798e-05	-0.451027305023919	-0.208808322605501
GULP1	BRD-A36267905-003-18-4::2.5::HTS002	2.5	buphenine	adrenergic receptor agonist	noncancer	ADRB2	rheumatology	Raynaud's disease	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.150813448958	-0.150813448958	-0.443942429801225	-0.393531150995	-5.16375338614888	14.9621963903434	0.000116427056159864	0.00325087463741378	-0.414150862722799	-0.172107098963651
GULP1	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.5150978925345	0.5150978925345	0.18157643361221	0.1739425463755	-11.2119463824278	36.4949853739488	2.23252655691286e-13	1.98381088066574e-11	-0.393822716039914	-0.273220201804666
GULP1	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	1.000532979453	1.000532979453	0.144489963140575	0.162581247373	-20.6412573489172	3.07562473292841	0.000211879430716553	0.00556245792577758	-0.986209725525136	-0.725876307099714
GULP1	BRD-A69815203-001-07-6::2.5::HTS002	2.5	cyclosporin-a	calcineurin inhibitor	noncancer	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.656058725864	-0.656058725864	-0.0666167098823011	0.011278782305325	14.3599567730643	191.355323365194	3.28817757505675e-32	1.59086187693982e-29	0.508478108819299	0.670405923144099
GULP1	BRD-A90547603-001-02-5::2.5::HTS002	2.5	eptifibatide	platelet aggregation inhibitor	noncancer	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.208382288942	0.208382288942	0.0427063546740426	0.04269931862485	-5.5495267841011	11.6384064815431	0.000140749647225284	0.00385074433752208	-0.230947202447275	-0.100404666088639
GULP1	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.292136872625	-1.292136872625	-0.349214673054461	-0.221401224326	13.7777898133979	19.5416025611898	1.60941964681263e-11	1.17488182384777e-09	0.799948378318084	1.08589602082299
GULP1	BRD-K03765900-001-01-9::2.49999::MTS010::PROS002_PR500	2.49999	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.292960153731	0.292960153731	-0.56447665074887	-0.353034364185	-11.0124108994941	92.456452782047	1.63562436887921e-18	2.35276332454707e-16	-1.01206520592976	-0.702808403029985
GULP1	BRD-K03765900-001-01-9::2.5::MTS006	2.5	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.592574616811	-0.592574616811	-1.17285481347225	-0.823393929272	-5.64054605352527	9.33505122400913	0.000277548644978174	0.0070557138571376	-0.811736165642475	-0.348824227680033
GULP1	BRD-K07572174-001-39-4::2.48092::HTS002	2.48092	curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	targeted cancer	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.94236236917	-3.94236236917	-1.14620755484563	-1.01297286124	35.9564385612161	145.04667139517	3.92343443748889e-74	1.4015096325876e-69	2.64245572234089	2.94985390630785
GULP1	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.714165537544	0.714165537544	0.423675326219805	0.3989310314435	-8.75458390227557	167.288813804639	2.16013172763957e-15	2.33003962281461e-13	-0.355998654393742	-0.224981768254648
GULP1	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2265688403865	0.2265688403865	0.344578404733201	0.3629794578985	3.59272667550576	60.1644810364231	0.000659983302460261	0.0153154570412522	0.0523098818120939	0.183709246881308
GULP1	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.930092837335	-2.930092837335	-2.08775551825775	-1.94028903858	6.33551176285664	7.78337407296294	0.000251575849479518	0.0064831069187322	0.534251103621762	1.15042353453274
GULP1	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.209071655405	-3.209071655405	-2.40750420202751	-2.32376274045	8.70150014933031	5.70618234874041	0.000167046903529882	0.0045086255870364	0.573318543310206	1.02981636344478
GULP1	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.494976523394	0.494976523394	0.238259143891305	0.274310189966	-7.66470711598506	6.01905503380334	0.000253908130384985	0.00653299828058625	-0.338610014582547	-0.174824744422842
GULP1	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.166316460811	0.166316460811	0.403261947486457	0.440216058218	6.26515831459764	7.50180135223254	0.000315376153200947	0.00792243970222758	0.148714939500339	0.325176033850575
GULP1	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.67866663869	-2.67866663869	-1.08558165833002	-0.864735754699	10.7316075041809	3.21472977479178	0.00126299346313573	0.027115709301855	1.13801718524886	2.0481527754711
GULP1	BRD-K17894950-001-14-3::2.5::MTS010::PROS002_PR500	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.0768135339877	-0.0768135339877	0.0206258500084839	0.0194695079215	3.78984391054233	104.782887124603	0.000252059006954532	0.00649165523931242	0.0464586656025678	0.1484201023898
GULP1	BRD-K18779551-003-07-8::2.5::HTS002	2.5	bifemelane	acetylcholine release enhancer	noncancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.40325166448	0.40325166448	0.0153143221250697	0.0566081056954	-9.51765966027943	6.95795012200614	3.07715617324568e-05	0.000965381085428209	-0.484437018211426	-0.291437666498434
GULP1	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2743381429415	0.2743381429415	-0.0297949169957349	-0.00807522835948	-12.5101046512404	167.76732863938	8.64913395023611e-26	2.3465319372407e-23	-0.352127944145162	-0.256138175729308
GULP1	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2591824587025	-0.2591824587025	-0.94795342711791	-0.900132875838	-12.5256275072347	24.1931190109381	4.566067474098e-12	3.55610710630796e-10	-0.802214638899929	-0.57532729793089
GULP1	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.239368226285	-1.239368226285	-0.681472939687919	-0.587603052309	8.63744726104371	10.6830740326485	3.82477327955322e-06	0.000142171320193091	0.415216753051472	0.70057382014269
GULP1	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0468420852435	0.0468420852435	-0.307159612463283	-0.19710233478	-6.2175316039587	124.716703783792	6.97494354519465e-09	3.78272438030877e-07	-0.466687711081971	-0.241315684331596
GULP1	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-5.746326377285	-5.746326377285	-3.24101632753522	-2.99271378173	13.6478898701606	2.52799177525782	0.00196098308597929	0.0394347479672411	1.85428865947777	3.15633144002179
GULP1	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.845023223825	0.845023223825	0.36842961549955	0.3847237758685	-15.6046684719857	64.8775659430413	1.21021554014922e-23	2.73901041715567e-21	-0.537591842108129	-0.41559537454277
GULP1	BRD-K25433859-003-25-4::2.5::HTS002	2.5	maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2	neurology/psychiatry	depression, dysthymic disorder	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.427355925042	0.427355925042	0.169813271866303	0.180847774452	-7.02728703814647	4.24123502808408	0.00173075516039003	0.035538959934432	-0.357054063538388	-0.158031242813005
GULP1	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3781549362455	-0.3781549362455	-0.180176706483054	-0.04268072142135	4.60343145463253	187.862538932926	7.63822966126753e-06	0.000268640322459765	0.113140186041209	0.282816273483684
GULP1	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.38051381438	-1.38051381438	-0.293420508835305	-0.250836974988	18.8341069336502	3.27916290986378	0.000186632003099249	0.00496964226515828	0.91194188175024	1.26224472933915
GULP1	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.55943094298	0.55943094298	0.237952771049325	0.2536769304835	-11.919797799757	119.92264836303	4.36730772232724e-22	8.62710319648549e-20	-0.374877449279554	-0.268078894581795
GULP1	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.526774096015	-3.526774096015	-2.20656972127099	-2.23277244437	12.0849995258057	133.03248294194	3.74897648030223e-23	8.19076840006827e-21	1.1041259831188	1.53628276636922
GULP1	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.8674341258665	0.8674341258665	0.420495979477408	0.420565301841	-8.21636735466416	69.4731281296297	7.67594760195734e-12	5.82157881663098e-10	-0.555442166839676	-0.338434125938508
GULP1	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.8660233960235	0.8660233960235	0.757775727006538	0.759014306598	-3.51171199512894	135.194826038378	0.000605678717943902	0.0141904803168123	-0.169208758479764	-0.0472865795541593
GULP1	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.4035226525415	-0.4035226525415	-0.175637634746487	-0.120119113317	6.05627024785061	32.5657560390956	8.61056269836782e-07	3.551074259339e-05	0.151291584928952	0.304478450661074
GULP1	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-7.875075428255	-7.875075428255	-6.58678610286121	-6.64618122736	11.602027427926	3.68589719706677	0.000492112054340068	0.0118138311485946	0.969349943312472	1.60722870747511
GULP1	BRD-K40530731-001-11-6::2.5::HTS002	2.5	hyoscyamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.165743028775	-1.165743028775	-0.187823456972861	-0.0938174605639	16.7889316611183	10.9589654717816	3.63742574037143e-09	2.03871815247926e-07	0.849658273939473	1.1061808696648
GULP1	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0806323267958	0.0806323267958	-0.297654289948516	-0.160539632789	-6.2973027447198	78.9969020870514	1.5904170325119e-08	8.30788428372516e-07	-0.497855448904668	-0.258717784583963
GULP1	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-6.02920259521	-6.02920259521	-5.44081088601144	-5.470053491025	7.11368448695757	76.5938591924007	5.17880401539479e-10	3.17405743727638e-08	0.423675838969949	0.75310757942718
GULP1	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.5077298818525	-0.5077298818525	-0.119456867146559	-0.0679983440509	7.99011950623977	4.84036723605944	0.000575970817115427	0.0135895254581167	0.26210846936977	0.514437560042112
GULP1	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-5.93911230416	-5.93911230416	-5.27351334571878	-5.30447708423	6.53454206559695	6.71127113459749	0.000386479470773124	0.0095123746544939	0.422625191670205	0.908572725212242
GULP1	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1216001488445	-0.1216001488445	0.205440759378399	0.242605983944	10.1102009763582	177.004606121018	2.95970295433798e-19	4.56367032014608e-17	0.263204282081693	0.390877534364105
GULP1	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.938333038916	-0.938333038916	-0.734458946256966	-0.670954227568	3.56047146258471	99.1443272846411	0.000570404504915333	0.0134730248108881	0.090259041942433	0.317489143375635
GULP1	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-4.824757567785	-4.824757567785	-3.13363789078193	-3.15598793833	14.5197462550086	10.2518584309496	3.61347630818222e-08	1.79733758100809e-06	1.43246919718325	1.94977015682289
GULP1	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.320956172955	-1.320956172955	-0.742945696867352	-0.6455499330205	7.83411800784751	48.2124761404326	3.81303207483004e-10	2.37570741734374e-08	0.4296803576651	0.726340594510195
GULP1	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.09391429685765	-0.09391429685765	-1.30767277458628	-1.05786698502	-13.2756372911348	17.1654552180816	1.8570050766776e-10	1.19343340653443e-08	-1.40651212890735	-1.02100482654991
GULP1	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3702777752845	-0.3702777752845	0.161878781681334	0.164761931788	13.0064437635726	3.82637025117365	0.000262341005355256	0.00671932186147067	0.416496656867991	0.647816457063677
GULP1	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.0119813743095	-0.0119813743095	0.258076724232175	0.250852150231	13.3226886148797	190.049259056124	4.99498231460087e-29	1.85540652427399e-26	0.230073952655307	0.310042244428042
GULP1	BRD-K73237276-001-01-0::2.5::HTS002	2.5	tacalcitol	vitamin D receptor agonist	noncancer	VDR	dermatology	psoriasis, chapped lips	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.1853677990365	0.1853677990365	0.0308400827733446	0.07201409986295	-4.65641274366159	63.009149298226	1.7077417775287e-05	0.000564930679790013	-0.220844458318803	-0.0882109742075078
GULP1	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.620584454948	-0.620584454948	-0.891808964026445	-0.708568317551	-4.46498111597811	176.27360372443	1.42597193619958e-05	0.000477915776565631	-0.391105227486558	-0.151343790670333
GULP1	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.4578612675995	-0.4578612675995	-1.11664946314654	-0.918129706972	-8.11722734956578	190.918472653604	5.73696810443954e-14	5.39061217385543e-12	-0.818872194305431	-0.498704196788645
GULP1	BRD-K80431395-001-07-3::2.48737::HTS002	2.48737	triciribine	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.302572128085	-1.302572128085	-0.933435356682094	-0.71098807564	5.54207398302109	70.450468480832	4.86348778565608e-07	2.07770873751621e-05	0.236309724123056	0.501963818682756
GULP1	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.79486909335	0.79486909335	0.341248492744467	0.3852845671545	-10.9431671275307	3.86992513952979	0.000471967152236471	0.011386340361514	-0.570252713727141	-0.336988487483925
GULP1	BRD-K84892605-001-01-1::2.5::HTS002	2.5	IOWH032	CFTR channel antagonist	noncancer	CFTR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.148646866461	-0.148646866461	0.120590043529305	0.126672721217	10.1255665601972	42.9955847432898	5.90961952087908e-13	5.01823630067549e-11	0.215613284551436	0.322860535429175
GULP1	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.296674190475	-0.296674190475	0.0466989665206597	0.06241133456585	11.1644801011705	20.3716539078834	3.88612463125836e-10	2.41913797877715e-08	0.279292513577441	0.407453800413879
GULP1	BRD-K89714990-001-01-5::2.5::HTS002	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4977220980925	0.4977220980925	-0.0113414743171458	-0.02895586832955	-15.313309914541	81.6140755125704	1.02371344880402e-25	2.76336876283019e-23	-0.575199588517826	-0.442927556301465
GULP1	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-6.53979822296	-6.53979822296	-3.07160437395247	-2.979502562735	18.9496373644413	2.18266871646855	0.00183372215006926	0.0372424746235378	2.74061858498736	4.19576911302769
GULP1	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.424975942899	0.424975942899	0.297723543259459	0.274833859863	-3.44366652284081	104.758816967285	0.000826250125561599	0.0187277245306146	-0.200524527231073	-0.0539802720480089
GULP1	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.904387501662	-0.904387501662	-0.286297913420196	-0.212124322286	8.8478408100992	188.088916235088	6.48744639123596e-16	7.34082824843142e-14	0.48028438091207	0.755894795571538
GULP1	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.232536481335	0.232536481335	-0.351112613804558	-0.28220904824	-15.0033930683783	117.428112447779	4.54669318596057e-29	1.70962842781359e-26	-0.66068782991234	-0.506610360366776
GULP1	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.090678547275	-1.090678547275	0.00411783560473883	0.0503184944333	23.6748310793441	20.3902187726199	2.62082949134624e-16	3.09317050688738e-14	0.998453279635961	1.19113948612352
GULP1	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.440257063505	-3.440257063505	-3.06639738392987	-3.05318317183	4.00703316535474	189.742902504766	8.8253254172134e-05	0.0025301273024959	0.189819486157344	0.557899872992919
HECTD4	BRD-A02180903-001-04-5::2.5::HTS002	2.5	betamethasone	glucocorticoid receptor agonist	noncancer	NR3C1	dermatology	corticosteroid-responsive dermatoses	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.4451686692095	0.4451686692095	-0.0774755409783824	-0.04557426840735	-8.36434670415937	5.39415091073897	0.000274765852846233	0.00699742044613596	-0.679799659830321	-0.365488760545444
HECTD4	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.127991752229	0.127991752229	-0.180054594744879	-0.1596607583295	-6.06640839144569	12.3581104096016	4.95529859331427e-05	0.0014951811861535	-0.418329817801893	-0.197762876145864
HECTD4	BRD-A24587114-066-22-5::2.5::HTS002	2.5	isoetharine	adrenergic receptor agonist	noncancer	ADRB1, ADRB2	pulmonary	bronchospasm, asthma	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.260219904337	0.260219904337	0.421039740918629	0.453152824306	4.83981291209865	12.9338551122772	0.00032766422589247	0.00820515783050675	0.0889966394847253	0.232643033678533
HECTD4	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.394799548987	-0.394799548987	-0.176139122883096	-0.001536499117528	3.90137836599696	52.1728480744318	0.000275361414358603	0.00700759161458857	0.106202826254662	0.331118025953147
HECTD4	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.368717034249	-0.368717034249	0.0806110859089496	0.1349064957195	11.224339006498	4.26857733717877	0.000250104473220418	0.0064521715985627	0.3408870190028	0.557769221313099
HECTD4	BRD-A91452556-001-04-0::2.5::HTS002	2.5	estradiol-cypionate	estrogen receptor agonist	noncancer	ESR1	endocrinology	hypoestrogenism, menopause	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.4953044224035	0.4953044224035	0.594321652235585	0.612598720084	4.18291003720577	188.183965376707	4.40954708608907e-05	0.00134456368959224	0.0523209450794545	0.145713514584715
HECTD4	BRD-K00673382-001-18-9::0.15625::HTS002	0.15625	famotidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	heartburn	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.1347096256623	-0.1347096256623	0.510656418545049	0.491238275219	12.5067795254566	3.2212364888559	0.000771340253304152	0.0176097768588012	0.487347470576427	0.803384617838271
HECTD4	BRD-K03765900-001-01-9::2.49999::MTS010::PROS002_PR500	2.49999	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.2285720713905	0.2285720713905	-0.563761227611754	-0.353034364185	-9.20043944569727	15.7756167306562	9.72998670344971e-08	4.59444441542999e-06	-0.975108841702553	-0.609557756301955
HECTD4	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.6601130156825	-0.6601130156825	-1.13860464722881	-1.07388474495	-7.00092155647676	175.204275193924	5.21263905297969e-11	3.56217892301504e-09	-0.613380927642647	-0.343602335449972
HECTD4	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.384843380275	-1.384843380275	-1.02283907152304	-0.9876270936225	5.55013903094597	7.67534070219285	0.000625271085362251	0.0145968550762015	0.210482009225388	0.513526608278532
HECTD4	BRD-K10843433-001-22-7::2.5::HTS002	2.5	phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	PTGIS, PTGS1, PTGS2	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.10812522006975	-0.10812522006975	0.130184904550487	0.1428689114125	4.74113905159472	7.06567399735513	0.00205234832072721	0.0410104198427319	0.119677482761666	0.356942766478808
HECTD4	BRD-K12244279-001-05-8::2.5::HTS002	2.5	MEK1-2-inhibitor	MEK inhibitor	noncancer	MAP2K2	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.7423184505685	0.7423184505685	-0.165124282865442	-0.176391740772	-26.8236619916912	22.5603680552678	1.29855398534334e-18	1.88307021058629e-16	-0.977500823664267	-0.837384643203617
HECTD4	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.1958784852385	0.1958784852385	0.402938865252277	0.440216058218	6.68407820200527	136.848506470107	5.40591821841366e-10	3.30663540477849e-08	0.145802614217289	0.268318145810265
HECTD4	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.09298378683955	0.09298378683955	0.261013675362143	0.263001454047	5.98435478301036	102.204097424156	3.24323741729348e-08	1.62373238124526e-06	0.112338254102758	0.223721522942429
HECTD4	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.3136515379055	-0.3136515379055	-1.13863899073225	-0.889953286616	-8.63260090712093	118.218317988825	3.29110178604171e-14	3.17881277467568e-12	-1.01423151994568	-0.635743385707825
HECTD4	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.2759348556155	-0.2759348556155	-0.947778009349187	-0.900132875838	-10.4686510665553	5.92698629277734	4.82416434153601e-05	0.00145956849118728	-0.829347924569903	-0.514338382897471
HECTD4	BRD-K19687926-379-07-4::2.5::HTS002	2.5	lapatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2	oncology	breast cancer	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.1889476153885	0.1889476153885	-0.667702153747325	-0.522756667285	-10.9650153069439	3.91538066426981	0.000440437742420502	0.0107026218321125	-1.07542293948955	-0.637876598782102
HECTD4	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.3380120053665	-0.3380120053665	-0.167183158856675	-0.149311762512	8.84631872465846	167.831320087283	1.21331013028397e-15	1.33976067446488e-13	0.132705617113949	0.2089520759057
HECTD4	BRD-K23984367-075-15-2::2.5::HTS002	2.5	sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.0321268623034	0.0321268623034	-0.861490140257931	-0.738304903661	-11.4842791129901	107.495488908745	2.10443154969644e-20	3.62572917696856e-18	-1.04786247967002	-0.739371525452638
HECTD4	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.1310172779315	-0.1310172779315	-0.980680083749758	-0.82417204092	-8.48176926952287	101.536465324104	1.87618605531378e-13	1.67410941319462e-11	-1.04837069851558	-0.650954913120932
HECTD4	BRD-K29582115-066-01-2::2.5::HTS002	2.5	ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.173931703855	-0.173931703855	0.268952511883906	0.27385544783	12.491150748751	115.32406883742	3.62625459710701e-23	7.94694807304037e-21	0.37265512296809	0.513113308509722
HECTD4	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.8683822024255	-0.8683822024255	-0.687960049218935	-0.601202853428	3.71061616101558	188.877578656891	0.000271850448474595	0.00693718713788683	0.0845078029856293	0.276336503427501
HECTD4	BRD-K34332569-001-01-3::2.5::HTS002	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.899336886205	-2.899336886205	-0.974777708318731	-0.8949729778575	13.9458151035678	2.70568090266654	0.00134394580928456	0.028610107405458	1.45706967314899	2.39204868262355
HECTD4	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.806349761771	0.806349761771	0.42123193567133	0.420565301841	-5.66497893702027	5.57199078018999	0.00166961050067402	0.0344513284874325	-0.554611345697046	-0.215624306502295
HECTD4	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.8518767830835	0.8518767830835	0.124324047182179	0.121836586496	-16.0610121050054	3.37465548010214	0.000263363589512204	0.00674470722625895	-0.863070661801757	-0.592034810000885
HECTD4	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.0499375204902	0.0499375204902	-0.239348760016075	-0.026104548309	-5.21035134508959	42.9340864809331	5.08759390931825e-06	0.000185099119842178	-0.401260934221676	-0.177311626790874
HECTD4	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.0895838217748	-0.0895838217748	0.0912360270802409	0.1259414280465	6.10394731041187	50.3748491049098	1.47025856463846e-07	6.77529666524178e-06	0.12133040901094	0.240309288699142
HECTD4	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-7.748948968315	-7.748948968315	-6.58811374980795	-6.64618122736	12.9279694938244	13.8475836700759	4.07127928626664e-09	2.27001357478211e-07	0.968050317949851	1.35362011906426
HECTD4	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.4874605618215	-0.4874605618215	-1.01964884542809	-1.03228700688	-7.67544257170886	33.1988659612756	7.44314182341087e-09	4.02340767684698e-07	-0.673222348786703	-0.391154218426479
HECTD4	BRD-K48141473-001-01-7::2.5::HTS002	2.5	cebranopadol	opioid receptor agonist	noncancer	OPRL1, OPRM1	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.1070074763827	0.1070074763827	0.346115475751315	0.370996268268	7.64053556704355	104.853099272076	1.06999770070507e-11	7.97674911980579e-10	0.177055446704991	0.301160552032239
HECTD4	BRD-K49071277-001-04-7::2.5::HTS002	2.5	securinine	GABA receptor antagonist, TP53 activator	noncancer	GABRA1	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.6681049861675	0.6681049861675	0.287424308423376	0.288445970299	-15.4826183189286	106.675662770538	4.81899368631609e-29	1.79939041427603e-26	-0.429424454099234	-0.331936901389013
HECTD4	BRD-K51967704-001-03-6::2.5::MTS010::PROS004_PR500	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.65874308143	-1.65874308143	-1.38215104082929	-1.35469471431	3.27549093502391	148.614285435444	0.00131264243318917	0.0280439932279706	0.109728159199963	0.443455922001466
HECTD4	BRD-K56301217-001-07-4::2.5::HTS002	2.5	ABT-737	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.3398585625615	-0.3398585625615	-0.132491010085602	-0.0854667375103	6.61491893010337	165.594389564651	4.90997450353272e-10	3.01878922939663e-08	0.145473354640086	0.26926175031171
HECTD4	BRD-K56981171-001-01-0::2.5::MTS006	2.5	brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	targeted cancer	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.05351258934015	0.05351258934015	-0.07188374573954	-0.00736994010253	-3.73401583156523	159.796414949638	0.00026170426125675	0.00670862487871044	-0.191718448637499	-0.0590742215218808
HECTD4	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.08098301411965	-0.08098301411965	-1.30780608677945	-1.05786698502	-14.282465743977	46.033561808188	1.56704278205086e-18	2.25865980117135e-16	-1.3997216619833	-1.05392448333631
HECTD4	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.7646654107675	-0.7646654107675	-2.09067716093114	-1.79411655002	-8.22157833897759	5.22821233374893	0.000349484960234497	0.0087058068389237	-1.73522179627253	-0.91680170405475
HECTD4	BRD-K63923597-001-10-0::2.5::HTS002	2.5	barasertib-HQPA	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.54375580671	-0.54375580671	-1.17500391669387	-1.00704468422	-6.44054148439516	5.35595176903126	0.00103363700288037	0.022761572504916	-0.878241152383554	-0.38425506758419
HECTD4	BRD-K65781196-001-03-0::2.5::HTS002	2.5	avanafil	phosphodiesterase inhibitor	noncancer	PDE5A	urology	erectile dysfunction	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.71557813417	0.71557813417	0.51558278582468	0.492981858555	-7.49651703711316	153.144643560435	4.91834427304355e-12	3.80969934838147e-10	-0.252700610874942	-0.147290085815699
HECTD4	BRD-K65928735-001-04-3::2.5::HTS002	2.5	AZD1480	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.2458225927375	-0.2458225927375	-0.021497819995143	-0.05528360346055	6.70588522076049	39.9798220315114	4.83764017508309e-08	2.36453040156302e-06	0.156714846435493	0.291934699049221
HECTD4	BRD-K67977190-066-02-3::2.5::HTS002	2.5	eprosartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.183239307678	0.183239307678	0.424033360792265	0.410651476159	6.83452854230593	18.5403293565242	1.82258041317782e-06	7.13222270177085e-05	0.166928708968863	0.314659397259668
HECTD4	BRD-K73589491-001-11-2::2.5::HTS002	2.5	nizatidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.4057580863535	-0.4057580863535	0.100939676086394	0.09959523720245	17.2896657518083	7.65805604042448	2.06205708390489e-07	9.30243386100296e-06	0.438588224642544	0.574807300237244
HECTD4	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.226453999895	-1.226453999895	-0.315221974059932	-0.3195858510195	12.5650101432129	15.6499868492163	1.3798994800772e-09	8.08729766654271e-08	0.757213622835654	1.06525042883448
HECTD4	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.760479321359	0.760479321359	0.452526105786538	0.472553592618	-9.71030683026792	170.002415395969	5.20818865948197e-18	7.17855863149911e-16	-0.37055728580592	-0.245349145339005
HECTD4	BRD-K84810405-003-01-1::2.5::HTS002	2.5	almorexant	orexin receptor antagonist	noncancer	HCRTR1, HCRTR2	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.6734686026925	0.6734686026925	0.25360729587116	0.26116496822	-14.2722065207502	54.8566738126614	4.09321991374582e-20	6.86459883328034e-18	-0.478819974296793	-0.360902639345887
HECTD4	BRD-K84892605-001-01-1::2.5::HTS002	2.5	IOWH032	CFTR channel antagonist	noncancer	CFTR	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.123075579099	-0.123075579099	0.120320872083389	0.126672721217	8.3262567815386	11.7697167072303	2.83974757182505e-06	0.000108183479794115	0.179566039816904	0.307226862547875
HECTD4	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.957391581735	-2.957391581735	-1.687121847367	-1.533280492745	11.9723716193711	2.62978065444013	0.00229186180471308	0.0450943219262232	0.90406032918724	1.63647913954876
HECTD4	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.08830497471	-1.08830497471	-1.96308018521586	-1.89031364576	-14.3735735791642	193.182516678259	2.45922534707915e-32	1.20338655117381e-29	-0.994810535235696	-0.754739885776021
HECTD4	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.0765576183193	-0.0765576183193	-0.273980444939316	-0.208293631699	-4.02567965405327	62.2943203353918	0.000156560141613689	0.00425128323728879	-0.295444913500624	-0.0994007397394082
HECTD4	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.3250064529255	-0.3250064529255	-1.03031609850003	-0.948156981669	-16.65078053592	58.7097824272378	6.56770117762827e-24	1.53171798226321e-21	-0.790078484171418	-0.620540806977644
HECTD4	BRD-K99107520-001-24-1::2.5::MTS006	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.2072155965	0.2072155965	0.066232352344205	0.0907077107149	-6.22208937901328	12.6921973101786	3.45776425170495e-05	0.00107499152060294	-0.190054917095071	-0.0919115712165185
HECTD4	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	NCIH23, 786O	LUNG, KIDNEY	carcinoma (non_small_cell_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.96538711263	-0.96538711263	-0.209864049245914	-0.135972658715	11.0456651431554	3.71654032636021	0.000562855730855463	0.0133123268526286	0.559763323459933	0.95128280330824
HIF1A	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.9068633103555	-0.9068633103555	-1.2153580647222	-1.12011346307	-4.47920164481383	184.530546311776	1.31090026338996e-05	0.000442088643823698	-0.444373929307248	-0.172615579426153
HIF1A	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.018852514498565	0.018852514498565	-0.496631239589743	-0.379151386241	-8.49409529519906	49.8563597496374	2.95637255622556e-11	2.08638911295116e-09	-0.637386495962401	-0.393581012214215
HIF1A	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.754631514273	-0.754631514273	-1.63062217719129	-1.545847432105	-8.18804648523765	5.64575698109725	0.000243848454891493	0.00631129036208656	-1.14180488407948	-0.610176441757101
HIF1A	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.1223163792145	0.1223163792145	-0.00528589034569945	0.000253415549772	-4.28162760108226	191.26390892803	2.93292144558644e-05	0.000923883187112135	-0.18638561919695	-0.0688189199234489
HIF1A	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.511618427735	-0.511618427735	0.0961573072917864	0.131172819567	16.9880414748163	4.31724855597889	4.05526009157439e-05	0.00124539309380577	0.51125727430994	0.704294195743633
HIF1A	BRD-A74765037-001-01-1::2.5::HTS002	2.5	estradiol-benzoate	contraceptive agent	noncancer	ESR1	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.145220457577	-0.145220457577	0.0316046026522782	0.0157796912763	5.48519227234021	13.4677161268494	9.22909210063741e-05	0.00263180159770824	0.107426745838079	0.246223374620478
HIF1A	BRD-A83650191-004-02-8::2.5::HTS002	2.5	A61603	adrenergic receptor agonist	noncancer	ADRA1A	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-3.09377605456	-3.09377605456	-2.02071332142227	-1.98407257251	11.2558794980222	109.273314617259	5.57510524932659e-20	9.22707901917312e-18	0.884120078855558	1.26200538741989
HIF1A	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.308796164108	-0.308796164108	-0.647726415470875	-0.593822379071	-5.36397608403588	26.5233213232175	1.21194345473305e-05	0.000410939137335043	-0.468687113908797	-0.209173388816952
HIF1A	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.6364760173985	-0.6364760173985	-1.13887324948204	-1.07388474495	-6.89530993322792	52.542366453237	6.92320743358288e-09	3.7584704306798e-07	-0.648567044333679	-0.356227419833394
HIF1A	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.321488469235	-1.321488469235	-1.02349221493582	-0.9876270936225	5.16750834473823	28.4203151018363	1.68346864991845e-05	0.000557589479629687	0.179948800038863	0.416043708559491
HIF1A	BRD-K10843433-001-22-7::2.5::HTS002	2.5	phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	PTGIS, PTGS1, PTGS2	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.1393470740935	-0.1393470740935	0.13058011789256	0.1428689114125	6.78314290437656	157.054804199081	2.26052342610853e-10	1.43895374337516e-08	0.191327075938764	0.348527308033355
HIF1A	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.4858960396135	-0.4858960396135	-0.282161138564928	-0.2553419121665	6.39862156164806	187.039229843607	1.22664136989542e-09	7.23458497986557e-08	0.140922370415804	0.26654743168134
HIF1A	BRD-K11267252-001-04-4::2.5::HTS002	2.5	alectinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.07469499896965	0.07469499896965	-0.158229375421912	-0.125024480839	-4.74876032457048	164.679616523401	4.42522957119314e-06	0.000163076861892066	-0.329771360072732	-0.136077388710392
HIF1A	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-6.169518583525	-6.169518583525	-4.2499829892962	-4.34713599697	13.4865301388606	25.5735670710053	3.93695629811011e-13	3.40930871279856e-11	1.62673481542264	2.21233637303496
HIF1A	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.758862528355	-1.758862528355	-2.87390329430056	-2.63264407289	-8.71169614750877	165.172777499293	3.00092308694128e-15	3.18250788867411e-13	-1.36775508439884	-0.862326447492281
HIF1A	BRD-K18849474-001-04-4::2.60504::HTS002	2.60504	dalcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.4778066154505	0.4778066154505	0.298636146451663	0.27891575921	-6.17281327907096	45.8138978392733	1.61796003356529e-07	7.41607690406361e-06	-0.237602657143155	-0.12073828085452
HIF1A	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.182804246395	0.182804246395	0.415587700366476	0.442474468431	8.23433042323266	35.0278031270078	1.04634996186258e-09	6.20883557519506e-08	0.175394194291821	0.29017271365113
HIF1A	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.302580428764	0.302580428764	-0.268339174692827	-0.316992636258	-10.2798256557037	110.684417236664	8.33803518947435e-18	1.12963511006628e-15	-0.680975054807542	-0.460864152106112
HIF1A	BRD-K23984367-075-15-2::2.5::HTS002	2.5	sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.007670584943765	0.007670584943765	-0.861215350624677	-0.738304903661	-11.5322438215202	177.85419966737	2.4787542780234e-23	5.47135865761563e-21	-1.01756927482181	-0.720202596315075
HIF1A	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.01033263606	-2.01033263606	-2.81357468297573	-2.6496200301	-7.39197646784991	76.514499716218	1.53983544514625e-10	9.97375010948174e-09	-1.01964171247605	-0.586842381355408
HIF1A	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.111221813668	-0.111221813668	-0.980922972881825	-0.82417204092	-8.97091438260811	162.875416659155	6.74973247066094e-16	7.62605909701786e-14	-1.06113573019414	-0.678266588233509
HIF1A	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.8507036550225	-0.8507036550225	-0.397349955219857	-0.300509996498	7.09231744367721	25.9203780185687	1.59394264300141e-07	7.30911708882859e-06	0.321940910832995	0.58476648877229
HIF1A	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.281746944055	-2.281746944055	-3.0923854918957	-2.9100349769	-7.7118355027	42.2918433662463	1.35644826190432e-09	7.96291973502304e-08	-1.02272819004683	-0.598548905634572
HIF1A	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.06398007958535	-0.06398007958535	-0.50512780875361	-0.436225052339	-7.10190807039652	4.99333229619944	0.000862451991068657	0.0194188961859181	-0.600888172926171	-0.28140728541035
HIF1A	BRD-K26997899-001-02-2::2.5::HTS002	2.5	D-64131	microtubule inhibitor	chemo	TUBB	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.659883591625	-2.659883591625	-3.02154915431746	-2.92524371085	-3.63945933284687	104.493252854314	0.000426576848033404	0.0104036723123155	-0.558715859059813	-0.164615266325108
HIF1A	BRD-K27184429-300-01-3::2.5::HTS002	2.5	levocetirizine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.06034381162255	-0.06034381162255	-0.356617596837064	-0.252619761318	-6.29380413064792	143.661960302936	3.53318029202431e-09	1.98340230175296e-07	-0.389320699434349	-0.20322687099468
HIF1A	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-3.30981063236	-3.30981063236	-4.69534632022809	-4.92315521315	-15.2996653189797	189.747246046859	5.98733943093853e-35	3.79662861802848e-32	-1.56416910690096	-1.20690226883522
HIF1A	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.519710803044	0.519710803044	-0.1186785097703	0.0546590882103	-10.8615719004114	158.038833749282	7.03295958001174e-21	1.25928754705458e-18	-0.754475206419149	-0.522303419209451
HIF1A	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.898981476188	0.898981476188	0.757439420066084	0.759014306598	-4.60088741410038	141.002775253805	9.28448581190586e-06	0.000321839650587089	-0.202360518922385	-0.0807235933214471
HIF1A	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.8063463701425	-0.8063463701425	-0.504962258423305	-0.3949049279025	5.74839240733213	43.9584320248776	7.92029466548313e-07	3.28982332433786e-05	0.195717005806722	0.407051217631669
HIF1A	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.318525199555	0.318525199555	-0.0993415839714558	-0.09070553113985	-9.35887372772127	18.6327429128963	1.80265599951773e-08	9.35273439168811e-07	-0.511443584049294	-0.324289983003617
HIF1A	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.67505788058	-1.67505788058	-2.59671935472253	-2.52528636523	-9.3347787932655	182.959625919337	3.43387010501827e-17	4.37301215530874e-15	-1.11646541985421	-0.726857528430839
HIF1A	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.0633409688661	0.0633409688661	-0.239489110260848	-0.026104548309	-5.82101090701256	183.551369424109	2.56484139486249e-08	1.3018420701473e-06	-0.405471255618484	-0.200188902635413
HIF1A	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.656122250132	-0.656122250132	-0.349390517823456	-0.263302729629	6.06925055839064	17.5279246604148	1.09689899793058e-05	0.000374836201096084	0.200348617231482	0.413114847385606
HIF1A	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.85381287502	-2.85381287502	-1.76290685982704	-1.638279082955	11.2449700524869	133.212932660714	4.84240311554166e-21	8.7880390969596e-19	0.899021273255414	1.2827907571305
HIF1A	BRD-K41599323-001-02-3::2.5::HTS002	2.5	lonafarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, HRAS, KRAS, NRAS	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.4484870381455	-0.4484870381455	-1.29429242564241	-1.19482949475	-8.12555632242486	4.39730425913256	0.000826217312685501	0.0187277245306146	-1.12479859938416	-0.566812175609669
HIF1A	BRD-K43457670-001-27-8::2.5::HTS002	2.5	acetazolamide	carbonic anhydrase inhibitor	noncancer	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.1019542450697	-0.1019542450697	0.262784108992189	0.242495378939	13.5273168710848	42.5906433153877	5.13395731320678e-17	6.44991756730537e-15	0.310346969099612	0.419129739024166
HIF1A	BRD-K48195801-001-01-6::2.5::HTS002	2.5	tecastemizole	histamine receptor antagonist	noncancer	KCNH2	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.140907779985	0.140907779985	0.343071434660309	0.312371086483	6.26596658885947	195.998645229344	2.30500239053885e-09	1.31776168941531e-07	0.138534956951995	0.265792352398624
HIF1A	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.577520155563	-0.577520155563	-0.949918060690632	-0.580173633208	-3.91504464773874	18.3729823943855	0.000981674445173081	0.0217772599577385	-0.571946600166648	-0.172849210088616
HIF1A	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.268299199668	-0.268299199668	0.0313949401402603	0.0483026079462	8.54325904557241	4.08192554977579	0.000941334569265114	0.0209899393358326	0.203063650442973	0.396324629173548
HIF1A	BRD-K49328571-001-15-0::2.5::MTS010::PROS005_PR500	2.5	dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor	targeted cancer	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.737837603845	-1.737837603845	-0.453181864811219	-0.279272959842	16.2708549476273	188.188219294165	9.72810248454704e-38	8.05024894753082e-35	1.12890633081616	1.4404051472514
HIF1A	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.0460694801158	0.0460694801158	-0.288110240797419	-0.277245593931	-8.40255419196174	17.5519383459469	1.46275268285655e-07	6.74215741427876e-06	-0.417889081175593	-0.250470360650845
HIF1A	BRD-K50071428-001-03-3::2.5::HTS002	2.5	abiraterone	androgen biosynthesis inhibitor	targeted cancer	CYP11B1, CYP17A1	oncology	prostate cancer	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.621944033408	0.621944033408	0.521266844982528	0.521292609125	-3.54632110211051	25.3763114766987	0.00154674656555238	0.0322702856661419	-0.159101889823785	-0.0422524870271594
HIF1A	BRD-K52172416-001-11-4::2.5::HTS002	2.5	anastrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.1532643318	0.1532643318	0.305954983919688	0.301007029734	5.5585346129292	73.4887220463795	4.15249226225878e-07	1.79290796550697e-05	0.097949976517896	0.20743132772148
HIF1A	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.1006614976546	-0.1006614976546	-0.769456521174317	-0.6098527820225	-9.77985178220432	163.381675418211	4.53806663374738e-18	6.28726104424332e-16	-0.803827340620025	-0.533762706419409
HIF1A	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.2589624823735	0.2589624823735	0.469635751546683	0.4617368983695	7.68097276478215	68.9629102508471	7.68097164348805e-11	5.16067389146442e-09	0.155955498670917	0.265391039675449
HIF1A	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.11895855084205	0.11895855084205	-0.240724456706212	-0.10314419939105	-5.34064538819095	9.02978740796904	0.000462905477714394	0.011192922848945	-0.511958709284751	-0.207407305811773
HIF1A	BRD-K58049875-001-04-7::2.5::HTS002	2.5	thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	noncancer	FOXM1	obstetrics/gynecology	mastitis	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.2774194763635	-0.2774194763635	-0.810752295105815	-0.698370160758	-7.5707348354771	19.7650938289195	2.91819571774105e-07	1.28906424152457e-05	-0.680393973460316	-0.386271664024313
HIF1A	BRD-K59369769-001-20-3::2.5::HTS002	2.5	tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, AURKC, LCK	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.26306289434	-1.26306289434	-1.78962726778389	-1.696260218435	-6.65295307165355	10.3090371759727	4.91839305766667e-05	0.00148660875145486	-0.702201952771119	-0.350926794116654
HIF1A	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.4797764875425	-0.4797764875425	-0.204199326300283	-0.243848377549	8.06232134665864	9.12398699801736	1.91751148590141e-05	0.000627543623853663	0.198414535249301	0.352739787235134
HIF1A	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.629024560411	-0.629024560411	-2.09208276559805	-1.79411655002	-11.7443133975145	130.293509112183	3.60413336265438e-22	7.18577022776141e-20	-1.70951147440157	-1.21660493597252
HIF1A	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.6912701152405	-0.6912701152405	-0.245308347732668	-0.116969809946	7.49744336749427	20.4180479931352	2.74295247864256e-07	1.21618149995882e-05	0.322047469442547	0.569876065573116
HIF1A	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.932549050875	-2.932549050875	-4.00256107157744	-4.1239035813	-7.85316172829518	5.82044101790983	0.000261822167964962	0.00671084470674029	-1.40591870607815	-0.734105335326738
HIF1A	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.0445743115929	0.0445743115929	-0.211520112809225	-0.1382371077965	-6.01289213557332	15.3922101678578	2.13029929771567e-05	0.000690539803660165	-0.346673699841851	-0.165515148962399
HIF1A	BRD-K63126190-003-01-6::2.5::HTS002	2.5	epinephrine	adrenergic receptor agonist, neurotransmitter	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.178696735001	-0.178696735001	-0.440980834456209	-0.3976462300305	-3.80391810510931	158.002314239457	0.000203156332038581	0.00535641450233695	-0.398468731395777	-0.126099467514641
HIF1A	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.21947813555	-1.21947813555	-2.13790707571482	-2.025815521035	-7.89214631653056	6.5610609832066	0.000139432205715973	0.00381957633165885	-1.19738251603852	-0.639475364291115
HIF1A	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.10913877486395	-0.10913877486395	-0.608099980670593	-0.456560974373	-6.49537198074451	8.11056083938209	0.000177986762216293	0.00477025444029711	-0.675684290614149	-0.322238120999137
HIF1A	BRD-K66715657-050-01-0::2.5::HTS002	2.5	UH-232-(+)	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4, HTR1A	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.3162374004525	-0.3162374004525	0.00126498758470371	0.0198593711464	7.66220087314208	4.45936208979577	0.000993505828606157	0.0220067290966649	0.206979981860985	0.428024794213422
HIF1A	BRD-K68202742-001-16-5::2.63491::HTS002	2.63491	trichostatin-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-6.33524942936	-6.33524942936	-5.49984301041757	-5.50871409078	9.34770800069243	10.292627941251	2.37702708820181e-06	9.16800141780106e-05	0.637041965706503	1.03377087217836
HIF1A	BRD-K68336408-001-10-9::2.5::HTS002	2.5	tyrphostin-AG-1478	EGFR inhibitor	targeted cancer	EGFR, MAPK14	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.8992725158	-1.8992725158	-2.64937609552572	-2.59421184968	-7.24700599084065	70.6070313634736	4.24040058948668e-10	2.62064826396796e-08	-0.956507207231306	-0.543699952220127
HIF1A	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.940603040545	-2.940603040545	-3.67899635164257	-3.50719189578	-6.58804131605651	180.441912798299	4.72662787997194e-10	2.91190982146165e-08	-0.959551045398474	-0.517235576796657
HIF1A	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.487211844167	-0.487211844167	-1.19760201189378	-1.12346956245	-9.29203847419271	40.9038922753682	1.23766321945738e-11	9.1629402474294e-10	-0.864798097784772	-0.555982237668789
HIF1A	BRD-K72703948-001-10-1::2.5::HTS002	2.5	ZM-447439	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.593954015366	-0.593954015366	-1.3801333051874	-1.23720066309	-11.5255883724085	192.983919160615	1.00492155875223e-23	2.28888238858456e-21	-0.9207153396341	-0.651643240008709
HIF1A	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.093226257145	-2.093226257145	-2.63618983020373	-2.52531204565	-6.59608849014183	83.8365742862973	3.57006243478958e-09	2.00305736017282e-07	-0.706662614454093	-0.379264531663363
HIF1A	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.92812069714	-1.92812069714	-0.667596846124543	-0.4541784692175	11.5914513616884	3.83811747297876	0.000397280198888227	0.00974687130809464	0.953507395183654	1.56754030684726
HIF1A	BRD-K81839095-001-30-1::2.5::HTS002	2.5	estrone	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.186505499818	0.186505499818	0.408621039159439	0.408585546428	8.8914149958796	38.4250588331274	7.29100944099593e-11	4.90944003292246e-09	0.171562718042872	0.272668360640006
HIF1A	BRD-K85090592-008-22-7::2.5::HTS002	2.5	pilocarpine	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.750724429935	0.750724429935	0.469154445155924	0.471563787015	-7.19280974829081	29.544325374713	5.7676046638193e-08	2.7954883310532e-06	-0.361568593011043	-0.201571376547109
HIF1A	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.4295451499735	-0.4295451499735	-0.782511227315312	-0.783090045771	-6.2604965529921	13.2942688203345	2.64141793678035e-05	0.000841707500702044	-0.474493916912987	-0.231438237770638
HIF1A	BRD-K90574421-001-03-5::2.5::HTS002	2.5	ipsapirone	serotonin receptor agonist	noncancer	HTR1A	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.18489550235	-0.18489550235	-0.0367750427510316	-0.0431604898369	5.63172263839161	43.7105900163751	1.19299154919569e-06	4.81711917384257e-05	0.0951041756760791	0.201136743521858
HIF1A	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.0847349185966	-0.0847349185966	-0.27389391266125	-0.208293631699	-3.61598526034893	19.916462559071	0.00173231339009578	0.0355667664067087	-0.298309016669976	-0.0800089714593233
HIF1A	BRD-K95523387-001-09-6::2.5::HTS002	2.5	OLDA	TRPV agonist	noncancer	GPR119	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.2166488293065	-0.2166488293065	0.282511328564105	0.369716989561	7.55510770203611	4.7868608506959	0.00077903552412623	0.0177797790278406	0.327023878919367	0.671296436821844
HIF1A	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.6723639520995	-0.6723639520995	-1.09313954347225	-1.03443241086	-5.68793327180432	13.037692711138	7.35960425066574e-05	0.00214346598646683	-0.580545982075402	-0.261005200670101
HIF1A	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.2514277224185	0.2514277224185	0.0926640134388652	0.162270559212	-5.38925167914148	185.494202622655	2.13038332227255e-07	9.59249846805365e-06	-0.216882103604739	-0.100645314354531
HIF1A	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	SKOV3, 786O	OVARY, KIDNEY	carcinoma (adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.222858835288	-0.222858835288	-0.0749614708697843	-0.0657751951103	4.72393615024937	30.9500559640322	4.74766081481056e-05	0.00143824932124033	0.0840399405176966	0.211754788318735
HMMR	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.240840282995	-2.240840282995	-1.20160572479808	-1.08580167806	14.1892434108163	40.6027319039878	2.49052466784031e-17	3.21174284917897e-15	0.891277368499507	1.18719174789433
HMMR	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.2583171758675	-0.2583171758675	-0.00132095748026197	0.008505826587825	6.2913090292709	4.50141889219167	0.00217319568023427	0.0430479535072949	0.148392926765392	0.365599510009084
HMMR	BRD-A25687296-300-04-3::2.5::HTS002	2.5	emetine	protein synthesis inhibitor	targeted cancer	RPS2	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.87210007067	-5.87210007067	-4.92902665091144	-4.931127887025	8.8708797698982	5.47806176708505	0.000187758839359599	0.00499468341580035	0.676811667245909	1.20933517227122
HMMR	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.403556314423	0.403556314423	-0.228132967174117	-0.09818472346655	-8.50355830408406	5.13747227994707	0.000323278965115983	0.00810576243733546	-0.821118984388801	-0.442259578805434
HMMR	BRD-A70858459-001-01-7::2.5::MTS010::PROS003_PR500	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.1369836572735	-0.1369836572735	-0.013798139686888	-0.0140777407944	6.45975006718772	167.198482842514	1.09771220060306e-09	6.50101017527088e-08	0.0855370822679223	0.160833952905302
HMMR	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.021556981561125	-0.021556981561125	-0.186981125782626	-0.138056758361	-3.42681333070596	60.8855166668711	0.00109985784605889	0.0240150195892376	-0.261956568937477	-0.0688917195055261
HMMR	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.1601305006155	-0.1601305006155	0.160765034768315	0.166606190016	8.74162895313277	3.40079836665192	0.00190611609634073	0.0384866657383526	0.211487035671334	0.430304035096297
HMMR	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.166941055565	-4.166941055565	-3.01084646700768	-2.85234115214	7.37903834531016	3.9330573824018	0.00192004067126974	0.0387131135496306	0.718165633514887	1.59402354359975
HMMR	BRD-K03273112-001-01-8::2.5::HTS002	2.5	1-azakenpaullone	glycogen synthase kinase inhibitor	noncancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.368023945525	-1.368023945525	-0.708340855390747	-0.635465288366	7.8615968896393	12.5144644904185	3.44802860279209e-06	0.0001292884048999	0.477684461474834	0.841681718793672
HMMR	BRD-K12244279-001-05-8::2.5::HTS002	2.5	MEK1-2-inhibitor	MEK inhibitor	noncancer	MAP2K2	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.42757879907	-0.42757879907	-0.152678567443756	-0.1558908725075	7.21231928255875	8.35428254382911	7.34469678846786e-05	0.00214028758392322	0.187650615609478	0.362149847643009
HMMR	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.132553116826	-0.132553116826	-0.514851081487309	-0.419130200084	-5.56682183591454	28.6408322627665	5.47908744514923e-06	0.000198299110609826	-0.522829363018139	-0.241766566304478
HMMR	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.4074195950065	-0.4074195950065	-0.109746095917473	-0.02484856783435	5.475115807812	193.806701184545	1.3438860212147e-07	6.22910352597155e-06	0.190443721033008	0.404903277145047
HMMR	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0843721481956	-0.0843721481956	-0.169881455209557	-0.1612454874865	-4.44458627477378	180.67646811591	1.53316572250354e-05	0.000511522223129609	-0.123471293648736	-0.0475473203791778
HMMR	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.427425180061	-0.427425180061	-0.778476776392633	-0.759682041762	-5.52811731393692	145.660872454479	1.45473466568331e-07	6.70952929118225e-06	-0.476557759897486	-0.22554543276578
HMMR	BRD-K24603946-001-02-1::2.5::HTS002	2.5	5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	noncancer	CHRM3	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-3.19787187454	-3.19787187454	-2.41209146079042	-2.16827680102	7.19077227245073	40.9347888148214	8.95544025964427e-09	4.80453205359023e-07	0.565081932787237	1.00647889471192
HMMR	BRD-K28143534-001-02-2::2.5::HTS002	2.5	cyproheptadine	histamine receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.120579351718	0.120579351718	-0.00618334727348231	0.02120744072425	-4.01630286458614	33.5840888711639	0.000313978784764145	0.00789103646338116	-0.190933746746945	-0.0625916512360195
HMMR	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.922619193735	-1.922619193735	-0.598675976705867	-0.471294403844	20.1914154306538	51.2933901819939	4.57673329132324e-26	1.27227843008563e-23	1.19232501292133	1.45556142113693
HMMR	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.08951449282005	-0.08951449282005	0.214098523011902	0.242460199933	12.1456163140208	6.42498778194954	1.13927528230955e-05	0.000387833119412523	0.24341323518315	0.363812796480754
HMMR	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.292966103846	0.292966103846	0.577845459060388	0.571651612309	7.63481141547762	12.5220291595393	4.67156691426638e-06	0.00017138861094964	0.203955157432642	0.365803552996135
HMMR	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.92829783819	-5.92829783819	-4.65215936084414	-5.03947371329	10.5357051895227	191.007150308623	9.37856525853894e-21	1.65986665012171e-18	1.03722385377021	1.51505310092152
HMMR	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.04332105411855	-0.04332105411855	0.25929546306584	0.300751796019	8.10568417407049	12.4629071137168	2.5626102401086e-06	9.82719073451846e-05	0.221606846390465	0.383626187978315
HMMR	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.24766400107	-1.24766400107	-1.7450624266539	-1.65992199057	-6.15735640739163	53.089189896567	1.01026410867774e-07	4.75783116125669e-06	-0.659418570270444	-0.335378280897358
HMMR	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.2952379005315	-0.2952379005315	-1.34078814209907	-1.07204580455	-9.14790724555028	5.85142263090743	0.000110795624982591	0.00310942981627522	-1.32694781175435	-0.764152671380796
HMMR	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.08122393428915	-0.08122393428915	-0.264153480660067	-0.234942866008	-5.02622249972242	179.709785538581	1.20268828669578e-06	4.84987728690913e-05	-0.254746137183908	-0.111112955557926
HMMR	BRD-K48195801-001-01-6::2.5::HTS002	2.5	tecastemizole	histamine receptor antagonist	noncancer	KCNH2	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.01414548448839	-0.01414548448839	0.344653610828405	0.312371086483	10.9140033421549	147.145704992594	1.09402999810684e-20	1.9267243670028e-18	0.293830735500688	0.423767455132902
HMMR	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.517835466675	-4.517835466675	-3.65156933183766	-3.66301517797	10.4531448713415	16.9906593586695	8.09966499965336e-09	4.36837720108381e-07	0.691415565929607	1.04111670374507
HMMR	BRD-K52313696-001-12-3::2.5::MTS010::PROS004_PR500	2.5	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.3180396573805	-0.3180396573805	-0.00789636172419995	0.011267309880105	9.93410706415076	26.9817223401202	1.64762484361555e-10	1.06429712208342e-08	0.246083018721325	0.374203572591275
HMMR	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.1251094886665	-0.1251094886665	0.140663799688245	0.155273340434	9.84494571941027	21.7357615989563	1.80839263785465e-09	1.04782640086172e-07	0.209747705623001	0.321798871086489
HMMR	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1333272166475	0.1333272166475	-0.297271197936473	-0.406253558846	-6.01132139766592	51.213388287675	1.94221186070249e-07	8.7784126084459e-06	-0.574389585521527	-0.286807243646418
HMMR	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.4103174216	-2.4103174216	-0.59699282428283	-0.573831164789	25.201126796523	143.010065325117	1.83075154758999e-54	6.8839148849722e-51	1.67109355899933	1.95555563563501
HMMR	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1662590059185	0.1662590059185	-0.138763027919647	0.01900224238145	-4.53084454259932	36.1639497305371	6.18957991544711e-05	0.00183283569176273	-0.441534330205107	-0.168509737471187
HMMR	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0457648993069	-0.0457648993069	-0.39260032444692	-0.201440599557	-5.33931302835929	129.641013711451	4.04819294529972e-07	1.75069642004266e-05	-0.475352006931951	-0.21831884334809
HMMR	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.513252027915	-1.513252027915	-1.32752901967767	-1.441894150425	3.09734525808584	140.387248050997	0.00235862045208068	0.0461915901748903	0.0671777690054407	0.304268247469226
HMMR	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.3612204051865	0.3612204051865	0.142943618986009	0.0968721731692	-6.7367402024894	17.4651109361202	3.02487024851657e-06	0.00011466526627066	-0.286498401324154	-0.150055171076828
HMMR	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-3.261361358005	-3.261361358005	-2.62414720029795	-2.476182958975	7.95398650997393	161.538724533171	2.97301329215088e-13	2.60295329204823e-11	0.479011237061142	0.795417078352948
HMMR	BRD-K74671368-001-01-8::2.5::MTS006	2.5	idronoxil	XIAP inhibitor	targeted cancer	ENOX2, SPHK1	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.223736464725	0.223736464725	-0.256427646741853	-0.195737211392	-9.22630182693992	4.42369365118025	0.000470938705392253	0.0113666465977496	-0.619360837310863	-0.340967385622844
HMMR	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.88366036964	-0.88366036964	-0.613848286535673	-0.517259346977	5.15317982815798	193.679661302568	6.28666031149521e-07	2.64302396606994e-05	0.16654630283778	0.373077863370874
HMMR	BRD-K81548480-001-01-2::2.5::HTS002	2.5	AC-264613	PAR agonist	noncancer	F2RL1	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.07727279471655	0.07727279471655	-0.374111151243067	-0.2564995934565	-8.99087316730729	115.754006942758	5.54529603929195e-15	5.7499649482603e-13	-0.55082287571984	-0.351945016199394
HMMR	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.043027668624195	0.043027668624195	-0.427779325410766	-0.2959843885325	-6.57963252291385	5.73530988226856	0.000710111366228938	0.01637305477173	-0.647873812987058	-0.293740175082864
HMMR	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.49252438176	-5.49252438176	-4.36436626696564	-4.35832408201	8.9922842272644	3.4441911877839	0.00164585546809205	0.0340233947357929	0.756500398521843	1.49981583106687
HMMR	BRD-K84892605-001-01-1::2.5::HTS002	2.5	IOWH032	CFTR channel antagonist	noncancer	CFTR	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.00143779368493	-0.00143779368493	0.119040474342189	0.126672721217	4.81418791782909	179.273725586045	3.12870052506067e-06	0.000118162335653873	0.07109549476018	0.169861041294057
HMMR	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0165729623974	-0.0165729623974	0.302252249980448	0.276885156297	6.56126972119481	4.59520494531568	0.00169361209684608	0.0348827779266695	0.190532244130552	0.447118180625144
HMMR	BRD-K95523387-001-09-6::2.5::HTS002	2.5	OLDA	TRPV agonist	noncancer	GPR119	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.5871728739005	0.5871728739005	0.272826729730286	0.3623330707505	-5.06839792066583	6.85744719317857	0.00154205870860229	0.0321923370508759	-0.46162234836832	-0.167069939972107
HMMR	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	MIAPACA2, NCIH650	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.467601323252	0.467601323252	-0.229836315800261	-0.0281474951666	-11.3572247661053	92.0870328862985	3.31363835541719e-19	5.09110247367893e-17	-0.819399996726118	-0.575475281378404
HOOK3	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.318614871218	0.318614871218	0.148674755663298	0.1611474271015	-7.39300099738192	178.438408029794	5.36551717646326e-12	4.13218085129067e-10	-0.215300712277314	-0.124579518832089
HOOK3	BRD-A10977446-001-12-1::2.5::HTS002	2.5	carvedilol	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA	cardiology	myocardial infarction, hypertension	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.6750021227205	-0.6750021227205	-0.211672326156997	-0.2026520966345	7.7265196408591	12.811751042092	3.57661545157165e-06	0.000133875727055519	0.333586995463261	0.593072597663745
HOOK3	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.4554509790965	-0.4554509790965	0.000732519636706787	0.008505826587825	11.075653609332	4.26152969153317	0.000266792013961028	0.00682191190172432	0.344542708181822	0.567824289284591
HOOK3	BRD-A16997652-001-02-3::2.5::HTS002	2.5	protirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	radiology	thyroid function diagnostic	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.4661399521795	0.4661399521795	0.333754966884027	0.352492434088	-5.48668589235471	27.1163297841056	8.14803672818458e-06	0.000285492980859093	-0.181882449277795	-0.0828875213131512
HOOK3	BRD-A17883755-001-06-1::2.5::HTS002	2.5	lenalidomide	anticancer agent	targeted cancer	CDH5, CRBN, PTGS2, TNF, TNFSF11	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.2496708960885	0.2496708960885	-0.0535324867998169	0.0179498928779	-5.02528590061561	180.03804755015	1.20607417818746e-06	4.86170157112543e-05	-0.422259177301187	-0.184147588475447
HOOK3	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.4730386401065	-0.4730386401065	-0.0479697059829023	0.009756743375275	11.5211272755691	45.7433918119686	4.05029118798248e-15	4.25536696092694e-13	0.350792441006044	0.499345427241152
HOOK3	BRD-A31095847-001-02-3::2.5::HTS002	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.386886110119	0.386886110119	0.0238490519012034	0.0703858703435	-10.9806298501105	187.678077079717	5.53795919552222e-22	1.08495910092969e-19	-0.42825714380908	-0.297816972626513
HOOK3	BRD-A72703248-003-04-9::2.5::HTS002	2.5	SKF-96365	calcium channel blocker	noncancer	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-5.296605183035	-5.296605183035	-3.51794809944231	-3.53004479557	10.5866377677991	3.06578184815545	0.00163500706225776	0.0338219697564563	1.25040749458885	2.30690667259653
HOOK3	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.3588146858695	0.3588146858695	0.0271043439130379	0.05909936864605	-5.88373503546653	54.5867764656402	2.53410949297533e-07	1.1265985345777e-05	-0.444712628060444	-0.21870805585248
HOOK3	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.07946262921255	-0.07946262921255	0.159924744441201	0.166606190016	9.22246233166769	93.9149619481974	8.33686571883363e-15	8.4965862703371e-13	0.187848550733101	0.290926196574401
HOOK3	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-4.3056394542	-4.3056394542	-2.7450012178462	-2.614624073445	15.2196311773358	136.674325396661	3.24408090208624e-31	1.43954578812265e-28	1.35786589263881	1.7634105800688
HOOK3	BRD-K02594908-001-16-4::2.5::HTS002	2.5	sulfanilamide	carbonic anhydrase inhibitor	noncancer	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.05196837291375	0.05196837291375	-0.365617313285898	-0.3369002650265	-5.75072080715531	166.011526518881	4.17044657460647e-08	2.05718675233332e-06	-0.560952604687855	-0.274218767711442
HOOK3	BRD-K03765900-001-01-9::2.5::MTS006	2.5	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.787961829964	-0.787961829964	-1.17080887406751	-0.823393929272	-4.46269788130255	176.581661045047	1.43834257199529e-05	0.000481685195489342	-0.552149245935171	-0.21354484227185
HOOK3	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.01571507160561	-0.01571507160561	0.243101401122313	0.240200693149	7.15733328902407	4.01368764037511	0.00199065027845921	0.0399376657803879	0.15855227134941	0.359080674106436
HOOK3	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.22630149385	-0.22630149385	-0.685758985821891	-0.506361258966	-6.41301623557927	45.3941652457014	7.32836367471686e-08	3.50990135874501e-06	-0.603722394469592	-0.31519258947419
HOOK3	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-5.49692610703	-5.49692610703	-3.00348623463372	-2.91986435367	17.4466717359232	3.08776888407459	0.00034586258501386	0.00862158432000878	2.0458387464705	2.94104099832206
HOOK3	BRD-K09900591-001-26-7::2.5::HTS002	2.5	caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	noncancer	ALOX5, MIF	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.288716762543	0.288716762543	-0.0571209645175956	-0.0732110977947	-10.7178053464769	162.359982211064	1.31958175904269e-20	2.31065881400213e-18	-0.409555979280033	-0.282119474841158
HOOK3	BRD-K13167095-001-02-9::2.5::HTS002	2.5	AR-42	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-3.803723506505	-3.803723506505	-3.24651156237701	-3.236768116465	4.81627578077093	172.706995535709	3.18248790044447e-06	0.000120003421747777	0.328856642907853	0.785567245348125
HOOK3	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.532937734608	0.532937734608	0.399255157608894	0.431459247123	-3.91374740736338	19.9994928589994	0.000860709589110905	0.0193836631911992	-0.204933323009417	-0.0624318309887939
HOOK3	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.545389524693	-0.545389524693	-0.0648692995839978	0.051024564158	9.46854701464213	8.02800979831679	1.24435411577957e-05	0.000421195788504296	0.363563627941144	0.597476822276861
HOOK3	BRD-K19687926-379-07-4::2.5::HTS002	2.5	lapatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2	oncology	breast cancer	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.3963493908915	-0.3963493908915	-0.661636899796237	-0.522756667285	-4.16833373657946	16.000783621201	0.000724895769072615	0.0166737696168238	-0.40020524655872	-0.130369771250754
HOOK3	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-4.924059225115	-4.924059225115	-4.16942150835512	-4.1358778776	6.35429572744728	4.89702535889496	0.00153936761892532	0.0321480076046799	0.447413810355513	1.06186162316424
HOOK3	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.216850259141	0.216850259141	-0.409017211112354	-0.310618907363	-10.8240042410402	182.41158450334	2.09452972716584e-21	3.91384883952683e-19	-0.739953760634781	-0.511781179871928
HOOK3	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.842567285591	-0.842567285591	-0.527754088626806	-0.447815997104	5.61892649654893	7.52967218220793	0.00061915480196564	0.0144682544211179	0.184195745970338	0.445430647958049
HOOK3	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-2.137663766565	-2.137663766565	-1.33202363542437	-1.36979496737	11.8982506734525	128.766419202065	1.76158924277089e-22	3.64439827040389e-20	0.671670344228516	0.939609918052753
HOOK3	BRD-K30519779-001-03-1::2.5::HTS002	2.5	homoquinolinic-acid	glutamate receptor agonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.149930804804	0.149930804804	0.430114777807508	0.45172565456	9.17957455003627	180.035526160346	1.01728395027786e-16	1.23812295161331e-14	0.219956027766798	0.340411918240219
HOOK3	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.6777644050045	-0.6777644050045	-0.396667307248252	-0.249189788856	4.51898765815519	131.530443416992	1.36897072827908e-05	0.00046003469304065	0.158048253777401	0.404145941735094
HOOK3	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.5595826581945	0.5595826581945	0.0370994462878313	0.143970790547	-10.2329676893435	8.9531964531619	3.07400025831799e-06	0.000116260349632087	-0.638078384037903	-0.406888039775434
HOOK3	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.036349380034	-0.036349380034	0.173098952677067	0.1694730901705	6.37499556749297	4.90398102579152	0.00150938275003527	0.0316014941322954	0.124492927709399	0.294403737712734
HOOK3	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.7397195799895	-0.7397195799895	-0.0317589031562734	-0.03550064325705	16.8429617204528	167.611836398634	6.89716644036471e-38	5.86612216665448e-35	0.624978301789903	0.79094305187655
HOOK3	BRD-K37590257-001-02-8::2.5::HTS002	2.5	GSK256066	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.3139576392565	-0.3139576392565	-0.0809416549766824	-0.072384668123	3.59315800330718	115.904075215093	0.000480778078255782	0.0115689552862337	0.104571439730271	0.361460528829364
HOOK3	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-6.12003662955	-6.12003662955	-4.65016208176747	-5.03947371329	11.7419188911763	112.656510115171	2.81900090051434e-21	5.1951302150158e-19	1.22185863948294	1.71789045608212
HOOK3	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.2394901968835	-0.2394901968835	-0.496136434854445	-0.332266676493	-4.24370248928306	16.0397862096295	0.000616137978611135	0.0144040397925115	-0.384825831433602	-0.128466644508287
HOOK3	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.1207870194474	-0.1207870194474	-1.34262446716312	-1.07204580455	-11.4384453369298	9.10396721223239	1.04815124846494e-06	4.26198461263975e-05	-1.4630576610614	-0.980617234370029
HOOK3	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.0448290925275	0.0448290925275	-0.956434806743936	-0.580280097075	-11.5387541725185	96.3799019285265	7.31254944598567e-20	1.18644315685743e-17	-1.17350027137794	-0.829027527164933
HOOK3	BRD-K50388907-001-30-4::2.5::HTS002	2.5	fenofibrate	PPAR receptor agonist	noncancer	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.462103240702	0.462103240702	0.195183617285558	0.187372218959	-9.28016385833908	18.947793060048	1.77159681135812e-08	9.20495934500786e-07	-0.327131210580506	-0.206708036252378
HOOK3	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.0758389387301	0.0758389387301	-0.326206291848411	-0.2394985033815	-7.63134269300075	23.8894814460647	7.42299460891478e-08	3.55125672217432e-06	-0.510805090680721	-0.293285370476301
HOOK3	BRD-K53523901-001-04-4::2.5::HTS002	2.5	arctigenin	MEK inhibitor	targeted cancer	CHUK, MAP2K1	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.938200825873	-0.938200825873	-0.428726665361619	-0.429548063404	13.2151649169013	47.1268806477844	1.83259611310884e-17	2.39520347287302e-15	0.431922576467583	0.587025744555178
HOOK3	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.536158991063	-0.536158991063	-0.203602686051388	-0.243848377549	11.6520226078729	157.641620805565	5.01569859380029e-23	1.08696629313511e-20	0.276184903430734	0.388927706592489
HOOK3	BRD-K62391742-001-03-0::2.5::HTS002	2.5	venetoclax	BCL inhibitor	targeted cancer	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.1077871965329	0.1077871965329	0.361367887151992	0.3408626748475	8.70993181044309	46.6130332163477	2.43186330295844e-11	1.73335161243692e-09	0.194998100497783	0.312163280740402
HOOK3	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.04189975915775	0.04189975915775	-0.49417602574875	0.00436707189359	-4.86731133039736	8.15507601056308	0.00117758275586464	0.0255248922412735	-0.789216186110211	-0.282935383702788
HOOK3	BRD-K62696033-001-01-4::2.5::HTS002	2.5	G-1	G protein-coupled receptor agonist	targeted cancer	GPER1	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.463171510919	-0.463171510919	-1.25556051115077	-1.18405970294	-9.4823253407486	21.5356641055519	3.84793842900329e-09	2.14996036379001e-07	-0.965908774799415	-0.618869225664119
HOOK3	BRD-K69172251-001-08-9::2.5::HTS002	2.5	cisplatin	DNA alkylating agent, DNA synthesis inhibitor	chemo	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.183791218562	0.183791218562	0.383358940691514	0.3712286324115	7.54273900081929	73.890344029872	9.52112070501626e-11	6.33153049824831e-09	0.146847195522136	0.252288248736893
HOOK3	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-1.482784038715	-1.482784038715	-0.882066595848287	-0.689609968602	9.03797696051858	30.6034052239348	3.81005414096102e-10	2.3752329667773e-08	0.465088070411112	0.736346815322313
HOOK3	BRD-K81016934-001-02-0::2.5::HTS002	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.2920917756905	0.2920917756905	0.142264400224946	0.2010478375385	-4.46193930806167	46.4388418726751	5.13927982177797e-05	0.00154552645562207	-0.217401126470468	-0.082253624460639
HOOK3	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.1405314369835	0.1405314369835	0.01566570626841	0.0495734767378	-4.30609175192997	56.5985032881181	6.67318593901363e-05	0.00196140601909333	-0.182941074613501	-0.0667903868166786
HOOK3	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-1.2393333641	-1.2393333641	-1.69186804561721	-1.42296021894	-4.37526892087389	9.81951505028776	0.00144895555872389	0.0305211986187452	-0.683566852407525	-0.221502510626889
HOOK3	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.3699712668175	-0.3699712668175	-0.100009937305903	-0.0599890522741	7.56105950121139	12.4014363798657	5.47871754039287e-06	0.000198299110609826	0.192447004699059	0.347475654324135
HOOK3	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.1676923363295	-0.1676923363295	-0.504155232562028	-0.3823931691785	-5.53125783338331	177.052866389943	1.12691091478077e-07	5.27933747440541e-06	-0.456506795993824	-0.216418996471232
HOOK3	BRD-K84783599-001-01-0::2.5::HTS002	2.5	riociguat	guanylate cyclase stimulant	noncancer	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.5054618950685	0.5054618950685	-0.00806790747520975	0.04755872580485	-9.07377464609623	15.5725940725234	1.30282185092565e-07	6.05579059828764e-06	-0.633773909417082	-0.393285695670338
HOOK3	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-2.579231611975	-2.579231611975	-2.22930682872141	-2.16824610201	4.88784742601739	41.3394265637329	1.58095420182932e-05	0.000525829194791864	0.205380323871122	0.494469242636067
HOOK3	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	0.3262771424955	0.3262771424955	0.151194412058145	0.185599499868	-8.66512816138372	151.27807427036	6.40379309406473e-15	6.58282287797506e-13	-0.215004025023202	-0.135161435851509
HOOK3	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.2894864464495	-0.2894864464495	0.102779865177031	0.1765205692495	8.94043965429742	6.43896558315765	7.30068259332969e-05	0.0021289088429194	0.286656262798339	0.497876360454724
HOOK3	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-3.21622678313	-3.21622678313	-0.934703157435351	-0.823450093444	25.0620657061636	42.1949462970938	5.77987690687551e-27	1.73500733553742e-24	2.09783282401694	2.46521442737236
HOOK3	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-0.3291133059375	-0.3291133059375	-0.0728206275722174	-0.0594618685141	4.70380233686404	15.3613459907217	0.000265590872485283	0.00679606328902797	0.140395410993236	0.372189945737329
HOOK3	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	CAL120, SH10TC	BREAST, STOMACH	carcinoma	-1.341860954485	-1.341860954485	-0.855473582363555	-0.7866589985	10.7914180871622	139.810290138768	3.98572729882735e-20	6.68956105113834e-18	0.397277180037999	0.575497564204892
IKZF3	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.181421542285	0.181421542285	-0.180714221782607	-0.1596607583295	-6.97108000811625	9.98091047488145	3.88524062576109e-05	0.00119728804574139	-0.477913807058577	-0.246357721076637
IKZF3	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.122559409601	0.122559409601	0.253730940234431	0.256070233499	4.71035724305556	68.9603958563341	1.23991498917257e-05	0.000419759500417578	0.0756167794270007	0.18672628183986
IKZF3	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3078487093905	0.3078487093905	-0.0156433450324972	0.03331372318045	-5.55371555013858	8.97943679659985	0.00035764156695471	0.00888626934892604	-0.455303883095322	-0.191680225750673
IKZF3	BRD-A50998626-001-02-1::2.5::HTS002	2.5	palomid-529	AKT inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3327925245045	0.3327925245045	0.0414688144169797	0.0209581438432	-9.90638026048842	190.236912292029	6.41780909745713e-19	9.5655257722454e-17	-0.349330734471388	-0.233316685703653
IKZF3	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.05903825014	-1.05903825014	-0.689062582198701	-0.624576558799	7.18001402698619	187.969440947568	1.57480698877943e-11	1.15236192249268e-09	0.268327124755427	0.47162421112717
IKZF3	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.651455818558	0.651455818558	0.354415415822285	0.3602013274625	-11.7116895444748	22.7017873307556	4.24061533501223e-11	2.93378581064505e-09	-0.349545367006902	-0.244535438464529
IKZF3	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.5899512142565	0.5899512142565	-0.241979175959919	-0.2322368233935	-12.3680542285304	3.23556111156306	0.000781212134692088	0.0178218643551273	-1.03744372647064	-0.6264170539622
IKZF3	BRD-A79981887-003-16-4::2.5::HTS002	2.5	midodrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.0266707132395	0.0266707132395	-1.04826972115648	-1.024762922465	-9.28783487625805	3.40202161088595	0.00155917609501641	0.03250706201729	-1.41982543415517	-0.730055434636782
IKZF3	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.05806365114765	-0.05806365114765	0.0683988712466062	0.07956967035945	4.2442498777352	37.0862703542352	0.000140723922187163	0.00385074433752208	0.0660944246848766	0.186830620103636
IKZF3	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.253367972242	-0.253367972242	-1.46640416278761	-1.380035679485	-16.1487698874974	77.5795643425521	1.58241270350727e-26	4.62697042742169e-24	-1.36259406544005	-1.06347831565118
IKZF3	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.2703243788625	-0.2703243788625	-2.05479170367573	-1.66463476506	-14.3673709200735	165.528564012917	6.55818173649927e-31	2.81685076834098e-28	-2.02969316448181	-1.53924148514464
IKZF3	BRD-K09602097-001-13-6::2.5::HTS002	2.5	forskolin	adenylyl cyclase activator	targeted cancer	ADCY2, ADCY5, GNAS	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0765305640124	-0.0765305640124	0.0434178819415975	0.0420503630099	3.59023560520681	116.588522085168	0.000484625490269201	0.0116484576319286	0.0537799828511605	0.186116909056835
IKZF3	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.4806782246775	0.4806782246775	0.181898543378464	0.22754908413	-7.99830024243468	51.7937684333482	1.3159964374508e-10	8.60714679409195e-09	-0.373745874516069	-0.223813488082003
IKZF3	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.175796968339	0.175796968339	-0.289200425883571	-0.2721742756055	-11.4011013970111	6.28200018740676	1.97753516514165e-05	0.000645413635464665	-0.563719480886604	-0.366275307558539
IKZF3	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.403103721722	-0.403103721722	-1.81844686990379	-1.56065418801	-13.2423519831354	142.772579069485	1.29117721495954e-26	3.80655737696097e-24	-1.62661496689841	-1.20407132946517
IKZF3	BRD-K13533483-001-16-2::2.5::MTS005	2.5	cyclosporine	calcineurin inhibitor	noncancer	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	transplant, rheumatology, dermatology	organ rejection, rheumatoid arthritis, psoriasis	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3400594469725	0.3400594469725	0.222815124964359	0.221127225806	-4.16149121117165	11.0586846032309	0.0015675206035947	0.0326557854548313	-0.179213943733461	-0.0552747002828213
IKZF3	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.6025823840495	0.6025823840495	0.237155494038428	0.274310189966	-13.9581728371259	171.03061536661	4.77125254050897e-30	1.92583387147787e-27	-0.417104687252163	-0.31374909276998
IKZF3	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.39188485727	-2.39188485727	-0.955241136383271	-0.729695465511	21.2649371073949	192.940421499447	1.82963110720211e-52	5.76680890552237e-49	1.30339416440886	1.5698932773646
IKZF3	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.090596678356	0.090596678356	-0.213782248572853	-0.0984348398408	-5.2860638321302	21.6242687445157	2.78972148130577e-05	0.000883057473588515	-0.423915847027896	-0.18484200682981
IKZF3	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.6741026440635	0.6741026440635	-0.246048540971617	-0.0866927101235	-12.1795575577315	7.62434186906479	2.87162941465579e-06	0.00010924271579939	-1.09587256531463	-0.744429804755599
IKZF3	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.538692757895	-3.538692757895	-3.07894222115944	-2.8750109584	4.60652235574261	146.408201674924	8.82815638921753e-06	0.000307014429781698	0.262507424607613	0.6569936488635
IKZF3	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.961937533401	-0.961937533401	-1.98485422046747	-1.88069436606	-10.2456853847759	190.125717397259	6.79398923519751e-20	1.1090243098177e-17	-1.21985065153028	-0.825982722602674
IKZF3	BRD-K34332569-001-01-3::2.5::HTS002	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.1915347809485	0.1915347809485	-1.00950660345529	-0.918687700318	-10.694506290026	6.30616267394915	2.83069335317393e-05	0.000894705317346138	-1.47263881390364	-0.929443954903937
IKZF3	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3143982190595	0.3143982190595	0.0235956151899958	0.046531478462	-8.66334161918041	188.076682795144	2.07442889612083e-15	2.23985023111678e-13	-0.357018846691516	-0.224586361047493
IKZF3	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.427772732775	0.427772732775	-0.0788194510891567	-0.0620606581655	-16.2186704848581	168.136066654977	3.2390234804537e-36	2.34532656602081e-33	-0.568255741097623	-0.44492862663069
IKZF3	BRD-K37237504-001-02-7::2.5::HTS002	2.5	CEP-33779	JAK inhibitor	targeted cancer	JAK2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.6281684379285	0.6281684379285	0.184846713432692	0.151776458835	-8.57897396132939	3.24642909232097	0.00244571825476335	0.0476578186948972	-0.600934425461006	-0.28570902353061
IKZF3	BRD-K37865504-001-04-1::2.5::HTS002	2.5	LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	noncancer	FAAH	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.02525261243148	-0.02525261243148	-1.30320279945802	-1.08170547456	-15.3677410139942	87.0405833015743	1.58871289167866e-26	4.63906328829149e-24	-1.44323457554947	-1.1126657985036
IKZF3	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.70818115075	-1.70818115075	-2.75722991503842	-2.75783530181	-10.581590705676	16.1169341017008	1.15601084094522e-08	6.1419595322e-07	-1.25909028602194	-0.839007242554893
IKZF3	BRD-K43236057-001-07-1::2.59978::HTS002	2.59978	polydatin	ICAM1 expression inhibitor	noncancer	ICAM1	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.3035907022285	-0.3035907022285	-1.32418274853973	-1.21412289307	-11.9334252821433	13.6075273238892	1.36920059506412e-08	7.22450503051449e-07	-1.20451996954538	-0.836664123077077
IKZF3	BRD-K47337578-034-02-5::2.5::HTS002	2.5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	noncancer	HTR2A	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.2423959515985	0.2423959515985	-0.128521964678805	-0.101623022714	-8.18034777844866	11.2006352232454	4.69828962461142e-06	0.000172251063454215	-0.470498545495535	-0.271337287059074
IKZF3	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.043881276	-2.043881276	-0.0460830585114037	0.365958476092	21.9553834599088	28.7926707358297	1.58243708594442e-19	2.49567445322576e-17	1.81163729157957	2.18395914339762
IKZF3	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.53303579475	-3.53303579475	-1.22518262432926	-0.855735961913	20.5826271326198	5.29289801594741	2.95374958831515e-06	0.000112207407925203	2.02435539722717	2.5913509436143
IKZF3	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.98831703741	-2.98831703741	-3.66784080448942	-3.70951336465	-9.30307602489738	185.589365153075	3.84943011075495e-17	4.87614956387706e-15	-0.823624920827253	-0.535422613331577
IKZF3	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-5.188305810125	-5.188305810125	-5.93096368222199	-5.96310429975	-8.58281369630364	6.277418198086	0.000107384296532483	0.00302120883322533	-0.952137866539951	-0.533177877654029
IKZF3	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.325711452242	0.325711452242	-0.591108229975796	-0.48109263675	-12.4167159325947	195.435494496471	1.77539365601674e-26	5.15607516125219e-24	-1.06244033928159	-0.771199025154007
IKZF3	BRD-K60184833-001-05-6::2.5::HTS002	2.5	tyrphostin-AG-99	tyrosine kinase inhibitor	targeted cancer	EGFR	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.32906401236	-1.32906401236	-1.68935233791404	-1.52742041275	-4.5734282127103	173.349758940252	9.10211854041821e-06	0.000315835264494847	-0.515777081631939	-0.204799569476146
IKZF3	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.8710230567465	-0.8710230567465	-1.54302509075198	-1.43484346641	-11.1261213493953	165.814457956295	7.83162972453654e-22	1.51493264190451e-19	-0.791251437527355	-0.552752630483611
IKZF3	BRD-K61642990-001-01-0::2.5::HTS002	2.5	FERb-033	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.5102225750975	0.5102225750975	0.178736096225849	0.239686907074	-6.85823367994825	6.6903145545076	0.00029413702333739	0.00744122923452307	-0.446859697567113	-0.21611326017619
IKZF3	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3694426057435	0.3694426057435	0.143315650497029	0.15713254048	-8.08093638720778	40.2750735583665	5.84423239606834e-10	3.55646929363127e-08	-0.282670205938293	-0.169583704554648
IKZF3	BRD-K66175015-001-09-0::2.5::HTS002	2.5	afatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.65737958838	-2.65737958838	-0.888861810849662	-0.737713790302	16.9043189601856	22.6523165194496	2.45898165445223e-14	2.40324249437799e-12	1.55191234035108	1.98512321470959
IKZF3	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.356565657957	-0.356565657957	-2.65024031793677	-2.62453052692	-17.0000052612048	109.339861784554	1.79452047102214e-32	8.88262766821486e-30	-2.56107634302831	-2.02627297693124
IKZF3	BRD-K69650333-003-14-0::2.5::HTS002	2.5	idarubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-6.17530950336	-6.17530950336	-6.63128514344741	-6.575075579375	-4.22392645440287	140.773115231787	4.28844505958695e-05	0.00131174274464994	-0.669389672247805	-0.242561607927015
IKZF3	BRD-K70821460-300-02-4::2.5::HTS002	2.5	4-methylhistamine	histamine receptor agonist	noncancer	HRH4	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.293809798785	0.293809798785	0.478778442783081	0.473971299308	6.32252103945824	180.452423943878	1.96314272089684e-09	1.1319839016064e-07	0.127241728705638	0.242695559290523
IKZF3	BRD-K72827473-001-01-0::2.5::HTS002	2.5	CEP-37440	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.2881528106655	0.2881528106655	-0.236617166012655	-0.1997036713495	-12.2470883784919	115.044715869597	1.39024636559596e-22	2.90136429690182e-20	-0.609644356561927	-0.439895596794383
IKZF3	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.06946126673825	0.06946126673825	-0.156363873096308	-0.1366984748555	-5.0067111258365	31.8954975484932	1.9644178463209e-05	0.000641425521913637	-0.317711781631434	-0.133938498037681
IKZF3	BRD-K75911534-001-01-6::2.5::HTS002	2.5	SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.1040375733963	0.1040375733963	-0.528499632314087	-0.4139887396705	-8.45865431280511	5.01996928787918	0.000371849481198586	0.00921472163901166	-0.824535252716529	-0.440539158704245
IKZF3	BRD-K76011241-001-01-8::2.5::HTS002	2.5	oseltamivir-phosphate	neuraminidase inhibitor	noncancer	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.470538197736	0.470538197736	0.323778362523142	0.301103308343	-5.19142398393674	10.99290617164	0.000299042417050619	0.00755106764892108	-0.208985855252172	-0.0845338151735429
IKZF3	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0152101174647	-0.0152101174647	-0.171813981879641	-0.171973558527	-4.67601701330067	32.6908560008288	4.86796143021624e-05	0.00147178065365611	-0.224766032613733	-0.0884416962161482
IKZF3	BRD-K76908866-001-07-6::2.5::HTS002	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.44254343809	-1.44254343809	-0.687754976601018	-0.619490026625	11.5266058326365	173.13697141207	3.54019718518873e-23	7.76629398673813e-21	0.625542129068681	0.884034793909282
IKZF3	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.205555694046	-0.205555694046	0.00469736888758956	0.03806515271055	7.83926099212064	179.042002504644	3.90861596934918e-13	3.38613481040679e-11	0.157328067894216	0.263178057972963
IKZF3	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.482954006595	-1.482954006595	-3.0795944646439	-2.99864068297	-13.0226932753399	5.48245336265876	2.47929124199004e-05	0.000794858824472248	-1.90364333113274	-1.28963758496506
IKZF3	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.32515625811	0.32515625811	-0.332853908809988	-0.3298674569485	-8.8895709391456	12.9992779845889	6.92600306155213e-07	2.90100314672544e-05	-0.817922560463531	-0.498097773376446
IKZF3	BRD-K82818427-001-02-2::2.39189::HTS002	2.39189	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.717410865053	-0.717410865053	-1.6226263158589	-1.52596467706	-13.4464287533409	21.7897004903901	5.01201666073286e-12	3.87805241472279e-10	-1.04490703955329	-0.765523862058505
IKZF3	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.909121062454	-0.909121062454	-1.70823803828742	-1.55120007366	-8.20067732258783	3.42457647278801	0.00228578118008738	0.0449994667536464	-1.08857546893285	-0.509658482734
IKZF3	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.125526185465	-1.125526185465	-2.07009170680188	-1.887176140495	-9.2470076497364	177.814372419694	7.16626203636605e-17	8.88338794674551e-15	-1.14614433874826	-0.742986703925502
IKZF3	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.9336532712335	0.9336532712335	-0.324106453066537	-0.108614953002	-16.5361815912126	123.301348104297	4.40888738534453e-33	2.36238106103377e-30	-1.40831430040174	-1.10720514819833
IKZF3	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0209483446636	-0.0209483446636	-0.97060516236194	-0.879578497328	-11.0076556091592	177.998974124809	7.9396997690723e-22	1.53445258052795e-19	-1.11990512080595	-0.779408514590726
IKZF3	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	NCIH2170, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.270058992375	-1.270058992375	-0.611658316822458	-0.6000769492995	10.6064471683397	7.12863483519216	1.27346222230002e-05	0.00043009751755963	0.51215064476325	0.804650706341835
IMMP2L	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-2.7417919651	-2.75505643691	-3.82303901390598	-3.84018189027	-7.35958223187602	6.79063581990089	0.000179316136068599	0.00480168017584293	-1.43083345728132	-0.731660640330648
IMMP2L	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.104491904191	-0.0779443605049	-0.450098716442709	-0.338375716384	-4.15106970624506	35.2407039796618	0.000199309579681319	0.00526795201671198	-0.514586836692418	-0.176626787811
IMMP2L	BRD-A74391928-051-01-3::2.5::HTS002	2.5	ibutilide	potassium channel blocker	noncancer	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.282792036971	-0.295677931613	0.17434733785191	0.166211801936	7.03438058515871	4.9396654940482	0.00094203733747323	0.0210012399108904	0.289470818693552	0.624807930952268
IMMP2L	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.557647091542	-0.568667553202	-1.23174186672018	-1.26677083286	-6.67932345886715	8.61609558814603	0.000111031246239616	0.00311504950932164	-0.903957673209499	-0.444231877146865
IMMP2L	BRD-K11590034-002-03-4::2.48778::HTS002	2.48778	morin	cytochrome P450 inhibitor	noncancer	ADORA2A, ESR2, FASN, MCL1, SLC22A12	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.345677221539667	0.334441011347	0.591426402627249	0.5787933623985	6.96420347275183	16.0321477222864	3.1552112305342e-06	0.000119100610748356	0.170955257358487	0.320543104816677
IMMP2L	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-2.66073088093667	-2.74304793907	-3.69467388522994	-3.61087064154	-6.74529644757676	5.10736539957127	0.000999210826865408	0.0221115491678865	-1.42549253030684	-0.642393478279712
IMMP2L	BRD-K16136380-001-01-7::2.5::HTS002	2.5	pyrithione-zinc	ATP synthase inhibitor	noncancer	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-5.22574744439	-5.13435504725	-6.35936756600091	-6.344923432095	-6.61237977872569	5.00015313718864	0.00118993895427038	0.0257692660533308	-1.57431417537192	-0.692926067849914
IMMP2L	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-4.57607147568	-4.56110541818	-4.17095233127335	-4.12140382517	4.33288806602937	106.067704774358	3.35465571908254e-05	0.00104521006776456	0.219750361443062	0.59048792737024
IMMP2L	BRD-K21782625-001-02-4::2.5::HTS002	2.5	AMG458	MET inhibitor	targeted cancer	MET	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.147787968078	-0.142346557161	0.0304243480165616	0.013560290369	3.95103577277715	111.492468614445	0.00013681278162438	0.00376013453056131	0.088837672592322	0.267586959596801
IMMP2L	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.206858891575667	-0.19003424642	-0.86557556465123	-0.560893595726	-5.77348415916167	17.5253634646584	1.99588880195019e-05	0.000650589625554459	-0.898884274152723	-0.418549071998404
IMMP2L	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.0440842570735333	0.0265322999523	-0.431844392978168	-0.3312681012	-10.7965340532006	37.4348543950763	4.7024969747207e-13	4.03798667505975e-11	-0.565211475890618	-0.386645824212785
IMMP2L	BRD-K28907958-001-04-3::2.5::HTS002	2.5	CD-437	retinoid receptor agonist	targeted cancer	RARG	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-3.02660173645667	-3.09560563167	-4.22243905257556	-4.12783481329	-7.05166512841558	4.01131817978644	0.00211002358955363	0.0420145374551612	-1.66614968616256	-0.725524946075229
IMMP2L	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-4.6660221682	-4.67128885545	-3.61145138479932	-3.57314682257	11.3143231364585	12.2205995348951	7.77996162913396e-08	3.71043924345939e-06	0.851896654664126	1.25724491213723
IMMP2L	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.0547999532987	0.0501947760866	-0.0734018280957756	0.031018744091	-3.5045042916788	21.4363920155909	0.0020612848668698	0.0411659638679964	-0.204184026725938	-0.0522195360630129
IMMP2L	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-1.17084932964667	-1.11884341717	-0.683959763509597	-0.628462635581	5.91748519290765	5.11849404902267	0.00181286754553086	0.0369063533592405	0.276846859760081	0.696932272514058
IMMP2L	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.605894802792667	-0.572094840877	-0.288483076113628	-0.267330713915	4.9444099106596	7.25210988212521	0.00150406831233108	0.031511774908466	0.166675365134959	0.468148088223119
IMMP2L	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-1.03553691860433	-1.0816579985	-0.281166517354423	-0.359027987102	7.48084545994915	6.39793232915553	0.000216963710287562	0.00568132132708892	0.511295998527222	0.997444803972599
IMMP2L	BRD-K54256913-001-08-7::2.5::MTS010::PROS004_PR500	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.254346484431333	0.258400508839	-1.23367645175284	-1.2377676824	-11.9953905693724	18.3723501146057	3.95153493458173e-10	2.45273249636249e-08	-1.74826330303518	-1.22778256933317
IMMP2L	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.0103420935340333	0.0189059455575	-0.144623753063822	-0.1473080580285	-5.42107380187503	6.53106749190513	0.00123898837279883	0.0266831932228296	-0.223556985538505	-0.0863747076572051
IMMP2L	BRD-K63923597-001-10-0::2.5::HTS002	2.5	barasertib-HQPA	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-1.88369669032667	-1.93756343726	-1.15638537526054	-0.9900702194875	6.39681277743878	6.0402001897761	0.000669560982555754	0.0155141984681289	0.449548068222474	1.00507456190978
IMMP2L	BRD-K71035033-001-07-1::2.5::HTS002	2.5	masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor	noncancer	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.481257478988	0.473879720543	0.275155114129902	0.308896006376	-5.05305972464407	57.1086146197847	4.77129912446787e-06	0.000174599243648297	-0.287774832313394	-0.124429897402802
IMMP2L	BRD-K73293050-001-03-1::2.5::HTS002	2.5	WZ-3146	EGFR inhibitor	targeted cancer	EGFR	NA	NA	RVH421, ONS76	SKIN, CENTRAL_NERVOUS_SYSTEM	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma	-1.962807876335	-1.962807876335	-2.5799046192219	-2.4237476511	-4.93976282860636	6.09340095412254	0.00249311627416172	0.0484536740954668	-0.921643460399446	-0.312550025374349
IMMP2L	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-1.17173050724333	-1.21004445459	-0.883955477391175	-0.6850177992955	3.95007008645084	21.1670579738351	0.000723012047310978	0.0166429437319423	0.136341395843432	0.439208663860884
IMMP2L	BRD-K74141488-003-11-2::2.5::HTS002	2.5	naftifine	fungal squalene epoxidase inhibitor	noncancer	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.241166091151667	0.245503183073	0.363856470128167	0.337388105067	4.6408031284918	57.2846738905683	2.06532518283096e-05	0.000671407676491698	0.0697562678081226	0.175624490144878
IMMP2L	BRD-K76011241-001-01-8::2.5::HTS002	2.5	oseltamivir-phosphate	neuraminidase inhibitor	noncancer	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.0579525050219	0.0569457475142	0.329490389973035	0.306389581038	11.029443540227	140.773262957895	8.95849665347111e-21	1.59077516921442e-18	0.222866410551337	0.320209359350933
IMMP2L	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-0.0304579645962	0.0650206132914	-1.071816546092	-0.791129598907	-6.70497967424224	4.82616160159389	0.0012814161404489	0.0274589722021867	-1.44496317375297	-0.637753989238644
IMMP2L	BRD-K79930101-300-03-7::2.5::HTS002	2.5	GW-583340	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.0861776537467333	0.12404681977	-0.537040779513419	-0.366813054419	-7.65448109305284	15.3339395376239	1.28401243868997e-06	5.16034318342363e-05	-0.796429844451607	-0.450007022068697
IMMP2L	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-3.66327383868	-3.7150951904	-2.87094775860566	-2.81855044317	5.14185356812443	7.62067109540697	0.00102750517943932	0.022650362265324	0.433883467277918	1.15076869287076
IMMP2L	BRD-K91623615-001-05-0::2.46068::HTS002	2.46068	ABT-751	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	-3.08299010387667	-3.05729588883	-3.49748512462988	-3.44393502818	-3.96702370403782	55.3614635201751	0.000211197930894475	0.00555153981065557	-0.623857191908693	-0.205132849597738
IMMP2L	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	RVH421, ONS76, HCC15	SKIN, CENTRAL_NERVOUS_SYSTEM, LUNG	malignant_melanoma, primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (squamous_cell_carcinoma)	0.333538609863667	0.338194810245	-0.0140413363297541	0.0436894050189	-6.43228064654109	12.5012848236707	2.67796644151694e-05	0.000851455080023563	-0.464794563320148	-0.230365329066693
ITCH	BRD-A06352418-001-25-9::2.5::HTS002	2.5	terfenadine	histamine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.675657580607	0.675657580607	0.0543636814265476	0.03270660508035	-10.1315268402578	4.0118852986027	0.000526294206657563	0.0125431014142899	-0.791354630729662	-0.451233167631243
ITCH	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.3038350788195	-0.3038350788195	-0.047842045422567	0.112237719657	4.76683393566556	188.977347808483	3.7258692746513e-06	0.000138904476564053	0.150058781267867	0.361927285525999
ITCH	BRD-A17883755-001-06-1::2.5::HTS002	2.5	lenalidomide	anticancer agent	targeted cancer	CDH5, CRBN, PTGS2, TNF, TNFSF11	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	1.107329311875	1.107329311875	-0.0624201387768791	0.0179498928779	-13.0051546858774	3.07434965075177	0.000867418636788242	0.019510228670814	-1.45211813926735	-0.887380762036408
ITCH	BRD-A27883417-300-01-6::2.5::HTS002	2.5	alexidine	phosphatidylglycerophosphatase inhibitor	targeted cancer	PTPMT1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.0290660584029	-0.0290660584029	-0.236174100919709	-0.2582141227055	-4.94625416189114	193.958596603571	1.63500260923111e-06	6.45475178179951e-05	-0.289690336494162	-0.124525748539456
ITCH	BRD-A51964809-003-12-6::2.5::HTS002	2.5	halofantrine	antimalarial agent	noncancer	KCNH2, KCNN4	infectious disease	malaria	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.004539684495205	0.004539684495205	-0.131332613589375	-0.13262425304	-4.73917654693517	194.144323350529	4.14040391737657e-06	0.00015315992944553	-0.192416988723489	-0.0793276074456712
ITCH	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.3359810786075	-0.3359810786075	0.191139118681221	0.190024427126	13.8959101630806	4.20199628045838	0.000113656077324291	0.00318179119603421	0.42376695119806	0.630473443379381
ITCH	BRD-A67748489-001-10-0::2.5::HTS002	2.5	K-858	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-5.00454829389	-5.00454829389	-2.61766057966016	-2.49115990214	16.1334963388158	3.06275312449511	0.000460470668584325	0.0111390765154639	1.92146791142037	2.85230751703931
ITCH	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.879252822055	0.879252822055	0.202984122129868	0.236646785158	-13.9168985475731	11.7365343750928	1.18574119890002e-08	6.29056251037235e-07	-0.782408714500901	-0.570128685349363
ITCH	BRD-A93477898-001-04-2::2.5::HTS002	2.5	PETCM	caspase activator	noncancer	CASP3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.512357718441	0.512357718441	0.176286956028316	0.179996842636	-7.91163774574847	24.166525013967	3.65608363181873e-08	1.81693153788946e-06	-0.423709143474478	-0.24843238135089
ITCH	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.1175686163418	-0.1175686163418	0.0690319027912248	0.07956967035945	5.22986115683995	5.89788581634748	0.00206284620263284	0.0411894693277523	0.0989274149734989	0.274273623292551
ITCH	BRD-K02594908-001-16-4::2.5::HTS002	2.5	sulfanilamide	carbonic anhydrase inhibitor	noncancer	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.3693718125795	0.3693718125795	-0.369395925662871	-0.3369002650265	-8.93169071248848	15.8600572934931	1.38579051082367e-07	6.40671040539963e-06	-0.914237482399229	-0.563297994085514
ITCH	BRD-K03109492-001-02-2::2.5::HTS002	2.5	NSC-663284	CDC inhibitor	targeted cancer	CDC25A, CDC25B, CDC25C	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.674502653479	-0.674502653479	-1.21572375280281	-0.957814328752	-5.40998863369305	13.3881296805829	0.000107459202487039	0.00302252275719745	-0.756711516514136	-0.325730682133489
ITCH	BRD-K03601870-001-01-2::2.5::HTS002	2.5	ixabepilone	microtubule stabilizing agent	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-4.71939199142	-4.71939199142	-3.61372489763393	-3.52276573862	11.8560030348962	183.036787249883	1.9946892918421e-24	4.85817910490029e-22	0.921668200957743	1.2896659866144
ITCH	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-3.0759988757	-3.0759988757	-1.66626603108357	-1.3362918287	12.0121401477289	165.251597217175	2.71180833517241e-24	6.51590996265883e-22	1.17801647156672	1.64144921766615
ITCH	BRD-K06753942-001-14-5::2.5::HTS002	2.5	nobiletin	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.53005199681	0.53005199681	-0.080939935140984	-0.0747677969197	-8.18352864659377	3.48008719470321	0.00215914825136073	0.0428092586092408	-0.831088357927001	-0.390895505974967
ITCH	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.491008765938	-0.491008765938	-0.852446815577825	-0.70967469814	-6.36653315312502	34.1461253084498	2.83647594679651e-07	1.25503520479139e-05	-0.476793567160602	-0.246082532119047
ITCH	BRD-K08109215-001-06-4::0.625::HTS002	0.625	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.778479117805	0.778479117805	0.313281319096974	0.333968556929	-7.3037991662492	166.680877195224	1.09747110494625e-11	8.17019397193553e-10	-0.590945962949212	-0.33944963446684
ITCH	BRD-K09372874-001-01-0::2.5::HTS002	2.5	merimepodib	inosine monophosphate dehydrogenase inhibitor	noncancer	IMPDH1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.6560862939665	-0.6560862939665	-0.903012286700061	-0.8954429864795	-4.43498717410179	87.2091227166559	2.67332845627436e-05	0.000850358882019632	-0.357585964301769	-0.136266021165354
ITCH	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.55114537361	-1.55114537361	-2.51901816120463	-2.34739362698	-9.09853542740211	173.847249345205	2.08716909447786e-16	2.49214966490443e-14	-1.17782899485199	-0.757916580337272
ITCH	BRD-K11073688-001-01-6::2.5::HTS002	2.5	CPI-1189	tumor necrosis factor release inhibitor	noncancer	TNF	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.06355799914	-0.06355799914	-0.262386882194765	-0.2451174209795	-3.91698526598271	25.3732174521261	0.000600357374335002	0.0140950811352664	-0.30329456836423	-0.0943631977452996
ITCH	BRD-K12244279-001-05-8::2.5::HTS002	2.5	MEK1-2-inhibitor	MEK inhibitor	noncancer	MAP2K2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.353871593207	-0.353871593207	-0.153462686655065	-0.1558908725075	6.29097972326234	125.019234367405	4.84863958631678e-09	2.6818169648921e-07	0.137360936326224	0.263456876777647
ITCH	BRD-K12885236-001-02-7::2.5::HTS002	2.5	dapivirine	non-nucleoside reverse transcriptase inhibitor	noncancer	CYP3A4, CYP3A5	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.5201407355635	-0.5201407355635	-1.34867333252317	-1.23896057589	-12.4367354833101	4.22172786573173	0.000174480193729402	0.00468506206988586	-1.00972981603149	-0.647335377887852
ITCH	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.9335243595815	0.9335243595815	0.501073999601071	0.505306635797	-18.1280639628184	68.27246939233	8.47271319933847e-28	2.77667912431348e-25	-0.480049425439725	-0.384851294521133
ITCH	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.04996424851555	0.04996424851555	-0.980545272194521	-0.735958486111	-14.4257683857966	71.667515764641	6.9197916360045e-23	1.47762770970752e-20	-1.17292453572944	-0.888094505690697
ITCH	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.11684970262355	-0.11684970262355	-0.374944351536099	-0.173057746988	-3.36367730446047	96.9071682023692	0.00110275994704148	0.024071029299262	-0.410384118036863	-0.105805179788235
ITCH	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.7677697811315	0.7677697811315	0.543188041407085	0.547894384564	-8.59005113735735	96.7036778923684	1.50351897316833e-13	1.35569086243246e-11	-0.276473146232666	-0.172690333216164
ITCH	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.36931848776	-1.36931848776	-1.90827739498878	-1.67956785013	-5.62191557464226	98.8380446202571	1.75245596513811e-07	7.96949150333303e-06	-0.729184652140343	-0.348733162317227
ITCH	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.0160902383524535	0.0160902383524535	-0.170950204002621	-0.1612454874865	-7.32244249849951	4.97626490405156	0.000759920206534055	0.0173749667107145	-0.252796280721788	-0.121284603988362
ITCH	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-4.374135570175	-4.374135570175	-3.25546044129427	-2.99271378173	8.52661361850103	14.57201437405	4.82339263910109e-07	2.06304713818778e-05	0.838316045588834	1.39903421217262
ITCH	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.597179250001	0.597179250001	0.0856999508673391	0.0863678330512	-20.4446894437828	172.919510383698	5.19114227321264e-48	1.05963079264323e-44	-0.560858698746399	-0.462099899520923
ITCH	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.283671216125	0.283671216125	-0.40974749479524	-0.310618907363	-11.7608534759148	135.634949323315	1.8852738000454e-22	3.88527738740318e-20	-0.810018307813116	-0.576819114027363
ITCH	BRD-K25412176-001-01-9::2.5::MTS006	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.0191581087858	-0.0191581087858	-0.669301696184438	-0.516853765181	-9.86294512576491	9.11419444761393	3.65384557769425e-06	0.000136432938819099	-0.798975684237435	-0.501311490559842
ITCH	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.813754849754	-0.813754849754	-0.497193684201561	-0.427199621459	5.5949729896355	8.97406323015734	0.000339960248637221	0.0084843199965262	0.188512874834184	0.444609456270693
ITCH	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.0649781643109	0.0649781643109	-0.0339458686615025	-0.0304287468122	-3.99687527122157	90.3310204489514	0.000130849224750955	0.00361262185902967	-0.14809245409803	-0.0497556118467751
ITCH	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.5342290593705	0.5342290593705	0.268173479100716	0.2845478404215	-8.4780695851184	8.4217121431497	2.09855217361492e-05	0.00068076371850872	-0.337795805201011	-0.194315355338558
ITCH	BRD-K28907958-001-04-3::2.5::HTS002	2.5	CD-437	retinoid receptor agonist	targeted cancer	RARG	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-3.38889595929	-3.38889595929	-4.21222402192777	-4.123946828915	-8.94221115910861	187.433648957334	3.63527137188766e-16	4.22988098732524e-14	-1.00495879317893	-0.6416973320966
ITCH	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-3.09018738329	-3.09018738329	-3.63508194858146	-3.592577528105	-5.97239872286469	7.18939750432399	0.000503643315044533	0.0120690259470237	-0.759485358055594	-0.330303772527327
ITCH	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.2074268339545	0.2074268339545	-0.0224660214763102	-0.0227579244188	-6.33358280193321	5.7301468182606	0.00086641923812858	0.0194938871392883	-0.319733314197788	-0.140052396663832
ITCH	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.367378840693	0.367378840693	0.577023218874234	0.571651612309	6.32533482954736	87.5615362170796	1.03697162975903e-08	5.52593467017958e-07	0.143773837209728	0.27551491915274
ITCH	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.06938104792635	0.06938104792635	-0.18048792911026	-0.13613940777	-6.92900860152441	79.8418233391721	9.78765654725818e-10	5.83040200143774e-08	-0.321635410525188	-0.178102543548032
ITCH	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.802736793219	0.802736793219	-0.804536260594409	-0.4002530483955	-13.3095215885937	38.4996565821343	5.52791900897914e-16	6.30880379805906e-14	-1.85163705960271	-1.36290904802411
ITCH	BRD-K41783120-001-02-8::2.5::HTS002	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.674369596468	-0.674369596468	-0.274490663776438	-0.1460716862095	5.71034170484287	19.6726173746402	1.46315354155076e-05	0.000489382389836193	0.253648870706479	0.546108994676644
ITCH	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.4484967680645	-0.4484967680645	-1.33917489086188	-1.07204580455	-7.37895831087845	4.47907151527476	0.00114216362628863	0.0248551921879193	-1.21213525859145	-0.569220987003321
ITCH	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-5.851199623325	-5.851199623325	-5.27444858700426	-5.30447708423	7.04049890223999	143.721037989246	7.27887980005959e-11	4.9028127865084e-09	0.414829206113	0.738672866528489
ITCH	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.257020519367	-0.257020519367	-0.679105166242565	-0.588520646364	-7.63470391318098	67.5882622261917	1.04391204104794e-10	6.89705992126273e-09	-0.532416327550463	-0.311752966200666
ITCH	BRD-K48195801-001-01-6::2.5::HTS002	2.5	tecastemizole	histamine receptor antagonist	noncancer	KCNH2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.1973674662565	-0.1973674662565	0.346523222887263	0.312371086483	15.9226693792612	51.8523302874964	1.30639681866179e-21	2.47348695889542e-19	0.475342478061934	0.612438900225593
ITCH	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.3739891121635	0.3739891121635	-0.12805338839967	-0.007473093877485	-12.5516455026368	179.999979507585	2.29769896611232e-26	6.54871704398786e-24	-0.580968067506433	-0.423116933619907
ITCH	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.563420675169	0.563420675169	-0.143175935355764	0.01900224238145	-11.2272512335582	151.130830360589	1.1870886322472e-21	2.25956944459068e-19	-0.83094432761621	-0.582248893433317
ITCH	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.817423623665	-1.817423623665	-0.450454903295423	-0.469747665561	21.7077895377291	187.000406599771	5.44564435676724e-53	1.85263414181201e-49	1.24274319415943	1.49119424657972
ITCH	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.378662391561	-0.378662391561	-0.689568786882299	-0.642732938193	-4.64160428042089	7.19102000044171	0.00220348771649683	0.043563446064851	-0.468445974503977	-0.153366816138622
ITCH	BRD-K65877271-001-01-8::2.5::HTS002	2.5	halobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.4547013178635	0.4547013178635	-0.290411806097842	-0.253825714787	-11.9447505925906	5.16711125614759	5.84636228928661e-05	0.0017396154145502	-0.903918575013663	-0.586307672909021
ITCH	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-3.97011639722	-3.97011639722	-2.56656391242839	-2.37614016574	12.0123354345365	173.395171036391	1.41747856315645e-24	3.54500306841025e-22	1.17293561521201	1.63416935437121
ITCH	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.784013472565	-1.784013472565	-0.71138800324295	-0.5475428257095	7.85111721221345	3.44720900789439	0.00257146436771417	0.0497912536333734	0.66806888707005	1.47718205157405
ITCH	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.4032547053895	-0.4032547053895	-0.791479747649008	-0.646845557406	-5.69818405235244	96.0183451251065	1.32607884213627e-07	6.15321827573553e-06	-0.523464397841899	-0.252985686677118
ITCH	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.3378693969305	0.3378693969305	-0.535881356609052	-0.376499820922	-13.599336143978	7.85720616914477	9.7181892271677e-07	3.97801714833771e-05	-1.02238039482638	-0.725121112252723
ITCH	BRD-K72414522-001-06-7::2.5::HTS002	2.5	AZD5438	CDK inhibitor	targeted cancer	KCNH2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.753067210015	-1.753067210015	-2.42427876060207	-2.22027282363	-5.42377011998466	8.00151007549124	0.000627573563524851	0.0146426316456257	-0.956578690573708	-0.385844410600427
ITCH	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.09520035517265	-0.09520035517265	0.244804357410096	0.276258886308	9.54470180297866	189.122066129205	7.16041942505914e-18	9.75022576209339e-16	0.269736531622077	0.410272893543415
ITCH	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-2.09420509255	-2.09420509255	-0.665866800339022	-0.4541784692175	15.8482001044517	11.6493546867248	3.05523677990462e-09	1.72549629459862e-07	1.23131258213058	1.62536400229138
ITCH	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.4561864962525	0.4561864962525	-0.153777040303061	-0.132191437107	-9.89011082559472	3.18735375170623	0.00169427377011863	0.0348897005068943	-0.799869937233651	-0.42005713587747
ITCH	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.3764372006365	-0.3764372006365	-0.962533431764836	-0.892479910689	-8.41604537526821	5.37114925165642	0.000272142561661705	0.00694216175891354	-0.761454982301177	-0.410737479955495
ITCH	BRD-K81332461-001-01-4::2.5::HTS002	2.5	maxacalcitol	vitamin D receptor agonist	noncancer	VDR	endocrinology	hyperparathyroidism	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.2329574671655	0.2329574671655	-0.144581550202861	-0.1171657345245	-9.6886257062182	13.2660014414229	2.18645941201641e-07	9.83053617197535e-06	-0.461551355986132	-0.293526678750589
ITCH	BRD-K81839095-001-30-1::2.5::HTS002	2.5	estrone	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.6835048739255	0.6835048739255	0.40344396234582	0.3953780325455	-10.4359373150863	13.7000255580531	6.73170621312083e-08	3.24006256670104e-06	-0.337737298343546	-0.222384524815815
ITCH	BRD-K82135108-001-04-3::0.15625::MTS010::PROS001_PR500	0.15625	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.832107207005	-1.832107207005	-0.967303981010736	-0.893367929172	10.6939991762879	20.002117195714	1.01075961751922e-09	6.00929536930036e-08	0.696116502921153	1.03348994906737
ITCH	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.037817978498	-1.037817978498	-1.69413226343296	-1.42296021894	-6.60144138657898	14.1467744129341	1.12669269760237e-05	0.000383976656359387	-0.869341280668142	-0.443287289201778
ITCH	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.9096407562895	0.9096407562895	0.45093079632204	0.472553592618	-14.7008168376439	186.818708896212	5.22128661216583e-33	2.73612014254008e-30	-0.520265525400541	-0.397154394534378
ITCH	BRD-K85406984-001-01-0::0.15625::HTS002	0.15625	sobetirome	thyroid hormone receptor agonist	noncancer	THRA, THRB	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.5527198042005	0.5527198042005	0.235358888066436	0.238622249408	-8.43863030464742	5.10350444306791	0.00034670106488827	0.00864047587633	-0.41344887681935	-0.221272955448778
ITCH	BRD-K86816506-001-01-8::2.5::HTS002	2.5	PF-04457845	FAAH inhibitor	noncancer	FAAH	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.111601803281	-0.111601803281	-0.410164759626888	-0.370640421909	-10.2534604602808	192.966456658582	5.71735756401999e-20	9.41887416863059e-18	-0.355993891408702	-0.241132021283074
ITCH	BRD-K87909389-003-03-4::2.5::HTS002	2.5	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-5.05345113796	-5.05345113796	-5.33392918537367	-5.39635429682	-3.93843621774493	68.0216419653382	0.000195683039295046	0.00518232424676484	-0.422585720183951	-0.138370374643379
ITCH	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-1.76481388551	-1.76481388551	-1.4036055150207	-1.36288222555	4.51998086952484	103.462029799951	1.64975355701037e-05	0.000547522499412319	0.202726816776318	0.519689924202274
ITCH	BRD-K96344439-002-02-7::2.5::MTS006	2.5	tofogliflozin	sodium/glucose cotransporter inhibitor	noncancer	GCK	endocrinology	diabetes mellitus, diabetes mellitus	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.032749878861	-0.032749878861	0.14013049811915	0.25364293864	4.85903479663205	190.526260446808	2.45650218596503e-06	9.44902471313172e-05	0.102700723461171	0.243060030499128
ITCH	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.086042163274	0.086042163274	-0.244417393125326	-0.195507988981	-7.31363955441118	94.0147244909985	8.54700806486848e-11	5.71627290688602e-09	-0.420173282544182	-0.24074583025447
ITCH	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	0.164556788883	0.164556788883	-0.727984229860606	-0.596555071115	-14.6676472374755	126.242673688874	4.76580900647909e-29	1.78263713533971e-26	-1.01296111678789	-0.772120920699321
ITCH	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.477425829173	-0.477425829173	-1.09518078036153	-1.03443241086	-9.42247736086157	98.0070437777722	2.16932060210421e-15	2.33759836766412e-13	-0.747860171646656	-0.487649730730413
ITCH	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	8305C, OVCAR8	THYROID, OVARY	carcinoma (anaplastic_carcinoma), carcinoma	-0.55413111178	-0.55413111178	-0.863722062391879	-0.791872957089	-6.05716577185864	14.4515204901618	2.57515413304835e-05	0.000822548748408523	-0.41889380237665	-0.200288098847108
KIF15	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-2.12079331111	-2.12079331111	-1.20284332244638	-1.08580167806	10.6629947878527	6.86688984261346	1.60255145247496e-05	0.00053271594689956	0.713582869939584	1.12231710738765
KIF15	BRD-A20644369-001-08-6::2.5::HTS002	2.5	canrenone	mineralocorticoid receptor antagonist	noncancer	NR3C2	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.8696649433255	0.8696649433255	0.505394159071376	0.518391273844	-10.4572143332566	15.0910774352873	2.60841647339004e-08	1.32134080436117e-06	-0.438479540709875	-0.290062027798374
KIF15	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.215550975524	-0.215550975524	-0.775890896247755	-0.4776049590865	-5.20932576896961	47.2615617811883	4.07896869331489e-06	0.000151069860215913	-0.7767007148314	-0.343979126616111
KIF15	BRD-A27376179-001-01-3::2.5::HTS002	2.5	lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	targeted cancer	FLT3, NTRK1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-1.45344832928	-1.45344832928	-2.92976911038896	-2.893945062805	-11.8333504442627	5.9246097315319	2.40917413904125e-05	0.000773335156577162	-1.7825399608118	-1.17010160140613
KIF15	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.160204753627	0.160204753627	0.359641490981125	0.3667280736395	6.82138552114987	6.29869769431092	0.000395375291707164	0.00970902737125398	0.128710797336305	0.270162677371945
KIF15	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.533398117419	-0.533398117419	-0.230154446152809	-0.218507717473	6.2367609067333	45.4590574117952	1.33630800554749e-07	6.19799953518692e-06	0.205341261708314	0.401146080824068
KIF15	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.413295995144	-0.413295995144	-0.182942579250844	-0.1257743846785	4.16227952835754	9.3100537029029	0.0022663089381658	0.0446530362574129	0.105791333344541	0.354915498441771
KIF15	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.3597529651685	0.3597529651685	0.220762283487299	0.209209067771	-5.14280546820072	187.809668758532	6.77072240589613e-07	2.83762644218481e-05	-0.192304682007452	-0.0856766813549495
KIF15	BRD-K00494077-066-01-9::2.5::HTS002	2.5	trovafloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.1628087672425	-0.1628087672425	-0.524111819806619	-0.32459433605	-5.07162595135568	160.027089823465	1.08076494535565e-06	4.38627665164043e-05	-0.501995021678026	-0.220611083450211
KIF15	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.245912936584	0.245912936584	-0.365576905067323	-0.264963110089	-8.58044077764679	12.8436460530236	1.12397670248472e-06	4.55302972343315e-05	-0.765640445381054	-0.457339237921591
KIF15	BRD-K03549949-001-01-0::2.5::HTS002	2.5	XL388	mTOR inhibitor	targeted cancer	MTOR	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.560723663038	-0.560723663038	-1.33858181867651	-1.14186011868	-10.967220024876	175.961024749882	1.16716616971861e-21	2.22560104972972e-19	-0.917832749875431	-0.637883561401595
KIF15	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.0740062292439	-0.0740062292439	-0.382802064318764	-0.278845004201	-4.40356543498686	8.86148989530437	0.0017768754939318	0.0362839127037832	-0.467806223034414	-0.149785447115315
KIF15	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.11002604053025	-0.11002604053025	-0.29431505485452	-0.208078798615	-3.45476839502246	134.997307924153	0.000736422247571711	0.0169080496946757	-0.289785818875112	-0.0787922097734278
KIF15	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.04128947096365	-0.04128947096365	-0.687737724034579	-0.506361258966	-8.08086434307037	10.3025952033613	8.962019439292e-06	0.000311467595979247	-0.823986517849221	-0.468909988292638
KIF15	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-2.796476021425	-2.796476021425	-1.47647912677567	-1.38645123972	13.4248195166887	3.45007613118481	0.00042340906923767	0.0103335051697382	1.02895477226978	1.61103901702888
KIF15	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.574123257322	-0.574123257322	-0.250929244183203	-0.133670857256	6.08313219495095	187.004163942069	6.51149648723359e-09	3.54844274246704e-07	0.218383736683441	0.428004289594153
KIF15	BRD-K13949769-001-01-7::2.5::HTS002	2.5	tenovin-6	SIRT inhibitor	targeted cancer	SIRT1, SIRT2, SIRT3	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-2.08929521558	-2.08929521558	-1.25681292634571	-1.214888952245	10.1059752561829	9.6767998392531	1.87114178888233e-06	7.31424308716691e-05	0.648104432137679	1.0168601463309
KIF15	BRD-K14880289-001-02-2::2.5::HTS002	2.5	GW-501516	PPAR receptor agonist	noncancer	PPARA, PPARD	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.552236167356	0.552236167356	0.296998151082519	0.308945987709	-7.51933020309919	3.58974458567827	0.00254727806199588	0.0493719985304317	-0.353885961689175	-0.156590070857787
KIF15	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.652254053351	-0.652254053351	-0.0484070086522653	-0.0356049990197	13.1979673708667	177.760448934773	3.64011471656189e-28	1.2502919023814e-25	0.513558049777031	0.694136039620438
KIF15	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-2.38466659014	-2.38466659014	-2.74453846499831	-2.77734094711	-7.8511633697811	188.7436025997	3.00859095539621e-13	2.63302691253211e-11	-0.450290029464797	-0.269453720251817
KIF15	BRD-K15519488-050-01-3::2.5::HTS002	2.5	CS-110266	dopamine receptor agonist	noncancer	SLC6A3	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.420361522946	0.420361522946	-0.121929207946815	-0.154725041554	-10.0493646333082	81.5936097241701	6.28555946068301e-16	7.12415480512284e-14	-0.649647713585207	-0.434933748200423
KIF15	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.33531281384	0.33531281384	0.0842465229746725	0.0959513505756	-7.94597312677069	98.8156120550303	3.16387753763439e-12	2.50780587560518e-10	-0.313762386380174	-0.188370195350481
KIF15	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.093199101056	0.093199101056	-0.30768342055156	-0.19710233478	-5.8968432229128	8.61153330322124	0.000273175257513932	0.00696436062420644	-0.555733789311002	-0.246031253904118
KIF15	BRD-K21361524-001-01-1::0.625::MTS006	0.625	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-2.393315223875	-2.393315223875	-2.75121164717876	-2.60110257698	-4.28431066274197	185.375128284389	2.94087668251624e-05	0.000926116894632712	-0.522700926454622	-0.193091920152897
KIF15	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-4.372138775515	-4.372138775515	-5.25956161464262	-5.45683590772	-9.50830836655552	5.78576786263252	9.55977134693704e-05	0.00271814305255727	-1.1178618421906	-0.656983836064636
KIF15	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.1426260246675	0.1426260246675	-0.172296329388952	-0.1612454874865	-10.843831041278	3.00466887764102	0.00166629277288702	0.0343894909696776	-0.407264538288157	-0.222580169824746
KIF15	BRD-K25224017-001-25-0::2.5::HTS002	2.5	pirenperone	serotonin receptor antagonist	noncancer	HTR2A, HTR7	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-2.01297063889	-2.01297063889	-2.55639291146025	-2.47770840728	-5.88646657218061	192.305584586191	1.72854136929347e-08	8.98778610236052e-07	-0.725506612659411	-0.361337932481091
KIF15	BRD-K25835157-001-01-4::2.5::HTS002	2.5	PRT062070	JAK inhibitor, syk inhibitor	targeted cancer	SYK	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.236773356225	-0.236773356225	-0.0807300257086997	-0.05777682074495	3.43854738259449	189.014598928858	0.000719420926895804	0.016570502437485	0.0665258341847391	0.245560826847862
KIF15	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.0981634831559	0.0981634831559	-0.137689965717434	-0.1059972226705	-5.23040855024875	8.97758822832999	0.000546039237869425	0.0129517534100615	-0.337899143035216	-0.133807754711453
KIF15	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.04094429511875	0.04094429511875	-0.475228428597457	-0.387317230447	-8.98080472077208	12.0501307225861	1.09467264866596e-06	4.44103907090528e-05	-0.64134247111931	-0.391002976313104
KIF15	BRD-K28578425-001-07-0::2.5::HTS002	2.5	cilostamide	phosphodiesterase inhibitor	targeted cancer	PDE3A, PDE3B	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.62433511331	-0.62433511331	-0.0810175412411275	-0.0458610158792	16.1103558133488	186.895371630387	3.49292977532683e-37	2.80388069594016e-34	0.476787486955534	0.60984765718221
KIF15	BRD-K30480208-001-18-5::2.5::HTS002	2.5	torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	noncancer	SLC12A1	cardiology	edema, congestive heart failure, hypertension	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.3412777088005	0.3412777088005	0.0256465288722496	0.129954580002	-6.34171111480784	175.787417321449	1.85964036691713e-09	1.07548532164323e-07	-0.413856121292349	-0.217406238564152
KIF15	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.2338463360305	0.2338463360305	-0.406365293855008	-0.2809944464045	-9.85600936668483	44.4844796242481	9.26262396736512e-13	7.7488248723708e-11	-0.771082546639137	-0.509340713131878
KIF15	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.8795366293165	-0.8795366293165	-0.609485122451137	-0.471294403844	4.33695559206323	192.972107758867	2.3258253362581e-05	0.000748373845510979	0.147239175607068	0.392863838123659
KIF15	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-3.913565717295	-3.913565717295	-3.11163014087007	-3.10613635441	6.3676704871716	9.28726787169257	0.00011335766229934	0.00317675659034455	0.518380285647939	1.08549086720192
KIF15	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.3250915572275	-0.3250915572275	-0.87848518324006	-0.7074523288895	-5.29763026546869	14.2900292768755	0.00010517913144457	0.00296578582599437	-0.777013473473958	-0.329773778551162
KIF15	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.02003961461195	-0.02003961461195	0.165506300747648	0.1606220898175	7.88387333487506	191.631786157676	2.34001705076595e-13	2.07416672652447e-11	0.139125259301971	0.231966571417224
KIF15	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.0889166450466	0.0889166450466	-0.147610512039079	-0.07517274316945	-5.18595674582853	129.947131318607	8.02633491369852e-07	3.32865992514957e-05	-0.326759780378616	-0.146294533792742
KIF15	BRD-K41312087-001-02-7::2.5::HTS002	2.5	GW-441756	growth factor receptor inhibitor	targeted cancer	NTRK1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.554783351104	0.554783351104	-0.0134898371212728	0.0262867427605	-16.6922060513638	44.3227863934663	9.82412440358246e-21	1.73728940535926e-18	-0.636870701575032	-0.499675674875514
KIF15	BRD-K42673188-001-01-1::2.5::MTS006	2.5	verubulin	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-1.66223932765	-1.66223932765	-2.47234078092479	-2.30487473877	-8.0955351295957	141.696588690856	2.35484235224668e-13	2.08644483883704e-11	-1.00791999192265	-0.61228291462694
KIF15	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.2344320845465	0.2344320845465	-0.958420178388114	-0.580280097075	-14.2308130792072	188.334527510445	1.11159321524314e-31	5.17927526586623e-29	-1.35820248340667	-1.02750204246256
KIF15	BRD-K49071277-001-04-7::2.5::HTS002	2.5	securinine	GABA receptor antagonist, TP53 activator	noncancer	GABRA1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.0136502742142395	0.0136502742142395	0.29442382405924	0.294659751206	10.3730448082103	18.3630910841358	4.13231529504216e-09	2.30165022055897e-07	0.223987098742196	0.337560000947805
KIF15	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.326691056582	-0.326691056582	-0.783998511459622	-0.640313618355	-5.50540382179105	19.4742464846275	2.38817950486596e-05	0.000766825655578152	-0.630878794786065	-0.283736114969178
KIF15	BRD-K50018155-003-02-1::2.5::HTS002	2.5	RS-67506	serotonin receptor partial agonist	noncancer	HTR4	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.6102049168475	0.6102049168475	0.295996924151121	0.322728889347	-6.70521978275839	7.7001024913163	0.000180638164731362	0.00483285447618375	-0.4230047962596	-0.205411189133159
KIF15	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.294044395598	0.294044395598	0.113736526563764	0.147357951686	-5.46422495316692	10.4319984203207	0.000237131194684794	0.00615005951423005	-0.253421118597593	-0.10719461947088
KIF15	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.5865114240635	0.5865114240635	0.466293415406989	0.458736917071	-4.5384486362713	167.040924188853	1.07927678380492e-05	0.000369532516299924	-0.172513962104655	-0.067922055208367
KIF15	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-6.187818212135	-6.187818212135	-4.63198732113435	-4.72849824175	12.4294740077795	4.43049941517648	0.000130167548707636	0.00359658122301908	1.22121692982664	1.89044485217467
KIF15	BRD-K58772419-001-07-0::2.5::HTS002	2.5	AZD6482	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-2.03397865976	-2.03397865976	-2.39428711196114	-2.271239781645	-3.76961759084088	120.897717864393	0.000254302627808158	0.00654157800233974	-0.549540302660496	-0.171076601741783
KIF15	BRD-K59753975-001-02-6::2.5::MTS006	2.5	vindesine	tubulin polymerization inhibitor	chemo	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-1.715619432465	-1.715619432465	-2.4199001467772	-2.28041477314	-6.87680919196022	39.5862478672201	2.93470958382478e-08	1.47754687752662e-06	-0.911334299552773	-0.497227129071627
KIF15	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-1.10687989767	-1.10687989767	-1.54044742035938	-1.43484346641	-5.6614732493678	6.37492461570021	0.00106050066208964	0.023248035839727	-0.618317840750663	-0.24881720462809
KIF15	BRD-K62627508-001-01-5::2.5::HTS002	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.1672984261005	-0.1672984261005	-1.11074195016556	-0.7188580200695	-9.61101004927111	187.961322385423	4.84510692740822e-18	6.69102398611132e-16	-1.13708584820058	-0.749801199929545
KIF15	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.2018013944205	0.2018013944205	-0.495868106545181	0.00402399396559	-7.83816408810693	188.469837915554	3.26975325446969e-13	2.84879246047656e-11	-0.873251991315972	-0.522087010615389
KIF15	BRD-K63932022-001-01-5::2.5::HTS002	2.5	2'-MeCCPA	adenosine receptor agonist	noncancer	ADORA1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.313608327261	-0.313608327261	0.202127712405013	0.269128450915	9.5020886332078	103.58560469819	9.02380201338044e-16	1.00679982390724e-13	0.408099485695702	0.623372593636323
KIF15	BRD-K64800655-001-07-4::2.5::HTS002	2.5	PHA-793887	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.73670858594	-0.73670858594	-1.63241720960274	-1.592670797355	-7.37342510540611	4.59785078115208	0.00102827055117626	0.0226620256003142	-1.21637421933759	-0.575043027987883
KIF15	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-2.02446801664	-2.02446801664	-2.49068526909794	-2.41136656484	-5.1587858701583	50.8438196861506	4.13484680278018e-06	0.000153007178935268	-0.64766304709448	-0.284771457821393
KIF15	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.2438441632565	-0.2438441632565	-0.606682029213829	-0.456560974373	-5.35928333543594	34.4253675066959	5.66193956060723e-06	0.000204468044496274	-0.50036368044286	-0.225312051471798
KIF15	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.0031170379678	0.0031170379678	-0.337863668495848	-0.3277516003215	-6.91392762253484	29.1043484174743	1.31895988204985e-07	6.1228363127542e-06	-0.441831524618636	-0.240129888308661
KIF15	BRD-K67537649-001-04-5::2.5::HTS002	2.5	PQ-401	IGF-1 inhibitor	targeted cancer	IGF1R	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.0008528589398	-0.0008528589398	0.178816815075328	0.20362806034	5.00916016641307	18.6991453659338	8.15415852258508e-05	0.0023550365745683	0.10451478488856	0.254824563141696
KIF15	BRD-K67578145-001-09-7::2.38272::HTS002	2.38272	GDC-0879	RAF inhibitor	targeted cancer	BRAF	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.780364544629	0.780364544629	0.582785891371329	0.659791110046	-3.95102245183474	131.513656379001	0.000126314431536742	0.00350051261082514	-0.296500762845284	-0.0986565436700583
KIF15	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-1.28163903977	-1.28163903977	-0.652657914321521	-0.503206841324	10.1660132381284	190.468549463193	1.13807217451353e-19	1.81895504169508e-17	0.506940812827378	0.751021438069581
KIF15	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.1659810003975	0.1659810003975	-0.534081478111324	-0.376499820922	-10.9814890692872	8.4917730504472	2.62101145089779e-06	0.000100385768988469	-0.845599909719531	-0.554525047298117
KIF15	BRD-K72726508-001-02-1::2.5::HTS002	2.5	arcyriaflavin-a	CDK inhibitor	targeted cancer	CCND1, CDK4	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.02410661817976	0.02410661817976	-0.499086343214836	-0.4023952462985	-9.47727161847016	18.5326830881872	1.55689071628163e-08	8.14665113110171e-07	-0.638935909988829	-0.407450012800364
KIF15	BRD-K77245796-003-01-6::2.5::HTS002	2.5	gamma-aminobutyric-acid	benzodiazepine receptor agonist	noncancer	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.6745753265685	0.6745753265685	0.503649720683985	0.490985614625	-4.45374338557231	8.1529045991555	0.00203145852781439	0.0406346686708288	-0.259137274809908	-0.0827139369591226
KIF15	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.2582687166495	0.2582687166495	-0.468113324463835	-0.217946401079	-7.60278177974823	20.2631731590615	2.32961952994433e-07	1.04239044725144e-05	-0.92551254937162	-0.527251532855049
KIF15	BRD-K81548480-001-01-2::2.5::HTS002	2.5	AC-264613	PAR agonist	noncancer	F2RL1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.526710225358	-0.526710225358	-0.367884522170134	-0.2459913879695	3.1270582619876	90.3572522588302	0.00237574532698086	0.0464632831632887	0.057926404571461	0.259725001804272
KIF15	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-0.846497742993	-0.846497742993	-1.69628192900043	-1.42296021894	-8.11748089711604	8.75508070041032	2.32189818437771e-05	0.000747334608739284	-1.08761340955527	-0.611954962459597
KIF15	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.2082380110895	0.2082380110895	0.11037397830168	0.0860999016039	-3.60161532181905	56.7616003429692	0.000665999907042496	0.0154383618944961	-0.152280500799153	-0.0434475647764864
KIF15	BRD-K88789588-001-14-9::2.5::HTS002	2.5	letrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.3373613848055	0.3373613848055	0.171667702595818	0.134941484208	-4.19166806457331	32.9968555460773	0.000194689487904784	0.00515983717733948	-0.246116928122375	-0.0852704362969895
KIF15	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.228162558233	0.228162558233	0.152221789903826	0.185599499868	-3.83165379746743	190.367349006816	0.000172783764980143	0.00464494595189368	-0.115034449774715	-0.0368470868836343
KIF15	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-2.505610076785	-2.505610076785	-2.88860488135489	-2.8540109683	-3.55932450596212	175.354507749767	0.000478551730880602	0.0115231450317839	-0.595358886043335	-0.170630723096443
KIF15	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.461759973222	0.461759973222	0.0992963149280912	0.1180798290625	-12.2621968907401	6.83377575417856	6.65535397938964e-06	0.000236831373576059	-0.432706760183413	-0.292220556404405
KIF15	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-1.214638672515	-1.214638672515	-1.8333835019648	-1.72447120363	-6.63648083502452	14.1099944858467	1.07748177935804e-05	0.000369083574057902	-0.818565459028207	-0.418924199871385
KIF15	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	0.0881980635868	0.0881980635868	-0.0953688361531451	-0.0469105128274	-6.04142172002634	144.384600245076	1.23573027799271e-08	6.5428071826062e-07	-0.243623221612057	-0.123510577867833
KIF15	BRD-K95581532-001-01-5::2.5::HTS002	2.5	RN-1734	TRPV antagonist	noncancer	TRPV4	NA	NA	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-1.883590991655	-1.883590991655	-2.4230421432406	-2.37248540058	-6.21232267956942	99.0673072884048	1.23404682815698e-08	6.53550834277385e-07	-0.711750495712034	-0.367151807459176
KIF15	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	U251MG, NCIH661	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma), carcinoma (large_cell_carcinoma)	-4.016195968195	-4.016195968195	-4.63548709149908	-4.64147020308	-6.53167999964233	111.371421644324	2.01324833801132e-09	1.15869361717945e-07	-0.807163402247543	-0.431418844360614
KLC1	BRD-A12417644-001-07-6::2.3139::HTS002	2.3139	usniacin-(+)	MAP kinase activator	targeted cancer	PTPN1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0039489432524	0.0039489432524	0.172919521609129	0.1617912757505	5.16863884197965	17.7795556590353	6.7059433516921e-05	0.00197022362251517	0.10022718531463	0.237713971398828
KLC1	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.04954078852255	-0.04954078852255	0.0913439985499901	0.131172819567	4.77027820819022	20.2237408785926	0.000113529796726021	0.00317908646491918	0.0793218736210324	0.202447700524048
KLC1	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.212589484238	-0.212589484238	0.0788369092042791	0.1349064957195	10.07203533199	175.085543559794	4.13599241866298e-19	6.29590283451434e-17	0.234321668698646	0.348531118185912
KLC1	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.138060642958	-0.138060642958	-0.534378218226731	-0.51783728433	-12.7097145435698	194.951830690683	2.37384099436299e-27	7.39510125698873e-25	-0.457815442178447	-0.334819708359015
KLC1	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2281282911595	0.2281282911595	0.358918900156311	0.3667280736395	5.72826214382995	187.881758006832	3.97093897231384e-08	1.96283989621091e-06	0.08574958253852	0.175831635455103
KLC1	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.43867526446	-1.43867526446	-1.12172057586058	-1.02154011458	4.98011111740702	19.1585944482818	8.11818931069535e-05	0.00234591262878795	0.183820651366659	0.450088725832184
KLC1	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.8463841380505	-0.8463841380505	-3.0475377036653	-2.92318120426	-19.3066734378221	93.1033595956107	2.57535515800168e-34	1.54614368532029e-31	-2.42755149004014	-1.97475564118946
KLC1	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3170590301595	-0.3170590301595	-1.0338471576067	-1.0089298839585	-12.9602700211631	58.8506279663955	6.86816716478104e-19	1.02012986851029e-16	-0.827462203068315	-0.606114051826094
KLC1	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.01098666427484	0.01098666427484	-0.478119266297974	-0.33490377325	-7.0447633043752	89.4283778753282	3.69857149942649e-10	2.30841913482988e-08	-0.627049376373432	-0.351162484772197
KLC1	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.989337148002	-0.989337148002	-2.46308326167389	-2.47219362388	-13.3494130226538	11.9981815236686	1.46513133953335e-08	7.70223534144821e-07	-1.71428634654616	-1.23320588079761
KLC1	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.0554826678688	-0.0554826678688	-0.515658101895237	-0.419130200084	-7.23595660689914	152.917003543607	2.08991826591843e-11	1.49809395323088e-09	-0.585814947005301	-0.334535921047574
KLC1	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.020390036649925	0.020390036649925	-0.424143047542583	-0.390164965854	-10.2788160604997	6.31486920976907	3.55932004110303e-05	0.00110400217813252	-0.54908993080033	-0.339976237584686
KLC1	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.584835548043	0.584835548043	-0.484062050536501	-0.373418715101	-9.85340469252355	7.82394624145259	1.10746542949433e-05	0.000378205796746478	-1.32003618154615	-0.817759015612855
KLC1	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.640673680695	-1.640673680695	-1.29099182098096	-1.25961873039	6.85984612683123	190.644382347607	9.36644574682803e-11	6.23298980498242e-09	0.249134067933508	0.450229651494576
KLC1	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1691438889035	-0.1691438889035	-0.570282627598963	-0.549657042838	-11.4869230015469	135.891616059592	9.1732325554601e-22	1.76330920213382e-19	-0.470198304508596	-0.33207917288233
KLC1	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.4544780362765	-0.4544780362765	-0.0505222601717786	-0.0356049990197	6.8389491146983	5.88550103720269	0.000521392451565853	0.0124359584633494	0.258739861973213	0.54917169023623
KLC1	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.5270677950605	-0.5270677950605	-0.0892438874278849	-0.0178822580687	10.9160816363957	135.546983589343	2.69038686875514e-20	4.58368781552798e-18	0.358505211467761	0.517142603797469
KLC1	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.41086727502	0.41086727502	-0.377883730859893	-0.1455477562875	-7.01722277381034	4.5137962912695	0.00136689529879749	0.0290208323423445	-1.08730681568901	-0.490195196070771
KLC1	BRD-K19284129-001-02-6::2.5::HTS002	2.5	salvinorin-a	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2309179360235	-0.2309179360235	0.0155731697946181	0.02724514887165	6.5044341712887	58.8863303551889	1.86961175192084e-08	9.6766968649467e-07	0.170658608763502	0.322323602872734
KLC1	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.38385573655	0.38385573655	-0.347870452704462	-0.216806871006	-12.9745301622417	184.279541987636	9.10231259652505e-28	2.96487774544167e-25	-0.842993244748135	-0.620459133760788
KLC1	BRD-K19412355-001-01-0::2.5::HTS002	2.5	SB-242235	p38 MAPK inhibitor	noncancer	HSPB1, MAPK14	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.06214419600445	-0.06214419600445	0.116358124720773	0.132605896616	4.47942781132184	7.70758320524978	0.00225745479688685	0.0445072237293682	0.0859991471780716	0.271005494272375
KLC1	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.930278540383	-0.930278540383	-3.15447790758085	-3.22475555586	-15.0735832766771	6.74796739191329	1.90711516545949e-06	7.44400084315729e-05	-2.57577336789673	-1.87262536649897
KLC1	BRD-K24603946-001-02-1::2.5::HTS002	2.5	5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	noncancer	CHRM3	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.4796308109	-1.4796308109	-2.43279316035235	-2.202066494735	-8.85026815244322	53.8156748871119	4.41718026775981e-12	3.45018159478386e-10	-1.16910217565503	-0.737222523249666
KLC1	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2659261296915	-0.2659261296915	-0.42613632306368	-0.326694667694	-4.08117944981937	190.492967860319	6.58629885738674e-05	0.0019387925392183	-0.237642191546382	-0.0827781951979775
KLC1	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2877489295695	-0.2877489295695	-1.04412729759226	-0.8676646214495	-9.24171243378061	26.612297725672	8.58319364022388e-10	5.14869104314454e-08	-0.924422856565084	-0.588333879480436
KLC1	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.5170321910205	-0.5170321910205	-0.773611396562741	-0.707312470978	-4.6454551191237	193.372537717201	6.26193461900421e-06	0.000224121968532334	-0.365514310992782	-0.1476441000917
KLC1	BRD-K31491153-003-05-9::2.5::HTS002	2.5	1-phenylbiguanide	serotonin receptor agonist	noncancer	HTR3A, HTR3B	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.462991949891	-0.462991949891	-0.0933211562503342	0.0251960831099	5.93740157688605	7.81174587719924	0.000380249497955924	0.00939668527134459	0.22549130868368	0.513850278597652
KLC1	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.3240750248975	0.3240750248975	-0.116629967590755	0.0546590882103	-6.15326639808213	8.01650645626779	0.000270737089471559	0.00691206785578913	-0.605804851227218	-0.275605133749293
KLC1	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4551300743225	0.4551300743225	-0.0459833038028448	-0.03775802467905	-11.0433816911238	43.8754706143081	2.97774031204135e-14	2.88654954020583e-12	-0.592571651345104	-0.409655104905586
KLC1	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0612295897389	0.0612295897389	-0.207634227744818	-0.158031671069	-7.58173919531589	80.9911094119403	4.98373519257386e-11	3.4137391501731e-09	-0.339422239099626	-0.198305395867811
KLC1	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0756204968079	0.0756204968079	-0.111197549395606	-0.11764531931	-3.46719455572425	27.6856873934751	0.00173505980905706	0.0355923759942845	-0.297246012395593	-0.0763900800114196
KLC1	BRD-K43236057-001-07-1::2.59978::HTS002	2.59978	polydatin	ICAM1 expression inhibitor	noncancer	ICAM1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.134477238665	-2.134477238665	-1.30480828783669	-1.19469399644	9.67598939514444	13.5005690399474	1.91366626027342e-07	8.65669429924319e-06	0.645123631109192	1.01421427054742
KLC1	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.7520461248065	-0.7520461248065	-0.357774861470342	-0.229271162585	5.91523615372723	45.9256128980778	3.8999485237938e-07	1.68931298940218e-05	0.260098838014376	0.528443688657939
KLC1	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.228556052504	0.228556052504	-0.789752367512326	-0.640313618355	-11.1374063377994	7.54633496201191	5.94979327610734e-06	0.000213961953536042	-1.23137635801681	-0.80524048201584
KLC1	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.542403648252	-0.542403648252	-1.59792075178887	-1.48697544025	-10.0702008251254	6.79220682180654	2.50009409827871e-05	0.00080108038270291	-1.3049127239544	-0.806121483119348
KLC1	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.14265112400695	0.14265112400695	-0.589240267442785	-0.48109263675	-8.37386531272647	11.9137122304268	2.46686992772106e-06	9.48209764595638e-05	-0.922476766174213	-0.541306016725258
KLC1	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0444406384067	0.0444406384067	0.262850893576132	0.254607479759	7.72391692645745	12.497012605601	4.18834106445455e-06	0.000154746242372605	0.157070332149675	0.279750178189189
KLC1	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.033641787862075	0.033641787862075	-0.208003102015329	-0.0810605722641	-4.32345524972465	13.8356144703627	0.000719555758603235	0.016570502437485	-0.36165423727817	-0.121635542476638
KLC1	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.316339645834	0.316339645834	-0.236288362373872	-0.1756829862115	-7.81465814362153	7.01061867397787	0.000104995798816945	0.00296139552107343	-0.719795456365182	-0.385460560050561
KLC1	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4711857676415	0.4711857676415	-0.498718734833234	0.00402399396559	-10.6421224829224	135.969768181007	1.29380723601256e-19	2.06018136023281e-17	-1.15013630607385	-0.789672698875619
KLC1	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.166811084079	-0.166811084079	0.108015463257308	0.101486674715	7.23255749794279	121.292726081961	4.65425269013493e-11	3.20546698208204e-09	0.199600269823638	0.350052824848978
KLC1	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.665606404535	-1.665606404535	-0.410947541638825	-0.2259650044755	16.5946139097357	11.1002962341966	3.47752125177702e-09	1.95420464701656e-07	1.08843358087879	1.42088414491356
KLC1	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.564564297055	-1.564564297055	-1.10458888670781	-1.10749370834	9.47951295656046	188.964271159541	1.09998218437549e-17	1.47303599635999e-15	0.364258853959488	0.555691966734893
KLC1	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4773020832075	0.4773020832075	-0.470348358816467	-0.217946401079	-11.1085567919974	189.883370500343	2.06969647195964e-22	4.22875095461047e-20	-1.11592383682236	-0.779377047225576
KLC1	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.425293581735	-3.425293581735	-4.14015929978772	-4.26693586682	-4.99912926140459	5.99719992023252	0.00245776514163003	0.0478664557056269	-1.06480893741168	-0.36492249869376
KLC1	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.217987378713	-0.217987378713	-0.425088448634094	-0.2959843885325	-3.77549330261944	193.650194958422	0.000212310267016476	0.00557083807854796	-0.315289143527747	-0.0989129963144415
KLC1	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2549019500045	0.2549019500045	-0.508903482970275	-0.3823931691785	-12.5202026397208	175.861945296529	4.00378284416342e-26	1.12173434406105e-23	-0.884203203117576	-0.643407662831975
KLC1	BRD-K86816506-001-01-8::2.5::HTS002	2.5	PF-04457845	FAAH inhibitor	noncancer	FAAH	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2392358332045	-0.2392358332045	-0.408842127192448	-0.370640421909	-5.7851903121062	190.157390959272	2.93676996499e-08	1.47754687752662e-06	-0.227435233372847	-0.111777354603048
KLC1	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.02947908460285	0.02947908460285	-0.787368626622999	-0.783090045771	-16.8337461660176	174.728372929204	2.05249118264782e-38	1.83295159452385e-35	-0.912617141059297	-0.7210782813924
KLC1	BRD-K90647725-001-07-3::2.50156::HTS002	2.50156	oleanolic-acid	G protein-coupled receptor agonist	noncancer	GPBAR1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.251593412205	0.251593412205	0.11896076444758	0.139454786175	-4.4185049174249	13.7917291474982	0.000604286178608369	0.0141624988928325	-0.197105198474372	-0.0681600970404673
KLC1	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.93723873221	-2.93723873221	-4.02377781139263	-3.85901121156	-7.89807685551241	10.5110034698835	9.74775644098958e-06	0.000336537836701169	-1.3910563292468	-0.782021829118464
KLC1	BRD-K91623615-001-05-0::2.46068::HTS002	2.46068	ABT-751	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.671384272495	-2.671384272495	-3.49965914932143	-3.442891314055	-7.12721444987137	8.59980184118401	6.9268186979155e-05	0.00202872113242079	-1.09304366617407	-0.563506087478786
KLC1	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.897679387215	-2.897679387215	-1.58182958616937	-1.34116610852	17.5577542387674	105.181592075293	4.87096249327163e-33	2.577749432643e-30	1.16725251778245	1.46444708430881
KLC1	BRD-K92441787-001-04-1::2.5::HTS002	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.25491162119	0.25491162119	0.154545119570946	0.1701725882685	-3.53015047899878	178.108438679587	0.000528664876879457	0.0125856063975005	-0.156471903347915	-0.0442610998901923
KLC1	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.8159067202195	0.8159067202195	0.30494885738514	0.328628776305	-15.5412448708021	158.501728007453	1.1101440908538e-33	6.22869300650798e-31	-0.57589244047555	-0.446023285193169
KLC1	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	HCC44, NCIH1793	LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.233712847494	0.233712847494	-0.0920934734067121	0.0692106615383	-6.27681788449302	179.679649165613	2.51846303991453e-09	1.4340586208338e-07	-0.428230645491908	-0.223381996309516
KMT2A	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.1808866771615	-0.1808866771615	-0.835440367856592	-0.720201208535	-11.0086836003212	194.146958553657	3.2611272715509e-22	6.55064805046141e-20	-0.771820105640999	-0.537287275749185
KMT2A	BRD-A08545410-311-03-4::2.5::HTS002	2.5	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.382333019161	0.382333019161	-0.504883208442495	-0.495379561508	-21.2855497533741	8.13337948313092	2.01898591568435e-08	1.03921045226396e-06	-0.983060543107353	-0.791371912099636
KMT2A	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.465679258639	0.465679258639	-0.0559850542845617	0.106263594851	-6.93233957936012	4.05793394680947	0.00215547442155454	0.0427561941043372	-0.729422986183424	-0.3139056396637
KMT2A	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.570390435595	-2.570390435595	-1.60998855308536	-1.53203888218	8.17814103927022	3.70596770927528	0.00167718642371461	0.0346009903752362	0.623889322805825	1.29691444221346
KMT2A	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5459241659355	0.5459241659355	0.16903823573046	0.1532922606755	-12.1089526871628	7.50995082550558	3.39391096962566e-06	0.000127392914922749	-0.449482763447678	-0.304289096962402
KMT2A	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.4023662679505	0.4023662679505	-0.520102428337244	-0.46624794895	-17.7557672150335	68.334768741307	2.65925464797726e-27	8.19966499121538e-25	-1.02613047169852	-0.818806920876969
KMT2A	BRD-A25687296-300-04-3::2.5::HTS002	2.5	emetine	protein synthesis inhibitor	targeted cancer	RPS2	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-6.600567345725	-6.600567345725	-4.92127699904915	-4.931127887025	20.9693723348372	187.92920884757	4.26207176421694e-51	1.12775997426278e-47	1.52131320517882	1.83726748817288
KMT2A	BRD-A27376179-001-01-3::2.5::HTS002	2.5	lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	targeted cancer	FLT3, NTRK1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.95923339522	-4.95923339522	-2.88753073610053	-2.875482162025	19.9738203617607	34.1836819776362	1.99383046164447e-20	3.44625555656288e-18	1.86095813768604	2.2824471805529
KMT2A	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.402597354932	0.402597354932	-0.184532774503296	-0.008049193223815	-8.75762371668307	6.46981635266486	8.04331024390369e-05	0.00232709859782078	-0.748331612990005	-0.425928645880586
KMT2A	BRD-A59303141-001-10-4::2.5::HTS002	2.5	quinethazone	thiazide diuretic	noncancer	CA1, CA2, SLC12A1, SLC12A2, SLC12A3	cardiology	hypertension	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.1519887543995	0.1519887543995	0.36620497080635	0.4119150559755	6.91158582247317	165.304858704273	9.91088466750361e-11	6.57643962817765e-09	0.15302150353461	0.27541092927909
KMT2A	BRD-A83937277-001-10-5::2.5::HTS002	2.5	mephenytoin	hydantoin antiepileptic	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.537540706516	0.537540706516	-0.0763497110265761	-0.0963568398651	-13.2542695270746	5.89070345994335	1.31401767392368e-05	0.000442887394298458	-0.727734308437449	-0.500046526647703
KMT2A	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.2626877797935	0.2626877797935	-0.189754506105553	-0.136086260588	-9.35514725790293	40.9689081102788	1.00739369978125e-11	7.5283711394845e-10	-0.550115445673256	-0.354769126124849
KMT2A	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.303537820003	-0.303537820003	-0.847132487191367	-0.797149374107	-7.19635520537482	5.63355340628431	0.000482660677239331	0.0116103457117877	-0.731382142856598	-0.355807191520136
KMT2A	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.050476887856	0.050476887856	0.224052454522538	0.2226649685355	5.75342541896525	22.1604075775158	8.45270363882113e-06	0.000295202789344125	0.111034966535182	0.236116166797894
KMT2A	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.393460468335	-3.393460468335	-1.88070926302827	-1.71824464082	10.8667826603	4.67675523679675	0.000170354843376289	0.00458866196129153	1.14733493851414	1.87816747209932
KMT2A	BRD-K02130563-001-11-4::0.15625::HTS002	0.15625	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.588052201435	-1.588052201435	-3.03765782870318	-3.136612886985	-10.9088884216598	167.99974574893	2.75223350395807e-21	5.08082217631206e-19	-1.71194124599992	-1.18727000853644
KMT2A	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.79580388253	-3.79580388253	-2.18542916407901	-2.01441788744	9.45390164950041	3.0983265904028	0.00219537415007247	0.043423066280074	1.07788148947044	2.14286794743154
KMT2A	BRD-K06222852-001-03-2::2.5::HTS002	2.5	posaconazole	sterol demethylase inhibitor	noncancer	CYP3A4	infectious disease	oropharyngeal candidiasis	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.181841989941	0.181841989941	-0.0504131824043465	-0.00340254964255	-5.40965103394046	8.80430861672104	0.000461026895807028	0.0111500150701224	-0.329707526367146	-0.134802818323547
KMT2A	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.28115069415	-2.28115069415	-1.24478911168043	-0.903447368813	10.7563707870465	165.618423730612	8.46367778027249e-21	1.50916106070551e-18	0.846131699825669	1.22659146511347
KMT2A	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.9166931273665	0.9166931273665	0.329950109321074	0.3338165124735	-12.8412199297616	2.57900959530794	0.00208784635304337	0.0416149931183329	-0.746551709179585	-0.426934326911267
KMT2A	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.381120207903	0.381120207903	-0.430155139397179	-0.399128631959	-14.584290905031	27.9614471602205	1.34845421213435e-14	1.34800766246522e-12	-0.925228467060783	-0.697322227539575
KMT2A	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.39849350735	-1.39849350735	-3.54307322324631	-3.39005054237	-15.6560489231716	24.0298655475282	4.16207196243298e-14	3.97173963328717e-12	-2.42727581109083	-1.86188362070179
KMT2A	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.956950230375	-1.956950230375	-0.457585115344647	-0.349104647656	17.0856637666926	182.910564126698	9.64940943020641e-40	1.00885281647157e-36	1.32622142534172	1.67250880471898
KMT2A	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-5.24647117637	-5.24647117637	-3.66184095615502	-3.56303502077	16.9096091974599	187.540015984245	1.43965772549224e-39	1.48346346464916e-36	1.39976547556758	1.76949496486238
KMT2A	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.72321263483	-1.72321263483	-0.962170382211665	-0.729695465511	9.3338240294112	10.5179057006749	2.05245247576134e-06	7.98511683930753e-05	0.580574127387347	0.941510377849323
KMT2A	BRD-K18849474-001-04-4::2.60504::HTS002	2.60504	dalcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5627322002395	0.5627322002395	0.297746873312511	0.27891575921	-9.74908357774825	187.634205937398	1.99200130362842e-18	2.83872105987616e-16	-0.31860403539902	-0.211366618454958
KMT2A	BRD-K19540840-001-09-4::2.5::MTS010::PROS004_PR500	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.673656999596	-0.673656999596	-0.399477700710935	-0.317398469231	4.69818152175801	49.9560126029817	2.09196838917353e-05	0.000679039062370398	0.156960042596519	0.391398555173611
KMT2A	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.7781446925175	0.7781446925175	0.369112049492484	0.3847237758685	-10.4967680638008	4.92161062672005	0.000148556298031401	0.00404830550550186	-0.509683533092462	-0.30838175295757
KMT2A	BRD-K23984367-075-15-2::2.5::HTS002	2.5	sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.0301107235366	0.0301107235366	-0.86146748701336	-0.738304903661	-8.60071058126934	4.42303568645404	0.000634059778583717	0.0147730621028448	-1.16885570392746	-0.614300717172456
KMT2A	BRD-K30519779-001-03-1::2.5::HTS002	2.5	homoquinolinic-acid	glutamate receptor agonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.2489692102795	-0.2489692102795	0.434522512780807	0.45172565456	22.3220410385741	161.069412989902	3.65232468561251e-51	1.00812838593663e-47	0.623024108193041	0.743959337927572
KMT2A	BRD-K32744045-001-31-2::2.5::HTS002	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.637733605877	0.637733605877	-1.29674130710716	-1.09614559515	-18.7812665992454	48.0884058714979	8.76199219981273e-24	2.01496676630221e-21	-2.14156093451004	-1.72738889145827
KMT2A	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.910784257089	-0.910784257089	-3.14307287867327	-3.16901733263	-13.3258971964379	2.54190098576285	0.00203025095553047	0.0406143043725864	-2.82409370442207	-1.64048353874648
KMT2A	BRD-K33127281-001-05-6::2.5::HTS002	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.382077577683	-0.382077577683	-0.161667112357464	-0.1501441638665	5.38169992689291	16.5352736187096	5.46251485714973e-05	0.00163642068964252	0.133816446915183	0.307004483735889
KMT2A	BRD-K33610132-001-02-9::2.5::HTS002	2.5	rociletinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.3534188513945	0.3534188513945	0.196343566286965	0.241806057711	-3.7757778097674	118.842931241876	0.000250531308396225	0.00646240519885119	-0.239450093837362	-0.0747004763777092
KMT2A	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.9330206756745	0.9330206756745	0.123460814282275	0.121836586496	-21.8558263851074	9.41303381005666	2.19103071962793e-09	1.25494768334349e-07	-0.892795110100947	-0.726324612683504
KMT2A	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.6219097653545	0.6219097653545	-0.186154890314651	-0.13613940777	-23.7167590172227	194.630208325332	2.56653643302661e-59	1.57166624901188e-55	-0.875261328445898	-0.740867982892405
KMT2A	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.26875622042	-3.26875622042	-2.61107025058772	-2.424137198535	6.26772682101503	13.6599049735079	2.3083866490377e-05	0.000743432309694368	0.432102098962119	0.883269840702439
KMT2A	BRD-K39160765-003-02-9::2.5::HTS002	2.5	4-chlorophenylguanidine	urokinase inhibitor	noncancer	PLAUR	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.251123289793	-0.251123289793	0.0576254059035978	0.0820318935995	7.21511893414408	3.9074216922959	0.00213924762806422	0.0425169514906692	0.188820881468544	0.428676509924652
KMT2A	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.43732677563	-2.43732677563	-3.04386572109635	-2.95683473862	-5.44624373237981	11.5666173267488	0.000169180393660775	0.00455874586282627	-0.850201845485088	-0.362876045447621
KMT2A	BRD-K43457670-001-27-8::2.5::HTS002	2.5	acetazolamide	carbonic anhydrase inhibitor	noncancer	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.090839839221	-0.090839839221	0.262666496231885	0.242495378939	12.4710795886967	19.1839025489931	1.18904922771675e-10	7.80544355060652e-09	0.294215759574801	0.412796911330969
KMT2A	BRD-K45446451-001-05-0::2.5::HTS002	2.5	JZL-184	monoacylglucerol lipase inhibitor	targeted cancer	MGLL	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.332788082985	0.332788082985	-0.0535922569639876	-0.08025310757335	-10.3902209299253	38.1979730479012	1.09585125501338e-12	9.09654158155547e-11	-0.461648517880081	-0.311112162017894
KMT2A	BRD-K47049295-300-01-5::2.5::HTS002	2.5	BAN-ORL-24	nociceptin/orphanin FQ receptor antagonist	noncancer	OPRL1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.199450640136	0.199450640136	0.365602630800734	0.375415378686	6.73868714340142	186.00801087177	1.94248782837046e-10	1.24687473425221e-08	0.117509789786835	0.214794191542634
KMT2A	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.729197982175	-1.729197982175	-0.937858607008831	-0.580157246683	9.39979193837964	186.670808277808	1.99260516819497e-17	2.5914628221727e-15	0.625259350825385	0.957419399506953
KMT2A	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.2366640948	-1.2366640948	-1.83575891665963	-1.58248812639	-5.49655123827419	14.6208951947582	6.73570573737703e-05	0.00197761243148806	-0.831937225829003	-0.366252417890252
KMT2A	BRD-K50140147-001-10-1::2.5::HTS002	2.5	NVP-TAE684	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, INSR	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.485334090135	-2.485334090135	-1.79887619685077	-1.63753619039	6.10695440350901	5.15198826057723	0.00153362725334923	0.0320371145792484	0.400054421340251	0.9728613652282
KMT2A	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.42786800671	0.42786800671	0.199266959877787	0.2395368500345	-7.04170954735799	177.906392665257	3.98856792096587e-11	2.76387253130519e-09	-0.292664831132616	-0.164537262531811
KMT2A	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-7.10884542493	-7.10884542493	-6.17167637669416	-6.268105536705	7.64937573736959	4.08795122955514	0.00143677928470141	0.0303064134741432	0.599877668544201	1.27446042792748
KMT2A	BRD-K52313696-001-12-3::0.15625::HTS002	0.15625	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.129418425077	0.129418425077	0.419585903816027	0.39525647476	9.39746227164562	162.627106055954	5.01421698393492e-17	6.30687859125462e-15	0.229195520879997	0.351139436598057
KMT2A	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.2276075721505	0.2276075721505	0.380470925595575	0.394227062385	5.19788092613016	7.80716377201527	0.000890940200725018	0.0199931234720126	0.0847539002024357	0.220972806687715
KMT2A	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.206666403056	-0.206666403056	-1.11700893601019	-1.00700802709	-13.0490551234833	8.28789705558316	8.17681186141246e-07	3.38391177726332e-05	-1.07024898392119	-0.750436081987188
KMT2A	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.73086010717	-1.73086010717	-0.603997538864583	-0.573831164789	14.9508769706902	58.9815433515068	1.00144231316292e-21	1.91641187087407e-19	0.976044555503903	1.27768058110693
KMT2A	BRD-K55187425-236-05-2::2.5::MTS010::PROS004_PR500	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.10494831393505	-0.10494831393505	-0.80796130651413	-0.733552010026	-7.03872831841869	10.2453185508	3.12876858404964e-05	0.000979886526095687	-0.92483451326968	-0.48119147188848
KMT2A	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-4.51573843757	-4.51573843757	-3.98580774473411	-4.06345371982	5.04665970063492	188.978801242465	1.0521801633474e-06	4.27708756422218e-05	0.322795776958656	0.73706560871312
KMT2A	BRD-K62304154-001-04-2::2.5::HTS002	2.5	deforolimus	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.654905641805	-1.654905641805	-2.77899875453908	-2.77605500784	-12.779729936848	7.23270295434655	3.16960358924165e-06	0.000119559656402424	-1.33073435994846	-0.917451865519704
KMT2A	BRD-K62627508-001-01-5::2.5::HTS002	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.311910108603	0.311910108603	-1.11583991330071	-0.7188580200695	-10.4292914346915	4.09803465743359	0.000420925206032396	0.0102775664711457	-1.80428079404402	-1.0512192497634
KMT2A	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.0709899206985	-0.0709899206985	-0.608501547556545	-0.456560974373	-7.50953139361368	15.3470201727688	1.61545253686422e-06	6.38933985557432e-05	-0.689775020349555	-0.385248233366535
KMT2A	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.4913964027575	0.4913964027575	0.252805752744562	0.248858708206	-10.8290148627426	37.2432366195293	4.6071379445675e-13	3.9576884509868e-11	-0.283222967129983	-0.193958332895893
KMT2A	BRD-K68938568-001-01-7::2.5::HTS002	2.5	GDC-0152	XIAP inhibitor	targeted cancer	BIRC2, BIRC3, BIRC7, XIAP	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.25302064832	-1.25302064832	-0.427581103719049	-0.281479895417	10.8113917351727	31.3823520935563	4.13803905729607e-12	3.24187865154566e-10	0.669801477946203	0.9810776112557
KMT2A	BRD-K71847383-001-12-5::2.5::HTS002	2.5	cytarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.3155727874155	-0.3155727874155	0.336349912080683	0.318284588664	15.7881031749145	2.96059734883664	0.000594494704231099	0.0139850132217262	0.519518086874544	0.784327312117823
KMT2A	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.05199309448625	0.05199309448625	0.223123277899354	0.235603358555	5.31504588106282	5.97568622541539	0.00182673985902212	0.0371288124461216	0.0922684337395994	0.249991933086608
KMT2A	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.01640472161064	0.01640472161064	-0.198684537675948	-0.124222212564	-5.58490541067529	27.5613117223712	5.9306349091414e-06	0.000213416227239988	-0.294035364269866	-0.136143154303311
KMT2A	BRD-K73197500-001-02-2::2.5::HTS002	2.5	SNX-5422	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.5713188366	-2.5713188366	-3.62857213394235	-3.70624580332	-8.88541156881338	4.76007088575167	0.00038533868612515	0.00948647544894524	-1.36781631203906	-0.746690282645638
KMT2A	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.35847134888	-2.35847134888	-0.663114026835584	-0.4541784692175	21.7100788502627	122.289707063713	8.99598002514676e-44	1.29402644483871e-40	1.54077246142459	1.84994218266424
KMT2A	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.682386433551	-0.682386433551	-0.945972165332459	-0.8151847008705	-4.17823603744347	185.627644553394	4.51810609707328e-05	0.00137414667472629	-0.388042269800376	-0.139129193762543
KMT2A	BRD-K80480517-001-02-4::2.5::HTS002	2.5	repsox	TGF beta receptor inhibitor	noncancer	TGFBR1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.76633983192	-1.76633983192	-0.882261629246671	-0.8152099544365	16.0432932942997	187.051623345975	5.37784428716928e-37	4.23760289788494e-34	0.7753695142859	0.992786891060756
KMT2A	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.65399747578	-1.65399747578	-2.51290239928638	-2.254263331985	-7.93460695364132	177.088176740935	2.31283345918633e-13	2.05261814689005e-11	-1.07252688450837	-0.645282962504391
KMT2A	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.3901130574	-1.3901130574	-0.490420168280337	-0.35792132397	14.8008973254706	177.223368574298	8.60532427633261e-33	4.43358304524542e-30	0.779734621154729	1.0196511570846
KMT2A	BRD-K84937637-001-09-9::2.5::HTS002	2.5	sirolimus	mTOR inhibitor	noncancer	FGF2, FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-1.177636984115	-1.177636984115	-1.35024577005134	-1.33822464732	-3.37277766050075	148.389713682725	0.000949247384541732	0.0211421846286444	-0.273738701651998	-0.0714788702206755
KMT2A	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.314285180279	0.314285180279	0.0324438010410485	0.0430886024597	-8.62303223018262	7.00144687977797	5.62290830129749e-05	0.00167942072646152	-0.359125219123962	-0.204557539351941
KMT2A	BRD-K86727142-001-12-4::2.5::HTS002	2.5	embelin	HCV inhibitor, XIAP inhibitor	targeted cancer	XIAP	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.6381644285125	-0.6381644285125	-0.164859979902432	-0.181229635182	11.7878312354788	160.972111000531	1.62029630995216e-23	3.64403449964046e-21	0.394011942416239	0.552596954803897
KMT2A	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.05752315087445	-0.05752315087445	0.113156817693973	0.0998567885779	6.68569103736098	190.153846734624	2.48514988726507e-10	1.57492516318047e-08	0.12032327390101	0.221036663235836
KMT2A	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.958222429447	-0.958222429447	-0.776916758749455	-0.768623385632	3.64616285415536	123.371572464845	0.000390900104617951	0.00961345135085036	0.0828809059936494	0.27973043540144
KMT2A	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.729917560075	-3.729917560075	-2.8746922963175	-2.82062384431	5.97943658034798	5.19879150989479	0.00163758800987842	0.033868821824687	0.491749353646294	1.2187011738687
KMT2A	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.8703857544735	-0.8703857544735	-0.21958059726585	-0.144721351966	10.3878567059281	103.528764912804	9.60425160397843e-18	1.29544974325305e-15	0.526560067344253	0.775050247071048
KMT2A	BRD-K94176593-001-09-4::2.5::HTS002	2.5	TWS-119	glycogen synthase kinase inhibitor	noncancer	GSK3B, JUN, MYC	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.7130848881905	-0.7130848881905	-0.291736032398488	-0.211299722741	8.69782121632988	9.69568966147845	6.91293538554252e-06	0.000245264447649055	0.312950076035258	0.529747635548767
KMT2A	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-3.06469503612	-3.06469503612	-4.64555588443109	-4.64147020308	-17.3285724670526	188.999340503728	6.76531454305397e-41	7.88045163422943e-38	-1.76081787628702	-1.40090382033515
KMT2A	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	0.5048759845945	0.5048759845945	-0.0950897511647286	0.0692106615383	-11.2626844500017	106.861672770446	7.1975080614877e-20	1.16954867726353e-17	-0.705569307358417	-0.494362164160041
KMT2A	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-0.940726300387	-0.940726300387	-0.214188231093161	0.00102328451077	10.1470059120013	9.38642362696571	2.29127332529804e-06	8.85957641237243e-05	0.565575632343886	0.887500506243792
KMT2A	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	HCC38, CAOV3	BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (adenocarcinoma)	-2.82363842849	-2.82363842849	-3.14524040567889	-3.23564927932	-5.53135112627133	178.985562598613	1.1126078155611e-07	5.2146101137414e-06	-0.436333308293221	-0.206870646084562
LDLRAD3	BRD-A68631409-001-05-4::2.5::HTS002	2.5	evodiamine	ATPase inhibitor, TRPV agonist	targeted cancer	TRPV1	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.305024054315	-1.305024054315	-2.38832756902101	-2.305746334225	-9.24710610488458	5.50924745947299	0.000146706729933184	0.00400044614756355	-1.37626555488759	-0.790341474524432
LDLRAD3	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.565944614385	-1.565944614385	-2.36461402864193	-2.31691828506	-8.34588434284398	8.64274308317023	2.0210850829321e-05	0.000658023917271388	-1.01652102486768	-0.580817803646178
LDLRAD3	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.0203839928	-2.0203839928	-3.73608472148726	-3.62613694573	-12.6135891412885	5.56762197695956	2.6323838736783e-05	0.000839078232096366	-2.05489675244945	-1.37650470492508
LDLRAD3	BRD-K03406345-001-27-8::2.5::HTS002	2.5	azacitidine	DNA methyltransferase inhibitor	chemo	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.2760672449945	-0.2760672449945	-0.586475168430018	-0.567938192977	-7.14750492191987	86.1243047646198	2.69028185380622e-10	1.70190501606975e-08	-0.396739843472109	-0.224076003398927
LDLRAD3	BRD-K03765900-001-01-9::2.5::MTS006	2.5	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.36628610206	-3.36628610206	-1.14381071415027	-0.818195851466	23.9429157692676	23.4201498705612	5.67987076266658e-18	7.81361373999721e-16	2.03064490612763	2.41430586969182
LDLRAD3	BRD-K06152156-001-01-8::2.5::HTS002	2.5	methoxyflurane	membrane permeability inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.408621887335	-1.408621887335	-1.86917761408262	-1.724302233865	-4.74824682684012	21.4452924758745	0.000103351376354757	0.0029200101690929	-0.66201293898427	-0.259098514510979
LDLRAD3	BRD-K06753942-001-14-5::2.5::HTS002	2.5	nobiletin	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.298242709635	0.298242709635	-0.0784338887931462	-0.0747677969197	-7.15033637198277	117.510731004253	7.93802825665629e-11	5.32670525429207e-09	-0.481000975682182	-0.27235222117411
LDLRAD3	BRD-K07359318-001-03-9::2.44929::HTS002	2.44929	benfotiamine	antioxidant	noncancer	AGER	rheumatology	lumbago	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.548742212834	0.548742212834	0.33225073977236	0.345721870697	-7.57756368386394	18.2295307224992	4.84956305353393e-07	2.07258624067971e-05	-0.276460821447568	-0.156522124675712
LDLRAD3	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.66175800552	-0.66175800552	0.0230775886205634	0.2036144024465	10.9013491245565	121.04114316232	1.07202565498357e-19	1.71980678598034e-17	0.560464929328697	0.80920625895243
LDLRAD3	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.148300050429	0.148300050429	-0.25861459852098	-0.1509093731905	-7.61397225297674	185.970303011365	1.29942781896261e-12	1.07323724474157e-10	-0.512347408434	-0.30148188946596
LDLRAD3	BRD-K14618467-001-04-6::2.5::HTS002	2.5	IKK-16	IKK inhibitor	noncancer	IKBKB	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.870362082909	-0.870362082909	-0.129896500505863	-0.07721544600385	12.4018101014398	2.9635684143537	0.00119871341997261	0.0259304651382025	0.549125349475136	0.931805815331139
LDLRAD3	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0221112603642	-0.0221112603642	-0.189106301806928	-0.123671466435	-3.98294233895853	82.8092001892698	0.000145614508678424	0.00397420247428219	-0.250390107428247	-0.0835999754572098
LDLRAD3	BRD-K18424115-003-01-3::2.5::HTS002	2.5	TG-100572	src inhibitor, VEGFR inhibitor	targeted cancer	KDR, SRC	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.763178402809	-0.763178402809	-1.20805825118771	-1.11267387683	-5.7402918742187	8.5759737768259	0.00033514394536899	0.00837582400501286	-0.621530195076204	-0.268229501681219
LDLRAD3	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.948794182375	-1.948794182375	-1.33411059215575	-1.36979496737	7.3012808872314	6.65391164902405	0.000207491131028354	0.0054606294968291	0.413491136420066	0.815876044018442
LDLRAD3	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3181371542765	0.3181371542765	-0.311985000296032	-0.26288025127	-12.0231487015947	5.14985512225881	5.78470563595311e-05	0.00172318300798915	-0.763673353496291	-0.496570955648773
LDLRAD3	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.08165570522425	0.08165570522425	-0.114091545395224	0.0546590882103	-3.28711871445639	125.486965634557	0.00131303247654498	0.0280467348679898	-0.313599218756424	-0.0778952824825239
LDLRAD3	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.175976121473	-0.175976121473	0.215003880379996	0.242460199933	17.5257121515316	16.075262386737	6.70051869624457e-12	5.11619334395227e-10	0.343705157816743	0.438254845889249
LDLRAD3	BRD-K33882852-003-02-8::2.5::HTS002	2.5	ZK-93423	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.29662147422	-1.29662147422	-0.879015358118755	-0.8036472341125	6.75219228067395	78.6813014429326	2.24977049022075e-09	1.28790347061572e-07	0.294494021417034	0.540718210785457
LDLRAD3	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.5706419365095	0.5706419365095	0.166841310238474	0.159843684784	-16.1114979287095	114.907045682284	2.95062930250689e-31	1.31751130786875e-28	-0.453445805676466	-0.354155446865585
LDLRAD3	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.263570226466	-0.263570226466	0.136190504730578	0.1319992768505	9.80047745143069	5.50132263489521	0.000109136272406905	0.00306768106605895	0.297716696224788	0.501804766168367
LDLRAD3	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-5.354441595405	-5.354441595405	-6.61331909057542	-6.671127343215	-14.2928524842269	17.0052615330736	6.61580279904697e-11	4.46882571105244e-09	-1.44470021697616	-1.07305477336468
LDLRAD3	BRD-K40797222-001-01-8::2.5::HTS002	2.5	SC-12267	dihydroorotate dehydrogenase inhibitor	noncancer	IL17A	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.01543340924283	0.01543340924283	0.188937296678732	0.185775968658	6.99395351111187	23.3171283022036	3.67462294592147e-07	1.59525675790238e-05	0.122223847598994	0.224783927272809
LDLRAD3	BRD-K48684885-001-04-2::2.5::HTS002	2.5	BAY-11-7085	NFkB pathway inhibitor	targeted cancer	NFKBIA	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.807101694518	-0.807101694518	-1.44918011176106	-1.33433747778	-7.89610796736406	11.0795576521081	7.07343264189076e-06	0.00025035496160486	-0.820896638278007	-0.463260196208113
LDLRAD3	BRD-K51040301-001-02-1::2.5::HTS002	2.5	cobicistat	cytochrome P450 inhibitor	noncancer	CYP3A4, CYP3A43, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.469393986809	0.469393986809	0.253601003161092	0.226380370277	-5.43409665622299	14.2587773849429	8.25509479021295e-05	0.00238130041896575	-0.300819650457668	-0.130766316838147
LDLRAD3	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.4071898887035	-0.4071898887035	-1.04702862089898	-1.14416779162	-8.01747441734468	141.229124206208	3.70322206825267e-13	3.2133922375163e-11	-0.797606566475079	-0.482070897915873
LDLRAD3	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.66785557212	-2.66785557212	-3.65057050377562	-3.579783032275	-8.17299807322676	95.7361229801972	1.24121488590045e-12	1.02674004353592e-10	-1.2213962972496	-0.744033566061632
LDLRAD3	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.2175626860625	-0.2175626860625	-0.491430391407794	0.00515603334304	-3.07423145214131	188.091244620445	0.00242445428679325	0.0473079809572206	-0.449601678402627	-0.0981337322879623
LDLRAD3	BRD-K66094457-001-01-5::2.5::HTS002	2.5	CPP	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.65050778046	-1.65050778046	-0.905408552367238	-0.85122207753	11.4148685172314	23.8540729795992	3.77166227927821e-11	2.62204542541492e-09	0.610335764799582	0.879862691385941
LDLRAD3	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.996467959535	-1.996467959535	-3.11661618147603	-3.18680355288	-11.9698464690802	171.975386095636	2.09200267605694e-24	5.08363765937198e-22	-1.30486314253495	-0.935433301347108
LDLRAD3	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.08770775301	-2.08770775301	-3.14612729892241	-3.04544241525	-8.382957896638	10.1851995546435	6.92645626267738e-06	0.000245662823816545	-1.33904914153529	-0.777789950289523
LDLRAD3	BRD-K69932463-001-10-6::2.5::HTS002	2.5	AZD8055	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.51375448186	-3.51375448186	-2.73325993947587	-2.73243511548	11.7841145915916	51.2775986302608	3.29421689866489e-16	3.8497612523116e-14	0.647544185330311	0.913444899437954
LDLRAD3	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.002680802715	-3.002680802715	-2.6268140101463	-2.476182958975	4.36123691404623	32.0136569664371	0.000125602169158785	0.00348255980771452	0.200319623617425	0.551413961519965
LDLRAD3	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.907354237251	-0.907354237251	-0.139719919339107	-0.1170838755295	16.8368812807756	23.3129237295411	1.52320608168682e-14	1.51986609069764e-12	0.673389193934526	0.86187944188926
LDLRAD3	BRD-K76973696-001-12-6::2.01421::HTS002	2.01421	tryptanthrin	cyclooxygenase inhibitor	targeted cancer	IDO1	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.09117285681	-1.09117285681	-1.38955563741756	-1.35544849592	-5.74913064656683	12.994135894075	6.7312535793471e-05	0.00197657603563212	-0.410512147539182	-0.186253413675942
LDLRAD3	BRD-K77625799-001-07-7::2.5::MTS010::PROS002_PR500	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.534102448342	-0.534102448342	-0.116389959131336	-0.0734176025033	10.227723985493	171.828263980075	1.77699556120059e-19	2.79428966717947e-17	0.337097433244158	0.498327545177171
LDLRAD3	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.3247028122225	-0.3247028122225	0.0996632078676538	0.2180824951125	8.61435427139142	16.4568397607807	1.68887467479049e-07	7.70487058691296e-06	0.32016895936244	0.528563080817867
LDLRAD3	BRD-K79239947-001-06-8::2.5::HTS002	2.5	PF-573228	focal adhesion kinase inhibitor	targeted cancer	CDK1, CDK2, CDK7, GSK3B, IKBKB	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.03500780404495	-0.03500780404495	-0.235931288940002	-0.1830123326315	-4.30294091576242	175.319349901596	2.79599301571618e-05	0.000884911971449251	-0.293079076208959	-0.108767893581145
LDLRAD3	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.024949827265065	0.024949827265065	-0.329442472095841	-0.3298674569485	-5.37939137667303	93.6083519484659	5.48908996367317e-07	2.32826274059788e-05	-0.48520497903069	-0.223579619691123
LDLRAD3	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.09349782295615	-0.09349782295615	0.1928809443433	0.205191667076	6.23363968515359	5.4184150873256	0.00115854055305226	0.0251681368533486	0.17097492484193	0.40178260975697
LDLRAD3	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.704678791135	-1.704678791135	-2.92246036634663	-2.87877770547	-10.0869932108667	3.77770394332954	0.000721990531310873	0.0166230001703006	-1.5608999866142	-0.87466316380907
LDLRAD3	BRD-K90647725-001-07-3::2.50156::HTS002	2.50156	oleanolic-acid	G protein-coupled receptor agonist	noncancer	GPBAR1	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.03048253470865	-0.03048253470865	0.12196157239347	0.1471527723635	5.91710022599806	187.369406792587	1.53038377837973e-08	8.01773710184185e-07	0.101620671995238	0.203267542209002
LDLRAD3	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.434398690976	-0.434398690976	-0.224145906831269	-0.144721351966	3.40854868452905	160.320002150809	0.000826037821805264	0.0187277245306146	0.0884348861796922	0.332070682109771
LDLRAD3	BRD-K97714174-001-01-3::2.5::HTS002	2.5	P22077	ubiquitin specific protease inhibitor	noncancer	USP7	NA	NA	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.574398917602	0.574398917602	0.25378151315568	0.3142607574065	-7.58734501315609	12.0140767381253	6.3936587635611e-06	0.000228467237268304	-0.412675238194178	-0.228559570698462
LDLRAD3	BRD-K97810537-001-13-6::2.5::HTS002	2.5	beclomethasone-dipropionate	glucocorticoid receptor agonist	noncancer	GPR97, NR3C1	allergy	allergic rhinitis	HCC95, HCC1419	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.226721560123	-0.226721560123	0.0781409749360748	0.06870536578965	7.57025524241801	165.009807789194	2.50111062414715e-12	2.00321576592988e-10	0.225349464952469	0.38437560516568
LINC01090	BRD-A36267905-003-18-4::2.5::HTS002	2.5	buphenine	adrenergic receptor agonist	noncancer	ADRB2	rheumatology	Raynaud's disease	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.150813448958	-0.150813448958	-0.443942429801225	-0.393531150995	-5.16375338614888	14.9621963903434	0.000116427056159864	0.00325087463741378	-0.414150862722799	-0.172107098963651
LINC01090	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.5150978925345	0.5150978925345	0.18157643361221	0.1739425463755	-11.2119463824278	36.4949853739488	2.23252655691286e-13	1.98381088066574e-11	-0.393822716039914	-0.273220201804666
LINC01090	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	1.000532979453	1.000532979453	0.144489963140575	0.162581247373	-20.6412573489172	3.07562473292841	0.000211879430716553	0.00556245792577758	-0.986209725525136	-0.725876307099714
LINC01090	BRD-A69815203-001-07-6::2.5::HTS002	2.5	cyclosporin-a	calcineurin inhibitor	noncancer	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.656058725864	-0.656058725864	-0.0666167098823011	0.011278782305325	14.3599567730643	191.355323365194	3.28817757505675e-32	1.59086187693982e-29	0.508478108819299	0.670405923144099
LINC01090	BRD-A90547603-001-02-5::2.5::HTS002	2.5	eptifibatide	platelet aggregation inhibitor	noncancer	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.208382288942	0.208382288942	0.0427063546740426	0.04269931862485	-5.5495267841011	11.6384064815431	0.000140749647225284	0.00385074433752208	-0.230947202447275	-0.100404666088639
LINC01090	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.292136872625	-1.292136872625	-0.349214673054461	-0.221401224326	13.7777898133979	19.5416025611898	1.60941964681263e-11	1.17488182384777e-09	0.799948378318084	1.08589602082299
LINC01090	BRD-K03765900-001-01-9::2.49999::MTS010::PROS002_PR500	2.49999	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.292960153731	0.292960153731	-0.56447665074887	-0.353034364185	-11.0124108994941	92.456452782047	1.63562436887921e-18	2.35276332454707e-16	-1.01206520592976	-0.702808403029985
LINC01090	BRD-K03765900-001-01-9::2.5::MTS006	2.5	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.592574616811	-0.592574616811	-1.17285481347225	-0.823393929272	-5.64054605352527	9.33505122400913	0.000277548644978174	0.0070557138571376	-0.811736165642475	-0.348824227680033
LINC01090	BRD-K07572174-001-39-4::2.48092::HTS002	2.48092	curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	targeted cancer	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.94236236917	-3.94236236917	-1.14620755484563	-1.01297286124	35.9564385612161	145.04667139517	3.92343443748889e-74	1.4015096325876e-69	2.64245572234089	2.94985390630785
LINC01090	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.714165537544	0.714165537544	0.423675326219805	0.3989310314435	-8.75458390227557	167.288813804639	2.16013172763957e-15	2.33003962281461e-13	-0.355998654393742	-0.224981768254648
LINC01090	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2265688403865	0.2265688403865	0.344578404733201	0.3629794578985	3.59272667550576	60.1644810364231	0.000659983302460261	0.0153154570412522	0.0523098818120939	0.183709246881308
LINC01090	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.930092837335	-2.930092837335	-2.08775551825775	-1.94028903858	6.33551176285664	7.78337407296294	0.000251575849479518	0.0064831069187322	0.534251103621762	1.15042353453274
LINC01090	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.209071655405	-3.209071655405	-2.40750420202751	-2.32376274045	8.70150014933031	5.70618234874041	0.000167046903529882	0.0045086255870364	0.573318543310206	1.02981636344478
LINC01090	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.494976523394	0.494976523394	0.238259143891305	0.274310189966	-7.66470711598506	6.01905503380334	0.000253908130384985	0.00653299828058625	-0.338610014582547	-0.174824744422842
LINC01090	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.166316460811	0.166316460811	0.403261947486457	0.440216058218	6.26515831459764	7.50180135223254	0.000315376153200947	0.00792243970222758	0.148714939500339	0.325176033850575
LINC01090	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.67866663869	-2.67866663869	-1.08558165833002	-0.864735754699	10.7316075041809	3.21472977479178	0.00126299346313573	0.027115709301855	1.13801718524886	2.0481527754711
LINC01090	BRD-K17894950-001-14-3::2.5::MTS010::PROS002_PR500	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.0768135339877	-0.0768135339877	0.0206258500084839	0.0194695079215	3.78984391054233	104.782887124603	0.000252059006954532	0.00649165523931242	0.0464586656025678	0.1484201023898
LINC01090	BRD-K18779551-003-07-8::2.5::HTS002	2.5	bifemelane	acetylcholine release enhancer	noncancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.40325166448	0.40325166448	0.0153143221250697	0.0566081056954	-9.51765966027943	6.95795012200614	3.07715617324568e-05	0.000965381085428209	-0.484437018211426	-0.291437666498434
LINC01090	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2743381429415	0.2743381429415	-0.0297949169957349	-0.00807522835948	-12.5101046512404	167.76732863938	8.64913395023611e-26	2.3465319372407e-23	-0.352127944145162	-0.256138175729308
LINC01090	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2591824587025	-0.2591824587025	-0.94795342711791	-0.900132875838	-12.5256275072347	24.1931190109381	4.566067474098e-12	3.55610710630796e-10	-0.802214638899929	-0.57532729793089
LINC01090	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.239368226285	-1.239368226285	-0.681472939687919	-0.587603052309	8.63744726104371	10.6830740326485	3.82477327955322e-06	0.000142171320193091	0.415216753051472	0.70057382014269
LINC01090	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0468420852435	0.0468420852435	-0.307159612463283	-0.19710233478	-6.2175316039587	124.716703783792	6.97494354519465e-09	3.78272438030877e-07	-0.466687711081971	-0.241315684331596
LINC01090	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-5.746326377285	-5.746326377285	-3.24101632753522	-2.99271378173	13.6478898701606	2.52799177525782	0.00196098308597929	0.0394347479672411	1.85428865947777	3.15633144002179
LINC01090	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.845023223825	0.845023223825	0.36842961549955	0.3847237758685	-15.6046684719857	64.8775659430413	1.21021554014922e-23	2.73901041715567e-21	-0.537591842108129	-0.41559537454277
LINC01090	BRD-K25433859-003-25-4::2.5::HTS002	2.5	maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2	neurology/psychiatry	depression, dysthymic disorder	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.427355925042	0.427355925042	0.169813271866303	0.180847774452	-7.02728703814647	4.24123502808408	0.00173075516039003	0.035538959934432	-0.357054063538388	-0.158031242813005
LINC01090	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3781549362455	-0.3781549362455	-0.180176706483054	-0.04268072142135	4.60343145463253	187.862538932926	7.63822966126753e-06	0.000268640322459765	0.113140186041209	0.282816273483684
LINC01090	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.38051381438	-1.38051381438	-0.293420508835305	-0.250836974988	18.8341069336502	3.27916290986378	0.000186632003099249	0.00496964226515828	0.91194188175024	1.26224472933915
LINC01090	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.55943094298	0.55943094298	0.237952771049325	0.2536769304835	-11.919797799757	119.92264836303	4.36730772232724e-22	8.62710319648549e-20	-0.374877449279554	-0.268078894581795
LINC01090	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.526774096015	-3.526774096015	-2.20656972127099	-2.23277244437	12.0849995258057	133.03248294194	3.74897648030223e-23	8.19076840006827e-21	1.1041259831188	1.53628276636922
LINC01090	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.8674341258665	0.8674341258665	0.420495979477408	0.420565301841	-8.21636735466416	69.4731281296297	7.67594760195734e-12	5.82157881663098e-10	-0.555442166839676	-0.338434125938508
LINC01090	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.8660233960235	0.8660233960235	0.757775727006538	0.759014306598	-3.51171199512894	135.194826038378	0.000605678717943902	0.0141904803168123	-0.169208758479764	-0.0472865795541593
LINC01090	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.4035226525415	-0.4035226525415	-0.175637634746487	-0.120119113317	6.05627024785061	32.5657560390956	8.61056269836782e-07	3.551074259339e-05	0.151291584928952	0.304478450661074
LINC01090	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-7.875075428255	-7.875075428255	-6.58678610286121	-6.64618122736	11.602027427926	3.68589719706677	0.000492112054340068	0.0118138311485946	0.969349943312472	1.60722870747511
LINC01090	BRD-K40530731-001-11-6::2.5::HTS002	2.5	hyoscyamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.165743028775	-1.165743028775	-0.187823456972861	-0.0938174605639	16.7889316611183	10.9589654717816	3.63742574037143e-09	2.03871815247926e-07	0.849658273939473	1.1061808696648
LINC01090	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0806323267958	0.0806323267958	-0.297654289948516	-0.160539632789	-6.2973027447198	78.9969020870514	1.5904170325119e-08	8.30788428372516e-07	-0.497855448904668	-0.258717784583963
LINC01090	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-6.02920259521	-6.02920259521	-5.44081088601144	-5.470053491025	7.11368448695757	76.5938591924007	5.17880401539479e-10	3.17405743727638e-08	0.423675838969949	0.75310757942718
LINC01090	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.5077298818525	-0.5077298818525	-0.119456867146559	-0.0679983440509	7.99011950623977	4.84036723605944	0.000575970817115427	0.0135895254581167	0.26210846936977	0.514437560042112
LINC01090	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-5.93911230416	-5.93911230416	-5.27351334571878	-5.30447708423	6.53454206559695	6.71127113459749	0.000386479470773124	0.0095123746544939	0.422625191670205	0.908572725212242
LINC01090	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1216001488445	-0.1216001488445	0.205440759378399	0.242605983944	10.1102009763582	177.004606121018	2.95970295433798e-19	4.56367032014608e-17	0.263204282081693	0.390877534364105
LINC01090	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.938333038916	-0.938333038916	-0.734458946256966	-0.670954227568	3.56047146258471	99.1443272846411	0.000570404504915333	0.0134730248108881	0.090259041942433	0.317489143375635
LINC01090	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-4.824757567785	-4.824757567785	-3.13363789078193	-3.15598793833	14.5197462550086	10.2518584309496	3.61347630818222e-08	1.79733758100809e-06	1.43246919718325	1.94977015682289
LINC01090	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.320956172955	-1.320956172955	-0.742945696867352	-0.6455499330205	7.83411800784751	48.2124761404326	3.81303207483004e-10	2.37570741734374e-08	0.4296803576651	0.726340594510195
LINC01090	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.09391429685765	-0.09391429685765	-1.30767277458628	-1.05786698502	-13.2756372911348	17.1654552180816	1.8570050766776e-10	1.19343340653443e-08	-1.40651212890735	-1.02100482654991
LINC01090	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3702777752845	-0.3702777752845	0.161878781681334	0.164761931788	13.0064437635726	3.82637025117365	0.000262341005355256	0.00671932186147067	0.416496656867991	0.647816457063677
LINC01090	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.0119813743095	-0.0119813743095	0.258076724232175	0.250852150231	13.3226886148797	190.049259056124	4.99498231460087e-29	1.85540652427399e-26	0.230073952655307	0.310042244428042
LINC01090	BRD-K73237276-001-01-0::2.5::HTS002	2.5	tacalcitol	vitamin D receptor agonist	noncancer	VDR	dermatology	psoriasis, chapped lips	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.1853677990365	0.1853677990365	0.0308400827733446	0.07201409986295	-4.65641274366159	63.009149298226	1.7077417775287e-05	0.000564930679790013	-0.220844458318803	-0.0882109742075078
LINC01090	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.620584454948	-0.620584454948	-0.891808964026445	-0.708568317551	-4.46498111597811	176.27360372443	1.42597193619958e-05	0.000477915776565631	-0.391105227486558	-0.151343790670333
LINC01090	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.4578612675995	-0.4578612675995	-1.11664946314654	-0.918129706972	-8.11722734956578	190.918472653604	5.73696810443954e-14	5.39061217385543e-12	-0.818872194305431	-0.498704196788645
LINC01090	BRD-K80431395-001-07-3::2.48737::HTS002	2.48737	triciribine	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.302572128085	-1.302572128085	-0.933435356682094	-0.71098807564	5.54207398302109	70.450468480832	4.86348778565608e-07	2.07770873751621e-05	0.236309724123056	0.501963818682756
LINC01090	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.79486909335	0.79486909335	0.341248492744467	0.3852845671545	-10.9431671275307	3.86992513952979	0.000471967152236471	0.011386340361514	-0.570252713727141	-0.336988487483925
LINC01090	BRD-K84892605-001-01-1::2.5::HTS002	2.5	IOWH032	CFTR channel antagonist	noncancer	CFTR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.148646866461	-0.148646866461	0.120590043529305	0.126672721217	10.1255665601972	42.9955847432898	5.90961952087908e-13	5.01823630067549e-11	0.215613284551436	0.322860535429175
LINC01090	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.296674190475	-0.296674190475	0.0466989665206597	0.06241133456585	11.1644801011705	20.3716539078834	3.88612463125836e-10	2.41913797877715e-08	0.279292513577441	0.407453800413879
LINC01090	BRD-K89714990-001-01-5::2.5::HTS002	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4977220980925	0.4977220980925	-0.0113414743171458	-0.02895586832955	-15.313309914541	81.6140755125704	1.02371344880402e-25	2.76336876283019e-23	-0.575199588517826	-0.442927556301465
LINC01090	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-6.53979822296	-6.53979822296	-3.07160437395247	-2.979502562735	18.9496373644413	2.18266871646855	0.00183372215006926	0.0372424746235378	2.74061858498736	4.19576911302769
LINC01090	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.424975942899	0.424975942899	0.297723543259459	0.274833859863	-3.44366652284081	104.758816967285	0.000826250125561599	0.0187277245306146	-0.200524527231073	-0.0539802720480089
LINC01090	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.904387501662	-0.904387501662	-0.286297913420196	-0.212124322286	8.8478408100992	188.088916235088	6.48744639123596e-16	7.34082824843142e-14	0.48028438091207	0.755894795571538
LINC01090	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.232536481335	0.232536481335	-0.351112613804558	-0.28220904824	-15.0033930683783	117.428112447779	4.54669318596057e-29	1.70962842781359e-26	-0.66068782991234	-0.506610360366776
LINC01090	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.090678547275	-1.090678547275	0.00411783560473883	0.0503184944333	23.6748310793441	20.3902187726199	2.62082949134624e-16	3.09317050688738e-14	0.998453279635961	1.19113948612352
LINC01090	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	MKN45, NCIH23	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.440257063505	-3.440257063505	-3.06639738392987	-3.05318317183	4.00703316535474	189.742902504766	8.8253254172134e-05	0.0025301273024959	0.189819486157344	0.557899872992919
LINGO2	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.7200809173485	-0.7200809173485	-0.212656437064713	-0.0782038921815	7.42167265137014	59.6742797343024	4.90842211861467e-10	3.01870072958555e-08	0.370647490434724	0.644201470132849
LINGO2	BRD-A58193911-003-18-7::2.5::HTS002	2.5	oxyphencyclimine	cholinergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.348024397525	-4.348024397525	-2.27984764611419	-2.128802868855	14.6871271686622	6.63735802574523	2.62162501659681e-06	0.00010039132895876	1.73147703116008	2.40487647166154
LINGO2	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.595201003859	0.595201003859	0.411153110630515	0.462027349437	-4.77401728272772	11.2249127980341	0.000545361105027409	0.0129413972851439	-0.268693291158965	-0.0994024952980042
LINGO2	BRD-A90547603-001-02-5::2.5::HTS002	2.5	eptifibatide	platelet aggregation inhibitor	noncancer	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.2088548429195	0.2088548429195	0.042701432236777	0.04269931862485	-6.5603677861358	190.548323970246	4.93004235324345e-10	3.0285212024314e-08	-0.216110402562489	-0.116196418802957
LINGO2	BRD-A93695607-322-02-5::2.4707::HTS002	2.4707	nicotine	acetylcholine receptor agonist	noncancer	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.0613216291852	-0.0613216291852	0.126735548258094	0.1533689039075	5.4135111023838	174.361755195405	2.02197542817243e-07	9.1293021180697e-06	0.119495121954533	0.256619232932054
LINGO2	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-5.36363739624	-5.36363739624	-2.73409402256743	-2.614624073445	25.009561252669	54.7958425095417	1.19281701664416e-31	5.53366403377328e-29	2.41881740471558	2.84026934262955
LINGO2	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-1.196841011565	-1.196841011565	-0.0720378631191518	-0.0155909227599	30.9089476326574	159.363961638547	3.30749555731275e-69	4.43057634564552e-65	1.05293259887428	1.19667369801741
LINGO2	BRD-K03406345-001-27-8::2.5::HTS002	2.5	azacitidine	DNA methyltransferase inhibitor	chemo	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-1.78897110381	-1.78897110381	-0.570797408235039	-0.551785683571	29.82407855612	192.064002336942	5.25221321691671e-74	1.60814515224077e-69	1.13761072226266	1.29873666888726
LINGO2	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.8227534748425	-0.8227534748425	-0.374878813042589	-0.261056095384	7.05194532186305	25.8497843555206	1.78768546903678e-07	8.12108602995304e-06	0.31728941835132	0.578459905248503
LINGO2	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.647856998259	0.647856998259	0.236079474457079	0.231867156581	-12.1508113661421	5.28136980746115	4.63107378844709e-05	0.00140491636801709	-0.497514095120676	-0.326040952483166
LINGO2	BRD-K06222852-001-03-2::2.5::HTS002	2.5	posaconazole	sterol demethylase inhibitor	noncancer	CYP3A4	infectious disease	oropharyngeal candidiasis	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.220097515536	-0.220097515536	-0.0461598543040607	0.00528280160376	4.47949251527318	26.667212509251	0.000126314985522825	0.00350051261082514	0.0942190076758513	0.253656314788027
LINGO2	BRD-K07572174-001-39-4::2.48092::HTS002	2.48092	curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	targeted cancer	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-2.47749099398	-2.47749099398	-1.1615465221251	-1.01297286124	10.9785848374042	3.0125874495594	0.00158771900626191	0.0329998280540253	0.935381686360858	1.69650725734893
LINGO2	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.007785738341425	-0.007785738341425	0.259799694952614	0.2294815220965	9.50309229770101	68.6353326209704	3.8436731064173e-14	3.68925487337803e-12	0.211406989475751	0.323763877112328
LINGO2	BRD-K10843433-001-22-7::2.5::HTS002	2.5	phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	PTGIS, PTGS1, PTGS2	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.2588478835605	0.2588478835605	0.12553967539061	0.1301341456285	-3.34035177036343	157.747716464862	0.00104443752872376	0.0229545991687689	-0.212132012661638	-0.054484403678141
LINGO2	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-3.736075995525	-3.736075995525	-2.43432159834904	-2.42612206257	13.8721069001547	190.976793679404	1.01259359759074e-30	4.27220813342571e-28	1.11665900566636	1.48684978868557
LINGO2	BRD-K13094524-001-07-5::2.63083::HTS002	2.63083	PFI-1	bromodomain inhibitor	targeted cancer	BRD4	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.684371882125	-4.684371882125	-2.20433841717656	-2.05881445025	22.9816593019581	37.0852538007809	1.55535483439705e-23	3.50165594854501e-21	2.26139671865332	2.69867021124356
LINGO2	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.39765568793	-4.39765568793	-1.61257636704927	-1.41573166417	19.4462926652167	2.16221544533418	0.00181570806849154	0.0369466338756028	2.21110722998651	3.35905141177495
LINGO2	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-5.148140030025	-5.148140030025	-3.50022012013002	-3.32713088666	9.75616076082408	4.5689250166711	0.000313589053464536	0.00788401504281531	1.20110522864464	2.09473459114532
LINGO2	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.768765153735	0.768765153735	0.302913223661456	0.3131581681635	-14.2891692880655	32.4870532497843	1.45864175344175e-15	1.59578911881572e-13	-0.532220498150572	-0.399483361996517
LINGO2	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.794086686375	-4.794086686375	-2.96957282516073	-2.85647744883	24.1414806990684	180.947449996935	1.76990328857766e-58	9.42904669538952e-55	1.67539047249814	1.97363724993039
LINGO2	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-2.338768741285	-2.338768741285	-0.669960892410432	-0.587603052309	25.7987214210034	8.67773819535162	1.66062123516194e-09	9.65335743723957e-08	1.52164610859722	1.81596958915192
LINGO2	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.6730782898505	0.6730782898505	0.295058233986169	0.330939410236	-15.7013058010619	161.71530152095	2.43265760044665e-34	1.47285048261619e-31	-0.425563366657583	-0.33047674507108
LINGO2	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.796361265765	-4.796361265765	-2.8499045284695	-2.68228454863	16.9653822497028	22.4478771158774	2.72139104779961e-14	2.64642931889221e-12	1.70879397142652	2.18411950316449
LINGO2	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-2.38164589153	-2.38164589153	-0.838935720645995	-0.52176141391	14.3129822740951	13.5539201823346	1.44116904695939e-09	8.42794872212167e-08	1.31082070634977	1.77459963541824
LINGO2	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.2959925810275	0.2959925810275	-0.0364034688393387	-0.0304287468122	-13.1911361869634	52.4327122046027	2.74388587000742e-18	3.86904154363697e-16	-0.38295048756651	-0.281841612167167
LINGO2	BRD-K28192623-066-08-1::2.5::HTS002	2.5	spiradoline	opioid receptor agonist	noncancer	OPRK1	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-2.75035166856	-2.75035166856	-2.31740034853928	-2.11804571815	4.5284778422381	10.5496062658218	0.00095553028231384	0.0212578212453854	0.2214218343913	0.64448080565015
LINGO2	BRD-K29582115-066-01-2::2.5::HTS002	2.5	ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.481071594371	0.481071594371	0.262093838604052	0.262353751493	-5.91094846730598	44.3475633710274	4.44277848299543e-07	1.91092969994366e-05	-0.293622798219822	-0.144332713314073
LINGO2	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-3.64029505775	-3.64029505775	-1.64340180731678	-1.528752793545	19.0157299636922	4.76109440558991	1.12784974082799e-05	0.000384187709952198	1.72282401179395	2.27096248907248
LINGO2	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-3.68192173962	-3.68192173962	-2.2929032746529	-2.022141704435	13.0873084228147	82.8007859699381	7.33789316960216e-22	1.4232790091834e-19	1.17791316543801	1.60012376449618
LINGO2	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-3.658280133395	-3.658280133395	-1.95050814887637	-2.01098817996	25.1701741192138	110.927121096643	1.13548031257159e-47	2.25339222141811e-44	1.57332362206544	1.84222034697181
LINGO2	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.5991006796615	-0.5991006796615	-0.173631706263205	-0.120119113317	12.3871084610833	194.857490197133	2.27482514965873e-26	6.50081332668276e-24	0.357727945077305	0.493210001719284
LINGO2	BRD-K37720887-001-07-8::2.5::HTS002	2.5	SB-525334	TGF beta receptor inhibitor	noncancer	TGFBR1	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.239170173409	0.239170173409	0.0271745736842342	0.0896615671228	-5.09172358410104	160.761097972508	9.82502739597426e-07	4.01561460097591e-05	-0.294218314699209	-0.129772884750322
LINGO2	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.965353554135	-4.965353554135	-3.01711411497461	-2.87565347972	20.260546814623	108.899832434971	9.77402808498607e-39	9.187972216785e-36	1.7576529199569	2.13882595836388
LINGO2	BRD-K40331046-305-01-5::2.5::HTS002	2.5	CR8-(R)	CDK inhibitor	targeted cancer	CCNA2	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-6.58358798546	-6.58358798546	-5.25182054437812	-5.161930725595	13.6129720386291	181.6285565811	1.52043049370835e-29	5.94657568040178e-27	1.13873647815236	1.52479840401141
LINGO2	BRD-K41783120-001-02-8::2.5::HTS002	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-1.118049671465	-1.118049671465	-0.269963316072387	-0.1460716862095	10.2628238496564	5.05481065718409	0.000141688687011147	0.00387544596712763	0.636352777204772	1.05981993358045
LINGO2	BRD-K43621685-001-02-5::2.5::HTS002	2.5	CP-673451	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	KIT, PDGFRA, PDGFRB	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.471732670143	-0.471732670143	0.00166074368695173	0.03337894475615	6.67235325271225	4.16976072035065	0.00225863031139385	0.0445231901516706	0.279531672703802	0.667255154956101
LINGO2	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.11019842016	-4.11019842016	-1.55714595439564	-1.40747957336	18.9909932966452	2.4140488569608	0.00109519765244876	0.0239230144365767	2.0600285636014	3.04607636792732
LINGO2	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-1.0285522562545	-1.0285522562545	-0.27667809466582	-0.2569086069275	13.5200772174291	2.6342705492402	0.00165805061528317	0.0342292747373363	0.560146897092596	0.943601426084764
LINGO2	BRD-K51662849-001-08-8::2.61265::HTS002	2.61265	ilomastat	matrix metalloprotease inhibitor	noncancer	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.558293378299	-0.558293378299	0.0258553244957449	0.0366644244554	20.3951908855432	187.627308437423	1.73417125148989e-49	4.17621561978177e-46	0.527647972423882	0.640649433165608
LINGO2	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-1.03656267105	-1.03656267105	-0.733419479250257	-0.670954227568	5.16113548724039	53.2728341197065	3.71618852774429e-06	0.000138615901664272	0.185348268461051	0.420938115138436
LINGO2	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.380418063749	0.380418063749	-0.128124821195064	-0.007473093877485	-11.8787787398072	46.1212598192581	1.24314973861234e-15	1.37200329725563e-13	-0.594710927613728	-0.422374842274401
LINGO2	BRD-K56751279-300-01-4::0.15625::HTS002	0.15625	Y-39983	rho associated kinase inhibitor	noncancer	ROCK1, ROCK2	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.876699115957	0.876699115957	0.779465916191523	0.797329257919	-3.62839816685553	126.863595855319	0.000411958344793952	0.0100746942128415	-0.150261819037475	-0.044204580493479
LINGO2	BRD-K59058747-001-18-3::2.5::HTS002	2.5	acetylcysteine	mucolytic agent	noncancer	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.842413829331	0.842413829331	0.386671602896445	0.3974557070265	-12.3520856772947	3.37273910104911	0.000632946716521913	0.014750335631774	-0.566151212386692	-0.345333240482419
LINGO2	BRD-K59369769-001-20-3::2.5::HTS002	2.5	tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, AURKC, LCK	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-3.476325213165	-3.476325213165	-1.76681013047641	-1.66496911729	23.8671141340431	27.4342456134605	6.89400888709477e-20	1.1227857376612e-17	1.56265865303619	1.85637151234098
LINGO2	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-9.63488110228	-9.63488110228	-7.18746228144298	-7.241239224365	18.312638197105	5.05033455440084	8.19467991481543e-06	0.000286986528016745	2.10489703519777	2.78994060647628
LINGO2	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.896193782985	-4.896193782985	-3.98178176224295	-4.06345371982	7.13929210712993	8.78652000823494	6.13530712612057e-05	0.00181877488386486	0.623594642822475	1.20522939866163
LINGO2	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.267648903376	0.267648903376	0.154051460470776	0.163841475196	-3.89723916009839	162.559803232151	0.000141958628152568	0.00388084831802447	-0.171155329741279	-0.0560395560691703
LINGO2	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.935784669144	-0.935784669144	-0.162810737360145	-0.0695637223616	10.6581881045626	3.33960048834271	0.00107981425949287	0.0236255114764033	0.554896196748529	0.991051666819182
LINGO2	BRD-K63923597-001-10-0::2.5::HTS002	2.5	barasertib-HQPA	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-3.61667467369	-3.61667467369	-1.14142010393999	-0.996883336969	33.4956733950562	118.853527697177	2.22478627764207e-62	1.7660600670398e-58	2.32892781132089	2.62158132817913
LINGO2	BRD-K64800655-001-07-4::2.5::HTS002	2.5	PHA-793887	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.28257357923	-4.28257357923	-1.59623491375284	-1.563662443425	28.1562399010813	31.2129261422318	9.40245786221666e-24	2.15301217003316e-21	2.49180596493818	2.88087136601614
LINGO2	BRD-K69172251-001-08-9::2.5::HTS002	2.5	cisplatin	DNA alkylating agent, DNA synthesis inhibitor	chemo	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.7097563775785	0.7097563775785	0.377763566659424	0.369534361464	-11.2981785805912	13.067297588232	4.07420252104177e-08	2.01063723723777e-06	-0.395441229205623	-0.268544392632529
LINGO2	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.673970691907	0.673970691907	0.337950496559177	0.355630945231	-7.66931538646977	3.60779979309418	0.0023355594263119	0.0458195072111674	-0.46306325967087	-0.208977131024777
LINGO2	BRD-K69694239-001-02-2::2.5::HTS002	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-7.00375902506	-7.00375902506	-5.67681023771251	-5.73883515181	12.3716293057308	3.83894380174101	0.000310698537446076	0.00781959920529358	1.02416203430387	1.6297355403911
LINGO2	BRD-K69694239-001-02-2::2.5::MTS010::PROS002_PR500	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-2.90523135232	-2.90523135232	-2.52226419236014	-2.6020166043	6.38180548504838	10.0155940707977	7.96147776782558e-05	0.00230560136265409	0.249286502051431	0.51664781786828
LINGO2	BRD-K70159787-001-01-1::2.5::HTS002	2.5	SMI-4a	Pim kinase inhibitor	targeted cancer	PIM1	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-1.182684043675	-1.182684043675	-0.627105758111248	-0.60780165798	9.51003870846571	30.9483708787561	1.0666745090753e-10	7.04310785137397e-09	0.436421462034082	0.674735109093423
LINGO2	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.68929117325	0.68929117325	0.306345953241573	0.289065772439	-11.9087027681279	5.67945017739932	3.12843008294634e-05	0.000979886526095687	-0.462719110918993	-0.303171329097862
LINGO2	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-2.874864424565	-2.874864424565	-1.17150744817358	-1.06477540936	23.733212737202	125.98166777644	2.52643615816635e-48	5.5253932177922e-45	1.56132402981703	1.8453899229658
LINGO2	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.9841663708595	-0.9841663708595	-0.188207353461601	-0.111990350412	22.9945515866767	188.882384979897	1.2029923325349e-56	5.26196211509943e-53	0.727677140495724	0.864240894300074
LINGO2	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.421344762862	-0.421344762862	-0.208817614442354	-0.182274470613	6.39891089743429	5.4634909208427	0.000988444449404507	0.0219127338018637	0.129283539218793	0.295770757620499
LINGO2	BRD-K77908580-001-09-6::2.5::HTS002	2.5	entinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC9	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-2.618168560335	-2.618168560335	-1.78384792983131	-1.479908957755	7.04784460698359	12.2919912255007	1.17866008917324e-05	0.000400350298339795	0.577071660715376	1.09156960029201
LINGO2	BRD-K78431006-001-10-2::2.5::HTS002	2.5	crizotinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-3.13935256663	-3.13935256663	-1.15456909244356	-1.07734518699	25.1702908503707	8.22420872730702	4.48957924995703e-09	2.49545391873454e-07	1.80380461100523	2.16576233736766
LINGO2	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.75927117384	-4.75927117384	-2.47986757271127	-2.2273850288	19.7457477997158	34.0161664710813	3.28211680846948e-20	5.56089180586921e-18	2.04481008714749	2.51399711510996
LINGO2	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.143498434867	0.143498434867	0.309129966913808	0.330760339171	6.32570607421505	172.87274814016	2.08648947650991e-09	1.19795125371255e-07	0.113950271228615	0.217312792865001
LINGO2	BRD-K88172511-003-20-3::2.41866::HTS002	2.41866	naltrexone	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.05188044056065	0.05188044056065	0.311591405479244	0.3037924157915	9.83052396213814	10.2452966074614	1.53967344468911e-06	6.1144463540258e-05	0.201036616986128	0.31838531285106
LINGO2	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.3510734812955	0.3510734812955	0.0908300474711223	0.09873309755385	-9.77468313352073	38.9235951799732	4.96221023748445e-12	3.84090125673458e-10	-0.314099406655585	-0.20638746099317
LINGO2	BRD-K92428232-001-10-6::2.5::HTS002	2.5	GSK461364	PLK inhibitor	targeted cancer	PLK1	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-4.17744842975	-4.17744842975	-2.68339698394039	-2.35101835033	11.2162457772683	21.3354074496956	2.07478404612044e-10	1.32742205916701e-08	1.21730299928685	1.77079989233238
LINGO2	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-0.09030280541835	-0.09030280541835	-0.969825898757954	-0.879578497328	-10.0599052550386	159.768082872763	9.50104539381174e-19	1.39380531020553e-16	-1.05218781517183	-0.70685837150738
LINGO2	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	-3.289371414345	-3.289371414345	-1.73364881068141	-1.68383825257	24.5050118041832	185.123057658359	5.2437725608707e-60	3.30556626234958e-56	1.43047373778799	1.68097146953918
LINGO2	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	MSTO211H, HGC27	PLEURA, STOMACH	mesothelioma, carcinoma (undifferentiated_adenocarcinoma)	0.2038218904835	0.2038218904835	-0.0917631865889165	0.0692106615383	-4.66103692459245	8.58290504051879	0.00134362796475694	0.0286090242458166	-0.44011216783893	-0.151057986305903
LRRC49	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.08728607084225	-0.08728607084225	0.175774514845117	0.161263687573	10.5171562640433	187.999879384663	1.22204751459285e-20	2.14688706356697e-18	0.21371931963122	0.312401851743515
LRRC49	BRD-A18696154-003-22-6::2.5::HTS002	2.5	idazoxan	adrenergic receptor antagonist	noncancer	ADRA2A	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-1.234875220535	-1.234875220535	-0.648959276148861	-0.5933012129785	8.91025681025798	4.68721825242054	0.000410964326523017	0.0100538264055875	0.413431260622441	0.758400628149837
LRRC49	BRD-A27376179-001-01-3::2.5::HTS002	2.5	lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	targeted cancer	FLT3, NTRK1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-4.732095098695	-4.732095098695	-2.89026734208276	-2.875482162025	18.9823307453483	150.438060360627	9.03577117625776e-42	1.11300448300928e-38	1.65011309544315	2.03354241778133
LRRC49	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-3.97362704653	-3.97362704653	-3.71577602971264	-3.697322932235	3.36569127417625	86.4868744603178	0.00114051428467753	0.0248243410298213	0.105564413071328	0.410137620563396
LRRC49	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-3.0369557175	-3.0369557175	-2.34904777358251	-2.27036498586	6.64500414179829	5.30110903865702	0.000925558994422824	0.0206790507365422	0.426277467654591	0.949538420180382
LRRC49	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.1821644247525	0.1821644247525	-0.188925010224885	-0.0590439534084	-6.652180058471	4.77940716483103	0.00137726674726214	0.0291803286549968	-0.516502167994693	-0.225676701960076
LRRC49	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.841762671798	0.841762671798	0.0239085018379316	0.005378846282065	-17.3155514484684	11.2704186215409	1.79076192712744e-09	1.03845295746563e-07	-0.921508354573899	-0.714199985346238
LRRC49	BRD-K00312224-001-09-5::2.5::HTS002	2.5	PPT	estrogen receptor agonist	noncancer	ESR1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.536287730479	0.536287730479	0.158761927575578	0.22700730099	-6.9977671407411	7.74582401248431	0.000131782606437974	0.00363464602435266	-0.502647684848363	-0.252403920958481
LRRC49	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-5.801169067895	-5.801169067895	-4.25811745745576	-4.2400927308	15.9689200995705	3.03564378972302	0.000499609402927153	0.0119817370168931	1.23756946171144	1.84853375916704
LRRC49	BRD-K09090949-001-01-9::2.5::HTS002	2.5	CP-945,598	cannabinoid receptor antagonist	noncancer	CNR1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-1.27897973396	-1.27897973396	-0.685958767126847	-0.6179289044455	9.58848786595171	23.5032896968367	1.36070764834693e-09	7.98569841235386e-08	0.465231746723599	0.720810186942707
LRRC49	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.08589446245275	-0.08589446245275	0.187958144310338	0.239804537816	7.5376461041751	101.288223553805	2.0860254544441e-11	1.49680532181302e-09	0.201783533874642	0.345921679651534
LRRC49	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.2708627416215	0.2708627416215	-0.429012574979754	-0.399128631959	-10.4118653882285	5.21040601162909	0.000110374424130532	0.00309882629676091	-0.870589511074552	-0.529161122127956
LRRC49	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.1507845973455	0.1507845973455	-0.258641029871155	-0.1509093731905	-6.9237245458681	24.3701802946803	3.38778310913144e-07	1.48032653618151e-05	-0.531373608616904	-0.287477645816407
LRRC49	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.659092604171	-0.659092604171	-1.81576635804569	-1.56065418801	-11.034777710845	190.974532315311	3.22109913570848e-22	6.47631291423324e-20	-1.3634288887518	-0.949918618997573
LRRC49	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-5.82878304948	-5.82878304948	-4.1191422887751	-4.11179699224	11.0489139242561	5.7318058512573	4.43891695523252e-05	0.00135255705444702	1.32668460792977	2.09259691348004
LRRC49	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.08171003109415	-0.08171003109415	0.343894960500288	0.357900779497	13.334348907761	150.992464396458	2.67404618847805e-27	8.22274957719243e-25	0.362541528264682	0.488668454924194
LRRC49	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-3.01662330379	-3.01662330379	-2.05623060761304	-2.351388502545	8.18325241189323	8.24007130886085	3.12162245231506e-05	0.000978221979678707	0.691124642738641	1.22966074961528
LRRC49	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.708968286452	-0.708968286452	-0.323598181454247	-0.309372115648	11.5509350352597	190.545744683307	9.77094064302956e-24	2.23500100008525e-21	0.319562494119444	0.451177715876062
LRRC49	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-7.319600571905	-7.319600571905	-3.47540342822282	-3.32713088666	20.3133507317863	2.80271169072545	0.000396970495685209	0.0097426187300716	3.21722713593048	4.47116715143388
LRRC49	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-1.80214689149	-1.80214689149	-1.09485699957023	-0.864735754699	5.36883767013504	5.34127152797816	0.00246574714505468	0.0479913839313861	0.375047502241423	1.03953228159811
LRRC49	BRD-K16505263-003-02-9::2.5::MTS006	2.5	forodesine	purinergic receptor antagonist	targeted cancer	PNP	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.3805736499655	0.3805736499655	0.221394493440702	0.234801911362	-7.03606023810954	19.3539036826223	9.61683620090412e-07	3.94255333990738e-05	-0.206471807786188	-0.111886505263407
LRRC49	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-1.210481748555	-1.210481748555	-1.87154437434089	-1.673362994515	-6.21051652792433	15.8506466059724	1.30176736946487e-05	0.000439103711882335	-0.886883473662746	-0.435241777909032
LRRC49	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.72135641449	-0.72135641449	-0.257387978508292	-0.291499790384	7.44660718386996	14.5734112846609	2.45141554099961e-06	9.43453836392359e-05	0.330826924484612	0.597109947478803
LRRC49	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.1128622719771	-0.1128622719771	0.0930962167212777	0.09201913789375	7.34559149352089	20.7483018651088	3.38760196784086e-07	1.48032653618151e-05	0.147606384257198	0.264310593139557
LRRC49	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-1.63925058623	-1.63925058623	-0.826109926470798	-0.73306047453	10.8521986044358	6.88284742986544	1.40527466297067e-05	0.000471495167877019	0.635349360286732	0.990931959231672
LRRC49	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-1.13291479715	-1.13291479715	-1.98306388262717	-1.88069436606	-7.71406477636117	28.3332954398067	1.94316256075693e-08	1.002349190095e-06	-1.07577968051731	-0.624518490437036
LRRC49	BRD-K27184429-300-01-3::2.5::HTS002	2.5	levocetirizine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.3632585577355	0.3632585577355	-0.361007258695697	-0.252619761318	-10.5897661935262	3.25113767172506	0.00125014827660126	0.026898570954781	-0.932713628997055	-0.515818003865338
LRRC49	BRD-K27316855-001-13-3::2.43597::HTS002	2.43597	calcitriol	vitamin D receptor agonist	noncancer	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.197132230937	-0.197132230937	-0.0345621664399248	0.01343134409051	3.94889491147598	157.542583380372	0.000118105223563593	0.00329301085744262	0.0812566723580427	0.243883456636108
LRRC49	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.1517084830425	0.1517084830425	-0.0737489988793372	0.0269217911151	-6.26572631560428	12.1700265153371	3.90119116118722e-05	0.0012013482764168	-0.303735648761606	-0.147179315082068
LRRC49	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-3.040140130555	-3.040140130555	-2.61350233665011	-2.424137198535	4.70697330693305	185.692282877117	4.90339338245317e-06	0.000178852859133391	0.247822201165525	0.605453386644245
LRRC49	BRD-K37723606-001-01-5::2.5::HTS002	2.5	dioscin	apoptosis stimulant	targeted cancer	CXCR3	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-2.26255622747	-2.26255622747	-0.993086262672938	-0.8388253651295	12.7487114895197	4.77416613900468	7.19809602923496e-05	0.00210156753010475	1.00981574915657	1.52912418043756
LRRC49	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-5.569816406995	-5.569816406995	-3.75162214137543	-3.68976707366	17.0415632129622	30.8350761321329	3.03721199496598e-17	3.89331704347525e-15	1.60054781767447	2.03584071356468
LRRC49	BRD-K38548312-001-01-0::2.5::HTS002	2.5	VER-49009	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-2.347397517955	-2.347397517955	-2.73851495008612	-2.671842712285	-4.26170785707203	102.334434063071	4.52228153797378e-05	0.00137522145254311	-0.57314519398352	-0.209089670278714
LRRC49	BRD-K40718343-001-02-6::2.5::HTS002	2.5	AEE788	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.0746578989209	-0.0746578989209	-0.395780189153286	-0.1963749895675	-4.45981601860908	20.310995765807	0.000232400712533543	0.00604272865663009	-0.471171629987321	-0.171072950477452
LRRC49	BRD-K40797222-001-01-8::2.5::HTS002	2.5	SC-12267	dihydroorotate dehydrogenase inhibitor	noncancer	IL17A	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.4825170426675	0.4825170426675	0.183968321855065	0.184399160559	-10.62017875862	6.82321170325133	1.7203012616469e-05	0.000568575148043328	-0.365372499852374	-0.231724941772496
LRRC49	BRD-K43644456-001-04-0::2.37833::HTS002	2.37833	WP1130	deubiquitinase inhibitor	targeted cancer	JAK2, UCHL5, USP14, USP9X	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-5.12107688502	-5.12107688502	-6.30395257517138	-6.296490539345	-11.9085261950541	3.84980629323924	0.000353026324859139	0.00878381462511429	-1.46295590946224	-0.902795470840523
LRRC49	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-1.74658637128	-1.74658637128	-0.66334256463502	-0.568122839674	19.8111037662709	68.9215975647231	3.63206911148398e-30	1.47714941289421e-27	0.974160731423155	1.19232688186681
LRRC49	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.5661878940775	-0.5661878940775	0.380926386322375	0.3764822376655	19.7228088858902	4.16043268323168	2.87586929301779e-05	0.000907244906834281	0.815789240583876	1.07843932021588
LRRC49	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.1308645725572	-0.1308645725572	-0.786027801449516	-0.640313618355	-7.06835384795142	7.02635079915443	0.000195664861996971	0.00518232424676484	-0.874172899420275	-0.436153558364358
LRRC49	BRD-K50140147-001-10-1::2.5::HTS002	2.5	NVP-TAE684	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, INSR	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-1.366843481345	-1.366843481345	-1.8112352091026	-1.65535849639	-4.47728069262073	12.4515528697058	0.00069105961334884	0.015974343816808	-0.659782805150822	-0.229000650364373
LRRC49	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.541362218119	0.541362218119	0.254797513128886	0.250850268444	-7.04149175050851	4.53313544467254	0.00132469869513829	0.0282705712068401	-0.394503808345518	-0.17862560163471
LRRC49	BRD-K56957086-001-06-3::2.5::HTS002	2.5	dacinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-7.153693326595	-7.153693326595	-5.56999336465979	-5.599173214095	19.6284818599162	187.989140136965	2.16309430207282e-47	4.03142468407797e-44	1.42453803477809	1.74286188909233
LRRC49	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-8.217324090675	-8.217324090675	-7.20254267518346	-7.241239224365	8.59623944340591	13.5623875518179	7.41734631430345e-07	3.08989780019115e-05	0.760821913721026	1.26874091726206
LRRC49	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.891898187565	-0.891898187565	-0.208459447822778	-0.1907303952045	10.5318289268823	6.53213012309888	2.44934624257696e-05	0.000785877141954007	0.527735509633871	0.839141969850573
LRRC49	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-4.53285172061	-4.53285172061	-2.92361029349687	-2.87845710522	14.5790316895972	5.59092424794723	1.16076033330461e-05	0.000394833520832952	1.33428649953991	1.88419635468634
LRRC49	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.6591809196345	-0.6591809196345	-1.22034416873437	-1.04907947641	-7.28059528073418	182.976210696773	9.51595108793831e-12	7.15378562163006e-10	-0.713236354702902	-0.409090143496842
LRRC49	BRD-K69280563-001-01-8::2.5::HTS002	2.5	vinorelbine	tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-3.954422540945	-3.954422540945	-3.35931730262014	-3.520745955955	6.33076393595818	172.617731131974	2.03727149767811e-09	1.17157596679864e-07	0.409563651861372	0.780646824788339
LRRC49	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-1.237039230395	-1.237039230395	-0.78274901963848	-0.642853768929	5.72894620359605	9.58842127729506	0.000223515014341649	0.00583007782753211	0.276571284800794	0.632009136712247
LRRC49	BRD-K70177501-003-01-4::2.5::HTS002	2.5	INH1	Hec1 inhibitor	targeted cancer	NDC80	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.313519598419	-0.313519598419	0.166614300892016	0.175739960051	19.4243816178741	58.5901479050779	3.26607904217095e-27	9.97173012862476e-25	0.430665845675681	0.529601952946351
LRRC49	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.308364625259	-0.308364625259	0.109579590784159	0.101486674715	7.76684602590149	3.5160751675561	0.00247045884997331	0.0480699931780235	0.260070354663911	0.575818077422407
LRRC49	BRD-K77625799-001-07-7::2.5::HTS002	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.1468310381205	-0.1468310381205	0.111013412784407	0.1701419093195	4.58302242512434	26.0253497351095	0.00010084424440223	0.00285632959673393	0.142204227991697	0.373484673818117
LRRC49	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.12475192223835	-0.12475192223835	0.505310834500299	0.518013519807	14.6935029242613	3.20703525591075	0.000473985789055412	0.0114286084129213	0.498449245722005	0.761676267755293
LRRC49	BRD-K79612754-001-19-1::2.62081::HTS002	2.62081	inosine	neurotrophic agent	noncancer	PARP1, PNP	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-2.056402459545	-2.056402459545	-1.39155506382804	-1.34952956082	10.0747743995884	188.48661532186	2.26312317616691e-19	3.52509394785375e-17	0.534671009914007	0.79502378151992
LRRC49	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.2410680542645	-0.2410680542645	-0.120234811503616	-0.0981289252682	3.89453023214176	40.9112669083347	0.000356241564331007	0.00885661735778916	0.05817003448808	0.183496451033688
LRRC49	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-4.35571550596	-4.35571550596	-2.48416071811425	-2.2273850288	12.0882401017977	3.55682558592403	0.000514343540949385	0.0122883443081196	1.41972351985299	2.32338605583851
LRRC49	BRD-K81801188-001-02-8::2.5::HTS002	2.5	PP-121	protein tyrosine kinase inhibitor	noncancer	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-6.02839517725	-6.02839517725	-4.60932976786835	-4.579711066605	13.9626417894927	153.312513620062	4.13894887868268e-29	1.56730878837311e-26	1.21828346797602	1.61984735078728
LRRC49	BRD-K83029223-001-01-3::2.5::MTS006	2.5	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-3.9195711747	-3.9195711747	-2.40424104053097	-2.23881824047	15.0114014092464	190.497822535516	3.97875494604185e-34	2.32995237385301e-31	1.31621605763437	1.7144442107037
LRRC49	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-0.02728119287195	-0.02728119287195	0.460951351928045	0.487412056788	15.617457459299	186.6601559479	1.02298772514119e-35	6.96050590926308e-33	0.42656034774654	0.54990474185345
LRRC49	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.2791576941975	0.2791576941975	0.040300834468743	0.0562766217073	-8.72893477191483	179.483347329256	1.74286419422736e-15	1.89713732800689e-13	-0.29285301306174	-0.184860706395774
LRRC49	BRD-K88789588-001-14-9::2.5::HTS002	2.5	letrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	0.723139364205	0.723139364205	0.167711005371208	0.134941484208	-10.0936618722987	3.03528996436703	0.00196952200585875	0.0395656277058487	-0.729403998852371	-0.381452718815213
LRRC49	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-6.65808542963	-6.65808542963	-5.60549136881772	-5.60058662575	10.7234894511616	185.889014309498	3.4139236393507e-21	6.25387042477263e-19	0.858947597937164	1.24624052368739
LRRC49	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	GI1, IM95	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma (gliosarcoma), carcinoma (intestinal_adenocarcinoma)	-2.204143332375	-2.204143332375	-1.24036807228209	-1.23927241763	13.7030167762036	160.512818994729	8.51313432424247e-29	3.10836723437916e-26	0.824877748798828	1.10267277138699
LSM14A	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.443572225965	-1.443572225965	-0.942195325430085	-0.8676021902365	8.24844826241118	193.000072879716	2.44916724421564e-14	2.39583553758784e-12	0.381489921963722	0.621263879106108
LSM14A	BRD-A08545410-311-03-4::2.5::HTS002	2.5	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.0023866358581	-0.0023866358581	-0.500812100981975	-0.495379561508	-12.6945172282999	15.8527492525674	1.01668262192232e-09	6.04115801702217e-08	-0.581722291680047	-0.415128638567703
LSM14A	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.5335792860295	0.5335792860295	-0.0567035730929268	0.106263594851	-8.82974195010888	7.542179110025	3.07573355589467e-05	0.000965322737298799	-0.746087183354373	-0.434478534890481
LSM14A	BRD-A50049929-001-01-9::2.5::HTS002	2.5	oxazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3	neurology/psychiatry	anxiety	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.02112557574932	0.02112557574932	-0.259404761354143	-0.09984291970545	-4.39319276809348	76.5105515295375	3.54488685353525e-05	0.00110059116504099	-0.407696234456776	-0.15336443975015
LSM14A	BRD-A59303141-001-10-4::2.5::HTS002	2.5	quinethazone	thiazide diuretic	noncancer	CA1, CA2, SLC12A1, SLC12A2, SLC12A3	cardiology	hypertension	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.617710628525	0.617710628525	0.360660662781047	0.3935946417985	-8.22783901291973	149.783523662196	8.54171579621471e-14	7.8843126825448e-12	-0.318780921629288	-0.195319009858618
LSM14A	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.1788886820945	-0.1788886820945	-0.533961605582481	-0.51783728433	-9.3109713358274	8.62331187722881	8.68826441032859e-06	0.000302345676700977	-0.44191791634806	-0.268227930627902
LSM14A	BRD-A75726477-003-21-3::2.5::HTS002	2.5	clenbuterol	adrenergic receptor agonist	noncancer	ADRB1, ADRB2, ADRB3, NGF, TNF	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.2044131968545	0.2044131968545	0.365584052023531	0.3771474213795	4.7933595889598	27.1612721005936	5.23449652979453e-05	0.00157217545786762	0.0921997250512203	0.230141985286841
LSM14A	BRD-A81370665-001-03-6::2.5::HTS002	2.5	BI-D1870	ribosomal protein inhibitor	noncancer	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.783376802206	0.783376802206	0.354789983736938	0.3549788764895	-11.1902913863918	11.1019598076213	2.18290839375707e-07	9.82075090523843e-06	-0.512789927219356	-0.344383709718767
LSM14A	BRD-A93695607-322-02-5::2.4707::HTS002	2.4707	nicotine	acetylcholine receptor agonist	noncancer	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.137997198132	-0.137997198132	0.12760686154158	0.1533689039075	6.05146051640754	6.72130036209336	0.000602060330791417	0.0141226867284879	0.160939770181812	0.370268349165348
LSM14A	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.863880063447	-0.863880063447	-0.178297382670401	-0.1257743846785	10.0820856148257	3.21170973281323	0.00154293519918569	0.0322012704059714	0.477026521608519	0.894138839944679
LSM14A	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-2.089534256465	-2.089534256465	-3.73532482847996	-3.62613694573	-11.7982109714788	4.9117655188722	8.62577260493541e-05	0.00247921847477967	-2.00631985778728	-1.28526128624263
LSM14A	BRD-K00494077-066-01-9::2.5::HTS002	2.5	trovafloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.10424881355325	-0.10424881355325	-0.524777273825815	-0.32459433605	-4.70361282495413	6.678062407744	0.00249449223991602	0.0484760202456217	-0.634022370785875	-0.207034549759255
LSM14A	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.452253381605	-1.452253381605	-1.90103603880555	-1.73380354334	-4.33769940044441	188.783380344257	2.34182686759783e-05	0.000752618699513233	-0.652870798180419	-0.24469451622068
LSM14A	BRD-K02130563-001-11-4::0.15625::HTS002	0.15625	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-3.660951288155	-3.660951288155	-3.01298045862318	-3.06864894207	4.7913738587617	148.442545651482	3.97834018888036e-06	0.000147572460080052	0.380732600278202	0.91520905878544
LSM14A	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.778345589195	-1.778345589195	-1.45018099664981	-1.361653967605	4.16847741732813	33.6692925255054	0.00020209130828348	0.00533226985265172	0.168117651749307	0.488211533341063
LSM14A	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3442570103165	0.3442570103165	0.0554762073092639	0.0542001317345	-6.36074502332487	189.255270457725	1.47197534055006e-09	8.60106332510232e-08	-0.378336765063025	-0.199224840951448
LSM14A	BRD-K06854232-001-19-9::2.5::HTS002	2.5	AM-580	retinoid receptor agonist	targeted cancer	RARA	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3319788281195	0.3319788281195	0.116648690749998	0.1496364875755	-6.1985836322972	11.1102654970745	6.44306960160461e-05	0.00190106919691949	-0.291696807420716	-0.138963467318288
LSM14A	BRD-K09426783-300-01-0::2.5::HTS002	2.5	TAS-103	topoisomerase inhibitor	chemo	TOP1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-3.930758057545	-3.930758057545	-2.69609669079927	-2.60256994036	9.54563257438335	4.37185719151335	0.000432832874752302	0.0105347078370186	0.887278964601036	1.58204376889042
LSM14A	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-2.8530691224	-2.8530691224	-2.41121256174631	-2.32376274045	6.1464604091562	160.395828033895	6.04304309028491e-09	3.30071198393903e-07	0.29988756658459	0.58382555472279
LSM14A	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.890915643951	0.890915643951	0.33371039845793	0.34680571662	-16.9908679854687	70.6299801149805	1.18094961779238e-26	3.49119656043894e-24	-0.622601350037475	-0.491809140948664
LSM14A	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.424231394882	-0.424231394882	-0.946225166006082	-0.900132875838	-9.05929254111684	13.8560838596517	3.39635348236677e-07	1.48376894725273e-05	-0.645696278840546	-0.398291263407619
LSM14A	BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500	2.5	sonidegib	smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.2323168150705	0.2323168150705	-0.00191926661105844	0.0115719304002	-8.76265176411807	3.58079668836863	0.00152169902898021	0.0318313713822272	-0.312009234831325	-0.156462928531792
LSM14A	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.14392608751825	0.14392608751825	-0.408220225630138	-0.310618907363	-7.21137664761974	5.25202243341267	0.00064825581680962	0.01507105119438	-0.746158442078496	-0.35813418421828
LSM14A	BRD-K25596805-001-01-8::2.5::HTS002	2.5	JNJ-16259685	glutamate receptor antagonist	noncancer	GRM1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.756342255797	0.756342255797	0.38782214887661	0.376431167142	-11.5669014784383	177.250215533491	2.05015774299891e-23	4.5581769595354e-21	-0.43139360796465	-0.30564660587613
LSM14A	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.1767976704805	-0.1767976704805	-0.503933971812921	-0.436225052339	-6.68144136513664	64.7927903521951	6.39610449372368e-09	3.48644628696669e-07	-0.424925967514652	-0.22934663515019
LSM14A	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.0599725920088	-0.0599725920088	-0.536079564090447	-0.4752073320215	-7.48129496108058	3.87312974163706	0.00193731765747666	0.0390174174224127	-0.655105133002203	-0.297108811161091
LSM14A	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.190089839619	-0.190089839619	-0.748102945026497	-0.6332790164525	-9.73385756912605	93.8936239856	6.83392493076633e-16	7.71711431236152e-14	-0.671838940488027	-0.444187270326967
LSM14A	BRD-K31627533-001-09-5::2.5::HTS002	2.5	rimexolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	ophthalmology	anterior uveitis	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.2364772234415	-0.2364772234415	0.266281246324938	0.264424524013	14.372892804988	15.1440901738724	3.10763225001871e-10	1.95209763339466e-08	0.42826289140308	0.577254048129795
LSM14A	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.37341089304	-1.37341089304	-0.0988552459369594	0.0673910689795	16.964736793014	5.53099398125904	5.55624851019641e-06	0.000200820436246524	1.08687423531855	1.46223705888753
LSM14A	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.5947268742935	-0.5947268742935	-0.93617370027918	-0.797793160199	-4.2965226498674	15.2676712722506	0.000612623733828939	0.0143281353391338	-0.510575914278289	-0.172317737693071
LSM14A	BRD-K36740062-001-06-6::2.5::HTS002	2.5	GSK1070916	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC, CYP2D6, CYP3A4	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-3.352217199965	-3.352217199965	-2.24616687402982	-1.941905488655	8.03796169386837	5.19396310811792	0.000402790087849357	0.00987075197103416	0.756266076196247	1.4558345756741
LSM14A	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.398419909797	-0.398419909797	-1.37836441157039	-1.00119520354	-6.82471444859197	3.96663802388564	0.00248472906627028	0.0483081908603631	-1.37993349510172	-0.579955508445058
LSM14A	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.193562719251	0.193562719251	-0.148871308113831	-0.07517274316945	-7.3896778179649	88.2506035311265	7.92114371063304e-11	5.31870554622891e-09	-0.434520415458007	-0.250347639271654
LSM14A	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.12238545536055	0.12238545536055	-0.208281379761979	-0.158031671069	-6.88883956508375	3.92073931267434	0.00250407672185955	0.0486420510664407	-0.46500649968354	-0.196327170561517
LSM14A	BRD-K43644456-001-04-0::2.37833::HTS002	2.37833	WP1130	deubiquitinase inhibitor	targeted cancer	JAK2, UCHL5, USP14, USP9X	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-6.718631347485	-6.718631347485	-6.28695731493239	-6.277258819915	4.80743021627183	6.49184270208934	0.00240076186053663	0.0468926354512854	0.215930979625814	0.6474170854794
LSM14A	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.257161521176	-0.257161521176	-0.697901120034166	-0.636668754802	-7.33240033490804	10.7560716190289	1.67764033090122e-05	0.000555830846315856	-0.573404494525334	-0.308074703190998
LSM14A	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.969080222939	-0.969080222939	-0.254708200993579	-0.219779888934	14.7159381764062	4.6694547938008	4.31967361813216e-05	0.00132054104535822	0.58688112422592	0.841862919664922
LSM14A	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.13797801698065	0.13797801698065	-0.461312089481074	-0.3435721987365	-9.42588018564486	7.37700634642185	2.25265226736501e-05	0.000726902601343081	-0.748087467207813	-0.450492745715635
LSM14A	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-6.83113545628	-6.83113545628	-6.17459963952205	-6.268105536705	7.48962628362023	189.91470709477	2.53064813848873e-12	2.02535954023208e-10	0.48362476887054	0.829446864645354
LSM14A	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.7643113653625	0.7643113653625	0.221402631246999	0.2005091684065	-16.7201151741025	14.1061797928875	1.07090662807193e-10	7.06669786601076e-09	-0.612501656539742	-0.47331581169126
LSM14A	BRD-K55044200-001-15-3::2.5::HTS002	2.5	amoxicillin	penicillin binding protein inhibitor	noncancer	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.38919065164	0.38919065164	0.094342727409546	0.127274405853	-9.42771436856111	7.01415742891933	3.11065853865688e-05	0.000974999025931254	-0.368770335629438	-0.22092551283147
LSM14A	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.829597084548	-0.829597084548	-0.57931936735549	-0.45596991553	3.18968911006225	62.6456563071934	0.00222530506195424	0.0439461355038782	0.0934613436487911	0.407094090736229
LSM14A	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.1684285546975	-0.1684285546975	0.265079890362564	0.254607479759	12.1061800509475	3.22684207944872	0.00084766667708913	0.0191503690559541	0.323949426950416	0.543067463169711
LSM14A	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-2.25064213957	-2.25064213957	-1.52794728656812	-1.40779088077	11.0647778717566	30.3372663639049	3.57278462894335e-12	2.81422769840793e-10	0.589366190300264	0.856023515703497
LSM14A	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.945051555268	-0.945051555268	-0.683729723338928	-0.630554296997	4.73276554342184	102.860669910633	7.09163897243174e-06	0.000250898628148287	0.151813224671608	0.370830439186536
LSM14A	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-4.779002246885	-4.779002246885	-3.98302188431808	-4.06345371982	7.60456357970843	188.480817490478	1.31548059642413e-12	1.08524111143567e-10	0.589502397082981	1.00245832805086
LSM14A	BRD-K64890080-001-13-8::2.5::HTS002	2.5	BI-2536	PLK inhibitor	targeted cancer	BRD4, PLK1, PLK2, PLK3	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-3.97693827936	-3.97693827936	-2.50507261925261	-2.50948766362	9.17074461662719	3.55494320033549	0.00134251031578958	0.0285909075390367	1.00337027672956	1.94036104348521
LSM14A	BRD-K67537649-001-04-5::2.5::HTS002	2.5	PQ-401	IGF-1 inhibitor	targeted cancer	IGF1R	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.579965082183	-0.579965082183	0.185010528692903	0.20362806034	22.8826584426989	44.9456088979201	2.10480885785667e-26	6.03911081252425e-24	0.697641151549557	0.832310070202249
LSM14A	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.14958643699	-0.14958643699	-1.03843595281321	-0.659178147727	-8.6628219714955	68.3615889140108	1.31904212697298e-12	1.08776060035395e-10	-1.09357515181349	-0.684123879832926
LSM14A	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.45618763222	-1.45618763222	-1.1870121125708	-1.06477540936	3.69556581005564	132.699146458817	0.000319800296505043	0.00802323279288649	0.125102903805128	0.413248135493278
LSM14A	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-2.881411638665	-2.881411638665	-1.31518466017102	-1.061822092665	18.3814498721226	189.083940104993	5.96144712708106e-44	8.75144521438464e-41	1.39814868139368	1.73430527559429
LSM14A	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.0942395471343	0.0942395471343	-0.196880675653266	-0.145323520972	-6.70460341563639	182.127636522926	2.45307344637337e-10	1.55505702066772e-08	-0.376792998083029	-0.205447447492103
LSM14A	BRD-K77791657-003-01-7::2.66704::HTS002	2.66704	3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.893342776045	-0.893342776045	-1.52524014635954	-1.46906470598	-8.52024401944576	51.3113549411433	2.14890515853665e-11	1.53934723838236e-09	-0.780766349634668	-0.483028390994413
LSM14A	BRD-K78809024-001-05-7::2.5::HTS002	2.5	SB-590885	RAF inhibitor	targeted cancer	BRAF	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.5819094272575	0.5819094272575	0.0883435265026048	0.1598746623085	-10.57956785629	130.288119891456	2.91374938046338e-19	4.50253057653451e-17	-0.585860863519527	-0.401270937990263
LSM14A	BRD-K81016934-001-02-0::2.5::HTS002	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.290509322837	0.290509322837	0.142281057623404	0.2010478375385	-4.60055070880079	124.557628480645	1.02170026987444e-05	0.000351492772298427	-0.211997221456704	-0.0844593089704877
LSM14A	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.55802983999	0.55802983999	0.27968111140891	0.273644438403	-6.29278732344486	4.66432835927997	0.00191448528216416	0.0386192673920905	-0.394559068885187	-0.162138388276994
LSM14A	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.3143919620335	-0.3143919620335	-0.778308943299284	-0.670066066219	-8.63804016422354	30.2771640185906	1.14077485287291e-09	6.75044542908331e-08	-0.573557743816731	-0.354276218714836
LSM14A	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-3.471421005725	-3.471421005725	-3.05786258487199	-2.99006854464	4.33825462879206	160.294561694567	2.5321925152353e-05	0.000810275141233003	0.225297056839771	0.601819784866251
LSM14A	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.147902526135	-1.147902526135	-0.316114604443568	-0.3195858510195	9.15780041495369	3.70231654716788	0.00112595052753365	0.0245272741758065	0.571406507873279	1.09216933550958
LSM14A	BRD-K84868168-001-01-0::2.5::MTS006	2.5	erdafitinib	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.5831127066025	0.5831127066025	0.0837132485204204	0.13174233615	-11.603873898925	20.407273689763	1.91895841971296e-10	1.23214032096663e-08	-0.589058983335149	-0.40973993282901
LSM14A	BRD-K85606544-001-09-1::2.5::HTS002	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.912090472515	-1.912090472515	-1.58576283366042	-1.498612061085	3.60389309631211	48.2698727532781	0.000740054750844141	0.0169823548922563	0.144293677138715	0.508361600570438
LSM14A	BRD-K85849709-001-01-5::2.5::HTS002	2.5	AZD2858	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-5.081843433755	-5.081843433755	-1.70416263537872	-1.560521012105	30.9085581528072	14.9812420220373	5.51616326717902e-15	5.7280705275737e-13	3.14473103200125	3.61063056475131
LSM14A	BRD-K87024524-065-17-7::2.5::HTS002	2.5	phenelzine	monoamine oxidase inhibitor	noncancer	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	1.058669706125	1.058669706125	0.344203577803554	0.3670145193675	-17.4942166169913	4.48299020311285	2.68382392205088e-05	0.000852811411992946	-0.823197313773585	-0.605734942869308
LSM14A	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.951189014175	-0.951189014175	-1.96449375181931	-1.89031364576	-15.2457772447513	32.3958438410928	2.45301755932473e-16	2.906317304989e-14	-1.14862388286176	-0.877985592426869
LSM14A	BRD-K88506063-001-01-8::2.5::HTS002	2.5	KD025	rho associated kinase inhibitor	targeted cancer	ROCK2	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.504329386698	-0.504329386698	-1.02014693532508	-0.939621254458	-7.01733538059769	7.0428297767659	0.000202511616464371	0.00534270214736486	-0.689418006651137	-0.342217090603019
LSM14A	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.2635537597845	0.2635537597845	0.0220949213076726	0.0377701807511	-8.52986458348887	5.616464788723	0.000201918897913175	0.00532903281256407	-0.311887593603437	-0.171030083350218
LSM14A	BRD-K97440753-066-18-1::2.5::HTS002	2.5	dihydroergocristine	adrenergic receptor antagonist, prolactin inhibitor	noncancer	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.01906129812673	-0.01906129812673	0.22072179385088	0.238959037731	7.77682541526527	60.7060983703273	1.09712489033376e-10	7.23525171139521e-09	0.178122600440276	0.301443583514944
LSM14A	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.212566015376	-0.212566015376	-0.867298660259984	-0.791872957089	-14.7413148651353	176.561571219034	1.39068848329484e-32	6.91565828158004e-30	-0.742384862518118	-0.56708042724985
LSM14A	BRD-K99616396-001-05-1::2.5::MTS006	2.5	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	MKN1, GCIY	STOMACH	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.637380458939	0.637380458939	-0.0235654526427394	-0.0209452377113	-16.0270419760392	2.99981425387973	0.000528455563657437	0.0125856063975005	-0.792192748037746	-0.529699075125733
MAD1L1	BRD-A24587114-066-22-5::2.5::HTS002	2.5	isoetharine	adrenergic receptor agonist	noncancer	ADRB1, ADRB2	pulmonary	bronchospasm, asthma	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.293864291206	0.293864291206	0.420626926355819	0.453152824306	3.87440580522103	15.324722124849	0.00144441585720524	0.0304396471829881	0.05715444589005	0.196370824409588
MAD1L1	BRD-A50157456-065-20-6::2.5::HTS002	2.5	terbutaline	adrenergic receptor agonist	noncancer	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.425624168093	-0.425624168093	0.157528104485043	0.167154929659	19.4481919523167	40.6830171961994	3.27756737690056e-22	6.57135395999739e-20	0.522582187530499	0.643722357625587
MAD1L1	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2855074474385	-0.2855074474385	-0.69729163329127	-0.633794699256	-5.95921161670905	4.96903718508665	0.00194430987944902	0.0391324999673611	-0.589745965242568	-0.233822406462974
MAD1L1	BRD-A69815203-001-07-6::2.5::HTS002	2.5	cyclosporin-a	calcineurin inhibitor	noncancer	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.447751668781	0.447751668781	-0.0781147348265198	0.001630441296925	-12.198266201417	70.3675757152451	4.99290166561188e-19	7.5096394462381e-17	-0.611838552679012	-0.439894254536028
MAD1L1	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.3993001596335	0.3993001596335	-0.239972322753361	-0.2322368233935	-13.401054692006	62.765447889357	4.4767849333976e-20	7.48443711380791e-18	-0.734606587266913	-0.54393837750681
MAD1L1	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.685489746429	0.685489746429	0.0256643774038754	0.005378846282065	-16.2534249394544	155.332135426154	2.47353623998279e-35	1.60166328936336e-32	-0.740016997582452	-0.579633740467797
MAD1L1	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.129422532859	-0.129422532859	0.266173252787232	0.320326091732	10.145347643406	89.3727727079023	1.53551814337297e-16	1.8478723646883e-14	0.318122321468708	0.473069249823756
MAD1L1	BRD-K00259736-001-16-4::0.15625::HTS002	0.15625	colchicine	microtubule inhibitor	noncancer	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.494074062965	-1.494074062965	-3.07294485664708	-2.82813961253	-13.6865415607902	87.724155384508	1.74663059359881e-23	3.90358277888884e-21	-1.80813334548827	-1.34960824187589
MAD1L1	BRD-K00312224-001-09-5::2.5::HTS002	2.5	PPT	estrogen receptor agonist	noncancer	ESR1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.490420471551	0.490420471551	0.159252486494594	0.22700730099	-6.0478621009138	7.02695167886024	0.000509455884820914	0.0121892353580913	-0.460549141748673	-0.201786828364139
MAD1L1	BRD-K00494077-066-01-9::2.5::HTS002	2.5	trovafloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.2557444726625	0.2557444726625	-0.528868106623721	-0.32459433605	-10.5766896393198	59.7093041687373	2.60325358226104e-15	2.78558530720133e-13	-0.933015913432209	-0.636209245140233
MAD1L1	BRD-K01773560-001-02-4::2.59308::HTS002	2.59308	UNC2250	MER tyrosine kinase inhibitor	targeted cancer	MERTK	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.1854467833835	0.1854467833835	-0.133055373287865	-0.120206350846	-7.27656421463116	175.964652981523	1.08944083816595e-11	8.1160502399468e-10	-0.404885759471462	-0.232118553871268
MAD1L1	BRD-K02407574-001-09-7::2.5::HTS002	2.5	parbendazole	tubulin polymerization inhibitor	noncancer	TUBB	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.916511948965	-1.916511948965	-3.0625156031661	-3.07168460551	-10.5547141661372	13.9047066049493	5.08806408256198e-08	2.48070902354738e-06	-1.37902888064892	-0.912978427753275
MAD1L1	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.647127647304	-0.647127647304	-0.376737287408076	-0.261056095384	4.70697292456732	188.988813170918	4.85054730221616e-06	0.000177136301369345	0.157075304688487	0.383705415103362
MAD1L1	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.27573645706	-0.27573645706	-0.648091716101239	-0.593822379071	-6.49174714259496	180.131253887747	7.98003302894262e-10	4.80166338871489e-08	-0.485535768806654	-0.259174749275825
MAD1L1	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.6096303290005	-0.6096303290005	-1.13917831412292	-1.07388474495	-6.16101284237871	7.24079766990237	0.000404514398365173	0.00990847616996675	-0.731428693769968	-0.327667276474878
MAD1L1	BRD-K08303368-001-10-0::2.5::HTS002	2.5	chlorpyrifos	acetylcholinesterase inhibitor	noncancer	ACHE	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.50035210227	0.50035210227	0.288206703595125	0.2721196218245	-7.66687101684201	17.5207586539977	5.32699919699059e-07	2.26354165521768e-05	-0.270392942875657	-0.153897854474092
MAD1L1	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.4215207885555	0.4215207885555	-0.483006577301316	-0.33490377325	-9.31153705932033	3.49866334137074	0.0013674725270475	0.0290273367583999	-1.19017984973788	-0.618874881975752
MAD1L1	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.6087570831325	0.6087570831325	-0.432514070746708	-0.399128631959	-12.8643156966125	2.62972372559169	0.00190216170784097	0.0384394132264611	-1.32065235458323	-0.761889953175183
MAD1L1	BRD-K13050303-001-17-3::2.5::HTS002	2.5	uridine	dopamine receptor agonist	noncancer	LSM6, TYMP	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2402601061485	-0.2402601061485	0.0682782406323951	0.0709396058819	11.267365846487	188.713344623068	7.51902362440092e-23	1.60034241747192e-20	0.254521534855253	0.362555158706538
MAD1L1	BRD-K13094524-001-07-5::2.63083::HTS002	2.63083	PFI-1	bromodomain inhibitor	targeted cancer	BRD4	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.740669071652	-0.740669071652	-2.24520580381359	-2.09295317057	-14.5889460103478	134.757331747531	1.63367555346048e-29	6.37785150633208e-27	-1.70849657490121	-1.30057688942196
MAD1L1	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.8001004485025	-0.8001004485025	-3.54991200106171	-3.39005054237	-16.842955332	5.1108637648483	1.12718961368903e-05	0.000384030059667158	-3.16676600419741	-2.33285710092101
MAD1L1	BRD-K16338837-001-02-6::2.5::HTS002	2.5	CCMI	acetylcholine receptor allosteric modulator	noncancer	CHRNA7	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2995594983795	-0.2995594983795	0.0919261147982775	0.1287819664105	9.66306375570495	4.5560646466005	0.000331941129197341	0.00830449518848336	0.284214606656476	0.498756619699079
MAD1L1	BRD-K16478699-001-09-2::2.5::HTS002	2.5	PLX-4720	RAF inhibitor	targeted cancer	BRAF, KDR	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.63853544656	0.63853544656	-1.53206358425734	-1.41373612569	-22.2395279935484	11.184271772692	1.30342593609193e-10	8.53534914319118e-09	-2.38498623742459	-1.9562118242101
MAD1L1	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.372472286915	-0.372472286915	-1.13802306665885	-0.889953286616	-7.73255535668044	50.6632236660734	3.97520459177526e-10	2.46528247960243e-08	-0.964340874639545	-0.566760684848162
MAD1L1	BRD-K17743125-001-08-4::2.5::MTS010::PROS003_PR500	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	1.188116973935	1.188116973935	-0.697067685435863	-0.635077786673	-20.1657890026701	17.1318547270721	2.24595753522358e-13	1.99491849385385e-11	-2.08230371794902	-1.68806560079271
MAD1L1	BRD-K19284129-001-02-6::2.5::HTS002	2.5	salvinorin-a	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.290822093592	-0.290822093592	0.0161844367085824	0.02724514887165	7.66677945762463	21.6236125997817	1.33194317887373e-07	6.17909198235559e-06	0.223877004262348	0.390136056338817
MAD1L1	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.602615259675	-1.602615259675	-2.45915672374404	-2.36107459971	-8.90266764669455	51.7399535414243	5.12872500665732e-12	3.95123832477303e-10	-1.04962761609772	-0.663455312040354
MAD1L1	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.5376067871985	-0.5376067871985	-1.9170322549947	-1.67956785013	-11.2318691926182	5.07277336849015	8.92910008958465e-05	0.00255611739428421	-1.69377031267159	-1.0650806229208
MAD1L1	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.332232451131	0.332232451131	-0.268656308621886	-0.316992636258	-8.66663236974171	6.14259082586307	0.000114427695744567	0.00320004874755185	-0.769591867776396	-0.432185651729376
MAD1L1	BRD-K24593301-001-02-3::2.54476::HTS002	2.54476	AZD3463	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-2.77327950018	-2.77327950018	-3.50388977044569	-3.310368963095	-5.7299496132383	16.589033746816	2.69621855864373e-05	0.000856081480068153	-1.00013567847032	-0.461084862061067
MAD1L1	BRD-K25244359-066-03-4::2.68145::HTS002	2.68145	apatinib	RET tyrosine kinase inhibitor	targeted cancer	CSK, KDR, KIT, RET	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.4551246699745	0.4551246699745	0.13339283811548	0.183294433483	-8.30297721726199	90.2316863516469	9.49517714501118e-13	7.93185440426989e-11	-0.398710735194356	-0.244752928523683
MAD1L1	BRD-K27184429-300-01-3::2.5::HTS002	2.5	levocetirizine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.022362940563045	-0.022362940563045	-0.357011180993121	-0.252619761318	-6.23596750020658	13.4636000985479	2.59659854933447e-05	0.000828410792617308	-0.45017820891928	-0.219118271940872
MAD1L1	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.5413915911995	0.5413915911995	-0.118905533730043	0.0546590882103	-11.2827014202905	170.378072015071	2.10232421256897e-22	4.28724116228064e-20	-0.775820595199777	-0.54477365465931
MAD1L1	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2430094494255	-0.2430094494255	0.24622535241433	0.255954419506	17.4249064267796	41.1862799363992	1.30073720713712e-20	2.281388746878e-18	0.432540435254328	0.545929168425333
MAD1L1	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.296312181234	0.296312181234	-0.6216700842185	-0.480230640816	-9.6763731233083	3.00146041070046	0.00233884908054541	0.0458798448274041	-1.21981284191594	-0.616151688989056
MAD1L1	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-2.253699278035	-2.253699278035	-3.67543739806484	-3.65355610334	-13.1718934416558	30.0667377806746	5.06625322330985e-14	4.7961351020264e-12	-1.64215490215847	-1.20132133790121
MAD1L1	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.05558958892055	-0.05558958892055	0.0387193738950504	0.0420255810144	4.62307604651032	99.3859246453404	1.13877133369174e-05	0.00038772314722608	0.0538336489450726	0.134784276686128
MAD1L1	BRD-K36627727-001-05-4::2.5::MTS010::PROS005_PR500	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.368289798131	-0.368289798131	-0.0747603025359724	-0.0262583009779	10.9103529248622	99.7704599305227	1.0382194771115e-18	1.51684077920812e-16	0.24015170200948	0.346907289180576
MAD1L1	BRD-K37720887-001-07-8::2.5::HTS002	2.5	SB-525334	TGF beta receptor inhibitor	noncancer	TGFBR1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.62770320816	0.62770320816	0.0223480763581348	0.0896615671228	-13.7512788560442	51.3248309187427	7.65921638981322e-19	1.13057313334179e-16	-0.69371887071979	-0.516991392883941
MAD1L1	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.7231324919035	-0.7231324919035	-3.80133171999175	-3.70292092273	-25.1291731843986	6.43350772599183	1.15064986042924e-07	5.38348906212484e-06	-3.37310542127409	-2.78329303490241
MAD1L1	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.6616187337425	-0.6616187337425	-0.349332044593557	-0.263302729629	6.48840194410457	36.518732778528	1.45724303618726e-07	6.71965238173363e-06	0.214722676176513	0.409850702121373
MAD1L1	BRD-K40530731-001-11-6::2.5::HTS002	2.5	hyoscyamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.593457196466	0.593457196466	-0.206341354080661	-0.0978191869653	-15.802646336476	116.100038007856	1.03605402408707e-30	4.36260162924474e-28	-0.900040458534528	-0.699556642558795
MAD1L1	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.803359598325	-1.803359598325	-2.29283156748526	-2.14029239454	-5.42624006093001	61.7576075788049	1.02064997231029e-06	4.15646756441747e-05	-0.669802531474924	-0.309141406845589
MAD1L1	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.500034540828	0.500034540828	-0.733536741218455	-0.623158972273	-13.5724943798049	188.017287884825	1.07269861757613e-29	4.22629452217784e-27	-1.4128617299845	-1.0542808341084
MAD1L1	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.0489839216343	-0.0489839216343	-0.264496459518097	-0.234942866008	-5.44373010898828	29.7659342544783	6.81850557834389e-06	0.000242074454547104	-0.296390996285832	-0.134634079481762
MAD1L1	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.0681267107172	0.0681267107172	0.155469107541421	0.14294893902	3.94491333228933	17.260443595857	0.00101834975141106	0.0224664831569924	0.0406836367185365	0.134001156929906
MAD1L1	BRD-K46937689-001-15-0::0.625::HTS002	0.625	phenazone	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.2773265853305	0.2773265853305	0.0914473585670799	0.0795356739513	-5.70308782482682	91.2378376232964	1.43863533516084e-07	6.64099230561466e-06	-0.250618416198387	-0.121140037328453
MAD1L1	BRD-K48195801-001-01-6::2.5::HTS002	2.5	tecastemizole	histamine receptor antagonist	noncancer	KCNH2	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.1452162622385	0.1452162622385	0.343027470555682	0.312371086483	6.13568222615341	195.924516223336	4.60720108858189e-09	2.55817824382038e-07	0.134230247416851	0.261392169217512
MAD1L1	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.255725075734	-0.255725075734	-1.25950001405718	-0.921278111753	-11.2269680104749	94.3444062015938	4.46387872206905e-19	6.76618573283124e-17	-1.18128714127223	-0.82626273537413
MAD1L1	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.04913612023165	0.04913612023165	0.382301402025512	0.394227062385	12.5811227347248	20.9700323336099	3.08902221458649e-11	2.17570503526161e-09	0.278089479612632	0.388241083975092
MAD1L1	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.293802865532	0.293802865532	0.136207285281878	0.1526722270265	-6.49781114513729	186.17723109035	7.24620672438641e-10	4.3773174775395e-08	-0.205442868156485	-0.109748292343759
MAD1L1	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.045778049584775	-0.045778049584775	-0.770028223758378	-0.6098527820225	-9.14399110692145	12.1972893648453	8.24014729197886e-07	3.40749089126478e-05	-0.896514051835094	-0.551986296512112
MAD1L1	BRD-K54247840-004-01-3::2.5::HTS002	2.5	halofuginone	collagenase inhibitor	noncancer	COL1A1, MMP2	rheumatology	scleroderma	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-3.653520985435	-3.653520985435	-5.7368574802208	-5.5836707127	-18.0100856070099	154.954173431466	7.82200390457745e-40	8.25853337371517e-37	-2.31184210920667	-1.85483088036494
MAD1L1	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.12161159386625	0.12161159386625	-0.75766577612063	-0.674815903064	-11.44039183436	22.7006155917346	6.70872137450923e-11	4.52873557000689e-09	-1.03838486848933	-0.72016987148443
MAD1L1	BRD-K59369769-001-20-3::2.5::HTS002	2.5	tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, AURKC, LCK	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.18962592221	-1.18962592221	-1.79038434997079	-1.696260218435	-8.32509575585835	31.5303713102652	1.84119823026472e-09	1.06510708635467e-07	-0.747834224936183	-0.453682630585405
MAD1L1	BRD-K60184833-001-05-6::2.5::HTS002	2.5	tyrphostin-AG-99	tyrosine kinase inhibitor	targeted cancer	EGFR	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.600614179035	-0.600614179035	-1.69686213001018	-1.52742041275	-12.7769292044882	25.3543300182412	1.50109025181189e-12	1.22516059627034e-10	-1.27282919881613	-0.91966670313422
MAD1L1	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.901179532707	-0.901179532707	-1.54269551177974	-1.43484346641	-10.3598712008513	95.8037162510839	2.57000584465906e-17	3.31025710745151e-15	-0.764435697451372	-0.518596260694102
MAD1L1	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.320489218201	0.320489218201	-0.236331587086028	-0.1756829862115	-9.95957694460534	191.014458640279	4.38067355766895e-19	6.65418414558206e-17	-0.667097310965095	-0.446544299608962
MAD1L1	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.929339304536	-0.929339304536	-0.327267573694669	-0.32021882125	10.8157719815805	7.69533283335058	6.33451642195845e-06	0.000226504933300289	0.472815474631618	0.731327987051044
MAD1L1	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.612595423925	0.612595423925	0.119810164243598	0.135505899737	-17.62080597034	83.2288319316161	8.02598596290053e-30	3.18555841748612e-27	-0.5484064504397	-0.437164068923104
MAD1L1	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.1574215158395	-0.1574215158395	0.346701993482824	0.3666851523545	12.578052037333	5.17647570946685	4.45532934990685e-05	0.00135678642261464	0.402143117951498	0.60610390069315
MAD1L1	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.345935843403	0.345935843403	-0.734047038519205	-0.60872932846	-10.9488870287514	59.018605004136	7.69168144949652e-16	8.64020122321353e-14	-1.27735696164556	-0.882608802198847
MAD1L1	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.3621818249725	0.3621818249725	-0.542470934060192	-0.407441526883	-11.1448786774432	8.96568834680644	1.48839680751383e-06	5.92068669928791e-05	-1.08838389221296	-0.720921625852427
MAD1L1	BRD-K70511574-001-06-9::2.5::HTS002	2.5	HMN-214	PLK inhibitor	targeted cancer	PLK1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.826717363295	-1.826717363295	-2.84223902725564	-2.842294760615	-9.34251494043874	16.0971749279915	6.66067147100706e-08	3.21092005332765e-06	-1.2458401630179	-0.785203164903377
MAD1L1	BRD-K72420232-001-12-3::2.5::HTS002	2.5	WZ-4002	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.3563149776765	0.3563149776765	-0.077148106697201	0.0237239176578	-7.91657890230854	13.780342614578	1.71601539101304e-06	6.74476183276057e-05	-0.55107424745089	-0.315851921296512
MAD1L1	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.349527716884	0.349527716884	-0.216974995180407	-0.195517916983	-21.3877243984684	54.686775233519	3.09582878988288e-28	1.07193196883168e-25	-0.61959124828112	-0.513414175847693
MAD1L1	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.5114678381875	-0.5114678381875	-0.893041920148033	-0.708568317551	-6.03790302666679	91.6165513074487	3.2908276765063e-08	1.64563650274829e-06	-0.507094701163907	-0.256053462757159
MAD1L1	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.927500570665	-1.927500570665	-0.667603305775324	-0.4541784692175	11.6328882704317	3.89874840287642	0.000359764880288577	0.00893799084587578	0.95608999919851	1.56370453058084
MAD1L1	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.3812947890825	-0.3812947890825	-1.48180621337268	-1.368540965995	-12.7041341419443	195.276322157204	2.40802814109158e-27	7.49071499930358e-25	-1.27135454415584	-0.929668304424527
MAD1L1	BRD-K76210423-001-01-6::2.5::MTS010::PROS001_PR500	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.02002374722913	-0.02002374722913	0.107344574644078	0.094360121778	5.25659087336306	11.0327518039219	0.000267186104712047	0.00683117388009405	0.0740572896023147	0.180679354144102
MAD1L1	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.283107870222	0.283107870222	-0.000732226270943777	0.03094358609725	-10.5919726953209	179.471040920284	1.1331253039523e-20	1.99393771158287e-18	-0.336719122504827	-0.23096107048106
MAD1L1	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.336561744356	0.336561744356	-0.213162580855569	-0.20601445055	-9.22130284682317	6.03411498348973	8.88160573740509e-05	0.00254422036366252	-0.695396328845264	-0.404052321577875
MAD1L1	BRD-K80700417-001-04-2::2.5::HTS002	2.5	SGI-1776	Pim kinase inhibitor	targeted cancer	FLT3, PIM1, PIM2, PIM3	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.7053022694135	0.7053022694135	-0.361464488130851	-0.325346333851	-10.5819079114983	2.92701212438806	0.00200863006706586	0.0402456458487574	-1.39216418616195	-0.741369328926749
MAD1L1	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.4531762575475	0.4531762575475	0.185961019273634	0.18484230673	-7.6348338824864	157.117576863351	2.0624754952045e-12	1.66496538761463e-10	-0.336345435903834	-0.198085040643898
MAD1L1	BRD-K84783599-001-01-0::2.5::HTS002	2.5	riociguat	guanylate cyclase stimulant	noncancer	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.11140975959	-1.11140975959	0.0111805646040581	0.07731711967405	14.0550550547673	2.49245467850969	0.00194608420761872	0.039160856458052	0.836459978655471	1.40872066973264
MAD1L1	BRD-K85406984-001-01-0::0.15625::HTS002	0.15625	sobetirome	thyroid hormone receptor agonist	noncancer	THRA, THRB	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2246506247225	-0.2246506247225	0.244897175537884	0.243956318012	12.9149464609698	5.92832410654128	1.45249784867277e-05	0.000485970045907252	0.380324220737162	0.558771379783605
MAD1L1	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-2.91269734429	-2.91269734429	-1.68758261270149	-1.533280492745	16.0627757677626	14.6316063249439	1.06927431640773e-10	7.05809962923783e-09	1.06219094617476	1.38803851700227
MAD1L1	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.733022249625	-1.733022249625	-2.7855856649569	-2.665674709255	-11.6041594176741	193.29287613641	5.74477976659918e-24	1.34712571399938e-21	-1.23146343246057	-0.873663398203233
MAD1L1	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-1.10881941673	-1.10881941673	-0.288960613023557	-0.17409866014	9.44067678484804	3.10870547954054	0.0021741092091153	0.0430620693725602	0.548872556392541	1.09084505102034
MAD1L1	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	1.069569395515	1.069569395515	-0.307186346194556	-0.214794605924	-17.3396309768808	16.5492317851393	4.82569586322587e-12	3.7436054805596e-10	-1.54462202181279	-1.20888946160632
MAD1L1	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.6156387669165	-0.6156387669165	-1.76164601117805	-1.69551344644	-13.7696890490055	5.61359243495374	1.53702392973672e-05	0.000512729652663878	-1.3531026611928	-0.938911827330296
MAD1L1	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	0.740596764798	0.740596764798	-0.084706295024834	-0.0625986180944	-16.6001280545158	58.1608557215199	9.83603347471546e-24	2.24749170426683e-21	-0.924815924096506	-0.725790195549162
MAD1L1	BRD-K97010173-001-04-1::2.5::HTS002	2.5	deferasirox	chelating agent	noncancer	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	786O, NCIH1355	KIDNEY, LUNG	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (adenocarcinoma)	-0.3882763862035	-0.3882763862035	0.0544335629322843	0.111819102778	10.9189409912428	190.940578076954	7.08087701233756e-22	1.37841715638265e-19	0.362736050519707	0.522683847751861
MAP4	BRD-A50311610-300-10-4::2.5::HTS002	2.5	meclizine	constitutive androstane receptor (CAR) agonist	noncancer	HRH1, NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.0639730535513	-0.0639730535513	0.114941464041399	0.122019939205	4.21689296402447	149.974098356195	4.26617020872396e-05	0.00130530191957972	0.0950806027621126	0.262748432423285
MAP4	BRD-A69651145-003-07-2::2.5::HTS002	2.5	minocycline	bacterial 30S ribosomal subunit inhibitor	noncancer	ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA	endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.0526613555274	-0.0526613555274	0.089295146644052	0.0643379541356	3.42072954914203	73.0129542191146	0.00102597855326657	0.0226231437595751	0.0592495675526575	0.224663436790246
MAP4	BRD-A69815203-001-07-6::2.5::HTS002	2.5	cyclosporin-a	calcineurin inhibitor	noncancer	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.471712037651	-0.471712037651	-0.0685369878845198	0.011278782305325	9.19736425507146	50.1827051557303	2.40058136012613e-12	1.92774148495494e-10	0.31513592750172	0.49121417203124
MAP4	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.03777727523735	-0.03777727523735	0.15949052200396	0.166606190016	7.46632657607596	62.0123717717907	3.33765578611165e-10	2.0904629660477e-08	0.144453184999165	0.250082409483455
MAP4	BRD-K03273112-001-01-8::2.5::HTS002	2.5	1-azakenpaullone	glycogen synthase kinase inhibitor	noncancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.0551240305878	-0.0551240305878	-0.721946035856418	-0.657905942127	-7.44953146959512	7.37251333644872	0.000110490232473098	0.0031016713864737	-0.876335269734809	-0.457308740802427
MAP4	BRD-K03765900-001-01-9::2.49999::MTS010::PROS002_PR500	2.49999	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.2064862471895	0.2064862471895	-0.563515829565076	-0.353034364185	-10.2501736541641	179.831157275051	1.04542956455602e-19	1.67839605349608e-17	-0.918233856810747	-0.621770296698405
MAP4	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-1.396475595475	-1.396475595475	-1.02271915177871	-0.9876270936225	6.51587690804142	30.7934946205118	2.94378019359114e-07	1.29875970587113e-05	0.256736348045491	0.490776539347089
MAP4	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.0723718160491	0.0723718160491	0.25894695501229	0.2294815220965	6.78720474832368	129.419391016509	3.70981519377104e-10	2.31408900077344e-08	0.13218866173927	0.240961616187109
MAP4	BRD-K08547377-394-03-5::2.5::HTS002	2.5	irinotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	colorectal cancer	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-2.233571381475	-2.233571381475	-1.95391263288849	-1.92016274671	3.40188395129451	125.853213342542	0.000897616861327259	0.020123987894499	0.116971629229396	0.442345867943617
MAP4	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-1.276704825245	-1.276704825245	-2.20758131908139	-2.14710453103	-10.4384317946172	10.0886781188695	9.95951387252652e-07	4.06438051939211e-05	-1.12934055033564	-0.732412437337148
MAP4	BRD-K10845183-304-01-6::2.5::HTS002	2.5	tiludronate	bone resorption inhibitor, osteoclast inhibitor	noncancer	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.272251207721	-0.272251207721	0.222432780572113	0.2180493051285	12.2984631813521	19.0965547177071	1.60141459282918e-10	1.03632122061137e-08	0.410524588624799	0.578843387961426
MAP4	BRD-K11663430-001-02-3::2.5::HTS002	2.5	pyroxamide	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-1.055372364365	-1.055372364365	-0.63385168003179	-0.605158922275	5.93774412963282	19.9560492024526	8.38131540583425e-06	0.000292900529857663	0.273417148558207	0.569624220108213
MAP4	BRD-K13390322-001-06-3::2.5::HTS002	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.0534348527344	0.0534348527344	-0.335817718689684	-0.191679875324	-4.86922180909336	152.297546783566	2.77798111089307e-06	0.000105999984603276	-0.547189900137433	-0.231315242710735
MAP4	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-2.984435443075	-2.984435443075	-2.05656589782882	-2.351388502545	9.75442480758915	191.77625738369	1.64951842565941e-18	2.36956859687102e-16	0.740248007954283	1.11549108253808
MAP4	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-3.347956938415	-3.347956938415	-2.59520999455959	-2.674840125005	10.5539315916107	167.703608995935	2.73306908493104e-20	4.65070461761974e-18	0.6119386668175	0.893555220893313
MAP4	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.03131177799265	-0.03131177799265	-0.373179698381035	-0.1455477562875	-3.64327686387824	17.1453827367652	0.00198726239392259	0.0398771614668135	-0.539715264239309	-0.144020576537461
MAP4	BRD-K18849474-001-04-4::2.60504::HTS002	2.60504	dalcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.04232270356565	0.04232270356565	0.303196187413808	0.287686302566	9.59519106961741	187.371676481102	5.48554494593459e-18	7.55598562157593e-16	0.207239682821986	0.31450728487433
MAP4	BRD-K18961567-001-01-1::2.5::MTS010::PROS002_PR500	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.001319189181645	-0.001319189181645	-0.417947976833275	-0.32717924466	-7.01459180788553	163.660358605031	5.78439356473025e-11	3.9307650232564e-09	-0.533907263582617	-0.299350311720643
MAP4	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.144066633331	0.144066633331	0.325126800845698	0.343759219436	5.9670213813185	187.982152139814	1.17897260112827e-08	6.25775182335859e-07	0.12120268848234	0.240917646547057
MAP4	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-1.265508561705	-1.265508561705	-0.812842343425998	-0.7654167490095	5.48766710268478	5.37357795807533	0.00218584918050871	0.0432506341404404	0.244982379718778	0.660350056839226
MAP4	BRD-K19540840-001-09-4::2.5::MTS010::PROS004_PR500	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.034077015621	0.034077015621	-0.406849930036112	-0.3364454572695	-7.22168937693078	22.2982874399311	2.85226822244894e-07	1.26176222053511e-05	-0.567451054195554	-0.31440283711867
MAP4	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.4187013904575	0.4187013904575	0.297916401395079	0.330939410236	-5.01864670026529	175.38384425753	1.26979468702699e-06	5.10511771667244e-05	-0.168283675727845	-0.0732863023969973
MAP4	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.00290725643605	0.00290725643605	-0.265134114026218	-0.316992636258	-4.2963267622632	14.5874502369742	0.000675819772855415	0.0156473777785814	-0.401347606812678	-0.134735134111859
MAP4	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.146601417021	0.146601417021	-0.0542457286199292	-0.030411088067	-10.9773441826862	164.282758255639	2.24457041692306e-21	4.19056213317685e-19	-0.236973785507661	-0.164720505774198
MAP4	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-1.213823390925	-1.213823390925	-1.66894361433599	-1.54523819361	-5.74904804081176	189.009131865705	3.55089295628266e-08	1.76743923926406e-06	-0.611279578356117	-0.298960868465867
MAP4	BRD-K36627727-001-05-4::2.5::MTS010::PROS005_PR500	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.122678213657	0.122678213657	-0.0799557312321417	-0.032678012842	-6.79858450664081	16.151405022305	4.06910242646692e-06	0.000150756552111016	-0.265770284165636	-0.139497605612647
MAP4	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.09559306769365	0.09559306769365	-0.239826828573179	-0.026104548309	-5.82473953872408	22.9900463195295	6.19446860529406e-06	0.000222090040432263	-0.454547204873684	-0.216292587659973
MAP4	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.008954441187295	-0.008954441187295	-0.498525406416063	-0.332266676493	-9.01392067525867	113.35778959017	5.69093359938196e-15	5.88389825095001e-13	-0.597170675246605	-0.381971255210931
MAP4	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-4.18460735704	-4.18460735704	-3.74949248951226	-3.638458649165	4.22035085342038	165.325498811591	4.0133915384362e-05	0.00123271165812768	0.231554030286766	0.638675704768704
MAP4	BRD-K47049295-300-01-5::2.5::HTS002	2.5	BAN-ORL-24	nociceptin/orphanin FQ receptor antagonist	noncancer	OPRL1	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.264141625294	0.264141625294	0.364910748606531	0.375415378686	3.76816860567925	38.515439271714	0.000550716575525348	0.0130540292983601	0.0466561491596501	0.154882097465412
MAP4	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.3501352620055	-0.3501352620055	-1.25851142571926	-0.921278111753	-8.54745295672848	8.16337499352144	2.38965237175628e-05	0.000767183647672486	-1.15259447124548	-0.664157856182033
MAP4	BRD-K51791723-003-01-7::2.5::MTS010::PROS004_PR500	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-3.01594435819	-3.01594435819	-2.2256946805596	-2.42069348361	10.7222954676898	169.807174953678	8.22069779890267e-21	1.46827828211751e-18	0.644760423886018	0.935738931374785
MAP4	BRD-K56032964-001-02-1::2.5::HTS002	2.5	AP26113	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, EGFR	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.3085598207025	-0.3085598207025	-0.548401052169766	-0.449925278333	-3.8703986935266	151.767328649154	0.000160966004237957	0.00436263059209876	-0.362272725360045	-0.117409737574488
MAP4	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.5412517412005	0.5412517412005	0.0322247439159163	0.07942712884705	-16.8606949721993	184.292212292525	3.39893811862617e-39	3.32644295902753e-36	-0.568589753174864	-0.449464241394304
MAP4	BRD-K62196610-001-01-6::2.5::HTS002	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-1.142744284065	-1.142744284065	-1.67762243227106	-1.62132235513	-6.78898845356871	11.594754503278	2.30046963598345e-05	0.000741105300782651	-0.707206170197368	-0.362550126214755
MAP4	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.601371905156	-0.601371905156	-1.48926063833249	-1.417507299725	-13.1718762871495	86.9512680196295	2.00902292997565e-22	4.12049641683016e-20	-1.0218703244557	-0.753907141897275
MAP4	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.3464962271355	0.3464962271355	-0.542304948897896	-0.407441526883	-13.3779224375058	188.019626348807	4.09972716543314e-29	1.55520428962853e-26	-1.01986066927433	-0.757741682792459
MAP4	BRD-K72420232-001-12-3::2.5::HTS002	2.5	WZ-4002	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.08089891358675	0.08089891358675	-0.0742024803433	0.0237239176578	-3.28365378408845	186.934817973651	0.00122317145385169	0.0263882359291582	-0.248282358832985	-0.0619204290271154
MAP4	BRD-K73589491-001-11-2::2.5::HTS002	2.5	nizatidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.02774962667425	-0.02774962667425	0.0970020879647351	0.09959523720245	4.98051525464155	69.3999418858313	4.45186403778143e-06	0.000164030181769581	0.0747875514219338	0.174715877856036
MAP4	BRD-K77791657-003-01-7::2.66704::HTS002	2.66704	3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-1.12617310137	-1.12617310137	-1.52285214302287	-1.46906470598	-5.42255719772105	72.5405521521265	7.35540959514843e-07	3.06827088968192e-05	-0.542489316687171	-0.250868766618576
MAP4	BRD-K79259477-001-04-9::2.5::HTS002	2.5	NVP-BHG712	ephrin inhibitor	targeted cancer	EPHB4	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.06914619332	-0.06914619332	0.153737331280925	0.151755478673	5.71438569641337	12.2137230814579	9.05476704893827e-05	0.00258759888910919	0.138065889345612	0.307701159856237
MAP4	BRD-K79930101-300-03-7::2.5::HTS002	2.5	GW-583340	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.0838741737231	0.0838741737231	-0.533804566145855	-0.365507892562	-8.07194148188173	12.7099418026768	2.35375271221765e-06	9.08640967321502e-05	-0.783378165066219	-0.451979314671691
MAP4	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.03213648237035	-0.03213648237035	-0.122469373769863	-0.118001057117	-3.1444100813865	186.047508912589	0.00193752857499615	0.0390179988678333	-0.147007573086371	-0.033658209712656
MAP4	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.2650000144685	-0.2650000144685	-0.950412446386528	-0.8151847008705	-8.43351972649834	5.90986839798668	0.000164308494543722	0.00444479052468275	-0.885016349416798	-0.485808514419259
MAP4	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.236859098292	0.236859098292	0.0146622931297798	0.0495734767378	-6.04207253199204	4.85563243007985	0.00198079966932964	0.0397809981566485	-0.317581445133484	-0.126812165190956
MAP4	BRD-K81332461-001-01-4::2.5::HTS002	2.5	maxacalcitol	vitamin D receptor agonist	noncancer	VDR	endocrinology	hyperparathyroidism	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.335341511146	-0.335341511146	-0.138661769178783	-0.1067653594475	5.54824928665864	59.4180124406988	7.04382114818538e-07	2.94574662023302e-05	0.125756949569862	0.267602534364572
MAP4	BRD-K82818427-001-02-2::2.39189::HTS002	2.39189	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-1.13004256947	-1.13004256947	-1.61835033964732	-1.52596467706	-7.52857337055602	43.7830897419256	1.9944107196869e-09	1.14877735861267e-07	-0.619044009662028	-0.35757153069262
MAP4	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.2298863091625	-0.2298863091625	0.194607380877558	0.205191667076	8.42667598058652	3.58680871481917	0.00172899610436048	0.035516005947046	0.278041074820472	0.570946305259643
MAP4	BRD-K85606544-001-09-1::2.5::HTS002	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.5670986299305	-0.5670986299305	-1.59992064252973	-1.5159358626	-11.3920275826523	43.5954204906764	1.17712732948224e-14	1.18169800187634e-12	-1.21558682049685	-0.850057204701623
MAP4	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.0959755674382	-0.0959755674382	-0.494711469714873	-0.41754362105	-6.35359327636917	5.13355153901988	0.00129390372347535	0.0276901490677486	-0.558805106496288	-0.238666698057058
MAP4	BRD-K90574421-001-03-5::2.5::HTS002	2.5	ipsapirone	serotonin receptor agonist	noncancer	HTR1A	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.2051849753325	0.2051849753325	-0.041474807542387	-0.0540308709753	-7.92935760903523	6.64766524398008	0.000126610309380598	0.00350778968449252	-0.321014269004244	-0.17230529674553
MAP4	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-3.52976438281	-3.52976438281	-4.01747434702455	-3.85901121156	-4.21552285824845	186.319305844914	3.88177761629502e-05	0.00119640137291184	-0.715948194197533	-0.259471734231563
MAP4	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.11417137391505	0.11417137391505	0.300911282428525	0.276885156297	4.67488101728543	21.8941367501297	0.000117412940035079	0.00327456057576817	0.103875026115672	0.269604790911278
MAP4	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	-0.5146130657955	-0.5146130657955	-0.343206269390479	-0.279710660695	4.12120555677476	30.9144529100222	0.000261579510431422	0.00670622905397802	0.0865710185307641	0.256242574279278
MAP4	BRD-K98157055-001-10-9::0.625::HTS002	0.625	SIB-1757	glutamate receptor antagonist	noncancer	GRM5	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.438387157487	0.438387157487	0.219993931435842	0.259105939105	-5.37767579107022	65.4594838029373	1.08334036892496e-06	4.39589659089963e-05	-0.29948836364356	-0.137298088458756
MAP4	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	ONS76, NCIH1339	CENTRAL_NERVOUS_SYSTEM, LUNG	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma)	0.4591962251085	0.4591962251085	-0.229742925820888	-0.0281474951666	-9.36712365385843	7.69605701295071	1.78433649019842e-05	0.000587728685427597	-0.859715623088565	-0.518162678770211
MATN2	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.161104501752333	0.151256205305	-0.0101237496141557	0.062505767768	-4.29751553809852	15.402444529476	0.000600036703376467	0.0140917263843571	-0.255959899102408	-0.08649660363057
MATN2	BRD-A19585813-003-03-3::2.5::HTS002	2.5	methylphenidate	dopamine-norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD), narcolepsy	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.0962157382080667	0.0939234208133	0.260378814494969	0.257332514557	4.95177203582787	35.0432050525009	1.85049549426837e-05	0.000607652595052927	0.0968631132058085	0.231463039367996
MATN2	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.568664483645667	0.542979561427	-0.23163277448109	-0.0957175883137	-9.49241541759413	11.3599326420182	9.66360528562829e-07	3.95945489822869e-05	-0.98514558065895	-0.615448935594563
MATN2	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-0.595092266915	-0.609100473626	-1.19787379272128	-1.04762820909	-5.73148466534905	5.45713344828965	0.00169246264063576	0.034865804046984	-0.866458556933277	-0.339104494679278
MATN2	BRD-A83650191-004-02-8::2.5::HTS002	2.5	A61603	adrenergic receptor agonist	noncancer	ADRA1A	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-2.93084186335	-2.91665328033	-2.01746743164723	-1.971836217865	7.22818139122764	9.20537808469485	4.38404753620482e-05	0.00133773992651942	0.628490765992483	1.19825809741306
MATN2	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-0.712262806269	-0.704783707126	-2.22787498913641	-2.04764605388	-9.98373587965484	9.66208152710002	2.10997110997278e-06	8.199963699535e-05	-1.85547214894076	-1.17575221679407
MATN2	BRD-K03243820-001-23-8::2.37329::HTS002	2.37329	trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	chemo	TYMS	infectious disease	virus herpes simplex (HSV)	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-0.810357515673	-0.729764745225	-2.27650354775398	-2.06576172179	-11.5944275359623	7.45921006655506	4.8883070813885e-06	0.000178363290508498	-1.7614675308729	-1.17082453328907
MATN2	BRD-K04623885-001-07-5::2.5::HTS002	2.5	BIBR-1532	telomerase inhibitor	targeted cancer	TERT	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-1.34445196466	-1.36267071967	-0.90259595651007	-0.8300169046705	7.47151001244466	18.6722467469213	5.08157710053125e-07	2.16699032705882e-05	0.317929895260318	0.565782121039541
MATN2	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-0.224400676018333	-0.173199065469	-0.858591060654009	-0.717228514136	-7.04974879132436	4.50799911901514	0.00134746411362658	0.0286736135831484	-0.873239377094685	-0.395141392176666
MATN2	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-2.38834668913	-2.47985131938	-3.03944569979848	-2.94087209611	-4.80835215513716	8.0041730304492	0.001339187728944	0.0285258166126853	-0.963326717658651	-0.3388713036783
MATN2	BRD-K09397065-003-06-1::2.5::HTS002	2.5	SR-57227A	serotonin receptor agonist	noncancer	HTR3A	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.491909715565333	0.455928750829	0.241244219077925	0.230144295567	-5.19987869312067	6.25707816084829	0.00177308354812878	0.0362168325347273	-0.367456533497701	-0.133874459477115
MATN2	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.288290468716	0.294345498542	-0.485000596927069	-0.383523896219	-8.60051564123216	168.116653124075	5.35810152508207e-15	5.57618206132265e-13	-0.950793456081375	-0.595788675204763
MATN2	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-2.77241038567667	-2.77379760086	-3.2749657345462	-3.08402011033	-3.82449645516088	29.627296575452	0.000626421798348378	0.0146189413782894	-0.771060405251893	-0.234050292487176
MATN2	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	MCF7, NCIH1650	BREAST, LUNG	carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.02606007949285	0.02606007949285	0.388325114024815	0.399212772621	13.3899488657	27.7007037304645	1.28230263498667e-13	1.16504722956362e-11	0.306818395233699	0.417711673830232
MATN2	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.209955741314333	0.152540415763	-0.511845655518862	-0.4446499038335	-8.71538370559668	4.1950849394951	0.000768162253658515	0.0175465680128292	-0.947588083642532	-0.496014710023859
MATN2	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.376077053789	0.382242644388	0.145044586555147	0.1923311194455	-5.43262047133222	138.872398846166	2.41794163753485e-07	1.07860532981329e-05	-0.315116370363245	-0.146948564104461
MATN2	BRD-K26997899-001-02-2::2.5::HTS002	2.5	D-64131	microtubule inhibitor	chemo	TUBB	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-2.09676368087333	-2.11728588773	-3.03245886333314	-2.94334566973	-7.7017377867719	13.7386282911543	2.39325447290183e-06	9.22229122478562e-05	-1.19673424098767	-0.674656123931935
MATN2	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-1.69810826305333	-1.68908741688	-2.31867966993388	-2.04919272485	-4.68954949991164	12.1665133366074	0.000504688228503679	0.0120873084508845	-0.908458204984249	-0.332684608776842
MATN2	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.471762019271667	0.455521037703	0.158753112337746	0.154506924686	-8.09460017937424	5.01097313674017	0.000461659075615718	0.0111640446821213	-0.412344923905223	-0.213672889962618
MATN2	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-1.23158316882333	-1.23193239485	-1.94774189411149	-1.77214463061	-7.18900398896967	32.3609802058852	3.42836575041154e-08	1.71201818014901e-06	-0.91898649888571	-0.513330951690602
MATN2	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	SNU449, NCIH1650	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.790966717032	0.790966717032	-0.804409700635409	-0.4002530483955	-14.1008516934536	167.387249465422	2.89946791276116e-30	1.19049819592756e-27	-1.81874251023715	-1.37201032509767
MATN2	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-0.277535058833033	-0.324595621427	-1.38543072238442	-1.003451682485	-6.78789211492301	5.32689207424353	0.000819114015340826	0.0185856328386602	-1.5198298181835	-0.695961508919273
MATN2	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-0.381522062240667	-0.415440331604	-1.4055451037751	-1.2792780931	-8.54982336657958	4.13047328053598	0.000889923422427216	0.0199765811903438	-1.35245937783126	-0.695586705237612
MATN2	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.583015896565	0.565910098945	0.195345803287972	0.238469912651	-6.95404856613655	4.55010280132264	0.00137596874153784	0.0291585924861641	-0.535341846006277	-0.239998340547779
MATN2	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-4.55432491922667	-4.53666598282	-5.60141756295307	-5.55232603448	-7.80777842807869	4.5518083909485	0.000839723328882076	0.01899093187253	-1.40229484555608	-0.691890441896724
MATN2	BRD-K59369769-001-20-3::2.5::HTS002	2.5	tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, AURKC, LCK	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-1.41691176477333	-1.38216210746	-1.78996414738049	-1.704816131	-4.26714057775555	10.8150774983023	0.00137837194042262	0.0292008579241712	-0.565874457283705	-0.180230307930603
MATN2	BRD-K61036791-001-01-6::2.5::HTS002	2.5	rucinol	tyrosinase inhibitor	noncancer	TYR	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.1150009599289	0.122447442809	0.408187329816852	0.443994935445	11.0279006660306	92.8101013434347	1.44583746119667e-18	2.0924030872439e-16	0.240390670802546	0.345982068973357
MATN2	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.463949785715667	0.49643180279	-0.731539239170771	-0.534951583535	-7.91603719440177	6.20985956166146	0.000181476926725619	0.00485105615217949	-1.56201827348994	-0.828959776282936
MATN2	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-3.14682715552333	-3.20815771197	-4.37634954146323	-4.09852844866	-9.16543477759851	30.4177667215296	2.93903067895594e-10	1.85107113250058e-08	-1.5033309275228	-0.955713844356983
MATN2	BRD-K73293050-001-03-1::2.5::HTS002	2.5	WZ-3146	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SNU449, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.71415009942	-1.71415009942	-2.58274642238664	-2.4237476511	-8.11251019050887	25.3678176561435	1.63289569516361e-08	8.52562488303827e-07	-1.088946533266	-0.648246112667284
MATN2	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.00133505233948667	0.00745939021486	-0.196946668942644	-0.152273323371	-3.73464337663232	16.9452638417498	0.00165688103842489	0.0342117202393611	-0.310324768793868	-0.0862386737703936
MATN2	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.1082079857209	0.0926803256748	-0.217572180435581	-0.189984916304	-9.42254490677017	21.9999071462361	3.52279265140433e-09	1.97808914378527e-07	-0.397483393327773	-0.254076938985189
MATN2	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.706155406962	0.709079104864	0.340256537498745	0.382920808601	-10.5122936094496	21.9156045324244	5.03481304707581e-10	3.09022464366183e-08	-0.438099789799625	-0.293697949126886
MATN2	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0906297840886667	-0.0826801338081	0.156855664949277	0.1908455788445	7.97879232990059	5.66205205102384	0.000275457421198703	0.00700920261523174	0.170475612110979	0.324495285964909
MATN2	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.777008652463333	0.79427892057	-0.32823119583088	-0.110807168876	-13.0680555300543	33.1316023748897	1.26230699498664e-14	1.26483869064278e-12	-1.27728442764196	-0.933195268946467
MATN2	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	SNU449, MCF7, NCIH1650	LIVER, BREAST, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.360636216254333	0.350089425964	0.0945359409628251	0.163098987383	-7.36270737081922	116.332454607362	2.79455022250742e-11	1.97739569045821e-09	-0.337681179400675	-0.194519371182341
MATN2	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	SNU449, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.441757606759	0.441757606759	-0.229549163394783	-0.0281474951666	-10.028865128429	18.7272921079207	5.79501515672187e-09	3.17901152681096e-07	-0.811546698904855	-0.531066841402711
MAU2	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.2637407232925	0.2637407232925	0.176185591104052	0.21394626854	-3.12890122078512	116.186655428605	0.00221860285148261	0.0438460977921084	-0.142977474735006	-0.0321327896418909
MAU2	BRD-A03623303-045-09-5::2.5::HTS002	2.5	metoprolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.2411654722915	-0.2411654722915	0.244359381539765	0.21036832824	15.1718639855266	18.2021766793483	8.93226301470829e-12	6.74099647774441e-10	0.418345346675612	0.552704360986919
MAU2	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-1.34048483497	-1.34048483497	-0.94325808203828	-0.8676021902365	6.53013729389888	193.058732059673	5.67240160064383e-10	3.45866406944946e-08	0.277250500025989	0.51720300583745
MAU2	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.1855133184435	-0.1855133184435	-0.00564466209209272	0.0742335248606	5.10246000808418	27.0456017637426	2.30216212439333e-05	0.00074153908319672	0.10754454546504	0.252192767237775
MAU2	BRD-A14240607-003-26-1::2.5::HTS002	2.5	octopamine	trace amine associated receptor agonist	noncancer	F10, TAAR1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.3955164853685	0.3955164853685	0.693678481440718	0.680383035614	8.26723305573628	4.43378391392215	0.000740534596391496	0.0169897280571605	0.201775860030648	0.394548132113787
MAU2	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-5.06998240777	-5.06998240777	-3.79315553508231	-3.74224322709	9.3412937521538	4.41431947049441	0.000451622288242812	0.0109522237403025	0.910967995048694	1.64268575032669
MAU2	BRD-A73427433-240-01-3::2.5::HTS002	2.5	adaprev	TGF beta receptor inhibitor	noncancer	IGF2R, M6PR	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.608895565846	-0.608895565846	-0.392758096400868	-0.3772229678335	4.66300612976793	8.67390842889771	0.00130273012918362	0.0278516554471618	0.110679041851598	0.321595897038665
MAU2	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.3022457794625	0.3022457794625	0.0559184307919375	0.0542001317345	-4.68148578058068	14.6486914875467	0.00031401897117087	0.00789112112464314	-0.358713277551958	-0.133941419789167
MAU2	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-1.41893991533	-1.41893991533	-1.02248756085237	-0.9876270936225	7.51027323917199	185.683196270247	2.40255413931214e-12	1.92860309409975e-10	0.292311005224527	0.500593703730734
MAU2	BRD-K08586861-001-01-1::2.5::HTS002	2.5	ramatroban	prostanoid receptor antagonist	noncancer	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.6933593207815	-0.6933593207815	-0.0362633398807067	-0.0764489475894	17.4429871096458	48.8295762614862	1.28578141541677e-22	2.69121332993027e-20	0.581386448567561	0.732805513234026
MAU2	BRD-K08859203-001-01-9::2.5::HTS002	2.5	DU-728	structural glycoprotein antagonist	targeted cancer	ITGA2B, ITGB3	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.313621710053	0.313621710053	0.167650106467568	0.170003044519	-4.54778641780392	35.6430156318008	6.03546977729906e-05	0.00179289840873005	-0.211090563499678	-0.0808526436711859
MAU2	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.1181774100103	0.1181774100103	0.345884325581107	0.3629794578985	5.54357824269315	5.31081653795837	0.00216488557035092	0.0429111032468086	0.12395009462906	0.331463736512554
MAU2	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-3.644986345495	-3.644986345495	-4.27968336856714	-4.413620661915	-4.89767846130706	169.985460322693	2.24428300531075e-06	8.68885354489247e-05	-0.890512774553118	-0.378881271591165
MAU2	BRD-K17743125-001-08-4::2.5::HTS002	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-1.56815865389	-1.56815865389	-2.6194805438187	-2.55701566981	-7.27651285518188	4.4945757023202	0.00119413301435354	0.0258470344206606	-1.43564405984472	-0.666999720012687
MAU2	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-3.65267070438	-3.65267070438	-2.3436119731011	-2.27083369545	10.9312585710822	4.75103826162797	0.000151191345519938	0.0041164494275842	0.996306296160677	1.62181116639713
MAU2	BRD-K18163608-001-05-6::2.48005::HTS002	2.48005	HA14-1	BCL inhibitor	targeted cancer	BCL2	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.156599911014	0.156599911014	-0.0452676779146147	0.0348368088463	-4.12249186618187	170.313764114537	5.84445724137765e-05	0.0017396154145502	-0.29852872094113	-0.1052064569161
MAU2	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.640008868668	-0.640008868668	-0.129919730435077	-0.0959676428829	9.5321997364325	3.5675742400636	0.00115653983250069	0.0251399620446288	0.354136404720719	0.666041871745126
MAU2	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.730061259203	-0.730061259203	-0.235327965396862	-0.109165735913	10.0141377199835	6.12027675296416	5.07461073288303e-05	0.00152751706096692	0.37442086356828	0.615045724043995
MAU2	BRD-K32107296-001-16-9::2.5::HTS002	2.5	temozolomide	DNA alkylating agent	chemo	MGMT	oncology	glioblastoma, astrocytoma	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.1192466276185	-0.1192466276185	0.22934560908935	0.232952381397	12.3063575641465	187.388208484002	6.83391423561088e-26	1.87063346641666e-23	0.292713034349349	0.404471439066351
MAU2	BRD-K32744045-001-31-2::2.5::HTS002	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.787982667306	-0.787982667306	-1.28072202313881	-1.09614559515	-5.03983311342426	177.466325373956	1.14178208684046e-06	4.62078951832383e-05	-0.685678768772801	-0.299799942892816
MAU2	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.0925796029775	0.0925796029775	0.212191778553289	0.242460199933	5.23136736089622	13.6697058080232	0.000137417331130502	0.00377209517979884	0.0704614764435318	0.168762874708047
MAU2	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.006699149492515	0.006699149492515	0.172655153403598	0.1694730901705	6.38024790463904	53.6862161417768	4.25734822605322e-08	2.09330852934563e-06	0.113800303475554	0.218111704346612
MAU2	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.220482074213	0.220482074213	0.428290582509378	0.4313451016155	3.66976406203623	32.300907190838	0.000868523377504552	0.0195330269650759	0.0925047789038387	0.323112237688917
MAU2	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.4261440960285	-0.4261440960285	-0.0157259051998953	-0.01606038970165	14.0898066912301	69.6548278556819	4.48400606780151e-22	8.83320346053152e-20	0.352317706609439	0.468518675047771
MAU2	BRD-K37237504-001-02-7::2.5::HTS002	2.5	CEP-33779	JAK inhibitor	targeted cancer	JAK2	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.03099696588105	0.03099696588105	0.19155650525345	0.159444358103	4.63139321211797	177.011042998105	7.01218970640909e-06	0.000248415802906604	0.0921444364695768	0.228974642275223
MAU2	BRD-K37249724-001-25-7::2.5::HTS002	2.5	astemizole	histamine receptor antagonist	noncancer	HRH1, KCNH1, KCNH2	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.2465278727205	0.2465278727205	0.0606120665837965	0.100436576625	-4.49488015917396	18.713561177194	0.000256628069406621	0.00659348327593524	-0.272576576305855	-0.0992550359675522
MAU2	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.332541744983	-0.332541744983	-0.0924882477131611	-0.0710979031402	5.76816469897703	66.4995677454761	2.2767224283806e-07	1.01999925031853e-05	0.156974199003045	0.323132795536633
MAU2	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.3006651445315	0.3006651445315	-0.241974180163104	-0.026104548309	-10.4509269710194	183.269618119542	2.37630931003179e-20	4.07449598487843e-18	-0.645082234506245	-0.440196414882963
MAU2	BRD-K37720887-001-07-8::2.5::HTS002	2.5	SB-525334	TGF beta receptor inhibitor	noncancer	TGFBR1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.267326564861	0.267326564861	0.0268248048463212	0.0896615671228	-5.3141837089924	34.4408672567969	6.47771927251544e-06	0.000231124204088391	-0.332430842956494	-0.148572677072864
MAU2	BRD-K37723606-001-01-5::2.5::HTS002	2.5	dioscin	apoptosis stimulant	targeted cancer	CXCR3	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.597959572906	-0.597959572906	-1.01042581115798	-0.8558575413485	-5.26978868468436	64.2228383280495	1.70167527893782e-06	6.70068640197436e-05	-0.568818043822617	-0.256114432681342
MAU2	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-6.03803276482	-6.03803276482	-3.74681992232081	-3.68976707366	23.6548172330083	194.92355569398	3.42383608802648e-59	1.98331720246116e-55	2.10018408621907	2.48224159877931
MAU2	BRD-K39558284-001-01-2::2.5::HTS002	2.5	SDZ-WAG-994	adenosine receptor agonist	noncancer	ADORA1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.00865921368965	0.00865921368965	0.299640162905926	0.3288329829755	7.30321340286969	3.96795867928227	0.00192830511832759	0.0388651220336688	0.180006240192996	0.401955658239555
MAU2	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.7183950853545	-0.7183950853545	-0.358134765635604	-0.229271162585	5.7676205024988	185.185784717295	3.31818630584207e-08	1.65893061055476e-06	0.237030633808546	0.483490005629245
MAU2	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.4956872270005	0.4956872270005	-0.0732442189713021	0.318163539168	-5.42613543006144	7.55987182867807	0.000758221820858067	0.0173453863424793	-0.813188723454181	-0.324674168489424
MAU2	BRD-K49071277-001-04-7::2.5::HTS002	2.5	securinine	GABA receptor antagonist, TP53 activator	noncancer	GABRA1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.1767053653745	0.1767053653745	0.292679919340949	0.294659751206	4.64990468345647	87.8397140192307	1.16358591630591e-05	0.000395669055776503	0.0664077492485298	0.165541358684367
MAU2	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.7115475990755	-0.7115475990755	-0.103497932057134	0.0520686308404	8.60674208674915	3.82233095888529	0.00122379543440444	0.0263957785710445	0.408250602435915	0.807848731600818
MAU2	BRD-K51143828-003-03-1::2.5::HTS002	2.5	lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.168142944033	0.168142944033	-0.0220114143087364	0.03172783000245	-5.8487422262503	12.77132595031	6.11809088365353e-05	0.00181492636816966	-0.260520339206415	-0.119788377477058
MAU2	BRD-K51662849-001-08-8::2.61265::HTS002	2.61265	ilomastat	matrix metalloprotease inhibitor	noncancer	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.3934710376365	-0.3934710376365	0.0241018953397609	0.0366644244554	11.917444205206	8.98947747748661	8.2515509803582e-07	3.41154836047298e-05	0.338295517356113	0.496850348596409
MAU2	BRD-K51747290-001-13-1::2.5::HTS002	2.5	hydroxyurea	ribonucleotide reductase inhibitor	chemo	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.07902018690595	-0.07902018690595	-0.218032231676107	-0.233330589947	-3.18403257872053	159.63595285205	0.00174647214018769	0.0357823943537221	-0.225235997619099	-0.0527880919212144
MAU2	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.3552139606065	0.3552139606065	-0.243237812129238	-0.10314419939105	-9.23198729938313	12.4089460300665	6.50201523215379e-07	2.72981473593005e-05	-0.73917601014182	-0.457727535329656
MAU2	BRD-K56301217-001-07-4::2.5::HTS002	2.5	ABT-737	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.2656881596195	0.2656881596195	-0.138733759798809	-0.0916218688464	-12.9331688513334	162.822239327371	8.99507491470237e-27	2.67764640471284e-24	-0.466169199536584	-0.342674639300033
MAU2	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.154805827951	-0.154805827951	-0.754845190183719	-0.674815903064	-7.38030753439777	12.0386963114073	8.3419565175494e-06	0.000291667732210415	-0.777119725055688	-0.42295899940975
MAU2	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-1.603972623945	-1.603972623945	-1.32658401346902	-1.441894150425	4.32668581654667	31.2237268291531	0.000144488024034165	0.00394546741027118	0.146671111788734	0.408106109163224
MAU2	BRD-K60369935-001-18-3::2.5::HTS002	2.5	ribavirin	antiviral	noncancer	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.4753008559305	0.4753008559305	0.371162223446018	0.414452156411	-3.52408672477492	117.798883038563	0.000605955006974027	0.0141938503486051	-0.162657763101792	-0.0456195018671727
MAU2	BRD-K60866521-001-07-1::2.5::MTS010::PROS003_PR500	2.5	idelalisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.174599670622	0.174599670622	-0.0134130607131985	0.000732567672741	-8.60071818475521	35.6014342269408	3.2513797200265e-10	2.04000282205375e-08	-0.232364349818433	-0.143661112851964
MAU2	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.2371995858325	0.2371995858325	-0.496242690581287	0.00402399396559	-8.13770996706994	174.184647050185	7.36322679948638e-14	6.85259677250159e-12	-0.911327455679145	-0.555557097148428
MAU2	BRD-K63784565-001-06-2::2.50835::HTS002	2.50835	10-hydroxycamptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-6.500991509085	-6.500991509085	-5.71086110431888	-5.76312410001	7.37064198676139	17.1019258630293	1.05423436853877e-06	4.28346915591557e-05	0.564061505443307	1.01619930408894
MAU2	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.7192685816405	-0.7192685816405	-0.210399106316312	-0.1907303952045	8.92702293993974	22.2132563887841	8.40049903578467e-09	4.52493228911961e-07	0.39071770259535	0.627021248053026
MAU2	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.0987708778108	-0.0987708778108	0.258985514844754	0.250852150231	15.2551462907182	14.3485724711836	2.88315297562813e-10	1.81855001210536e-08	0.307572275305125	0.407940510005982
MAU2	BRD-K68202742-001-16-5::2.63491::HTS002	2.63491	trichostatin-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-6.183747074015	-6.183747074015	-5.50151706959265	-5.50871409078	7.6948841910152	11.1765418499243	8.58022944145261e-06	0.000299169024883211	0.487465621625379	0.876994387219318
MAU2	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.07482383601385	0.07482383601385	-0.264340444433105	-0.236194067289	-8.37815649038435	165.185199312095	2.2217929392019e-14	2.1853816377522e-12	-0.41909306735925	-0.25923549353466
MAU2	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.250536347079	0.250536347079	-0.0820695433534628	0.0411624842104	-6.32121767943961	8.29028280978462	0.000195633346050429	0.00518232424676484	-0.453206222846851	-0.212005558018075
MAU2	BRD-K69116396-001-04-1::2.5::HTS002	2.5	sertindole	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.1487902181005	0.1487902181005	0.0136768004980506	0.0316933159242	-5.31241590645059	191.944845145777	2.98002969045594e-07	1.31242402049554e-05	-0.185278487730435	-0.0849483474744642
MAU2	BRD-K70821460-300-02-4::2.5::HTS002	2.5	4-methylhistamine	histamine receptor agonist	noncancer	HRH4	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.708673716609	0.708673716609	0.474194311094418	0.464047664982	-6.86724918933287	13.366183247144	9.85500597778281e-06	0.000340021502931779	-0.308039403606058	-0.160919407423106
MAU2	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.695525325108	-0.695525325108	-1.03271931524129	-0.654329018583	-3.42497911189103	182.609748227696	0.000759296490585759	0.0173662637424773	-0.531442539528761	-0.142945440737817
MAU2	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-2.442738152385	-2.442738152385	-0.662236247632407	-0.4541784692175	20.7406778627995	18.75601142875	2.16421163420406e-14	2.12972137441378e-12	1.60066606759394	1.96033774191125
MAU2	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-2.124132444775	-2.124132444775	-2.93353395363799	-2.86819814614	-8.03584436164138	127.396905068629	5.43739871905824e-13	4.63008434667077e-11	-1.00870993881733	-0.610093078908646
MAU2	BRD-K75911534-001-01-6::2.5::HTS002	2.5	SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.240881783675	-0.240881783675	-0.524943762653558	-0.4139887396705	-4.98345223179514	159.010309988801	1.61603429886768e-06	6.39046153583048e-05	-0.396638768648364	-0.171485189308753
MAU2	BRD-K76973696-001-12-6::2.01421::HTS002	2.01421	tryptanthrin	cyclooxygenase inhibitor	targeted cancer	IDO1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.9065013330435	-0.9065013330435	-1.39145946755949	-1.35544849592	-9.72092940754135	20.1253676155455	4.78534950005088e-09	2.65023042117934e-07	-0.588981224453539	-0.380935044578431
MAU2	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.2918481183215	-0.2918481183215	0.0253242123825891	0.0294162092714	10.4488748495966	20.3155028150113	1.27364562049845e-09	7.50561430288184e-08	0.253916542945637	0.380428118462541
MAU2	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-5.567530520065	-5.567530520065	-4.11772749938636	-4.24145212342	9.39618041606572	4.08312887547015	0.000647547553526744	0.0150562182251935	1.02482357589273	1.87478246546455
MAU2	BRD-K81528515-001-13-8::2.5::HTS002	2.5	nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	targeted cancer	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.10232268453515	-0.10232268453515	0.193332169733848	0.2381526124685	4.69987282139326	7.89817238744262	0.00159604387283918	0.0331599929451094	0.150264887845644	0.441044820692353
MAU2	BRD-K82135108-001-04-3::0.15625::MTS010::PROS001_PR500	0.15625	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-1.291730312535	-1.291730312535	-0.973341711675206	-0.893367929172	4.26292384953989	97.9843860057187	4.64731060809246e-05	0.00140964256343313	0.170172705622593	0.466604496096996
MAU2	BRD-K84564571-001-02-4::2.5::HTS002	2.5	telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.5198342901825	-0.5198342901825	-0.18085020923752	-0.148494319003	8.16160249061268	168.083116840079	7.43844036121543e-14	6.91059160892476e-12	0.256988547272714	0.420979614617245
MAU2	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.1893214553955	-0.1893214553955	0.0376625226542557	0.0524875741405	8.7692891218157	192.502769405294	9.47469301750556e-16	1.05272238452512e-13	0.175931380779765	0.278036575319747
MAU2	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.378913732671	-0.378913732671	-0.148699835314627	-0.137644446714	6.34969575964253	180.024937464391	1.70688721535843e-09	9.91423929486606e-08	0.158672716569684	0.301755078143063
MAU2	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-1.7620932517	-1.7620932517	-1.00480370386343	-0.9517219897545	9.67213558401186	3.16936691683613	0.00186037789413048	0.0377022838495271	0.515482791025896	0.999096304647241
MAU2	BRD-K92049597-001-20-8::2.5::HTS002	2.5	triamterene	sodium channel blocker	noncancer	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	-0.4759608662975	-0.4759608662975	-0.0517428607167987	-0.0499338044925	9.76672410308633	3.43706024008972	0.00126099699954771	0.0270836983581582	0.29541929705778	0.553016714103622
MAU2	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	SKUT1, MKN7	SOFT_TISSUE, STOMACH	leiomyosarcoma, carcinoma (tubular_adenocarcinoma)	0.1435216608195	0.1435216608195	0.0233651022491012	0.0377701807511	-5.55621413720754	188.232509376687	9.31316979513194e-08	4.4015046725928e-06	-0.162816264943298	-0.0774968521974996
MB21D2	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	MCF7, T24, NCIH1650	BREAST, URINARY_TRACT, LUNG	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.894052684589	0.901520467269	0.461286687552807	0.471822397403	-8.47721531397139	10.642849502042	4.67975716805558e-06	0.000171630334372379	-0.545589121906985	-0.319942872165401
MB21D2	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.0481805813060983	-0.0229582343571965	-0.694577356817131	-0.540248640547	-5.37002476057129	6.29328731802875	0.00147013372080421	0.0308998853735648	-0.937639160115169	-0.355154390906896
MB21D2	BRD-K21361524-001-01-1::0.625::MTS006	0.625	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.887496160185	-1.90441928036	-2.76570407628652	-2.61362403643	-6.60286278427997	8.03886555695473	0.000165259513130984	0.00446600758918808	-1.18465803636309	-0.57175779583996
MB21D2	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.36341367508975	0.3680441629685	0.144090200563418	0.188754003369	-3.91797977440021	13.8941860277338	0.00156700122691004	0.0326483723109169	-0.339471716585095	-0.0991752324675702
MB21D2	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	MCF7, NCIH1650	BREAST, LUNG	carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-0.015012327502985	-0.015012327502985	0.407490418786201	0.468890554884	13.2295083490315	43.1049560606989	8.92988592518034e-17	1.09367629740456e-14	0.358101411254445	0.486904081323928
MB21D2	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.766800944599	-0.749249069422	-1.19240660496729	-1.13522122812	-5.40774920655188	12.650107498715	0.000131492932747624	0.00362712339547818	-0.59611228103844	-0.255099039698137
MB21D2	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	MCF7, NCIH1650	BREAST, LUNG	carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	-1.14767092266	-1.14767092266	-0.778934608841907	-0.683338343709	5.31421637564608	20.0643317658263	3.31759849706519e-05	0.00103501829443593	0.224027790684013	0.513444836952172
MB21D2	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	MCF7, T24, NCIH1650, KYSE410	BREAST, URINARY_TRACT, LUNG, OESOPHAGUS	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.185918128129	-0.1697508970825	-1.04707284311527	-0.667789074223	-5.02006045445177	6.59197377014028	0.00182712765671485	0.0371296523690183	-1.2719344555368	-0.45037497443574
MB21D2	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	MCF7, T24, NCIH1650	BREAST, URINARY_TRACT, LUNG	carcinoma, carcinoma (transitional_cell_carcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.28908077459	-1.20810591219	-2.22244202916234	-2.08207952886	-7.06688869031098	11.9143264903467	1.35791089012526e-05	0.000456676107280176	-1.22135822383929	-0.645364285305391
MB21D2	BRD-K93869735-001-01-1::2.5::HTS002	2.5	taltirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	neurology/psychiatry	spinocerebellar ataxia	MCF7, NCIH1650	BREAST, LUNG	carcinoma, carcinoma (bronchioloalveolar_adenocarcinoma)	0.1901267333825	0.1901267333825	-0.184905105046609	-0.1119517959605	-8.17576603075936	123.870443037992	2.94129968171389e-13	2.57623955652659e-11	-0.465824640958655	-0.284239035899563
MED1	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.527408885508	0.527408885508	0.173365610759501	0.21394626854	-12.9247320043848	167.298415100498	6.07983856026021e-27	1.82249750878603e-24	-0.408123177916646	-0.299963371580351
MED1	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2128095813995	0.2128095813995	-0.0097723605360616	0.0633629143304	-6.88700338148235	173.971683750223	9.98270569466979e-11	6.61999792336906e-09	-0.286370000375955	-0.158793883495169
MED1	BRD-A14240607-003-26-1::2.5::HTS002	2.5	octopamine	trace amine associated receptor agonist	noncancer	F10, TAAR1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.805245269879	0.805245269879	0.689319664584223	0.666876685048	-4.40854543466388	187.826822658724	1.7484464189634e-05	0.000577326717809283	-0.167798379651114	-0.0640528309384406
MED1	BRD-A27883417-300-01-6::2.5::HTS002	2.5	alexidine	phosphatidylglycerophosphatase inhibitor	targeted cancer	PTPMT1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.508289481111	-0.508289481111	-0.231233653262925	-0.2422575452235	5.7750379556937	16.0305000653277	2.8220896331552e-05	0.00089224907653713	0.175369689142456	0.378741966553694
MED1	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.288643396795	-1.288643396795	-2.36754843306087	-2.31691828506	-11.5343620379672	10.1964907151379	3.54519460259526e-07	1.54187908680933e-05	-1.28677831856712	-0.871031753964622
MED1	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.286892045088	0.286892045088	-1.20392164219107	-1.043529721605	-20.6363269400418	26.0953592528312	1.10033202701097e-17	1.47303599635999e-15	-1.63928325312426	-1.34234412143387
MED1	BRD-A83650191-004-02-8::2.5::HTS002	2.5	A61603	adrenergic receptor agonist	noncancer	ADRA1A	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	1.0025224536255	1.0025224536255	-2.06597628836355	-2.01906141095	-22.1918735078059	2.94294277984627	0.000227132738363055	0.00591580175970533	-3.51340566786454	-2.62359181611356
MED1	BRD-K03109492-001-02-2::2.5::HTS002	2.5	NSC-663284	CDC inhibitor	targeted cancer	CDC25A, CDC25B, CDC25C	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.4632958434995	-0.4632958434995	-1.21798264916623	-0.957814328752	-6.37721044144094	4.34859267669923	0.0023226331579409	0.0455993076951832	-1.07312338580846	-0.436250225525003
MED1	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2116201452985	-0.2116201452985	-1.46684828860616	-1.380035679485	-16.9623577302492	111.470780485369	1.17066648654377e-32	5.94568192877819e-30	-1.40185885641744	-1.10859743019788
MED1	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.16429025615525	-0.16429025615525	-2.04599626917554	-1.93975006052	-16.542708849007	4.73055846630368	2.28227367715385e-05	0.000735685719582955	-2.17918646443354	-1.58422556160705
MED1	BRD-K06749501-001-02-1::2.5::HTS002	2.5	GSK1838705A	insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R, INSR, RPS6KA1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.6914148387465	0.6914148387465	-0.243901049398648	-0.164638438825	-13.103313353511	5.24196895836701	3.31580654841529e-05	0.00103476048589881	-1.11628579347063	-0.754345982819667
MED1	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.3731716750925	-0.3731716750925	-0.853687206007777	-0.70967469814	-9.20879105655851	189.817490037051	6.15967813682514e-17	7.68450323275666e-15	-0.583442860048173	-0.377588201782382
MED1	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.15455388557	0.15455388557	0.278780435719819	0.26768413301	4.18487486496748	29.6526537123692	0.000233381983057637	0.00606529975103193	0.0635726120986439	0.184880488200995
MED1	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1905199706775	0.1905199706775	-0.289357053568024	-0.2721742756055	-14.3186877719561	63.6868246532917	1.39715188321987e-21	2.62215556898977e-19	-0.54683535004186	-0.412918698449187
MED1	BRD-K11267252-001-04-4::2.5::HTS002	2.5	alectinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.6915899819575	0.6915899819575	-0.165573363314625	-0.125024480839	-14.8211082719227	10.2830859407654	2.85155222352463e-08	1.43703347405551e-06	-0.985546191905324	-0.728780498638926
MED1	BRD-K13646352-001-03-8::2.5::HTS002	2.5	midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	targeted cancer	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.435155332133	-0.435155332133	-2.98091669255442	-2.8725192622	-21.6511807716769	8.09324651392616	1.87862468602518e-08	9.72099831798866e-07	-2.8163601735896	-2.27516254725323
MED1	BRD-K16551357-001-03-2::2.5::HTS002	2.5	evacetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.647989884096	0.647989884096	0.0536236513772957	0.0357605741878	-17.1876275018472	25.292045889962	1.83025391716744e-15	1.99125122747502e-13	-0.665545565207366	-0.523186900230043
MED1	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1083209892616	0.1083209892616	0.310775654190901	0.322928237233	5.95931428981663	19.4544130553035	8.87867051212062e-06	0.000308670976835734	0.131460998064373	0.273448331794229
MED1	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.7540055493375	0.7540055493375	-0.891824701870234	-0.806977834222	-21.5192198425177	38.6192351595765	4.15268137002306e-23	9.0359395467581e-21	-1.80057822358715	-1.49108227882832
MED1	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2813545029765	-0.2813545029765	-0.94772125911504	-0.900132875838	-10.7678154041207	7.43674259693086	8.44004221766117e-06	0.000294856692497001	-0.810977388698242	-0.521756123578839
MED1	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.193982281262	0.193982281262	-0.345902852131529	-0.216806871006	-7.12105083942673	4.77550389809203	0.00102371686424557	0.0225779184808489	-0.737562908513343	-0.342207358273715
MED1	BRD-K19687926-379-07-4::2.5::HTS002	2.5	lapatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2	oncology	breast cancer	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.076160819235	-2.076160819235	-0.644229527481797	-0.498501703786	18.8878051441431	4.21584581143468	3.10433815880142e-05	0.000973160294336331	1.22562488995987	1.63823769354653
MED1	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.553935964132	0.553935964132	-0.119555846520927	-0.0402228786984	-12.0036884186207	94.5102074385751	1.03315057071207e-20	1.82250311662673e-18	-0.784885877595181	-0.562097743710673
MED1	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.43144596304	-1.43144596304	-3.28643612136938	-3.04327234152	-15.9990712767345	126.189510255023	3.74432378302019e-32	1.79936585670613e-29	-2.08443582279096	-1.6255444938678
MED1	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.00408509631145	-0.00408509631145	-0.843980587562804	-0.742464669951	-13.5095084515935	71.3140934945017	2.4187072153666e-21	4.49219323017597e-19	-0.963850869669658	-0.71594011283305
MED1	BRD-K26756394-001-02-2::2.5::HTS002	2.5	VE-821	ATR kinase inhibitor	targeted cancer	ATR	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.3549898132365	-0.3549898132365	-0.11268169303603	-0.0474319307103	5.507963183146	20.4825185625222	1.99059241090645e-05	0.000649180889892221	0.150680122831539	0.333936117569402
MED1	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5784472932225	0.5784472932225	-0.41003126148471	-0.2809944464045	-10.6771799391445	2.98067211678348	0.0018071880413099	0.036808211128567	-1.28418878469961	-0.692768324714806
MED1	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.10309843026785	-0.10309843026785	-1.03942929809713	-1.017015264785	-10.631509964481	8.25923691587247	4.20587348561889e-06	0.000155367228248744	-1.13831939320547	-0.734342342453097
MED1	BRD-K36363294-001-04-2::2.5::HTS002	2.5	I-BET151	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.948636826452	0.948636826452	0.106762059874159	0.1571782830975	-13.9356486562365	107.776264483594	7.34440844613847e-26	2.00524804821963e-23	-0.961623845043134	-0.722125688112549
MED1	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.0353156055079	0.0353156055079	-0.356746239691965	-0.2780855887145	-8.05524398061537	29.6142590814584	5.97364068675255e-09	3.26863526870305e-07	-0.491516893915186	-0.292606796484544
MED1	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.395086804486	0.395086804486	-1.02874727188487	-1.03228700688	-22.2310247263275	154.732135996588	4.94549715548858e-50	1.23251565097525e-46	-1.5503537422575	-1.29731441048423
MED1	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.44675930879	-1.44675930879	-3.05434791651265	-2.95683473862	-16.4987691548532	85.9843934142867	2.23528827789902e-28	7.91879506303832e-26	-1.80128721807937	-1.41388999736593
MED1	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.274782167925	-1.274782167925	-1.78064877788429	-1.67706700871	-5.29499463677523	176.319681583451	3.51033769823047e-07	1.52764907314526e-05	-0.694409316438709	-0.317323903479869
MED1	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.398970660968	0.398970660968	-0.520961333038201	-0.465030888818	-19.0871406584909	177.554088633462	6.97086796628019e-45	1.10671048914435e-41	-1.01504353816587	-0.824820449846529
MED1	BRD-K42673188-001-01-1::2.5::MTS006	2.5	verubulin	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.927885531607	-0.927885531607	-2.48003034946975	-2.30487473877	-13.2458248144346	9.98056157774695	1.17126214924978e-07	5.47395214100648e-06	-1.81330691594291	-1.29098271978259
MED1	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.207127170505	-2.207127170505	-0.613472367552305	-0.4180119465525	19.277902262419	5.37545047787715	3.61021505380817e-06	0.000134991936892472	1.38553898081513	1.80177062509026
MED1	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.107487059	-1.107487059	-3.25844272719323	-3.15387343916	-20.7396661060617	2.91049374849514	0.000296861926964629	0.00750131100499905	-2.48683125108237	-1.8150800853041
MED1	BRD-K43236057-001-07-1::2.59978::HTS002	2.59978	polydatin	ICAM1 expression inhibitor	noncancer	ICAM1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.4071836347835	-0.4071836347835	-1.32308652703121	-1.21412289307	-9.69624479011674	6.27289480502518	5.25921413805544e-05	0.00157937803978602	-1.14462140918353	-0.687184375311882
MED1	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.522493391874	0.522493391874	-0.130475297881602	-0.075355311638	-14.9146600389156	8.77844797482285	1.54633880169898e-07	7.11060392682559e-06	-0.75238900062457	-0.553548378886635
MED1	BRD-K45551181-001-02-1::2.49051::HTS002	2.49051	MPI-0479605	mitotic kinase inhibitor	targeted cancer	TTK	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.9743746139375	-0.9743746139375	-2.31976155263557	-2.31598955621	-12.2170762591342	6.00233633798298	1.82519747579015e-05	0.000599988880043907	-1.61482396175136	-1.07594991564477
MED1	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.440755634927	0.440755634927	-0.107074365841932	-0.112273492753	-12.4138694760881	193.001828053214	2.15787332382694e-26	6.18308598425809e-24	-0.634869936300539	-0.460790065237326
MED1	BRD-K51791723-003-01-7::2.5::MTS010::PROS004_PR500	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.259160836517	0.259160836517	-2.25998897579213	-2.452542786	-26.4004434673915	4.77234096532624	2.33942908623751e-06	9.03436930854415e-05	-2.76799819594551	-2.27030142867276
MED1	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1003920913257	0.1003920913257	-0.217926508379472	-0.1500661795165	-8.3994387837392	19.4972420179275	6.62193789796276e-08	3.1929658666647e-06	-0.397502499609082	-0.239134699801261
MED1	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.227887830723	0.227887830723	0.30395556902981	0.306467449749	3.50264938908829	185.714183342163	0.000577062994882968	0.0136137957765847	0.0332236113306763	0.118911865282945
MED1	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.696064470917	0.696064470917	-0.629017379875789	-0.594419082347	-16.9917249190374	28.9496984541864	1.34307900685318e-16	1.62266505332489e-14	-1.48458897840869	-1.16557472317689
MED1	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-4.81329718046	-4.81329718046	-5.59318052523626	-5.54901350857	-9.88133795307589	177.083967324967	1.29113307572378e-18	1.87611702363933e-16	-0.935637695765731	-0.624128993786796
MED1	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.541976144735	-1.541976144735	-3.66254794449248	-3.579783032275	-18.3295939386893	182.827069269272	2.86216704057818e-43	3.9072955391088e-40	-2.34883325410682	-1.89231034540813
MED1	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.412856172115	-3.412856172115	-2.06323476962184	-1.75619766488	11.0887930496151	192.507334524625	2.05610178272383e-22	4.21302331729842e-20	1.10956425534585	1.58967854964047
MED1	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-5.66543483896	-5.66543483896	-7.22969043318043	-7.25572463628	-15.184894594763	146.822049692223	6.6588298595279e-32	3.11611429031169e-29	-1.76783719207999	-1.36067399636086
MED1	BRD-K62196610-001-01-6::2.5::HTS002	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.455299061542	-0.455299061542	-1.68605734297687	-1.62132235513	-18.544847459969	159.408002372532	1.20943953180518e-41	1.47282934893337e-38	-1.36182947207014	-1.09968709079959
MED1	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.783335305116	0.783335305116	-0.241152900491393	-0.1756829862115	-18.1701871527244	172.560857379691	6.39540241911749e-42	8.01590763208792e-39	-1.13577719154342	-0.913199219671361
MED1	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.345141048425	-0.345141048425	-0.207374204723928	-0.128286851934	3.37154735243299	27.139951612258	0.00225868009704293	0.0445231901516706	0.0539459759954207	0.221587711406723
MED1	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5030569285495	0.5030569285495	-0.499055995795223	0.00402399396559	-8.7236366718761	6.09560282177703	0.000114994689903732	0.00321506612214676	-1.28213257842725	-0.722093270262196
MED1	BRD-K66911501-003-01-2::2.5::HTS002	2.5	MK-3207	calcitonin antagonist	noncancer	CALCA	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.407740850291	0.407740850291	0.19514193087459	0.213447590059	-6.03394573432762	8.15254786087833	0.000288927214636121	0.00732239340023002	-0.293584367904104	-0.131613470928715
MED1	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.846202602795	-1.846202602795	-3.11819792207329	-3.18680355288	-13.8074739608466	189.028196770628	1.92121887420283e-30	8.01299515359983e-28	-1.45371786337334	-1.09027277518324
MED1	BRD-K68747584-001-02-0::2.5::HTS002	2.5	PF-03814735	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2508390535565	0.2508390535565	-1.28605919256657	-1.09893939309	-19.7030958736311	173.876365269501	3.62988708885889e-46	6.27411346667773e-43	-1.69085263157273	-1.38294386067341
MED1	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.052578089455	-1.052578089455	-2.59844957699413	-2.40345273405	-13.1628605043503	158.319573350003	3.35271970257864e-27	1.02071741638349e-24	-1.77782646098377	-1.31391651409449
MED1	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.581151516575	-1.581151516575	-0.649521658019898	-0.503206841324	10.6355219065534	3.89831673837474	0.000506034729386314	0.0121168492363579	0.68590180086379	1.17735791624641
MED1	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1594009115145	0.1594009115145	-1.48732351644	-1.368540965995	-17.0172447338531	21.5994873319155	5.39038068430562e-14	5.09398104800061e-12	-1.84762491309767	-1.44582394281133
MED1	BRD-K76037122-001-02-5::2.5::HTS002	2.5	guanidine	HSP inhibitor	noncancer	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.0906736203222	-0.0906736203222	0.216289560347058	0.217996960587	9.70568771359694	13.0183955348946	2.51165039419055e-07	1.11758249829861e-05	0.238646703671733	0.375279657666783
MED1	BRD-K77791657-003-01-7::2.66704::HTS002	2.66704	3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.179339109015	-1.179339109015	-1.52230685063677	-1.46906470598	-4.93370870148566	194.219861596141	1.72948583621693e-06	6.79521484492281e-05	-0.480069337250677	-0.205866145992865
MED1	BRD-K77908580-001-09-6::2.5::HTS002	2.5	entinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC9	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2406385961775	-0.2406385961775	-1.80887456103296	-1.534233909595	-12.7666537796865	8.5731156743092	7.14036257692999e-07	2.98495566754599e-05	-1.84823940264218	-1.28823252706875
MED1	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.03168152145	-2.03168152145	-3.9909461203084	-3.95467393468	-16.951041890396	165.209073828245	5.48557664823828e-38	4.75999254024398e-35	-2.18747625003926	-1.73105294767753
MED1	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.666199642008	-0.666199642008	-2.2241970910196	-2.0670113581	-12.0980836164253	6.64485233016555	9.0342491837615e-06	0.000313723524514974	-1.86584560293566	-1.25014929508753
MED1	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.304674152933	-0.304674152933	0.025457124658356	0.0294162092714	9.90067046174856	8.0436678414817	8.79877710319048e-06	0.000306042372241109	0.253311701781313	0.406950853401399
MED1	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3289027146505	0.3289027146505	-0.126330755556183	-0.118001057117	-15.5546570674461	136.315727352484	5.22780213747926e-32	2.47344283515186e-29	-0.513108943412651	-0.397357997000715
MED1	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.3478553634005	-0.3478553634005	-0.777958541190729	-0.670066066219	-8.65774697702476	169.348358598971	3.64683726562934e-15	3.84089918577431e-13	-0.528171911214347	-0.33203444436611
MED1	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.4914396600505	0.4914396600505	0.327364492453292	0.364286574892	-5.96243910117518	160.885843465336	1.52441823201628e-08	7.99038971019364e-07	-0.218418483160093	-0.109731852034324
MED1	BRD-K81548480-001-01-2::2.5::HTS002	2.5	AC-264613	PAR agonist	noncancer	F2RL1	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.052506499316	-0.052506499316	-0.372773220376752	-0.2564995934565	-6.33857967009438	101.066134811232	6.5442642832938e-09	3.56539303399613e-07	-0.420497059230581	-0.220036382890924
MED1	BRD-K82135108-001-04-3::0.15625::MTS010::PROS001_PR500	0.15625	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.556835179335	-2.556835179335	-0.959206461766826	-0.893367929172	22.3428282691795	173.55263058044	6.08328663884818e-53	2.00588421848875e-49	1.45649694107173	1.73876049406462
MED1	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.772183820935	-1.772183820935	-0.306505739060122	-0.18498925291	22.6802041541926	6.62522223666342	1.57611938147825e-07	7.23822778900477e-06	1.31109744749435	1.62025871625541
MED1	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.8600935102745	-0.8600935102745	-1.70874347696969	-1.55120007366	-12.1509852383276	66.6618276660459	1.45313391321043e-18	2.10154344456463e-16	-0.98806832349353	-0.709231609896845
MED1	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.926795299549	0.926795299549	-0.32403501586149	-0.108614953002	-16.0329798078468	65.3980268502487	2.41448061480147e-24	5.84078121546031e-22	-1.40662122102117	-1.09503940979981
MED1	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.0143546623474	-0.0143546623474	-0.970679248680099	-0.879578497328	-11.1178121911092	177.000029517738	4.07178718325984e-22	8.08806371826597e-20	-1.12607611724111	-0.786573055424285
MED1	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.40921276968	0.40921276968	-0.0940326990662259	0.0692106615383	-9.68754555498532	176.93299216988	4.50342375186769e-18	6.24734180785792e-16	-0.605762249476186	-0.400728688016266
MED1	BRD-K97010173-001-04-1::2.5::HTS002	2.5	deferasirox	chelating agent	noncancer	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.974387980434	0.974387980434	0.040164826108855	0.106077867549	-16.3327574446391	3.79467303460925	0.000117527561448303	0.00327733082457108	-1.09648106897351	-0.771965239676784
MED1	BRD-K99964838-001-11-9::2.5::HTS002	2.5	bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	targeted cancer	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	NCIN87, BT474	STOMACH, BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.477649312889	0.477649312889	-0.40258369894545	-0.289629896197	-10.380054183712	3.24203083263353	0.0013493172139751	0.0286988001542195	-1.13905856258026	-0.621407461088638
MGAT4C	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.0859120609668	0.0859120609668	-0.516823110130159	-0.46624794895	-9.33539434941218	5.81778802220483	0.000102401128363548	0.00289583473295037	-0.761926037991014	-0.443544304202903
MGAT4C	BRD-A23067620-300-01-3::2.5::HTS002	2.5	itraconazole	cytochrome P450 inhibitor	noncancer	CYP51A1	infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.5344885620115	0.5344885620115	0.433500946292383	0.442558304417	-3.32892549148367	27.8226365271332	0.00246511309496018	0.0479834006475089	-0.163146765945644	-0.0388284654925897
MGAT4C	BRD-A24514565-001-09-7::2.5::HTS002	2.5	warfarin	vitamin K antagonist	noncancer	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.064205593281	0.064205593281	-0.125147301599326	-0.09418085429645	-5.06652868260783	63.2818865114337	3.76226348778486e-06	0.000140066383719548	-0.264030964736456	-0.114674825024196
MGAT4C	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.486684058828	-0.486684058828	-1.24303884004182	-1.05465528871	-7.10758175234085	11.2413329082199	1.75721343032282e-05	0.000579864199088005	-0.989961049121596	-0.522748513306039
MGAT4C	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.4811510806485	-0.4811510806485	-0.998100888996143	-0.927705434	-7.37747508931688	16.9403668187085	1.1034054415804e-06	4.47308085660081e-05	-0.664827135767553	-0.369072480927733
MGAT4C	BRD-A45498368-001-07-1::2.5::HTS002	2.5	WYE-125132	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.738093466745	-1.738093466745	-2.34847988044639	-2.40199548357	-7.62751918078042	9.83940838466773	1.95646685058416e-05	0.000639024053061341	-0.789086785373301	-0.431686042029473
MGAT4C	BRD-A59303141-001-10-4::2.5::HTS002	2.5	quinethazone	thiazide diuretic	noncancer	CA1, CA2, SLC12A1, SLC12A2, SLC12A3	cardiology	hypertension	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.6500394466635	0.6500394466635	0.360275795898445	0.3935946417985	-9.36565210410441	165.664406618183	5.38472324370441e-17	6.75703950878174e-15	-0.350849159495808	-0.228678142034302
MGAT4C	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.62010610159	0.62010610159	0.41087327807174	0.462027349437	-5.90384594280357	32.1807500512972	1.4044679745788e-06	5.60764188754656e-05	-0.281406023192531	-0.137059623843989
MGAT4C	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.348065378872	0.348065378872	-0.190648512378626	-0.136086260588	-11.0668938026767	35.4674938586834	4.70449753262202e-13	4.03808671073025e-11	-0.637488876354577	-0.439938906146675
MGAT4C	BRD-A93093700-001-02-9::2.5::HTS002	2.5	temazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.4153114882125	0.4153114882125	0.29503475865105	0.2827443589055	-4.81490091581138	181.080133819724	3.09732556562606e-06	0.000117059899692306	-0.16956625249114	-0.0709872066317602
MGAT4C	BRD-A93477898-001-04-2::2.5::HTS002	2.5	PETCM	caspase activator	noncancer	CASP3	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.687830206543	0.687830206543	0.174410244925621	0.179996842636	-11.9112876000128	18.9576264528044	3.01854102268935e-10	1.89835938630277e-08	-0.603650586322983	-0.423189336911775
MGAT4C	BRD-K04430056-236-02-1::2.5::HTS002	2.5	7-nitroindazole	nitric oxide synthase inhibitor	noncancer	NOS1, NOS2, NOS3	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.433297238814	0.433297238814	0.307127778016526	0.309926543901	-4.70427103259853	79.6018224757495	1.05621988748581e-05	0.000362321626544408	-0.179547446334846	-0.0727914752601021
MGAT4C	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.66388912529	-2.66388912529	-3.18485385423977	-3.102963726805	-4.07001328344507	10.3489699702522	0.00209690997753956	0.0417878771339913	-0.804869930801441	-0.237059527098091
MGAT4C	BRD-K07955840-001-02-3::2.5::HTS002	2.5	PF-05212384	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.611424074875	-3.611424074875	-4.71385448115057	-4.691855544975	-10.9253474349355	42.0360039826109	7.40038287769865e-14	6.88418690014876e-12	-1.30606129233289	-0.898799520218248
MGAT4C	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.1718994487435	0.1718994487435	-0.289158962909151	-0.2721742756055	-10.6362822291809	4.57935636930045	0.000211599997295161	0.00555920762690299	-0.575637349039479	-0.346479474265824
MGAT4C	BRD-K12932420-001-02-3::2.5::HTS002	2.5	YM-976	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.4511493389065	0.4511493389065	0.311471774362481	0.3289563739625	-3.78809687845513	28.4047639245084	0.000726776935718935	0.0167098576422542	-0.215159517998844	-0.0641956110891933
MGAT4C	BRD-K13249881-001-02-3::2.5::HTS002	2.5	piperazine	benzodiazepine receptor agonist	noncancer	GABRB3	infectious disease	gastrointestinal roundworms	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.2184465049925	-0.2184465049925	0.0401720386248857	0.0803711832404	5.84727356212074	23.6499338757913	5.25642963905158e-06	0.000190853008319208	0.16726300082778	0.349974086406992
MGAT4C	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.5266587799335	0.5266587799335	0.256565726715026	0.261395016509	-9.47416988412414	67.023521775895	5.4381620787891e-14	5.13460722548365e-12	-0.326995612426742	-0.213190494010207
MGAT4C	BRD-K18910433-001-36-6::2.58082::HTS002	2.58082	estradiol	estrogen receptor agonist	noncancer	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.657396951167	0.657396951167	0.303069618326236	0.322506570142	-10.9137434918156	31.5065721668291	3.11162674558813e-12	2.467302437126e-10	-0.420499377481846	-0.288155288199681
MGAT4C	BRD-K21283037-001-21-5::2.5::HTS002	2.5	riluzole	glutamate inhibitor	noncancer	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.6107390887745	0.6107390887745	0.0384916302061777	0.0176424857247	-17.5759976089729	15.1831197729246	1.66614473048867e-11	1.21257430879765e-09	-0.641571351526002	-0.502923565610642
MGAT4C	BRD-K22503835-001-11-0::2.5::HTS002	2.5	scriptaid	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.423984075491	-0.423984075491	-1.35242975451318	-1.31516080895	-13.0274754447267	27.8167386672966	2.3219893540496e-13	2.05989096135802e-11	-1.07447546097968	-0.782415897064685
MGAT4C	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.6035090288805	0.6035090288805	-0.245309340812633	-0.0866927101235	-12.9359720366591	38.5000553604223	1.36020999910967e-15	1.49580527911327e-13	-0.981596201626191	-0.716040537760074
MGAT4C	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0080339662401	-0.0080339662401	-0.505719831117052	-0.436225052339	-9.52630796719342	19.7902377216869	7.8424809375865e-09	4.23286602083097e-07	-0.606737597659049	-0.388634132094855
MGAT4C	BRD-K31698212-001-02-9::2.5::HTS002	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.5543163559765	-0.5543163559765	-0.107432152084221	0.0673910689795	7.47870617522883	111.332141493734	1.85168347349605e-11	1.33851422324093e-09	0.328481133698408	0.56528727408615
MGAT4C	BRD-K34332569-001-01-3::2.5::HTS002	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.05763673880562	0.05763673880562	-1.00800213107166	-0.918687700318	-9.87551966731166	8.29478302645423	7.20497158307441e-06	0.000254640372364071	-1.31294223092149	-0.818335508833069
MGAT4C	BRD-K39160765-003-02-9::2.5::HTS002	2.5	4-chlorophenylguanidine	urokinase inhibitor	noncancer	PLAUR	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.1750625715155	-0.1750625715155	0.0568162493261776	0.0820318935995	6.66681765753233	15.4810846895501	6.40528588928847e-06	0.000228730176502051	0.157944946239617	0.305812695443738
MGAT4C	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.01975806104976	0.01975806104976	-0.207195375589378	-0.158031671069	-5.64816188198428	11.5388915382516	0.000124693043314841	0.00345869487260599	-0.314891707085713	-0.139015166192562
MGAT4C	BRD-K41876534-001-13-7::2.5::HTS002	2.5	tioxolone	carbonic anhydrase inhibitor	noncancer	CA2	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.567388280096	0.567388280096	0.212414397121818	0.2726226138565	-6.79783722518532	10.733685075431	3.34829491199327e-05	0.00104353162744308	-0.470255229714848	-0.239692536233516
MGAT4C	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.5293634213695	0.5293634213695	-0.130548774132891	-0.075355311638	-16.4170263636219	21.0313571424009	1.81387816177912e-13	1.62188857962435e-11	-0.743498463105465	-0.576325927899317
MGAT4C	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.3747215240845	-0.3747215240845	-0.119734381330248	0.007652771570785	5.71848993696909	24.215746439057	6.61358641347007e-06	0.000235501472406152	0.163001392489711	0.346972893018794
MGAT4C	BRD-K58529924-001-01-5::2.64858::MTS010::PROS001_PR500	2.64858	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.175808012764	0.175808012764	-0.119646580979995	-0.0782443732808	-6.65068172174776	24.543484991186	6.28319369706948e-07	2.6420896662143e-05	-0.387035361862169	-0.203873825625821
MGAT4C	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.4545108735525	-0.4545108735525	-2.64916987842207	-2.62453052692	-15.1320196287377	25.0848505028228	4.04538124883161e-14	3.86531375488042e-12	-2.49331112321352	-1.89600688652562
MGAT4C	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.4119173896175	0.4119173896175	-0.342509127037322	-0.3277516003215	-15.7828497713175	44.9494264053367	5.95729568939073e-20	9.76909891209966e-18	-0.850704452118284	-0.65814858119136
MGAT4C	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.09105598655005	-0.09105598655005	-0.273054870198298	-0.224936831672	-5.18807828589305	26.560808124806	1.92574300375944e-05	0.00062985284946247	-0.254033263447681	-0.109964503848815
MGAT4C	BRD-K72951360-001-01-4::2.5::HTS002	2.5	valrubicin	DNA inhibitor, topoisomerase inhibitor	chemo	TOP2A	oncology	bladder cancer	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.08292340018	-2.08292340018	-3.29987573499612	-3.181546610205	-8.04335423901529	3.72946715813406	0.00173374191951802	0.0355827991830295	-1.64932076055774	-0.784583909074503
MGAT4C	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.692708069308	-0.692708069308	-0.205946045061973	-0.182274470613	18.8629452431023	113.030890777747	1.03803730824481e-36	7.97424724870258e-34	0.435637425333295	0.53788662315876
MGAT4C	BRD-K76703230-004-04-1::2.5::HTS002	2.5	YM-155	survivin inhibitor	targeted cancer	BIRC5	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.95612860006	-3.95612860006	-5.50440406620934	-5.55235554655	-18.593251594998	185.105084241601	3.26970128263312e-44	4.90064200143688e-41	-1.71255736719692	-1.38399356510176
MGAT4C	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.390746927775	-1.390746927775	-1.10642822394887	-1.10749370834	5.77904971341672	168.832318851268	3.54221804487616e-08	1.76353089742221e-06	0.187195867312988	0.381441540339277
MGAT4C	BRD-K80608265-001-01-6::2.5::HTS002	2.5	erteberel	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.4698781523375	0.4698781523375	8.43347694260735e-05	0.05335983697175	-8.8470798692705	7.39223073530245	3.43153839147482e-05	0.00106776740985251	-0.594021010781497	-0.345566624354651
MGAT4C	BRD-K81473043-001-14-6::2.5::HTS002	2.5	tanespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.95364733263	-3.95364733263	-4.83889551808494	-4.75693780059	-8.74094168608351	184.142737137176	1.41801582022874e-15	1.55379300988653e-13	-1.08505881635838	-0.685437554551506
MGAT4C	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.420084757525	-1.420084757525	-3.08028156026215	-2.99864068297	-17.575372487536	161.16941323766	2.66514523456393e-39	2.66924258401333e-36	-1.84673873723172	-1.47365486824259
MGAT4C	BRD-K82967180-001-01-6::2.5::MTS006	2.5	LY3023414	PI3K inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.145795658985	-2.145795658985	-3.38989693166707	-3.49521149321	-13.021756355035	2.80126559680304	0.0013690858116033	0.0290443227670122	-1.56072775535982	-0.927474790004319
MGAT4C	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.02355330850471	0.02355330850471	-0.120646078412144	-0.0479466221371	-4.12998973928936	35.1998191812063	0.000212328598853437	0.00557083807854796	-0.215066615180867	-0.0733321586528419
MGAT4C	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.271600531265	-1.271600531265	-0.773600588359847	-0.768623385632	8.60740677810412	10.2696516878784	5.16252920069836e-06	0.000187666167071994	0.369543549689654	0.626456336120653
MGAT4C	BRD-K88677950-001-03-9::2.5::HTS002	2.5	PD-198306	MAP kinase inhibitor, MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.971404229998	-0.971404229998	-0.662270169227923	-0.550135683891	6.43691716095495	158.853162688303	1.37486226720668e-09	8.05997961893162e-08	0.214283853479728	0.403984268060427
MGAT4C	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-4.04895743775	-4.04895743775	-5.63310118883762	-5.62740406384	-13.2519597886053	8.4262313749316	6.19328415888966e-07	2.60939728816722e-05	-1.85739588504422	-1.31089161713102
MGAT4C	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.1921312534115	0.1921312534115	0.308147380516105	0.317996860903	4.17042942625451	29.5484729789782	0.000244195279493424	0.00631874080146639	0.0591662359628268	0.172866018246382
MGAT4C	BRD-K97010173-001-04-1::2.5::HTS002	2.5	deferasirox	chelating agent	noncancer	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.8999348030625	0.8999348030625	0.0409444405315932	0.106077867549	-16.4487722065235	5.82901025242714	4.16427885673275e-06	0.000153989945321717	-0.987687527996935	-0.730293197064879
MGAT4C	BRD-K97752965-001-16-4::2.5::HTS002	2.5	nicorandil	nitric oxide donor, potassium channel activator	noncancer	KCNJ11	cardiology	angina pectoris	HARA, BT474	LUNG, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.4704923080385	0.4704923080385	0.247306176869182	0.245556311183	-8.21146371149226	132.726895934935	1.69836633106586e-13	1.52305086766115e-11	-0.276947784037422	-0.169424478301214
MIPOL1	BRD-A06352418-001-25-9::2.5::HTS002	2.5	terfenadine	histamine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.7410889599325	-0.7410889599325	0.0718543794578994	0.03730027167595	14.1397103111035	5.23376162874409	2.27253346689824e-05	0.000732876655773148	0.667114783037119	0.95877189574368
MIPOL1	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1747882617965	0.1747882617965	-0.00937835722411342	0.0633629143304	-4.64960960626116	7.88865211626456	0.00170791523884387	0.0351334835613944	-0.275730148783983	-0.0926030892572434
MIPOL1	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.00113333687215	-0.00113333687215	-0.449262031637805	-0.3315553181695	-5.21800973217198	12.430306171288	0.000191969700386516	0.00509720935507206	-0.634531747216867	-0.261725642314443
MIPOL1	BRD-A55913614-316-09-6::2.5::HTS002	2.5	primaquine	antimalarial agent, DNA inhibitor	noncancer	KRT7, NQO2	infectious disease	malaria	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.8396271246495	-0.8396271246495	0.107659812943742	0.123868059835	28.2113867620963	78.4354083669547	8.05528179621457e-43	1.07234813173967e-39	0.880443766934035	1.01413010825245
MIPOL1	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.31100003816	0.31100003816	-0.183568592221485	-0.008049193223815	-9.42116061425983	189.950928638153	1.55399888363954e-17	2.04964324142511e-15	-0.598117674566349	-0.391019586196621
MIPOL1	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.407623204471	-0.407623204471	-0.531627579843946	-0.51783728433	-3.5934173665892	26.3762692584594	0.00131622067008471	0.0281008327521252	-0.19488892966006	-0.0531198210858315
MIPOL1	BRD-A83937277-001-10-5::2.5::HTS002	2.5	mephenytoin	hydantoin antiepileptic	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.26399954173	-0.26399954173	-0.0668075652141237	-0.09044120254575	5.04123496172339	34.7935196791268	1.43659463149978e-05	0.000481250220029255	0.117765816245669	0.276618136786083
MIPOL1	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.338845735364	-0.338845735364	0.215739080846297	0.255620963174	12.4563271392591	39.3756424162275	3.08460143020428e-15	3.26640088900323e-13	0.464557346292625	0.644612286127969
MIPOL1	BRD-A88138582-001-04-8::2.5::HTS002	2.5	halcinonide	glucocorticoid receptor agonist	noncancer	NR3C1	dermatology	corticosteroid-responsive dermatoses	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.1601348336865	-0.1601348336865	0.288739769235712	0.271498437294	12.4199746144695	107.444417040759	1.68774539241679e-22	3.5017694308935e-20	0.3772319879389	0.520517217905524
MIPOL1	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.117146474097	0.117146474097	-0.188411058315184	-0.138056758361	-6.58008264465232	155.235225330074	6.82692242108007e-10	4.13335439431546e-08	-0.397286961046612	-0.213828103777757
MIPOL1	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2387941492925	-0.2387941492925	0.227129805981565	0.2226649685355	17.1279575157079	160.3841124296	4.70640082940482e-38	4.1340909154324e-35	0.412202596331758	0.519645314216372
MIPOL1	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.44012018211	-1.44012018211	-2.77454265364094	-2.64361455145	-9.17542662696845	3.58719725339334	0.00128772595980396	0.0275733616530653	-1.75721570678689	-0.91162923627499
MIPOL1	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.7552830327375	-0.7552830327375	-2.21902607954633	-2.04082568027	-11.8974396940873	31.0300929652623	4.27422247088866e-13	3.68203307059122e-11	-1.71465470204706	-1.21283139157061
MIPOL1	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2026568181535	0.2026568181535	-0.344024828610534	-0.229059189804	-9.45254323307062	4.48260717345733	0.000397270806740007	0.00974687130809464	-0.700662077848637	-0.392701215679432
MIPOL1	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.22108047751	-3.22108047751	-4.28513409191005	-4.26036322773	-12.909400638727	6.07909170827394	1.20224502477419e-05	0.000407908776183041	-1.26510524999417	-0.863001978805936
MIPOL1	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.07789335726495	-0.07789335726495	-0.358396263306763	-0.164030729397	-4.11452812494229	25.6643086029743	0.000353826452503289	0.00880065797128669	-0.420725366861793	-0.140280445221833
MIPOL1	BRD-K06222852-001-03-2::2.5::HTS002	2.5	posaconazole	sterol demethylase inhibitor	noncancer	CYP3A4	infectious disease	oropharyngeal candidiasis	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.617987587058	-0.617987587058	-0.041949377356738	0.00528280160376	10.8204571854469	3.04747001731957	0.00157338680505398	0.0327336847738706	0.408100617305738	0.743975802096786
MIPOL1	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.020339465795	-2.020339465795	-3.19162806118182	-3.102963726805	-8.89728186950062	8.10254865240607	1.85920070306375e-05	0.000609857097470081	-1.47419656484333	-0.868380625930305
MIPOL1	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.3321202553695	-0.3321202553695	0.190591575250624	0.239804537816	14.7140835354812	154.55092661281	3.37832821056669e-31	1.49293547843824e-28	0.452535402227332	0.592888259012917
MIPOL1	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.991198530141	-0.991198530141	-1.33832008666919	-1.3496917977	-4.92410074565881	34.5453305600409	2.07761778430471e-05	0.00067489200074605	-0.490300171132087	-0.203942941924287
MIPOL1	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.7800489376655	-0.7800489376655	-1.81449979957977	-1.56065418801	-8.16348708856195	9.59719674872779	1.27237061193617e-05	0.000429796565619648	-1.31840800830657	-0.750493715521985
MIPOL1	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.014816368405	-3.014816368405	-1.92058342882621	-2.01595157397	14.1746617661876	186.831539953383	1.92187162560089e-31	8.70851635609754e-29	0.941944300160595	1.24652157899699
MIPOL1	BRD-K13183738-317-10-2::2.5::HTS002	2.5	pentamidine	anti-pneumocystis agent	noncancer	TRDMT1	infectious disease	pneumonia	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.218571039785	-1.218571039785	-0.904161623427698	-0.814219930729	5.2611675625528	96.1288824684151	8.67544031873253e-07	3.57576624629543e-05	0.195788012823954	0.43303081989065
MIPOL1	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.266621334285	-2.266621334285	-2.60709280339619	-2.686193418095	-4.10003378052277	12.4437303796513	0.00136798885275835	0.0290325460761308	-0.520689582631005	-0.160253355591366
MIPOL1	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.978324775015	-1.978324775015	-1.28745620742787	-1.25961873039	10.6027007135493	6.24762732687299	3.17322570228647e-05	0.000992288140568072	0.532947978221038	0.848789156953224
MIPOL1	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.855370899605	-1.855370899605	-2.75013947759656	-2.77734094711	-15.6151776716014	7.07383640702939	9.6587312498879e-07	3.95821455077863e-05	-1.02997823173908	-0.759558924244042
MIPOL1	BRD-K18518344-001-15-9::2.5::HTS002	2.5	digitoxigenin	ATPase inhibitor	noncancer	ATP1A1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.83124493574	-2.83124493574	-4.14748657866225	-4.343421581	-10.1491000264949	172.99898194466	2.77999281206926e-19	4.29893996694079e-17	-1.57222100346871	-1.0602622823758
MIPOL1	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.64143477019	-1.64143477019	-3.05351038169764	-3.177325410155	-13.5743312119445	86.0969908067843	4.17886552912216e-23	9.07448905766185e-21	-1.61886799437414	-1.20528322864114
MIPOL1	BRD-K21396683-001-04-8::2.5::HTS002	2.5	marimastat	matrix metalloprotease inhibitor	targeted cancer	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.8607846069295	-0.8607846069295	-1.8044977421731	-1.72083973318	-12.3480055043544	134.590057476126	6.81659058152093e-24	1.58287436917313e-21	-1.09486512411588	-0.792561146371322
MIPOL1	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.604658101135	-0.604658101135	-0.258636088811554	-0.291499790384	5.81584477693892	27.0320746053349	3.42659212609894e-06	0.000128529587643448	0.223952195116535	0.468091829530357
MIPOL1	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1113194933054	0.1113194933054	-0.506982830688962	-0.436225052339	-9.99403247300953	5.03222623244917	0.000165308918999539	0.00446621647551396	-0.777031060812834	-0.459573587175891
MIPOL1	BRD-K28360340-001-08-3::2.30697::HTS002	2.30697	TW-37	BCL inhibitor	targeted cancer	BCL2, BCL2L1, MCL1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.052306151845	-3.052306151845	-2.76588873337553	-2.71718912157	3.24235889636966	154.100679756696	0.00145318741411167	0.0306024961160662	0.111911362710518	0.460923474228414
MIPOL1	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.17991297171	-1.17991297171	-2.23484515650358	-2.28506663454	-9.32763673372176	62.9671236148248	1.77070199703189e-13	1.58394318999101e-11	-1.28094176855511	-0.828922601032057
MIPOL1	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.418789857845	-2.418789857845	-1.32440207935277	-1.23672379758	12.2802828878571	3.08405350601542	0.0010160034055515	0.0224216427006227	0.815099261738866	1.37367629524558
MIPOL1	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5047145621055	0.5047145621055	0.160040111406841	0.154760250633	-9.75516620538116	3.16833383130555	0.00181449645771431	0.0369324986975736	-0.453812949041305	-0.235535952356013
MIPOL1	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.544636747007	0.544636747007	0.167109404975613	0.159843684784	-12.0951481482605	6.30753164341288	1.34261008898187e-05	0.000451813907617203	-0.453009460865827	-0.302045223196946
MIPOL1	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.513296929195	-0.513296929195	0.0322174396509802	0.056211415311	15.6027848681463	68.3394345505753	3.24217663261606e-24	7.74685033993275e-22	0.475753804123247	0.615274933568713
MIPOL1	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3038349816895	0.3038349816895	0.57772536096267	0.571651612309	7.079448102058	9.10390146378863	5.4685553305826e-05	0.00163750321831912	0.186523843857523	0.361256914688817
MIPOL1	BRD-K38548312-001-01-0::2.5::HTS002	2.5	VER-49009	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.01751247347	-2.01751247347	-2.74202436545298	-2.671842712285	-7.39518984870179	25.7900404624284	7.86487083606775e-08	3.7475987137029e-06	-0.925973363294797	-0.523050420671159
MIPOL1	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-5.391128595555	-5.391128595555	-6.61293291162647	-6.671127343215	-11.0399082561029	3.74209560836703	0.000544289451714351	0.0129188276740294	-1.53761275075326	-0.905995881389692
MIPOL1	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.222483062685	-0.222483062685	-0.896164988490127	-0.852653660565	-9.14179422427924	8.16744226965606	1.44195910368371e-05	0.000482519364142741	-0.843012690256946	-0.504351161353308
MIPOL1	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3460825468515	0.3460825468515	-0.731907619589074	-0.623158972273	-9.21196634420953	6.3190900320809	6.81704497032503e-05	0.00200067154791838	-1.36086069273775	-0.795119640143394
MIPOL1	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.14215505153	-1.14215505153	-0.284240892008034	-0.269064169965	19.5287557102027	177.074176749201	4.94670789989277e-46	8.34821226359147e-43	0.771218825745202	0.94460949329873
MIPOL1	BRD-K49669041-001-08-4::2.5::HTS002	2.5	BX-912	pyruvate dehydrogenase kinase inhibitor	targeted cancer	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.15802819225	-1.15802819225	-1.94499250500171	-1.738347180205	-7.44534354465802	15.1305065095663	1.95642193105726e-06	7.63090001931887e-05	-1.01208696488968	-0.561841660613747
MIPOL1	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.4700853024005	-0.4700853024005	-0.222436722493049	-0.176181988507	6.1068569786115	9.29106828766918	0.000155835270034396	0.00423267235980256	0.156348574078763	0.338948585736139
MIPOL1	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.4850104862095	0.4850104862095	0.224373917195435	0.2005091684065	-8.70916414370711	57.1203737468366	4.54630873576097e-12	3.5432938364615e-10	-0.320561021291665	-0.200712116736465
MIPOL1	BRD-K53561341-001-07-5::2.5::HTS002	2.5	aurora-a-inhibitor-i	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2328952198605	-0.2328952198605	-0.621873299117502	-0.52264323687	-6.72214485800138	184.327408613663	2.17040244669424e-10	1.38446483927836e-08	-0.503141283873845	-0.27481487464016
MIPOL1	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.537362157695	-1.537362157695	-2.75223948076508	-2.66953815971	-14.5598320395331	187.275786256674	1.30139919905302e-32	6.51699974144471e-30	-1.37948109074869	-1.05027355539146
MIPOL1	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.229426036235	-1.229426036235	-0.609166962276284	-0.573831164789	6.84853707701494	6.81845922047365	0.000272604671970126	0.00695229494748753	0.404938186789328	0.835579961128105
MIPOL1	BRD-K55044200-001-15-3::2.5::HTS002	2.5	amoxicillin	penicillin binding protein inhibitor	noncancer	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.4768385283245	0.4768385283245	0.0934152366509799	0.127274405853	-10.0107320331537	2.90964792133359	0.00241407115510077	0.0471311219349238	-0.507484392907297	-0.259362190439743
MIPOL1	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.58872551233	-1.58872551233	-3.16752304319507	-3.19197499768	-12.2956468270326	5.3673651027819	3.90065657520617e-05	0.0012013482764168	-1.90218725112233	-1.25540781060781
MIPOL1	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.592878877299	-0.592878877299	-0.201442676202124	-0.0713354708951	6.82542084924229	10.6623716543585	3.3398750023259e-05	0.00104105885598241	0.264720869759136	0.518151532434616
MIPOL1	BRD-K62391742-001-03-0::2.5::HTS002	2.5	venetoclax	BCL inhibitor	targeted cancer	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.125320206037	0.125320206037	0.361181365774289	0.3408626748475	7.66443764733522	18.9484768213233	3.20499351159561e-07	1.40647636025138e-05	0.171439740729877	0.300282578744701
MIPOL1	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.312498324218	0.312498324218	-0.34137936493051	-0.3277516003215	-13.4902024058517	35.9888697381119	1.20745539307554e-15	1.33398302547674e-13	-0.752181600364871	-0.555573777932148
MIPOL1	BRD-K67844266-003-01-9::2.5::MTS010::PROS003_PR500	2.5	pevonedistat	nedd activating enzyme inhibitor	targeted cancer	NAE1, UBA3	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.370677883075	-1.370677883075	-0.938713113810361	-0.949123876335	4.62455135625614	122.18395964622	9.40495208371456e-06	0.000325594245703514	0.247059371226438	0.61687016730284
MIPOL1	BRD-K69694239-001-02-2::2.5::HTS002	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-4.952919822895	-4.952919822895	-5.69922378090557	-5.75788752099	-9.86807093248437	182.010171440828	1.14439176267134e-18	1.66741225086055e-16	-0.89552460262261	-0.597083313398538
MIPOL1	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.042382289065	-0.042382289065	-0.729915994556779	-0.60872932846	-7.37830501171635	187.463475120087	5.04446220781432e-12	3.8961244704095e-10	-0.871356038028479	-0.503711372955079
MIPOL1	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.379843969266	-0.379843969266	-0.61190388649924	-0.443084865138	-4.53535158417463	187.484356023526	1.02416719062122e-05	0.000352171875178334	-0.332996766135371	-0.131123068331108
MIPOL1	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.6251078549155	0.6251078549155	-0.694192976875121	-0.481859441946	-13.2325267988168	5.69457340368576	1.71604506643873e-05	0.000567414722376961	-1.56646841168646	-1.07213325189478
MIPOL1	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.735861414895	-2.735861414895	-3.98368653377804	-3.95467393468	-10.7827030786601	175.520530277657	4.01133713968676e-21	7.31698619414403e-19	-1.47621612027728	-1.01943411748879
MIPOL1	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.1715450590035	-0.1715450590035	0.124839475121236	0.135109067247	6.0663082970735	4.84284959048583	0.0019643377361552	0.0394762815426542	0.169556621745461	0.423212446504011
MIPOL1	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.20785861861	-3.20785861861	-4.38779873633128	-4.37968901574	-13.1496845977869	73.2390664588039	5.80148160138327e-21	1.04753643651464e-18	-1.3587647832603	-1.00111545218226
MIPOL1	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.2338701616	-1.2338701616	-1.70489010943025	-1.55120007366	-6.48029633363192	31.4835987990738	2.93465606001755e-07	1.29526750141578e-05	-0.619169623723303	-0.322870271937195
MIPOL1	BRD-K86972824-001-01-4::2.5::HTS002	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1239275223505	0.1239275223505	0.00693559621824238	-0.004832023318045	-3.86217459618688	195.210674572668	0.000152797406930121	0.00415437212101051	-0.176732983938481	-0.0572508683260341
MIPOL1	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1716093052245	0.1716093052245	-0.49748436994972	-0.41754362105	-10.2559814741486	4.22708890294949	0.000382607992994918	0.00943876479403864	-0.846453294133962	-0.491734056214477
MIPOL1	BRD-K89714990-001-01-5::2.5::MTS006	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.368285936037	0.368285936037	0.134939969086161	0.163955716777	-5.86444114042239	7.07553363594497	0.000597229495677394	0.0140324052377812	-0.327231074663902	-0.139460859237777
MIPOL1	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.520359945625	-2.520359945625	-2.88843726920898	-2.8540109683	-3.38961904590699	170.544102829002	0.000869505078160132	0.0195489514210619	-0.582430074968189	-0.153724572199772
MIPOL1	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.373469810255	-2.373469810255	-3.11500362825148	-3.009227373135	-6.69651584679726	112.737010128815	8.7259357858154e-10	5.2270013723813e-08	-0.960923924710626	-0.522143711282343
MIPOL1	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2710057880075	0.2710057880075	0.101262852919993	0.1180798290625	-6.04803137306714	10.4500628365398	0.000103234910611472	0.00291748881282253	-0.231914321156931	-0.107571549018083
MIPOL1	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-5.015744752625	-5.015744752625	-5.62287063524106	-5.62740406384	-6.03701829605485	124.91389377343	1.66190562330147e-08	8.66864371712293e-07	-0.806162146581828	-0.408089618650289
MIPOL1	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.774904678205	-1.774904678205	-0.0147684420106335	0.0202365059018	25.9588670690843	4.58746586460625	3.7274754650759e-06	0.00013891603007377	1.58101684201426	1.93925563037447
MIPOL1	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.54867197628	-0.54867197628	-0.34284585763932	-0.279710660695	4.61712982385209	12.549969232034	0.000528230840288635	0.0125822613656616	0.109167234426344	0.302485002855016
MIPOL1	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2539277976935	0.2539277976935	0.600715127215243	0.600417589144	9.66206824531036	186.000143736445	3.73414266506523e-18	5.20712467964063e-16	0.275980328124013	0.417594330919472
MIPOL1	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3173326044005	0.3173326044005	0.0663092666576125	0.0390021562258	-9.38695685548861	6.86020514750204	3.67996667510829e-05	0.00113878656873994	-0.314519603686366	-0.187527071799409
MOCOS	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.570753534476	-0.570753534476	0.481914776112109	0.483115092089	22.6700212173858	8.13972336370747	1.20598566986916e-08	6.393215499317e-07	0.945909541793292	1.15942707938293
MOCOS	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.10404018211505	-0.10404018211505	-0.495330787773726	-0.379151386241	-5.4434462948805	6.96414796958498	0.000979322582961922	0.0217307412655188	-0.561444160390385	-0.221137050926967
MOCOS	BRD-A16997652-001-02-3::2.5::HTS002	2.5	protirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	radiology	thyroid function diagnostic	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5580144869045	0.5580144869045	0.332797940480641	0.352492434088	-7.27151747179438	3.88806370494398	0.00211853067920302	0.0421560265474798	-0.312195021406996	-0.138238071440721
MOCOS	BRD-A57382968-001-29-0::2.5::HTS002	2.5	piroxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.336459662363	-0.336459662363	0.0236595928849557	0.0121600555155	10.5961467790613	4.12746248643797	0.000380438259463631	0.00939821942284239	0.266897536502405	0.453340973993506
MOCOS	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.887336337701	-0.887336337701	-1.19169009653702	-1.043529721605	-4.57414509767824	188.300445048146	8.65349865967875e-06	0.000301314997688918	-0.435609127159743	-0.173098390512288
MOCOS	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0949525386296	0.0949525386296	-0.188182254856758	-0.138056758361	-5.05411502737891	8.44558717274601	0.000834218456304214	0.0188843691932009	-0.411141831416207	-0.155127755556509
MOCOS	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.03863290131536	-0.03863290131536	-0.358813927731759	-0.164030729397	-4.57347099733292	17.7601791399363	0.000243195625903059	0.0062974357018457	-0.46740554266099	-0.172956510171808
MOCOS	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.559608587186	0.559608587186	0.197333142971112	0.204355413473	-12.399228840126	47.8108318765503	1.50830797167423e-16	1.81818975962298e-14	-0.421027328752505	-0.303523559677271
MOCOS	BRD-K09397065-003-06-1::2.5::HTS002	2.5	SR-57227A	serotonin receptor agonist	noncancer	HTR3A	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0411364980065	-0.0411364980065	0.248174523939141	0.2503216696235	9.05484397167829	185.721844641087	1.87073686228932e-16	2.24246734316335e-14	0.226277532189849	0.352344511701433
MOCOS	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.254935015464	0.254935015464	-0.290042320001923	-0.2721742756055	-11.0786917649309	2.89396726689617	0.0018524140531513	0.0375634799500266	-0.704822052127123	-0.385132618804722
MOCOS	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.924619854258	-0.924619854258	-1.81298596799242	-1.56065418801	-6.55957388692573	6.0876510993518	0.000566610690136962	0.0133907930980665	-1.21859935187174	-0.558132875597094
MOCOS	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.561921807745	-2.561921807745	-4.15389613177228	-4.14163208451	-11.422713157958	12.4565206240705	5.7830914253815e-08	2.80172740079248e-06	-1.89440399852788	-1.28954464952668
MOCOS	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.7115584330915	-0.7115584330915	-1.65353300321414	-1.461946185705	-7.95653194312739	3.96109662318776	0.00140780251161579	0.0297772529864898	-1.27195527635388	-0.611993863891409
MOCOS	BRD-K13646352-001-03-8::2.5::HTS002	2.5	midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	targeted cancer	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.13769530675	-4.13769530675	-2.94214664046419	-2.8284008656	11.8090790619936	75.9446653629856	7.24177088450756e-19	1.07487639328644e-16	0.993909776646615	1.39718755592501
MOCOS	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.8232604361785	0.8232604361785	-0.0625221320355917	0.1891566141585	-13.6336775659145	195.928255611082	3.34768325139754e-30	1.36407909427525e-27	-1.01391324180118	-0.757651894627008
MOCOS	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.393158769008	0.393158769008	0.083647083024745	0.0959513505756	-8.78643402301394	14.4628480622019	3.52826419308617e-07	1.53513872561909e-05	-0.384837920341577	-0.234185451624933
MOCOS	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.285871503543	0.285871503543	-0.0978921778385604	-0.0311349339001	-8.03133584981762	8.98484374043055	2.16687527003517e-05	0.00070154714463953	-0.491884803331856	-0.275642559431265
MOCOS	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.86943304879	-1.86943304879	-2.36209111979115	-2.30540806626	-5.53049359920483	192.479206758414	1.03166592125831e-07	4.85755547533769e-06	-0.668356982788079	-0.316959159214223
MOCOS	BRD-K18163608-001-05-6::2.48005::HTS002	2.48005	HA14-1	BCL inhibitor	targeted cancer	BCL2	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.537159678958	0.537159678958	-0.0494727582233882	0.0348368088463	-9.50380349122065	6.46399131978175	4.9288689734167e-05	0.00148830594280562	-0.735081161658553	-0.438183712704223
MOCOS	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.5673618652025	-0.5673618652025	-0.87827221556726	-0.806977834222	-4.1699595757685	93.1545313252285	6.82457164109822e-05	0.00200260626405386	-0.458967622666452	-0.162853078063068
MOCOS	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.253491991518	-0.253491991518	-0.823608477151392	-0.81565114113	-9.06805873213555	181.229539835149	1.97925903851032e-16	2.36857962291948e-14	-0.69416947231405	-0.446063498952733
MOCOS	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.34899942432	0.34899942432	-0.216432533146843	-0.0984348398408	-10.0915232829632	31.8887519115323	1.88467162793282e-11	1.36098310425611e-09	-0.679577738875657	-0.451286176058028
MOCOS	BRD-K23984367-075-15-2::2.5::HTS002	2.5	sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.404504935409	-0.404504935409	-0.856584165002736	-0.738304903661	-5.4381748507795	28.6050460921629	7.83850579617117e-06	0.000275458125723491	-0.622202608388255	-0.281955850799216
MOCOS	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.213843065275	-1.213843065275	-2.82209328801086	-2.6496200301	-15.609046454492	186.490984230694	1.10840964345373e-35	7.42388532724359e-33	-1.81151065471468	-1.40498979075704
MOCOS	BRD-K28578425-001-07-0::2.5::HTS002	2.5	cilostamide	phosphodiesterase inhibitor	targeted cancer	PDE3A, PDE3B	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2948146933465	0.2948146933465	-0.0908480204567051	-0.0710584788856	-11.414390600775	186.005836771161	3.2566289813142e-23	7.16622210406665e-21	-0.452318509633822	-0.319006917972588
MOCOS	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4000747442545	0.4000747442545	-0.622745343938919	-0.480230640816	-14.0124941264335	11.8043586180434	1.02658446035131e-08	5.47466585724399e-07	-1.18215195575093	-0.863488220635904
MOCOS	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.178838346615	-0.178838346615	-1.03854860139542	-1.017015264785	-11.3474607940663	58.0478607075392	2.3048522199113e-16	2.73985951991885e-14	-1.01136240587386	-0.708058103686984
MOCOS	BRD-K38305202-001-17-4::2.5::HTS002	2.5	domperidone	dopamine receptor antagonist	noncancer	DRD2, DRD3	infectious disease	fescue toxicosis	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1716135598115	0.1716135598115	-0.363164630550496	-0.225769257521	-6.56297058164078	4.16614001420492	0.00241508915585344	0.0471467022210505	-0.757500445799638	-0.312055934924354
MOCOS	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1811279602395	0.1811279602395	-0.148721491740198	-0.07517274316945	-7.29268394541063	148.479694413442	1.68354690855308e-11	1.22482323612788e-09	-0.419227459942179	-0.240471444017218
MOCOS	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.059129087125	-3.059129087125	-1.72648329756616	-1.64538262922	15.380784830678	15.5969655794996	7.67559866282968e-11	5.15868104674074e-09	1.14858316983618	1.51670840928151
MOCOS	BRD-K50388907-001-30-4::2.5::HTS002	2.5	fenofibrate	PPAR receptor agonist	noncancer	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.373484853659	0.373484853659	0.196092523819332	0.187372218959	-6.60249623616766	64.7162742552217	8.83542583509608e-09	4.74370737427432e-07	-0.231054820693025	-0.123729838986311
MOCOS	BRD-K50853363-001-02-3::2.5::HTS002	2.5	dienogest	progesterone receptor agonist	noncancer	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4881153782235	0.4881153782235	-0.285265899019272	-0.2219400984365	-12.8707503283715	7.10696166163236	3.49677336221566e-06	0.000131047375056884	-0.91503513431175	-0.631727420173794
MOCOS	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.143017672301	-0.143017672301	0.205681405709371	0.242605983944	8.66451193524249	7.80927643804128	2.83892447962274e-05	0.00089704237769875	0.255499057520893	0.441899098499849
MOCOS	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.12123720662535	-0.12123720662535	0.261593404664725	0.257282112096	10.3861550674155	7.84083168190828	7.41272638158906e-06	0.000261309577736777	0.297530699984926	0.468130522595224
MOCOS	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.50477189564	0.50477189564	0.13396293389775	0.1526722270265	-11.6699656951188	5.33432557211227	5.33145646160284e-05	0.00160039667919619	-0.45097229044778	-0.290645633036719
MOCOS	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.6560910473005	0.6560910473005	0.109905345064266	0.147357951686	-19.0640333238776	73.0851227386488	4.40203759517438e-30	1.78690211313661e-27	-0.603284069479164	-0.489087334993304
MOCOS	BRD-K55966568-001-05-4::2.5::HTS002	2.5	orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.431434751537	0.431434751537	0.318334204102344	0.334471064367	-4.31802506397511	89.0112971772287	4.07706557102829e-05	0.00125173096515245	-0.165144707049786	-0.0610563878195251
MOCOS	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.5291975670755	-0.5291975670755	-1.04564217000838	-1.14416779162	-6.60709230641946	175.286406513179	4.52835010765888e-10	2.79136252581082e-08	-0.67071063425964	-0.36217857160613
MOCOS	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.168091384145	-2.168091384145	-1.3207077763836	-1.441894150425	13.0237720371129	22.8798319591089	4.58131806700635e-12	3.56668841258047e-10	0.7127485628868	0.982018652635991
MOCOS	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.774807769025	-4.774807769025	-3.62815611870216	-3.494830245985	7.04045979083283	4.01770665663063	0.00211004801574848	0.0420145374551612	0.695247955183487	1.59805534546219
MOCOS	BRD-K60230970-001-17-5::2.40205::HTS002	2.40205	MG-132	proteasome inhibitor	targeted cancer	PSMB1	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.911888638155	-4.911888638155	-6.17577903587989	-6.116258820345	-18.4569892657277	185.88912810318	6.79002827816311e-44	9.89999980156749e-41	-1.39898354987928	-1.1287972455705
MOCOS	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.169348000774	0.169348000774	-0.254714010202772	-0.132231172134	-5.9664360649951	4.92111938917635	0.00199914284488851	0.0400930370358482	-0.607649430940049	-0.240474591013495
MOCOS	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.9112782513	-1.9112782513	-1.47547215047834	-1.34809352963	5.26508723003689	6.56511819085358	0.00142923622112478	0.0301740317215773	0.237420288563032	0.634191913080286
MOCOS	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2543644483565	-0.2543644483565	-0.606571289370671	-0.456560974373	-5.65372802893068	189.927762090277	5.68954324125132e-08	2.75890070894605e-06	-0.475088523669331	-0.229325158359012
MOCOS	BRD-K66030860-001-03-6::2.5::HTS002	2.5	salidroside	beta amyloid protein neurotoxicity inhibitor	noncancer	APP	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.28442388178	0.28442388178	0.131561196759424	0.132086067756	-5.29675878988739	50.1292468776447	2.6314129202593e-06	0.000100730148202582	-0.210825325667109	-0.094900044374043
MOCOS	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3823996694075	0.3823996694075	0.253947079795347	0.248858708206	-6.30094201000901	190.947939038849	1.99641920657459e-09	1.14962528781818e-07	-0.168663766057691	-0.0882414131666145
MOCOS	BRD-K68507560-003-24-6::2.5::HTS002	2.5	dicycloverine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.791322186957	0.791322186957	0.224884205748302	0.216100311033	-16.4449416280493	23.7662013890241	1.74466723719225e-14	1.73036920074122e-12	-0.637564985760892	-0.495310976656504
MOCOS	BRD-K69172251-001-08-9::2.5::HTS002	2.5	cisplatin	DNA alkylating agent, DNA synthesis inhibitor	chemo	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.638861217442	0.638861217442	0.378517770490663	0.369534361464	-9.01081293667796	16.031206619769	1.12830779221671e-07	5.28357178933831e-06	-0.321582777372845	-0.199104116529828
MOCOS	BRD-K69932463-001-10-6::2.5::HTS002	2.5	AZD8055	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.569726255685	-3.569726255685	-2.73264822610073	-2.73243511548	13.5006731985647	182.435860989151	3.00576908476623e-29	1.15867532764184e-26	0.714743469146488	0.95941259002205
MOCOS	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.363758982259	-0.363758982259	-0.79189331543048	-0.646845557406	-6.34795711988342	123.637557338387	3.76428530284573e-09	2.10706582573419e-07	-0.561629603303352	-0.294639063039607
MOCOS	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.273644076497	0.273644076497	-0.668943601402851	-0.50591048476	-10.6031496788161	3.68558834487096	0.000680607298660422	0.0157531189756576	-1.19793504056288	-0.687240315236823
MOCOS	BRD-K78126613-001-28-5::2.5::HTS002	2.5	menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	noncancer	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1576362444435	0.1576362444435	-0.127857519654504	-0.050497524351	-6.13132221889888	45.8262046291075	1.86518561348226e-07	8.45881014287009e-06	-0.379230145840825	-0.191757382355183
MOCOS	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.892607106215	-2.892607106215	-4.14573716864134	-4.26693586682	-8.61846246505304	5.4015738859201	0.000234418563080373	0.00608928568736557	-1.61868925372669	-0.887570871125983
MOCOS	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.42580247183	-1.42580247183	-0.938063484074172	-0.8093705059295	7.08043981166493	29.2803368641117	8.18911985774357e-08	3.89258343311227e-06	0.34691107649041	0.628566899021246
MOCOS	BRD-K84663978-003-02-9::2.5::HTS002	2.5	trequinsin	phosphodiesterase inhibitor	noncancer	PDE5A	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.193513088259	0.193513088259	-0.047706861332059	-0.0657758455345	-9.05039050165635	50.2725485111583	3.93379874871395e-12	3.08837784620188e-10	-0.294746861463626	-0.187693037718492
MOCOS	BRD-K85849709-001-01-5::2.5::HTS002	2.5	AZD2858	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.567495330706	-0.567495330706	-1.75168208909502	-1.58142257926	-8.3684087248917	3.58902014754677	0.00176631362619002	0.0360957506853243	-1.59546780525221	-0.772905711525833
MOCOS	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.645167656015	-5.645167656015	-4.83340659092214	-4.95161811894	8.64449267641992	117.699622486164	3.17393081303269e-14	3.06702171878487e-12	0.625798687660756	0.997723442524965
MOCOS	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.6397353456	-0.6397353456	-0.307716988307854	-0.0918736144378	4.36785555520404	148.74675948127	2.33981182553679e-05	0.000752309524085621	0.181811514191198	0.482225200393094
MOCOS	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0070714331906	-0.0070714331906	-0.366374154955804	-0.291376214184	-5.05332600364658	10.2878317815715	0.000455150300400884	0.0110315400581953	-0.517129594616513	-0.201475848913894
MOCOS	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5290993422675	0.5290993422675	0.0941631726642207	0.163411081458	-12.7111868956943	189.420193223849	3.61514110804471e-27	1.09904904758314e-24	-0.502431100748185	-0.367441238458374
MOCOS	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.504982746564	0.504982746564	0.304836782704967	0.301488629615	-7.769625478776	155.917307497393	9.8796706419638e-13	8.23609462863267e-11	-0.251029685636433	-0.149262242081633
MOCOS	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.3232409510935	-0.3232409510935	0.305397562685023	0.276885156297	17.7753016140148	194.645868457832	1.24947369273823e-42	1.63291736031032e-39	0.558889063915145	0.698387963641901
MOCOS	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.349491054197	0.349491054197	-0.0385047071771363	0.00448333894144	-6.4654752512379	13.5168841295503	1.75580791894053e-05	0.000579489614195573	-0.517138194182423	-0.25885332856585
MOCOS	BRD-K95581532-001-01-5::2.5::HTS002	2.5	RN-1734	TRPV antagonist	noncancer	TRPV4	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.14525938259	-2.14525938259	-2.42024355082419	-2.37248540058	-3.12736043374516	74.1217234699692	0.00252046309047473	0.0489057230393925	-0.450180784310972	-0.0997875521574039
MOCOS	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.07764889300055	0.07764889300055	-0.349473591705781	-0.28220904824	-9.23627677766208	8.87722736233368	7.59083088102791e-06	0.000267077352295467	-0.531954661955508	-0.322290307457154
MOCOS	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.52770767595	-0.52770767595	-0.863998747583816	-0.791872957089	-7.20499902644133	61.4482242565479	9.92265955954727e-10	5.90589753051432e-08	-0.429609109198763	-0.24297303406887
MOCOS	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.149832498169	-0.149832498169	-0.0211105880762713	0.015242959648	4.58208076129127	190.190602394198	8.31703652360136e-06	0.000290891338294216	0.0733091014660472	0.18413471871941
MOCOS	BRD-K99964838-001-11-9::2.5::HTS002	2.5	bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	targeted cancer	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.399637806285	-1.399637806285	-0.382718226784878	-0.266678994425	17.5303088088856	133.527080742377	1.92470425084945e-36	1.44743837677303e-33	0.902183742936881	1.13165541606336
MOCOS	BRD-M97302542-001-03-6::2.5::HTS002	2.5	dichloroacetate	pyruvate dehydrogenase kinase inhibitor	targeted cancer	PDK1	NA	NA	CAKI1, TE11	KIDNEY, OESOPHAGUS	carcinoma (clear_cell_renal_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2405621111325	0.2405621111325	-0.264938735376001	-0.170283353784	-9.16038275347775	5.27176342620986	0.000196011953844573	0.00518847055150717	-0.645182716602272	-0.36581897641473
MRPL33	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0814256497674	-0.0814256497674	0.255889512291239	0.256070233499	12.7996931385887	188.932463773628	2.04158071516981e-27	6.44037194162012e-25	0.285330496940046	0.389299827177232
MRPL33	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2989282738485	0.2989282738485	0.1424669745969	0.135666555282	-5.37135891253131	26.528900993391	1.18767280355863e-05	0.000403347685491866	-0.216278383603559	-0.0966442148996415
MRPL33	BRD-A72703248-003-04-9::2.5::HTS002	2.5	SKF-96365	calcium channel blocker	noncancer	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.375410673665	-4.375410673665	-3.5293915094966	-3.53004479557	7.02461082784411	36.8573730410533	2.68389761635699e-08	1.35733150593718e-06	0.601959865485047	1.09007846285176
MRPL33	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.6178923385475	-0.6178923385475	-1.13018225550916	-1.042052398785	-9.01494744941377	178.677094018975	2.99914348207396e-16	3.51835480771445e-14	-0.624427776525376	-0.400152057397947
MRPL33	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2008029219835	0.2008029219835	-0.0524848710690803	-0.0230394948173	-7.22307523783499	14.4786156266497	3.63033122813154e-06	0.000135673105805441	-0.328265324886201	-0.17831026121896
MRPL33	BRD-A93695607-322-02-5::2.4707::HTS002	2.4707	nicotine	acetylcholine receptor agonist	noncancer	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.1635777740565	-0.1635777740565	0.127897549904359	0.1533689039075	8.44795187467829	175.599561926449	1.09200991077317e-14	1.09919170812056e-12	0.223382410451325	0.359568237470393
MRPL33	BRD-A95696066-003-13-8::2.5::HTS002	2.5	nisoxetine	norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.643256236624	0.643256236624	0.335239418909125	0.334888037039	-12.3156541484506	12.2007239594958	3.03547484944484e-08	1.52505928037193e-06	-0.362410070477245	-0.253623564952505
MRPL33	BRD-K01507359-001-22-9::2.5::HTS002	2.5	rifampin	RNA polymerase inhibitor	noncancer	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2413738165815	-0.2413738165815	-0.0923129634751387	-0.0471468975624	5.24881310599123	192.944256734624	4.01634999639275e-07	1.73797754568314e-05	0.0930485752494091	0.205073130963313
MRPL33	BRD-K03549949-001-01-0::2.5::HTS002	2.5	XL388	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.6736523850145	-0.6736523850145	-1.33729853774496	-1.14186011868	-9.17597877109155	144.654517310168	4.20549131092902e-16	4.86694787894225e-14	-0.806595060857907	-0.520697244603018
MRPL33	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.07293826275	-1.07293826275	-0.284125507529443	-0.201937004263	14.7723543205569	113.279538757902	3.54549296480474e-28	1.22170733384829e-25	0.683024702130309	0.894600808310804
MRPL33	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.8255463329	-1.8255463329	-0.838399051715067	-0.6898846907305	17.9341961875028	53.0035158513184	3.64260118960579e-24	8.6649841328193e-22	0.876745698674801	1.09754886369507
MRPL33	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1304224379215	0.1304224379215	0.337973279621533	0.348412196747	7.1685190444199	157.8192182791	2.74942965037589e-11	1.9493301605538e-09	0.150365299818996	0.264736383581071
MRPL33	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.389588358995	-3.389588358995	-4.14509116846111	-4.14163208451	-5.23259610158583	9.40235672187663	0.000468335569607617	0.0113101852730626	-1.08000372158748	-0.431001897344731
MRPL33	BRD-K13646352-001-03-8::2.5::HTS002	2.5	midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	targeted cancer	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.26062874048	-4.26062874048	-2.94085937937801	-2.8284008656	12.0463949641177	18.1679002856729	4.23128482451362e-10	2.61576880632587e-08	1.0897505929015	1.54978812930248
MRPL33	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.208070514635	-0.208070514635	-0.0531576347347893	-0.0356049990197	3.40327235360007	186.721152960625	0.000814745442720635	0.0184982601687363	0.0651156534731415	0.24471010632728
MRPL33	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.73266462031	-3.73266462031	-1.0744282405351	-0.864735754699	23.1647956850166	12.5400463610508	1.14000809129365e-11	8.47802894513802e-10	2.40939946904509	2.90707329050471
MRPL33	BRD-K17743125-001-08-4::2.5::MTS010::PROS003_PR500	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.991241217004	-0.991241217004	-0.674005693997355	-0.579023272912	3.80446059319771	187.88321839399	0.000192117073453015	0.00510049055321583	0.152744083162711	0.481726962850578
MRPL33	BRD-K18424115-003-01-3::2.5::HTS002	2.5	TG-100572	src inhibitor, VEGFR inhibitor	targeted cancer	KDR, SRC	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.70879505413	-1.70879505413	-1.19825911490459	-1.10820806652	6.52458529907966	7.96427556722102	0.000186943936518331	0.00497609376180295	0.329954680336931	0.691117198113884
MRPL33	BRD-K19412355-001-01-0::2.5::HTS002	2.5	SB-242235	p38 MAPK inhibitor	noncancer	HSPB1, MAPK14	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.416440473632	0.416440473632	0.110485920185357	0.111624443211	-7.99034423501344	10.3297873180556	9.75877136006118e-06	0.000336863860014584	-0.390903410881014	-0.221005696012272
MRPL33	BRD-K28192623-066-08-1::2.5::HTS002	2.5	spiradoline	opioid receptor agonist	noncancer	OPRK1	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.865788689065	-3.865788689065	-2.30572037973818	-2.11804571815	19.6187377262619	188.903772153351	1.87942641283167e-47	3.5647396781929e-44	1.40320841271422	1.71692820593943
MRPL33	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.153572404795	-2.153572404795	-1.33184784936658	-1.36979496737	11.0168835292116	19.3683844256068	8.72002875542205e-10	5.22638434877196e-08	0.665811325811757	0.977637785045093
MRPL33	BRD-K29582115-066-01-2::2.5::HTS002	2.5	ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1166285964465	0.1166285964465	0.265909995650382	0.27385544783	4.02918800537574	44.7861263038963	0.000214106812410249	0.00561543061638232	0.0746490399497655	0.223913758457999
MRPL33	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.518395731955	-3.518395731955	-2.20667066541629	-2.23277244437	10.9573626481864	21.9524226182892	2.28737260443659e-10	1.45431706596348e-08	1.06342689018123	1.56002324289618
MRPL33	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4373807799175	0.4373807799175	0.762149631252518	0.7663988354595	10.0190713481885	38.9507905091034	2.45881910580108e-12	1.97155346100725e-10	0.259200544682046	0.390337157987989
MRPL33	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	1.01013387167	1.01013387167	0.569920953338576	0.566004994618	-13.5211168121601	121.606150020477	5.43635361985914e-26	1.49764554626065e-23	-0.504665708924334	-0.375760127738513
MRPL33	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.01951653379	-2.01951653379	-2.59295477927761	-2.52528636523	-5.26340896749575	27.7846289659098	1.38087488936222e-05	0.000463962273337694	-0.796686209266684	-0.350190281708531
MRPL33	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.853295618035	-1.853295618035	-2.62612834210246	-2.459947367395	-6.6003795081705	5.86870596745325	0.000636508071621953	0.0148236595113182	-1.0609004388094	-0.484765009325509
MRPL33	BRD-K38904395-001-02-3::2.5::HTS002	2.5	SAR131675	VEGFR inhibitor	targeted cancer	FLT4	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.961329740923	-0.961329740923	-0.528062451812496	-0.519013652075	9.23718631205348	164.139834400311	1.26394601890468e-16	1.52878265398318e-14	0.340652958647467	0.525881619573541
MRPL33	BRD-K39558284-001-01-2::2.5::HTS002	2.5	SDZ-WAG-994	adenosine receptor agonist	noncancer	ADORA1	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.191694104517	0.191694104517	0.297733549459808	0.3288329829755	3.75536367234715	191.313699265229	0.000229600873332334	0.00597572866793512	0.0503440167028636	0.161734873182752
MRPL33	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.08507854092845	0.08507854092845	-0.207886597598676	-0.158031671069	-8.61926872232727	188.485345659696	2.70572756383567e-15	2.88802730592298e-13	-0.360013954065056	-0.225916322989196
MRPL33	BRD-K40797222-001-01-8::2.5::HTS002	2.5	SC-12267	dihydroorotate dehydrogenase inhibitor	noncancer	IL17A	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.361317029245	0.361317029245	0.185257683699985	0.184399160559	-5.8831093871566	4.91227603083261	0.00213971112972583	0.0425201090166104	-0.253402241178324	-0.0987164499117054
MRPL33	BRD-K47337578-034-02-5::2.5::HTS002	2.5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	noncancer	HTR2A	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.04479213226535	0.04479213226535	-0.126484811902174	-0.101623022714	-4.32636969954762	105.407425319225	3.45595775332131e-05	0.00107458576717192	-0.249771216408489	-0.0927826719265599
MRPL33	BRD-K50018155-003-02-1::2.5::HTS002	2.5	RS-67506	serotonin receptor partial agonist	noncancer	HTR4	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.616734034713	0.616734034713	0.295918260080452	0.322728889347	-8.34583179834881	133.161184325404	7.9329542304505e-14	7.35089557828891e-12	-0.396848234772021	-0.244783314493074
MRPL33	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.3579673971405	-0.3579673971405	-0.0988401077793808	-0.09755826700195	5.22488396993123	22.4262031468077	2.88768557928552e-05	0.000910838502608808	0.15638709842403	0.361867480298208
MRPL33	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.159024224325	-1.159024224325	-0.758431909438167	-0.600108513836	5.33962216779825	23.9807073319124	1.76751016758406e-05	0.000582992746549899	0.245746695274406	0.555437934499259
MRPL33	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.9202754329725	-0.9202754329725	-0.286296170336264	-0.3736278329815	9.32410822889708	170.310118601747	5.80805613289404e-17	7.27123167585891e-15	0.499760601765142	0.768197923507329
MRPL33	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.03190549801955	0.03190549801955	-0.711272663775808	-0.5410189846345	-10.0881082144207	40.8254059592843	1.18962788936061e-12	9.86351086649011e-11	-0.891974513743217	-0.594381809847499
MRPL33	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.953938142092	-0.953938142092	-0.683638109041773	-0.630554296997	5.05156399041908	191.969728583434	1.01613033756854e-06	4.13884832992642e-05	0.164760566261308	0.375839499839145
MRPL33	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.065798779443	-0.065798779443	-0.210345930989694	-0.1382371077965	-3.90229765248895	187.998852220188	0.0001326355576667	0.00365534864846937	-0.217617637146889	-0.0714766659464987
MRPL33	BRD-K62696033-001-01-4::2.5::HTS002	2.5	G-1	G protein-coupled receptor agonist	targeted cancer	GPER1	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.607753845408	-0.607753845408	-1.25401417602254	-1.18405970294	-7.15480033552265	9.520455079069	3.99327390771693e-05	0.00122758807138133	-0.848900504980375	-0.443620156248711
MRPL33	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.463905475228	-0.463905475228	-0.167830728784783	-0.0695637223616	5.77457829313961	90.1859899520168	1.08172023128498e-07	5.077617508784e-06	0.194216635750178	0.397932857136256
MRPL33	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.357270004515	-1.357270004515	-0.776424440196937	-0.683338343709	9.05103570144211	80.9738511952405	6.3140703854019e-14	5.91213801499696e-12	0.453157842039026	0.7085332865971
MRPL33	BRD-K67772619-001-05-1::2.5::HTS002	2.5	rheochrysidin	protein tyrosine kinase inhibitor	targeted cancer	PTPN1	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.201438484584	0.201438484584	0.018894436161803	0.07194686545995	-4.57727184270797	191.420999177669	8.46099958681056e-06	0.000295396250275537	-0.261205784147988	-0.103882312696406
MRPL33	BRD-K68103045-001-02-9::2.5::HTS002	2.5	CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.678724212727	0.678724212727	0.444543067258652	0.4684149214555	-8.4710555880334	189.002453946372	6.73835538501175e-15	6.91678626108326e-13	-0.288713255631048	-0.17964903530565
MRPL33	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.503291371145	-3.503291371145	-3.10075488240645	-3.15624915805	4.22815451651238	129.232444361521	4.42405896131102e-05	0.00134841315858764	0.214176594128534	0.590896383348567
MRPL33	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.07035322764325	0.07035322764325	-0.153665387499941	0.0566391407425	-3.53706661161007	177.918818440265	0.000516030594649591	0.0123231555789028	-0.34900224790241	-0.0990349823839715
MRPL33	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.491397878445	-1.491397878445	-1.18662730113664	-1.06477540936	4.15233919020959	110.023071657475	6.51902003288282e-05	0.00192162707279293	0.159314651627126	0.450226502989585
MRPL33	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.833036058475	-2.833036058475	-1.31569387680459	-1.061822092665	16.2007136535824	27.8299062452339	1.06216958340591e-15	1.17589744133164e-13	1.32543763464737	1.70924672869344
MRPL33	BRD-K75911534-001-01-6::2.5::HTS002	2.5	SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.1662823155145	-0.1662823155145	-0.525712829335625	-0.4139887396705	-6.25077974650743	128.655906113641	5.53809833479059e-09	3.04508742431332e-07	-0.473201932998849	-0.245659094643401
MRPL33	BRD-K78318619-001-02-7::2.5::HTS002	2.5	PF-4981517	cytochrome P450 inhibitor	noncancer	CYP3A4	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.542575695925	-1.542575695925	-0.577522957077321	-0.46824260427	9.2487248793718	4.30209954164246	0.00053502192709584	0.0127228131157799	0.683195626575311	1.24690985112005
MRPL33	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.423452954705	-3.423452954705	-3.97659796120268	-3.95467393468	-4.57524389298987	65.6658909764704	2.1682454567588e-05	0.00070177873829909	-0.794551706772651	-0.311738306222699
MRPL33	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.684303473715	-1.684303473715	-2.51257999505303	-2.254263331985	-7.61029245391869	163.219190200616	2.06725623556213e-12	1.66819639198718e-10	-1.0431853169503	-0.613367725725755
MRPL33	BRD-K84868168-001-01-0::2.5::MTS006	2.5	erdafitinib	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.534892357937	0.534892357937	0.0842181736373366	0.13174233615	-9.47926697405875	7.81104519002166	1.484301792598e-05	0.000496068796048239	-0.560772239306145	-0.340576129293181
MRPL33	BRD-K89053832-001-01-0::2.5::HTS002	2.5	VLX600	ubiquitin C-terminal hydrolase inhibitor	targeted cancer	USP14	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.00832912655	-3.00832912655	-2.05595730496099	-1.884641143255	6.88982485069458	5.09199979306762	0.000916117932296951	0.0204980311422145	0.598965833136666	1.30577781004136
MRPL33	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.465237718025	-3.465237718025	-4.01816080090524	-3.85901121156	-4.1735067436847	15.6194415687873	0.000752139320465119	0.0172227850871761	-0.834333889181573	-0.271512276578904
MRPL33	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.67544789458	-2.67544789458	-1.58415661750587	-1.34116610852	15.0595741502625	190.04217226492	3.0157784068263e-34	1.79546880599076e-31	0.948352325709459	1.23423022843881
MRPL33	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.6902606156655	-0.6902606156655	-0.221466724373787	-0.144721351966	5.91300701209754	5.65253261699184	0.00128778350175284	0.0275733616530653	0.271870612839052	0.665717169744374
MRPL33	BRD-K98572433-001-02-9::2.5::HTS002	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.61504077295	-3.61504077295	-2.69965948803231	-2.69732165055	8.50415023470945	11.8705467048287	2.15700630432533e-06	8.36909855538998e-05	0.680571291035882	1.1501912787995
MRPL33	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	MKN1, KYSE30	STOMACH, OESOPHAGUS	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.372885279409	0.372885279409	0.245699522241397	0.250792854427	-4.18526404690368	65.3200695200287	8.68925967114489e-05	0.00249579246322275	-0.187871033166853	-0.0665004811683523
MYH9	BRD-A12417644-001-07-6::2.3139::HTS002	2.3139	usniacin-(+)	MAP kinase activator	targeted cancer	PTPN1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.0768609468804	-0.0768609468804	0.173779201291393	0.1617912757505	8.72602160272615	187.999915925614	1.40219080820634e-15	1.53802535175055e-13	0.193978763012106	0.30730153333148
MYH9	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.331027721789	0.331027721789	0.171324368114997	0.1532922606755	-6.38778419715305	187.196850423108	1.29815699618433e-09	7.63955768355823e-08	-0.209023993578086	-0.110382713769919
MYH9	BRD-A28329383-001-02-1::2.5::HTS002	2.5	MTPG	glutamate receptor antagonist	noncancer	GRM2, GRM3	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.2842141850165	-0.2842141850165	0.0257882417620495	0.05552529169545	7.18790362425353	6.6090917841779	0.0002352031835591	0.00610596694876918	0.206784461712436	0.413220391844663
MYH9	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.6796689856665	-0.6796689856665	-1.02938281960449	-0.797857785181	-3.89458685709869	22.2992948436123	0.000764304416063689	0.0174643740079677	-0.535792141518115	-0.163635526357859
MYH9	BRD-A68631409-001-05-4::2.5::HTS002	2.5	evodiamine	ATPase inhibitor, TRPV agonist	targeted cancer	TRPV1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.66302354913	-2.66302354913	-2.37403283749664	-2.292575025235	3.2143698454914	186.95349490153	0.00154008829682909	0.0321595464313212	0.111630328026019	0.466351095240692
MYH9	BRD-A88138582-001-04-8::2.5::HTS002	2.5	halcinonide	glucocorticoid receptor agonist	noncancer	NR3C1	dermatology	corticosteroid-responsive dermatoses	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.0221404927004	-0.0221404927004	0.287294802314391	0.271498437294	8.8355507824347	190.91115160183	6.49042804789718e-16	7.34082824843142e-14	0.240356277326976	0.378514312702606
MYH9	BRD-A94756469-001-04-7::2.5::HTS002	2.5	digoxin	ATPase inhibitor	noncancer	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-5.347250517025	-5.347250517025	-5.67494366792926	-5.6771282936	-4.10419927771457	154.988195972596	6.54032383560569e-05	0.00192711172307057	-0.48541483479863	-0.169971467009891
MYH9	BRD-K03765900-001-01-9::2.5::MTS006	2.5	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.5217857259735	-0.5217857259735	-1.17359605840249	-0.823393929272	-6.53276174942324	12.2112204942557	2.57438558112126e-05	0.000822548748408523	-0.86878640666419	-0.434834258193789
MYH9	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.6917597276365	-0.6917597276365	-0.3762649902617	-0.261056095384	5.25356566514518	80.2539118875255	1.19957607041478e-06	4.84005910383902e-05	0.195990369684647	0.434999105064953
MYH9	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-3.230514548075	-3.230514548075	-4.28503530583084	-4.26036322773	-15.7373127358596	73.1731751899455	3.44127539021713e-25	8.94018318921028e-23	-1.18806153963628	-0.920979975875391
MYH9	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.145438564894	-0.145438564894	-0.357677697268156	-0.164030729397	-3.4134603188564	176.796881027672	0.000795312047211753	0.0180992180682574	-0.334943988296552	-0.0895342764517603
MYH9	BRD-K05445342-001-05-3::2.56563::HTS002	2.56563	WP1066	STAT inhibitor	targeted cancer	STAT3	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-4.787764599615	-4.787764599615	-5.16849222065084	-5.12208699866	-6.25139396116918	89.6659418978062	1.34744538986668e-08	7.11321731440234e-07	-0.501727876291247	-0.259727365780428
MYH9	BRD-K09372874-001-01-0::2.5::HTS002	2.5	merimepodib	inosine monophosphate dehydrogenase inhibitor	noncancer	IMPDH1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.130518062305	-1.130518062305	-0.897681592673786	-0.886556137179	3.77132711717868	14.8652290855269	0.00187515272734218	0.0379652001604498	0.101139764406004	0.364533174856425
MYH9	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.333931583775	-1.333931583775	-2.45947494297469	-2.47219362388	-10.4575383849648	16.1844339640339	1.31079673032666e-08	6.92657180508339e-07	-1.35349732696435	-0.89758939143503
MYH9	BRD-K12932420-001-02-3::2.5::HTS002	2.5	YM-976	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.1287653165965	-0.1287653165965	0.31757613915725	0.348254117444	11.177076075792	10.4445601489068	3.85628612156084e-07	1.67208971909369e-05	0.357874427977894	0.534808483529606
MYH9	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.096555197925	-1.096555197925	-0.412323521250785	-0.389042162364	13.6441830562091	3.21905979435604	0.000587338664193184	0.0138377747835681	0.530609135763376	0.837854217585053
MYH9	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.701733823885	-2.701733823885	-2.05951070636205	-2.351388502545	5.36203111842652	7.22139037498833	0.00094868741244914	0.0211338885158821	0.360757169857252	0.923689065188652
MYH9	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.27158396875	-2.27158396875	-3.53309504654459	-3.39005054237	-9.3886695495079	36.649981234621	2.73268570858631e-11	1.94118063955487e-09	-1.5338487583406	-0.98917339724859
MYH9	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.8516468920555	-0.8516468920555	-0.563210057618113	-0.546522000374	7.9748497429713	59.4305646729392	5.75535068422665e-11	3.91226944750908e-09	0.216075183191568	0.360798485683205
MYH9	BRD-K17472821-001-01-2::2.5::MTS006	2.5	GSK2830371	protein phosphatase inhibitor	targeted cancer	PPM1D	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.0288180587388	0.0288180587388	0.215918762092547	0.228521183111	9.87598460402282	190.930234716236	7.63743694974936e-19	1.12813523363393e-16	0.149732288942301	0.224469117765194
MYH9	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.537420445468	0.537420445468	0.320942185822964	0.339932692016	-5.65366551865473	6.95824664868023	0.000787929371267853	0.0179559930052597	-0.307129726909239	-0.125826792380832
MYH9	BRD-K19284129-001-02-6::2.5::HTS002	2.5	salvinorin-a	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.3656067954855	-0.3656067954855	0.0169475459115773	0.02724514887165	8.79465506583098	9.00560663835885	1.02661912588428e-05	0.00035273204654	0.284163225888384	0.480945456905771
MYH9	BRD-K19687926-379-07-4::2.5::HTS002	2.5	lapatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2	oncology	breast cancer	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.1442661692515	-0.1442661692515	-0.664249161160382	-0.522756667285	-7.69516602912469	8.90176979714877	3.20629726231727e-05	0.00100189894435807	-0.673100528501699	-0.366865455316066
MYH9	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.6358714141135	-0.6358714141135	-0.442185450314307	-0.343450980127	3.9368964561175	10.5758298162983	0.00250489940918476	0.0486517975053158	0.0848704821442327	0.302501445454153
MYH9	BRD-K21361524-001-01-1::0.625::MTS006	0.625	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.46021979704	-2.46021979704	-2.750511075732	-2.60110257698	-3.4281788183337	148.614669447109	0.000786381269387498	0.0179245252671013	-0.457619647296114	-0.122962910087895
MYH9	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.14268236402205	-0.14268236402205	-0.862754481576931	-0.55802362728	-5.75625453781494	4.92931394548109	0.00232735629487824	0.0456836658416483	-1.0430280385757	-0.397116196534063
MYH9	BRD-K25412176-001-01-9::2.5::MTS006	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.351078660703	-0.351078660703	-0.66582608831096	-0.516853765181	-4.64954828976443	7.6475078044098	0.00185466024114946	0.0376000259955849	-0.472111850431203	-0.157383004784717
MYH9	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.477039871647	-0.477039871647	-1.0421135641659	-0.8676646214495	-7.60676415177969	187.838578324542	1.31279459244355e-12	1.08385960016885e-10	-0.711615109495494	-0.418532275542313
MYH9	BRD-K26756394-001-02-2::2.5::HTS002	2.5	VE-821	ATR kinase inhibitor	targeted cancer	ATR	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.0542732590731	0.0542732590731	-0.116922761142865	-0.0693224120433	-3.98413677992387	29.3240975880726	0.000411366097480898	0.0100625067686582	-0.259036167369983	-0.0833558730619463
MYH9	BRD-K28143534-001-02-2::2.5::HTS002	2.5	cyproheptadine	histamine receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.212490623499	-0.212490623499	-0.002677347534356	0.0299978587143	6.22963091474481	13.6899705448968	2.43438743831061e-05	0.000781311508334345	0.13742332337681	0.282203228552478
MYH9	BRD-K31812033-003-11-0::2.5::HTS002	2.5	levobunolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.0255966517638	0.0255966517638	0.175113458128973	0.217104915628	4.22958561942273	175.101605958957	3.76721339899416e-05	0.00116360149962966	0.0797494422187393	0.219284170511607
MYH9	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.326666892569	0.326666892569	0.240352400435006	0.2536769304835	-3.1685641057978	101.990246183295	0.0020220701111856	0.0404769377266848	-0.140346721465384	-0.0322822628026047
MYH9	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.356684424781	-0.356684424781	-0.69337484051676	-0.621232482709	-5.74850330821611	9.85987424621139	0.000195822049183901	0.00518472439524846	-0.467444565982339	-0.205936265489181
MYH9	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.03565274856995	0.03565274856995	0.258455316228728	0.300751796019	6.86241128550635	147.445030256127	1.74579121169936e-10	1.12533438981146e-08	0.158641617849835	0.286963517467722
MYH9	BRD-K43236057-001-07-1::2.59978::HTS002	2.59978	polydatin	ICAM1 expression inhibitor	noncancer	ICAM1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.727141774892	-0.727141774892	-1.31970072660678	-1.21412289307	-6.3948495748637	7.19205026519401	0.000329842784612459	0.00825585357739154	-0.810489012493965	-0.374628890935593
MYH9	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.21228907585	-1.21228907585	-1.83601282310702	-1.58248812639	-5.29981591981565	7.51245499125224	0.000894398437412746	0.0200644256533637	-0.898208833581141	-0.349238660932905
MYH9	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.1818239744645	0.1818239744645	0.470422879178407	0.4617368983695	8.77118337844059	6.91243873585115	5.43038362456713e-05	0.00162713363885062	0.210595260006011	0.366602549421804
MYH9	BRD-K60184833-001-05-6::2.5::HTS002	2.5	tyrphostin-AG-99	tyrosine kinase inhibitor	targeted cancer	EGFR	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.1442096063	-1.1442096063	-1.69125805344043	-1.52742041275	-6.63793550086397	57.9630695957708	1.18889420216442e-08	6.30572891501358e-07	-0.71201710283895	-0.382079791441919
MYH9	BRD-K60997853-001-02-3::2.5::MTS010::PROS004_PR500	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.689364009005	-1.689364009005	-0.71475800467894	-0.651377728199	13.2408062429207	11.6794931855852	2.17461166435182e-08	1.11476284001163e-06	0.81374230721076	1.13546970144136
MYH9	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.506785560198	-0.506785560198	-0.203913516007632	-0.243848377549	9.66960487161604	23.0574495604542	1.40074596614618e-09	8.19826548820711e-08	0.23808633695642	0.367657751424317
MYH9	BRD-K68567222-001-01-2::2.5::HTS002	2.5	BVT-948	tyrosine phosphatase inhibitor	noncancer	PTPN1, PTPN11, PTPN2	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.04868953525165	0.04868953525165	0.340446698252158	0.377734553397	9.13331281245119	63.9141853493848	3.35162416500205e-13	2.91775083534007e-11	0.227939463954558	0.355574862046458
MYH9	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.1518634544285	-0.1518634544285	-0.530753263924664	-0.376499820922	-6.92415525535312	72.3834733876081	1.49139593259406e-09	8.70742028975629e-08	-0.487962273250402	-0.269817345741927
MYH9	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.2012705112415	0.2012705112415	-0.689778004545183	-0.481859441946	-11.1575036367606	88.3428636940222	1.48976443564656e-18	2.15306622877742e-16	-1.04974673018125	-0.732350301392121
MYH9	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.5148368401545	-0.5148368401545	-1.0614551216971	-0.7851415156885	-4.80631652114196	8.73316509862282	0.00105069374069781	0.0230708061417908	-0.805094750090944	-0.288141812994247
MYH9	BRD-K80431395-001-07-3::2.48737::HTS002	2.48737	triciribine	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.6469562950145	-0.6469562950145	-0.940229303138783	-0.783018318744	-4.00619269553118	14.7961193651614	0.00117384061095543	0.0254566512501736	-0.449493067146834	-0.137052949101732
MYH9	BRD-K81916719-001-13-9::2.5::HTS002	2.5	triclabendazole	microtubule inhibitor	noncancer	DNMT1	infectious disease	tapeworm	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.661459523865	-2.661459523865	-2.32888001464524	-2.31061831786	4.12181617152985	88.3356311215427	8.4606573798479e-05	0.00243651484646647	0.172238324137807	0.492920694301717
MYH9	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.174643065703	-0.174643065703	0.0453430651343041	0.06241133456585	7.64725378722301	72.6199529394411	6.65270397196574e-11	4.49233582106945e-09	0.162649157706729	0.277323103967879
MYH9	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.227039423778	0.227039423778	0.110177104870387	0.0860999016039	-4.26588672075011	47.4248351171667	9.44142792519318e-05	0.00268729711579862	-0.171960144174591	-0.061764493640635
MYH9	BRD-K87696786-003-04-4::2.5::HTS002	2.5	LY456236	glutamate receptor antagonist	noncancer	GRM1	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-3.50289621425	-3.50289621425	-2.17389211475625	-2.00238452918	11.4208040882602	7.29767165890605	6.44732959856329e-06	0.000230154847689952	1.05609902246006	1.60190917652743
MYH9	BRD-K88789588-001-14-9::2.5::HTS002	2.5	letrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.0888393611237	-0.0888393611237	0.176038992297656	0.141775811794	5.94862213293028	8.39835106072686	0.000283375484310923	0.00719104714384037	0.163038943468613	0.366717763374098
MYH9	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	PATU8988T, NCIH1299	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma)	0.0767883667638	0.0767883667638	-0.0780506172826894	-0.07508781022425	-4.49246898813948	9.84626114265256	0.00120209072979742	0.02599040694308	-0.231797630251613	-0.0778803378413654
MYO5B	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.03586857478575	0.03586857478575	0.254648303565809	0.256070233499	8.10519970324951	144.592663586154	2.02911546359518e-13	1.8060560141067e-11	0.165428848648347	0.272130608911771
MYO5B	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0628044404827	-0.0628044404827	-0.344043830607416	-0.266254262221	-7.65874348860311	187.659602819462	9.68013204787719e-13	8.08232575648411e-11	-0.353679075917638	-0.208799704331794
MYO5B	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.227391976625	-3.227391976625	-3.81234918540673	-3.817245684415	-5.75386491438343	150.205325498915	4.73753039812872e-08	2.31824235776377e-06	-0.785832139985234	-0.384082277578234
MYO5B	BRD-A50311610-300-10-4::2.5::HTS002	2.5	meclizine	constitutive androstane receptor (CAR) agonist	noncancer	HRH1, NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.551239486781	0.551239486781	0.107346247494086	0.1128949576435	-7.55249567401347	4.01773662232203	0.00161801948970808	0.033537609986476	-0.60679336023529	-0.280993118338537
MYO5B	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.274815940913	0.274815940913	0.0281287188515318	0.05909936864605	-4.2260225275812	28.8344775579628	0.000217898753503997	0.00570301892047358	-0.366103966459355	-0.127270477663581
MYO5B	BRD-K01507359-001-22-9::2.5::HTS002	2.5	rifampin	RNA polymerase inhibitor	noncancer	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.146791042785	0.146791042785	-0.0963353972509573	-0.0621919503453	-8.0452723210148	52.5608565671937	1.0030608742138e-10	6.64756984859027e-09	-0.303751486827348	-0.182501393244567
MYO5B	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.05681732601385	-0.05681732601385	0.281017168117532	0.26768413301	8.83943442681623	3.89864929315754	0.00101567952419847	0.0224191119198696	0.230624669424796	0.445044318837968
MYO5B	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.2436519436815	-0.2436519436815	-0.0682919715256871	-0.00125185876287	4.31248555992022	176.166962008648	2.6828880345601e-05	0.00085264043528949	0.0951100420819621	0.255609902229664
MYO5B	BRD-K11267252-001-04-4::2.5::HTS002	2.5	alectinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.3919009784065	-0.3919009784065	-0.152674661405529	-0.10378431841385	4.09899248790365	10.3816438772299	0.00198669406572886	0.0398732233742485	0.109832254492618	0.368620379509324
MYO5B	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.1444368334135	0.1444368334135	-0.258573500467623	-0.1509093731905	-6.38483003649708	11.3450708993697	4.50495776641951e-05	0.00137034217019433	-0.54142265950467	-0.264598008257577
MYO5B	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.01715975761	-2.01715975761	-4.15969147273116	-4.14163208451	-16.4222011040674	26.9025674605777	1.51714388713203e-15	1.65817405499806e-13	-2.41027031009569	-1.87479312014663
MYO5B	BRD-K13050303-001-17-3::2.5::HTS002	2.5	uridine	dopamine receptor agonist	noncancer	LSM6, TYMP	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.133117832483	-0.133117832483	0.0671444599586861	0.0709396058819	7.13185987378706	141.280446184223	4.71062214380573e-11	3.24116511544057e-09	0.144751102257563	0.255773482625809
MYO5B	BRD-K13094524-001-07-5::2.63083::HTS002	2.63083	PFI-1	bromodomain inhibitor	targeted cancer	BRD4	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.372737717565	-3.372737717565	-2.21793048105801	-2.05881445025	8.05932823581539	3.87530215734785	0.00146991490821954	0.0308998853735648	0.751875427380202	1.55773904563378
MYO5B	BRD-K13167095-001-02-9::2.5::HTS002	2.5	AR-42	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.552791681585	-1.552791681585	-3.27020558158669	-3.28129580755	-14.1856143693245	52.4446197793096	1.37093013089076e-19	2.1716931561248e-17	-1.96030417745178	-1.47452362255161
MYO5B	BRD-K13249881-001-02-3::2.5::HTS002	2.5	piperazine	benzodiazepine receptor agonist	noncancer	GABRB3	infectious disease	gastrointestinal roundworms	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.5541648765355	0.5541648765355	0.030633626507256	0.0696303010169	-11.6281861539557	17.468186963083	1.18747884116564e-09	7.0132585436261e-08	-0.61832707699555	-0.428735423060938
MYO5B	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.379920957986	0.379920957986	0.506994891596745	0.511327989939	5.24681639176305	59.7712859222845	2.14513199832307e-06	8.32754928579216e-05	0.0786244167416983	0.175523450479791
MYO5B	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.152917618485	-1.152917618485	-0.9349409953595	-0.8524847758	3.38452402212855	189.007751867832	0.000866980302653459	0.019504463239993	0.090933795924416	0.345019450326583
MYO5B	BRD-K19284129-001-02-6::2.5::HTS002	2.5	salvinorin-a	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.307830927321	0.307830927321	0.0100757324135518	0.0190895048791	-6.15139994871931	4.7441494821943	0.00198690396110273	0.0398737021609725	-0.424228486625831	-0.171281903189066
MYO5B	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.366902217974	0.366902217974	-0.38066922633607	-0.173057746988	-7.65107259870082	5.31905543707682	0.000458877812861639	0.0111105764519682	-0.994273480319703	-0.500869408300437
MYO5B	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.200579032575	-2.200579032575	-3.14117633174638	-3.22475555586	-7.98094345109498	186.97883804684	1.42440649527981e-13	1.28869404696845e-11	-1.17309447963413	-0.708100118708627
MYO5B	BRD-K21283037-001-21-5::2.5::HTS002	2.5	riluzole	glutamate inhibitor	noncancer	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.274808730532	0.274808730532	0.0424908011376361	0.0176424857247	-6.36022841982667	6.49043275327238	0.000518708830122628	0.0123774599032902	-0.320083617837382	-0.144552240951346
MYO5B	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.437496414173	-0.437496414173	-0.109439189599447	-0.02484856783435	5.78465487708358	77.8274125482867	1.44512697164221e-07	6.66952236660428e-06	0.21514909243429	0.440965356712815
MYO5B	BRD-K24048528-001-02-5::2.5::HTS002	2.5	abiraterone-acetate	androgen biosynthesis inhibitor	targeted cancer	CYP17A1	oncology	prostate cancer	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0512205720754	-0.0512205720754	0.407173465279649	0.3679428252945	15.0684434986502	154.755398581423	3.71071044087284e-32	1.78721990580188e-29	0.398300442213431	0.518487632496667
MYO5B	BRD-K28453807-003-11-2::2.5::HTS002	2.5	nitrocaramiphen	cholinergic receptor antagonist	noncancer	CHRM1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.469337739064	0.469337739064	0.355935208688129	0.3384293751915	-4.26845264789397	176.729957902294	3.20555250864149e-05	0.00100181228291721	-0.165833097747036	-0.0609719630047071
MYO5B	BRD-K29582115-066-01-2::2.5::HTS002	2.5	ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.185199083051	-0.185199083051	0.269070494912136	0.27385544783	10.79593412482	8.70244676809177	2.47137621506706e-06	9.49771548859795e-05	0.358584456499316	0.549954699426956
MYO5B	BRD-K30867024-003-03-3::2.5::HTS002	2.5	SB-216641	serotonin receptor antagonist	noncancer	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.2103356950935	-0.2103356950935	-0.0464226880064463	-0.01731915547495	4.32433372025257	60.1925838626756	5.84375111869265e-05	0.0017396154145502	0.0880971063090296	0.239728907865078
MYO5B	BRD-K31309378-001-01-5::2.5::HTS002	2.5	lucitanib	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.520507910696	-0.520507910696	-0.764337117389809	-0.647544423054	-3.63271640398531	19.1779219120592	0.00174999852021852	0.0358135618103613	-0.384225558294651	-0.103432855092967
MYO5B	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3064109634515	0.3064109634515	-0.407137257976508	-0.2809944464045	-11.2483260810768	74.16241818143	1.07333552400433e-17	1.44139680153085e-15	-0.839942506358915	-0.587153936497101
MYO5B	BRD-K32821942-001-21-3::2.5::HTS002	2.5	azathioprine	dehydrogenase inhibitor	noncancer	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0664933641075	-0.0664933641075	-0.644089624964636	-0.577859685861	-13.4180661964347	162.831548846449	4.01036627141442e-28	1.37306356643128e-25	-0.662596931251431	-0.492595590462841
MYO5B	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-4.952763846975	-4.952763846975	-3.75795088558076	-3.68976707366	11.9012770609593	134.965866981485	8.87440421397437e-23	1.87393318303144e-20	0.996264708229273	1.39336121455921
MYO5B	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.27444906261	-1.27444906261	-0.782200928811301	-0.3920750884915	4.39109793170029	185.381361803984	1.89252227827506e-05	0.000619933375180216	0.271089687528668	0.713406580068729
MYO5B	BRD-K39160765-003-02-9::2.5::HTS002	2.5	4-chlorophenylguanidine	urokinase inhibitor	noncancer	PLAUR	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0691129477519	-0.0691129477519	0.055689125669118	0.0820318935995	3.94194896931503	79.3472930166865	0.000173065498872393	0.00465173756054942	0.0617887237609147	0.187815423081121
MYO5B	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-3.574096948555	-3.574096948555	-4.60066538327089	-4.62878838486	-9.99623121893311	59.07829068357	2.5703093773474e-14	2.50519253541379e-12	-1.23205605226768	-0.821080817164098
MYO5B	BRD-K51791723-003-01-7::2.5::MTS010::PROS004_PR500	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.9340494595125	-0.9340494595125	-2.24749462714261	-2.452542786	-17.5904819599811	111.113965974585	6.7500642983774e-34	3.87864485524646e-31	-1.46140301617746	-1.16548731908276
MYO5B	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-6.51570918775	-6.51570918775	-6.1779199160329	-6.268105536705	3.85448657925786	189.940047214855	0.00015859916486056	0.00430392509564433	0.164925728842515	0.510652814591695
MYO5B	BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500	2.49998	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.2006994182325	0.2006994182325	-0.200415728241619	-0.112315878397	-7.35025749478613	12.4287995072506	7.23703263737365e-06	0.00025562062757674	-0.519563022621536	-0.282667270326701
MYO5B	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.040321402567705	-0.040321402567705	-0.512396580541515	-0.339269333107	-6.98141346321174	15.733195608621	3.39612645753274e-06	0.000127453753723785	-0.615618561703202	-0.328531794244418
MYO5B	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3003362878665	0.3003362878665	-0.496910803830324	0.00402399396559	-8.07094006804263	25.2411909021026	1.86337161755522e-08	9.6513913827693e-07	-1.00058969102486	-0.593904492368791
MYO5B	BRD-K65928735-001-04-3::2.5::HTS002	2.5	AZD1480	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.0998871811336	0.0998871811336	-0.0250254707489297	-0.0593866490267	-3.86984760399738	91.9617749945138	0.000203322140754704	0.00536012682728352	-0.189020779147429	-0.0608045246176303
MYO5B	BRD-K67537649-001-04-5::2.5::HTS002	2.5	PQ-401	IGF-1 inhibitor	targeted cancer	IGF1R	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.0215975234356	0.0215975234356	0.17857670403388	0.20362806034	4.82208635725738	123.375667343724	4.09922150497142e-06	0.00015179371906341	0.0925420799454572	0.221416281251103
MYO5B	BRD-K67977190-066-02-3::2.5::HTS002	2.5	eprosartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.9247480699255	0.9247480699255	0.416186707223509	0.407016532415	-12.8427700779375	6.36620930515742	8.66523813599804e-06	0.000301642329779166	-0.604121522159557	-0.413001203244425
MYO5B	BRD-K68103045-001-02-9::2.5::HTS002	2.5	CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.6204291313985	0.6204291313985	0.445156699693688	0.4684149214555	-6.3341871579092	189.055509029626	1.70009354717934e-09	9.87745594669018e-08	-0.229855738692124	-0.120689124717499
MYO5B	BRD-K71035033-001-07-1::2.5::HTS002	2.5	masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor	noncancer	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.5833268936935	0.5833268936935	0.275165558467387	0.3093136114795	-8.31416860879906	187.606925772317	1.83926245683694e-14	1.82081885963697e-12	-0.381278281616706	-0.23504438883552
MYO5B	BRD-K73237276-001-01-0::2.5::HTS002	2.5	tacalcitol	vitamin D receptor agonist	noncancer	VDR	dermatology	psoriasis, chapped lips	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3185931912935	0.3185931912935	0.0294523182706675	0.07201409986295	-9.21496588992996	191.991402249038	5.53554601969426e-17	6.93817568921082e-15	-0.351029393527284	-0.227252352518381
MYO5B	BRD-K75009076-001-02-1::2.429::HTS002	2.429	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.57632060281	-1.57632060281	-1.91912444900454	-1.72291152257	-3.48554843002805	40.7395673235654	0.00119006747678506	0.0257694455679798	-0.541464359736937	-0.144143332652146
MYO5B	BRD-K76180386-001-01-6::2.5::HTS002	2.5	JIB04	histone lysine demethylase inhibitor	noncancer	KDM4E	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.117782876025	-1.117782876025	-1.70201608754629	-1.602559897845	-7.0403042755547	52.0495645686539	4.24765009085653e-09	2.36343353147245e-07	-0.750749187133058	-0.417717235909522
MYO5B	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.2958035788945	0.2958035788945	-0.125976754104247	-0.118001057117	-10.5314355470437	4.11455303261562	0.000396409731947157	0.00972997038920088	-0.53176565233897	-0.311795013658523
MYO5B	BRD-K84663978-003-02-9::2.5::HTS002	2.5	trequinsin	phosphodiesterase inhibitor	noncancer	PDE5A	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.496902902344	-0.496902902344	-0.0403227330903157	-0.0536519890124	13.5248109275795	4.64131899581639	6.6228533162509e-05	0.00194848253729408	0.367744209547385	0.545416128959983
MYO5B	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.2510962778575	-0.2510962778575	-0.161762574063392	-0.116252087164	4.07671377583649	157.779382130503	7.22230762337545e-05	0.00210806205993523	0.0460527172239392	0.132614690364277
MYO5B	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.469269372477	0.469269372477	0.000685958898848016	0.041364371782	-14.6712093858619	192.008290286919	3.52072203767982e-33	1.8959618935022e-30	-0.531579721750542	-0.405587105405762
MYO5B	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	0.355384108511	0.355384108511	0.16554890757561	0.180090535551	-7.18182344231157	5.6261532695718	0.00049054090656152	0.0117840329480413	-0.25556997521286	-0.124100426657921
MYO5B	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.177540638415	-1.177540638415	-1.83377196305485	-1.72447120363	-6.23108559542883	5.58931008191059	0.00103392908847363	0.0227656654616257	-0.918589896121262	-0.393872753158435
MYO5B	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.4947311244175	-0.4947311244175	-1.60699134808348	-1.38505413113	-14.8804431998368	120.116660110364	4.96977801173606e-29	1.85246530691718e-26	-1.26025151815164	-0.964268929180324
MYO5B	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	KYSE410, HCC1937	OESOPHAGUS, BREAST	carcinoma (squamous_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.7019716844895	-0.7019716844895	-0.0267565201527061	0.0202365059018	9.93836922370192	5.3126452566034	0.000124459295402748	0.00345310502580915	0.503615736676077	0.84681459199751
MYO5C	BRD-A08545410-311-03-4::2.5::HTS002	2.5	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.202346211342	-0.202346211342	-0.49869612663823	-0.495379561508	-7.8679650804675	29.6916178581924	9.49403693190278e-09	5.07949935491211e-07	-0.373306405002268	-0.219393425590192
MYO5C	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.2085946897715	0.2085946897715	-0.00972868290261085	0.0633629143304	-6.80570834425501	189.960948668812	1.27845040777422e-10	8.37435811270909e-09	-0.281601072959632	-0.155045672388589
MYO5C	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.3590183684245	0.3590183684245	-0.182906775191737	-0.1596607583295	-9.65039704890346	5.73501902402653	9.28331992238911e-05	0.0026458572814438	-0.680887019052039	-0.402963268180434
MYO5C	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.2222115488515	-0.2222115488515	-0.513630119354839	-0.46624794895	-5.40255414467316	36.8207901817124	4.10049635120128e-06	0.000151800635873666	-0.400731150703898	-0.182105990302781
MYO5C	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.280891751512	0.280891751512	-0.0557421842470105	0.002007296385155	-9.17973231488306	53.7378899834918	1.35246088380636e-12	1.11147081581799e-10	-0.410163945446585	-0.263103926071436
MYO5C	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	1.75812653662	1.75812653662	0.384903441905313	0.4040524647295	-22.1769141249639	6.27431429874023	3.37459296658179e-07	1.47576644753011e-05	-1.52314767412743	-1.22329851530194
MYO5C	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.340597126584	0.340597126584	-0.453379266137277	-0.3315553181695	-8.79993785108788	8.0105795646736	2.16743316473344e-05	0.000701621783362262	-1.00198831975074	-0.58596446569181
MYO5C	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.475331700817	0.475331700817	0.244715583301138	0.260666777641	-7.1684984083509	189.877809969659	1.6381962863477e-11	1.19344993832976e-09	-0.294074130817084	-0.167158104214639
MYO5C	BRD-A93477898-001-04-2::2.5::HTS002	2.5	PETCM	caspase activator	noncancer	CASP3	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.562119449548	0.562119449548	0.175754745000433	0.179996842636	-8.06027057935311	7.25039618787904	7.17300424576574e-05	0.00209509788360687	-0.498922955156557	-0.273806453938576
MYO5C	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.0793612724861	-0.0793612724861	0.265654483249689	0.320326091732	9.03048631958715	151.218161174231	7.43092420616147e-16	8.3604333552881e-14	0.269529919134355	0.420501592337223
MYO5C	BRD-K00312224-001-09-5::2.5::HTS002	2.5	PPT	estrogen receptor agonist	noncancer	ESR1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.5270558807225	0.5270558807225	0.15886066393661	0.22700730099	-6.18447553679962	4.47296256367205	0.00238300079221376	0.0465796786862183	-0.526821935703108	-0.209568497868672
MYO5C	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-1.847260858435	-1.847260858435	-2.77034532708089	-2.64361455145	-6.74666133825378	4.63626522460318	0.00145519921863559	0.0306406713165288	-1.28325753363132	-0.562911403660452
MYO5C	BRD-K02389548-001-02-5::2.5::HTS002	2.5	RG2833	HDAC inhibitor	noncancer	HDAC1, HDAC3	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.6528151455515	0.6528151455515	0.313496047446882	0.3525103772395	-8.29754442492199	25.3219806559851	1.08680108655518e-08	5.7842808562276e-07	-0.423487429100003	-0.255150767109233
MYO5C	BRD-K06593056-001-04-8::2.5::HTS002	2.5	LE-135	retinoid receptor agonist	noncancer	RARB	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.571871654335	0.571871654335	-0.149027593238952	-0.158245986785	-24.1533229262626	186.251643754083	2.77364657494916e-59	1.65131360211744e-55	-0.779780484725659	-0.662018010422246
MYO5C	BRD-K07359318-001-03-9::2.44929::HTS002	2.44929	benfotiamine	antioxidant	noncancer	AGER	rheumatology	lumbago	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.4871916518765	0.4871916518765	0.332942319108961	0.345721870697	-6.13322357787457	177.001333528098	5.47246318363574e-09	3.01131594784458e-07	-0.203881379755493	-0.104617285779584
MYO5C	BRD-K08109215-001-06-4::0.625::HTS002	0.625	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.12495450836175	-0.12495450836175	0.324100883482204	0.349176591288	5.37243704117061	5.58527792178104	0.00213980327372012	0.0425201090166104	0.240791869883718	0.65731891380419
MYO5C	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.8237595542935	-0.8237595542935	-2.0481637375029	-1.66463476506	-9.51264907549505	94.0202783980077	1.99399901367677e-15	2.1639079220371e-13	-1.47996668247183	-0.968841683946973
MYO5C	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.1987029293685	0.1987029293685	-0.480353983739566	-0.33490377325	-9.71427854886483	72.9722121133379	8.66583039545424e-15	8.81508667692127e-13	-0.818374223362161	-0.53973960285397
MYO5C	BRD-K13571841-001-14-4::2.5::HTS002	2.5	pepstatin	aspartic protease inhibitor	noncancer	CTSB, CTSD, CTSL, REN	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.169572822169	-0.169572822169	-0.725134534571034	-0.751877550498	-8.41238791204136	86.2764931465113	7.55832285766217e-13	6.37280794555419e-11	-0.686840684876217	-0.42428273992785
MYO5C	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.5644438487485	-0.5644438487485	-0.325111526351666	-0.309372115648	6.09408938141175	12.6374739878842	4.31125768394015e-05	0.00131834434033558	0.154240388723574	0.324424256070095
MYO5C	BRD-K17555800-003-01-5::2.5::HTS002	2.5	talmapimod	p38 MAPK inhibitor	targeted cancer	MAPK11, MAPK14	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.000874974682950001	0.000874974682950001	0.416571254055807	0.422256044569	13.4137178294555	8.40998238394436	5.71889786439733e-07	2.42094738372193e-05	0.344834213979789	0.486558344765926
MYO5C	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.6793990156515	0.6793990156515	0.319431775501863	0.339932692016	-8.78897196740151	4.73798114415086	0.000414280439092934	0.0101257055799235	-0.467025331578524	-0.25290914872075
MYO5C	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.210607674385	0.210607674385	0.300254533036343	0.3347260991415	3.69293275927972	159.774359540675	0.000303893420783361	0.00766272623330318	0.0417051175410075	0.137588599761678
MYO5C	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.9208051523645	-0.9208051523645	-1.91299858799295	-1.67956785013	-8.73923854814158	8.32522691156887	1.79034754028053e-05	0.000589618005471398	-1.25223177899168	-0.73215509226522
MYO5C	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.7965298693655	0.7965298693655	-0.27362205641049	-0.316992636258	-13.2979635723908	3.1520015246093	0.00071215332168785	0.0164141423039074	-1.31941178170483	-0.82089206984715
MYO5C	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-1.320840032075	-1.320840032075	-0.829589823237519	-0.73306047453	8.27923904435858	182.495311181817	2.56666483031545e-14	2.50277846413412e-12	0.374179020006472	0.60832139766849
MYO5C	BRD-K25690923-001-02-4::2.5::HTS002	2.5	4-iodo-6-phenylpyrimidine	macrophage migration inhibiting factor inhibitor	targeted cancer	MIF	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.406973527267	0.406973527267	0.237940939795132	0.237522768994	-5.00482971005636	6.52931420281526	0.00190979326733553	0.0385463867779224	-0.250077188043956	-0.0879879868997791
MYO5C	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.2785778492025	0.2785778492025	-0.139589064307398	-0.1059972226705	-8.97637825934809	6.992135723034	4.36883152447095e-05	0.00133404657616232	-0.528348669721142	-0.307985157298655
MYO5C	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.07144319421455	-0.07144319421455	-0.535957536407407	-0.4752073320215	-8.25276701258981	7.21773337940025	6.29426148259578e-05	0.00186126209892835	-0.596799719935173	-0.33222896445054
MYO5C	BRD-K32107296-001-16-9::2.5::HTS002	2.5	temozolomide	DNA alkylating agent	chemo	MGMT	oncology	glioblastoma, astrocytoma	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.1318839728165	0.1318839728165	0.226729665334819	0.232952381397	3.32693818889318	182.578099834054	0.00106170587761362	0.0232720759913122	0.03859740979992	0.151093975236718
MYO5C	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.2476033252945	-0.2476033252945	-0.694529137865823	-0.621232482709	-7.18154715113764	6.35937707527451	0.000282665672659697	0.00717558343663156	-0.597141466892137	-0.29671015825051
MYO5C	BRD-K37249724-001-25-7::2.5::HTS002	2.5	astemizole	histamine receptor antagonist	noncancer	HRH1, KCNH1, KCNH2	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.2459860275555	-0.2459860275555	0.0658238538883044	0.115244087444	6.90308233289733	7.96500458043159	0.000126743483805413	0.00351057174212076	0.207568745196034	0.416051017691575
MYO5C	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-6.17734905034	-6.17734905034	-4.64956507738424	-5.03947371329	12.2964251193591	134.800224763466	8.98905723721511e-24	2.06496854083074e-21	1.28205994898697	1.77350799692455
MYO5C	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.959400268617	-0.959400268617	-0.506737553670819	-0.419049148621	9.33930052845433	182.171788312827	3.4279084057905e-17	4.36801534307177e-15	0.357030718162756	0.548294711729605
MYO5C	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.144667833254	0.144667833254	-0.500117347083849	-0.332266676493	-11.0522179675885	24.6720006114941	4.81720501897077e-11	3.31024922895475e-09	-0.765019480270728	-0.524550880404969
MYO5C	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.10959880186875	-0.10959880186875	-0.635321621392266	-0.4291875223905	-6.25858082818153	5.35937537256475	0.00118363758332155	0.0256502611466923	-0.73736932397874	-0.314076315068291
MYO5C	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.7863576447415	0.7863576447415	0.363984515827021	0.394038132066	-9.83413513649328	126.954871236205	2.59900298725798e-17	3.3455958633995e-15	-0.50736311984789	-0.337383137981067
MYO5C	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-2.133526294355	-2.133526294355	-3.77420430954461	-3.649368876965	-13.9697013095813	15.9548309717062	2.29742395194283e-10	1.45984161931798e-08	-1.88970856901417	-1.39164746136506
MYO5C	BRD-K47114202-001-14-6::2.57945::HTS002	2.57945	chlorogenic-acid	antioxidant	noncancer	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.19933215286	-0.19933215286	-1.06092715672399	-0.967874485397	-10.0084642977052	5.83690701455878	6.83410935455914e-05	0.00200485604140885	-1.0736764059786	-0.649513601749372
MYO5C	BRD-K51313569-003-03-3::2.5::HTS002	2.5	palbociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.11197806813425	-0.11197806813425	-0.76656695036508	-0.762324031266	-9.41698524315529	38.449122706703	1.57008992650563e-11	1.14930260880473e-09	-0.795253621814435	-0.513924142647225
MYO5C	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-3.32791730331	-3.32791730331	-4.6032431806033	-4.62878838486	-12.3966535244449	54.7046586358679	1.61133566125552e-17	2.12004887011193e-15	-1.48152026278793	-1.06913149179867
MYO5C	BRD-K52313696-001-12-3::2.5::MTS010::PROS004_PR500	2.5	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.451184153521	0.451184153521	-0.0159091097544239	-0.0070642593788	-16.5777765964367	191.997395789089	6.78775012733059e-39	6.46582976462506e-36	-0.522667253400016	-0.411519273150832
MYO5C	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.385838185036	0.385838185036	0.225428941676004	0.2005091684065	-5.09413243585186	23.3162071136719	3.55389991792483e-05	0.00110285890122575	-0.225500398684155	-0.0953180880358366
MYO5C	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.254465909569	0.254465909569	-0.515483358679072	-0.339269333107	-13.152371912746	190.010883600757	1.63024444071815e-28	5.85274138584054e-26	-0.885422437865045	-0.654476098631099
MYO5C	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-6.56796013567	-6.56796013567	-7.2200891002367	-7.25572463628	-5.41485570173052	11.3260405089301	0.000191286346765648	0.00508095320559358	-0.916272869204218	-0.387985059929184
MYO5C	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.6267529914215	-0.6267529914215	-0.246013452911018	-0.116969809946	6.96525418459769	106.974406314575	2.77589516918842e-10	1.75502901391441e-08	0.272376832055895	0.489102244965069
MYO5C	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.40111646641	0.40111646641	-0.697607744180969	-0.642732938193	-20.0390176455246	93.3920300028831	1.38083604833849e-35	9.21972614966795e-33	-1.2075982020579	-0.989850219124042
MYO5C	BRD-K62398570-300-01-2::2.5::HTS002	2.5	lerisetron	serotonin receptor antagonist	noncancer	HTR3A	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.6390436730735	0.6390436730735	0.496888746055538	0.5032243317015	-6.22866168726511	47.231655099139	1.19008213638083e-07	5.55948374473338e-06	-0.188062349722973	-0.0962475043129515
MYO5C	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.4633789395655	0.4633789395655	-0.223687280711885	-0.209793035138	-12.0415240916694	21.1438484738431	6.2528182712305e-11	4.23967189893882e-09	-0.805675853575939	-0.568456586978831
MYO5C	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.11292874251235	-0.11292874251235	-1.08809493215021	-0.4202572111255	-6.782674125951	6.970842100336	0.00026204816934115	0.00671503133509317	-1.31542406992319	-0.634908309352528
MYO5C	BRD-K66175015-001-09-0::2.5::HTS002	2.5	afatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.2121796690565	-0.2121796690565	-0.919049464174643	-0.7732511578805	-7.41201476993227	159.546628872486	6.86345801198848e-12	5.23687466091662e-10	-0.895216490788459	-0.518523099447827
MYO5C	BRD-K67977190-066-02-3::2.5::HTS002	2.5	eprosartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.6816417140805	0.6816417140805	0.418759261253615	0.407016532415	-7.12405183269963	11.2096776333836	1.74589954267211e-05	0.00057666343516932	-0.343915365608084	-0.181849540045686
MYO5C	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-2.895444342255	-2.895444342255	-3.86959529828482	-3.711772040445	-14.204234231254	179.747488349457	3.43440403002506e-31	1.5083860273591e-28	-1.1094798261209	-0.838822085938732
MYO5C	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.1857052361665	0.1857052361665	0.343090132935393	0.3666851523545	5.17661200194721	189.509642384788	5.73611737964497e-07	2.42727798985573e-05	0.0974129898565081	0.217356803681277
MYO5C	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.158645933129	-0.158645933129	0.225317434437012	0.235603358555	14.3507236896638	38.0972247080197	6.01875818294727e-17	7.51307176815903e-15	0.329803864549611	0.438122870582414
MYO5C	BRD-K72280606-001-01-2::2.5::MTS006	2.5	gilteritinib	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.2703016591445	-0.2703016591445	0.0255381603573705	0.043697431473	9.21029237149049	7.01761686670328	3.61298482442791e-05	0.00111918980262294	0.219925381511991	0.37175425749175
MYO5C	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.700631598386	-0.700631598386	-1.33814023954237	-1.10972386317	-6.52605548420957	17.11750303852	5.00797429182955e-06	0.000182512178539965	-0.843501783560476	-0.431515498752271
MYO5C	BRD-K76210423-001-01-6::2.5::MTS010::PROS001_PR500	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.186009298656	0.186009298656	0.105152733730407	0.08882373034095	-3.53010221335002	20.7477736895277	0.00201424447858358	0.040339282830344	-0.128525152921761	-0.0331879769294261
MYO5C	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.547085869619	0.547085869619	-0.3353758362135	-0.3298674569485	-10.7288996296916	5.7801560879106	4.9424964254319e-05	0.00149200044558647	-1.0855926088405	-0.679330802824504
MYO5C	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.0851007728326	-0.0851007728326	-0.505083227657499	-0.3823931691785	-5.33441723440162	6.05814582214193	0.00171773785628439	0.0353189699495335	-0.612182241030367	-0.22778266861943
MYO5C	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.4636380000735	0.4636380000735	-0.158009799212356	-0.140788868193	-12.2685291658997	4.04205814395028	0.000238568204468468	0.00618358745864341	-0.761755169152276	-0.481540429419435
MYO5C	BRD-K86972824-001-01-4::2.5::HTS002	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.179041162466	-0.179041162466	0.0100271134102475	0.002128528664087	6.20554464596109	185.246957543285	3.48173445585916e-09	1.95605940809918e-07	0.128960119927893	0.249176431824602
MYO5C	BRD-K90574421-001-03-5::2.5::HTS002	2.5	ipsapirone	serotonin receptor agonist	noncancer	HTR1A	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.221434319809	0.221434319809	-0.0416705827770436	-0.0540308709753	-10.5748454003022	139.968902795348	1.42355810907687e-19	2.25173273771467e-17	-0.312294608357619	-0.213915196814468
MYO5C	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	-0.1243379437325	-0.1243379437325	0.105338561494632	0.135507608915	8.52687117933595	15.5797972888107	2.93278685132744e-07	1.2949758406637e-05	0.172450134023364	0.286902876430901
MYO5C	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.10829811615415	0.10829811615415	-0.301705299231768	-0.183745665678	-5.73407545406228	7.80665121544194	0.000478006662903965	0.0115126070405151	-0.575603102256413	-0.244403728515424
MYO5C	BRD-K95785537-001-23-1::2.5::HTS002	2.5	PP-2	src inhibitor	targeted cancer	ABL1, LCK, LYN, RIPK2, SRC	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.7102015020845	0.7102015020845	-0.28442619954788	-0.127481786851	-8.50265675174582	3.5573078402027	0.00173503764512541	0.0355923759942845	-1.33599023764988	-0.653265165614881
MYO5C	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	1.50321272163	1.50321272163	0.58735379113036	0.574544422816	-25.5856125911353	172.430295355962	1.34116923983816e-60	8.98285818766481e-57	-0.986513411379953	-0.845204449619327
MYO5C	BRD-K99383816-001-03-5::2.5::HTS002	2.5	ftorafur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.174410402486	0.174410402486	0.0266753095146271	0.0625789324056	-4.20962108001612	16.8051718748865	0.000602863623875065	0.0141368881445863	-0.221843733716578	-0.0736264522261681
MYO5C	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	EBC1, QGP1	LUNG, PANCREAS	carcinoma (squamous_cell_carcinoma), carcinoma	0.08696663029845	0.08696663029845	-0.22088346016663	-0.147984722712	-6.1713631562697	89.1112196156718	1.95555625246909e-08	1.00825695461979e-06	-0.406966126511301	-0.20873405441886
MYO6	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.2648076763065	-0.2648076763065	-0.493629544448949	-0.379151386241	-3.88056610747154	103.360626254876	0.000183700647428494	0.00490254962802911	-0.345762380606813	-0.111881355678084
MYO6	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.5353097352585	0.5353097352585	-0.226761950015354	-0.093015492892	-9.69487799744641	8.94054408193598	4.8571562771601e-06	0.000177317228364409	-0.940070323397611	-0.584073047150097
MYO6	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.506809508938	0.506809508938	0.0706619206454609	0.128125201883	-10.3796266258401	3.54634780574443	0.000886078377335017	0.0198986056722377	-0.558940756063515	-0.313354420521564
MYO6	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.0651883969389	0.0651883969389	0.18663159648407	0.190024427126	3.89956826275766	19.164615730571	0.000950769329382378	0.0211715781833136	0.0562985917654025	0.186587807324938
MYO6	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.13980566772	-2.13980566772	-1.11449242737336	-1.02154011458	17.219744231759	51.2187135786916	5.96805246059831e-23	1.28169009601961e-20	0.905788304394027	1.14483817629925
MYO6	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.226442099933	0.226442099933	-0.0527533441366143	-0.0230394948173	-7.21191557492816	6.45608189034827	0.000257242135686918	0.00660609270304835	-0.372324199897676	-0.186066688241553
MYO6	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.378986382746	0.378986382746	-0.190972292523903	-0.136086260588	-12.1694272987952	80.7863782304118	5.88743969728613e-20	9.66934147800489e-18	-0.663149949887929	-0.476767400651878
MYO6	BRD-K09397065-003-06-1::2.5::HTS002	2.5	SR-57227A	serotonin receptor agonist	noncancer	HTR3A	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.4667412402465	0.4667412402465	0.242828442483847	0.2348348168625	-6.68162887949539	66.295745530121	5.83840696730498e-09	3.20035786929798e-07	-0.290815511383134	-0.157010084142172
MYO6	BRD-K11071038-001-01-7::2.5::HTS002	2.5	ICI-162846	histamine receptor antagonist	noncancer	HRH2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.29908809324	-0.29908809324	0.100005327909494	0.0637321133413	10.567618175194	8.04286540710913	5.39111873309236e-06	0.000195379284231477	0.312086302046811	0.486100540252177
MYO6	BRD-K11663430-001-02-3::2.5::HTS002	2.5	pyroxamide	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.178125352215	-0.178125352215	-0.643708388033475	-0.612220843488	-7.23841684939232	138.512718648749	2.84218559838716e-11	2.00911212769367e-09	-0.592761238472708	-0.338404833164242
MYO6	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.041825329755	-2.041825329755	-2.4196630179197	-2.32972185313	-4.65261270675113	15.8586823101708	0.000271445944507099	0.00692768966899999	-0.550119511359917	-0.205555864969474
MYO6	BRD-K12932420-001-02-3::2.5::HTS002	2.5	YM-976	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.604672265703	0.604672265703	0.309855743554097	0.3289563739625	-8.50440345023326	101.33762111655	1.69536027810274e-13	1.52099151546874e-11	-0.363582433630976	-0.226050610666829
MYO6	BRD-K13566078-001-02-3::2.5::HTS002	2.5	BMS-345541	IKK inhibitor	targeted cancer	CHUK, IKBKB	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.59411584711	-2.59411584711	-1.47358219178431	-1.48395465403	14.2089297341095	4.82852895655504	4.00196981388629e-05	0.00122955588910613	0.915629868300763	1.32543744235061
MYO6	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.367294751298	0.367294751298	-0.481796000570407	-0.373418715101	-8.52049199367954	17.4712992049381	1.24208577950712e-07	5.78728267469526e-06	-1.05890853688252	-0.639272966854298
MYO6	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.6390675961215	0.6390675961215	0.398095268412026	0.431459247123	-7.49721603266988	55.7742491300257	5.33811353350973e-10	3.2670260865894e-08	-0.305365390083875	-0.176579265335073
MYO6	BRD-K15519488-050-01-3::2.5::HTS002	2.5	CS-110266	dopamine receptor agonist	noncancer	SLC6A3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.6676580229	-1.6676580229	-0.0997162340548361	-0.120574600447	29.0229143074514	46.4990133677625	1.9308067583077e-31	8.71216593055434e-29	1.45922805533625	1.67665552235408
MYO6	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.0332005054965	-1.0332005054965	-0.0838594968913317	-0.0178822580687	16.8191575290073	3.50340704239948	0.000178123469915165	0.00477212814793093	0.783465666393864	1.11521635081647
MYO6	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.067936394415	-2.067936394415	-2.36003409030281	-2.30540806626	-3.27483865550268	191.987218364642	0.00125422016295601	0.0269597586306488	-0.468024748902996	-0.116170642872622
MYO6	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.043812824779635	0.043812824779635	-0.826771294346047	-0.81565114113	-10.6027950575996	5.3899346481134	8.19094614745509e-05	0.00236406853869903	-1.07714071097283	-0.66402752727853
MYO6	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.7364417408	-0.7364417408	-1.87658735314679	-1.673362994515	-9.90035112011963	7.64136187069197	1.26082184013946e-05	0.000426567772968034	-1.4078952222654	-0.872396002428189
MYO6	BRD-K21728777-001-02-3::2.5::HTS002	2.5	AMG900	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.8396050652075	-0.8396050652075	-1.55070537270013	-1.404443241845	-8.47418777103178	176.341064305826	9.1225567057665e-15	9.24457898907909e-13	-0.876704629395708	-0.545495985589547
MYO6	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.4447314344105	-0.4447314344105	-0.166047845781739	-0.149311762512	13.980782259861	72.6026550671373	2.77415671210166e-22	5.60397958480712e-20	0.238952849985209	0.318414327272313
MYO6	BRD-K25835157-001-01-4::2.5::HTS002	2.5	PRT062070	JAK inhibitor, syk inhibitor	targeted cancer	SYK	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.2283785181275	-0.2283785181275	-0.0808183924255155	-0.05777682074495	3.26481858660802	189.695425174722	0.00129954975549166	0.0278030744205202	0.0584067794326486	0.23671347197132
MYO6	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.710589560383	-0.710589560383	-0.42150441232731	-0.310239188826	7.21453845936357	132.733783015	3.72563603687167e-11	2.59172945844423e-09	0.20982716683331	0.36834312927807
MYO6	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.545828161595	-1.545828161595	-1.97874018247591	-1.88069436606	-3.79681666149923	17.858052458311	0.00133658219618887	0.0284760442637793	-0.672595146324902	-0.193228895436927
MYO6	BRD-K31309378-001-01-5::2.5::HTS002	2.5	lucitanib	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.11742825359335	-0.11742825359335	-0.768625198848348	-0.647544423054	-8.08915958677954	4.65652506447455	0.000650686624592997	0.0151226429800903	-0.862811508579788	-0.439582381930208
MYO6	BRD-K31812033-003-11-0::2.5::HTS002	2.5	levobunolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.357034289262	0.357034289262	0.171347121339221	0.2093635994345	-5.23711354781803	175.955719357	4.61757996129536e-07	1.9797585427575e-05	-0.255660951448471	-0.115713384397087
MYO6	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.5029418904	-1.5029418904	-2.31738619430706	-2.045349051995	-7.03905734677171	18.5427160889562	1.21864021128393e-06	4.90958529782468e-05	-1.05701957982315	-0.571869027990972
MYO6	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.80654782941	-2.80654782941	-3.66958714884394	-3.65355610334	-8.47138528936337	114.515483334784	9.42478655383763e-14	8.65469184788974e-12	-1.06484712769467	-0.661231511173211
MYO6	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.264157725074	0.264157725074	0.0353712344814949	0.0389416186426	-10.8204648473242	40.7389565300168	1.49694476187395e-13	1.35089967944287e-11	-0.27149571122905	-0.18607726995596
MYO6	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.06582998538895	-0.06582998538895	-1.03986265210735	-1.017015264785	-13.2901097088737	122.625002575821	1.63247003420224e-25	4.35723125729181e-23	-1.11911021368605	-0.828955119750752
MYO6	BRD-K36529613-001-02-6::2.5::HTS002	2.5	PU-H71	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.380106335485	-2.380106335485	-3.49163383633271	-3.372344193665	-9.56800778621085	13.3668352553993	2.37693016819479e-07	1.06134388753963e-05	-1.36180189249729	-0.861253109198136
MYO6	BRD-K38332599-001-01-3::2.5::MTS010::PROS002_PR500	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.146269706265	-1.146269706265	-0.563684583113352	-0.5253626676245	6.48070342281439	17.6909832401371	4.6516069891519e-06	0.000170831781079153	0.393485248565836	0.77168499773746
MYO6	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.299053729164	0.299053729164	-0.359551964411711	-0.2780855887145	-14.7723621503314	177.570786060066	9.9550244108438e-33	5.10442685873622e-30	-0.746587654628266	-0.570623732523156
MYO6	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.663157728065	-1.663157728065	-1.00752825608537	-1.02230629729	10.2670404589871	190.530330457028	5.79095343986095e-20	9.52547398167274e-18	0.52967062887876	0.78158831508049
MYO6	BRD-K41312087-001-02-7::2.5::HTS002	2.5	GW-441756	growth factor receptor inhibitor	targeted cancer	NTRK1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.3266179512065	-0.3266179512065	-0.00435614486935058	0.0338208037479	7.82488102435255	6.08213434205187	0.000215041827957162	0.00563788378522698	0.221816554732796	0.422707057941503
MYO6	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.196646974548	0.196646974548	-0.298881958178698	-0.160539632789	-7.91867542325676	32.7620494658693	4.14166064229381e-09	2.30565710078491e-07	-0.622878442617678	-0.368179422835717
MYO6	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.511473322139	-0.511473322139	-1.39892693077855	-1.273586296615	-12.645955719019	59.7307460105572	1.54322840691985e-18	2.22733064799141e-16	-1.02784126784446	-0.747065949434642
MYO6	BRD-K47114202-001-14-6::2.57945::HTS002	2.57945	chlorogenic-acid	antioxidant	noncancer	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.4552833939485	-0.4552833939485	-1.05830201578974	-0.967874485397	-8.48418761074862	46.3236037073062	5.463476373172e-11	3.71976311177122e-09	-0.746059394518833	-0.459977849163657
MYO6	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.4057973459	-2.4057973459	-0.0422122984055214	0.365958476092	23.0759903937776	7.64553763981919	2.39789062499008e-08	1.22249643140699e-06	2.12547017932759	2.60169991566137
MYO6	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.444254924675	-1.444254924675	-1.83359651218176	-1.58248812639	-3.95244766661318	82.7961121381445	0.00016213717049799	0.00439017441045611	-0.585274089658194	-0.193409085355332
MYO6	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.4763951936785	-0.4763951936785	-1.25718933219389	-0.921278111753	-7.09484684314203	6.4953054693079	0.000275206995628657	0.00700532543540313	-1.04517876875526	-0.516409508275512
MYO6	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.507740293957	0.507740293957	-0.116469079855352	0.03876057814515	-10.499278785069	10.2193239379081	8.47497117709136e-07	3.4985209888575e-05	-0.756293656443309	-0.492125091181394
MYO6	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.8933811521345	-0.8933811521345	-0.20735445259798	-0.1324820733985	15.5059269471437	5.17392441260254	1.55116575659652e-05	0.000516643054305479	0.573437120078418	0.798616278994622
MYO6	BRD-K54095730-001-03-1::2.5::HTS002	2.5	CMPD-1	p38 MAPK inhibitor	noncancer	GNRHR, MAPK14	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.12308021848	-1.12308021848	-1.51662700683854	-1.5570935433	-4.70500511865838	7.07828259879694	0.00213105553050663	0.0423698516510164	-0.590891522504978	-0.196202054212111
MYO6	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.7203033317495	0.7203033317495	-0.595134677725873	-0.48109263675	-12.737926629214	4.0795059094661	0.00019458767066325	0.00515777651070785	-1.59996943467281	-1.03090658427793
MYO6	BRD-K58049875-001-04-7::2.5::HTS002	2.5	thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	noncancer	FOXM1	obstetrics/gynecology	mastitis	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.10253675907	-1.10253675907	-0.800628156667698	-0.684325273756	4.6552838013755	95.391970193566	1.044307845206e-05	0.000358522274796021	0.173166163129775	0.430651041674829
MYO6	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.06063922351625	-0.06063922351625	-0.143052702901396	-0.139438991422	-4.3171057130865	188.066329525468	2.55395494826135e-05	0.000816628557087241	-0.12007149275939	-0.0447554660109029
MYO6	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.47480061007	-1.47480061007	-2.08331824694873	-1.79411655002	-4.46879664191973	22.2687067149456	0.000187133799786059	0.00497929238663517	-0.890720234765978	-0.326315038991486
MYO6	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-3.595666275735	-3.595666275735	-2.93396593377173	-2.87845710522	7.64399071284284	147.826322898731	2.46107799947176e-12	1.97188929550947e-10	0.490636084786339	0.832764599140191
MYO6	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.270853163159	0.270853163159	-0.34090612446393	-0.3277516003215	-12.2274136784822	21.9991615624879	2.77125184384147e-11	1.96220560435646e-09	-0.715519080781646	-0.507999494464214
MYO6	BRD-K67511046-001-02-3::0.625::HTS002	0.625	naloxone	opioid receptor antagonist	noncancer	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.337987263583	-0.337987263583	0.0742405684045551	0.0434785043643	8.99090936572674	3.25050135918661	0.00209990310671917	0.0418358554526877	0.272474283098424	0.551981380876686
MYO6	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.1340384035705	-0.1340384035705	0.127753077302061	0.138278646354	9.1852028635807	62.146157980295	3.5062382978837e-13	3.04739881649277e-11	0.204820585354568	0.318762376390553
MYO6	BRD-K73293050-001-03-1::2.5::HTS002	2.5	WZ-3146	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.759464954035	-1.759464954035	-2.5822285383339	-2.4237476511	-8.5288079352896	174.05359733973	6.96241229589364e-15	7.13652254885981e-13	-1.01316275306543	-0.632364415532367
MYO6	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.441447354829	-0.441447354829	-1.34086849473771	-1.10972386317	-9.36906298049417	21.0061302413779	5.97343286382993e-09	3.26863526870305e-07	-1.0990585446557	-0.69978373516172
MYO6	BRD-K79259477-001-04-9::2.5::HTS002	2.5	NVP-BHG712	ephrin inhibitor	targeted cancer	EPHB4	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.7019617848465	0.7019617848465	0.145355722822593	0.138812266601	-16.1298076051409	74.6027483334367	4.97610297550215e-26	1.37261669837375e-23	-0.625355358190203	-0.487856765857611
MYO6	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-4.28745131441	-4.28745131441	-3.04894422084264	-2.99006854464	11.2780594945322	12.4600284739422	6.67178701025716e-08	3.21483236987727e-06	1.00021550525206	1.47679868188265
MYO6	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.020463277008645	-0.020463277008645	0.112768756187525	0.0998567885779	4.60232625764687	19.073966201912	0.000192662589933744	0.00511244029192887	0.0726573015383055	0.193806764854034
MYO6	BRD-K89015388-001-01-7::2.5::HTS002	2.5	GSK923295	centromere associated protein inhibitor	targeted cancer	CENPE	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.097117321985	-1.097117321985	-1.64549966108483	-1.4981509162	-6.19092484695176	177.245808759736	4.04458010780107e-09	2.2568883361752e-07	-0.723186390550644	-0.373578287649007
MYO6	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.342128575125	-1.342128575125	-1.00952240809461	-0.9517219897545	5.63400882050484	19.4559371986785	1.80406964842371e-05	0.000593681012861977	0.20923927047945	0.455973063581327
MYO6	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.3422581930875	-0.3422581930875	-0.0909081495554839	-0.0408206395104	7.84021363301064	40.1147962299002	1.27824163363365e-09	7.52649041469962e-08	0.186561999391659	0.316138087672374
MYO6	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-3.66163988969	-3.66163988969	-3.13660121535724	-3.215000704775	6.82846894100804	5.01889874496866	0.00101204946151935	0.0223527977161975	0.327611150230163	0.722466198435352
MYO9B	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.60448711346	-1.60448711346	-2.10117024041598	-2.089022441025	-6.56526515884626	51.3995789914719	2.56117484060177e-08	1.30048339827372e-06	-0.648534542508713	-0.344831711403254
MYO9B	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.170963991597	-0.170963991597	0.176664705491444	0.161263687573	12.3429942673771	19.4906373643237	1.15561479405824e-10	7.59527026052464e-09	0.288780938437708	0.406476455739181
MYO9B	BRD-A14886633-001-01-6::2.5::HTS002	2.5	norgestrel	progesterone receptor agonist	noncancer	PGR	endocrinology	contraceptive	CAL120, MCF7	BREAST	carcinoma	-0.8537708387855	-0.8537708387855	-0.125944843830602	-0.0685599407545	14.9611663534898	81.1674792391268	4.7717910225392e-25	1.23220867237326e-22	0.631035404028885	0.82461658588091
MYO9B	BRD-A28329383-001-02-1::2.5::HTS002	2.5	MTPG	glutamate receptor antagonist	noncancer	GRM2, GRM3	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.48917123924	0.48917123924	0.0178151961511577	0.0389518722109	-13.9629430824831	193.977751550716	3.99769878347231e-31	1.75219382937186e-28	-0.537935193618463	-0.404776892559221
MYO9B	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	CAL120, MCF7	BREAST	carcinoma	-2.436993612015	-2.436993612015	-3.82058250170475	-3.817245684415	-9.24429583960026	3.15212536588391	0.00218771542772098	0.0432835650242786	-1.84715983387035	-0.920017945509158
MYO9B	BRD-A44090213-001-25-6::2.5::HTS002	2.5	indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	CXCR1, CXCR2, PTGS1, PTGS2	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.045559592339	-1.045559592339	-1.91212112284026	-1.821377260325	-8.29072229824614	7.53672425618255	4.77291941494517e-05	0.0014452882809915	-1.11019272244586	-0.622930338556667
MYO9B	BRD-A50157456-065-20-6::2.5::HTS002	2.5	terbutaline	adrenergic receptor agonist	noncancer	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	CAL120, MCF7	BREAST	carcinoma	0.3710663545285	0.3710663545285	0.148474803091617	0.1597653685015	-7.3331003877173	40.4574958822674	6.05621275215015e-09	3.30622012979009e-07	-0.283918393878473	-0.161264708995293
MYO9B	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.401059035418	-0.401059035418	-0.531694561160813	-0.51783728433	-4.05357762460047	112.494211250159	9.32043170344759e-05	0.00265502233727833	-0.194486562005751	-0.0667844894798752
MYO9B	BRD-A83937277-001-10-5::2.5::HTS002	2.5	mephenytoin	hydantoin antiepileptic	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	CAL120, MCF7	BREAST	carcinoma	-0.265562076871	-0.265562076871	-0.0667889636053023	-0.09044120254575	5.15972786467551	46.4576059103652	5.02043470926648e-06	0.000182841928768458	0.121249024627786	0.276297201903609
MYO9B	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	CAL120, MCF7	BREAST	carcinoma	0.707253464705	0.707253464705	0.257503035195895	0.303778240807	-8.92256667623913	4.8590032955603	0.000340846636418198	0.00850545101139549	-0.580462140644648	-0.319038718373561
MYO9B	BRD-K02389548-001-02-5::2.5::HTS002	2.5	RG2833	HDAC inhibitor	noncancer	HDAC1, HDAC3	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.0244662158051445	0.0244662158051445	0.320556147781111	0.362491356389	6.76778610897633	11.4510796851255	2.52236671970239e-05	0.00080749266119058	0.200257835032719	0.391922028919213
MYO9B	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.1720412847845	0.1720412847845	-0.364791036431158	-0.264963110089	-7.24180472792031	9.0866078136718	4.62236557801794e-05	0.00140267165789467	-0.704281871512114	-0.369382770919202
MYO9B	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.2035181733895	0.2035181733895	-0.344033801060909	-0.229059189804	-9.37136029863469	4.28754194073584	0.000515276223312417	0.0123092552013294	-0.705572901593176	-0.389531047307642
MYO9B	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.10245687984	-1.10245687984	-0.638956683805328	-0.586240520956	6.5732582811963	8.17562736261358	0.000158111443078521	0.00429123306110882	0.301502918502538	0.625497473566806
MYO9B	BRD-K06234293-001-04-2::2.5::HTS002	2.5	LY364947	TGF beta receptor inhibitor, p38 MAPK inhibitor	targeted cancer	TGFBR1	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.3223065995495	0.3223065995495	0.790872168043718	0.824104228749	13.9959793445166	84.8807919372894	9.18047600172637e-24	2.10668334151393e-21	0.401999824992727	0.53513131199571
MYO9B	BRD-K06593056-001-04-8::2.5::HTS002	2.5	LE-135	retinoid receptor agonist	noncancer	RARB	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.585158183959	-0.585158183959	-0.136652942562011	-0.152062454998	11.7486159447468	6.94274679500506	7.80668308694824e-06	0.000274429814555114	0.358084218254479	0.538926264539498
MYO9B	BRD-K08303368-001-10-0::2.5::HTS002	2.5	chlorpyrifos	acetylcholinesterase inhibitor	noncancer	ACHE	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.0489119067896	0.0489119067896	0.293336705816493	0.280025726935	9.94336936808081	161.632573870549	1.7832283924161e-18	2.54968350979419e-16	0.195882122156868	0.292967475896919
MYO9B	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.5595425082505	0.5595425082505	0.00950758291200225	0.1859491052615	-7.74718270103446	14.1496883185378	1.85591612951968e-06	7.25737362021206e-05	-0.702159623416375	-0.397910227260621
MYO9B	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	CAL120, MCF7	BREAST	carcinoma	0.175936105429	0.175936105429	-0.480082950121238	-0.33490377325	-9.44686144089784	85.8051206469903	6.18049587531557e-15	6.38082611011807e-13	-0.794071781807444	-0.517966329293032
MYO9B	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	CAL120, MCF7	BREAST	carcinoma	-0.6945674992615	-0.6945674992615	-1.81539489317563	-1.56065418801	-10.6294667293474	185.716260615116	6.44934289435317e-21	1.15963189027166e-18	-1.32885199089778	-0.912802796930473
MYO9B	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAL120, MCF7	BREAST	carcinoma	-3.060354330365	-3.060354330365	-1.9200963917999	-2.01595157397	12.2690769220617	9.77103446357659	2.95991687053601e-07	1.30534161099817e-05	0.932520540912147	1.34799533621805
MYO9B	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	CAL120, MCF7	BREAST	carcinoma	0.131565938436	0.131565938436	0.241986431942156	0.282942219323	3.79186311812183	21.1301269561779	0.00105825942233389	0.0232030296003058	0.0498840493866173	0.170956937625696
MYO9B	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.0927402055985	0.0927402055985	-0.948053182981432	-0.8887322701185	-12.791391240891	6.75437101429412	5.54221668849243e-06	0.00020044295043496	-1.23462259718273	-0.846964179977138
MYO9B	BRD-K18849474-001-04-4::2.60504::HTS002	2.60504	dalcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.04711786229135	0.04711786229135	0.303145976327675	0.287686302566	9.39082846961458	182.764535005474	2.41525619129843e-17	3.12031009177095e-15	0.202236177226188	0.309820050846461
MYO9B	BRD-K18961567-001-01-1::2.5::MTS010::PROS002_PR500	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.06317453588025	-0.06317453588025	-0.41726069520329	-0.32717924466	-5.34598744874738	19.5404309508445	3.36637316533622e-05	0.00104855601533694	-0.49245647965365	-0.21571583899243
MYO9B	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.027545556752385	0.027545556752385	-0.826598238303204	-0.81565114113	-11.7781151431426	13.4546757918184	1.81858339099695e-08	9.43308711541591e-07	-1.01027630394706	-0.69801128616412
MYO9B	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.67112115367	-1.67112115367	-3.14672039330559	-3.22475555586	-9.21743653173	4.50874904145997	0.000429965081768559	0.0104784345223736	-1.90097678309382	-1.05022169617736
MYO9B	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.192807446101	0.192807446101	-0.308808938574667	-0.19710233478	-8.63052764170963	73.3636707817411	8.85851769994466e-13	7.41655171918531e-11	-0.61744204125446	-0.385790728096874
MYO9B	BRD-K21396683-001-04-8::2.5::HTS002	2.5	marimastat	matrix metalloprotease inhibitor	targeted cancer	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.8005895206615	-0.8005895206615	-1.80512805721256	-1.72083973318	-9.34507598719587	3.6628001575906	0.0010998039026586	0.0240150195892376	-1.3141438841484	-0.694933188953722
MYO9B	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.3836798257735	-0.3836798257735	-0.977579929788506	-0.82417204092	-5.92260847202317	102.621168044087	4.25451440698852e-08	2.09239517745627e-06	-0.792784171218914	-0.395016036811099
MYO9B	BRD-K24696047-001-02-3::2.5::HTS002	2.5	NVP-AEW541	IGF-1 inhibitor	targeted cancer	IGF1R, INSR	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.0522013752998	-0.0522013752998	0.167103176839443	0.195838010554	6.7858306294893	168.725980943479	1.87106895997127e-10	1.20175109116477e-08	0.155504804013268	0.283104300265219
MYO9B	BRD-K25224017-001-25-0::2.5::HTS002	2.5	pirenperone	serotonin receptor antagonist	noncancer	HTR2A, HTR7	NA	NA	CAL120, MCF7	BREAST	carcinoma	-3.215839241785	-3.215839241785	-2.54392795184476	-2.42480640669	7.13237980222639	153.731730230371	3.62496972037223e-11	2.52908898176322e-09	0.485806355822538	0.858016224057945
MYO9B	BRD-K25433859-003-25-4::2.5::HTS002	2.5	maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2	neurology/psychiatry	depression, dysthymic disorder	CAL120, MCF7	BREAST	carcinoma	-0.1439668598265	-0.1439668598265	0.176232628999657	0.1863876312595	10.1182668946926	10.1089753002509	1.30861202165734e-06	5.25132945122253e-05	0.249791404533304	0.39060757311901
MYO9B	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.1384252163075	0.1384252163075	-0.507269663736604	-0.436225052339	-13.3888572468206	84.8504585391531	1.24977018541935e-22	2.6235258968731e-20	-0.741584099609379	-0.549805660478829
MYO9B	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	CAL120, MCF7	BREAST	carcinoma	-0.226413086722	-0.226413086722	-0.0308459617356206	-0.0206189181826	8.17488051159639	181.50649925291	4.95482960360761e-14	4.69479962029892e-12	0.148364306296526	0.242769943676233
MYO9B	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.8745248070375	-0.8745248070375	-0.527414114994397	-0.447815997104	7.74931177426936	187.478695156017	5.66737539538615e-13	4.8182582352944e-11	0.258748697219293	0.435472686866913
MYO9B	BRD-K26997899-001-02-2::2.5::HTS002	2.5	D-64131	microtubule inhibitor	chemo	TUBB	NA	NA	CAL120, MCF7	BREAST	carcinoma	-2.17306553621	-2.17306553621	-3.02670066813138	-2.92524371085	-8.19643600365417	35.2280071896044	1.11629673966673e-09	6.60924762198981e-08	-1.06501610104439	-0.642254162798359
MYO9B	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	CAL120, MCF7	BREAST	carcinoma	-3.96358938817	-3.96358938817	-3.62526844290865	-3.57671972887	4.58898036986197	157.010617393442	9.06421764428852e-06	0.000314662245462053	0.192700903358487	0.48394098716421
MYO9B	BRD-K31309378-001-01-5::2.5::HTS002	2.5	lucitanib	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.10364774907885	-0.10364774907885	-0.768771799960204	-0.647544423054	-9.25756238724659	9.28623021325295	5.44291516081659e-06	0.000197089806302189	-0.826891822448128	-0.50335627931458
MYO9B	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.549237391831	0.549237391831	0.0372072094791178	0.143970790547	-8.88364705626566	4.41163581860852	0.000560058564987116	0.013259338581147	-0.666337042610774	-0.357723322092991
MYO9B	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.098387346905	-1.098387346905	-1.9778866813522	-2.04775511057	-13.1371705862371	184.854703749114	2.85050494529751e-28	9.88585557315001e-26	-1.01157851942955	-0.747420149464858
MYO9B	BRD-K36363294-001-04-2::2.5::HTS002	2.5	I-BET151	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.5680948585045	-0.5680948585045	0.122561348259122	0.175731719762	8.64964317492814	4.59203412180946	0.000517938456340202	0.0123659609456321	0.479792583481571	0.901519830045673
MYO9B	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.2930101578415	0.2930101578415	0.577844972275908	0.571651612309	8.45768262043117	58.3663705743677	1.00319486872649e-11	7.50222445984926e-10	0.217430696373744	0.352238932495071
MYO9B	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	CAL120, MCF7	BREAST	carcinoma	-6.04313207943	-6.04313207943	-4.65096317083122	-5.03947371329	10.7843362712021	53.7537277986525	4.68113723809929e-15	4.88463224491033e-13	1.13332836119699	1.65100945600058
MYO9B	BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500	0.625	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.337332329155	-1.337332329155	-1.7257246412118	-1.77978641517	-4.15087790129548	47.9471445997761	0.000134954023548729	0.00371446781985047	-0.576530180921258	-0.200254443192341
MYO9B	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	CAL120, MCF7	BREAST	carcinoma	-5.409407075325	-5.409407075325	-6.61274050657626	-6.671127343215	-12.2309886934942	6.5909623091009	8.97256031164529e-06	0.000311682314268172	-1.4389336435803	-0.967733218922229
MYO9B	BRD-K41859756-001-06-8::2.5::HTS002	2.5	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-3.1192766848	-3.1192766848	-3.99627149969143	-3.99973792001	-7.63053153117232	6.71530602910637	0.00015191464598593	0.00413299240410237	-1.15111979833757	-0.602869831445283
MYO9B	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	CAL120, MCF7	BREAST	carcinoma	0.0541125343922	0.0541125343922	-0.110945994279633	-0.11764531931	-3.21648950080674	72.2197576267522	0.00194286163511614	0.0391143707864745	-0.267350502026919	-0.0627665553167471
MYO9B	BRD-K42898655-001-01-8::2.5::HTS002	2.5	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	CAL120, MCF7	BREAST	carcinoma	-1.178340767225	-1.178340767225	-1.34672616001855	-1.32952488095	-3.18810438732055	57.7697247349411	0.00231286404879378	0.0454345195268757	-0.274118628651072	-0.0626521569360212
MYO9B	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.66364689642	0.66364689642	0.365296930247572	0.394038132066	-6.29510655147293	19.0210201151602	4.80146085868082e-06	0.00017561302122529	-0.397539224883642	-0.199160707461214
MYO9B	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.017507939025	-1.017507939025	-1.39581453935898	-1.171371713075	-5.15911451699906	182.478436257295	6.43155392818348e-07	2.7023495821871e-05	-0.522986007700357	-0.23362719296761
MYO9B	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.5345404657405	0.5345404657405	-0.37153514586122	-0.243490121847	-11.7813959064343	7.78282569188309	3.0937750607633e-06	0.000116946334214874	-1.084289321962	-0.72786190124144
MYO9B	BRD-K49071277-001-04-7::2.5::HTS002	2.5	securinine	GABA receptor antagonist, TP53 activator	noncancer	GABRA1	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.01530202076474	0.01530202076474	0.294406158320732	0.294659751206	8.29451534738755	3.98843900258048	0.00116807150077165	0.0253443608715212	0.185571972798982	0.372636302313002
MYO9B	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	CAL120, MCF7	BREAST	carcinoma	0.1744920386895	0.1744920386895	0.0268534915417218	0.0405492292056	-5.72073761194909	124.278974648144	7.47963510952761e-08	3.57755570941741e-06	-0.198717900452678	-0.0965591938428788
MYO9B	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	CAL120, MCF7	BREAST	carcinoma	0.4832031889515	0.4832031889515	0.377849432089924	0.393436647762	-3.97125933202713	21.8302204800948	0.000654746256036768	0.0152054513284326	-0.16039646863507	-0.050311045088082
MYO9B	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.8374143901935	-0.8374143901935	-0.207949843682459	-0.1324820733985	14.7649192147196	6.42141962725128	3.39268814194401e-06	0.000127369321558017	0.526783970963165	0.732145122058917
MYO9B	BRD-K55966568-001-05-4::2.5::HTS002	2.5	orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.0853583747849	0.0853583747849	0.322015867684813	0.338245080864	8.98345072916688	73.5752873920564	1.87443008907662e-13	1.67323917768306e-11	0.184161453788842	0.289153532010984
MYO9B	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	CAL120, MCF7	BREAST	carcinoma	-2.65089798918	-2.65089798918	-2.0013089864787	-2.19151625043	7.17305490205911	66.2928975089403	7.80165368823512e-10	4.70092952866389e-08	0.468795831587437	0.830382173815168
MYO9B	BRD-K60369935-001-18-3::2.5::HTS002	2.5	ribavirin	antiviral	noncancer	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	CAL120, MCF7	BREAST	carcinoma	0.47741407652	0.47741407652	0.37114009548173	0.414452156411	-3.70759204021282	190.852922132806	0.0002741507100153	0.00698507459900965	-0.162812676718406	-0.0497352853581344
MYO9B	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.25106366281	-1.25106366281	-0.362136721309096	-0.394478559639	19.114034267617	169.348252402679	3.87730633823111e-44	5.7709665983801e-41	0.797119789515947	0.980734093485861
MYO9B	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	CAL120, MCF7	BREAST	carcinoma	-2.931309860265	-2.931309860265	-4.00257418470559	-4.1239035813	-10.251516262105	188.27564251073	7.07979705678247e-20	1.15216843081483e-17	-1.27740194056679	-0.865126708314396
MYO9B	BRD-K62391742-001-03-0::2.5::HTS002	2.5	venetoclax	BCL inhibitor	targeted cancer	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	CAL120, MCF7	BREAST	carcinoma	0.1291017729965	0.1291017729965	0.36114113633855	0.3408626748475	7.95137568045715	44.7976209587977	4.18544538256848e-10	2.58892445425836e-08	0.173255881389607	0.290822845294492
MYO9B	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.02725286795	-1.02725286795	-1.48477768082939	-1.417507299725	-6.88225209981096	135.703218411365	1.98374956941747e-10	1.27221741910137e-08	-0.588993534687342	-0.326056091071445
MYO9B	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.350617204325	-1.350617204325	-2.49785389476086	-2.41136656484	-11.757105147712	14.6248161096555	7.55744284950561e-09	4.08313377487191e-07	-1.35568529445967	-0.938788086412054
MYO9B	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.15551550038415	0.15551550038415	-0.610885815146889	-0.456560974373	-8.92710210676497	4.30529972553192	0.000616876472762306	0.0144191367563583	-0.998241716559914	-0.534560914502163
MYO9B	BRD-K68202742-001-16-5::2.63491::HTS002	2.63491	trichostatin-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	CAL120, MCF7	BREAST	carcinoma	-4.889721987545	-4.889721987545	-5.51581568933265	-5.55299903679	-6.32776175872925	5.28195155100866	0.00118574885765248	0.0256889080068532	-0.87640732758644	-0.375780075988864
MYO9B	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	CAL120, MCF7	BREAST	carcinoma	-2.4655178963	-2.4655178963	-3.68397106519487	-3.50719189578	-9.10833856211154	9.72398810781982	4.52866952243772e-06	0.000166659548433131	-1.51766961417599	-0.919236723613748
MYO9B	BRD-K70511574-001-06-9::2.5::HTS002	2.5	HMN-214	PLK inhibitor	targeted cancer	PLK1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-2.37982999639	-2.37982999639	-2.83641678901253	-2.842294760615	-4.0136052545015	10.4337347520993	0.0022633680041214	0.0446032917391812	-0.708638309928821	-0.204535275316244
MYO9B	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.4628475956355	-0.4628475956355	-1.19786828783402	-1.12346956245	-9.23070807873665	20.9994423956346	7.72321700612593e-09	4.16954503200495e-07	-0.900615971134431	-0.5694254132626
MYO9B	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	CAL120, MCF7	BREAST	carcinoma	0.05249706554295	0.05249706554295	0.223118028200846	0.235603358555	6.61423715677291	97.7989896613565	1.99415379034858e-09	1.14877735861267e-07	0.119428294839613	0.221813630476179
MYO9B	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.485980793055	-1.485980793055	-0.882030474330321	-0.689609968602	9.26122811484275	43.2702151208739	7.91863281204329e-12	6.00351132639698e-10	0.472459985012139	0.735440652437218
MYO9B	BRD-K74501079-001-18-1::2.5::HTS002	2.5	azithromycin	bacterial 50S ribosomal subunit inhibitor	noncancer	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	CAL120, MCF7	BREAST	carcinoma	-0.13205447223955	-0.13205447223955	-0.78783925005042	-0.6289149698795	-8.72552896100906	22.269065961848	1.22631483992776e-08	6.49616493640326e-07	-0.811541785627716	-0.500027769994025
MYO9B	BRD-K75009076-001-02-1::2.429::HTS002	2.429	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.4385567033685	-0.4385567033685	-1.9312283202752	-1.72291152257	-16.5063069315486	187.499383382701	2.19317289736567e-38	1.95045872995638e-35	-1.6710633403999	-1.31427989341349
MYO9B	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.5459856724095	0.5459856724095	-0.693368787474017	-0.481859441946	-15.9672134413121	162.154594847796	4.30609143631305e-35	2.74678652218316e-32	-1.39262824597905	-1.08608067378799
MYO9B	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.2553085311415	-0.2553085311415	-1.48309178743331	-1.368540965995	-12.8685753795823	28.4596151917675	2.18546679120961e-13	1.94441225360383e-11	-1.42307848849819	-1.03248802408543
MYO9B	BRD-K77245796-003-01-6::2.5::HTS002	2.5	gamma-aminobutyric-acid	benzodiazepine receptor agonist	noncancer	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.00251313065035	-0.00251313065035	0.511131361095243	0.500110131001	11.4687820294713	3.57799197063336	0.000599141117859087	0.0140726922355748	0.383294550064532	0.643994433426653
MYO9B	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	CAL120, MCF7	BREAST	carcinoma	-0.01073030441355	-0.01073030441355	-0.209526014899867	-0.20601445055	-4.21710710658008	152.272923012023	4.23010879489904e-05	0.00129463799500488	-0.291929183148075	-0.10566223782456
MYO9B	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	CAL120, MCF7	BREAST	carcinoma	-2.54413110899	-2.54413110899	-1.27067373389366	-1.21704769228	19.0485461262357	24.5948279123486	3.09584616865725e-16	3.62981188994606e-14	1.13565540845373	1.41125934173894
MYO9B	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.715700216889	-0.715700216889	-0.321025994321363	-0.3195858510195	5.42885142001392	16.1979029214502	5.33751327514778e-05	0.00160176964820659	0.240711277986729	0.548637167148544
MYO9B	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	CAL120, MCF7	BREAST	carcinoma	1.06464494081	1.06464494081	0.449272997557115	0.472553592618	-12.2948880705203	2.62650937286411	0.00215108739465383	0.042681600588071	-0.788269690442454	-0.442474196063316
MYO9B	BRD-K85606544-001-09-1::2.5::HTS002	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	CAL120, MCF7	BREAST	carcinoma	-0.6936483660905	-0.6936483660905	-1.59858854004384	-1.5159358626	-9.79040686517433	31.0552874693127	5.20369373527877e-11	3.5575836510002e-09	-1.09344148060458	-0.716438867302103
MYO9B	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	CAL120, MCF7	BREAST	carcinoma	-1.425810069665	-1.425810069665	-1.65128228599303	-1.74044254788	-3.71679921804704	44.42010425819	0.000562270247139526	0.0132999470035501	-0.347697823808363	-0.103246608847699
MYO9B	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	CAL120, MCF7	BREAST	carcinoma	-4.954074723745	-4.954074723745	-5.62352322813926	-5.62740406384	-6.39911151835417	48.2364496742647	6.02282580068318e-08	2.91260431190123e-06	-0.87976613901936	-0.459130869769157
MYO9B	BRD-K93869735-001-01-1::2.5::HTS002	2.5	taltirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	neurology/psychiatry	spinocerebellar ataxia	CAL120, MCF7	BREAST	carcinoma	0.218984490942	0.218984490942	-0.185233034109785	-0.1119517959605	-6.78126739187931	5.10706828054055	0.000974950001953505	0.021649405197751	-0.556483484334517	-0.251951565769053
MYO9B	BRD-K95763993-001-19-3::2.5::HTS002	2.5	trapidil	PDGFR tyrosine kinase receptor inhibitor	noncancer	PDGFRA	cardiology	coronary artery disease (CAD)	CAL120, MCF7	BREAST	carcinoma	-0.020203035176895	-0.020203035176895	0.397845818428136	0.422554855711	13.540209893034	9.20478000560349	2.18452827250146e-07	9.82597607800558e-06	0.348441747906999	0.487655959303062
MYO9B	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	CAL120, MCF7	BREAST	carcinoma	0.3776601825445	0.3776601825445	-0.2288369697924	-0.0281474951666	-9.00534382005766	17.506555733656	5.50691147161085e-08	2.6770034674504e-06	-0.748277690012412	-0.464716614661387
NAALADL2	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	1.07827719397	1.07827719397	0.461681270241606	0.473952429855	-11.7545659397172	4.5234690351514	0.000146229936155793	0.00398896728857516	-0.755824707038805	-0.477367140417984
NAALADL2	BRD-A64553394-001-04-4::2.6791::HTS002	2.6791	DPI-201106	sodium channel activator	noncancer	ADRB2	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-2.216710002385	-2.216710002385	-1.64220829503993	-1.49161103544	4.87039055840191	6.2434190012292	0.00250097643381578	0.0485932171229537	0.28857478484469	0.860428629845452
NAALADL2	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	RVH421, OV7, KYSE180	SKIN, OVARY, OESOPHAGUS	malignant_melanoma, carcinoma, carcinoma (squamous_cell_carcinoma)	0.632665339390333	0.617879196297	0.353128416008206	0.36000313707	-6.6884040737331	4.02936537550373	0.00253169544392062	0.0491143874728514	-0.39524364356579	-0.163830203198465
NAALADL2	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.460479013285	-1.460479013285	-1.90094990653665	-1.73380354334	-4.07784162653751	75.4923570283359	0.000111518648421878	0.00312767343596083	-0.655626189709023	-0.225315596794274
NAALADL2	BRD-K12932420-001-02-3::2.5::HTS002	2.5	YM-976	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	RVH421, OV7, KYSE180	SKIN, OVARY, OESOPHAGUS	malignant_melanoma, carcinoma, carcinoma (squamous_cell_carcinoma)	0.502344733394	0.499732032668	0.309920114320119	0.328634271021	-5.6697807574957	188.042202021988	5.31406204591385e-08	2.58795183876089e-06	-0.25937400062779	-0.125475237519972
NAALADL2	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.022594285345	-1.022594285345	-0.505531278675591	-0.370831351035	8.01266932053728	106.43571901481	1.52794885543323e-12	1.24660734768233e-10	0.389130701802815	0.644995311536002
NAALADL2	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.7717550091955	-0.7717550091955	-0.4699308988986	-0.349104647656	3.44802821480107	191.3833943034	0.000694355410621303	0.0160436072448311	0.129166305844354	0.474481914749447
NAALADL2	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.05175296280675	0.05175296280675	0.261436555608634	0.263001454047	7.38039647244228	74.6830165879476	1.82374476780166e-10	1.17311342238344e-08	0.153082270616957	0.26628491498681
NAALADL2	BRD-K17743125-001-08-4::2.5::MTS010::PROS003_PR500	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.3750517743725	-0.3750517743725	-0.680526217199805	-0.635077786673	-3.68241514660115	188.19215282423	0.000301770934851262	0.00761637572959682	-0.469115430319935	-0.141833455334675
NAALADL2	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.482750087825	0.482750087825	0.306318164922289	0.3131581681635	-5.87119904573778	167.126135197619	2.27112144020637e-08	1.16209791505739e-06	-0.23575924256215	-0.117104603243272
NAALADL2	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.0600158784361	0.0600158784361	-0.0275507048019611	-0.00807522835948	-3.57021373188832	152.708311571571	0.000477236303034727	0.0114992219891096	-0.13602259760542	-0.0391105688707023
NAALADL2	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.0615980692305	0.0615980692305	-0.44933898347681	-0.359947291571	-12.4788915874183	194.415912411467	1.23824693358837e-26	3.65554031720472e-24	-0.59168869818088	-0.43018540723374
NAALADL2	BRD-K25244359-066-03-4::2.68145::HTS002	2.68145	apatinib	RET tyrosine kinase inhibitor	targeted cancer	CSK, KDR, KIT, RET	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.3671152306985	0.3671152306985	0.134314402924653	0.183294433483	-5.90598586566405	60.9322230088848	1.68609653446608e-07	7.69547240493144e-06	-0.31162331548894	-0.153978340058754
NAALADL2	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.0539616263571	0.0539616263571	-0.429468487189186	-0.326694667694	-10.1595278906968	8.8694015678579	3.5058166280401e-06	0.000131363316795665	-0.591314502098077	-0.375545724994495
NAALADL2	BRD-K39171998-001-01-1::2.5::HTS002	2.5	STF-118804	NAMPT inhibitor	targeted cancer	NAMPT	NA	NA	RVH421, OV7	SKIN, OVARY	malignant_melanoma, carcinoma	-4.235541528435	-4.235541528435	-4.6710400499202	-4.69138817122	-4.21589746825985	38.9603837952614	0.000143037352795709	0.00390784611693454	-0.644447517704514	-0.226549525265892
NAALADL2	BRD-K42981054-001-01-9::2.5::HTS002	2.5	mibampator	glutamate receptor modulator	noncancer	GRIA1	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.5246734697095	-0.5246734697095	-1.05913799513234	-1.074754636055	-7.45420270059134	4.03097303615478	0.00167848369492653	0.0346244207747746	-0.7329331669092	-0.335995883936475
NAALADL2	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.006030156702	-1.006030156702	-1.39593664342625	-1.171371713075	-5.2291461175736	135.897278615555	6.28127234454777e-07	2.6420896662143e-05	-0.537362493706083	-0.242450479742416
NAALADL2	BRD-K49669041-001-08-4::2.5::HTS002	2.5	BX-912	pyruvate dehydrogenase kinase inhibitor	targeted cancer	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1	NA	NA	RVH421, OV7, KYSE180	SKIN, OVARY, OESOPHAGUS	malignant_melanoma, carcinoma, carcinoma (squamous_cell_carcinoma)	-0.608214673383	-0.529801331995	-1.95761636442841	-1.73927680134	-10.9654874620862	9.75030606455709	8.43790841776302e-07	3.48590684901837e-05	-1.62454895771482	-1.07425442437601
NAALADL2	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	RVH421, OV7, KYSE180	SKIN, OVARY, OESOPHAGUS	malignant_melanoma, carcinoma, carcinoma (squamous_cell_carcinoma)	-5.11925829612	-5.1316197475	-5.93596263176995	-5.9784652889	-9.94234788634892	17.8841631858964	1.03869612402204e-08	5.53374848534723e-07	-0.989362657330755	-0.64404601396914
NAALADL2	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-1.53917269772	-1.53917269772	-2.01313585128146	-2.23082742718	-5.10797487043189	40.0467526412495	8.36498121029142e-06	0.000292425062440149	-0.661489610725271	-0.286436696397655
NAALADL2	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	RVH421, OV7, KYSE180	SKIN, OVARY, OESOPHAGUS	malignant_melanoma, carcinoma, carcinoma (squamous_cell_carcinoma)	-4.31165335625	-4.36254464535	-5.60526949252413	-5.55232603448	-13.8614699265299	20.1004190478105	9.48148594194856e-12	7.13037684369085e-10	-1.48822551160457	-1.09900676094368
NAALADL2	BRD-K66030860-001-03-6::2.5::HTS002	2.5	salidroside	beta amyloid protein neurotoxicity inhibitor	noncancer	APP	NA	NA	RVH421, OV7	SKIN, OVARY	malignant_melanoma, carcinoma	0.527090494047	0.527090494047	0.12900681136714	0.132086067756	-11.9391157480892	7.92702981272203	2.40634498270553e-06	9.2694017576976e-05	-0.47509571598097	-0.321071649378751
NAALADL2	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.430656976564	0.430656976564	0.253441767678525	0.248858708206	-6.86645253182056	6.83543292125442	0.000265357050473176	0.00679089089801376	-0.238542548274705	-0.115887869496244
NAALADL2	BRD-K67173685-001-06-9::2.38783::HTS002	2.38783	4E1RCat	protein synthesis inhibitor	noncancer	EIF4E, EIF4G1	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.7340694184765	0.7340694184765	0.463939417159615	0.4775114804595	-6.71156719612131	6.53761433201831	0.000369456195521398	0.00915965030999487	-0.366684100752376	-0.173575901881394
NAALADL2	BRD-K77841042-001-14-1::2.5::HTS002	2.5	brefeldin-a	protein synthesis inhibitor	targeted cancer	ARF1, CYTH2	NA	NA	RVH421, OV7, KYSE180	SKIN, OVARY, OESOPHAGUS	malignant_melanoma, carcinoma, carcinoma (squamous_cell_carcinoma)	-4.05373965374667	-4.0589716927	-4.74859105352577	-4.82779314514	-5.24971115370183	21.9778494587132	2.89299175917202e-05	0.000912377914584432	-0.969365134587568	-0.420337664970633
NAALADL2	BRD-K81916719-001-13-9::2.5::HTS002	2.5	triclabendazole	microtubule inhibitor	noncancer	DNMT1	infectious disease	tapeworm	RVH421, OV7, KYSE180	SKIN, OVARY, OESOPHAGUS	malignant_melanoma, carcinoma, carcinoma (squamous_cell_carcinoma)	-0.806970929215667	-0.684427664512	-2.35641099503854	-2.33226843739	-9.75848664367226	3.38395614883506	0.00135645970490567	0.0288249704632884	-2.02380870896405	-1.07507142268171
NAALADL2	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.571427418353	0.571427418353	0.304649035149557	0.320041105609	-10.2662851652178	185.826809490132	7.1522740281157e-20	1.16308022774811e-17	-0.31804362943118	-0.215513136975707
NAALADL2	BRD-K89085489-001-23-2::2.5::MTS006	2.5	fenretinide	apoptosis stimulant, retinoid receptor agonist	targeted cancer	RARA	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.5199209999285	0.5199209999285	0.316385452381531	0.36259103347	-5.41163811485332	6.56319454214983	0.00123098208823592	0.0265284234450643	-0.293684811412959	-0.113386283680979
NAALADL2	BRD-K91623615-001-05-0::2.46068::HTS002	2.46068	ABT-751	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-3.041291604515	-3.041291604515	-3.49572396493823	-3.442891314055	-4.73003637178979	171.674332918386	4.66465448561625e-06	0.000171222937360446	-0.644070300966446	-0.264794419880022
NAALADL2	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	RVH421, OV7, KYSE180	SKIN, OVARY, OESOPHAGUS	malignant_melanoma, carcinoma, carcinoma (squamous_cell_carcinoma)	0.411263638801667	0.415811428583	-0.0417255696220135	0.0033629428541	-6.02405598204558	7.07528480080914	0.000508137116672524	0.0121644722527985	-0.630418352152824	-0.275560064694536
NAALADL2	BRD-K97752965-001-16-4::2.5::HTS002	2.5	nicorandil	nitric oxide donor, potassium channel activator	noncancer	KCNJ11	cardiology	angina pectoris	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.4706284482975	0.4706284482975	0.247304780558834	0.245556311183	-6.13857752294335	4.45921530580157	0.00248235134468936	0.048279481066781	-0.320358757407864	-0.126288578069469
NAALADL2	BRD-K99616396-001-05-1::2.5::MTS006	2.5	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.1730539390085	-0.1730539390085	-0.0150792285804619	-0.0150428280254	5.14683553264377	20.7975679656381	4.36535250016164e-05	0.00133321124844426	0.0941061043942868	0.221843316461789
NAALADL2	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	RVH421, KYSE180	SKIN, OESOPHAGUS	malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.1688426007085	-0.1688426007085	0.097134974323195	0.1722526996835	8.44892424791535	42.9707992798756	1.11289381469861e-10	7.33039463713188e-09	0.202489558534793	0.329465591528597
NCOA2	BRD-A13561534-003-02-0::2.5::HTS002	2.5	ornithine	NFkB pathway modulator	noncancer	ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	1.081795937305	1.081795937305	0.620800375390326	0.6438914807695	-15.3329029040651	15.3090395698271	1.05725202057695e-10	6.98304370780391e-09	-0.524966749376411	-0.397024374452938
NCOA2	BRD-A73556557-001-06-4::2.5::HTS002	2.5	tagatose	phosphorylase inhibitor	noncancer	PYGL	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.488399471724	0.488399471724	0.111031600035263	0.1416103571295	-10.1740651604019	6.06045602290943	4.9261608462699e-05	0.00148811716422858	-0.467907657595917	-0.286828085781558
NCOA2	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.590465687303	0.590465687303	0.411206316434515	0.462027349437	-5.00534993575603	27.232651233047	2.93602010091647e-05	0.000924723368419288	-0.25271335109253	-0.10580539064444
NCOA2	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.2045466069215	-0.2045466069215	0.0612530874907166	0.0780850986405	4.95556969339718	12.00954561953	0.000332459062535905	0.00831648207449322	0.148945978000513	0.382653410823921
NCOA2	BRD-K06152156-001-01-8::2.5::HTS002	2.5	methoxyflurane	membrane permeability inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.39294891509	-1.39294891509	-1.86934434782991	-1.724302233865	-4.81446982128969	16.5913975106935	0.000172788040775665	0.00464494595189368	-0.685555621495663	-0.26723524398416
NCOA2	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.9438917258945	-0.9438917258945	-0.416424445782697	-0.37916191768	8.03239270455195	5.98188751682206	0.000202020740380116	0.00533106417938068	0.366666646258115	0.68826791396549
NCOA2	BRD-K13514097-001-05-3::2.5::HTS002	2.5	everolimus	mTOR inhibitor	targeted cancer	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.06601437662605	-0.06601437662605	-0.753812312439157	-0.7206768922275	-10.1284579632593	9.87330392935384	1.56492208188715e-06	6.2066651533825e-05	-0.839368798529082	-0.536227073097131
NCOA2	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.546249521263	-0.546249521263	-0.0485475406331274	0.2281371067585	7.65996010584668	195.003422731954	8.48230649663354e-13	7.1126927586736e-11	0.369559047588647	0.625844913671098
NCOA2	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.4394850474095	0.4394850474095	0.0958992473553066	0.13724327771	-11.1357198898571	4.27696153037888	0.000255628465434926	0.00657173963874322	-0.427107252643044	-0.260064347465343
NCOA2	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.1070789935875	0.1070789935875	-0.0538275019169292	-0.030411088067	-8.91178313417257	188.996552555279	4.21715446548471e-16	4.87781165371221e-14	-0.196522644793037	-0.125290346215822
NCOA2	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.10308014486965	0.10308014486965	0.414713528683772	0.43502168689	9.39424878843347	4.07109247918782	0.000657382954147507	0.0152633767933573	0.220161822094544	0.403104945533699
NCOA2	BRD-K35960502-001-20-0::2.5::HTS002	2.5	niclosamide	DNA replication inhibitor, STAT inhibitor	noncancer	STAT3	infectious disease	tapeworm	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.949962691765	-1.949962691765	-0.690107735327586	-0.652327741583	17.8910077633109	6.74113901018111	6.21754007390451e-07	2.61858743662779e-05	1.09203704136961	1.42767287150522
NCOA2	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.0421424603735	0.0421424603735	-0.356818865807557	-0.2780855887145	-7.68935259294378	12.9404321152721	3.53995536566208e-06	0.000132596136589827	-0.51110432141107	-0.286818330951044
NCOA2	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.02985562708485	0.02985562708485	-0.207302228140013	-0.158031671069	-6.63017207954013	66.3167145199918	7.1912953111555e-09	3.89119700263733e-07	-0.308567575042069	-0.165748135407658
NCOA2	BRD-K44827188-001-06-0::2.5::HTS002	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.3436362598485	0.3436362598485	-0.116946435974175	-0.06245449085225	-7.98381029931595	13.7139711738599	1.60806631334808e-06	6.3636492775772e-05	-0.584557093163975	-0.336608298481374
NCOA2	BRD-K45462423-001-03-7::2.5::HTS002	2.5	VU0361737	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.156172716539	-0.156172716539	0.0844410191679934	0.109184936724	6.04160756264864	31.621046661879	1.00831457423715e-06	4.11150389534594e-05	0.159452455814431	0.321775015599555
NCOA2	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.2263137646045	0.2263137646045	0.30397231441405	0.306467449749	3.5967294978308	187.58326077055	0.000412042466959635	0.0100756018141462	0.0350653192452496	0.12025178037385
NCOA2	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.050890816311	-0.050890816311	-0.710427803425496	-0.5410189846345	-8.30050681521898	13.8748318372354	9.47090521304563e-07	3.88495625532413e-05	-0.830100583136924	-0.488973391092069
NCOA2	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.4234656287725	0.4234656287725	-0.141620879284692	0.01900224238145	-8.87528163890015	121.142943516784	7.57526218039943e-15	7.73879107656258e-13	-0.691135968171968	-0.439037047942415
NCOA2	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.4957270296505	0.4957270296505	0.231815158426602	0.271076937361	-7.04385086918351	190.766375828895	3.30346505026333e-11	2.31684673022869e-09	-0.337814656641759	-0.190009085806037
NCOA2	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.510734541423	-0.510734541423	-0.247281414113187	-0.116969809946	4.35050669758276	16.5738102447675	0.00045937251378996	0.0111212980354782	0.13543854258676	0.391467712032865
NCOA2	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.193241121839	-0.193241121839	0.128382893453853	0.138278646354	9.85828490669264	9.43729071505907	2.82345273161682e-06	0.000107658388278723	0.248339733436054	0.394908297149653
NCOA2	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-3.13214542184	-3.13214542184	-0.505493926157414	-0.39621393329	22.8297828112195	2.08420167673237	0.00155463260982414	0.0324253457211949	2.15029522575026	3.10300776561492
NCOA2	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.680057127255	-1.680057127255	-1.02241008171095	-0.654329018583	6.70722939205011	187.911221141219	2.26167437101971e-10	1.43925892596878e-08	0.464225934337224	0.851068156750868
NCOA2	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.03499485363695	-0.03499485363695	0.244170615288668	0.276258886308	7.71458513743479	170.565127477144	9.68927416081175e-13	8.08680857325787e-11	0.207733991926833	0.350596945924402
NCOA2	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.02311586499545	-0.02311586499545	-0.171729878182505	-0.171973558527	-4.77188757633534	164.325968344764	4.00755218941678e-06	0.00014860461128123	-0.210107327134123	-0.0871206992399866
NCOA2	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.3906044823	-1.3906044823	-1.10642973130839	-1.10749370834	5.7731822929832	167.400578964432	3.6898111058361e-08	1.83105701436153e-06	0.186996430472161	0.381353071511057
NCOA2	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.703929620018	-0.703929620018	-0.488411427719227	-0.397290410403	4.40922093663278	101.330870916945	2.58796742949371e-05	0.000825903024413278	0.118559295712206	0.312477088885339
NCOA2	BRD-K88568253-011-19-9::2.5::HTS002	2.5	iproniazid	monoamine oxidase inhibitor	noncancer	MAOA, MAOB	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.7568972151005	0.7568972151005	0.46976767511394	0.4917980145095	-8.28453997451034	19.0461730576827	9.75605290777793e-08	4.60573802570735e-06	-0.35965866570408	-0.21460041426904
NCOA2	BRD-K93441486-067-12-8::2.5::HTS002	2.5	diphemanil	acetylcholine receptor antagonist	noncancer	CHRM3	neurology/psychiatry	spasms	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.320190084128	-0.320190084128	0.138115693933361	0.150302134	17.7217733062838	92.7902769788476	1.54629875155208e-31	7.08155267353431e-29	0.406949091594949	0.509662464527772
NCOA2	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.722405918625	-1.722405918625	-1.24569113762739	-1.23927241763	5.50191414201932	7.72753838226521	0.000645293159818349	0.0150070570367521	0.275677542131701	0.677752019863514
NCOA2	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.3847295191095	0.3847295191095	0.599316178323093	0.600417589144	4.81902191524958	8.09482140887921	0.00127978283916878	0.0274349446025411	0.11211138601921	0.317061932407976
NCOA2	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.4409110633565	0.4409110633565	0.308896180088961	0.328628776305	-3.69910276375183	29.921670997242	0.000869168246564544	0.019545479080677	-0.204908224285719	-0.0591215422493579
NCOA2	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	HCC827, BT474	LUNG, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.308188722772	0.308188722772	-0.0804361879631864	-0.07508781022425	-12.523582625297	33.5574990948672	3.35974833930881e-14	3.24147007281341e-12	-0.451719046442235	-0.325530775028137
NFAT5	BRD-A18696154-003-22-6::2.5::HTS002	2.5	idazoxan	adrenergic receptor antagonist	noncancer	ADRA2A	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.2816517866445	-0.2816517866445	-0.659099950977484	-0.606488441652	-6.27613908961151	7.94813466052677	0.000245434912473307	0.00634698592609694	-0.516289360214599	-0.238606968451368
NFAT5	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.825736648072	0.825736648072	-0.788436530266984	-0.4776049590865	-11.1152219251327	3.54517995785896	0.000700359669254893	0.0161701376227224	-2.03861675425798	-1.18972960241998
NFAT5	BRD-A93093700-001-02-9::2.5::HTS002	2.5	temazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.452195571954	0.452195571954	0.294629439049495	0.2827443589055	-5.6213733019656	21.6344169536283	1.26106513712226e-05	0.000426582749012432	-0.215753446343052	-0.0993788194659571
NFAT5	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.2474036461035	-0.2474036461035	0.0704131265120939	0.07956967035945	9.63291046465056	9.96264322141839	2.3012560400423e-06	8.89496674132057e-05	0.244266832677637	0.39136671255355
NFAT5	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.014458790407	-0.014458790407	-2.2272119827765	-2.04082568027	-16.3044129324702	9.20511800994763	4.20491784604089e-08	2.07167238124911e-06	-2.51872215588071	-1.9067842288583
NFAT5	BRD-K04430056-236-02-1::2.5::HTS002	2.5	7-nitroindazole	nitric oxide synthase inhibitor	noncancer	NOS1, NOS2, NOS3	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.5896921772425	0.5896921772425	0.305472805123103	0.309926543901	-9.23588733687383	9.96040772545116	3.3724288049314e-06	0.000126741941667919	-0.352823674013567	-0.215615070225228
NFAT5	BRD-K09549677-300-03-4::2.5::HTS002	2.5	mibefradil	T-type calcium channel blocker	noncancer	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.1920892756415	-0.1920892756415	0.21624810902093	0.2434500151	12.1089590258421	22.8391688582393	2.02750802300912e-11	1.45823411766282e-09	0.33855107981748	0.478123689507381
NFAT5	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.522259359042	0.522259359042	0.33757067369258	0.34680571662	-5.67651125318026	104.602317389057	1.23930825170032e-07	5.77685294211999e-06	-0.249203623963196	-0.120173746735645
NFAT5	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.603287918025	-1.603287918025	-2.07095285121476	-2.39516504125	-4.49109313412503	32.5073490259489	8.41772409330308e-05	0.00242560148856353	-0.679644405251297	-0.255685461128216
NFAT5	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.31858383491	-2.31858383491	-2.74523775341344	-2.77734094711	-8.89822462022036	80.1852701669541	1.36712548151099e-13	1.24001116092581e-11	-0.522070507479409	-0.331237329527469
NFAT5	BRD-K16478699-001-09-2::2.5::HTS002	2.5	PLX-4720	RAF inhibitor	targeted cancer	BRAF, KDR	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.5621397913405	-0.5621397913405	-1.51962135381278	-1.41373612569	-11.355752270913	177.553711629302	8.15611820004767e-23	1.72907285627895e-20	-1.12387373787492	-0.791089387069639
NFAT5	BRD-K18424115-003-01-3::2.5::HTS002	2.5	TG-100572	src inhibitor, VEGFR inhibitor	targeted cancer	KDR, SRC	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.4852049432005	-0.4852049432005	-1.21093880517329	-1.11267387683	-8.19510190455743	4.0540769647433	0.0011400930851021	0.0248202144069933	-0.970319528561411	-0.481148195384172
NFAT5	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.377892867597	0.377892867597	-0.0308792596622847	-0.00807522835948	-16.7647759690667	147.155508237843	5.96657335437736e-36	4.13854271996875e-33	-0.456957800013424	-0.360586454505146
NFAT5	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.567252868365	-1.567252868365	-3.00390084450127	-2.880185474935	-14.8151832957578	6.26760637070965	4.10082481469389e-06	0.000151800635873666	-1.6714939627253	-1.20180198954723
NFAT5	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.678850485665	-1.678850485665	-2.45835424768098	-2.36107459971	-8.64512259650038	189.409981989936	2.2470535812621e-15	2.41528960390334e-13	-0.957364031985655	-0.60164349204631
NFAT5	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.97564555374	-1.97564555374	-3.10180630265723	-2.8622910827	-9.02856036881667	8.95684415206003	8.5940000890453e-06	0.000299551706795412	-1.40853410807886	-0.843787389755596
NFAT5	BRD-K21528677-001-02-8::2.43672::HTS002	2.43672	desonide	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.189675702829	-0.189675702829	0.0893750896014719	0.124628316908	6.81836340384523	39.2583023139512	3.68626291349465e-08	1.83056775715105e-06	0.196286827397547	0.361814757463397
NFAT5	BRD-K24603946-001-02-1::2.5::HTS002	2.5	5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	noncancer	CHRM3	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.47097565054	-1.47097565054	-2.43289743939283	-2.202066494735	-8.6689944387981	30.5477890153376	9.7870808985027e-10	5.83040200143774e-08	-1.18836445352617	-0.735479124179493
NFAT5	BRD-K25279140-001-01-5::2.5::HTS002	2.5	MK-8745	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.537190417566	-0.537190417566	-1.58417142232263	-1.48579667397	-12.9755785323162	173.387981932224	2.42554687417413e-27	7.53427588398358e-25	-1.20623930079106	-0.88772270872221
NFAT5	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.05292047271185	0.05292047271185	-0.137213723502234	-0.1059972226705	-4.55630112701126	19.8270437001362	0.000195720750931135	0.00518268258294037	-0.277230041001049	-0.103038351427119
NFAT5	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.2976450584295	-0.2976450584295	-1.04402201962566	-0.8676646214495	-9.55515666451929	65.7351866626521	4.72130755710074e-14	4.48344318744282e-12	-0.902345282377373	-0.590408640014956
NFAT5	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.321831416227	0.321831416227	0.14682219777168	0.195908235522	-4.2275762709774	170.572101916496	3.84299298219964e-05	0.00118512927033362	-0.256725737000694	-0.0932926999099455
NFAT5	BRD-K28453807-003-11-2::2.5::HTS002	2.5	nitrocaramiphen	cholinergic receptor antagonist	noncancer	CHRM1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.04659990548955	-0.04659990548955	0.361423907034443	0.350372820253	12.1165276726927	6.1768357303178	1.55195610469334e-05	0.00051674568892779	0.326192573704057	0.489855051343929
NFAT5	BRD-K29968218-001-03-2::2.5::HTS002	2.5	KX2-391	src inhibitor, tubulin polymerization inhibitor	targeted cancer	SRC	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.23247396126	-1.23247396126	-2.7643881207839	-2.71621218929	-10.7962580969433	4.87135766513771	0.000138164193041395	0.00378774537354429	-1.89957817906252	-1.16425013998527
NFAT5	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.13466111408	-2.13466111408	-3.71371658075174	-3.85009077555	-16.0813591057827	97.6770081154659	3.3593873774212e-29	1.28344765992033e-26	-1.77392168883108	-1.3841892445124
NFAT5	BRD-K32821942-001-21-3::2.5::HTS002	2.5	azathioprine	dehydrogenase inhibitor	noncancer	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.1475595267655	-0.1475595267655	-0.643231781973546	-0.577859685861	-7.97916338470159	3.47853316918154	0.00235330364322051	0.0461001020517145	-0.678838883531571	-0.312505626884521
NFAT5	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.43327828292	-1.43327828292	-2.23179256239262	-2.28506663454	-7.44476905128622	165.534751355879	5.05555801591319e-12	3.90328780256721e-10	-1.01028517431867	-0.586743384626562
NFAT5	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.6896815420865	0.6896815420865	-0.103248492840208	-0.09070553113985	-12.725003061821	2.69555755895727	0.00174697955033276	0.0357859485848486	-1.00452992883774	-0.581330141015675
NFAT5	BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500	0.625	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.1860329268575	-0.1860329268575	-1.73803800380322	-1.77978641517	-15.5503826136474	15.5129022772821	7.08369215659626e-11	4.7758435238475e-09	-1.76412332301799	-1.33988683087344
NFAT5	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.1056587719691	0.1056587719691	-0.111548874251293	-0.11764531931	-4.40270733880146	164.150279927007	1.92009393361277e-05	0.000628292843812657	-0.314620682358794	-0.119794610081991
NFAT5	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	1.31640215226	1.31640215226	0.35831559061292	0.394038132066	-20.2223467223192	16.1505152197289	6.75030410574515e-13	5.71190717798884e-11	-1.05844660025037	-0.857726523043786
NFAT5	BRD-K43644456-001-04-0::2.37833::HTS002	2.37833	WP1130	deubiquitinase inhibitor	targeted cancer	JAK2, UCHL5, USP14, USP9X	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-6.06539033395	-6.06539033395	-6.29390668741681	-6.296490539345	-3.15543593507209	119.086567588079	0.00202959402906394	0.0406049527354845	-0.371913916942924	-0.0851187899906933
NFAT5	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.330468434924	-0.330468434924	-0.724748349940656	-0.623158972273	-4.1851300041736	119.279653286285	5.47757052505869e-05	0.0016396678953426	-0.580820072684536	-0.207739757348776
NFAT5	BRD-K44408410-001-17-6::2.5::HTS002	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.718606499145	-0.718606499145	-1.12142709656741	-1.07322078363	-5.56142946960374	17.5477163657154	3.07114826729731e-05	0.000964166012862994	-0.55527437214036	-0.250366822704453
NFAT5	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.8184951634205	-0.8184951634205	-0.256310169711861	-0.219779888934	15.2980206307629	134.01453149124	3.42584370456385e-31	1.50771592475455e-28	0.489502200969789	0.634867786447489
NFAT5	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.454370224743	-0.454370224743	-2.25930810059611	-2.140330076935	-19.3241871329767	2.99967374535916	0.00030289196855302	0.00764107023634654	-2.10220633454656	-1.50766941715967
NFAT5	BRD-K48684885-001-04-2::2.5::HTS002	2.5	BAY-11-7085	NFkB pathway inhibitor	targeted cancer	NFKBIA	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.20613254378	-1.20613254378	-1.44504507705368	-1.33433747778	-3.49425313191117	192.113418811662	0.000590119177191403	0.0138988629811271	-0.373770673224631	-0.104054393322733
NFAT5	BRD-K50853363-001-02-3::2.5::HTS002	2.5	dienogest	progesterone receptor agonist	noncancer	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.9743256336275	-0.9743256336275	-0.269708015914474	-0.206947214108	11.0027561087904	4.98650772000446	0.000109713843143528	0.00308270297418842	0.539863232850666	0.869372002575385
NFAT5	BRD-K51662849-001-08-8::2.61265::HTS002	2.61265	ilomastat	matrix metalloprotease inhibitor	noncancer	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.423728217468	0.423728217468	0.0154082862429044	0.02919742667555	-14.0768583944668	178.947135162556	8.84289216505769e-31	3.75304600959337e-28	-0.465558665644601	-0.35108119680559
NFAT5	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.025946562535	-2.025946562535	-4.61687638207738	-4.62878838486	-17.2819681166302	2.79347989836762	0.000634192762264559	0.0147745544068914	-3.08863412054186	-2.0932255185429
NFAT5	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.4240925226195	0.4240925226195	0.134821225100096	0.1526722270265	-8.96745097432689	5.0086388035482	0.000285032240757286	0.00722881021527255	-0.372149916204515	-0.206392678834293
NFAT5	BRD-K54256913-001-08-7::2.5::MTS010::PROS004_PR500	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.025123814872345	0.025123814872345	-1.22353859615231	-1.224724300865	-12.0770466686995	177.163640790201	6.91921911676795e-25	1.77603510667995e-22	-1.45269955915205	-1.04462526289726
NFAT5	BRD-K56032964-001-02-1::2.5::HTS002	2.5	AP26113	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, EGFR	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.294498357081	-0.294498357081	-0.548554729367815	-0.449925278333	-4.15186598016297	180.322471362371	5.08051243970879e-05	0.00152892607510579	-0.374798660106264	-0.133314084467367
NFAT5	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.5454701861065	0.5454701861065	0.231294287678372	0.271076937361	-7.99602852625307	71.2429113646177	1.66520989938998e-11	1.21230561320093e-09	-0.392516281327226	-0.23583551552903
NFAT5	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.1922739141995	0.1922739141995	-1.05384070956833	-1.14416779162	-10.4518838558461	3.00069822519378	0.00186773049397759	0.037829220283852	-1.62548842442586	-0.866740823109798
NFAT5	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.0321338862701	0.0321338862701	-1.21204188025681	-1.18840349692	-16.8522910376508	112.790976006882	1.37354667094122e-32	6.84629963805026e-30	-1.39044585077457	-1.09790568227925
NFAT5	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.5166921522905	0.5166921522905	-0.499200283877138	0.00402399396559	-11.0149425979047	100.303204770727	5.74768829759187e-19	8.58464310198305e-17	-1.19886452486569	-0.832920347469583
NFAT5	BRD-K63784565-001-06-2::2.50835::HTS002	2.50835	10-hydroxycamptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-3.1367005696	-3.1367005696	-5.74684282559679	-5.78036148178	-21.6286067942119	5.59245215186307	1.32030164572277e-06	5.29526443536892e-05	-2.91073145102716	-2.30955306096642
NFAT5	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.9050295219465	-0.9050295219465	-2.14125227373188	-2.025815521035	-13.606979135404	187.087272719855	9.25018455235601e-30	3.66466322536398e-27	-1.41544898216116	-1.05699652140959
NFAT5	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.421146854185	-1.421146854185	-2.49710357933682	-2.41136656484	-10.7991477794616	11.8902085989775	1.68808637298417e-07	7.7029138649207e-06	-1.29326196500584	-0.858651485297803
NFAT5	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.885472911387	-0.885472911387	-2.64445991079546	-2.62453052692	-10.6710462943478	7.20854159646056	1.12809255865853e-05	0.000384209359613419	-2.14649111332705	-1.37148288548987
NFAT5	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.42749889699	-1.42749889699	-0.775583375616398	-0.683338343709	10.1863843287897	84.7374485641299	2.24039457508382e-16	2.66767516046189e-14	0.524663235630018	0.779167807117186
NFAT5	BRD-K67537649-001-04-5::2.5::HTS002	2.5	PQ-401	IGF-1 inhibitor	targeted cancer	IGF1R	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.311834150024	0.311834150024	0.175472568990154	0.199537593573	-4.063957162867	59.0298522213486	0.000144544463387266	0.00394600309429746	-0.203502054053233	-0.0692211080144585
NFAT5	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.4741362274025	-0.4741362274025	-0.269043558775759	-0.221588123992	5.16715059067937	7.44632219386272	0.00107208391669361	0.0234707531952017	0.112365316533226	0.297820020720255
NFAT5	BRD-K68747584-001-02-0::2.5::HTS002	2.5	PF-03814735	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.4318624958865	-0.4318624958865	-1.27859797344697	-1.09893939309	-10.8893477071811	182.008901078044	1.38652631452044e-21	2.60906758968263e-19	-1.0001587850494	-0.693312170071543
NFAT5	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.2353770532415	-0.2353770532415	0.316130802199155	0.309773585289	16.9445814623517	5.12920049603759	1.06160785431985e-05	0.000363995120474354	0.468471153300452	0.634544557580857
NFAT5	BRD-K70511574-001-06-9::2.5::HTS002	2.5	HMN-214	PLK inhibitor	targeted cancer	PLK1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.40201661286	-1.40201661286	-2.84670956147074	-2.842294760615	-14.1709273418344	40.1226833677758	3.28850912081447e-17	4.20538706059096e-15	-1.65071724115546	-1.23866865606602
NFAT5	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.2924800638575	-0.2924800638575	-0.612833289748266	-0.443084865138	-6.07618614941311	119.236755700311	1.51614925608936e-08	7.95482873704715e-07	-0.424747401888262	-0.215959049893271
NFAT5	BRD-K72414522-001-06-7::2.5::HTS002	2.5	AZD5438	CDK inhibitor	targeted cancer	KCNH2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.8918966580285	-0.8918966580285	-2.43369046062378	-2.22027282363	-13.9441581773983	23.9656735655604	5.38525594120514e-13	4.58750604380984e-11	-1.77001462319521	-1.31357298199535
NFAT5	BRD-K72951360-001-01-4::2.5::HTS002	2.5	valrubicin	DNA inhibitor, topoisomerase inhibitor	chemo	TOP2A	oncology	bladder cancer	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.555633021745	-1.555633021745	-3.30548520710713	-3.181546610205	-14.2476665807542	12.9926221488479	2.61884271628282e-09	1.4900290431064e-07	-2.01519697139344	-1.48450739933082
NFAT5	BRD-K73197500-001-02-2::2.5::HTS002	2.5	SNX-5422	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.013180389295	-2.013180389295	-3.63529669354843	-3.70624580332	-17.7660288530486	76.4026003791584	7.47361083136597e-29	2.74282797239013e-26	-1.80394924788187	-1.440283360625
NFAT5	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.737473196175	-1.737473196175	-2.32937028499939	-2.24109191203	-6.19960751585068	25.5822744686477	1.58160147897797e-06	6.26470270537552e-05	-0.788301380440999	-0.395492797207784
NFAT5	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.297160927745	0.297160927745	-0.152137601452468	-0.132191437107	-8.42006129314345	5.94242170014546	0.000161023069341265	0.00436362541773221	-0.580174208657561	-0.318422849737375
NFAT5	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.4758021026985	0.4758021026985	-0.470333052892906	-0.217946401079	-11.1151278859589	193.279842698839	1.64870408791203e-22	3.43072911124366e-20	-1.11402123925128	-0.778249071931533
NFAT5	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.7636886883705	0.7636886883705	-0.130980872922172	-0.118001057117	-23.7242984330496	4.86761497937236	3.21538002129486e-06	0.000121222371958506	-0.992407432631813	-0.796931689953531
NFAT5	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.299101470159	-0.299101470159	0.0202452157178111	0.0546599136262	8.79942657137933	5.13227631718947	0.000275266984241154	0.00700602036164617	0.226774323322523	0.4119190484311
NFAT5	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.128252508486	0.128252508486	-0.624280378062745	-0.529789535968	-14.0177823979968	122.321892476723	3.27153917119048e-27	9.97419230472381e-25	-0.858803243961447	-0.646262529136044
NFAT5	BRD-K87696786-003-04-4::2.5::HTS002	2.5	LY456236	glutamate receptor antagonist	noncancer	GRM1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-1.74428494273	-1.74428494273	-2.192700791457	-2.03818987744	-4.58477261027369	74.4981710400396	1.79552193240268e-05	0.000591231249423774	-0.64327585454615	-0.253555842907856
NFAT5	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-2.495443998785	-2.495443998785	-5.24657271993383	-5.37506459637	-28.1878345185918	17.6166506822642	4.19246048315702e-16	4.85448872444387e-14	-2.95649872237441	-2.54575871992326
NFAT5	BRD-K90647725-001-07-3::2.50156::HTS002	2.50156	oleanolic-acid	G protein-coupled receptor agonist	noncancer	GPBAR1	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.229833703898	0.229833703898	0.119192250706165	0.139454786175	-4.17041124564415	124.720593722063	5.64747521923814e-05	0.00168558378535593	-0.163148975658437	-0.0581339307252325
NFAT5	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-3.796039137595	-3.796039137595	-5.63577757296624	-5.62740406384	-15.2627121041111	7.78323634097804	4.44769507023043e-07	1.91266058729418e-05	-2.11905306036664	-1.56042381037585
NFAT5	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.206353149698	-0.206353149698	-1.43016740514221	-1.12582537284	-12.7797504149807	46.2309109649445	8.84393765268298e-17	1.08500991022432e-14	-1.41654715395515	-1.03108135693328
NFAT5	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.6612922482735	-0.6612922482735	-1.41516071541062	-1.39259151278	-8.3556230490768	12.7916057014984	1.54904916816706e-06	6.1471238504736e-05	-0.949106459596641	-0.55863047467759
NFAT5	BRD-K96344439-002-02-7::2.5::MTS006	2.5	tofogliflozin	sodium/glucose cotransporter inhibitor	noncancer	GCK	endocrinology	diabetes mellitus, diabetes mellitus	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.3952518437995	0.3952518437995	0.13564880468815	0.243893587025	-7.33241863874095	190.242211310562	6.31580038833106e-12	4.82932280210705e-10	-0.329439495162074	-0.189766583060626
NFAT5	BRD-K98521173-001-19-4::2.5::HTS002	2.5	desoxycortone	mineralocorticoid receptor agonist	noncancer	NR3C1, NR3C2	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	0.4196894354095	0.4196894354095	0.629206360728995	0.651102905922	5.36805611273637	11.679356051066	0.000185073942731502	0.00493551238916262	0.124217512534314	0.294816338104676
NFAT5	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.4111186992085	-0.4111186992085	-1.09587509585854	-1.03443241086	-9.33356305192422	13.9212141799936	2.28313182888177e-07	1.02265697335925e-05	-0.842192153451845	-0.527320639848244
NFAT5	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	KYSE70, NCIH1793	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma)	-0.1906515671235	-0.1906515671235	-0.622902144168828	-0.6228392960495	-6.58610028909659	5.24072658397661	0.00101027824898511	0.022327482658974	-0.598655314152739	-0.265845839937916
NIPBL	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-3.201674357375	-3.201674357375	-2.08322431632705	-2.05580997476	14.1753912497834	22.1711068471035	1.34592089147335e-12	1.10694504508285e-10	0.954892935271161	1.28200714682474
NIPBL	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-2.58534021119	-2.58534021119	-1.60981866927178	-1.53203888218	10.268380888687	13.7434025468168	7.97241511535287e-08	3.7946252703941e-06	0.771404023766574	1.17963906006987
NIPBL	BRD-A24514565-001-09-7::2.5::HTS002	2.5	warfarin	vitamin K antagonist	noncancer	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.2104584575805	0.2104584575805	-0.126809265966366	-0.09418085429645	-9.52886965795068	175.9269020108	1.28853390935649e-17	1.7121524132577e-15	-0.407119803465757	-0.267415643627974
NIPBL	BRD-A25234499-001-18-3::2.5::HTS002	2.5	aminoglutethimide	glucocorticoid receptor antagonist	targeted cancer	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.113430415698	0.113430415698	0.21631023501069	0.21588142899	3.80200172738569	149.56596591345	0.000208491287068365	0.00548425737187969	0.0494117792248779	0.156347859400502
NIPBL	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.2998592280645	0.2998592280645	-0.347841355932518	-0.266254262221	-16.842693613257	58.1711096557205	4.85657072590757e-24	1.14259489254999e-21	-0.724673568247296	-0.570727599746739
NIPBL	BRD-A68631409-001-05-4::2.5::HTS002	2.5	evodiamine	ATPase inhibitor, TRPV agonist	targeted cancer	TRPV1	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.4062434055	-1.4062434055	-2.38726210216643	-2.305746334225	-11.0143593270372	189.60477486156	3.97852830049842e-22	7.91014834988429e-20	-1.15670870487262	-0.805328688460246
NIPBL	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-2.89406915509	-2.89406915509	-2.35055980069796	-2.27036498586	6.44060998819481	40.4491903460537	1.08277085388856e-07	5.08143626763916e-06	0.373014087926248	0.714004620857825
NIPBL	BRD-A79981887-003-16-4::2.5::HTS002	2.5	midodrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.923985168405	-1.923985168405	-1.02635223934025	-1.01219584287	9.77371140063966	13.3077031243294	1.92083402053987e-07	8.6854522107234e-06	0.699686642830558	1.09557921529895
NIPBL	BRD-K00259736-001-16-4::0.15625::HTS002	0.15625	colchicine	microtubule inhibitor	noncancer	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-2.54121641914	-2.54121641914	-3.05968989011322	-2.82813961253	-4.57368575916355	144.373342588797	1.02273607324778e-05	0.000351792649403183	-0.742533306603944	-0.294413635342485
NIPBL	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.802680396481	-0.802680396481	-1.9078378501681	-1.73380354334	-10.139905868823	57.3875051538665	2.08725518058018e-14	2.05587920771402e-12	-1.32337602919673	-0.886938878177478
NIPBL	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.337233296298	0.337233296298	0.1555841618838	0.1638819685105	-5.99242546409012	9.36385310263577	0.000174255328531189	0.00468019678054652	-0.249818152358207	-0.113480116470194
NIPBL	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.28603982218	-1.28603982218	-2.50251012743586	-2.37307934162	-11.5549393956368	190.82114888186	9.34964344304738e-24	2.14320826685016e-21	-1.42412658933775	-1.00881402117398
NIPBL	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.115452830985	-1.115452830985	-0.414646610496785	-0.37916191768	12.8535087729417	41.1778104102553	5.30937495104839e-16	6.07232136543891e-14	0.59071011188226	0.810902329094169
NIPBL	BRD-K12251893-065-04-7::2.5::HTS002	2.5	vincristine	tubulin polymerization inhibitor	chemo	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.96399512067	-1.96399512067	-2.71280022302143	-2.6144312066	-5.44332991413265	5.57816510443154	0.00201734728885929	0.0403901006140983	-1.0916793042968	-0.405930900406057
NIPBL	BRD-K12539581-001-23-7::2.5::HTS002	2.5	nocodazole	tubulin polymerization inhibitor	targeted cancer	HPGDS	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-2.991072218165	-2.991072218165	-3.5034834128339	-3.357933574425	-4.70288427914739	89.2250376276286	9.29944010548567e-06	0.000322305902064786	-0.728898500535035	-0.295923888802754
NIPBL	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.2121443598895	-0.2121443598895	-0.514017665329575	-0.419130200084	-4.80970027048926	188.233558754378	3.08799493901799e-06	0.000116769030925333	-0.425683394917603	-0.178063215962548
NIPBL	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.4192242759285	-0.4192242759285	0.34742914107447	0.357900779497	17.3645288084736	3.8124361830698	9.04299055932959e-05	0.00258530543150695	0.641656414862386	0.891650419143554
NIPBL	BRD-K13514097-001-05-3::2.5::HTS002	2.5	everolimus	mTOR inhibitor	targeted cancer	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.22533379762	-1.22533379762	-0.740010890760658	-0.6865974577345	8.35877903388642	117.569424104116	1.46735944046639e-13	1.32587555445076e-11	0.37034104842065	0.600304765298035
NIPBL	BRD-K13646352-001-03-8::2.5::HTS002	2.5	midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	targeted cancer	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-3.41533673807	-3.41533673807	-2.94971060453413	-2.8284008656	4.79081866226598	190.166632174383	3.3362659883613e-06	0.000125470881386119	0.27391453327852	0.657337733793213
NIPBL	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.581179253717	0.581179253717	-0.484023964137272	-0.373418715101	-12.1983674241335	191.910843948508	1.03864519482309e-25	2.80014825108475e-23	-1.23744014161785	-0.892966294090699
NIPBL	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.00762084031527	-0.00762084031527	0.262045517691936	0.263001454047	9.05527233831916	28.2338809321326	7.61123711736531e-10	4.59006426597577e-08	0.208687472004465	0.330645244009948
NIPBL	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.335936053499	0.335936053499	-0.098424779433837	-0.0311349339001	-9.80820188205986	19.173797470102	6.58168708356698e-09	3.58395937737253e-07	-0.526994554735979	-0.341727111129695
NIPBL	BRD-K17979676-001-01-2::2.5::HTS002	2.5	eprobemide	monoamine oxidase inhibitor	noncancer	MAOA	neurology/psychiatry	depression	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.32502359251	-1.32502359251	-0.0297022650333643	-0.00773751956823	27.8591395944146	160.160453684014	2.68635346547558e-63	2.50331935609529e-59	1.20349822674079	1.38714442821248
NIPBL	BRD-K18910433-001-36-6::2.58082::HTS002	2.58082	estradiol	estrogen receptor agonist	noncancer	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.11322555289685	0.11322555289685	0.30925338421567	0.326005969483	5.72815810106104	15.7796832153557	3.28306256945907e-05	0.00102469130253327	0.123398465890384	0.268657196747256
NIPBL	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.690412061408	0.690412061408	0.5440066416158	0.547894384564	-5.80203595551753	188.993459933966	2.71789964990617e-08	1.37420314712135e-06	-0.196180822296957	-0.0966300172874445
NIPBL	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.96526906349	-1.96526906349	-0.843365261369825	-0.52176141391	11.7978742020476	135.867298316322	1.4820048355839e-22	3.08985033468736e-20	0.933848533204192	1.30995907103616
NIPBL	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.20281244954	0.20281244954	0.374982786665723	0.395322173914	5.91868310637239	195.80062089824	1.43016696572199e-08	7.53135763135696e-07	0.114801770371859	0.229538903879588
NIPBL	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.374087514305	-0.374087514305	0.154109306991911	0.201815706844	9.03540469180247	3.71456551907837	0.00116411207996805	0.0252735207206812	0.360850783092665	0.695542859501156
NIPBL	BRD-K28360340-001-08-3::2.30697::HTS002	2.30697	TW-37	BCL inhibitor	targeted cancer	BCL2, BCL2L1, MCL1	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.88113203913	-1.88113203913	-2.77828211022966	-2.74381570724	-9.5402284355726	35.0640613112413	2.81025330910779e-11	1.98785076398602e-09	-1.08804618469829	-0.706253957501037
NIPBL	BRD-K32285926-001-02-1::2.5::HTS002	2.5	AMG-208	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.1150100631735	0.1150100631735	0.410254585499281	0.419799796324	8.0581715122679	195.738511363778	7.48443681693359e-14	6.95031134547903e-12	0.222986352554997	0.367502692096564
NIPBL	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.09402852609195	0.09402852609195	-0.882851017441304	-0.7074523288895	-10.4964691904647	105.256691274418	4.5808931384966e-18	6.3424951258452e-16	-1.1614098447298	-0.792349242336703
NIPBL	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.247077490058	-0.247077490058	0.175271407419582	0.1694730901705	11.6490047260475	3.25148863818481	0.000922425176532264	0.0206133318382842	0.311853465680599	0.532844329274566
NIPBL	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.07244739110895	-0.07244739110895	-0.516025018356767	-0.465030888818	-6.68987970467161	4.36974982199591	0.00188306244642509	0.0380965538115766	-0.621688354855275	-0.26546689964036
NIPBL	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.521964831475	-0.521964831475	-1.29311464240317	-1.33795379646	-8.65668034271638	19.7049670364663	3.80290682010477e-08	1.88499818650841e-06	-0.957149022239145	-0.585150599617188
NIPBL	BRD-K41859756-001-06-8::2.5::HTS002	2.5	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-3.582380583965	-3.582380583965	-3.99134486246627	-3.99973792001	-3.99907566883925	19.7312814933832	0.000720962420960849	0.0166011124540307	-0.622471104426313	-0.195457452576218
NIPBL	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.0628295230002	-0.0628295230002	-0.296368145137582	-0.290098649131	-4.54120135166425	13.9275458695023	0.000467294436960927	0.0112875858649159	-0.343891601588323	-0.123185642686442
NIPBL	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.8540672556205	-0.8540672556205	-0.672787211361575	-0.568122839674	3.41216984587155	175.66571373094	0.00079991146398436	0.0181903686115972	0.0764297201210072	0.286130368396843
NIPBL	BRD-K48684885-001-04-2::2.5::HTS002	2.5	BAY-11-7085	NFkB pathway inhibitor	targeted cancer	NFKBIA	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.229462082855	-1.229462082855	-1.44480332017208	-1.33433747778	-3.14978877547843	192.001187734473	0.00189527628980997	0.0383111074147582	-0.350187830067003	-0.0804946445671485
NIPBL	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.401129585204	-0.401129585204	0.0327573030688346	0.0483026079462	15.8996982224647	30.782684583206	2.1607494966574e-16	2.57857059503944e-14	0.37821467326794	0.489559103277729
NIPBL	BRD-K49328571-001-15-0::2.5::MTS010::PROS005_PR500	2.5	dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor	targeted cancer	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.7532599765	-1.7532599765	-0.453018665100584	-0.279272959842	12.4690437207355	5.42639660488946	3.35920963264686e-05	0.00104647680429588	1.03840046943309	1.56208215336574
NIPBL	BRD-K51662849-001-08-8::2.61265::HTS002	2.61265	ilomastat	matrix metalloprotease inhibitor	noncancer	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.2533071374595	0.2533071374595	0.0172212764557608	0.02919742667555	-7.1414018366123	16.3351978363918	2.07846977810239e-06	8.08047068875216e-05	-0.306050598785195	-0.166121123222283
NIPBL	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.500704121796	-0.500704121796	-0.739089940088923	-0.696454065727	-4.3145757694414	188.977295343445	2.57510631717749e-05	0.000822548748408523	-0.347374298567755	-0.129397338018092
NIPBL	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.190557206105	-0.190557206105	0.118864585841044	0.150496276102	9.33871078081571	9.8724240379644	3.25596501246396e-06	0.000122644591415885	0.235466802872204	0.383376781019885
NIPBL	BRD-K58435339-001-03-0::2.5::HTS002	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-4.005834694645	-4.005834694645	-4.68715408270193	-4.73299399791	-6.55338148368213	25.0930150672242	7.13735115680731e-07	2.98427884527381e-05	-0.89539815886387	-0.467240617249982
NIPBL	BRD-K60341624-001-02-2::2.5::HTS002	2.5	GSK1292263	glucose dependent insulinotropic receptor agonist	noncancer	GRPR	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.40600966183	-1.40600966183	-1.00926657005005	-0.954160275858	10.0457280682427	36.6725778178138	4.47342361787687e-12	3.49156740930784e-10	0.316697106773919	0.476789076785973
NIPBL	BRD-K61936403-001-01-7::2.5::HTS002	2.5	AS-1949490	SHIP2 phosphatase inhibitor	noncancer	INPP5D	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.1743880303535	-0.1743880303535	0.245984292848869	0.276762978408	10.1564126749247	16.976323796239	1.24950047009292e-08	6.6140821500258e-07	0.333038109953306	0.507706536451432
NIPBL	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-2.93785788511	-2.93785788511	-4.00250489343739	-4.1239035813	-9.6480459796254	66.3957168583983	2.93563122414024e-14	2.8508876512857e-12	-1.28494030917312	-0.844353707481661
NIPBL	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.315456220478	0.315456220478	-0.497070803117218	0.00402399396559	-7.4591933186033	8.7733320021461	4.42196254486046e-05	0.00134796588007026	-1.0599168119837	-0.565137235206737
NIPBL	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.073601388877225	-0.073601388877225	-0.719461625478898	-0.5340799664045	-5.40730497547623	10.3800178679255	0.000262141439264277	0.00671661835458137	-0.910679178661741	-0.381041294541604
NIPBL	BRD-K66094457-001-01-5::2.5::HTS002	2.5	CPP	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.412455249385	-1.412455249385	-0.907901249027709	-0.85122207753	6.7477078244783	6.67073550254832	0.000328103450335073	0.00821519677650302	0.325956592916926	0.683151407797655
NIPBL	BRD-K67537649-001-04-5::2.5::HTS002	2.5	PQ-401	IGF-1 inhibitor	targeted cancer	IGF1R	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.642588316346	0.642588316346	0.17193509127548	0.199537593573	-13.1349826493827	17.6914054845872	1.46762654734132e-10	9.54353550561645e-09	-0.546027782727779	-0.395278667413261
NIPBL	BRD-K68488863-001-04-9::0.15625::HTS002	0.15625	ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	targeted cancer	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.3162868295035	0.3162868295035	0.515117903798177	0.524698126717	8.57391989424148	182.287145269043	4.21615713132391e-15	4.41880069339619e-13	0.1530753061738	0.244586842415555
NIPBL	BRD-K70159787-001-01-1::2.5::HTS002	2.5	SMI-4a	Pim kinase inhibitor	targeted cancer	PIM1	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.2319448549975	-0.2319448549975	-0.637274091679991	-0.609589789336	-7.59973960333062	186.076345454334	1.41061180743597e-12	1.15483200181797e-10	-0.510547501740076	-0.300110971624906
NIPBL	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.7162127910395	-0.7162127910395	-1.19509926930501	-1.12346956245	-6.29151850082251	46.1151516563882	1.04705276902224e-07	4.92567543748394e-06	-0.632090118010453	-0.325682838520568
NIPBL	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.9132049556	-1.9132049556	-2.52857071169493	-2.26266997363	-5.79707244437729	188.880154781987	2.78916642507092e-08	1.4075800582035e-06	-0.82475979713404	-0.405971715055828
NIPBL	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.7221945623105	-0.7221945623105	-0.147468863781153	-0.1187166368295	13.5676776619597	110.950830293412	2.60574406871202e-25	6.8191272344686e-23	0.490786285421186	0.658665111637508
NIPBL	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.9026838033555	-0.9026838033555	-1.47648591730867	-1.368540965995	-6.49329349498852	168.428273689825	9.05337236044473e-10	5.41406318259419e-08	-0.748254530188432	-0.399349697717913
NIPBL	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.92736789846	-1.92736789846	-2.3273501285921	-2.24109191203	-4.08807843256063	18.3813095157402	0.000664705326222013	0.0154116862682646	-0.605233598689691	-0.194730861574516
NIPBL	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-2.371335828925	-2.371335828925	-1.09661308030543	-0.895557196833	12.240073929094	6.14754192533514	1.51348186056731e-05	0.000505348268723371	1.02136826810738	1.52807722913176
NIPBL	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.5041318707045	-0.5041318707045	-0.166612686632409	-0.1689019992055	9.7182824348415	18.324957983958	1.17049149332962e-08	6.2173549262415e-07	0.264646098411807	0.410392269732376
NIPBL	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.5507597717195	0.5507597717195	0.0906378204043342	0.1896034324075	-8.79824504830855	9.1742232290827	9.05399886292419e-06	0.00031435841929235	-0.578084431861343	-0.342159470768988
NIPBL	BRD-K81916719-001-13-9::2.5::HTS002	2.5	triclabendazole	microtubule inhibitor	noncancer	DNMT1	infectious disease	tapeworm	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-3.280888292165	-3.280888292165	-2.32239384953215	-2.31061831786	11.2921802176792	28.5090186552789	4.88183370359029e-12	3.78415383673347e-10	0.784762822760269	1.13222606250543
NIPBL	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-0.253926012416	-0.253926012416	-0.851793680315812	-0.774088070041	-6.65019538903009	188.059240260067	3.09221636731562e-10	1.94301590069501e-08	-0.775214161902214	-0.420521173897409
NIPBL	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-2.985121941575	-2.985121941575	-1.94352537112447	-1.864714539655	17.0964368331809	193.845610419199	1.46355024734485e-40	1.65095400506933e-37	0.921436013739417	1.16175712716165
NIPBL	BRD-K88172511-003-20-3::2.41866::HTS002	2.41866	naltrexone	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.478914132427	0.478914132427	0.307143137855636	0.300369801672	-7.27914320542584	48.2557085657662	2.66909726691739e-09	1.51781625927603e-07	-0.219210844156615	-0.124331144986113
NIPBL	BRD-K88506063-001-01-8::2.5::HTS002	2.5	KD025	rho associated kinase inhibitor	targeted cancer	ROCK2	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.80558833988	-1.80558833988	-1.00652118712422	-0.931623279463	11.2115833677426	8.57026383002088	2.05917747878424e-06	8.0083732507775e-05	0.636598855940019	0.961535449571542
NIPBL	BRD-K89391146-001-08-0::2.5::HTS002	2.5	RG108	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3B	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	0.7053655431805	0.7053655431805	0.376870977908942	0.397149460871	-12.8461461870663	174.103070414029	5.35203483618256e-27	1.61562855549883e-24	-0.378964504982304	-0.278024625560812
NIPBL	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-3.405033412805	-3.405033412805	-2.87838416162739	-2.82062384431	4.89181062648269	175.757004399209	2.24631316057688e-06	8.69514273782339e-05	0.314177748307727	0.739120754047494
NIPBL	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-2.250812178535	-2.250812178535	-3.11628131191523	-3.009227373135	-8.01887184937239	186.749336520121	1.13771502191825e-13	1.03808140882383e-11	-1.07838595957187	-0.652552307188602
NIPBL	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	MFE280, NCIH1693	ENDOMETRIUM, LUNG	carcinoma (adenocarcinoma)	-1.80618044981	-1.80618044981	-1.24476545219993	-1.23927241763	6.74454769827619	10.5438308486719	3.9193618937254e-05	0.00120590427120338	0.377233642171009	0.745596353049123
NUMB	BRD-A73556557-001-06-4::2.5::HTS002	2.5	tagatose	phosphorylase inhibitor	noncancer	PYGL	NA	NA	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.285932943116	-0.265028826166	0.123232610014338	0.150414983947	6.83770345338242	5.0623017474305	0.000971697450589863	0.0215794159037897	0.255910581354474	0.562420524906202
NUMB	BRD-A93695607-322-02-5::2.4707::HTS002	2.4707	nicotine	acetylcholine receptor agonist	noncancer	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	MFE280, CAL54, RMGI	ENDOMETRIUM, KIDNEY, OVARY	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.0537103256493333	-0.0488232246463	0.127679681211441	0.156456879064	4.97736667338094	109.948295824493	2.40285649028919e-06	9.25762769561734e-05	0.109168223414668	0.25361179030688
NUMB	BRD-K22064724-001-01-8::2.49999::MTS010::PROS004_PR500	2.49999	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.543196893377	0.490669490507	-2.34832905678954	-2.45044712374	-16.6093070018102	4.11070902750377	6.35440467250605e-05	0.00187801047856253	-3.3697883809972	-2.41326351933588
NUMB	BRD-K28360340-001-08-3::2.30697::HTS002	2.30697	TW-37	BCL inhibitor	targeted cancer	BCL2, BCL2L1, MCL1	NA	NA	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.9100674317725	-1.87741220007	-2.78725835927581	-2.74719815551	-5.95886562221438	7.05052947195143	0.000549868399824016	0.0130382502783363	-1.2247767551008	-0.529605099905817
NUMB	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.050256049915	-2.0012515036	-1.3249753147781	-1.35467804181	5.89522269264997	5.95983315950984	0.00108344450991614	0.0236922551949723	0.423748211343526	1.02681325893027
NUMB	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.076128184546775	-0.04493317248685	-0.40658317115319	-0.294292920541	-3.84103694162347	12.0198320656941	0.002341218036213	0.0459093164488585	-0.517869958582351	-0.143040014630479
NUMB	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.727378107356	-0.669739074962	-0.19692145684762	-0.148572066554	6.06470639358634	5.3254589895201	0.00140755642515809	0.0297749862857983	0.30968841584489	0.75122488517187
NUMB	BRD-K42898655-001-01-8::2.5::HTS002	2.5	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.1148340737775	-2.108821012005	-1.32887693258073	-1.27737046266	13.2837050605139	30.9478212295468	2.5209153202817e-14	2.46152737895516e-12	0.665276977164019	0.90663730522952
NUMB	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	MFE280, CAL54, RMGI	ENDOMETRIUM, KIDNEY, OVARY	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.20470409093667	-1.24712734958	-1.59256796888935	-1.488048221985	-3.75813927561156	15.8253085004493	0.00174723936098742	0.0357878502485734	-0.606848038346166	-0.168879717559198
NUMB	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.3531355803775	-2.34824694358	-1.46143469559561	-1.338530309235	6.32148715521302	4.81562596550335	0.00167401099773356	0.0345388046913012	0.524882203759391	1.25851956580439
NUMB	BRD-K65781196-001-03-0::2.5::HTS002	2.5	avanafil	phosphodiesterase inhibitor	noncancer	PDE5A	urology	erectile dysfunction	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.3321426641895	0.335362063944	0.522024553911221	0.5046492922025	4.76432823559305	9.48245569880711	0.000885145129595946	0.0198818141355239	0.100418232943372	0.279345546500071
NUMB	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.52243016044625	-0.474804590675	-0.16258993648665	-0.1643545594495	5.93610462204951	5.42189965052543	0.00146301381403454	0.0307870680165153	0.207591722329257	0.512088725589944
NUMB	BRD-K92428232-001-10-6::2.5::HTS002	2.5	GSK461364	PLK inhibitor	targeted cancer	PLK1	NA	NA	MFE280, CAL54, RMGI, PC3	ENDOMETRIUM, KIDNEY, OVARY, PROSTATE	carcinoma (adenocarcinoma), carcinoma (renal_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.181999624035	-2.16596093145	-2.7094057981656	-2.3957048051	-3.91065757016992	56.8626215297629	0.000247906493877431	0.00640471925340598	-0.797480433652614	-0.257331914608583
NUP210L	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.3570093709075	-0.3570093709075	-0.833633981254069	-0.720201208535	-6.04966343152383	5.38432007190093	0.00136940107022193	0.0290458640899007	-0.674877032698631	-0.278372187994508
NUP210L	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.1409902177605	0.1409902177605	-0.00902811842581293	0.0633629143304	-4.48036865900433	76.2679486934688	2.57854718806871e-05	0.000823387127937393	-0.216702678241399	-0.0833339941312265
NUP210L	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-4.06387817706	-4.06387817706	-3.71481591130274	-3.697322932235	4.59446772424542	106.084879926371	1.20048552102272e-05	0.000407505323464172	0.198436874249838	0.499687657264672
NUP210L	BRD-A50157456-065-20-6::2.5::HTS002	2.5	terbutaline	adrenergic receptor agonist	noncancer	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.3443433268885	0.3443433268885	0.148778473860253	0.1597653685015	-6.11682152304152	18.1947302757098	8.47198771236153e-06	0.000295731702671455	-0.262683296326936	-0.128446409729557
NUP210L	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.0487892454658	-0.0487892454658	-0.18650664718595	-0.0590439534084	-3.31409492952955	187.331458520348	0.00110369223377807	0.0240866774110196	-0.219693406385794	-0.0557413970545053
NUP210L	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.3108740827465	-0.3108740827465	0.21544618396025	0.255620963174	8.62854735346177	3.35373875527081	0.00210605611872516	0.0419428453698426	0.343283349076837	0.709357184336663
NUP210L	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.18078609478	0.18078609478	0.0439604860404502	0.06773998743725	-4.049292349011	25.3506933493358	0.000427230793434512	0.0104172865444853	-0.206368644390097	-0.0672825730890027
NUP210L	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.7142392150575	0.7142392150575	0.257430644000533	0.303778240807	-9.93107333080052	8.3878955975373	6.36514213023413e-06	0.000227524107343388	-0.562032143757665	-0.35158499835627
NUP210L	BRD-K07106112-003-03-8::2.5::HTS002	2.5	BMS-599626	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.868660525354	-0.868660525354	0.154573509584529	0.20496253929	30.95006815628	182.013725158527	1.981732923358e-74	1.06185708932599e-69	0.958002328418403	1.08846574145866
NUP210L	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.157200198126	0.157200198126	0.278752432412348	0.26768413301	4.30690773084012	84.9735640564891	4.42090769147413e-05	0.00134783602362156	0.0654378461799577	0.177666622392739
NUP210L	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.245651591435	-1.245651591435	-2.52247006834785	-2.34739362698	-12.0441804762478	175.376451344263	9.86381187489655e-25	2.50783029102574e-22	-1.48604044939602	-1.06759650442968
NUP210L	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.1459342526015	0.1459342526015	-0.479725785206625	-0.33490377325	-9.28810281789703	160.16212862158	1.08656502944391e-16	1.31944700394155e-14	-0.758691236727611	-0.492628838888639
NUP210L	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.5497671124175	0.5497671124175	-0.521995795929649	-0.419130200084	-11.7548190538217	3.41961301033629	0.000695146013234008	0.0160601433513454	-1.34278836404078	-0.800737452653521
NUP210L	BRD-K14560436-001-01-4::2.5::HTS002	2.5	TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-2.66449688843	-2.66449688843	-3.74768565311525	-3.62828968956	-8.44892132855788	27.7162245285906	3.75067094934013e-09	2.09999360998203e-07	-1.34592473150603	-0.820452797864459
NUP210L	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.3205037852205	-0.3205037852205	-1.11053576259954	-0.898661589303	-7.83855745976663	172.167227516705	4.53918224421733e-13	3.90714213341709e-11	-0.988971081838484	-0.591092872919592
NUP210L	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.3380307818295	-0.3380307818295	-0.0570531763176699	-0.0602706039178	7.54948707574975	16.5695721727853	9.36199843968818e-07	3.84469776505064e-05	0.202298594821577	0.359656616202083
NUP210L	BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500	2.5	sonidegib	smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.130965647629	-0.130965647629	0.00186492570872802	0.01374069413735	6.24746499031342	15.4645407772028	1.36020336973247e-05	0.000457349033920546	0.087631004152752	0.178030142522704
NUP210L	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.563194398615	-1.563194398615	-3.05433396455633	-3.177325410155	-13.5049672733031	25.5949414207572	3.76684444911126e-13	3.26727642223216e-11	-1.71827405494543	-1.26400507693723
NUP210L	BRD-K21396683-001-04-8::2.5::HTS002	2.5	marimastat	matrix metalloprotease inhibitor	targeted cancer	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.8924151531505	-0.8924151531505	-1.80416653226503	-1.72083973318	-12.0314923910899	162.975993167611	2.89260950977857e-24	6.9425543518626e-22	-1.06138939959303	-0.762113358636028
NUP210L	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.4680526354625	0.4680526354625	-0.118679486024299	-0.0402228786984	-10.0903559613898	42.3653848099994	7.7704454101184e-13	6.54650862541379e-11	-0.704049180362277	-0.469415062611322
NUP210L	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.442470858477	0.442470858477	-0.243623077248198	-0.0866927101235	-10.8281799501807	87.3989461153035	7.94860591198054e-18	1.07823845348663e-15	-0.812024445932239	-0.560163425518158
NUP210L	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-2.54325906604	-2.54325906604	-3.08958857080495	-2.9100349769	-5.5938795718854	186.589797470845	7.81232564119189e-08	3.72421695362771e-06	-0.739000188281592	-0.353658821248311
NUP210L	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-2.773480325615	-2.773480325615	-1.0176833465705	-0.8397340938795	20.2087793685338	11.1482088713123	3.90087883877489e-10	2.42761748152086e-08	1.56487876144082	1.94671519664818
NUP210L	BRD-K27316855-001-13-3::2.43597::HTS002	2.43597	calcitriol	vitamin D receptor agonist	noncancer	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.2573543732875	-0.2573543732875	-0.0338855131550877	0.01343134409051	5.45476138024029	167.928751614111	1.73027711842595e-07	7.87698735163795e-06	0.142590845212429	0.304346875052396
NUP210L	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-5.251251109195	-5.251251109195	-4.67501710057537	-4.90330008871	6.34974313214931	190.989724364647	1.53684418811488e-09	8.95812559136452e-08	0.39723463093607	0.755233386303197
NUP210L	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.62388856106	-1.62388856106	-2.31602724295133	-2.045349051995	-5.69762717624891	11.0620247160702	0.00013574183580994	0.00373566740407299	-0.959328064009114	-0.424949299773545
NUP210L	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.310149101555	0.310149101555	-0.621813471993847	-0.480230640816	-14.9391259239479	184.412262892591	1.37550495253146e-33	7.60937522083448e-31	-1.05504069362684	-0.808884453470853
NUP210L	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.21649355588	-1.21649355588	-2.23440442657382	-2.28506663454	-7.84968153600459	9.56835589808975	1.8037764642754e-05	0.000593681012861977	-1.30862231359409	-0.72719942779355
NUP210L	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.7687466947245	-0.7687466947245	-1.94016069401485	-1.836818850415	-13.6687365600464	146.437876242272	6.19368580354126e-28	2.05811858075534e-25	-1.34078306336453	-1.00204493521617
NUP210L	BRD-K36627727-001-05-4::2.5::MTS010::PROS005_PR500	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.229919959896	-0.229919959896	-0.0762245336284062	-0.0262583009779	5.39608121571683	30.8818681235142	6.97647023917803e-06	0.000247313908351437	0.0955953934215596	0.211795459113628
NUP210L	BRD-K36740062-001-06-6::2.5::HTS002	2.5	GSK1070916	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC, CYP2D6, CYP3A4	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.43335663688	-1.43335663688	-2.26772710507572	-1.977136981175	-6.97520634349752	14.9661894206121	4.51662103936314e-06	0.000166244697019691	-1.08938350431112	-0.579357432080323
NUP210L	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.1346569295495	0.1346569295495	-0.181157425332036	-0.13613940777	-8.70313459097629	67.1476321374942	1.28164024614962e-12	1.05895401818428e-10	-0.388241433758512	-0.24338727600456
NUP210L	BRD-K37590257-001-02-8::2.5::HTS002	2.5	GSK256066	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.849761754662	-0.849761754662	-0.074367371352075	-0.072384668123	10.1845302380937	9.38129821181104	2.22857154791193e-06	8.63114404214703e-05	0.604227305928402	0.946561460691448
NUP210L	BRD-K37865504-001-04-1::2.5::HTS002	2.5	LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	noncancer	FAAH	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.2584552350225	-0.2584552350225	-1.30077360547269	-1.08170547456	-13.0669245909719	191.042492228771	2.69860719510416e-28	9.43472558257426e-26	-1.19965688090464	-0.884979859995744
NUP210L	BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500	0.625	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.25298557256	-1.25298557256	-1.72662674556041	-1.77978641517	-4.69343886020322	15.0242308141314	0.000287222670897978	0.00728091636083889	-0.688707460766276	-0.258574885234542
NUP210L	BRD-K38904395-001-02-3::2.5::HTS002	2.5	SAR131675	VEGFR inhibitor	targeted cancer	FLT4	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.927850872507	-0.927850872507	-0.528432384060186	-0.519013652075	8.41140630536339	129.736646389266	6.35417279521198e-14	5.94449367536005e-12	0.305472630673971	0.493364346219656
NUP210L	BRD-K44827188-001-06-0::2.5::HTS002	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.320797723731	-0.320797723731	-0.109480885596877	-0.054617955294	4.15732307661992	134.28695686316	5.70429046898974e-05	0.00170159341952415	0.110785861735239	0.311847814533007
NUP210L	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.615415849512	-0.615415849512	-1.59708632663162	-1.48697544025	-9.02532790446313	5.49946180211321	0.000168117381748318	0.00453295135397348	-1.25380078780713	-0.709540166432099
NUP210L	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.9522840804205	-0.9522840804205	-0.277489458238522	-0.2569086069275	18.4031923496138	60.5573472617545	1.75167484668567e-26	5.09409386994971e-24	0.601463065345547	0.748126179018409
NUP210L	BRD-K52233191-001-02-4::0.0024414::HTS002	0.0024414	R547	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK7	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.0705620672222	0.0705620672222	0.40670353346017	0.420404312044	11.8841493089472	162.997858973185	7.42810273533441e-24	1.71373286454412e-21	0.280289485308445	0.391993447167496
NUP210L	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.632306189436	-0.632306189436	-0.289295849956436	-0.3736278329815	5.06141380196962	183.032610807183	1.00845783714913e-06	4.11150389534594e-05	0.209300133067823	0.476720545891305
NUP210L	BRD-K53972329-001-07-0::2.5::MTS010::PROS003_PR500	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.1163264037455	-0.1163264037455	-0.0123220475573923	-0.0140997876931	3.96235624452248	17.4213442123573	0.00096496749514978	0.0214421471996789	0.0487275401912416	0.159281172184974
NUP210L	BRD-K56483981-342-06-4::2.5::HTS002	2.5	chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	noncancer	MIF	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.10886759614345	0.10886759614345	0.265543577649839	0.2788714906115	5.20815508091123	62.5221929468674	2.2645927413195e-06	8.75957223703786e-05	0.0965512743366085	0.216800688676169
NUP210L	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.5690575526595	-0.5690575526595	-1.04518921562675	-1.14416779162	-4.94930998093634	8.46094643642674	0.000951000928251755	0.0211724397996541	-0.695886820471975	-0.256376505462522
NUP210L	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.1503936969335	-0.1503936969335	0.039355109257504	0.0957301689988	5.85243571202094	42.4542516874133	6.24844076178696e-07	2.63005117838381e-05	0.124338904537175	0.255158707844833
NUP210L	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.04897906750295	-0.04897906750295	-0.143176090795717	-0.139438991422	-4.2368342757523	13.8653895448874	0.000846153517880969	0.0191222308449926	-0.141925274082336	-0.0464687725031977
NUP210L	BRD-K63504947-001-15-4::0.15625::HTS002	0.15625	semaxanib	VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.315475858233	0.315475858233	0.00418079410524997	0.0147466219169	-8.54553155383838	99.4936380733707	1.55355871798095e-13	1.39904490111823e-11	-0.383571321030085	-0.239018807225415
NUP210L	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.28722069219	-1.28722069219	0.00617000687376963	0.0201994348842	24.7758082242687	62.3674583719419	5.54721314928143e-34	3.22008140338725e-31	1.18904907020021	1.39773232792733
NUP210L	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.14657993831	0.14657993831	-0.0809636241112393	0.0411624842104	-5.1400703333298	102.870966266598	1.31326601847908e-06	5.26803279944979e-05	-0.31534113852915	-0.139745986313328
NUP210L	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.866277675443	0.866277675443	-0.161956267164521	0.0566391407425	-10.7474555531168	2.97582571826096	0.00178575997163443	0.0364271579861459	-1.33410999050762	-0.722357894707419
NUP210L	BRD-K70177501-003-01-4::2.5::HTS002	2.5	INH1	Hec1 inhibitor	targeted cancer	NDC80	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.4540818134845	0.4540818134845	0.158700884274454	0.1724439449425	-11.988491063688	74.5285981871452	4.60538708249946e-19	6.96098736251782e-17	-0.344468841364112	-0.24629301705598
NUP210L	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.2086927198815	0.2086927198815	-1.04218756702128	-0.659178147727	-8.98449389426349	3.76111344093226	0.00112377265070271	0.0244872985413237	-1.64731325434598	-0.854447319459584
NUP210L	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.4161995318555	-0.4161995318555	-1.19837810273872	-1.12346956245	-10.945960539788	176.032370007038	1.33644192084344e-21	2.51703216566303e-19	-0.923203594338545	-0.641153547427885
NUP210L	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.03745481772345	0.03745481772345	0.223274718282299	0.235603358555	7.13809032144158	77.2100111893101	4.49354006377618e-10	2.77070180762107e-08	0.133985499997469	0.23765430112023
NUP210L	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.2534620576805	0.2534620576805	0.100280785118844	0.129185439077	-4.00433169874962	115.872622836445	0.000110162009780535	0.0030940763166773	-0.22894880371173	-0.0774137414115822
NUP210L	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.00015939037031	0.00015939037031	-0.195885118438832	-0.145323520972	-4.49201404922855	172.163019308759	1.28959360893792e-05	0.00043513430196797	-0.282188558852426	-0.109900458765858
NUP210L	BRD-K74671368-001-01-8::2.5::MTS006	2.5	idronoxil	XIAP inhibitor	targeted cancer	ENOX2, SPHK1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.09747902727085	-0.09747902727085	-0.253064133736661	-0.195737211392	-4.0710934670414	186.325647918721	6.90969596307462e-05	0.00202453619421711	-0.230978807316346	-0.080191405615276
NUP210L	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.12972490909775	-0.12972490909775	-1.48437325296436	-1.368540965995	-11.1549153616741	4.07958555988648	0.000330123996520893	0.00826096276127571	-1.68924039754187	-1.02005629019136
NUP210L	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.02501722554845	0.02501722554845	-0.209900334585333	-0.20601445055	-4.43039854230493	16.1328316493684	0.000412133650329533	0.0100766818550626	-0.347248298684631	-0.122586821582935
NUP210L	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-2.67789227319	-2.67789227319	-3.98428415379561	-3.95467393468	-9.47629139263925	9.79059820291383	3.03684931047162e-06	0.000115058312862661	-1.61445368580916	-0.998330075402066
NUP210L	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.19884750575	-1.19884750575	-2.21821228356182	-2.0670113581	-10.0102159999238	177.776840791542	5.45684310646048e-19	8.16731652349559e-17	-1.22032070667316	-0.81840884895048
NUP210L	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.352243259393	0.352243259393	-0.126580387050755	-0.118001057117	-16.7969773621787	186.002664446839	3.9332501488101e-39	3.83186168701964e-36	-0.535061339411438	-0.422585953476071
NUP210L	BRD-K81548480-001-01-2::2.5::HTS002	2.5	AC-264613	PAR agonist	noncancer	F2RL1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.714611558758	-0.714611558758	-0.36594739502168	-0.2459913879695	6.42508027345322	23.6335495827652	1.30084034766444e-06	5.22208734374923e-05	0.236572429682025	0.460755897790615
NUP210L	BRD-K82135108-001-04-3::0.15625::MTS010::PROS001_PR500	0.15625	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.2479306206385	-0.2479306206385	-0.985004278065111	-0.922667792506	-10.1740399250608	172.233274403377	2.45817799774574e-19	3.81781762375976e-17	-0.880070980792096	-0.594076334061125
NUP210L	BRD-K83003151-057-02-4::2.34747::HTS002	2.34747	alogliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.6096719775025	0.6096719775025	0.242359297208585	0.320568591806	-7.9034393030738	15.9244605366898	6.69946536274577e-07	2.80886093844276e-05	-0.465873366642878	-0.268751993944951
NUP210L	BRD-K83029223-001-01-3::2.5::MTS006	2.5	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.787121894115	-1.787121894115	-2.42657035236955	-2.31559247235	-5.35038082072597	12.2838489805813	0.000160151151917875	0.00434439137316875	-0.899182535585567	-0.37971438092354
NUP210L	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-3.183624291445	-3.183624291445	-4.38804729353297	-4.37968901574	-12.0490558116558	12.9585056738595	2.05924063790953e-08	1.05840524384295e-06	-1.42044365579706	-0.988402348378889
NUP210L	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.13285331525405	0.13285331525405	-0.788462533825657	-0.783090045771	-12.8132250142766	3.19632280871957	0.000743729471889605	0.017055723730005	-1.14239556735585	-0.700236130803567
NUP210L	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.36665450262	0.36665450262	0.0958731183447207	0.163411081458	-7.11085708666002	25.4540099276555	1.69158880053292e-07	7.71396885168978e-06	-0.34913772739155	-0.192425041159009
NUP210L	BRD-K93441486-067-12-8::2.5::HTS002	2.5	diphemanil	acetylcholine receptor antagonist	noncancer	CHRM3	neurology/psychiatry	spasms	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.232290530386	0.232290530386	0.13239050621819	0.147275600233	-3.63321270929197	30.2063046696245	0.00102752997637158	0.022650362265324	-0.156038947955614	-0.0437611003800068
NUP210L	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-1.41925365983	-1.41925365983	-0.213833289356358	-0.144721351966	18.3185798930484	30.3188115489834	5.9992929508891e-18	8.23717142133959e-16	1.07109163016925	1.33974911077803
NUP210L	BRD-K93869735-001-01-1::2.5::HTS002	2.5	taltirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	neurology/psychiatry	spinocerebellar ataxia	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	0.1863273460545	0.1863273460545	-0.184861930190609	-0.1119517959605	-8.22339603547846	166.742802646111	5.34090339248603e-14	5.04945074198562e-12	-0.460305312325643	-0.282073240164575
NUP210L	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-3.594817441025	-3.594817441025	-3.13729010658059	-3.215000704775	7.70148989984328	108.749430266247	6.64939893336994e-12	5.08078083418982e-10	0.339780279599583	0.575274389289231
NUP210L	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	JHH1, MCF7	LIVER, BREAST	carcinoma (hepatocellular_carcinoma), carcinoma	-0.1216595838265	-0.1216595838265	-0.0214055924149362	0.015242959648	3.54496269028983	188.618779883682	0.000495159197365206	0.0118803286255555	0.0444669146588528	0.156041068164275
ORC4	BRD-A13561534-003-02-0::2.5::HTS002	2.5	ornithine	NFkB pathway modulator	noncancer	ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.8194731069715	0.8194731069715	0.623591043798129	0.6438914807695	-7.44076995355295	187.889289271703	3.48080462310011e-12	2.74379321097618e-10	-0.247813612669192	-0.14395051367755
ORC4	BRD-A14886633-001-01-6::2.5::HTS002	2.5	norgestrel	progesterone receptor agonist	noncancer	PGR	endocrinology	contraceptive	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.2226528021225	0.2226528021225	-0.138039491481254	-0.0793835829582	-7.59549401481076	159.608648506679	2.43494777799438e-12	1.95314342181796e-10	-0.454477514360058	-0.26690707284745
ORC4	BRD-A22707317-001-10-8::2.5::HTS002	2.5	SB-205384	GABA receptor modulator	noncancer	GABRA3, GABRA5, GABRA6	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.83027728232	-0.83027728232	-0.507328920044285	-0.44146156083	5.38358345281372	9.80686536446519	0.000329886399138763	0.00825598108839468	0.188929950212448	0.456966774338982
ORC4	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.2069156517615	-0.2069156517615	-0.342534812688266	-0.266254262221	-3.55217356332118	84.3383111682064	0.00062834974658279	0.0146575503738945	-0.2115382466479	-0.0597000752056329
ORC4	BRD-A43671941-003-11-9::2.5::HTS002	2.5	oxprenolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	angina pectoris, hypertension, cardiac arrythmia	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.672877990487	-0.672877990487	-0.404171247285622	-0.38193178245	7.56617383956581	173.478482620592	2.1602810212309e-12	1.74129699510868e-10	0.19861116049119	0.338802325911567
ORC4	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.0706750457763	0.0706750457763	-0.18774390156087	-0.136086260588	-5.7174490182275	187.220852663229	4.21020349423795e-08	2.07250506365762e-06	-0.347582341479924	-0.169255553194416
ORC4	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.1912389756795	-0.1912389756795	-0.848394271959047	-0.797149374107	-9.10276325295421	7.35599878966458	2.91271121397395e-05	0.000917921602381744	-0.826203905222119	-0.488106687336975
ORC4	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.1786054366925	-0.1786054366925	0.03537331204569	0.01565074111015	4.36607382023205	9.12541833193072	0.00174887822494725	0.0357996173962632	0.103343574413127	0.324613923063253
ORC4	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.0827819892711	-0.0827819892711	0.159959321108478	0.166606190016	9.6227869472409	178.864437683339	6.31329463569359e-18	8.64062660264094e-16	0.192963089133268	0.292519531625888
ORC4	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.4028505053045	0.4028505053045	0.0112486051669578	0.1859491052615	-5.9237626342552	40.1068089273367	5.99379932244714e-07	2.5313202265631e-05	-0.525197953938036	-0.258005846337048
ORC4	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.9817015203455	-0.9817015203455	-0.505959475167733	-0.370831351035	6.52878903020519	13.2190017826142	1.76692503537133e-05	0.000582889450371097	0.318584264300464	0.63289982605507
ORC4	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.772111294175	-0.772111294175	-0.415756790073537	-0.389042162364	10.4962447129249	185.22810404385	1.60233289626771e-20	2.78529121917406e-18	0.28937479751259	0.423334210690337
ORC4	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-1.93777780219	-1.93777780219	-1.28788078305954	-1.25961873039	10.2635415538016	7.53084072075925	1.08086970959113e-05	0.000370007545099756	0.502280024415187	0.797514013845724
ORC4	BRD-K15519488-050-01-3::2.5::HTS002	2.5	CS-110266	dopamine receptor agonist	noncancer	SLC6A3	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.4203245549415	-0.4203245549415	-0.112985739033118	-0.120574600447	5.88133557737837	176.635066906226	1.99310636708117e-08	1.02638273558419e-06	0.204211113481498	0.410466518335266
ORC4	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.6382435335425	-0.6382435335425	-0.973413585333816	-0.735958486111	-4.90958562791492	192.6541242474	1.94068011082254e-06	7.57225609817013e-05	-0.469819704173134	-0.200520399409497
ORC4	BRD-K17894950-001-14-3::2.5::MTS010::PROS002_PR500	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.1270430502855	0.1270430502855	0.0183607768498928	0.01698904715675	-4.1577770876566	69.7040730471942	9.00582144481233e-05	0.00257601588742184	-0.160819782267547	-0.0565447646036678
ORC4	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.190817889852	-0.190817889852	-0.058578698514328	-0.0602706039178	3.76717255646662	41.4923523887409	0.000514121174835444	0.0122871406424293	0.0613727114039162	0.203105671271428
ORC4	BRD-K19284129-001-02-6::2.5::HTS002	2.5	salvinorin-a	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.596282638565	-0.596282638565	0.0193013810450416	0.02724514887165	15.2800458262168	18.4610794871924	6.32044529498738e-12	4.83115092592493e-10	0.531095883169084	0.700072156050999
ORC4	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.272868893335	-0.272868893335	-0.823402339898019	-0.81565114113	-6.78444280666629	5.85058959049993	0.000557762150711371	0.0132078890730104	-0.75032731173561	-0.350739581390429
ORC4	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.545613259134	-0.545613259134	-0.191858271048	-0.144534319806	6.58853520088126	39.889538308225	7.13440653627714e-08	3.41938362183949e-06	0.245229017174257	0.462280958997743
ORC4	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.2323094100055	-0.2323094100055	-0.426486497227075	-0.326694667694	-4.66693780803906	53.8240564878723	2.06892708284982e-05	0.000672374636452038	-0.277600261765294	-0.110753912677857
ORC4	BRD-K29950728-048-17-4::2.5::HTS002	2.5	clomifene	estrogen receptor antagonist	noncancer	ESR1	obstetrics/gynecology	infertility	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.372297429934	-0.372297429934	-0.13549900042348	-0.112752624282	6.56344080437406	27.997221786894	4.07671037082715e-07	1.76231798521382e-05	0.162894851017796	0.310702008003243
ORC4	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.352534538036	-0.352534538036	0.168969789533315	0.1606220898175	13.9822399288725	2.66513735032651	0.00143615174532458	0.0302961582109914	0.393906865415983	0.649101789722647
ORC4	BRD-K34332569-001-01-3::2.5::HTS002	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.2120759599945	-0.2120759599945	-1.00497165130986	-0.918687700318	-8.78599023316664	119.772392061431	1.3255636566728e-14	1.32636196531757e-12	-0.971578871107547	-0.614212511523174
ORC4	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.206190717459	0.206190717459	0.024722776665001	0.046531478462	-5.37070592427095	177.181512667052	2.43912499373399e-07	1.08707677434396e-05	-0.248147571800278	-0.11478830978772
ORC4	BRD-K35960502-001-20-0::2.5::HTS002	2.5	niclosamide	DNA replication inhibitor, STAT inhibitor	noncancer	STAT3	infectious disease	tapeworm	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.09295751861555	-0.09295751861555	-0.709351312251414	-0.681426229631	-9.59323924886995	16.1505247010491	4.49007975645115e-08	2.20319208818777e-06	-0.752500832128319	-0.480286755143409
ORC4	BRD-K39558284-001-01-2::2.5::HTS002	2.5	SDZ-WAG-994	adenosine receptor agonist	noncancer	ADORA1	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.658362534904	0.658362534904	0.29287241997661	0.325539232433	-13.0033019380396	191.015642375234	4.20569841372409e-28	1.43307334708278e-25	-0.420931031885246	-0.310049197969535
ORC4	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.60088613043	0.60088613043	-0.303159621203904	-0.160539632789	-10.6354598278912	3.27979616568102	0.00118372564142945	0.0256502611466923	-1.16196493826508	-0.646126565002732
ORC4	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-1.147756952325	-1.147756952325	-1.39442891155792	-1.16796153731	-3.33818311416729	165.531089374856	0.0010416339332884	0.0229053001402171	-0.392568338054852	-0.100775580410988
ORC4	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-1.996952992185	-1.996952992185	-2.24272118911824	-2.140330076935	-3.80863859959265	106.466997864005	0.000234030544063511	0.00608025993343056	-0.373697027202729	-0.117839366663757
ORC4	BRD-K48578705-001-17-6::2.5::HTS002	2.5	methyldopa	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.0311385607915	-0.0311385607915	0.257253608182257	0.2888342624615	8.89382942948042	15.6072813929158	1.66717069927308e-07	7.61558032405156e-06	0.219511071800245	0.357273266147268
ORC4	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.6585326702425	0.6585326702425	0.368168880444042	0.3732554744945	-7.75661395411774	49.3809629829491	4.29117234386894e-10	2.64973401696654e-08	-0.365576252399259	-0.215151327197657
ORC4	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.638744336258	0.638744336258	-0.0747742415302059	0.318163539168	-8.50949766679068	186.553994409237	5.63366362158701e-15	5.83031139715655e-13	-0.878934001174564	-0.548103154401848
ORC4	BRD-K49071277-001-04-7::2.5::HTS002	2.5	securinine	GABA receptor antagonist, TP53 activator	noncancer	GABRA1	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.460080690144	0.460080690144	0.289649167204376	0.288445970299	-5.61549900221038	6.77176714661431	0.000900764498134092	0.020186003886389	-0.242691601825656	-0.0981714440535915
ORC4	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.4490287853305	-0.4490287853305	-0.212081605436321	-0.1324820733985	6.91203816190505	147.398430259561	1.34219564966234e-10	8.77088620157477e-09	0.169202703718696	0.304691656069662
ORC4	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.6002599918815	-0.6002599918815	-0.289629664514296	-0.3736278329815	4.52136738635226	143.061573821183	1.27872045832817e-05	0.000431737361551698	0.174826656284832	0.446433998449577
ORC4	BRD-K59369769-001-20-3::2.5::HTS002	2.5	tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, AURKC, LCK	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-1.553632575555	-1.553632575555	-1.78663170406002	-1.696260218435	-3.28845979261149	46.0857833167145	0.00193384421370371	0.0389621072080187	-0.375612811751115	-0.0903854452589263
ORC4	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-1.803065371495	-1.803065371495	-1.53283883594599	-1.40779088077	4.52001744299803	182.77103365929	1.10845361304683e-05	0.00037842267351181	0.15227021633882	0.388182854759203
ORC4	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.07190630886365	0.07190630886365	-0.219288711827595	-0.209793035138	-4.69638897859721	9.29678470006109	0.0010310849268536	0.0227170437178871	-0.4307782735937	-0.151611767788789
ORC4	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.2272359781835	-0.2272359781835	-1.08687889772818	-0.4202572111255	-5.90552794475037	6.46670063458822	0.000798983971216677	0.0181731333510452	-1.20969024878399	-0.509595590305362
ORC4	BRD-K81839095-001-30-1::2.5::HTS002	2.5	estrone	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.0226627594365	0.0226627594365	0.410327734371747	0.408585546428	16.7890038364225	188.993081123436	2.57017741702815e-39	2.58621387612313e-36	0.342116935888915	0.433213013981578
ORC4	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.4828771565415	0.4828771565415	0.185585058526874	0.18484230673	-8.55082222169623	157.0538816924	1.02569590733045e-14	1.03403752644509e-12	-0.365964624509773	-0.228619571519479
ORC4	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-2.06307303833	-2.06307303833	-2.78218307950634	-2.665674709255	-7.1530278422759	26.9281590055924	1.09924750765387e-07	5.15424675274441e-06	-0.925410949133463	-0.512809133219208
ORC4	BRD-K88789588-001-14-9::2.5::HTS002	2.5	letrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.298533416933	-0.298533416933	0.178189700562367	0.141775811794	12.0384245185061	29.8750917318818	5.470965875459e-13	4.65681749452443e-11	0.395834690969126	0.557611544021607
ORC4	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.3500464484125	0.3500464484125	0.15094551880247	0.185599499868	-7.1502001182396	4.03712976110265	0.00195430561778072	0.0393151610824867	-0.276132830279956	-0.122069028940104
ORC4	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-0.246138013963	-0.246138013963	0.0274884850510324	0.0455215007673	8.50582681175222	3.27430541464427	0.0024283395645839	0.0473794802492218	0.175934471120556	0.371318526907509
ORC4	BRD-K94176593-001-09-4::2.5::HTS002	2.5	TWS-119	glycogen synthase kinase inhibitor	noncancer	GSK3B, JUN, MYC	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.0589966169971	0.0589966169971	-0.299695635544752	-0.2225830716545	-8.2491010173581	37.5355129049588	5.91239261272834e-10	3.59692647258998e-08	-0.446753933553536	-0.270630571530167
ORC4	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.1628602482155	0.1628602482155	0.300411909358777	0.276885156297	3.68345823807222	79.9154493225163	0.000416939819957342	0.0101883815610121	0.0632353643998044	0.21186795788675
ORC4	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.07539659521805	0.07539659521805	-0.349449757866813	-0.28220904824	-8.10777772181269	4.3175375335017	0.000904142315737532	0.0202512193948907	-0.566207468525251	-0.283485237644475
ORC4	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	-2.44690897446	-2.44690897446	-1.74247040691058	-1.68383825257	10.9229018650712	179.787421611905	1.2552096430462e-21	2.38347675565509e-19	0.577180167244659	0.831696967854189
ORC4	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	SW1990, SH10TC	PANCREAS, STOMACH	carcinoma (ductal_carcinoma), carcinoma	0.120395830647	0.120395830647	0.312270024643798	0.3392697962385	5.68308999376189	96.5325422446598	1.40193018598625e-07	6.47853158327396e-06	0.124861274548638	0.258887113444959
PAK1	BRD-A03932035-004-04-3::2.5::HTS002	2.5	methscopolamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3780623550875	0.3780623550875	0.239105762297101	0.224710721764	-4.97048118594353	168.955265049476	1.62778224804387e-06	6.43098509568652e-05	-0.194145373417581	-0.083767812163217
PAK1	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.329763202985	-1.329763202985	-2.10425702592694	-2.089022441025	-10.1936190697919	44.9277851768933	2.89540441013095e-13	2.53811505856424e-11	-0.927528758771228	-0.621458887112648
PAK1	BRD-A27376179-001-01-3::2.5::HTS002	2.5	lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	targeted cancer	FLT3, NTRK1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.721916407015	-1.721916407015	-2.92653455523553	-2.893945062805	-10.1210465441663	8.17173735878603	6.64976010998789e-06	0.00023667160986609	-1.4780805246588	-0.931155771782257
PAK1	BRD-A48300215-001-04-8::2.5::HTS002	2.5	ajmaline	sodium channel blocker	noncancer	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.259779387559	-0.259779387559	0.085238413295299	0.1404901413085	7.24341276298721	165.004298763901	1.5881759444165e-11	1.16135162739967e-09	0.250971143514737	0.439064458193861
PAK1	BRD-A55484088-050-02-5::2.5::HTS002	2.5	BNTX	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.777553544694	-0.777553544694	-1.39042409399517	-1.31545762585	-7.52888876101484	7.86403477686461	7.37584282793806e-05	0.00214761176126767	-0.801151531224553	-0.424589567377782
PAK1	BRD-A58193911-003-18-7::2.5::HTS002	2.5	oxyphencyclimine	cholinergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.874469948709	-0.874469948709	-2.31680035301649	-2.14599876689	-11.1066324924434	13.1854470861116	4.57031793894277e-08	2.2415370103791e-06	-1.72247979744812	-1.16218101116685
PAK1	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.77551392514	-0.77551392514	-2.37297837455987	-2.31691828506	-16.5657377982412	7.66116880921379	2.8272984779601e-07	1.25149123395851e-05	-1.82156023393386	-1.37336866490587
PAK1	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.405251573077	0.405251573077	-0.240034969210661	-0.2322368233935	-12.6108530791708	18.5613397215802	1.51581517791238e-10	9.8300499626863e-09	-0.752556355706171	-0.538016728869152
PAK1	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.77190059443	-1.77190059443	-2.77112223701908	-2.64361455145	-9.55666517590954	91.6706344854135	2.01953692535414e-15	2.18940480361268e-13	-1.20689193377632	-0.791551351401846
PAK1	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.383360094351	0.383360094351	-0.0887595679436597	-0.0325205860223	-9.06530453444277	3.85233233150216	0.000975954278267253	0.0216672161287282	-0.618928872626337	-0.325310451962982
PAK1	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5945984693675	0.5945984693675	-0.365550431675193	-0.164030729397	-10.4262260259089	3.16978112556585	0.00147419261374977	0.0309706164195624	-1.24453630716407	-0.675761494921319
PAK1	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.272209364821	0.272209364821	-1.70207574488593	-1.35955217781	-11.7457963274417	3.52022593647574	0.00060008298788324	0.0140917263843571	-2.46714901734555	-1.48142120206832
PAK1	BRD-K07310275-001-02-5::2.5::HTS002	2.5	PF-04691502	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.54171582345	-2.54171582345	-3.93930132345007	-3.94541046238	-14.2718101419169	138.077171705757	5.857380081318e-29	2.15705569664743e-26	-1.59121455409682	-1.20395644590332
PAK1	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.78581739511	-1.78581739511	-3.04234601172189	-2.93942386342	-13.1564890352266	190.999694137977	1.45468735485382e-28	5.24228974097299e-26	-1.44491131916961	-1.06814591405416
PAK1	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.536241816698	0.536241816698	0.340847405018604	0.3517633375585	-5.46805679649206	15.3725624863208	5.94245443189426e-05	0.00176613925210209	-0.27139873203215	-0.119390091326641
PAK1	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0797274543472	-0.0797274543472	-1.82183300882918	-1.56065418801	-15.6671086904115	51.3486203931255	3.32432818861035e-21	6.1053979120537e-19	-1.96530221884865	-1.51890889011531
PAK1	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.07056154525065	-0.07056154525065	-0.483745647523576	-0.4134526693685	-8.96499761693628	183.669882191532	3.51688275252202e-16	4.10326599600051e-14	-0.50411523255792	-0.322252971987931
PAK1	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.583318344359	0.583318344359	-0.060073743343556	0.1891566141585	-7.59768412723159	5.81578347966475	0.000313872677224097	0.00788929483250423	-0.852204536196774	-0.434579639208338
PAK1	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.88445268467	-1.88445268467	-2.74983173383926	-2.77734094711	-16.9928855306011	21.9718086306148	3.99162520426945e-14	3.81929035002619e-12	-0.971000888330834	-0.759757210007685
PAK1	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	1.341383911115	1.341383911115	-0.38778284400984	-0.1455477562875	-15.0815633671886	3.98069285715472	0.000116292724375142	0.00324839089307961	-2.04810808414793	-1.41022542610174
PAK1	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.202652120035	-1.202652120035	-2.46336686205604	-2.36107459971	-10.6308716722102	5.44572445020936	7.5795079871724e-05	0.00220212602329222	-1.55820592872041	-0.963223555321661
PAK1	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.601855642885	-2.601855642885	-4.19386575658912	-4.20452435995	-11.8465642021975	2.99959971286588	0.00129401309697974	0.0276901490677486	-2.01971802353916	-1.16430220386909
PAK1	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3966553961445	0.3966553961445	0.547115177756154	0.548346398175	4.81368060401433	7.92411042744526	0.00136824966969101	0.0290352062826936	0.0782613647471171	0.222658198476191
PAK1	BRD-K21680192-300-14-4::2.5::HTS002	2.5	mitoxantrone	topoisomerase inhibitor	chemo	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.52392694855	-2.52392694855	-4.75028006639346	-4.76808598937	-14.4443815251784	7.68143067393332	7.64914006167371e-07	3.18336415588051e-05	-2.58436624879736	-1.86833998688955
PAK1	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.00106123674175	-0.00106123674175	-2.08206723154744	-1.99815705335	-20.7088818343895	12.5079193331004	4.6917742568393e-11	3.22923341263362e-09	-2.2989697563761	-1.86304223323529
PAK1	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1273456579715	0.1273456579715	-0.430232904185169	-0.326694667694	-13.0499171690033	29.5119703674345	8.68823634253649e-14	8.01265493571215e-12	-0.644898465465388	-0.47025865884795
PAK1	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.0031434890885	-1.0031434890885	-1.97285488665375	-1.89093805071	-13.4189596569941	165.999082525781	2.81389227070044e-28	9.7746955670495e-26	-1.11238693672244	-0.827035858408057
PAK1	BRD-K33882852-003-02-8::2.5::HTS002	2.5	ZK-93423	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.207198116813	-0.207198116813	-0.890131922990255	-0.832624878756	-11.4823377560914	184.902198567824	2.20173223144209e-23	4.8850421059291e-21	-0.80027439501696	-0.56559321733755
PAK1	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.00555994032	-2.00555994032	-3.67806321116235	-3.65355610334	-14.7855215618647	15.3193218161658	1.76737065991931e-10	1.13890194278366e-08	-1.91317082395012	-1.43183571773459
PAK1	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.1825817108015	-0.1825817108015	0.1353289247767	0.1319992768505	10.2483731743331	187.355937106451	7.5256564266295e-20	1.22002468455374e-17	0.256716101965492	0.379105169190908
PAK1	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2545032497875	-0.2545032497875	-0.0175518716492676	-0.01606038970165	7.96420541555029	47.5662331028343	2.65392994492091e-10	1.67990003297387e-08	0.177116791214417	0.296785965062048
PAK1	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.280172147204	0.280172147204	0.57798682874704	0.571651612309	7.44704744171856	7.1422248801654	0.000129887651740171	0.00358931027718143	0.203631450467259	0.391997912618821
PAK1	BRD-K37249724-001-25-7::2.5::HTS002	2.5	astemizole	histamine receptor antagonist	noncancer	HRH1, KCNH1, KCNH2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.7898163891915	0.7898163891915	0.0548629817534156	0.100436576625	-17.2381286383589	11.8894774989714	8.94471581724027e-10	5.3520714583844e-08	-0.827943688554569	-0.6419631263216
PAK1	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.219931308672	0.219931308672	-1.95931263606759	-1.74375486562	-17.7509309964822	3.72667988498867	9.74392077905438e-05	0.00276829904116377	-2.53019133769783	-1.82829655178135
PAK1	BRD-K38305202-001-17-4::2.5::HTS002	2.5	domperidone	dopamine receptor antagonist	noncancer	DRD2, DRD3	infectious disease	fescue toxicosis	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.6129523253035	0.6129523253035	-0.367785978880255	-0.225769257521	-16.9177500082328	190.138417261616	8.95626319252157e-40	9.40973987151939e-37	-1.09508713405697	-0.866389474310543
PAK1	BRD-K40175214-001-11-6::2.5::HTS002	2.5	torin-1	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.31069455385	-3.31069455385	-3.733644100195	-3.718490926125	-5.84820930981283	167.757039752544	2.53360013511769e-08	1.28770211847199e-06	-0.56572649908428	-0.28017259360572
PAK1	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.658825901073	-0.658825901073	-2.305764151635	-2.14029239454	-15.4161303116159	6.89775256565959	1.3399521554642e-06	5.37307026245997e-05	-1.90031721843674	-1.39355928268726
PAK1	BRD-K42205652-001-02-7::2.5::HTS002	2.5	MNS-(3,4-Methylenedioxy-nitrostyrene)	src inhibitor, syk inhibitor	noncancer	SRC, SYK	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.359327384599	0.359327384599	0.239157699820849	0.255658141899	-3.12783453052434	128.423661838882	0.00217911335910979	0.0431452366877267	-0.19618673904947	-0.0441526305068318
PAK1	BRD-K42756753-001-01-9::2.5::HTS002	2.5	epiandrosterone	steroid	noncancer	G6PD	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.326506437431	0.326506437431	0.221334622305236	0.2292300635955	-3.72946600240569	185.530391951585	0.000254817439256505	0.00655324777278707	-0.160806162722039	-0.0495374675294889
PAK1	BRD-K44084986-300-08-4::2.5::HTS002	2.5	Y-27632	rho associated kinase inhibitor	targeted cancer	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2423261655385	-0.2423261655385	-0.945153418870099	-0.864137598244	-8.32555081374813	3.79194968509329	0.00142957249348632	0.0301751864247025	-0.942369265065145	-0.463285241598054
PAK1	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.28373277821	-2.28373277821	-3.77239459287166	-3.649368876965	-12.3531441377197	12.3516162388958	2.5708876779655e-08	1.30356230217806e-06	-1.75040119648363	-1.22692243283969
PAK1	BRD-K45662124-050-01-5::2.5::HTS002	2.5	3'-fluorobenzylspiperone	dopamine receptor ligand	noncancer	DRD2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1101322359871	0.1101322359871	0.513202850399109	0.5308791065105	9.10342600560786	3.52827566031307	0.00142301834402534	0.0300486796706016	0.2733771599703	0.532764068853719
PAK1	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.7165343611	-1.7165343611	-2.24573644321593	-2.140330076935	-7.68782594068542	26.655752352208	3.1296537798955e-08	1.57127094165196e-06	-0.670528059171555	-0.387876105060307
PAK1	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.113401781736	0.113401781736	0.348895418535327	0.3889604534415	7.31137981877696	165.671230131397	1.07139849150445e-11	7.98441471786016e-10	0.171900241739551	0.299087031859103
PAK1	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.752011271392	0.752011271392	-0.373861036830754	-0.243490121847	-11.782056870515	2.91198819239864	0.0015108667348211	0.0316232965241671	-1.43524765341443	-0.816496963031074
PAK1	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.175407575106	0.175407575106	-0.269697724731485	-0.2054130743915	-9.25757648153441	144.17963808498	2.66443785047303e-16	3.141178768174e-14	-0.540138244011478	-0.350072355663492
PAK1	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1905358327435	0.1905358327435	0.0266889398078346	0.0405492292056	-5.66406900439537	15.1350247952928	4.34701877925876e-05	0.0013283321755628	-0.225456350767832	-0.102237435103499
PAK1	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1202368813974	0.1202368813974	-0.326668770417862	-0.2394985033815	-7.48409197441455	7.01330900301678	0.000137841723506349	0.00378035556716471	-0.58805270769405	-0.305758595936474
PAK1	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1757278313715	0.1757278313715	-0.104342120444453	-0.112273492753	-5.95308002976563	57.9882969884845	1.6295258304942e-07	7.46111176509273e-06	-0.374243610744653	-0.185896292887253
PAK1	BRD-K51967704-001-03-6::2.5::MTS010::PROS004_PR500	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3459510366135	0.3459510366135	-1.40303327122557	-1.39474896106	-19.4858145327135	29.5665337733522	2.02947364267521e-18	2.888280586726e-16	-1.93240490263289	-1.56556371304526
PAK1	BRD-K52313696-001-12-3::0.15625::HTS002	0.15625	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.282439417075	-0.282439417075	0.42463937427188	0.39525647476	19.3717964020487	10.1301106262173	2.44894633038082e-09	1.39670095275197e-07	0.625892145643126	0.788265437050634
PAK1	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.201190247036	-0.201190247036	-0.768409346701594	-0.6098527820225	-7.1563615366674	12.2579793994872	1.02649552329426e-05	0.00035273204654	-0.739511356281413	-0.394926843049776
PAK1	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.79645820149	-1.79645820149	-2.74952643318607	-2.66953815971	-10.9054331154326	71.5985991753331	7.1655968954566e-17	8.88338794674551e-15	-1.12730145746338	-0.778835005928768
PAK1	BRD-K54256913-001-08-7::2.5::MTS010::PROS004_PR500	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.01352628516065	-0.01352628516065	-1.22313599094363	-1.224724300865	-9.99692621070495	11.6419015815709	4.63725401349186e-07	1.98779603091539e-05	-1.47414425362984	-0.945075157936129
PAK1	BRD-K55187425-236-05-2::2.5::MTS010::PROS004_PR500	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4927695258	0.4927695258	-0.81418753401137	-0.733552010026	-15.7947794232274	191.595411028334	1.55479875196035e-36	1.17752106610922e-33	-1.47016744572399	-1.14374667389875
PAK1	BRD-K56334280-001-05-1::2.5::HTS002	2.5	amonafide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.691003609894	0.691003609894	-0.41585045905453	-0.361016794992	-11.5791649378605	3.15395316495729	0.00109059074387668	0.0238345287594927	-1.40283410136868	-0.810874036528377
PAK1	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.029041784719915	-0.029041784719915	0.263620343032955	0.254607479759	8.29469164483177	3.4424125719078	0.00215631586032537	0.0427649691891993	0.188114042380973	0.397210213124768
PAK1	BRD-K58122457-001-02-2::2.5::HTS002	2.5	hesperadin	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.35347667963	-1.35347667963	-2.72052708375788	-2.71475551237	-12.8715647401113	18.4115718362657	1.19907438601824e-10	7.86884305207911e-09	-1.58982605837073	-1.14427474988502
PAK1	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.3093212724515	-0.3093212724515	-2.02621937708219	-2.23082742718	-16.2320714244338	7.76195601884341	2.87183507858117e-07	1.26934898127031e-05	-1.96211689023257	-1.47167931902881
PAK1	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.00772023204218	-0.00772023204218	-0.207569991859264	-0.0810605722641	-4.07148659637644	147.159037319836	7.6003094774392e-05	0.00220757112073461	-0.296852709570316	-0.102846810063851
PAK1	BRD-K61443650-236-13-1::2.5::HTS002	2.5	thiomersal	other antibiotic	noncancer	OXCT1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.567075296239	0.567075296239	-0.177336049180647	-0.0402678564845	-9.69023612782155	3.20639871460443	0.00175925393153866	0.0359789251806059	-0.98022309626662	-0.508599594572673
PAK1	BRD-K61642990-001-01-0::2.5::HTS002	2.5	FERb-033	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4130661126615	0.4130661126615	0.179753441382247	0.239686907074	-5.68625515407634	40.9343783438416	1.21404971242849e-06	4.89293081637996e-05	-0.316180468516205	-0.150444874042301
PAK1	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4964620982175	0.4964620982175	-0.498986209230863	0.00402399396559	-10.1229819895097	26.5394378726058	1.31561542956799e-10	8.60714679409195e-09	-1.19738001230535	-0.79351660259138
PAK1	BRD-K62696033-001-01-4::2.5::HTS002	2.5	G-1	G protein-coupled receptor agonist	targeted cancer	GPER1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.10252460546265	0.10252460546265	-1.26161073699442	-1.18405970294	-14.8309534150465	7.83227545232439	5.19240839432449e-07	2.21073440355021e-05	-1.57703237495336	-1.15123830996078
PAK1	BRD-K66030860-001-03-6::2.5::HTS002	2.5	salidroside	beta amyloid protein neurotoxicity inhibitor	noncancer	APP	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2510320790035	0.2510320790035	0.131912689420229	0.132086067756	-3.9916222267611	27.2304632511515	0.000447028248262046	0.0108481790559054	-0.180326595771472	-0.0579121833950695
PAK1	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.8786550239955	-0.8786550239955	-2.64453442322597	-2.62453052692	-9.18194930170716	3.45506313867668	0.00151445154616808	0.0316890447562881	-2.33475914230671	-1.19699965615423
PAK1	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.47483014692	-1.47483014692	-3.15351136646566	-3.04544241525	-15.9769598391797	164.740875216956	2.62847347154799e-35	1.69176603808832e-32	-1.88613641419394	-1.47122602489738
PAK1	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2668765768485	0.2668765768485	0.10322333440728	0.0827932765815	-4.13943609526629	48.8264914991192	0.000137141568924187	0.00376693775803563	-0.243109250335716	-0.084197234546723
PAK1	BRD-K71035033-001-07-1::2.5::HTS002	2.5	masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor	noncancer	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.664964150905	0.664964150905	0.27429707700769	0.3093136114795	-9.67446792992832	33.6170375853514	3.04067722936818e-11	2.14447288546645e-09	-0.472766089318979	-0.308568058475641
PAK1	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.7065992038105	0.7065992038105	0.095434398529218	0.129185439077	-13.8364114857071	10.3236669287896	5.37032653873004e-08	2.61416469843169e-06	-0.709166739563911	-0.513162870998653
PAK1	BRD-K75009076-001-02-1::2.429::HTS002	2.429	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.6661826963825	-0.6661826963825	-1.92880676715803	-1.72291152257	-10.6163689384473	5.60477437650565	6.37442508778395e-05	0.00188340798819913	-1.55868728503162	-0.966560856519429
PAK1	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.762785977295	-0.762785977295	-2.94809380890515	-2.86819814614	-19.0164902313362	11.3725329059133	5.63185598149066e-10	3.435031475973e-08	-2.43723007463269	-1.93338558858762
PAK1	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.652634376799	-0.652634376799	-0.959671284861598	-0.892479910689	-5.54291001070537	76.3374309212578	4.07936117504637e-07	1.76275282517442e-05	-0.417353201893341	-0.196720614231854
PAK1	BRD-K78177893-001-02-4::2.5::HTS002	2.5	A-674563	AKT inhibitor	targeted cancer	AKT1, PKIA, PRKACA	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.998083119615	-2.998083119615	-2.67003159752783	-2.61788937322	3.77539524269645	76.4496676661846	0.000313841730351742	0.00788929483250423	0.155007629851283	0.501095414323062
PAK1	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	1.002368677137	1.002368677137	-0.475706181203503	-0.217946401079	-11.4827706654529	3.04034478707294	0.001331964175699	0.0283973490314723	-1.88466471658394	-1.07148500009706
PAK1	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.184184999363	-0.184184999363	-1.70372364522099	-1.42296021894	-15.3130657709675	13.2520976421244	8.25100812478378e-10	4.95914279410203e-08	-1.73350147279586	-1.30557581892013
PAK1	BRD-K82850175-001-01-1::2.5::HTS002	2.5	navarixin	CC chemokine receptor antagonist	targeted cancer	CXCR1, CXCR2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.1377893693237	-0.1377893693237	-0.890258319130941	-0.794282488065	-10.7977005970259	10.040855722073	7.56485607486147e-07	3.14951056268257e-05	-0.90765764320674	-0.597280256407742
PAK1	BRD-K85849709-001-01-5::2.5::HTS002	2.5	AZD2858	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2055145077345	-0.2055145077345	-1.75549241354735	-1.58142257926	-11.3253419183584	4.02696152665754	0.000333944589456445	0.00834974450695409	-1.92895889274577	-1.17099691887993
PAK1	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.228788391487	-0.228788391487	-0.0478997062843539	-0.0538286289263	4.13276944376417	187.298990193602	5.40041566135279e-05	0.00161883313046445	0.094544402591807	0.267232967813485
PAK1	BRD-K88677950-001-03-9::2.5::HTS002	2.5	PD-198306	MAP kinase inhibitor, MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.222220666658	-0.222220666658	-0.669993711118026	-0.5546333344115	-8.26490222804095	15.6801035798559	4.19120511838002e-07	1.80889408340167e-05	-0.562815275720674	-0.332730813199378
PAK1	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4606231536685	0.4606231536685	0.149787647543244	0.185599499868	-13.5257933733624	13.5477886753786	2.97647570119025e-09	1.68590132283405e-07	-0.360279526709249	-0.261391485541263
PAK1	BRD-K89015388-001-01-7::2.5::HTS002	2.5	GSK923295	centromere associated protein inhibitor	targeted cancer	CENPE	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.4296344405745	-0.4296344405745	-1.65299946874112	-1.4981509162	-10.5988362441823	5.68334220151252	5.88918301660116e-05	0.00175138435793688	-1.50965726232269	-0.937072794010559
PAK1	BRD-K89053832-001-01-0::2.5::HTS002	2.5	VLX600	ubiquitin C-terminal hydrolase inhibitor	targeted cancer	USP14	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.139911598115	-0.139911598115	-2.08522687157767	-1.90794289133	-18.2453384195711	101.169633752734	9.1141897516194e-34	5.19530631722031e-31	-2.1568160793209	-1.73381446760444
PAK1	BRD-K89162000-001-06-4::2.5::HTS002	2.5	tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFD, PDGFRB	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.372651153914	-0.372651153914	0.060194320708956	0.145916428293	8.62797370423344	5.65572532065171	0.000183241046188199	0.00489394021040132	0.308255287554402	0.55743566169151
PAK1	BRD-K89704198-001-12-3::2.5::HTS002	2.5	vincamine	adrenergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2201020519825	0.2201020519825	-0.197734350154493	-0.1128406004625	-9.42699230148115	193.830257596261	1.31728271126809e-17	1.74818505401473e-15	-0.505254496183661	-0.330418308090326
PAK1	BRD-K93123848-001-04-1::2.5::HTS002	2.5	RAF265	RAF inhibitor, VEGFR inhibitor	targeted cancer	BRAF	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.212407587756	-0.212407587756	-1.29860690577655	-1.194488826315	-13.7979569592488	7.00495666545845	2.46361932251062e-06	9.47470062397954e-05	-1.27231997912957	-0.900078656911531
PAK1	BRD-K95763993-001-19-3::2.5::HTS002	2.5	trapidil	PDGFR tyrosine kinase receptor inhibitor	noncancer	PDGFRA	cardiology	coronary artery disease (CAD)	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.08540950412365	-0.08540950412365	0.398521533132247	0.422554855711	19.0827031797542	192.981750226754	2.63875575439413e-46	4.67406514118627e-43	0.433913328853354	0.53394874565844
PAK1	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.5199905588725	-0.5199905588725	-1.76264756309474	-1.69551344644	-15.9952406647895	8.65911053514535	9.93842670727385e-08	4.68667339437469e-06	-1.41946245056382	-1.06585155788066
PAK1	BRD-K98572433-001-02-9::2.5::HTS002	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.404884570755	-1.404884570755	-2.72256266111205	-2.74521955492	-11.6605403932078	7.77520052613756	3.36599084788535e-06	0.000126522176856615	-1.57958114393485	-1.05577503677925
PAK1	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.931617643505	-1.931617643505	-3.15443649624575	-3.23564927932	-16.261416072655	5.3423825795349	9.35970916628949e-06	0.000324185052666719	-1.41245298882973	-1.03318471665176
PAK1	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.07915458907165	-0.07915458907165	-1.09935115983904	-1.03443241086	-16.0818837412373	181.751223073795	9.07050588868407e-37	7.04374078483974e-34	-1.14536549273268	-0.895027648802092
PAK1	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.305287010725	-0.305287010725	-0.866327759785125	-0.791872957089	-10.8032021053012	11.9001966848831	1.66828289091241e-07	7.61903694281625e-06	-0.674297982543914	-0.447783515576337
PAK1	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	0.303915577309	0.303915577309	-0.223155176889254	-0.147984722712	-10.4166773846779	59.8563383695216	4.58458735714847e-15	4.79555892469631e-13	-0.628288300908566	-0.425853207487941
PAK4	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.277505728995	-1.277505728995	-0.824192992965992	-0.696430068405	7.50870959324515	177.974315997517	2.77163614335453e-12	2.20751394637322e-10	0.334176476687251	0.572448995370764
PAK4	BRD-A10977446-001-12-1::2.5::HTS002	2.5	carvedilol	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA	cardiology	myocardial infarction, hypertension	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.6608095616215	-0.6608095616215	-0.211833605260395	-0.2026520966345	8.46310831521262	98.9644668934271	2.42484550836878e-13	2.14227004519033e-11	0.343710889760338	0.554241022961872
PAK4	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-4.317751532855	-4.317751532855	-3.71211513092195	-3.697322932235	7.12070624650461	14.2566520403853	4.6655999363583e-06	0.000171228316568448	0.423523779078599	0.787749024787508
PAK4	BRD-A48300215-001-04-8::2.5::HTS002	2.5	ajmaline	sodium channel blocker	noncancer	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.07115097098575	-0.07115097098575	0.0829657817703201	0.1404901413085	3.21901058721316	165.959865798767	0.00154738301108648	0.0322804217815023	0.0595901460896133	0.248643359422527
PAK4	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.6835196860905	-0.6835196860905	-0.441040509358066	-0.316823475009	3.31748975718519	165.377935587628	0.00111688931447736	0.0243521637723926	0.0981670904233221	0.386791263041546
PAK4	BRD-A81370665-001-03-6::2.5::HTS002	2.5	BI-D1870	ribosomal protein inhibitor	noncancer	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	0.18515353489	0.18515353489	0.360957233915453	0.3647781877755	5.38008859432624	180.144555900873	2.2929601083021e-07	1.02663013798262e-05	0.111325319598457	0.24028207845245
PAK4	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.2891031574805	-0.2891031574805	-0.0816435546967656	-0.0155909227599	5.59844792088761	180.212208764048	7.9513896098137e-08	3.78629945274774e-06	0.134338904679433	0.280580300888035
PAK4	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.98041070745	-1.98041070745	-1.44803136773221	-1.361653967605	6.85785871099563	43.0147890481106	2.06415581848346e-08	1.0604229444385e-06	0.375823972820479	0.688934706615103
PAK4	BRD-K06234293-001-04-2::2.5::HTS002	2.5	LY364947	TGF beta receptor inhibitor, p38 MAPK inhibitor	targeted cancer	TGFBR1	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	0.9022331813475	0.9022331813475	0.78466974470898	0.806042544038	-3.64827816962597	186.475729839584	0.000342538489716702	0.00854667426804319	-0.181134599778511	-0.0539922734985284
PAK4	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	0.1015710754289	0.1015710754289	0.430558410063794	0.408179294611	9.50857775768493	65.073818611431	6.2871082030081e-14	5.8894650963397e-12	0.259889835004421	0.398084834265368
PAK4	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.323918897355	-1.323918897355	-1.80880482617988	-1.56065418801	-4.48501642456584	120.35165756031	1.67706769626878e-05	0.000555727028870733	-0.698934604046903	-0.270837253602866
PAK4	BRD-K19687926-379-07-4::2.5::HTS002	2.5	lapatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2	oncology	breast cancer	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.363825656874	-0.363825656874	-0.661973933309372	-0.522756667285	-4.64863161096121	14.6382340944463	0.000335387414511273	0.00838093146377366	-0.435147437690611	-0.161149115180133
PAK4	BRD-K19761926-001-03-6::2.44857::HTS002	2.44857	eplerenone	cytochrome P450 inhibitor	noncancer	NR3C2	cardiology	congestive heart failure, hypertension	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.567138210885	-1.567138210885	-0.8609693341464	-0.765433856572	9.44518516505999	184.237426939785	1.61803119554499e-17	2.12755219699363e-15	0.558663317384107	0.853674436093092
PAK4	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.05109062440435	-0.05109062440435	-0.306053028173477	-0.19710233478	-4.58381423809258	176.863444953046	8.60475637405758e-06	0.000299877858356974	-0.364731264341021	-0.145193543197233
PAK4	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-3.6563121334	-3.6563121334	-3.26301647747085	-2.99271378173	3.4650762610264	189.5266203593	0.000655539696635539	0.0152222283467171	0.169404714809434	0.617186597048861
PAK4	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.33161396226	-1.33161396226	-0.965948836089285	-0.757900155601	3.68950444758628	134.300554693013	0.000325416334137481	0.00815553759113099	0.169647701959123	0.561682550382306
PAK4	BRD-K26756394-001-02-2::2.5::HTS002	2.5	VE-821	ATR kinase inhibitor	targeted cancer	ATR	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.240378204787	-0.240378204787	-0.113869378097682	-0.0474319307103	3.14634384909854	126.688640283969	0.00206096117300383	0.041163334940708	0.0469421717319191	0.206075481646716
PAK4	BRD-K29968218-001-03-2::2.5::HTS002	2.5	KX2-391	src inhibitor, tubulin polymerization inhibitor	targeted cancer	SRC	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-3.091222882675	-3.091222882675	-2.74407392492144	-2.69887921665	3.22623106858119	158.719821089329	0.00152351086898986	0.0318568352233881	0.134632512602324	0.559665402904797
PAK4	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.54533260237	-1.54533260237	-2.62940454439676	-2.459947367395	-12.0310184102139	187.617108550247	4.42517222219645e-25	1.14684732431819e-22	-1.26182385597134	-0.906320028082187
PAK4	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.11385827234485	-0.11385827234485	0.260045859004418	0.300751796019	8.04886535999609	3.47781837164337	0.00228793152544935	0.0450252571773055	0.236918007579277	0.510890255119258
PAK4	BRD-K42205652-001-02-7::2.5::HTS002	2.5	MNS-(3,4-Methylenedioxy-nitrostyrene)	src inhibitor, syk inhibitor	noncancer	SRC, SYK	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.265895014974	-0.265895014974	0.246066234622761	0.262709081551	13.7478716198778	180.758604829583	6.67141149616032e-30	2.66768088537415e-27	0.438481582883377	0.585440916310145
PAK4	BRD-K47114202-001-14-6::2.57945::HTS002	2.57945	chlorogenic-acid	antioxidant	noncancer	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-2.038553764985	-2.038553764985	-1.04206334531758	-0.939963064432	10.7627628800763	4.0922834539516	0.000374207021549555	0.00926671481475386	0.741698211437079	1.25128262789777
PAK4	BRD-K53734668-003-02-0::2.65747::HTS002	2.65747	PRT062607	syk inhibitor	targeted cancer	FGR, MAP3K9, SYK	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.306447534314	-0.306447534314	-0.0617116987996338	-0.0448082329464	5.65153077363881	148.645980364333	7.87472987144159e-08	3.75146249970261e-06	0.15916421161599	0.330307459412743
PAK4	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.34647133094	-1.34647133094	-0.742685338112403	-0.6455499330205	8.5877244812071	154.440093303345	9.0157974928338e-15	9.16238435676422e-13	0.464896452926516	0.742675532728678
PAK4	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-2.07977639745	-2.07977639745	-1.17420156713253	-1.09615123005	13.4357495695356	9.85944853457019	1.16175485125809e-07	5.43188820932144e-06	0.75510669497023	1.05604296566471
PAK4	BRD-K59753975-001-02-6::2.5::MTS006	2.5	vindesine	tubulin polymerization inhibitor	chemo	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.698480547315	-1.698480547315	-2.42007961154317	-2.28041477314	-6.63749033751994	16.1630780708237	5.42183731506256e-06	0.000196359744829341	-0.951877103383544	-0.491321025072795
PAK4	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.151438715985	-1.151438715985	-0.681602020651124	-0.630554296997	7.38164281933733	10.5303906960127	1.77686035716847e-05	0.000585446123737988	0.328979429307577	0.610693961360175
PAK4	BRD-K61734568-003-02-1::2.5::HTS002	2.5	2,3-DCPE	Bcl-XL downregulator	targeted cancer	BCL2L1	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	0.08938395292	0.08938395292	-0.361549690866593	-0.146091240972	-5.31373977528101	8.69256082370068	0.000544447277418806	0.0129211427883839	-0.643944408454535	-0.257922879118651
PAK4	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	0.390006101991	0.390006101991	0.152550145150346	0.163841475196	-7.53736446518538	34.8118927146861	8.11703875173187e-09	4.376646034264e-07	-0.301424517122529	-0.173487396558779
PAK4	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-3.94070121886	-3.94070121886	-3.12380207644229	-3.01726219862	6.35662698332259	8.92067844840176	0.000137031556757259	0.00376439842709903	0.525791598573451	1.10800668626197
PAK4	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.398841155014	-0.398841155014	-0.00353905910629595	0.0201994348842	5.91003070377439	5.20041003086127	0.00172653945085802	0.0354757428782425	0.225338484448909	0.565265707366499
PAK4	BRD-K69650333-003-14-0::2.5::HTS002	2.5	idarubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-5.168806316155	-5.168806316155	-6.64341168787157	-6.575075579375	-12.9860563942631	40.4732087234214	5.09372050467715e-16	5.83501882440914e-14	-1.70402094449637	-1.24518979893676
PAK4	BRD-K73319509-001-08-0::2.5::HTS002	2.5	PF-04217903	c-Met inhibitor	targeted cancer	MET	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	0.226638103593	0.226638103593	0.0444435522447389	0.085387538628	-5.38726905158874	124.221870270732	3.45080642602875e-07	1.50510356223914e-05	-0.249131565842384	-0.115257536854138
PAK4	BRD-K76674262-001-03-3::2.5::HTS002	2.5	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-5.09255218666	-5.09255218666	-4.750809786536	-4.86837811059	3.36673309935477	58.8774951251855	0.00134483655289882	0.0286233836689426	0.13862123954996	0.54486356069804
PAK4	BRD-K77841042-001-14-1::2.5::HTS002	2.5	brefeldin-a	protein synthesis inhibitor	targeted cancer	ARF1, CYTH2	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-5.14908958873	-5.14908958873	-4.73340394157974	-4.786446704285	3.53811585141208	61.7661425952308	0.000771656414181162	0.0176151184998439	0.180813079266434	0.650558215034092
PAK4	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.998700377007	-0.998700377007	-0.455287109222442	-0.176655264129	6.36557892292289	192.311653969187	1.3947018895354e-09	8.1651204939151e-08	0.375036531088437	0.71179000448068
PAK4	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	0.218328485432	0.218328485432	0.020037408198615	0.0259313359155	-7.25008362209562	175.220223383078	1.28212339200112e-11	9.47246551134807e-10	-0.252269256916922	-0.144312897549848
PAK4	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-2.250036078255	-2.250036078255	-1.27370564142701	-1.21704769228	10.9496765183009	3.391870849774	0.000917196320350766	0.0205157347259924	0.710241278459877	1.2424195951961
PAK4	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.1193851820585	-0.1193851820585	0.124287518751448	0.135109067247	5.37262528174205	7.42437943791317	0.000855698810068446	0.0192850757374511	0.137656648440332	0.349688753179563
PAK4	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-3.818103279555	-3.818103279555	-3.05407370756237	-2.99006854464	8.09063604466689	178.205793282819	8.88281305438459e-14	8.17451455188147e-12	0.577677172725239	0.950381971260018
PAK4	BRD-K82818427-001-02-2::2.39189::HTS002	2.39189	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-2.69458457382	-2.69458457382	-1.60213746913592	-1.52191219559	18.1929889342285	192.682178829921	1.05845230236702e-43	1.51238015676014e-40	0.97401189535958	1.21088231400857
PAK4	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.159467857018	-0.159467857018	0.351294144853604	0.388891879995	13.403680873878	5.64466127824826	1.70837853905364e-05	0.000565054110951896	0.416078244140281	0.605445759602927
PAK4	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.7410272744385	-0.7410272744385	-0.377830214121025	-0.338570487031	8.52760869914673	102.369335625154	1.41345771377933e-13	1.27986894100807e-11	0.278722211941864	0.447671908693085
PAK4	BRD-K83029223-001-01-3::2.5::MTS006	2.5	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.791185836195	-1.791185836195	-2.42652779800222	-2.31559247235	-4.91274533270623	6.63960474222833	0.00200972763543398	0.0402638730954318	-0.944544871697648	-0.3261390519168
PAK4	BRD-K84163249-001-01-9::2.5::HTS002	2.5	ercalcitriol	vitamin D receptor agonist	noncancer	VDR	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.871658113045	-0.871658113045	-0.514188332164373	-0.503488543469	7.51239539333519	43.7245039202243	2.12218638811787e-09	1.21812020990604e-07	0.261553472195895	0.453386089565359
PAK4	BRD-K85849709-001-01-5::2.5::HTS002	2.5	AZD2858	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-2.629880282585	-2.629880282585	-1.72997277381208	-1.560521012105	8.02516335273739	16.0206842239265	5.27670484200779e-07	2.24261525298966e-05	0.662215333049267	1.13759968449657
PAK4	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-3.50537500746	-3.50537500746	-2.76731398704108	-2.642391718485	7.54526352830347	43.8163644768034	1.87767914331817e-09	1.08533196631133e-07	0.540898875122787	0.935223165715059
PAK4	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	0.007416856472075	0.007416856472075	-0.314458157079438	-0.108614953002	-4.29975190160945	189.031227513657	2.73667514552436e-05	0.000867932594354972	-0.469541299065533	-0.174208728037494
PAK4	BRD-K89162000-001-06-4::2.5::HTS002	2.5	tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFD, PDGFRB	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.2925301738675	-0.2925301738675	0.0593186815827648	0.145916428293	6.60768245421023	4.27168192895754	0.00214982909219502	0.0426679062414174	0.207642918981138	0.496054791919392
PAK4	BRD-K92000912-001-12-6::2.5::HTS002	2.5	AM-251	cannabinoid receptor antagonist	targeted cancer	CNR1, GPR18, GPR55	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	0.240490244292	0.240490244292	-0.130361909774936	-0.0852704438558	-10.4605850058068	192.041718857476	1.48240729343767e-20	2.58521458743045e-18	-0.440778117026207	-0.300926191107666
PAK4	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-0.2387364379175	-0.2387364379175	0.0973834910179334	0.110191949027	12.1328758329029	19.9921900033482	1.12450386490228e-10	7.39759941254267e-09	0.278330542916224	0.393909314954643
PAK4	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-2.01678512303	-2.01678512303	-1.4110093948424	-1.11082774233	5.99627506715658	20.2659808097491	6.91163875170593e-06	0.000245259043379864	0.39521772842724	0.816333727947954
PAK4	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	NCIH1975, G361	LUNG, SKIN	carcinoma (non_small_cell_carcinoma), malignant_melanoma	-6.33479804556	-6.33479804556	-4.61095161978093	-4.61970061714	15.6615016683831	9.60762825038875	3.68867963318064e-08	1.83091944673454e-06	1.4772328843277	1.97045996723044
PARD3	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.238837373005	0.238837373005	-0.010042078583787	0.0633629143304	-7.10686424657688	29.7196377898694	7.01136407704913e-08	3.36484247933243e-06	-0.320427292453317	-0.177331610724257
PARD3	BRD-A25234499-001-18-3::2.5::HTS002	2.5	aminoglutethimide	glucocorticoid receptor antagonist	targeted cancer	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.110774306203	0.110774306203	0.216338341989473	0.21588142899	3.9629011169031	187.369840746866	0.000105193680917376	0.00296580589809792	0.0530149647721363	0.15811310680081
PARD3	BRD-A55913614-316-09-6::2.5::HTS002	2.5	primaquine	antimalarial agent, DNA inhibitor	noncancer	KRT7, NQO2	infectious disease	malaria	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.4245655259815	0.4245655259815	0.0942821129370652	0.121843056182	-9.80834573521324	123.943056796668	3.7034077085186e-17	4.69673177963955e-15	-0.396933424094387	-0.263633401994482
PARD3	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.00340897956194	-0.00340897956194	0.417879065500414	0.4743784763675	12.775924958392	142.557636523133	2.16069494497713e-25	5.67524003507357e-23	0.356104596803166	0.486471493321541
PARD3	BRD-K00259736-001-16-4::0.15625::HTS002	0.15625	colchicine	microtubule inhibitor	noncancer	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.559557273185	-2.559557273185	-3.05945772740378	-2.82813961253	-4.23753766849622	62.1153054438597	7.62354611548362e-05	0.00221372038393915	-0.735709537078745	-0.264091371358825
PARD3	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.215928441622	0.215928441622	-0.297764308633909	-0.208078798615	-8.30072058114478	10.910725704171	4.84368945589497e-06	0.000176916005008949	-0.650037520025976	-0.377347980485842
PARD3	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-3.28223515122	-3.28223515122	-4.28449372883455	-4.26036322773	-11.247572803764	4.1654369473037	0.000284559789827166	0.00721853653614233	-1.24583702331023	-0.758680131918883
PARD3	BRD-K05638300-001-01-2::2.5::HTS002	2.5	sevoflurane	membrane integrity inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.27700562218	-1.27700562218	-0.567907482120278	-0.4301086882785	10.292107135441	8.59847071243303	3.99380136973882e-06	0.000148120341542611	0.552125139114973	0.866071141004472
PARD3	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.19233872115	-1.19233872115	-2.50349129079743	-2.37307934162	-9.73298495642318	6.34515535290986	4.78881581435159e-05	0.00144989702595587	-1.63648358549762	-0.98582155379724
PARD3	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.0682624317509	0.0682624317509	0.202532573187356	0.216719294223	4.58212641878225	49.1398444838842	3.17445883838801e-05	0.000992528940004177	0.0753877569659885	0.193152525906924
PARD3	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-3.39951071767	-3.39951071767	-2.18569672225227	-2.0949684601	16.1767140671768	169.588731626881	3.32249705206196e-36	2.39766825141882e-33	1.06569177764293	1.36193621319254
PARD3	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.681727186897	-0.681727186897	-0.0636562546662639	-0.00125185876287	10.8892633770448	3.89179568327993	0.000466835230222473	0.0112777646594175	0.458737729931717	0.777404134529756
PARD3	BRD-K11073688-001-01-6::2.5::HTS002	2.5	CPI-1189	tumor necrosis factor release inhibitor	noncancer	TNF	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.680307010669	-0.680307010669	-0.256028644962507	-0.239432802339	7.89406550480067	12.3441143878507	3.60223652304974e-06	0.000134764138898364	0.307535846816572	0.541020884596414
PARD3	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.32710332801	-2.32710332801	-3.53246053958162	-3.39005054237	-8.51386260056095	16.949975070249	1.58314177486057e-07	7.26736332114136e-06	-1.50412328278598	-0.906591140357265
PARD3	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.6077353808315	0.6077353808315	-0.484300590461381	-0.373418715101	-11.7703243237989	55.7405790402493	9.64801466035304e-17	1.1762510433099e-14	-1.2779132302022	-0.906158712383559
PARD3	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.4902684924205	-0.4902684924205	0.0928017696716725	0.105022107206	15.2008032703202	6.73961898086103	1.82519961689376e-06	7.14116846822239e-05	0.491653114250268	0.674487409934077
PARD3	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.776717848623	-0.776717848623	-0.189475749506876	-0.144534319806	11.8176493430248	193.783399113862	1.27691217622974e-24	3.20467575900638e-22	0.489235582093847	0.6852486161384
PARD3	BRD-K19687926-379-07-4::2.5::HTS002	2.5	lapatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2	oncology	breast cancer	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.164021588405	-2.164021588405	-0.64331905318988	-0.498501703786	18.406580793995	3.08034334625811	0.000297894335103144	0.00752473717717405	1.26161465312802	1.77979041730222
PARD3	BRD-K21283037-001-21-5::2.5::HTS002	2.5	riluzole	glutamate inhibitor	noncancer	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.440256186932	0.440256186932	0.0405211885614456	0.0176424857247	-11.4557932719638	8.58980254892724	1.69723937435931e-06	6.68567575568932e-05	-0.479248383125354	-0.320221613615755
PARD3	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-6.501812743325	-6.501812743325	-4.15281357658449	-4.1358778776	25.236041684291	44.3912232774113	5.82957768263089e-28	1.94921615466552e-25	2.16145316865765	2.53654516482338
PARD3	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.2497163147	-2.2497163147	-2.87657096774766	-2.75215171608	-5.3238218914141	17.8628888956105	4.7498519737424e-05	0.00143870975647292	-0.874364383459776	-0.379344922635554
PARD3	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.231570931225	-1.231570931225	-0.766245017797746	-0.681873859599	8.10154747323538	94.4161000384378	1.90493585621141e-12	1.54365226593359e-10	0.351290609452933	0.579361217401575
PARD3	BRD-K28192623-066-08-1::2.5::HTS002	2.5	spiradoline	opioid receptor agonist	noncancer	OPRK1	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.885633789155	-2.885633789155	-2.31598378183147	-2.11804571815	5.64153543809813	6.95380209593746	0.000799673518614667	0.0181868872634935	0.330561825185433	0.808738189461619
PARD3	BRD-K28360340-001-08-3::2.30697::HTS002	2.30697	TW-37	BCL inhibitor	targeted cancer	BCL2, BCL2L1, MCL1	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.85064858176	-1.85064858176	-2.77860468649813	-2.74381570724	-8.45589541197044	6.77709185119593	7.67084556436771e-05	0.00222624869189623	-1.18919198857929	-0.66672022089696
PARD3	BRD-K33720171-001-01-0::2.5::HTS002	2.5	difluprednate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	endogenous uveitis	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.90188837556	-1.90188837556	-1.46522416349296	-1.420636846445	6.23866451866261	191.998857186688	2.75667767379522e-09	1.56554310849723e-07	0.298609827238046	0.574718596896026
PARD3	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.997007474251	-0.997007474251	-0.0854938716156032	-0.0710979031402	14.4583170267623	2.59418289557507	0.00149964972046674	0.0314345647861042	0.69189952398251	1.13112768128828
PARD3	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.07387937859645	-0.07387937859645	-0.51601002372339	-0.465030888818	-6.56924872918953	4.10403375288072	0.00253811280128417	0.0492288594432553	-0.62714057375666	-0.257120716497221
PARD3	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.718892830245	-1.718892830245	-0.480805837617538	-0.306530142238	15.84109111206	3.17873007777319	0.000393210597967217	0.00966472869859126	0.997085180092508	1.47908880516242
PARD3	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.335182118935	-2.335182118935	-0.612138461839492	-0.4180119465525	21.4072246341694	6.12921891055166	5.40608474904616e-07	2.29623610419801e-05	1.52709658047877	1.91899073371225
PARD3	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.1308183808275	0.1308183808275	0.259008219152388	0.257282112096	4.29740559997696	194.964084289143	2.72621872167104e-05	0.000864744313152334	0.0693597364390255	0.187019940210751
PARD3	BRD-K56032964-001-02-1::2.5::HTS002	2.5	AP26113	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, EGFR	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.28905554414	-1.28905554414	-0.537685251913619	-0.444840636203	8.68001274726816	3.80284949950744	0.00121319650378409	0.0261988104241351	0.506037562351411	0.996703022101351
PARD3	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.943170533835	-1.943170533835	-0.37151803961883	-0.1848985030465	17.8745354662687	3.95886351233425	6.20316583976168e-05	0.00183660496100329	1.32652460079836	1.81678038763398
PARD3	BRD-K59753975-001-02-6::2.5::MTS006	2.5	vindesine	tubulin polymerization inhibitor	chemo	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.470062155475	-1.470062155475	-2.42247142716453	-2.28041477314	-10.0561439526677	190.970039585394	2.31370283069333e-19	3.60126081335999e-17	-1.13921974049995	-0.765598802879113
PARD3	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.904712403255	-1.904712403255	-3.65868904812524	-3.579783032275	-14.4843624981329	71.8267878320176	5.29478690752497e-23	1.1439782087731e-20	-1.99538406624485	-1.51256922349564
PARD3	BRD-K61323504-001-04-0::2.5::HTS002	2.5	SB-225002	CC chemokine receptor antagonist	noncancer	CXCR2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.5178455329695	-0.5178455329695	-1.20541562219368	-1.18840349692	-9.45665996966544	163.66599988046	3.3309528179717e-17	4.25458752397531e-15	-0.831135736378393	-0.544004442069965
PARD3	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-8.347214991705	-8.347214991705	-7.20116085708739	-7.241239224365	11.2676265844113	185.906013154959	8.82863452004478e-23	1.86610691128864e-20	0.945395797611513	1.3467124716237
PARD3	BRD-K62196610-001-01-6::2.5::HTS002	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.97431254737	-2.97431254737	-1.65514920204646	-1.61645478176	14.8215861536807	4.76583846016277	3.60552938656956e-05	0.00111720327872498	1.08695145680913	1.55137523383795
PARD3	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.492399528886	-0.492399528886	-0.167527600554379	-0.0695637223616	5.34175392686247	8.14260452333364	0.000653217196901365	0.0151748741160495	0.185052985561454	0.464690871101788
PARD3	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.06670255936929	-0.06670255936929	-0.719535017282174	-0.5340799664045	-5.29074897275676	8.01781440622414	0.000731237707634277	0.0168013823213278	-0.93726332719849	-0.368401588627277
PARD3	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.100860293445	-2.100860293445	-2.48987258530214	-2.41136656484	-3.925327851226	13.0344198703239	0.00173246290182868	0.0355667664067087	-0.603054138829329	-0.174970444884949
PARD3	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.008011994103	-0.008011994103	-1.08921106777158	-0.4202572111255	-8.10181191817883	12.625257862978	2.36437522406232e-06	9.12412994955083e-05	-1.37037585352491	-0.792022293812255
PARD3	BRD-K68095457-001-10-1::2.5::HTS002	2.5	palmitoylethanolamide	cannabinoid receptor agonist	noncancer	CNR2, GPR119, GPR55	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.185738589072	0.185738589072	0.305480245336911	0.326165847724	4.40195139372593	29.0409599659982	0.000132753366428968	0.0036581250030026	0.0641108325190455	0.175372480010777
PARD3	BRD-K68202742-001-16-5::2.63491::HTS002	2.63491	trichostatin-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-6.42030065476	-6.42030065476	-5.49890321787171	-5.50871409078	8.79483495558222	4.02792194541943	0.00089323123372772	0.0200403388562366	0.631314595032562	1.21148027874401
PARD3	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.6683576556035	-0.6683576556035	-0.255386450558197	-0.207366437463	8.25073811311199	8.09112967719146	3.27013666238002e-05	0.00102107754949268	0.297775504136233	0.528166905954373
PARD3	BRD-K68870568-066-01-5::2.5::HTS002	2.5	flumatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, PDGFRB	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.2093734475585	-0.2093734475585	0.162931467689358	0.184523838067	8.11532206478901	5.01168607555975	0.000455831337981301	0.0110430512985412	0.254457536956994	0.490152293538722
PARD3	BRD-K69694239-001-02-2::2.5::HTS002	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-6.510973058955	-6.510973058955	-5.68219587668634	-5.73883515181	10.0316824614489	32.8156147931392	1.59081978414468e-11	1.16288817706666e-09	0.660657841000533	0.99689652353679
PARD3	BRD-K70401845-003-09-6::2.5::HTS002	2.5	erlotinib	EGFR inhibitor	targeted cancer	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.59862233682	-1.59862233682	-1.08329283020154	-1.046302066785	7.0118011145462	14.3940581559802	5.26670142054119e-06	0.000191161193694017	0.358103161439868	0.67255585179706
PARD3	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-5.06006810692	-5.06006810692	-2.90213357222467	-2.84610122618	13.8860127534496	2.65920913991826	0.00147829773096956	0.031050771695509	1.62550837019924	2.69036069919141
PARD3	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.7008461695305	-0.7008461695305	-0.141848868490865	-0.1170838755295	11.2205863303442	9.36110532000247	9.74373826299255e-07	3.9869524210938e-05	0.446958334103771	0.671036267975499
PARD3	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.5251908219665	-0.5251908219665	0.00824887030892844	0.03806515271055	17.5014576922295	16.2274677699409	5.83287134677924e-12	4.47602392726046e-10	0.468899085349855	0.597980299201002
PARD3	BRD-K78126613-001-28-5::2.5::HTS002	2.5	menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	noncancer	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.34045077976	0.34045077976	-0.129934957555828	-0.050497524351	-10.1261521428288	45.814504184266	2.8566202814059e-13	2.506166877992e-11	-0.563900117677613	-0.376871356954043
PARD3	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.3198469972715	0.3198469972715	-0.4687416742661	-0.217946401079	-9.30252680017608	195.891142572718	2.78300299380466e-17	3.57600868500695e-15	-0.955770516677592	-0.621406826397608
PARD3	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.2130134887395	0.2130134887395	0.0314782541097249	0.114428305936	-3.8268098806764	177.106018187561	0.000179817125839518	0.00481449403673431	-0.275151210104514	-0.0879192591550362
PARD3	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.04405919192	-1.04405919192	-0.770668448745498	-0.659860660516	4.80150784080962	14.1319918246973	0.000274578006487545	0.00699429873454587	0.151376687007457	0.395404799341546
PARD3	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.7988805125905	-0.7988805125905	-0.377230698699761	-0.338570487031	10.054767412419	147.74660578939	1.91489667481195e-18	2.73247596148981e-16	0.338779327973672	0.504520299807806
PARD3	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.1714706592616	-0.1714706592616	-0.852666223735435	-0.774088070041	-5.89310108904934	6.11991043755407	0.000987106846132509	0.0218876084445204	-0.962701138489965	-0.399689990457705
PARD3	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.4536583545455	-0.4536583545455	-0.0455074726347954	-0.0538286289263	7.26885052962866	6.15363931455365	0.00030714400387146	0.00773558956589496	0.271582390917847	0.544719372903562
PARD3	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.28597215825	-2.28597215825	-1.64139536543458	-1.710789940465	11.4566693967225	173.52054105167	5.46043730770344e-23	1.17858012862313e-20	0.533530530444906	0.755623055185928
PARD3	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.2476602947985	-0.2476602947985	0.106609925938612	0.135507608915	15.2012792693496	193.589048931588	7.32793199363896e-35	4.60583089813679e-32	0.308305341623016	0.400235099851208
PARD3	BRD-K92000912-001-12-6::2.5::HTS002	2.5	AM-251	cannabinoid receptor antagonist	targeted cancer	CNR1, GPR18, GPR55	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.21860716776	-1.21860716776	-0.115241729339164	-0.0809111569398	24.5315904431906	5.96208451729386	3.24178337889333e-07	1.42116627084236e-05	0.993139998381843	1.21359087845983
PARD3	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.817094775125	-1.817094775125	-0.950423741794958	-0.823450093444	10.0535426588211	177.778747791275	4.12296429451163e-19	6.2894719877465e-17	0.696553227041312	1.03678883961877
PARD3	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.4031230555605	-0.4031230555605	-0.00369529498292591	0.0503184944333	6.81411547671985	4.12235495029005	0.00217155848997725	0.0430194989923592	0.238566415481756	0.560289105673392
PARD3	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.06262341747	-1.06262341747	-0.607491029142267	-0.5106967244835	7.56041587161181	187.627370540346	1.73202253453877e-12	1.40828018894219e-10	0.336377778906613	0.573886997748854
PARD3	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-7.319296070935	-7.319296070935	-5.62888721135508	-5.72114668903	17.2680951009117	21.624155588729	3.9236444672865e-14	3.7575996203264e-12	1.48718843888181	1.89362928027803
PARD3	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	MFE280, HDQP1	ENDOMETRIUM, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.27712308718	-1.27712308718	-0.611584732501572	-0.6000769492995	9.46080954916909	3.81234415095727	0.000874642707212191	0.0196541514776768	0.466373501302275	0.864703208054581
PARVA	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.1290618186975	-0.1290618186975	0.180386687809827	0.215520353965	10.3349949372406	26.0628886998789	1.03456505262811e-10	6.8395216892267e-09	0.247909451400275	0.370987561614379
PARVA	BRD-A27376179-001-01-3::2.5::HTS002	2.5	lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	targeted cancer	FLT3, NTRK1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.280942404585	-1.280942404585	-2.93184749502384	-2.893945062805	-15.934312555588	39.0292567207393	1.12270266665909e-18	1.63803771165675e-16	-1.86046484985637	-1.44134533102132
PARVA	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.6933586056195	-0.6933586056195	-0.995878820671839	-0.927705434	-4.80481224119438	134.531530596559	4.07693705098284e-06	0.000151020712271016	-0.427043443990561	-0.177996986114117
PARVA	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.3716023313255	0.3716023313255	-0.0865364695553133	-0.0709548517643	-11.1986544899784	176.949939522691	2.39521587949526e-22	4.86601160413593e-20	-0.53887341747299	-0.377404184288637
PARVA	BRD-A74391928-051-01-3::2.5::HTS002	2.5	ibutilide	potassium channel blocker	noncancer	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.75971560775	-0.75971560775	0.177169541071996	0.1653845655485	14.9909435834957	2.60301339414493	0.00134379672262313	0.0286097752819204	0.719681093281103	1.15408920436289
PARVA	BRD-A91452556-001-04-0::2.5::HTS002	2.5	estradiol-cypionate	estrogen receptor agonist	noncancer	ESR1	endocrinology	hypoestrogenism, menopause	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.4888070218675	0.4888070218675	0.594390407796812	0.612598720084	4.3265927905347	121.01769351521	3.13429146143975e-05	0.000981117954983168	0.0572705765577741	0.15389619530085
PARVA	BRD-A93695607-322-02-5::2.4707::HTS002	2.4707	nicotine	acetylcholine receptor agonist	noncancer	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.142034459657	-0.142034459657	0.127652739513455	0.1533689039075	6.49652773596049	10.1052384959469	6.59968674971686e-05	0.00194193336268543	0.177321957759235	0.362052440581675
PARVA	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.115958626705	-2.115958626705	-3.73503445078501	-3.62613694573	-13.1234796491971	11.0912874370423	4.21980417819929e-08	2.07627734093039e-06	-1.89034432682748	-1.34780732133254
PARVA	BRD-K04623885-001-07-5::2.5::HTS002	2.5	BIBR-1532	telomerase inhibitor	targeted cancer	TERT	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.509891448598	-0.509891448598	-0.913533661381956	-0.834266968334	-7.52489196866454	28.03397921733	3.36307627878156e-08	1.6798060493008e-06	-0.51351467976318	-0.293769745804732
PARVA	BRD-K06749501-001-02-1::2.5::HTS002	2.5	GSK1838705A	insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R, INSR, RPS6KA1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.840010580186	-0.840010580186	-0.22697922156514	-0.0999889784018	8.83456406191499	6.30956625714892	8.80706831948952e-05	0.00252556883308519	0.44523891156776	0.78082380567396
PARVA	BRD-K14175878-001-01-6::2.5::HTS002	2.5	MK-0812	CC chemokine receptor antagonist	noncancer	CCR2	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.1451526577785	0.1451526577785	0.3318291884287	0.3199556031455	7.25775578263704	194.877016631801	9.12613419290874e-12	6.88246029356769e-10	0.135949326282462	0.237403735017939
PARVA	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.120952939936	0.120952939936	-0.0719205425959449	0.0407112965926	-4.5911504021543	145.585936939328	9.45273485300562e-06	0.000327142775441602	-0.275901415769937	-0.109845549293953
PARVA	BRD-K16803204-001-01-6::2.5::HTS002	2.5	filgotinib	JAK inhibitor	noncancer	JAK1, JAK2, JAK3, TYK2	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.630169001878	0.630169001878	0.238502000514636	0.219510761126	-12.2656835670017	25.4812026467062	3.42823153501835e-12	2.7053366593113e-10	-0.457369134555798	-0.325964868170931
PARVA	BRD-K17894950-001-14-3::2.5::HTS002	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.3013394280305	0.3013394280305	-0.102411898919763	-0.04764598998285	-9.61714219851589	137.40627524318	4.6615875943762e-17	5.8702315365162e-15	-0.486766574710797	-0.320736079189729
PARVA	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.52834822408	-1.52834822408	-0.868415945219798	-0.775615128041	7.87783026909027	12.8914164916525	2.79162021357123e-06	0.000106501454032486	0.478801354520814	0.84106320319959
PARVA	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.3558098191415	-0.3558098191415	-0.946941622296559	-0.900132875838	-9.40372749271821	6.75672172429741	4.00058042080252e-05	0.00122948150417291	-0.740867329992474	-0.441396276317644
PARVA	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.9237195133445	-0.9237195133445	-0.187960268427273	-0.144534319806	10.3388168655829	3.70759336056615	0.000723627328091639	0.0166535296470045	0.531874271526364	0.93964421830809
PARVA	BRD-K20755323-001-05-9::2.5::HTS002	2.5	SKI-II	sphingosine kinase inhibitor	targeted cancer	SPHK1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.358177294605	-0.358177294605	0.0600961548691985	0.07792704644355	11.8351701637852	148.569198624205	3.49503691211465e-23	7.67507957312111e-21	0.34843639107387	0.488110507874527
PARVA	BRD-K21361524-001-01-1::0.625::MTS006	0.625	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.8721097869675	-0.8721097869675	-2.76714049992125	-2.60110257698	-19.1002516083563	9.37370064292804	8.02493607143709e-09	4.33025307969547e-07	-2.11811397165007	-1.67194745425742
PARVA	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.1994403176835	0.1994403176835	0.415400778217167	0.442474468431	8.13828353832294	143.673107663575	1.73408136906254e-13	1.55377895380353e-11	0.163508332334817	0.268412588732516
PARVA	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.505900378448	-0.505900378448	-0.0278726926747057	-0.0206189181826	15.0618236838033	4.82849520203193	3.03641715834706e-05	0.000954100942869618	0.395563971972339	0.560491399574249
PARVA	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-3.411698490045	-3.411698490045	-4.69427943166594	-4.92315521315	-9.93904098550809	3.79490241369258	0.000745576762250228	0.017096257823508	-1.6486339894149	-0.916527893826982
PARVA	BRD-K28453807-003-11-2::2.5::HTS002	2.5	nitrocaramiphen	cholinergic receptor antagonist	noncancer	CHRM1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.1275002770405	0.1275002770405	0.359571777433059	0.350372820253	7.09702426901642	7.68277823296205	0.000124575089426605	0.00345587035227995	0.15612015120099	0.308022849584129
PARVA	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.0362257693563	0.0362257693563	-0.308904001553735	-0.26288025127	-8.69311882422375	181.845626312085	2.03660895887784e-15	2.20679657000671e-13	-0.4234645939649	-0.26679494785517
PARVA	BRD-K33277808-331-01-3::2.5::HTS002	2.5	ouabain	ATPase inhibitor	noncancer	ATP1A1	cardiology	hypertension, cardiac arrythmia	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-6.96824687695	-6.96824687695	-5.35259801291261	-5.28170504445	13.7673196108598	4.77030273025319	5.05696744109909e-05	0.00152333770159287	1.30955920122812	1.92173852684666
PARVA	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.176009964196	-0.176009964196	0.174538752513789	0.1694730901705	13.2532177718794	35.2656189872118	2.92599844243512e-15	3.11074563575732e-13	0.296866646307614	0.404230787111963
PARVA	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.261641256125	0.261641256125	0.413035633326572	0.43502168689	5.62518141890254	18.442302514421	2.23978439909837e-05	0.000723076894825057	0.0949478641752795	0.207840890227865
PARVA	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.3614698106705	0.3614698106705	-0.0997936325095137	-0.09070553113985	-10.2683907365335	17.1353181349708	9.69584946071045e-09	5.18488452860431e-07	-0.555980884269946	-0.366546002090082
PARVA	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.0903049871263	0.0903049871263	-0.207941903907648	-0.158031671069	-8.80028019018006	188.876833285292	8.57523176745851e-16	9.58248618085305e-14	-0.365099628561118	-0.231394153506778
PARVA	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.84802940769	-2.84802940769	-1.76297184260603	-1.638279082955	11.3140696461127	164.839387535	2.50498036234628e-22	5.0793749865782e-20	0.895700184742503	1.27441494542544
PARVA	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.78570216817	0.78570216817	-0.119502598183467	-0.11764531931	-15.7915880121619	11.4012014780056	4.20021971043363e-09	2.33764967623352e-07	-1.03082999041679	-0.77957954229014
PARVA	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.4356670413945	0.4356670413945	-0.732855603658312	-0.623158972273	-10.5222382071074	9.01030056543704	2.31757898134818e-06	8.95644402259961e-05	-1.41969746589528	-0.917347824210346
PARVA	BRD-K46937689-001-15-0::0.625::HTS002	0.625	phenazone	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.2906648624675	0.2906648624675	0.0912826884789688	0.0795356739513	-5.18598528364399	8.66664162439468	0.00064850839856665	0.0150752881297605	-0.286866473985172	-0.11189787399189
PARVA	BRD-K48578705-001-17-6::2.5::HTS002	2.5	methyldopa	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.483108468591	0.483108468591	0.251896868292856	0.280469769999	-8.07992345211014	169.579355150005	1.16209455808537e-13	1.05897348868996e-11	-0.287700214457847	-0.174722986138441
PARVA	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.9934844491775	0.9934844491775	-0.0785682534330883	0.318163539168	-8.62839918848106	3.32067837138278	0.00219275789481869	0.0433793249804868	-1.44671387738528	-0.697391527835895
PARVA	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.1560988328475	-0.1560988328475	0.264950783327485	0.254607479759	15.1087803904006	13.6155482815592	6.77646593802996e-10	4.10512483898254e-08	0.361120244798549	0.480978987551421
PARVA	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.022342466121249	0.022342466121249	-0.20788478451019	-0.0810605722641	-4.34574525893473	27.7927888858239	0.000167464414966674	0.00451761870300722	-0.338783452260225	-0.121671049002652
PARVA	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.1249615347355	0.1249615347355	-0.145016732089245	-0.139438991422	-14.1231031308736	186.899617722693	2.71811821659593e-31	1.21622454957158e-28	-0.307689268681927	-0.232267264967563
PARVA	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.632322831782	-0.632322831782	-2.09204858662011	-1.79411655002	-11.7866100629603	149.717682461843	4.24729515722271e-23	9.21375024040877e-21	-1.70443768768484	-1.21501382199138
PARVA	BRD-K62391742-001-03-0::2.5::HTS002	2.5	venetoclax	BCL inhibitor	targeted cancer	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.6040618713635	0.6040618713635	0.356088369334645	0.3310204610865	-8.44779589991671	39.6865593789377	2.10219291723156e-10	1.34415544677006e-08	-0.30731400663365	-0.188632997424059
PARVA	BRD-K65928735-001-04-3::2.5::HTS002	2.5	AZD1480	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.2111589567515	-0.2111589567515	-0.0218515305664287	-0.05528360346055	4.996223084206	8.79952170053888	0.000794929322251495	0.0180924292990167	0.103295448624767	0.275319403745376
PARVA	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.9216289726015	-0.9216289726015	-0.327355191103015	-0.32021882125	9.80730138108533	4.74240746180616	0.000250934484799008	0.00647202613627996	0.435929786828941	0.752617776168028
PARVA	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.14456456099	-0.14456456099	0.148324310115546	0.1059379473725	10.2698392652147	186.36726937325	6.8197904766198e-20	1.11238879228573e-17	0.236626671955572	0.34915107025552
PARVA	BRD-K68633617-003-02-9::2.5::HTS002	2.5	ACDPP	glutamate receptor antagonist	noncancer	GRM5	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.9595361562835	0.9595361562835	0.228750934372535	0.319454889976	-11.9145058871735	7.79655159325832	2.80531878641272e-06	0.000107005013378368	-0.872870751689069	-0.588699692132861
PARVA	BRD-K76908866-001-07-6::2.5::HTS002	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.175460735055	-2.175460735055	-0.679999238008796	-0.619490026625	21.3970130139727	32.2880512103169	1.22366301879281e-20	2.14796454672271e-18	1.35314771042776	1.63777528366465
PARVA	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.237872389685	-1.237872389685	-0.3150922196305	-0.3195858510195	13.6554191276424	45.9078643792046	8.86275412137579e-18	1.19844774979577e-15	0.786749138754123	1.05881120135488
PARVA	BRD-K84783599-001-01-0::2.5::HTS002	2.5	riociguat	guanylate cyclase stimulant	noncancer	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.104584272375	-1.104584272375	0.0110993088038795	0.07731711967405	14.9627709236674	2.97928893971704	0.000672628111527158	0.0155785293403398	0.877451803671824	1.35391535868593
PARVA	BRD-K85090592-008-22-7::2.5::HTS002	2.5	pilocarpine	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.761780336082	0.761780336082	0.469017952487443	0.471563787015	-6.52499482552025	7.17581309898506	0.000293660959653533	0.00743058111183262	-0.398333268651865	-0.187191498537249
PARVA	BRD-K85402309-001-06-6::2.5::HTS002	2.5	dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	0.29564040901	0.29564040901	-0.170591748291678	-0.192386953034	-11.978335611418	123.951229642515	1.94630090907615e-22	4.00719238752529e-20	-0.543271876862742	-0.389192437740615
PARVA	BRD-K85406984-001-01-0::0.15625::HTS002	0.15625	sobetirome	thyroid hormone receptor agonist	noncancer	THRA, THRB	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.2071666736285	-0.2071666736285	0.244682648530596	0.243956318012	15.8116051886584	136.73550898528	1.13615747689312e-32	5.7978927586911e-30	0.395339161270679	0.508359483047513
PARVA	BRD-K86727142-001-12-4::2.5::HTS002	2.5	embelin	HCV inhibitor, XIAP inhibitor	targeted cancer	XIAP	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.302250736044	-0.302250736044	-0.169032820802662	-0.181229635182	3.3040121168878	160.838842102943	0.00117491457712723	0.025474432900234	0.0535929611505488	0.212842869332127
PARVA	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-1.032572011557	-1.032572011557	-1.9636547518463	-1.89031364576	-11.414718284137	5.02254221741851	8.78305079514471e-05	0.00251935558601789	-1.14047879549505	-0.721686685083554
PARVA	BRD-K88506063-001-01-8::2.5::HTS002	2.5	KD025	rho associated kinase inhibitor	targeted cancer	ROCK2	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.4523259013285	-0.4523259013285	-1.02069147443889	-0.939621254458	-9.7065555443095	187.915831156181	2.60258851829943e-18	3.67948677136279e-16	-0.683874809100453	-0.452856337120336
PARVA	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-5.62362594317	-5.62362594317	-4.61847725049405	-4.61970061714	7.9459926714781	4.35965092821723	0.00094132646362221	0.0209899393358326	0.6650718720049	1.345225513347
PARVA	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-2.352983802155	-2.352983802155	-3.17497969868623	-3.253760660665	-10.7353380808167	24.784677069924	8.31288644633787e-11	5.5677894973661e-09	-0.979762545819516	-0.664229247242941
PARVA	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.1841573910405	-0.1841573910405	-0.867596132766115	-0.791872957089	-12.1129212933259	6.26713204808082	1.39603198373973e-05	0.000468614156684343	-0.820085104671935	-0.546792378779295
PARVA	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	MKN1, 786O	STOMACH, KIDNEY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma)	-0.311160659334	-0.311160659334	-0.0194212879593603	0.015242959648	10.3927423164079	190.921856805721	2.45702198381652e-20	4.20952090143413e-18	0.236369353999267	0.347109388750013
PAWR	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	EFO21, ISHIKAWAHERAKLIO02ER, KNS81	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.162057630805333	0.151252129782	0.474842151511764	0.483424436558	6.10331566201695	10.6163658559223	8.95253757689623e-05	0.002561800302161	0.199488483423717	0.426080557989144
PAWR	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	EFO21, KNS81, MKN7	OVARY, CENTRAL_NERVOUS_SYSTEM, STOMACH	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (tubular_adenocarcinoma)	0.129506858784033	0.137705668505	0.406192144564665	0.413880380852	4.18648228958383	10.3941543379092	0.00171775607945699	0.0353189699495335	0.130180655543721	0.423189916017543
PAWR	BRD-A50998626-001-02-1::2.5::HTS002	2.5	palomid-529	AKT inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, MKN7	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, STOMACH	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (tubular_adenocarcinoma)	-0.090051419551675	-0.08843890026085	0.047335102015126	0.0459611199462	3.55819582847985	17.5747444108633	0.00231653196632327	0.0454955878156377	0.0561262924096116	0.21864675072399
PAWR	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	EFO21, KNS81, MKN7	OVARY, CENTRAL_NERVOUS_SYSTEM, STOMACH	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (tubular_adenocarcinoma)	-0.321815850408333	-0.306314112246	0.0390095266778126	0.0170189391807	8.28883975926472	69.8217763055755	5.46066176947898e-12	4.20092669199806e-10	0.274000701943956	0.447650052228336
PAWR	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, MKN7	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, STOMACH	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (tubular_adenocarcinoma)	-2.68688637286	-2.62962520278	-3.74033689891579	-3.64668409645	-5.97711166800738	7.14107618633488	0.000514276522775269	0.0122883443081196	-1.46854620794653	-0.63835484416505
PAWR	BRD-K06854232-001-19-9::2.5::HTS002	2.5	AM-580	retinoid receptor agonist	targeted cancer	RARA	NA	NA	ISHIKAWAHERAKLIO02ER, MKN7	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.7225490920365	0.7225490920365	0.111943024919673	0.1496364875755	-18.5200925816608	16.5013854071938	1.79817902123672e-12	1.45886110992343e-10	-0.680326986963784	-0.540885147269871
PAWR	BRD-K10845183-304-01-6::2.5::HTS002	2.5	tiludronate	bone resorption inhibitor, osteoclast inhibitor	noncancer	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.5500558111345	-0.5500558111345	0.225949294539372	0.2180493051285	13.7270188385322	2.64446270745406	0.00156471871482804	0.0326103264712542	0.581608883665558	0.970401327682186
PAWR	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	EFO21, KNS81, MKN7	OVARY, CENTRAL_NERVOUS_SYSTEM, STOMACH	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (tubular_adenocarcinoma)	0.136483881620867	0.139801429371	0.346931522555283	0.363552212499	5.24988665732989	12.3613548019815	0.000185322639807613	0.00494030050588631	0.123389798843372	0.297505483025461
PAWR	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299, MKN7	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG, STOMACH	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.0261112949183	-0.0322466737215	-0.481681834028113	-0.3987810633055	-4.72458277494116	7.30363143502607	0.00191310177305164	0.038598624674422	-0.681673193047166	-0.229467885172459
PAWR	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299, MKN7	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG, STOMACH	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.41501676046	-1.324210735925	-2.32863954162282	-2.08992208713	-5.18707877536641	6.85364622096425	0.00135715509188035	0.0288368884393401	-1.33192408994379	-0.495321472381853
PAWR	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299, MKN7	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG, STOMACH	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (tubular_adenocarcinoma)	0.24892506503606	0.232622088499	-0.553625969960847	-0.415596207988	-6.7615055784105	8.6223752347967	0.000101124427056616	0.00286388706747058	-1.07285910458569	-0.532242965408127
PAWR	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	EFO21, KNS81, MKN7	OVARY, CENTRAL_NERVOUS_SYSTEM, STOMACH	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (tubular_adenocarcinoma)	0.400245508916667	0.356887673984	-0.118025155763429	-0.1199225066305	-6.76891037875478	5.65259479818586	0.000651425338545628	0.0151348879550294	-0.708448600338718	-0.328092729021473
PAWR	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	EFO21, KNS81, NCIH1299, MKN7	OVARY, CENTRAL_NERVOUS_SYSTEM, LUNG, STOMACH	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.7794033494845	-0.7664473856185	-1.60464349977814	-1.48912100372	-7.20977186219259	13.2853339001965	6.05783350307531e-06	0.000217591653574766	-1.07198005696866	-0.578500243618623
PAWR	BRD-K50140147-001-10-1::2.5::HTS002	2.5	NVP-TAE684	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, INSR	NA	NA	EFO21, KNS81, MKN7	OVARY, CENTRAL_NERVOUS_SYSTEM, STOMACH	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (tubular_adenocarcinoma)	-1.41567929994333	-1.38127453603	-1.81289012172461	-1.663164894725	-4.11501383402467	33.9469149118245	0.000233095660976653	0.0060600630666503	-0.593389022654702	-0.201032620907856
PAWR	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299, MKN7	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG, STOMACH	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.0313998471811	-0.0473622976252	-0.520166970492868	-0.343938082718	-4.85433597947921	9.3692326648783	0.000804430046358817	0.0182834239030794	-0.715175315365163	-0.262358931258374
PAWR	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	ISHIKAWAHERAKLIO02ER, MKN7	ENDOMETRIUM, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.0514231058314	0.0514231058314	-0.264058507924883	-0.236194067289	-6.67552298441153	13.4900920440471	1.26795166606191e-05	0.000428574061875704	-0.41720369837353	-0.213759529139035
PAWR	BRD-K74501079-001-18-1::2.5::HTS002	2.5	azithromycin	bacterial 50S ribosomal subunit inhibitor	noncancer	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	EFO21, KNS81, NCIH1299, MKN7	OVARY, CENTRAL_NERVOUS_SYSTEM, LUNG, STOMACH	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (tubular_adenocarcinoma)	-1.303637382875	-1.332010273335	-0.768444065642834	-0.6041988593065	5.0122764953901	8.34902821078501	0.00091180686174329	0.0204100942945773	0.290746534328576	0.779640100135756
PAWR	BRD-K76011241-001-01-8::2.5::HTS002	2.5	oseltamivir-phosphate	neuraminidase inhibitor	noncancer	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, MKN7	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, STOMACH	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (tubular_adenocarcinoma)	0.188429487908	0.192476183825	0.328172652885702	0.3080448265265	4.42809908864435	16.1237309138595	0.000414639757895778	0.010133332345501	0.07288431224955	0.206602017705854
PAWR	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	EFO21, KNS81, NCIH1299, MKN7	OVARY, CENTRAL_NERVOUS_SYSTEM, LUNG, STOMACH	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (tubular_adenocarcinoma)	-0.43036839790625	-0.445015657416	-1.06890882134334	-0.791213004088	-5.51274262263146	23.531420989253	1.22078743689647e-05	0.000413610734370191	-0.877853753666481	-0.39922709320769
PAWR	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	EFO21, KNS81, MKN7	OVARY, CENTRAL_NERVOUS_SYSTEM, STOMACH	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (tubular_adenocarcinoma)	0.450242520806667	0.422490689022	0.0265159078273289	0.110562434048	-7.55679329941857	21.8925419166857	1.54888356681025e-07	7.12077790628215e-06	-0.54004650239337	-0.307406723565305
PAWR	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299, MKN7	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG, STOMACH	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (tubular_adenocarcinoma)	0.283727318939	0.156318510671	-0.308267296959333	-0.2262444497735	-4.86648500695711	9.08154853411798	0.00086503552089217	0.0194688856617975	-0.866803643762376	-0.317185588034291
PCCA	BRD-A03623303-045-09-5::2.5::HTS002	2.5	metoprolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.6592581860415	0.6592581860415	0.234831088858993	0.206481560524	-11.7192639520422	6.3460392976473	1.55562611924403e-05	0.000517726382781761	-0.511886663773724	-0.336967530591291
PCCA	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.52067975483	-0.52067975483	-2.11334785118711	-2.089022441025	-16.8649122179421	4.82763802614439	1.77684264891531e-05	0.000585446123737988	-1.83805579060335	-1.34728040211086
PCCA	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-4.878228919215	-4.878228919215	-3.79515296725476	-3.74224322709	8.91236801939792	8.81027703956518	1.06535382338843e-05	0.000365045914649109	0.807262129676454	1.35888977424404
PCCA	BRD-A43671941-003-11-9::2.5::HTS002	2.5	oxprenolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	angina pectoris, hypertension, cardiac arrythmia	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.0056488019358	0.0056488019358	-0.411239234706692	-0.3932406545145	-9.63169263124061	8.06123150897521	1.06500889394749e-05	0.00036498607488147	-0.516566879304172	-0.317209193980813
PCCA	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.04211509541785	0.04211509541785	0.249275758094814	0.2649123832205	6.42626657221234	188.971106466057	1.03753840272333e-09	6.16337495336163e-08	0.143570940432939	0.270750384920988
PCCA	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-4.81172601492	-4.81172601492	-3.7054106333321	-3.617290410825	9.42517775907623	20.0124525083846	8.43179147473183e-09	4.53836623552938e-07	0.861477410980381	1.35115335219542
PCCA	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.587782084955	-2.587782084955	-1.93406915106947	-1.85386313087	6.3337530705818	157.252049859849	2.39822161270115e-09	1.36886402138116e-07	0.449854239947108	0.857571627823951
PCCA	BRD-K07972848-001-02-0::2.5::HTS002	2.5	GSK2126458	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.62524182417	-2.62524182417	-3.8805230073144	-3.827765844565	-14.401642182884	165.955125818006	4.97949006739521e-31	2.15605884172676e-28	-1.42737121557564	-1.08319115071315
PCCA	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.025020859751135	0.025020859751135	0.280151155569754	0.26768413301	7.68592164477125	8.40676295660848	4.44317143548608e-05	0.00135366096744321	0.179223567107398	0.331037024529841
PCCA	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.321807664495	-0.321807664495	0.435315474557321	0.408179294611	22.9774454309825	148.275254960417	1.02238584303295e-50	2.64008355845071e-47	0.692009496366675	0.822236781737968
PCCA	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.30713976603	-1.30713976603	-0.243131196218224	-0.133670857256	19.0655710672371	59.4571663993784	5.16878582473919e-27	1.56251156139708e-24	0.952355278585085	1.17566186103847
PCCA	BRD-K12539581-001-23-7::2.5::HTS002	2.5	nocodazole	tubulin polymerization inhibitor	targeted cancer	HPGDS	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-4.289886561385	-4.289886561385	-3.48966623896985	-3.337748803945	7.14519674230244	46.2412500945643	5.36922232892674e-09	2.95678327989861e-07	0.574819500502955	1.02562114432734
PCCA	BRD-K17743125-001-08-4::2.5::HTS002	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-3.261455553375	-3.261455553375	-2.60137041655148	-2.51013089586	5.56024985815729	20.6473283899836	1.71724712606929e-05	0.000567724601701845	0.41294673164547	0.90722354200156
PCCA	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.345813809061	0.345813809061	-0.03054335329018	-0.00807522835948	-12.4840161418927	7.06233481021871	4.53532020340736e-06	0.000166847003754908	-0.447516426498308	-0.305197898204052
PCCA	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.436107470545	-0.436107470545	-0.745338701982385	-0.6332790164525	-4.82200319957997	14.2871573732609	0.00025626918190813	0.00658663118949366	-0.446515794377062	-0.171946668497707
PCCA	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-5.73970522784	-5.73970522784	-4.65412386720195	-5.03947371329	7.35730033955896	9.25628554468163	3.69666747806907e-05	0.00114329443565233	0.753199948242466	1.41796277303364
PCCA	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.6683386801675	-0.6683386801675	-1.01778412255854	-1.03228700688	-4.81128581397127	17.11581650678	0.000159993286366077	0.00434065836374113	-0.502603168019824	-0.196287716762265
PCCA	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.4967441186455	0.4967441186455	-0.302655489425736	-0.290098649131	-15.728964892423	14.2754593519873	2.04884211566213e-10	1.31199964687107e-08	-0.90820797767595	-0.690591238466523
PCCA	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.9876188202505	-0.9876188202505	-1.39401821430317	-1.273586296615	-6.02947869787315	172.104356218422	9.76171281005642e-09	5.21880305529205e-07	-0.539440560582677	-0.27335822752267
PCCA	BRD-K47114202-001-14-6::2.57945::HTS002	2.57945	chlorogenic-acid	antioxidant	noncancer	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.468489605382	-0.468489605382	-1.05816656746735	-0.967874485397	-8.76061638570704	168.924014148588	1.97541242459114e-15	2.14482355395236e-13	-0.722554065661974	-0.456799858508726
PCCA	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.125619526846	0.125619526846	-0.288956517890293	-0.277245593931	-10.6408443541333	22.631988122524	2.80471572008143e-10	1.77220493976808e-08	-0.495245226074501	-0.333906863398085
PCCA	BRD-K51967704-001-03-6::2.5::MTS010::PROS004_PR500	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.77796297943	-1.77796297943	-1.38090916689179	-1.35469471431	4.22576367768957	18.0815643072312	0.00050380719048357	0.0120716032788321	0.199714460879745	0.594393164196683
PCCA	BRD-K53734668-003-02-0::2.65747::HTS002	2.65747	PRT062607	syk inhibitor	targeted cancer	FGR, MAP3K9, SYK	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.124928819026	0.124928819026	-0.0661819200777685	-0.0530930824029	-4.05463466997488	24.6470737956584	0.000440154532352998	0.0106971176737369	-0.288255350909704	-0.0939661272978333
PCCA	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.139519362575	-0.139519362575	-0.586360976763378	-0.48109263675	-5.77423452330739	86.5611056158827	1.18446291060696e-07	5.53443974640244e-06	-0.600664530180067	-0.293018698196688
PCCA	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.3134159104455	0.3134159104455	-0.140398104636614	0.01900224238145	-6.62903264453665	26.8289222962921	4.23894085970764e-07	1.82875997487979e-05	-0.594321295575672	-0.313306734588556
PCCA	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.019479962378725	0.019479962378725	0.263112261911504	0.254607479759	7.44958804448188	4.67512655513172	0.000917142817904878	0.0205157347259924	0.157775781424599	0.329488817640958
PCCA	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	1.11595019988	1.11595019988	-0.244617638978518	-0.1756829862115	-24.4867093348628	188.825391955514	1.66014512888497e-60	1.0782340767539e-56	-1.47017282411717	-1.25096285359987
PCCA	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.822874659091	0.822874659091	0.336383086378293	0.355630945231	-10.8523550249517	3.29431829396069	0.00108652169598917	0.0237528670521892	-0.62220857007905	-0.350774575346365
PCCA	BRD-K72280606-001-01-2::2.5::MTS006	2.5	gilteritinib	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.226500730774	-0.226500730774	0.025079511892758	0.043697431473	8.03867939730929	8.48082923321699	3.0169621494538e-05	0.000948544052413501	0.180117091976907	0.323043393356609
PCCA	BRD-K72951360-001-01-4::2.5::HTS002	2.5	valrubicin	DNA inhibitor, topoisomerase inhibitor	chemo	TOP2A	oncology	bladder cancer	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.52609800501	-2.52609800501	-3.29516111154048	-3.181546610205	-5.95542500788418	8.80668189722755	0.000233148003768141	0.00606068872039077	-1.06217073556835	-0.47595547749262
PCCA	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.10294744235685	-0.10294744235685	0.0973770700339873	0.2180824951125	3.92573591625932	11.5942478040847	0.00214693987435582	0.0426263526012791	0.0887098329960128	0.311939191785662
PCCA	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	0.2903538079945	0.2903538079945	0.500871201021873	0.518013519807	7.15121700444968	156.081061906691	3.12526515574862e-11	2.19834248626993e-09	0.152369152225706	0.26866563382904
PCCA	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.3008934501765	-0.3008934501765	0.115705197791377	0.0998567885779	11.8520744767099	4.32929771864606	0.000183512903484446	0.00490051748078069	0.32186596467995	0.511331331255803
PCCA	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.5744811857225	-0.5744811857225	-1.96837733767965	-1.89031364576	-19.3094134026238	10.7012049784659	1.16228525434103e-09	6.87014440920181e-08	-1.55332245969077	-1.23446984422353
PCCA	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-6.65905254467	-6.65905254467	-6.20970992893556	-6.171939349	7.61913100909593	188.384463040055	1.20881079410703e-12	1.001094314877e-10	0.333005241548851	0.565679989920039
PCCA	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	CALU6, HT1376	LUNG, URINARY_TRACT	carcinoma (undifferentiated_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.5568783599415	-0.5568783599415	-1.02793792509474	-0.948156981669	-10.9914912139792	50.1194119230772	5.88121306739926e-15	6.07769776047549e-13	-0.557134794932805	-0.384984335373672
PDE4C	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.3018927754415	-0.3018927754415	-0.0789691088051222	-0.05385103964535	5.38375028536389	162.030413784945	2.52307827685826e-07	1.12192706224223e-05	0.141157195606015	0.30469013766674
PDE4C	BRD-A70858459-001-01-7::2.5::HTS002	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.3737539983275	0.3737539983275	0.0972628471087387	0.09357088918285	-7.21702268959975	5.39673436074623	0.000574164444748618	0.013551381045978	-0.372834418287632	-0.18014788414989
PDE4C	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.00400443722574	-0.00400443722574	0.417885756035962	0.4743784763675	12.744733908105	131.135138226347	1.04871075396495e-24	2.65370870350121e-22	0.356404995374167	0.487375391149237
PDE4C	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.772994663504	-0.772994663504	0.0536929427576339	0.0776480680764	19.5934984656117	3.98258917809077	4.13602688556215e-05	0.00126783539238508	0.709341769031184	0.944033443492084
PDE4C	BRD-K00259736-001-16-4::0.15625::HTS002	0.15625	colchicine	microtubule inhibitor	noncancer	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-2.52994403818	-2.52994403818	-3.0598325784798	-2.82813961253	-4.73399535913217	157.995070262711	4.85984508734067e-06	0.000177354969815195	-0.750965839279264	-0.308811241320331
PDE4C	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-2.3939081845	-2.3939081845	-1.11890242940134	-1.061699565275	17.5078604107803	43.6038242780584	2.41522649721639e-21	4.48961907998171e-19	1.1281994190759	1.42181209112143
PDE4C	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.151439007215	-1.151439007215	-1.95225070901555	-1.885064313955	-5.93684395610518	5.70667195464271	0.00122024271812891	0.0263350520122699	-1.13502826245619	-0.4665951411449
PDE4C	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.0473581851098	0.0473581851098	0.202753782146521	0.216719294223	5.30651279416039	49.5820309075192	2.60911147735859e-06	9.9947855912563e-05	0.0965647868681421	0.214226407205301
PDE4C	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.210257124557	0.210257124557	0.344774931429942	0.3629794578985	4.31319188132363	165.145753089073	2.76115188618776e-05	0.000874789242593846	0.0729401234452275	0.196095490300656
PDE4C	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.5736008147415	-0.5736008147415	-0.250934802082996	-0.133670857256	5.03403392927859	9.95367174491065	0.000518412657444641	0.0123717700097375	0.179759046556528	0.46557297876048
PDE4C	BRD-K13049116-001-05-7::2.5::HTS002	2.5	BMS-754807	IGF-1 inhibitor	targeted cancer	AKT1, IGF1R	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.241877680785	-1.241877680785	-1.54130282015426	-1.37567614357	-3.36927806158117	39.117457265494	0.00170454990595933	0.0350709875006582	-0.479162863813195	-0.119687414925316
PDE4C	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.244930697194	0.244930697194	0.508438637701472	0.511327989939	11.0871691770078	87.65910048286	2.290856323015e-18	3.25163539639392e-16	0.216273607161598	0.310742273853346
PDE4C	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.1375624649065	-0.1375624649065	-0.329581488486137	-0.31281935927	-5.09875290014951	20.6955852298722	4.95582359197049e-05	0.0014951811861535	-0.270407480817085	-0.113630566342188
PDE4C	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.4954586684045	0.4954586684045	-0.4831310413736	-0.373418715101	-8.24785820559139	4.69915174862714	0.000572629930440745	0.0135181408042113	-1.28955111374317	-0.667628305813032
PDE4C	BRD-K16180792-001-01-7::2.5::MTS006	2.5	bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	noncancer	PTPN1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.150791951474	0.150791951474	-0.237856740431587	-0.0973395896878	-6.98540027048496	190.054629173544	4.6469013101756e-11	3.20349215473987e-09	-0.498394598453317	-0.278902785357858
PDE4C	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.480818950848	-0.480818950848	0.0927038469610766	0.105022107206	12.7937284023892	3.32183455284897	0.000610865349025532	0.0142979315705246	0.438368093093542	0.708677502524611
PDE4C	BRD-K17472821-001-01-2::2.5::MTS006	2.5	GSK2830371	protein phosphatase inhibitor	targeted cancer	PPM1D	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.625401352211	0.625401352211	0.209671816611163	0.222894017996	-21.7798427960689	156.135444452913	3.48474451815916e-49	8.11828051991886e-46	-0.453433195696504	-0.37802587550317
PDE4C	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.4885678698325	0.4885678698325	-0.378710332932367	-0.1455477562875	-8.6932683386784	9.15733258107728	1.01208573103212e-05	0.000348352854739656	-1.09237114279437	-0.642185262735359
PDE4C	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.1377509454054	0.1377509454054	-1.14336571830619	-0.889953286616	-10.0099799054021	4.31107717498069	0.000381409829178533	0.00941354068148384	-1.62656980114306	-0.935663526280119
PDE4C	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.29808499838	-1.29808499838	-1.90902722119278	-1.67956785013	-5.22057352753434	6.84908246600724	0.00131167278268099	0.0280288649889565	-0.888905344997051	-0.332979100628518
PDE4C	BRD-K22503835-001-11-0::2.5::HTS002	2.5	scriptaid	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.93954978287	-1.93954978287	-1.33672441039527	-1.30328750996	8.02859998826556	14.5467899638355	1.01483591098564e-06	4.13436164162024e-05	0.442350660669607	0.76330008427986
PDE4C	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.36381782702	-1.36381782702	-0.965553696644377	-0.757900155601	4.07621827871161	161.07272754879	7.17293644635365e-05	0.00209509788360687	0.205317510636246	0.591210750114999
PDE4C	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.0564755754764	0.0564755754764	-0.137251145636597	-0.1059972226705	-4.8638237378576	42.1241156390048	1.64480312341311e-05	0.000546078333467061	-0.274100157299978	-0.113353284926017
PDE4C	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.03005021987	-0.03005021987	-0.403557883685853	-0.2809944464045	-5.97805305534566	116.647215835225	2.52270372736609e-08	1.28246813847876e-06	-0.497249578635555	-0.249765748996152
PDE4C	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.505161632415	-1.505161632415	-0.340358183969381	-0.263302729629	16.525898845833	2.59984751754796	0.00105140568693749	0.0230793455013954	0.919639147085392	1.40996774980585
PDE4C	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.565585739425	-1.565585739425	-1.00853415287548	-1.02230629729	6.56953986032142	5.11339884529452	0.00112466367000987	0.0245017320318708	0.3405299200722	0.773573253026845
PDE4C	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-3.11257415653	-3.11257415653	-3.76240855216901	-3.649368876965	-5.8865123089679	46.4737868983736	4.143278733222e-07	1.78929032362026e-05	-0.871984450664224	-0.427684340613801
PDE4C	BRD-K45551181-001-02-1::2.49051::HTS002	2.49051	MPI-0479605	mitotic kinase inhibitor	targeted cancer	TTK	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-2.66671288076	-2.66671288076	-2.30106168228394	-2.3121762476	3.9119856089936	32.6725165473427	0.000436911160964578	0.0106255227752612	0.175413707749496	0.55588868920263
PDE4C	BRD-K48578705-001-17-6::2.5::HTS002	2.5	methyldopa	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.1303671962155	-0.1303671962155	0.258287239801257	0.2888342624615	13.8462200296409	191.000323209421	1.20922948488153e-30	5.07187761771379e-28	0.333288704987975	0.444020167045539
PDE4C	BRD-K51747290-001-13-1::2.5::HTS002	2.5	hydroxyurea	ribonucleotide reductase inhibitor	chemo	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.387265008824	-0.387265008824	-0.21477038170872	-0.221646260579	3.57113597696425	20.5454696687305	0.00185065719254979	0.0375366239634715	0.0719086910021682	0.273080563228392
PDE4C	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-6.47437412156	-6.47437412156	-5.91749699833262	-5.9507974936	6.50499901440986	6.7642262847894	0.00038411959378071	0.00946516077436488	0.353008223549271	0.760746022905493
PDE4C	BRD-K59632282-052-03-1::2.5::HTS002	2.5	quinidine	sodium channel blocker	noncancer	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.2064923222175	0.2064923222175	0.442631883933897	0.447983088223	8.82492813243505	47.8444497129448	1.32165929437887e-11	9.74776032019717e-10	0.182333991329947	0.289945132102847
PDE4C	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.166249114065	-1.166249114065	-0.681449336134835	-0.630554296997	8.52989235178029	49.5587187477522	2.73374895733285e-11	1.94118063955487e-09	0.370617342314003	0.598982213546326
PDE4C	BRD-K61642990-001-01-0::2.5::HTS002	2.5	FERb-033	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.907483770185	0.907483770185	0.174576293135927	0.239686907074	-16.8174254488833	14.7649262742557	4.89876142030927e-11	3.35982923665109e-09	-0.825925538263017	-0.639889415835129
PDE4C	BRD-K61734568-003-02-1::2.5::HTS002	2.5	2,3-DCPE	Bcl-XL downregulator	targeted cancer	BCL2L1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.10114597305335	0.10114597305335	-0.36167616420136	-0.146091240972	-5.886033793711	18.3718529509532	1.31123530123653e-05	0.000442088643823698	-0.627779470414182	-0.297864804095239
PDE4C	BRD-K63126190-003-01-6::2.5::HTS002	2.5	epinephrine	adrenergic receptor agonist, neurotransmitter	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.745075140069	-0.745075140069	-0.433988508467715	-0.389178555772	4.38801689784967	94.7879075773846	2.96777104086406e-05	0.000933626008245052	0.170339026046059	0.451834237156511
PDE4C	BRD-K67772619-001-05-1::2.5::HTS002	2.5	rheochrysidin	protein tyrosine kinase inhibitor	targeted cancer	PTPN1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.7209769456495	0.7209769456495	0.0134825771923707	0.07194686545995	-17.5756602403419	163.482943362446	1.64763845926865e-39	1.67363366510232e-36	-0.786979572167475	-0.628009164746784
PDE4C	BRD-K68103045-001-02-9::2.5::HTS002	2.5	CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.5377340275125	0.5377340275125	0.446027174471436	0.4684149214555	-3.1951163041941	106.659356139914	0.00183861694038819	0.0373249127888064	-0.148607686426193	-0.0348060196559357
PDE4C	BRD-K68488863-001-04-9::0.15625::HTS002	0.15625	ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	targeted cancer	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.301974811915	0.301974811915	0.515274319290948	0.524698126717	7.93350781577751	14.4583019126595	1.21929638612437e-06	4.91038284745679e-05	0.155805996931564	0.270793017820332
PDE4C	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-2.885834246395	-2.885834246395	-3.67956984686927	-3.50719189578	-6.5695797436992	34.3748680770143	1.5041919235747e-07	6.9212527004689e-06	-1.03917247501531	-0.54829872593322
PDE4C	BRD-K68938568-001-01-7::2.5::HTS002	2.5	GDC-0152	XIAP inhibitor	targeted cancer	BIRC2, BIRC3, BIRC7, XIAP	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.918957959273	0.918957959273	-0.451318574840284	-0.296863885148	-19.1013642207903	102.465227607466	1.5261484426772e-35	1.01268690269523e-32	-1.51255898400447	-1.2279940842221
PDE4C	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.215948908072	-0.215948908072	-0.0771069342561117	0.061565492344	3.25303584518723	187.040221482316	0.00135477607162382	0.0287958756978558	0.0546444734179043	0.223039474213872
PDE4C	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.6151947882235	-0.6151947882235	-0.206766291422655	-0.182274470613	13.4832027516316	9.70905666248106	1.31790968505882e-07	6.11928650106093e-06	0.34065932914812	0.476197664453569
PDE4C	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.219097134347	0.219097134347	-0.689963698535866	-0.481859441946	-10.2380838813933	14.3394226879617	5.58700252728971e-08	2.71409035510307e-06	-1.09907887769444	-0.719042788071296
PDE4C	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.954830904892	-0.954830904892	-0.418275124109372	-0.2259650044755	6.76652332814885	8.06370739963428	0.000137487034041996	0.0037730420639164	0.353950869716099	0.719160691849158
PDE4C	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.5050395884005	-0.5050395884005	-0.166603030061175	-0.1689019992055	9.62259729338762	15.7410201654744	5.40909972883307e-08	2.63124588239007e-06	0.263777506751382	0.413095609927269
PDE4C	BRD-K77245796-003-01-6::2.5::HTS002	2.5	gamma-aminobutyric-acid	benzodiazepine receptor agonist	noncancer	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.8959843304305	0.8959843304305	0.501203212354018	0.490985614625	-8.59372606144886	3.31997607682967	0.00222313822153783	0.0439195310059897	-0.5333205309939	-0.256241705159064
PDE4C	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-5.25109899848	-5.25109899848	-4.12104091846055	-4.24145212342	8.8793593115533	14.9667174008509	2.37126338081631e-07	1.05925491693826e-05	0.858740263045656	1.40137589699324
PDE4C	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.037146786865	-1.037146786865	-0.612265952337477	-0.517259346977	7.692166205811	65.5905643550205	9.75971081360836e-11	6.4781327314025e-09	0.314586700966792	0.535174968088253
PDE4C	BRD-K81801188-001-02-8::2.5::HTS002	2.5	PP-121	protein tyrosine kinase inhibitor	noncancer	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-3.93736760044	-3.93736760044	-4.63157474208973	-4.63633744063	-6.17718582518636	21.4543231144574	3.60737712948399e-06	0.00013490935836419	-0.927618208250054	-0.460796075049414
PDE4C	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.7686543898295	-0.7686543898295	-0.377543922769823	-0.338570487031	6.90238935923701	4.37692337590786	0.00164869078124737	0.0340688629438842	0.238990270968106	0.543230663151248
PDE4C	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.4434994905425	0.4434994905425	0.30598859460307	0.320041105609	-4.38179745673368	9.35081849398131	0.00161204802559042	0.0334503476887181	-0.208098663817551	-0.0669231280613101
PDE4C	BRD-K86797399-001-05-1::2.54945::HTS002	2.54945	SB-939	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-6.695615353295	-6.695615353295	-5.45148705147005	-5.51001928833	15.705655383106	189.331668910115	3.89792779082788e-36	2.77554473581511e-33	1.08787034227473	1.40038626137516
PDE4C	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.4169719090085	-0.4169719090085	-0.115959639927961	-0.0422450278637	8.83770936915383	55.7276991178416	3.44131059534773e-12	2.71365952387889e-10	0.232774557713477	0.369249980447601
PDE4C	BRD-K88172511-003-20-3::2.41866::HTS002	2.41866	naltrexone	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.4906500048045	0.4906500048045	0.307020889185037	0.300369801672	-8.25281882521404	182.881548767984	2.98832409684362e-14	2.89419121261815e-12	-0.227529751601892	-0.139728479637033
PDE4C	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	0.170736012747	0.170736012747	0.0230771196890218	0.0377701807511	-6.65609264473286	135.003297380349	6.46564805838856e-10	3.92126735344188e-08	-0.191532048608876	-0.103785737507081
PDE4C	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.669492813661	-0.669492813661	-0.359580089515082	-0.28708101882	4.39459681782104	11.0910558585114	0.00105201100791048	0.0230879036774979	0.154851698801191	0.464973749490645
PDE4C	BRD-K97810537-001-13-6::2.5::HTS002	2.5	beclomethasone-dipropionate	glucocorticoid receptor agonist	noncancer	GPR97, NR3C1	allergy	allergic rhinitis	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.320203782177	-0.320203782177	0.0792672667680507	0.06870536578965	8.45520425061643	12.6324452371644	1.48552789652838e-06	5.91037142259201e-05	0.297100463415464	0.501841634474637
PDE4C	BRD-K99383816-001-03-5::2.5::HTS002	2.5	ftorafur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-0.2221751801575	-0.2221751801575	0.0307428539519964	0.0749758772654	7.52213982726173	30.3534452904757	2.03206956524728e-08	1.04469042420217e-06	0.18428391540494	0.321552152814053
PDE4C	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-7.398788163695	-7.398788163695	-5.62803702854481	-5.72114668903	18.8713605884324	43.03766673089	1.95361643900845e-22	4.01454130159389e-20	1.58152420562555	1.95997806467482
PDE4C	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	MFE280, G361	ENDOMETRIUM, SKIN	carcinoma (adenocarcinoma), malignant_melanoma	-1.42909508038	-1.42909508038	-0.854560136019104	-0.7866589985	13.0873395655574	190.038923779184	2.55116028746301e-28	8.96373169265015e-26	0.487940959706881	0.66112892901491
PEAK1	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.650678636909	0.650678636909	0.248142376982494	0.251620004261	-14.8771520002734	122.48683585922	3.15616112290202e-29	1.21446473484823e-26	-0.456096847911904	-0.348975671941108
PEAK1	BRD-A19585813-003-03-3::2.5::HTS002	2.5	methylphenidate	dopamine-norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD), narcolepsy	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.4020375392295	0.4020375392295	0.256252183227257	0.248593111525	-4.95591632781692	175.411272558142	1.68690926825792e-06	6.64766305772223e-05	-0.203841037210097	-0.0877296747943884
PEAK1	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.567904456415	-0.567904456415	-0.174316965962801	-0.001536499117528	6.34628495940839	11.899269835639	3.82938971187665e-05	0.00118144417382584	0.258333667840349	0.528841313064049
PEAK1	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.9087702010915	0.9087702010915	0.0203975693371599	0.05909936864605	-16.910953166465	163.124901558456	1.04254454112127e-37	8.5612080058996e-35	-0.992103770305171	-0.784641493203509
PEAK1	BRD-A90547603-001-02-5::2.5::HTS002	2.5	eptifibatide	platelet aggregation inhibitor	noncancer	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.209989344277	0.209989344277	0.042689614514303	0.04269931862485	-5.76458491159914	15.6040882759604	3.20014924600889e-05	0.00100040474459797	-0.228950712723431	-0.105648746801963
PEAK1	BRD-A98990573-003-01-3::2.5::HTS002	2.5	epinastine	histamine receptor antagonist	noncancer	ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7	ophthalmology	conjunctivitis	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.5964270726315	0.5964270726315	0.398497653131285	0.387038692764	-7.70609890096376	40.3967251901809	1.86270267062494e-09	1.07696574235871e-07	-0.249824411116465	-0.146034427883965
PEAK1	BRD-K01507359-001-22-9::2.5::HTS002	2.5	rifampin	RNA polymerase inhibitor	noncancer	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.52851396448	-0.52851396448	-0.089337417901061	-0.0471468975624	13.1728390945349	11.8799934742139	1.90305878825129e-08	9.84030608026804e-07	0.366454437206035	0.511898655951843
PEAK1	BRD-K03765900-001-01-9::2.5::MTS006	2.5	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.593428435371	-0.593428435371	-1.17284587296377	-0.823393929272	-5.6055519458586	8.98940545847508	0.000333326862333498	0.00833624423303108	-0.813287150314806	-0.345547724870738
PEAK1	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-3.695040961995	-3.695040961995	-4.28017115489974	-4.26036322773	-7.99756482332546	17.2095191013247	3.36639601637923e-07	1.47248222815213e-05	-0.739348746384569	-0.430911639424908
PEAK1	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-2.675154613605	-2.675154613605	-3.18473527015224	-3.102963726805	-4.55494785342085	77.5536036395879	1.91748300918941e-05	0.000627543623853663	-0.732325059787161	-0.286836253307317
PEAK1	BRD-K08109215-001-06-4::2.5::MTS010::PROS002_PR500	2.5	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.278150640676	0.278150640676	-0.178462602708872	-0.0490787543204	-6.67511878584351	4.4352631771266	0.0017980746831105	0.036640002734017	-0.639407104967553	-0.27381938180219
PEAK1	BRD-K09602097-001-13-6::2.5::HTS002	2.5	forskolin	adenylyl cyclase activator	targeted cancer	ADCY2, ADCY5, GNAS	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.7515538807155	0.7515538807155	0.0332573366075129	0.0393855631996	-22.5145227018542	162.294883003124	8.50375973575399e-52	2.5313921116728e-48	-0.781296419740823	-0.655296668475151
PEAK1	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.5318983755955	0.5318983755955	-0.076498853211158	-0.00556532595827	-14.9920469214493	165.833114839062	1.14827634045015e-32	5.84581757178955e-30	-0.688519888142709	-0.528274569470607
PEAK1	BRD-K11267252-001-04-4::2.5::HTS002	2.5	alectinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.01636442436743	0.01636442436743	-0.157534963819505	-0.125024480839	-3.44902959378137	100.586531646498	0.00082322896962037	0.01867109437352	-0.273923696430335	-0.0738750799435346
PEAK1	BRD-K15071410-001-01-1::2.5::HTS002	2.5	tiotidine	histamine receptor antagonist	noncancer	HRH2	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.05741203229915	0.05741203229915	0.381852955314113	0.366990824591	8.42667755291521	4.97782405138657	0.000394508163287815	0.0096910647712681	0.225336537372719	0.423545308657207
PEAK1	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-2.525635170705	-2.525635170705	-1.08720103894362	-0.864735754699	13.3673511845046	36.2387168136482	1.40882221161227e-15	1.54450872528208e-13	1.22024486786258	1.65662339566018
PEAK1	BRD-K16180792-001-01-7::2.5::MTS006	2.5	bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	noncancer	PTPN1	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.0564096758621	-0.0564096758621	-0.235687089883565	-0.0973395896878	-3.23334939424588	190.458519540025	0.00144212291638235	0.0304036853420984	-0.288645209370057	-0.0699096186728728
PEAK1	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.7623933267705	0.7623933267705	0.31854885729847	0.339932692016	-14.628071594281	184.05353115868	1.18824327134319e-32	6.02068539252282e-30	-0.503707251567465	-0.383981687376596
PEAK1	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.0669671775984	0.0669671775984	-0.307387014636785	-0.19710233478	-5.79080014584256	13.4915617419073	5.4148251135919e-05	0.00162292553736686	-0.51349867727444	-0.235209707195929
PEAK1	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-2.99500529241	-2.99500529241	-1.85256008132116	-1.64856167258	8.47082185455224	3.51284125054019	0.00185122070917333	0.037544500697995	0.746594413695073	1.53829600848262
PEAK1	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-2.34064910351	-2.34064910351	-1.89805286219142	-1.63390971887	4.4712133828491	46.9073467764797	4.91316709551296e-05	0.00148523863246008	0.243447790620989	0.641744692016179
PEAK1	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.2471290612075	0.2471290612075	0.414864949638245	0.442474468431	5.57190336291085	14.7301907451628	5.7062152187296e-05	0.00170193070082813	0.103468479125658	0.232003297735832
PEAK1	BRD-K22064724-001-01-8::2.49999::MTS010::PROS004_PR500	2.49999	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-3.62280944521	-3.62280944521	-2.2744281951272	-2.41370110422	16.6698314188478	20.3646948140063	2.43533284946446e-13	2.15064876099245e-11	1.17984634755654	1.51691615260905
PEAK1	BRD-K25279140-001-01-5::2.5::HTS002	2.5	MK-8745	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.684331956566	-0.684331956566	-1.58251814660353	-1.48579667397	-10.7001469198759	78.3780315414339	5.46149254720384e-17	6.84936358191721e-15	-1.06528814863886	-0.731084231436207
PEAK1	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.2369264456445	0.2369264456445	-0.539238064491014	-0.4752073320215	-12.1695061296291	3.76413284691023	0.000368927393990493	0.00914865665007386	-0.957707805076089	-0.594621215194938
PEAK1	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.1200617022035	-0.1200617022035	0.151449350844251	0.201815706844	6.66442702958158	190.040475136973	2.79827049057321e-10	1.76865383654988e-08	0.191149685090314	0.351872421005188
PEAK1	BRD-K26838195-075-04-9::2.5::HTS002	2.5	AST-1306	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.2168570359245	-0.2168570359245	-0.658355242247163	-0.557623655143	-5.40061335703337	13.7392666594259	9.98244115803728e-05	0.00282931318561356	-0.61714642703269	-0.265849985612637
PEAK1	BRD-K28192623-066-08-1::2.5::HTS002	2.5	spiradoline	opioid receptor agonist	noncancer	OPRK1	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-3.14602255258	-3.14602255258	-2.31325719792126	-2.11804571815	10.0266480782753	90.425610366625	2.39591338282198e-16	2.84023074904232e-14	0.667772264893274	0.997758444424196
PEAK1	BRD-K32744045-001-31-2::2.5::HTS002	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-3.037926934815	-3.037926934815	-1.25544175047017	-1.069460523895	11.8930154930929	2.89566654742195	0.00150985764998342	0.0316083493126877	1.2956395112352	2.26933085745447
PEAK1	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-3.404745901025	-3.404745901025	-2.20803994048774	-2.23277244437	8.21521161602419	4.65442970633056	0.000609184685898626	0.0142617088524267	0.813731896607435	1.57968002446709
PEAK1	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.891758631556	0.891758631556	-0.805493484662549	-0.4002530483955	-10.6889167588475	3.8524596246808	0.000527843226105128	0.012575823789227	-2.14485239512958	-1.24965183730751
PEAK1	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.234929202324	-0.234929202324	-1.38007635615126	-1.00119520354	-11.2958135307658	190.131312685879	5.71473158562178e-23	1.23098764423591e-20	-1.3451172602802	-0.945177047374318
PEAK1	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-2.55831590526	-2.55831590526	-1.7662270504985	-1.638279082955	7.39620426423898	19.8628895162967	4.00052576535347e-07	1.73147957746858e-05	0.568595856162314	1.01558185336068
PEAK1	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.1067424027356	0.1067424027356	-0.499724337441171	-0.332266676493	-10.0463853382787	15.8369790889285	2.83594966053003e-08	1.43017942303939e-06	-0.734545489210212	-0.47838799114333
PEAK1	BRD-K43457670-001-27-8::2.5::HTS002	2.5	acetazolamide	carbonic anhydrase inhibitor	noncancer	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.443809698868	0.443809698868	0.25700882916216	0.234175192161	-5.77073713052244	6.23773701380672	0.00103173586041157	0.0227290487435658	-0.265282256411009	-0.10831948300067
PEAK1	BRD-K49328571-001-15-0::2.5::MTS010::PROS005_PR500	2.5	dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor	targeted cancer	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.02196833425495	-0.02196833425495	-0.471339211579367	-0.286018332538	-4.60729457243505	8.64791472364128	0.00141802081026095	0.0299638156602997	-0.671386531615918	-0.227355223032917
PEAK1	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.0258642266262	0.0258642266262	-1.26244859313948	-0.921278111753	-14.926196005419	187.023117074942	1.08945986802649e-33	6.16102490908307e-31	-1.45858343883933	-1.11804220069204
PEAK1	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.4774244578195	0.4774244578195	0.377908701127175	0.393436647762	-3.7671582945792	23.2116856136035	0.000989129431330838	0.0219211169359639	-0.154135227185705	-0.0448962861989442
PEAK1	BRD-K66175015-001-09-0::2.5::HTS002	2.5	afatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.0927336545897	0.0927336545897	-0.922813826194967	-0.7732511578805	-10.2202247590479	68.5909404370487	2.01787886880304e-15	2.18871437283242e-13	-1.21379922288388	-0.817295738685456
PEAK1	BRD-K68095457-001-10-1::2.5::HTS002	2.5	palmitoylethanolamide	cannabinoid receptor agonist	noncancer	CNR2, GPR119, GPR55	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.6006108457115	0.6006108457115	0.301090062726969	0.308579390748	-10.3874648065073	13.080593106812	1.09208968941805e-07	5.12292604603373e-06	-0.36177565325252	-0.237265912716541
PEAK1	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-4.249294028275	-4.249294028275	-3.09290222285771	-3.15624915805	8.61066607329839	3.56311492429227	0.00165034036890171	0.0340963756435642	0.764780341220693	1.54800326961388
PEAK1	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-5.655172725445	-5.655172725445	-3.65057153818812	-3.47824152187	17.9613239513392	171.491722962898	2.94440252249321e-41	3.50594915690804e-38	1.78430175374583	2.22490062076794
PEAK1	BRD-K69694239-001-02-2::2.5::HTS002	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-6.461647868065	-6.461647868065	-5.68273494981082	-5.73883515181	7.7988932600454	5.43232522426727	0.000378140751863203	0.00935224200393358	0.528202029111947	1.02962380739641
PEAK1	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.5971221444525	0.5971221444525	0.307321286879641	0.289065772439	-8.84956407022805	5.2370290880895	0.000241080225022592	0.00624492186957543	-0.372847758471988	-0.206753956673729
PEAK1	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.609699207015	-0.609699207015	-0.891931961178231	-0.708568317551	-4.59675737896322	168.870178907053	8.37282315025532e-06	0.00029265146982568	-0.40343969401438	-0.161025814312081
PEAK1	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-0.003014872363025	-0.003014872363025	-0.428087660527196	-0.2512002355925	-6.57322831107877	186.196753148254	4.80883500531263e-10	2.96000229136602e-08	-0.552647520497088	-0.297498055831254
PEAK1	BRD-K76703230-004-04-1::2.5::HTS002	2.5	YM-155	survivin inhibitor	targeted cancer	BIRC5	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-6.065446085975	-6.065446085975	-5.48172323302746	-5.502396220135	6.46300407248284	44.5305824107093	6.68637932203863e-08	3.22113956779775e-06	0.401760978271877	0.76568472762321
PEAK1	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.2076558320815	0.2076558320815	0.000106129708395111	0.03094358609725	-7.64508742663945	169.546951058055	1.4805408696413e-12	1.20884892971181e-10	-0.2611415589169	-0.15395784582931
PEAK1	BRD-K78126613-001-28-5::2.5::HTS002	2.5	menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	noncancer	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.09238922742525	0.09238922742525	-0.127116076279297	-0.050497524351	-4.37669273460736	15.071636933728	0.000535890868638599	0.0127406493604484	-0.326360158697203	-0.11265044871189
PEAK1	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	-2.747452099885	-2.747452099885	-0.475169167802977	-0.35792132397	36.2005922043353	41.3615012655198	6.02503801046775e-33	3.13432129064452e-30	2.1455515592802	2.39901430488384
PEAK1	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.03705154223305	0.03705154223305	0.19122842073331	0.205191667076	4.41886396391102	157.719144009475	1.83696993206673e-05	0.00060348854777733	0.085263755613389	0.223090001387132
PEAK1	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	MKN45, NCIH1651	STOMACH, LUNG	carcinoma (diffuse_adenocarcinoma), carcinoma (adenocarcinoma)	0.1268075133635	0.1268075133635	-0.367747272356359	-0.291376214184	-7.73368768753918	40.011968635547	1.81799336045399e-09	1.05225141494124e-07	-0.62379755236681	-0.365312019072907
PIP4K2B	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.1302625874385	0.1302625874385	0.253649425125039	0.256070233499	3.95911941249468	12.1455231265766	0.0018538196425334	0.0375865396050082	0.0555737759751554	0.191199899397923
PIP4K2B	BRD-A19585813-003-03-3::2.5::HTS002	2.5	methylphenidate	dopamine-norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD), narcolepsy	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.4229084411865	0.4229084411865	0.256030152355374	0.248593111525	-4.63898775804309	8.0961725912786	0.00161646352917189	0.0335127695631536	-0.249660958948198	-0.0840956187140535
PIP4K2B	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.450530554944	-0.450530554944	-0.998421522773153	-0.927705434	-8.936653862513	190.84613075173	3.41723263243306e-16	3.98917240128946e-14	-0.668819861412	-0.426962074246306
PIP4K2B	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.03221899534113	-0.03221899534113	-0.448887505632155	-0.3315553181695	-5.15625332893926	26.3393275491068	2.14595100763134e-05	0.000695297858676669	-0.5826684402634	-0.250668580318649
PIP4K2B	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.3240730687255	0.3240730687255	-0.0158256412048005	0.03331372318045	-6.70497929066669	56.2803674498901	1.03980442639698e-08	5.53827641414605e-07	-0.441438783687474	-0.238358636173127
PIP4K2B	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.2489699038405	-0.2489699038405	-1.03386926837351	-0.797857785181	-8.1792098367989	10.416502630452	7.49472870902899e-06	0.00026398318972514	-0.997564441751884	-0.572234287314132
PIP4K2B	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.376947718819	0.376947718819	0.183128682755081	0.1739425463755	-5.55062530206672	6.77450885466482	0.000961078473303492	0.0213679448241353	-0.276948382002478	-0.110689690125361
PIP4K2B	BRD-A73556557-001-06-4::2.5::HTS002	2.5	tagatose	phosphorylase inhibitor	noncancer	PYGL	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.5203715211585	0.5203715211585	0.110701991278206	0.1416103571295	-13.7379041635972	93.603699217536	3.63328534408959e-24	8.65242682792643e-22	-0.468881862746786	-0.350457197013802
PIP4K2B	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.603784369564	0.603784369564	0.205868608543386	0.236646785158	-9.49836608793444	168.273354815979	2.12048119449385e-17	2.75275962407433e-15	-0.480619474228522	-0.315212047812705
PIP4K2B	BRD-K02594908-001-16-4::2.5::HTS002	2.5	sulfanilamide	carbonic anhydrase inhibitor	noncancer	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.134790125803	-0.134790125803	-0.363393997824984	-0.3369002650265	-3.10335480095234	139.58481139	0.00231671330253894	0.0454955878156377	-0.374244278783852	-0.0829634652601165
PIP4K2B	BRD-K06152156-001-01-8::2.5::HTS002	2.5	methoxyflurane	membrane permeability inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-1.29668855449	-1.29668855449	-1.87036839421927	-1.724302233865	-5.81400245838446	17.0822009921089	2.03415534095636e-05	0.00066181166551727	-0.781783490608337	-0.36557618885021
PIP4K2B	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.1693519772215	0.1693519772215	0.27862384215737	0.26768413301	4.03204637927569	188.722870867307	8.01834032844844e-05	0.00232024711936099	0.0558123651230836	0.162731364748656
PIP4K2B	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.5099129912145	-0.5099129912145	-0.0489183215519897	0.2281371067585	6.19928609491345	17.0058728078555	9.69325588452668e-06	0.000334818024250559	0.30410754833257	0.61788179099245
PIP4K2B	BRD-K14560436-001-01-4::2.5::HTS002	2.5	TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-1.863561271905	-1.863561271905	-3.7566346544172	-3.62828968956	-11.7699134631061	4.23072043311715	0.000216286569676112	0.00566843778333472	-2.33019456974247	-1.45595219528194
PIP4K2B	BRD-K19540840-001-09-4::2.5::MTS010::PROS004_PR500	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.2356700308185	-0.2356700308185	-0.404040064969034	-0.3364454572695	-3.07867458687138	191.985954833943	0.00238377081013437	0.0465904809379254	-0.276238731968336	-0.0605013363327318
PIP4K2B	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.556466367229	0.556466367229	-0.119581666960692	-0.0402228786984	-11.8879699014217	67.4308598597597	3.31817129757364e-18	4.6543215709271e-16	-0.78954420396348	-0.562551864415904
PIP4K2B	BRD-K24593301-001-02-3::2.54476::HTS002	2.54476	AZD3463	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-1.74701369384	-1.74701369384	-3.51582309377523	-3.310368963095	-10.8506660732334	3.40607598226434	0.000926314028419904	0.020693762705567	-2.25429871649969	-1.28332008337076
PIP4K2B	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.03222232108272	-0.03222232108272	-0.778609436459007	-0.707312470978	-11.4854046212773	11.9557463226029	8.15975838138339e-08	3.87948725404508e-06	-0.888036951840965	-0.604737278911608
PIP4K2B	BRD-K30480208-001-18-5::2.5::HTS002	2.5	torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	noncancer	SLC12A1	cardiology	edema, congestive heart failure, hypertension	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.536652936539	0.536652936539	0.0234263558297666	0.129954580002	-9.94241972955223	92.4109014425113	2.88672842619123e-16	3.39204833803257e-14	-0.615742058054668	-0.410711103363799
PIP4K2B	BRD-K32107296-001-16-9::2.5::HTS002	2.5	temozolomide	DNA alkylating agent	chemo	MGMT	oncology	glioblastoma, astrocytoma	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.0626691554254	0.0626691554254	0.227450653015976	0.232952381397	5.42066634628985	42.3427310741616	2.63324519290137e-06	0.000100782287312385	0.103449038042034	0.226113957139119
PIP4K2B	BRD-K37723606-001-01-5::2.5::HTS002	2.5	dioscin	apoptosis stimulant	targeted cancer	CXCR3	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.4087747229255	-0.4087747229255	-1.01239648667861	-0.8558575413485	-7.15553073637292	17.5025512934746	1.3598197522592e-06	5.44052282400525e-05	-0.78121177144526	-0.426031756060959
PIP4K2B	BRD-K40718343-001-02-6::2.5::HTS002	2.5	AEE788	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.11594283169455	-0.11594283169455	-0.395345610913564	-0.1963749895675	-3.92877770562656	24.2521868053045	0.000621217728892102	0.0145069704309997	-0.426100271421679	-0.132705287016349
PIP4K2B	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.7817492536845	-0.7817492536845	-1.29033619938488	-1.33795379646	-6.44454493997391	186.116272864026	9.66833591256503e-10	5.76413009124937e-08	-0.664274630278207	-0.352899261122559
PIP4K2B	BRD-K44827188-001-06-0::2.5::MTS010::PROS003_PR500	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.245228631542	0.245228631542	0.0348573383702922	0.0567242940999	-9.95055753901297	179.87422758138	7.32834492324229e-19	1.08622188039668e-16	-0.252088863549996	-0.16865372279342
PIP4K2B	BRD-K49027941-001-01-1::2.5::HTS002	2.5	PSB-1115	adenosine receptor antagonist	noncancer	ADORA1, ADORA2B, ADORA3	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.4826784953135	0.4826784953135	0.112584156779414	0.170361291898	-6.97832256048399	101.081184425012	3.18362162775004e-10	1.99807449444814e-08	-0.475300204085341	-0.264888472982832
PIP4K2B	BRD-K52313696-001-12-3::0.15625::HTS002	0.15625	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.051595953897	-0.051595953897	0.421806939140862	0.39525647476	11.8819113424109	5.94556387937695	2.29503127002851e-05	0.000739575638361059	0.375695474366787	0.571110311708937
PIP4K2B	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.116421425795	0.116421425795	-0.218097033214252	-0.1500661795165	-9.9786230128423	187.739204247178	4.40017314754193e-19	6.67907018795691e-17	-0.400649629779601	-0.268387288238903
PIP4K2B	BRD-K59632282-052-03-1::2.5::HTS002	2.5	quinidine	sodium channel blocker	noncancer	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.700923125904	0.700923125904	0.437399811937215	0.439082857511	-10.5318520864197	188.974439914311	1.0580381800863e-20	1.86487060114899e-18	-0.312880752824796	-0.214165875108775
PIP4K2B	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.020639470775175	0.020639470775175	0.157082251054835	0.164761931788	4.36617635454381	41.7014223124161	8.17043465241959e-05	0.00235941941339051	0.0733644535960485	0.199521106963271
PIP4K2B	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.37912422119	0.37912422119	0.143210984384094	0.15713254048	-7.17069862428317	6.78151379943751	0.000211482620027281	0.00555680501015412	-0.314219456253522	-0.15760701735829
PIP4K2B	BRD-K68336408-001-10-9::2.5::HTS002	2.5	tyrphostin-AG-1478	EGFR inhibitor	targeted cancer	EGFR, MAPK14	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-3.890004747105	-3.890004747105	-2.62885308283185	-2.53878806693	10.3390567886754	7.77974057213331	8.11463937442559e-06	0.00028441578781378	0.978474485685972	1.54382884286033
PIP4K2B	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-3.01909052114	-3.01909052114	-1.19550301503431	-0.979171957663	17.1711712089601	4.00673869389779	6.66824062822247e-05	0.00196022129420696	1.52892303373437	2.118251978477
PIP4K2B	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.1195518306555	-0.1195518306555	-0.272756484396147	-0.224936831672	-4.45298345451828	37.1733646653483	7.47374832038634e-05	0.00217405130803486	-0.222904722951465	-0.083504584529829
PIP4K2B	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.26909086757	0.26909086757	-0.0822669318693244	0.0411624842104	-8.10338992937042	162.269940295401	1.22117448361165e-13	1.11045017351719e-11	-0.436979139807093	-0.265736459071555
PIP4K2B	BRD-K71164191-001-01-0::2.5::HTS002	2.5	KD-023	ACAT inhibitor	noncancer	ACACA, ACACB	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-1.28475228042	-1.28475228042	-0.943914108691013	-0.959659141772	6.33155986879743	188.372911125539	1.73497112773578e-09	1.00746309086015e-07	0.234647890527302	0.447028452930671
PIP4K2B	BRD-K73237276-001-01-0::2.5::HTS002	2.5	tacalcitol	vitamin D receptor agonist	noncancer	VDR	dermatology	psoriasis, chapped lips	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.325787378728	0.325787378728	0.0293773788182248	0.07201409986295	-8.08769262016658	13.0852416106779	1.89961785690249e-06	7.42014207494177e-05	-0.375534061322173	-0.217285938497377
PIP4K2B	BRD-K75911534-001-01-6::2.5::HTS002	2.5	SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.1697476857585	0.1697476857585	-0.529177056152872	-0.4139887396705	-12.07026809582	99.4954578391695	3.35909357516155e-21	6.15869261651668e-19	-0.813813067767575	-0.58403641605517
PIP4K2B	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.4938279888805	0.4938279888805	-0.433209751880222	-0.2512002355925	-12.8110921201576	18.754330826714	1.01425721708678e-10	6.70940540373434e-09	-1.07862778372124	-0.7754476978002
PIP4K2B	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.00948373055254	-0.00948373055254	-0.171874900889344	-0.171973558527	-4.48741442417054	11.9950041866734	0.000743516244728742	0.0170526584501302	-0.24124199098906	-0.0835403496845492
PIP4K2B	BRD-K76908866-001-07-6::2.5::HTS002	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-1.38139360701	-1.38139360701	-0.688402064760595	-0.619490026625	8.45988260277227	6.91137221453593	6.84650919435921e-05	0.00200821878899386	0.498788607014403	0.887194477484408
PIP4K2B	BRD-K77245796-003-01-6::2.5::HTS002	2.5	gamma-aminobutyric-acid	benzodiazepine receptor agonist	noncancer	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.73347422191	0.73347422191	0.502998904160874	0.490985614625	-7.40594059772426	180.780835299726	4.78654873210256e-12	3.71566897212173e-10	-0.291881117712273	-0.169069517785979
PIP4K2B	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.350907174972	-0.350907174972	0.0259362233323352	0.0294162092714	9.98308510902098	4.08138011882687	0.00051112425317877	0.0122236944944826	0.272856657432634	0.480830139176037
PIP4K2B	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.1723787097755	0.1723787097755	0.0153339638434934	0.0495734767378	-4.59744699918025	7.43676251530848	0.00212985553368494	0.0423538510557765	-0.236866444438594	-0.0772230474254189
PIP4K2B	BRD-K81548480-001-01-2::2.5::HTS002	2.5	AC-264613	PAR agonist	noncancer	F2RL1	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.02812857508025	-0.02812857508025	-0.373024539183306	-0.2564995934565	-6.92984324358875	146.753789821325	1.23580927399097e-10	8.10494999648747e-09	-0.443253799778893	-0.246538128427219
PIP4K2B	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.4596319313925	0.4596319313925	0.344777304975599	0.3852845671545	-3.77070856681594	97.7088973518689	0.000278859723829876	0.00708736223748767	-0.175303147310223	-0.0544061055235792
PIP4K2B	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	0.2973785602065	0.2973785602065	0.0326189991765148	0.0430886024597	-7.55505247245533	4.77130378608698	0.000790112723537297	0.0179961817133927	-0.356157467473324	-0.173361654586646
PIP4K2B	BRD-K86816506-001-01-8::2.5::HTS002	2.5	PF-04457845	FAAH inhibitor	noncancer	FAAH	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.298529266028	-0.298529266028	-0.408227687474069	-0.370640421909	-3.72110122261916	180.850281221135	0.000264628306212187	0.00677304994532503	-0.167867604673569	-0.0515292382185692
PIP4K2B	BRD-K93441486-067-12-8::2.5::HTS002	2.5	diphemanil	acetylcholine receptor antagonist	noncancer	CHRM3	neurology/psychiatry	spasms	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.357965515675	-0.357965515675	0.138507149182552	0.150302134	12.6435675278113	2.75174161716992	0.0016149966111647	0.033492076311013	0.364881555209994	0.628063774505111
PIP4K2B	BRD-K94176593-001-09-4::2.5::HTS002	2.5	TWS-119	glycogen synthase kinase inhibitor	noncancer	GSK3B, JUN, MYC	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-0.07420672608785	-0.07420672608785	-0.29832240520367	-0.2225830716545	-5.43326338027703	131.515916384492	2.59094669537966e-07	1.15115052710205e-05	-0.305712691842013	-0.142518666389626
PIP4K2B	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	DAOY, BT474	CENTRAL_NERVOUS_SYSTEM, BREAST	primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (ductal_carcinoma)	-1.16370183218	-1.16370183218	-0.714075762624344	-0.590290062749	7.17363889475202	67.5131996335634	7.13630895575256e-10	4.31457817257402e-08	0.324538645982471	0.574713493128841
PLEKHM1	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.02700467941585	-0.02700467941585	0.175133223446964	0.161263687573	7.87139567312701	129.845227444802	1.21102987815948e-12	1.00254469971434e-10	0.151332409020936	0.252943396704692
PLEKHM1	BRD-A54927599-001-16-9::2.5::HTS002	2.5	KF-38789	P selectin inhibitor	noncancer	SELP	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.444813007635	-4.444813007635	-2.925282411827	-2.70844162047	13.0731581538191	8.6462317037964	5.4267159771598e-07	2.30408599181593e-05	1.25494447129239	1.78411672032362
PLEKHM1	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.154447400346	0.154447400346	-0.18192066971818	-0.008049193223815	-5.65344889814093	18.9441572405024	1.90844244637292e-05	0.000624957312587719	-0.460923357078667	-0.211812783049693
PLEKHM1	BRD-A67748489-001-10-0::2.5::HTS002	2.5	K-858	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.630446151395	-4.630446151395	-2.6217943049916	-2.49115990214	20.1931800665558	149.36502653287	1.52855605860674e-44	2.39134227361404e-41	1.81209820346646	2.20520548934035
PLEKHM1	BRD-K07972848-001-02-0::2.5::HTS002	2.5	GSK2126458	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.81601847848	-2.81601847848	-3.87822449340705	-3.827765844565	-10.5658196230774	15.3213408841736	1.95649251453944e-08	1.00849707587476e-06	-1.27609474726997	-0.848317282584129
PLEKHM1	BRD-K11590034-002-03-4::2.48778::HTS002	2.48778	morin	cytochrome P450 inhibitor	noncancer	ADORA2A, ESR2, FASN, MCL1, SLC22A12	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.8699624387495	0.8699624387495	0.584275465524999	0.559642670397	-10.0570899342871	180.538124151066	3.5649511369685e-19	5.46938018779758e-17	-0.341738472522702	-0.2296354739263
PLEKHM1	BRD-K12885236-001-02-7::2.5::HTS002	2.5	dapivirine	non-nucleoside reverse transcriptase inhibitor	noncancer	CYP3A4, CYP3A5	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-1.892067747155	-1.892067747155	-1.3343076046531	-1.23321321289	7.98895189743058	3.58381336058735	0.00208385765747343	0.0415509468665571	0.354709785558103	0.760810499445688
PLEKHM1	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-3.44971248792	-3.44971248792	-2.73326813803767	-2.77483229013	15.5374071572259	176.620460727194	7.11884242006804e-35	4.48757169720813e-32	0.625445049829708	0.807443649934949
PLEKHM1	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.632403966685	-2.632403966685	-0.919367454852132	-0.8524847758	22.5203698365465	10.0986745574289	5.76841815729406e-10	3.51232754328034e-08	1.54377490560541	1.88229811806033
PLEKHM1	BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500	2.5	sonidegib	smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.1355749047735	0.1355749047735	-0.000911538378798028	0.0115719304002	-7.28114064657496	166.753782966663	1.24508625184774e-11	9.21471309641831e-10	-0.173494947410666	-0.0994779388939301
PLEKHM1	BRD-K22064724-001-01-8::2.49999::MTS010::PROS004_PR500	2.49999	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.760296507564	-0.760296507564	-2.30440215258947	-2.44622434478	-17.8634345156207	9.77434498263282	8.68539836219731e-09	4.66432659877571e-07	-1.73730917759126	-1.35090211245967
PLEKHM1	BRD-K28143534-001-02-2::2.5::HTS002	2.5	cyproheptadine	histamine receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.123217507642	0.123217507642	-0.0062111173358402	0.02120744072425	-4.23009778770041	63.2225686495111	7.68211025601813e-05	0.00222921609675347	-0.190567790888766	-0.0682894590669145
PLEKHM1	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0966864199195	-0.0966864199195	0.214173621724985	0.242460199933	14.6283949534456	34.3904218745138	2.48799035178175e-16	2.94287242884675e-14	0.267691973753498	0.354028109535473
PLEKHM1	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.17987205282	0.17987205282	0.0410547650938157	0.143970790547	-3.23529588429989	147.519895187501	0.00150012962086655	0.0314415491404956	-0.223609323397483	-0.0540252520548859
PLEKHM1	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0315048289892	-0.0315048289892	0.133721723906357	0.1319992768505	5.29898223352526	187.896897820316	3.24101335777572e-07	1.42111937798427e-05	0.103717115623322	0.226735990167792
PLEKHM1	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.454148526305	-0.454148526305	-0.17511839501558	-0.120119113317	7.52552635265186	42.3852691824006	2.45752577760907e-09	1.40084851699249e-07	0.204224200861769	0.353836061717072
PLEKHM1	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.9795207497	-5.9795207497	-4.65162578884924	-5.03947371329	10.1151316387799	38.4111184472296	2.19656647658988e-12	1.76854957310681e-10	1.06222978061664	1.59356014108488
PLEKHM1	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.94164930919	-5.94164930919	-5.44174230394782	-5.470053491025	6.32362008153564	187.967355438928	1.81688542815117e-09	1.05189421104865e-07	0.34396009576881	0.655853914715551
PLEKHM1	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.0392370516172	-0.0392370516172	0.375437315046747	0.3764822376655	11.5739432614632	136.265328643037	5.30880684176764e-22	1.04101670776689e-19	0.343823023159046	0.485525710168849
PLEKHM1	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.223084108353	-0.223084108353	-0.457471003041354	-0.3435721987365	-4.6107003012193	187.158108622618	7.4181448219299e-06	0.000261371619519877	-0.334670957126051	-0.134102832250658
PLEKHM1	BRD-K51791723-003-01-7::2.5::MTS010::PROS004_PR500	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.50787929441	-2.50787929441	-2.23101473358347	-2.42069348361	3.75793749278563	178.274409500899	0.000231943044774314	0.00603187324470133	0.131478034840875	0.422251086812178
PLEKHM1	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.152249445148	-0.152249445148	0.140952522629538	0.155273340434	10.3752313234479	12.5773217902461	1.58016145222303e-07	7.25523615881554e-06	0.231941159330354	0.354462776224721
PLEKHM1	BRD-K54256913-001-08-7::2.5::HTS002	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-3.906301336345	-3.906301336345	-3.33918087638424	-3.37045155966	5.0610305543231	187.512614496073	9.90786573249103e-07	4.0471563837985e-05	0.346067415652149	0.788173504269369
PLEKHM1	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.256828787774	-0.256828787774	-0.708326395553425	-0.5410189846345	-5.18594933657355	6.66813545737276	0.00147917197580282	0.0310605067157991	-0.659461166078028	-0.243534049480822
PLEKHM1	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.910129165496	-0.910129165496	-0.365903953323616	-0.394478559639	11.6711511386942	177.235060027563	1.02676657475203e-23	2.33615555414043e-21	0.452203838558196	0.636246585786573
PLEKHM1	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-2.580940396265	-2.580940396265	-2.94517837442886	-2.90935015871	-4.27172043008221	180.674896209587	3.13170707008324e-05	0.000980592614497986	-0.532485747962035	-0.195990208365689
PLEKHM1	BRD-K65928735-001-04-3::2.5::HTS002	2.5	AZD1480	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.327296469727	-0.327296469727	-0.0206664539034134	-0.05528360346055	9.76083764713279	168.745722781623	4.00161343927687e-18	5.56658809002053e-16	0.244614331177636	0.368645700469538
PLEKHM1	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.621734733647	-0.621734733647	-2.64734229525164	-2.62453052692	-9.94875967302511	2.88243552072698	0.00255490254984682	0.0495108235629403	-2.68877694962715	-1.36243817358213
PLEKHM1	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.360963154527	0.360963154527	0.142946355695153	0.0968721731692	-6.70286882504314	16.6726693905519	4.10315603992519e-06	0.000151860702966867	-0.28674320974228	-0.149290387921415
PLEKHM1	BRD-K67578145-001-09-7::2.38272::HTS002	2.38272	GDC-0879	RAF inhibitor	targeted cancer	BRAF	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.9941273462505	0.9941273462505	0.580423871463909	0.659791110046	-7.64974829500857	24.8505164435064	5.47695473486212e-08	2.66304498949243e-06	-0.525118671541521	-0.302288278031662
PLEKHM1	BRD-K69172251-001-08-9::2.5::HTS002	2.5	cisplatin	DNA alkylating agent, DNA synthesis inhibitor	chemo	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.210171442873	0.210171442873	0.383078300007355	0.3712286324115	6.80642251608062	182.29428140077	1.39625163749602e-10	9.10980874316237e-09	0.122784185538327	0.223029528730383
PLEKHM1	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2367815039685	0.2367815039685	0.342552488011161	0.3666851523545	3.45476159603108	180.477793131506	0.000686480434901766	0.0158787680910922	0.045359629858548	0.166182338226774
PLEKHM1	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.07655420449245	0.07655420449245	0.222867433003456	0.235603358555	4.72841262722838	7.70163673052822	0.00164835399151433	0.0340684727721577	0.0744735427861712	0.21815291423584
PLEKHM1	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-4.179108071315	-4.179108071315	-2.30339544590216	-2.223018080895	13.9837182931685	2.7815768295541	0.00116420940074968	0.0252735207206812	1.42922932955194	2.32219592127375
PLEKHM1	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-3.27120917092	-3.27120917092	-1.03303891210157	-0.7722654685825	24.3579504189653	192.837797715538	9.4095606996826e-61	6.95428184552508e-57	2.05693836332276	2.4194021543141
PLEKHM1	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-5.84329101766	-5.84329101766	-3.9516511770485	-3.94724012749	15.7232529236295	63.0109239729285	1.72914179101967e-23	3.8685305942323e-21	1.65122344724424	2.13205623397876
PLEKHM1	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.2620345674765	0.2620345674765	-0.106697829732294	-0.0756772814281	-11.411483958382	51.9579138584688	9.06098227745458e-16	1.00989665654943e-13	-0.433573215068366	-0.303891579349223
PLEKHM1	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.293622766472	0.293622766472	0.166195623199055	0.180090535551	-6.06779123552779	94.919953231811	2.64214402653559e-08	1.33747776821763e-06	-0.169119021894379	-0.085735264651512
PLEKHM1	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	-0.940826782123	-0.940826782123	-1.41223365222894	-1.39259151278	-6.02383855747337	166.827726222669	1.05547712213704e-08	5.62035667355301e-07	-0.62590833925117	-0.31690540096072
PLEKHM1	BRD-K96344439-002-02-7::2.5::MTS006	2.5	tofogliflozin	sodium/glucose cotransporter inhibitor	noncancer	GCK	endocrinology	diabetes mellitus, diabetes mellitus	NUGC4, NCIH650	STOMACH, LUNG	carcinoma (signet_ring_adenocarcinoma), carcinoma (bronchioloalveolar_adenocarcinoma)	0.4685816929065	0.4685816929065	0.13488095286504	0.243893587025	-9.30904600806704	175.015532091584	5.35485624953894e-17	6.72349727655202e-15	-0.40444864821405	-0.26295283186887
PPFIBP1	BRD-A10977446-001-12-1::2.5::HTS002	2.5	carvedilol	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA	cardiology	myocardial infarction, hypertension	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.03432409078135	-0.03432409078135	-0.218952758338124	-0.214242337971	-3.53995971768627	151.504124784179	0.000531841776847748	0.0126528045498947	-0.287674845175242	-0.0815824899383055
PPFIBP1	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3456885871895	-0.3456885871895	-0.0492825931263765	0.009756743375275	8.43891981878054	155.886389071097	2.06043260874543e-14	2.03039292229793e-12	0.227026214962846	0.365785773163401
PPFIBP1	BRD-A31095847-001-02-3::2.5::HTS002	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.0969073391303	-0.0969073391303	0.0289685593006669	0.0832482326418	3.53834699849682	41.9907420655637	0.000998419411360852	0.0221041456479248	0.0540826269267541	0.19766916993518
PPFIBP1	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.9194525460095	-0.9194525460095	-0.690547536497962	-0.624576558799	4.01959162572895	26.8822193239285	0.000422898920555695	0.0103222301268399	0.112034781517982	0.345775237505093
PPFIBP1	BRD-A75919782-399-02-6::2.5::HTS002	2.5	leucovorin	folate receptor ligand	targeted cancer	TYMS	oncology	osteosarcoma	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.956001602666	0.956001602666	0.579117888366416	0.639167031898	-9.24436737978853	17.6140450528389	3.56124702004967e-08	1.77218136187654e-06	-0.462670954111486	-0.291096474487683
PPFIBP1	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.3208238582655	-0.3208238582655	-1.13324481716155	-1.042052398785	-10.2232115325013	3.89618665610564	0.000589366005293824	0.0138826493624156	-1.03539822923282	-0.58944368855929
PPFIBP1	BRD-A97701745-001-16-0::2.5::HTS002	2.5	pindolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B	cardiology	hypertension	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.2754532156855	-0.2754532156855	0.162309334260587	0.163040623516	11.699640553177	114.529043534285	2.79567171406828e-21	5.15657076423872e-19	0.363643924744912	0.511881175147263
PPFIBP1	BRD-A98990573-003-01-3::2.5::HTS002	2.5	epinastine	histamine receptor antagonist	noncancer	ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7	ophthalmology	conjunctivitis	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.3080875691295	0.3080875691295	0.401565094657902	0.397262536215	3.65332491656943	44.8932404625892	0.00067441245655247	0.0156164809205309	0.0419393339858852	0.145015717070919
PPFIBP1	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.634779142475	-0.634779142475	-1.13889253215162	-1.07388474495	-6.97372929995471	62.5409472992233	2.29523979479052e-09	1.31253054956686e-07	-0.64858916596251	-0.359637613390734
PPFIBP1	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.323039630535	-2.323039630535	-3.71961348745685	-3.60790168659	-12.9872595070474	190.628942988824	4.85468650872237e-28	1.63600645397478e-25	-1.60868350443352	-1.18446420941018
PPFIBP1	BRD-K10843433-001-22-7::2.5::HTS002	2.5	phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	PTGIS, PTGS1, PTGS2	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.10865456514425	-0.10865456514425	0.13019160512105	0.1428689114125	4.72130099518588	6.77866694564558	0.00234902271674408	0.0460330702987147	0.118425688122042	0.359266652408559
PPFIBP1	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.7108209337335	-0.7108209337335	-0.418839687152241	-0.37916191768	5.41636619048676	57.1303032755663	1.26385655906558e-06	5.08219723166919e-05	0.18403923515753	0.399923258004987
PPFIBP1	BRD-K11630072-001-13-2::2.5::MTS010::PROS004_PR500	2.5	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.551846800961	-0.551846800961	-0.235650989505242	-0.1778523821605	6.2372303086186	142.915232502667	4.74827526379061e-09	2.63241875068023e-07	0.215987076788028	0.416404546123488
PPFIBP1	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-5.97732907301	-5.97732907301	-4.25224404236108	-4.34713599697	9.41869153686296	3.85382063184745	0.000845193870301888	0.0191025579487434	1.20886570502767	2.24130435627016
PPFIBP1	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-5.00424537195	-5.00424537195	-4.12791396619563	-4.11179699224	5.56720137775882	5.35046710958699	0.00207229757080299	0.0413473716302955	0.479540387507605	1.27312242400114
PPFIBP1	BRD-K13390322-001-06-3::2.5::HTS002	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.03884061710065	0.03884061710065	-0.33563864831381	-0.191679875324	-4.72329894224222	162.497233418826	4.98844785904352e-06	0.000181831469588595	-0.53103786943403	-0.21792066139489
PPFIBP1	BRD-K13514097-001-05-3::2.5::HTS002	2.5	everolimus	mTOR inhibitor	targeted cancer	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.317632513475	-1.317632513475	-0.738912096524288	-0.6865974577345	10.2638482040756	167.453252381107	1.76226722442907e-19	2.77316425803714e-17	0.467404629948616	0.690036203952807
PPFIBP1	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4008163372925	0.4008163372925	-0.0991149952188742	-0.0311349339001	-9.74790848291542	5.5960995323805	0.000101587120181735	0.00287585073060773	-0.627652277272369	-0.37221038775038
PPFIBP1	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.168676985791	-0.168676985791	-0.0588081379346492	-0.0602706039178	3.28028267143064	125.700652438182	0.00134210365186415	0.0285850873099863	0.043584243127244	0.176153452585458
PPFIBP1	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2957807395085	0.2957807395085	-0.346957758434602	-0.216806871006	-9.16116926217137	7.35178985250709	2.79843112977001e-05	0.000885552850453974	-0.807042393836147	-0.478434602050057
PPFIBP1	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0897179059611	0.0897179059611	-0.307644085013765	-0.19710233478	-6.32929680110021	18.8673042967474	4.64345197325135e-06	0.000170590746996056	-0.528827509039232	-0.265896472910497
PPFIBP1	BRD-K23984367-075-15-2::2.5::HTS002	2.5	sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.027683493913165	0.027683493913165	-0.8614402147704	-0.738304903661	-11.2440864612124	72.6199349633325	1.46174764406114e-17	1.9351137171339e-15	-1.04673342257935	-0.731513994787784
PPFIBP1	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1371298276415	-0.1371298276415	-0.980605083139819	-0.82417204092	-8.53935651212464	136.984567626529	2.29912956931103e-14	2.25627354148747e-12	-1.03879629273944	-0.648154218257196
PPFIBP1	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.8657485045795	-0.8657485045795	-0.233907156544752	-0.109165735913	11.4608966643916	3.6472983832849	0.00054352705024103	0.0129050192922466	0.472757376503904	0.790925319565591
PPFIBP1	BRD-K26818574-305-04-3::2.5::HTS002	2.5	BIX-01294	histone lysine methyltransferase inhibitor	targeted cancer	EHMT1, EHMT2	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.501962430155	-0.501962430155	-0.773766754922179	-0.707312470978	-4.2475187213897	14.6255581198525	0.00074042522605027	0.0169890373915136	-0.408503361467459	-0.135105288066899
PPFIBP1	BRD-K27316855-001-13-3::2.43597::HTS002	2.43597	calcitriol	vitamin D receptor agonist	noncancer	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.384824277417	0.384824277417	-0.0411010036124416	-0.004671498458915	-7.40756565852957	3.86934824332842	0.00201648009344675	0.0403765098980147	-0.587715743451354	-0.264134818607529
PPFIBP1	BRD-K28360340-001-08-3::2.30697::HTS002	2.30697	TW-37	BCL inhibitor	targeted cancer	BCL2, BCL2L1, MCL1	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.484385090745	-3.484385090745	-2.76131646947183	-2.71718912157	8.29148785960609	183.37454796802	2.33264702587986e-14	2.28707184084997e-12	0.551012214318576	0.895125028227763
PPFIBP1	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-4.0532775862	-4.0532775862	-3.11016718936321	-3.10613635441	7.63536138710689	10.8985219634229	1.07194426135531e-05	0.00036724543093354	0.670938270333126	1.21528252334045
PPFIBP1	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.2709568464775	0.2709568464775	-0.0771511969796088	-0.0620606581655	-9.42774049084878	10.7612564069317	1.5698869723798e-06	6.22520453104886e-05	-0.429597306193109	-0.266618780721109
PPFIBP1	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.0426220406092	0.0426220406092	-0.239272158132504	-0.026104548309	-5.29594371572558	115.774238847543	5.70768754393498e-07	2.417634315423e-05	-0.387321764656144	-0.176466632827264
PPFIBP1	BRD-K38183498-001-02-0::2.5::HTS002	2.5	clonazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-5.8422857364	-5.8422857364	-4.65305532023778	-5.03947371329	8.29943007313089	11.9255060167579	2.6863783630733e-06	0.000102614291245614	0.876810558041983	1.50165027428245
PPFIBP1	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.1125715374475	0.1125715374475	-0.79711512881192	-0.4002530483955	-6.19543710986197	5.62759544725242	0.0010371368122726	0.0228316039274419	-1.27481365395627	-0.544559678562571
PPFIBP1	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.493802342698	-0.493802342698	-0.697707517539692	-0.5759216002185	-3.13514354119068	98.7523692913934	0.00226266751491132	0.0445935876600853	-0.332959762065217	-0.0748505876181663
PPFIBP1	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.423295079139	0.423295079139	-0.0724699714005909	0.318163539168	-4.91747735877566	10.2598291770503	0.000562997086610466	0.0133142008800766	-0.719630474433764	-0.271899626645418
PPFIBP1	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-5.37893121712	-5.37893121712	-5.92896760466183	-5.96310429975	-8.1042049319409	186.494499800985	6.81523760585253e-14	6.35917745243695e-12	-0.683928979902696	-0.416143795180969
PPFIBP1	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1313017020465	-0.1313017020465	0.118237543470055	0.150496276102	8.81995484880051	124.9118787348	8.38632645040344e-15	8.5429323278922e-13	0.193544339557724	0.305534151475385
PPFIBP1	BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500	2.49998	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.578175588725	-0.578175588725	-0.192129823912283	-0.0644082695915	8.32774147314968	187.027596071142	1.71447923166595e-14	1.70200379455179e-12	0.294596752959092	0.477494776666341
PPFIBP1	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-4.80574967584	-4.80574967584	-3.13383692629968	-3.15598793833	15.609711377111	27.3634906661658	3.7671884436804e-15	3.96570595258141e-13	1.45228340948503	1.89154208959561
PPFIBP1	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.305398832555	-1.305398832555	-0.743104445238781	-0.6455499330205	8.0662291003505	181.779471584594	9.49715018417354e-14	8.71740771658986e-12	0.424750177089727	0.699838597542712
PPFIBP1	BRD-K56751279-300-01-4::0.15625::HTS002	0.15625	Y-39983	rho associated kinase inhibitor	noncancer	ROCK1, ROCK2	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.6321004388055	0.6321004388055	0.782139125777878	0.797735671319	5.41074416503221	54.9500537214103	1.41279516792495e-06	5.6373252107534e-05	0.0944658522670557	0.2056115216777
PPFIBP1	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.1207544024735	0.1207544024735	0.262051796570197	0.254607479759	5.23230222568301	21.8045066013903	3.09071635235895e-05	0.000969315401060493	0.0852636925181043	0.19733109567529
PPFIBP1	BRD-K58435339-001-03-0::2.5::HTS002	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-4.129198966695	-4.129198966695	-4.68585551141719	-4.73299399791	-5.37355568629332	26.720462681112	1.15468839772294e-05	0.000392830491421522	-0.769313546841086	-0.343999542603293
PPFIBP1	BRD-K60341624-001-02-2::2.5::HTS002	2.5	GSK1292263	glucose dependent insulinotropic receptor agonist	noncancer	GRPR	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.171679434245	-1.171679434245	-1.0117594448116	-0.954160275858	3.91094358732874	21.9250363214492	0.000753062740608751	0.0172420878252252	0.0751017071202286	0.244738271746579
PPFIBP1	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.337155105003	-0.337155105003	-0.14012660891741	-0.134482434125	8.51785680174257	9.40160322590352	1.01140290539593e-05	0.000348322469061202	0.145040771207061	0.24901622096412
PPFIBP1	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-9.067871377075	-9.067871377075	-7.19349429979622	-7.241239224365	17.9296901391551	95.3050649288933	2.69809814129473e-32	1.31427426483081e-29	1.66684670042421	2.08190745413335
PPFIBP1	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.9065254202875	-0.9065254202875	-0.223550184601773	-0.157800770878	9.66710635075577	6.99065584962954	2.69651147158812e-05	0.000856081480068153	0.515870679887649	0.850079791483805
PPFIBP1	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.1454602655195	0.1454602655195	-0.174313343048054	-0.07625513394025	-6.315545661612	123.255135559841	4.4432340248313e-09	2.47033438471613e-07	-0.419996023120205	-0.219551194014903
PPFIBP1	BRD-K64890080-001-13-8::2.5::HTS002	2.5	BI-2536	PLK inhibitor	targeted cancer	BRD4, PLK1, PLK2, PLK3	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-4.89989869906	-4.89989869906	-2.49545844821407	-2.50948766362	18.5357366122126	11.4538387234164	6.73645172485605e-10	4.08203834248423e-08	2.12030448578607	2.68857601590579
PPFIBP1	BRD-K68095457-001-10-1::2.5::HTS002	2.5	palmitoylethanolamide	cannabinoid receptor agonist	noncancer	CNR2, GPR119, GPR55	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.1910285885605	0.1910285885605	0.305424266506345	0.326165847724	4.17777015820771	26.1661378828261	0.000290614395277523	0.00736167033748213	0.0581285709382106	0.17066278495348
PPFIBP1	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.3501010038945	0.3501010038945	-0.0117242193129462	-0.0198550434605	-7.05653393366239	149.204030197794	5.97699872206961e-11	4.05778954419531e-09	-0.463144569416738	-0.260505876998155
PPFIBP1	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.3418326338595	0.3418326338595	0.0993356452666619	0.129185439077	-6.28680907933478	92.2549496287122	1.06282490892244e-08	5.6580774939006e-07	-0.319102180788639	-0.165891796397037
PPFIBP1	BRD-K72726508-001-02-1::2.5::HTS002	2.5	arcyriaflavin-a	CDK inhibitor	targeted cancer	CCND1, CDK4	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.0892586902497	-0.0892586902497	-0.497917628694945	-0.4023952462985	-6.47792063081851	6.01475333791051	0.000636501284716155	0.0148236595113182	-0.562930379296684	-0.254387497593806
PPFIBP1	BRD-K73838513-003-05-5::2.5::HTS002	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.40208673558	-0.40208673558	0.181621544317706	0.2005508196795	14.5832728011472	22.6753150563064	5.23230713341754e-13	4.46463869841879e-11	0.500842792211936	0.666573767583476
PPFIBP1	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.4984971156455	-0.4984971156455	-0.208001187428772	-0.182274470613	9.12252427952701	6.91806028231853	4.19863026620265e-05	0.00128592201532573	0.215016109151193	0.365975747282264
PPFIBP1	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4520310632275	0.4520310632275	0.327848033518605	0.364286574892	-4.19946464720676	38.680595220055	0.000151832396776076	0.00413180367808781	-0.184012136684438	-0.0643539227333529
PPFIBP1	BRD-K84091759-001-07-1::2.5::HTS002	2.5	candesartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension, congestive heart failure	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.4403487433345	0.4403487433345	0.332583941889105	0.339578920682	-3.53027822431987	98.6560900208575	0.00063259817647215	0.014743816285896	-0.1683373551432	-0.0471922477475898
PPFIBP1	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.26693380297	-0.26693380297	0.115349599391309	0.0998567885779	15.0358267532198	190.634421046148	3.30594905752264e-34	1.94659548227959e-31	0.332133270110213	0.432433534612404
PPFIBP1	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-2.02579750629	-2.02579750629	-1.6443858786755	-1.710789940465	6.36680189498808	56.6162648058217	3.67227432588728e-08	1.82404376359929e-06	0.261433681184125	0.50138957404487
PPFIBP1	BRD-K88172511-003-20-3::2.41866::HTS002	2.41866	naltrexone	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	0.437350109177	0.437350109177	0.307576096431157	0.300369801672	-5.10836918241366	15.5360057831511	0.000115239367611229	0.00322106656504265	-0.183759518329529	-0.0757885071621573
PPFIBP1	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-3.225877721965	-3.225877721965	-2.90685832603043	-2.82333441128	3.44674743074074	32.9650107379148	0.00156813545923903	0.032660763866152	0.130703882196544	0.507334909672596
PPFIBP1	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.1009076574897	-0.1009076574897	-0.273722772567143	-0.208293631699	-3.67539031118958	169.003032802288	0.000318621011274672	0.0079973911143564	-0.265636372945792	-0.0799938572090935
PPFIBP1	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.6014599553555	-0.6014599553555	0.106063796849726	0.1765205692495	20.7323530489554	188.929859272772	1.48230364624915e-50	3.78215069282064e-47	0.640205719976834	0.774841784433618
PPFIBP1	BRD-K93123848-001-04-1::2.5::HTS002	2.5	RAF265	RAF inhibitor, VEGFR inhibitor	targeted cancer	BRAF	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-0.797893783854	-0.797893783854	-1.29237832922232	-1.194488826315	-7.37334432404378	49.3911625306084	1.67794723726796e-09	9.7514304071693e-08	-0.629227320093356	-0.359741770643279
PPFIBP1	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.98334157314	-1.98334157314	-1.41136329484124	-1.11082774233	6.21121811615997	129.433612904507	6.63730082416845e-09	3.61057372675939e-07	0.389785813403983	0.754170743193539
PPFIBP1	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	SKOV3, NCIH23	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (non_small_cell_carcinoma)	-1.0197170888645	-1.0197170888645	-0.0651472522063618	-0.0594618685141	16.2990381541435	7.37994224846575	4.69257250063454e-07	2.01030256144014e-05	0.817515498536434	1.09162417477984
PPIE	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.982192493433	-0.982192493433	0.00621941041104533	0.008505826587825	30.2590025882034	19.9104295242739	4.03976628053039e-18	5.61140030550743e-16	0.920254142417917	1.05656966527017
PPIE	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.515389247635	-2.515389247635	-1.11062043170414	-1.02154011458	20.0273854412867	6.85955061166332	2.42860024074926e-07	1.08261119176279e-05	1.2382174848705	1.57132014699123
PPIE	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.9245959451265	0.9245959451265	0.214753315615405	0.209209067771	-22.7334008720111	11.9466341016835	3.36012748208731e-11	2.34978907185856e-09	-0.777909032340368	-0.641776226681821
PPIE	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.804876523025	-2.804876523025	-1.43926045480056	-1.361653967605	12.2911525714993	2.89611110862108	0.00137357023455899	0.029119281385044	1.00474345869831	1.72648867775057
PPIE	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.9529987643155	0.9529987643155	-0.305563994588337	-0.208078798615	-24.5503183745274	188.998218979582	1.07803645556908e-60	7.45337017695693e-57	-1.35968710351841	-1.15743841428926
PPIE	BRD-K06854232-001-19-9::2.5::HTS002	2.5	AM-580	retinoid receptor agonist	targeted cancer	RARA	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.04691744865585	-0.04691744865585	0.121213706132833	0.154475017862	4.6811022222064	8.48410725939367	0.00134872024308651	0.0286917976159295	0.0861218625431737	0.250140447034193
PPIE	BRD-K09090949-001-01-9::2.5::HTS002	2.5	CP-945,598	cannabinoid receptor antagonist	noncancer	CNR1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.4191158898375	0.4191158898375	-0.703833457903663	-0.6321793589915	-16.8062770149996	9.31291323695827	2.79086977174486e-08	1.40777671760015e-06	-1.27332984785499	-0.972568847627332
PPIE	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.1818624889245	0.1818624889245	0.337448381141911	0.348412196747	4.45554534580512	8.51828136739958	0.00181845778006038	0.0369955612285298	0.0759060227868417	0.23526576164798
PPIE	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.10183141197	-2.10183141197	-2.60890368166338	-2.686193418095	-5.85210093986292	8.55574125169773	0.000295529310259201	0.00747116083257186	-0.704645946042711	-0.309498593344057
PPIE	BRD-K17743125-001-08-4::2.5::HTS002	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-3.972806372105	-3.972806372105	-2.59376238640464	-2.51013089586	8.75139702203682	3.21970625152397	0.0023757387668235	0.0464632831632887	0.89636884250983	1.86171912889089
PPIE	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.43811026814	0.43811026814	-0.065096088752587	-0.0626502991923	-14.5140404384361	47.2329764461156	4.95059870612716e-19	7.45707751009938e-17	-0.572944954295326	-0.433467759489848
PPIE	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.7186070487015	-0.7186070487015	-0.336445967883203	-0.200723129444	6.51127276438213	80.7278968508606	5.8821667774469e-09	3.22269663405781e-07	0.265375997789376	0.498946163847219
PPIE	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.3213030007155	0.3213030007155	-0.697815046776929	-0.593823716309	-18.5461925060811	140.749758238432	1.27763193468728e-39	1.32286751173715e-36	-1.12775261292582	-0.910483482059037
PPIE	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-3.64852220881	-3.64852220881	-3.083914573726	-2.85883819524	5.13746902490965	45.9629533111752	5.54393390618369e-06	0.00020044295043496	0.343385679614241	0.785829590553766
PPIE	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-4.24961779991	-4.24961779991	-2.85562959093918	-2.68228454863	10.5471592092066	6.37338666557398	2.86610543110473e-05	0.000904430964286286	1.07512443619298	1.71285198174865
PPIE	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.5243342500395	0.5243342500395	-0.244480285536811	-0.0866927101235	-11.0089993165051	15.6099274673238	9.19703962157913e-09	4.92798076263358e-07	-0.917159560317929	-0.620469510834692
PPIE	BRD-K25835157-001-01-4::2.5::HTS002	2.5	PRT062070	JAK inhibitor, syk inhibitor	targeted cancer	SYK	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.512523892864	0.512523892864	-0.0886173651727944	-0.0811687124677	-12.0110456137703	24.3688234131091	9.97616472420254e-12	7.47354564548621e-10	-0.704354721899005	-0.497927794174584
PPIE	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.86739098208	-1.86739098208	-1.02732259490598	-0.8397340938795	9.00880714152427	7.09437097776307	3.90673688721066e-05	0.00120271044283105	0.62016114228669	1.05997563206135
PPIE	BRD-K31491153-003-05-9::2.5::HTS002	2.5	1-phenylbiguanide	serotonin receptor agonist	noncancer	HTR3A, HTR3B	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.15626197028	-1.15626197028	-0.084968505402274	0.0251960831099	13.6857383262244	2.73941215253035	0.00133103427821134	0.0283873449330558	0.808219954036783	1.33436697571867
PPIE	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.944356885025	-2.944356885025	-3.66812885195913	-3.65355610334	-7.31304423327304	188.925214196929	7.20812888462414e-12	5.48229615228036e-10	-0.919000194270102	-0.528543739598152
PPIE	BRD-K36529613-001-02-6::2.5::HTS002	2.5	PU-H71	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-4.435439875275	-4.435439875275	-3.46976858590941	-3.273820150365	7.46980497789445	5.93848744582168	0.000311789318810907	0.00784336771260831	0.648546784830446	1.28279579390072
PPIE	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.142416507859	0.142416507859	-0.266532634299941	-0.234942866008	-8.69257666074406	5.67824444259399	0.000172431248051377	0.00463759781197185	-0.525665894051507	-0.292232390266374
PPIE	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.954477824362	-0.954477824362	-1.3943598740546	-1.273586296615	-5.36750207771639	8.26706026914	0.000601700550492046	0.0141173374150421	-0.627808248272255	-0.251955851112947
PPIE	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	1.066838621505	1.066838621505	-0.798439233512337	-0.640313618355	-20.1070742885684	6.34683198073504	5.48826916761203e-07	2.32826274059788e-05	-2.08929790492634	-1.64125780510833
PPIE	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.2023521464835	0.2023521464835	0.304227225245124	0.306467449749	4.65061945098738	167.400270538471	6.68686086350839e-06	0.000237755176180307	0.0586280443786601	0.145122113144589
PPIE	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.01924851019	-2.01924851019	-0.601024462544789	-0.573831164789	13.9127541400352	3.69388287013135	0.000251829721411026	0.0064880889963101	1.1257073005084	1.71074079478203
PPIE	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.07000708331105	0.07000708331105	-0.124675810301309	-0.007473093877485	-4.741120992272	134.674655845349	5.33815169769418e-06	0.000193557894639671	-0.275893912618766	-0.113471874605953
PPIE	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.333087795717	0.333087795717	-0.243002427396371	-0.10314419939105	-8.56111778594232	8.95667793175303	1.32278803640883e-05	0.000445493144336058	-0.728426419605471	-0.423754026621271
PPIE	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.5226098939825	0.5226098939825	-0.142722482231469	0.01900224238145	-8.41819812880484	6.50262435149535	9.92027820268029e-05	0.00281355472661408	-0.855157712110554	-0.475507040317385
PPIE	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.462548137068	0.462548137068	-0.498627331335101	0.00402399396559	-7.87620189525458	4.48813730531068	0.000860471085186727	0.0193804021875773	-1.28595000288298	-0.636400933923218
PPIE	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.0621458221865	0.0621458221865	-0.720905744745533	-0.5340799664045	-7.4698349235348	69.5184362818537	1.78869509423081e-10	1.15160477876658e-08	-0.992150876784408	-0.573952257079658
PPIE	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.489964800195	-1.489964800195	-0.593564969877634	-0.422114365645	14.0123027024218	109.663721077581	3.45300984535384e-26	9.76359033172616e-24	0.769617339175877	1.02318232145885
PPIE	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-3.554764705735	-3.554764705735	-2.93441788482146	-2.87845710522	6.74439569700034	37.7593877367776	5.63616390913785e-08	2.73487293294455e-06	0.434104881659434	0.806588760167648
PPIE	BRD-K68488863-001-04-9::0.15625::HTS002	0.15625	ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	targeted cancer	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.7210069815285	0.7210069815285	0.510694732737795	0.514244743777	-8.53345278705341	56.4506039611663	9.70273288950198e-12	7.28398261812284e-10	-0.259674666482584	-0.160949831098826
PPIE	BRD-K69608737-001-10-2::2.5::HTS002	2.5	tacrolimus	calcineurin inhibitor	noncancer	FKBP1A	transplant	organ rejection	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.1479957430465	0.1479957430465	0.30626783302148	0.32803780098	5.06061316508341	12.3801102676217	0.000253847661026242	0.00653299828058625	0.0903604346129418	0.226183745337018
PPIE	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.3801153123555	0.3801153123555	-0.00181008673909379	0.03094358609725	-13.4886001145662	60.0143647098998	7.97631618435024e-20	1.28925782162564e-17	-0.438562913477072	-0.325287884712116
PPIE	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	1.219974746525	1.219974746525	0.490928731091065	0.515272690573	-15.1424887047757	2.34679044552555	0.00215112886393239	0.042681600588071	-0.909461524384809	-0.54863050648306
PPIE	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.4522636446885	-0.4522636446885	-0.948420280107592	-0.8151847008705	-7.6868331246208	119.990867150678	4.59612315375152e-12	3.57561698519205e-10	-0.623953916008982	-0.368359354829203
PPIE	BRD-K81330143-001-04-8::2.38257::HTS002	2.38257	tideglusib	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.225315720285	0.225315720285	-0.275872156101052	-0.2593232641565	-10.5621447516266	167.482244673737	2.62579122616809e-20	4.48790436773032e-18	-0.594867701638532	-0.407508051133572
PPIE	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.04508607916222	0.04508607916222	-0.427800546137962	-0.2959843885325	-6.57185546087673	5.56238930262104	0.000807450533908533	0.0183442935639264	-0.652370348726901	-0.293402901873463
PPIE	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.056739457185	-1.056739457185	-0.374558585284274	-0.338570487031	13.5949440870431	8.52929202591257	4.47961988308848e-07	1.92445870900475e-05	0.567705917476235	0.796655826325217
PPIE	BRD-K84937637-001-09-9::2.5::HTS002	2.5	sirolimus	mTOR inhibitor	noncancer	FGF2, FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.27426640552	-2.27426640552	-1.33899828880616	-1.32265051102	13.855707345113	4.6752613083373	5.64354994944189e-05	0.0016847080741812	0.758063916806121	1.11247231662156
PPIE	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.389835979899	0.389835979899	0.0316608912004267	0.0430886024597	-12.0820054953135	16.0574566012725	1.78712618917511e-09	1.03690570925748e-07	-0.421002118385925	-0.295348059011222
PPIE	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.5324398020635	0.5324398020635	-0.158770040118323	-0.140788868193	-16.2550388123367	11.7094672106378	2.14858119693168e-09	1.23228059769112e-07	-0.784114675528334	-0.598305008835311
PPIE	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.365921505082	-0.365921505082	-0.16054749229382	-0.116252087164	7.73080515841261	8.11200935346985	5.17520541418338e-05	0.00155567545752666	0.144260393883805	0.266487631692554
PPIE	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.910565795165	-2.910565795165	-2.22580064688871	-2.16824610201	10.1624030796815	160.010867175784	4.95447577060572e-19	7.45707751009938e-17	0.551691991357661	0.817838305194926
PPIE	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.642135374415	-1.642135374415	-1.01680708392065	-0.939851070617	15.23186121148	133.820311718251	5.14562992393993e-31	2.21902960959381e-28	0.544129708463597	0.7065268725251
PPIE	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.897945339148	-0.897945339148	-1.60276920970934	-1.38505413113	-8.33348778439833	14.1144745629844	8.01062667759905e-07	3.32283647219494e-05	-0.886086202181748	-0.523561538940936
PPIE	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-3.57029124367	-3.57029124367	-2.22966583903552	-2.181327009095	15.8357885932429	185.014804043324	2.93106471652403e-36	2.15880470662501e-33	1.17360636665024	1.50764444261872
PPIE	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.51052816132	-2.51052816132	-1.39579698857243	-1.36288222555	14.1341757316874	126.80843968004	8.03078117633948e-28	2.63992223733691e-25	0.958663785904281	1.27079855959086
PPIE	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.560724807789	0.560724807789	-0.230871021184005	-0.0281474951666	-11.3208009474979	11.4456914104173	1.45331918869608e-07	6.70444357283773e-06	-0.944769523197844	-0.638422134748166
PPIE	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-5.00328538062	-5.00328538062	-5.65365737916594	-5.73830939241	-5.79323960425481	6.61839854764947	0.000818129168805134	0.0185652521567851	-0.918968603854142	-0.381775393237731
PPIE	BRD-M97302542-001-03-6::2.5::HTS002	2.5	dichloroacetate	pyruvate dehydrogenase kinase inhibitor	targeted cancer	PDK1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.343187714135	-1.343187714135	-0.248090332979538	-0.1625176596575	18.8001696109191	3.86646698674781	6.05098015581374e-05	0.00179650994017925	0.931144532574977	1.25905022973595
PPM1E	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.163265789777	-0.163265789777	-0.955394360854703	-0.8814928301585	-13.0627959582228	193.23242646843	2.31133515770893e-28	8.16122163124543e-26	-0.911729950470238	-0.672527191685169
PPM1E	BRD-A20239487-001-24-9::2.5::HTS002	2.5	atenolol-(+/-)	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.306395812505	0.306395812505	0.198134344915686	0.207866793196	-4.0209521033633	29.2391676143617	0.000373591825762654	0.00925361867836403	-0.163308360268487	-0.0532145749101421
PPM1E	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.4350738144785	0.4350738144785	-0.0170728405952836	0.03331372318045	-7.57986000565063	7.46683111066637	9.22548471809905e-05	0.00263112297291477	-0.591430818350324	-0.312862491797244
PPM1E	BRD-A51964809-003-12-6::2.5::HTS002	2.5	halofantrine	antimalarial agent	noncancer	KCNH2, KCNN4	infectious disease	malaria	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.2072830642555	0.2072830642555	-0.133412032868968	-0.13262425304	-11.2442083806478	61.3223171273322	1.54347041146909e-16	1.85535877633068e-14	-0.401276466385107	-0.280113727863829
PPM1E	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.489695012092	0.489695012092	0.244564390550875	0.260666777641	-7.56481264503701	180.668983454666	1.90499663759657e-12	1.54365226593359e-10	-0.309069703614528	-0.181191539467721
PPM1E	BRD-A73427433-240-01-3::2.5::HTS002	2.5	adaprev	TGF beta receptor inhibitor	noncancer	IGF2R, M6PR	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.567029315142	-0.567029315142	-0.3931987937767	-0.3772229678335	4.54926256138636	179.895656382396	9.87451524888755e-06	0.000340584966008822	0.0984316881179823	0.249229354612618
PPM1E	BRD-K01507359-001-22-9::2.5::HTS002	2.5	rifampin	RNA polymerase inhibitor	noncancer	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.1198362288235	0.1198362288235	-0.096056072753947	-0.0621919503453	-6.6759183882834	17.4166359693464	3.44681723288022e-06	0.000129265597673838	-0.283997436707809	-0.147787166447085
PPM1E	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.0639431658551	-0.0639431658551	-1.14537930461321	-1.07388474495	-15.6293457780482	149.234909317769	3.13075581999097e-33	1.69447415187587e-30	-1.21816000119244	-0.944712276323786
PPM1E	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.3608780565335	-0.3608780565335	-0.853816612518925	-0.70967469814	-8.67922326762971	33.2147330413862	4.69148003325595e-10	2.89108747569785e-08	-0.608460965114741	-0.377416146856109
PPM1E	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.9833466163095	-0.9833466163095	-2.52543396637187	-2.34739362698	-14.0751242723731	89.5069906225637	2.06808959372888e-24	5.03123240107057e-22	-1.75976610956609	-1.32440859055865
PPM1E	BRD-K13049116-001-05-7::2.5::HTS002	2.5	BMS-754807	IGF-1 inhibitor	targeted cancer	AKT1, IGF1R	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.8930214056255	-0.8930214056255	-1.54495576544388	-1.37567614357	-7.26162881885401	31.7431756992906	3.13301166874041e-08	1.57222022465339e-06	-0.834864163173318	-0.46900455646345
PPM1E	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.00479098577535	-0.00479098577535	-1.11387663878414	-0.898661589303	-9.95873440255259	21.7198292289709	1.48221139736002e-09	8.6585142159928e-08	-1.34022188184222	-0.877949424175364
PPM1E	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-2.10638073361	-2.10638073361	-3.04861621366164	-3.177325410155	-8.23216825537413	16.570756747094	2.96814211246372e-07	1.30816148637104e-05	-1.18419761848554	-0.700273341617748
PPM1E	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.598537939695	0.598537939695	0.37094477146006	0.3847237758685	-7.61082443697225	126.857654266761	5.41413843129786e-12	4.16663151110104e-10	-0.286768185568883	-0.168418150900997
PPM1E	BRD-K30480208-001-18-5::2.5::HTS002	2.5	torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	noncancer	SLC12A1	cardiology	edema, congestive heart failure, hypertension	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.5483000320395	0.5483000320395	0.0232940024718064	0.129954580002	-10.0486193197876	68.8376333873173	3.91858279920256e-15	4.1210300921015e-13	-0.629239498081203	-0.420772561054184
PPM1E	BRD-K36627727-001-05-4::2.5::MTS010::PROS005_PR500	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.0218110245923	0.0218110245923	-0.0788883535700814	-0.032678012842	-3.82523855594489	173.967263553854	0.000181889724420373	0.00485966626094416	-0.152656859943115	-0.0487418963816483
PPM1E	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-1.507893058755	-1.507893058755	-2.62980283741394	-2.459947367395	-9.01947716492513	4.31162332186398	0.000587088942755492	0.0138350946687017	-1.45764000614963	-0.786179551168264
PPM1E	BRD-K37865504-001-04-1::2.5::HTS002	2.5	LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	noncancer	FAAH	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.17153998137945	-0.17153998137945	-1.30167897269814	-1.08170547456	-10.3452447530665	4.5394166998884	0.000251108640808887	0.00647495956158903	-1.41974562163236	-0.84053236100502
PPM1E	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.1898089364855	-0.1898089364855	-0.514796101651254	-0.465030888818	-6.32019238771469	48.909553733197	7.55038387596214e-08	3.60897909400332e-06	-0.428325270955315	-0.221649059376192
PPM1E	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.5622479129715	0.5622479129715	-0.544301323839801	-0.407422571936	-16.2715132708107	140.053615994948	4.35353721527126e-34	2.54247759621764e-31	-1.24099893100869	-0.972099542613915
PPM1E	BRD-K48195801-001-01-6::2.5::HTS002	2.5	tecastemizole	histamine receptor antagonist	noncancer	KCNH2	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.8258257187725	0.8258257187725	0.336082476101253	0.3035817228905	-12.9154788379943	11.7638520584453	2.64189941299598e-08	1.33747776821763e-06	-0.572546165999708	-0.406940319342786
PPM1E	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.66309003715	0.66309003715	-0.466898387567982	-0.3435721987365	-21.1500575311343	54.4943373483143	6.08404721450176e-28	2.02797473629385e-25	-1.2370812689862	-1.02289558044977
PPM1E	BRD-K50071428-001-03-3::2.5::HTS002	2.5	abiraterone	androgen biosynthesis inhibitor	targeted cancer	CYP11B1, CYP17A1	oncology	prostate cancer	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.8736220048075	0.8736220048075	0.518685532455353	0.521292609125	-12.9749366491159	45.0138758486448	8.17154433906814e-17	1.0071299175665e-14	-0.410032900869098	-0.299840043835196
PPM1E	BRD-K52172416-001-11-4::2.5::HTS002	2.5	anastrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.4170147848835	0.4170147848835	0.302718782041363	0.296380524619	-4.00588098240511	34.1830559254725	0.000316235873343968	0.00794031378841838	-0.172268672672642	-0.0563233330116318
PPM1E	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-1.55200815902	-1.55200815902	-2.75208611949466	-2.66953815971	-11.1191678517341	5.84616004965754	3.75778420718801e-05	0.00116102368652501	-1.46586387526251	-0.934292045686811
PPM1E	BRD-K60997853-001-02-3::2.5::MTS010::PROS004_PR500	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.1766082712815	0.1766082712815	-0.734195215931924	-0.7041999710785	-14.4261856028533	170.670861171573	2.32909446492848e-31	1.04872371339004e-28	-1.03543037668685	-0.786176597739999
PPM1E	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.4617755796955	-0.4617755796955	-0.24781648473316	-0.116969809946	4.03116614330891	182.592919880377	8.14150233350177e-05	0.00235201516867112	0.109237509847486	0.318680680077194
PPM1E	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.4051665222235	0.4051665222235	0.15236412772418	0.163841475196	-8.73631578219913	162.080080083971	2.86668539176851e-15	3.05222957442799e-13	-0.309944447905749	-0.195660341092891
PPM1E	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.8137963854495	0.8137963854495	-0.728902027333437	-0.5340799664045	-15.301844338772	157.942646752538	5.3397441318826e-33	2.79137078059089e-30	-1.74182342523198	-1.34357340033389
PPM1E	BRD-K67772619-001-05-1::2.5::HTS002	2.5	rheochrysidin	protein tyrosine kinase inhibitor	targeted cancer	PTPN1	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.222110344698	0.222110344698	0.0186791042856155	0.07194686545995	-5.08358233673512	191.637997058122	8.77308534182979e-07	3.61253911283196e-05	-0.282362168557097	-0.124500312267672
PPM1E	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.9004640154365	-0.9004640154365	-1.17952403978032	-1.01733335597	-4.39414458856125	17.6069064813968	0.000367039584998174	0.00910711127727179	-0.41269764055369	-0.145422408133956
PPM1E	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.546831865766	0.546831865766	0.33928879999224	0.355630945231	-5.65180673669332	9.45656315511431	0.000260724947687086	0.00668591975506407	-0.290005607925915	-0.125080523621605
PPM1E	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.0150318578486	-0.0150318578486	-0.213117221902813	-0.195517916983	-7.84185717390743	188.928814496834	3.17058147394491e-13	2.76576132164892e-11	-0.247913249769887	-0.148257478338539
PPM1E	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-2.29464175115	-2.29464175115	-2.63411338181192	-2.52531204565	-4.1248242490988	85.9108675813055	8.54114832791071e-05	0.00245687260766713	-0.503080360258913	-0.175862901064935
PPM1E	BRD-K74501079-001-18-1::2.5::HTS002	2.5	azithromycin	bacterial 50S ribosomal subunit inhibitor	noncancer	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.246924714517	-0.246924714517	-0.786533906388177	-0.6289149698795	-7.8314844708317	130.521093148939	1.46843620736564e-12	1.20033739087899e-10	-0.675919519393554	-0.403298864348799
PPM1E	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.679726972606	-0.679726972606	-1.4787609870102	-1.368540965995	-8.87487871539675	105.184576821721	2.00652945326897e-14	1.9818315723027e-12	-0.977549630634753	-0.620518398173643
PPM1E	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-4.13999721097	-4.13999721097	-2.91197390266264	-2.84610122618	12.3268847366927	154.018288154493	9.9927728104943e-25	2.53760782428961e-22	1.03122231994709	1.42482429666763
PPM1E	BRD-K75478907-001-02-3::2.5::HTS002	2.5	GS-39783	GABA receptor modulator	noncancer	GABBR1	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.6275076964275	0.6275076964275	0.477218424292111	0.475315506582	-4.83273111357322	6.44147076311156	0.00238665169945269	0.0466382815547042	-0.22513736677902	-0.0754411774917575
PPM1E	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.04268987279565	0.04268987279565	-0.21008538848321	-0.20601445055	-4.67058947313681	12.9014847441915	0.000446735744653848	0.0108423083926978	-0.369786602415614	-0.135763920142106
PPM1E	BRD-K77841042-001-14-1::2.5::HTS002	2.5	brefeldin-a	protein synthesis inhibitor	targeted cancer	ARF1, CYTH2	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-3.818815845895	-3.818815845895	-4.74740682308326	-4.82176824359	-6.94313514771486	9.83486699581944	4.32915348876236e-05	0.00132306165420355	-1.22726704369792	-0.629914910678602
PPM1E	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.3635307845475	0.3635307845475	-0.469187427197488	-0.217946401079	-8.20743799309433	10.4932198670242	6.93059076285594e-06	0.000245768793450058	-1.05735080937588	-0.608085614114095
PPM1E	BRD-K79612754-001-19-1::2.62081::HTS002	2.62081	inosine	neurotrophic agent	noncancer	PARP1, PNP	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.535116863762	-0.535116863762	-1.40765332410087	-1.36932187497	-12.0236529703109	26.7539764543827	2.69626284951932e-12	2.14907891511576e-10	-1.02149847580083	-0.723574444876916
PPM1E	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.046523773809395	-0.046523773809395	-0.952736661712689	-0.8151847008705	-11.501406881468	7.02686671892443	8.20694495187121e-06	0.000287322166708527	-1.09238082671456	-0.720044949092032
PPM1E	BRD-K81016934-001-02-0::2.5::HTS002	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.04426275225105	0.04426275225105	0.144873126787467	0.2067474126465	3.14392683570425	147.369980150837	0.00201624563458275	0.0403755872759494	0.0373692620609199	0.163851487011914
PPM1E	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.3839686073265	0.3839686073265	-0.858543887932134	-0.774088070041	-10.5408689965477	5.3791320605403	8.54773465183554e-05	0.00245843722516541	-1.53920936064835	-0.945815629868916
PPM1E	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.6147635382395	-0.6147635382395	-1.71127265193912	-1.55120007366	-13.3947559067128	7.94458920817924	9.84768840228987e-07	4.0241090706852e-05	-1.28551051156236	-0.907507715836885
PPM1E	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-2.626276167195	-2.626276167195	-1.63748382510188	-1.710789940465	17.6696331442653	173.728284176255	1.18164865595118e-40	1.34713603607107e-37	0.878343396110422	1.09924128807581
PPM1E	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.226692682478	0.226692682478	0.0922120563468723	0.09873309755385	-4.61438303960584	11.9262441168739	0.000605531602619333	0.0141901358908593	-0.19802307839276	-0.0709381738694954
PPM1E	BRD-K92441787-001-04-1::2.5::HTS002	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	0.7514042922365	0.7514042922365	0.149426638426137	0.1701725882685	-20.5759099356746	68.1653622022051	5.92128016706878e-31	2.54839770467406e-28	-0.660355385195083	-0.543599922425643
PPM1E	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	SKMEL30, NCIH596	SKIN, LUNG	malignant_melanoma, carcinoma (mixed_adenosquamous_carcinoma)	-0.35922185711	-0.35922185711	-1.42854974686272	-1.12582537284	-9.33200154644316	6.39882615836394	5.85433632042798e-05	0.00174150457907149	-1.34553046147491	-0.79312531803053
PPP1R12A	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	EFO21, ISHIKAWAHERAKLIO02ER, KNS81	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.162057630805333	0.151252129782	0.474842151511764	0.483424436558	6.10331566201695	10.6163658559223	8.95253757689623e-05	0.002561800302161	0.199488483423717	0.426080557989144
PPP1R12A	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.333576783597	-0.333576783597	-0.174356217759372	-0.1573284327925	3.51466361047588	74.3815062255466	0.000753420802174889	0.0172484433998442	0.0689624635700027	0.249478668105253
PPP1R12A	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.169103032863	0.169103032863	0.404048303396361	0.4132826179685	4.0104098442904	11.6849229541095	0.00182070975191141	0.0370343456787911	0.106919237527101	0.362971303539621
PPP1R12A	BRD-A67748489-001-10-0::2.5::HTS002	2.5	K-858	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-1.61082190144	-1.61082190144	-2.65516031880326	-2.53659706209	-9.78178973611916	37.4427402945293	7.35080301453916e-12	5.58486444276201e-10	-1.26057557179454	-0.828101262931971
PPP1R12A	BRD-A72703248-003-04-9::2.5::HTS002	2.5	SKF-96365	calcium channel blocker	noncancer	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-1.33052180019	-1.33052180019	-3.56721621599939	-3.55274052264	-12.7110380364761	2.65749430479253	0.00187049284719482	0.0378744318796805	-2.8398223251972	-1.63356650642158
PPP1R12A	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.305395477258	-0.305395477258	0.0367979192430552	0.01565074111015	8.5214676203057	177.176804977022	6.67973836438576e-15	6.85990246238829e-13	0.262946556155813	0.421440236846297
PPP1R12A	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	EFO21, ISHIKAWAHERAKLIO02ER, KNS81	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.193473267506667	-0.157924275738	0.228894304965076	0.22545527648	8.60574536551219	4.05280243544269	0.000944899764108642	0.0210541034974157	0.286797748545422	0.557937396398063
PPP1R12A	BRD-K01773560-001-02-4::2.59308::HTS002	2.59308	UNC2250	MER tyrosine kinase inhibitor	targeted cancer	MERTK	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.01926740372075	0.01926740372075	-0.131177640184331	-0.120206350846	-3.40393291446474	162.753769959468	0.000836354759952725	0.0189227361285662	-0.237719340029585	-0.063170747780577
PPP1R12A	BRD-K10845183-304-01-6::2.5::HTS002	2.5	tiludronate	bone resorption inhibitor, osteoclast inhibitor	noncancer	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.5500558111345	-0.5500558111345	0.225949294539372	0.2180493051285	13.7270188385322	2.64446270745406	0.00156471871482804	0.0326103264712542	0.581608883665558	0.970401327682186
PPP1R12A	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.159130817084	0.159130817084	0.34539091103805	0.3629794578985	5.10006802212123	12.2534689321959	0.000245163308615974	0.00634149249002572	0.10686962655405	0.265650561354051
PPP1R12A	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.955598910303	-0.955598910303	-1.33871345263425	-1.3496917977	-5.62716412800742	70.9912060452917	3.40439105313285e-07	1.48669737083683e-05	-0.518868595932803	-0.247360488729693
PPP1R12A	BRD-K12244279-001-05-8::2.5::HTS002	2.5	MEK1-2-inhibitor	MEK inhibitor	noncancer	MAP2K2	NA	NA	ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-0.547547904516667	-0.584786394229	-0.149283874673883	-0.15168868432	7.49149027498215	4.5537032494677	0.0010002482781716	0.0221286347246327	0.257477850123408	0.539050209562159
PPP1R12A	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-0.846277028573333	-0.865523235185	-0.473510554755153	-0.398900140022	5.22096297734198	5.78759714926433	0.00220314472678382	0.043563446064851	0.196495764047204	0.549037183589158
PPP1R12A	BRD-K23566484-001-15-1::2.5::HTS002	2.5	nilutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	EFO21, ISHIKAWAHERAKLIO02ER, KNS81	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.205469379203333	-0.201315719943	0.0956290953096393	0.0921041759904	9.22916703021194	11.2868098091065	1.34997360369011e-06	5.40718543272844e-05	0.229514068487511	0.372682880538434
PPP1R12A	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	0.031994038822125	0.03440707052175	-0.480501150408282	-0.395673116995	-5.65002106176647	5.96740191545485	0.00134351797113947	0.0286090242458166	-0.734740905256978	-0.290249473203835
PPP1R12A	BRD-K28907958-001-04-3::2.5::HTS002	2.5	CD-437	retinoid receptor agonist	targeted cancer	RARG	NA	NA	ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-3.38455669968	-3.38632211125	-4.21669645958267	-4.12783481329	-6.14817324751661	6.9547524869303	0.000480470681452396	0.0115641550460427	-1.1526082815248	-0.511671238280547
PPP1R12A	BRD-K32744045-001-31-2::2.5::HTS002	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	EFO21, ISHIKAWAHERAKLIO02ER, KNS81	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-2.14855208402	-2.21166674173	-1.26044536271898	-1.06682322061	6.33589557351624	7.44108694246101	0.000303497852224612	0.00765365233197423	0.560597376417247	1.21561606618479
PPP1R12A	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.199523779991	-0.199523779991	0.433350894005812	0.4313451016155	12.1584259004458	161.149335964308	1.50194181341161e-24	3.72149927082886e-22	0.530081987903747	0.735667360089876
PPP1R12A	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-1.6855120893425	-1.68005724736	-2.63804661932237	-2.477915056355	-5.52306511423676	5.69472596301944	0.00175890871346386	0.0359752978001713	-1.38008561931967	-0.524983440640077
PPP1R12A	BRD-K37723606-001-01-5::2.5::HTS002	2.5	dioscin	apoptosis stimulant	targeted cancer	CXCR3	NA	NA	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-2.003489394335	-1.991738572865	-0.985177459530548	-0.812303673116	8.92159428778169	8.86831584456371	1.01158777772647e-05	0.000348322469061202	0.759523398256569	1.27710047135233
PPP1R12A	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-0.02844153821655	-0.0661453821721	-0.735425715806234	-0.630178440526	-6.49381851148289	33.4047975979142	2.14839016395639e-07	9.6674851028891e-06	-0.928380611688441	-0.485587743490927
PPP1R12A	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	EFO21, KNS81, NCIH1299	OVARY, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-0.816564167006333	-0.864973874318	-1.59926003654332	-1.488048221985	-6.10316949024766	5.89140001712003	0.000943937211191591	0.0210371000665477	-1.09790556486188	-0.467486174212096
PPP1R12A	BRD-K52172416-001-11-4::2.5::HTS002	2.5	anastrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.950195834811	0.950195834811	0.296176683269247	0.296380524619	-22.4059207976871	17.4490388487871	2.65063284081099e-14	2.57996133577738e-12	-0.715483251192328	-0.592555051891179
PPP1R12A	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	0.027735964872375	-0.04066147254955	-0.518832452635208	-0.341964516438	-5.86781037247241	8.36222435102712	0.000316712780835327	0.00795135687052299	-0.759756767458551	-0.333380067556615
PPP1R12A	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	0.72561982119825	0.743496177312	0.22415698430682	0.260667879394	-7.47273713212284	6.2878625719756	0.000237322380750207	0.00615427326603885	-0.663859328470335	-0.339066345312524
PPP1R12A	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-4.09262549069333	-4.04451566832	-3.63296839241698	-3.48550815168	3.41323830348079	28.3553300826965	0.00195177544414998	0.0392680070561551	0.18395598445646	0.735358212096238
PPP1R12A	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-0.7807454593365	-0.7807454593365	-0.367333607535323	-0.394478559639	8.30767121846011	45.6194488263826	1.11292005044708e-10	7.33039463713188e-09	0.313222250885269	0.513601452717085
PPP1R12A	BRD-K66527818-001-02-6::2.5::HTS002	2.5	VU0364770	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-1.3853984354	-1.40631809512	-1.13987959550559	-0.970557295979	3.52079853831806	84.2703444496963	0.000696990241619411	0.0161010154662693	0.10685192960086	0.38418575018796
PPP1R12A	BRD-K76674262-001-03-3::0.625::MTS010::PROS003_PR500	0.625	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	EFO21, KNS81, NCIH1299	OVARY, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-1.00834199365333	-1.09481304974	-1.61032161180207	-1.860816321225	-4.440801986447	9.99648558369579	0.00125399390891626	0.0269597586306488	-0.904032738361621	-0.299926497935849
PPP1R12A	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	EFO21, KNS81, NCIH1299	OVARY, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-0.490230710772	-0.4635843906	-1.06466981946751	-0.791129598907	-5.51733601490685	43.1398264432599	1.81606567348711e-06	7.10932492662683e-05	-0.784387948077931	-0.364490269313089
PPP1R12A	BRD-K78177893-001-02-4::2.5::HTS002	2.5	A-674563	AKT inhibitor	targeted cancer	AKT1, PKIA, PRKACA	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	-1.818657868795	-1.818657868795	-2.68306392074131	-2.66704888005	-7.50385008529609	4.20005154670558	0.00138738517150471	0.0293685803874996	-1.17831938820259	-0.550492715690022
PPP1R12A	BRD-K80431395-001-07-3::2.48737::HTS002	2.48737	triciribine	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	EFO21, ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	OVARY, ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-0.52558373034275	-0.5375954984655	-0.945842058504938	-0.790275734137	-5.57737894826528	33.8111912918751	3.10547982555796e-06	0.000117347388140341	-0.573420484589709	-0.267096171734668
PPP1R12A	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.419933958127	0.419933958127	0.0291918400833436	0.114428305936	-8.30719089419312	180.782630920096	2.25505294063479e-14	2.21403225704679e-12	-0.483553492068752	-0.29793074401856
PPP1R12A	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	ISHIKAWAHERAKLIO02ER, KNS81, NCIH1299	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (adenocarcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-1.29138117546	-1.25959591873	-1.69354257243889	-1.42344760781	-3.79503761337013	16.5700952345545	0.00150471029466687	0.0315159828736105	-0.626181943398144	-0.178140850559628
PPP1R12A	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	EFO21, KNS81, NCIH1299	OVARY, CENTRAL_NERVOUS_SYSTEM, LUNG	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma)	-1.26802569531	-1.32236622096	-1.96481911292936	-1.89912472252	-7.77097840868523	6.9441682138395	0.000114331427364571	0.00319777378254225	-0.909166146104747	-0.484420689133974
PPP1R12A	BRD-K88568253-011-19-9::2.5::HTS002	2.5	iproniazid	monoamine oxidase inhibitor	noncancer	MAOA, MAOB	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.01120602815185	0.01120602815185	0.478751906281996	0.497154810155	10.1884710445922	3.17322227731342	0.00157567994309295	0.0327750297479783	0.325912458414069	0.609179297846224
PPP1R12A	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	EFO21, KNS81	OVARY, CENTRAL_NERVOUS_SYSTEM	carcinoma (serous_carcinoma), glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme)	0.248883043972	0.248883043972	-0.0922610998871319	0.0692106615383	-5.49962976416355	10.2357549031502	0.000241057487960544	0.00624492186957543	-0.478926162829264	-0.203362124889
PPP6R3	BRD-A02180903-001-04-5::2.5::HTS002	2.5	betamethasone	glucocorticoid receptor agonist	noncancer	NR3C1	dermatology	corticosteroid-responsive dermatoses	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.7029112673965	-0.7029112673965	-0.0633017146005306	-0.03162794181575	10.9075967234604	7.83004820073783	5.21758287519134e-06	0.000189538867806252	0.503875407384702	0.775343698207237
PPP6R3	BRD-A23072235-050-18-5::2.5::HTS002	2.5	pheniramine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.763384406838	-0.763384406838	-1.71990892533306	-1.478667912985	-10.8148675185395	187.064920267962	1.74359695611899e-21	3.26663804202821e-19	-1.13100296988975	-0.782046067100362
PPP6R3	BRD-A36267905-003-18-4::2.5::HTS002	2.5	buphenine	adrenergic receptor agonist	noncancer	ADRB2	rheumatology	Raynaud's disease	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.0175686783822	0.0175686783822	-0.445971130130625	-0.393531150995	-6.77651546941916	4.19187299331524	0.00208608457112614	0.0415873415551698	-0.650079615201514	-0.277000001824136
PPP6R3	BRD-A50049929-001-01-9::2.5::HTS002	2.5	oxazepam	GABA benzodiazepine site receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3	neurology/psychiatry	anxiety	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	1.0664044952	1.0664044952	-0.27184855801427	-0.09984291970545	-22.1034418009939	162.017159550018	8.90735194140037e-51	2.32817540762e-47	-1.45781214031243	-1.21869396611611
PPP6R3	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.0393515931716	-0.0393515931716	0.0768682968057973	0.1349064957195	3.54610604301956	19.8441284767404	0.00204582324240142	0.0408952853684624	0.0478201937931701	0.184619586161624
PPP6R3	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.259758734078	-0.259758734078	-0.697565555773829	-0.633794699256	-8.05758386239115	64.7900703472572	2.35530877219269e-11	1.68046262927858e-09	-0.546327480767815	-0.329286162623843
PPP6R3	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.01412487591877	0.01412487591877	0.145513000243207	0.138064341376	4.76494848766618	80.0682737617914	8.30361655589932e-06	0.000290469370460151	0.076515069929863	0.186261178719011
PPP6R3	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.338026727374	0.338026727374	-0.239327339255893	-0.2322368233935	-9.01191085213668	3.90713610086159	0.000935388018901955	0.0208768904199976	-0.756908655942902	-0.397799477316884
PPP6R3	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.5065057950945	0.5065057950945	0.206887232359821	0.236646785158	-7.2509067766756	190.744747893474	1.00619797043752e-11	7.52205806787245e-10	-0.381124405659413	-0.218112719809945
PPP6R3	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.3659723498335	-0.3659723498335	0.0495396538426288	0.0776480680764	13.1941426772361	99.2296808156051	1.46703888877636e-23	3.30629840160409e-21	0.353026522467339	0.477997484884918
PPP6R3	BRD-K02407574-001-09-7::2.5::HTS002	2.5	parbendazole	tubulin polymerization inhibitor	noncancer	TUBB	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.83597741524	-1.83597741524	-3.0633678204542	-3.07168460551	-12.2970601006324	48.5894119978268	1.56887681993203e-16	1.88484192791038e-14	-1.42801239575287	-1.02676841467552
PPP6R3	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.1867429988295	-0.1867429988295	-1.46711293910051	-1.380035679485	-11.7567945619492	3.0803728006871	0.00116614320025039	0.0253102081991358	-1.62189314806025	-0.938846732481778
PPP6R3	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.075770247355	-1.075770247355	-2.03645197607398	-1.93975006052	-9.2324511210998	8.52008154411551	1.00816006587683e-05	0.000347392184500507	-1.19810697777554	-0.723256479662412
PPP6R3	BRD-K05445342-001-05-3::2.56563::HTS002	2.56563	WP1066	STAT inhibitor	targeted cancer	STAT3	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-6.067847996985	-6.067847996985	-5.15508820601869	-5.11032297983	10.0997495586641	2.88767663638202	0.00243015492253574	0.0473976407673277	0.61871410924672	1.2068054726859
PPP6R3	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.486282111565	-1.486282111565	-0.67228325729018	-0.479061239467	9.98143476555215	8.69457836281983	4.70102011202025e-06	0.000172321693105728	0.628524433629243	0.999473274920398
PPP6R3	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.1638250947285	-0.1638250947285	-1.69741227473032	-1.35955217781	-12.020227813963	27.2171208851321	2.13439209519694e-12	1.7210764611417e-10	-1.79526997768893	-1.27190438231472
PPP6R3	BRD-K09426783-300-01-0::2.5::HTS002	2.5	TAS-103	topoisomerase inhibitor	chemo	TOP1	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.170853809155	-1.170853809155	-2.72710685089354	-2.622314881585	-16.6138892311765	177.733789889044	5.12196192395158e-38	4.46254055771796e-35	-1.74110509244921	-1.37140099102787
PPP6R3	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-3.44359354699	-3.44359354699	-1.78660928011041	-1.54559270123	11.122735975808	3.80528694456904	0.000485198773964622	0.0116596219335198	1.2348877007984	2.07908083296078
PPP6R3	BRD-K15071410-001-01-1::2.5::HTS002	2.5	tiotidine	histamine receptor antagonist	noncancer	HRH2	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	1.22117594799	1.22117594799	0.369977813317267	0.358823468762	-29.2477718474752	108.582788742788	2.64695049413761e-53	9.30029922062328e-50	-0.908881837775812	-0.793514431569653
PPP6R3	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.393893056935	-1.393893056935	-3.7026089785829	-3.60112771075	-18.4177463216676	4.73874987469187	1.36288706444681e-05	0.00045813397370737	-2.63636277658429	-1.98106906671152
PPP6R3	BRD-K15916496-001-27-9::2.5::HTS002	2.5	clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	noncancer	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.05780745868915	0.05780745868915	0.335020644088061	0.346280454324	11.0970825588561	188.482650996836	2.41497830907565e-22	4.90151407202533e-20	0.22793545548068	0.326490915317141
PPP6R3	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.144963738504	0.144963738504	-0.190846666378472	-0.123671466435	-8.00181667817199	78.0638005547912	9.28876391934419e-12	6.99034930501798e-10	-0.419358751582042	-0.252262058182902
PPP6R3	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.3108708978565	0.3108708978565	-0.376819939613473	-0.1455477562875	-8.38718734923055	187.322016267034	1.17989444215459e-14	1.18392132908498e-12	-0.849439205653235	-0.525942469286711
PPP6R3	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.53622463264	-2.53622463264	-0.953745387415707	-0.729695465511	15.6717823442568	3.21894623197674	0.000378107737106501	0.00935224200393358	1.27314581169813	1.89181267875046
PPP6R3	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.682605914229	0.682605914229	-0.384405364753289	-0.173057746988	-9.93974830756371	3.51153005169898	0.00107718244188418	0.023572742044782	-1.38214179868923	-0.751880759275349
PPP6R3	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.537969216845	0.537969216845	0.371562819652407	0.3847237758685	-5.40005521154025	60.8136667919976	1.16595003407901e-06	4.71421931825513e-05	-0.228029985166977	-0.104782809218208
PPP6R3	BRD-K23984367-075-15-2::2.5::HTS002	2.5	sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.019623494504965	0.019623494504965	-0.861349652979297	-0.738304903661	-11.5532701263118	164.15137344938	5.67154733830293e-23	1.222914556812e-20	-1.03153658085677	-0.730409714111758
PPP6R3	BRD-K24696047-001-02-3::2.5::HTS002	2.5	NVP-AEW541	IGF-1 inhibitor	targeted cancer	IGF1R, INSR	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.9342091836245	0.9342091836245	0.156553331289451	0.182728129692	-22.1657453517076	22.5919178124128	7.96565523761158e-17	9.84017822145275e-15	-0.850304576964835	-0.705007127705264
PPP6R3	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.3354416022235	0.3354416022235	-0.509354493217196	-0.436225052339	-17.2892761340626	56.6032104013329	2.98164246071018e-24	7.14823766176232e-22	-0.942656296878868	-0.746935894002525
PPP6R3	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-4.002442324795	-4.002442324795	-1.95301647396073	-1.79694475109	20.0836721591422	121.835974458533	1.81750340015792e-40	2.01593373739205e-37	1.84741608676432	2.25143561490422
PPP6R3	BRD-K26838195-075-04-9::2.5::HTS002	2.5	AST-1306	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.379418861475	-1.379418861475	-0.64409067997047	-0.552150781562	10.3907348831205	156.278527747786	1.48082111606913e-19	2.33885710380237e-17	0.595543618455273	0.875112744553787
PPP6R3	BRD-K30519779-001-03-1::2.5::HTS002	2.5	homoquinolinic-acid	glutamate receptor agonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.559516900004	0.559516900004	0.425588964600878	0.440439645693	-4.16172496207756	71.7863867286791	8.65358901701037e-05	0.00248654656177345	-0.198082591435081	-0.0697732793711618
PPP6R3	BRD-K33127281-001-05-6::2.5::HTS002	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.174233381145	-1.174233381145	-0.153239922958932	-0.1501441638665	29.2028297670319	187.661768136621	1.02570086158978e-71	2.44263822181862e-67	0.952024141280026	1.08996277509211
PPP6R3	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.2959305963025	0.2959305963025	0.0398458219325396	0.143970790547	-5.04215013989724	9.58636605189225	0.000575011435053508	0.0135698773247724	-0.369914648154354	-0.142254900585567
PPP6R3	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.04113858075875	0.04113858075875	-0.180198262780336	-0.13613940777	-6.35800383226426	182.370753719255	1.59537839110524e-09	9.28668808221606e-08	-0.290023536868462	-0.15265015020971
PPP6R3	BRD-K38305202-001-17-4::2.5::HTS002	2.5	domperidone	dopamine receptor antagonist	noncancer	DRD2, DRD3	infectious disease	fescue toxicosis	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.1992022271295	0.1992022271295	-0.363453517119271	-0.225769257521	-6.89632962415558	4.14015053075416	0.00204073683115536	0.0408088341374041	-0.786187177301135	-0.339124311196407
PPP6R3	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.900593927952	0.900593927952	-0.120846361455771	-0.11764531931	-15.9780169441072	5.26132535241381	1.16307077100356e-05	0.000395556641190768	-1.18334713859196	-0.85953344022358
PPP6R3	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.440639209098	-0.440639209098	-0.893831767672875	-0.852653660565	-6.5025925102622	13.5216461645632	1.65120252467499e-05	0.000547918541432213	-0.603169247869476	-0.303215869280275
PPP6R3	BRD-K47114202-001-14-6::2.57945::HTS002	2.57945	chlorogenic-acid	antioxidant	noncancer	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.303681376576	-0.303681376576	-1.05985690827562	-0.967874485397	-11.2999199831342	181.678876294593	9.1459533638029e-23	1.92747594740463e-20	-0.888213241223448	-0.624137822175786
PPP6R3	BRD-K47598052-001-15-8::2.5::HTS002	2.5	PP-1	src inhibitor	targeted cancer	HCK, RET	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.2552378055005	0.2552378055005	-0.296980111807209	-0.119341908815	-8.27967231563995	69.6577354814858	5.76881713492226e-12	4.43004230638034e-10	-0.685249638253739	-0.41918619636168
PPP6R3	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.656199223726	0.656199223726	0.368193187178589	0.3732554744945	-7.88881178391204	88.9935372916637	7.34458179694084e-12	5.58211656722175e-10	-0.360547053907587	-0.215465019187235
PPP6R3	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-3.23826409376	-3.23826409376	-1.22826923899931	-0.855735961913	20.6384912182317	16.4085708589772	3.60757470179453e-13	3.13293305616256e-11	1.80395304420856	2.21603666531281
PPP6R3	BRD-K50168500-001-07-9::2.5::HTS002	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.164559699495	-1.164559699495	-0.463373825550038	-0.351276488642	12.182704727857	53.7426585630456	4.3442177090033e-17	5.48023447529705e-15	0.585780695027553	0.816591052862371
PPP6R3	BRD-K52313696-001-12-3::2.5::MTS010::PROS004_PR500	2.5	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.1598880954355	0.1598880954355	-0.0128747758160333	-0.0070642593788	-5.67966935151873	44.7958840330236	9.43694998218885e-07	3.87251015265662e-05	-0.234035109035311	-0.111490633467756
PPP6R3	BRD-K54095730-001-03-1::2.5::HTS002	2.5	CMPD-1	p38 MAPK inhibitor	noncancer	GNRHR, MAPK14	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.1853892706785	-0.1853892706785	-1.52634401147897	-1.5570935433	-15.3560743808681	5.20632303839372	1.55153496988653e-05	0.000516685734246131	-1.56277895060862	-1.11913053099233
PPP6R3	BRD-K54247840-004-01-3::2.5::HTS002	2.5	halofuginone	collagenase inhibitor	noncancer	COL1A1, MMP2	rheumatology	scleroderma	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-4.736678927385	-4.736678927385	-5.72440738893402	-5.5836707127	-8.4976603841354	163.213684039943	1.15507273688976e-14	1.16010114632073e-12	-1.21724738246661	-0.758209540631437
PPP6R3	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.0079731900307	0.0079731900307	-0.744472768785502	-0.696454065727	-12.8116906630059	48.5918284601527	3.38870149845489e-17	4.3206246487944e-15	-0.870495805027758	-0.634396112604646
PPP6R3	BRD-K56981171-001-01-0::2.5::MTS006	2.5	brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	targeted cancer	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.308963685675	0.308963685675	-0.0745586263294337	-0.00736994010253	-11.0968229004833	73.0679826141743	2.47583524302048e-17	3.19472180494483e-15	-0.4524021068445	-0.314642517164368
PPP6R3	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.013783885377	-1.013783885377	-0.577439910204174	-0.45596991553	4.76786196572393	8.20828119961712	0.00131536329453087	0.0280917451946824	0.226232171209463	0.64645577913619
PPP6R3	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.902440270045	-1.902440270045	-1.32347497548881	-1.441894150425	9.64830982521057	130.225998207182	6.00335191004024e-17	7.50594482496788e-15	0.460250727850243	0.697679861262132
PPP6R3	BRD-K62304154-001-04-2::2.5::HTS002	2.5	deforolimus	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.71355942024	-1.71355942024	-2.77835064649008	-2.77605500784	-15.0317503019637	169.051321337743	5.6481678506746e-33	2.9454164653704e-30	-1.20462858330789	-0.924953869192262
PPP6R3	BRD-K62965247-001-04-9::2.5::HTS002	2.5	tipifarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, FNTB	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.5063940293475	-0.5063940293475	-1.47981966255045	-1.40587252118	-12.326241127302	4.27776966077851	0.000167206189104107	0.00451122045625556	-1.18718415816301	-0.759667108242888
PPP6R3	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.523812612025	-2.523812612025	-1.83194740256556	-1.66645178592	7.04230211433934	64.1079682734522	1.55599605224012e-09	9.0623662467547e-08	0.495606259810815	0.888124159108068
PPP6R3	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.795974565601	-0.795974565601	-2.50375434836431	-2.41136656484	-20.3035839389065	186.817615653174	3.77118658137496e-49	8.69112525590876e-46	-1.87371165014901	-1.54184791537761
PPP6R3	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.9726469678	-1.9726469678	-1.06831069571098	-0.4089077458395	7.15775063208741	24.9032060116174	1.71668645443359e-07	7.82009970440588e-06	0.644075381216795	1.16459716296125
PPP6R3	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.438513200623	0.438513200623	-0.342811352162385	-0.3277516003215	-16.5069799308534	54.4271915077355	7.60861177542657e-23	1.61780372342798e-20	-0.8762044088746	-0.68644469669617
PPP6R3	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.397754776675	0.397754776675	0.253786293331813	0.248858708206	-5.57245702774636	6.82076579321663	0.000918184861698422	0.0205357031433748	-0.205387217457231	-0.0825497492291421
PPP6R3	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.3901621852165	0.3901621852165	-1.23138988562754	-1.04907947641	-17.6972000974504	9.4599259284484	1.43735196748772e-08	7.5654766660038e-07	-1.82730208084559	-1.41580206084249
PPP6R3	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	1.070850857935	1.070850857935	-0.0196012668980883	-0.0198550434605	-21.5400165079386	149.672257945756	1.03677576589787e-47	2.07673937503854e-44	-1.1904830850832	-0.990421164582974
PPP6R3	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.56455330669	-1.56455330669	-0.522082202508208	-0.39621393329	15.6594193228808	188.775615453859	5.76701139766817e-36	4.01310969432085e-33	0.911151476158502	1.17379073220508
PPP6R3	BRD-K70401845-003-09-6::2.5::HTS002	2.5	erlotinib	EGFR inhibitor	targeted cancer	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.83153479521	-1.83153479521	-1.08086665875997	-1.046302066785	10.1204639507819	12.8038111366749	1.79046252872566e-07	8.13197803177032e-06	0.590176529110612	0.91115974378944
PPP6R3	BRD-K71164191-001-01-0::2.5::HTS002	2.5	KD-023	ACAT inhibitor	noncancer	ACACA, ACACB	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.5092204753	0.5092204753	-0.962798032435434	-0.979843337188	-27.6650650950569	172.048710931506	3.0854576806298e-65	3.48054241700898e-61	-1.57704414518848	-1.36699287028239
PPP6R3	BRD-K72726508-001-02-1::2.5::HTS002	2.5	arcyriaflavin-a	CDK inhibitor	targeted cancer	CCND1, CDK4	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.115843502565	-1.115843502565	-0.487334280114375	-0.3795984420275	8.88488488320623	3.5507078235496	0.0015043704488787	0.0315150243317097	0.421905502165501	0.835112942735749
PPP6R3	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.518989280821	-0.518989280821	-2.54332431671905	-2.26266997363	-19.041232206932	176.217560642706	1.25321398979178e-44	1.9750007442506e-41	-2.23414607208706	-1.81452399970904
PPP6R3	BRD-K72951360-001-01-4::2.5::HTS002	2.5	valrubicin	DNA inhibitor, topoisomerase inhibitor	chemo	TOP2A	oncology	bladder cancer	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.45834520534	-2.45834520534	-3.29588188600506	-3.181546610205	-7.75285528307484	139.825438771177	1.67992005592611e-12	1.36695362819509e-10	-1.0511190282188	-0.623954333111315
PPP6R3	BRD-K77638923-001-02-0::2.5::HTS002	2.5	CUDC-907	PI3K inhibitor	targeted cancer	HDAC2, PIK3R1	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-5.64655049937	-5.64655049937	-5.89355211528958	-5.8647928098	-3.48497942569	188.788852236383	0.000611894031259555	0.0143141929519569	-0.38681239355732	-0.107190838281848
PPP6R3	BRD-K79612754-001-19-1::2.62081::HTS002	2.62081	inosine	neurotrophic agent	noncancer	PARP1, PNP	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.4463360790675	-0.4463360790675	-1.40859280330399	-1.36932187497	-10.034040281023	3.49616094230309	0.00106458864950823	0.0233257228235994	-1.24435314702146	-0.680160301451524
PPP6R3	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.01369638747186	0.01369638747186	-0.781744423398816	-0.670066066219	-16.2487364316247	189.166781576824	9.78410819964284e-38	8.06545433200481e-35	-0.892006702108367	-0.698874919632986
PPP6R3	BRD-K84091759-001-07-1::2.5::HTS002	2.5	candesartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension, congestive heart failure	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.02849557432848	-0.02849557432848	0.338165421861283	0.3438554060475	10.0881378705606	7.95961238385542	8.24434018167997e-06	0.000288537097779113	0.282773450268482	0.450548542111045
PPP6R3	BRD-K86727142-001-12-4::2.5::HTS002	2.5	embelin	HCV inhibitor, XIAP inhibitor	targeted cancer	XIAP	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.7119057283935	0.7119057283935	-0.181631037752196	-0.186017590175	-21.3574140538493	59.4557756177048	1.41429953057889e-29	5.541597880977e-27	-0.97723960586057	-0.809833926430822
PPP6R3	BRD-K86930074-001-05-0::2.5::HTS002	2.5	cediranib	KIT inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.49421370496	-1.49421370496	-3.0335576415267	-2.830173101285	-11.5680752556553	3.23527574105913	0.0009665714213879	0.0214722518837735	-1.94592640531058	-1.13276146782282
PPP6R3	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.9440332418455	-0.9440332418455	-0.304547218555297	-0.0918736144378	8.13216305859961	62.0818042439699	2.31389675881608e-11	1.65366848422905e-09	0.48229772894241	0.796674317637996
PPP6R3	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.0207808491726	-0.0207808491726	-1.4321311331901	-1.12582537284	-12.2040388686125	5.95691506432594	1.94119894538859e-05	0.000634617493542085	-1.69482311995433	-1.12787744808067
PPP6R3	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.379183744464	0.379183744464	-0.0388364690795609	0.00448333894144	-8.09667442355865	178.536943046148	8.50184856210056e-14	7.85089487490931e-12	-0.519901069438656	-0.316139357648466
PPP6R3	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.6681479651225	0.6681479651225	-0.978347817528076	-0.879578497328	-18.5656658077293	97.4150076110859	9.19786831418677e-34	5.22909792549426e-31	-1.82250145805507	-1.47049010724608
PPP6R3	BRD-K98157055-001-10-9::0.625::HTS002	0.625	SIB-1757	glutamate receptor antagonist	noncancer	GRM5	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.5450603235575	0.5450603235575	0.218668798938072	0.259105939105	-7.92846614977819	47.3627782391887	3.09226807257565e-10	1.94301590069501e-08	-0.409192195623443	-0.243590853615413
PPP6R3	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.20306974754	-1.20306974754	-0.713663533144134	-0.590290062749	6.95368359163567	11.6107139706218	1.82007097237298e-05	0.00059839544629196	0.335487320642983	0.643325108148748
PPP6R3	BRD-K99383816-001-03-5::2.5::HTS002	2.5	ftorafur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.4151024691365	0.4151024691365	0.0242066729335963	0.0625789324056	-12.7996920253563	194.251339754992	1.33617351993731e-27	4.30647720834051e-25	-0.45112730996679	-0.330664282439017
PPP6R3	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	MDAMB175VII, VMCUB1	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.2090010714335	-0.2090010714335	-1.09799151080907	-1.03443241086	-10.3118306020958	4.52778311520691	0.000258314100814878	0.00663203197335315	-1.1177376932242	-0.66024318552694
PRH1	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.865519408062	0.865519408062	-0.78891584062831	-0.4776049590865	-14.6785709197688	19.1675651464492	7.01988760285059e-12	5.34861532183208e-10	-1.89020241145747	-1.41866808592315
PRH1	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.2809430433395	0.2809430433395	-0.0557427130287373	0.002007296385155	-9.18560987603	54.3154262956976	1.19946220845298e-12	9.93736125533509e-11	-0.410162046243276	-0.263209466493199
PRH1	BRD-A50998626-001-02-1::2.5::HTS002	2.5	palomid-529	AKT inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.4673420469725	0.4673420469725	0.0400599188937545	0.0209581438432	-13.7592367905384	61.980278995506	1.67270507792965e-20	2.9005599243332e-18	-0.489358987631125	-0.365205268526366
PRH1	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.398082042309	0.398082042309	0.150732978033259	0.162581247373	-8.24649255500427	44.2658957437192	1.71134586423712e-10	1.10412717560529e-08	-0.307788665704962	-0.186909462846519
PRH1	BRD-K00317371-001-06-1::2.40436::HTS002	2.40436	RITA	MDM inhibitor	targeted cancer	MDM2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-1.03517946231	-1.03517946231	-2.20173770732824	-1.66399627555	-8.66017740888398	188.962238001447	2.0680136309968e-15	2.23517545899099e-13	-1.43227451249955	-0.90084197753692
PRH1	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.6294611623465	-0.6294611623465	-1.03062651706869	-1.0089298839585	-5.80344719953072	5.39064439195617	0.00166240582423206	0.0343125749135047	-0.575053646481984	-0.227277062962405
PRH1	BRD-K06593056-001-04-8::2.5::HTS002	2.5	LE-135	retinoid receptor agonist	noncancer	RARB	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.5809775877845	0.5809775877845	-0.149124982901514	-0.158245986785	-23.5841978085243	101.997061436797	4.31424003572984e-43	5.81551416740844e-40	-0.791506206279387	-0.668698935092641
PRH1	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-1.896460828845	-1.896460828845	-2.51511629165395	-2.34739362698	-4.68218620802315	7.5784698840221	0.00182402678524159	0.0370842190148023	-0.926322216627655	-0.310988708990254
PRH1	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.155413273279	-0.155413273279	-0.514611708121309	-0.419130200084	-5.35266104884995	43.5899189713526	3.05730960081355e-06	0.000115731209719669	-0.494478677024386	-0.223918192660231
PRH1	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.429837703445	0.429837703445	-0.0585076143546377	0.1891566141585	-5.6294138795235	5.14643290700628	0.00223302085468712	0.0440903847779122	-0.709445431113792	-0.267245204485483
PRH1	BRD-K15567136-003-27-2::2.5::HTS002	2.5	papaverine	phosphodiesterase inhibitor	noncancer	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.013601548103395	-0.013601548103395	-0.528300663166347	-0.5051056770975	-14.2168095641825	23.4627432420033	5.04641545831321e-13	4.30913617037774e-11	-0.589510236984481	-0.439887993141423
PRH1	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.08149404150175	0.08149404150175	0.311095022616614	0.322928237233	7.39899877335967	106.81021827007	3.28678774823078e-11	2.30741543167558e-09	0.168083682718252	0.291118279511475
PRH1	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.371410827026	0.371410827026	-0.347741489911467	-0.216806871006	-12.7899115454978	189.738312099434	2.04633684300459e-27	6.44037194162012e-25	-0.830064792568303	-0.608239841306631
PRH1	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-3.33730244187	-3.33730244187	-4.18612421133665	-4.20452435995	-8.69527119998788	25.9980979260643	3.5821244249523e-09	2.00877327544637e-07	-1.04948076077008	-0.648162778163214
PRH1	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.0860782864604	-0.0860782864604	-0.428009738097337	-0.326694667694	-8.01263931834835	31.9474003947064	3.83920840324591e-09	2.14620161152658e-07	-0.428861179010759	-0.255001724263115
PRH1	BRD-K28307902-001-21-7::2.5::HTS002	2.5	flutamide	androgen receptor antagonist	targeted cancer	AHR, AR	oncology	prostate cancer	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.4317378052925	0.4317378052925	0.241049570970914	0.2782830589715	-6.70048086443257	19.7691791837827	1.70538927595648e-06	6.71037962413212e-05	-0.250096900040793	-0.131279568602378
PRH1	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.143126380435	0.143126380435	-0.500101373479507	-0.332266676493	-11.1515044175126	29.5235285502657	4.1864689154971e-12	3.27714279105032e-10	-0.761107446834662	-0.525348060994351
PRH1	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.00580283388185	0.00580283388185	-0.636523721764668	-0.4291875223905	-7.34236090347349	4.39622693565664	0.001258429211932	0.0270339655772451	-0.876821683156577	-0.407831428136458
PRH1	BRD-K46937689-001-15-0::0.625::HTS002	0.625	phenazone	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.7058886602945	0.7058886602945	0.0861564687527096	0.0795356739513	-17.1285824819248	13.1449107324923	2.2556502781192e-10	1.43627827825018e-08	-0.697809358219202	-0.541655024864379
PRH1	BRD-K47557313-001-02-7::2.5::HTS002	2.5	LY2109761	TGF beta receptor inhibitor	targeted cancer	TGFBR1, TGFBR2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.7852863729475	0.7852863729475	0.251161562800624	0.273399788387	-11.5297088223005	6.82120509278186	1.01038086422394e-05	0.000348045516310276	-0.644253058043089	-0.423996562250664
PRH1	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.8208696954395	0.8208696954395	-0.276492062840259	-0.2054130743915	-15.1947824595231	2.8862452279822	0.000762583682551498	0.0174284280334378	-1.33240739503688	-0.862316121522638
PRH1	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.0921811666449	-0.0921811666449	-0.458863587527611	-0.3435721987365	-7.20252917557553	187.998344718348	1.38319535507549e-11	1.01736059457095e-09	-0.467111139080629	-0.266253702684792
PRH1	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.524745903191	0.524745903191	-0.116649990591884	0.03876057814515	-11.9080664293109	34.713246653488	8.2130416310583e-14	7.59729391343588e-12	-0.750774482538241	-0.532017305027526
PRH1	BRD-K59831625-001-01-6::2.5::HTS002	2.5	LDN-212854	bone morphogenic protein inhibitor	noncancer	ABL1, ACVR1, RIPK2	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-4.43880153777	-4.43880153777	-3.63173065307721	-3.494830245985	6.64988405512429	77.0626265737522	3.7846924996651e-09	2.11738282109298e-07	0.565403121623022	1.04873864776255
PRH1	BRD-K66175015-001-09-0::2.5::HTS002	2.5	afatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.17178159291	-0.17178159291	-0.919548205855464	-0.7732511578805	-6.91501401493148	16.9932584727454	2.50581927886336e-06	9.61628899229195e-05	-0.975921946225626	-0.519611279665302
PRH1	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	1.0015083399985	1.0015083399985	-0.0188434251720063	-0.0198550434605	-18.2731207060483	21.3481252665601	1.61992206047539e-14	1.61186757335019e-12	-1.13636001140595	-0.904343518935067
PRH1	BRD-K71164191-001-01-0::2.5::HTS002	2.5	KD-023	ACAT inhibitor	noncancer	ACACA, ACACB	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.08834252942765	-0.08834252942765	-0.956507895543564	-0.979843337188	-13.928964409505	13.0178147211051	3.37322198262627e-09	1.90007698899949e-07	-1.00279822993284	-0.733532502298987
PRH1	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-2.742078632405	-2.742078632405	-4.37413888178058	-4.09603677997	-12.0931838782959	13.9416575608301	8.87065132508419e-09	4.76023492201795e-07	-1.92162798368247	-1.34249251506869
PRH1	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-0.4824373693625	-0.4824373693625	-1.11639212176682	-0.918129706972	-6.94534729071942	20.7098182436818	7.93368924137052e-07	3.29347217008271e-05	-0.823939031398031	-0.44397047341061
PRH1	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.824999563451	0.824999563451	-0.21827711299269	-0.20601445055	-16.5049162617543	4.29026626244956	4.79995811970527e-05	0.00145286008168099	-1.21419089190338	-0.872362460984
PRH1	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.740974608174	0.740974608174	0.088676842708927	0.1896034324075	-11.4811399896275	5.28850920875147	6.13478940480545e-05	0.00181877488386486	-0.795980457899755	-0.508615073030391
PRH1	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.9568169615765	0.9568169615765	0.49374325285522	0.515272690573	-13.5328044067403	11.0650291145033	3.13907975929349e-08	1.57452802651443e-06	-0.538334386169241	-0.387813031273319
PRH1	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.1599334023125	0.1599334023125	-0.42898453916013	-0.2959843885325	-9.80752666760004	30.2620820157504	6.55387173843971e-11	4.43118225813263e-09	-0.711506877141557	-0.466329005803703
PRH1	BRD-K87024524-065-17-7::2.5::HTS002	2.5	phenelzine	monoamine oxidase inhibitor	noncancer	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.6536770119495	0.6536770119495	0.349024919400881	0.3670145193675	-8.42976739862167	10.6722766437936	4.84294414233406e-06	0.000176916005008949	-0.384494806746298	-0.22480937835094
PRH1	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-1.513196958135	-1.513196958135	-1.95869985548983	-1.89031364576	-6.93127643533586	73.7278806501339	1.34021372593452e-09	7.8719284095867e-08	-0.573580077712046	-0.317425716997609
PRH1	BRD-K88568253-011-19-9::2.5::HTS002	2.5	iproniazid	monoamine oxidase inhibitor	noncancer	MAOA, MAOB	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.82076809628	0.82076809628	0.468998146425031	0.4917980145095	-7.87737294537669	3.51343394605898	0.00236282624969486	0.0462486015772466	-0.482828412987589	-0.22071148672235
PRH1	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	-5.35409940563	-5.35409940563	-3.99806652763285	-3.812026280445	8.70800565949046	4.72126707832103	0.000439451828388414	0.0106824623938596	0.948521616522332	1.76354413947198
PRH1	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.571626496651	0.571626496651	-0.234680201989666	-0.164801274437	-8.89510786656732	3.20081137732585	0.00231296764580501	0.0454345195268757	-1.08480981481896	-0.527803582462377
PRH1	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.494557315426	0.494557315426	0.308331482698756	0.328628776305	-5.69683142778769	186.803565116865	4.68011685108369e-08	2.29224123531974e-06	-0.25071360987399	-0.121738055580498
PRH1	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	QGP1, NCIH1792	PANCREAS, LUNG	carcinoma, carcinoma (adenocarcinoma)	0.1515231210325	0.1515231210325	-0.0242661442982765	0.013127326234	-5.29117511010921	11.8283277783731	0.00020054451680135	0.00529602091443032	-0.248292885319512	-0.103285645342041
PRKCE	BRD-A26032986-050-02-1::2.5::HTS002	2.5	zaldaride	calmodulin antagonist	noncancer	CALM1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.616755968998	-0.616755968998	-0.162349372251916	-0.153177968043	12.4393596026808	13.2355627940028	1.11065655415875e-08	5.9068463671536e-07	0.37563142695158	0.533181766540588
PRKCE	BRD-A43885598-001-08-1::2.5::HTS002	2.5	SID-7969543	steroidogenic factor antagonist	noncancer	NR5A1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0453811641496	0.0453811641496	0.412718973205161	0.426109956866	11.3192739349871	180.403617665932	8.69124169160018e-23	1.84069677916895e-20	0.303302667224534	0.431372950886588
PRKCE	BRD-A51964809-003-12-6::2.5::HTS002	2.5	halofantrine	antimalarial agent	noncancer	KCNH2, KCNN4	infectious disease	malaria	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.3678663913655	-0.3678663913655	-0.127513064093368	-0.125815846573	8.1344636895708	120.588172086102	4.21860229944793e-13	3.63704268800633e-11	0.181854176077435	0.298852478466829
PRKCE	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.575711725325	-1.575711725325	-1.12030782884135	-1.02154011458	7.38404380677019	30.045223446044	3.13211441928765e-08	1.57213805941804e-06	0.329456629777477	0.581351163189818
PRKCE	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2277390747645	0.2277390747645	-0.189388551079071	-0.136086260588	-8.73152968758403	53.2545908174522	7.43242823350175e-12	5.6428795992143e-10	-0.512936577556725	-0.321318674130417
PRKCE	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.05145730288485	0.05145730288485	0.224042024575423	0.2226649685355	5.63541791373686	18.1549544062205	2.32295744997397e-05	0.000747563284227434	0.108283306864091	0.236886136517055
PRKCE	BRD-K03243820-001-23-8::2.37329::HTS002	2.37329	trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	chemo	TYMS	infectious disease	virus herpes simplex (HSV)	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.547434503825	-3.547434503825	-2.23978238368846	-2.04414920989	14.7717121391332	187.924687475802	2.81886526167688e-33	1.52953056372138e-30	1.13302353106144	1.48228070921165
PRKCE	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5280037467145	0.5280037467145	0.0535420311366534	0.0542001317345	-8.21807616258701	6.67602135213212	9.94659715929541e-05	0.00282050298321854	-0.612335309350575	-0.336588121805118
PRKCE	BRD-K05445342-001-05-3::2.56563::HTS002	2.56563	WP1066	STAT inhibitor	targeted cancer	STAT3	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.61148416185	-4.61148416185	-5.17033808910911	-5.12208699866	-9.50365956734283	185.302107485768	1.06892749885082e-17	1.43637719060311e-15	-0.674865477847593	-0.442842376670626
PRKCE	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.6755831026935	0.6755831026935	0.196105899420768	0.204355413473	-11.1983285048624	2.79067121997734	0.00211069929685678	0.0420196980861989	-0.62170833641272	-0.337246070132744
PRKCE	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.350941263655	-0.350941263655	-0.0671566348063909	-0.00125185876287	5.54868901085799	6.66735016688415	0.00101660249062856	0.0224325538159096	0.161613241338381	0.405956016358837
PRKCE	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.487308273564	-0.487308273564	-0.282146114799497	-0.2553419121665	6.41146324720293	187.211292097621	1.1429301101454e-09	6.7613322544122e-08	0.142036665131341	0.268287652397665
PRKCE	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.78506558005	-0.78506558005	-1.81444726929303	-1.56065418801	-8.72552820051092	20.3428601451796	2.58655623808262e-08	1.31088676271461e-06	-1.27520461797412	-0.783558760511928
PRKCE	BRD-K13049116-001-05-7::2.5::HTS002	2.5	BMS-754807	IGF-1 inhibitor	targeted cancer	AKT1, IGF1R	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.00491303059	-2.00491303059	-1.53331292120342	-1.35806508341	5.1633310647419	24.4144978493348	2.61652283015166e-05	0.000834394765159314	0.283260248020093	0.659939970753072
PRKCE	BRD-K13514097-001-05-3::2.5::HTS002	2.5	everolimus	mTOR inhibitor	targeted cancer	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.5556086994525	-0.5556086994525	-0.747983808595985	-0.7206768922275	-3.40239859644522	167.165607466853	0.000835873394163759	0.0189138417121753	-0.304001608491284	-0.0807486097956859
PRKCE	BRD-K13533483-001-16-2::2.5::MTS005	2.5	cyclosporine	calcineurin inhibitor	noncancer	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	transplant, rheumatology, dermatology	organ rejection, rheumatoid arthritis, psoriasis	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.01804302397295	-0.01804302397295	0.226794041308197	0.2295047390715	10.0330068743107	107.658049266256	4.04426132596213e-17	5.11570562767679e-15	0.19646402934033	0.293210101221965
PRKCE	BRD-K16136380-001-01-7::2.5::HTS002	2.5	pyrithione-zinc	ATP synthase inhibitor	noncancer	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.101442557185	-5.101442557185	-6.35400386692697	-6.34443535145	-10.7935218900416	22.2741699899592	2.56625149538827e-10	1.62584131467654e-08	-1.49305747051477	-1.01206514896917
PRKCE	BRD-K17894950-001-14-3::2.5::MTS010::PROS002_PR500	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2392909909115	0.2392909909115	0.0171135775096039	0.01698904715675	-8.45480685377738	59.088842818117	9.24603997580695e-12	6.96064103257719e-10	-0.274758388867828	-0.169596437935964
PRKCE	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1425455267166	0.1425455267166	-0.308241007282188	-0.19710233478	-6.1958111250878	5.56267129966777	0.00108260493011688	0.0236793174882151	-0.632264111340423	-0.269308956657154
PRKCE	BRD-K25596805-001-01-8::2.5::HTS002	2.5	JNJ-16259685	glutamate receptor antagonist	noncancer	GRM1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.06766887011075	0.06766887011075	0.395560052086568	0.392933353126	7.92034467509437	5.79851082628388	0.000254779032652572	0.00655304635658144	0.22573305682911	0.430049307122525
PRKCE	BRD-K26838195-075-04-9::2.5::HTS002	2.5	AST-1306	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.9188486309565	-0.9188486309565	-0.64974184844309	-0.552150781562	3.5473129295628	39.9613902328498	0.00101136153994719	0.0223468152057052	0.115779045165826	0.422434519860994
PRKCE	BRD-K29582115-066-01-2::2.5::HTS002	2.5	ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.017391217827215	-0.017391217827215	0.267313344490945	0.27385544783	6.8585096542349	9.93619507341169	4.55487862347044e-05	0.00138428017564678	0.192131405308186	0.377277719328133
PRKCE	BRD-K29968218-001-03-2::2.5::HTS002	2.5	KX2-391	src inhibitor, tubulin polymerization inhibitor	targeted cancer	SRC	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.087225439945	-3.087225439945	-2.74411761282013	-2.69887921665	3.22617225112984	181.807193584349	0.00148793454293609	0.0312195323204063	0.13326615001921	0.552949504230535
PRKCE	BRD-K31491153-003-05-9::2.5::HTS002	2.5	1-phenylbiguanide	serotonin receptor agonist	noncancer	HTR3A, HTR3B	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.522203812166	0.522203812166	-0.105190984708852	0.0097375334851	-9.70931921565889	6.02012930262859	6.71357147102032e-05	0.00197212924570573	-0.785380779631283	-0.469408814118421
PRKCE	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.413608027871	0.413608027871	0.57651239912641	0.571651612309	5.08925895120715	178.173405264985	9.07211635798679e-07	3.73022996818183e-05	0.0997379585137084	0.226070783997113
PRKCE	BRD-K43389675-003-20-9::2.5::HTS002	2.5	daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.901487734535	-5.901487734535	-5.05579474112262	-5.07769741889	9.53808565153244	6.21857744528104	6.11201194811102e-05	0.00181387622379768	0.630573075431912	1.06081291139284
PRKCE	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.6805408443275	-0.6805408443275	-0.289427568493455	-0.269064169965	8.2667330054595	46.6837566627276	1.07423452136672e-10	7.0864761689753e-09	0.295917368976924	0.486309182691165
PRKCE	BRD-K47337578-034-02-5::2.5::HTS002	2.5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	noncancer	HTR2A	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.4295539154165	-0.4295539154165	-0.121594646462155	-0.0894405664739	6.94821017011366	14.1521710269551	6.39838394270374e-06	0.000228559872009292	0.212993622678882	0.402924915229808
PRKCE	BRD-K51350053-048-16-5::2.5::HTS002	2.5	toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	ESR1	oncology	breast cancer	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.12035743820045	-0.12035743820045	-0.507236046573266	-0.436805913717	-4.82951734671799	8.347405196712	0.00115735458617987	0.0251551212961511	-0.570276211942691	-0.203481004802941
PRKCE	BRD-K52075715-001-06-7::2.5::HTS002	2.5	oxibendazole	tubulin polymerization inhibitor	noncancer	TUBB, TUBB4B	infectious disease	strongyles	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.99560833802	-3.99560833802	-2.8604030807927	-2.67119320704	8.71073653664513	6.39459595367341	8.8759408641629e-05	0.00254301529267745	0.821027270266175	1.44938324418841
PRKCE	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.04858602973665	-0.04858602973665	-0.216341634751149	-0.1500661795165	-4.22183411404207	11.744461921035	0.00124154163130438	0.0267301231839113	-0.254540647655885	-0.0809705623731134
PRKCE	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.042609110955	-1.042609110955	-0.285021861190613	-0.3736278329815	9.78388020481535	14.7955196196793	7.52132656505396e-08	3.59589203961956e-06	0.592345560960087	0.922828938568687
PRKCE	BRD-K56751279-300-01-4::0.15625::HTS002	0.15625	Y-39983	rho associated kinase inhibitor	noncancer	ROCK1, ROCK2	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.689491078832	0.689491078832	0.781511905668299	0.797735671319	3.33245852304257	61.2016989977113	0.00146410722896384	0.0308070526483988	0.0368079109914717	0.147233742681126
PRKCE	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2562518102355	0.2562518102355	-0.139762947967614	0.01900224238145	-6.05143275278607	64.1926067221023	8.19881011407072e-08	3.89632543888839e-06	-0.526741603327196	-0.265287913079032
PRKCE	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.92233660627	-4.92233660627	-5.59203274180668	-5.54901350857	-8.0918725162743	59.9409787393787	3.43901068464457e-11	2.40169345398887e-09	-0.835247291832993	-0.504144979240375
PRKCE	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2147330368425	0.2147330368425	0.0355909161257926	0.07942712884705	-5.5826330862419	52.7628991351183	8.38038700850718e-07	3.46281080999872e-05	-0.243511618328728	-0.114772623104687
PRKCE	BRD-K59632282-052-03-1::2.5::HTS002	2.5	quinidine	sodium channel blocker	noncancer	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1008127307778	0.1008127307778	0.443750186488815	0.447983088223	10.6869253134438	6.22614432952945	3.09784852966568e-05	0.000971267960085891	0.265103597123319	0.420771314298711
PRKCE	BRD-K61734568-003-02-1::2.5::HTS002	2.5	2,3-DCPE	Bcl-XL downregulator	targeted cancer	BCL2L1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.255943483751	0.255943483751	-0.363340653563701	-0.146091240972	-7.72086643046	14.3870492516029	1.73676451749313e-06	6.82256235831718e-05	-0.790882475963148	-0.447685798666254
PRKCE	BRD-K63932022-001-01-5::2.5::HTS002	2.5	2'-MeCCPA	adenosine receptor agonist	noncancer	ADORA1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.518196078263	-0.518196078263	0.204388350537631	0.269128450915	9.52148351773626	3.58688702674626	0.0011328954665227	0.0246685311840234	0.501955790312355	0.943213067288908
PRKCE	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.393015986195	-3.393015986195	-3.86406672446326	-3.711772040445	-5.37079370113232	6.66967387924816	0.00121810812840137	0.0262942790867296	-0.680542909330427	-0.261558567206095
PRKCE	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.68956411497	-1.68956411497	-1.2094980298361	-0.979171957663	5.91038855512506	56.6159059830573	2.05693816066006e-07	9.28324908477806e-06	0.317393680905935	0.642738489361857
PRKCE	BRD-K76908866-001-07-6::2.5::HTS002	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.080280428895	-1.080280428895	-0.691588447597791	-0.619490026625	4.94902432327799	9.53458461788053	0.000667594983372016	0.0154703173522695	0.212531115521892	0.564852847072526
PRKCE	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.41246507919	-3.41246507919	-2.19334017599508	-2.035043186635	10.7535804146787	22.5144955645025	2.43516740540178e-10	1.54416270660461e-08	0.98432267269142	1.45392713369842
PRKCE	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.668708063585	-0.668708063585	-0.946117679906566	-0.8151847008705	-4.19775511553858	68.7036185328995	7.93181478159447e-05	0.00229763201827863	-0.409256191809984	-0.145563040833147
PRKCE	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.81564104315	-0.81564104315	-0.418927070650207	-0.2916892525045	5.53546555660916	5.70364877136183	0.00173077681412969	0.035538959934432	0.219116934808788	0.574311010190797
PRKCE	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0741832132122	-0.0741832132122	0.113331268608504	0.0998567885779	6.0952892983549	10.0155031152686	0.000115662937408411	0.00323206280466849	0.118982762476178	0.256046201165231
PRKCE	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.06289293279645	0.06289293279645	-0.121064585053546	-0.0479466221371	-4.88967658330871	12.8077796826569	0.00030844408100895	0.00776650745283919	-0.265358241639676	-0.102556794060316
PRKCE	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.826268762188	-0.826268762188	-2.07345414976005	-1.887176140495	-9.87633204259101	7.98916805368614	9.4032813799671e-06	0.000325594245703514	-1.53845683635091	-0.955913938793192
PRKCE	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-6.28885669665	-6.28885669665	-5.20726274379016	-5.34898111958	9.73331008095635	6.84261437288881	2.96355293557339e-05	0.000932846728048918	0.817599811201172	1.34558809451852
PRKCE	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.823471113535	-3.823471113535	-2.87362918775546	-2.82062384431	8.85045524009245	175.026838629016	9.37908031024943e-16	1.04372217228217e-13	0.73803159407283	1.16165225748625
PRKCE	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.9865112344745	-0.9865112344745	-1.60184181813524	-1.38505413113	-8.11430219884018	93.0818458695686	1.94483101959078e-12	1.57299887765238e-10	-0.765917830719449	-0.464743336602036
PRKCE	BRD-K93123848-001-04-1::2.5::HTS002	2.5	RAF265	RAF inhibitor, VEGFR inhibitor	targeted cancer	BRAF	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.4567506122685	-0.4567506122685	-1.29600751189876	-1.194488826315	-11.9179949051601	20.437198893251	1.16780769335113e-10	7.66835340405191e-09	-0.985947804396304	-0.692565994864215
PRKCE	BRD-K97440753-066-18-1::2.5::HTS002	2.5	dihydroergocristine	adrenergic receptor antagonist, prolactin inhibitor	noncancer	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.312746041712	0.312746041712	0.217210605069518	0.229709741117	-3.2672920092518	188.725068422041	0.00128995035435202	0.0276114820231612	-0.153214548491587	-0.0378563247933776
PRKCE	BRD-K98572433-001-02-9::2.5::HTS002	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	HCC38, HCC15	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.038012754275	-3.038012754275	-2.70563905299267	-2.69732165055	3.53334982038682	121.565777297362	0.000581003364142325	0.0137037383111324	0.146150849487562	0.518596553077097
PRMT3	BRD-A03932035-004-04-3::2.5::HTS002	2.5	methscopolamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.4297138220165	0.4297138220165	0.238525408736101	0.224710721764	-6.79304000283325	150.866846643714	2.37451325890478e-10	1.50703894660291e-08	-0.246797176692099	-0.135579649868699
PRMT3	BRD-A36267905-003-18-4::2.5::HTS002	2.5	buphenine	adrenergic receptor agonist	noncancer	ADRB2	rheumatology	Raynaud's disease	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.6831884945645	-0.6831884945645	-0.437528272625243	-0.382206582003	4.65804889835784	45.1777116943216	2.82641301296191e-05	0.000893484180907246	0.139450222210389	0.351870221668125
PRMT3	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.3446142593115	0.3446142593115	0.183491980052918	0.1739425463755	-5.26116204282069	23.9966700528099	2.14904869835781e-05	0.000696196279429159	-0.22432931977429	-0.097915238742875
PRMT3	BRD-A70858459-001-01-7::2.5::HTS002	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.1483436181315	-0.1483436181315	0.102817077071069	0.0978091979841	7.28117687886402	11.2006433639883	1.42967334264387e-05	0.000479081391268789	0.175404373473459	0.326917016931678
PRMT3	BRD-A74391928-051-01-3::2.5::HTS002	2.5	ibutilide	potassium channel blocker	noncancer	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.6954825717	0.6954825717	0.1606331981237	0.15975952739	-10.8739499441385	7.20895136306447	9.91456436366565e-06	0.000341856284668612	-0.650476575299995	-0.419222171852604
PRMT3	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.3945894605265	-0.3945894605265	-1.13248434703515	-1.042052398785	-9.90717860284723	5.22014182680395	0.000139952750093275	0.00383138753030293	-0.926950738733083	-0.548839034284219
PRMT3	BRD-A83937277-001-10-5::2.5::HTS002	2.5	mephenytoin	hydantoin antiepileptic	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.2463031210795	0.2463031210795	-0.0728825969142368	-0.0963568398651	-8.07002620200854	28.0411013861528	8.60356914333382e-09	4.62385749980339e-07	-0.40019897813978	-0.238172457847693
PRMT3	BRD-A93695607-322-02-5::2.4707::HTS002	2.4707	nicotine	acetylcholine receptor agonist	noncancer	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.2764964620095	0.2764964620095	0.1228967063127	0.1466714970605	-4.43993828409154	175.925199846975	1.58522475259405e-05	0.000527167782775377	-0.221874419145371	-0.0853250922482299
PRMT3	BRD-A97701745-001-16-0::2.5::HTS002	2.5	pindolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B	cardiology	hypertension	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.006312660224345	0.006312660224345	0.159089152821618	0.163040623516	4.06401349351334	113.043938025663	8.93971445141349e-05	0.00255881418089877	0.0782992513656242	0.227253733828921
PRMT3	BRD-K02407574-001-09-7::2.5::HTS002	2.5	parbendazole	tubulin polymerization inhibitor	noncancer	TUBB	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.48166740782	-4.48166740782	-3.03537110095599	-2.97464571571	15.2086980144481	147.684241276785	4.99948647980586e-32	2.3864920662145e-29	1.25837035603353	1.63422225769449
PRMT3	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.1910969954455	0.1910969954455	-0.361257862803683	-0.164030729397	-8.69172856506645	106.469045383679	4.73477628104171e-14	4.49424209716293e-12	-0.678341481843807	-0.426368234654559
PRMT3	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.9870520810475	-0.9870520810475	-1.68860770803172	-1.35955217781	-5.96791517299649	169.382691225683	1.36836596487407e-08	7.22187906637516e-07	-0.933616350379544	-0.469494903588904
PRMT3	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.267153585745	-4.267153585745	-2.47129427650848	-2.25904256326	12.7568866737172	4.90548147973681	5.98961293676524e-05	0.00177976951493686	1.4318766329396	2.15984198553344
PRMT3	BRD-K06749501-001-02-1::2.5::HTS002	2.5	GSK1838705A	insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R, INSR, RPS6KA1	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.667282849253	0.667282849253	-0.24363439758104	-0.164638438825	-13.0284805762464	5.8735360509341	1.48220939421575e-05	0.000495446751797985	-1.08289580637949	-0.738938687288586
PRMT3	BRD-K09602097-001-13-6::2.5::HTS002	2.5	forskolin	adenylyl cyclase activator	targeted cancer	ADCY2, ADCY5, GNAS	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.0943406690114	-0.0943406690114	0.0436364108372908	0.0420503630099	4.20328256315648	156.66567567264	4.40682536136499e-05	0.0013439249756346	0.0731383863035645	0.202815773393817
PRMT3	BRD-K11630072-001-13-2::0.625::HTS002	0.625	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.469709427988	-0.469709427988	-0.27047998474168	-0.1902642862985	3.71130396560636	31.8603437726033	0.000785845422365582	0.0179142164997014	0.089864412540354	0.308594473952287
PRMT3	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-2.88516351548	-2.88516351548	-2.41087824515173	-2.32376274045	5.60713473033386	10.4795823123552	0.000189734758536954	0.0050442896574069	0.286978441965674	0.661592098690873
PRMT3	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.6183470924615	0.6183470924615	0.398321722003938	0.431459247123	-7.24333682600678	182.136914818901	1.19370673770346e-11	8.86200108712313e-10	-0.279959953268257	-0.160090787646867
PRMT3	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.06727671811415	0.06727671811415	-1.11463925998932	-0.898661589303	-11.7974013220573	181.025960162338	3.40013931229098e-24	8.11523896062377e-22	-1.37959540943634	-0.984236546770601
PRMT3	BRD-K16551357-001-03-2::2.5::HTS002	2.5	evacetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.0961672534472	-0.0961672534472	0.0615402166703085	0.05179178276535	4.93913648619004	166.353579877318	1.89716680743285e-06	7.41191878728172e-05	0.0946668739703634	0.220748066264654
PRMT3	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.62894381469	-4.62894381469	-2.84165518995972	-2.57172187262	11.9089926067093	10.9639731945603	1.29903190887775e-07	6.03948394789281e-06	1.45683469664628	2.11774255281429
PRMT3	BRD-K18961567-001-01-1::2.5::MTS010::PROS002_PR500	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.771529434803	-0.771529434803	-0.40939008521526	-0.3114029090515	5.15908056236715	10.4913154948834	0.000365197363207317	0.00906454958411824	0.206723300048279	0.517555399127201
PRMT3	BRD-K19761926-001-03-6::2.44857::HTS002	2.44857	eplerenone	cytochrome P450 inhibitor	noncancer	NR3C2	cardiology	congestive heart failure, hypertension	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.334796966629	-0.334796966629	-0.874009982233766	-0.799528598077	-7.19011470906433	180.655384585942	1.65463197521201e-11	1.20501398781928e-09	-0.687189183162832	-0.391236848046699
PRMT3	BRD-K21283037-001-21-5::2.5::HTS002	2.5	riluzole	glutamate inhibitor	noncancer	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.522196301156	0.522196301156	0.0395457110111599	0.0176424857247	-15.5556610873061	31.1393526501473	3.11585042869387e-16	3.65126903516418e-14	-0.545919765744534	-0.419381414545146
PRMT3	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.37681051562	-1.37681051562	-0.965394277152353	-0.757900155601	3.75304915851801	19.5990498275159	0.0012885387717303	0.0275867771857141	0.182448776386441	0.640383700548853
PRMT3	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.520669040485	-1.520669040485	-0.489713110754672	-0.427199621459	19.9584871261629	19.9432593166598	1.19388615239645e-14	1.19740021131015e-12	0.923185802686559	1.1387260567741
PRMT3	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.5053114724405	0.5053114724405	0.144900940638555	0.195908235522	-6.99924107796925	6.99881433716192	0.000211863319013979	0.00556245792577758	-0.482175840799113	-0.238645222804778
PRMT3	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.617049487737	-0.617049487737	-1.34882600314622	-1.37381285511	-9.1785189323271	9.77893812938844	4.06695674077865e-06	0.000150703107070254	-0.909965361381366	-0.553587669437077
PRMT3	BRD-K31627533-001-09-5::2.5::HTS002	2.5	rimexolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	ophthalmology	anterior uveitis	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.254891417399	-0.254891417399	0.266476105520255	0.264424524013	13.2006810845455	5.79336353092482	1.52717807579862e-05	0.000509683198081348	0.423883765980664	0.618851279857846
PRMT3	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.811592479954	-0.811592479954	-0.504907611446102	-0.3949049279025	5.31194279252747	11.6331114654211	0.000205146315786907	0.00540356454667469	0.180449746368895	0.432919990646902
PRMT3	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.435266858473	0.435266858473	-0.0788991758306248	-0.0620606581655	-11.1371474677017	3.21963194017434	0.00111573429249477	0.0243367529831239	-0.655578859743076	-0.372753208864174
PRMT3	BRD-K37237504-001-02-7::2.5::HTS002	2.5	CEP-33779	JAK inhibitor	targeted cancer	JAK2	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.03851293747385	-0.03851293747385	0.192337515403505	0.159444358103	6.06931522574053	30.3458393874304	1.09723666824505e-06	4.4505987484537e-05	0.153208363802628	0.308492541952082
PRMT3	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.05657773118	-4.05657773118	-2.57069181537171	-2.46753908401	11.0264465775392	4.49572888735554	0.000200662993259874	0.00529719161009922	1.12746378026818	1.84430805134841
PRMT3	BRD-K37590257-001-02-8::2.5::HTS002	2.5	GSK256066	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.2506231442495	0.2506231442495	-0.0878690265534432	-0.0822950455219	-5.0183515456134	47.2710402868452	7.81312609810934e-06	0.000274611266559803	-0.47416528093282	-0.202819060673066
PRMT3	BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500	0.625	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.353620162985	-1.353620162985	-1.72555043978046	-1.77978641517	-3.67663884634097	14.678731679056	0.00231776769070004	0.0455079545053178	-0.587960330871255	-0.15590022271967
PRMT3	BRD-K38904395-001-02-3::2.5::HTS002	2.5	SAR131675	VEGFR inhibitor	targeted cancer	FLT4	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.2019639260005	0.2019639260005	-0.540916525480159	-0.521573448397	-14.7007772376051	29.8402763009962	3.30778101403463e-15	3.49238126579816e-13	-0.846106618904329	-0.639654284056989
PRMT3	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.33530915893	-1.33530915893	-1.01090813824141	-1.02230629729	4.42289576597013	15.2820610027606	0.000473210842818474	0.0114124909114933	0.168318994142194	0.480483047234995
PRMT3	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.03677149768565	0.03677149768565	-0.297190154190736	-0.160539632789	-5.56673723787451	82.160720614831	3.17752710399993e-07	1.39499427831463e-05	-0.453302052959763	-0.214621250793009
PRMT3	BRD-K42898655-001-01-8::2.5::HTS002	2.5	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.910697449895	-1.910697449895	-1.3391369715971	-1.3029360022	11.4696560721622	191.139642685492	1.64472701858237e-23	3.69262743412286e-21	0.473268423172975	0.669852533422834
PRMT3	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-3.908245667045	-3.908245667045	-2.22216965497996	-2.12735654465	25.0278521269512	27.5663998742934	1.70711710555193e-20	2.95544993631535e-18	1.54798109169273	1.82417093243734
PRMT3	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.02897703193293	0.02897703193293	-0.366128050312475	-0.243490121847	-5.87421249614271	38.4213679486936	8.15344018221141e-07	3.37489123370643e-05	-0.531218723925805	-0.258991440565006
PRMT3	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.0549498718897	-0.0549498718897	-0.459259665131389	-0.3435721987365	-6.31217901140888	7.12151736373724	0.000372373635801529	0.00922664381360763	-0.555247156934575	-0.253372429548803
PRMT3	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-6.746525400895	-6.746525400895	-5.91464724671654	-5.9507974936	11.5759365096231	49.7633752066019	1.00017532323816e-15	1.10898384301248e-13	0.687520648388386	0.976235659968524
PRMT3	BRD-K53734668-003-02-0::2.65747::HTS002	2.65747	PRT062607	syk inhibitor	targeted cancer	FGR, MAP3K9, SYK	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.0873805041657	0.0873805041657	-0.0657928183693716	-0.0530930824029	-3.61463527519794	192.341002650705	0.00038403608753948	0.00946516077436488	-0.236754404381949	-0.0695922406881943
PRMT3	BRD-K56334280-001-05-1::2.5::HTS002	2.5	amonafide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.65954273705	-1.65954273705	-0.391865292248979	-0.351314644036	13.4807995566149	3.29623178712695	0.000536981927856761	0.0127623419400767	0.98306795214427	1.55228693745777
PRMT3	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.011610737947245	-0.011610737947245	-0.207529253577535	-0.0810605722641	-3.99384961419186	149.231288377942	0.000101727745355389	0.00287907116522846	-0.292850722329832	-0.0989863089307485
PRMT3	BRD-K60230970-001-17-5::2.40205::HTS002	2.40205	MG-132	proteasome inhibitor	targeted cancer	PSMB1	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-5.76654015855	-5.76654015855	-6.16658923458532	-6.116258820345	-5.00312126832208	14.5603745182289	0.00017199058231183	0.00462690718166337	-0.570928853640917	-0.229169298429729
PRMT3	BRD-K60369935-001-18-3::2.5::HTS002	2.5	ribavirin	antiviral	noncancer	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.0957725018583	0.0957725018583	0.375136342336826	0.419717410769	9.46993348085779	116.2172956638	4.08540039463039e-16	4.74076762956544e-14	0.220936356894895	0.337791324062157
PRMT3	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-5.46932965149	-5.46932965149	-3.9757168324175	-4.06345371982	14.3313574001833	188.342322505247	5.55585519537947e-32	2.62286539244601e-29	1.28802450592078	1.69920113222422
PRMT3	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.015273370875	-4.015273370875	-2.46950648873373	-2.38802069166	13.6267858277147	4.81419079250136	4.97911446304675e-05	0.00150178528532275	1.2507527548111	1.84078100947143
PRMT3	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.434864181405	-4.434864181405	-2.92469302873671	-2.87845710522	14.8842659539153	9.96905463018667	3.90147819731468e-08	1.93073174913936e-06	1.28400700216457	1.73633530317201
PRMT3	BRD-K67578145-001-09-7::2.38272::HTS002	2.38272	GDC-0879	RAF inhibitor	targeted cancer	BRAF	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	1.239447906395	1.239447906395	0.577713147042423	0.659791110046	-13.165976585517	102.834414052159	8.57038052548048e-24	1.97301942819088e-21	-0.761417447472107	-0.562052071233048
PRMT3	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-3.037270766455	-3.037270766455	-3.86801944912704	-3.711772040445	-9.81551203915866	8.32830749104598	7.33717603667085e-06	0.000258859193870556	-1.02458922102399	-0.636908144320092
PRMT3	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.03864255018595	0.03864255018595	0.12591604587912	0.138278646354	3.13703543150066	119.753577254539	0.00214822875011141	0.0426479918286984	0.0321899389494337	0.142357052436906
PRMT3	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.602850953889	0.602850953889	0.237456448893658	0.2560401890915	-10.0843014565609	163.25172137903	6.80648481788147e-19	1.01307436425814e-16	-0.436942213943232	-0.293846796047453
PRMT3	BRD-K73589491-001-11-2::2.5::HTS002	2.5	nizatidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.261945061629	0.261945061629	0.0939844349615762	0.09689104741345	-7.07566723602477	191.035761706481	2.74544765702028e-11	1.94715106181833e-09	-0.214782438011772	-0.121138815323076
PRMT3	BRD-K76703230-004-04-1::2.5::HTS002	2.5	YM-155	survivin inhibitor	targeted cancer	BIRC5	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.25782991973	-4.25782991973	-5.50115996599783	-5.55235554655	-13.159643378495	19.6786019382736	3.29213104495551e-11	2.3096535343184e-09	-1.44061952694121	-1.04604056559446
PRMT3	BRD-K76973696-001-12-6::2.01421::HTS002	2.01421	tryptanthrin	cyclooxygenase inhibitor	targeted cancer	IDO1	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.16695894747	-1.16695894747	-1.38877433751385	-1.35544849592	-4.46044143197519	21.7547758394255	0.000200569605633857	0.00529603092348144	-0.325015443766133	-0.118615336321569
PRMT3	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.1095156822753	-0.1095156822753	-1.11998622654675	-1.11451105929	-13.1002126668342	2.64386415734283	0.00176993861567359	0.0361594865655042	-1.27575401514949	-0.7451870733934
PRMT3	BRD-K79930101-300-03-7::2.5::HTS002	2.5	GW-583340	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.739251643776	-0.739251643776	-0.525318732975761	-0.359521455226	3.20003255977708	144.715502750624	0.00168892116528951	0.0347961919095776	0.0817977733354539	0.346068048265024
PRMT3	BRD-K81916719-001-13-9::2.5::HTS002	2.5	triclabendazole	microtubule inhibitor	noncancer	DNMT1	infectious disease	tapeworm	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-3.262069199325	-3.262069199325	-2.32259090809592	-2.31061831786	8.37104083822641	3.55328962161202	0.00183858217415073	0.0373249127888064	0.611804800542025	1.26715178191614
PRMT3	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.794473351011	0.794473351011	0.181640802900678	0.18484230673	-15.9864965907601	24.1243370632676	2.43993804517784e-14	2.38898803693431e-12	-0.691929260931429	-0.533735835289215
PRMT3	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.90550164325	-4.90550164325	-4.37038701300164	-4.35832408201	6.20859331556689	192.229121168936	3.22731056612561e-09	1.82027959559772e-07	0.365116341318096	0.705112919178623
PRMT3	BRD-K84868168-001-01-0::2.5::MTS006	2.5	erdafitinib	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.122466136415	-0.122466136415	0.0911015086567294	0.154218588669	5.20744965698222	49.221555386946	3.74573130577493e-06	0.000139547861122099	0.131160436109557	0.295974854033901
PRMT3	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.25839652455	-1.25839652455	-1.70463726032767	-1.55120007366	-6.20182919959975	37.8497173882691	3.05790449340905e-07	1.34550936597797e-05	-0.591921133747229	-0.300560337808115
PRMT3	BRD-K86816506-001-01-8::2.5::HTS002	2.5	PF-04457845	FAAH inhibitor	noncancer	FAAH	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.1400092902075	-0.1400092902075	-0.409870381524023	-0.370640421909	-7.08050505964583	5.66054169882851	0.000513924548484554	0.0122838111466651	-0.364493479363298	-0.175228703269748
PRMT3	BRD-K88568253-011-19-9::2.5::HTS002	2.5	iproniazid	monoamine oxidase inhibitor	noncancer	MAOA, MAOB	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.175721445175	0.175721445175	0.476769792823886	0.497154810155	7.52079866653117	5.70053153510621	0.000363798011126523	0.00903190825051969	0.201840562091397	0.400256133206376
PRMT3	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.40083461512	-4.40083461512	-2.89480748610063	-2.82333441128	12.5653773832903	3.84047528924852	0.000292385909648533	0.00740304543757359	1.16773257028741	1.84432168775132
PRMT3	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.726489777385	-4.726489777385	-3.09049300359388	-2.979502562735	15.13337678369	172.541775765399	1.79415049459701e-33	9.78469418209882e-31	1.42261783065397	1.84937571692827
PRMT3	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-2.25241494854	-2.25241494854	-0.272033072712492	-0.212124322286	24.0166257579638	10.0467380680231	3.30741568457491e-10	2.07212831411651e-08	1.79676803477104	2.16399571688398
PRMT3	BRD-K97440753-066-18-1::2.5::HTS002	2.5	dihydroergocristine	adrenergic receptor antagonist, prolactin inhibitor	noncancer	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.33441672308	0.33441672308	0.216981285689962	0.229709741117	-3.72659299205417	39.5754794686685	0.000605876863538069	0.0141935711318451	-0.181146501767859	-0.053724373012217
PRMT3	BRD-K99383816-001-03-5::2.5::HTS002	2.5	ftorafur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.6861684770405	0.6861684770405	0.0214265087499656	0.0625789324056	-16.1146775359183	4.66859707117122	2.85068751080236e-05	0.000900366357390529	-0.77308481232994	-0.556399124251129
PRMT3	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	HCT15, NCIH1048	LARGE_INTESTINE, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.716571590239	-0.716571590239	-0.86202111497346	-0.791872957089	-3.22763437810538	150.307095298915	0.0015324351538158	0.0320163058045084	-0.234489881440861	-0.0564091680280596
PTK2	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.2265798440373	0.096867868022	-0.787325637941135	-0.496854009417	-6.1073322539289	4.96918626722519	0.00174265163665	0.0357250171014386	-1.44145641554288	-0.586354548413992
PTK2	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.428437004437333	0.400008618101	-0.371775097822463	-0.275672246386	-8.71278575974143	6.28782661831363	9.74386835354774e-05	0.00276829904116377	-1.02247462766378	-0.577949576855813
PTK2	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.529915667309667	0.558337956834	0.0510013037431965	0.0482732137466	-6.92583431379865	6.16618765263081	0.000398362862810462	0.00977007827249153	-0.647016530549292	-0.310812196583649
PTK2	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.0072489617583	-0.0318984907448	-0.361262198403616	-0.172198955209	-4.5123153583722	10.6453693582915	0.000958587885336625	0.0213214178991608	-0.548994201977984	-0.188028118345849
PTK2	BRD-K07972848-001-02-0::2.5::HTS002	2.5	GSK2126458	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-2.53696553393333	-2.54890167259	-3.88973579551958	-3.83029987907	-8.01531154521165	3.70199396234181	0.00180885509452133	0.0368386643437536	-1.83661788207616	-0.868922641096324
PTK2	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-1.08269257009533	-0.977001053016	-2.21542024788598	-2.17094660797	-8.51146056062424	4.18450318738543	0.000854303279081337	0.0192762769076621	-1.49588699113293	-0.769568364448366
PTK2	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	U2OS, OVCAR8	BONE, OVARY	osteosarcoma, carcinoma	-0.179242080601	-0.179242080601	-0.475854638382786	-0.33490377325	-4.23550461071434	74.9521841951632	6.40657133067705e-05	0.00189212350383448	-0.436121010309288	-0.157104105254284
PTK2	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-1.99138485781333	-2.03278257685	-1.32357876763314	-1.325892128275	7.25537450008263	7.76802207852253	0.000101515737341824	0.00287420957314871	0.454446280911743	0.881165899448647
PTK2	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-1.06797717552333	-1.05370665228	-1.2981939665378	-1.2620418644	-3.99163167741293	37.4814236138586	0.000294252652228853	0.0074432758998652	-0.347026509430837	-0.113407072598106
PTK2	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-5.08525588362333	-5.13644049648	-4.16287003908377	-4.12140382517	8.01453208099862	11.5739303385622	4.65287079238478e-06	0.000170848919660962	0.670600432211689	1.17417125686743
PTK2	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-0.728991249784	-0.682840090798	-1.34521363980142	-1.28392139415	-6.07378144063605	4.57355893756012	0.00237845149471868	0.0465034784174019	-0.884510290904394	-0.347934489130441
PTK2	BRD-K37764012-001-04-1::2.5::HTS002	2.5	PF-03758309	p21 activated kinase inhibitor	targeted cancer	PAK4	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-4.03632989718667	-3.99895986141	-3.18482170497265	-3.07856626361	6.05086222679037	6.74095317072311	0.000595732396858436	0.0140018345088575	0.516136287527414	1.18688009690062
PTK2	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-2.38198850588333	-2.35052389373	-1.92938436213713	-1.730078887575	4.0793044064389	13.3465028699972	0.00123696060794712	0.0266421997930559	0.213539476688193	0.691668810804217
PTK2	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.325904548092	0.328620532283	-0.303580371228478	-0.166636475312	-9.83974628378517	44.1035388993179	1.06948423144875e-12	8.88799867554006e-11	-0.75840687963705	-0.500562959003906
PTK2	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.1557095533416	0.179834553957	-0.301391624522683	-0.30210527459	-6.7948665795404	6.16710632264081	0.000442500295977558	0.0107492514945681	-0.620633560675342	-0.293568795053224
PTK2	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.338371743438	0.334325348577	-0.373242508467102	-0.243541333758	-10.2028459060606	40.3113377926906	9.86474199595674e-13	8.22684936673701e-11	-0.852543570088117	-0.570684933722088
PTK2	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.0129109526792333	0.0194818019197	-0.961200646110918	-0.5989281937055	-11.4991713802937	187.607994098378	1.66277575642509e-23	3.72394007417799e-21	-1.14122099798268	-0.807002199597627
PTK2	BRD-K50168500-001-07-9::2.5::HTS002	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-0.109478843141767	-0.146017149852	-0.476550599320705	-0.364597721894	-5.23361705120861	12.3273957232126	0.000192173652266031	0.00510136075260418	-0.519438880574129	-0.214704631783748
PTK2	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.143476266233	0.163056092489	-0.0821306430748235	0.0393108833872	-4.29384820073785	17.1601791996798	0.000482002072615751	0.0115958044922731	-0.336381841182542	-0.114831977433105
PTK2	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	-5.87390278320333	-5.73883665945	-4.33306262673815	-4.05728995078	7.62620949584413	4.46088426603464	0.00101184391869643	0.0223527977161975	1.00200669231128	2.0796736206191
PTK2	BRD-K78789465-001-01-6::2.5::HTS002	2.5	pentagastrin	CCK receptor agonist	noncancer	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	U2OS, OVCAR8	BONE, OVARY	osteosarcoma, carcinoma	0.5430672037465	0.5430672037465	0.14126249857165	0.1708900100665	-6.88172595573164	11.6208657676944	2.0002036446818e-05	0.000651720351111287	-0.529481332382701	-0.274128077966999
PTK2	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.211203501852	0.20464446761	-0.107848038244716	-0.0774945721544	-8.17007630306717	12.5738539680954	2.22049790731853e-06	8.60298438137514e-05	-0.403708171918749	-0.234394908274684
PTK2	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.415282135458333	0.425895036641	0.0883000508436761	0.0957687092427	-11.6421130974211	33.0385357591717	3.10139641606636e-13	2.70982141238926e-11	-0.38412124582549	-0.269842923403824
PTK2	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.290814873954333	0.289143179141	0.0203755480045538	0.0369083290512	-10.4368156720713	20.4321432591525	1.22242653984948e-09	7.21171092373793e-08	-0.324417728439213	-0.216460923460346
PTK2	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	U2OS, OVCAR8, SW480	BONE, OVARY, LARGE_INTESTINE	osteosarcoma, carcinoma, carcinoma (adenocarcinoma)	0.421853625289333	0.440908415999	0.244271966018436	0.245761732854	-4.87147071279047	13.9472247829848	0.000249790488188688	0.00644484718225513	-0.255794185605399	-0.0993691329363958
PTPRG	BRD-A23067620-300-01-3::2.5::HTS002	2.5	itraconazole	cytochrome P450 inhibitor	noncancer	CYP51A1	infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis	PANC0327, MCF7, OVCAR8	PANCREAS, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.045497503056	0.0181962046412	0.441680500550751	0.448164937642	9.7178969798348	6.57217855778418	3.87538235926613e-05	0.00119460207921638	0.298494240627882	0.49387175436162
PTPRG	BRD-A58193911-003-18-7::2.5::HTS002	2.5	oxyphencyclimine	cholinergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	PANC0327, OVCAR8	PANCREAS, OVARY	carcinoma (ductal_carcinoma), carcinoma	-3.96613312929	-3.96613312929	-2.28391031918052	-2.128802868855	13.2546920798717	16.6708195860506	2.80852232038628e-10	1.77408718068397e-08	1.41405166376524	1.95039395645373
PTPRG	BRD-A73556557-001-06-4::2.5::HTS002	2.5	tagatose	phosphorylase inhibitor	noncancer	PYGL	NA	NA	PANC0327, PC14, MCF7, OVCAR8	PANCREAS, LUNG, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	-0.0406657616936	-0.0454284381483	0.118122877068038	0.150414983947	3.99156867837235	13.4293172881354	0.00144549608382121	0.0304543133932287	0.0731254408239196	0.244451836699357
PTPRG	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	PANC0327, PC14, MCF7, OVCAR8	PANCREAS, LUNG, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	-1.598412408205	-1.54109383266	-0.823880731404826	-0.7702773872585	6.36734718953356	4.98767778993874	0.001425755035169	0.030103502209904	0.461610552966473	1.08745280063388
PTPRG	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	PANC0327, PC14, MCF7, OVCAR8	PANCREAS, LUNG, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	-3.2629931022825	-3.191524716235	-1.90338790009828	-2.01384678676	8.49968499032073	5.05676466269315	0.000350530583663031	0.00872982447895813	0.949800721091216	1.76940968327723
PTPRG	BRD-K16180792-001-01-7::2.5::MTS006	2.5	bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	noncancer	PTPN1	NA	NA	PANC0327, PC14, MCF7, OVCAR8	PANCREAS, LUNG, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	0.185429585216	0.169056142546	-0.242702496615604	-0.0974239564619	-6.63903345557144	41.8255877813065	4.87520494132118e-08	2.38234792491662e-06	-0.558288418543679	-0.297975745119529
PTPRG	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	PANC0327, PC14, MCF7, OVCAR8	PANCREAS, LUNG, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	-2.53696786212	-2.5312469913	-1.31409907316458	-1.35467804181	8.94177101946052	5.0455886818076	0.000278179385274515	0.00707090956671034	0.87227150299076	1.57346607492008
PTPRG	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	PANC0327, MCF7	PANCREAS, BREAST	carcinoma (ductal_carcinoma), carcinoma	-1.21318442674	-1.21318442674	-2.2344442955996	-2.28506663454	-7.98894711841272	10.8132515740179	7.36543078365789e-06	0.000259770514140301	-1.30321481641743	-0.739304921301783
PTPRG	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	PANC0327, MCF7, OVCAR8	PANCREAS, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.695843555313	0.685981507935	0.363173597221489	0.3934453202675	-7.56180481108241	117.643368164749	9.5915334837638e-12	7.20807777013188e-10	-0.419791722179077	-0.245548194003945
PTPRG	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	PANC0327, MCF7, OVCAR8	PANCREAS, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma	-1.68862060369667	-1.69630713217	-2.24904965053661	-2.14204820147	-8.49726097662772	102.175373121149	1.66754913300395e-13	1.49729425273399e-11	-0.691245960658091	-0.4296121330218
PTPRG	BRD-K62196610-001-01-6::2.5::HTS002	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	PANC0327, PC14, MCF7, OVCAR8	PANCREAS, LUNG, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), carcinoma	-1.4202853368975	-1.43007289047	-1.67737145143306	-1.62481444709	-3.30138841425978	40.7115417635042	0.00200827000379281	0.0402421934969063	-0.414385898489692	-0.0997863305814324
PTPRG	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	PANC0327, MCF7, OVCAR8	PANCREAS, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.604371366414	0.589225501391	0.337277363126008	0.352693543168	-5.74012966905798	6.02262841810284	0.00119947906159253	0.0259417908972821	-0.380847654636371	-0.153340351939612
PTPRG	BRD-K93869735-001-01-1::2.5::HTS002	2.5	taltirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	neurology/psychiatry	spinocerebellar ataxia	PANC0327, MCF7, OVCAR8	PANCREAS, BREAST, OVARY	carcinoma (ductal_carcinoma), carcinoma	0.207114735774667	0.179423712646	-0.187339367021498	-0.118631164529	-6.02411605210178	7.00145511850237	0.000528969918648777	0.0125914697572272	-0.549281206696992	-0.239626998895337
PUM2	BRD-A03623303-045-09-5::2.5::HTS002	2.5	metoprolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.370396988684	-0.370396988684	0.24572691081376	0.21036832824	21.644696599747	164.120256096311	5.92565100185003e-50	1.45981477422473e-46	0.559918384620055	0.672329414375465
PUM2	BRD-A23067620-300-01-3::2.5::HTS002	2.5	itraconazole	cytochrome P450 inhibitor	noncancer	CYP51A1	infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.5744801524945	0.5744801524945	0.43302485592949	0.442558304417	-4.35606540262621	11.9584217153411	0.000942320383074625	0.0210053650945399	-0.212235571549871	-0.0706750215801485
PUM2	BRD-A23072235-050-18-5::2.5::HTS002	2.5	pheniramine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-4.347149847925	-4.347149847925	-1.68178376106618	-1.46192148427	22.8462475469994	4.87792825542317	3.78156208154798e-06	0.000140711531141683	2.36319672067347	2.96753545304417
PUM2	BRD-A35588707-001-05-5::2.5::HTS002	2.5	teniposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-4.26845895601	-4.26845895601	-3.80150473770481	-3.74224322709	3.98108545087353	12.2684170410238	0.00174763103166738	0.035792452115264	0.212013061698554	0.72189537491183
PUM2	BRD-A50311610-300-10-4::2.5::HTS002	2.5	meclizine	constitutive androstane receptor (CAR) agonist	noncancer	HRH1, NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.11764666184885	-0.11764666184885	0.115604101180875	0.122019939205	4.90781638363585	18.1900535540122	0.0001101408476687	0.00309388961205567	0.133476263546688	0.333025262512761
PUM2	BRD-A68631409-001-05-4::2.5::HTS002	2.5	evodiamine	ATPase inhibitor, TRPV agonist	targeted cancer	TRPV1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-4.497272223705	-4.497272223705	-2.35472495671164	-2.292575025235	22.8141513006478	50.8374897241121	2.28420671600375e-28	8.07874160452754e-26	1.95399425278388	2.33110028120283
PUM2	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-4.77254788722	-4.77254788722	-3.70584116220792	-3.617290410825	9.45004813892616	37.0859640205519	2.0472411889036e-11	1.47193276342341e-09	0.838011167295989	1.29540228272817
PUM2	BRD-K00317371-001-06-1::2.40436::HTS002	2.40436	RITA	MDM inhibitor	targeted cancer	MDM2	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.13174159430125	0.13174159430125	-2.21408607829767	-1.66399627555	-16.3098121612519	43.601890104008	3.56202754188917e-20	6.01138426004382e-18	-2.63577120457352	-2.05588414062431
PUM2	BRD-K00494077-066-01-9::2.5::HTS002	2.5	trovafloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.657953594711	0.657953594711	-0.533438664828818	-0.32459433605	-17.109213371626	175.382085597963	3.10348515843978e-39	3.06528511761861e-36	-1.32882177736073	-1.0539627417189
PUM2	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.3823006045	0.3823006045	0.063714145122695	0.06410268662525	-10.736824822588	37.7554220155447	4.94884659792504e-13	4.23425685623423e-11	-0.378667703983539	-0.25850521477107
PUM2	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.07430494869205	-0.07430494869205	0.159871018602446	0.166606190016	9.39554331659593	191.222503090039	1.75990774787722e-17	2.30561899568934e-15	0.185014385884072	0.28333754870492
PUM2	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-3.11896863265	-3.11896863265	-2.01505722858398	-1.91516760225	12.5815980788419	101.907354298297	1.81289562127785e-22	3.7469248371539e-20	0.929877317526666	1.27794549060538
PUM2	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.8389583632015	0.8389583632015	0.0502688246473166	0.0542001317345	-14.2110021125515	8.43614745886928	3.47579311806413e-07	1.51446079122091e-05	-0.915526746157339	-0.661852330951029
PUM2	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-2.194597439605	-2.194597439605	-1.48368725350405	-1.38645123972	10.0770884678919	83.4780834379616	4.35052724773821e-16	5.026653123884e-14	0.570606563397597	0.851213808804296
PUM2	BRD-K10670311-001-15-5::0.625::HTS002	0.625	sulfasalazine	cyclooxygenase inhibitor	noncancer	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.4447586864585	0.4447586864585	0.275454992720176	0.3245071237905	-4.57052323334692	56.0494988852354	2.72321651114567e-05	0.000863919881020338	-0.243507330031509	-0.0951000574451391
PUM2	BRD-K13050303-001-17-3::2.5::HTS002	2.5	uridine	dopamine receptor agonist	noncancer	LSM6, TYMP	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.312134595544	-0.312134595544	0.0690388172397549	0.0709396058819	12.4995993833364	23.3214025566876	8.02356179778892e-12	6.07661475815654e-10	0.318138079930159	0.44420874563735
PUM2	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.3729347947175	0.3729347947175	-0.427873679903087	-0.390164965854	-15.624870060616	2.97460096383615	0.000597161415856734	0.0140324052377812	-0.964706474389399	-0.636910474851775
PUM2	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-2.96534961442	-2.96534961442	-2.05676470854397	-2.351388502545	7.48136971537379	6.55397068987138	0.000192961143312709	0.00511846149567692	0.617400211664678	1.19976960008737
PUM2	BRD-K13533483-001-16-2::2.5::MTS005	2.5	cyclosporine	calcineurin inhibitor	noncancer	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	transplant, rheumatology, dermatology	organ rejection, rheumatoid arthritis, psoriasis	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.6516543293925	0.6516543293925	0.219352959604137	0.221127225806	-11.6705221135408	2.76576184361424	0.00196175289641139	0.039446527491787	-0.556040457881953	-0.308562281694773
PUM2	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-5.624767817495	-5.624767817495	-3.49477294541608	-3.32713088666	11.8713327242504	3.53740860373875	0.000563879078156038	0.0133335877032332	1.60506138956794	2.6549283545899
PUM2	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.475680443294	0.475680443294	-0.0604704792046182	-0.0387919597267	-11.8184618611877	186.816421636717	1.99261956511698e-24	4.85817910490029e-22	-0.625645506923284	-0.446656338073953
PUM2	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.180320382639	0.180320382639	-0.191214964754878	-0.123671466435	-8.66351388294349	47.1482110231924	2.58571274617282e-11	1.83934028268992e-09	-0.457801809661256	-0.285268885126501
PUM2	BRD-K16803204-001-01-6::2.5::HTS002	2.5	filgotinib	JAK inhibitor	noncancer	JAK1, JAK2, JAK3, TYK2	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.1646692506145	-0.1646692506145	0.248078365002497	0.2325578097185	12.1334096750802	11.8317557789309	4.94930218154278e-08	2.41800544168653e-06	0.338512906836227	0.486982324397767
PUM2	BRD-K17555800-003-01-5::2.5::HTS002	2.5	talmapimod	p38 MAPK inhibitor	targeted cancer	MAPK11, MAPK14	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.7118230346265	0.7118230346265	0.409087590266928	0.416811773993	-8.95627520673791	5.06331186658476	0.00027105320584676	0.00691931426345048	-0.389299169104676	-0.216171719614469
PUM2	BRD-K17979676-001-01-2::2.5::HTS002	2.5	eprobemide	monoamine oxidase inhibitor	noncancer	MAOA	neurology/psychiatry	depression	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.887054620086	-0.887054620086	-0.0349161813717453	-0.00773751956823	15.0135566874827	9.30848405198219	7.7516629475941e-08	3.69941253149609e-06	0.724388775627543	0.979888101800967
PUM2	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-6.08107752944	-6.08107752944	-3.05789793928076	-2.85883819524	29.7974379242163	165.582963946878	1.97989787876023e-68	2.49617372033412e-64	2.82286208310008	3.22349709721841
PUM2	BRD-K21283037-001-21-5::2.5::HTS002	2.5	riluzole	glutamate inhibitor	noncancer	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.110768206937	-0.110768206937	0.0470810027741718	0.027710059388	5.52438903914408	167.016278048353	1.24688037984452e-07	5.80358070316686e-06	0.101438104983807	0.214260314438537
PUM2	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.181465502623	0.181465502623	0.3005819731685	0.3347260991415	4.9401185668259	172.970292810299	1.83119676021108e-06	7.16332488445485e-05	0.0715247059848982	0.166708235106102
PUM2	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-3.35835411557	-3.35835411557	-1.88734017785394	-1.63390971887	15.0287013860683	51.961961830811	1.47503722215459e-20	2.57445645592158e-18	1.27459930566397	1.66742856976814
PUM2	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.1532681524545	0.1532681524545	-0.0348851238545195	-0.0304287468122	-7.41767187447039	49.3517703202068	1.43897873828896e-09	8.41743651743272e-08	-0.239118055075338	-0.137188497542701
PUM2	BRD-K26838195-075-04-9::2.5::HTS002	2.5	AST-1306	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.9411969398295	-0.9411969398295	-0.64946763606428	-0.552150781562	3.99396484361451	90.6521314356954	0.000131922034179207	0.0036380233741116	0.146631786189154	0.436826821341287
PUM2	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-2.924685296975	-2.924685296975	-2.57213014286623	-2.525806741025	3.95420757037648	195.487635541543	0.000107298158843581	0.00301918171022527	0.176717173728603	0.528393134488945
PUM2	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.412194443299	0.412194443299	0.161003862644409	0.154760250633	-8.16250792280786	5.66630571473421	0.000243411512065559	0.00630226455297164	-0.327579231321823	-0.17480192998736
PUM2	BRD-K35629949-001-02-0::2.5::HTS002	2.5	SR-27897	CCK receptor antagonist	targeted cancer	CCKAR	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	1.152337132685	1.152337132685	0.754854158265094	0.759014306598	-12.4643732342312	52.7377112722892	2.3983290238626e-17	3.10031038211971e-15	-0.461452693541778	-0.333513255298033
PUM2	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-1.314203878465	-1.314203878465	-1.02534667660647	-1.006604825335	4.02820443765011	171.182734207201	8.43639288289861e-05	0.00243065418765799	0.147310090786737	0.430404312930326
PUM2	BRD-K36529613-001-02-6::2.5::HTS002	2.5	PU-H71	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-6.235834316145	-6.235834316145	-3.45061545355973	-3.273820150365	20.7960642903584	4.49805987394198	1.21126881833474e-05	0.00041077537114694	2.4290580203744	3.14137970479613
PUM2	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-4.82489050627	-4.82489050627	-2.56229495444176	-2.46753908401	15.9753803420949	3.5604444525252	0.000192421676355623	0.00510731213270889	1.84946133603156	2.67572976762492
PUM2	BRD-K38305202-001-17-4::2.5::HTS002	2.5	domperidone	dopamine receptor antagonist	noncancer	DRD2, DRD3	infectious disease	fescue toxicosis	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.1936542597095	0.1936542597095	-0.363395423219585	-0.225769257521	-9.55926852613184	190.095316162308	6.29479682444961e-18	8.62081475135758e-16	-0.671994949293948	-0.442104416564222
PUM2	BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500	0.625	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-3.14948897301	-3.14948897301	-1.70634328673207	-1.7628298459	13.4906737025102	8.30481497418371	6.15545611076378e-07	2.59447935646783e-05	1.1980312931003	1.68826007945557
PUM2	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.1505598716825	-0.1505598716825	-0.70132059618196	-0.5759216002185	-8.4644888730028	93.1548558917319	3.55933931294033e-13	3.09229686097766e-11	-0.679968489108531	-0.421552959890389
PUM2	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-2.81042842554	-2.81042842554	-1.26863909594258	-1.26660735332	19.7302597898134	186.057499554887	1.73911175401682e-47	3.32805431363099e-44	1.38762835846872	1.69595030072613
PUM2	BRD-K43457670-001-27-8::2.5::HTS002	2.5	acetazolamide	carbonic anhydrase inhibitor	noncancer	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.0551559189742	-0.0551559189742	0.262288888610226	0.242495378939	12.549497894048	181.711934737701	2.02679393214805e-26	5.82306590728363e-24	0.26753428952958	0.367355325639272
PUM2	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.07134509885565	0.07134509885565	0.349402125557982	0.3889604534415	7.3521870277384	12.4582532678841	7.1198566278543e-06	0.000251855380622443	0.195990035594115	0.36012401781055
PUM2	BRD-K49669041-001-08-4::2.5::HTS002	2.5	BX-912	pyruvate dehydrogenase kinase inhibitor	targeted cancer	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-2.46451873354	-2.46451873354	-1.93152353034924	-1.72310448833	5.10331131738507	17.6366235419734	7.90000642722989e-05	0.00228996548220416	0.313248191680921	0.752742214700599
PUM2	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.378144396442	0.378144396442	-0.463867050964705	-0.3435721987365	-16.6376254522022	187.990127096919	8.37250262690728e-39	7.94013325452393e-36	-0.941845713945727	-0.742177180867684
PUM2	BRD-K50071428-001-03-3::2.5::HTS002	2.5	abiraterone	androgen biosynthesis inhibitor	targeted cancer	CYP11B1, CYP17A1	oncology	prostate cancer	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.7962484153745	0.7962484153745	0.519479107731589	0.521292609125	-9.46910136682217	16.5408029935618	4.36079516740125e-08	2.14122535494603e-06	-0.338567095824819	-0.214971519461003
PUM2	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.719509048401	-0.719509048401	-0.103413235787713	0.0520686308404	12.1487807785587	137.087079037314	1.65744408085104e-23	3.71588213812471e-21	0.515815774933502	0.716375850293072
PUM2	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-8.40711378614	-8.40711378614	-6.15801039394458	-6.268105536705	17.5089240148264	3.25918970725316	0.000245825472664381	0.00635631894446665	1.85809346220696	2.64011332218388
PUM2	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-7.787338911255	-7.787338911255	-5.90374867592743	-5.9507974936	28.3103307472306	186.443742316965	2.00526338659053e-69	3.30604689526587e-65	1.75233464699666	2.01484582365847
PUM2	BRD-K53972329-001-07-0::2.5::MTS010::PROS003_PR500	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.185967928016	0.185967928016	-0.0155209293749743	-0.0154250985054	-8.16138498476724	44.679641562218	2.11716104238944e-10	1.3533224248562e-08	-0.251223028510474	-0.151754686271474
PUM2	BRD-K59753975-001-02-6::2.5::MTS006	2.5	vindesine	tubulin polymerization inhibitor	chemo	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-2.82216257621	-2.82216257621	-2.40831330757568	-2.27131346061	4.36490181338087	190.627522590798	2.0827226994035e-05	0.000676345262788565	0.226831975582496	0.60086656168614
PUM2	BRD-K60997853-001-02-3::2.5::MTS010::PROS004_PR500	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-2.084505370275	-2.084505370275	-0.710641948832377	-0.651377728199	19.7210894710005	20.1157668266022	1.24948360601384e-14	1.25257517209233e-12	1.22859903665834	1.5191278062269
PUM2	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.02550386901035	0.02550386901035	-0.209546208380207	-0.255561480265	-7.94006256813755	68.0864821493741	2.79354522931317e-11	1.97733736939717e-09	-0.294120687426661	-0.175979467354453
PUM2	BRD-K61688984-001-02-9::2.5::HTS002	2.5	RGFP966	HDAC inhibitor	targeted cancer	HDAC3	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.4521094957555	0.4521094957555	0.141396706207256	0.1478975736545	-7.8449385091137	15.0504160937046	1.07098114128045e-06	4.3473923679829e-05	-0.395108028967897	-0.226317550128591
PUM2	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.183241810727	0.183241810727	-0.495671708834138	0.00402399396559	-7.58760718901646	187.550931057398	1.4773243756773e-12	1.20668237848529e-10	-0.85542346692357	-0.502403572198707
PUM2	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.295250469678	0.295250469678	-0.175906855858251	-0.07625513394025	-9.40728647535074	153.211978377094	7.14584073967528e-17	8.86833178861531e-15	-0.570102285463103	-0.372212365609399
PUM2	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-4.861697647645	-4.861697647645	-2.0991600596287	-1.97310817512	30.6566510526883	173.859191533521	5.04804408521687e-72	1.35242780092556e-67	2.5846829454939	2.9403922305387
PUM2	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.6621570101665	-0.6621570101665	-2.64690052173776	-2.62453052692	-12.2714634836989	8.14546710413754	1.54705627924858e-06	6.14035231990869e-05	-2.3565523397158	-1.61293468342673
PUM2	BRD-K68103045-001-02-9::2.5::HTS002	2.5	CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.00993002517135	0.00993002517135	0.451583006075027	0.47087721143	10.7684402768876	3.29058934038964	0.00112000597487071	0.0244151505886966	0.317413806701348	0.565892155106006
PUM2	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-4.933869993575	-4.933869993575	-3.08569616006508	-3.15624915805	14.0554622594851	3.75352356652095	0.000220320153556454	0.00575514907880576	1.47344324573163	2.22290442128821
PUM2	BRD-K69195780-004-08-4::2.5::HTS002	2.5	NAN-190	serotonin receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.4985152306205	-0.4985152306205	0.350292453638414	0.3666851523545	17.8418706426434	2.66236443541071	0.000758401243618495	0.0173476392895953	0.685942701368963	1.01167266714886
PUM2	BRD-K69650333-003-14-0::2.5::HTS002	2.5	idarubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-7.692938197265	-7.692938197265	-6.61300046038831	-6.534390959045	8.11353227883894	7.11590091563253	7.61394773425863e-05	0.00221123279666114	0.766234726217858	1.39364074753552
PUM2	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.242589717477	-0.242589717477	-0.663538011937154	-0.50591048476	-5.39989610068578	7.2316243688914	0.000905648156582265	0.020282827978278	-0.60409217073452	-0.237804418185789
PUM2	BRD-K72827473-001-01-0::2.5::HTS002	2.5	CEP-37440	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.945945237742	-0.945945237742	-0.223488463370022	-0.1874682903165	14.2524107616131	8.67301517930624	2.56843104955787e-07	1.14138349247499e-05	0.607125295904596	0.83778825283936
PUM2	BRD-K73293050-001-03-1::2.5::HTS002	2.5	WZ-3146	EGFR inhibitor	targeted cancer	EGFR	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-4.998635462895	-4.998635462895	-2.54520944680407	-2.38223243926	16.9157028763721	3.02338575132081	0.00043013551141597	0.0104809588479165	1.99386240495734	2.91298962722453
PUM2	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-2.39999070817	-2.39999070817	-1.09631302921386	-0.895557196833	12.9709082126613	7.70402517922947	1.65429626161214e-06	6.52611197230018e-05	1.07034714600048	1.53700821191179
PUM2	BRD-K78126613-001-28-5::2.5::HTS002	2.5	menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	noncancer	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.351430504449	0.351430504449	-0.130059727154566	-0.050497524351	-8.39964594724408	5.34316323684835	0.000282154636376221	0.00716430767206245	-0.626041403833735	-0.336939059373398
PUM2	BRD-K80480517-001-02-4::2.5::HTS002	2.5	repsox	TGF beta receptor inhibitor	noncancer	TGFBR1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.488508488197	-0.488508488197	-0.89585557971181	-0.828383638665	-6.74329574044418	34.6048919550199	8.68961014671443e-08	4.12134422025925e-06	-0.530031346636986	-0.284662836392633
PUM2	BRD-K80700417-001-04-2::2.5::HTS002	2.5	SGI-1776	Pim kinase inhibitor	targeted cancer	FLT3, PIM1, PIM2, PIM3	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-1.27092098438	-1.27092098438	-0.33925973247025	-0.3090790625965	9.92929083892978	3.71612626116362	0.000827829514880713	0.0187536066055246	0.663109351657767	1.20021315216173
PUM2	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.2099550990485	0.2099550990485	0.0149425431218996	0.0495734767378	-6.83507112319953	81.6212500587402	1.3610736904632e-09	7.98569841235386e-08	-0.251774079427122	-0.138251032426079
PUM2	BRD-K82818427-001-02-2::2.39189::HTS002	2.39189	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-1.17822974036	-1.17822974036	-1.61785099072618	-1.52596467706	-7.17547138142173	167.869371849721	2.20833124098529e-11	1.58033197512232e-09	-0.560574789950124	-0.318667710782244
PUM2	BRD-K83988098-001-02-0::0.039::MTS010::PROS005_PR500	0.039	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-3.017370152795	-3.017370152795	-0.953261646140792	-0.896138988933	20.630862696551	119.511411157882	3.38824487030877e-41	3.99010513630994e-38	1.86600911424833	2.26220789906008
PUM2	BRD-K85606544-001-09-1::2.5::HTS002	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-3.542681791225	-3.542681791225	-1.56859871451611	-1.498612061085	22.4992171676351	70.2375885542077	7.9269922687746e-34	4.54273883950319e-31	1.79910141452267	2.14906473889511
PUM2	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.313022492946	-0.313022492946	0.046880614325893	0.06241133456585	11.7889313137212	22.4124277036808	4.39927736240908e-11	3.0406085708087e-09	0.2966575252654	0.423148689278386
PUM2	BRD-K87909389-003-03-4::2.5::HTS002	2.5	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-6.56774896843	-6.56774896843	-5.31807266358864	-5.33986830829	18.4088660545577	171.523338325349	1.80079125428807e-42	2.31114843557071e-39	1.11567973789589	1.38367287178683
PUM2	BRD-K89839824-001-05-3::2.5::HTS002	2.5	raltitrexed	thymidylate synthase inhibitor	targeted cancer	FPGS, TYMS	oncology	mesothelioma	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-3.99380663947	-3.99380663947	-2.89898213200474	-2.82333441128	12.4449907897459	91.0336289701283	2.37047314196765e-21	4.41408460508066e-19	0.920077607021232	1.26957140790929
PUM2	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.3763232010125	0.3763232010125	-0.278772834561875	-0.208293631699	-13.8402822240861	132.008727607821	1.79189154327842e-27	5.67288511934004e-25	-0.748724467118468	-0.561467604030282
PUM2	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-7.18390234125	-7.18390234125	-5.59992716869476	-5.60058662575	14.2527455915176	16.7832954778033	8.3481955105648e-11	5.5896919574628e-09	1.34927053111744	1.81867981399303
PUM2	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-2.04624234955	-2.04624234955	-1.74666586895152	-1.68383825257	4.05389864880831	15.0443242419505	0.00103330192253569	0.0227569197042812	0.142106253872124	0.457046707324838
PUM2	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	-0.6935067910225	-0.6935067910225	-0.068771811071273	-0.0594618685141	12.4608583479028	52.8797998714317	2.31763322987474e-17	3.00324070450921e-15	0.524169983306247	0.725299976596207
PUM2	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.08260736631085	0.08260736631085	0.248707583517026	0.266502193274	5.4253355230713	54.6544556365258	1.35697315860228e-06	5.43162723098388e-05	0.104736347139172	0.22746408727318
PUM2	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	DANG, 5637	PANCREAS, URINARY_TRACT	carcinoma	0.4048051237835	0.4048051237835	-0.224211611930872	-0.147984722712	-9.13934933032477	3.66130364874428	0.00119211120393586	0.0258058784191868	-0.827283396106673	-0.43075007532207
PUS7	BRD-A54927599-001-16-9::2.5::HTS002	2.5	KF-38789	P selectin inhibitor	noncancer	SELP	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-2.584770308455	-2.584770308455	-2.94486180866047	-2.73649504122	-3.63804498242406	101.340253562935	0.000434175605414398	0.0105661886377725	-0.556432007835538	-0.163750992575398
PUS7	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.1518902731055	0.1518902731055	-0.181893752589333	-0.008049193223815	-6.35670112243857	189.602331324425	1.49943042815748e-09	8.75194510448158e-08	-0.437360902432221	-0.230207148957444
PUS7	BRD-A74914197-001-02-9::0.15625::MTS010::PROS005_PR500	0.15625	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.38744339093	0.38744339093	-0.407512005488013	-0.2745905537905	-11.4943417054692	103.503402666645	3.36412131950421e-20	5.69532984429714e-18	-0.932111176710922	-0.657799616125104
PUS7	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-3.133221684935	-3.133221684935	-3.72385573585941	-3.62613694573	-5.07307266108098	23.1711175539359	3.81169874278702e-05	0.00117632480898891	-0.831379772023718	-0.349888329825095
PUS7	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.9438386161955	-0.9438386161955	-1.90635975362659	-1.73380354334	-8.13422922390568	15.4688598716898	5.65840432604952e-07	2.39818101799064e-05	-1.21407079304212	-0.71097148182006
PUS7	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.511550460987	-0.511550460987	-0.0792896149771201	-0.0155909227599	10.1100969646351	13.2773106447165	1.31369058285297e-07	6.10366331958148e-06	0.340089229378377	0.524432462641382
PUS7	BRD-K03406345-001-27-8::2.5::HTS002	2.5	azacitidine	DNA methyltransferase inhibitor	chemo	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.008706062731	-1.008706062731	-0.578883056329122	-0.551785683571	8.30905033484841	7.71676241715643	4.10082193344202e-05	0.00125794341516058	0.309768137266089	0.549877875537668
PUS7	BRD-K06234293-001-04-2::2.5::HTS002	2.5	LY364947	TGF beta receptor inhibitor, p38 MAPK inhibitor	targeted cancer	TGFBR1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.9536442437975	0.9536442437975	0.784119893773686	0.806042544038	-4.36733473255422	9.98559263931474	0.00140973724969633	0.0298083484646229	-0.256029667058225	-0.0830190329894017
PUS7	BRD-K09426783-300-01-0::2.5::HTS002	2.5	TAS-103	topoisomerase inhibitor	chemo	TOP1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-2.372162869715	-2.372162869715	-2.71360899628051	-2.622314881585	-3.56267070107933	151.164879631482	0.00049144628664237	0.0118029173822578	-0.530804897579203	-0.152087355551813
PUS7	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.346284404769	-0.346284404769	-0.0672059137364014	-0.00125185876287	5.65271944365106	8.50015364170475	0.000385187398180891	0.00948601974775504	0.166385111489011	0.391771870576187
PUS7	BRD-K11630072-001-13-2::2.5::MTS010::PROS004_PR500	2.5	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.4029869363735	0.4029869363735	-0.245597174269143	-0.182730639513	-12.990032949578	178.632823773805	1.35473947972867e-27	4.35322275788255e-25	-0.747111378422197	-0.550056842863089
PUS7	BRD-K13566078-001-02-3::2.5::HTS002	2.5	BMS-345541	IKK inhibitor	targeted cancer	CHUK, IKBKB	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-2.22550236498	-2.22550236498	-1.47752458196752	-1.48395465403	10.7831452791744	11.8968372056699	1.70675911018163e-07	7.77818357061701e-06	0.596697958309255	0.899257607715703
PUS7	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.63870613855	-1.63870613855	-0.929827431990395	-0.8524847758	8.4075056437692	5.60974666851139	0.000219213120835645	0.00573112088016382	0.499037840983963	0.918719572135246
PUS7	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-2.765974655065	-2.765974655065	-2.35280053319763	-2.27083369545	4.33496685268993	45.8174871165585	7.90352525647136e-05	0.00229067567909973	0.221300501798078	0.605047741936667
PUS7	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.11227568906455	0.11227568906455	-0.028097927949903	-0.00807522835948	-4.73937422093539	8.32010077408786	0.00131554779497821	0.0280920636993011	-0.20821952335024	-0.0725277106786664
PUS7	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-2.113631365505	-2.113631365505	-2.99808830729765	-2.880185474935	-11.3651874959981	133.534713176226	2.33528883525067e-21	4.35613682132672e-19	-1.03837937035074	-0.730534513234556
PUS7	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.2555904603	-1.2555904603	-3.15107150004245	-3.22475555586	-15.4548517670387	69.1527619806752	4.0045454230482e-24	9.4943607962002e-22	-2.14014415584532	-1.65081792363959
PUS7	BRD-K20482099-001-09-4::2.5::HTS002	2.5	rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	noncancer	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.31458783457	-1.31458783457	-0.435224256258343	-0.343450980127	15.5774533238962	4.2611683772068	6.43002189880803e-05	0.00189800325512963	0.726347118824629	1.03238003779868
PUS7	BRD-K21361524-001-01-1::0.625::MTS006	0.625	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.55278360773	-1.55278360773	-2.76001302535829	-2.60110257698	-13.4654439767076	35.4918057554716	1.63298636980918e-15	1.78024585785774e-13	-1.38914637501991	-1.02531246023667
PUS7	BRD-K27184429-300-01-3::2.5::HTS002	2.5	levocetirizine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.7966490899365	-0.7966490899365	-0.348987490326039	-0.229917154619	7.52205638315215	6.01045371868462	0.00028356736616958	0.00719506452276072	0.302099433190053	0.59322376603087
PUS7	BRD-K39160765-003-02-9::2.5::HTS002	2.5	4-chlorophenylguanidine	urokinase inhibitor	noncancer	PLAUR	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.270375579809	0.270375579809	0.0520775455886829	0.07182611721785	-7.13201111098377	170.291817138997	2.70433440677521e-11	1.92244540321633e-09	-0.278718393408617	-0.157877675032017
PUS7	BRD-K39171998-001-01-1::2.5::HTS002	2.5	STF-118804	NAMPT inhibitor	targeted cancer	NAMPT	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-4.35205826724	-4.35205826724	-4.66979388159074	-4.69138817122	-3.24630386033632	136.189601330506	0.00147173816021047	0.0309281466947496	-0.511289164198236	-0.124182064503238
PUS7	BRD-K45446451-001-05-0::2.5::HTS002	2.5	JZL-184	monoacylglucerol lipase inhibitor	targeted cancer	MGLL	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.226132630466	-0.226132630466	-0.0476462919272748	-0.06430876639615	5.08570062226771	153.831837784984	1.05226463643014e-06	4.27708756422218e-05	0.109154557333559	0.247818119743891
PUS7	BRD-K45551181-001-02-1::2.49051::HTS002	2.49051	MPI-0479605	mitotic kinase inhibitor	targeted cancer	TTK	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.35494023588	-1.35494023588	-2.31555640764173	-2.31598955621	-8.25014792972127	4.6011999477323	0.000630581847878976	0.0147000192379871	-1.26789870512561	-0.653333638397847
PUS7	BRD-K48578705-001-17-6::2.5::HTS002	2.5	methyldopa	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.5120550473235	0.5120550473235	0.251595341431059	0.280469769999	-8.43527916542648	31.1060700398165	1.53624768392049e-09	8.95708459866687e-08	-0.32342592834127	-0.197493483443612
PUS7	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.434520255435	-0.434520255435	-1.25762781322261	-0.921278111753	-8.10344397973151	11.9851938112956	3.32239057001484e-06	0.000124992917058226	-1.04445086114427	-0.601764254430955
PUS7	BRD-K51040301-001-02-1::2.5::HTS002	2.5	cobicistat	cytochrome P450 inhibitor	noncancer	CYP3A4, CYP3A43, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.5222726132065	0.5222726132065	0.253053038120704	0.226380370277	-6.06185559652048	5.9254900389985	0.000957164911027776	0.0212919769813879	-0.378224107678912	-0.16021504249268
PUS7	BRD-K51143828-003-03-1::2.5::HTS002	2.5	lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.120154858961	0.120154858961	-0.0215115384225697	0.03172783000245	-4.59730633429068	24.8538243618218	0.000107170338101413	0.00301598101299077	-0.205150190202037	-0.0781826045651028
PUS7	BRD-K51313569-003-03-3::2.5::HTS002	2.5	palbociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.971611455676	-0.971611455676	-0.756209921599517	-0.730954040019	3.18143185224818	71.6334346915985	0.00216717703748627	0.0429485794976786	0.08042059648971	0.350382471663256
PUS7	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.364286202973	0.364286202973	-0.220733892545933	-0.1500661795165	-11.2292916353296	2.84773789502035	0.0019156256681623	0.0386386348420437	-0.755947800255439	-0.414092390782426
PUS7	BRD-K56751279-300-01-4::0.15625::HTS002	0.15625	Y-39983	rho associated kinase inhibitor	noncancer	ROCK1, ROCK2	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	1.09901629099	1.09901629099	0.777036220289523	0.797329257919	-10.3145118608809	10.1948329035716	1.02151218434153e-06	4.15918854402994e-05	-0.391354386418172	-0.252605754982781
PUS7	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.3353379792995	0.3353379792995	-0.39683480087588	-0.201440599557	-10.6773016916726	35.8421249472467	1.10663598151432e-12	9.1825080635688e-11	-0.871266195986452	-0.593079364364309
PUS7	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.07030283012325	0.07030283012325	0.236269862086573	0.281721742376	4.44009573552654	190.475538613385	1.52119322131065e-05	0.000507764868291996	0.0922367728162264	0.23969729111042
PUS7	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.130797895645	-1.130797895645	-1.33151291688881	-1.45938861893	-3.22176229131175	54.8839613635109	0.00214424795517208	0.0425944455556042	-0.325572466087558	-0.0758575764000673
PUS7	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.311796485845	-1.311796485845	-1.53820789480555	-1.43484346641	-3.65814061919113	104.59454581387	0.000399796129985016	0.00980410809422865	-0.349138316414681	-0.103684501506421
PUS7	BRD-K61734568-003-02-1::2.5::HTS002	2.5	2,3-DCPE	Bcl-XL downregulator	targeted cancer	BCL2L1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.0550350626723	0.0550350626723	-0.361180347960704	-0.146091240972	-5.3996442898904	24.1992123764932	1.47631146911014e-05	0.000493706289378852	-0.575235574020214	-0.257195247245794
PUS7	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-2.311803983935	-2.311803983935	-1.47125609013481	-1.34809352963	10.0072420230381	5.90007035780771	6.40059234375467e-05	0.00189061818694128	0.634175316841034	1.04692047075934
PUS7	BRD-K65877271-001-01-8::2.5::HTS002	2.5	halobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.579158941812	-0.579158941812	-0.279471485889636	-0.22089502774	6.26429127172047	164.719939094013	3.1430357761802e-09	1.77368013394662e-07	0.205227604920522	0.394147306924207
PUS7	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-2.09324076722	-2.09324076722	-1.75424726399337	-1.67073793274	4.97670393854295	47.4498547567735	8.92943454904787e-06	0.000310385465044256	0.201995935581065	0.475991070872187
PUS7	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.0481071667335	0.0481071667335	-0.274512075991843	-0.224936831672	-9.38435994796449	36.2081089561849	3.11656060658935e-11	2.19293932452294e-09	-0.392327949601819	-0.252910535848868
PUS7	BRD-K69608737-001-10-2::2.5::HTS002	2.5	tacrolimus	calcineurin inhibitor	noncancer	FKBP1A	transplant	organ rejection	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.09466509149505	-0.09466509149505	0.308795550047954	0.32803780098	13.7801489731544	26.1704337425971	1.65461129484797e-13	1.48630001765914e-11	0.343297108917618	0.46362417416839
PUS7	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.55055702461	-0.55055702461	-0.147197572372303	0.06127291355585	6.00647603425368	45.4206546509469	2.95764207700632e-07	1.30460685063323e-05	0.268138730407938	0.538580174067457
PUS7	BRD-K70159787-001-01-1::2.5::HTS002	2.5	SMI-4a	Pim kinase inhibitor	targeted cancer	PIM1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.16547321729	-1.16547321729	-0.627289831120713	-0.60780165798	10.1044130411619	186.001040740369	2.0655063941554e-19	3.2360959060887e-17	0.433107692770938	0.643259079567637
PUS7	BRD-K72414522-001-06-7::2.5::HTS002	2.5	AZD5438	CDK inhibitor	targeted cancer	KCNH2	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.9605187688	-1.9605187688	-2.42201153045141	-2.22027282363	-4.36143134397733	60.8533440303744	5.07511768876142e-05	0.00152751706096692	-0.673087698736538	-0.249897824566285
PUS7	BRD-K73589491-001-11-2::2.5::HTS002	2.5	nizatidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.334184898412	-0.334184898412	0.100194122045337	0.09959523720245	18.4310140569836	191.411156225158	2.7387166437534e-44	4.22292373769081e-41	0.387893006704858	0.480865034209815
PUS7	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-4.0153074119	-4.0153074119	-2.91330748340136	-2.84610122618	7.72949488263048	3.54442871428872	0.002434596374183	0.0474669886548047	0.685264330827188	1.5187355261701
PUS7	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-3.403353112395	-3.403353112395	-2.31164815823109	-2.223018080895	12.6984172208722	187.994015334125	4.42305821826436e-27	1.33896842494687e-24	0.92211168589763	1.26129822243018
PUS7	BRD-K76703230-004-04-1::2.5::HTS002	2.5	YM-155	survivin inhibitor	targeted cancer	BIRC5	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-5.844456259335	-5.844456259335	-5.48409946772251	-5.502396220135	4.26845461218761	185.517423328217	3.13660659622151e-05	0.000981410696667398	0.193803766247861	0.526909816977119
PUS7	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.366044447358	0.366044447358	0.119150697276141	0.120954188254	-6.78737983014852	187.673460402782	1.45421978022056e-10	9.46209688144785e-09	-0.3186509806706	-0.175136519493118
PUS7	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-3.851739094615	-3.851739094615	-3.0537061030262	-2.99006854464	8.38886992311108	161.683448281763	2.31086097821401e-14	2.26674838718366e-12	0.610175559120828	0.985890424056779
PUS7	BRD-K82850175-001-01-1::2.5::HTS002	2.5	navarixin	CC chemokine receptor antagonist	targeted cancer	CXCR1, CXCR2	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.6958022412445	-0.6958022412445	-0.883953088939746	-0.794282488065	-3.18891022376342	160.715638350282	0.00171696517253113	0.0353094826773579	-0.304669272114256	-0.071632423276236
PUS7	BRD-K84091759-001-07-1::2.5::HTS002	2.5	candesartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension, congestive heart failure	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.5770016614595	0.5770016614595	0.330957121435236	0.339578920682	-7.37934993381932	18.5994130492431	6.20619868833514e-07	2.61432460430853e-05	-0.315932656259092	-0.176156423789436
PUS7	BRD-K84810405-003-01-1::2.5::HTS002	2.5	almorexant	orexin receptor antagonist	noncancer	HCRTR1, HCRTR2	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.491423417165	0.491423417165	0.255513528180349	0.26116496822	-7.44836659029544	17.3778096260739	8.30811527431096e-07	3.43427201278263e-05	-0.302622949163694	-0.169196828805609
PUS7	BRD-K88568253-011-19-9::2.5::HTS002	2.5	iproniazid	monoamine oxidase inhibitor	noncancer	MAOA, MAOB	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.6404863694095	0.6404863694095	0.47117021542347	0.4917980145095	-5.47189792285329	161.749185671138	1.66511240688592e-07	7.6094216856173e-06	-0.230420214854115	-0.108212093117944
PUS7	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.0667562156304	0.0667562156304	0.168571189176454	0.182655209923	4.18833376198085	10.0628839198175	0.00183759445693571	0.037317584078129	0.0476965826312605	0.155933364460847
PUS7	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.09463212040745	-0.09463212040745	0.100728767008168	0.1765205692495	5.67289038522116	189.889306338628	5.17227274487757e-08	2.51947282985651e-06	0.127431442323876	0.263290332507359
PUS7	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	0.957890075362	0.957890075362	-0.306004554446905	-0.214794605924	-15.530880181272	12.8821020469522	1.01650128129094e-09	6.04115801702217e-08	-1.43986796490116	-1.08792129471665
PUS7	BRD-K95581532-001-01-5::2.5::HTS002	2.5	RN-1734	TRPV antagonist	noncancer	TRPV4	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-2.965164936865	-2.965164936865	-2.41147450746296	-2.34576789044	6.60915080033947	186.999970839447	3.91801633098005e-10	2.4353956120699e-08	0.388422253945042	0.718958604859043
PUS7	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-2.125363928125	-2.125363928125	-1.74583737074655	-1.68383825257	5.32612716062966	23.8789851056931	1.85299183222142e-05	0.000608099657645359	0.232418834280301	0.526634280476609
PUS7	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-3.747192061685	-3.747192061685	-3.16014769592527	-3.187890366305	8.43809262478739	182.972989890097	9.58103528169216e-15	9.68629108910282e-13	0.449780327789302	0.724308403730155
PUS7	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-0.6124632026255	-0.6124632026255	-0.213559587570568	-0.135972658715	8.35443106061156	190.000283667179	1.35787404601893e-14	1.3567915450312e-12	0.304720227896697	0.493087002213167
PUS7	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	AGS, PC3	STOMACH, PROSTATE	carcinoma (adenocarcinoma)	-1.29820564657	-1.29820564657	-0.611365122507927	-0.6000769492995	12.8894591758203	38.8326097793698	1.31678288442579e-15	1.45028139175794e-13	0.579042550006596	0.794638498117551
PVT1	BRD-A55484088-050-02-5::2.5::HTS002	2.5	BNTX	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.577566461746667	-0.566575978125	-1.39694469506045	-1.329869990725	-7.18674518192554	4.44745157805476	0.00131220086909593	0.0280373542091975	-1.12375446689204	-0.515001999735532
PVT1	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0810045602605767	-0.00210656624547	-1.04316153411611	-0.80592067456	-8.72596189121682	5.26604840829142	0.000251191842020012	0.00647632579192917	-1.45036465981605	-0.797967528937314
PVT1	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.263701719229	0.314361465557	-0.18543459049444	-0.01201826892	-5.91370115577502	7.33629538594122	0.000495652394334349	0.011890830761729	-0.627070354404883	-0.271202265041998
PVT1	BRD-K09397065-003-06-1::2.5::HTS002	2.5	SR-57227A	serotonin receptor agonist	noncancer	HTR3A	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.506288528026667	0.494371858498	0.241015983959491	0.230144295567	-5.59957315244857	6.60320240367319	0.000998329993253552	0.0221041456479248	-0.378672721138134	-0.151872366996217
PVT1	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.716881780138333	-0.851617841656	-1.82094165397186	-1.561508988965	-6.15746846727187	4.61088056039102	0.00218486764759194	0.0432431894025979	-1.57692481126577	-0.63119493640128
PVT1	BRD-K15025317-001-15-1::2.5::HTS002	2.5	BAY-11-7082	NFkB pathway inhibitor	noncancer	RELA	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.662988123365	0.696994231403	-0.066374102660057	-0.04320132136775	-9.36181690265776	4.53414248483728	0.000390721186305212	0.0096101539063128	-0.935981703478407	-0.522742748571707
PVT1	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.341081793949333	0.295252331379	-0.190656556540926	-0.0662920006189	-7.87310898241617	5.59507476490688	0.000312939662096335	0.00786861154826906	-0.699942171625843	-0.363534529354675
PVT1	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.343535802605667	-0.375413172664	-0.942190293911318	-0.800050374419	-6.25758438635711	8.58891139527762	0.00018088472172005	0.00483884691981237	-0.816661272674177	-0.380647709937126
PVT1	BRD-K36788280-001-01-2::2.5::HTS002	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.74733206603667	-1.81464619463	-1.05452752100538	-0.985286649613	6.0039800322368	5.07888881331581	0.00174329820950233	0.0357310282054533	0.397563281255479	0.988045808807085
PVT1	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.701552178780667	-0.796958104349	-1.95619983544196	-1.77214463061	-7.81015970646164	3.96433108880672	0.00150465031246323	0.0315159828736105	-1.70225130867555	-0.80704400464703
PVT1	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.38328522186333	-5.31164963495	-6.61952198272249	-6.68323175146	-8.70983338762428	4.01954786930622	0.000936112406772786	0.020890882552187	-1.62955891759907	-0.842914604119241
PVT1	BRD-K50140147-001-10-1::2.5::HTS002	2.5	NVP-TAE684	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, INSR	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.06685280331633	-1.09600627046	-1.8187038966684	-1.663164894725	-6.02827055354392	6.79307175412134	0.000591244044638892	0.0139222967307635	-1.04860003172965	-0.455102154974472
PVT1	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.154853726232667	0.154062406987	-0.105468792135642	-0.112334547227	-5.8502250514103	192.308180966516	2.08040292274772e-08	1.06800162402299e-06	-0.348089057020556	-0.172555979716061
PVT1	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.367947202312667	0.328345877967	-0.596459650142103	-0.501898439547	-10.7800037823769	19.0735451192701	1.48505161564359e-09	8.67274189998025e-08	-1.15160531018614	-0.777208394723393
PVT1	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.461186913931	0.472609781173	0.257420216884535	0.2398236125465	-6.65367400285793	13.5520288638368	1.28277790589172e-05	0.000432970875262783	-0.269654402616557	-0.137878991476374
PVT1	BRD-K61036791-001-01-6::2.5::HTS002	2.5	rucinol	tyrosinase inhibitor	noncancer	TYR	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.610749333315	0.630107456937	0.400318308017072	0.437616797698	-5.52816044144455	6.20483735463352	0.00132052995071201	0.0281872187836026	-0.302833129803705	-0.118028920792151
PVT1	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.232663913490667	0.227415058443	-0.475630134301199	-0.4999617184645	-7.20233898211519	5.79558289654616	0.000423769619517162	0.0103411270387674	-0.95100124396374	-0.465586851619992
PVT1	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.02577976662033	-1.00724281242	-0.681120881546254	-0.628858637857	5.2702306802159	17.2739096499699	5.93360486858947e-05	0.0017638607460193	0.206849106888989	0.48246866325917
PVT1	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.210728780873	-0.223330572564	-1.09174074003553	-0.420967883368	-7.66189118847348	187.688829596679	9.49621301893655e-13	7.93185440426989e-11	-1.10784343546179	-0.654180482863277
PVT1	BRD-K67511046-001-02-3::0.625::HTS002	0.625	naloxone	opioid receptor antagonist	noncancer	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.187819271506333	-0.173113904351	0.0740085917727827	0.0447820081781	5.48774944507693	5.89505971358074	0.00162294266456739	0.0336048380208737	0.144576803144069	0.379078923414163
PVT1	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.422666116944333	-0.442955930033	-0.612457862297091	-0.441483488236	-3.4314791142021	75.1962809595194	0.000978561423776971	0.0217160997511591	-0.299968248486049	-0.0796152422194668
PVT1	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.64643008001	-3.71006027715	-4.36841933631265	-4.09852844866	-4.90435389237531	14.2666066566233	0.000220137166456751	0.00575177115073864	-1.03717909365002	-0.406799418955276
PVT1	BRD-K76908866-001-07-6::2.5::HTS002	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.39856630492333	-1.40847326204	-0.684441907122353	-0.6189488689725	9.70104432800709	35.3088803196028	1.7010177172558e-11	1.23669411913745e-09	0.56472848413419	0.86352031146777
PVT1	BRD-K76973696-001-12-6::2.01421::HTS002	2.01421	tryptanthrin	cyclooxygenase inhibitor	targeted cancer	IDO1	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.038240714294	-1.03143513418	-1.3919244416049	-1.3602365619	-5.6324080140507	7.94271339308723	0.000504183211669764	0.012079262639612	-0.498669884767504	-0.20869756985429
PVT1	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	HCC1419, NCIH2170	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.552841092312	0.552841092312	0.326611100646402	0.364286574892	-7.60389492968743	33.5601032564795	8.4841817442798e-09	4.56541850130491e-07	-0.2867222446539	-0.165737738677295
PVT1	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.1366289299458	-0.115845727161	0.125858816328426	0.141810912898	5.22307895080946	8.65940909595094	0.000619697436873754	0.0144793559301989	0.148116933969851	0.3768585585786
PVT1	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	HCC1419, NCIH2170	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.848597354245	-0.848597354245	-1.69625833786277	-1.42296021894	-8.81544362291288	20.8430169319461	1.78770030105148e-08	9.28188027674571e-07	-1.04772082990992	-0.647601137325618
PVT1	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.12644956510533	-1.13501376059	-1.70900037749924	-1.55245273459	-5.52520772682658	5.49609728234322	0.00196938829798367	0.0395656277058487	-0.846384824976297	-0.318716799811506
PVT1	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	CORL23, HCC1419	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.01505946388	-1.01505946388	-1.65600355732389	-1.74044254788	-11.3356672354339	172.98273060402	1.25216940000791e-22	2.62599036530623e-20	-0.752545637800077	-0.529342549087709
PVT1	BRD-K89704198-001-12-3::2.5::HTS002	2.5	vincamine	adrenergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0248798908900667	0.0242421886293	-0.196864764241849	-0.114107902929	-4.98230600408281	192.828523900406	1.39261627765746e-06	5.56239385341122e-05	-0.30952658999928	-0.133962720264552
PVT1	BRD-K91701654-001-03-1::2.66738::HTS002	2.66738	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.572272079962667	0.559738462471	-0.0874557458657182	-0.00406864447869	-13.8224518832729	41.6041316014523	3.79239345663815e-17	4.80674096491897e-15	-0.756075426242367	-0.563380225414403
PVT1	BRD-K92049597-001-20-8::2.5::HTS002	2.5	triamterene	sodium channel blocker	noncancer	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.576666445644667	-0.604873742401	-0.0479400610119704	-0.0458936243702	8.5590215771326	3.34518767296133	0.0021843707014415	0.0432375297078429	0.343126109488823	0.714326659776569
PVT1	BRD-K95523387-001-09-6::2.5::HTS002	2.5	OLDA	TRPV agonist	noncancer	GPR119	NA	NA	CORL23, HCC1419, NCIH2170	LUNG, BREAST	carcinoma (large_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.665927223024667	0.689687786025	0.269489704326997	0.36213641084	-6.55797144261768	16.4593386473841	5.72653293528137e-06	0.000206557064538189	-0.524298379292801	-0.268576658102539
PVT1	BRD-K98157055-001-10-9::0.625::HTS002	0.625	SIB-1757	glutamate receptor antagonist	noncancer	GRM5	NA	NA	HCC1419, NCIH2170	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5912308273485	0.5912308273485	0.218095252307128	0.259105939105	-8.47080219265665	16.3859278945168	2.19210012349661e-07	9.85190856265498e-06	-0.466338158863582	-0.279932991219162
R3HDM2	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.673206103505333	0.683300000457	0.245641745813795	0.2493322764875	-7.96647354834686	3.45429213478992	0.00243115330799664	0.0474127986669346	-0.586336959443392	-0.268791755939686
R3HDM2	BRD-A14344385-001-03-2::2.5::HTS002	2.5	IDRA-21	glutamate receptor positive allosteric modulator	noncancer	GRIA1, GRIA2, GRIA3, GRIA4	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.353821988790667	0.340328102444	0.13825677885896	0.112477706002	-6.47577983208255	13.4854726763786	1.74625683140352e-05	0.000576692573833412	-0.287217094581605	-0.143913325281809
R3HDM2	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-0.231734323569667	-0.214151247996	-1.2511736207209	-1.05827625236	-11.0812831469086	162.341610919263	1.31622229169221e-21	2.48989062273698e-19	-1.20110336692928	-0.837775227373193
R3HDM2	BRD-A48300215-001-04-8::2.5::HTS002	2.5	ajmaline	sodium channel blocker	noncancer	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.500457144969333	0.482643715525	0.0735069478605675	0.0929093466211	-6.58908144163577	9.46211679272381	7.97790863462054e-05	0.00230942352748458	-0.572446303735843	-0.281454090481688
R3HDM2	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.832093523434667	0.831197488721	0.40609816457427	0.461750260596	-7.2115914808189	4.07100668898745	0.00183204027946171	0.0372188967826302	-0.588880496282384	-0.26311022143841
R3HDM2	BRD-K03765900-001-01-9::2.49999::MTS010::PROS002_PR500	2.49999	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-0.131736970980537	-0.164963819057	-0.562148971588788	-0.356722462734	-4.30995464660407	10.5887282792446	0.0013477316754247	0.0286764600677157	-0.65125864545082	-0.209565355765683
R3HDM2	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.0907544234459667	0.126916317211	-0.656268537771012	-0.5945525862225	-6.98693509704372	3.89499770782258	0.00243563786153699	0.0474829750068547	-1.04705530389516	-0.446990618538799
R3HDM2	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-0.643817161142	-0.61967130112	-1.03248194379582	-1.02167878601	-5.72220868670628	12.0426128000062	9.44250875013619e-05	0.00268729711579862	-0.536596401524191	-0.240733163783454
R3HDM2	BRD-K09900591-001-26-7::2.5::HTS002	2.5	caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	noncancer	ALOX5, MIF	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.194598852557	0.211639126313	-0.0574586453532477	-0.07637429857195	-5.89804524972872	10.0175265037598	0.000150403128777481	0.00409707068985114	-0.347256147433981	-0.156858848386515
R3HDM2	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.557987436023	0.575893682986	0.424681225051662	0.397234495947	-3.52015598174648	31.1559138683911	0.00135134388774471	0.0287362024125842	-0.210525708253573	-0.0560867136891026
R3HDM2	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.58345234442	0.587511179614	0.338804823231663	0.350164931412	-5.22012314051195	6.34216777588095	0.00166661343407559	0.034392797103022	-0.357841890358054	-0.131453152018621
R3HDM2	BRD-K29950728-048-17-4::2.5::HTS002	2.5	clomifene	estrogen receptor antagonist	noncancer	ESR1	obstetrics/gynecology	infertility	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.0957449520041667	0.123402826049	-0.14170819572297	-0.123038002235	-4.9805280769577	7.17296020815032	0.00148946943313458	0.0312486779692934	-0.349640947742047	-0.125265347712225
R3HDM2	BRD-K33127281-001-05-6::2.5::HTS002	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.408189222198667	0.458791967126	-0.173166523770937	-0.166072315871	-9.06531950027732	4.15658923538905	0.000685202508221402	0.0158509194154976	-0.756793757586934	-0.405917734352274
R3HDM2	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.699819338231333	0.671259339085	-0.0795954435931532	0.3130523972605	-7.44012535926422	15.2648564441302	1.86977378608701e-06	7.31022885440062e-05	-1.00236482572925	-0.556464737919721
R3HDM2	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-0.0612228637227233	-0.00388746693383	-0.790528261633869	-0.650726618415	-7.52594898222617	10.9172928962825	1.21369565022707e-05	0.000411429443666661	-0.942790139250481	-0.51582065657181
R3HDM2	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-0.313193379294667	-0.298387088805	-0.0981934485264087	-0.0900251061909	4.44353938883542	64.0342710001012	3.58472581895715e-05	0.00111156061928713	0.118341102599331	0.311658758937185
R3HDM2	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-0.131303971992867	-0.0748374967568	-0.712572918913029	-0.544582582296	-5.37468920935919	5.5558492042671	0.00217101315904853	0.0430126714148376	-0.851114513305871	-0.311423380534454
R3HDM2	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-6.11076729245667	-6.13046026847	-4.62501533096611	-4.72452188359	11.0887007387025	6.84556778213624	1.26935209849256e-05	0.000428979763351957	1.16746616520445	1.80403775777667
R3HDM2	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-0.356032372210667	-0.338485642441	-1.18958906585412	-1.019667230775	-9.12529753289884	5.00273778484726	0.00026393997382447	0.00675704618368667	-1.06832964628885	-0.59878374099806
R3HDM2	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.468240842650667	0.459211030918	0.0262159357965955	0.110562434048	-8.17099562154818	31.0538396620214	3.10608591989256e-09	1.75375207883207e-07	-0.552348352998576	-0.331701460709567
R3HDM2	BRD-K81839095-001-30-1::2.5::HTS002	2.5	estrone	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.690270375371	0.675993127514	0.401871410430028	0.393237041414	-9.12692304925375	9.0557355835104	7.29764247229658e-06	0.000257591635942828	-0.359813198290882	-0.216984731591062
R3HDM2	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	0.0831234638625333	0.0856909394477	-0.0962456231352656	-0.05050386114625	-4.99286491240571	19.5885203778378	7.40840029142351e-05	0.00215650553586922	-0.254408541035863	-0.104329632959735
R3HDM2	BRD-K94176593-001-09-4::2.5::HTS002	2.5	TWS-119	glycogen synthase kinase inhibitor	noncancer	GSK3B, JUN, MYC	NA	NA	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-0.1137929700185	-0.101798858354	-0.298868296122446	-0.227331064368	-3.94027895010944	26.6762011072562	0.000526937775664507	0.0125556471951527	-0.281504792227714	-0.088645859980179
R3HDM2	BRD-K99107520-001-24-1::2.5::MTS006	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	GB1, NCIH522, NCIH1792	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (astrocytoma_Grade_IV\, glioblastoma_multiforme), carcinoma (non_small_cell_carcinoma), carcinoma (adenocarcinoma)	-0.02941747020034	-0.0339404434835	0.0692266468491798	0.09679079817665	4.26795288504968	21.5328240784715	0.00032647222648805	0.00817721933282192	0.05065084516392	0.14663738893512
RAB27A	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.752034607568	0.752034607568	0.247069827028431	0.251620004261	-18.6070610937494	103.268750004876	9.28489587662018e-35	5.75150996630094e-32	-0.55878561576317	-0.451143945315969
RAB27A	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.1881641924635	0.1881641924635	-0.222861438298556	-0.093015492892	-5.42635862275191	12.7559644597513	0.000123773419957078	0.00343674482782493	-0.574983987668748	-0.247067273855364
RAB27A	BRD-A64092382-003-18-3::2.5::HTS002	2.5	mexiletine	sodium channel blocker	noncancer	AHR, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.90040651698	-1.90040651698	-3.10108296380631	-3.114732961095	-12.4782212045383	173.812460068432	6.29355370852079e-26	1.72713325581761e-23	-1.39058995231079	-1.01076294134184
RAB27A	BRD-A73556557-001-06-4::2.5::HTS002	2.5	tagatose	phosphorylase inhibitor	noncancer	PYGL	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.213402480184	-0.213402480184	0.118266671704417	0.145010239158	10.7687248034118	45.950599646769	3.7147808576233e-14	3.57033751763921e-12	0.269671584174007	0.393666719602827
RAB27A	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.55233611668	-1.55233611668	-1.12054881449749	-1.02154011458	7.6885421820052	193.518782951198	7.32781186459136e-13	6.1857526156991e-11	0.321023343442014	0.542551260923014
RAB27A	BRD-K00312224-001-09-5::2.5::HTS002	2.5	PPT	estrogen receptor agonist	noncancer	ESR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.2518782555175	-0.2518782555175	0.167191510313509	0.257314113773	8.59077794088581	20.4764298389234	3.15817547904847e-08	1.58336512806779e-06	0.31746521413111	0.520674317530907
RAB27A	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.73694744356	-2.73694744356	-2.3134964097462	-2.417981872085	6.13212400156808	167.959547937914	6.00457394087142e-09	3.28271221614575e-07	0.287124335171196	0.559777732456398
RAB27A	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.354827132855	0.354827132855	-0.36673556672978	-0.264963110089	-10.7406140567884	26.5268536317323	3.70086061677425e-11	2.57784125814952e-09	-0.859521383229461	-0.5836040159401
RAB27A	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.818229562975	-1.818229562975	-1.44975669905641	-1.361653967605	4.41733732861778	14.930544198866	0.000504588393182718	0.0120862679618304	0.19060561226576	0.546340115571419
RAB27A	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.5982153058795	-0.5982153058795	-1.22772467946564	-1.264129385735	-8.03220845727025	41.4266796550689	5.56453264620742e-10	3.39686903312159e-08	-0.787737641557368	-0.47128110561492
RAB27A	BRD-K06519765-065-01-6::2.5::MTS006	2.5	vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	chemo	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.36679873139	-1.36679873139	-2.50166448440748	-2.37307934162	-8.70914094206716	7.94959230580477	2.45198251913656e-05	0.000786487520718379	-1.43568719995464	-0.834044306080328
RAB27A	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.402724862035	-2.402724862035	-3.18760295174771	-3.102963726805	-6.50441944156635	19.1766068836925	2.98943256375855e-06	0.000113442296734739	-1.03728268294481	-0.532473496480616
RAB27A	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.9710596117505	0.9710596117505	0.00493517065089117	0.1859491052615	-15.7622646429956	175.508174067339	1.9121722195959e-35	1.26102756816545e-32	-1.08709162700268	-0.845157255196538
RAB27A	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.1948325447345	-0.1948325447345	-0.475669037619292	-0.33490377325	-3.68472708644214	17.2933349928331	0.00179358360432198	0.0365589139639302	-0.441431434294903	-0.12024155147468
RAB27A	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.6230032959255	0.6230032959255	0.504395080495788	0.505306635797	-5.1654827915795	185.65167427383	6.15063253731896e-07	2.5929561783852e-05	-0.163907596966398	-0.0733088338930268
RAB27A	BRD-K16551357-001-03-2::2.5::HTS002	2.5	evacetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.5101636149645	-0.5101636149645	0.0659444332821947	0.05179178276535	14.5380329969509	6.74882700356203	2.41597906137169e-06	9.30316881503293e-05	0.481691930814003	0.670524165679386
RAB27A	BRD-K16803204-001-01-6::2.5::HTS002	2.5	filgotinib	JAK inhibitor	noncancer	JAK1, JAK2, JAK3, TYK2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.06944217738815	0.06944217738815	0.245257745388007	0.2325578097185	4.98213569765337	9.07226664476397	0.000739273680973183	0.0169686567594481	0.0960826864754883	0.255548449524226
RAB27A	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-3.556163996675	-3.556163996675	-2.344612042611	-2.27083369545	10.0868527072805	4.70372601630784	0.000230991583527658	0.00600973477857482	0.896852100399542	1.52625180772847
RAB27A	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.619033997475	-2.619033997475	-0.857229424467029	-0.775615128041	23.7661379719147	72.6924180923471	5.25480792328937e-36	3.70479515589042e-33	1.61405142223601	1.90955772377994
RAB27A	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-3.96816086171	-3.96816086171	-3.08049597850782	-2.85883819524	6.51293514099468	5.17158073616775	0.0011211310210728	0.0244342571645098	0.540781074426257	1.23454869197811
RAB27A	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.137386287504	0.137386287504	-0.115305339616559	-0.0402228786984	-4.49895914304978	100.594145278705	1.83636024494645e-05	0.000603380737297451	-0.364116674089461	-0.141266580151657
RAB27A	BRD-K21728777-001-02-3::2.5::HTS002	2.5	AMG900	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.98684763157	-1.98684763157	-1.53850066454733	-1.382083596445	4.8405737557101	23.6774024233777	6.4428698084745e-05	0.00190106919691949	0.257045204044959	0.639648730000372
RAB27A	BRD-K21782625-001-02-4::2.5::HTS002	2.5	AMG458	MET inhibitor	targeted cancer	MET	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.134510480732	-0.134510480732	0.0293578517103815	0.0127189864736	3.77817505837613	167.64859646491	0.000219210447098499	0.00573112088016382	0.0782419785284181	0.249494686356345
RAB27A	BRD-K26253904-001-01-5::2.5::HTS002	2.5	NMS-873	ATPase inhibitor	targeted cancer	VCP	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.20876706436	-2.20876706436	-3.09316602536837	-2.9100349769	-8.51708310907579	54.1237848112552	1.43093698407531e-11	1.05139284490873e-09	-1.09257120348291	-0.676226718533835
RAB27A	BRD-K33610132-001-02-9::2.5::HTS002	2.5	rociletinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.3134878385965	-0.3134878385965	0.203712700982998	0.245890456129	12.8511148758779	180.901939104138	2.82287231009317e-27	8.65555649999942e-25	0.437789405221553	0.596611673937443
RAB27A	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.646415451826	0.646415451826	0.0361949380208365	0.143970790547	-11.0792902836604	5.44430897331837	6.11501780708601e-05	0.00181426585212478	-0.748396219075751	-0.472044808534576
RAB27A	BRD-K35960502-001-20-0::2.5::HTS002	2.5	niclosamide	DNA replication inhibitor, STAT inhibitor	noncancer	STAT3	infectious disease	tapeworm	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.482809568515	-0.482809568515	-0.705311394635876	-0.681426229631	-3.91693983005007	178.447701747253	0.000127560394380041	0.00353137325847066	-0.334597832336571	-0.11040581990518
RAB27A	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.0909006111634	-0.0909006111634	-0.51241481841267	-0.4097580139535	-8.66420473436366	191.014443037922	1.91308170467729e-15	2.07820014537141e-13	-0.517474584065765	-0.325553830432775
RAB27A	BRD-K37764012-001-04-1::2.5::HTS002	2.5	PF-03758309	p21 activated kinase inhibitor	targeted cancer	PAK4	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.236855646645	-4.236855646645	-3.18731041598534	-3.08603561013	11.070925336085	180.800467023623	4.4370979408292e-22	8.74883868040461e-20	0.862484720148546	1.23660574117077
RAB27A	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2375681340715	0.2375681340715	0.0878633265045058	0.1179670530315	-5.31413638858304	168.606676903784	3.35533339689859e-07	1.46794295085503e-05	-0.205318227663006	-0.0940913874709828
RAB27A	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.10129969818835	0.10129969818835	0.257756944424277	0.300751796019	4.55904414672915	41.1787835306681	4.541321529809e-05	0.00138042391456876	0.0871597899303719	0.225754702541482
RAB27A	BRD-K40718343-001-02-6::2.5::HTS002	2.5	AEE788	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.03516244558671	0.03516244558671	-0.396936192779682	-0.1963749895675	-5.69294919868405	11.2404712783533	0.000128619083297385	0.00355884320992064	-0.59871987508682	-0.265477401645965
RAB27A	BRD-K41859756-001-06-8::2.5::HTS002	2.5	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.691470365085	-4.691470365085	-3.97954603500754	-3.96236214096	6.40982588089279	8.55856485623293	0.000154461882374685	0.00419682644912016	0.458682458962241	0.965166201192672
RAB27A	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.48463033503	-1.48463033503	-2.29643302808746	-2.14029239454	-9.01767118181558	61.9988968698844	6.93212321201876e-13	5.85935361269501e-11	-0.991757251446996	-0.631848134667924
RAB27A	BRD-K42673188-001-01-1::2.5::MTS006	2.5	verubulin	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.613521058825	-1.613521058825	-2.47285091986537	-2.30487473877	-8.77986664967907	190.999591884793	9.21717119414938e-16	1.02623744668615e-13	-1.0523846736357	-0.666275048445037
RAB27A	BRD-K42898655-001-01-8::2.5::HTS002	2.5	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.797140436264	-0.797140436264	-1.35067642251555	-1.32952488095	-8.41123265637793	5.27650295009832	0.000298434133850403	0.0075365959083331	-0.720071877241574	-0.38700009526153
RAB27A	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.272262358322	-0.272262358322	-0.895632589606309	-0.852653660565	-9.53416390859855	30.9549773626576	1.00335878300134e-10	6.64756984859027e-09	-0.756727170929767	-0.490013291638851
RAB27A	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.216693619585	-2.216693619585	-1.57878600925935	-1.40747957336	7.16147042336738	43.4683373497683	7.08623772024472e-09	3.8362875583287e-07	0.458326810263278	0.817488410388017
RAB27A	BRD-K51350053-048-16-5::2.5::HTS002	2.5	toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	ESR1	oncology	breast cancer	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.05916247877855	-0.05916247877855	-0.507870191230488	-0.436805913717	-6.75031857782082	145.485706130323	3.26777261472305e-10	2.04908846325622e-08	-0.580083398691723	-0.317332026212152
RAB27A	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.0483718683154	0.0483718683154	0.259853824408923	0.257282112096	5.57807014056352	6.63227667064329	0.00100482306970659	0.0222183765301913	0.120814166170792	0.302149746016253
RAB27A	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.532742231906	-0.532742231906	-0.764955680192532	-0.6098527820225	-3.38585782648481	161.659262761285	0.000890807906160095	0.0199922479287316	-0.367648206364339	-0.0967786902087248
RAB27A	BRD-K53972329-001-07-0::2.5::HTS002	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.3255873032235	0.3255873032235	0.558033725757516	0.4808891597695	4.68455575439414	161.205572654157	5.92772032113062e-06	0.000213387732965374	0.1344579114588	0.330434933609233
RAB27A	BRD-K54247840-004-01-3::2.5::HTS002	2.5	halofuginone	collagenase inhibitor	noncancer	COL1A1, MMP2	rheumatology	scleroderma	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.539290434325	-4.539290434325	-5.72667622218759	-5.5836707127	-7.98789665818678	6.01371931637543	0.00020283221467053	0.00534984318706866	-1.55091357612472	-0.823857999600455
RAB27A	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.6674830612795	-0.6674830612795	-1.30175969454069	-1.05786698502	-7.46110043283624	63.9144505033215	2.89500695299259e-10	1.8249527800822e-08	-0.804110281209185	-0.464442985313197
RAB27A	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.6372946129855	0.6372946129855	0.230332775355032	0.271076937361	-8.32365714578142	5.6250665666288	0.000227860673162409	0.00593187783532442	-0.528556522465541	-0.285367152795396
RAB27A	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.266695130595	-2.266695130595	-1.02589787951385	-1.108311362665	13.9665934142775	16.8158603611245	1.11364036262151e-10	7.33063345455485e-09	1.053203992283	1.42839050987931
RAB27A	BRD-K60866521-001-07-1::2.5::MTS010::PROS003_PR500	2.5	idelalisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.349497515691	0.349497515691	-0.0152638315604895	0.000732567672741	-16.8426838591384	37.3097346002703	5.04062237574812e-19	7.57078873981583e-17	-0.408630225194083	-0.320892469308896
RAB27A	BRD-K63923597-001-10-0::2.5::HTS002	2.5	barasertib-HQPA	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.740718539835	-1.740718539835	-1.16192235676901	-0.996883336969	7.38876401670639	63.1119537251173	4.14781047596828e-10	2.56786849076778e-08	0.422262326558733	0.73533003957325
RAB27A	BRD-K66030860-001-03-6::2.5::HTS002	2.5	salidroside	beta amyloid protein neurotoxicity inhibitor	noncancer	APP	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.4095146623045	0.4095146623045	0.130244451701271	0.132086067756	-9.17914164191187	19.8740619500735	1.38395024169536e-08	7.29514686060809e-07	-0.342760264020745	-0.215780157185712
RAB27A	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.37911854124	-4.37911854124	-2.60627799134352	-2.56925440076	13.5303716378792	182.659135790291	2.40354567288194e-29	9.33241921237524e-27	1.51432001023383	2.03136108955914
RAB27A	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.054043908735	-1.054043908735	-1.76501614335591	-1.7012260142	-10.4612288738239	47.1171036108037	7.10549134336301e-14	6.621360235355e-12	-0.847686365858882	-0.574258103382944
RAB27A	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.185502657631	0.185502657631	-0.0813776955933777	0.0411624842104	-6.25142698667273	187.65469465316	2.67486730356782e-09	1.52029073006202e-07	-0.351096515890513	-0.182664190558242
RAB27A	BRD-K70401845-003-09-6::2.5::HTS002	2.5	erlotinib	EGFR inhibitor	targeted cancer	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.5005911987575	-0.5005911987575	-1.09473065455635	-1.05295046381	-8.99438023501981	89.0160054847061	3.85311936649346e-14	3.69501217315963e-12	-0.725392470188348	-0.46288644140936
RAB27A	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.3045933160685	0.3045933160685	0.102806574857888	0.0827932765815	-5.46488539676306	180.118026286638	1.52528502297733e-07	7.01529643110962e-06	-0.274646467023353	-0.12892701539787
RAB27A	BRD-K70821460-300-02-4::2.5::HTS002	2.5	4-methylhistamine	histamine receptor agonist	noncancer	HRH4	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2343700832395	0.2343700832395	0.479435235220047	0.473971299308	7.87333498512574	53.8166817587548	1.61497820310885e-10	1.04446790372395e-08	0.182656480036986	0.307473823924109
RAB27A	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.1963797639	-1.1963797639	-0.885302802343372	-0.689609968602	4.94337277495894	102.779575446062	2.99653361287993e-06	0.000113671513754857	0.186270773989489	0.435883149123768
RAB27A	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-2.33779420376	-2.33779420376	-2.63366851116646	-2.52531204565	-3.75888932982745	193.000479725543	0.000226074794985593	0.00589397697779676	-0.451122895006364	-0.140625719806557
RAB27A	BRD-K76180386-001-01-6::2.5::HTS002	2.5	JIB04	histone lysine demethylase inhibitor	noncancer	KDM4E	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.687915479236	-0.687915479236	-1.70673990509342	-1.602559897845	-12.1439307937401	38.9258970499101	8.18944888126813e-15	8.35031583859809e-13	-1.18852996755471	-0.849118884160138
RAB27A	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2930648267905	0.2930648267905	0.093294469321128	0.1896034324075	-4.48730558434046	112.50154297707	1.75094486618288e-05	0.000577973605766381	-0.287974755370919	-0.111565959567825
RAB27A	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.352625072191	0.352625072191	0.500205198196242	0.518013519807	5.10631652389758	186.079021318962	8.08548748799247e-07	3.34935146465778e-05	0.0905634333628976	0.204596818647586
RAB27A	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2471770773005	0.2471770773005	0.0197384590600814	0.0259313359155	-7.7898617161781	38.9811521277255	1.81543621645452e-09	1.05133917545658e-07	-0.286495525367542	-0.168381711113296
RAB27A	BRD-K79930101-300-03-7::2.5::HTS002	2.5	GW-583340	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.0609331315514	-0.0609331315514	-0.532311707328592	-0.365507892562	-5.70323454120012	6.90757599091719	0.000768349366767157	0.0175471019104782	-0.667348714647498	-0.275408436906886
RAB27A	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.5506207716705	-0.5506207716705	-1.71193391757385	-1.55120007366	-15.6679318377617	21.0132996549835	4.57971355629527e-13	3.93728610833217e-11	-1.31544898539118	-1.00717730641553
RAB27A	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-4.06642317582	-4.06642317582	-2.76152998530541	-2.642391718485	11.4554555028085	7.23901025555516	6.7181680679656e-06	0.000238789095164013	1.03733076280283	1.57245561822636
RAB27A	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-5.394262055845	-5.394262055845	-4.8360900732769	-4.95161811894	5.1179652901546	10.6289238235951	0.000372847800765165	0.00923625708393402	0.317103240675362	0.79924072446084
RAB27A	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.235464308741	0.235464308741	0.00310880930025736	0.041364371782	-7.10146985320958	158.134447473453	3.95157396797555e-11	2.74089610673862e-09	-0.296978810296176	-0.167732188585309
RAB27A	BRD-K88429204-001-35-1::2.5::HTS002	2.5	pyrimethamine	dihydrofolate reductase inhibitor	noncancer	DHFR, SLC47A1	infectious disease	malaria	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-1.01755169112	-1.01755169112	-0.776288935874609	-0.768623385632	4.99248618433449	188.878327634394	1.34986801860624e-06	5.40718543272844e-05	0.145936362403078	0.336589148087704
RAB27A	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-6.000781723495	-6.000781723495	-6.21667575773106	-6.19873542132	-3.3677919888223	36.9259497488865	0.00178279152040732	0.0363839196131574	-0.345792935136705	-0.0859951333354109
RAB27A	BRD-K89162000-001-06-4::2.5::HTS002	2.5	tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFD, PDGFRB	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.2733417700495	0.2733417700495	0.0531342887530708	0.117993019303	-4.5850768865964	7.51599527866561	0.00210428609080813	0.0419153841595554	-0.332211720489044	-0.108203242103814
RAB27A	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.283191638327	0.283191638327	0.101137225597112	0.1180798290625	-6.76428777445779	15.8962740004939	4.70374714902445e-06	0.000172362698359251	-0.239139932827704	-0.124968892632072
RAB27A	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	-0.8426320976815	-0.8426320976815	-1.02500711752817	-0.948156981669	-4.26767197132123	57.0911584753794	7.52863426754541e-05	0.00218942286828866	-0.267945570517126	-0.0968044691762229
RAB27A	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.32071283012	0.32071283012	-0.369736044835912	-0.291376214184	-9.95191158450815	12.6133174622219	2.46918904255657e-07	1.09956122647436e-05	-0.840800480519685	-0.54009726939214
RAB27A	BRD-K95523387-001-09-6::2.5::HTS002	2.5	OLDA	TRPV agonist	noncancer	GPR119	NA	NA	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.770468781433	0.770468781433	0.270618345302184	0.3623330707505	-8.28876150865786	8.17926460548985	2.96564159210891e-05	0.000933230064300558	-0.638384356159777	-0.361316516101856
RAB27A	BRD-K95763993-001-19-3::2.5::HTS002	2.5	trapidil	PDGFR tyrosine kinase receptor inhibitor	noncancer	PDGFRA	cardiology	coronary artery disease (CAD)	U2OS, HCC15	BONE, LUNG	osteosarcoma, carcinoma (squamous_cell_carcinoma)	0.204510328808	0.204510328808	0.395517182531919	0.422554855711	7.12511321877837	74.5550214328849	5.55266385824252e-10	3.39155569128886e-08	0.137598243831937	0.244415463615901
RAD51C	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.0566585422182	-0.0566585422182	-0.448593053260142	-0.3315553181695	-5.31705677505656	161.247024615819	3.46866315873391e-07	1.51205966178268e-05	-0.537501221673206	-0.246367800410678
RAD51C	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3489438128585	0.3489438128585	-0.0161050877680926	0.03331372318045	-7.56232739996004	166.732780574328	2.52531988439021e-12	2.02185015129425e-10	-0.46035208371161	-0.269745717541576
RAD51C	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5255211731385	0.5255211731385	0.070449288097728	0.128125201883	-14.6105704142927	39.5310061827728	1.58892441605162e-17	2.09313202930502e-15	-0.518045101378343	-0.392098668703201
RAD51C	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.318874947375	-1.318874947375	-2.36722852247272	-2.31691828506	-12.9804339786761	101.474036971593	2.733276057252e-23	6.02695806661279e-21	-1.20855882885632	-0.888148321339134
RAD51C	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3609084970145	0.3609084970145	-0.190782995291113	-0.136086260588	-10.0256120254119	8.47721561294462	5.470077383534e-06	0.000198039901272882	-0.677354050667708	-0.426028933943518
RAD51C	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2019458091485	-0.2019458091485	0.0612257106720533	0.0780850986405	5.03213973991509	15.6629797040328	0.00013071282648037	0.00361025120962773	0.152110233248833	0.374232806392274
RAD51C	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.03560262593245	-0.03560262593245	-0.358846164703917	-0.164030729397	-5.15436790742883	151.400903601097	7.83462954329246e-07	3.25676554574152e-05	-0.447148271002783	-0.199338806540151
RAD51C	BRD-K07359318-001-03-9::2.44929::HTS002	2.44929	benfotiamine	antioxidant	noncancer	AGER	rheumatology	lumbago	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1591927866895	0.1591927866895	0.33662769961668	0.3600151541855	6.99957500100422	174.344399179395	5.31874703837923e-11	3.62698610877754e-09	0.127403743288251	0.227466082566109
RAD51C	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1579310880505	0.1579310880505	0.278744698127433	0.26768413301	4.24724606664703	70.0741675397938	6.53866390841523e-05	0.00192688752485457	0.0640825753907857	0.177544644763081
RAD51C	BRD-K13533483-001-16-2::2.5::MTS005	2.5	cyclosporine	calcineurin inhibitor	noncancer	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	transplant, rheumatology, dermatology	organ rejection, rheumatoid arthritis, psoriasis	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.317563374844	0.317563374844	0.223065081321342	0.221127225806	-3.8248522448457	85.0059011814292	0.000248882450189685	0.00642683453815722	-0.143621167819265	-0.0453754192260504
RAD51C	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.203693014895	0.203693014895	-0.0727960989447174	0.0407112965926	-5.70937430602105	12.1383002156446	9.34726056449985e-05	0.00266195722764907	-0.381869777294916	-0.171108450384519
RAD51C	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.06975097014	-2.06975097014	-2.36001528640929	-2.30540806626	-3.26036568184629	192.915253932685	0.00131540181111204	0.0280917451946824	-0.465857837968138	-0.114670794570433
RAD51C	BRD-K19284129-001-02-6::2.5::HTS002	2.5	salvinorin-a	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.6353301200815	-0.6353301200815	0.0196998247339855	0.02724514887165	11.5337923294615	2.66988032971078	0.00236484953920015	0.0462839774346844	0.460967303545051	0.84909258608592
RAD51C	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.615996918055	-1.615996918055	-2.45901586418214	-2.36107459971	-7.70294721899293	9.39334480883655	2.34755495522983e-05	0.000754346485756303	-1.08902055746028	-0.597017334794003
RAD51C	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.4456434749245	0.4456434749245	0.0958347612033171	0.13724327771	-12.9840909346254	9.48105761034241	2.36434034308458e-07	1.05682315201872e-05	-0.410286106344914	-0.289331321097451
RAD51C	BRD-K21673112-003-01-3::2.5::HTS002	2.5	BF2.649	histamine receptor antagonist	noncancer	HRH3	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.492204088794	0.492204088794	-0.118925929425641	-0.0402228786984	-8.62828940161254	5.58216750114082	0.000196304403707541	0.00519557008424716	-0.78763515775485	-0.434624878684432
RAD51C	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.304636765619	-0.304636765619	-0.978549783287334	-0.82417204092	-6.09582849475944	17.3706506290312	1.08163053990271e-05	0.000370208866155874	-0.906781216788831	-0.441044818547838
RAD51C	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.329148933027	0.329148933027	0.146745574559115	0.195908235522	-3.8269910661428	13.3505190802844	0.00200401239349338	0.0401606332197329	-0.285097449992609	-0.0797092669431613
RAD51C	BRD-K28453807-003-11-2::2.5::HTS002	2.5	nitrocaramiphen	cholinergic receptor antagonist	noncancer	CHRM1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.01056283547198	-0.01056283547198	0.36104053394915	0.350372820253	12.2689642624081	14.5449993208872	4.5545513871388e-09	2.53025516913964e-07	0.306869516536582	0.436337222305677
RAD51C	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.3624036023595	-0.3624036023595	-0.746166835332784	-0.6332790164525	-6.936167241799	177.989105845574	7.18724313222323e-11	4.84413406693797e-09	-0.492946203991677	-0.27458026195489
RAD51C	BRD-K30867024-003-03-3::2.5::HTS002	2.5	SB-216641	serotonin receptor antagonist	noncancer	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.306135728632	0.306135728632	-0.0519170648545899	-0.02368862812505	-10.0410684931527	187.114603453562	2.99189978545875e-19	4.60999920285829e-17	-0.428397801104623	-0.287707785868557
RAD51C	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.09887811361585	0.09887811361585	-0.0731899473510128	0.0269217911151	-5.62953585667119	188.871214050856	6.4583039733709e-08	3.1147655992543e-06	-0.232361149123172	-0.111774972810553
RAD51C	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-4.225710283395	-4.225710283395	-3.10836161138211	-3.10613635441	9.63346337985974	21.8569100373489	2.52541261404642e-09	1.43763389151648e-07	0.876716710242231	1.35798063378355
RAD51C	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.521573651795	0.521573651795	0.0374953734378261	0.143970790547	-11.1287363171898	96.7241481288384	5.19458123653936e-19	7.79110848037959e-17	-0.570412967251408	-0.39774358946294
RAD51C	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.257540063239	0.257540063239	0.0354405293698195	0.0389416186426	-9.08881693418127	7.64114383641702	2.3152478088886e-05	0.000745529969397963	-0.278914360697049	-0.165284707041312
RAD51C	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.06714430051805	-0.06714430051805	-1.03984736937329	-1.017015264785	-13.3252718377937	133.839446194053	2.60290297469715e-26	7.38910717435584e-24	-1.11707972669779	-0.828326411012693
RAD51C	BRD-K36529613-001-02-6::2.5::HTS002	2.5	PU-H71	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.31151431658	-2.31151431658	-3.49236353866149	-3.372344193665	-11.8452624292168	187.88182798035	1.54657329362901e-24	3.82766174884771e-22	-1.37750393624579	-0.984194507917184
RAD51C	BRD-K39160765-003-02-9::2.5::HTS002	2.5	4-chlorophenylguanidine	urokinase inhibitor	noncancer	PLAUR	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.171134448609	-0.171134448609	0.0567744607846191	0.0820318935995	6.90586762498986	32.3733221774841	7.6269193786279e-08	3.6423128420275e-06	0.160715992311717	0.295101826475522
RAD51C	BRD-K40718343-001-02-6::2.5::HTS002	2.5	AEE788	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.08241469346175	-0.08241469346175	-0.395698538684435	-0.1963749895675	-4.90586906379008	189.389510018863	1.99743454326362e-06	7.78520000405797e-05	-0.439250105974317	-0.187317584471053
RAD51C	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.744160992922	-0.744160992922	-1.29073821286897	-1.33795379646	-6.29790339799102	29.5446125029026	6.50355376484606e-07	2.72992592022266e-05	-0.723934900313368	-0.36921953958058
RAD51C	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.7205652579005	0.7205652579005	0.470798068695106	0.492327571576	-7.59110888587083	16.2766798000026	9.75910697636862e-07	3.99247879201777e-05	-0.31942133951335	-0.180113038897438
RAD51C	BRD-K45662124-050-01-5::2.5::HTS002	2.5	3'-fluorobenzylspiperone	dopamine receptor ligand	noncancer	DRD2	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.7254241010235	0.7254241010235	0.506586808839578	0.5255641700865	-5.67309778508717	6.89814064244473	0.000796254000623147	0.0181187306189148	-0.310325399825512	-0.127349184542331
RAD51C	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.682682923295	-1.682682923295	-2.24610043717082	-2.140330076935	-8.85402948689161	142.399528855559	3.03403666522049e-15	3.21603384975293e-13	-0.689206916574348	-0.4376281111773
RAD51C	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.595547963555	-0.595547963555	-1.59731338818541	-1.48697544025	-10.3280361474235	12.6137457981484	1.62151855738851e-07	7.42762237415091e-06	-1.21196401179281	-0.791566837468005
RAD51C	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-4.34984232608	-4.34984232608	-6.20071851457679	-6.32403693229	-20.642157100903	103.712287041968	1.6220509696504e-38	1.47937260542213e-35	-2.02869078226155	-1.67306159473203
RAD51C	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5096370896265	0.5096370896265	0.224111932052701	0.2005091684065	-9.02668849545586	21.2718470576433	1.00854299820578e-08	5.38247042486172e-07	-0.35125472804357	-0.219795587104028
RAD51C	BRD-K53561341-001-07-5::2.5::HTS002	2.5	aurora-a-inhibitor-i	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2163748640615	-0.2163748640615	-0.622047197599597	-0.52264323687	-6.51541598028469	37.164558500596	1.23881052387212e-07	5.77578900959295e-06	-0.531811231288102	-0.279533435788092
RAD51C	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.455864603885	-1.455864603885	-2.75309285829189	-2.66953815971	-10.494037867938	3.26855080851948	0.00125539252558195	0.0269822527692994	-1.67296049196035	-0.921496016853423
RAD51C	BRD-K53972329-001-07-0::2.5::MTS010::PROS003_PR500	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.1075453260805	-0.1075453260805	-0.0124149690141648	-0.0140997876931	4.07986914244196	172.400340009201	6.87713376921002e-05	0.00201554656587039	0.0491067798695782	0.141153934263092
RAD51C	BRD-K56957086-001-06-3::2.5::HTS002	2.5	dacinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-4.43337392102	-4.43337392102	-5.5989329328042	-5.64321489528	-11.1142405346558	6.00685275528559	3.13728079654327e-05	0.000981477530057396	-1.42209760681162	-0.909020416756788
RAD51C	BRD-K57136142-001-02-4::2.5::HTS002	2.5	CCT129202	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.03549820651	-1.03549820651	-0.744628677564745	-0.642523913736	6.28977272307509	186.88140593508	2.19755968867495e-09	1.25835097652689e-07	0.199640522216601	0.382098535673909
RAD51C	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.19790154666	-1.19790154666	-0.456942045463015	-0.469747665561	8.69183941627148	4.83430586927709	0.000394468046601987	0.0096910647712681	0.519544789094593	0.962374213299377
RAD51C	BRD-K61642990-001-01-0::2.5::HTS002	2.5	FERb-033	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5403852443955	0.5403852443955	0.17842025675676	0.239686907074	-9.54531475470236	190.011650927269	6.91462984300921e-18	9.43952674918676e-16	-0.43676460155976	-0.287165373717721
RAD51C	BRD-K61936403-001-01-7::2.5::HTS002	2.5	AS-1949490	SHIP2 phosphatase inhibitor	noncancer	INPP5D	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.492724945176	0.492724945176	0.238849394714864	0.265760037454	-5.74102155505333	9.11243560007295	0.000266677783512035	0.00681980463695871	-0.353723289173785	-0.154027811748487
RAD51C	BRD-K63126190-003-01-6::2.5::HTS002	2.5	epinephrine	adrenergic receptor agonist, neurotransmitter	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.11097098412245	-0.11097098412245	-0.441816954837426	-0.3976462300305	-4.67275854624653	97.4482465905535	9.53373529364514e-06	0.000329786305963794	-0.471362438682545	-0.190329502747406
RAD51C	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3640794184135	0.3640794184135	0.143373630900597	0.15713254048	-8.35451151405498	151.636677112206	3.87196586454656e-14	3.70976563157085e-12	-0.272899798763491	-0.168511776262315
RAD51C	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.711977920958	-0.711977920958	-0.21048102385207	-0.1907303952045	9.78319951958636	175.27786507829	2.6160956659104e-18	3.69614481199018e-16	0.400328603530508	0.602665190681351
RAD51C	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.442497855494	-0.442497855494	-2.64930116823692	-2.62453052692	-15.7406123685024	45.4174938893934	5.17140085941644e-20	8.5808357724193e-18	-2.48910507514682	-1.92450155033901
RAD51C	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3439496201855	0.3439496201855	-0.341736766021049	-0.3277516003215	-10.1855339917334	3.15486743139023	0.00161828759747927	0.033537609986476	-0.894099099049735	-0.477273673363364
RAD51C	BRD-K66808046-065-03-7::2.5::HTS002	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.707015890135	-1.707015890135	-0.438580512674501	-0.317855994101	10.3325838116141	3.22138436495151	0.00140936696754015	0.0298044610543576	0.892514343786442	1.64435641113456
RAD51C	BRD-K67772619-001-05-1::2.5::HTS002	2.5	rheochrysidin	protein tyrosine kinase inhibitor	targeted cancer	PTPN1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.254863258057	-0.254863258057	0.0236475793143134	0.07894128154425	5.48984165135496	6.69954206277816	0.00106194496694723	0.0232749363759926	0.157449347966643	0.399572326775984
RAD51C	BRD-K68103045-001-02-9::2.5::HTS002	2.5	CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.143616958797	-0.143616958797	0.453199290116799	0.47087721143	14.1345988564442	2.95743783250246	0.000826644847843219	0.0187331328519665	0.461340642438731	0.732291855388866
RAD51C	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.37565437119	-2.37565437119	-3.68491204451539	-3.50719189578	-11.745431277547	185.994972989031	3.45671710180799e-24	8.24109810582208e-22	-1.5291648085585	-1.08935053809229
RAD51C	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.1590885985515	-0.1590885985515	0.128019568738029	0.138278646354	9.22807768967166	14.9325867925087	1.47646857442353e-07	6.80245127015522e-06	0.220767451232715	0.353448883346343
RAD51C	BRD-K69608737-001-10-2::2.5::HTS002	2.5	tacrolimus	calcineurin inhibitor	noncancer	FKBP1A	transplant	organ rejection	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5256790121295	0.5256790121295	0.302333632301865	0.3216320959495	-8.22591877605212	145.91226821452	9.79396556794918e-14	8.97831841836176e-12	-0.277006241406055	-0.169684518249214
RAD51C	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5086732724815	0.5086732724815	0.100551547715203	0.0827932765815	-8.30050493365531	5.13270150322112	0.000365021188911617	0.00906122612905234	-0.533536302033638	-0.282707147498955
RAD51C	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.3701466623755	-0.3701466623755	-0.6120070493385	-0.443084865138	-4.67776204699715	178.336453831639	5.71179226923217e-06	0.000206129436819711	-0.343891336254625	-0.139829437671376
RAD51C	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.81252312403	-1.81252312403	-2.52963612790202	-2.26266997363	-6.62192661635249	148.541532934769	6.07705105759748e-10	3.69488020758317e-08	-0.931108210351306	-0.503117797392741
RAD51C	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.327936277937	-0.327936277937	-1.34206334817868	-1.10972386317	-9.22338108925202	6.20174806421197	7.558790118688e-05	0.00219759621181264	-1.28106198269978	-0.747192157783574
RAD51C	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.06218573972005	0.06218573972005	-0.156282125601721	-0.1366984748555	-4.50224012115538	12.3817406935283	0.000670159661064574	0.0155263917410344	-0.323832751220496	-0.113102979423046
RAD51C	BRD-K75009076-001-02-1::2.429::HTS002	2.429	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.5379226069255	-0.5379226069255	-1.9301712361948	-1.72291152257	-10.160260434039	3.13009142208788	0.00168855027442905	0.0347918949978951	-1.81825931492905	-0.966237943609553
RAD51C	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.507136783855	0.507136783855	-0.692964111551574	-0.481859441946	-12.8778315371744	8.94984808724741	4.44067803515598e-07	1.91040963989752e-05	-1.41109430586301	-0.989107484950135
RAD51C	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.0963752478899	0.0963752478899	-0.215742622101453	-0.189464823924	-10.6816698759039	186.850562994825	4.30216424413319e-21	7.83414239830775e-19	-0.369761274314835	-0.254474465667871
RAD51C	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.064109589185	-1.064109589185	0.107285958145618	0.2180824951125	17.0070115583678	2.55748323289747	0.00106384264692283	0.0233117606249181	0.929097844112674	1.41369325054856
RAD51C	BRD-K78789465-001-01-6::2.5::HTS002	2.5	pentagastrin	CCK receptor agonist	noncancer	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2205362771495	-0.2205362771495	0.150462540510156	0.184916881491	7.4139248794151	151.399039930567	8.09723559248163e-12	6.12808053425493e-10	0.272130341050202	0.46986729426911
RAD51C	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.343801009312	0.343801009312	-0.126490095606038	-0.118001057117	-15.8259970592904	92.2546857680021	4.94927360858012e-28	1.66526352159085e-25	-0.529308199979104	-0.411274009856972
RAD51C	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2484036284855	0.2484036284855	-0.388083384099512	-0.347155123363	-10.7441857246743	3.61420536610712	0.000715914209378543	0.0164955038251875	-0.808124954828385	-0.46484907034164
RAD51C	BRD-K85090592-008-22-7::2.5::HTS002	2.5	pilocarpine	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.625607998561	0.625607998561	0.470699092456838	0.471563787015	-4.13486369552615	72.6712936592888	9.41247471648303e-05	0.00267981707426819	-0.229580420166083	-0.0802373920422414
RAD51C	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.68175614002	-1.68175614002	-1.95696213196524	-1.89031364576	-4.13495386392082	35.6667116882029	0.000205532126660563	0.00541239650756013	-0.41023162797273	-0.14018035591775
RAD51C	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-5.00419329568	-5.00419329568	-6.22722166702011	-6.19873542132	-18.676437708935	21.710114598453	7.33738135997664e-15	7.5065088759066e-13	-1.35894136994076	-1.08711537273945
RAD51C	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.873198743934	0.873198743934	-0.323476718407167	-0.108614953002	-11.0725328806989	3.50295338142748	0.00075367484202864	0.0172524164495521	-1.51430390738172	-0.879047017300614
RAD51C	BRD-K89085489-001-23-2::2.5::MTS006	2.5	fenretinide	apoptosis stimulant, retinoid receptor agonist	targeted cancer	RARA	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2270360619125	0.2270360619125	0.319452310371227	0.367607553977	3.11652132196651	188.754584234184	0.00211596547623413	0.0421167129045119	0.0339211042153675	0.150911392702087
RAD51C	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2737148951085	0.2737148951085	0.101234923980808	0.1180798290625	-6.46866550316134	17.8134747611362	4.60578117475254e-06	0.000169351942597965	-0.228540860560782	-0.116419081694603
RAD51C	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.9702101734685	-0.9702101734685	-0.356495808901671	-0.28708101882	9.91655113862663	81.2047934414836	1.20585734689253e-15	1.33359235966011e-13	0.49058159605402	0.736847133079638
RAD51C	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.309252990853	0.309252990853	-0.0117904773285339	0.0437990200838	-7.04937099632954	35.5785186522915	3.01626148107094e-08	1.5161170426277e-06	-0.413445224847016	-0.228641711516052
RAD51C	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	MCF7, BT474	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.139698972185	-2.139698972185	-3.08008746910166	-3.084015642295	-7.54237573247616	5.02778612305853	0.000633348675161311	0.0147580983038322	-1.2603583531709	-0.620418640662417
RAD9A	BRD-A19585813-003-03-3::2.5::HTS002	2.5	methylphenidate	dopamine-norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD), narcolepsy	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.4621369715725	0.4621369715725	0.255612827564034	0.248593111525	-6.11342930863104	14.011783488029	2.67067086720823e-05	0.000849765760537223	-0.278973708347497	-0.134074579669436
RAD9A	BRD-A44090213-001-25-6::2.5::HTS002	2.5	indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	CXCR1, CXCR2, PTGS1, PTGS2	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-1.0029478524635	-1.0029478524635	-1.91259990643437	-1.821377260325	-10.1488488095824	46.2731024817845	2.37208416760132e-13	2.09998524393979e-11	-1.09004128531072	-0.729262822631016
RAD9A	BRD-A55913614-316-09-6::2.5::HTS002	2.5	primaquine	antimalarial agent, DNA inhibitor	noncancer	KRT7, NQO2	infectious disease	malaria	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.4272144144795	0.4272144144795	0.0942540823709488	0.121843056182	-9.67751801528078	72.1728273371057	1.13119421103215e-14	1.1371844467932e-12	-0.401543737095558	-0.264376927121544
RAD9A	BRD-A75919782-399-02-6::2.5::HTS002	2.5	leucovorin	folate receptor ligand	targeted cancer	TYMS	oncology	osteosarcoma	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.05092558740259	0.05092558740259	0.590574546787472	0.648962847525	9.90649335269672	3.03636328112334	0.00207872308046275	0.0414562798094819	0.367456163477912	0.711841755291851
RAD9A	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.5746690432625	-0.5746690432625	-1.19494704752075	-1.043529721605	-8.627886960763	34.292369493114	4.1215392317178e-10	2.55307913871343e-08	-0.76633471882155	-0.47422128969495
RAD9A	BRD-A83650191-004-02-8::2.5::HTS002	2.5	A61603	adrenergic receptor agonist	noncancer	ADRA1A	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-1.628231288945	-1.628231288945	-2.0369071862357	-2.01906141095	-4.37074580935778	172.690087782537	2.13283481385173e-05	0.000691257149278736	-0.593230891766386	-0.224120902815013
RAD9A	BRD-K03273112-001-01-8::2.5::HTS002	2.5	1-azakenpaullone	glycogen synthase kinase inhibitor	noncancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.4665377136395	-0.4665377136395	-0.717682681627902	-0.657905942127	-3.45986506425989	170.678161987791	0.000682658192022949	0.0157954709746396	-0.394430972658044	-0.10785896331876
RAD9A	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-5.7426094032	-5.7426094032	-3.68417753126343	-3.52000958617	16.0639369157234	9.98829874255422	1.83242973622277e-08	9.49801288838913e-07	1.77287295426017	2.34399078961297
RAD9A	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-2.47711507972	-2.47711507972	-3.07906803307849	-3.12584681211	-5.15163904140337	8.09205070152955	0.000841800843723713	0.0190318916703017	-0.870869751938937	-0.333036154778047
RAD9A	BRD-K09090949-001-01-9::2.5::HTS002	2.5	CP-945,598	cannabinoid receptor antagonist	noncancer	CNR1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-1.445311568045	-1.445311568045	-0.684207905715426	-0.6179289044455	13.5721542620776	172.518849200856	5.12638075592996e-29	1.90092052082649e-26	0.650415699622065	0.871791625037083
RAD9A	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-2.505651925675	-2.505651925675	-1.92602903783936	-2.01595157397	7.47763244528813	186.836787819556	2.85362388899466e-12	2.27197011331477e-10	0.426707299573408	0.732538476097864
RAD9A	BRD-K13167095-001-02-9::2.5::HTS002	2.5	AR-42	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-1.66554431039	-1.66554431039	-3.2690187118098	-3.28129580755	-11.6658345932181	9.64895407857338	5.27458182320322e-07	2.2423034304044e-05	-1.91125017790043	-1.29569862493917
RAD9A	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.04459102176585	0.04459102176585	0.342572436386571	0.357900779497	7.26219724183369	5.67681830361373	0.000445074298020263	0.0108056557793821	0.196178133773855	0.399784695467586
RAD9A	BRD-K13390322-001-06-3::2.5::HTS002	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.800391823029	-0.800391823029	-0.325341317760072	-0.176785309489	5.09229820472127	11.7701064126632	0.000281721130183402	0.00715414788045953	0.271352146714504	0.678748863823352
RAD9A	BRD-K13662825-001-07-5::2.5::HTS002	2.5	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-4.569417618475	-4.569417618475	-4.92951704909863	-4.88144799249	-3.96253426482718	11.8756682541569	0.00192214488085551	0.0387518944754849	-0.558331473257613	-0.161867387989649
RAD9A	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.326979548912	0.326979548912	0.239982189783428	0.274310189966	-3.17241963851698	62.7075164278714	0.00234135730096593	0.0459093164488585	-0.141802914629066	-0.032191803628077
RAD9A	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.283683264691	0.283683264691	-0.0570162425306173	0.1891566141585	-4.28678881936401	8.96160051266703	0.0020496773631433	0.0409646866435231	-0.52060562463829	-0.160793389804945
RAD9A	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.704778506891	0.704778506891	-0.485311456357834	-0.373418715101	-10.9399473711419	7.61951281260978	6.28566072963414e-06	0.000224795491159979	-1.44314331324882	-0.93703661324885
RAD9A	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-2.24723503709	-2.24723503709	-3.69357890471883	-3.60112771075	-15.2646838740978	168.417911806032	1.37752594641126e-33	7.60937522083448e-31	-1.63339649624341	-1.25929123901425
RAD9A	BRD-K16136380-001-01-7::2.5::HTS002	2.5	pyrithione-zinc	ATP synthase inhibitor	noncancer	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-7.63584085999	-7.63584085999	-6.32328388749903	-6.32859212175	12.6720345979132	164.001961884153	4.29257617450078e-26	1.19638954343898e-23	1.10803662696197	1.51707731801997
RAD9A	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.1618825458375	-0.1618825458375	-1.14022819483768	-0.889953286616	-10.0378642801148	70.4371509387263	3.19154015576349e-15	3.37538958583874e-13	-1.17271328869946	-0.783978009300888
RAD9A	BRD-K17743125-001-08-4::2.5::HTS002	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-1.04716602343	-1.04716602343	-2.62505265751346	-2.55701566981	-15.0263316395759	186.926223205401	5.55888432854762e-34	3.22008140338725e-31	-1.78503991717267	-1.37073335099425
RAD9A	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.484571941899	0.484571941899	0.306296476183313	0.3131581681635	-4.88953434189899	9.44956437614328	0.000746320522040697	0.0171078215153434	-0.260160827051967	-0.0963901043794075
RAD9A	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-3.00761176573	-3.00761176573	-1.85242596990286	-1.64856167258	9.42365717028738	5.25793347704936	0.000172562327905176	0.00464054092566981	0.844667797316449	1.46570379433784
RAD9A	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.31448643783	-0.31448643783	-0.167433430851744	-0.149311762512	7.57925268814571	155.602796471273	2.92355532845569e-12	2.32591941348396e-10	0.10872762373951	0.185378390217002
RAD9A	BRD-K25630527-001-03-8::2.5::HTS002	2.5	LY2784544	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.313155356173	-0.313155356173	-1.08641460339589	-0.892196306228	-10.3521565198527	50.2958430732403	4.61615151460976e-14	4.38747289567537e-12	-0.92326766173973	-0.623250832706048
RAD9A	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.72510902216	-0.72510902216	-0.129023939345688	-0.0959676428829	16.2206654100089	189.906311374678	1.06312643973399e-37	8.69690178250944e-35	0.52359740656791	0.668572759060715
RAD9A	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.0777346994277	0.0777346994277	-0.0535169802856086	-0.030411088067	-7.2487005480334	188.465089804842	1.05308037916504e-11	7.85883233238383e-10	-0.166969964805334	-0.0955333946212835
RAD9A	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.513196490295	-0.513196490295	0.155565945483952	0.201815706844	11.6705155572265	3.96606029589566	0.000323212511631723	0.0081050443904897	0.509123772332351	0.828401099225554
RAD9A	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-6.336266281775	-6.336266281775	-4.66365568515568	-4.90330008871	18.0782779269389	124.197863219093	1.3869451274527e-36	1.05412256107024e-33	1.48948956356804	1.8557316296706
RAD9A	BRD-K28143534-001-02-2::2.5::HTS002	2.5	cyproheptadine	histamine receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.226044294465	0.226044294465	-0.00729350456555598	0.02120744072425	-6.86931234375395	12.5062211908521	1.39150830525004e-05	0.000467168833890875	-0.30701713402324	-0.159658464037872
RAD9A	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.274884135129	-0.274884135129	0.276781066276242	0.290224760638	21.4158770525672	149.805393299477	1.91017979103614e-47	3.59128881081566e-44	0.500766061244104	0.60256434156638
RAD9A	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.3414092822695	-0.3414092822695	-0.180567617695564	-0.04268072142135	3.46125203612255	39.6550404533956	0.00130164770604164	0.0278365510923355	0.066898421775383	0.254784907372488
RAD9A	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-4.383922706555	-4.383922706555	-3.10670493679405	-3.10613635441	12.3211940652194	190.745430004286	4.82824881761696e-26	1.34045821351169e-23	1.07275017292159	1.48168536660031
RAD9A	BRD-K33127281-001-05-6::2.5::HTS002	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.529805408813	-0.529805408813	-0.160095539685868	-0.1501441638665	10.3463951530475	187.993683280356	3.81573910561631e-20	6.41933710178679e-18	0.299220291472739	0.440199446781524
RAD9A	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.168649724523	-0.168649724523	0.214927164181567	0.242460199933	19.7137172661434	190.974642325691	6.40821020503796e-48	1.2957219670147e-44	0.345197953700635	0.421955823708498
RAD9A	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-3.00895429929	-3.00895429929	-3.6674452814378	-3.65355610334	-6.16530715173784	39.3802680995095	2.93963993653265e-07	1.29720009873812e-05	-0.874459563105915	-0.442522401189693
RAD9A	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.0331762823601	-0.0331762823601	0.173066240329913	0.1694730901705	7.85251114785559	43.1887099856506	7.45340173530125e-10	4.49994405781798e-08	0.153281739944087	0.25920330543594
RAD9A	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.07064362698735	0.07064362698735	-0.0750202052829051	-0.0620606581655	-4.70250281892388	187.075015065813	4.97748488034604e-06	0.00018149359593734	-0.206770613691287	-0.0845570508492227
RAD9A	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-3.1224512079	-3.1224512079	-3.77672332290461	-3.70292092273	-6.58373997752862	176.883470841726	5.0408104293914e-10	3.09301992133132e-08	-0.850389196903458	-0.458155033105753
RAD9A	BRD-K38852836-001-02-1::2.5::HTS002	2.5	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-5.40228889237	-5.40228889237	-4.8482463403223	-4.86851000212	5.62684821001247	8.10050973741142	0.00047288185026041	0.0114058399824964	0.327473383491686	0.780611720603708
RAD9A	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.1882561805955	0.1882561805955	-0.148807373913162	-0.07517274316945	-6.56587817695428	15.265714537617	8.20288884620326e-06	0.000287227081117121	-0.446317232522769	-0.227809876494555
RAD9A	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.5328331059515	-0.5328331059515	-1.01918108724118	-1.03228700688	-7.63230382813052	193.670122981268	1.02282831009134e-12	8.51016183515401e-11	-0.612026755304201	-0.360669207275166
RAD9A	BRD-K41859756-001-06-8::2.5::HTS002	2.5	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-5.354032605355	-5.354032605355	-3.97249750053659	-3.96236214096	10.1437886221987	3.13076212962711	0.00169534172184445	0.0349083385436832	0.958164790371948	1.80490541926488
RAD9A	BRD-K42205652-001-02-7::2.5::HTS002	2.5	MNS-(3,4-Methylenedioxy-nitrostyrene)	src inhibitor, syk inhibitor	noncancer	SRC, SYK	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.4555309572175	-0.4555309572175	0.248161659398932	0.262709081551	15.2040378642206	7.53892228220188	6.28301781282617e-07	2.6420896662143e-05	0.595816247967903	0.811568985264961
RAD9A	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-6.222211639875	-6.222211639875	-5.43875759830223	-5.470053491025	9.72396736028286	142.423756301907	1.87301549354831e-17	2.44037408946331e-15	0.624187673773765	0.942720409371766
RAD9A	BRD-K47337578-034-02-5::2.5::HTS002	2.5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	noncancer	HTR2A	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.10120435372195	0.10120435372195	-0.127066381195541	-0.101623022714	-5.27518721535588	18.9322264061964	4.36547389367833e-05	0.00133321124844426	-0.318863145532617	-0.137678324302366
RAD9A	BRD-K50388907-001-30-4::2.5::HTS002	2.5	fenofibrate	PPAR receptor agonist	noncancer	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.00358571205275	-0.00358571205275	0.199959914236889	0.198833641083	6.68463307739368	10.4747572881087	4.3728120978888e-05	0.00133488170364394	0.136113801406525	0.270977451172752
RAD9A	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.5851831853195	-0.5851831853195	-0.319320644722895	-0.231836238549	5.33936906196003	72.0052562913004	1.03794035293761e-06	4.22367036082713e-05	0.166602380587656	0.365122700605555
RAD9A	BRD-K52313696-001-12-3::2.5::MTS010::PROS004_PR500	2.5	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.337729522966	0.337729522966	-0.0147272906861427	-0.0070642593788	-9.5751693019932	5.78566913623175	9.20030539234273e-05	0.0026242909960546	-0.443341344084652	-0.261572283219633
RAD9A	BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500	2.49998	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.1583088815745	0.1583088815745	-0.199964765085682	-0.112315878397	-7.72539190421681	187.135276985859	6.57633376707504e-13	5.57114245044833e-11	-0.449760812923175	-0.266786480397189
RAD9A	BRD-K56301217-001-07-4::2.5::HTS002	2.5	ABT-737	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.02556293492375	0.02556293492375	-0.13625824201844	-0.0916218688464	-5.21672464506341	191.509956158402	4.70619846873238e-07	2.01533428892096e-05	-0.223005295985011	-0.100637057899369
RAD9A	BRD-K58435339-001-03-0::2.5::HTS002	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-6.00367403365	-6.00367403365	-4.66612419492293	-4.69893624844	12.5100179966609	16.3285448600299	8.75487310314187e-10	5.23994190819127e-08	1.11126325372463	1.56383642372951
RAD9A	BRD-K58466253-003-14-0::2.5::HTS002	2.5	palmatine-chloride	dopamine synthesis inhibitor	noncancer	CYP3A4	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.786388826643	-0.786388826643	-0.0477988367154861	-0.0597563096057	16.645018992635	5.26138765557459	9.4119397388443e-06	0.000325783532346053	0.626209018644856	0.850970961210171
RAD9A	BRD-K61314889-001-04-4::2.5::HTS002	2.5	endo-IWR-1	PARP inhibitor	targeted cancer	TNKS, TNKS2	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-2.162744258815	-2.162744258815	-1.43522244810883	-1.402650367965	8.65114379271377	5.08825233504732	0.000312245763188786	0.00785392819839096	0.512470460704377	0.942573160707967
RAD9A	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-1.837706368085	-1.837706368085	-1.47624659135429	-1.34809352963	5.17628578291859	43.0026966316148	5.67085680475639e-06	0.000204721082719662	0.220634516937094	0.50228503652433
RAD9A	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-2.11838123465	-2.11838123465	-2.4896861923106	-2.41136656484	-4.07101850839267	42.369570018709	0.000200308337329728	0.00529173987816384	-0.555320370567395	-0.187289544753797
RAD9A	BRD-K66094457-001-01-5::2.5::HTS002	2.5	CPP	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-1.574838962565	-1.574838962565	-0.906200896010118	-0.85122207753	11.3070707572667	184.29238516133	7.44588209827732e-23	1.58635036206926e-20	0.551970423525819	0.785305709583946
RAD9A	BRD-K67537649-001-04-5::2.5::HTS002	2.5	PQ-401	IGF-1 inhibitor	targeted cancer	IGF1R	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.0880140619498	-0.0880140619498	0.179749020455115	0.20362806034	7.81076245628357	36.853004808426	2.49167027205336e-09	1.4199340540785e-07	0.198293219758603	0.337232945051226
RAD9A	BRD-K68095457-001-10-1::2.5::HTS002	2.5	palmitoylethanolamide	cannabinoid receptor agonist	noncancer	CNR2, GPR119, GPR55	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.1632076027105	0.1632076027105	0.305718668473012	0.326165847724	5.2613526413112	31.0369916476964	1.011672414795e-05	0.000348322469061202	0.087270671372549	0.197751460152475
RAD9A	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.486720069931	0.486720069931	-0.158002542107105	0.0566391407425	-10.2386526508204	185.10612547294	8.86461237486918e-20	1.42960384175571e-17	-0.768952733623945	-0.520492490452264
RAD9A	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-1.561987255715	-1.561987255715	-1.02364641544436	-0.654329018583	4.93080554517971	22.1454318248789	6.12183019807459e-05	0.00181553306285198	0.312003456634716	0.76467822390657
RAD9A	BRD-K72280606-001-01-2::2.5::MTS006	2.5	gilteritinib	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.1025175415214	0.1025175415214	0.0216342943818114	0.0368466353563	-3.11551146826647	161.118652775661	0.00217434361172917	0.0430627325779248	-0.132151875685058	-0.029614618594119
RAD9A	BRD-K72414522-001-06-7::2.5::HTS002	2.5	AZD5438	CDK inhibitor	targeted cancer	KCNH2	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-3.80480995523	-3.80480995523	-2.40185534262158	-2.18452453626	13.7904456941102	138.611979723759	8.89507029169099e-28	2.91064354282113e-25	1.20180384076579	1.60410538445106
RAD9A	BRD-K76037122-001-02-5::2.5::HTS002	2.5	guanidine	HSP inhibitor	noncancer	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.1107120302513	-0.1107120302513	0.216497212263422	0.217996960587	11.0060038228718	28.6760296592723	8.26626943948312e-12	6.25379902116123e-10	0.266374573251939	0.388043911777505
RAD9A	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.628833228547	-0.628833228547	-0.142591269944303	-0.1170838755295	8.11231040928707	3.52789815953606	0.00210570651496709	0.0419397799132405	0.310663562769957	0.661820354435437
RAD9A	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.325685122801	-0.325685122801	-0.168511056290956	-0.1689019992055	4.98598457205412	126.19497796571	1.99122350396771e-06	7.7624034627482e-05	0.0947915634793109	0.219556569540776
RAD9A	BRD-K76908866-001-07-6::2.5::HTS002	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-1.318959020785	-1.318959020785	-0.689062748212711	-0.619490026625	9.24383537877241	70.2216891389304	9.19555664625218e-14	8.45505989032425e-12	0.493998268449171	0.765794276695406
RAD9A	BRD-K77245796-003-01-6::2.5::HTS002	2.5	gamma-aminobutyric-acid	benzodiazepine receptor agonist	noncancer	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.03802960147725	0.03802960147725	0.510683375104882	0.500110131001	14.6486414841487	81.7125196776976	1.43256299571781e-24	3.57855238122614e-22	0.408462943817518	0.536844603437747
RAD9A	BRD-K77841042-001-14-1::2.5::HTS002	2.5	brefeldin-a	protein synthesis inhibitor	targeted cancer	ARF1, CYTH2	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-4.34033870643	-4.34033870643	-4.74191710876184	-4.82176824359	-3.35289974518645	41.048188425267	0.00172782743618823	0.03549880431085	-0.643451164759647	-0.159705639904037
RAD9A	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.9596019052235	-0.9596019052235	-2.52028958620719	-2.254263331985	-14.642425191588	187.371548445903	7.30359504829692e-33	3.79024751357489e-30	-1.7709518427399	-1.35042351922749
RAD9A	BRD-K81528515-001-13-8::2.5::HTS002	2.5	nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	targeted cancer	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.56648365459	0.56648365459	0.186292103006215	0.2214201178065	-7.36147587693148	153.074470728774	1.04301505231555e-11	7.78642888010238e-10	-0.482222699530273	-0.278160403637297
RAD9A	BRD-K84091759-001-07-1::2.5::HTS002	2.5	candesartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension, congestive heart failure	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.187709178532	0.187709178532	0.335591555755801	0.3438554060475	5.0237920114534	167.358573343706	1.28995174769396e-06	5.18226931830365e-05	0.089767846146674	0.205996908300929
RAD9A	BRD-K84783599-001-01-0::2.5::HTS002	2.5	riociguat	guanylate cyclase stimulant	noncancer	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.282216011138	0.282216011138	-0.00541021838079903	0.04755872580485	-5.6479749643214	106.24944372734	1.3683821199144e-07	6.3330591962672e-06	-0.388588348340028	-0.18666411069757
RAD9A	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.6300781004895	-0.6300781004895	-0.145924538432654	-0.137644446714	10.4662111300965	6.45634600557394	2.7543491679827e-05	0.000873021151766585	0.372873901084295	0.595433223029396
RAD9A	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.6045755030515	-0.6045755030515	-0.158022053161868	-0.116252087164	20.6599797347568	164.03127423942	1.64669297826587e-47	3.17958612016888e-44	0.403875093544464	0.489231806234801
RAD9A	BRD-K87024524-065-17-7::2.5::HTS002	2.5	phenelzine	monoamine oxidase inhibitor	noncancer	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.465091884668	0.465091884668	0.351269980439947	0.3670145193675	-3.62383277004613	100.181287525825	0.000458040773153428	0.0110915626335104	-0.176135599849142	-0.0515082086069647
RAD9A	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-2.286691518595	-2.286691518595	-1.64138709692487	-1.710789940465	11.4626072598883	173.77222367905	5.16292187847942e-23	1.11774129625517e-20	0.534191524285636	0.756417319054624
RAD9A	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-3.841381005595	-3.841381005595	-5.23262518618451	-5.37506459637	-15.5400357894918	140.026927625676	2.80785778089444e-32	1.36463798258804e-29	-1.56824247764778	-1.21424588353124
RAD9A	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.6038746970985	-0.6038746970985	-0.2684003700316	-0.201241346164	5.92799502323032	8.88068371762289	0.000233225667823744	0.0060619723695119	0.20719271604988	0.463755938083921
RAD9A	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-7.04671616495	-7.04671616495	-5.60137887426407	-5.60058662575	11.7916951441095	7.12712274455545	6.21633355969759e-06	0.000222724934054902	1.15654414001174	1.73413044136012
RAD9A	BRD-K92150287-066-01-2::0.625::HTS002	0.625	exatecan-mesylate	topoisomerase inhibitor	chemo	TOP1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-2.147466016905	-2.147466016905	-4.13634710709841	-4.13500952518	-15.6041938086531	159.850098913965	6.03431861939278e-34	3.47669213810708e-31	-2.240600114194	-1.73716206619282
RAD9A	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-2.196923193725	-2.196923193725	-1.58916734735775	-1.34116610852	8.10820762454029	125.311823335099	3.99041950617325e-13	3.45421091413007e-11	0.459412950991174	0.756098741743325
RAD9A	BRD-K95581532-001-01-5::2.5::HTS002	2.5	RN-1734	TRPV antagonist	noncancer	TRPV4	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-3.56926173529	-3.56926173529	-2.40501357913756	-2.34576789044	9.17490619520786	3.06646168576126	0.00250601792512754	0.0486691116232929	0.765318853350717	1.56317745895417
RAD9A	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.0985097421395	0.0985097421395	-0.0775719947730729	-0.0625986180944	-3.57011084201932	86.9544673065103	0.000583952731477411	0.0137642147789313	-0.274113455821933	-0.0780500180032134
RAD9A	BRD-K97746869-001-27-0::2.5::HTS002	2.5	chlorpropamide	ATP channel blocker	noncancer	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-0.473856354413	-0.473856354413	-0.00289150749596568	0.0503184944333	9.19308919190709	8.70695987234962	8.99977516689158e-06	0.000312577023455632	0.35447652976768	0.587453164066389
RAD9A	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	-3.929203236195	-3.929203236195	-3.15821140683474	-3.187890366305	7.82354403301401	3.79983899529033	0.00177551802696837	0.0362596477562747	0.491600749568892	1.05038290915163
RAD9A	BRD-M97302542-001-03-6::2.5::HTS002	2.5	dichloroacetate	pyruvate dehydrogenase kinase inhibitor	targeted cancer	PDK1	NA	NA	HDQP1, ZR751	BREAST	carcinoma (ductal_carcinoma)	0.100028746318	0.100028746318	-0.263443699580102	-0.170283353784	-7.70791570385472	19.1765030405829	2.72628280640228e-07	1.20952487603683e-05	-0.46210908867939	-0.264835803116814
RLF	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-3.50282055194	-3.50282055194	-4.28218393406262	-4.26036322773	-8.82332343886639	4.37237275472634	0.000601507477222168	0.0141158979618471	-1.01658504916268	-0.542141715082553
RLF	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.1782643879345	-0.1782643879345	-1.03527803020696	-1.0089298839585	-15.1953389862485	37.5310240737324	1.284670677951e-17	1.70807805046253e-15	-0.971235880694656	-0.742791403850268
RLF	BRD-K06749501-001-02-1::2.5::HTS002	2.5	GSK1838705A	insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R, INSR, RPS6KA1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.531992233695	-1.531992233695	-0.219333015449018	-0.0999889784018	18.3092245592117	4.9042526491502	1.05281265971292e-05	0.000361268467088712	1.12727676250496	1.49804167398701
RLF	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.593158599051	0.593158599051	-0.0496673589535087	0.0935597000564	-7.99661818243653	5.03572173664921	0.000477748215796804	0.0115089690169173	-0.849027785827617	-0.4366241301814
RLF	BRD-K18779551-003-07-8::2.5::HTS002	2.5	bifemelane	acetylcholine release enhancer	noncancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.465157089513	-0.465157089513	0.024313376570593	0.0610865008582	11.0222368098644	4.36617368250591	0.000237496645324954	0.00615730234617781	0.370148223375509	0.608792708791677
RLF	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.7258949897155	-0.7258949897155	-0.336370445178394	-0.200723129444	6.84201678508633	168.177910546651	1.3883092652496e-10	9.06074715321808e-09	0.27713258323831	0.501916505835901
RLF	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.39756155312	-1.39756155312	-0.359787998275786	-0.151227527586	14.109093500486	168.786427200912	2.32013224007966e-30	9.58134148138792e-28	0.892570184171614	1.18297692551681
RLF	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.580825797695	-1.580825797695	-1.96589485883921	-1.89093805071	-5.17823615163593	124.312768325888	8.75207094309019e-07	3.6045784265211e-05	-0.532250576230951	-0.237887546057471
RLF	BRD-K28392481-001-05-1::2.5::HTS002	2.5	AZD4547	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.08048930942035	-0.08048930942035	0.377101212879686	0.422629133595	10.4102474104845	41.9287076428452	3.40107283815038e-13	2.9583950500322e-11	0.368879702595698	0.546301342004375
RLF	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-4.227674652785	-4.227674652785	-3.10834104206913	-3.10613635441	9.49731824300566	17.7027623067512	2.28162169549964e-08	1.16682819464267e-06	0.871425090067902	1.36724213136384
RLF	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.48811367368	-1.48811367368	-3.00664975454618	-3.11792642927	-15.0397496875867	44.9479751156974	3.71585029740201e-19	5.67974779535696e-17	-1.72190292143154	-1.31516924030082
RLF	BRD-K40331046-305-01-5::2.5::HTS002	2.5	CR8-(R)	CDK inhibitor	targeted cancer	CCNA2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-5.67433557643	-5.67433557643	-5.26139162236791	-5.161930725595	3.89750923545851	35.096948787339	0.000418165677784593	0.0102160072442601	0.197873771411718	0.628014136712471
RLF	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.936812244023	-0.936812244023	-0.506974077488557	-0.419049148621	7.48838812150478	10.6818495722732	1.44011151539521e-05	0.000482051633582915	0.303039625828199	0.556636707240686
RLF	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-5.10238041868	-5.10238041868	-3.73843498274552	-3.638458649165	13.2841190795273	165.912253613851	6.79800044666371e-28	2.24155175035844e-25	1.16122768684984	1.56666318501913
RLF	BRD-K47114202-001-14-6::2.57945::HTS002	2.57945	chlorogenic-acid	antioxidant	noncancer	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.6031441452495	-0.6031441452495	-1.05678549526358	-0.967874485397	-5.42791498829292	7.12725316337571	0.000921843228173057	0.0206024752086656	-0.650553240897591	-0.256729459130571
RLF	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.1368575445545	-0.1368575445545	0.0300468206006346	0.0483026079462	6.19184175926555	43.7738099013224	1.79708322838092e-07	8.15686258482959e-06	0.112571138010842	0.221237592299427
RLF	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.0646283166364	-0.0646283166364	-1.26150102724145	-0.921278111753	-9.36672975598902	3.29193699613731	0.00174832338627849	0.0357963701812841	-1.5838635880421	-0.809881833167988
RLF	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.187586541021	-0.187586541021	0.141328449181378	0.155273340434	9.42779277455974	3.58998400698735	0.00116791890105277	0.0253436154848374	0.227527956722923	0.430302023681834
RLF	BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500	2.49998	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.04864728494	-1.04864728494	-0.187124805867443	-0.0644082695915	14.5206684138176	6.20346612535881	5.05916912425125e-06	0.000184158739679288	0.71749176579223	1.00555319235288
RLF	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.0308530461682	0.0308530461682	-0.666401286949146	-0.50591048476	-8.27548609700799	4.64684050650893	0.000594391760291522	0.0139841264096072	-0.918885552494294	-0.475623113740397
RLF	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.1586098860385	0.1586098860385	-0.534004293667774	-0.376499820922	-9.97439891907944	5.04327868979703	0.000164821527479166	0.00445641896847259	-0.870653556716459	-0.51457480269609
RLF	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.1102902273925	0.1102902273925	-0.199667631977329	-0.124222212564	-8.85727931902492	190.086612112594	5.78266452434742e-16	6.58201117811396e-14	-0.378985695708989	-0.24093002303067
RLF	BRD-K74141488-003-11-2::2.5::HTS002	2.5	naftifine	fungal squalene epoxidase inhibitor	noncancer	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.636738964606	0.636738964606	0.359170131021063	0.330392231243	-11.5658915334549	194.931694358191	6.78619903041637e-24	1.57923914439751e-21	-0.324899692110275	-0.230237975059598
RLF	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-4.31881220521	-4.31881220521	-4.84759221071684	-5.01992364798	-4.79538028119854	9.68084039689372	0.000798292040814185	0.0181612498477511	-0.775576212188496	-0.281983798825194
RLF	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.839998960335	-2.839998960335	-2.22654738588162	-2.16824610201	6.98350009088318	5.3039232075715	0.000726460557452938	0.0167043841667558	0.39148081419187	0.835422334714896
RLF	BRD-K88506063-001-01-8::2.5::HTS002	2.5	KD025	rho associated kinase inhibitor	targeted cancer	ROCK2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.678359783035	-1.678359783035	-1.00785342332155	-0.931623279463	8.87484459704424	5.90581881617537	0.000124389541548435	0.00345161652648038	0.484921913976775	0.856090805450126
RLF	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.1270728862715	-0.1270728862715	0.170600813280138	0.182655209923	10.5762040595453	4.11438985774701	0.000389835995910762	0.00959058300821369	0.220378384196518	0.374969014906759
RLF	BRD-K92000912-001-12-6::2.5::HTS002	2.5	AM-251	cannabinoid receptor antagonist	targeted cancer	CNR1, GPR18, GPR55	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.5059473480545	-0.5059473480545	-0.122626805191035	-0.0809111569398	8.5039447209886	6.76970504195403	7.44932461551528e-05	0.00216753501971053	0.275994185726775	0.490646900000156
RLF	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.429552391475	-2.429552391475	-1.3966449023928	-1.36288222555	10.4615480433986	6.26653890090838	3.36893481002589e-05	0.00104904900319343	0.793783954629028	1.27203102353538
RLF	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.7278279929375	-0.7278279929375	-0.0264676228516112	0.0202365059018	12.7344939195158	44.0726499748818	2.28162063395368e-16	2.71374843981497e-14	0.590367883891805	0.812352856279973
RLF	BRD-K97714174-001-01-3::2.5::HTS002	2.5	P22077	ubiquitin specific protease inhibitor	noncancer	USP7	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.4765546062215	0.4765546062215	0.254790217396716	0.3142607574065	-6.19442618407017	193.01789102312	3.45627815109927e-09	1.94430614133059e-07	-0.292375073309237	-0.151153704340331
RLF	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.134512132808	-0.134512132808	-0.0212710107502085	0.015242959648	4.02169414200831	190.995545764801	8.31520101131938e-05	0.00239734828834419	0.0577013832654076	0.168780860850175
ROBO1	BRD-A13561534-003-02-0::2.5::HTS002	2.5	ornithine	NFkB pathway modulator	noncancer	ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.8419357535285	0.8419357535285	0.623352079473054	0.6438914807695	-6.5980403885472	7.0615658909734	0.000293575384585694	0.00742965150582917	-0.296782066602689	-0.140385281508203
ROBO1	BRD-A14240607-003-26-1::2.5::HTS002	2.5	octopamine	trace amine associated receptor agonist	noncancer	F10, TAAR1	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.4592718079755	0.4592718079755	0.693000233327877	0.680383035614	8.51248439664668	81.1917110954345	7.19488532681614e-13	6.07833100989822e-11	0.179099296628574	0.28835755407618
ROBO1	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-1.61723892213	-1.61723892213	-0.759003089662141	-0.407935159141	8.55836961849652	165.161916383644	7.56266632428189e-15	7.72960758520273e-13	0.660239275646687	1.05623238928903
ROBO1	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.2476663194345	0.2476663194345	0.358711048791684	0.3667280736395	4.55753718329199	49.0937012147379	3.4513814267952e-05	0.00107347428504366	0.0620836443223904	0.160005814391977
ROBO1	BRD-A75726477-003-21-3::2.5::HTS002	2.5	clenbuterol	adrenergic receptor agonist	noncancer	ADRB1, ADRB2, ADRB3, NGF, TNF	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.7062398348445	0.7062398348445	0.359945550473081	0.3641308840805	-8.06098727758069	3.94686185369957	0.00136069606359054	0.0288978028748808	-0.466204378884088	-0.226384189858749
ROBO1	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.09997716215855	0.09997716215855	-0.188050730004663	-0.136086260588	-5.06779797003718	6.91258697908487	0.00150645534380149	0.0315494496171222	-0.422766403655164	-0.153289380671262
ROBO1	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.2041238235615	-0.2041238235615	-0.848249498387339	-0.797149374107	-9.87570909263859	18.8929636541012	6.79692066359057e-09	3.6917820803515e-07	-0.7806918355011	-0.507559514150578
ROBO1	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.207479432977	-0.207479432977	0.0699884008405354	0.07956967035945	9.90125590615833	143.637717415491	6.11079221015235e-18	8.37952644663943e-16	0.222076100818429	0.332859566816641
ROBO1	BRD-K00673382-001-18-9::0.15625::HTS002	0.15625	famotidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	heartburn	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.3797239651895	0.3797239651895	0.50414460093933	0.491238275219	3.5582593373679	157.990147890006	0.000493195821320958	0.011837196773561	0.0553581233486149	0.193483148151045
ROBO1	BRD-K04623885-001-07-5::2.5::HTS002	2.5	BIBR-1532	telomerase inhibitor	targeted cancer	TERT	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.5468345666175	-0.5468345666175	-0.913150831143412	-0.834266968334	-7.42089557398158	171.967613914661	5.12514619379081e-12	3.94990096572812e-10	-0.463751285812193	-0.26888124323963
ROBO1	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.164439637306	-0.164439637306	-1.2323393142377	-1.264129385735	-14.7263291203529	187.986756444432	3.82170644503275e-33	2.05288852295094e-30	-1.21095004583897	-0.924849308024432
ROBO1	BRD-K06152156-001-01-8::2.5::HTS002	2.5	methoxyflurane	membrane permeability inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.282676990761	-0.282676990761	-1.88115575128022	-1.724302233865	-17.559854569306	56.1698112949268	1.77510584202786e-24	4.35803734268028e-22	-1.7808221914331	-1.41613532960534
ROBO1	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-2.0326870787	-2.0326870787	-3.19149808630913	-3.102963726805	-8.84239647395757	8.38172437673276	1.56818781540458e-05	0.00052174499578989	-1.45863775702959	-0.858984258188677
ROBO1	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.949942651093	0.949942651093	-1.2810935312899	-0.9430769633885	-23.7843769013085	177.107794556933	4.99671119613218e-57	2.27859598714003e-53	-2.41615080588288	-2.04592155888293
ROBO1	BRD-K11071038-001-01-7::2.5::HTS002	2.5	ICI-162846	histamine receptor antagonist	noncancer	HRH2	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.420210212825	-0.420210212825	0.101241267905259	0.0637321133413	13.1862696474314	5.872941546024	1.38492068032729e-05	0.000465030024273645	0.42417854331028	0.618724418150239
ROBO1	BRD-K17555800-003-01-5::2.5::HTS002	2.5	talmapimod	p38 MAPK inhibitor	targeted cancer	MAPK11, MAPK14	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.00765118524845	0.00765118524845	0.416499925523539	0.422256044569	10.6936106936645	3.09933131217547	0.00151024480580715	0.0316133664404571	0.289350892768378	0.528346587781799
ROBO1	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-2.159942588815	-2.159942588815	-2.87751100676217	-2.75215171608	-6.90131673995668	188.791378686416	7.58765943562303e-11	5.10277834696469e-09	-0.922671597892695	-0.512465238001639
ROBO1	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.2413809603105	0.2413809603105	-0.215328754028796	-0.0984348398408	-8.6073622338892	108.811251818634	6.35165071461265e-14	5.94449367536005e-12	-0.561875664710304	-0.351543763968289
ROBO1	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.01849454696655	-0.01849454696655	-0.406445136728665	-0.310618907363	-5.92496210885246	18.6425609877126	1.1385121992059e-05	0.000387696506424533	-0.525174239146392	-0.250726940377839
ROBO1	BRD-K25412176-001-01-9::2.5::MTS006	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.3690413957945	-0.3690413957945	-0.665637996844033	-0.516853765181	-5.08555244930109	44.7588301081361	6.99684891693288e-06	0.000247954304152994	-0.414079426866804	-0.179113775232262
ROBO1	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-2.32219887335	-2.32219887335	-3.64371103296281	-3.592577528105	-11.4277845938574	2.64116472545032	0.00253828518636029	0.0492288594432553	-1.71949963389569	-0.923524685329927
ROBO1	BRD-K33127281-001-05-6::2.5::HTS002	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.3050279094935	-0.3050279094935	-0.162486789678629	-0.1501441638665	3.81035489573908	82.7265438501224	0.000265818361868463	0.00680107242221628	0.068132718977339	0.216949520652403
ROBO1	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.1624938420095	0.1624938420095	-0.181442932126498	-0.13613940777	-7.99080820406703	7.45211399218466	6.53636352896034e-05	0.00192647450329832	-0.444475413825327	-0.243398134446668
ROBO1	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.201672201189	0.201672201189	-0.240937604840146	-0.026104548309	-8.39487163267617	141.90742225184	4.30576331880498e-14	4.10155531713845e-12	-0.546835442140908	-0.338384169917383
ROBO1	BRD-K37764012-001-04-1::2.5::HTS002	2.5	PF-03758309	p21 activated kinase inhibitor	targeted cancer	PAK4	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-2.328488933755	-2.328488933755	-3.20839734098965	-3.15071894959	-9.1988902373819	175.563821334845	1.04956735825003e-16	1.27596552652508e-14	-1.06868763197759	-0.691129182491714
ROBO1	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.478093331454	-0.478093331454	-0.140779066539072	-0.03734266076635	5.7189198107332	5.32080124665482	0.00186136550057536	0.0377181248343401	0.188404477969773	0.486224051860084
ROBO1	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-1.18324193025	-1.18324193025	-1.78167731988064	-1.67706700871	-5.2434476691884	10.1951597197468	0.000353707068791903	0.00879973097470687	-0.852074887028257	-0.344795892233018
ROBO1	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.2722877568805	-0.2722877568805	-0.63362694477756	-0.4291875223905	-5.62506192916151	180.530734541298	6.9610653451285e-08	3.34154206305313e-06	-0.488091825601418	-0.234586550192702
ROBO1	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-2.208378579175	-2.208378579175	-0.704876284922127	-0.576037096811	16.437410521129	183.692299471882	6.28824168641365e-38	5.39101020962941e-35	1.32303873997786	1.68396584852789
ROBO1	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-2.007686892405	-2.007686892405	-2.24260577083631	-2.140330076935	-3.44788188331515	32.439033187787	0.00158456606260634	0.0329434221452556	-0.373630194475213	-0.0962075623874016
ROBO1	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.5823383062205	0.5823383062205	-0.0741709684816765	0.318163539168	-6.62585636214421	11.933444584298	2.5117404417949e-05	0.000804210960784969	-0.87252605132392	-0.440492498080433
ROBO1	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.126997624636	-0.126997624636	-0.324093410980014	-0.2394985033815	-3.94139720580319	65.5916145436925	0.000199258724525733	0.00526725742092695	-0.29694874467675	-0.0972428280112782
ROBO1	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-3.563900732555	-3.563900732555	-3.14684058015607	-3.15598793833	4.13272815554196	114.546980583294	6.85115737191017e-05	0.00200930720903686	0.217155730250586	0.616964574547284
ROBO1	BRD-K59369769-001-20-3::2.5::HTS002	2.5	tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, AURKC, LCK	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-1.485996038305	-1.485996038305	-1.7873289879492	-1.696260218435	-3.86081133198276	11.8282908807588	0.00232437051126012	0.0456292367931737	-0.471661586352224	-0.131004312936168
ROBO1	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.323894825561	0.323894825561	0.0344655368606534	0.07942712884705	-9.20698420427646	82.7135528428534	2.59096465152939e-14	2.52417664908019e-12	-0.351957113901507	-0.226901463499186
ROBO1	BRD-K62398570-300-01-2::2.5::HTS002	2.5	lerisetron	serotonin receptor antagonist	noncancer	HTR3A	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.3571828720575	0.3571828720575	0.499887265215283	0.5169878880615	6.69634092151226	187.84220542541	2.40372359513176e-10	1.52467497609054e-08	0.100665141023058	0.184743645292507
ROBO1	BRD-K67173685-001-06-9::2.38783::HTS002	2.38783	4E1RCat	protein synthesis inhibitor	noncancer	EIF4E, EIF4G1	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.339028342751	0.339028342751	0.468698948192452	0.4806347706055	4.07095903501512	161.376529143578	7.31551417634641e-05	0.00213294359665644	0.0667689563865132	0.192572254496392
ROBO1	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-1.315127269685	-1.315127269685	-1.76231061629944	-1.7012260142	-6.50682468543869	39.2723406152439	9.94660627973821e-08	4.68949885026399e-06	-0.586162531158122	-0.308204162070751
ROBO1	BRD-K68336408-001-10-9::2.5::HTS002	2.5	tyrphostin-AG-1478	EGFR inhibitor	targeted cancer	EGFR, MAPK14	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.8399398055925	-0.8399398055925	-2.66029705130105	-2.59421184968	-17.9485420408826	97.2523508548603	1.25404072259505e-32	6.30932615101113e-30	-2.02164305682926	-1.61907143458784
ROBO1	BRD-K69932463-001-10-6::2.5::HTS002	2.5	AZD8055	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-2.062917663905	-2.062917663905	-2.74911607956281	-2.74184167239	-10.9939938584096	181.96087572947	6.92946524514826e-22	1.35139704870553e-19	-0.809350123193772	-0.563046708121842
ROBO1	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-1.78312557859	-1.78312557859	-2.52994721303895	-2.26266997363	-6.35463512315906	25.8041486305416	1.02750223472076e-06	4.18278302878376e-05	-0.988484782017553	-0.505158486880356
ROBO1	BRD-K72951360-001-01-4::2.5::HTS002	2.5	valrubicin	DNA inhibitor, topoisomerase inhibitor	chemo	TOP2A	oncology	bladder cancer	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-2.462447096235	-2.462447096235	-3.29583824886788	-3.181546610205	-5.974461762013	5.3818120051871	0.0014561347607154	0.0306573582641818	-1.18444932657921	-0.482332978686543
ROBO1	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.1326705518225	-0.1326705518225	-1.34411877687462	-1.10972386317	-13.5802122309391	79.8532620362679	1.87437787484783e-22	3.87026527493507e-20	-1.38898056184052	-1.03391588826372
ROBO1	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-1.54019817639	-1.54019817639	-2.64189115062388	-2.52531204565	-9.64352700821973	3.54737301751594	0.00114026133789349	0.0248213561130787	-1.43549553422733	-0.767890414240435
ROBO1	BRD-K76703230-004-04-1::2.5::HTS002	2.5	YM-155	survivin inhibitor	targeted cancer	BIRC5	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-4.92958198114	-4.92958198114	-5.49393682555256	-5.55235554655	-6.6615383228861	181.016120983833	3.14667666716036e-10	1.97604472134724e-08	-0.73151744471481	-0.397192244110319
ROBO1	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.004285232840863	-0.004285232840863	-0.122767248096382	-0.118001057117	-4.07108010504059	172.939179296646	7.10932026458801e-05	0.00207847974763182	-0.1759254894495	-0.0610385410615378
ROBO1	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.09492965168575	0.09492965168575	0.33222964593016	0.372094584014	8.35179063531371	87.2613265346515	9.32630753045474e-13	7.79905644438094e-11	0.180828329780177	0.293771658708642
ROBO1	BRD-K81473043-001-14-6::2.5::HTS002	2.5	tanespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-4.088034486985	-4.088034486985	-4.83748832275138	-4.75693780059	-7.1555156570641	89.8230609646574	2.17588493585869e-10	1.3875490699722e-08	-0.95753958186677	-0.541368089665994
ROBO1	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.476120783361	-0.476120783361	-1.29199342797231	-1.24885809452	-9.02069579803299	3.2591915124959	0.00205526165197166	0.0410609782443545	-1.09118140824296	-0.540563880979661
ROBO1	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-1.294569269375	-1.294569269375	-0.282169005825349	-0.212124322286	9.92829917642545	3.4893008033723	0.0011136904217625	0.0242947739853368	0.71216755714241	1.31263296995689
ROBO1	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	0.01473128714541	0.01473128714541	-0.348807796934827	-0.28220904824	-8.07846726269251	11.2776241907829	5.07824301448839e-06	0.000184821658524755	-0.46228894022872	-0.264789227931754
ROBO1	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.227787698882	-0.227787698882	0.0720777354754168	0.0444292294665	12.4724927732763	17.220919305212	4.73171512054594e-10	2.91420623583762e-08	0.249190474210873	0.35054039450396
ROBO1	BRD-K99616396-001-05-1::2.5::MTS006	2.5	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	SW1990, NCIH446	PANCREAS, LUNG	carcinoma (ductal_carcinoma), carcinoma (small_cell_carcinoma)	-0.224669810152	-0.224669810152	-0.014538748254352	-0.0150428280254	5.80118723362621	5.24353657315587	0.00182928201216898	0.0371699075072209	0.11830506804576	0.301957055749536
RPS6KB1	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	RMGI, MKN45, PANC1, MCF7, TE11, DAOY, SBC5, VMCUB1	OVARY, STOMACH, PANCREAS, BREAST, OESOPHAGUS, CENTRAL_NERVOUS_SYSTEM, LUNG, URINARY_TRACT	carcinoma (clear_cell_carcinoma), carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma), carcinoma, carcinoma (squamous_cell_carcinoma), primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.245435961386937	0.259068704237	0.0287607218649623	0.0326634495047	-4.50866116846116	10.1950820926818	0.00107451202084506	0.0235191060984172	-0.323477065731762	-0.109873413312188
RPS6KB1	BRD-K70177501-003-01-4::2.5::HTS002	2.5	INH1	Hec1 inhibitor	targeted cancer	NDC80	NA	NA	RMGI, PANC1, MCF7, TE11, DAOY, SBC5, VMCUB1	OVARY, PANCREAS, BREAST, OESOPHAGUS, CENTRAL_NERVOUS_SYSTEM, LUNG, URINARY_TRACT	carcinoma (clear_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma, carcinoma (squamous_cell_carcinoma), primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (small_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.454561550535143	0.446454899187	0.150868805938979	0.14887686087	-4.74866832251073	8.0553495583679	0.00142051744375563	0.0300047386619396	-0.450992991799008	-0.156392497393319
RPTOR	BRD-A08545410-311-03-4::2.5::HTS002	2.5	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.938989513266	-0.938989513266	-0.490900959422103	-0.488941484078	13.042659563851	187.535920904784	4.3049424386861e-28	1.46224090006522e-25	0.380315432934791	0.515861674753003
RPTOR	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.4380555880715	-0.4380555880715	0.000551317646863067	0.008505826587825	10.9973317300079	4.94221997268589	0.000116098104094042	0.00324380009808004	0.335722751050448	0.541491060386279
RPTOR	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-2.108507348805	-2.108507348805	-1.22578540078674	-1.016750192265	7.50331587307185	5.53395707105095	0.000422098720122831	0.010305045743844	0.588876982489772	1.17656691354674
RPTOR	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.8359002523165	0.8359002523165	0.352453240995067	0.3602013274625	-17.9766198108019	10.7138292986503	2.40725911918143e-09	1.37329102942517e-07	-0.542831789983806	-0.424062232659061
RPTOR	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-2.915448548215	-2.915448548215	-2.35033356373368	-2.27036498586	5.97420928539688	9.58618221681463	0.000162247077925652	0.00439179767172607	0.353110111449195	0.777119857513451
RPTOR	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.02120332188619	-0.02120332188619	0.418079001931023	0.4743784763675	10.8274537740973	7.2500486128959	9.79323380953705e-06	0.000337999035292152	0.344013466998323	0.534551180636104
RPTOR	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.7349297803975	0.7349297803975	0.0225175744675745	0.05909936864605	-13.4438345804596	163.537556129746	3.14244994515501e-28	1.08631960370182e-25	-0.817048430933341	-0.60777598092651
RPTOR	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.3349115956615	0.3349115956615	0.15560834626543	0.1638819685105	-5.65784361642915	6.80736592383326	0.000847241805274934	0.0191448064188478	-0.254672805974631	-0.103933692817509
RPTOR	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.8278395385465	-0.8278395385465	-0.354154006395722	-0.221401224326	6.09255515694115	6.53611673687412	0.000644320789762714	0.0149890101605783	0.287161704983435	0.660209359318122
RPTOR	BRD-K06234293-001-04-2::2.5::HTS002	2.5	LY364947	TGF beta receptor inhibitor, p38 MAPK inhibitor	targeted cancer	TGFBR1	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.400375359655	0.400375359655	0.79003720804259	0.824104228749	12.099761947584	186.789715817164	2.93167030175794e-25	7.64406282366761e-23	0.326131370636067	0.453192326139113
RPTOR	BRD-K06593056-001-04-8::2.5::HTS002	2.5	LE-135	retinoid receptor agonist	noncancer	RARB	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.30523383486	-0.30523383486	-0.139646785867883	-0.152062454998	4.7023376506296	14.2226712969258	0.000325845454228056	0.00816533735054892	0.0901717999953908	0.241002297988844
RPTOR	BRD-K07572174-001-39-4::2.48092::HTS002	2.48092	curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	targeted cancer	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.753716045745	-1.753716045745	-1.16912531739458	-1.01297286124	6.1427713284583	9.66154129213554	0.000126477376092029	0.00350455973373348	0.371533634061019	0.79764782263982
RPTOR	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.511503836329	0.511503836329	0.25427533777527	0.2240846909	-9.28703809208346	103.940470276085	2.6443417195375e-15	2.82531962316428e-13	-0.312154213172713	-0.202302783934748
RPTOR	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.76757543094	-1.76757543094	-1.48880128953597	-1.38645123972	3.6924406623862	24.0384933086982	0.00113943213559155	0.0248083452041042	0.122965869912568	0.434582412895492
RPTOR	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.131237477287	-0.131237477287	-0.422538523585579	-0.390164965854	-6.64283237088553	5.9186725599494	0.000594341587377666	0.0139841264096072	-0.39896128073826	-0.183640811858898
RPTOR	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.3150555153595	-0.3150555153595	-0.481144647841567	-0.4134526693685	-3.49538500572756	103.34501737436	0.000698736264680009	0.01613787121472	-0.260323544840791	-0.0718547201233426
RPTOR	BRD-K16180792-001-01-7::2.5::MTS006	2.5	bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	noncancer	PTPN1	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.2037989030695	0.2037989030695	-0.238411787045153	-0.0973395896878	-6.07231721219143	5.53930664797138	0.00121417482526485	0.026217295599858	-0.62405953412163	-0.260361846107675
RPTOR	BRD-K16478699-001-09-2::2.5::HTS002	2.5	PLX-4720	RAF inhibitor	targeted cancer	BRAF, KDR	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.22768170614	-1.22768170614	-1.51272454640553	-1.41373612569	-3.23216206478721	66.4528625018805	0.00191329489782516	0.0385988876276325	-0.461096515779136	-0.108989164751922
RPTOR	BRD-K16551357-001-03-2::2.5::HTS002	2.5	evacetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.299120542862	0.299120542862	0.0573350273478702	0.0357605741878	-6.5587962328141	12.7617835343501	2.00055938976849e-05	0.000651737184146058	-0.321577403051607	-0.161993627976653
RPTOR	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.4506586983055	-0.4506586983055	-0.18464226599504	-0.102291191228	6.44185021814682	119.841911984585	2.56536089734923e-09	1.45998734935731e-07	0.18425403779164	0.347778826829281
RPTOR	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-2.240496124305	-2.240496124305	-0.923492800561395	-0.8524847758	14.1404630322293	3.51110394597066	0.000320604072278767	0.0080424567190351	1.04357435835501	1.5904322891322
RPTOR	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.6446808342	-1.6446808342	-0.356863509742295	-0.151227527586	17.5634437047347	168.939128932997	5.90488104706854e-40	6.29645397978683e-37	1.14306852661026	1.43256612230515
RPTOR	BRD-K21361524-001-01-1::2.5::HTS002	2.5	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-6.384354546585	-6.384354546585	-4.15404997865544	-4.1358778776	18.5748287991965	4.33306603978123	2.69219971172057e-05	0.000854973297765461	1.90679991559019	2.55380922026893
RPTOR	BRD-K22503835-001-11-0::2.5::HTS002	2.5	scriptaid	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.961939275165	-1.961939275165	-1.33649239493107	-1.30328750996	7.06338572743135	4.57939009910369	0.00125581273159956	0.0269885778553095	0.391393385179564	0.859500375288298
RPTOR	BRD-K25630527-001-03-8::2.5::HTS002	2.5	LY2784544	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.689995748475	-1.689995748475	-1.07192154663482	-0.867561627106	8.54266409133291	111.433001918476	7.65497767694634e-14	7.10560290395077e-12	0.474711096547121	0.761437307133248
RPTOR	BRD-K27316855-001-13-3::2.43597::HTS002	2.43597	calcitriol	vitamin D receptor agonist	noncancer	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.195909830675	-0.195909830675	-0.0345759012743293	0.01343134409051	3.93824762745633	168.922694595471	0.000119851350984194	0.00333865612231497	0.0804628254358366	0.242205033365505
RPTOR	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.7080886306025	-0.7080886306025	-0.300769417947627	-0.250836974988	7.81124720320839	5.40730736610743	0.000383394381358738	0.00945539070482945	0.276256379859169	0.538382045450576
RPTOR	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-2.16369421742	-2.16369421742	-2.59137906688821	-2.52528636523	-4.09971318750857	65.2324676864364	0.000116864709082724	0.00326087134096545	-0.636013550889264	-0.219356148047154
RPTOR	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-4.10123797483	-4.10123797483	-3.22692955965818	-3.119370710775	11.5807242858462	27.7645156644148	3.84209271485458e-12	3.02080663786525e-10	0.719600977752732	1.02901585259091
RPTOR	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.5160912164465	-0.5160912164465	0.380404545930386	0.3764822376655	23.4888656908192	25.9322417348035	5.29582440174716e-19	7.93740383358089e-17	0.818032722573379	0.974958802180393
RPTOR	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.8566248473295	-0.8566248473295	-0.278507109654384	-0.2569086069275	15.670767339849	56.2744981565343	3.48756319281233e-22	6.96631809461579e-20	0.504223184857531	0.652012290492701
RPTOR	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.645165687128	0.645165687128	0.196825412906798	0.2395368500345	-11.3291621548077	8.6832703153549	1.69716454237034e-06	6.68567575568932e-05	-0.538363130375654	-0.35831741806675
RPTOR	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.6856216873135	0.6856216873135	0.299086059917146	0.2999355775105	-16.5927347974762	34.980362529283	3.72810330220468e-18	5.20547656454871e-16	-0.433828903584982	-0.339242351207727
RPTOR	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.2280938464935	0.2280938464935	0.469950737627091	0.4617368983695	9.1046508276661	151.943924418566	4.6369634695264e-16	5.32187479299891e-14	0.189374196813348	0.294339585453834
RPTOR	BRD-K56981171-001-01-0::2.5::MTS006	2.5	brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	targeted cancer	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.181269294437	-0.181269294437	-0.0694252966947531	-0.00661629893245	3.38944085339443	190.737047312655	0.00085100114801399	0.0192196232932234	0.0467565738881801	0.176931421596314
RPTOR	BRD-K60341624-001-02-2::2.5::HTS002	2.5	GSK1292263	glucose dependent insulinotropic receptor agonist	noncancer	GRPR	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.378331447985	-1.378331447985	-1.00956101913351	-0.954160275858	9.61277959635327	68.3373417802057	2.54696466976203e-14	2.48583055876788e-12	0.292226058167411	0.445314799535567
RPTOR	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-8.31852931332	-8.31852931332	-7.20146602387872	-7.241239224365	10.2668138836934	43.8551872698976	3.06327543314514e-13	2.67760505836283e-11	0.897764182347309	1.33636239653524
RPTOR	BRD-K61936403-001-01-7::2.5::HTS002	2.5	AS-1949490	SHIP2 phosphatase inhibitor	noncancer	INPP5D	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.1709825882195	-0.1709825882195	0.245947871007864	0.276762978408	10.4629145910158	28.9346697040313	2.40289836896712e-11	1.71327612948222e-09	0.335423326211593	0.498437592243134
RPTOR	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-3.00886597842	-3.00886597842	-3.67828155648157	-3.50719189578	-5.00639472223749	9.95226930328553	0.000540082507716411	0.0128289198488696	-0.967538507735263	-0.371292648387878
RPTOR	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.187087297983	-0.187087297983	-0.72837657956829	-0.60872932846	-5.76149223093749	183.655338039308	3.45826235342525e-08	1.72574135494128e-06	-0.726648350660128	-0.355930212510452
RPTOR	BRD-K76674262-001-03-3::0.625::MTS010::PROS003_PR500	0.625	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-2.855424204875	-2.855424204875	-1.58658600936786	-1.84636117372	10.164697825743	7.79353847137868	9.07112519197096e-06	0.000314851043120639	0.979651708323982	1.5580246826903
RPTOR	BRD-K76703230-004-04-1::2.5::HTS002	2.5	YM-155	survivin inhibitor	targeted cancer	BIRC5	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-5.121286569815	-5.121286569815	-5.49187548588939	-5.55235554655	-4.13013296549003	51.9336444633002	0.000132059935679688	0.00364135777103974	-0.550646964433938	-0.190530867714846
RPTOR	BRD-K80700417-001-04-2::2.5::HTS002	2.5	SGI-1776	Pim kinase inhibitor	targeted cancer	FLT3, PIM1, PIM2, PIM3	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.12616535036	-1.12616535036	-0.340886200268228	-0.3090790625965	8.54829121286641	4.06168664398139	0.000960309106241983	0.0213552698103069	0.53174459063745	1.03881370954609
RPTOR	BRD-K81197548-003-01-4::2.5::HTS002	2.5	NSC-632839	ubiquitin specific protease inhibitor	targeted cancer	SENP2, USP1, USP2, USP7	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.045832672245	-1.045832672245	-0.612176407127374	-0.517259346977	7.39653593623476	21.8692105486278	2.19626535838573e-07	9.86427824806069e-06	0.312023651533488	0.555288878701763
RPTOR	BRD-K82967180-001-01-6::2.5::MTS006	2.5	LY3023414	PI3K inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-4.25280196065	-4.25280196065	-3.36783403845592	-3.47125881494	9.6501350390167	3.20831040665089	0.0017775863309123	0.0362915127374836	0.603553440033417	1.16638240435475
RPTOR	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.295713654571	0.295713654571	0.0401168793534819	0.0562766217073	-7.85717365452507	11.2060895837964	6.91461187418211e-06	0.000245283324790066	-0.327035313268013	-0.184158237167023
RPTOR	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-0.397678664948	-0.397678664948	-0.0461030012475347	-0.0538286289263	7.31581281769821	27.5636567155027	6.34687468508292e-08	3.06378221707013e-06	0.253065206676709	0.450086120724221
RPTOR	BRD-K88789588-001-14-9::2.5::HTS002	2.5	letrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.7552294615415	0.7552294615415	0.167381876167756	0.134941484208	-15.8117643886641	112.555869336573	2.31174599929277e-30	9.58134148138792e-28	-0.661506779741776	-0.514188391005712
RPTOR	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	0.573304560769	0.573304560769	0.304113800544068	0.301488629615	-8.11332500057757	5.55471254717784	0.000277420806337968	0.00705413738303599	-0.351980473425837	-0.186401047024028
RPTOR	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.093803880835	-1.093803880835	-0.714807678345234	-0.590290062749	5.21690821794994	8.90386791983719	0.000570960791052748	0.0134846782793988	0.214384897127566	0.543607507851967
RPTOR	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-7.369265556975	-7.369265556975	-5.6283527783493	-5.72114668903	19.9452961672017	186.922904708554	3.60385508833089e-48	7.49913259443564e-45	1.56872371400989	1.9131018432415
RPTOR	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	MFE280, GI1	ENDOMETRIUM, CENTRAL_NERVOUS_SYSTEM	carcinoma (adenocarcinoma), glioma (gliosarcoma)	-1.392107372155	-1.392107372155	-0.854947441864392	-0.7866589985	9.40150212258581	5.91216974762198	8.96916297816761e-05	0.00256621510071777	0.396849292563493	0.677470568017722
RSF1	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.389910785146	-0.389910785146	-0.953057814510693	-0.8814928301585	-8.24752570955252	21.4466165340716	4.29793652814573e-08	2.11132807275028e-06	-0.704964730867344	-0.421329327862042
RSF1	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.227067453206	-0.227067453206	-0.83496671887152	-0.720201208535	-8.20138053498383	7.74943618667934	4.38592676011935e-05	0.00133812284209199	-0.779790693807665	-0.436007837523376
RSF1	BRD-A36267905-003-18-4::2.5::HTS002	2.5	buphenine	adrenergic receptor agonist	noncancer	ADRB2	rheumatology	Raynaud's disease	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.03091909685261	0.03091909685261	-0.446131978545931	-0.393531150995	-7.97060690013104	8.96591354317643	2.33075038808251e-05	0.000749620948270312	-0.612522595865133	-0.34157955493195
RSF1	BRD-A54927599-001-16-9::2.5::HTS002	2.5	KF-38789	P selectin inhibitor	noncancer	SELP	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.6192023688745	-0.6192023688745	-2.96555199749816	-2.73649504122	-20.3230832794178	8.4398425500605	1.82912667339171e-08	9.48318555349232e-07	-2.61018757460488	-2.08251168264244
RSF1	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.382253986095	0.382253986095	-0.239792889347693	-0.2322368233935	-13.7992970497266	189.283030301435	1.98238391296924e-30	8.23415429617799e-28	-0.710966968863096	-0.533126782022291
RSF1	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.497403054142	0.497403054142	0.206982549019009	0.236646785158	-6.93782853777944	173.793144467785	7.55576034199204e-11	5.0829207731915e-09	-0.373040771614357	-0.207800238631624
RSF1	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.3757516891315	-0.3757516891315	0.049639443019139	0.0776480680764	12.0024034493143	13.183826678997	1.793735414398e-08	9.30870502742152e-07	0.348931380377231	0.501850883924047
RSF1	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.2620694844235	0.2620694844235	0.0304219084376451	0.005378846282065	-5.1228700012723	21.028487634395	4.46891936444531e-05	0.0013607316642452	-0.325676464347344	-0.137618687624366
RSF1	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.11300135595015	-0.11300135595015	-1.91505962022602	-1.73380354334	-14.6200070836639	9.79722840733857	5.62099378603071e-08	2.72874740014989e-06	-2.07747051329908	-1.52664601525266
RSF1	BRD-K01507359-001-22-9::2.5::HTS002	2.5	rifampin	RNA polymerase inhibitor	noncancer	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.1908043113305	-0.1908043113305	-0.0928369997989832	-0.0471468975624	3.44995336434747	192.816489796756	0.000688692071640748	0.015926487162569	0.041959252404785	0.153975370658249
RSF1	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.402263828278	0.402263828278	-0.0889596074561148	-0.0325205860223	-12.0385363548223	23.1494571091578	1.90112678778453e-11	1.37194142524939e-09	-0.575603311195755	-0.406843560272474
RSF1	BRD-K03243820-001-23-8::2.37329::HTS002	2.37329	trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	chemo	TYMS	infectious disease	virus herpes simplex (HSV)	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.5437808736785	-0.5437808736785	-2.27156707818736	-2.05370099582	-18.574417604558	59.5135173459515	1.90019677445483e-26	5.48877728399095e-24	-1.9138845370084	-1.54168787200932
RSF1	BRD-K03406345-001-27-8::2.5::HTS002	2.5	azacitidine	DNA methyltransferase inhibitor	chemo	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3760069262545	0.3760069262545	-0.593232413727935	-0.567938192977	-20.6294492132025	16.6604599897139	2.69186398460453e-13	2.36743748853634e-11	-1.06851952541495	-0.869959154549918
RSF1	BRD-K06222852-001-03-2::2.5::HTS002	2.5	posaconazole	sterol demethylase inhibitor	noncancer	CYP3A4	infectious disease	oropharyngeal candidiasis	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.1840861763375	0.1840861763375	-0.0504369304085422	-0.00340254964255	-5.14792996831544	5.93857925602619	0.00218580466933165	0.0432506341404404	-0.346276599838007	-0.122769613654077
RSF1	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.0201189780445	0.0201189780445	-1.69937959101667	-1.35955217781	-9.91911667364312	3.19954624874305	0.00165102929307211	0.0341073211908292	-2.25221893766448	-1.18677820045785
RSF1	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.185082440889	0.185082440889	-2.06024567756497	-1.66463476506	-17.4144897593632	74.1437382421163	6.4787896108875e-28	2.14620169785457e-25	-2.50222739538172	-1.98842884152621
RSF1	BRD-K09426783-300-01-0::2.5::HTS002	2.5	TAS-103	topoisomerase inhibitor	chemo	TOP1	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.053594063438	-1.053594063438	-2.72842437612632	-2.622314881585	-11.705273444454	3.00207386818083	0.00133541981151379	0.0284596989939286	-2.13000764350342	-1.21965298187321
RSF1	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.015667662525285	-0.015667662525285	-0.28716356810842	-0.2721742756055	-7.50795260069383	18.3971223331878	5.20900052079009e-07	2.2173582375778e-05	-0.347350200962822	-0.195641610203447
RSF1	BRD-K11590034-002-03-4::2.48778::HTS002	2.48778	morin	cytochrome P450 inhibitor	noncancer	ADORA2A, ESR2, FASN, MCL1, SLC22A12	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.479151312745	0.479151312745	0.588593820508474	0.572569437985	3.83796970067063	180.942806829624	0.000171300930205254	0.00461124806203992	0.0531763745871946	0.165708640939754
RSF1	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.554366935237	-0.554366935237	-2.11263222927448	-1.95679219665	-14.6493899501349	190.391665955664	4.92018112396055e-33	2.59100122878954e-30	-1.76808165428792	-1.34844893378705
RSF1	BRD-K13094524-001-07-5::2.63083::HTS002	2.63083	PFI-1	bromodomain inhibitor	targeted cancer	BRD4	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0386082834756	-0.0386082834756	-2.25248104514184	-2.09295317057	-22.1960279570043	192.37710772671	5.96985867400858e-55	2.28484614239569e-51	-2.41060077926723	-2.01714474406525
RSF1	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.0544915036999	0.0544915036999	0.242776938965091	0.282942219323	6.52749112169342	23.881337317582	9.68436805045057e-07	3.96720359305241e-05	0.128736637940153	0.247834232590228
RSF1	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.88228594028	-1.88228594028	-2.74985466235132	-2.77734094711	-17.3585077980763	29.1976808222139	6.30086276458339e-17	7.84693559250665e-15	-0.969758127682722	-0.765379316459923
RSF1	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	1.062135280445	1.062135280445	-0.0546831523374017	0.0935597000564	-17.9346399883515	85.0009087134521	1.24099306681638e-30	5.19493755893921e-28	-1.24063100482864	-0.993005860736168
RSF1	BRD-K18779551-003-07-8::2.5::HTS002	2.5	bifemelane	acetylcholine release enhancer	noncancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.3191900894945	-0.3191900894945	0.0228007651714376	0.0610865008582	10.5801909093583	192.912106385621	6.36421623479703e-21	1.14528639915014e-18	0.278237625610074	0.405744083721801
RSF1	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.190360992945	-1.190360992945	-2.46349624234119	-2.36107459971	-10.0285408873147	3.98434058885023	0.000566890471949607	0.0133959281105278	-1.62615528206498	-0.920115216727405
RSF1	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.8498475677	-1.8498475677	-3.103151735663	-2.8622910827	-10.3741702517941	11.7117016022237	2.97745602805975e-07	1.31172697438441e-05	-1.51724712625887	-0.989361209667134
RSF1	BRD-K21396683-001-04-8::2.5::HTS002	2.5	marimastat	matrix metalloprotease inhibitor	targeted cancer	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.41482555463	-1.41482555463	-1.79869626628095	-1.72083973318	-5.02131621195762	145.551217474648	1.47947200366792e-06	5.88955711504719e-05	-0.534962722070922	-0.232778701230981
RSF1	BRD-K22064724-001-01-8::2.49999::MTS010::PROS004_PR500	2.49999	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.719999503705	-1.719999503705	-2.29435290655657	-2.44622434478	-7.4335826002816	50.8106416753301	1.15020358516464e-09	6.80248300785742e-08	-0.729482763290222	-0.419224042412927
RSF1	BRD-K26997899-001-02-2::2.5::HTS002	2.5	D-64131	microtubule inhibitor	chemo	TUBB	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.8019107504875	-0.8019107504875	-3.04121024258347	-2.92524371085	-23.7270729224841	188.020652302898	1.9289588159379e-58	9.84361462050369e-55	-2.42547413893406	-2.05312484525787
RSF1	BRD-K28307902-001-21-7::2.5::HTS002	2.5	flutamide	androgen receptor antagonist	targeted cancer	AHR, AR	oncology	prostate cancer	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.0712713955647	-0.0712713955647	0.2464582720554	0.2821058302255	12.1070091918609	84.9839794597966	3.42187333277415e-20	5.78852951491832e-18	0.265550519940384	0.369908815299817
RSF1	BRD-K28392481-001-05-1::2.5::HTS002	2.5	AZD4547	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.879623411904	0.879623411904	0.36704767653074	0.402350667123	-12.4368393720142	177.694824556834	5.99917043003779e-26	1.65057278446671e-23	-0.593908220273994	-0.431243250472526
RSF1	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.5933174219285	-0.5933174219285	-1.6754752561149	-1.54523819361	-11.6549760645539	11.7670097814385	8.12976843905631e-08	3.86694438476365e-06	-1.28490450968885	-0.879411158683959
RSF1	BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500	2.5	icotinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.6077729015825	-0.6077729015825	-0.0657121588303954	0.0394654487081	17.4775379542911	141.41208526946	3.7607772011948e-37	3.00762543565254e-34	0.480748335623782	0.603373149880427
RSF1	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-1.088505676385	-1.088505676385	-1.93675900272059	-1.836818850415	-9.62574661330533	78.5398193521951	6.2072422918967e-15	6.40535403553167e-13	-1.02367450790965	-0.672832144761527
RSF1	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.1956826836955	0.1956826836955	0.413733607637995	0.43502168689	7.2651670788099	6.86122736101472	0.000184671872813715	0.00492662905505238	0.146788956463225	0.289312891421766
RSF1	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.25890746615	-0.25890746615	-0.0175050182837091	-0.01606038970165	7.63742648469186	17.8987796842245	4.88959356916425e-07	2.0876129483773e-05	0.174969941160261	0.30783495457232
RSF1	BRD-K36788280-001-01-2::2.5::HTS002	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.02250317577145	-0.02250317577145	-1.07679882383099	-1.010750177675	-9.8565987407143	3.05054992132902	0.00206866044708881	0.0412940230012199	-1.39153207019278	-0.717059225926289
RSF1	BRD-K38548312-001-01-0::2.5::HTS002	2.5	VER-49009	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.8209460147305	-0.8209460147305	-2.7547537958651	-2.671842712285	-22.0813286712466	187.890830902736	4.25053029637792e-54	1.57071018602135e-50	-2.10656753122266	-1.76104803104654
RSF1	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.6016270467765	-0.6016270467765	-2.30641046637281	-2.14029239454	-20.146670797686	176.39989884626	1.29239426384911e-47	2.51815972887742e-44	-1.87177854920337	-1.53778828998925
RSF1	BRD-K42756753-001-01-9::2.5::HTS002	2.5	epiandrosterone	steroid	noncancer	G6PD	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.332890564976	0.332890564976	0.221268120976642	0.2292300635955	-3.75193052843154	55.3137384064305	0.000422338726315793	0.0103097308510863	-0.171236517194539	-0.0520083708041758
RSF1	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.15333657801	-0.15333657801	0.157788094857936	0.14294893902	16.0256193814488	186.133450543167	6.92394013978576e-37	5.41606265043847e-34	0.272824505252356	0.349424840483517
RSF1	BRD-K47869605-001-32-0::0.625::HTS002	0.625	podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	noncancer	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.8457499644665	-0.8457499644665	-3.2947626911114	-3.15922322391	-15.5700941822075	3.10103556159657	0.000478179156191473	0.011515467457007	-2.9404771234353	-1.9575483298545
RSF1	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.112915539565	0.112915539565	0.348901276874737	0.3889604534415	7.33150156348187	165.376785174678	9.61945399416566e-12	7.22652630604813e-10	0.172433522066884	0.29953795255259
RSF1	BRD-K52075715-001-06-7::2.5::HTS002	2.5	oxibendazole	tubulin polymerization inhibitor	noncancer	TUBB, TUBB4B	infectious disease	strongyles	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.369897553199	-0.369897553199	-2.89836863874895	-2.70188227417	-14.9839198754793	2.37963160613433	0.00206737233280343	0.041272153941638	-3.15407881119598	-1.90286335990391
RSF1	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3157925130515	0.3157925130515	0.135973352861458	0.1526722270265	-6.92536869758724	42.9211584962795	1.66575570850124e-08	8.68449903301783e-07	-0.232185926230494	-0.12745239414959
RSF1	BRD-K53561341-001-07-5::2.5::HTS002	2.5	aurora-a-inhibitor-i	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.1141885981273	0.1141885981273	-0.625526812991058	-0.52264323687	-9.11630519354713	3.91803535402838	0.000884300761375243	0.0198649300791106	-0.966872696342386	-0.51255812589433
RSF1	BRD-K54247840-004-01-3::2.5::HTS002	2.5	halofuginone	collagenase inhibitor	noncancer	COL1A1, MMP2	rheumatology	scleroderma	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-4.73244192732	-4.73244192732	-5.7244560900842	-5.5836707127	-8.48019838380413	147.771716056408	2.13426573686931e-14	2.10121746034663e-12	-1.22318404529671	-0.760844280231675
RSF1	BRD-K56334280-001-05-1::2.5::HTS002	2.5	amonafide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.7266138136175	0.7266138136175	-0.41621382848028	-0.361016794992	-15.7025185989903	15.8205464444271	4.56104144630668e-11	3.14936679170575e-09	-1.29725648165133	-0.988398802544234
RSF1	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.4393752309845	0.4393752309845	0.232405229616822	0.271076937361	-5.51762189016043	190.472219754415	1.11131432501952e-07	5.20968696341009e-06	-0.280959789232119	-0.132980213503237
RSF1	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.647443138034	0.647443138034	-0.259939093670094	-0.132231172134	-17.3055414618562	182.412783901636	2.47175520232241e-40	2.70290214672735e-37	-1.01083547072865	-0.803928992679542
RSF1	BRD-K62965247-001-04-9::2.5::HTS002	2.5	tipifarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, FNTB	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.424193736857	-0.424193736857	-1.48068039859747	-1.40587252118	-16.7665622556228	25.5958885892628	2.55699174964517e-15	2.73744997357492e-13	-1.18610830529356	-0.926865018187379
RSF1	BRD-K66527818-001-02-6::2.5::HTS002	2.5	VU0364770	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.1980045261935	-0.1980045261935	-1.15381739687957	-1.028958953375	-13.5906592075352	34.8778076026409	1.69175893844458e-15	1.84338079063492e-13	-1.09860552690492	-0.813020214467211
RSF1	BRD-K68164687-001-01-6::2.5::HTS002	2.5	epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.1139918339267	-0.1139918339267	-3.13643171964033	-3.18680355288	-19.3253969022525	2.22456261893939	0.00159902732028447	0.0332058837834755	-3.63428089314135	-2.4105988782859
RSF1	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-5.13699648512	-5.13699648512	-3.84468916336409	-3.68860468998	18.8658758789151	179.410696169437	1.87069840637238e-44	2.9053979618796e-41	1.1571385468576	1.42747609665421
RSF1	BRD-K68633617-003-02-9::2.5::HTS002	2.5	ACDPP	glutamate receptor antagonist	noncancer	GRM5	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.04410535386295	-0.04410535386295	0.241065554128933	0.327184190562	5.63643188201483	139.622073330487	9.25702352214893e-08	4.37786538940569e-06	0.185141045023378	0.385200770960388
RSF1	BRD-K73982490-001-02-9::2.5::HTS002	2.5	BI-78D3	JNK inhibitor	noncancer	MAPK8	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.518156925429	-0.518156925429	-0.89296633724135	-0.708568317551	-5.47707093686846	20.34376397965	2.18674024416196e-05	0.000707124094434202	-0.517402535696343	-0.232216287928356
RSF1	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.679740165342	-0.679740165342	-1.47876085239044	-1.368540965995	-9.12220503176309	189.028963905727	1.10051482797453e-16	1.33487403828496e-14	-0.971801578696453	-0.626239795400433
RSF1	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-2.53552509895	-2.53552509895	-1.09489382093344	-0.895557196833	11.4564962852838	2.85873821420012	0.00178000472398894	0.0363374257060507	1.02902209666707	1.85224045936605
RSF1	BRD-K76840893-003-02-5::2.5::HTS002	2.5	RS-17053	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1D	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.43476302868	-0.43476302868	-0.167350653036925	-0.1689019992055	8.37509015792046	88.2200305249726	7.78469470192007e-13	6.55593646667123e-11	0.203961425128673	0.330863326157478
RSF1	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.0872077023423	0.0872077023423	-0.210551543766421	-0.20601445055	-5.8285051778917	26.5070304164235	3.5666098097889e-06	0.0001335245264493	-0.402671840792288	-0.192846651425153
RSF1	BRD-K77625799-001-07-7::2.5::MTS010::PROS002_PR500	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.489597462817	-0.489597462817	-0.116907458963022	-0.0734176025033	8.60463454116799	54.8614625786263	9.30499033451327e-12	7.00010274975744e-10	0.285884474827157	0.459495532880799
RSF1	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.91412613482	-0.91412613482	-1.11147183022352	-1.11451105929	-3.98984054793369	154.24159246921	0.000101897999188362	0.00288274765945649	-0.295056173844467	-0.09963521696258
RSF1	BRD-K78318619-001-02-7::2.5::HTS002	2.5	PF-4981517	cytochrome P450 inhibitor	noncancer	CYP3A4	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.3465993528485	0.3465993528485	-0.597728037812867	-0.549021652731	-9.71898043286996	6.15233836508832	5.84625210873108e-05	0.0017396154145502	-1.1806574707461	-0.707997310576633
RSF1	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.2521302327765	-0.2521302327765	-2.22884955629186	-2.0670113581	-16.3150734107851	10.0161351416224	1.52481204955006e-08	7.99049979872897e-07	-2.2466196463451	-1.70681900068562
RSF1	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.149265820741	-0.149265820741	0.335225909395519	0.372094584014	14.2264435608225	7.16234509867287	1.63805006082854e-06	6.46440124263156e-05	0.404331306216497	0.56465215405654
RSF1	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.4417832057745	-0.4417832057745	-0.159744722974323	-0.116252087164	13.1439264960265	188.995219962172	1.88768709701802e-28	6.74310146361291e-26	0.239711114785248	0.324365850815106
RSF1	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.418772160642	-0.418772160642	-2.07803276326057	-1.887176140495	-15.8805892404821	119.416488110915	3.21722970228949e-31	1.43059258270125e-28	-1.86614108867854	-1.45238011655859
RSF1	BRD-K89015388-001-01-7::2.5::HTS002	2.5	GSK923295	centromere associated protein inhibitor	targeted cancer	CENPE	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.259163398391	-0.259163398391	-1.65491487370948	-1.4981509162	-10.7248549747626	3.37525315331202	0.00100585376882213	0.0222388727478728	-1.78505144251435	-1.0064515081226
RSF1	BRD-K89299012-001-06-0::2.5::HTS002	2.5	DCEBIO	potassium channel activator	noncancer	KCNN2, KCNN3, KCNN4	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.32737314502	-0.32737314502	-2.06172489946425	-1.8672769967	-19.0785942928654	114.350657143451	2.48598264966489e-37	2.01063462384916e-34	-1.91442919661973	-1.55427431226878
RSF1	BRD-K89714990-001-01-5::2.5::HTS002	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.6211486324115	0.6211486324115	-0.0126271673829688	-0.02895586832955	-18.4979599159341	38.5362850789676	9.1548875240005e-21	1.62430288752608e-18	-0.703103766067809	-0.564447833521128
RSF1	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.883192793831	-0.883192793831	-3.13052734717257	-3.009227373135	-20.5844956056274	123.065747736725	1.13939096305335e-41	1.39545443268721e-38	-2.46344076401769	-2.03122834266544
RSF1	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.427685609436	-0.427685609436	-1.02926297894608	-0.948156981669	-11.8467404100938	6.80599081768081	8.60892703488319e-06	0.000299925670100696	-0.722350333969581	-0.480804405050573
RSF1	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.2164238217245	0.2164238217245	0.092326154799689	0.09873309755385	-4.18064331611706	10.1131935010502	0.00184024598820224	0.0373537344829432	-0.190137241241554	-0.0580580926080684
RSF1	BRD-K92213669-001-01-3::2.5::HTS002	2.5	lomitapide	microsomal trigylceride transfer protein inhibitor	noncancer	MTTP	endocrinology	hypercholesterolemia	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.7039247986715	0.7039247986715	0.22176798620935	0.227576049132	-10.6891035633909	14.7774355214594	2.39523377943383e-08	1.22172313353706e-06	-0.578427061932914	-0.385886562991386
RSF1	BRD-K92428232-001-10-6::2.5::HTS002	2.5	GSK461364	PLK inhibitor	targeted cancer	PLK1	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.16144983707245	0.16144983707245	-2.72812789390763	-2.38486964806	-17.8436453240841	4.36654907547729	3.01477754614513e-05	0.000947996268614641	-3.32469089779322	-2.45446456416694
RSF1	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.173310631781	-0.173310631781	-2.26619251228164	-2.18755983006	-24.939732780383	185.865468366398	3.30524403082082e-61	2.5300344567207e-57	-2.25843526547568	-1.92732849552559
RSF1	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.10992499915935	-0.10992499915935	-1.09902895659204	-1.03443241086	-13.2803110235038	11.5629423032404	2.35396612495571e-08	1.20210437358978e-06	-1.15206260843616	-0.826145306429226
RSF1	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	0.2867500935015	0.2867500935015	-0.222975433603311	-0.147984722712	-8.69414136948697	8.56234231381474	1.55892699329278e-05	0.000518744393021967	-0.643393294665089	-0.376057759544534
SENP6	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.2648076763065	-0.2648076763065	-0.493629544448949	-0.379151386241	-3.88056610747154	103.360626254876	0.000183700647428494	0.00490254962802911	-0.345762380606813	-0.111881355678084
SENP6	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.5353097352585	0.5353097352585	-0.226761950015354	-0.093015492892	-9.69487799744641	8.94054408193598	4.8571562771601e-06	0.000177317228364409	-0.940070323397611	-0.584073047150097
SENP6	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.506809508938	0.506809508938	0.0706619206454609	0.128125201883	-10.3796266258401	3.54634780574443	0.000886078377335017	0.0198986056722377	-0.558940756063515	-0.313354420521564
SENP6	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.0651883969389	0.0651883969389	0.18663159648407	0.190024427126	3.89956826275766	19.164615730571	0.000950769329382378	0.0211715781833136	0.0562985917654025	0.186587807324938
SENP6	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.13980566772	-2.13980566772	-1.11449242737336	-1.02154011458	17.219744231759	51.2187135786916	5.96805246059831e-23	1.28169009601961e-20	0.905788304394027	1.14483817629925
SENP6	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.226442099933	0.226442099933	-0.0527533441366143	-0.0230394948173	-7.21191557492816	6.45608189034827	0.000257242135686918	0.00660609270304835	-0.372324199897676	-0.186066688241553
SENP6	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.378986382746	0.378986382746	-0.190972292523903	-0.136086260588	-12.1694272987952	80.7863782304118	5.88743969728613e-20	9.66934147800489e-18	-0.663149949887929	-0.476767400651878
SENP6	BRD-K09397065-003-06-1::2.5::HTS002	2.5	SR-57227A	serotonin receptor agonist	noncancer	HTR3A	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.4667412402465	0.4667412402465	0.242828442483847	0.2348348168625	-6.68162887949539	66.295745530121	5.83840696730498e-09	3.20035786929798e-07	-0.290815511383134	-0.157010084142172
SENP6	BRD-K11071038-001-01-7::2.5::HTS002	2.5	ICI-162846	histamine receptor antagonist	noncancer	HRH2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.29908809324	-0.29908809324	0.100005327909494	0.0637321133413	10.567618175194	8.04286540710913	5.39111873309236e-06	0.000195379284231477	0.312086302046811	0.486100540252177
SENP6	BRD-K11663430-001-02-3::2.5::HTS002	2.5	pyroxamide	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.178125352215	-0.178125352215	-0.643708388033475	-0.612220843488	-7.23841684939232	138.512718648749	2.84218559838716e-11	2.00911212769367e-09	-0.592761238472708	-0.338404833164242
SENP6	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.041825329755	-2.041825329755	-2.4196630179197	-2.32972185313	-4.65261270675113	15.8586823101708	0.000271445944507099	0.00692768966899999	-0.550119511359917	-0.205555864969474
SENP6	BRD-K12932420-001-02-3::2.5::HTS002	2.5	YM-976	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.604672265703	0.604672265703	0.309855743554097	0.3289563739625	-8.50440345023326	101.33762111655	1.69536027810274e-13	1.52099151546874e-11	-0.363582433630976	-0.226050610666829
SENP6	BRD-K13566078-001-02-3::2.5::HTS002	2.5	BMS-345541	IKK inhibitor	targeted cancer	CHUK, IKBKB	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.59411584711	-2.59411584711	-1.47358219178431	-1.48395465403	14.2089297341095	4.82852895655504	4.00196981388629e-05	0.00122955588910613	0.915629868300763	1.32543744235061
SENP6	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.367294751298	0.367294751298	-0.481796000570407	-0.373418715101	-8.52049199367954	17.4712992049381	1.24208577950712e-07	5.78728267469526e-06	-1.05890853688252	-0.639272966854298
SENP6	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.6390675961215	0.6390675961215	0.398095268412026	0.431459247123	-7.49721603266988	55.7742491300257	5.33811353350973e-10	3.2670260865894e-08	-0.305365390083875	-0.176579265335073
SENP6	BRD-K15519488-050-01-3::2.5::HTS002	2.5	CS-110266	dopamine receptor agonist	noncancer	SLC6A3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.6676580229	-1.6676580229	-0.0997162340548361	-0.120574600447	29.0229143074514	46.4990133677625	1.9308067583077e-31	8.71216593055434e-29	1.45922805533625	1.67665552235408
SENP6	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.0332005054965	-1.0332005054965	-0.0838594968913317	-0.0178822580687	16.8191575290073	3.50340704239948	0.000178123469915165	0.00477212814793093	0.783465666393864	1.11521635081647
SENP6	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.067936394415	-2.067936394415	-2.36003409030281	-2.30540806626	-3.27483865550268	191.987218364642	0.00125422016295601	0.0269597586306488	-0.468024748902996	-0.116170642872622
SENP6	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.043812824779635	0.043812824779635	-0.826771294346047	-0.81565114113	-10.6027950575996	5.3899346481134	8.19094614745509e-05	0.00236406853869903	-1.07714071097283	-0.66402752727853
SENP6	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.7364417408	-0.7364417408	-1.87658735314679	-1.673362994515	-9.90035112011963	7.64136187069197	1.26082184013946e-05	0.000426567772968034	-1.4078952222654	-0.872396002428189
SENP6	BRD-K21728777-001-02-3::2.5::HTS002	2.5	AMG900	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.8396050652075	-0.8396050652075	-1.55070537270013	-1.404443241845	-8.47418777103178	176.341064305826	9.1225567057665e-15	9.24457898907909e-13	-0.876704629395708	-0.545495985589547
SENP6	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.4447314344105	-0.4447314344105	-0.166047845781739	-0.149311762512	13.980782259861	72.6026550671373	2.77415671210166e-22	5.60397958480712e-20	0.238952849985209	0.318414327272313
SENP6	BRD-K25835157-001-01-4::2.5::HTS002	2.5	PRT062070	JAK inhibitor, syk inhibitor	targeted cancer	SYK	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.2283785181275	-0.2283785181275	-0.0808183924255155	-0.05777682074495	3.26481858660802	189.695425174722	0.00129954975549166	0.0278030744205202	0.0584067794326486	0.23671347197132
SENP6	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.710589560383	-0.710589560383	-0.42150441232731	-0.310239188826	7.21453845936357	132.733783015	3.72563603687167e-11	2.59172945844423e-09	0.20982716683331	0.36834312927807
SENP6	BRD-K26667523-001-02-5::2.5::HTS002	2.5	TAK-733	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.545828161595	-1.545828161595	-1.97874018247591	-1.88069436606	-3.79681666149923	17.858052458311	0.00133658219618887	0.0284760442637793	-0.672595146324902	-0.193228895436927
SENP6	BRD-K31309378-001-01-5::2.5::HTS002	2.5	lucitanib	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.11742825359335	-0.11742825359335	-0.768625198848348	-0.647544423054	-8.08915958677954	4.65652506447455	0.000650686624592997	0.0151226429800903	-0.862811508579788	-0.439582381930208
SENP6	BRD-K31812033-003-11-0::2.5::HTS002	2.5	levobunolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.357034289262	0.357034289262	0.171347121339221	0.2093635994345	-5.23711354781803	175.955719357	4.61757996129536e-07	1.9797585427575e-05	-0.255660951448471	-0.115713384397087
SENP6	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.5029418904	-1.5029418904	-2.31738619430706	-2.045349051995	-7.03905734677171	18.5427160889562	1.21864021128393e-06	4.90958529782468e-05	-1.05701957982315	-0.571869027990972
SENP6	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.80654782941	-2.80654782941	-3.66958714884394	-3.65355610334	-8.47138528936337	114.515483334784	9.42478655383763e-14	8.65469184788974e-12	-1.06484712769467	-0.661231511173211
SENP6	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.264157725074	0.264157725074	0.0353712344814949	0.0389416186426	-10.8204648473242	40.7389565300168	1.49694476187395e-13	1.35089967944287e-11	-0.27149571122905	-0.18607726995596
SENP6	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.06582998538895	-0.06582998538895	-1.03986265210735	-1.017015264785	-13.2901097088737	122.625002575821	1.63247003420224e-25	4.35723125729181e-23	-1.11911021368605	-0.828955119750752
SENP6	BRD-K36529613-001-02-6::2.5::HTS002	2.5	PU-H71	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.380106335485	-2.380106335485	-3.49163383633271	-3.372344193665	-9.56800778621085	13.3668352553993	2.37693016819479e-07	1.06134388753963e-05	-1.36180189249729	-0.861253109198136
SENP6	BRD-K38332599-001-01-3::2.5::MTS010::PROS002_PR500	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.146269706265	-1.146269706265	-0.563684583113352	-0.5253626676245	6.48070342281439	17.6909832401371	4.6516069891519e-06	0.000170831781079153	0.393485248565836	0.77168499773746
SENP6	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.299053729164	0.299053729164	-0.359551964411711	-0.2780855887145	-14.7723621503314	177.570786060066	9.9550244108438e-33	5.10442685873622e-30	-0.746587654628266	-0.570623732523156
SENP6	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.663157728065	-1.663157728065	-1.00752825608537	-1.02230629729	10.2670404589871	190.530330457028	5.79095343986095e-20	9.52547398167274e-18	0.52967062887876	0.78158831508049
SENP6	BRD-K41312087-001-02-7::2.5::HTS002	2.5	GW-441756	growth factor receptor inhibitor	targeted cancer	NTRK1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.3266179512065	-0.3266179512065	-0.00435614486935058	0.0338208037479	7.82488102435255	6.08213434205187	0.000215041827957162	0.00563788378522698	0.221816554732796	0.422707057941503
SENP6	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.196646974548	0.196646974548	-0.298881958178698	-0.160539632789	-7.91867542325676	32.7620494658693	4.14166064229381e-09	2.30565710078491e-07	-0.622878442617678	-0.368179422835717
SENP6	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.511473322139	-0.511473322139	-1.39892693077855	-1.273586296615	-12.645955719019	59.7307460105572	1.54322840691985e-18	2.22733064799141e-16	-1.02784126784446	-0.747065949434642
SENP6	BRD-K47114202-001-14-6::2.57945::HTS002	2.57945	chlorogenic-acid	antioxidant	noncancer	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.4552833939485	-0.4552833939485	-1.05830201578974	-0.967874485397	-8.48418761074862	46.3236037073062	5.463476373172e-11	3.71976311177122e-09	-0.746059394518833	-0.459977849163657
SENP6	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-2.4057973459	-2.4057973459	-0.0422122984055214	0.365958476092	23.0759903937776	7.64553763981919	2.39789062499008e-08	1.22249643140699e-06	2.12547017932759	2.60169991566137
SENP6	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.444254924675	-1.444254924675	-1.83359651218176	-1.58248812639	-3.95244766661318	82.7961121381445	0.00016213717049799	0.00439017441045611	-0.585274089658194	-0.193409085355332
SENP6	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.4763951936785	-0.4763951936785	-1.25718933219389	-0.921278111753	-7.09484684314203	6.4953054693079	0.000275206995628657	0.00700532543540313	-1.04517876875526	-0.516409508275512
SENP6	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.507740293957	0.507740293957	-0.116469079855352	0.03876057814515	-10.499278785069	10.2193239379081	8.47497117709136e-07	3.4985209888575e-05	-0.756293656443309	-0.492125091181394
SENP6	BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.8933811521345	-0.8933811521345	-0.20735445259798	-0.1324820733985	15.5059269471437	5.17392441260254	1.55116575659652e-05	0.000516643054305479	0.573437120078418	0.798616278994622
SENP6	BRD-K54095730-001-03-1::2.5::HTS002	2.5	CMPD-1	p38 MAPK inhibitor	noncancer	GNRHR, MAPK14	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.12308021848	-1.12308021848	-1.51662700683854	-1.5570935433	-4.70500511865838	7.07828259879694	0.00213105553050663	0.0423698516510164	-0.590891522504978	-0.196202054212111
SENP6	BRD-K57080016-001-15-9::2.5::HTS002	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.7203033317495	0.7203033317495	-0.595134677725873	-0.48109263675	-12.737926629214	4.0795059094661	0.00019458767066325	0.00515777651070785	-1.59996943467281	-1.03090658427793
SENP6	BRD-K58049875-001-04-7::2.5::HTS002	2.5	thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	noncancer	FOXM1	obstetrics/gynecology	mastitis	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.10253675907	-1.10253675907	-0.800628156667698	-0.684325273756	4.6552838013755	95.391970193566	1.044307845206e-05	0.000358522274796021	0.173166163129775	0.430651041674829
SENP6	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.06063922351625	-0.06063922351625	-0.143052702901396	-0.139438991422	-4.3171057130865	188.066329525468	2.55395494826135e-05	0.000816628557087241	-0.12007149275939	-0.0447554660109029
SENP6	BRD-K61228301-001-01-2::2.5::HTS002	2.5	SGI-1027	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3A, DNMT3B	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.47480061007	-1.47480061007	-2.08331824694873	-1.79411655002	-4.46879664191973	22.2687067149456	0.000187133799786059	0.00497929238663517	-0.890720234765978	-0.326315038991486
SENP6	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-3.595666275735	-3.595666275735	-2.93396593377173	-2.87845710522	7.64399071284284	147.826322898731	2.46107799947176e-12	1.97188929550947e-10	0.490636084786339	0.832764599140191
SENP6	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.270853163159	0.270853163159	-0.34090612446393	-0.3277516003215	-12.2274136784822	21.9991615624879	2.77125184384147e-11	1.96220560435646e-09	-0.715519080781646	-0.507999494464214
SENP6	BRD-K67511046-001-02-3::0.625::HTS002	0.625	naloxone	opioid receptor antagonist	noncancer	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.337987263583	-0.337987263583	0.0742405684045551	0.0434785043643	8.99090936572674	3.25050135918661	0.00209990310671917	0.0418358554526877	0.272474283098424	0.551981380876686
SENP6	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.1340384035705	-0.1340384035705	0.127753077302061	0.138278646354	9.1852028635807	62.146157980295	3.5062382978837e-13	3.04739881649277e-11	0.204820585354568	0.318762376390553
SENP6	BRD-K73293050-001-03-1::2.5::HTS002	2.5	WZ-3146	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.759464954035	-1.759464954035	-2.5822285383339	-2.4237476511	-8.5288079352896	174.05359733973	6.96241229589364e-15	7.13652254885981e-13	-1.01316275306543	-0.632364415532367
SENP6	BRD-K73309154-003-02-8::2.5::HTS002	2.5	OSI-420	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.441447354829	-0.441447354829	-1.34086849473771	-1.10972386317	-9.36906298049417	21.0061302413779	5.97343286382993e-09	3.26863526870305e-07	-1.0990585446557	-0.69978373516172
SENP6	BRD-K79259477-001-04-9::2.5::HTS002	2.5	NVP-BHG712	ephrin inhibitor	targeted cancer	EPHB4	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	0.7019617848465	0.7019617848465	0.145355722822593	0.138812266601	-16.1298076051409	74.6027483334367	4.97610297550215e-26	1.37261669837375e-23	-0.625355358190203	-0.487856765857611
SENP6	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-4.28745131441	-4.28745131441	-3.04894422084264	-2.99006854464	11.2780594945322	12.4600284739422	6.67178701025716e-08	3.21483236987727e-06	1.00021550525206	1.47679868188265
SENP6	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.020463277008645	-0.020463277008645	0.112768756187525	0.0998567885779	4.60232625764687	19.073966201912	0.000192662589933744	0.00511244029192887	0.0726573015383055	0.193806764854034
SENP6	BRD-K89015388-001-01-7::2.5::HTS002	2.5	GSK923295	centromere associated protein inhibitor	targeted cancer	CENPE	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.097117321985	-1.097117321985	-1.64549966108483	-1.4981509162	-6.19092484695176	177.245808759736	4.04458010780107e-09	2.2568883361752e-07	-0.723186390550644	-0.373578287649007
SENP6	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-1.342128575125	-1.342128575125	-1.00952240809461	-0.9517219897545	5.63400882050484	19.4559371986785	1.80406964842371e-05	0.000593681012861977	0.20923927047945	0.455973063581327
SENP6	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-0.3422581930875	-0.3422581930875	-0.0909081495554839	-0.0408206395104	7.84021363301064	40.1147962299002	1.27824163363365e-09	7.52649041469962e-08	0.186561999391659	0.316138087672374
SENP6	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MCF7, JHH7	BREAST, LIVER	carcinoma, carcinoma (hepatocellular_carcinoma)	-3.66163988969	-3.66163988969	-3.13660121535724	-3.215000704775	6.82846894100804	5.01889874496866	0.00101204946151935	0.0223527977161975	0.327611150230163	0.722466198435352
SHC4	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.483629238988	0.483629238988	-0.0561750011665617	0.106263594851	-9.93182999154847	165.913627347547	1.55409875342553e-18	2.24151030769139e-16	-0.647112839607378	-0.432495640701745
SHC4	BRD-A16997652-001-02-3::2.5::HTS002	2.5	protirelin	thyrotropin releasing hormone receptor agonist	noncancer	TRHR	radiology	thyroid function diagnostic	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4053427216565	0.4053427216565	0.334388271368641	0.352492434088	-3.12800828817343	100.407408001473	0.00230338246622401	0.0452794332388632	-0.115955806202353	-0.0259530943733641
SHC4	BRD-A17883755-001-06-1::2.5::HTS002	2.5	lenalidomide	anticancer agent	targeted cancer	CDH5, CRBN, PTGS2, TNF, TNFSF11	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.627920520801	-0.627920520801	-0.0444382752258325	0.0255769508677	9.7375039069963	189.733551245197	1.98709017157299e-18	2.83360644965448e-16	0.465285062396552	0.701679428753783
SHC4	BRD-A45498368-001-07-1::2.5::HTS002	2.5	WYE-125132	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.51265274284	-1.51265274284	-2.35089101118334	-2.40199548357	-10.2765211633379	8.31970251524472	5.17993938463609e-06	0.000188203293502232	-1.02508434559724	-0.651392191089435
SHC4	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.185170190392	-0.185170190392	-0.533897508559038	-0.51783728433	-10.0014103086993	21.7067038195308	1.38093336331039e-09	8.09114452774609e-08	-0.421095430359595	-0.27635920597448
SHC4	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.468865848106	0.468865848106	0.244783644908623	0.260666777641	-6.94223009046736	187.548415600436	6.1215918265077e-11	4.15463791825069e-09	-0.287757058644428	-0.160407347750326
SHC4	BRD-A70858459-001-01-7::2.5::HTS002	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.373459684246	0.373459684246	0.0972659781096057	0.09357088918285	-9.33186732562459	149.459185295321	1.3366296845188e-16	1.61578400255628e-14	-0.334675964447518	-0.21771144782527
SHC4	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2978118663795	0.2978118663795	0.142478914783734	0.135666555282	-5.41851030060752	34.6704099948026	4.6396662408562e-06	0.000170480889034197	-0.21355003257868	-0.0971158706128524
SHC4	BRD-A83650191-004-02-8::2.5::HTS002	2.5	A61603	adrenergic receptor agonist	noncancer	ADRA1A	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.202271978435	-4.202271978435	-2.0084647476778	-1.98407257251	15.769217464196	3.03921615474337	0.000515454390060513	0.0123111582032838	1.75428097183375	2.63333348968065
SHC4	BRD-K00673382-001-18-9::0.15625::HTS002	0.15625	famotidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	heartburn	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.918769814767	0.918769814767	0.497321235754805	0.4883209569055	-10.6261508648909	16.78399755874	7.19943344550701e-09	3.89461729162563e-07	-0.505209039172628	-0.337688118851762
SHC4	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.14315559294	-1.14315559294	-0.283382466998332	-0.201937004263	11.2227158383909	3.33357894466621	0.000920414624858595	0.0205799514552444	0.629202899196891	1.09034335268644
SHC4	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.63094842581	-2.63094842581	-2.19362004484876	-2.0949684601	4.89627210659875	10.23434577742	0.000585609225418002	0.0138017417720052	0.238930013922652	0.635726747999822
SHC4	BRD-K11433652-001-17-0::0.15625::HTS002	0.15625	aspirin	cyclooxygenase inhibitor	noncancer	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4852542237865	0.4852542237865	0.341461713366936	0.3517633375585	-4.24001277245388	32.036438831012	0.000177319964589428	0.00475535669300393	-0.212868409408652	-0.074716611430476
SHC4	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.732152416455	-3.732152416455	-2.43436268294663	-2.42612206257	11.9209421193829	14.0393213806632	9.87309214590871e-09	5.27177370837187e-07	1.06435592408853	1.53122354292821
SHC4	BRD-K13049116-001-05-7::2.5::HTS002	2.5	BMS-754807	IGF-1 inhibitor	targeted cancer	AKT1, IGF1R	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.19359694582	-3.19359694582	-1.52086596921148	-1.35806508341	13.0222583887492	2.7630577765355	0.00146181328303407	0.030764825131521	1.24337525197718	2.10208670123986
SHC4	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.399849197085	-1.399849197085	-2.61661777193685	-2.686193418095	-16.9640754948034	135.766852720127	2.37396731590238e-35	1.54184860863649e-32	-1.35861366985229	-1.07492347985141
SHC4	BRD-K14880289-001-02-2::2.5::HTS002	2.5	GW-501516	PPAR receptor agonist	noncancer	PPARA, PPARD	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.605124423878	0.605124423878	0.296420137350038	0.308945987709	-12.6039442176128	75.1992868027495	3.18508338528807e-20	5.40503354620274e-18	-0.357494074217308	-0.259914498838617
SHC4	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.557518411436	0.557518411436	0.256249217673975	0.261395016509	-8.08537889780858	4.38440357100881	0.00085449895674266	0.0192762769076621	-0.401241471244531	-0.20129691627952
SHC4	BRD-K18424115-003-01-3::2.5::HTS002	2.5	TG-100572	src inhibitor, VEGFR inhibitor	targeted cancer	KDR, SRC	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.66347384068	-1.66347384068	-1.1987287647849	-1.10820806652	7.37057947750851	192.104225798832	4.91754210891864e-12	3.80969934838147e-10	0.340377866294197	0.589112285495997
SHC4	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.974664369885	-3.974664369885	-2.43418778574182	-2.31886428958	12.3969946693093	4.30549769674184	0.00015696400337451	0.00426117009236927	1.20491296448902	1.87604020379733
SHC4	BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500	2.5	sonidegib	smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.204888890538	0.204888890538	-0.0016335590638449	0.0115719304002	-10.2918500884529	34.290002116559	5.03614738398132e-12	3.89250787111912e-10	-0.247289989380172	-0.165754909823517
SHC4	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.60671540158	-4.60671540158	-3.07366651818835	-2.85883819524	11.8196015583989	6.6719542068146	1.0164957878593e-05	0.00034975842946877	1.22326420594792	1.84283356083538
SHC4	BRD-K21680192-300-14-4::2.5::HTS002	2.5	mitoxantrone	topoisomerase inhibitor	chemo	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-7.241243111475	-7.241243111475	-4.69204159524623	-4.740808103055	20.1074108147165	113.753215967324	3.0008343157953e-39	2.97761952810227e-36	2.29804704714085	2.80035598531669
SHC4	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.207727146664	0.207727146664	0.415307667779183	0.442474468431	7.94413669502495	176.789840688047	2.19971698112076e-13	1.95627859272461e-11	0.156013605523302	0.259147436707065
SHC4	BRD-K24048528-001-02-5::2.5::HTS002	2.5	abiraterone-acetate	androgen biosynthesis inhibitor	targeted cancer	CYP17A1	oncology	prostate cancer	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.594180587826	0.594180587826	0.399490118137966	0.363692430058	-5.02091421718705	6.35223937018494	0.00203477805095018	0.0406972699591361	-0.28831080784547	-0.101070131530599
SHC4	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.52343905321	-4.52343905321	-2.7866965394768	-2.61952250038	16.7887100847721	185.549620371681	4.47339802789511e-39	4.33836618063679e-36	1.53265891998257	1.94082610748383
SHC4	BRD-K25596805-001-01-8::2.5::HTS002	2.5	JNJ-16259685	glutamate receptor antagonist	noncancer	GRM1	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.7868661374355	0.7868661374355	0.38747918391438	0.376431167142	-9.55776935921909	5.46317080704526	0.000129499026979202	0.0035799557530537	-0.504120730267291	-0.294653176774949
SHC4	BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500	2.49998	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0381282576987	0.0381282576987	-0.429303556265661	-0.326694667694	-11.8912537521916	183.171223247319	1.55749467245786e-24	3.85024539392412e-22	-0.544988211240777	-0.389875416687945
SHC4	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.07125763689255	-0.07125763689255	-0.535959510421471	-0.4752073320215	-8.27265688584205	7.31514097094269	5.74312131309323e-05	0.00171198532394153	-0.596379194402812	-0.333024552655029
SHC4	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.700088129878	0.700088129878	0.142861394487377	0.195908235522	-13.7207034753112	190.520024413799	3.02831475074958e-30	1.23865586300268e-27	-0.637333867802097	-0.47711960297915
SHC4	BRD-K28307902-001-21-7::2.5::HTS002	2.5	flutamide	androgen receptor antagonist	targeted cancer	AHR, AR	oncology	prostate cancer	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.1837930072885	-0.1837930072885	0.247668181858882	0.2821058302255	12.2690843460624	4.06690883144757	0.000230145242142219	0.00598916945156624	0.334453491790599	0.528468886504165
SHC4	BRD-K29968218-001-03-2::2.5::HTS002	2.5	KX2-391	src inhibitor, tubulin polymerization inhibitor	targeted cancer	SRC	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.23513181098	-3.23513181098	-2.74250114974871	-2.69887921665	4.26975340844127	33.7055080593512	0.000150493754031636	0.0040990184023188	0.258081225787579	0.727180096675007
SHC4	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.194867146715	-5.194867146715	-3.68133344813126	-3.84343615246	15.8765986650954	183.479722200252	2.77495586605681e-36	2.05797064296225e-33	1.32544756537998	1.70161983178749
SHC4	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.04660270759265	0.04660270759265	-0.309017410714788	-0.26288025127	-8.90243015623503	172.44964723401	7.38420482264327e-16	8.31660134226121e-14	-0.434466968297632	-0.276773268317243
SHC4	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2291871284615	-0.2291871284615	0.0405371491782017	0.0420255810144	11.0747767942019	7.73149491892954	5.14283875659533e-06	0.000186982101418545	0.213220625084432	0.326227930194971
SHC4	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.600623918165	-1.600623918165	-1.97251516722108	-2.04775511057	-4.77334900995038	13.6327317038916	0.000319425788126607	0.00801571358662775	-0.539414735416976	-0.204367762695184
SHC4	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.72865220061	-3.72865220061	-2.73562059899713	-2.72063669108	11.5060573373342	186.000010537585	1.7519601059083e-23	3.9114151827002e-21	0.822768860979763	1.16329434224597
SHC4	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.695911955005	-1.695911955005	-1.32604420468356	-1.04970341453	4.16685063361058	185.101322105832	4.73468906152182e-05	0.00143472525359382	0.194747880894962	0.544987619747914
SHC4	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.5103940568715	-0.5103940568715	0.16152691662612	0.14294893902	21.3048105412329	2.38542342593064	0.000887210008594012	0.0199219312657879	0.555211561372809	0.78863038562243
SHC4	BRD-K51662849-001-08-8::2.61265::HTS002	2.61265	ilomastat	matrix metalloprotease inhibitor	noncancer	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.500000651507	-0.500000651507	0.0252351891043406	0.0366644244554	16.8855645836956	35.6738561325335	1.35711611324709e-18	1.96533337456849e-16	0.462130700897686	0.588340980324995
SHC4	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.553822541957	0.553822541957	0.377125131033457	0.393436647762	-6.0914937890816	8.61380712467489	0.000216701642076049	0.0056779274137552	-0.242767553335659	-0.110627268511426
SHC4	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.8971830688255	0.8971830688255	0.463123296582887	0.458736917071	-11.9779680483007	4.12267342222121	0.000234042730805454	0.00608025993343056	-0.533503312663795	-0.334616231821431
SHC4	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.691667738335	-1.691667738335	-1.17826553214944	-1.09615123005	8.91989563578448	136.406256431941	2.72065527132028e-15	2.90251529938678e-13	0.399582833767688	0.627221578603427
SHC4	BRD-K59632282-052-03-1::2.5::HTS002	2.5	quinidine	sodium channel blocker	noncancer	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.6274560722695	0.6274560722695	0.438177241076204	0.439082857511	-7.26180158467009	90.0185922658166	1.31502753893849e-10	8.60606221047777e-09	-0.241061349972103	-0.137496312414489
SHC4	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-6.616729291835	-6.616729291835	-7.21957027942644	-7.25572463628	-5.8741473367888	174.607416187154	2.10077762217521e-08	1.07820298607086e-06	-0.80538836056918	-0.400293614613691
SHC4	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.499258897104	-0.499258897104	-0.16745462855206	-0.0695637223616	6.22051560057527	37.3516889611972	3.04070081358545e-07	1.33848914494754e-05	0.223760861053882	0.439847676049999
SHC4	BRD-K63932022-001-01-5::2.5::HTS002	2.5	2'-MeCCPA	adenosine receptor agonist	noncancer	ADORA1	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.6601815393725	0.6601815393725	0.191367603381438	0.258471111718	-8.94530652716114	180.358555984196	4.40287077634407e-16	5.08165261509449e-14	-0.572227458970372	-0.365400413011752
SHC4	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.398685014344	0.398685014344	-0.222960382675688	-0.209793035138	-9.74464901293994	7.33837091289582	1.85570941073826e-05	0.000608898258257991	-0.771094455804821	-0.472196338234556
SHC4	BRD-K66527818-001-02-6::2.5::HTS002	2.5	VU0364770	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.140984576085	-2.140984576085	-1.13314739634881	-0.9798482890525	14.9456196808203	85.3215194199806	1.50947570460548e-25	4.04405522865485e-23	0.87376837837345	1.14190598109894
SHC4	BRD-K67578145-001-09-7::2.38272::HTS002	2.38272	GDC-0879	RAF inhibitor	targeted cancer	BRAF	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.803737725261	0.803737725261	0.582527624182025	0.659791110046	-4.28828174106331	61.8626380561124	6.42422188318835e-05	0.00189681368232797	-0.324331176149747	-0.118089026008203
SHC4	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.155695368809	-0.155695368809	-0.272378018028047	-0.224936831672	-3.50279701434595	75.0282093214426	0.000779537887103749	0.0177893500644229	-0.183041711255968	-0.0503235871821274
SHC4	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.47847443896	-1.47847443896	-1.18676854091244	-1.06477540936	4.09711895727573	182.941913788108	6.27822993372393e-05	0.00185780304219953	0.151231473225773	0.432180322869354
SHC4	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.70515513211	-2.70515513211	-1.45809335272954	-1.346974687905	13.6579817871156	68.1187378108544	3.49556432099585e-21	6.39249833920409e-19	1.06486835316237	1.42925520559854
SHC4	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0423075658991	-0.0423075658991	-0.214290446040835	-0.189464823924	-5.75772715192819	130.785574227662	5.77685273163718e-08	2.79933770996849e-06	-0.231073620737067	-0.112892139546403
SHC4	BRD-K79239947-001-06-8::2.5::HTS002	2.5	PF-573228	focal adhesion kinase inhibitor	targeted cancer	CDK1, CDK2, CDK7, GSK3B, IKBKB	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3284589633875	0.3284589633875	-0.239757254912975	-0.1830123326315	-11.9587002264919	110.799185592378	1.14299742701139e-21	2.18145588186931e-19	-0.662372007427809	-0.474060429173141
SHC4	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.13099065757	-1.13099065757	0.0289107280866756	0.0546599136262	30.54159598883	3.48332300459319	2.34138992660433e-05	0.000752618699513233	1.04799411039272	1.27180866092064
SHC4	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.498163740472	0.498163740472	0.0283274225988685	0.114428305936	-8.50387947901539	12.4107142544187	1.58123112744387e-06	6.26439346236446e-05	-0.589774597703388	-0.349898038042875
SHC4	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.815568867478	0.815568867478	0.323387446963384	0.364286574892	-18.2031590895402	162.510845481521	4.53989375680903e-41	5.31710868307717e-38	-0.545573000781862	-0.438789840247371
SHC4	BRD-K81839095-001-30-1::2.5::HTS002	2.5	estrone	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.268992612608	0.268992612608	0.40776179840121	0.408585546428	5.9764686120157	190.26621053412	1.10393321544144e-08	5.87254659052738e-07	0.0929689494347288	0.184569422151691
SHC4	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.046432833655	-0.046432833655	0.311118776008279	0.330760339171	13.1587819258635	65.27007456137	4.99295422585206e-20	8.31495638129484e-18	0.303289454710237	0.411813764616321
SHC4	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	0.443374219382	0.443374219382	0.0311060907912765	0.0430886024597	-13.6934731174695	13.30935538645	3.17003923786233e-09	1.7884478542032e-07	-0.477156802408343	-0.347379454773104
SHC4	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-6.06146203144	-6.06146203144	-4.82895424466091	-4.95161811894	10.1640431112731	5.11102610953554	0.000139296578615696	0.00381683666557447	0.922820689670173	1.54219488388801
SHC4	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.224726002355	-4.224726002355	-3.09571970958378	-2.979502562735	10.3675089485675	160.509676527398	1.33732535008704e-19	2.12159589162698e-17	0.913947656204104	1.34406492933834
SHC4	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.719772639144	-0.719772639144	-1.01651517142024	-0.966558687453	-5.09985896111105	23.85770413798	3.28283789753245e-05	0.00102469130253327	-0.416871314847037	-0.176613749705444
SHC4	BRD-K94176593-001-09-4::2.5::HTS002	2.5	TWS-119	glycogen synthase kinase inhibitor	noncancer	GSK3B, JUN, MYC	NA	NA	MKN1, EBC1	STOMACH, LUNG	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.525486671398	-0.525486671398	-0.293670034633462	-0.211299722741	5.62486649819401	134.175362211443	1.03677330274897e-07	4.87945949066499e-06	0.150305821245615	0.313327452283461
SIPA1L3	BRD-A14344385-001-03-2::2.5::HTS002	2.5	IDRA-21	glutamate receptor positive allosteric modulator	noncancer	GRIA1, GRIA2, GRIA3, GRIA4	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	0.546790415754	0.551005638148	0.13468328947075	0.112477706002	-10.6583629955895	6.58114232692671	2.16027378485112e-05	0.000699515515989358	-0.504728604696961	-0.319485647869539
SIPA1L3	BRD-A27883417-300-01-6::2.5::HTS002	2.5	alexidine	phosphatidylglycerophosphatase inhibitor	targeted cancer	PTPMT1	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	0.340263490700333	0.37330190586	-0.242988073405857	-0.266354340659	-8.58374144963417	5.11438541362037	0.000315981920936611	0.00793579671108777	-0.756750034775952	-0.409753093436428
SIPA1L3	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	ABC1, 5637	LUNG, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma	-0.434455288807	-0.434455288807	-0.219217950118479	-0.08022384013305	3.49425917376259	27.989235919056	0.00160077078135662	0.0332388685136003	0.0890585640635364	0.341416113313505
SIPA1L3	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	-0.348657024312	-0.3516212055	-0.698480592944919	-0.638722037178	-6.72461232247581	187.840715929953	2.05602777641476e-10	1.3162078174767e-08	-0.452444754891041	-0.247202382374797
SIPA1L3	BRD-K09443272-001-03-3::2.5::HTS002	2.5	PHA-680632	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	-5.93469869006	-5.91609510778	-2.44979777960375	-2.30532883255	30.1717473670372	31.5365036780212	7.85350517005854e-25	2.00863235035021e-22	3.24949509654641	3.72030672436609
SIPA1L3	BRD-K13662825-001-07-5::2.5::HTS002	2.5	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	-5.74962653937333	-5.69549105711	-4.91268886215645	-4.86558007404	7.8952527977183	8.78997175003096	2.8179567720124e-05	0.000891205337153086	0.596261029848153	1.0776143245856
SIPA1L3	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	0.469485789154	0.452434247587	0.23733004504191	0.273307517444	-5.72523357914156	5.70451545037078	0.00146437939074783	0.0308097546323346	-0.332636206173191	-0.13167528205099
SIPA1L3	BRD-K39624409-003-02-6::2.5::HTS002	2.5	ADL5859	opioid receptor agonist	noncancer	OPRD1	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	0.779195497101667	0.797473655586	0.229839447484628	0.27661386861	-12.9175025369986	12.8027478675489	1.02387427806191e-08	5.46157168100375e-07	-0.641376393190603	-0.457335706043474
SIPA1L3	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	ABC1, 5637	LUNG, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma	0.436806900793	0.436806900793	0.254187718864653	0.2832758926905	-4.87820161034004	12.328861769153	0.00035120931649284	0.00874372815587812	-0.26394404284448	-0.101294321012214
SIPA1L3	BRD-K40175214-001-11-6::2.5::HTS002	2.5	torin-1	mTOR inhibitor	targeted cancer	MTOR	NA	NA	ABC1, 5637	LUNG, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma	-3.420672654185	-3.420672654185	-3.7324741204042	-3.718490926125	-4.1269805549923	60.4938445966533	0.00011422488552741	0.0031952108444537	-0.462902514459663	-0.160700417978741
SIPA1L3	BRD-K43389675-003-20-9::2.5::HTS002	2.5	daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	chemo	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	-6.22788090932	-6.18825202497	-5.0445992042038	-5.06586339007	9.77759226658863	4.31161216469647	0.000420271024691374	0.0102639321389104	0.85664084838687	1.50992256184552
SIPA1L3	BRD-K51318897-001-15-3::2.5::HTS002	2.5	fenbendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	ABC1, 5637	LUNG, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma	-3.91093433762	-3.91093433762	-2.74067088176515	-2.64876474406	8.01106437728243	3.68191254173476	0.0018525070479113	0.0375634799500266	0.750478191528964	1.59004872018073
SIPA1L3	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	-0.0417944566694933	-0.00049909892548	-0.696415989991086	-0.647957316617	-7.4611324475232	4.97513039007941	0.000697519701668253	0.0161115098759408	-0.88049762481316	-0.428745441830025
SIPA1L3	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	0.295765139499333	0.262392657173	-0.501078535993065	-0.003081886328155	-6.9857989749697	12.9715306185552	9.65460126783376e-06	0.000333697957609021	-1.04332374938257	-0.550363601602229
SIPA1L3	BRD-K66527818-001-02-6::2.5::HTS002	2.5	VU0364770	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	ABC1, 5637	LUNG, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma	-0.779477510365	-0.779477510365	-1.14763151406923	-1.028958953375	-4.50812259865334	7.2396548431819	0.00254677252315576	0.0493666643859502	-0.559971753952706	-0.176336253455755
SIPA1L3	BRD-K70511574-001-06-9::2.5::HTS002	2.5	HMN-214	PLK inhibitor	targeted cancer	PLK1	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	-3.49023864834667	-3.43977281378	-2.82120705799006	-2.76225459975	5.90680704936269	21.8118963580458	6.27079865783819e-06	0.000224338842519746	0.434017873557702	0.904045307155513
SIPA1L3	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	0.452244423036333	0.424489495846	-0.474822602208829	-0.232894328891	-10.3652655184928	109.151093208135	6.13846163808239e-18	8.41208660120564e-16	-1.10433099932644	-0.749803051163879
SIPA1L3	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	-0.361298551991	-0.370226210485	0.0497003421717416	0.065240968148	9.50983830662574	5.4946195608636	0.000128656033069033	0.00355940608127699	0.302844419358872	0.519153368966611
SIPA1L3	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	-4.38122042133	-4.38573656169	-3.08735065434976	-2.96865870691	7.46570171629195	5.2133112255307	0.00056630544815256	0.0133850551827404	0.853793308260445	1.73394622570003
SIPA1L3	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	ABC1, HGC27, 5637	LUNG, STOMACH, URINARY_TRACT	carcinoma (non_small_cell_carcinoma), carcinoma (undifferentiated_adenocarcinoma), carcinoma	-7.14261578651	-7.12972141316	-5.59216059684192	-5.57864424691	15.7396367308346	185.036084812284	5.59383622118054e-36	3.90528118387428e-33	1.35611509329204	1.74479528604413
SLC44A1	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.651097555355	-1.651097555355	-1.20768554673251	-1.08580167806	5.89765017269416	27.9360483181124	2.43224284374587e-06	9.36411310323708e-05	0.289387612074707	0.597436405170264
SLC44A1	BRD-A25687296-300-04-3::2.5::HTS002	2.5	emetine	protein synthesis inhibitor	targeted cancer	RPS2	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-6.57817995629	-6.57817995629	-4.92151516276654	-4.931127887025	19.6019598994279	65.2754596570103	4.73956569519243e-29	1.77903043062154e-26	1.4878896602786	1.82543992676832
SLC44A1	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.7644903780045	0.7644903780045	-0.020774150297823	0.03331372318045	-11.0558268811348	3.22636971288769	0.00113054635604782	0.0246198811161729	-1.00259230557008	-0.567936751034566
SLC44A1	BRD-A70858459-001-01-7::2.5::MTS010::PROS003_PR500	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.1667530936365	0.1667530936365	-0.0170122851991631	-0.0158635898493	-8.5153014322609	15.7398247600862	2.76502799550267e-07	1.22493940729246e-05	-0.229575760039135	-0.137954997632191
SLC44A1	BRD-A95696066-003-13-8::2.5::HTS002	2.5	nisoxetine	norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.712615653389	0.712615653389	0.334501552773327	0.334888037039	-11.7330272931426	3.07026819717555	0.00119191217924958	0.0258041763097356	-0.479357946988303	-0.276870254243042
SLC44A1	BRD-A98299281-050-09-6::2.5::HTS002	2.5	hydroxytacrine-maleate-(r,s)	cholinesterase inhibitor	noncancer	ACHE	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.04716422290685	0.04716422290685	-0.252612111563013	-0.147378080883	-6.65795455443981	186.469380764397	3.0154194449192e-10	1.89695284476104e-08	-0.388600767539448	-0.210951901400278
SLC44A1	BRD-K00662280-001-09-4::2.5::HTS002	2.5	CL-218872	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.007892287393395	-0.007892287393395	0.189075676224011	0.1913856373495	7.43522840037544	193.341012757652	3.30396282558135e-12	2.61400903818392e-10	0.144719154346736	0.249216772888077
SLC44A1	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.84115696814	-1.84115696814	-2.32416058207263	-2.459290757005	-6.80566055366889	114.492796606429	4.86740775358553e-10	2.99519562566245e-08	-0.623589859515141	-0.342417368350121
SLC44A1	BRD-K03549949-001-01-0::2.5::HTS002	2.5	XL388	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.8507056877825	-0.8507056877825	-1.33528656839533	-1.14186011868	-6.37039300200597	46.8423709485818	7.48568367917493e-08	3.57964992698323e-06	-0.637622865970962	-0.331538895254689
SLC44A1	BRD-K04623885-001-07-5::2.5::HTS002	2.5	BIBR-1532	telomerase inhibitor	targeted cancer	TERT	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-2.05871284962	-2.05871284962	-0.897483698677065	-0.830912857483	19.732297682693	8.65769232359134	1.68995181139836e-08	8.79780621290257e-07	1.02729641471028	1.29516188717559
SLC44A1	BRD-K05638300-001-01-2::2.5::HTS002	2.5	sevoflurane	membrane integrity inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.611244705935	-1.611244705935	-0.564351747186714	-0.4301086882785	13.3366487164628	4.05663174892415	0.000167650901929977	0.00452208031207527	0.830143785762509	1.26364213173406
SLC44A1	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.504481956785	-1.504481956785	-2.20523310123046	-2.14710453103	-6.7295056306352	4.09548536243885	0.00233290997173412	0.0457801008360926	-0.987226489466347	-0.414275799424581
SLC44A1	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.65452525836	0.65452525836	0.504057947207718	0.505306635797	-6.355931624951	103.315846540051	5.69111347118172e-09	3.126815327262e-07	-0.197416460182829	-0.103518162121735
SLC44A1	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-2.951273266	-2.951273266	-2.73854262715852	-2.77483229013	4.60740691406592	185.792005937113	7.55603087203497e-06	0.000265967571156575	0.121642937456728	0.303818340226234
SLC44A1	BRD-K15519488-050-01-3::2.5::HTS002	2.5	CS-110266	dopamine receptor agonist	noncancer	SLC6A3	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.9086645766045	-0.9086645766045	-0.107790632419682	-0.120574600447	13.4088456918198	14.0403651923733	2.14454054947197e-09	1.23062177089097e-07	0.672806201702986	0.928941686666651
SLC44A1	BRD-K15916496-001-27-9::2.5::HTS002	2.5	clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	noncancer	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.05157143609915	-0.05157143609915	0.336178092710159	0.346280454324	13.8956077064103	20.8827309895948	5.07480373525805e-12	3.9167360812896e-10	0.329699163649218	0.4457998939694
SLC44A1	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.2611192139025	0.2611192139025	-0.346598571640757	-0.216806871006	-10.6335595097538	149.785858224003	5.0149653640535e-20	8.34512819497067e-18	-0.72064392017895	-0.494791650907564
SLC44A1	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.06586940659085	0.06586940659085	-0.377106707858163	-0.173057746988	-5.41368744560386	26.0959657216573	1.11848220688596e-05	0.000381724797642773	-0.611140145186776	-0.27481208371125
SLC44A1	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-4.085332901675	-4.085332901675	-3.02778513820833	-3.15858467957	10.2742025083045	119.798456936185	3.84522730373841e-18	5.35854176061735e-16	0.853745390655322	1.26135013627802
SLC44A1	BRD-K21361524-001-01-1::0.625::MTS006	0.625	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-4.23141731943	-4.23141731943	-2.73196450481693	-2.56675339383	14.1870090259036	6.27486749541858	5.29158674967901e-06	0.000191999406885382	1.2435553371404	1.75535029208574
SLC44A1	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.05937958173365	-0.05937958173365	0.303288097711833	0.3347260991415	12.8333543537137	11.159980594899	4.99376227468388e-08	2.4380593953775e-06	0.300576951502327	0.42475840738864
SLC44A1	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.274941506395	-0.274941506395	-0.167854121611691	-0.149311762512	5.55682341704709	176.505465788516	9.98629894210843e-08	4.70614218549507e-06	0.0690555038496414	0.145119265716977
SLC44A1	BRD-K25244359-066-03-4::2.68145::HTS002	2.68145	apatinib	RET tyrosine kinase inhibitor	targeted cancer	CSK, KDR, KIT, RET	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.512689604674	0.512689604674	0.132790063930145	0.183294433483	-9.96273828507972	132.702144482107	8.46335491012033e-18	1.14588906792873e-15	-0.455324794212179	-0.304474287275531
SLC44A1	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.714333109352	-0.714333109352	-0.235492658065459	-0.109165735913	12.3198056952693	166.266453974276	3.40057535978096e-25	8.84516888697201e-23	0.402102939254694	0.555577963318388
SLC44A1	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.3723529112345	-0.3723529112345	-1.34571913087997	-1.265409369745	-11.0454560491993	3.21205346337517	0.00115805394241668	0.0251652178266476	-1.24362640636318	-0.703106032927759
SLC44A1	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.4937796771125	-0.4937796771125	0.177814728935608	0.1694730901705	26.3255354149923	53.9391177504314	1.84742219229088e-32	9.12341361869844e-30	0.620446328681167	0.722742483415049
SLC44A1	BRD-K35960502-001-20-0::2.5::HTS002	2.5	niclosamide	DNA replication inhibitor, STAT inhibitor	noncancer	STAT3	infectious disease	tapeworm	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.283023660092	-0.283023660092	-0.707381714930415	-0.681426229631	-7.24887090563418	86.7234535600254	1.64124819894376e-10	1.0604976943968e-08	-0.540720384980683	-0.307995724696147
SLC44A1	BRD-K42205652-001-02-7::2.5::HTS002	2.5	MNS-(3,4-Methylenedioxy-nitrostyrene)	src inhibitor, syk inhibitor	noncancer	SRC, SYK	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.3288272258945	-0.3288272258945	0.246761618168844	0.262709081551	12.7478390514473	9.31365795409098	3.31380931890883e-07	1.45036846541231e-05	0.47397015766628	0.677207530460408
SLC44A1	BRD-K42756753-001-01-9::2.5::HTS002	2.5	epiandrosterone	steroid	noncancer	G6PD	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.380258265088	0.380258265088	0.220774707433809	0.2292300635955	-5.57390798246364	142.423383789712	1.20876368620436e-07	5.6395749468993e-06	-0.216043658198719	-0.102923457109663
SLC44A1	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.7978069258695	-0.7978069258695	-0.288358636481158	-0.148713622851	8.87317786215973	188.920537400884	5.3992918079102e-16	6.17186567412045e-14	0.396192595879219	0.622703982897466
SLC44A1	BRD-K42898655-001-01-8::2.5::HTS002	2.5	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.4665928321185	-0.4665928321185	-1.35410178628908	-1.32952488095	-11.6458001955869	2.94499097777081	0.00148273031269998	0.0311225252365757	-1.13262147419113	-0.642396434150034
SLC44A1	BRD-K44408410-001-17-6::2.5::HTS002	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.608168112285	-1.608168112285	-1.11211231527798	-1.05890648187	7.41953260001113	70.3040085498264	2.08729270733988e-10	1.33502643590406e-08	0.36272167266529	0.629389921348746
SLC44A1	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.3595922612805	-0.3595922612805	-0.696667014731702	-0.636668754802	-5.18360631570537	6.1501039597557	0.00189942573134817	0.0383877432884604	-0.495253628448034	-0.17889587845437
SLC44A1	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.13647835878335	0.13647835878335	-0.326837952473966	-0.2394985033815	-7.29373332525408	4.94747311621346	0.000793128597952087	0.0180552797950582	-0.627128961779175	-0.299503660735457
SLC44A1	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.469110572455	-0.469110572455	0.234524141223781	0.2141011890955	15.1505686200636	2.40809019220427	0.00190491052426429	0.0384659475932768	0.532995355121937	0.874274072235624
SLC44A1	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.817880444935	-1.817880444935	-2.74930211650079	-2.66953815971	-10.4776182064313	48.8349011546248	4.35716494092103e-14	4.14867527597807e-12	-1.11008078715012	-0.752762555981457
SLC44A1	BRD-K56301217-001-07-4::2.5::HTS002	2.5	ABT-737	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.1484834311315	0.1484834311315	-0.137525463628829	-0.0916218688464	-9.11484243172899	159.028032338114	3.26268345249653e-16	3.81613018493172e-14	-0.347980972132922	-0.224036817387736
SLC44A1	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.8291482319295	-0.8291482319295	-1.30009304329688	-1.05786698502	-5.2282133970732	22.3236260267568	2.90466529088752e-05	0.000915924683140551	-0.657597385239034	-0.284292237495719
SLC44A1	BRD-K60369935-001-18-3::2.5::HTS002	2.5	ribavirin	antiviral	noncancer	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.201165592944	0.201165592944	0.374032749760013	0.419717410769	5.78407225309307	86.8411531953308	1.12746896707316e-07	5.28079755777588e-06	0.113462460733165	0.23227185289886
SLC44A1	BRD-K62810658-001-12-2::2.5::HTS002	2.5	PD-98059	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.0766713468922	-0.0766713468922	0.158276248817625	0.164761931788	7.16216289428954	18.9416637965617	8.47213518229808e-07	3.4985209888575e-05	0.166273718650394	0.303621472769256
SLC44A1	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.05958483555	-1.05958483555	-1.84727963059147	-1.7566794361	-7.25847263333136	13.3404878548485	5.50221339754606e-06	0.000199068854706727	-1.02153278018218	-0.553856809900765
SLC44A1	BRD-K67977190-066-02-3::2.5::HTS002	2.5	eprosartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.924983584181	0.924983584181	0.416184215009165	0.407016532415	-13.431297901893	8.59506983017524	4.5944046865753e-07	1.97061069055233e-05	-0.595112936786587	-0.422485801557083
SLC44A1	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.8225913428025	-0.8225913428025	-1.21862405901681	-1.04907947641	-4.96482715305168	88.0519188118467	3.33747411150479e-06	0.000125494296288546	-0.554552904520516	-0.237512527908113
SLC44A1	BRD-K69116396-001-04-1::2.5::HTS002	2.5	sertindole	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.7093637664325	0.7093637664325	0.00783749270292563	0.0316933159242	-28.015204623232	189.602204143493	2.58871952152092e-69	3.96312618805755e-65	-0.75092084260307	-0.652131704856079
SLC44A1	BRD-K69172251-001-08-9::2.5::HTS002	2.5	cisplatin	DNA alkylating agent, DNA synthesis inhibitor	chemo	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.07967970184615	-0.07967970184615	0.386161822823516	0.3712286324115	14.6280501853454	6.63377674490506	2.7036869247687e-06	0.000103220255592937	0.389687255793952	0.54199579354538
SLC44A1	BRD-K69694239-001-02-2::2.5::MTS010::PROS002_PR500	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-3.191895414915	-3.191895414915	-2.51907903610909	-2.6020166043	9.33695263058136	3.59341391776284	0.00120270470780889	0.026001058838004	0.46349516284194	0.882137594769881
SLC44A1	BRD-K72951360-001-01-4::2.5::HTS002	2.5	valrubicin	DNA inhibitor, topoisomerase inhibitor	chemo	TOP2A	oncology	bladder cancer	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-3.70944471674	-3.70944471674	-3.28257231673485	-3.154872737575	3.98663549406695	170.758971929114	9.91697910373693e-05	0.00281336361922546	0.215509610015998	0.63823518999431
SLC44A1	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.780736881844	0.780736881844	-0.217813629415653	-0.20601445055	-16.6356839440068	5.52381343639147	6.25031607677336e-06	0.000223867646126129	-1.14854993035927	-0.84855109216004
SLC44A1	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.19154650607	0.19154650607	-0.124861705197033	-0.118001057117	-11.0216016881047	186.997443028803	4.35939388726785e-22	8.62710319648549e-20	-0.373041391347833	-0.259775031186233
SLC44A1	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.026655201273	-0.026655201273	-0.164137611910847	-0.121855279851	-6.38019943339298	188.981910268428	1.32941159979773e-09	7.81704962340323e-08	-0.179988494780599	-0.0949763264950946
SLC44A1	BRD-K93441486-067-12-8::2.5::HTS002	2.5	diphemanil	acetylcholine receptor antagonist	noncancer	CHRM3	neurology/psychiatry	spasms	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.011487534826745	-0.011487534826745	0.134916703785161	0.150302134	5.81782785689556	191.151824949575	2.47259733542743e-08	1.25848804156928e-06	0.0967679584540688	0.196040518769743
SLC44A1	BRD-K93779381-001-01-9::2.5::HTS002	2.5	ingenol-mebutate	PKC activator	noncancer	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.9332841056235	-0.9332841056235	-0.218921975787839	-0.144721351966	9.40600608898536	7.23107079663067	2.60018702472426e-05	0.000829308757175784	0.535931786200447	0.892792473470874
SLC44A1	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.6786306577265	0.6786306577265	-0.307677367729908	-0.183745665678	-15.3920841572368	21.5977344078272	4.02711468529942e-13	3.48035267494169e-11	-1.11934321217609	-0.853272838736728
SLC44A1	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.553836756349	0.553836756349	-0.0956307541675408	0.0692106615383	-10.4290188149716	9.61388582859557	1.48933785759265e-06	5.92333074188114e-05	-0.788984041819929	-0.509950979213153
SLC44A1	BRD-K97472745-001-01-8::2.5::HTS002	2.5	gestrinone	progesterone receptor antagonist	noncancer	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	CAOV3, OAW42	OVARY	carcinoma (adenocarcinoma), carcinoma	0.2808072000355	0.2808072000355	-0.165467030563742	-0.1123477003	-8.00858499011393	3.39727752483307	0.00254886372347362	0.0493982650319539	-0.612440564832986	-0.280107896365499
SLC7A6	BRD-A18696154-003-22-6::2.5::HTS002	2.5	idazoxan	adrenergic receptor antagonist	noncancer	ADRA2A	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.10537672654	-1.07556336954	-0.647903551750994	-0.587312063064	7.56506557615083	15.3750383741855	1.45911959764002e-06	5.813936498282e-05	0.328853868932388	0.586092480645624
SLC7A6	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	AGS, SKOV3	STOMACH, OVARY	carcinoma (adenocarcinoma)	-1.633907922265	-1.633907922265	-0.986030136727907	-0.915436263548	10.37068622969	152.23792827665	2.14047448213286e-19	3.34377372653829e-17	0.524453729869831	0.771301841204355
SLC7A6	BRD-A81370665-001-03-6::2.5::HTS002	2.5	BI-D1870	ribosomal protein inhibitor	noncancer	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.0707823866455667	0.0422807131955	0.363645923779488	0.369609262574	5.95727353397735	6.18379661939157	0.000897164245183788	0.0201159447124172	0.173433101126197	0.412293973141647
SLC7A6	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.304888889969	-0.33405297656	0.158616420600019	0.188567655386	6.38804097272089	4.627693504519	0.00184796176307207	0.0374961466171991	0.27238328774451	0.654627333393529
SLC7A6	BRD-K05638300-001-01-2::2.5::HTS002	2.5	sevoflurane	membrane integrity inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	AGS, SKOV3	STOMACH, OVARY	carcinoma (adenocarcinoma)	-1.408173377555	-1.408173377555	-0.566512080467352	-0.4301086882785	13.8644981771964	37.9853183109721	1.92489778987832e-16	2.30610071775757e-14	0.718766416723548	0.964556177451748
SLC7A6	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-3.15813572445	-3.1534184302	-1.91238885351592	-2.014899180365	14.6045604739938	47.4080392453939	3.59335083048852e-19	5.50900779790968e-17	1.07418743317851	1.41730630868965
SLC7A6	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	AGS, SKOV3	STOMACH, OVARY	carcinoma (adenocarcinoma)	0.0682200048698	0.0682200048698	0.342325012479723	0.357900779497	7.32148697805787	10.8110634906685	1.653148539301e-05	0.000548479370402235	0.191527531788718	0.356682483431128
SLC7A6	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-4.28591275647	-4.28516283587	-3.50561530352525	-3.326069012825	5.23272321421691	20.6901852225905	3.63027815296652e-05	0.00112438422868087	0.469904923210403	1.09068998267909
SLC7A6	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.295136782782333	0.293536101606	0.402440433864267	0.440316343345	3.28645878923652	77.4027011818154	0.00152650368403683	0.0319163016384674	0.0422941251680143	0.172313176995854
SLC7A6	BRD-K16478699-001-09-2::2.5::HTS002	2.5	PLX-4720	RAF inhibitor	targeted cancer	BRAF, KDR	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-1.18170199685333	-1.13901468097	-1.51492757748952	-1.424707254615	-3.4361888225432	28.8392371812746	0.00181102856776873	0.0368794244086749	-0.531610456956777	-0.134840704315589
SLC7A6	BRD-K24869513-001-02-1::2.5::HTS002	2.5	CNX-2006	EGFR inhibitor	targeted cancer	EGFR	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.399497709387333	-0.392110834218	-0.118646560188827	-0.00883703821511	5.88679619118592	63.4572397410273	1.61901377459388e-07	7.4193201474221e-06	0.185526444893954	0.376175853503058
SLC7A6	BRD-K31627533-001-09-5::2.5::HTS002	2.5	rimexolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	ophthalmology	anterior uveitis	SKOV3, NCIH841	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.09282689151855	-0.09282689151855	0.26476113699242	0.264424524013	11.4040907796512	119.02062648294	8.23719960734358e-21	1.470000628345e-18	0.295499891509501	0.419676165512438
SLC7A6	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.00578467794323333	-0.0364403153931	-0.239991495201369	-0.02070399858225	-3.88378316921356	26.7597363466098	0.000608585024592851	0.0142523404431776	-0.357991962356143	-0.110421672160128
SLC7A6	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	SKOV3, NCIH841	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.4042220705835	-0.4042220705835	0.20861628658895	0.242605983944	12.0059805902224	2.72620100437062	0.00193831603552524	0.039026523022836	0.440760949928706	0.784915764416192
SLC7A6	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.838145717141333	-0.85486412032	-0.0900335676272377	-0.0900251061909	12.5840924018803	9.66757343922186	2.59714966721472e-07	1.15366733891081e-05	0.615031450688847	0.881192848339344
SLC7A6	BRD-K52172416-001-11-4::2.5::HTS002	2.5	anastrozole	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	SKOV3, NCIH841	OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.136518967734	0.136518967734	0.306160448509455	0.301007029734	6.17364419741858	72.4483246412683	3.47731375211782e-08	1.73403717817045e-06	0.11487020614093	0.22441275540998
SLC7A6	BRD-K61734568-003-02-1::2.5::HTS002	2.5	2,3-DCPE	Bcl-XL downregulator	targeted cancer	BCL2L1	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.0247122863553333	0.0797681518463	-0.36293844029412	-0.150427962805	-4.22856834842215	10.8702311558359	0.00145324340368929	0.0306024961160662	-0.589718610517737	-0.185582842781171
SLC7A6	BRD-K76406695-001-02-9::2.5::HTS002	2.5	CCT128930	AKT inhibitor	targeted cancer	PKIA, PRKACA	NA	NA	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	-0.786521325494333	-0.768992987425	-0.137620771242517	-0.112214999812	13.4015312301123	23.3656115808243	1.85775640533848e-12	1.50651181460383e-10	0.548823052119279	0.748978056384353
SLC7A6	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.327586216574333	0.3269777367	0.118451127820126	0.119262267006	-4.78424282087719	19.9675243630485	0.000113523592709194	0.00317908646491918	-0.300328963549989	-0.117941213958426
SLC7A6	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	AGS, SKOV3, NCIH841	STOMACH, OVARY, LUNG	carcinoma (adenocarcinoma), carcinoma (small_cell_carcinoma)	0.188467395677	0.170502861013	0.0220087524451496	0.0369083290512	-5.26625519810054	7.09149455276063	0.00111816012691136	0.0243773921107502	-0.241005923062637	-0.0919113634010638
SMAP2	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.982192493433	-0.982192493433	0.00621941041104533	0.008505826587825	30.2590025882034	19.9104295242739	4.03976628053039e-18	5.61140030550743e-16	0.920254142417917	1.05656966527017
SMAP2	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.515389247635	-2.515389247635	-1.11062043170414	-1.02154011458	20.0273854412867	6.85955061166332	2.42860024074926e-07	1.08261119176279e-05	1.2382174848705	1.57132014699123
SMAP2	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.9245959451265	0.9245959451265	0.214753315615405	0.209209067771	-22.7334008720111	11.9466341016835	3.36012748208731e-11	2.34978907185856e-09	-0.777909032340368	-0.641776226681821
SMAP2	BRD-K03289018-001-02-7::2.5::HTS002	2.5	CCT137690	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.804876523025	-2.804876523025	-1.43926045480056	-1.361653967605	12.2911525714993	2.89611110862108	0.00137357023455899	0.029119281385044	1.00474345869831	1.72648867775057
SMAP2	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.9529987643155	0.9529987643155	-0.305563994588337	-0.208078798615	-24.5503183745274	188.998218979582	1.07803645556908e-60	7.45337017695693e-57	-1.35968710351841	-1.15743841428926
SMAP2	BRD-K06854232-001-19-9::2.5::HTS002	2.5	AM-580	retinoid receptor agonist	targeted cancer	RARA	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.04691744865585	-0.04691744865585	0.121213706132833	0.154475017862	4.6811022222064	8.48410725939367	0.00134872024308651	0.0286917976159295	0.0861218625431737	0.250140447034193
SMAP2	BRD-K09090949-001-01-9::2.5::HTS002	2.5	CP-945,598	cannabinoid receptor antagonist	noncancer	CNR1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.4191158898375	0.4191158898375	-0.703833457903663	-0.6321793589915	-16.8062770149996	9.31291323695827	2.79086977174486e-08	1.40777671760015e-06	-1.27332984785499	-0.972568847627332
SMAP2	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.1818624889245	0.1818624889245	0.337448381141911	0.348412196747	4.45554534580512	8.51828136739958	0.00181845778006038	0.0369955612285298	0.0759060227868417	0.23526576164798
SMAP2	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.10183141197	-2.10183141197	-2.60890368166338	-2.686193418095	-5.85210093986292	8.55574125169773	0.000295529310259201	0.00747116083257186	-0.704645946042711	-0.309498593344057
SMAP2	BRD-K17743125-001-08-4::2.5::HTS002	2.5	belinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-3.972806372105	-3.972806372105	-2.59376238640464	-2.51013089586	8.75139702203682	3.21970625152397	0.0023757387668235	0.0464632831632887	0.89636884250983	1.86171912889089
SMAP2	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.43811026814	0.43811026814	-0.065096088752587	-0.0626502991923	-14.5140404384361	47.2329764461156	4.95059870612716e-19	7.45707751009938e-17	-0.572944954295326	-0.433467759489848
SMAP2	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.7186070487015	-0.7186070487015	-0.336445967883203	-0.200723129444	6.51127276438213	80.7278968508606	5.8821667774469e-09	3.22269663405781e-07	0.265375997789376	0.498946163847219
SMAP2	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.3213030007155	0.3213030007155	-0.697815046776929	-0.593823716309	-18.5461925060811	140.749758238432	1.27763193468728e-39	1.32286751173715e-36	-1.12775261292582	-0.910483482059037
SMAP2	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-3.64852220881	-3.64852220881	-3.083914573726	-2.85883819524	5.13746902490965	45.9629533111752	5.54393390618369e-06	0.00020044295043496	0.343385679614241	0.785829590553766
SMAP2	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-4.24961779991	-4.24961779991	-2.85562959093918	-2.68228454863	10.5471592092066	6.37338666557398	2.86610543110473e-05	0.000904430964286286	1.07512443619298	1.71285198174865
SMAP2	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.5243342500395	0.5243342500395	-0.244480285536811	-0.0866927101235	-11.0089993165051	15.6099274673238	9.19703962157913e-09	4.92798076263358e-07	-0.917159560317929	-0.620469510834692
SMAP2	BRD-K25835157-001-01-4::2.5::HTS002	2.5	PRT062070	JAK inhibitor, syk inhibitor	targeted cancer	SYK	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.512523892864	0.512523892864	-0.0886173651727944	-0.0811687124677	-12.0110456137703	24.3688234131091	9.97616472420254e-12	7.47354564548621e-10	-0.704354721899005	-0.497927794174584
SMAP2	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.86739098208	-1.86739098208	-1.02732259490598	-0.8397340938795	9.00880714152427	7.09437097776307	3.90673688721066e-05	0.00120271044283105	0.62016114228669	1.05997563206135
SMAP2	BRD-K31491153-003-05-9::2.5::HTS002	2.5	1-phenylbiguanide	serotonin receptor agonist	noncancer	HTR3A, HTR3B	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.15626197028	-1.15626197028	-0.084968505402274	0.0251960831099	13.6857383262244	2.73941215253035	0.00133103427821134	0.0283873449330558	0.808219954036783	1.33436697571867
SMAP2	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.944356885025	-2.944356885025	-3.66812885195913	-3.65355610334	-7.31304423327304	188.925214196929	7.20812888462414e-12	5.48229615228036e-10	-0.919000194270102	-0.528543739598152
SMAP2	BRD-K36529613-001-02-6::2.5::HTS002	2.5	PU-H71	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-4.435439875275	-4.435439875275	-3.46976858590941	-3.273820150365	7.46980497789445	5.93848744582168	0.000311789318810907	0.00784336771260831	0.648546784830446	1.28279579390072
SMAP2	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.142416507859	0.142416507859	-0.266532634299941	-0.234942866008	-8.69257666074406	5.67824444259399	0.000172431248051377	0.00463759781197185	-0.525665894051507	-0.292232390266374
SMAP2	BRD-K47000838-001-01-6::1.04252::HTS002	1.04252	cytochalasin-b	microtubule inhibitor	noncancer	ACTB	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.954477824362	-0.954477824362	-1.3943598740546	-1.273586296615	-5.36750207771639	8.26706026914	0.000601700550492046	0.0141173374150421	-0.627808248272255	-0.251955851112947
SMAP2	BRD-K49294207-300-03-8::2.5::HTS002	2.5	BIBU-1361	EGFR inhibitor	targeted cancer	EGFR	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	1.066838621505	1.066838621505	-0.798439233512337	-0.640313618355	-20.1070742885684	6.34683198073504	5.48826916761203e-07	2.32826274059788e-05	-2.08929790492634	-1.64125780510833
SMAP2	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.2023521464835	0.2023521464835	0.304227225245124	0.306467449749	4.65061945098738	167.400270538471	6.68686086350839e-06	0.000237755176180307	0.0586280443786601	0.145122113144589
SMAP2	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.01924851019	-2.01924851019	-0.601024462544789	-0.573831164789	13.9127541400352	3.69388287013135	0.000251829721411026	0.0064880889963101	1.1257073005084	1.71074079478203
SMAP2	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.07000708331105	0.07000708331105	-0.124675810301309	-0.007473093877485	-4.741120992272	134.674655845349	5.33815169769418e-06	0.000193557894639671	-0.275893912618766	-0.113471874605953
SMAP2	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.333087795717	0.333087795717	-0.243002427396371	-0.10314419939105	-8.56111778594232	8.95667793175303	1.32278803640883e-05	0.000445493144336058	-0.728426419605471	-0.423754026621271
SMAP2	BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500	2.5	selumetinib	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.5226098939825	0.5226098939825	-0.142722482231469	0.01900224238145	-8.41819812880484	6.50262435149535	9.92027820268029e-05	0.00281355472661408	-0.855157712110554	-0.475507040317385
SMAP2	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.462548137068	0.462548137068	-0.498627331335101	0.00402399396559	-7.87620189525458	4.48813730531068	0.000860471085186727	0.0193804021875773	-1.28595000288298	-0.636400933923218
SMAP2	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.0621458221865	0.0621458221865	-0.720905744745533	-0.5340799664045	-7.4698349235348	69.5184362818537	1.78869509423081e-10	1.15160477876658e-08	-0.992150876784408	-0.573952257079658
SMAP2	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.489964800195	-1.489964800195	-0.593564969877634	-0.422114365645	14.0123027024218	109.663721077581	3.45300984535384e-26	9.76359033172616e-24	0.769617339175877	1.02318232145885
SMAP2	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-3.554764705735	-3.554764705735	-2.93441788482146	-2.87845710522	6.74439569700034	37.7593877367776	5.63616390913785e-08	2.73487293294455e-06	0.434104881659434	0.806588760167648
SMAP2	BRD-K68488863-001-04-9::0.15625::HTS002	0.15625	ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	targeted cancer	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.7210069815285	0.7210069815285	0.510694732737795	0.514244743777	-8.53345278705341	56.4506039611663	9.70273288950198e-12	7.28398261812284e-10	-0.259674666482584	-0.160949831098826
SMAP2	BRD-K69608737-001-10-2::2.5::HTS002	2.5	tacrolimus	calcineurin inhibitor	noncancer	FKBP1A	transplant	organ rejection	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.1479957430465	0.1479957430465	0.30626783302148	0.32803780098	5.06061316508341	12.3801102676217	0.000253847661026242	0.00653299828058625	0.0903604346129418	0.226183745337018
SMAP2	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.3801153123555	0.3801153123555	-0.00181008673909379	0.03094358609725	-13.4886001145662	60.0143647098998	7.97631618435024e-20	1.28925782162564e-17	-0.438562913477072	-0.325287884712116
SMAP2	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	1.219974746525	1.219974746525	0.490928731091065	0.515272690573	-15.1424887047757	2.34679044552555	0.00215112886393239	0.042681600588071	-0.909461524384809	-0.54863050648306
SMAP2	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.4522636446885	-0.4522636446885	-0.948420280107592	-0.8151847008705	-7.6868331246208	119.990867150678	4.59612315375152e-12	3.57561698519205e-10	-0.623953916008982	-0.368359354829203
SMAP2	BRD-K81330143-001-04-8::2.38257::HTS002	2.38257	tideglusib	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.225315720285	0.225315720285	-0.275872156101052	-0.2593232641565	-10.5621447516266	167.482244673737	2.62579122616809e-20	4.48790436773032e-18	-0.594867701638532	-0.407508051133572
SMAP2	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.04508607916222	0.04508607916222	-0.427800546137962	-0.2959843885325	-6.57185546087673	5.56238930262104	0.000807450533908533	0.0183442935639264	-0.652370348726901	-0.293402901873463
SMAP2	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.056739457185	-1.056739457185	-0.374558585284274	-0.338570487031	13.5949440870431	8.52929202591257	4.47961988308848e-07	1.92445870900475e-05	0.567705917476235	0.796655826325217
SMAP2	BRD-K84937637-001-09-9::2.5::HTS002	2.5	sirolimus	mTOR inhibitor	noncancer	FGF2, FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.27426640552	-2.27426640552	-1.33899828880616	-1.32265051102	13.855707345113	4.6752613083373	5.64354994944189e-05	0.0016847080741812	0.758063916806121	1.11247231662156
SMAP2	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.389835979899	0.389835979899	0.0316608912004267	0.0430886024597	-12.0820054953135	16.0574566012725	1.78712618917511e-09	1.03690570925748e-07	-0.421002118385925	-0.295348059011222
SMAP2	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.5324398020635	0.5324398020635	-0.158770040118323	-0.140788868193	-16.2550388123367	11.7094672106378	2.14858119693168e-09	1.23228059769112e-07	-0.784114675528334	-0.598305008835311
SMAP2	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.365921505082	-0.365921505082	-0.16054749229382	-0.116252087164	7.73080515841261	8.11200935346985	5.17520541418338e-05	0.00155567545752666	0.144260393883805	0.266487631692554
SMAP2	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.910565795165	-2.910565795165	-2.22580064688871	-2.16824610201	10.1624030796815	160.010867175784	4.95447577060572e-19	7.45707751009938e-17	0.551691991357661	0.817838305194926
SMAP2	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.642135374415	-1.642135374415	-1.01680708392065	-0.939851070617	15.23186121148	133.820311718251	5.14562992393993e-31	2.21902960959381e-28	0.544129708463597	0.7065268725251
SMAP2	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-0.897945339148	-0.897945339148	-1.60276920970934	-1.38505413113	-8.33348778439833	14.1144745629844	8.01062667759905e-07	3.32283647219494e-05	-0.886086202181748	-0.523561538940936
SMAP2	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-3.57029124367	-3.57029124367	-2.22966583903552	-2.181327009095	15.8357885932429	185.014804043324	2.93106471652403e-36	2.15880470662501e-33	1.17360636665024	1.50764444261872
SMAP2	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-2.51052816132	-2.51052816132	-1.39579698857243	-1.36288222555	14.1341757316874	126.80843968004	8.03078117633948e-28	2.63992223733691e-25	0.958663785904281	1.27079855959086
SMAP2	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	0.560724807789	0.560724807789	-0.230871021184005	-0.0281474951666	-11.3208009474979	11.4456914104173	1.45331918869608e-07	6.70444357283773e-06	-0.944769523197844	-0.638422134748166
SMAP2	BRD-K99475619-001-01-2::2.5::HTS002	2.5	genz-644282	topoisomerase inhibitor	chemo	TOP1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-5.00328538062	-5.00328538062	-5.65365737916594	-5.73830939241	-5.79323960425481	6.61839854764947	0.000818129168805134	0.0185652521567851	-0.918968603854142	-0.381775393237731
SMAP2	BRD-M97302542-001-03-6::2.5::HTS002	2.5	dichloroacetate	pyruvate dehydrogenase kinase inhibitor	targeted cancer	PDK1	NA	NA	COLO668, DMS273	LUNG	carcinoma (small_cell_carcinoma)	-1.343187714135	-1.343187714135	-0.248090332979538	-0.1625176596575	18.8001696109191	3.86646698674781	6.05098015581374e-05	0.00179650994017925	0.931144532574977	1.25905022973595
SMARCA4	BRD-A12417644-001-07-6::2.3139::HTS002	2.3139	usniacin-(+)	MAP kinase activator	targeted cancer	PTPN1	NA	NA	OAW42, GCIY	OVARY, STOMACH	carcinoma, carcinoma (adenocarcinoma)	0.6867126358515	0.6867126358515	0.165656078070841	0.15773571254	-15.5483745960817	12.3372700326444	1.78921815991784e-09	1.03783853585123e-07	-0.59385208233387	-0.448261033227448
SMARCA4	BRD-A20239487-001-24-9::2.5::HTS002	2.5	atenolol-(+/-)	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	GCIY, MCF7	STOMACH, BREAST	carcinoma (adenocarcinoma), carcinoma	0.500397562591	0.500397562591	0.195929779573799	0.207866793196	-9.2935979750653	4.96097062717493	0.000252962887046377	0.00651336888728531	-0.388882343774303	-0.220053222260098
SMARCA4	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-0.659526175803	-0.729140193624	-1.19686174179633	-1.04762820909	-5.43717398087545	6.54401739329469	0.00121110637315139	0.0261668566382221	-0.774364297508955	-0.300306834477715
SMARCA4	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	0.749085760056333	0.741139165329	0.254506955427337	0.30050000161	-11.5108797214962	30.8437368321998	1.07596719280175e-12	8.93494662789643e-11	-0.582226952741834	-0.406930656516157
SMARCA4	BRD-K00494077-066-01-9::2.5::HTS002	2.5	trovafloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	GCIY, MCF7	STOMACH, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.1908719605775	-0.1908719605775	-0.523792919882358	-0.32459433605	-4.33388447984374	32.0223630855181	0.000135759105908787	0.00373566740407299	-0.489390111392355	-0.17645180721736
SMARCA4	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-1.44810348767	-1.46284322667	-2.78133266687851	-2.65566566317	-11.3177052622073	24.7052551129696	2.89373788372561e-11	2.04285885006926e-09	-1.57599030932697	-1.09046804909004
SMARCA4	BRD-K08303368-001-10-0::2.5::HTS002	2.5	chlorpyrifos	acetylcholinesterase inhibitor	noncancer	ACHE	NA	NA	GCIY, MCF7	STOMACH, BREAST	carcinoma (adenocarcinoma), carcinoma	0.04025655351595	0.04025655351595	0.293435062103694	0.280025726935	10.2713395422955	154.319088547321	3.47738124280536e-19	5.33885132083976e-17	0.204485450738459	0.301871566437029
SMARCA4	BRD-K13566078-001-02-3::2.5::HTS002	2.5	BMS-345541	IKK inhibitor	targeted cancer	CHUK, IKBKB	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-2.49287485773333	-2.459079484	-1.46919073647681	-1.48270508682	10.2368300475649	4.60300561643303	0.000243620996050175	0.00630616479014951	0.759811968315526	1.28755627419752
SMARCA4	BRD-K18910433-001-36-6::2.58082::HTS002	2.58082	estradiol	estrogen receptor agonist	noncancer	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	GCIY, MCF7	STOMACH, BREAST	carcinoma (adenocarcinoma), carcinoma	-0.0593406483737	-0.0593406483737	0.311214363775562	0.326005969483	9.85269885149385	6.83745066348949	2.75341541629601e-05	0.00087285427120146	0.28119230088277	0.459917723415755
SMARCA4	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-0.07536891832681	-0.100624298814	-0.829514817820948	-0.823394249703	-10.690552863594	36.7597951833431	7.81309320607129e-13	6.57468572345525e-11	-0.897111550336218	-0.611180248652057
SMARCA4	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	OAW42, GCIY	OVARY, STOMACH	carcinoma, carcinoma (adenocarcinoma)	0.05252433950725	0.05252433950725	-0.376948778070192	-0.173057746988	-5.57522585624571	86.605047800392	2.75949321550804e-07	1.22274017239326e-05	-0.582593231354679	-0.276353003800204
SMARCA4	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-0.0338639801413667	-0.0339828775959	0.391303340472258	0.401788667856	8.87526903221375	3.6539963172941	0.00133371699704301	0.0284262361037422	0.287045145767983	0.563289495459267
SMARCA4	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-0.236001982357	-0.175278867658	-0.750477389530415	-0.640609088287	-6.23245313399398	6.55331246972229	0.000560478539900643	0.0132678158800933	-0.7123997818738	-0.31655103247303
SMARCA4	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-0.662238149599333	-0.650620627269	-0.936936958521313	-0.800050374419	-3.8091914026321	128.2621269199	0.000215222990258267	0.0056419432826644	-0.417387339999518	-0.13201027784444
SMARCA4	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	0.416608382011	0.409287649989	0.0366096013487938	0.141689028059	-5.70581643851411	5.49655397801351	0.00168794390042888	0.0347827447586791	-0.546646851346533	-0.21335070997788
SMARCA4	BRD-K35329391-334-01-7::2.5::HTS002	2.5	GZD824	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-0.829159137896333	-0.750755696512	-1.94545575642006	-1.84222232008	-7.48524080079415	4.28625780961472	0.00128991893522399	0.0276114820231612	-1.51967521659418	-0.712918020453275
SMARCA4	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-4.56237350783667	-4.61769318416	-5.46119642372759	-5.49801230394	-8.57686282661958	10.4526725126379	4.73636809230193e-06	0.000173469076701124	-1.13096001426733	-0.666685817514528
SMARCA4	BRD-K43471985-001-03-0::2.69009::HTS002	2.69009	OTX015	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	OAW42, GCIY	OVARY, STOMACH	carcinoma, carcinoma (adenocarcinoma)	-0.4121540466235	-0.4121540466235	-0.80948333859945	-0.721568534239	-3.94660420133443	10.8278918374685	0.00235579076523131	0.0461403891913791	-0.619346690090738	-0.175311893861161
SMARCA4	BRD-K49669041-001-08-4::2.5::HTS002	2.5	BX-912	pyruvate dehydrogenase kinase inhibitor	targeted cancer	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-1.016437651412	-1.09619849918	-1.95127092953677	-1.73927680134	-7.50732257710799	9.4211368299012	2.85146911188509e-05	0.000900475207427759	-1.2146157359518	-0.655050820297738
SMARCA4	BRD-K51350053-048-16-5::2.5::HTS002	2.5	toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	ESR1	oncology	breast cancer	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-1.85488328188333	-1.79413201317	-0.482149073017663	-0.4066458025585	10.6989156761083	3.55139803716016	0.000792422346420041	0.0180451136919432	0.998031883525822	1.74743653420552
SMARCA4	BRD-K60230970-001-17-5::2.40205::HTS002	2.40205	MG-132	proteasome inhibitor	targeted cancer	PSMB1	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-5.80746612568667	-5.80821000195	-6.16808799769141	-6.11685813758	-4.57057013477724	34.1481733660971	6.09732321104699e-05	0.0018097676035182	-0.520942068912206	-0.200301675097271
SMARCA4	BRD-K61443650-236-13-1::2.5::HTS002	2.5	thiomersal	other antibiotic	noncancer	OXCT1	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	0.307690508882667	0.305903798036	-0.177160304302265	-0.0429652749088	-5.80271586253717	5.17283515433247	0.00191259823575762	0.0385920982180092	-0.697497265345449	-0.272204361024413
SMARCA4	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	0.340522704433	0.345091893893	0.142558219783361	0.1562002579115	-6.24562927488382	17.9442681826775	6.93874515919838e-06	0.000246017255785911	-0.264571153279175	-0.131357816020103
SMARCA4	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-0.140179768313333	-0.143440887071	0.129251556313296	0.139022611825	7.89480268535458	13.8969530192654	1.67614344150691e-06	6.60743328443506e-05	0.196183771709776	0.342678877543484
SMARCA4	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	0.611757377228333	0.590297488314	0.305546252007831	0.286690241796	-7.28142529633922	4.63916885602495	0.00104594025371274	0.0229829125115848	-0.416892294464369	-0.195529955976636
SMARCA4	BRD-K71221037-001-01-6::2.5::HTS002	2.5	birinapant	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-0.0640923714173333	-0.116833640602	-1.04446401445816	-0.663483610975	-7.43788390178537	9.63410212951692	2.72218581128553e-05	0.000863720744259091	-1.27557683994384	-0.685166446137807
SMARCA4	BRD-K85090592-008-22-7::2.5::HTS002	2.5	pilocarpine	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	GCIY, MCF7	STOMACH, BREAST	carcinoma (adenocarcinoma), carcinoma	0.662912016346	0.662912016346	0.470238549027393	0.471563787015	-4.37255224407311	8.22204521652345	0.002222013343664	0.043905402224962	-0.293810251366496	-0.0915366832707177
SMARCA4	BRD-K92428232-001-10-6::2.5::HTS002	2.5	GSK461364	PLK inhibitor	targeted cancer	PLK1	NA	NA	OAW42, MCF7	OVARY, BREAST	carcinoma	-1.29992689523	-1.29992689523	-2.71306215439936	-2.38486964806	-10.9593622626568	36.0810021973824	4.93763098508452e-13	4.22634788898634e-11	-1.67462380942516	-1.15164670891355
SMARCA4	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	0.822329555357333	0.818056333336	0.298708131693057	0.299029225163	-16.9813613250053	16.2835347675326	8.77486919911822e-12	6.6245471665298e-10	-0.588896463996349	-0.458346383332203
SMARCA4	BRD-K95523387-001-09-6::2.5::HTS002	2.5	OLDA	TRPV agonist	noncancer	GPR119	NA	NA	OAW42, GCIY	OVARY, STOMACH	carcinoma, carcinoma (adenocarcinoma)	0.8236306404855	0.8236306404855	0.26997784097625	0.3623330707505	-9.81065932971797	14.6866057081328	7.75382151377493e-08	3.69961890299614e-06	-0.674162542542109	-0.433143056476392
SMARCA4	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	OAW42, GCIY, MCF7	OVARY, STOMACH, BREAST	carcinoma, carcinoma (adenocarcinoma)	-2.0462272672	-2.05660704449	-3.08654674747135	-3.087127735	-9.81124688817332	34.5810460162361	1.58318728541612e-11	1.15809879759711e-09	-1.25567190990023	-0.824967050642464
SNRPD1	BRD-A28329383-001-02-1::2.5::HTS002	2.5	MTPG	glutamate receptor antagonist	noncancer	GRM2, GRM3	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.4476291875115	-0.4476291875115	0.0274729325094206	0.05552529169545	14.0405607852566	193.362983977217	2.46959392230918e-31	1.10965533705368e-28	0.40836348497372	0.541840755068121
SNRPD1	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.305892139605	0.305892139605	0.0729450725696995	0.128125201883	-6.9979027588047	16.0563527345622	2.94887435089765e-06	0.000112061930984671	-0.303494617736595	-0.162399516334006
SNRPD1	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.0443564417484	0.0443564417484	-0.18766064561056	-0.138056758361	-4.24732284151294	10.3846458311377	0.00155930884107964	0.03250706201729	-0.353124545229143	-0.110909629488777
SNRPD1	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.08793137597675	-0.08793137597675	-0.340997868255011	-0.229059189804	-5.21907724484855	16.2811539989142	7.97707123122052e-05	0.00230942352748458	-0.355713957793929	-0.150419026762593
SNRPD1	BRD-K06222852-001-03-2::2.5::HTS002	2.5	posaconazole	sterol demethylase inhibitor	noncancer	CYP3A4	infectious disease	oropharyngeal candidiasis	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.2869937185445	0.2869937185445	-0.0515258991091454	-0.00340254964255	-8.69933607592187	25.0512457735848	4.8475879395839e-09	2.6818169648921e-07	-0.418654686321779	-0.258384548985511
SNRPD1	BRD-K06593056-001-04-8::2.5::HTS002	2.5	LE-135	retinoid receptor agonist	noncancer	RARB	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.128268018563	0.128268018563	-0.144283169326952	-0.158245986785	-8.02311124979048	21.6937073721057	6.22499226457861e-08	3.00697851493096e-06	-0.34305994888628	-0.202042426893625
SNRPD1	BRD-K09602097-001-13-6::2.5::HTS002	2.5	forskolin	adenylyl cyclase activator	targeted cancer	ADCY2, ADCY5, GNAS	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.2997970608885	-0.2997970608885	0.0461573481609362	0.0420503630099	8.91203817659041	10.3797256219	3.48426782050137e-06	0.000130601545592906	0.259887781521148	0.432021036577724
SNRPD1	BRD-K11267252-001-04-4::2.5::HTS002	2.5	alectinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.3648190330145	-0.3648190330145	-0.152997065517339	-0.10378431841385	4.28567787555672	151.300294593007	3.2285388723922e-05	0.00100840791020249	0.114168593222525	0.309475341771797
SNRPD1	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.204653120001	-0.204653120001	-0.328878968537503	-0.31281935927	-3.67602322879994	182.665123245564	0.000311283572189062	0.00783248376892574	-0.190901724896778	-0.0575499721762288
SNRPD1	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-1.211803407655	-1.211803407655	-0.559477865746616	-0.546522000374	19.2753330947178	192.75858077586	7.72869798878569e-47	1.41579838567389e-43	0.585576371354588	0.71907471246218
SNRPD1	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.48674759144	0.48674759144	0.297151837339096	0.330939410236	-6.94609861167926	16.9749645846919	2.38030039258356e-06	9.17732331070411e-05	-0.247190246078431	-0.132001262123377
SNRPD1	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.66988735613	0.66988735613	-0.219723691421817	-0.0984348398408	-16.7721012989946	94.3994360258989	4.57833364454431e-30	1.85495212041878e-27	-0.994919626656164	-0.78430246844747
SNRPD1	BRD-K22503835-001-11-0::2.5::HTS002	2.5	scriptaid	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.7504043459	-0.7504043459	-1.34904716103744	-1.31516080895	-8.93431979012658	111.622736019904	9.67746591782818e-15	9.77455981480771e-13	-0.731409249258252	-0.465876381016633
SNRPD1	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.02779108015025	0.02779108015025	-0.864568028855359	-0.55802362728	-8.39317213319046	16.7323581524613	2.12477337562487e-07	9.57327207955231e-06	-1.11694759257704	-0.667770625434178
SNRPD1	BRD-K24696047-001-02-3::2.5::HTS002	2.5	NVP-AEW541	IGF-1 inhibitor	targeted cancer	IGF1R, INSR	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.548717260098	0.548717260098	0.160676239562461	0.182728129692	-10.8920499928462	21.8518852062271	2.69660483526365e-10	1.70540164572801e-08	-0.461954030337531	-0.314128010733546
SNRPD1	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.3617063179225	-0.3617063179225	-0.0488668107898392	-0.0260340961769	13.918184773097	7.35169458221656	1.50777578493728e-06	5.9944365833764e-05	0.26020088303709	0.365478131228231
SNRPD1	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.786232279202	-0.786232279202	-0.528353397205413	-0.447815997104	5.13755945547872	22.2874922245712	3.63714898636109e-05	0.00112628717293173	0.153858991259784	0.361898772733391
SNRPD1	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.7175623535615	-0.7175623535615	-0.176565989277564	-0.04268072142135	9.76608231152296	6.05749159204391	6.25309009834621e-05	0.00185087494501926	0.405759858040699	0.676232870527172
SNRPD1	BRD-K30867024-003-03-3::2.5::HTS002	2.5	SB-216641	serotonin receptor antagonist	noncancer	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.354365796727	0.354365796727	-0.0524301506853878	-0.02368862812505	-10.9785389564127	97.0972593334335	1.0366381723559e-18	1.51556359374398e-16	-0.480336437530822	-0.333255457293953
SNRPD1	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.3697615703285	-0.3697615703285	0.169149237786362	0.1606220898175	20.6404910009044	21.2152336465468	1.58389246848946e-15	1.72848314093115e-13	0.484646863447471	0.593174752782253
SNRPD1	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-3.81231077158	-3.81231077158	-3.22997089863976	-3.119370710775	6.65752365997274	6.61577202129573	0.000368044371850426	0.00912992849239929	0.373043707085288	0.791636038795196
SNRPD1	BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.157207789779	0.157207789779	-0.126568499998233	-0.075355311638	-7.88091211849418	186.07329363134	2.64876314861079e-13	2.33240245225391e-11	-0.354812794739597	-0.21273978481487
SNRPD1	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.006618415744335	-0.006618415744335	-0.264947156389267	-0.234942866008	-7.09874518500756	178.471413221134	2.86968596594199e-11	2.02654669981674e-09	-0.330140274969138	-0.186517206320726
SNRPD1	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.673526128687	0.673526128687	0.368012698585245	0.3732554744945	-8.72976429170548	191.655275885679	1.24413231191062e-15	1.37238103077453e-13	-0.374541696143168	-0.236485164060342
SNRPD1	BRD-K49071277-001-04-7::2.5::HTS002	2.5	securinine	GABA receptor antagonist, TP53 activator	noncancer	GABRA1	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.470190362047	0.470190362047	0.289541042371189	0.288445970299	-7.11818237403098	56.7278992981008	2.07029628567671e-09	1.18929116218924e-07	-0.231474321386718	-0.129824317964904
SNRPD1	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.1294310985935	-0.1294310985935	-0.458467311655817	-0.3435721987365	-5.99335729835444	40.5711490340207	4.59047307587777e-07	1.96931846252964e-05	-0.439944917469956	-0.218127508654678
SNRPD1	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.8136565554965	-0.8136565554965	-1.11065301818358	-1.00700802709	-4.92693865941707	61.1926111015068	6.67841317445541e-06	0.00023753362384133	-0.417526343265641	-0.176466582108528
SNRPD1	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.5020170912335	-0.5020170912335	-0.739076046232442	-0.696454065727	-4.28822608611684	188.875164074273	2.87028932370978e-05	0.000905617901459432	-0.346107151217748	-0.128010758780136
SNRPD1	BRD-K55044200-001-15-3::2.5::HTS002	2.5	amoxicillin	penicillin binding protein inhibitor	noncancer	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.538827275697	0.538827275697	0.0927592710703185	0.127274405853	-16.6935949801072	37.0125282727278	8.18041312967172e-19	1.20667568180964e-16	-0.500209087090271	-0.391926922163092
SNRPD1	BRD-K58466253-003-14-0::2.5::HTS002	2.5	palmatine-chloride	dopamine synthesis inhibitor	noncancer	CYP3A4	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.3373299169815	0.3373299169815	-0.0598172190002401	-0.0643126933566	-9.79783279183522	10.2465264846697	1.58684345417212e-06	6.28430470600992e-05	-0.487169245345222	-0.307125026618258
SNRPD1	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.09713766226495	0.09713766226495	-0.253924826175351	-0.132231172134	-5.97865201702993	24.8074458691566	3.14122507040192e-06	0.000118593557885181	-0.472044843452648	-0.230080133427954
SNRPD1	BRD-K62200014-003-10-5::2.5::HTS002	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.3777698982015	0.3777698982015	-0.0848873585705462	0.0371962455536	-6.57603715403122	5.59406033562398	0.000786884458403701	0.0179340875250114	-0.637883835514448	-0.287430678029644
SNRPD1	BRD-K62391742-001-03-0::2.5::HTS002	2.5	venetoclax	BCL inhibitor	targeted cancer	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.1108368386034	0.1108368386034	0.361335444151242	0.3408626748475	8.25186711861792	22.7174602803747	2.7566294284838e-08	1.3927996906589e-06	0.187657954933627	0.313339256162058
SNRPD1	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.00706801087221	-0.00706801087221	-0.493657848288115	0.00436707189359	-5.38069165263262	168.019221178611	2.45990868021024e-07	1.0958839482868e-05	-0.665120352812383	-0.308059322019427
SNRPD1	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.021619656330725	0.021619656330725	-0.218723693259809	-0.209793035138	-4.5216083379581	89.9596490548329	1.86489746883538e-05	0.000611351498314497	-0.345944475526852	-0.134742223654216
SNRPD1	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-5.087704470905	-5.087704470905	-3.84523685241093	-3.68860468998	16.2318047884429	21.812986488019	1.16303816356475e-13	1.05938294330076e-11	1.08364353102205	1.4012917059661
SNRPD1	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.519754180031	0.519754180031	-0.0849335628529521	0.0411624842104	-13.2744394489048	46.8236773646637	1.7465863550475e-17	2.28956640300291e-15	-0.696337244822157	-0.513038240945748
SNRPD1	BRD-K72420232-001-12-3::2.5::HTS002	2.5	WZ-4002	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.2557456668105	0.2557456668105	-0.0760724990943561	0.0237239176578	-6.78469620581438	97.0860840454588	9.19209404873108e-10	5.49089276859109e-08	-0.428883651675631	-0.234752680134081
SNRPD1	BRD-K73589491-001-11-2::2.5::HTS002	2.5	nizatidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.1875162285285	0.1875162285285	0.0947597353063731	0.09689104741345	-3.90369131055963	191.07218330383	0.000131264033248673	0.00362220792869253	-0.139624496336033	-0.0458884901082203
SNRPD1	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.6365023361275	-0.6365023361275	-0.202973428180349	-0.177852990832	8.2183901959422	16.8058101196897	2.74298922255082e-07	1.21618149995882e-05	0.322135826920623	0.544921988973678
SNRPD1	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.115916599271	-0.115916599271	-1.06556770150002	-0.7851415156885	-10.1636501841502	187.604846678499	1.30472829222302e-19	2.07141563069532e-17	-1.13397138367304	-0.765330820784994
SNRPD1	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.84516179918	0.84516179918	0.494937425715076	0.515272690573	-11.6534848838542	89.1739936561883	1.29590247325986e-19	2.06198575494664e-17	-0.409937812715659	-0.290510934214189
SNRPD1	BRD-K80608265-001-01-6::2.5::HTS002	2.5	erteberel	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.5615499296415	0.5615499296415	-0.00086073509968731	0.05335983697175	-10.5430836272932	7.10299025428184	1.36033858751895e-05	0.000457349033920546	-0.688179456431787	-0.436641873050588
SNRPD1	BRD-K81332461-001-01-4::2.5::HTS002	2.5	maxacalcitol	vitamin D receptor agonist	noncancer	VDR	endocrinology	hyperparathyroidism	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.03810216414275	0.03810216414275	-0.142551807463041	-0.1171657345245	-5.39941502004297	191.915447614956	1.96117520660736e-07	8.86225428751735e-06	-0.246646723428652	-0.114661219782929
SNRPD1	BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.3890973299015	0.3890973299015	-0.318433995344328	-0.108614953002	-9.34557658137933	155.731978811282	9.26022689960938e-17	1.13090323143383e-14	-0.857077645725259	-0.557985004766397
SNRPD1	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.02793655952825	0.02793655952825	0.103768721254831	0.135507608915	3.22606269400908	193.81320150944	0.00147334266267916	0.0309557944857722	0.029471557653136	0.122192765800026
SNRPD1	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.376025268949	-0.376025268949	-1.42837193298083	-1.12582537284	-11.4338807612623	122.727913607298	4.67098596362486e-21	8.49132952160943e-19	-1.23453341395313	-0.870159914110526
SNRPD1	BRD-K97810537-001-13-6::2.5::HTS002	2.5	beclomethasone-dipropionate	glucocorticoid receptor agonist	noncancer	GPR97, NR3C1	allergy	allergic rhinitis	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	-0.289668699241	-0.289668699241	0.0788993742025567	0.06870536578965	8.16012424186376	21.5067253677473	5.0178180368894e-08	2.44813094019683e-06	0.274772793951884	0.46236335293523
SNRPD1	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	EFM192A, SH10TC	BREAST, STOMACH	carcinoma	0.628318903321	0.628318903321	0.243052541682724	0.250792854427	-13.2984189058544	180.267110394045	1.45776105222341e-28	5.24228974097299e-26	-0.442431942110083	-0.328100781166469
SOX5	BRD-A03932035-004-04-3::2.5::HTS002	2.5	methscopolamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.717779236832	0.717779236832	0.235288718681994	0.224710721764	-15.3335209145011	16.1428054526999	4.80558222680811e-11	3.30332146597035e-09	-0.549148353484442	-0.41583268281557
SOX5	BRD-A14886633-001-01-6::2.5::HTS002	2.5	norgestrel	progesterone receptor agonist	noncancer	PGR	endocrinology	contraceptive	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.6258185912105	0.6258185912105	-0.142569444167636	-0.0793835829582	-11.6738596607712	3.94127028219546	0.000334307155954147	0.00835783488026321	-0.952216118406917	-0.584559952349355
SOX5	BRD-A20239487-001-24-9::2.5::HTS002	2.5	atenolol-(+/-)	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.04970371141825	0.04970371141825	0.201051300609853	0.2153434781075	6.16346053553716	175.798474271806	4.73055032174343e-09	2.62327068540478e-07	0.10288584591393	0.199809332469276
SOX5	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.03767754552605	0.03767754552605	-0.778941842284503	-0.4776049590865	-7.15693640652315	18.0421000808561	1.1367938274346e-06	4.60320960212034e-05	-1.05629830327575	-0.576940472345357
SOX5	BRD-A59303141-001-10-4::2.5::HTS002	2.5	quinethazone	thiazide diuretic	noncancer	CA1, CA2, SLC12A1, SLC12A2, SLC12A3	cardiology	hypertension	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.616253101916	0.616253101916	0.360678014288297	0.3935946417985	-8.2412648206293	163.759629666708	5.21222303910412e-14	4.93214371632736e-12	-0.316809299134942	-0.194340876120465
SOX5	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.275398343293	0.275398343293	0.142718631608188	0.135666555282	-4.65218282452108	38.3009933141698	3.85378038482456e-05	0.0011882849893527	-0.190400300837103	-0.0749591225325205
SOX5	BRD-A93695607-322-02-5::2.4707::HTS002	2.4707	nicotine	acetylcholine receptor agonist	noncancer	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-0.1754352924065	-0.1754352924065	0.128032294431063	0.1533689039075	8.43900939482399	86.9921708308827	6.31457171531875e-13	5.35362278944839e-11	0.231992911791802	0.374942261883324
SOX5	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.37958696849	0.37958696849	0.260898542928693	0.303778240807	-3.14442400690352	189.083237383824	0.00193286873522285	0.0389496991247372	-0.19314515899558	-0.0442316921270337
SOX5	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.4105772696615	0.4105772696615	0.220221599396948	0.209209067771	-5.49599383911161	6.28037222368485	0.00130850265774807	0.0279666998536583	-0.274196595227489	-0.106514745301615
SOX5	BRD-K01669786-001-02-2::2.5::HTS002	2.5	triapine	ribonucleotide reductase inhibitor	chemo	RRM1, RRM2	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-3.761820285295	-3.761820285295	-3.18372593650294	-3.03572619257	5.24760436309378	39.5521820412549	5.5173515868995e-06	0.000199582860467271	0.355367101300956	0.80082159628316
SOX5	BRD-K02130563-001-11-4::0.15625::HTS002	0.15625	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-3.713180623465	-3.713180623465	-3.01235868082187	-3.06864894207	5.16485170062239	139.670077088208	8.13192509668303e-07	3.36663583937991e-05	0.432548768086254	0.969095117200007
SOX5	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-3.16911917902	-3.16911917902	-2.01453209197277	-1.91516760225	12.8035086575691	52.1903779385361	9.8877318497363e-18	1.33200985519933e-15	0.973648611184772	1.33552556290968
SOX5	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.3578498748625	0.3578498748625	0.239148332905719	0.231867156581	-4.12517454945537	22.3664140323106	0.000432052926375539	0.0105216988588959	-0.178320429583672	-0.0590826543298897
SOX5	BRD-K04623885-001-07-5::2.5::HTS002	2.5	BIBR-1532	telomerase inhibitor	targeted cancer	TERT	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-0.4418719892705	-0.4418719892705	-0.914238526245453	-0.834266968334	-7.11278837839419	4.58632692534359	0.00121174872762977	0.0261754578758477	-0.647818115839298	-0.296914958110609
SOX5	BRD-K07572174-001-39-4::2.48092::HTS002	2.48092	curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	targeted cancer	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-1.649551691345	-1.649551691345	-1.17021604361866	-1.01297286124	5.06438457771746	10.1598072434606	0.000465399853825176	0.0112481602695643	0.268894752517209	0.689776542935463
SOX5	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-5.658279591755	-5.658279591755	-3.00179666934864	-2.91986435367	18.1544458943146	2.86305583960106	0.000480220840560873	0.0115612236461259	2.17794753865122	3.1350183061615
SOX5	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-0.172273668792	-0.172273668792	-1.26848435915636	-0.9430769633885	-9.8452520734706	13.0462811692672	2.0908016009985e-07	9.42615516071533e-06	-1.33666827115545	-0.855753109573281
SOX5	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	1.22047333414	1.22047333414	0.417986474572658	0.3989310314435	-22.9043825210302	36.1368580609138	4.14430512693252e-23	9.02687777998292e-21	-0.873534607329741	-0.731439111804942
SOX5	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-2.877818843175	-2.877818843175	-2.4109547521549	-2.32376274045	5.80635282948488	17.7765293177468	1.76449025407115e-05	0.00058217584923771	0.297785554966908	0.635942627073285
SOX5	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.641278923187	0.641278923187	0.504199619241654	0.505306635797	-4.93773002370328	9.29823563710784	0.000730803331050867	0.0167934327373004	-0.199574699092161	-0.0745839087985315
SOX5	BRD-K13646352-001-03-8::2.5::HTS002	2.5	midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	targeted cancer	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-4.20383665279	-4.20383665279	-2.9414540609245	-2.8284008656	13.0925989835742	190.657670433244	2.3333461385952e-28	8.22539053518044e-26	1.0721965036896	1.4525686800414
SOX5	BRD-K14618467-001-04-6::2.5::HTS002	2.5	IKK-16	IKK inhibitor	noncancer	IKBKB	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-0.318747217056	-0.318747217056	-0.135764743759618	-0.07721544600385	4.6686613127033	187.944230149221	5.75454589265468e-06	0.000207392982449434	0.105666221775427	0.260298724817337
SOX5	BRD-K15409150-001-05-8::2.5::HTS002	2.5	penfluridol	T-type calcium channel blocker	noncancer	CACNA1G	neurology/psychiatry	schizophrenia	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-2.5674823465	-2.5674823465	-2.85510733591798	-2.6535756676	-3.072308062662	173.831581556804	0.00246628830346571	0.047997557958186	-0.472400350345011	-0.102849628490957
SOX5	BRD-K18849474-001-04-4::2.60504::HTS002	2.60504	dalcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.812900737455	0.812900737455	0.295127307477794	0.27891575921	-12.2886520490522	2.80683059303322	0.00159205856761925	0.0330868147715763	-0.657238331250498	-0.378308528703914
SOX5	BRD-K20285085-074-04-5::2.5::HTS002	2.5	R406	SYK inhibitor	targeted cancer	RET, SYK	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-1.84568555954	-1.84568555954	-0.67512406708839	-0.587603052309	21.4249235143729	149.226080296862	2.20107685155678e-47	4.0668500044596e-44	1.06260235584344	1.27852062905978
SOX5	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.645349629899	0.645349629899	0.295369791963152	0.330939410236	-10.1394017354496	3.58817711167779	0.000908622409843066	0.0203430619951169	-0.450311523567792	-0.249648152303904
SOX5	BRD-K21680192-300-14-4::2.5::HTS002	2.5	mitoxantrone	topoisomerase inhibitor	chemo	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-7.14921032502	-7.14921032502	-4.69317780248642	-4.740808103055	17.8189253342394	22.6413884762448	8.15642573963107e-15	8.32456463023518e-13	2.17065353414175	2.74141151092541
SOX5	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.5500109894025	0.5500109894025	0.382598874572251	0.383188744526	-6.7036212639633	167.637095244183	2.96584270698801e-10	1.86740922898365e-08	-0.216714976020425	-0.118109253640074
SOX5	BRD-K28143534-001-02-2::2.5::HTS002	2.5	cyproheptadine	histamine receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.213508514454	0.213508514454	-0.00716154898649285	0.02120744072425	-5.96235129248425	6.44278085462296	0.000767887671997472	0.0175421655139145	-0.309744186091612	-0.131595940789374
SOX5	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-3.727150392145	-3.727150392145	-3.11358213380358	-3.10613635441	5.92270205161798	190.0978970239	1.45786198334865e-08	7.66966374641955e-07	0.409222897779671	0.817913618903173
SOX5	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-1.1988383432	-1.1988383432	-0.869383654219513	-0.652322906708	3.31620880135158	27.9171817813106	0.00253942936067562	0.0492465938693672	0.125924819918299	0.532984558042674
SOX5	BRD-K33720171-001-01-0::2.5::HTS002	2.5	difluprednate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	endogenous uveitis	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-1.765649796035	-1.765649796035	-1.46664331536302	-1.420636846445	3.897350731315	30.3765769058509	0.000498002720179107	0.0119458785689164	0.142403841562769	0.455609119781199
SOX5	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-0.773939286585	-0.773939286585	-1.03162882302368	-1.017015264785	-3.55962795375792	166.880901017444	0.000483917582197683	0.011634051763864	-0.400612230695129	-0.114766842182227
SOX5	BRD-K36740062-001-06-6::2.5::HTS002	2.5	GSK1070916	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC, CYP2D6, CYP3A4	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-3.55833772246	-3.55833772246	-2.24385091310291	-1.941905488655	8.50260844601849	3.23351936192379	0.00255521360423825	0.0495123747023579	0.841989436372054	1.78698418234212
SOX5	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.5218946345475	0.5218946345475	-0.244290719325575	-0.026104548309	-10.7069786597301	4.1880835504225	0.000337331645846972	0.00842656810288294	-0.961396293654236	-0.570974414091914
SOX5	BRD-K38350380-001-01-8::2.5::HTS002	2.5	FK-3311	cyclooxygenase inhibitor	noncancer	PTGS2	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.1633450403425	0.1633450403425	-0.358108254956163	-0.2780855887145	-9.17004674854538	6.27958249736425	7.26744205946238e-05	0.00211986286410386	-0.659108583202937	-0.383798007394389
SOX5	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.205894611558	0.205894611558	-0.149019885129578	-0.07517274316945	-6.93475770653314	15.7629581752021	3.64504827098299e-06	0.000136175623299898	-0.463542042978091	-0.246286950397064
SOX5	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-1.4732361834	-1.4732361834	-2.2965617755635	-2.14029239454	-9.46941938942141	140.890983642812	9.09248289535109e-17	1.11168440757427e-14	-0.995212497010112	-0.651438687316897
SOX5	BRD-K42898655-001-01-8::2.5::HTS002	2.5	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-0.816775686018	-0.816775686018	-1.35047294842484	-1.32952488095	-9.71770160834365	26.2680533850572	3.45722321704081e-10	2.16345458360625e-08	-0.646531129105227	-0.420863395708446
SOX5	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-2.54756622684	-2.54756622684	-3.2432839991107	-3.15387343916	-8.87893711688006	16.9585968729672	8.75681677296159e-08	4.15138195561178e-06	-0.861065179031677	-0.530370365509734
SOX5	BRD-K44408410-001-17-6::2.5::HTS002	2.5	2-methoxyestradiol	hypoxia inducible factor inhibitor	targeted cancer	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-0.143636017075	-0.143636017075	-1.12744772988751	-1.07322078363	-15.5403677867112	190.989013326261	9.72687106072288e-36	6.63933295405629e-33	-1.10868211143986	-0.858941314185162
SOX5	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-0.2438641356595	-0.2438641356595	-0.69806132949822	-0.636668754802	-8.41472757158179	45.3699569793009	8.1186870029852e-11	5.44452461408891e-09	-0.562886899800461	-0.345507487876979
SOX5	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-6.119022357805	-6.119022357805	-5.27159940897787	-5.30447708423	10.4526492014199	170.036982947255	4.60090427606415e-20	7.68594865615397e-18	0.687384625634963	1.00746127201929
SOX5	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.05910524299405	0.05910524299405	-0.29773819868808	-0.290098649131	-8.08636130797248	177.091976500515	9.34948546450784e-14	8.59290681870713e-12	-0.443929921669026	-0.269756961695233
SOX5	BRD-K46937689-001-15-0::0.625::HTS002	0.625	phenazone	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.2974777031755	0.2974777031755	0.0911985793344256	0.0795356739513	-5.90368037030443	23.6141688103131	4.60551137255041e-06	0.000169351942597965	-0.278455727899801	-0.134102519782347
SOX5	BRD-K50071428-001-03-3::2.5::HTS002	2.5	abiraterone	androgen biosynthesis inhibitor	targeted cancer	CYP11B1, CYP17A1	oncology	prostate cancer	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.8669992950945	0.8669992950945	0.518753457683179	0.521292609125	-13.2810211076213	124.728842197141	1.24720500574569e-25	3.35397994575242e-23	-0.400142176708379	-0.296349498114263
SOX5	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.7771070336085	0.7771070336085	0.221266507116722	0.2005091684065	-13.7192031822111	3.6032451407632	0.000306549467100596	0.00772333851348344	-0.673386995990188	-0.438294056993367
SOX5	BRD-K59369769-001-20-3::2.5::HTS002	2.5	tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, AURKC, LCK	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-2.4184261724	-2.4184261724	-1.7777163061544	-1.66496911729	9.65041865610518	188.548932703959	3.66864222503428e-18	5.12579152183424e-16	0.509743463902259	0.771676268588937
SOX5	BRD-K60230970-001-17-5::2.40205::HTS002	2.40205	MG-132	proteasome inhibitor	targeted cancer	PSMB1	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-5.419091118675	-5.419091118675	-6.17032524576677	-6.116258820345	-9.62658424148668	18.8671706947275	1.0336321656413e-08	5.51087931417247e-07	-0.914646260032291	-0.587821994151257
SOX5	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-2.283977532225	-2.283977532225	-1.52758296533692	-1.40779088077	8.93032908643571	3.86456118321188	0.00101711791260983	0.0224416167481731	0.517944737070834	0.994844396705331
SOX5	BRD-K62391742-001-03-0::2.5::HTS002	2.5	venetoclax	BCL inhibitor	targeted cancer	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.6348873293565	0.6348873293565	0.355760438930465	0.3310204610865	-8.34205857274773	8.31055207111369	2.57107868530347e-05	0.000821736837969592	-0.355787222529077	-0.202466558322994
SOX5	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-1.252779606135	-1.252779606135	-1.84525664870053	-1.7566794361	-5.7625399766585	26.824717962663	4.05970060379617e-06	0.000150460240482627	-0.803501048730181	-0.381453036400883
SOX5	BRD-K67511046-001-02-3::0.625::HTS002	0.625	naloxone	opioid receptor antagonist	noncancer	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.269966757901	0.269966757901	0.0669158211577599	0.0354570800606	-5.40906722355714	9.09654386431147	0.000412518925153444	0.0100849513755233	-0.287832851886629	-0.118269021599851
SOX5	BRD-K68103045-001-02-9::2.5::HTS002	2.5	CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.6582599246	0.6582599246	0.444758480817883	0.4684149214555	-6.19849134304247	7.78053627388684	0.000291214062554458	0.00737511743037155	-0.293321345529918	-0.133681542034316
SOX5	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.406075918081	0.406075918081	-0.268331433373673	-0.236194067289	-15.1116731094456	24.9546551986239	4.58346177943611e-14	4.36220594904424e-12	-0.766329398506204	-0.582485304403143
SOX5	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-1.494107811385	-1.494107811385	-0.71447210602146	-0.5475428257095	6.27284432881664	5.13905813415262	0.00136741519110381	0.0290273367583999	0.462727523901703	1.09654388682538
SOX5	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.0701481454894	0.0701481454894	-0.156371590835085	-0.1366984748555	-5.49241655042893	177.580911566056	1.3559747533629e-07	6.28145110183821e-06	-0.307907761998543	-0.145131710650426
SOX5	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-2.125538446915	-2.125538446915	-0.665540411231053	-0.4541784692175	19.1260921708677	191.490051535255	2.69477268451015e-46	4.73416339916702e-43	1.30943180308593	1.61056426828196
SOX5	BRD-K76674262-001-03-3::0.625::MTS010::PROS003_PR500	0.625	homoharringtonine	protein synthesis inhibitor	targeted cancer	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-1.981680318695	-1.981680318695	-1.59624063794443	-1.84636117372	3.78143012123126	170.383077071554	0.000215505664435036	0.00564866253548941	0.184232179401545	0.586647182099589
SOX5	BRD-K76973696-001-12-6::2.01421::HTS002	2.01421	tryptanthrin	cyclooxygenase inhibitor	targeted cancer	IDO1	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-1.737229768935	-1.737229768935	-1.38289525688019	-1.323892199525	6.10216897568297	5.63102458358592	0.00111622002242045	0.0243425235231332	0.209962115677346	0.498706908432271
SOX5	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.6146849540555	0.6146849540555	0.279081586392343	0.273644438403	-7.99948177461056	6.10615815796596	0.000186238884407241	0.0049610233477653	-0.437827929008474	-0.233378806317839
SOX5	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	-0.0149689729756	-0.0149689729756	-0.324905894536137	-0.193950713334	-4.99924445844661	10.5515309982976	0.000457183530945173	0.0110720552546834	-0.447101796733523	-0.172772046387552
SOX5	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.06534395172815	0.06534395172815	-0.15360876000412	-0.140788868193	-4.73112888305698	6.61250151425833	0.00248355692967849	0.0482985457926742	-0.329699078608952	-0.108206344855588
SOX5	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MKN1, U2OS	STOMACH, BONE	carcinoma (mixed_adenosquamous_carcinoma), osteosarcoma	0.2855192837175	0.2855192837175	0.0218624819009742	0.0377701807511	-12.066660122735	172.795339867849	1.03777070834048e-24	2.6322409248273e-22	-0.306784110816981	-0.220529492816071
SPC24	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-2.59840580655	-2.59840580655	-1.60967019659723	-1.53203888218	9.96942736128237	9.25204910042573	2.97972338451457e-06	0.000113113909542973	0.765310399511957	1.21216082039358
SPC24	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.02066076764085	0.02066076764085	-0.778736820864199	-0.4776049590865	-6.34659936816436	7.32962823974222	0.000319681384583325	0.00802118841914769	-1.09454426714206	-0.504250909868041
SPC24	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.4023156170445	0.4023156170445	-0.0569939766751806	0.002007296385155	-12.5782258077538	56.240639875945	5.52865270489139e-18	7.61047273979876e-16	-0.53245351919336	-0.386165668246002
SPC24	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.5289525020795	0.5289525020795	0.204407513941015	0.2241591843385	-7.59027127506057	4.83519774169902	0.00073032925888255	0.0167843383794808	-0.435594388647679	-0.213495587629291
SPC24	BRD-A79981887-003-16-4::2.5::HTS002	2.5	midodrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.49228083278	-1.49228083278	-1.03120284985289	-1.01219584287	4.95975588395514	12.1467872823018	0.000319149071653677	0.00800970742136544	0.258798303845444	0.663357662008782
SPC24	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.2216367736175	-0.2216367736175	0.15524738560926	0.185523876977	6.62220689499357	5.02485546864464	0.00115962712057421	0.0251840836078173	0.230804163823115	0.522964154630405
SPC24	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.2674069749315	-0.2674069749315	-0.685319355008185	-0.506361258966	-5.65173701604834	26.0084325625556	6.06670777989155e-06	0.000217832315682229	-0.569904173454124	-0.265920586699246
SPC24	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-3.930313971175	-3.930313971175	-3.06369026703135	-3.06417251019	8.70817100655581	66.4892914704715	1.35599552140224e-12	1.11394850175017e-10	0.667955990999447	1.06529141728785
SPC24	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-3.922473489755	-3.922473489755	-3.0199726494743	-2.91986435367	9.25998419324194	154.242307353103	1.65709227435436e-16	1.9885942333152e-14	0.709967309440939	1.09503437112047
SPC24	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.0424436823509	-0.0424436823509	-0.308527289797435	-0.199486634258	-4.77453882533822	143.721130255858	4.3896023114026e-06	0.000161875270784688	-0.376239350375257	-0.155927864517814
SPC24	BRD-K08586861-001-01-1::2.5::HTS002	2.5	ramatroban	prostanoid receptor antagonist	noncancer	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.2835404013255	-0.2835404013255	-0.040920373056343	-0.0764489475894	6.78656642081005	174.805626351765	1.71502157019856e-10	1.10616568799003e-08	0.172062755438134	0.31317730110018
SPC24	BRD-K10843433-001-22-7::2.5::HTS002	2.5	phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	PTGIS, PTGS1, PTGS2	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.550813420807	0.550813420807	0.121843909096351	0.1301341456285	-9.08513319773684	11.1723542373107	1.70484056754647e-06	6.71037962413212e-05	-0.532697380544119	-0.325241642877179
SPC24	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.16296015137	-1.16296015137	-1.81049025807502	-1.56065418801	-5.75702169050919	46.3001940138084	6.5571030622497e-07	2.75186477820426e-05	-0.87389411220419	-0.421166101205841
SPC24	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-5.416304592565	-5.416304592565	-4.12353035746568	-4.11179699224	9.09100530317482	10.4951529187516	2.67447540831912e-06	0.000102196049169126	0.977939367674317	1.60760910252432
SPC24	BRD-K12932420-001-02-3::2.5::HTS002	2.5	YM-976	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.0427467489707	0.0427467489707	0.315770748993385	0.348254117444	6.01108748272367	4.69870555379879	0.00226628474291839	0.0446530362574129	0.153979819066932	0.392068180978437
SPC24	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-3.49056749579	-3.49056749579	-2.59364284557745	-2.674840125005	10.5563150263406	9.73721115235882	1.20396631765611e-06	4.85411769934002e-05	0.70691443891263	1.08693486151247
SPC24	BRD-K13949769-001-01-7::2.5::HTS002	2.5	tenovin-6	SIRT inhibitor	targeted cancer	SIRT1, SIRT2, SIRT3	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.6669196443035	-0.6669196443035	-1.27194458135929	-1.229883421555	-7.30813092543347	9.44003498818057	3.51322719473336e-05	0.00109160114731807	-0.790981896617136	-0.419067977494449
SPC24	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.0932296322932	0.0932296322932	0.261011153870311	0.263001454047	5.52553477054578	21.5974681254792	1.58937736635419e-05	0.000528466741472737	0.104740750751963	0.230822292402259
SPC24	BRD-K16664969-001-03-3::2.5::HTS002	2.5	GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRB	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.38640401602	0.38640401602	-0.0989616726521455	-0.0311349339001	-10.8432878421973	16.6106975372713	5.95688959625485e-09	3.26196778302429e-07	-0.579973836792625	-0.390757540551666
SPC24	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.7103923185015	-0.7103923185015	-1.13448463700873	-0.889953286616	-4.0861898446287	22.6358315363813	0.000466167654506649	0.0112641766880221	-0.638982836423728	-0.209201800590739
SPC24	BRD-K18424115-003-01-3::2.5::HTS002	2.5	TG-100572	src inhibitor, VEGFR inhibitor	targeted cancer	KDR, SRC	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.734639903545	-1.734639903545	-1.19799129263086	-1.10820806652	6.80396836814152	7.52116208885786	0.000182412110464138	0.00487240842767551	0.352731985354398	0.720565236473879
SPC24	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-2.64960880632	-2.64960880632	-0.856915836684004	-0.775615128041	20.1167678625001	6.95956827557631	2.00450076686337e-07	9.05421801603916e-06	1.58172256378769	2.0036633754843
SPC24	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-2.67148573032	-2.67148573032	-2.99215368639536	-2.880185474935	-3.6388968824714	14.6442810288936	0.0025107808735425	0.0487439450947002	-0.508894347691683	-0.132441564459041
SPC24	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-2.042691288375	-2.042691288375	-2.87873876907044	-2.75215171608	-7.89128498759904	137.413980923081	8.43704853315192e-13	7.07751144838324e-11	-1.04554213310619	-0.626552828284691
SPC24	BRD-K24844714-001-24-5::2.5::HTS002	2.5	5-fluorouracil	thymidylate synthase inhibitor	chemo	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.58867042048	-0.58867042048	-1.05474368625608	-0.97521082715	-8.95210515766515	159.854102355495	8.45434037701685e-16	9.45725636046787e-14	-0.568893239971174	-0.363253291580993
SPC24	BRD-K25433859-003-25-4::2.5::HTS002	2.5	maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2	neurology/psychiatry	depression, dysthymic disorder	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.0317397358127	0.0317397358127	0.174258397587981	0.1863876312595	4.61360723087806	13.1103225879555	0.000475141477252328	0.0114526088256876	0.0758398855272721	0.20919743802329
SPC24	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.538885589284	0.538885589284	0.144549379205638	0.195908235522	-8.36840116255506	14.7588727632493	5.5356131996905e-07	2.34706714436491e-05	-0.494917590019086	-0.293754830137637
SPC24	BRD-K27316855-001-13-3::2.43597::HTS002	2.43597	calcitriol	vitamin D receptor agonist	noncancer	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.420856338775	-0.420856338775	-0.0320484124192731	0.01343134409051	9.14737832205676	71.5663974973718	1.17105062469838e-13	1.06622816202624e-11	0.304067288522213	0.473548564189241
SPC24	BRD-K30577245-341-01-9::2.5::HTS002	2.5	docetaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-5.17453869291	-5.17453869291	-3.68154856404455	-3.84343615246	15.1569709629323	92.0606416254748	9.38388588837888e-27	2.78951300772588e-24	1.29735861059006	1.68862164714085
SPC24	BRD-K31309378-001-01-5::2.5::HTS002	2.5	lucitanib	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.4267583439075	-0.4267583439075	-0.765334453206708	-0.647544423054	-4.64291535380924	8.44353589606541	0.00143854430355006	0.0303406575512282	-0.505211999767603	-0.171940218830813
SPC24	BRD-K32107296-001-16-9::2.5::HTS002	2.5	temozolomide	DNA alkylating agent	chemo	MGMT	oncology	glioblastoma, astrocytoma	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.338117115404	0.338117115404	0.224581403432866	0.214329388476	-3.99753262762727	188.894969425245	9.17216957141864e-05	0.00261731052066647	-0.16956046774521	-0.0575109561970586
SPC24	BRD-K33882852-003-02-8::2.5::HTS002	2.5	ZK-93423	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.3308941022005	-0.3308941022005	-0.888869719057729	-0.832624878756	-8.38255849453401	19.7713270157959	6.13990305888696e-08	2.96855240854542e-06	-0.696928460453891	-0.419022773260567
SPC24	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.4127261870805	0.4127261870805	-1.38685808797748	-1.00119520354	-11.2457347629849	2.74453239350282	0.0022440714164096	0.0442759442702433	-2.33674764770411	-1.26242090241186
SPC24	BRD-K39624409-003-02-6::2.5::HTS002	2.5	ADL5859	opioid receptor agonist	noncancer	OPRD1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.03791519515185	-0.03791519515185	0.242106736440381	0.2967828750075	6.89885253456665	9.32578314226607	5.94291779747972e-05	0.00176613925210209	0.188688425004203	0.37135543818026
SPC24	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.0439641028058	0.0439641028058	-0.210697106166881	-0.158274399371	-5.81368745870073	188.62828882541	2.56851716996348e-08	1.30297684383693e-06	-0.341069332917096	-0.168253085028266
SPC24	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.436079741031	0.436079741031	-0.732859970850232	-0.623158972273	-9.51944494454191	4.8642420712712	0.000251037864699102	0.00647391342835926	-1.48726242265325	-0.850617001109212
SPC24	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.272126093637	-0.272126093637	-0.697720823980419	-0.636668754802	-6.22463032287415	4.71079389667799	0.00193610863885857	0.0389967323050389	-0.604647884716839	-0.246541575969998
SPC24	BRD-K51911221-001-01-2::2.5::HTS002	2.5	nemorubicin	topoisomerase inhibitor	chemo	TOP1, TOP2A	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-7.15544835462	-7.15544835462	-6.17118581953953	-6.268105536705	10.2853412561196	30.7731556117005	1.77206083749216e-11	1.28312171364479e-09	0.789031617602046	1.1794934525589
SPC24	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.423489472615	-0.423489472615	-0.76609372976848	-0.6098527820225	-4.19044021320765	9.39972734365091	0.00212622739419325	0.0422934748185657	-0.526362907899187	-0.158845606407772
SPC24	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.739314810858	-0.739314810858	-1.54446452513328	-1.43484346641	-13.0257932272583	95.3481447641783	6.91616097278538e-23	1.47762770970752e-20	-0.927856176507864	-0.682443252042692
SPC24	BRD-K61036791-001-01-6::2.5::HTS002	2.5	rucinol	tyrosinase inhibitor	noncancer	TYR	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.7168289233885	0.7168289233885	0.400309212465235	0.439884501288	-12.3717513923637	134.111435572562	6.27455079280677e-24	1.46494356957678e-21	-0.36712015364187	-0.265919268204661
SPC24	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.3506702271255	-0.3506702271255	-0.689857365897098	-0.642732938193	-6.20524452297196	131.557570319654	6.60298314595674e-09	3.59464255699711e-07	-0.447316086493224	-0.231058191049972
SPC24	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.448951558467	-0.448951558467	-0.206269837595822	-0.128286851934	6.43651195221194	151.051704869073	1.53280076874075e-09	8.93941920988942e-08	0.168186565625669	0.317176876116688
SPC24	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.3349909930945	0.3349909930945	-0.497277520287763	0.00402399396559	-8.18386107730578	16.9834968412068	2.69374789144062e-07	1.19558561156467e-05	-1.04684486604964	-0.617692160714881
SPC24	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.3865918797355	0.3865918797355	-0.176878572986522	-0.07625513394025	-11.4643455298941	187.999965705055	2.05721277014092e-23	4.56912285815059e-21	-0.660426457646952	-0.466514447797093
SPC24	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.075747031155	-1.075747031155	-1.84711039294116	-1.7566794361	-7.62961995464737	35.1635816011309	5.81486237402434e-09	3.18908300348583e-07	-0.976575484481115	-0.566151239091205
SPC24	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.1373527465655	-0.1373527465655	-0.607802991494787	-0.456560974373	-6.79948254733752	23.9334332286208	5.01470032983385e-07	2.13932266519299e-05	-0.613270600444669	-0.327629889413905
SPC24	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.0535384098057	0.0535384098057	0.146216831702826	0.1059379473725	3.1517130252326	111.205992349999	0.00208626502433729	0.0415873415551698	0.0344101944439424	0.15094664935031
SPC24	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.8462808476785	-0.8462808476785	-1.76716912844458	-1.7012260142	-14.3767237690953	177.032102416109	1.48354432638352e-31	6.80870603703327e-29	-1.04729617245887	-0.794480389073288
SPC24	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.926726740815	-1.926726740815	-0.709869776984971	-0.5475428257095	11.9184533181279	29.5774013716307	8.0912174724623e-13	6.79804997904889e-11	1.00821887885168	1.42549504880838
SPC24	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.0930273033249	-0.0930273033249	-0.665104110514663	-0.50591048476	-9.02587518504704	142.154981798467	1.13335480855015e-15	1.25405680310658e-13	-0.697369601819762	-0.446784012559765
SPC24	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.3347096560215	0.3347096560215	-0.535848270316811	-0.376499820922	-13.1544861217337	6.46699078937502	6.58821849179771e-06	0.000234637135448407	-1.02970067886502	-0.711415173811606
SPC24	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-3.062907698765	-3.062907698765	-2.5164045451006	-2.24664413304	4.81142976133431	48.1968060772583	1.51634920820709e-05	0.000506226805990371	0.318150587534348	0.774855719794462
SPC24	BRD-K72827473-001-01-0::2.5::HTS002	2.5	CEP-37440	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.025429966376565	0.025429966376565	-0.233822242137241	-0.1997036713495	-5.22721371543157	11.0739432171695	0.000276201620592608	0.00702563697365215	-0.368324801279833	-0.150179615747778
SPC24	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.579646499598	-0.579646499598	-0.149070527407136	-0.1187166368295	8.99033854504411	13.7824215861132	3.87959627825569e-07	1.68185677735086e-05	0.327702957862374	0.533448986519353
SPC24	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.371695745896	-0.371695745896	-0.962582566010851	-0.892479910689	-8.86856282270724	6.94393294956224	4.92428622301258e-05	0.00148776056088534	-0.748693170632117	-0.433080469597585
SPC24	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-2.89064678047	-2.89064678047	-2.19920330294699	-2.035043186635	6.74259823963191	172.693603752842	2.2428004659035e-10	1.42937014884517e-08	0.489033616501843	0.89385333854418
SPC24	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.253152820307	0.253152820307	-0.468061121439932	-0.217946401079	-7.42255050108697	16.3970788535073	1.24412578824965e-06	5.00661351989784e-05	-0.926790404523879	-0.515637478969984
SPC24	BRD-K80431395-001-07-3::2.48737::HTS002	2.48737	triciribine	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.69778942506	-1.69778942506	-0.929339840651265	-0.71098807564	9.11640777411343	5.0897390648759	0.000242162626348715	0.00627220224080891	0.552911530144967	0.983987638672502
SPC24	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.71548833162	-0.71548833162	-1.28952572128923	-1.24885809452	-9.46932140194278	193.016779237468	1.02585342614361e-17	1.38109383776341e-15	-0.693601554585547	-0.454473224752913
SPC24	BRD-K82967180-001-01-6::2.5::MTS006	2.5	LY3023414	PI3K inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-4.350815691245	-4.350815691245	-3.36680771666958	-3.47125881494	13.218977869035	8.98721790990808	3.41068709819427e-07	1.48881701643356e-05	0.815578660300962	1.15243728884988
SPC24	BRD-K84663978-003-02-9::2.5::HTS002	2.5	trequinsin	phosphodiesterase inhibitor	noncancer	PDE5A	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.2201218874665	-0.2201218874665	-0.0432829578483638	-0.0536519890124	6.00183669468285	12.0893414118086	6.01005317363757e-05	0.00178559562885024	0.112694671387335	0.240983187848937
SPC24	BRD-K85406984-001-01-0::0.15625::HTS002	0.15625	sobetirome	thyroid hormone receptor agonist	noncancer	THRA, THRB	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.51792754148	0.51792754148	0.235785786995522	0.238622249408	-9.45907779466011	59.8339569130291	1.7264933428117e-13	1.54762689950434e-11	-0.34180927848169	-0.222474230487266
SPC24	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.3054358484035	0.3054358484035	0.0325355039620381	0.0430886024597	-9.69383671632007	35.0895284848654	1.85062223450312e-11	1.33819842408509e-09	-0.330046616209888	-0.215754072673036
SPC24	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-5.40074774434	-5.40074774434	-4.83602070762455	-4.95161811894	5.60380989004364	26.9592365364081	6.07702236244855e-06	0.000218134671901061	0.357938052924505	0.771516020506405
SPC24	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.243271122995	-1.243271122995	-2.24344397675294	-2.18551801488	-13.5460837379527	22.4854849951348	2.6879354029774e-12	2.14323849324681e-10	-1.15310546987545	-0.847240237640433
SPC24	BRD-K88807631-001-01-3::2.5::MTS006	2.5	elacridar	P glycoprotein inhibitor	targeted cancer	ABCB1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.406921037521	0.406921037521	0.150349973366778	0.185599499868	-13.0014601502958	190.291702984851	4.52569432838093e-28	1.53236578152852e-25	-0.295496590697362	-0.217645537611082
SPC24	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	0.36304799094	0.36304799094	0.100313964229967	0.1180798290625	-7.88580778109317	3.84199168031813	0.00164985903049593	0.0340897171644811	-0.356757611814746	-0.168710441605319
SPC24	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.0486653160207	-0.0486653160207	0.16977979160212	0.182655209923	7.50486953030334	3.65350564682614	0.00239866363882865	0.0468559222608919	0.134516510145114	0.302373705100526
SPC24	BRD-K92428232-001-10-6::2.5::HTS002	2.5	GSK461364	PLK inhibitor	targeted cancer	PLK1	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-4.84351361044	-4.84351361044	-2.67653033259307	-2.35101835033	18.3716124184641	193.150604359677	2.92440175413962e-44	4.41397256030276e-41	1.93434236227322	2.39962419342065
SPC24	BRD-K93441486-067-12-8::2.5::HTS002	2.5	diphemanil	acetylcholine receptor antagonist	noncancer	CHRM3	neurology/psychiatry	spasms	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.00589071191509	-0.00589071191509	0.134858705620273	0.150302134	5.59203029192724	191.02184295585	7.67858415925967e-08	3.66616900037862e-06	0.091103285581063	0.190395549489664
SPC24	BRD-K95581532-001-01-5::2.5::HTS002	2.5	RN-1734	TRPV antagonist	noncancer	TRPV4	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-3.95667180269	-3.95667180269	-2.40087015595681	-2.34576789044	18.2124262149035	120.017205157839	2.42824330800763e-36	1.81973062923765e-33	1.38666578033359	1.7249375131328
SPC24	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-1.157276983625	-1.157276983625	-1.75597440681461	-1.69551344644	-9.31091980509283	187.126330850642	3.47896980518622e-17	4.42518765208165e-15	-0.725544589515025	-0.471850256864191
SPC24	BRD-K99604664-001-01-1::2.5::HTS002	2.5	tanaproget	progesterone receptor agonist	noncancer	PGR	NA	NA	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.575739942377	-0.575739942377	-0.863495791914424	-0.791872957089	-6.50103749992593	190.318725040081	6.82956608453449e-10	4.13378726159896e-08	-0.375065056731944	-0.200446642342904
SPC24	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	CAOV3, OVCAR8	OVARY	carcinoma (adenocarcinoma), carcinoma	-0.2950049254355	-0.2950049254355	-0.621815130019744	-0.6228392960495	-6.25875019181557	65.1459013912241	3.43243590291067e-08	1.71365142006741e-06	-0.431089384639588	-0.222531024528901
STARD3	BRD-A27376179-001-01-3::2.5::HTS002	2.5	lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	targeted cancer	FLT3, NTRK1	NA	NA	HCC1419, MKN7, NCIH2170	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.45657893373333	-2.50064307591	-2.92047777079956	-2.89462322225	-3.75630819417752	13.4221316050259	0.0022765293604175	0.0448296822205919	-0.729850889953937	-0.197946784178524
STARD3	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.09619597207845	-0.1694875570434	-1.04534766024779	-0.806876903601	-5.81115905160291	5.21399037733379	0.00184978712474061	0.0375296312626402	-1.36388114389066	-0.534422232448021
STARD3	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.59310607606075	0.6088434918175	0.352476266169153	0.3582199630325	-5.40037252419714	5.51580763126148	0.00217081063927477	0.0430126350656487	-0.352021895776045	-0.129237724007148
STARD3	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.0122056563675	-1.911522103645	-3.09545061917543	-3.13670117965	-5.86287389359652	5.50810243133212	0.00147007297877428	0.0308998853735648	-1.54531452487744	-0.621175400738418
STARD3	BRD-K12932420-001-02-3::2.5::HTS002	2.5	YM-976	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.53742514065875	0.530288891145	0.308150187468348	0.324728973755	-4.84687170761374	12.1836039955476	0.000383414286520596	0.00945539070482945	-0.332168857616094	-0.12638104876471
STARD3	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.76664921377	-1.696655172275	-2.88639724197233	-2.664027353575	-6.24876180597779	12.0482119487885	4.18672930018266e-05	0.00128264365948949	-1.51000758772086	-0.729488468683798
STARD3	BRD-K21680192-300-14-4::2.5::HTS002	2.5	mitoxantrone	topoisomerase inhibitor	chemo	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-5.43451536116	-5.47762012578	-4.70534477005125	-4.72423487691	4.69341296440159	24.3637157123933	8.74744181812471e-05	0.00251048534739803	0.408775575407379	1.04956560681012
STARD3	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.3486267303685	0.3639965252345	-0.193677621574081	-0.0712585443276	-6.40519816448849	5.43997744756506	0.00100010557614521	0.0221277617455999	-0.754756603503443	-0.329852100381719
STARD3	BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.402334404391	0.39970198062	-0.0837196180471799	-0.06418952050595	-14.1796589987344	65.2766233200744	1.31944175165461e-21	2.49359257834855e-19	-0.554506933457067	-0.417601111419293
STARD3	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.7037481974325	-1.69377166566	-0.263531568753732	-0.144417226424	7.60581147424064	3.59738092298361	0.00242992605020274	0.0473974900267476	0.890437290573708	1.98999596678383
STARD3	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.23109873523125	-0.275023552811	-0.903261751524858	-0.870699604194	-7.31599741178507	9.03342685015977	4.40026260950026e-05	0.00134230555768799	-0.879883310062837	-0.464442722524378
STARD3	BRD-K53417444-003-03-1::2.5::HTS002	2.5	OTS167	maternal embryonic leucine zipper kinase inhibitor	targeted cancer	MELK	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-5.15002603317	-5.188305810125	-5.93963264969296	-5.99382627805	-6.12149131292881	5.69048948553413	0.00105704396693	0.0231817432096736	-1.10944039545018	-0.469772837595746
STARD3	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.03053401093475	-0.985011292104	-2.02917069565923	-2.25782217809	-7.03827964642757	7.47713079115801	0.000149989077150196	0.00408683052587394	-1.32985319880128	-0.667420170647674
STARD3	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.209530904982	-0.224702391255	-1.09650312424374	-0.4202572111255	-4.75024172479686	7.67834772513865	0.00161734712958577	0.0335278453367819	-1.32071269622689	-0.45323174229659
STARD3	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.877407223845	-3.04947150685	-0.482850342203483	-0.394866165707	9.44500184084215	3.39845134996788	0.0014820473122377	0.031111235884877	1.6386859587836	3.15042780449943
STARD3	BRD-K70402238-001-02-8::2.5::HTS002	2.5	nexturastat-a	HDAC inhibitor	targeted cancer	HDAC1, HDAC6	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4445377907615	0.455908742358	0.097424723566306	0.0794720535849	-5.12387492438466	6.11632686926009	0.00204924316443378	0.0409598282374267	-0.512116049681717	-0.182110084708671
STARD3	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.270012208185	-1.269807158695	-0.405328567498439	-0.282407127235	12.4888764673771	20.26127433412	5.62773099847234e-11	3.82673209762556e-09	0.720378542293238	1.00898873907988
STARD3	BRD-K93123848-001-04-1::2.5::HTS002	2.5	RAF265	RAF inhibitor, VEGFR inhibitor	targeted cancer	BRAF	NA	NA	HCC1419, MKN7, NCIH2170, BT474	BREAST, STOMACH, LUNG	carcinoma (ductal_carcinoma), carcinoma (tubular_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.189908728280408	-0.1995377923335	-1.31077031477625	-1.19686473631	-10.9243678989672	7.4819564027886	7.2857882587545e-06	0.000257215567733585	-1.36034420799927	-0.881378964992408
STAU1	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.1872184817395	-0.1872184817395	-0.955147425886018	-0.8814928301585	-11.878638529419	54.14824299021	1.04777200468525e-16	1.27450582288414e-14	-0.897532038272531	-0.638325850020504
STAU1	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.1600798938095	-0.1600798938095	-1.22305686283092	-1.12011346307	-15.6462949054784	193.965237585382	3.1674883852442e-36	2.30913135415308e-33	-1.19696890352595	-0.92898503451689
STAU1	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.115433887218	0.115433887218	0.25380634258769	0.256070233499	5.22989597275544	188.961073674399	4.47470950373164e-07	1.92312013881151e-05	0.0861815153795515	0.190563395359828
STAU1	BRD-A20239487-001-24-9::2.5::HTS002	2.5	atenolol-(+/-)	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.3110199378165	0.3110199378165	0.198081798037146	0.207866793196	-4.45609457493911	104.293161753867	2.10595937229221e-05	0.000683063205665885	-0.163195861321916	-0.0626804182367925
STAU1	BRD-A24514565-001-09-7::2.5::HTS002	2.5	warfarin	vitamin K antagonist	noncancer	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.05301750440235	0.05301750440235	-0.125020164225705	-0.09418085429645	-4.20288015965141	10.5067045707977	0.00163363971988761	0.0337969466721806	-0.271810189231158	-0.0842651480249516
STAU1	BRD-A50064262-001-04-7::2.5::HTS002	2.5	flumethasone-pivalate	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.370223896821	0.370223896821	-0.016344189835087	0.03331372318045	-6.9350139736592	13.2498596465826	9.30295280619986e-06	0.000322375516895717	-0.506759844164076	-0.266376329148098
STAU1	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-1.04767738638	-1.04767738638	-0.212694310782596	-0.08022384013305	12.1561596200367	8.11785396350913	1.71405053197936e-06	6.73827469678292e-05	0.676987492486195	0.992978658708613
STAU1	BRD-A72703248-003-04-9::2.5::HTS002	2.5	SKF-96365	calcium channel blocker	noncancer	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-2.949603246795	-2.949603246795	-3.54710340299809	-3.55274052264	-5.15474264413542	84.7454116034935	1.63727888721485e-06	6.46254781985032e-05	-0.827975660197183	-0.367024652208988
STAU1	BRD-A73427433-240-01-3::2.5::HTS002	2.5	adaprev	TGF beta receptor inhibitor	noncancer	IGF2R, M6PR	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.5852256092035	-0.5852256092035	-0.393007253839211	-0.3772229678335	4.2992735441342	11.82309254591	0.00106826216808698	0.0233966444128258	0.094642825046485	0.289793885682094
STAU1	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.6530720696425	0.6530720696425	0.205352506971884	0.236646785158	-7.62691563448515	3.86241737986073	0.00182497350195182	0.0370999474248156	-0.613019393732663	-0.28241973160857
STAU1	BRD-A88138582-001-04-8::2.5::HTS002	2.5	halcinonide	glucocorticoid receptor agonist	noncancer	NR3C1	dermatology	corticosteroid-responsive dermatoses	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.647653529635	0.647653529635	0.280281252342293	0.260075782914	-8.42481542506834	7.65236747479769	3.9091141267003e-05	0.00120326945520831	-0.468728539463279	-0.266016015122135
STAU1	BRD-A98299281-050-09-6::2.5::HTS002	2.5	hydroxytacrine-maleate-(r,s)	cholinesterase inhibitor	noncancer	ACHE	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.0491034356422	-0.0491034356422	-0.25158251093682	-0.147378080883	-4.46327066207582	183.759087443749	1.40505526793935e-05	0.000471495167877019	-0.29198353826577	-0.11297461232347
STAU1	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.545495209793	0.545495209793	-0.347596061856779	-0.229059189804	-18.5449847606671	15.4765029485672	5.48134294522246e-12	4.21532383245994e-10	-0.995463262599238	-0.790719280700321
STAU1	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.0103517633383	0.0103517633383	-0.359335041185521	-0.164030729397	-5.29500971068765	18.3162851091711	4.65293802474528e-05	0.0014111497861973	-0.516187560089829	-0.223186048957814
STAU1	BRD-K07762753-001-04-4::2.5::HTS002	2.5	aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK6	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.357839051544	-0.357839051544	-0.85384860204513	-0.70967469814	-8.91487588554494	49.4017866804409	7.35344218171442e-12	5.58488982765652e-10	-0.607796131456633	-0.384222969545628
STAU1	BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.867412648264	0.867412648264	-0.487005561997136	-0.373418715101	-12.7176440333691	8.80698690428463	5.74406173884973e-07	2.43015990609144e-05	-1.59614326928567	-1.1126931512366
STAU1	BRD-K17472821-001-01-2::2.5::MTS006	2.5	GSK2830371	protein phosphatase inhibitor	targeted cancer	PPM1D	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.4987150048575	0.4987150048575	0.210998375222195	0.222894017996	-12.1267960195985	7.21376012767039	4.65965206461961e-06	0.000171068613798879	-0.343483722871988	-0.231949536398623
STAU1	BRD-K17610631-001-03-3::2.5::MTS006	2.5	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.7194033225205	-0.7194033225205	-1.13439028094571	-0.889953286616	-4.43196203331658	183.727255732305	1.60265406249661e-05	0.00053271594689956	-0.599725147707412	-0.230248769143002
STAU1	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.6603575823555	-0.6603575823555	-0.190675339880768	-0.144534319806	9.44109434914776	193.848364909577	1.20059299464473e-17	1.60026054694782e-15	0.371563999886612	0.567800485062852
STAU1	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.5651733757475	0.5651733757475	-0.383015630570076	-0.173057746988	-11.1060747145159	14.2709000853305	2.06544510260038e-08	1.06083101700272e-06	-1.13097612456099	-0.765401888074166
STAU1	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.624346834896	-0.624346834896	-3.15768138093673	-3.22475555586	-15.9971032300688	4.55475018273659	3.54587894091993e-05	0.00110062952574718	-2.95268272034311	-2.11398637173836
STAU1	BRD-K25279140-001-01-5::2.5::HTS002	2.5	MK-8745	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.13673227152495	-0.13673227152495	-1.58867095205343	-1.48579667397	-16.5272653548897	27.7116750389459	7.00882703717853e-16	7.90628889500756e-14	-1.631977920178	-1.27189944087897
STAU1	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.1050911516705	0.1050911516705	-0.0538064665527281	-0.030411088067	-8.81512048253012	188.50327002473	7.88758965619776e-16	8.85099059383879e-14	-0.194455383171973	-0.123339853274483
STAU1	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.1597480258675	0.1597480258675	-0.185899078420426	-0.06456986921455	-7.55938433662856	53.6207889291508	5.30603948312936e-10	3.24925181822752e-08	-0.437333536284752	-0.2539606722911
STAU1	BRD-K30480208-001-18-5::2.5::HTS002	2.5	torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	noncancer	SLC12A1	cardiology	edema, congestive heart failure, hypertension	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.543545415598	0.543545415598	0.0233480322040962	0.129954580002	-9.64435418207405	35.5996933845394	1.81869632195961e-11	1.31555640900871e-09	-0.629631488254551	-0.410763278533257
STAU1	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-1.611586151545	-1.611586151545	-2.58552911373796	-2.555934411265	-9.36296845180133	13.1889048546394	3.41769284121093e-07	1.49157134792079e-05	-1.19833936737902	-0.749546557006903
STAU1	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.1005882028211	-0.1005882028211	-1.34855001325927	-1.265409369745	-19.7376324766938	39.0243300297135	6.55481473128576e-22	1.27949625368101e-19	-1.37584901824657	-1.12007460262977
STAU1	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.014372608763525	-0.014372608763525	-0.276438731795987	-0.153671266635	-4.61609237016725	33.6283909767494	5.48794401911466e-05	0.00164208509517357	-0.377488272382265	-0.14664397368266
STAU1	BRD-K37865504-001-04-1::2.5::HTS002	2.5	LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	noncancer	FAAH	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.04897003555808	-0.04897003555808	-1.30295574296712	-1.08170547456	-13.5017540195951	13.6407142028638	2.79967108202728e-09	1.58911732876013e-07	-1.45367776434241	-1.05429365047566
STAU1	BRD-K43457670-001-27-8::2.5::HTS002	2.5	acetazolamide	carbonic anhydrase inhibitor	noncancer	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.1523519213575	-0.1523519213575	0.263317417735975	0.242495378939	11.2570560059239	3.37899648670693	0.000852587394954401	0.0192453084542582	0.305272541568528	0.526066136618423
STAU1	BRD-K44827188-001-06-0::2.5::MTS010::PROS003_PR500	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.2506287607045	0.2506287607045	0.0348001941463504	0.0567242940999	-10.2610556111607	187.462842011311	6.88635821236161e-20	1.12239260022605e-17	-0.257321847629681	-0.174335285486618
STAU1	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-3.78145152475	-3.78145152475	-1.30409115658098	-1.04970341453	27.9687240335057	129.022093882264	1.2868906906639e-56	5.51635989678605e-53	2.30211067819513	2.65261005814291
STAU1	BRD-K45462423-001-03-7::2.5::HTS002	2.5	VU0361737	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.16166703811	-0.16166703811	0.0845000978945633	0.109184936724	5.81036125805603	13.7726262642621	4.82509864908801e-05	0.00145964512118615	0.155158180228741	0.337176091780385
STAU1	BRD-K47557313-001-02-7::2.5::HTS002	2.5	LY2109761	TGF beta receptor inhibitor	targeted cancer	TGFBR1, TGFBR2	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.018507163415325	-0.018507163415325	0.259534412137736	0.276216738452	6.61653790380986	16.4391438836081	5.17118530837776e-06	0.000187931581190261	0.189151474428622	0.366931676677501
STAU1	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.260567279253	0.260567279253	-0.242230932540371	-0.10314419939105	-6.9561540636076	5.64003139882678	0.000571811950189307	0.0135032925817677	-0.682436276356973	-0.323160147229769
STAU1	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-2.096665340285	-2.096665340285	-1.2870258566128	-1.034969229585	7.47775404935531	4.88209611446159	0.000749345589190552	0.0171734913158278	0.529280751710478	1.08999821563392
STAU1	BRD-K58435339-001-03-0::2.5::HTS002	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-5.91317081714	-5.91317081714	-4.66707686035987	-4.69893624844	13.3437666088891	189.927855783345	4.36383643775606e-29	1.6466491194856e-26	1.06189098743895	1.4302969261213
STAU1	BRD-K62200014-003-10-5::2.5::HTS002	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.381577648083	0.381577648083	-0.0849306284555632	0.0371962455536	-7.2150841801142	9.87663838516353	3.07072216088213e-05	0.000964166012862994	-0.610818127394751	-0.322198425682375
STAU1	BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.9114297710555	0.9114297710555	-0.729940680371799	-0.5340799664045	-10.7145552106876	2.92700345838139	0.00193815314333567	0.039026523022836	-2.1358426004494	-1.1468983024052
STAU1	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.9548148823845	-0.9548148823845	-1.17895492075469	-1.01733335597	-3.70203599375632	36.2771003588199	0.000706820997665446	0.0163052672057515	-0.346898578121612	-0.101381498618767
STAU1	BRD-K72420232-001-12-3::2.5::HTS002	2.5	WZ-4002	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.4568105994015	-0.4568105994015	-0.0684515764610727	0.037173334974	6.32911733999484	5.79011363718239	0.000835353127872096	0.0189060613034528	0.236885597795441	0.539832448085413
STAU1	BRD-K73319509-001-08-0::2.5::HTS002	2.5	PF-04217903	c-Met inhibitor	targeted cancer	MET	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.6807679808165	-0.6807679808165	0.0539951952385232	0.0909616793379	20.7112928727678	31.9948484256276	4.23103185522054e-20	7.09017065283474e-18	0.662499552864073	0.807026799245973
STAU1	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.3166209860695	-0.3166209860695	0.0255809260380088	0.0294162092714	12.2278975640554	96.4974972816897	2.5296517442407e-21	4.69011876030593e-19	0.286655099272315	0.397748724942702
STAU1	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.1501678806732	-0.1501678806732	-0.951634064831159	-0.8151847008705	-9.60279784177994	5.09657936377199	0.000186819278304844	0.004974011068298	-1.01479431679222	-0.588138051523695
STAU1	BRD-K81405859-300-01-4::2.5::MTS006	2.5	JTE-607	cytokine production inhibitor	noncancer	IL10, IL1B, IL6, TNF	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.3395949484815	-0.3395949484815	-0.778045037682027	-0.670066066219	-8.9662960730275	190.038111913324	2.89410560722001e-16	3.39885348323209e-14	-0.534906199793783	-0.341993978607272
STAU1	BRD-K81548480-001-01-2::2.5::HTS002	2.5	AC-264613	PAR agonist	noncancer	F2RL1	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.00101516916235	-0.00101516916235	-0.373304058831944	-0.2564995934565	-6.04844994480409	6.95898022486419	0.000528575099152327	0.0125856063975005	-0.51800826520447	-0.226569514134719
STAU1	BRD-K82823804-001-04-1::2.5::HTS002	2.5	PD-407824	PKC inhibitor	targeted cancer	WEE1	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	0.79629442765	0.79629442765	-0.514986544516854	-0.3823931691785	-14.5925252344674	3.24228434454861	0.000455635173082245	0.011039546802119	-1.58553752576539	-1.03702441856832
STAU1	BRD-K87696786-003-04-4::2.5::HTS002	2.5	LY456236	glutamate receptor antagonist	noncancer	GRM1	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-1.2726488863	-1.2726488863	-2.19774502735465	-2.03818987744	-9.62700526720289	109.838061421364	2.84008925077058e-16	3.33907563921233e-14	-1.11553474817269	-0.734657533936613
STAU1	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.4486721010675	-0.4486721010675	0.0101983057749568	0.0499653436317	13.8812453524724	112.251611466112	4.106745196389e-26	1.14907910077919e-23	0.393374076081955	0.524366737602958
STAU1	BRD-K89299012-001-06-0::2.5::HTS002	2.5	DCEBIO	potassium channel activator	noncancer	KCNN2, KCNN3, KCNN4	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-1.0073485202035	-1.0073485202035	-2.05408472670938	-1.8672769967	-11.3227303302121	91.4317139934164	4.30620977485156e-19	6.54571372222808e-17	-1.23035628509075	-0.863116127921014
STAU1	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-0.4076652515805	-0.4076652515805	-1.42803711834981	-1.12582537284	-11.0514919571439	114.053098739169	9.61986667138513e-20	1.55023789760248e-17	-1.20327375212472	-0.837469981413886
STAU1	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-3.43046141582	-3.43046141582	-4.64168534073056	-4.64147020308	-12.0768919626435	30.353540255088	4.0124849871674e-13	3.47151383000255e-11	-1.41594892002636	-1.00649892979476
STAU1	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	NCIH596, BT474	LUNG, BREAST	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (ductal_carcinoma)	-1.13535834119	-1.13535834119	-0.714372553105914	-0.590290062749	5.49360054214918	6.18847520494185	0.00137687799404491	0.0291749761330352	0.234849612681592	0.607121963486579
STK24	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.123399526684	-0.123399526684	0.180326128536955	0.215520353965	9.26256680006195	9.4426754415628	4.81522916895697e-06	0.000175982242051557	0.230074755746256	0.377376554695655
STK24	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.115267479635	-1.115267479635	-0.82585697501071	-0.696430068405	4.50698195743976	43.4070721822179	4.9212227290271e-05	0.00148704461622677	0.159946116547878	0.418874892700702
STK24	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.51649691064	0.51649691064	-0.0565228072157892	0.106263594851	-9.84227899691717	35.0577329911885	1.26058295889628e-11	9.31974767151708e-10	-0.691206104925329	-0.45483333078625
STK24	BRD-A26503646-001-16-6::2.5::HTS002	2.5	formestane	aromatase inhibitor	targeted cancer	CYP19A1	oncology	breast cancer	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.114496628476	-0.114496628476	0.144410815731342	0.129884484973	6.76956824451924	45.9672781560157	2.02770508602517e-08	1.04294697236066e-06	0.181921195227924	0.335893693186761
STK24	BRD-A31095847-001-02-3::2.5::HTS002	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.547701597143	0.547701597143	0.0221473007157643	0.0703858703435	-13.3712587577548	10.4132013196897	6.85650193446357e-08	3.29421027373154e-06	-0.612662024621949	-0.438446568232522
STK24	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3902233663985	0.3902233663985	0.205883355809962	0.2241591843385	-5.79508346249779	187.804074964661	2.83797920977486e-08	1.43052974142012e-06	-0.247090292198879	-0.121589728978197
STK24	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.1841590673045	0.1841590673045	0.0743284029367507	0.128125201883	-3.76075416788314	174.265696403978	0.000231067676729915	0.00601025535022403	-0.167470573261344	-0.0521907554741542
STK24	BRD-A68631409-001-05-4::2.5::HTS002	2.5	evodiamine	ATPase inhibitor, TRPV agonist	targeted cancer	TRPV1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.66018967167	-1.66018967167	-2.38458898357517	-2.305746334225	-6.10064705274485	5.19614369800594	0.00149475864457525	0.0313473704044196	-1.02620056792457	-0.422598055885772
STK24	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3048733406005	0.3048733406005	0.142403390995274	0.135666555282	-5.05607852857046	8.97425118069789	0.000690728852172265	0.0159684202521011	-0.235192983339005	-0.0897469158714468
STK24	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.793150961636	0.793150961636	0.40892895380156	0.462027349437	-9.83920838808531	9.73813732850446	2.26164115564428e-06	8.7497344268607e-05	-0.4715492278038	-0.296894787865079
STK24	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.2004909839285	0.2004909839285	-0.0524816047020122	-0.0230394948173	-7.18145298483155	13.7919577888127	5.11522704024839e-06	0.00018604131958415	-0.328631521645429	-0.177313655615595
STK24	BRD-A95696066-003-13-8::2.5::HTS002	2.5	nisoxetine	norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.66863368187	0.66863368187	0.334969446087359	0.334888037039	-13.6766892667013	15.688806270936	3.9336526470448e-10	2.44304792288747e-08	-0.385466142185677	-0.281862329379605
STK24	BRD-K09900591-001-26-7::2.5::HTS002	2.5	caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	noncancer	ALOX5, MIF	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.6121011005765	0.6121011005765	-0.0605430210047226	-0.0732110977947	-20.9067216232174	142.152033868065	3.31849461934522e-45	5.34774160353115e-42	-0.736244627515413	-0.609043615647033
STK24	BRD-K13314656-001-01-0::2.5::HTS002	2.5	ebastine	histamine receptor antagonist	noncancer	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.917727531067	0.917727531067	0.33342964571326	0.34680571662	-12.0604321655199	2.88374402252426	0.00147919596530643	0.0310605067157991	-0.74205618791181	-0.42653958279567
STK24	BRD-K14880289-001-02-2::2.5::HTS002	2.5	GW-501516	PPAR receptor agonist	noncancer	PPARA, PPARD	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.588118630109	0.588118630109	0.296605993019644	0.308945987709	-11.5713961099758	41.1111013108809	1.64411827837066e-14	1.63366818027308e-12	-0.342385789712507	-0.240639484466205
STK24	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.1171222948269	0.1171222948269	0.310670876743695	0.322928237233	5.11350875009118	7.16987969628439	0.00128135891087993	0.0274589722021867	0.104474600403147	0.282622563430443
STK24	BRD-K18961567-001-01-1::2.5::HTS002	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.439528649245	-1.439528649245	-0.869326915218106	-0.775615128041	6.75344666745198	11.997027779991	2.03638945544161e-05	0.000662302451586259	0.386236856167307	0.754166611886481
STK24	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.278003891995	0.278003891995	-0.829262688678126	-0.81565114113	-14.7622016575062	9.53156787304875	6.96125363881334e-08	3.34154206305313e-06	-1.2755123480477	-0.939020813298555
STK24	BRD-K19412355-001-01-0::2.5::HTS002	2.5	SB-242235	p38 MAPK inhibitor	noncancer	HSPB1, MAPK14	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3741130590575	0.3741130590575	0.111005274965412	0.111624443211	-6.87281844171261	10.4298140968591	3.51148320017046e-05	0.00109121746093858	-0.347932139284484	-0.178283428899691
STK24	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.1903268538125	-0.1903268538125	0.102494136373338	0.137732029225	11.0779461655599	11.3934191950689	1.90655769436602e-07	8.63000219801004e-06	0.234886982256357	0.350754998115319
STK24	BRD-K25412176-001-01-9::2.5::MTS006	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.0453878977614	-0.0453878977614	-0.669027038708254	-0.516853765181	-11.4591972538036	188.845895292889	2.02479962046267e-23	4.50647225186026e-21	-0.730993429563428	-0.51628485233028
STK24	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.00349556442315	-0.00349556442315	-1.0471512695619	-0.8676646214495	-13.3675630512232	62.3759777546483	5.67856215290538e-20	9.36936526304894e-18	-1.19970418658714	-0.887607223690363
STK24	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.1647204994705	-0.1647204994705	-0.74838799379221	-0.6332790164525	-8.48499306509574	7.62549090549249	3.79775907642615e-05	0.0011725293936781	-0.743659732292107	-0.423675256351314
STK24	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.5740823357875	-0.5740823357875	-0.93639932365083	-0.797793160199	-5.07298205668123	101.756089625903	1.76751351501157e-06	6.93318821667121e-05	-0.503984097324041	-0.220649878402619
STK24	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.2681502925255	-0.2681502925255	-0.615820732158815	-0.480230640816	-4.87757562475836	16.2446652854119	0.000160714026609025	0.00435690318860179	-0.498591167060635	-0.196749712205996
STK24	BRD-K32821942-001-21-3::2.5::HTS002	2.5	azathioprine	dehydrogenase inhibitor	noncancer	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.3577110034275	-0.3577110034275	-0.641007956823684	-0.577859685861	-6.65854417312266	188.915557706355	2.92593213585013e-10	1.84336304745627e-08	-0.367223975765748	-0.199369931026619
STK24	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.519740267715	-1.519740267715	-1.97338023300129	-2.04775511057	-5.8010833416521	13.0625091575044	6.04813271250436e-05	0.00179616216729714	-0.622496881061781	-0.284783049510808
STK24	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	1.02400808102	1.02400808102	0.569767647157913	0.566004994618	-14.1165588198133	155.283636733318	1.22749979396857e-29	4.81847625167565e-27	-0.517803220221098	-0.390677647503075
STK24	BRD-K36788280-001-01-2::2.5::HTS002	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.34070887873	-1.34070887873	-1.06262456896046	-0.990767487764	3.92407582268852	184.355483537813	0.000122798852645102	0.00341322205791364	0.138271311642366	0.417897307896707
STK24	BRD-K37723606-001-01-5::2.5::HTS002	2.5	dioscin	apoptosis stimulant	targeted cancer	CXCR3	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.4131107839755	-0.4131107839755	-1.01235131937601	-0.8558575413485	-7.67710433860076	67.0250427860598	9.17508682090107e-11	6.1171487140526e-09	-0.755038978042207	-0.443442092758805
STK24	BRD-K39841531-001-02-1::2.5::HTS002	2.5	TG-101209	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.164187483785	-0.164187483785	-1.0229815575728	-1.03228700688	-9.78290484479939	4.29949438374634	0.000425428002827549	0.0103792326030763	-1.09597291641896	-0.621615231156638
STK24	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.1027252863026	0.1027252863026	-0.517859287230187	-0.465030888818	-8.81622129461415	3.44265557603679	0.00176106574512733	0.0359988040140577	-0.82915547860352	-0.412013668462054
STK24	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.02293944221852	0.02293944221852	-1.29894249559775	-1.33795379646	-15.6063470766056	40.5230897799115	9.79826951295518e-19	1.43544313495706e-16	-1.49300136695866	-1.15076250867388
STK24	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.428141358405	-1.428141358405	-2.29707132160865	-2.14029239454	-8.2013819336055	7.7306633029248	4.44737947661283e-05	0.0013545579022921	-1.11473889274021	-0.623121033667087
STK24	BRD-K43187018-001-03-3::2.52451::HTS002	2.52451	GDC-0349	Pim kinase inhibitor	targeted cancer	PIK3CA	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-2.48709019855	-2.48709019855	-3.24392058888218	-3.15387343916	-10.5112633340322	73.2571181769381	2.79674342715797e-16	3.29016248277399e-14	-0.900321382881534	-0.613339397782824
STK24	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.0107673580525	-1.0107673580525	-1.74749213581305	-1.65992199057	-7.3709835457484	5.40975074057074	0.000511519009179965	0.0122304058142049	-0.98790829060174	-0.485541264919368
STK24	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-5.05272315566	-5.05272315566	-3.73903326302287	-3.638458649165	9.43751878025476	4.73187923309802	0.000302337942104414	0.00762799161781012	0.949683218052797	1.67769656722147
STK24	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.1863125274575	-0.1863125274575	-0.698754722368124	-0.636668754802	-8.14062135388222	7.45015182986067	5.7729687499019e-05	0.00171992579816197	-0.659488463725187	-0.36539592609606
STK24	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-6.085802445425	-6.085802445425	-5.27195281230106	-5.30447708423	9.8964914277315	126.912257114092	1.8338763764981e-17	2.39520347287302e-15	0.651117995000752	0.976581271247121
STK24	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.08806370842815	0.08806370842815	-0.298063574704193	-0.290098649131	-7.37272683085872	11.4462425000222	1.12420433223293e-05	0.000383433466459504	-0.500852199001524	-0.271402367263162
STK24	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.06293933119585	-0.06293933119585	-0.324760684870016	-0.2394985033815	-5.2578730919735	71.9386044925861	1.43300106539007e-06	5.71198968465667e-05	-0.361089428565103	-0.162553278783228
STK24	BRD-K51967704-001-03-6::2.5::MTS010::PROS004_PR500	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.6084228348865	-0.6084228348865	-1.39309187673078	-1.39474896106	-8.36918260371273	18.1606337530653	1.19864869539796e-07	5.59462491803025e-06	-0.981520274356427	-0.587817809332134
STK24	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3873759696045	0.3873759696045	0.256376859267496	0.250850268444	-4.05434846092767	36.9205014848054	0.000249065835341361	0.00642847199215781	-0.196471702511558	-0.06552651816245
STK24	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.5738631282255	0.5738631282255	0.300274980758507	0.2999355775105	-11.9929344608399	58.6606448496082	2.02241742136576e-17	2.62704668790244e-15	-0.319241268711898	-0.227935026222087
STK24	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.02139093394145	0.02139093394145	-0.51304278301805	-0.339269333107	-8.98349126318908	175.109307683839	4.09666800023617e-16	4.74870068049009e-14	-0.651844691012087	-0.417022742906914
STK24	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-2.696876691325	-2.696876691325	-3.15591936592811	-3.19197499768	-4.23681790490548	25.6870589808324	0.000256808141309668	0.00659652829802971	-0.681883388655055	-0.236201960551159
STK24	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.0941765702112	-0.0941765702112	0.0387755512500576	0.0957301689988	3.96878655415656	24.3927206347483	0.000556547983911576	0.0131820502645358	0.0638715368418811	0.202032706080634
STK24	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.7855472069235	-0.7855472069235	-0.244277997003892	-0.116969809946	9.51225414986764	41.1746784738644	5.97232380894913e-12	4.57321253893626e-10	0.426367472517582	0.656170947321634
STK24	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-4.83730182247	-4.83730182247	-3.98240495759231	-4.06345371982	7.02261266735354	13.9610808434167	6.12126408920048e-06	0.000219575633635857	0.593733227680101	1.11606050207527
STK24	BRD-K62814476-001-03-3::2.5::HTS002	2.5	BMS-265246	CDK inhibitor	targeted cancer	CDK1, CDK2	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-1.3394504488	-1.3394504488	-2.54936547927998	-2.46335728498	-9.93774977810741	3.73996504574331	0.000800346120316489	0.0181963916008606	-1.55741943490828	-0.862410626051688
STK24	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.470673992847	-0.470673992847	-0.167758723278198	-0.0695637223616	6.08661828789712	175.472446670431	7.06136995424707e-09	3.8257238648226e-07	0.204695516738639	0.401135022398965
STK24	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.380364175145	0.380364175145	-0.222754530549857	-0.209793035138	-11.0251743294025	43.33127949206	3.71148347684475e-14	3.57033751763921e-12	-0.713415005240282	-0.492822406149432
STK24	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.06745134554505	0.06745134554505	-1.0900138692572	-0.4202572111255	-9.7610189164071	86.3765177628954	1.3334136538592e-15	1.46709042617038e-13	-1.39318052621651	-0.921749903387999
STK24	BRD-K66175015-001-09-0::2.5::HTS002	2.5	afatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.4301082427465	-0.4301082427465	-0.916358987956248	-0.7732511578805	-4.30691955676563	11.0082662884928	0.00123938808628835	0.026686438531856	-0.734718964228814	-0.237782526190682
STK24	BRD-K67868012-001-07-6::2.5::HTS002	2.5	PI-103	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.022597475050585	0.022597475050585	-0.528540398084833	-0.5017718155375	-12.9738982680515	40.1160288170791	6.12162702502445e-16	6.94569718711734e-14	-0.63698646076382	-0.465289285507016
STK24	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.271899590666	0.271899590666	-0.0108695590590828	-0.0198550434605	-4.50514723946191	7.6279877656428	0.002241677916277	0.0442368645721143	-0.428745266183003	-0.136793033267163
STK24	BRD-K69726342-238-02-4::2.5::HTS002	2.5	atorvastatin	HMGCR inhibitor	noncancer	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.0487002966688	0.0487002966688	-0.153439836135623	0.0599731342785	-3.17907645169179	167.119950134276	0.0017608009116073	0.0359988040140577	-0.32767259763756	-0.0766076679712871
STK24	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.505440780336	-0.505440780336	-0.207927709495539	-0.182274470613	11.3754963160322	95.0055818447618	1.97701228004705e-19	3.10198437020647e-17	0.245591145110696	0.349434996570226
STK24	BRD-K74514084-001-03-9::2.5::HTS002	2.5	pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.07439316121525	0.07439316121525	-0.196670660987456	-0.145323520972	-5.3999325837359	13.5787736839827	0.000104114090984201	0.00294000909177245	-0.37904120666051	-0.163086437744902
STK24	BRD-K77677632-003-02-6::2.5::HTS002	2.5	SB-200646	serotonin receptor antagonist	noncancer	HTR2B, HTR2C	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.376382296715	0.376382296715	-0.621457495564027	-0.496261939988	-11.0202747665141	5.44372454996912	6.2929907322795e-05	0.00186114310840173	-1.22500294952216	-0.770676635035893
STK24	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.7172932354625	-0.7172932354625	-1.6977336650401	-1.42296021894	-10.2285128520096	21.4533832320978	1.04141981460239e-09	6.1830046383356e-08	-1.17952283583476	-0.781358023320442
STK24	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.0078645672389	-0.0078645672389	-0.324980286219244	-0.193950713334	-4.79202113808146	6.52668525174241	0.0024058607104965	0.0469836647125289	-0.475926662748247	-0.158304775212441
STK24	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3550504730495	0.3550504730495	0.00186957443695684	0.041364371782	-8.45315851069369	5.80815085536059	0.000177765208572361	0.0047655083662421	-0.456239349445454	-0.250122447779632
STK24	BRD-K90647725-001-07-3::2.50156::HTS002	2.50156	oleanolic-acid	G protein-coupled receptor agonist	noncancer	GPBAR1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.2958097614715	-0.2958097614715	0.124784202465415	0.1471527723635	14.4272482465231	17.8258956620168	2.85306464052645e-11	2.0154729444278e-09	0.359303401584867	0.481884526288964
STK24	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-3.45864257724	-3.45864257724	-4.01823096197742	-3.85901121156	-4.11824281519867	11.9777712594767	0.00143054836985866	0.0301868663545768	-0.855707241403342	-0.263469528071499
STK24	BRD-K91701654-001-03-1::2.66738::HTS002	2.66738	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.1345498597825	0.1345498597825	-0.0792899359391825	-0.00292791542841	-4.38823474766305	17.9343951588694	0.000357360107748276	0.00888236513203992	-0.31624511220535	-0.111434479238015
STK24	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.3221674417145	0.3221674417145	-0.303944768609364	-0.183745665678	-10.7060852870865	156.539238415066	2.05113668177383e-20	3.53675039314484e-18	-0.741627666473495	-0.510596754174233
STK24	BRD-K94441233-001-13-0::2.59892::HTS002	2.59892	mevastatin	HMGCR inhibitor	noncancer	HMGCR	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	-0.674085839199	-0.674085839199	-1.42521785287236	-1.12582537284	-8.07900134165213	99.6895343925328	1.5634535078846e-12	1.27363522193614e-10	-0.935595574611489	-0.566668452735233
STK24	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MKN1, JHOS2	STOMACH, OVARY	carcinoma (mixed_adenosquamous_carcinoma), carcinoma (adenocarcinoma)	0.827623597297	0.827623597297	-0.30462607319754	-0.214794605924	-11.7794362841281	4.36013270152397	0.00018059256776764	0.0048322377599339	-1.39065147648067	-0.873847864508413
SULF2	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.653292741155	-1.653292741155	-1.23062810937876	-1.016750192265	4.18319163696525	20.2945750356985	0.000446223785320958	0.0108311095904933	0.212097350374018	0.633231913178453
SULF2	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.248470907067	0.248470907067	0.0882397100542656	0.1234730068455	-6.09255029774196	190.977936157906	6.00549370337541e-09	3.28271221614575e-07	-0.212106054509494	-0.108356339515975
SULF2	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.04555771592265	-0.04555771592265	0.210519324770825	0.242459349924	7.6280875477802	60.7389621687484	1.97019609836403e-10	1.26390350064731e-08	0.188943280400234	0.323210800986716
SULF2	BRD-A48300215-001-04-8::2.5::HTS002	2.5	ajmaline	sodium channel blocker	noncancer	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.236618816081	0.236618816081	0.0792577120466243	0.10011510474205	-3.27246688997868	163.347773088968	0.00130101087023003	0.0278287783239053	-0.252312152656389	-0.0624100554123619
SULF2	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.687977818137	-0.687977818137	-1.19376674778247	-1.043529721605	-6.50535658573835	12.3041633500889	2.58595423543961e-05	0.000825383447993351	-0.674727486335356	-0.336850372955592
SULF2	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.138136929115	-3.138136929115	-4.28600261074141	-4.26036322773	-16.2649803117113	25.7592637647149	4.59721167021541e-15	4.7993949345621e-13	-1.29299622125737	-1.00273514199546
SULF2	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.1033518227415	0.1033518227415	0.258617380473009	0.2294815220965	5.5207421492142	73.8930614696737	4.77891672628499e-07	2.04484017374313e-05	0.0992258427359539	0.211305272727064
SULF2	BRD-K08109215-001-06-4::2.5::MTS010::PROS002_PR500	2.5	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.255067213135	-1.255067213135	-0.161426848777638	-0.03477254501165	22.2758234491252	179.676511040356	1.40877493063754e-53	5.03235536847687e-50	0.996762636042106	1.19051809267262
SULF2	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.760712279545	-1.760712279545	-1.48888348296585	-1.38645123972	3.56192871690623	20.6741066099426	0.00187694269463252	0.0379799141614325	0.112970476947309	0.43068711621099
SULF2	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.040388475395	-3.040388475395	-1.92030993035573	-2.01595157397	13.4329802813292	37.9779471185007	5.2643425010747e-16	6.02403237540224e-14	0.951275817575154	1.28888127250339
SULF2	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.93965847138	-1.93965847138	-1.28786109018844	-1.25961873039	12.8668481019907	190.682575998194	1.113269843382e-27	3.60432042692178e-25	0.55187709031479	0.751717672068321
SULF2	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.208871617945	0.208871617945	-0.0728508989769925	0.0407112965926	-5.4847973490128	7.50620210692348	0.000726932485367722	0.0167098576422542	-0.401538809098193	-0.161906224745792
SULF2	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.09619264047525	-0.09619264047525	0.262953946411526	0.263001454047	13.3304129162027	194.226797874069	3.27229801050736e-29	1.25240778623934e-26	0.306010351294558	0.412282822478994
SULF2	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.400996585816	-0.400996585816	-0.0390346831795301	0.10879840342	6.02082201633931	186.326218667297	9.04624390910034e-09	4.85081914133992e-07	0.243361768931776	0.480562036341164
SULF2	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.231123738324	0.231123738324	-0.191744166376597	-0.123671466435	-10.58550051196	191.117259855962	6.67491498328798e-21	1.19818078178654e-18	-0.501663196893791	-0.344072612507403
SULF2	BRD-K17075857-001-18-4::2.5::HTS002	2.5	chloroxine	opioid receptor antagonist	noncancer	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.869414049141	-0.869414049141	-0.672523710417405	-0.654840996033	3.73271115875409	193.523198008721	0.000248970417094191	0.00642755727841254	0.0928569937189337	0.300923683728256
SULF2	BRD-K17894950-001-14-3::2.5::HTS002	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.414879630871	-0.414879630871	-0.0948727509313261	-0.04443726691935	7.76605845101333	188.409234028505	5.0417745767309e-13	4.30860647231323e-11	0.238722821247001	0.401290938632347
SULF2	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.508764061386	0.508764061386	0.321247040972773	0.339932692016	-5.143089315315	10.0329479652118	0.000431263226589575	0.0105036609195133	-0.268718808435723	-0.106315232390732
SULF2	BRD-K21528677-001-02-8::2.43672::HTS002	2.43672	desonide	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.176983477263	-0.176983477263	0.089244912929	0.124628316908	5.39004945884736	5.76123372440074	0.00191058998011423	0.0385552057101877	0.144144524060941	0.388312256323059
SULF2	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-2.235033481665	-2.235033481665	-2.81117146537567	-2.6496200301	-5.30992895874137	81.0187521296964	9.38929909453483e-07	3.85443226514567e-05	-0.792022198623874	-0.360253768797474
SULF2	BRD-K26619122-001-02-1::2.5::HTS002	2.5	thiocolchicoside	GABA receptor antagonist	noncancer	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.306823971137	0.306823971137	0.156766919268437	0.1631740037055	-5.94251890034122	133.854452938793	2.29668955775925e-08	1.17397370909845e-06	-0.200000459333876	-0.100113644403249
SULF2	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.2112074739635	-0.2112074739635	-0.031007723573477	-0.0206189181826	5.99232858782714	6.86791254569936	0.000587396362512318	0.0138377747835681	0.108813205801819	0.251586294978227
SULF2	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.3433392286935	0.3433392286935	-0.407530111862061	-0.2809944464045	-11.9663541724709	96.3175703559596	9.22878120275482e-21	1.6347069805002e-18	-0.875418649936283	-0.626320031174839
SULF2	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.118303874265	-0.118303874265	-0.880639221604253	-0.7074523288895	-8.4196694051642	188.13550011083	9.46569596398239e-15	9.57872120049283e-13	-0.940943723737488	-0.583726970941017
SULF2	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.853989614665	-3.853989614665	-2.6048443634149	-2.424137198535	10.1675621753011	4.53113080908365	0.000273611933930937	0.00697300501634765	0.923247080815314	1.57504342168488
SULF2	BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500	0.625	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.346821708155	-1.346821708155	-1.72562315052731	-1.77978641517	-3.88955499761353	23.7697414637741	0.000705777514385664	0.0162829482110619	-0.579906382144119	-0.177696502600496
SULF2	BRD-K45446451-001-05-0::2.5::HTS002	2.5	JZL-184	monoacylglucerol lipase inhibitor	targeted cancer	MGLL	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.598073158185	-0.598073158185	-0.0436894778026046	-0.06430876639615	10.81964515355	3.231165129295	0.00120193564537624	0.0259896756394112	0.397724614939449	0.711042745825342
SULF2	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.639715669672	-0.639715669672	-0.258212079219824	-0.219779888934	9.96101262556564	53.7969198687132	8.18338315937909e-14	7.57639883009313e-12	0.304710717316732	0.45829646358762
SULF2	BRD-K51313569-003-03-3::2.5::HTS002	2.5	palbociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.27538704815	-1.27538704815	-0.75254997470224	-0.730954040019	7.24746245793057	21.6441493983748	3.22334603041876e-07	1.41395114890222e-05	0.373083659025976	0.672590487869544
SULF2	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.857869134046	-0.857869134046	-1.18699640758702	-1.12103485225	-4.90732538805565	10.8614708825198	0.000483785219223442	0.011632174360662	-0.476974220900653	-0.181280326181394
SULF2	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-4.30362256113	-4.30362256113	-5.59854552122921	-5.54901350857	-12.3019277378321	4.75078126302871	8.77090060563254e-05	0.00251620714215582	-1.56983262505761	-1.02001329514081
SULF2	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.20105334782	-1.20105334782	-0.362689321474732	-0.394478559639	11.404464416	2.69173620179748	0.0023516586101229	0.0460740241194759	0.588504203580905	1.08822384910963
SULF2	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.06117547534905	-0.06117547534905	-0.143047028278827	-0.139438991422	-4.2853869494852	188.542726318152	2.9061298710206e-05	0.000916116942382667	-0.119558218867999	-0.0441848869915549
SULF2	BRD-K62814476-001-03-3::2.5::HTS002	2.5	BMS-265246	CDK inhibitor	targeted cancer	CDK1, CDK2	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.741901314785	-3.741901314785	-2.52407652279593	-2.448908605325	9.91847628997588	3.62504099939095	0.000935094493638368	0.0208746867750253	0.862556239446388	1.57309334453175
SULF2	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.358391393389	0.358391393389	0.143435123063024	0.15713254048	-7.64618007981593	37.0452431233765	3.94298676414158e-09	2.20134516845976e-07	-0.271916061481836	-0.157996479170117
SULF2	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.649380397985	-3.649380397985	-2.93337240755903	-2.87845710522	7.76648424708075	35.8315828736052	3.43759120331139e-09	1.93480957199193e-07	0.529003356886579	0.903012623965366
SULF2	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.388520804612	0.388520804612	0.142653189204887	0.0968721731692	-6.86288268021549	7.08476189307003	0.000226520639679372	0.00590219840026937	-0.330376921672692	-0.161358309141535
SULF2	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-2.579948921305	-2.579948921305	-3.14019668243693	-3.04544241525	-4.7479613395872	21.9400324186125	9.78077686040339e-05	0.00277729746119952	-0.804998468520441	-0.315497053743411
SULF2	BRD-K68567222-001-01-2::2.5::HTS002	2.5	BVT-948	tyrosine phosphatase inhibitor	noncancer	PTPN1, PTPN11, PTPN2	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.0086288366703795	-0.0086288366703795	0.341037609302901	0.377734553397	11.0658116506156	81.0883547601551	7.04476221448634e-18	9.60494173453335e-16	0.286795770451078	0.412537121495483
SULF2	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.020958262015	0.020958262015	-0.730589830206567	-0.60872932846	-6.55736822524843	8.46374578314425	0.000137721909274624	0.00377803648955855	-1.01334252363246	-0.489753660810678
SULF2	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.575776122178	0.575776122178	0.307547170713234	0.289065772439	-10.1938929180081	51.4470491359156	6.03420932699437e-14	5.65750678410051e-12	-0.321042778863495	-0.215415124066037
SULF2	BRD-K70821460-300-02-4::2.5::HTS002	2.5	4-methylhistamine	histamine receptor agonist	noncancer	HRH4	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.199186222087	-0.199186222087	0.48422591262697	0.473971299308	20.128740369382	12.1863228760152	1.01128127388998e-10	6.69178462956362e-09	0.609562206703313	0.757262062724627
SULF2	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.023498783625825	0.023498783625825	0.223420093637483	0.235603358555	6.04523174275494	5.16163566377733	0.00159654301435014	0.0331639336812028	0.115704330278155	0.284138289745161
SULF2	BRD-K78431006-001-10-2::2.5::HTS002	2.5	crizotinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.549344806705	-1.549344806705	-1.17104585679511	-1.07734518699	4.87545150582684	11.5045515576222	0.000430788285271374	0.0104944785626197	0.208428170779676	0.548169729040103
SULF2	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.338025207771	0.338025207771	-0.126428322327525	-0.118001057117	-14.5901342336858	23.5787220255557	2.68087359166909e-13	2.35873955676865e-11	-0.530216607310113	-0.398690452886937
SULF2	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.0567323755047	0.0567323755047	-0.104525319764339	-0.0756772814281	-4.4392906676648	10.6945214016226	0.00106654827434559	0.0233614946440692	-0.241488223379695	-0.0810271671583833
SULF2	BRD-K83003151-057-02-4::2.34747::HTS002	2.34747	alogliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.576280047859	0.576280047859	0.2427819798623	0.320568591806	-7.9807607877697	104.833214365057	1.94488241244946e-12	1.57299887765238e-10	-0.416357001312431	-0.250639134680968
SULF2	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.661797953024	-0.661797953024	-0.145574042824538	-0.137644446714	11.1536114709495	6.40651018300326	1.96653488070468e-05	0.000641921191663957	0.404692523580287	0.627755296818637
SULF2	BRD-K89299012-001-06-0::2.5::HTS002	2.5	DCEBIO	potassium channel activator	noncancer	KCNN2, KCNN3, KCNN4	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-2.792548274805	-2.792548274805	-2.03402630250038	-1.82556226868	7.04487089906035	9.65237316165051	4.22204526897408e-05	0.00129253926646757	0.517441713228872	0.999602231380377
SULF2	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.3306993789305	-0.3306993789305	-0.0910279300130694	-0.0408206395104	6.30666197270665	6.44060940394414	0.000561213997263304	0.0132778932353954	0.148202200826096	0.331140697008766
SULF2	BRD-K93441486-067-12-8::2.5::HTS002	2.5	diphemanil	acetylcholine receptor antagonist	noncancer	CHRM3	neurology/psychiatry	spasms	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.2157830923215	0.2157830923215	0.132561567752537	0.147275600233	-3.2582396859199	156.239366714252	0.00137549379709395	0.0291514100699445	-0.133673451074767	-0.032769598063159
SULF2	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.543561368615	-0.543561368615	-0.342899938143712	-0.279710660695	4.76474742785734	25.2201218240785	6.71518984139355e-05	0.00197212924570573	0.113964887062712	0.287357973879865
SULF2	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.2966315991645	0.2966315991645	0.0665283249140781	0.0390021562258	-10.6991934447123	155.782172318294	2.24881265395919e-20	3.85897331713707e-18	-0.272585457005727	-0.187621091495117
TANC1	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.3020844081025	-0.3020844081025	-0.834197314205915	-0.720201208535	-8.92764959024912	194.843866114512	3.24235156677216e-16	3.79535755846374e-14	-0.649662376391289	-0.414563435815542
TANC1	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5759767902225	0.5759767902225	-0.502526734570949	-0.379151386241	-16.0092108657936	10.6504393925693	8.61444714178198e-09	4.62854309714462e-07	-1.22737472681075	-0.929632322776145
TANC1	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.629964058567	0.629964058567	0.203332922914552	0.2241591843385	-12.459844595628	37.6495266259448	6.28472537563936e-15	6.47595627420869e-13	-0.495968571982335	-0.35729369932256
TANC1	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3010152122625	0.3010152122625	-0.452902375603283	-0.3315553181695	-10.1766033629339	146.134953728718	1.01368966367663e-18	1.48302451826722e-16	-0.900330904455555	-0.607504271276011
TANC1	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.804424397334	0.804424397334	0.352788090516157	0.3602013274625	-19.7996642760177	174.652722877631	1.66428607078097e-46	3.02292177342724e-43	-0.496655624897318	-0.406616988738368
TANC1	BRD-A91452556-001-04-0::2.5::HTS002	2.5	estradiol-cypionate	estrogen receptor agonist	noncancer	ESR1	endocrinology	hypoestrogenism, menopause	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.067051813295	0.067051813295	0.598853425876944	0.612598720084	22.4578045061559	171.69377246664	5.60702861888044e-53	1.87773255758754e-49	0.485060132083822	0.578543093080066
TANC1	BRD-K00615600-001-12-9::2.5::HTS002	2.5	AG-14361	PARP inhibitor	targeted cancer	PARP1	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.370333057007	0.370333057007	0.0638414594577269	0.06410268662525	-11.0787229345484	178.512589411296	4.81642964871254e-22	9.45330174156511e-20	-0.361083880236738	-0.251899314861808
TANC1	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.96340114168	-1.96340114168	-2.76914800457321	-2.64361455145	-7.82644702483658	139.047247307802	1.14619733840913e-12	9.50709478885024e-11	-1.00930027485966	-0.602193450926749
TANC1	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.999712983845	-2.999712983845	-3.71260132835519	-3.60790168659	-6.33074727716733	76.2402073222094	1.53847972135348e-08	8.05818231177832e-07	-0.937153788543877	-0.488622900476507
TANC1	BRD-K09951645-001-06-8::2.5::HTS002	2.5	dabrafenib	RAF inhibitor	targeted cancer	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1779147788135	0.1779147788135	-0.480106505756768	-0.33490377325	-8.34998140311871	11.7376878738994	2.80988704974866e-06	0.000107160192435157	-0.830149434404602	-0.485893134735934
TANC1	BRD-K11071038-001-01-7::2.5::HTS002	2.5	ICI-162846	histamine receptor antagonist	noncancer	HRH2	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2114906979825	0.2114906979825	0.0947953402439582	0.05414346753185	-3.46902347792632	29.7678213127344	0.00161453183400506	0.0334889183635412	-0.185418353936194	-0.0479723615408895
TANC1	BRD-K11927976-050-02-9::2.5::HTS002	2.5	ER-27319	mediator release inhibitor, SYK inhibitor	targeted cancer	SYK	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.87009646484	-1.87009646484	-2.42145186026256	-2.32972185313	-6.8654240489863	17.9400760860269	2.04910176213623e-06	7.97352816951519e-05	-0.720118766218184	-0.382592024626935
TANC1	BRD-K12885236-001-02-7::2.5::HTS002	2.5	dapivirine	non-nucleoside reverse transcriptase inhibitor	noncancer	CYP3A4, CYP3A5	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.11902870771	-1.11902870771	-1.3424022542808	-1.23896057589	-4.45691184658111	96.5164336740242	2.24256193175693e-05	0.000723864542577606	-0.32285110529494	-0.123895987846662
TANC1	BRD-K13183738-317-10-2::2.5::HTS002	2.5	pentamidine	anti-pneumocystis agent	noncancer	TRDMT1	infectious disease	pneumonia	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.4731935566095	-0.4731935566095	-0.913596781442578	-0.8497746890035	-6.80875990714303	21.1746380438406	9.42979335852258e-07	3.87031440202755e-05	-0.574848988017147	-0.305957461649008
TANC1	BRD-K13249881-001-02-3::2.5::HTS002	2.5	piperazine	benzodiazepine receptor agonist	noncancer	GABRB3	infectious disease	gastrointestinal roundworms	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4490871731085	0.4490871731085	0.0319308821051202	0.0696303010169	-7.67135347588818	4.47956261213893	0.000969691486448722	0.0215393311844821	-0.561969372201054	-0.272343209805705
TANC1	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.151701783436	0.151701783436	0.509435738383376	0.511327989939	10.1226486822567	2.88523479422829	0.00242324271177293	0.0472886449213858	0.242692791657779	0.472775118236972
TANC1	BRD-K17979676-001-01-2::2.5::HTS002	2.5	eprobemide	monoamine oxidase inhibitor	noncancer	MAOA	neurology/psychiatry	depression	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.131455999579	0.131455999579	-0.0470413077963286	-0.01607222471295	-3.45480470417777	31.7412785461683	0.00158437910987123	0.0329431888086525	-0.283771964620465	-0.0732226501301923
TANC1	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.190864630365	-1.190864630365	-0.938197592859663	-0.89400890482	4.61590613935162	27.8606047408537	8.00481609981263e-05	0.00231689970270998	0.140515352333826	0.364818722676848
TANC1	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.205490382366	0.205490382366	0.300312030699478	0.3347260991415	3.96549118993021	177.400149304562	0.000106113744840836	0.00298894254740748	0.0476336581401259	0.14200963852683
TANC1	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.221037064615	0.221037064615	0.415158118139284	0.442474468431	6.92980002228692	42.1835317718484	1.79156461265081e-08	9.29969125368939e-07	0.137596816862674	0.250645290185895
TANC1	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.774908516025	-1.774908516025	-0.764440491643008	-0.7406610501725	13.1381311254395	7.6853115669634	1.53750922169242e-06	6.10698320934239e-05	0.831838654283361	1.18909739448062
TANC1	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.076701995155	-1.076701995155	-2.07031159484347	-1.99815705335	-11.1309036029141	118.820192523791	3.77219175273816e-20	6.351061163964e-18	-1.1703676506898	-0.81685154868715
TANC1	BRD-K25224017-001-25-0::2.5::HTS002	2.5	pirenperone	serotonin receptor antagonist	noncancer	HTR2A, HTR7	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.63865928498	-1.63865928498	-2.56027178559403	-2.47770840728	-7.40255137903413	4.84528177482997	0.000810360387950145	0.0184045492835612	-1.24474644627089	-0.598478554957177
TANC1	BRD-K25244359-066-03-4::2.68145::HTS002	2.68145	apatinib	RET tyrosine kinase inhibitor	targeted cancer	CSK, KDR, KIT, RET	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.722569709128	0.722569709128	0.130592366501307	0.183294433483	-14.7053431639718	35.1128539019427	1.40976578222141e-16	1.70227431176188e-14	-0.67369184757068	-0.510262837682705
TANC1	BRD-K25835157-001-01-4::2.5::HTS002	2.5	PRT062070	JAK inhibitor, syk inhibitor	targeted cancer	SYK	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.526183376313	0.526183376313	-0.0887611492090997	-0.0811687124677	-13.6663905970392	189.840890531411	4.71021871651565e-30	1.90478578734355e-27	-0.703702556738758	-0.526186494305442
TANC1	BRD-K26756394-001-02-2::2.5::HTS002	2.5	VE-821	ATR kinase inhibitor	targeted cancer	ATR	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.355121725075	0.355121725075	-0.120040361826822	-0.0693224120433	-9.06739062699799	4.92145913102923	0.000296223824896769	0.00748606958687651	-0.610518490189086	-0.339805683614558
TANC1	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.6720319690345	0.6720319690345	0.143155176276314	0.195908235522	-10.9177946051742	10.9715846856786	3.12567291943812e-07	1.37391786536147e-05	-0.635530008100386	-0.422223577415987
TANC1	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.25420841446	-5.25420841446	-4.67498613402809	-4.90330008871	6.39365263043117	190.434089880387	1.21992298874331e-09	7.19892274929416e-08	0.400526995427457	0.757917565436367
TANC1	BRD-K28392481-001-05-1::2.5::HTS002	2.5	AZD4547	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.671500707667	0.671500707667	0.369226971863065	0.402350667123	-5.91750242166143	7.51984609957413	0.000449516198808587	0.0109060852812368	-0.421389550814945	-0.183157920792925
TANC1	BRD-K28578425-001-07-0::2.5::HTS002	2.5	cilostamide	phosphodiesterase inhibitor	targeted cancer	PDE3A, PDE3B	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.7631368682715	-0.7631368682715	-0.0795330304928762	-0.0458610158792	19.7442604230052	115.362714923894	8.48282710001781e-39	8.00932092299435e-36	0.615024800445805	0.752182875111442
TANC1	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.013001610075775	0.013001610075775	-0.750384871427562	-0.6332790164525	-13.4607159823775	114.150537450575	2.58642806293873e-25	6.77685257092415e-23	-0.875731274353014	-0.65104168865366
TANC1	BRD-K32744045-001-31-2::2.5::HTS002	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.14495241552235	-0.14495241552235	-1.28794708214761	-1.09614559515	-8.31940618074121	3.94494471610753	0.00121084738590734	0.0261638985153882	-1.52655629830462	-0.759433034945903
TANC1	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.357674410873	-0.357674410873	-0.792058720765463	-0.4002530483955	-3.79018409283514	145.216988247089	0.00022002196870871	0.00575016321562848	-0.660898961212811	-0.207869658572114
TANC1	BRD-K42673188-001-01-1::2.5::MTS006	2.5	verubulin	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.099666659555	-2.099666659555	-2.46776039001479	-2.30487473877	-3.65906421369673	129.434465006722	0.000367243867616013	0.00911112523466519	-0.567122573339385	-0.169064887580203
TANC1	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.66165031551	-1.66165031551	-1.32640485352035	-1.04970341453	3.68859658142507	117.260239334471	0.00034323989552908	0.0085631781595684	0.15525270327415	0.515238220705147
TANC1	BRD-K47869605-001-32-0::0.625::HTS002	0.625	podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	noncancer	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.841403013825	-1.841403013825	-3.2842821326971	-3.15922322391	-10.072742053086	4.54623440560313	0.000279961946635414	0.00711368868529007	-1.82243839642888	-1.06331984131533
TANC1	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.08295106095935	0.08295106095935	-0.228227679177445	-0.187297921894	-8.84562892506119	66.6903065205905	7.51370867886425e-13	6.33768464160684e-11	-0.381401942300584	-0.240955537973007
TANC1	BRD-K51350053-048-16-5::2.5::HTS002	2.5	toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	ESR1	oncology	breast cancer	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.05100240350575	0.05100240350575	-0.509011796228252	-0.436805913717	-8.09581708351168	53.9082756600347	6.99390295969439e-11	4.71679114993184e-09	-0.698703675038439	-0.421324724429566
TANC1	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.426880479175	-3.426880479175	-4.60220691698168	-4.62878838486	-10.1677009419523	10.7110583988158	7.80567398559396e-07	3.24598816386955e-05	-1.43058725100435	-0.920065624609003
TANC1	BRD-K51791723-003-01-7::2.5::MTS010::PROS004_PR500	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.94167100872	-1.94167100872	-2.23694361615614	-2.452542786	-3.6527406547142	25.3310271575405	0.0011833197637006	0.0256466520006254	-0.461647029061786	-0.1288981858105
TANC1	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3802487004935	0.3802487004935	0.22548840427752	0.2005091684065	-5.25890246641289	88.6247334211128	9.94957753128386e-07	4.06109884346322e-05	-0.213237013805054	-0.0962835786269054
TANC1	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.247138297064	0.247138297064	-0.515406629752318	-0.339269333107	-12.9153615415661	186.258382817273	1.15078265453923e-27	3.72015227096137e-25	-0.879021345097222	-0.646068508535414
TANC1	BRD-K55044200-001-15-3::2.5::HTS002	2.5	amoxicillin	penicillin binding protein inhibitor	noncancer	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.252659735058	0.252659735058	0.0957874990135884	0.127274405853	-4.97195866998326	6.749983377281	0.00179623653797856	0.036606026523572	-0.232043299059699	-0.0817011730291239
TANC1	BRD-K60184833-001-05-6::2.5::HTS002	2.5	tyrphostin-AG-99	tyrosine kinase inhibitor	targeted cancer	EGFR	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.28003070682	-1.28003070682	-1.6898578359093	-1.52742041275	-5.28220408636854	193.060879963874	3.42445282228058e-07	1.49391318735309e-05	-0.562852912808329	-0.256801345370272
TANC1	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0351553380953	-0.0351553380953	-0.143322373646592	-0.139438991422	-5.62378313471042	185.100397225787	6.80198600145201e-08	3.27125938228495e-06	-0.146112796693559	-0.070221274409024
TANC1	BRD-K62398570-300-01-2::2.5::HTS002	2.5	lerisetron	serotonin receptor antagonist	noncancer	HTR3A	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.6376345348665	0.6376345348665	0.496903736887527	0.5032243317015	-6.02187530875804	30.3560631647534	1.25203613149262e-06	5.03750050735275e-05	-0.188435095645873	-0.0930265003120728
TANC1	BRD-K67578145-001-09-7::2.38272::HTS002	2.38272	GDC-0879	RAF inhibitor	targeted cancer	BRAF	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.8165298897535	0.8165298897535	0.58238627429813	0.659791110046	-4.10164206606511	12.9938911414217	0.00125046819687618	0.0269006923786284	-0.357474880108723	-0.110812350802017
TANC1	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.171760773434	-0.171760773434	-0.272209793895848	-0.224936831672	-3.11762439452151	167.28299662863	0.00214674388047456	0.0426263526012791	-0.164058714926609	-0.0368393259970881
TANC1	BRD-K72280606-001-01-2::2.5::MTS006	2.5	gilteritinib	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.274752167221	-0.274752167221	0.025584762536182	0.043697431473	10.1452630314478	13.7767260120887	9.04043865660656e-08	4.27638088022915e-06	0.236746716955233	0.363927142559131
TANC1	BRD-K77908580-001-09-6::2.5::HTS002	2.5	entinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC9	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-4.27188548101	-4.27188548101	-1.76644038329788	-1.479908957755	24.9703492738271	171.763060420447	4.72078822868333e-59	2.59436364170633e-55	2.3073931393356	2.70349705608863
TANC1	BRD-K78177893-001-02-4::2.5::HTS002	2.5	A-674563	AKT inhibitor	targeted cancer	AKT1, PKIA, PRKACA	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.52854293887	-1.52854293887	-2.68626961057473	-2.66704888005	-14.0404365540935	180.777127748398	9.23315292227721e-31	3.90321978832101e-28	-1.32042784423039	-0.99502549917908
TANC1	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.54728655957	-2.54728655957	-3.98563060445149	-3.95467393468	-11.4398064023271	28.2496553311194	4.05841658974069e-12	3.18155219188929e-10	-1.69579084981079	-1.18089723995219
TANC1	BRD-K79239947-001-06-8::2.5::HTS002	2.5	PF-573228	focal adhesion kinase inhibitor	targeted cancer	CDK1, CDK2, CDK7, GSK3B, IKBKB	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.288018281319	0.288018281319	-0.23933156352278	-0.1830123326315	-9.78425935910843	12.8763437129139	2.51174357847253e-07	1.11758249829861e-05	-0.643902687789895	-0.410797001893665
TANC1	BRD-K79821389-001-03-5::2.5::MTS006	2.5	rubitecan	topoisomerase inhibitor	chemo	TOP1	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.776479105145	-5.776479105145	-4.11553955608709	-4.24145212342	13.3953886478634	19.7073569771706	2.35058409184983e-11	1.67765014259768e-09	1.40204744493662	1.91983165317919
TANC1	BRD-K80431395-001-07-3::2.48737::HTS002	2.48737	triciribine	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.557773383515	-0.557773383515	-0.941153478387483	-0.783018318744	-5.6678353993241	49.5512982654511	7.33551319882141e-07	3.06116278892172e-05	-0.519272253716676	-0.247487936028289
TANC1	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.03869401451415	0.03869401451415	0.285176728609712	0.278924535231	6.50129378933413	13.5698983557359	1.62646557448339e-05	0.000540379383217255	0.164925233305613	0.328040194885512
TANC1	BRD-K81801188-001-02-8::2.5::HTS002	2.5	PP-121	protein tyrosine kinase inhibitor	noncancer	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.58339004389	-3.58339004389	-4.63534046077644	-4.63633744063	-9.4210793650881	22.9244350379313	2.39990437548762e-09	1.3694598106866e-07	-1.28297725936994	-0.820923574402936
TANC1	BRD-K83003151-057-02-4::2.34747::HTS002	2.34747	alogliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.595654698987	0.595654698987	0.242536731113845	0.320568591806	-6.44734595670254	4.7902881547308	0.00156575563431214	0.032628764156197	-0.49578168341716	-0.210454252329151
TANC1	BRD-K87510569-001-02-8::2.5::HTS002	2.5	RS-504393	CC chemokine receptor antagonist	noncancer	CCL2, CCR2	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.397351535645	-0.397351535645	-0.0461064813465028	-0.0538286289263	7.64294893284924	66.0025030429995	1.15304320963265e-10	7.58069319255691e-09	0.259489517593688	0.443000591003306
TANC1	BRD-K88506063-001-01-8::2.5::HTS002	2.5	KD025	rho associated kinase inhibitor	targeted cancer	ROCK2	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.6245581328415	-0.6245581328415	-1.01888799557488	-0.939621254458	-6.03924243531077	21.991407083771	4.45487495430578e-06	0.000164084704258705	-0.52974562360622	-0.258914101860548
TANC1	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.7630928138575	-0.7630928138575	-1.01602842788413	-0.966558687453	-4.59182719936409	66.906915042499	1.99377534293248e-05	0.000650119999201848	-0.362886291250194	-0.142984936803073
TANC1	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.97152042398	-5.97152042398	-3.991498218927	-3.812026280445	17.0900634464263	167.922024130123	1.38348206924444e-38	1.27261943527507e-35	1.75129609785542	2.20874831225059
TANC1	BRD-K91701654-001-03-1::2.66738::HTS002	2.66738	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.379158157449	0.379158157449	-0.0818921518718048	-0.00292791542841	-10.7520328104755	187.297998591982	2.62608968400582e-21	4.85213082658002e-19	-0.545640716013346	-0.376459902628263
TANC1	BRD-K92150287-066-01-2::0.625::HTS002	0.625	exatecan-mesylate	topoisomerase inhibitor	chemo	TOP1	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.0326241541	-5.0326241541	-4.10028263038348	-4.11703772867	6.09640753325783	10.6619860466288	8.87621246052562e-05	0.00254301529267745	0.59443184657016	1.27025120086289
TANC1	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1962402358625	0.1962402358625	-0.0964884441560021	-0.0469105128274	-9.75497498014284	178.226408223793	2.77333691760641e-18	3.90799821310759e-16	-0.351945660190501	-0.233511699846503
TANC1	BRD-K92991072-001-04-9::2.5::HTS002	2.5	PAC-1	caspase activator	targeted cancer	CASP3	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3721514926985	0.3721514926985	0.0958152552912628	0.163411081458	-7.67000916988333	75.4930188173079	4.87748382952295e-11	3.34737826352169e-09	-0.348100309871196	-0.204572164943278
TANC1	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0587937033126	0.0587937033126	-0.296490307123631	-0.214794605924	-5.00504524219258	170.868437754064	1.37990795466521e-06	5.51574584139202e-05	-0.49540482570952	-0.215163195162941
TANC1	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.82859669328	-3.82859669328	-3.15928168920618	-3.187890366305	8.51209035612022	17.5884498910754	1.19673544666671e-07	5.58812879190914e-06	0.503839689602753	0.834790318544896
TANC1	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	JHH1, EBC1	LIVER, LUNG	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.8636117091435	-0.8636117091435	-0.609608174975527	-0.5106967244835	3.96845924804938	57.2229001357056	0.000204070762668273	0.00537589509487812	0.125845391078266	0.382161677257679
TBL1X	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.52224978216	-2.52224978216	-2.09085830031823	-2.05580997476	5.25611352261026	14.7543952898466	0.000102200927835074	0.00289055458722137	0.256200425138563	0.606582538544977
TBL1X	BRD-A45498368-001-07-1::2.5::HTS002	2.5	WYE-125132	mTOR inhibitor	targeted cancer	MTOR	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-3.037984500805	-3.037984500805	-2.334577302542	-2.38754178221	7.53122692937361	4.01329855969678	0.00164265990118011	0.0339704413315353	0.444429220257633	0.962385176268363
TBL1X	BRD-A55484088-050-02-5::2.5::HTS002	2.5	BNTX	opioid receptor antagonist	noncancer	OPRD1, OPRK1, OPRM1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.02093755313	-2.02093755313	-1.37712586930601	-1.26699176708	8.94819341454595	29.8261137483367	6.00144037091772e-10	3.65006445306023e-08	0.496836721853711	0.790786645794264
TBL1X	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.05231041487155	0.05231041487155	0.186776292911793	0.190024427126	4.88947451119216	177.330522060483	2.25494910697522e-06	8.72699507311109e-05	0.0801943504483114	0.188737405632176
TBL1X	BRD-A67748489-001-10-0::2.5::HTS002	2.5	K-858	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.912069976745	-1.912069976745	-2.65183161078884	-2.53659706209	-6.00015778875	7.54406229902	0.000406576039863671	0.00995556221272029	-1.02708854348511	-0.452434724602559
TBL1X	BRD-A93477898-001-04-2::2.5::HTS002	2.5	PETCM	caspase activator	noncancer	CASP3	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.241018466428	-0.241018466428	0.184344455331728	0.198279920588	11.0244482941672	172.530436148524	9.85578924038189e-22	1.88774035040376e-19	0.349206254735133	0.501519588784322
TBL1X	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.201875511831	0.201875511831	-0.189284553549556	-0.138056758361	-8.5429022204647	190.356681658662	4.16490646285306e-15	4.36935994751265e-13	-0.481476560431504	-0.300843570329607
TBL1X	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.2110457715875	-0.2110457715875	0.0357378101905777	0.01565074111015	5.95677775980909	117.987813185174	2.72474632930972e-08	1.37733999060053e-06	0.164742716534933	0.328824447021222
TBL1X	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.455326496264	0.455326496264	0.260113677355906	0.303778240807	-4.40024167091634	11.6835770345948	0.000921264591107581	0.0205938379795053	-0.292165060600735	-0.0982605772154543
TBL1X	BRD-K00317371-001-06-1::2.40436::HTS002	2.40436	RITA	MDM inhibitor	targeted cancer	MDM2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.7780262330525	-0.7780262330525	-2.20445890552144	-1.66399627555	-7.89310434950105	4.94349061131821	0.000553086164508884	0.0131087476006883	-1.89258702370259	-0.960278321235289
TBL1X	BRD-K01773560-001-02-4::2.59308::HTS002	2.59308	UNC2250	MER tyrosine kinase inhibitor	targeted cancer	MERTK	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.3319080256055	-0.3319080256055	-0.127209556237142	-0.110029885293	4.04134105587835	14.1140687258715	0.00119510641093857	0.0258602687481123	0.0961449233127225	0.313252015423994
TBL1X	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.310611520215	-2.310611520215	-3.03135839557509	-2.92318120426	-6.32349496399281	122.373235617971	4.34660419529596e-09	2.41759843577247e-07	-0.946373186185465	-0.495120564534705
TBL1X	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.678640412655	-1.678640412655	-0.345102933266908	-0.221401224326	15.3606848400242	3.66409525071944	0.000184781399008055	0.00492893745712477	1.08353067870325	1.58354428007294
TBL1X	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.720618180835	-2.720618180835	-1.93238768150137	-1.85386313087	7.39049831250598	101.250532060433	4.29518212918344e-11	2.96961964698631e-09	0.576662847177073	0.999798151490187
TBL1X	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.676291480805	-2.676291480805	-2.02597772640696	-1.59680097986	4.87464124130123	44.6617537527397	1.41531951032539e-05	0.00047471676890224	0.381561056720676	0.919066452075414
TBL1X	BRD-K09602097-001-13-6::2.5::HTS002	2.5	forskolin	adenylyl cyclase activator	targeted cancer	ADCY2, ADCY5, GNAS	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.1555732828065	-0.1555732828065	0.0443877312519546	0.0420503630099	5.141850045927	10.4738329490501	0.000376779531824416	0.00932430608915779	0.113839517000837	0.286082511116073
TBL1X	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.146612932304	-0.146612932304	0.188607539709817	0.239804537816	8.84775613263785	38.5089259094669	8.13406516892089e-11	5.45142605875436e-09	0.258554257598517	0.411886686429116
TBL1X	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.7719378729115	0.7719378729115	0.423026198856125	0.3989310314435	-9.30515896489321	16.7128444958131	5.09986265454067e-08	2.48589598108949e-06	-0.428126221139671	-0.269697126971079
TBL1X	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.04395707248715	-0.04395707248715	-0.286862616938612	-0.2721742756055	-7.41256732083672	125.070120081283	1.63036914689598e-11	1.18815161130591e-09	-0.307759941623197	-0.178051147279728
TBL1X	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.04009880426	-1.04009880426	-0.505347985283811	-0.370831351035	8.59180553410286	190.022918296609	3.09149055274371e-15	3.27207940088398e-13	0.41198148473433	0.657520153218048
TBL1X	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.151127604015	-1.151127604015	-1.648648901315	-1.461946185705	-5.18737578394806	17.0335102703204	7.37208902348351e-05	0.00214681041890516	-0.699843423484796	-0.295199171115194
TBL1X	BRD-K13183738-317-10-2::2.5::HTS002	2.5	pentamidine	anti-pneumocystis agent	noncancer	TRDMT1	infectious disease	pneumonia	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.450194317245	-1.450194317245	-0.901229683206685	-0.814219930729	9.51250692166912	157.964511983171	3.03511632483322e-17	3.89295898734398e-15	0.434982317319658	0.662946950756972
TBL1X	BRD-K14329163-001-03-9::2.5::HTS002	2.5	BAY-K-8644-(s)-(-)	L-type calcium channel activator	noncancer	CACNA1C	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.118064451102	0.118064451102	0.289686660166791	0.2983677815075	6.57329665336053	187.286774256024	4.75175238140853e-10	2.92570622279491e-08	0.120116686147021	0.223127731982562
TBL1X	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.593720200545	-1.593720200545	-1.29148348045897	-1.25961873039	5.0710207762009	12.8317802044275	0.000223189942861052	0.00582301610023936	0.173305294450502	0.431168145721562
TBL1X	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.04762276612065	0.04762276612065	0.261478916600286	0.263001454047	7.80105861371128	175.508102792214	5.26876655291142e-13	4.49363098495404e-11	0.159753152797607	0.267959148161665
TBL1X	BRD-K18518344-001-15-9::2.5::HTS002	2.5	digitoxigenin	ATPase inhibitor	noncancer	ATP1A1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.59961437748	-1.59961437748	-4.16172508222595	-4.343421581	-12.661243434601	2.77443445073791	0.00154817881754336	0.0322938800764234	-3.23676326895376	-1.88745814053815
TBL1X	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.04148583779615	-0.04148583779615	-0.343462767996211	-0.216806871006	-4.73045371395186	17.8719548628293	0.000170007256856756	0.00457987498175612	-0.436161936032028	-0.167791924368095
TBL1X	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.411798876542	0.411798876542	-0.381200547739242	-0.173057746988	-9.44647464793191	17.6759818023181	2.50568353847352e-08	1.2744201402883e-06	-0.969596707385802	-0.616402141176682
TBL1X	BRD-K20463415-300-01-4::2.5::MTS006	2.5	LY2606368	CHK inhibitor	targeted cancer	CHEK1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.586602382275	-1.586602382275	-3.14760540661863	-3.22475555586	-12.0803938399477	26.1652800716457	3.30864105437656e-12	2.61674438576927e-10	-1.82653257037659	-1.29547347831067
TBL1X	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.0585780372283	0.0585780372283	-0.213453852253594	-0.0984348398408	-4.71649762384319	21.1889420924825	0.000114842475722724	0.00321122935149063	-0.391912004904761	-0.152151774059028
TBL1X	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.63702463015	-1.63702463015	-2.06418785019872	-1.99815705335	-4.70691443311299	85.2623920572965	9.63857012888486e-06	0.000333305114093863	-0.607595051345692	-0.246731388751749
TBL1X	BRD-K24593301-001-02-3::2.54476::HTS002	2.54476	AZD3463	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-3.129631192955	-3.129631192955	-3.4997461461111	-3.310368963095	-3.28587084549709	164.468229218349	0.00124269680119078	0.0267497844977339	-0.592518493049037	-0.14771141326316
TBL1X	BRD-K24603946-001-02-1::2.5::HTS002	2.5	5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	noncancer	CHRM3	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.77786506833	-1.77786506833	-2.42919997652789	-2.202066494735	-5.3071124521201	9.603070512344	0.000394028192166753	0.00968354658388234	-0.926331317879757	-0.376338498516023
TBL1X	BRD-K28143534-001-02-2::2.5::HTS002	2.5	cyproheptadine	histamine receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.1827958540285	-0.1827958540285	-0.0029899240550981	0.0299978587143	5.8127189447952	49.0564735554162	4.52628942961948e-07	1.94333951754991e-05	0.117645170700478	0.241966689246326
TBL1X	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.63359535921	-1.63359535921	-2.31591817780358	-2.045349051995	-6.65447755159779	176.824334450756	3.43799872098392e-10	2.15205265148879e-08	-0.884674404856897	-0.479971232330256
TBL1X	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.156528004353	-0.156528004353	-0.880241053582503	-0.7074523288895	-8.00633938384179	190.363620876517	1.14122456661966e-13	1.04084051122989e-11	-0.90201262401539	-0.545413474443615
TBL1X	BRD-K37865504-001-04-1::2.5::HTS002	2.5	LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	noncancer	FAAH	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.5269673587655	-0.5269673587655	-1.2979766041837	-1.08170547456	-7.96824345243097	9.6770398602949	1.48618802678368e-05	0.000496544339193326	-0.987583818922144	-0.554434671914265
TBL1X	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-3.54303093855	-3.54303093855	-2.98513229627529	-3.07991378512	5.48243439394722	43.4414139009657	2.00125883717147e-06	7.79836605016093e-05	0.352738080178931	0.763059204370494
TBL1X	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.276133840562	-0.276133840562	0.482663534152993	0.4963205206125	15.8046822482403	2.29780674973568	0.00214941353938148	0.0426636094167525	0.575872724803797	0.941722024626189
TBL1X	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-4.391582057945	-4.391582057945	-3.74699881841702	-3.638458649165	4.94078279168852	6.91614111923229	0.00173300451033351	0.0355744778943847	0.335330297612001	0.953836181443951
TBL1X	BRD-K48195801-001-01-6::2.5::HTS002	2.5	tecastemizole	histamine receptor antagonist	noncancer	KCNH2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.2272685246995	-0.2272685246995	0.346828335728518	0.312371086483	13.3793481838572	4.99284674295495	4.21544149094388e-05	0.00129088635421133	0.463747753030236	0.684445967825801
TBL1X	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.0727688885605	0.0727688885605	-0.26861731750469	-0.2054130743915	-6.29425756067951	15.4061852931761	1.27178987198667e-05	0.000429735852866201	-0.456726278026769	-0.226046134103611
TBL1X	BRD-K50071428-001-03-3::2.5::HTS002	2.5	abiraterone	androgen biosynthesis inhibitor	targeted cancer	CYP11B1, CYP17A1	oncology	prostate cancer	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.3760208984255	0.3760208984255	0.523789133546451	0.541027308905	4.78611054380212	9.80033598005223	0.000781883932755438	0.0178352917649575	0.0787853630560844	0.216751107185817
TBL1X	BRD-K52075715-001-06-7::2.5::HTS002	2.5	oxibendazole	tubulin polymerization inhibitor	noncancer	TUBB, TUBB4B	infectious disease	strongyles	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.107893957015	-2.107893957015	-2.88016972352574	-2.70188227417	-6.58322521545543	15.4970955307508	7.38311348350805e-06	0.000260308493141437	-1.02161859328121	-0.522932939740276
TBL1X	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.182460906107	-0.182460906107	0.11877891070879	0.150496276102	10.1726174606647	41.8832445252815	6.93294923309237e-13	5.85935361269501e-11	0.241473805168618	0.361005828462962
TBL1X	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.1367027079595	0.1367027079595	-0.51425023614913	-0.339269333107	-9.98308759299717	24.8500918728314	3.53355572656342e-10	2.21057637279221e-08	-0.78528742483412	-0.51661846338314
TBL1X	BRD-K56301217-001-07-4::2.5::HTS002	2.5	ABT-737	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.8972956836395	-0.8972956836395	-0.126744235641499	-0.0854667375103	25.3904414894841	193.561837577693	1.61710419288841e-63	1.57541965707991e-59	0.710696041509177	0.830406854486825
TBL1X	BRD-K60184833-001-05-6::2.5::HTS002	2.5	tyrphostin-AG-99	tyrosine kinase inhibitor	targeted cancer	EGFR	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.097880755515	-1.097880755515	-1.69173567045884	-1.52742041275	-7.43031830615501	123.42522241004	1.56382661330693e-11	1.1451089655055e-09	-0.752052600895648	-0.435657228992025
TBL1X	BRD-K61314889-001-04-4::2.5::HTS002	2.5	endo-IWR-1	PARP inhibitor	targeted cancer	TNKS, TNKS2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.158445737545	-1.158445737545	-1.44557604111161	-1.44393711798	-3.89327509256698	13.2675560474256	0.00178385152268146	0.0363951559262061	-0.446132194697739	-0.128128412435483
TBL1X	BRD-K61642990-001-01-0::2.5::HTS002	2.5	FERb-033	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.711538985545	0.711538985545	0.176628070985561	0.239686907074	-9.41856331490637	3.21426601360369	0.00190247825488533	0.0384398766330158	-0.70902391717593	-0.360797911942948
TBL1X	BRD-K62398570-300-01-2::2.5::HTS002	2.5	lerisetron	serotonin receptor antagonist	noncancer	HTR3A	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.644683809099	0.644683809099	0.496828744608458	0.5032243317015	-6.81974672732493	157.878076629295	1.83322607221251e-10	1.17885841833554e-08	-0.190676171769264	-0.10503395721182
TBL1X	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.4094553238495	0.4094553238495	0.253663774513232	0.248858708206	-7.41414125593211	115.612696614063	2.20207905825779e-11	1.57638410981074e-09	-0.197411431944953	-0.114171666727582
TBL1X	BRD-K67977190-066-02-3::2.5::HTS002	2.5	eprosartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.301133308445	0.301133308445	0.422785805228593	0.410651476159	3.58165207162452	32.5565927585681	0.00109772769506165	0.0239758360496146	0.0525134565303394	0.190791537036848
TBL1X	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-3.36473211932	-3.36473211932	-3.86438098965076	-3.711772040445	-6.95755640597089	87.2457965768314	6.07857434688645e-10	3.69488020758317e-08	-0.642380991572834	-0.356916749088687
TBL1X	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-3.44268548669	-3.44268548669	-4.3667640727881	-4.09603677997	-6.06298128113043	5.68140690221163	0.00111584186724689	0.0243367529831239	-1.3021489071763	-0.546008265019914
TBL1X	BRD-K74501079-001-18-1::2.5::HTS002	2.5	azithromycin	bacterial 50S ribosomal subunit inhibitor	noncancer	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.425536789488	-0.425536789488	-0.784504223718052	-0.6289149698795	-5.13713934721573	96.0909111142565	1.46068720897916e-06	5.81910090731032e-05	-0.497670333627651	-0.220264534832452
TBL1X	BRD-K76011241-001-01-8::2.5::HTS002	2.5	oseltamivir-phosphate	neuraminidase inhibitor	noncancer	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.06513119442505	0.06513119442505	0.328001352140965	0.306165315644	10.506153786861	63.9816998391799	1.45932033130319e-15	1.59578911881572e-13	0.212885509409477	0.312854806022352
TBL1X	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.3637073473425	-0.3637073473425	-0.210925003303208	-0.185900015084	5.19588641095577	179.348971357327	5.50157448146394e-07	2.33309647217587e-05	0.0947590900053007	0.210805598073284
TBL1X	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.2845041915735	-0.2845041915735	-0.963486105433883	-0.892479910689	-11.9746612436332	41.968214379221	4.01793172496725e-15	4.22343937557875e-13	-0.793412852274498	-0.564550975446267
TBL1X	BRD-K80700417-001-04-2::2.5::HTS002	2.5	SGI-1776	Pim kinase inhibitor	targeted cancer	FLT3, PIM1, PIM2, PIM3	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.14464166147	-1.14464166147	-0.340678601266992	-0.3090790625965	10.095840012255	9.08615532131084	3.07361403341765e-06	0.000116260349632087	0.624080509738993	0.983845610667024
TBL1X	BRD-K81528515-001-13-8::2.5::HTS002	2.5	nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	targeted cancer	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.0378290257608	-0.0378290257608	0.192653289115171	0.2381526124685	4.0116782833108	18.8362405875972	0.000757051778300851	0.0173223177742546	0.110161339262655	0.350803290489287
TBL1X	BRD-K82135108-001-04-3::0.15625::MTS010::PROS001_PR500	0.15625	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.06716623881	0.06716623881	-0.988524913366211	-0.922667792506	-14.2880435947695	109.930201631911	8.16825558677712e-27	2.4382925510562e-24	-1.20211755635716	-0.909264747995261
TBL1X	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.176478010647	-0.176478010647	-0.852613235890087	-0.774088070041	-7.51489017331567	187.071060946579	2.28491196980444e-12	1.83829916507589e-10	-0.853626793433502	-0.498643657052671
TBL1X	BRD-K83988098-001-02-0::0.039::MTS010::PROS005_PR500	0.039	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.5192893407735	-0.5192893407735	-0.979836973928255	-0.942675371448	-4.36443146971362	45.0615452593971	7.35546369709389e-05	0.00214278059473708	-0.673073729384539	-0.248021536924971
TBL1X	BRD-K84892605-001-01-1::2.5::HTS002	2.5	IOWH032	CFTR channel antagonist	noncancer	CFTR	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.005619008191465	0.005619008191465	0.118966192217174	0.126672721217	4.06170259256877	20.3542010246555	0.000591025802741598	0.013918686877904	0.055200486349655	0.171493881701763
TBL1X	BRD-K87696786-003-04-4::2.5::HTS002	2.5	LY456236	glutamate receptor antagonist	noncancer	GRM1	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.090338419305	-1.090338419305	-2.19969487192144	-2.03818987744	-11.4141112671055	79.9877932432585	1.82920521493344e-18	2.6136781634098e-16	-1.302774478596	-0.915938426636879
TBL1X	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.505571429725	-2.505571429725	-1.6388712358774	-1.710789940465	10.0040389572449	2.94364319521577	0.00230360991910011	0.0452797514995238	0.587978485372214	1.14542190232299
TBL1X	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-3.977859331335	-3.977859331335	-2.03804301976963	-1.827878240625	19.140919218722	177.981916138821	4.52023869265796e-45	7.22998685640812e-42	1.73982596340383	2.1398066597269
TBL1X	BRD-K89714990-001-01-5::2.5::HTS002	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.568126878315	-0.568126878315	-0.000238880812901066	-0.0169713507313	16.1279726451419	25.1310176425294	9.10635666349528e-15	9.23689691117027e-13	0.495387990847091	0.640388004157107
TBL1X	BRD-K92000912-001-12-6::2.5::HTS002	2.5	AM-251	cannabinoid receptor antagonist	targeted cancer	CNR1, GPR18, GPR55	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.3551953030095	-0.3551953030095	-0.124189002549014	-0.0809111569398	6.47849694387571	192.694250069063	7.54419792083731e-10	4.55219706130389e-08	0.160677394081633	0.301335206839339
TBL1X	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-0.0395254837583	-0.0395254837583	0.0951700359717201	0.110191949027	5.43784573910353	179.46512658956	1.74461204004304e-07	7.93887375648373e-06	0.0858175770067795	0.183573462453261
TBL1X	BRD-K92441787-001-04-1::2.5::HTS002	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.4627468945205	0.4627468945205	0.152402487887127	0.1701725882685	-10.5769125517578	79.2556080657101	8.20883536056758e-17	1.01114452528453e-14	-0.368744635551914	-0.251944177714833
TBL1X	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-1.323112177205	-1.323112177205	-2.25382905480396	-2.18755983006	-10.3382552986319	61.7183258577509	4.28539960863609e-15	4.48917601524616e-13	-1.11069361373568	-0.750740141462239
TBL1X	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	-2.340139337065	-2.340139337065	-1.23886535399822	-1.23927241763	10.9123509732021	3.52374359561108	0.000769330068041295	0.0175676266943557	0.805488871100039	1.39705909503352
TBL1X	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	RVH421, RMGI	SKIN, OVARY	malignant_melanoma, carcinoma (clear_cell_carcinoma)	0.194345025013	0.194345025013	0.0676107225241469	0.0390021562258	-5.85250753897172	141.179252011273	3.23709202380675e-08	1.6210343373142e-06	-0.169543692862713	-0.0839249121149934
TBL1XR1	BRD-A31095847-001-02-3::2.5::HTS002	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.1947806059055	0.1947806059055	0.0258819143796532	0.0703858703435	-4.87286766095829	73.9962134466104	6.09458758084848e-06	0.000218728543472149	-0.237962392555241	-0.0998349904964527
TBL1XR1	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.422098278639	0.422098278639	0.150484105117922	0.162581247373	-9.15126339742739	54.8046023470492	1.25205334929604e-12	1.03530610455737e-10	-0.331100013774306	-0.212128333267849
TBL1XR1	BRD-A91452556-001-04-0::2.5::HTS002	2.5	estradiol-cypionate	estrogen receptor agonist	noncancer	ESR1	endocrinology	hypoestrogenism, menopause	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.009754372568005	0.009754372568005	0.59945974800104	0.612598720084	25.3043984695274	188.873100833119	1.39632806698739e-62	1.19709439307736e-58	0.543734910682628	0.635675840183441
TBL1XR1	BRD-K03109492-001-02-2::2.5::HTS002	2.5	NSC-663284	CDC inhibitor	targeted cancer	CDC25A, CDC25B, CDC25C	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.8592366899155	-0.8592366899155	-1.21374798770723	-0.957814328752	-4.06399894262819	159.00547452335	7.56299698572093e-05	0.00219792485552893	-0.526794385348676	-0.182228210234794
TBL1XR1	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-2.43134034739	-2.43134034739	-3.0795524217804	-3.12584681211	-5.77255919061994	11.1798701245503	0.000116593785965721	0.00325510349775265	-0.894880767337304	-0.40154338144349
TBL1XR1	BRD-K07955840-001-02-3::2.5::HTS002	2.5	PF-05212384	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-3.09258029	-3.09258029	-4.71920338614928	-4.691855544975	-14.3661454339879	9.31996826681853	1.13545971754214e-07	5.31474002623039e-06	-1.88142420789528	-1.37182198440327
TBL1XR1	BRD-K08078237-001-19-8::2.5::HTS002	2.5	tetrandrine	calcium channel blocker	targeted cancer	SLC6A3	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.7604225868245	-0.7604225868245	-0.300929629432635	-0.169768923228	6.54387762244546	6.15589788523593	0.000548458173811218	0.0130062504906821	0.288726841098833	0.630259073684897
TBL1XR1	BRD-K26756394-001-02-2::2.5::HTS002	2.5	VE-821	ATR kinase inhibitor	targeted cancer	ATR	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.0965132768522	0.0965132768522	-0.117360481534358	-0.0693224120433	-4.65382620603761	12.4140022382931	0.000509282865131402	0.0121864560902923	-0.313635350362018	-0.114112166411098
TBL1XR1	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-3.052163549805	-3.052163549805	-3.63550918266556	-3.592577528105	-8.0544543253434	177.211975840781	1.12867884706586e-13	1.03027516444965e-11	-0.726272529573717	-0.440418736147406
TBL1XR1	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.597703196513	-0.597703196513	-1.67542909006664	-1.54523819361	-11.7291727147123	13.0463283676796	2.64658100168171e-08	1.33940746047093e-06	-1.2761580524114	-0.879293734695886
TBL1XR1	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-2.883768617215	-2.883768617215	-3.66876999765024	-3.65355610334	-7.5934601631312	79.8273801398392	5.0931828784495e-11	3.48759358835528e-09	-0.990738206659123	-0.579264554211353
TBL1XR1	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.487645604647	0.487645604647	0.167696942525716	0.159843684784	-11.4759569928773	16.5121968574589	2.75778764418156e-09	1.56575859070143e-07	-0.378902783725766	-0.260994540516801
TBL1XR1	BRD-K36198571-001-02-0::2.5::HTS002	2.5	WAY-170523	metalloproteinase inhibitor	targeted cancer	MMP13	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.337218670112	-0.337218670112	-0.509849005298622	-0.4097580139535	-3.38972942529707	86.8635848941102	0.00105411742562901	0.0231317634603912	-0.273856432844695	-0.0714042375285492
TBL1XR1	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.452262042465	-1.452262042465	-2.63039465673618	-2.459947367395	-11.9694624700513	30.5647816819986	4.55123562008408e-13	3.91594451712967e-11	-1.37899416625517	-0.977271062287185
TBL1XR1	BRD-K39558284-001-01-2::2.5::HTS002	2.5	SDZ-WAG-994	adenosine receptor agonist	noncancer	ADORA1	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.4569232334605	0.4569232334605	0.294970746033313	0.325539232433	-5.43858282089014	67.8420511421857	7.93340370384112e-07	3.29347217008271e-05	-0.221376935290009	-0.102528039564365
TBL1XR1	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.210945160459	-0.210945160459	-0.514574779934254	-0.465030888818	-6.11143734397165	111.95853413765	1.47124228864507e-08	7.73056848450624e-07	-0.402068917706782	-0.205190321243726
TBL1XR1	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.167396499708	-0.167396499708	-0.634719562039773	-0.4291875223905	-6.44180500343188	17.1356341708295	5.85471930592407e-06	0.000210967742790753	-0.620288157332475	-0.314357967331071
TBL1XR1	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.567743373458	-0.567743373458	-0.290694955806596	-0.269064169965	6.1097098501072	129.054152248059	1.09592092995041e-08	5.8313713256043e-07	0.187331407283645	0.366765428019163
TBL1XR1	BRD-K47337578-034-02-5::2.5::HTS002	2.5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	noncancer	HTR2A	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.382225243539	-0.382225243539	-0.122082570914501	-0.0894405664739	5.90178626200673	15.1156488586747	2.81674025696873e-05	0.000890952069858102	0.166253857656051	0.354031487592947
TBL1XR1	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.5876762579615	0.5876762579615	0.400602549238036	0.450986520291	-6.23590606423299	173.698785461153	3.31133647589274e-09	1.8666897305145e-07	-0.246284071679615	-0.127863345767313
TBL1XR1	BRD-K59058747-001-18-3::2.5::HTS002	2.5	acetylcysteine	mucolytic agent	noncancer	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.8946977518435	0.8946977518435	0.386115390954822	0.3974557070265	-17.7646476781898	15.8262157441688	7.10711524713291e-12	5.41122878793161e-10	-0.569327129996671	-0.447837591780685
TBL1XR1	BRD-K61314889-001-04-4::2.5::HTS002	2.5	endo-IWR-1	PARP inhibitor	targeted cancer	TNKS, TNKS2	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.280225144231	-0.280225144231	-1.45462986166124	-1.44393711798	-15.2356808361276	8.35091888339523	2.1921322795936e-07	9.85190856265498e-06	-1.35086553101868	-0.997943903841804
TBL1XR1	BRD-K61642990-001-01-0::2.5::HTS002	2.5	FERb-033	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.4470700851265	0.4470700851265	0.179397378843346	0.239686907074	-6.89785986549395	150.030833341146	1.3789252938208e-10	9.00498718157583e-09	-0.344347943773046	-0.190997468793262
TBL1XR1	BRD-K81728688-001-04-4::2.5::HTS002	2.5	WZ8040	EGFR inhibitor	targeted cancer	EGFR	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.0798363794567	0.0798363794567	-0.428158796656462	-0.2959843885325	-9.10904710118667	159.911180601791	3.26365850117335e-16	3.81613018493172e-14	-0.618132350818105	-0.397858001408219
TBL1XR1	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-1.27107986557	-1.27107986557	-1.9611959079905	-1.89031364576	-8.6620343223749	5.7640847941397	0.00016217284700645	0.00439034282253952	-0.887015387368421	-0.493216697472574
TBL1XR1	BRD-K89053832-001-01-0::2.5::HTS002	2.5	VLX600	ubiquitin C-terminal hydrolase inhibitor	targeted cancer	USP14	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.808795808911	-0.808795808911	-2.07840152248792	-1.90794289133	-8.86924823212161	4.29907273402973	0.000637984210070615	0.0148564230508719	-1.65637516972712	-0.882836257426712
TBL1XR1	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-3.088720517285	-3.088720517285	-5.24042477673694	-5.37506459637	-15.7790309506565	2.78966782929586	0.000821984606500559	0.0186448448223789	-2.60478866469457	-1.69861985420932
TBL1XR1	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	-0.271864033095	-0.271864033095	-1.02154785238708	-0.966558687453	-12.7662319311381	19.4705689172593	6.50801719940586e-11	4.40295712857152e-09	-0.87239375568869	-0.626973882895476
TBL1XR1	BRD-K92000912-001-12-6::2.5::HTS002	2.5	AM-251	cannabinoid receptor antagonist	targeted cancer	CNR1, GPR18, GPR55	NA	NA	OV7, NCIH1299	OVARY, LUNG	carcinoma, carcinoma (non_small_cell_carcinoma)	0.0228346893295	0.0228346893295	-0.12810641179605	-0.0852704438558	-4.04594747143621	77.6956244392597	0.000122040141240959	0.00339433447080631	-0.22521769380321	-0.0766645084478907
TBPL2	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.5031721742955	0.5031721742955	0.146752283756241	0.1611474271015	-15.1078150298323	87.4066184704214	4.23324932365972e-26	1.18293102254324e-23	-0.403307985213513	-0.309531795865005
TBPL2	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.301567519545	-1.301567519545	-0.943659291475652	-0.8676021902365	4.98371440129684	12.1361205781063	0.000307278348575136	0.0077380638199695	0.201629996691586	0.514186459447111
TBPL2	BRD-A08545410-003-07-8::2.3757::HTS002	2.3757	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.181639207435	-0.181639207435	-0.835432649597377	-0.720201208535	-10.9921767542837	194.368000858034	3.60941417586134e-22	7.18961088195339e-20	-0.771098711579347	-0.536488172745407
TBPL2	BRD-A14240607-003-26-1::2.5::HTS002	2.5	octopamine	trace amine associated receptor agonist	noncancer	F10, TAAR1	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.3449218111855	0.3449218111855	0.69421672265543	0.680383035614	9.51418877864675	4.08885754662224	0.000612313337663944	0.0143224386498063	0.248230830231958	0.450358992707903
TBPL2	BRD-A20644369-001-08-6::2.5::HTS002	2.5	canrenone	mineralocorticoid receptor antagonist	noncancer	NR3C2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.40937860257	0.40937860257	0.510264914000005	0.523877694724	3.26409028724502	150.190068251862	0.00135994174633784	0.0288846451839108	0.0398157736843493	0.161956849175661
TBPL2	BRD-A43671941-003-11-9::2.5::HTS002	2.5	oxprenolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	angina pectoris, hypertension, cardiac arrythmia	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.20265248245	-0.20265248245	-0.409069429661007	-0.3932406545145	-4.96339604277028	11.4682489894127	0.00037653037519492	0.00931994211631275	-0.297497257020821	-0.115336637401193
TBPL2	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.1505356780635	0.1505356780635	-0.0840525745748414	-0.0709548517643	-4.94025426910352	13.9528112848003	0.000219508418671124	0.00573814122031509	-0.336465893378047	-0.132710611898636
TBPL2	BRD-A55913614-316-09-6::2.5::HTS002	2.5	primaquine	antimalarial agent, DNA inhibitor	noncancer	KRT7, NQO2	infectious disease	malaria	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.5486266234235	0.5486266234235	0.0929692970911181	0.121843056182	-9.42980212597422	3.35625755090302	0.00157358486954096	0.0327346279242787	-0.600601910097406	-0.310712742567357
TBPL2	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.2042127489395	0.2042127489395	0.0741005201908984	0.128125201883	-4.48566539777125	175.006549882779	1.3124697943653e-05	0.000442435260390879	-0.187359264901095	-0.0728651925961082
TBPL2	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.1907422337735	0.1907422337735	-0.22586898759274	-0.09818472346655	-5.89240872771416	6.88182211465148	0.000643513133050355	0.0149721936314503	-0.58438111651668	-0.2488413262158
TBPL2	BRD-A72703248-003-04-9::2.5::HTS002	2.5	SKF-96365	calcium channel blocker	noncancer	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-3.03576546678	-3.03576546678	-3.54603306486163	-3.55274052264	-4.45782802598173	113.840677394419	1.95030365720224e-05	0.000637205232537347	-0.737026313444677	-0.283508882718575
TBPL2	BRD-A73427433-240-01-3::2.5::HTS002	2.5	adaprev	TGF beta receptor inhibitor	noncancer	IGF2R, M6PR	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.6012854683165	-0.6012854683165	-0.392838202690653	-0.3772229678335	4.91644382805506	21.7730217355363	6.63107539763163e-05	0.0019504320863952	0.120466070013546	0.296428461238149
TBPL2	BRD-A73556557-001-06-4::2.5::HTS002	2.5	tagatose	phosphorylase inhibitor	noncancer	PYGL	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.216162774195	-0.216162774195	0.118295128343706	0.145010239158	11.2960967073377	117.874024329835	1.68780027124736e-20	2.9243698006158e-18	0.275824814237033	0.393090990840379
TBPL2	BRD-A79981887-003-16-4::2.5::HTS002	2.5	midodrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.512153331355	-1.512153331355	-1.03097956335204	-1.01219584287	5.72068591767512	51.4617839292589	5.45645134527717e-07	2.3162522487263e-05	0.312350266573938	0.649997269431973
TBPL2	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.371871397166	-0.371871397166	-0.846364694189536	-0.797149374107	-7.80364409250619	66.7001466406641	5.58500863669893e-11	3.79888707107282e-09	-0.59586875241741	-0.353117841629661
TBPL2	BRD-A97701745-001-16-0::2.5::HTS002	2.5	pindolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B	cardiology	hypertension	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.506529856831	-0.506529856831	0.164950210159393	0.163040623516	17.1787815388063	37.4702383826677	2.35466431167325e-19	3.66235738212348e-17	0.592314281020433	0.750645852960353
TBPL2	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.79937124768	-1.79937124768	-2.32465803112573	-2.459290757005	-5.79563133985132	5.52381696268528	0.00153938572030304	0.0321480076046799	-0.751780337748018	-0.298793229143436
TBPL2	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.1314552666489	0.1314552666489	-0.296870412602448	-0.208078798615	-6.13766814474793	4.95658873398144	0.00171987964893537	0.035359240793925	-0.608190898110584	-0.248460460392111
TBPL2	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.163550117465	-0.163550117465	-0.649331344163063	-0.593822379071	-6.8403058074454	7.7565577707755	0.000152768372383266	0.00415437212101051	-0.65044680315616	-0.321115650239965
TBPL2	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.2693713699655	0.2693713699655	0.0562644772076954	0.0542001317345	-4.64910649038481	183.643283456813	6.35251066095242e-06	0.000227110468298794	-0.303544192052294	-0.122669593463316
TBPL2	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.6079819758405	-0.6079819758405	0.02248007717968	0.2036144024465	10.0802846652819	135.836334445298	3.47571674284595e-18	4.86575371507138e-16	0.506776011090543	0.754148094949817
TBPL2	BRD-K10799896-001-26-2::2.5::HTS002	2.5	clobetasol-propionate	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.5625128279315	-0.5625128279315	-0.0649177822743644	-0.00125185876287	12.2020192978757	157.56564392961	1.56920821491254e-24	3.87473303564504e-22	0.417049611768121	0.57814047954615
TBPL2	BRD-K11663430-001-02-3::2.5::HTS002	2.5	pyroxamide	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.3755102374585	-0.3755102374585	-0.64149058033411	-0.612220843488	-4.10144490796674	118.077343573521	7.57800851000181e-05	0.00220198886380176	-0.394400918952521	-0.137559766798699
TBPL2	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-3.690324045885	-3.690324045885	-4.27914998385667	-4.413620661915	-4.40117269875246	102.776076983058	2.63952532794609e-05	0.000841229478086776	-0.854170583635759	-0.323481292307581
TBPL2	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.370649355565	-1.370649355565	-0.557831793747549	-0.546522000374	17.0266448159335	3.91245714731201	8.14719763804206e-05	0.00235334329186512	0.679097854283817	0.946537269351086
TBPL2	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-3.003778810265	-3.003778810265	-1.08214131789007	-0.864735754699	13.6526354156003	3.82221626938908	0.000220060679720923	0.00575047371664299	1.52357286130306	2.3197021234468
TBPL2	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.1033459536172	-0.1033459536172	-0.305462572476157	-0.19710233478	-3.47209291888317	74.4662360476803	0.000863391945910835	0.0194370757932598	-0.318094005214624	-0.086139232503289
TBPL2	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.850639831735	-0.850639831735	-0.204128540777048	-0.0787988061569	9.35284306546838	4.82461221782966	0.000284515689543145	0.0072182721619428	0.466860347958356	0.826162233957548
TBPL2	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.7030036689795	-0.7030036689795	-0.235611290948941	-0.109165735913	12.1514304642286	189.200517458237	1.73570984519662e-25	4.61554535249561e-23	0.39151903856259	0.543265717498528
TBPL2	BRD-K26823213-001-02-9::2.5::HTS002	2.5	GW-842166	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.5378228431445	0.5378228431445	0.144560507437466	0.195908235522	-8.25009801037962	13.0649761350943	1.54033960957952e-06	6.11482586000315e-05	-0.496189877905561	-0.290334793508507
TBPL2	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-3.985439631125	-3.985439631125	-3.62502293456084	-3.57671972887	4.96401724066999	177.797399898205	1.60926438609895e-06	6.36721481647039e-05	0.217136580141342	0.503696812986971
TBPL2	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.281546290898	-0.281546290898	-1.34666503317514	-1.265409369745	-16.7228026312346	36.2160238284486	1.29415998173298e-18	1.87924129217376e-16	-1.19426656917981	-0.93597091537447
TBPL2	BRD-K33720171-001-01-0::2.5::HTS002	2.5	difluprednate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	endogenous uveitis	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.91495473828	-1.91495473828	-1.46508805554796	-1.420636846445	6.24468918666106	119.587111414828	6.72030650342093e-09	3.65387258389575e-07	0.307227710784122	0.592505654679949
TBPL2	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.3260078261	-0.3260078261	-0.0925570258066664	-0.0710979031402	5.28648727169287	22.2333605112483	2.55433368639468e-05	0.000816628557087241	0.141924453040846	0.324977147545821
TBPL2	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.3262726107925	0.3262726107925	-0.242242321171072	-0.026104548309	-9.31280933767277	11.4117379181651	1.13324376749788e-06	4.58970150121039e-05	-0.702288389969633	-0.434741473957512
TBPL2	BRD-K39558284-001-01-2::2.5::HTS002	2.5	SDZ-WAG-994	adenosine receptor agonist	noncancer	ADORA1	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.04782501923525	0.04782501923525	0.299232185764826	0.3288329829755	8.31495733895694	46.9662860450946	8.71135861956599e-11	5.82012712460399e-09	0.190579967352582	0.31223436570657
TBPL2	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.289547383315	-1.289547383315	-0.623030490335534	-0.4180119465525	7.38242153096189	3.86070650127742	0.00205935773529351	0.0411389769827312	0.412240020948144	0.920793765010788
TBPL2	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.4368018300095	0.4368018300095	0.199166579840714	0.2395368500345	-7.17408486568116	141.678869257345	3.72445968941788e-11	2.59172945844423e-09	-0.303116650875036	-0.172153849462537
TBPL2	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.0028980541544	0.0028980541544	-0.227389427797289	-0.187297921894	-6.05155312193554	17.5029776265497	1.14345290753028e-05	0.000389193454372016	-0.310399595111963	-0.150175368791415
TBPL2	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-4.042487028815	-4.042487028815	-3.14182920532612	-3.15598793833	7.58066558080837	9.13068538335335	3.13430036895136e-05	0.000981117954983168	0.632476492203828	1.16883915477394
TBPL2	BRD-K60230970-001-17-5::2.40205::HTS002	2.40205	MG-132	proteasome inhibitor	targeted cancer	PSMB1	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-6.83998604405	-6.83998604405	-6.15504680570898	-6.09839932339	7.45591424852278	5.15058813810437	0.000601239748148983	0.0141142512575053	0.45085376864756	0.919024708034485
TBPL2	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.3034774004895	0.3034774004895	-0.49694404311734	0.00402399396559	-6.65797515706664	4.83059656801314	0.00131727311117295	0.0281205008610146	-1.11274496493749	-0.488097922276187
TBPL2	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.279141462528	0.279141462528	0.144291879072332	0.15713254048	-4.76113645738112	33.1123065876547	3.69614542542968e-05	0.00114329443565233	-0.192465700429165	-0.0772334664821712
TBPL2	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.05495923602139	-0.05495923602139	-0.608670291605778	-0.456560974373	-6.8546737183354	5.86227875545511	0.000523796369475287	0.0124891258285982	-0.75250029002818	-0.354921821140595
TBPL2	BRD-K66808046-065-03-7::2.5::HTS002	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.686170243562	0.686170243562	-0.467414080550369	-0.3317635225235	-13.4407874843033	77.1897734162536	6.5427943844368e-22	1.27831410904463e-19	-1.32448128504194	-0.982687363182803
TBPL2	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-1.26663133173	-1.26663133173	-0.777509933284183	-0.683338343709	6.05203366074677	5.54338389484	0.00123100115546717	0.0265284234450643	0.287347012628084	0.690895784263551
TBPL2	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.09757107834955	0.09757107834955	-0.264614507593776	-0.236194067289	-7.88419843652587	18.5084464541999	2.49063146803132e-07	1.10887941817965e-05	-0.458508389802259	-0.265862782084394
TBPL2	BRD-K68633617-003-02-9::2.5::HTS002	2.5	ACDPP	glutamate receptor antagonist	noncancer	GRM5	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.559031084349	0.559031084349	0.233665107034308	0.319454889976	-5.80990799820114	19.9069705004121	1.12205292899923e-05	0.000382882474477754	-0.442218933227484	-0.2085130214019
TBPL2	BRD-K71106091-001-06-1::2.5::HTS002	2.5	fludarabine-phosphate	ribonucleotide reductase inhibitor	chemo	DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.4283700164015	-0.4283700164015	-0.199749823293273	-0.21623153212	8.80846464165744	173.162934341761	1.28840521132248e-15	1.42048662827951e-13	0.177392083342504	0.27984830287395
TBPL2	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.268819013481	0.268819013481	-0.216120934826936	-0.195517916983	-17.2165142193402	20.2142989556354	1.5131401397917e-13	1.36379231716322e-11	-0.543655664403045	-0.426224232212826
TBPL2	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.370762638465	-2.370762638465	-0.662985992569074	-0.4541784692175	20.8398663595261	39.6348218983142	5.78243475468183e-23	1.24432074150221e-20	1.54210685802904	1.87344643376282
TBPL2	BRD-K78086729-001-02-7::2.5::HTS002	2.5	GW-788388	ALK tyrosine kinase receptor inhibitor	noncancer	LCK, MAPK14, TGFBR1	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.679100650336	0.679100650336	0.496713480782926	0.515272690573	-5.94278105257585	58.0242862939466	1.69124413119896e-07	7.71396885168978e-06	-0.243820415953747	-0.1209539231524
TBPL2	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.2331605424965	0.2331605424965	-0.46785711860513	-0.217946401079	-7.86941237787831	73.9065911930907	2.30348924340756e-11	1.64677967328318e-09	-0.878519798184902	-0.523515524018359
TBPL2	BRD-K82746043-001-15-1::2.5::HTS002	2.5	navitoclax	BCL inhibitor	targeted cancer	BCL2, BCL2L1, BCL2L2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.8242895128585	-0.8242895128585	-0.319792025048983	-0.3195858510195	6.81901491053218	13.2574362349379	1.10791085102612e-05	0.000378297633884939	0.344979860038707	0.664015115580328
TBPL2	BRD-K82818427-001-02-2::2.39189::HTS002	2.39189	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.403602161205	-2.403602161205	-1.60515283092468	-1.52191219559	10.9119772901103	9.17866215097886	1.46506732495137e-06	5.83546579984206e-05	0.633412995858333	0.963485664702304
TBPL2	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.07482347552975	-0.07482347552975	0.350403151364254	0.388891879995	12.8839686343394	19.1917177610612	6.74563608930949e-11	4.55222115045848e-09	0.356194466948726	0.494258786839282
TBPL2	BRD-K84663978-003-02-9::2.5::HTS002	2.5	trequinsin	phosphodiesterase inhibitor	noncancer	PDE5A	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.19338000695	-0.19338000695	-0.0435689672656526	-0.0536519890124	5.48565508798732	32.4740262996256	4.62027939103705e-06	0.000169826764123063	0.0942150357611483	0.205407043607547
TBPL2	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.3816809667755	-0.3816809667755	-0.148669258142201	-0.137644446714	6.40436151560584	180.916265740163	1.26426978722435e-09	7.45241141985719e-08	0.161221550491807	0.304801866774791
TBPL2	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.07167386642935	-0.07167386642935	0.113304992725961	0.0998567885779	6.39434379185454	19.077297737264	3.85152332193074e-06	0.000143066402437798	0.124447385374829	0.245510332935794
TBPL2	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.01222796986872	-0.01222796986872	-0.164290281026236	-0.121855279851	-6.087047190592	14.098078448837	2.72045033728523e-05	0.000863297898045611	-0.205606907911034	-0.0985177144039978
TBPL2	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-6.57319330845	-6.57319330845	-6.2106184922818	-6.171939349	5.03235993669088	8.98560818833449	0.000710553072292471	0.0163807819115169	0.19954961082072	0.525600021515682
TBPL2	BRD-K89085489-001-23-2::2.5::MTS006	2.5	fenretinide	apoptosis stimulant, retinoid receptor agonist	targeted cancer	RARA	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.07628881510495	0.07628881510495	0.3210308155734	0.367607553977	7.38028725797761	20.490884244084	3.40631915299207e-07	1.48721323638549e-05	0.175674234202884	0.313809766734016
TBPL2	BRD-K89162000-001-06-4::2.5::HTS002	2.5	tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFD, PDGFRB	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.752411508342	0.752411508342	0.047898553908344	0.117993019303	-13.4835896506669	4.48727919047308	8.41201939287676e-05	0.00242428358808106	-0.84357481651866	-0.565451092348653
TBPL2	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-3.69225773505	-3.69225773505	-2.8751202488746	-2.82062384431	6.72541986635878	19.4653633999183	1.75532395950214e-06	6.88915636176769e-05	0.563246246921919	1.07102872542887
TBPL2	BRD-K92213669-001-01-3::2.5::HTS002	2.5	lomitapide	microsomal trigylceride transfer protein inhibitor	noncancer	MTTP	endocrinology	hypercholesterolemia	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.5354953711305	0.5354953711305	0.223660451687339	0.227576049132	-7.67860629294989	96.220273804903	1.33665784774036e-11	9.8549893308684e-10	-0.392444513898919	-0.231225324987404
TBPL2	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.703560631369	-0.703560631369	-0.341206824252135	-0.279710660695	9.35714283254704	144.431104866025	1.46548435275017e-16	1.76855740901234e-14	0.2858132008362	0.43889441339753
TBPL2	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.4975913389075	0.4975913389075	-0.0950092578422203	0.0692106615383	-10.6561668364591	40.3261674527077	2.70466735146639e-13	2.37772210325037e-11	-0.70496640465475	-0.48023478884469
TBPL2	BRD-K98572433-001-02-9::2.5::HTS002	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	CAOV3, MKN7	OVARY, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-3.868542775765	-3.868542775765	-2.69703252427257	-2.69732165055	10.6133093296674	9.36925331219369	1.57327578947873e-06	6.23633487485087e-05	0.923302629137194	1.41971787384767
TENM4	BRD-A27376179-001-01-3::2.5::HTS002	2.5	lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	targeted cancer	FLT3, NTRK1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.721916407015	-1.721916407015	-2.92653455523553	-2.893945062805	-10.1210465441663	8.17173735878603	6.64976010998789e-06	0.00023667160986609	-1.4780805246588	-0.931155771782257
TENM4	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.59693862803	-0.648630348455	-1.24531472813598	-1.05827625236	-5.06983292613745	7.73150651540284	0.00107120399349992	0.0234562812344549	-0.945080986357007	-0.351671213854947
TENM4	BRD-A58193911-003-18-7::2.5::HTS002	2.5	oxyphencyclimine	cholinergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.784287816201667	-0.806970168186	-2.32596012201023	-2.15815631879	-10.3922907190739	10.2181460704634	9.34182561698063e-07	3.8378841147438e-05	-1.87125752852267	-1.21208708309444
TENM4	BRD-A70858459-001-01-7::2.5::HTS002	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.317393330945333	0.322389869334	0.0966884666324165	0.0915343135028	-5.23148584539058	7.23260342642705	0.0010917284077492	0.0238545272611356	-0.319816449254016	-0.121593279371817
TENM4	BRD-A74914197-001-02-9::2.5::HTS002	2.5	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.88680070088	-0.833231618307	-2.37969967308221	-2.319019286365	-10.6960497288303	4.15898240076825	0.000351723902974404	0.00875344082682315	-1.87464791209559	-1.11115003230882
TENM4	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.398013349495333	0.383536902332	-0.243334291282316	-0.237747007696	-13.4073853422743	98.6086626368786	5.9558239627727e-24	1.39508829958154e-21	-0.736268112403888	-0.54642716915141
TENM4	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.41472358605	-0.394181902733	0.0524205036494269	0.0807207161616	9.25057522933748	4.86727620657714	0.00028584819431016	0.00724778867127675	0.336260529119831	0.598027650279022
TENM4	BRD-A93093700-001-02-9::2.5::HTS002	2.5	temazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO	NA	NA	MDAMB175VII, NCIH520	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.199655694502	0.199655694502	0.297404602537979	0.2970613680105	3.66281939303017	51.2241898563373	0.000591446656176175	0.0139255377756326	0.0441786253970763	0.151319190674881
TENM4	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.278540867943333	0.282782540873	0.0288339890786318	0.00163524469207	-5.52077120407281	41.4577575369212	2.0088407756704e-06	7.82538776097167e-05	-0.341020973794926	-0.158392783934477
TENM4	BRD-K02113016-001-15-4::2.5::HTS002	2.5	olaparib	PARP inhibitor	targeted cancer	PARP1, PARP2	oncology	ovarian cancer	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.383586645807333	0.38403974872	-0.0912744579259132	-0.0352109165825	-11.1886932056951	28.1601138594752	7.08998192509101e-12	5.40010211806265e-10	-0.561775612313219	-0.387946595153274
TENM4	BRD-K03449891-001-08-6::2.5::HTS002	2.5	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.974879642109	-1.04152429562	-2.04310120525533	-1.94265299892	-7.38078310916904	4.62033529173906	0.00100328078420585	0.0221934324696103	-1.44964815796834	-0.686794968324315
TENM4	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.164046954409667	-0.119113575141	-1.03993951177612	-1.02167878601	-12.066159945819	8.34931426926681	1.42556049936655e-06	5.68656162793103e-05	-1.04207607771808	-0.709709037014819
TENM4	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.145010416513333	0.149625436191	-1.71063858501918	-1.366726913685	-9.99295206703895	5.27463933341798	0.000126216606531049	0.00349869103222882	-2.32561554495504	-1.38568245810999
TENM4	BRD-K07310275-001-02-5::2.5::HTS002	2.5	PF-04691502	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.54171582345	-2.54171582345	-3.93930132345007	-3.94541046238	-14.2718101419169	138.077171705757	5.857380081318e-29	2.15705569664743e-26	-1.59121455409682	-1.20395644590332
TENM4	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.305191502445333	0.224259602932	-2.07594239625848	-1.67548621627	-13.7565242063873	7.94813182354	7.99808995804522e-07	3.3189208569562e-05	-2.78073687677569	-1.98153092063194
TENM4	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.868592149509333	-0.812677420395	-1.50336861304734	-1.403807480235	-5.68984449278786	5.02394337906914	0.00230189116466323	0.0452667246014411	-0.921147836129488	-0.348405090946532
TENM4	BRD-K09426783-300-01-0::2.5::HTS002	2.5	TAS-103	topoisomerase inhibitor	chemo	TOP1	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.19525901002533	-1.16221230472	-2.73548559348748	-2.62676711601	-8.51425925649277	3.71235313304003	0.00144305621739497	0.0304148683270771	-2.0582112222597	-1.0222419446646
TENM4	BRD-K11215326-001-03-7::2.31084::HTS002	2.31084	tazemetostat	histone lysine methyltransferase inhibitor	targeted cancer	EZH2	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.03658821650759	-0.0328650297333	-0.288279794010217	-0.279404831022	-6.37704919898494	16.2429169489866	8.54087372601244e-06	0.000297942207816165	-0.335259150212209	-0.168124004793046
TENM4	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.14373670094967	-1.03722274642	-2.46840193248877	-2.47957916758	-7.4467390161941	3.82862711314856	0.00206065329397078	0.0411610214206396	-1.82739583389103	-0.821934629187188
TENM4	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.517203331396333	0.52892834499	-0.0623560359015794	0.163538035025	-5.91253674571192	6.39185155203883	0.000828265027035099	0.0187614896406051	-0.815891231668454	-0.343227502927371
TENM4	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.89069996874667	-1.9031945369	-2.75433512318468	-2.78705834209	-18.0906312885611	112.452138117543	4.37124500372219e-35	2.78007290920704e-32	-0.958220423352671	-0.769049885523357
TENM4	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	1.14938771161667	1.08031593979	-0.0620948497906136	0.07648452394105	-11.4203428085258	4.23654335008845	0.000242996719480692	0.00629304541923359	-1.49963744432521	-0.923327678489352
TENM4	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.16864263294	-1.12520591293	-2.47057714355501	-2.38347567797	-12.2720950567122	23.7707832809416	8.9628699012938e-12	6.76171398477437e-10	-1.52100326662863	-1.08286575460139
TENM4	BRD-K21283037-001-21-5::2.5::HTS002	2.5	riluzole	glutamate inhibitor	noncancer	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	MDAMB175VII, NCIH520	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.297954569573	0.297954569573	0.042215255434767	0.0176424857247	-7.78239591965285	15.567895822632	9.47399518838303e-07	3.88548012769029e-05	-0.325559544557753	-0.185919083718713
TENM4	BRD-K21680192-300-14-4::2.5::HTS002	2.5	mitoxantrone	topoisomerase inhibitor	chemo	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.67526260072333	-2.61605100457	-4.76128842764391	-4.77531837589	-10.2934033750773	5.07248000998919	0.000136843060123854	0.00376013453056131	-2.60474016609844	-1.56731148774272
TENM4	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1648375724245	0.0518874635561	-2.09623592617549	-2.00148151566	-11.9787949868505	3.13296240992303	0.00101455845906792	0.0223989802197742	-2.84761237613417	-1.67453462106581
TENM4	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.0031434890885	-1.0031434890885	-1.97285488665375	-1.89093805071	-13.4189596569941	165.999082525781	2.81389227070044e-28	9.7746955670495e-26	-1.11238693672244	-0.827035858408057
TENM4	BRD-K32730239-001-01-0::2.5::HTS002	2.5	SU3327	JNK inhibitor	noncancer	MAPK8	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.242957077775733	0.277795437624	-0.625617568359529	-0.480678971711	-7.43503986420525	3.86323503222963	0.00200158188202244	0.0401269332328115	-1.1975029741731	-0.539646318097428
TENM4	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.261019291214	-0.265242941342	-0.0161802165561246	-0.0118465080062	8.36293329623044	112.813244679719	1.82043968895356e-13	1.62707680606225e-11	0.186835615910478	0.302842533405273
TENM4	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.320405200255333	0.30818858867	-1.97250766595849	-1.77214463061	-16.2638502260275	4.88852866022801	1.91469753820969e-05	0.000626897425615202	-2.65781879652716	-1.92800693590049
TENM4	BRD-K40308497-001-01-2::2.53691::HTS002	2.53691	crizotinib-(S)	MTH1 inhibitor	targeted cancer	NUDT1	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.137855543026433	-0.0798743017912	-1.80277672412528	-1.69530013735	-9.98291521277852	4.29690100053328	0.000392413379130092	0.00964845326781847	-2.11561920547435	-1.21422315672334
TENM4	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.642583249808667	-0.61009794728	-2.3153986187052	-2.153093363415	-17.8432392265413	44.5414851702201	6.49397562170845e-22	1.26993366881857e-19	-1.86169254525931	-1.48393819253374
TENM4	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.17437918424767	-1.23051882859	-2.77147967129538	-2.76881618955	-11.7605307904765	5.51733496770333	4.08441037349231e-05	0.0012534472951607	-1.93657077809553	-1.2576301959999
TENM4	BRD-K42756753-001-01-9::2.5::HTS002	2.5	epiandrosterone	steroid	noncancer	G6PD	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.332046237536667	0.330357582658	0.220696971962604	0.227587512124	-3.87936706045489	173.820195913383	0.000148420497251666	0.00404511911946239	-0.168000435954872	-0.0546980951932536
TENM4	BRD-K44084986-300-08-4::2.5::HTS002	2.5	Y-27632	rho associated kinase inhibitor	targeted cancer	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2423261655385	-0.2423261655385	-0.945153418870099	-0.864137598244	-8.32555081374813	3.79194968509329	0.00142957249348632	0.0301751864247025	-0.942369265065145	-0.463285241598054
TENM4	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	NCIH1435, NCIH520	LUNG	carcinoma (non_small_cell_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.28373277821	-2.28373277821	-3.77239459287166	-3.649368876965	-12.3531441377197	12.3516162388958	2.5708876779655e-08	1.30356230217806e-06	-1.75040119648363	-1.22692243283969
TENM4	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	NCIH1435, MDAMB175VII	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma)	-0.15333657801	-0.15333657801	0.157788094857936	0.14294893902	16.0256193814488	186.133450543167	6.92394013978576e-37	5.41606265043847e-34	0.272824505252356	0.349424840483517
TENM4	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.113622642043333	0.114064362658	0.350318637055796	0.389842478875	7.31761547638653	164.284168253181	1.06172411379414e-11	7.92058014567991e-10	0.17282841154271	0.300563578482216
TENM4	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.100853312540233	0.0836751433408	-0.328704136623327	-0.240168973437	-7.75319261980025	25.894396306545	3.25649033795596e-08	1.62960615840243e-06	-0.543464495830399	-0.315650402496722
TENM4	BRD-K55187425-236-05-2::2.5::MTS010::PROS004_PR500	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.566084414065	0.496376920051	-0.822181783878419	-0.737710082333	-12.5581343814807	10.1489144347585	1.64439935286653e-07	7.51957475785216e-06	-1.63409162331993	-1.14244077256691
TENM4	BRD-K56334280-001-05-1::2.5::HTS002	2.5	amonafide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.690852380529	0.690549921799	-0.421524307161471	-0.361570491465	-14.7061691680411	21.132447732681	1.42081322628132e-12	1.16273951117086e-10	-1.26961895983335	-0.955134415547589
TENM4	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.71221537842333	-2.88001565241	-4.67867667697716	-4.7477139028	-10.3027373183169	3.31519526510257	0.00124755124462853	0.0268460251716857	-2.54248835014729	-1.39043424696036
TENM4	BRD-K62965247-001-04-9::2.5::HTS002	2.5	tipifarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, FNTB	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.356949698604333	-0.396822396595	-1.4873026026843	-1.407061833485	-12.6515569823673	5.57090574287052	2.57900375286495e-05	0.000823410241840892	-1.35311957917833	-0.907586228981609
TENM4	BRD-K66030860-001-03-6::2.5::HTS002	2.5	salidroside	beta amyloid protein neurotoxicity inhibitor	noncancer	APP	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.269195796008667	0.263769087417	0.130994115131347	0.129116420686	-4.13098953439096	16.3528763515587	0.00075180017588179	0.0172168586276919	-0.208998641674462	-0.0674047200801773
TENM4	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.32273444160667	-1.46294802617	-3.16645056849891	-3.06669625223	-9.99280056601709	4.3019261921051	0.000388430692491963	0.00955930208877139	-2.34211030224341	-1.34532195154107
TENM4	BRD-K79131256-001-17-9::2.5::HTS002	2.5	albendazole	tubulin polymerization inhibitor	noncancer	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.412777792824	-0.319774425242	-2.23729462207363	-2.08207952886	-9.4243587372738	3.75460092882454	0.000952453672047309	0.021200638501312	-2.37616776341543	-1.27286589508382
TENM4	BRD-K81458380-001-04-9::0.15625::HTS002	0.15625	CX-4945	casein kinase inhibitor	targeted cancer	CSNK2A1, CSNK2A2, DAPK3, HIPK3	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.1198704808297	-0.128540257759	0.337672240941214	0.3721178326705	10.9670949223666	5.93266285800198	3.68179821726441e-05	0.00113918886979654	0.355177032630239	0.559908410911588
TENM4	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.282486930407333	-0.235666028427	-1.71064247489741	-1.42344760781	-10.7115023091232	5.65176534741629	5.76119331753397e-05	0.00171689488675436	-1.75933543737252	-1.09697565160763
TENM4	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	MDAMB175VII, NCIH520	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.452308996713	0.452308996713	0.185971997258881	0.18484230673	-7.00677451544279	32.3619437614253	5.73707845465475e-08	2.7813216197867e-06	-0.343729649937957	-0.188944348970282
TENM4	BRD-K85849709-001-01-5::2.5::HTS002	2.5	AZD2858	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0317110886386667	-0.109033266003	-1.76645213927804	-1.58909179466	-8.3939024458545	3.28535797384687	0.00249861960112416	0.0485518259736482	-2.36128120873352	-1.10820089254523
TENM4	BRD-K89015388-001-01-7::2.5::HTS002	2.5	GSK923295	centromere associated protein inhibitor	targeted cancer	CENPE	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.340837568409333	-0.355082972703	-1.66141616729854	-1.50238366978	-9.9772203543515	6.42704571680249	3.80171329445464e-05	0.00117358117339359	-1.63930471295259	-1.00185248482581
TENM4	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.05448847827067	-0.909729655316	-3.13960298853394	-3.01977244738	-10.3194437863969	3.80501974251178	0.000640702222608885	0.0149140157872928	-2.65763558290005	-1.5125934376265
TENM4	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.204448750219667	0.199891279624	0.0918335712666705	0.0957687092427	-3.86516672648262	24.3307225456693	0.000726407887033823	0.0167043841667558	-0.17270553168197	-0.0525248262240225
TENM4	BRD-K96123349-236-02-8::2.5::HTS002	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.597534091828667	-0.565050543441	-1.76796349154397	-1.70195176188	-11.3103019748373	5.1054289837742	8.28804783612623e-05	0.00239048446328771	-1.43479836444997	-0.906060434980633
TENM4	BRD-K99545815-001-06-3::2.5::HTS002	2.5	PF-562271	focal adhesion kinase inhibitor	targeted cancer	PTK2, PTK2B	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.1027698944841	-0.0884596851336	-1.1043477422313	-1.03488967293	-14.8635244455473	80.9367551247483	7.55441193997578e-25	1.93444391479459e-22	-1.13565434887765	-0.867501346616749
TENM4	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	NCIH1435, MDAMB175VII, NCIH520	LUNG, BREAST	carcinoma (non_small_cell_carcinoma), carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.286825936225	0.286977621672	-0.225659397052129	-0.151752254605	-9.90183755129122	69.718906349679	6.2723309786598e-15	6.46629353691763e-13	-0.615717911974596	-0.409252754579661
THSD4	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-5.85387063417	-5.85387063417	-4.11887539957627	-4.11179699224	10.0893678371291	3.5861370783909	0.000926936678596338	0.0207055144749218	1.23501453304758	2.23497593613989
THSD4	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-3.38275212395	-3.38275212395	-2.59482762988338	-2.674840125005	10.4759499061301	49.9604260535567	3.31745380775664e-14	3.20282232956159e-12	0.636852372036369	0.938996616096863
THSD4	BRD-K14175878-001-01-6::2.5::HTS002	2.5	MK-0812	CC chemokine receptor antagonist	noncancer	CCR2	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.03305097423515	0.03305097423515	0.332973083158734	0.3199556031455	11.4513808956479	140.529848265064	7.37824839297898e-22	1.42981247723218e-19	0.248142970949065	0.351701246898104
THSD4	BRD-K17894950-001-14-3::2.5::MTS010::PROS002_PR500	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.754344014289	0.754344014289	0.0113907661387428	0.01698904715675	-29.0844285485737	62.5325707559915	4.78442477029995e-38	4.1854733738515e-35	-0.794007743383288	-0.691898752917227
THSD4	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.1237079472975	0.1237079472975	-0.0618380336143228	-0.0626502991923	-5.57699037133913	145.727108524528	1.15426488762029e-07	5.39804580184964e-06	-0.251299856619413	-0.119792105204232
THSD4	BRD-K30867024-003-03-3::2.5::HTS002	2.5	SB-216641	serotonin receptor antagonist	noncancer	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-0.3517285572115	-0.3517285572115	-0.0449185086222123	-0.01731915547495	7.79757526181259	28.4126014742514	1.54417032358544e-08	8.08403715886036e-07	0.226264370596548	0.387355726582027
THSD4	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-3.09444568133	-3.09444568133	-2.61292461802485	-2.424137198535	4.81017705406292	24.9040291411043	6.15052178387119e-05	0.00182252894153923	0.275311395816393	0.687730730793908
THSD4	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-5.49127450287	-5.49127450287	-3.75242769936645	-3.68976707366	16.8432463987432	60.1589505126651	1.8984409070869e-24	4.63957743643134e-22	1.53235321066201	1.94534039634509
THSD4	BRD-K47869605-001-32-0::0.625::HTS002	0.625	podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	noncancer	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-4.459437884045	-4.459437884045	-3.25672387090531	-3.14383737587	8.21773727820548	4.1721164241473	0.000995529675603562	0.0220470014302992	0.80289157947579	1.60253644680358
THSD4	BRD-K50071428-001-03-3::2.5::HTS002	2.5	abiraterone	androgen biosynthesis inhibitor	targeted cancer	CYP11B1, CYP17A1	oncology	prostate cancer	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.6629258687875	0.6629258687875	0.520846518465815	0.521292609125	-5.41101051481001	133.414891749848	2.81438478312382e-07	1.24628982682261e-05	-0.194014091070988	-0.0901446095723829
THSD4	BRD-K50853363-001-02-3::2.5::HTS002	2.5	dienogest	progesterone receptor agonist	noncancer	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.134891546161	0.134891546161	-0.281508198678182	-0.2219400984365	-7.87727769274482	27.6904087437364	1.51491415944523e-08	7.95029473260866e-07	-0.524734893459764	-0.3080645962186
THSD4	BRD-K53720352-001-03-2::2.5::HTS002	2.5	cinalukast	leukotriene receptor antagonist	noncancer	CYSLTR1	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.1275985994635	0.1275985994635	0.305022475745337	0.306467449749	8.18483606940111	186.023323829317	4.21278646989577e-14	4.01834584470979e-12	0.134659237747074	0.220188514816601
THSD4	BRD-K54256913-001-08-7::2.5::MTS010::PROS004_PR500	2.5	MK-1775	WEE1 kinase inhibitor	targeted cancer	WEE1	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-0.16027003518605	-0.16027003518605	-1.2216074102142	-1.224724300865	-7.72029124081823	4.94555942703853	0.000611568180632314	0.0143096939505178	-1.41589815434761	-0.706776595708691
THSD4	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.700144432232	0.700144432232	0.465133894915474	0.458736917071	-6.67028441943345	4.77165462020046	0.0013694295061725	0.0290458640899007	-0.326897713242009	-0.143123361391044
THSD4	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.174435050397	0.174435050397	0.0360063592850246	0.07942712884705	-4.21676496355167	33.9080373241258	0.000173930115218355	0.00467321896259683	-0.205150231459631	-0.0717071507643194
THSD4	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-1.702270105055	-1.702270105055	-0.514518639310774	-0.364234530081	15.2340581430628	3.10200630877264	0.000510397651256056	0.0122090422093816	0.944178817677491	1.43132411381096
THSD4	BRD-K72703948-001-10-1::2.5::HTS002	2.5	ZM-447439	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-2.18310435094	-2.18310435094	-1.36366542606229	-1.20810086616	11.5536050532996	92.7710441888187	1.17095736516744e-19	1.87012012756314e-17	0.678591438403732	0.960286411351697
THSD4	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-2.34451192723	-2.34451192723	-2.93117695382564	-2.86819814614	-5.39694610702465	25.8722329070041	1.20099243323521e-05	0.000407612838040965	-0.810161262341731	-0.363168790849541
THSD4	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-0.503965935714	-0.503965935714	-0.209456326985182	-0.185900015084	8.93662767845063	18.4565405523713	3.97273459977335e-08	1.96327469226383e-06	0.225395564345848	0.363623653111788
THSD4	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-4.378792332715	-4.378792332715	-3.96674910163556	-3.94724012749	3.60202936009464	193.004678677909	0.000401584209170078	0.00984345173458527	0.186424361571998	0.637662100586877
THSD4	BRD-K79259477-001-04-9::2.5::HTS002	2.5	NVP-BHG712	ephrin inhibitor	targeted cancer	EPHB4	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-0.7354841566935	-0.7354841566935	0.160980135230637	0.151755478673	25.6563669136972	42.0319244545352	2.6627133210559e-27	8.19966499121538e-25	0.825951678722337	0.966976905125936
THSD4	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-2.60195043167	-2.60195043167	-1.27007765840212	-1.21704769228	15.6300292413656	3.90995054740939	0.000113899300548648	0.003186935141944	1.09312066450235	1.57062488203342
THSD4	BRD-K83988098-001-02-0::0.039::MTS010::PROS005_PR500	0.039	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-1.638717536445	-1.638717536445	-0.967928163336005	-0.896138988933	6.77041594189267	180.657932544874	1.73863183960846e-10	1.12105662921613e-08	0.475293312886284	0.866285433331707
THSD4	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.2903891229115	0.2903891229115	0.0401760408163652	0.0562766217073	-8.58103527425865	52.6717234920963	1.40337734508046e-11	1.03185064491853e-09	-0.308706829989621	-0.191719334200649
THSD4	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.365276485082	0.365276485082	0.108729596375057	0.0860999016039	-8.62312847420213	13.5631956032325	7.15037509326255e-07	2.98855839189522e-05	-0.320549817616763	-0.192543959797122
THSD4	BRD-K86930074-001-05-0::2.5::HTS002	2.5	cediranib	KIT inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-4.479294320875	-4.479294320875	-3.0027836145585	-2.793440773595	16.1632750821283	131.4501859379	4.8907612642373e-33	2.58185214532689e-30	1.29580493235329	1.6572164802797
THSD4	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-0.0744403140802	-0.0744403140802	-0.163631949341458	-0.121855279851	-4.05941475419501	149.355325588589	7.90966614205037e-05	0.00229183565575167	-0.132606862462407	-0.0457764080601098
THSD4	BRD-K89053832-001-01-0::2.5::HTS002	2.5	VLX600	ubiquitin C-terminal hydrolase inhibitor	targeted cancer	USP14	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-3.012840434085	-3.012840434085	-2.05591127121063	-1.884641143255	7.33051163889235	7.06179158124552	0.000151893663984063	0.00413294618611658	0.648796461844657	1.26506186390408
THSD4	BRD-K89714990-001-01-5::2.5::MTS006	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	0.7907478563865	0.7907478563865	0.130516284056323	0.163955716777	-12.9090864408722	2.52624783293581	0.00226068553545072	0.0445586233334207	-0.841704359344487	-0.478758785315867
THSD4	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-2.27628706369	-2.27628706369	-1.58833631207016	-1.34116610852	9.45889881714769	190.000717980435	1.21413083602253e-17	1.61729924147839e-15	0.544487729257094	0.831413773982588
THSD4	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	IM95, OVK18	STOMACH, OVARY	carcinoma (intestinal_adenocarcinoma), carcinoma (endometrioid_carcinoma)	-0.172306108765	-0.172306108765	0.31535109769024	0.3392697962385	11.9197857661218	6.91157375108806	7.34288668488321e-06	0.000259018031646533	0.390665235786712	0.584649177123769
TMCO4	BRD-A70858459-001-01-7::2.5::MTS010::PROS003_PR500	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.342660036138333	0.345593193169	-0.0207967862967225	-0.0162841171901	-11.2635236684388	4.46914470093282	0.000189318167440223	0.00503491419646303	-0.44945856729153	-0.277455077578582
TMCO4	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.700454717018333	-0.704994092942	0.0275520340319352	0.208078137774	9.64462902072755	16.2943141755233	3.85037234273465e-08	1.90720234306904e-06	0.568224252090334	0.887789250010203
TMCO4	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.804946594217	-0.804946594217	-1.3467497920249	-1.37381285511	-7.16911614156248	16.9876243456022	1.57752063041566e-06	6.25084894058712e-05	-0.701260548522759	-0.382345847093032
TMCO4	BRD-K30519779-001-03-1::2.5::HTS002	2.5	homoquinolinic-acid	glutamate receptor agonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.5597041267455	0.5597041267455	0.425586895797105	0.440439645693	-4.37559054678083	180.969792496339	2.04229937195799e-05	0.000664123778019092	-0.194596988638494	-0.0736374732582963
TMCO4	BRD-K39558284-001-01-2::2.5::HTS002	2.5	SDZ-WAG-994	adenosine receptor agonist	noncancer	ADORA1	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.0448131964343333	0.0441805147415	0.300595759769707	0.330222013101	8.91489208738024	186.493528038048	4.44123788039196e-16	5.12041997668923e-14	0.199180742373498	0.31238438429725
TMCO4	BRD-K42828737-044-09-0::2.5::HTS002	2.5	sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.305223592344667	0.294457126692	-0.116348298412158	-0.1199225066305	-7.52591282574706	31.7682366348627	1.5025348254842e-08	7.88919124476247e-07	-0.535705501242247	-0.307438280271403
TMCO4	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.247245766455333	-0.284178275482	-0.89938753587988	-0.8616766323795	-8.11613446238972	9.88310345747204	1.11596747085561e-05	0.000380927205066114	-0.831463024464299	-0.472820514384794
TMCO4	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.998420528238667	-0.997739733484	-0.273140773930306	-0.251562924643	20.3173858074929	145.004900041412	2.91003762934931e-44	4.41397256030276e-41	0.65472512134769	0.795834387269032
TMCO4	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.630016800939333	-0.606445475508	-0.101554310278471	0.0544022530009	6.13369432745751	4.4754486721236	0.00245970413664167	0.0478921151029896	0.298947990995727	0.757976990325997
TMCO4	BRD-K51471001-303-04-7::2.5::HTS002	2.5	demecarium	acetylcholinesterase inhibitor	noncancer	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.1096650347332	0.11362575359	0.281557703089028	0.2819831208515	7.07136907074261	172.240700204746	3.67927157269655e-11	2.56447023383571e-09	0.123912234341167	0.219873102370489
TMCO4	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.150559197577667	0.143458530119	-0.105402037804217	-0.112334547227	-4.85435725150514	22.6131431823409	6.99108988360538e-05	0.00204558812786793	-0.365141054026818	-0.146781416736949
TMCO4	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.276645642755	0.230161121212	-0.245177634691704	-0.106614148702	-6.58830353043494	7.54610998726984	0.000222017507807518	0.00579595498549055	-0.706399217958666	-0.337247336934743
TMCO4	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-2.23889447366	-2.26009845877	-1.28062001783665	-1.0254545794	11.4402051423198	133.471397506273	1.51827034621212e-21	2.84697607203236e-19	0.792598379741369	1.12395053190534
TMCO4	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-5.90374407981333	-5.91111023076	-5.57999821119772	-5.45696617164	3.89609993881169	100.104857825873	0.000176725951062312	0.00474120620418503	0.158890152918391	0.488601584312826
TMCO4	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-3.87712185600333	-3.85195174297	-3.12000716096442	-3.01350141086	5.17722247343679	8.64236726100669	0.000661831715328485	0.0153517023500691	0.424199249495402	1.09003014058242
TMCO4	BRD-K75911534-001-01-6::2.5::HTS002	2.5	SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.136500153659633	-0.1242727699	-0.528038098762494	-0.415318183691	-5.18123554934126	9.77408006801711	0.000443820568936867	0.0107790151204782	-0.560443981791794	-0.222631908413928
TMCO4	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	0.4677175669245	0.4677175669245	0.0286638444060232	0.114428305936	-6.88666425892279	4.73219426468114	0.00123003815610856	0.0265144169728042	-0.605768378038312	-0.272339066998641
TMCO4	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.117047669527367	-0.125318329004	0.353323252998576	0.389267014766	11.0134373584252	6.94292052495363	1.19784379621735e-05	0.000406672996989494	0.369212055151243	0.571529789900642
TMCO4	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-0.5483478001015	-0.5483478001015	-1.25866415551163	-1.28599874522	-8.62549008114382	11.4972012385466	2.33256197157208e-06	9.01109723873597e-05	-0.890617576165168	-0.530015134655091
TMCO4	BRD-K98572433-001-02-9::2.5::HTS002	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	GP2D, LS513, MKN7	LARGE_INTESTINE, STOMACH	carcinoma (adenocarcinoma), carcinoma (tubular_adenocarcinoma)	-3.81147558129	-3.75612531069	-2.69182258329305	-2.68071119765	10.2627848720378	20.7615142329908	1.38383890583618e-09	8.10595268786453e-08	0.892611743562421	1.34669425243148
TPCN2	BRD-A13561534-003-02-0::2.5::HTS002	2.5	ornithine	NFkB pathway modulator	noncancer	ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.04419354554785	0.04419354554785	0.631838698706891	0.6528532936085	17.4243450386403	5.87737573377919	2.77485028251153e-06	0.000105899374323436	0.504702611762607	0.670587694555475
TPCN2	BRD-A75975749-001-01-4::2.5::MTS006	2.5	bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	targeted cancer	ABL1, BCR, LYN	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.040104612653	-1.040104612653	-0.176126381560953	-0.0542138701025	14.4612750314702	3.48281310121212	0.000311110910065909	0.00782905838247227	0.687920550903849	1.04003591128025
TPCN2	BRD-A94756469-001-04-7::2.5::HTS002	2.5	digoxin	ATPase inhibitor	noncancer	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-6.318419509845	-6.318419509845	-5.66390765664722	-5.6162004602	6.5456427093637	6.62415605053769	0.000404202861417254	0.00990310872024447	0.41532143927113	0.893702267124439
TPCN2	BRD-K00494077-066-01-9::2.5::HTS002	2.5	trovafloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.085246610084	-0.085246610084	-0.524993207956147	-0.32459433605	-5.65894131299898	26.3122265249787	5.71510736550042e-06	0.000206179640892163	-0.599386057078849	-0.280107138665445
TPCN2	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.02233812881075	-0.02233812881075	0.159329697562016	0.166606190016	7.225011487803	187.641928569112	1.22163809222935e-11	9.05994708198697e-10	0.132065998835286	0.231269653910245
TPCN2	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.759046433965	-1.759046433965	-1.1261167674756	-1.061699565275	7.568114822003	8.75875968721558	3.99093170651324e-05	0.00122704404206753	0.442945718643645	0.822913614335157
TPCN2	BRD-K09900591-001-26-7::2.5::HTS002	2.5	caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	noncancer	ALOX5, MIF	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.4116353699125	0.4116353699125	-0.0584216905215057	-0.0732110977947	-11.0378834976563	4.9225008231556	0.000116876454615552	0.00326087134096545	-0.580047757184001	-0.36006636368401
TPCN2	BRD-K10670311-001-15-5::0.625::HTS002	0.625	sulfasalazine	cyclooxygenase inhibitor	noncancer	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.1563835078695	-0.1563835078695	0.282697669760272	0.3338993038355	12.6572363276748	165.017982308073	4.28834432610176e-26	1.19638954343898e-23	0.370587456563147	0.507574898696397
TPCN2	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.165075652538	-0.165075652538	-0.329293392280571	-0.31281935927	-4.90855705333414	190.438026923259	1.96562946455757e-06	7.6654184408508e-05	-0.230208486237495	-0.098226993247648
TPCN2	BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500	2.42119	indisulam	CDK inhibitor	targeted cancer	CA1, CA12, CA14, CA2, CA6, CA7, CA9	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.251178103792	0.251178103792	-0.376184909889382	-0.1455477562875	-6.0960909714233	7.36983513907996	0.000402957512676506	0.00987372593282758	-0.868258232092662	-0.386467795270103
TPCN2	BRD-K18779551-003-07-8::2.5::HTS002	2.5	bifemelane	acetylcholine release enhancer	noncancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.28602282696	-0.28602282696	0.0224570629690076	0.0610865008582	6.94958976357993	4.44631049006724	0.00150921930194637	0.0316011590237264	0.189967198722113	0.426992581135902
TPCN2	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.5368680140215	0.5368680140215	0.371574056415912	0.3847237758685	-5.29776957613974	46.359398939074	3.15577649978968e-06	0.00011910097225276	-0.228084511776345	-0.10250340343483
TPCN2	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.00327822721222	0.00327822721222	-0.184234506094306	-0.06456986921455	-4.36514003425904	187.313691156586	2.09778013309943e-05	0.000680719331032655	-0.272254150657184	-0.102771315955869
TPCN2	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.798306855404	-0.798306855404	-0.395384940754641	-0.249189788856	5.84113239094922	17.705251457619	1.66945044632961e-05	0.000553630890780411	0.257826968861349	0.548016860437369
TPCN2	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.021816880306865	0.021816880306865	-0.18000009149365	-0.13613940777	-4.76520788102798	8.47105541972625	0.00120949446664785	0.0261399354181877	-0.298543996809308	-0.105089946791722
TPCN2	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.06213190085135	-0.06213190085135	-0.795236597217308	-0.4002530483955	-6.48230251405677	178.919105031656	8.50683638246923e-10	5.10804206772394e-08	-0.956272919298898	-0.509936473433018
TPCN2	BRD-K42898655-001-01-8::2.5::HTS002	2.5	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.08256008732	-1.08256008732	-1.3477187059243	-1.32952488095	-4.5537608019747	12.980285121333	0.000543471211975032	0.0129050192922466	-0.390973049616968	-0.139344187591627
TPCN2	BRD-K43457670-001-27-8::2.5::HTS002	2.5	acetazolamide	carbonic anhydrase inhibitor	noncancer	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.581509467946	0.581509467946	0.255551688748637	0.234175192161	-12.669086009794	131.922118800128	1.46481720757121e-24	3.63371304723993e-22	-0.376851760530252	-0.275063797864475
TPCN2	BRD-K45446451-001-05-0::2.5::HTS002	2.5	JZL-184	monoacylglucerol lipase inhibitor	targeted cancer	MGLL	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.3679181488495	0.3679181488495	-0.053965981068929	-0.08025310757335	-9.11563997767454	4.86501174149413	0.000306753836847524	0.00772757911350412	-0.541853893651235	-0.301914366185623
TPCN2	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.45748754244	0.45748754244	-0.272666987545527	-0.2054130743915	-11.3970967996643	4.54953482313576	0.000161897091815095	0.00438509311154272	-0.899866183989004	-0.56044287598205
TPCN2	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.505918041445	-1.505918041445	-1.03454307370873	-1.108311362665	5.86025462919314	121.440175405672	4.05730335730437e-08	2.00414328478379e-06	0.312136679211908	0.630613256260629
TPCN2	BRD-K62200014-003-10-5::2.5::HTS002	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.158853115273	0.158853115273	-0.0823996678554496	0.0371962455536	-4.45029716754469	169.386920228872	1.54950657941493e-05	0.000516250887081336	-0.348267969744502	-0.134237596512397
TPCN2	BRD-K62391742-001-03-0::2.5::HTS002	2.5	venetoclax	BCL inhibitor	targeted cancer	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.1966456728845	0.1966456728845	0.360422584212082	0.3408626748475	4.81369662481616	7.48188385056968	0.00160738772805643	0.0333697989506593	0.0843636399632966	0.243190182691867
TPCN2	BRD-K62398570-300-01-2::2.5::HTS002	2.5	lerisetron	serotonin receptor antagonist	noncancer	HTR3A	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.10934329731105	-0.10934329731105	0.504850309570267	0.5169878880615	20.7409996278915	3.87531953083856	4.07943469353384e-05	0.00125227894361274	0.530922236786495	0.697464976976139
TPCN2	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.96760412316	-1.96760412316	-0.472911434401472	0.00515603334304	12.4654226813599	4.76164601771753	8.12948616090889e-05	0.00234886039280324	1.18176261802724	1.80762275948982
TPCN2	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-5.11184147583	-5.11184147583	-3.84496866346732	-3.68860468998	16.8239543853601	27.6767681413173	4.59134069821496e-16	5.27927822160791e-14	1.11254301935506	1.4212026053703
TPCN2	BRD-K68633617-003-02-9::2.5::HTS002	2.5	ACDPP	glutamate receptor antagonist	noncancer	GRM5	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.08787741218305	-0.08787741218305	0.241602634599118	0.327184190562	5.48429247633758	9.59425783210498	0.000309844068023093	0.00779900989492911	0.194848748282331	0.464111345282005
TPCN2	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.131265292248	0.131265292248	0.312250989019372	0.309773585289	6.14558247025124	10.9300602339896	7.45414009346144e-05	0.00216864177017985	0.116116655567956	0.245854737974788
TPCN2	BRD-K72726508-001-02-1::2.5::HTS002	2.5	arcyriaflavin-a	CDK inhibitor	targeted cancer	CCND1, CDK4	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.057716574805	-1.057716574805	-0.487933526792313	-0.3795984420275	11.6260883611224	187.587381857824	7.02346996032325e-24	1.62914858563433e-21	0.473103430312273	0.666462665713101
TPCN2	BRD-K73319509-001-08-0::2.5::HTS002	2.5	PF-04217903	c-Met inhibitor	targeted cancer	MET	NA	NA	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.5289471843525	-0.5289471843525	0.0523970815915337	0.0909616793379	13.0572025408376	4.59408735890193	8.31109686127172e-05	0.00239680984819632	0.463785094895744	0.698903436992324
TPCN2	BRD-K77625799-001-07-7::2.5::MTS010::PROS002_PR500	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.4968497191005	-0.4968497191005	-0.116823130401586	-0.0734176025033	9.18082296971677	152.078784335402	2.92635145501084e-16	3.43484107886648e-14	0.298246000503681	0.461807176894148
TPCN2	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.4294999658205	0.4294999658205	0.186260719168912	0.18484230673	-6.83384506510775	128.673000575296	2.97198092479977e-10	1.87072452167815e-08	-0.313663200072175	-0.172815293231001
TPCN2	BRD-K84466663-001-05-4::2.5::HTS002	2.5	nelarabine	DNA synthesis inhibitor, T cell inhibitor	chemo	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.4062751453335	0.4062751453335	0.610538417644931	0.607124565028	7.42753493033594	15.0383537200608	2.08970080636584e-06	8.12266021268741e-05	0.145659688218168	0.262866856404695
TPCN2	BRD-K95785345-300-14-8::2.5::HTS002	2.5	thiamine	vitamin B	noncancer	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.7016121407135	0.7016121407135	0.16886860186725	0.1869116591445	-17.8996950820305	8.53338185543155	4.58553190161393e-08	2.24848425289639e-06	-0.60063688679269	-0.46485019089981
TPCN2	BRD-K99964838-001-11-9::2.5::HTS002	2.5	bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	targeted cancer	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	MDAMB175VII, KU1919	BREAST, URINARY_TRACT	carcinoma (ductal_carcinoma), carcinoma (transitional_cell_carcinoma)	0.1211474803068	0.1211474803068	-0.398811192780559	-0.289629896197	-7.4323715419317	8.50225278749804	5.37089859857132e-05	0.00161066087272029	-0.67963975087209	-0.360277595302627
TPRG1	BRD-A12230535-001-06-7::2.5::HTS002	2.5	nutlin-3	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.517574682759	0.517574682759	-0.0565342122117575	0.106263594851	-7.51974856320818	3.82597399689039	0.00199442413733745	0.0400096341193745	-0.789938818975539	-0.358278970965976
TPRG1	BRD-A26032986-050-02-1::2.5::HTS002	2.5	zaldaride	calmodulin antagonist	noncancer	CALM1	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.0013096828519	-0.0013096828519	-0.168793835981195	-0.166433097848	-4.90360836217735	35.4913771923269	2.08050741772087e-05	0.000675728253269733	-0.236788772194026	-0.0981795340645635
TPRG1	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-3.0215079597	-3.0215079597	-3.72590495616828	-3.729909299115	-7.45224216389224	6.14410711063143	0.000269101056239661	0.00687521281234835	-0.934374120296188	-0.474419872640364
TPRG1	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.244209391082	-0.244209391082	-1.03391885704808	-0.797857785181	-9.8332531657637	191.527524078417	9.90007678361423e-19	1.44936718371261e-16	-0.94811528798037	-0.631303643951781
TPRG1	BRD-A67097164-001-18-7::2.5::HTS002	2.5	ifosfamide	DNA alkylating agent	chemo	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.00444882381868	-0.00444882381868	0.18741403716674	0.190024427126	6.48628127636069	43.0999090224013	7.09680731912077e-08	3.40356145871523e-06	0.132213520777025	0.251512201193815
TPRG1	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.258266189786	0.258266189786	0.142901863196499	0.135666555282	-3.76143584437921	13.7783259153274	0.0021601746167896	0.04282564660456	-0.18124498264903	-0.0494836705299728
TPRG1	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.303140153315	0.303140153315	0.0277833016271172	0.05909936864605	-5.17909385546189	163.989089183946	6.46648633252238e-07	2.7154301511818e-05	-0.380336971457091	-0.170376731918675
TPRG1	BRD-A83650191-004-02-8::2.5::HTS002	2.5	A61603	adrenergic receptor agonist	noncancer	ADRA1A	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.684159177913	-0.684159177913	-2.0473389222692	-2.01906141095	-13.6584150498004	37.0033808928154	5.00616511624378e-16	5.74085801604822e-14	-1.56540350130742	-1.16095598740498
TPRG1	BRD-A97701745-001-16-0::2.5::HTS002	2.5	pindolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B	cardiology	hypertension	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.05429283256415	-0.05429283256415	0.159781787024915	0.163040623516	5.27563026265537	23.8589280279623	2.10891532095707e-05	0.000683918462438201	0.130299494144792	0.297849745033337
TPRG1	BRD-K02130563-001-11-4::0.15625::HTS002	0.15625	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.01629221922	-1.01629221922	-3.04446449515812	-3.136612886985	-15.2756719797378	166.821725665865	1.62256304770566e-33	8.93990528153487e-31	-2.2903010292003	-1.76604352267594
TPRG1	BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500	2.5	panobinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.139882838505	-1.139882838505	-2.33250908361591	-2.459290757005	-14.5434810068702	10.2761708348903	3.46184528397796e-08	1.72712718312316e-06	-1.37467951892206	-1.01057297129975
TPRG1	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.8032802733335	0.8032802733335	0.0506443834880323	0.0542001317345	-10.9484983671344	3.07069043323787	0.00146729180544398	0.0308558855346352	-0.968585989537612	-0.536685790153324
TPRG1	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.4767204906695	-0.4767204906695	-1.22901717749979	-1.264129385735	-7.29772698429127	3.8999891812947	0.00206642440982901	0.041257072876967	-1.04142849767198	-0.463164875988604
TPRG1	BRD-K05638300-001-01-2::2.5::HTS002	2.5	sevoflurane	membrane integrity inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.03800740663725	-0.03800740663725	-0.58108831420052	-0.439418069219	-9.42138142055355	136.296352711193	1.54086927479019e-16	1.85327144105784e-14	-0.657072103995722	-0.429089711130818
TPRG1	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.0159933008502	-0.0159933008502	-1.96662343947586	-1.885064313955	-18.1005164536646	60.7174547314116	3.7833427008669e-26	1.06694744438698e-23	-2.16614294806568	-1.73511732918564
TPRG1	BRD-K07442505-001-03-6::2.5::HTS002	2.5	BAM7	BAX activator	targeted cancer	BAX	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.2183017150315	0.2183017150315	-0.303168268684342	-0.257563051703	-8.61255968821028	183.000211410143	3.25574873222328e-15	3.43913932986044e-13	-0.640931156769191	-0.402008810662494
TPRG1	BRD-K07487750-001-03-3::2.5::HTS002	2.5	WHI-P154	JAK inhibitor	targeted cancer	EGFR, JAK1, JAK2, JAK3	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.230677550708	-0.230677550708	-0.642952013230077	-0.57901895305	-6.06033290269372	15.528200260538	1.88021786172965e-05	0.00061599696436358	-0.556845061150307	-0.267703863893847
TPRG1	BRD-K07572174-001-39-4::2.48092::HTS002	2.48092	curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	targeted cancer	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.4459145674785	-0.4459145674785	-1.18281957371151	-1.06303888181	-8.29777452344434	19.6938187527221	7.41029186106586e-08	3.54597107454875e-06	-0.922339112307319	-0.551470900158696
TPRG1	BRD-K07955840-001-02-3::2.5::HTS002	2.5	PF-05212384	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-3.10596353104	-3.10596353104	-4.71906541459216	-4.691855544975	-16.7242610021148	109.486636840678	6.29489112617098e-32	2.96522575863978e-29	-1.8042586710558	-1.42194509604853
TPRG1	BRD-K08542803-001-03-1::0.795227::HTS002	0.795227	gambogic-acid	caspase activator	targeted cancer	BCL2	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.6567737458465	-0.6567737458465	-2.05016356754418	-1.66463476506	-9.15473048170497	8.50043355466875	1.093805627289e-05	0.000373957993764913	-1.74080934042332	-1.04597030297204
TPRG1	BRD-K09549677-300-03-4::2.5::HTS002	2.5	mibefradil	T-type calcium channel blocker	noncancer	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.524100536599	0.524100536599	0.208109588427288	0.2370962732805	-10.124457922036	112.658509837285	1.59696855634543e-17	2.10243657071843e-15	-0.377826910412003	-0.25415498593142
TPRG1	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.892065333645	-1.892065333645	-4.16102226447547	-4.14163208451	-16.6086842153941	14.5089826663864	7.64119830430929e-11	5.13717186751665e-09	-2.56100060893388	-1.97691325272706
TPRG1	BRD-K13167095-001-02-9::2.5::HTS002	2.5	AR-42	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.406459746445	-1.406459746445	-3.27174591774606	-3.28129580755	-12.1311561445901	4.74846767169529	9.38584374360431e-05	0.00267259001424601	-2.26691992558918	-1.46365241701294
TPRG1	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.377339619454	0.377339619454	0.507022499495483	0.511327989939	5.52267093191918	127.514922856719	1.79594050960028e-07	8.15512994665507e-06	0.0832182159864248	0.176147544096541
TPRG1	BRD-K14109347-001-03-4::2.5::HTS002	2.5	LY2603618	CHK inhibitor	targeted cancer	CHEK1	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.370907344843	0.370907344843	-0.0579062841648213	0.1891566141585	-6.59328233325173	195.407263264815	3.91905876760918e-10	2.4353956120699e-08	-0.557080086831394	-0.300547171184249
TPRG1	BRD-K16338837-001-02-6::2.5::HTS002	2.5	CCMI	acetylcholine receptor allosteric modulator	noncancer	CHRNA7	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.03300616369025	-0.03300616369025	0.0891781422757079	0.1287819664105	3.90792222622103	72.9337414530779	0.000206294211831909	0.00543113034365817	0.0598707071850345	0.184497904746881
TPRG1	BRD-K18898553-001-01-1::2.5::MTS006	2.5	salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	noncancer	MMP9	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.3328297419075	0.3328297419075	-0.0304073944718187	-0.00807522835948	-14.0812827198147	40.8730299206414	2.83408369786977e-17	3.63728338251934e-15	-0.415337609426856	-0.311136663331782
TPRG1	BRD-K21283037-001-21-5::2.5::HTS002	2.5	riluzole	glutamate inhibitor	noncancer	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.272789892455	0.272789892455	0.042514834924267	0.0176424857247	-6.52287077327058	8.15270844048771	0.000168935616842238	0.00455444048077737	-0.311418607952237	-0.149131507109229
TPRG1	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.390131647819	0.390131647819	0.547184212129969	0.548346398175	6.02009720768253	105.170816624906	2.58499987476375e-08	1.31040784805638e-06	0.105325770327946	0.208779358293992
TPRG1	BRD-K21728777-001-02-3::2.5::HTS002	2.5	AMG900	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.8341885791405	-0.8341885791405	-1.55076299489233	-1.404443241845	-7.73393770375911	23.1296516421458	7.33986915305201e-08	3.51462648727543e-06	-0.908182821549571	-0.524966009954088
TPRG1	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.4269289843015	0.4269289843015	-0.987526050157525	-0.82417204092	-14.23188257067	108.203518088966	1.53776026077076e-26	4.514885190832e-24	-1.61145184838114	-1.21745822053691
TPRG1	BRD-K24844714-001-24-5::2.5::HTS002	2.5	5-fluorouracil	thymidylate synthase inhibitor	chemo	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.363608465329	-0.363608465329	-1.05730120847371	-0.97521082715	-12.0636969824185	21.0477321627652	6.41187273352422e-11	4.34065151959417e-09	-0.81325922891112	-0.574126257378297
TPRG1	BRD-K27184429-300-01-3::2.5::HTS002	2.5	levocetirizine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.6441122468675	-0.6441122468675	-0.350568183000329	-0.229917154619	5.70259188931212	22.4223465613898	9.12938862966988e-06	0.000316616947509469	0.186906768485589	0.400181359248753
TPRG1	BRD-K28537285-001-01-8::2.5::MTS006	2.5	chidamide	HDAC inhibitor	targeted cancer	HDAC10, HDAC3	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.127042645632	0.127042645632	-0.476129982005972	-0.387317230447	-10.9448110501602	19.0165957272765	1.19445657117427e-09	7.05252568714078e-08	-0.718513152757616	-0.487832102518328
TPRG1	BRD-K29905972-001-06-3::2.5::HTS002	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.325623989421	-0.325623989421	-0.746580089410744	-0.6332790164525	-7.37873258052178	109.442279210253	3.28947745347167e-11	2.30854752169329e-09	-0.5340220574155	-0.307890142563989
TPRG1	BRD-K31812033-003-11-0::2.5::HTS002	2.5	levobunolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.024517251846375	-0.024517251846375	0.175682934306361	0.217104915628	5.06577945848981	22.7276786826702	4.09802061124972e-05	0.00125726404178148	0.118392362553697	0.282008009751775
TPRG1	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.1798193442705	-0.1798193442705	-0.940708208804021	-0.797793160199	-8.0033392840124	4.33251467033902	0.000939098736008217	0.0209509829280634	-1.01704864304784	-0.504729086019205
TPRG1	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.343307071967	0.343307071967	-0.407529769769226	-0.2809944464045	-9.08632373371126	4.54605183272186	0.000439023643220961	0.0106744751478055	-0.969794745421251	-0.531878938051201
TPRG1	BRD-K33127281-001-05-6::2.5::HTS002	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.1976020682225	0.1976020682225	-0.16783391710114	-0.163237656736	-9.4134450153329	35.2343686544403	3.76676646463747e-11	2.61949153017289e-09	-0.44422734467864	-0.286644625968639
TPRG1	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.82746936073	-1.82746936073	-1.01937847332432	-1.006604825335	8.38833045701164	4.88727681855735	0.000440480883039925	0.0107026218321125	0.558725718780121	1.05745605603124
TPRG1	BRD-K36627727-001-05-4::2.5::MTS010::PROS005_PR500	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.0824213159868	0.0824213159868	-0.0795297323149967	-0.032678012842	-6.23896964615195	188.08303223337	2.84655543803331e-09	1.61487395573912e-07	-0.213157240258001	-0.110744856345592
TPRG1	BRD-K38904395-001-02-3::2.5::HTS002	2.5	SAR131675	VEGFR inhibitor	targeted cancer	FLT4	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.829386079783	-0.829386079783	-0.529520392819567	-0.519013652075	5.72180131766875	19.2670075332599	1.544198469456e-05	0.000514882566521523	0.190278183439227	0.409453190487638
TPRG1	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.9741509692755	-0.9741509692755	-3.05934906296254	-2.95683473862	-19.2694563359328	13.5528152503525	3.0667861138373e-11	2.16217500326525e-09	-2.31801156479535	-1.85238462257873
TPRG1	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.108436287134	-0.108436287134	-0.515648171277971	-0.465030888818	-8.38245960778932	178.090454199291	1.52436987511498e-14	1.52031954845751e-12	-0.503076510252386	-0.311347258035556
TPRG1	BRD-K41599323-001-02-3::2.5::HTS002	2.5	lonafarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, HRAS, KRAS, NRAS	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.9424601907035	-0.9424601907035	-1.28911993189835	-1.19482949475	-4.19313421752454	32.8745506992775	0.000194941587216597	0.00516587975352944	-0.514883977948541	-0.178435504441161
TPRG1	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-4.993973975105	-4.993973975105	-5.45182395643809	-5.49470441072	-5.23537170960524	25.7986026703434	1.84932394630765e-05	0.000607360944051752	-0.637680921575861	-0.278019041090309
TPRG1	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.515287501233	0.515287501233	0.401429849314933	0.450986520291	-3.7754016408464	168.079603985037	0.00022129344932881	0.00577984467296027	-0.173394448101681	-0.0543208557344532
TPRG1	BRD-K51791723-003-01-7::2.5::MTS010::PROS004_PR500	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.9245358324765	-0.9245358324765	-2.24759424627388	-2.452542786	-17.0372558302613	44.0024527585432	5.39780213095725e-21	9.76291588967034e-19	-1.47956512208581	-1.16655170550895
TPRG1	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-5.15311805000113e-06	-5.15311805000113e-06	0.260349998987727	0.257282112096	7.29364388180784	10.2696841180976	2.26831306407524e-05	0.000731735807811833	0.18110133293535	0.339608971276204
TPRG1	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.84930294111	-1.84930294111	-1.09980855341276	-0.990481977481	8.80458158572121	3.20711122480744	0.00236858058444535	0.0463485353860665	0.488220308387888	1.01076846700659
TPRG1	BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500	2.49998	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.185912398518	0.185912398518	-0.200258419521252	-0.112315878397	-6.06858879473927	4.50811245076168	0.00250647551195539	0.048673587931674	-0.555265102025468	-0.217076534053035
TPRG1	BRD-K54955827-001-02-2::2.5::MTS006	2.5	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.0624644316229	-0.0624644316229	-0.512164716362926	-0.339269333107	-7.51777950394385	161.088961533111	3.66165369946397e-12	2.88211008355642e-10	-0.567829320963188	-0.331571248516865
TPRG1	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.00293588113705	0.00293588113705	-0.710977055440272	-0.5410189846345	-8.78372573945621	11.0606860618213	2.55649496103159e-06	9.80549406769757e-05	-0.89268224497453	-0.535143628180115
TPRG1	BRD-K58049875-001-04-7::2.5::HTS002	2.5	thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	noncancer	FOXM1	obstetrics/gynecology	mastitis	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.308830548883	-0.308830548883	-0.81036688317306	-0.698370160758	-6.60188093041222	9.18324620713301	9.02629731351296e-05	0.00258118382509396	-0.67286816251896	-0.33020450606116
TPRG1	BRD-K60184833-001-05-6::2.5::HTS002	2.5	tyrphostin-AG-99	tyrosine kinase inhibitor	targeted cancer	EGFR	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.944811022397	-0.944811022397	-1.69331370894459	-1.52742041275	-9.63677219165766	193.984781533817	3.30977855599747e-18	4.6455895751695e-16	-0.901691767320256	-0.595313605774922
TPRG1	BRD-K60230970-001-17-5::2.40205::HTS002	2.40205	MG-132	proteasome inhibitor	targeted cancer	PSMB1	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-7.235310903495	-7.235310903495	-6.15079600076871	-6.09839932339	14.6533014584568	41.1315612097751	6.35341104812832e-18	8.6899823646094e-16	0.935059876999797	1.23396992845278
TPRG1	BRD-K61496577-001-20-2::2.5::HTS002	2.5	flumethasone	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.383857930115	0.383857930115	-0.473504971921392	-0.490948289652	-11.034866545673	8.32647328005437	2.95228874177567e-06	0.000112171794670455	-1.03531430688307	-0.679411497189715
TPRG1	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.4343478276365	0.4343478276365	-0.498328915362281	0.00402399396559	-7.33673618707919	3.79913511548168	0.00223966112815364	0.0442092770248702	-1.29311289818166	-0.572240587815905
TPRG1	BRD-K63923597-001-10-0::2.5::HTS002	2.5	barasertib-HQPA	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.5776505289685	-0.5776505289685	-1.17463348257083	-1.00704468422	-7.69280092760597	78.671366779912	3.52801544883087e-11	2.46224690046393e-09	-0.751457512507681	-0.442508394696976
TPRG1	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.53288326526	-1.53288326526	-1.84232362609189	-1.7566794361	-3.32151014122246	190.964642524642	0.00107274737315099	0.0234828793524746	-0.493200170201678	-0.125680551462108
TPRG1	BRD-K66956375-001-11-3::2.5::HTS002	2.5	oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	noncancer	CNR1, GPR119, GPR55, PPARA	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.567763323329	0.567763323329	0.328896585018215	0.332357226456	-8.1325246131643	6.21763551114695	0.000154476360441699	0.00419682644912016	-0.310131477181349	-0.167601999440221
TPRG1	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.05658182843595	0.05658182843595	-0.793356797477787	-0.692855994301	-9.13166436631468	3.08378808163531	0.00248414021647942	0.0483011238735205	-1.14164657092189	-0.558230680905585
TPRG1	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-3.27319084773	-3.27319084773	-3.86539811489065	-3.711772040445	-8.39090911829506	131.031815907139	6.73885124596509e-14	6.29064132707514e-12	-0.731825581558456	-0.452588952762844
TPRG1	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.196030687245	0.196030687245	-0.276061013379398	-0.224936831672	-12.0482846414023	7.87079402550725	2.38496635448379e-06	9.19365924083015e-05	-0.562707419345941	-0.381475981902856
TPRG1	BRD-K68633617-003-02-9::2.5::HTS002	2.5	ACDPP	glutamate receptor antagonist	noncancer	GRM5	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.703471119937	0.703471119937	0.231892836658995	0.319454889976	-8.09976435208501	12.5296334825622	2.49307350227717e-06	9.57251792672096e-05	-0.597839289571149	-0.345317276984862
TPRG1	BRD-K71164191-001-01-0::2.5::HTS002	2.5	KD-023	ACAT inhibitor	noncancer	ACACA, ACACB	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.00964099807845	0.00964099807845	-0.95753930109626	-0.979843337188	-16.0630891188875	18.9370306357192	1.73623306598005e-12	1.41116836101039e-10	-1.09323247418875	-0.84112812416067
TPRG1	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.79820590775	-1.79820590775	-2.5297876328362	-2.26266997363	-6.50829794709982	59.7401312743852	1.74303622427112e-08	9.06095587950048e-07	-0.95645039018537	-0.506713059987037
TPRG1	BRD-K73237276-001-01-0::2.5::HTS002	2.5	tacalcitol	vitamin D receptor agonist	noncancer	VDR	dermatology	psoriasis, chapped lips	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.3295978823545	0.3295978823545	0.0293376860721154	0.07201409986295	-8.82595774589179	36.2199296961622	1.48304883585569e-10	9.62629842338324e-09	-0.369241666178908	-0.231278726385861
TPRG1	BRD-K74501079-001-18-1::2.5::HTS002	2.5	azithromycin	bacterial 50S ribosomal subunit inhibitor	noncancer	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.324132738835	-1.324132738835	-0.774292906111836	-0.6097866963755	7.67115583399377	51.6585028882632	4.3993000828723e-10	2.71415540432337e-08	0.405988240389376	0.693691425056953
TPRG1	BRD-K74763371-002-04-0::2.5::HTS002	2.5	bosentan	endothelin receptor antagonist	noncancer	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.0343222964016	0.0343222964016	-0.155969053204885	-0.1366984748555	-4.59575513051699	177.567522679732	8.1568741945069e-06	0.00028575591520668	-0.272002311572243	-0.108580387640727
TPRG1	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.81658497026	-1.81658497026	-2.93682323144029	-2.86819814614	-9.45368814642277	9.54348802736727	3.73968346978721e-06	0.000139346769540338	-1.38598911516654	-0.854487407194038
TPRG1	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.183384322129	0.183384322129	0.000375813152311784	0.03094358609725	-5.80823397854966	12.7402303756293	6.59959484256689e-05	0.00194193336268543	-0.251219755099064	-0.114797262854313
TPRG1	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.368885112535	0.368885112535	-0.46924206319736	-0.217946401079	-7.82620659085866	6.97699383074141	0.000106668578571414	0.00300304344892062	-1.09152981237128	-0.58472453909344
TPRG1	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.02648630818295	0.02648630818295	-0.385783722749227	-0.347155123363	-9.76014962761885	124.531553884366	4.65158785252883e-17	5.86108273277279e-15	-0.495871572731782	-0.328668489132572
TPRG1	BRD-K82967180-001-01-6::2.5::MTS006	2.5	LY3023414	PI3K inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-2.640879524865	-2.640879524865	-3.38471280741702	-3.49521149321	-11.9601171961399	164.336410694376	4.08790108216698e-24	9.67059327858463e-22	-0.866633265466316	-0.621033299637715
TPRG1	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-3.663822732725	-3.663822732725	-4.38312218131472	-4.37968901574	-7.34908215239279	16.9738988412136	1.14683315471403e-06	4.64035497860492e-05	-0.925824146098412	-0.512774751081024
TPRG1	BRD-K85606544-001-09-1::2.5::HTS002	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.07443353812	-1.07443353812	-1.59458027507511	-1.5159358626	-5.74654259371874	48.0088742492342	6.09661918005423e-07	2.57119695443102e-05	-0.702137925081275	-0.33815554882894
TPRG1	BRD-K86003836-001-10-5::2.5::HTS002	2.5	flubendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-1.247933514835	-1.247933514835	-2.79058657974855	-2.665674709255	-17.0766684329387	193.313841372417	1.82472341612221e-40	2.01593373739205e-37	-1.720825543398	-1.36448058642911
TPRG1	BRD-K86727142-001-12-4::2.5::HTS002	2.5	embelin	HCV inhibitor, XIAP inhibitor	targeted cancer	XIAP	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.5209673905455	0.5209673905455	-0.179259132934209	-0.186017590175	-17.5922755362781	160.168565863759	2.96844282187571e-39	2.95917851892929e-36	-0.778833032374382	-0.621620014585036
TPRG1	BRD-K86797399-001-05-1::2.54945::HTS002	2.54945	SB-939	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-4.121294470925	-4.121294470925	-5.47858516602132	-5.519676819535	-13.4979482863654	6.59062582402345	4.79246930336414e-06	0.000175314072934073	-1.59809330503758	-1.11648808515505
TPRG1	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-5.41539183445	-5.41539183445	-6.22287035973153	-6.19873542132	-10.0153622711178	4.50751449989035	0.000300556206485686	0.00758750426146885	-1.02172867570687	-0.593228374856202
TPRG1	BRD-K89085489-001-23-2::2.5::MTS006	2.5	fenretinide	apoptosis stimulant, retinoid receptor agonist	targeted cancer	RARA	NA	NA	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.7839221325645	0.7839221325645	0.313621042615709	0.36259103347	-10.8310248513044	3.34333301452123	0.00101913386328986	0.0224814678658968	-0.60079700285676	-0.339805177040823
TPRG1	BRD-K89714990-001-01-5::2.5::MTS006	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.304920105183	0.304920105183	0.135603485639606	0.163955716777	-4.51351091225695	11.2443936756217	0.000834331990103477	0.0188849446728153	-0.251664382841279	-0.0869688562455095
TPRG1	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.3046215614665	-0.3046215614665	0.0981155479462557	0.110191949027	14.9307607884536	28.4824126141464	5.31778767948496e-15	5.54086589964187e-13	0.34752622306695	0.457947995758561
TPRG1	BRD-K93441486-067-12-8::2.5::HTS002	2.5	diphemanil	acetylcholine receptor antagonist	noncancer	CHRM3	neurology/psychiatry	spasms	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.10112416614875	-0.10112416614875	0.135845580793679	0.150302134	8.20438138566124	15.0066039649428	6.28320527259226e-07	2.6420896662143e-05	0.175408773981407	0.298530719903451
TPRG1	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	0.444982589027	0.444982589027	0.244952399861936	0.250792854427	-6.46898354885651	43.9318622284068	6.93588136395391e-08	3.3316013376398e-06	-0.26235095638106	-0.137709421949067
TPRG1	BRD-K99964838-001-11-9::2.5::HTS002	2.5	bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	targeted cancer	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	EFO21, HCC1937	OVARY, BREAST	carcinoma (serous_carcinoma), carcinoma (ductal_carcinoma)	-0.194910704271	-0.194910704271	-0.395466661726825	-0.289629896197	-3.51759219201193	188.531329826438	0.000545659855791092	0.0129470531641591	-0.31302551345464	-0.088086401457011
TRAPPC9	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-2.564926811395	-2.564926811395	-1.61005063972399	-1.53203888218	11.27148618787	96.4133542716124	2.68932754086189e-19	4.16775764645978e-17	0.786725274182478	1.12302706915953
TRAPPC9	BRD-A31095847-001-02-3::2.5::MTS006	2.5	mozavaptan	vasopressin receptor antagonist	noncancer	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.1504200417965	0.1504200417965	-0.346276547699345	-0.266254262221	-12.5931312374077	37.2060093969937	5.5046310846902e-15	5.71886609670658e-13	-0.576598466489168	-0.416794712502522
TRAPPC9	BRD-A69815203-001-07-6::2.5::HTS002	2.5	cyclosporin-a	calcineurin inhibitor	noncancer	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.595103498557	0.595103498557	-0.0796496497200198	0.001630441296925	-16.469567844616	191.445409495619	1.54630249507724e-38	1.41631396353594e-35	-0.755563112911721	-0.593943183642318
TRAPPC9	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.3504129315215	0.3504129315215	0.141916336546921	0.135666555282	-7.34131494776707	40.6630965654841	5.72657315712044e-09	3.14307477129953e-07	-0.265866887883363	-0.151126302065795
TRAPPC9	BRD-A71725768-001-01-3::2.5::HTS002	2.5	metoxibutropate	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.5418037283965	0.5418037283965	0.355581927419747	0.3602013274625	-7.90552218152005	106.463528475263	2.62546105620477e-12	2.09498303319178e-10	-0.232921344310077	-0.139522257643429
TRAPPC9	BRD-A74914197-001-02-9::0.15625::MTS010::PROS005_PR500	0.15625	pralatrexate	dihydrofolate reductase inhibitor	targeted cancer	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.147586856651	0.147586856651	-0.404932902968884	-0.2745905537905	-8.09905622664117	150.604424541705	1.74307404635188e-13	1.56118394183265e-11	-0.687312145114897	-0.417727374124871
TRAPPC9	BRD-A81370665-001-03-6::2.5::HTS002	2.5	BI-D1870	ribosomal protein inhibitor	noncancer	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.7483288469835	0.7483288469835	0.355151302862943	0.3549788764895	-10.3282094508963	11.8306721959262	2.85822936136361e-07	1.26361683331621e-05	-0.476253136520107	-0.310101951721007
TRAPPC9	BRD-A98990573-003-01-3::2.5::HTS002	2.5	epinastine	histamine receptor antagonist	noncancer	ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7	ophthalmology	conjunctivitis	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.08051849357925	0.08051849357925	0.403986042270139	0.397262536215	11.0940011772199	8.46216284836462	2.48528910099342e-06	9.54775995208493e-05	0.256865286873534	0.390069810508244
TRAPPC9	BRD-K00634421-001-01-0::2.5::MTS006	2.5	brivaracetam	voltage-gated sodium channel blocker	noncancer	SV2A	neurology/psychiatry	seizures	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.943616244879	-0.943616244879	-1.90636208212205	-1.73380354334	-9.03568361553589	101.605466218006	1.13780828369409e-14	1.14329728849447e-12	-1.17409573492843	-0.751395939557678
TRAPPC9	BRD-K03765900-001-01-9::2.5::MTS006	2.5	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.2024054954345	0.2024054954345	-1.18117921255336	-0.823393929272	-11.8121423915458	4.23466101891754	0.000211959455856936	0.00556387730733143	-1.70181095030408	-1.06535846567163
TRAPPC9	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-3.528745124485	-3.528745124485	-4.28191247257	-4.26036322773	-10.949307650096	44.2542313338036	3.5088449073987e-14	3.38150728488244e-12	-0.891775454238297	-0.614559241931703
TRAPPC9	BRD-K04923131-001-15-4::2.5::HTS002	2.5	GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	targeted cancer	GSK3A, GSK3B	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.580433898454	0.580433898454	0.0529901348025534	0.0542001317345	-10.4713047139493	24.7034416469813	1.43608385679901e-10	9.35261066374584e-09	-0.631246719625269	-0.423640807677624
TRAPPC9	BRD-K08547377-394-03-5::2.5::HTS002	2.5	irinotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	colorectal cancer	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-3.548923630455	-3.548923630455	-1.9380650154309	-1.92016274671	16.3433511283932	7.66718288037718	3.10220494501012e-07	1.3638820177622e-05	1.38184183668186	1.83987539336634
TRAPPC9	BRD-K08799216-001-05-3::2.5::HTS002	2.5	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.972131847263	-0.972131847263	-2.21072124668945	-2.14710453103	-16.7488396886098	193.974614058515	1.55435448061561e-39	1.59398680131992e-36	-1.38444019928779	-1.09273859956512
TRAPPC9	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-2.055451257295	-2.055451257295	-1.3265603880266	-1.32870952416	10.6632015218354	60.6216110433429	1.56107964073541e-15	1.70445562057657e-13	0.592187892858559	0.865593845678237
TRAPPC9	BRD-K11851476-003-01-7::2.5::MTS006	2.5	pardoprunox	serotonin receptor agonist, dopamine receptor agonist	noncancer	DRD2, DRD3, DRD4, HTR1A, HTR7	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-1.010457085554	-1.010457085554	-2.10785641618216	-1.95679219665	-7.31438868024365	4.05918381721794	0.00175528645569137	0.035914920359129	-1.51157321292731	-0.683225448329008
TRAPPC9	BRD-K11973162-003-01-8::2.5::HTS002	2.5	tipiracil	thymidine phosphorylase inhibitor	targeted cancer	TYMP	oncology	colorectal cancer	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-3.77128251906	-3.77128251906	-2.43395294365234	-2.42612206257	13.5840346369511	72.5463073083321	1.28810732518775e-21	2.44317482212536e-19	1.14110106805859	1.53355808275674
TRAPPC9	BRD-K18779551-003-07-8::2.5::HTS002	2.5	bifemelane	acetylcholine release enhancer	noncancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.2094045394435	-0.2094045394435	0.0216630910776449	0.0610865008582	6.6124688939365	39.2260320026004	7.13458447380717e-08	3.41938362183949e-06	0.16039927458253	0.301735986459759
TRAPPC9	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-2.364990235545	-2.364990235545	-3.09764218841332	-2.8622910827	-6.43586920656405	24.5360486368249	1.06134897872417e-06	4.31074218800404e-05	-0.967332453299	-0.497971452437646
TRAPPC9	BRD-K21718444-001-06-8::2.5::HTS002	2.5	KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	targeted cancer	ABL1, AURKA, AURKB, FLT3	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-1.364456620905	-1.364456620905	-1.90832857253463	-1.67956785013	-5.58920178197236	68.190136890777	4.34261838997704e-07	1.87122850202129e-05	-0.73803649128444	-0.349707411974814
TRAPPC9	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.8979202457225	0.8979202457225	0.378796587617934	0.383188744526	-20.0656825686136	56.6755810999035	1.99586854290259e-27	6.30932904029158e-25	-0.570936307183057	-0.467311009026075
TRAPPC9	BRD-K25279140-001-01-5::2.5::HTS002	2.5	MK-8745	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-1.0452694916385	-1.0452694916385	-1.57846266868137	-1.48579667397	-5.43055626323074	8.90127847854815	0.000432203922169199	0.0105236942129602	-0.755676649628741	-0.310709704456998
TRAPPC9	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.5081601528735	-0.5081601528735	-0.838471570551197	-0.742464669951	-5.13549686198609	38.4353044462112	8.45186744514063e-06	0.000295202789344125	-0.460470565090713	-0.200152270264681
TRAPPC9	BRD-K25630527-001-03-8::2.5::HTS002	2.5	LY2784544	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.7761031633505	-0.7761031633505	-1.08154146858349	-0.892196306228	-4.35990787229907	189.20353945639	2.1337941615722e-05	0.000691463515052327	-0.443629739316505	-0.167246871149484
TRAPPC9	BRD-K28307902-001-21-7::2.5::HTS002	2.5	flutamide	androgen receptor antagonist	targeted cancer	AHR, AR	oncology	prostate cancer	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.8034769657095	0.8034769657095	0.237052375697613	0.2782830589715	-22.7352505712878	185.999117846203	1.36998993136026e-55	5.49627694841142e-52	-0.615574808389561	-0.517274371634212
TRAPPC9	BRD-K28453807-003-11-2::2.5::HTS002	2.5	nitrocaramiphen	cholinergic receptor antagonist	noncancer	CHRM1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.2029062884775	0.2029062884775	0.358769585822028	0.350372820253	5.78967841547983	136.439478938726	4.63068154090874e-08	2.27010371450464e-06	0.102627139917172	0.209099454771883
TRAPPC9	BRD-K28570407-001-02-0::2.5::HTS002	2.5	A-803467	sodium channel blocker	noncancer	SCN10A	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.544242405807	0.544242405807	0.268066954138625	0.2845478404215	-10.309118550228	73.2150016090275	6.62788883586516e-16	7.4923459193151e-14	-0.329564075483321	-0.222786827853429
TRAPPC9	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.413811716909	0.413811716909	0.208828091496415	0.239322143773	-9.87995509495058	60.635371192267	3.01094145931144e-14	2.91477900647137e-12	-0.246475711555532	-0.163491539269638
TRAPPC9	BRD-K33277808-331-01-3::2.5::HTS002	2.5	ouabain	ATPase inhibitor	noncancer	ATP1A1	cardiology	hypertension, cardiac arrythmia	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-5.687938974905	-5.687938974905	-5.36850245890075	-5.28170504445	3.56818736698599	134.806001762509	0.000498470443973637	0.01195576004772	0.142384335800736	0.496488696207774
TRAPPC9	BRD-K33882852-003-02-8::2.5::HTS002	2.5	ZK-93423	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.4119164925615	-0.4119164925615	-0.888042959972413	-0.832624878756	-6.16441070392924	5.65786467473795	0.00104252313539068	0.0229195754523693	-0.667926140254723	-0.284326794567103
TRAPPC9	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.2557470263155	0.2557470263155	0.0242065651144124	0.046531478462	-5.57029176853073	7.71071164003794	0.0006013776268429	0.0141158979618471	-0.328023786627086	-0.135057135775089
TRAPPC9	BRD-K36740062-001-06-6::2.5::HTS002	2.5	GSK1070916	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC, CYP2D6, CYP3A4	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.919990482111	-0.919990482111	-2.27349526411807	-1.977136981175	-13.0237291978358	174.613262030025	1.56993230268415e-27	5.00717292413678e-25	-1.55861770008018	-1.14839186393396
TRAPPC9	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-3.96945667293	-3.96945667293	-2.60361599045464	-2.424137198535	11.4677904267253	5.22972400588262	6.6346111930806e-05	0.00195113828540309	1.06367954099749	1.66800182395324
TRAPPC9	BRD-K37764012-001-04-1::2.5::HTS002	2.5	PF-03758309	p21 activated kinase inhibitor	targeted cancer	PAK4	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-3.93869015308	-3.93869015308	-3.19060506232308	-3.08603561013	6.65786870006787	11.6822315027898	2.6631079116935e-05	0.000847706612177166	0.502530794290991	0.993639387222856
TRAPPC9	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-2.31633556711	-2.31633556711	-1.93247383314926	-1.73054296956	4.11350958940569	45.4478968049744	0.000161681823899825	0.00437981592955328	0.195962093168594	0.571761374752886
TRAPPC9	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.151422589229	0.151422589229	-0.208588651019846	-0.158031671069	-7.6426950591699	4.22250952760561	0.00126213124516498	0.0271026277572352	-0.488122759221713	-0.231899721275979
TRAPPC9	BRD-K42191735-001-05-3::2.5::HTS002	2.5	buparlisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CG	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.8319913379595	-0.8319913379595	-2.30380748003176	-2.14029239454	-13.5080661556467	6.20197517493741	7.84179533961778e-06	0.000275528549728679	-1.73633694378607	-1.20729534035844
TRAPPC9	BRD-K42205652-001-02-7::2.5::HTS002	2.5	MNS-(3,4-Methylenedioxy-nitrostyrene)	src inhibitor, syk inhibitor	noncancer	SRC, SYK	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.7163580064445	0.7163580064445	0.2352126100767	0.255658141899	-9.44539122940665	4.56413509792802	0.000363383708403468	0.00902266761334649	-0.615942166779417	-0.346348625956182
TRAPPC9	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.3245465559965	0.3245465559965	-0.30023539290302	-0.160539632789	-8.29863188925366	5.51641135079612	0.000255533641106819	0.00657087819613478	-0.81298986264167	-0.436574035157371
TRAPPC9	BRD-K43644456-001-04-0::2.37833::HTS002	2.37833	WP1130	deubiquitinase inhibitor	targeted cancer	JAK2, UCHL5, USP14, USP9X	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-7.004589594575	-7.004589594575	-6.2839152059208	-6.277258819915	9.06641130369105	18.6574294505278	2.90976716880952e-08	1.4653371417382e-06	0.554096291676842	0.887252485631562
TRAPPC9	BRD-K45446451-001-05-0::2.5::HTS002	2.5	JZL-184	monoacylglucerol lipase inhibitor	targeted cancer	MGLL	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.1231595770355	0.1231595770355	-0.0513621664751631	-0.08025310757335	-4.554023443882	24.2174316131023	0.000126630235953716	0.00350788830835258	-0.253578015433539	-0.0954654715877873
TRAPPC9	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.20437155793	0.20437155793	-0.299370404473877	-0.290098649131	-9.99333506228023	16.8258002388752	1.72459033309827e-08	8.96941813886481e-07	-0.61017704577324	-0.397306879034513
TRAPPC9	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.3403949408685	0.3403949408685	-0.369458723135316	-0.243490121847	-8.58398134490643	5.12584342187113	0.000312404912986073	0.00785608736306371	-0.920868157820928	-0.498839170186703
TRAPPC9	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.02559566135885	0.02559566135885	-0.956233409558924	-0.580280097075	-11.7423204735783	190.999549242813	2.5580851166236e-24	6.18119306607463e-22	-1.14675563345979	-0.816902508375762
TRAPPC9	BRD-K49071277-001-04-7::2.5::HTS002	2.5	securinine	GABA receptor antagonist, TP53 activator	noncancer	GABRA1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.484204772854	0.484204772854	0.28939115562459	0.288445970299	-8.05450799181832	171.70805510204	1.28288510423145e-13	1.16508254874924e-11	-0.242555566654326	-0.147071667804494
TRAPPC9	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.01237437764779	0.01237437764779	-0.287751782260525	-0.277245593931	-7.50659992945407	16.5684015124743	1.00871461604175e-06	4.11176863715506e-05	-0.384647741049199	-0.215604578767431
TRAPPC9	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.3712401306975	-0.3712401306975	-1.25829043232981	-0.921278111753	-10.1807038783744	173.866285761506	2.17612875579395e-19	3.3969956307397e-17	-1.05902004331604	-0.715080559948582
TRAPPC9	BRD-K50168500-001-07-9::2.5::HTS002	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.1535102178155	-0.1535102178155	-0.47412967109982	-0.3595601778475	-5.86124746890038	181.789328612486	2.1198958091032e-08	1.08749437259282e-06	-0.428551092139475	-0.212687814429165
TRAPPC9	BRD-K56751279-300-01-4::0.15625::HTS002	0.15625	Y-39983	rho associated kinase inhibitor	noncancer	ROCK1, ROCK2	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.322517459092	0.322517459092	0.785522546321195	0.797735671319	17.0782958768326	76.173960723497	9.1746205906471e-28	2.98389568523946e-25	0.409011380769528	0.516998793688862
TRAPPC9	BRD-K56957086-001-06-3::2.5::HTS002	2.5	dacinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-5.116199694545	-5.116199694545	-5.59166882883053	-5.64321489528	-5.18504256991797	20.1733457593752	4.38114478167202e-05	0.00133704453924389	-0.666646960427469	-0.284291308143595
TRAPPC9	BRD-K58466253-003-14-0::2.5::HTS002	2.5	palmatine-chloride	dopamine synthesis inhibitor	noncancer	CYP3A4	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.110791989206	0.110791989206	-0.0573943534625342	-0.0643126933566	-4.4115459565299	20.5417268292739	0.000254253259818124	0.00654109313690539	-0.247577645077825	-0.0887950402592435
TRAPPC9	BRD-K60997853-001-02-3::2.5::MTS010::PROS004_PR500	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.268568244566	0.268568244566	-0.735153132320304	-0.7041999710785	-10.7903947328108	3.24039601635357	0.00119618141300876	0.0258809172288265	-1.28770760836232	-0.719735145410285
TRAPPC9	BRD-K61567297-001-01-9::2.5::HTS002	2.5	resatorvid	toll-like receptor antagonist	noncancer	TLR4	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.3619158691025	-0.3619158691025	-0.689741431443727	-0.642732938193	-5.62076600823559	30.9868315202046	3.62805801972389e-06	0.000135611797577503	-0.446780195573391	-0.208870929109064
TRAPPC9	BRD-K62196610-001-01-6::2.5::HTS002	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-1.296808276605	-1.296808276605	-1.67573207653437	-1.62132235513	-5.45838299920848	84.8388127978214	4.68691184554932e-07	2.00827894631095e-05	-0.516954182823494	-0.240893417035254
TRAPPC9	BRD-K62696033-001-01-4::2.5::HTS002	2.5	G-1	G protein-coupled receptor agonist	targeted cancer	GPER1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.4808564098875	-0.4808564098875	-1.25537136784629	-1.18405970294	-9.2975931512835	22.553905376543	3.55339821420992e-09	1.99422960422466e-07	-0.947028595786901	-0.602001320130682
TRAPPC9	BRD-K63784565-001-06-2::2.50835::HTS002	2.50835	10-hydroxycamptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-6.193509134795	-6.193509134795	-5.71414968586209	-5.76312410001	4.6281342577217	28.1322429401268	7.58681400838337e-05	0.0022039499316926	0.267240405422967	0.691478492442861
TRAPPC9	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.4897506266845	0.4897506266845	0.142015023243613	0.15713254048	-12.681177317007	57.637593177985	2.55721639251329e-18	3.61772694515498e-16	-0.402632843392093	-0.29283836348968
TRAPPC9	BRD-K66296774-236-11-3::2.62965::HTS002	2.62965	fluvastatin	HMGCR inhibitor	noncancer	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-5.437065851945	-5.437065851945	-2.59471572565275	-2.56925440076	20.668457239493	60.9386839877328	3.1802955079146e-29	1.22155834393518e-26	2.56735398386123	3.11734626872326
TRAPPC9	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.290504882973	-0.290504882973	-1.18591104640298	-1.01733335597	-16.1887062215211	190.004751993541	1.30355067444266e-37	1.06231449620769e-34	-1.00450775465073	-0.786304572209228
TRAPPC9	BRD-K68392338-003-02-0::2.5::HTS002	2.5	ZK-93426	benzodiazepine receptor antagonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA5	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-1.553812592835	-1.553812592835	-1.210926993227	-0.979171957663	4.19559657275955	50.0881833108068	0.000111039468533037	0.00311504950932164	0.178743041415203	0.5070281578008
TRAPPC9	BRD-K70463136-001-01-5::2.5::HTS002	2.5	BAY-87-2243	hypoxia inducible factor inhibitor	targeted cancer	HIF1A	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-1.429918399595	-1.429918399595	-1.62821355545875	-1.609919901395	-3.51550249325217	171.309824323103	0.000561722949922725	0.0132884677852083	-0.309635283452229	-0.0869550282752807
TRAPPC9	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-5.709548321155	-5.709548321155	-4.34290235874111	-4.06811907991	11.4140028619284	121.109774495506	6.20765329815659e-21	1.11805052415177e-18	1.12960279566203	1.60368912916576
TRAPPC9	BRD-K72703948-001-10-1::2.5::HTS002	2.5	ZM-447439	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.6359087353845	-0.6359087353845	-1.37969854124939	-1.23720066309	-9.73985343118219	22.0321700461181	1.91807100068657e-09	1.10688809775485e-07	-0.902148972249993	-0.585430639479786
TRAPPC9	BRD-K72726508-001-02-1::2.5::HTS002	2.5	arcyriaflavin-a	CDK inhibitor	targeted cancer	CCND1, CDK4	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.249048273526	0.249048273526	-0.501405329352426	-0.4023952462985	-14.7883505298645	81.426692835205	8.84423514835056e-25	2.25395490500693e-22	-0.851414738610774	-0.649492467146079
TRAPPC9	BRD-K76210423-001-01-6::2.5::HTS002	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.136639784298	0.136639784298	-0.42952739925566	-0.2512002355925	-8.19457699534543	41.2973112057183	3.3997902508915e-10	2.12875736103805e-08	-0.705667720023215	-0.426666647084106
TRAPPC9	BRD-K77625799-001-07-7::2.5::MTS010::PROS002_PR500	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.2136836282025	0.2136836282025	-0.1250851460679	-0.08759243402935	-7.74304374933919	44.9250017718096	8.26521612379983e-10	4.96628961759993e-08	-0.426892617898252	-0.250644930642547
TRAPPC9	BRD-K77841042-001-14-1::2.5::HTS002	2.5	brefeldin-a	protein synthesis inhibitor	targeted cancer	ARF1, CYTH2	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-5.679969448055	-5.679969448055	-4.72781573253421	-4.786446704285	8.32646071973543	115.90828812375	1.88796691108907e-13	1.68321988388856e-11	0.725661788408317	1.17864564263326
TRAPPC9	BRD-K77943374-001-02-8::2.5::HTS002	2.5	NVP-BVU972	MET inhibitor	targeted cancer	MET	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.562699051777	0.562699051777	0.0905147350429166	0.1896034324075	-10.6603881655774	119.823382099192	4.55972011839321e-19	6.8968260639033e-17	-0.559883386051955	-0.384485247416212
TRAPPC9	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.2557792827025	0.2557792827025	-0.46808792207662	-0.217946401079	-7.5479508171114	19.281135989276	3.57904995369541e-07	1.55534103310134e-05	-0.92439549496958	-0.52333891458866
TRAPPC9	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.404671493656	0.404671493656	0.118741945463464	0.120954188254	-6.89309045736797	16.4248880132952	3.13821008545391e-06	0.000118500604194019	-0.373679984853883	-0.198179111531189
TRAPPC9	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.2305974783995	0.2305974783995	-0.106365162123014	-0.0756772814281	-8.44964128724632	5.52032119269808	0.00023195507506137	0.00603187324470133	-0.436635538421033	-0.237289742623995
TRAPPC9	BRD-K86797399-001-05-1::2.54945::HTS002	2.54945	SB-939	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-5.13767278494	-5.13767278494	-5.46788644692642	-5.519676819535	-4.15808491908994	189.604548013189	4.85738404004979e-05	0.00146920443680473	-0.486863772473184	-0.173563551499659
TRAPPC9	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.49914192318	0.49914192318	-0.125705531759754	-0.0479466221371	-18.8126143477851	82.9678923673165	1.14009742757517e-31	5.30056272353055e-29	-0.690909701599508	-0.558785208279999
TRAPPC9	BRD-K89085489-001-23-2::2.5::MTS006	2.5	fenretinide	apoptosis stimulant, retinoid receptor agonist	targeted cancer	RARA	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.4405030634125	0.4405030634125	0.317217053811018	0.36259103347	-4.16272132830806	189.765900319311	4.76629952219337e-05	0.0014434876505471	-0.181706218905859	-0.0648658002971052
TRAPPC9	BRD-K89561498-001-01-7::2.5::HTS002	2.5	SN-38	topoisomerase inhibitor	chemo	TOP1	oncology	colorectal cancer	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-6.29589833275	-6.29589833275	-5.20718977346788	-5.34898111958	12.0590530596212	121.500033263228	1.67118501982285e-22	3.47413592738712e-20	0.909980084060212	1.26743703450404
TRAPPC9	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.553418802409	-0.553418802409	-1.0279734077361	-0.948156981669	-11.0062157322869	44.1417547717284	3.06512705286824e-14	2.96589442940946e-12	-0.561443255025524	-0.387665955628671
TRAPPC9	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.4287172554855	0.4287172554855	0.0899673388690112	0.09873309755385	-13.719078514472	178.181791293457	1.05967856570793e-29	4.18268595413654e-27	-0.3874760714109	-0.290023761822078
TRAPPC9	BRD-K94455792-001-01-8::2.5::HTS002	2.5	ICG-001	beta-catenin inhibitor	targeted cancer	CTNNB1	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.972822414087	-0.972822414087	-0.665146631599716	-0.6707896523965	4.89379015538475	6.93275794844593	0.00181483663127577	0.036935914950594	0.158717506032216	0.456634058942351
TRAPPC9	BRD-K95785345-300-14-8::2.5::HTS002	2.5	thiamine	vitamin B	noncancer	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.00079501189282	0.00079501189282	0.176655458854146	0.197775982352	6.79082780175306	65.8643107985367	3.84060312377222e-09	2.14642145219029e-07	0.124153906414574	0.227566987508078
TRAPPC9	BRD-K98157055-001-10-9::0.625::HTS002	0.625	SIB-1757	glutamate receptor antagonist	noncancer	GRM5	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	0.0473462741153	0.0473462741153	0.224851582160957	0.266385718245	4.41504206553522	83.2964779112775	3.00919236424906e-05	0.000946378855813848	0.0975440460280062	0.257466570063307
TRAPPC9	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	OVCAR8, SW480	OVARY, LARGE_INTESTINE	carcinoma, carcinoma (adenocarcinoma)	-0.1141212169105	-0.1141212169105	0.0708749155603744	0.0444292294665	8.44804811276774	104.281714267688	1.88212338707764e-13	1.67870837881384e-11	0.14157277545166	0.228419489490088
TSEN2	BRD-A43885598-001-08-1::2.5::HTS002	2.5	SID-7969543	steroidogenic factor antagonist	noncancer	NR5A1	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.74817578671	0.74817578671	0.404953286768029	0.415971610724	-9.77040707329373	39.065097962667	4.83295477001176e-12	3.74762070514418e-10	-0.414273382743944	-0.272171617139998
TSEN2	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.10297488286485	0.10297488286485	-0.181378853744694	-0.008049193223815	-4.94934222143184	32.0727623377441	2.28992563185733e-05	0.000738041309399023	-0.401370918081325	-0.167336555137763
TSEN2	BRD-A73427433-240-01-3::2.5::HTS002	2.5	adaprev	TGF beta receptor inhibitor	noncancer	IGF2R, M6PR	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.1337401735005	-0.1337401735005	-0.397759732109768	-0.383170209678	-5.5800606789013	7.45072088225388	0.000670756349841849	0.0155368569874909	-0.374543814485813	-0.153495302732724
TSEN2	BRD-A73556557-001-06-4::2.5::HTS002	2.5	tagatose	phosphorylase inhibitor	noncancer	PYGL	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.2530793713735	0.2530793713735	0.113457580451247	0.1416103571295	-4.66588216325946	96.7853313574983	9.86629969130462e-06	0.000340356373175218	-0.199014282694228	-0.0802292991502779
TSEN2	BRD-A92537424-001-04-7::2.5::HTS002	2.5	danazol	estrogen receptor antagonist, progesterone receptor agonist	noncancer	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.08270440797415	0.08270440797415	-0.187869863468701	-0.136086260588	-5.8373315632437	114.740954033667	5.01979909221909e-08	2.44854009930866e-06	-0.362391639846044	-0.178756903039658
TSEN2	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.05263923211905	0.05263923211905	0.224029450860166	0.2226649685355	5.1001269234023	7.6425961571212	0.00107017336323665	0.0234361077724683	0.0932613904405606	0.24951904704167
TSEN2	BRD-K00312224-001-09-5::2.5::HTS002	2.5	PPT	estrogen receptor agonist	noncancer	ESR1	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.44687471339	0.44687471339	0.159718216528402	0.22700730099	-5.08537149339877	5.84809617193854	0.00242991159015892	0.0473974900267476	-0.426201319101225	-0.148111674621972
TSEN2	BRD-K06593056-001-04-8::2.5::HTS002	2.5	LE-135	retinoid receptor agonist	noncancer	RARB	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.3364563656575	-0.3364563656575	-0.139312855057214	-0.152062454998	6.43777961094608	178.189922295105	1.08828002202773e-09	6.44693114541683e-08	0.13671329684184	0.257573724358731
TSEN2	BRD-K06854232-001-19-9::2.5::HTS002	2.5	AM-580	retinoid receptor agonist	targeted cancer	RARA	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.189538168499	-0.189538168499	0.122932028058654	0.154475017862	9.45976467045953	18.6435547621104	1.51784343789682e-08	7.96176862949064e-07	0.243244904751293	0.381695488364016
TSEN2	BRD-K08859203-001-01-9::2.5::HTS002	2.5	DU-728	structural glycoprotein antagonist	targeted cancer	ITGA2B, ITGB3	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.3084745215155	0.3084745215155	0.167708266790026	0.170003044519	-4.76632410407026	176.510367323274	3.90584224921642e-06	0.000145008706639928	-0.199050474920008	-0.0824820345309408
TSEN2	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.1274022124807	0.1274022124807	-0.258392281095998	-0.1509093731905	-5.66313233858782	6.41448611210468	0.00103642345318193	0.0228182436874196	-0.549911109948771	-0.221677877204625
TSEN2	BRD-K13302470-001-02-7::2.5::HTS002	2.5	KY02111	Wnt pathway inhibitor	noncancer	DKK1	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.7878654161855	0.7878654161855	0.50263184926306	0.505306635797	-11.079214499107	19.4318690985183	7.64034172248912e-10	4.60632011544127e-08	-0.339037377247022	-0.231429756597857
TSEN2	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.598869758061	0.598869758061	0.398534589046567	0.431459247123	-5.89561592202714	21.2435938745732	7.15282075576412e-06	0.000252979689729731	-0.270951895428554	-0.129718442600313
TSEN2	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.121110754341	0.121110754341	-0.0618111196976751	-0.0626502991923	-5.62705862828938	192.268675155287	6.40660181102441e-08	3.0912214307858e-06	-0.247039077842697	-0.118804670234653
TSEN2	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.0764260881326	-0.0764260881326	0.327472468095311	0.343759219436	9.90237351256569	4.8073051380283	0.000222912472243787	0.00581719314057453	0.297772734019278	0.510024378436544
TSEN2	BRD-K19540840-001-09-4::2.5::MTS010::PROS004_PR500	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.8852291702535	-0.8852291702535	-0.397273823933252	-0.317398469231	8.78160887196217	156.62631182313	2.64609928549867e-15	2.82578880798029e-13	0.378200745952068	0.597709946688427
TSEN2	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.2330313535535	0.2330313535535	-0.199885535096325	-0.14719250083	-6.56163612559406	5.23593028701932	0.00103196274634305	0.0227317105304173	-0.600243095719919	-0.26559068157973
TSEN2	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.861353194285	-1.861353194285	-2.88063759728081	-2.75215171608	-7.05006465093746	4.12566063228833	0.00189910532529101	0.0383848873316009	-1.41592118450166	-0.622647621489949
TSEN2	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.953909396815	-1.953909396815	-0.843486108887644	-0.52176141391	8.41415740800571	3.87247926889841	0.00125719757662204	0.0270129222455965	0.739205590554157	1.48164098530055
TSEN2	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.211336909131	0.211336909131	0.386300230640792	0.399212772621	5.56432149253649	6.58911117292266	0.00104166006684441	0.0229053001402171	0.0996602704138556	0.250266372605728
TSEN2	BRD-K29415052-050-04-8::0.625::HTS002	0.625	BGT226	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CG	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.21873943042	-3.21873943042	-3.63363754355753	-3.592577528105	-4.78581140021913	10.7019735147124	0.000611303671341284	0.0143050665547446	-0.606359238457764	-0.223436987817292
TSEN2	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.346155275468	0.346155275468	0.240151489271098	0.2536769304835	-4.03229256293283	193.99989511958	7.93410057624209e-05	0.0022979835708181	-0.157852163588519	-0.0541554088052838
TSEN2	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.30854162721	-3.30854162721	-2.5682132415373	-2.525806741025	6.83502915157337	9.24693600732945	6.66645200544162e-05	0.00195996432355871	0.496299218709065	0.984357552636341
TSEN2	BRD-K33588785-001-01-9::2.5::HTS002	2.5	obidoxime	cholinesterase reactivator	noncancer	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.311193345675	0.311193345675	0.171807221248279	0.177010520924	-5.6026022651981	193.544356342707	7.18110263892795e-08	3.44090889223963e-06	-0.188454535304297	-0.0903177135491459
TSEN2	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.02021876696365	0.02021876696365	0.165086942606235	0.1606220898175	6.15337101888286	191.470969125543	4.34725322819922e-09	2.41759843577247e-07	0.0984314358744513	0.19130491541072
TSEN2	BRD-K37890730-001-15-1::2.5::HTS002	2.5	camptothecin	topoisomerase inhibitor	chemo	TOP1	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-5.01991997558	-5.01991997558	-3.75726210477455	-3.68976707366	9.05956823094662	3.84158169378741	0.000990778873627603	0.0219531319348424	0.869321529305108	1.65599421230578
TSEN2	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.9194333789025	-0.9194333789025	-0.10128638120791	0.0520686308404	16.5779561395738	187.840511774671	1.2823322503687e-38	1.18978783068949e-35	0.720792599905222	0.915501395483958
TSEN2	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.8176246031325	-0.8176246031325	-0.287365449813764	-0.3736278329815	5.88397680212051	4.95273454202699	0.00208004762996363	0.0414788359213318	0.297933893817082	0.762584412820389
TSEN2	BRD-K56751279-300-01-4::0.15625::HTS002	0.15625	Y-39983	rho associated kinase inhibitor	noncancer	ROCK1, ROCK2	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	1.08229548458	1.08229548458	0.777218961343184	0.797329257919	-9.83473059806978	10.8185034327621	9.97523838913577e-07	4.07002259414635e-05	-0.373491803310049	-0.236661243163583
TSEN2	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-5.14023453016	-5.14023453016	-4.64295678377283	-4.72849824175	5.30027107514903	138.934038321294	4.43532668986988e-07	1.90849053224879e-05	0.311775803544357	0.682779689229989
TSEN2	BRD-K59522102-001-14-6::2.5::HTS002	2.5	piperine	monoamine oxidase inhibitor	targeted cancer	MAOA, MAOB, TRPV1	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.191428617354	0.191428617354	0.0358311678730968	0.07942712884705	-4.90997265479889	70.765620819967	5.64805053788263e-06	0.000204000846601592	-0.21878931070047	-0.0924055882613367
TSEN2	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.0814349141247	0.0814349141247	-0.173632222288535	-0.07625513394025	-4.63925435916394	22.9403782861711	0.00011506042311547	0.00321648433884382	-0.368818706008673	-0.141315566817797
TSEN2	BRD-K65781196-001-03-0::2.5::HTS002	2.5	avanafil	phosphodiesterase inhibitor	noncancer	PDE5A	urology	erectile dysfunction	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.6495385321255	0.6495385321255	0.51632480382518	0.492981858555	-4.81772626228892	68.1337769808473	8.45640793509893e-06	0.000295284043063183	-0.188387972611972	-0.0780394839886689
TSEN2	BRD-K68938568-001-01-7::2.5::HTS002	2.5	GDC-0152	XIAP inhibitor	targeted cancer	BIRC2, BIRC3, BIRC7, XIAP	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.1816824819845	0.1816824819845	-0.443260919350792	-0.296863885148	-8.55650230322013	82.2562382968207	5.36960059077754e-13	4.57598856867101e-11	-0.770230982850059	-0.479655819820525
TSEN2	BRD-K77677632-003-02-6::2.5::HTS002	2.5	SB-200646	serotonin receptor antagonist	noncancer	HTR2B, HTR2C	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.035822930475	-1.035822930475	-0.60659217738308	-0.486816676167	6.08697170461585	145.100939107133	9.77018664815514e-09	5.22203075838515e-07	0.289858943649789	0.568602562534051
TSEN2	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.3021178532395	0.3021178532395	-0.1071219914864	-0.0756772814281	-9.81055481602206	4.40580086248051	0.000370540716578028	0.00918547550814854	-0.520969008224971	-0.297510681226829
TSEN2	BRD-K83607951-001-02-2::2.5::HTS002	2.5	skepinone-l	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.31050479008	0.31050479008	0.457338667618398	0.487412056788	4.52563507740198	107.989427092562	1.5549280847175e-05	0.00051757443930644	0.0825223419521725	0.211145413124624
TSEN2	BRD-K84892605-001-01-1::2.5::HTS002	2.5	IOWH032	CFTR channel antagonist	noncancer	CFTR	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.279316516099	0.279316516099	0.116085165818147	0.1106185229635	-6.59189653976103	189.840742360904	4.17868207859016e-10	2.58548715710782e-08	-0.212076196065249	-0.114386504496457
TSEN2	BRD-K85402309-001-06-6::2.5::HTS002	2.5	dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.285611764283	-0.285611764283	-0.163588710059233	-0.1901331802295	3.16566802920452	158.719797967257	0.00185537041035899	0.0376108658547084	0.0458943097309129	0.198151798716622
TSEN2	BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.331630924765	0.331630924765	-0.167928999487968	-0.121855279851	-23.3079972937571	178.093061095602	5.50550577650651e-56	2.26921066840935e-52	-0.541855213244945	-0.457264635260992
TSEN2	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.789915187963	-0.789915187963	-1.83783086829518	-1.72447120363	-11.6188439664687	20.2442783298597	2.06901401780243e-10	1.32412572535556e-08	-1.23590547717606	-0.859925883488309
TSEN2	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.4279888973025	-0.4279888973025	-1.6076902195716	-1.38505413113	-16.0766899667392	175.185316380034	2.57390262113177e-36	1.92216715987649e-33	-1.32452317847716	-1.03487946606104
TSEN2	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.03450794271611	0.03450794271611	-0.243847954224134	-0.195507988981	-5.20079521265856	8.40614678729616	0.000701506364327369	0.0161948683282982	-0.40074707286452	-0.155964721015967
TSEN2	BRD-K99749624-001-07-0::2.5::HTS002	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.1653598596835	0.1653598596835	-0.221704331678516	-0.147984722712	-8.02024872625694	182.36053633099	1.23708087207473e-13	1.1244372613694e-11	-0.482285687991437	-0.291842694732595
TSEN2	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.224201497348	0.224201497348	0.0929536541311046	0.162270559212	-4.14376189440683	39.4772980731487	0.00017496128760464	0.00469621512974513	-0.195288983370144	-0.0672067030636471
TSEN2	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	NUGC4, TE5	STOMACH, OESOPHAGUS	carcinoma (signet_ring_adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.09990368597795	0.09990368597795	-0.0782889195426291	-0.07508781022425	-6.15683327606281	174.911086843709	4.93753434272715e-09	2.72887260995969e-07	-0.235313592211349	-0.121071618829809
TTC6	BRD-A06352418-001-25-9::2.5::HTS002	2.5	terfenadine	histamine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.7410889599325	-0.7410889599325	0.0718543794578994	0.03730027167595	14.1397103111035	5.23376162874409	2.27253346689824e-05	0.000732876655773148	0.667114783037119	0.95877189574368
TTC6	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1747882617965	0.1747882617965	-0.00937835722411342	0.0633629143304	-4.64960960626116	7.88865211626456	0.00170791523884387	0.0351334835613944	-0.275730148783983	-0.0926030892572434
TTC6	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.00113333687215	-0.00113333687215	-0.449262031637805	-0.3315553181695	-5.21800973217198	12.430306171288	0.000191969700386516	0.00509720935507206	-0.634531747216867	-0.261725642314443
TTC6	BRD-A55913614-316-09-6::2.5::HTS002	2.5	primaquine	antimalarial agent, DNA inhibitor	noncancer	KRT7, NQO2	infectious disease	malaria	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.8396271246495	-0.8396271246495	0.107659812943742	0.123868059835	28.2113867620963	78.4354083669547	8.05528179621457e-43	1.07234813173967e-39	0.880443766934035	1.01413010825245
TTC6	BRD-A57886255-001-01-1::2.5::HTS002	2.5	golgicide-a	ARF inhibitor	noncancer	GBF1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.31100003816	0.31100003816	-0.183568592221485	-0.008049193223815	-9.42116061425983	189.950928638153	1.55399888363954e-17	2.04964324142511e-15	-0.598117674566349	-0.391019586196621
TTC6	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.407623204471	-0.407623204471	-0.531627579843946	-0.51783728433	-3.5934173665892	26.3762692584594	0.00131622067008471	0.0281008327521252	-0.19488892966006	-0.0531198210858315
TTC6	BRD-A83937277-001-10-5::2.5::HTS002	2.5	mephenytoin	hydantoin antiepileptic	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.26399954173	-0.26399954173	-0.0668075652141237	-0.09044120254575	5.04123496172339	34.7935196791268	1.43659463149978e-05	0.000481250220029255	0.117765816245669	0.276618136786083
TTC6	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.338845735364	-0.338845735364	0.215739080846297	0.255620963174	12.4563271392591	39.3756424162275	3.08460143020428e-15	3.26640088900323e-13	0.464557346292625	0.644612286127969
TTC6	BRD-A88138582-001-04-8::2.5::HTS002	2.5	halcinonide	glucocorticoid receptor agonist	noncancer	NR3C1	dermatology	corticosteroid-responsive dermatoses	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.1601348336865	-0.1601348336865	0.288739769235712	0.271498437294	12.4199746144695	107.444417040759	1.68774539241679e-22	3.5017694308935e-20	0.3772319879389	0.520517217905524
TTC6	BRD-A95121829-001-08-9::2.5::HTS002	2.5	ginkgolide-a	GABA receptor antagonist	noncancer	GLRA1, GLRB	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.117146474097	0.117146474097	-0.188411058315184	-0.138056758361	-6.58008264465232	155.235225330074	6.82692242108007e-10	4.13335439431546e-08	-0.397286961046612	-0.213828103777757
TTC6	BRD-K00077635-304-01-2::2.5::HTS002	2.5	estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2387941492925	-0.2387941492925	0.227129805981565	0.2226649685355	17.1279575157079	160.3841124296	4.70640082940482e-38	4.1340909154324e-35	0.412202596331758	0.519645314216372
TTC6	BRD-K01683783-001-02-6::2.5::HTS002	2.5	TAK-901	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.44012018211	-1.44012018211	-2.77454265364094	-2.64361455145	-9.17542662696845	3.58719725339334	0.00128772595980396	0.0275733616530653	-1.75721570678689	-0.91162923627499
TTC6	BRD-K03063480-001-06-6::0.604864::HTS002	0.604864	PF-477736	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.7552830327375	-0.7552830327375	-2.21902607954633	-2.04082568027	-11.8974396940873	31.0300929652623	4.27422247088866e-13	3.68203307059122e-11	-1.71465470204706	-1.21283139157061
TTC6	BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500	0.625	foretinib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, MET	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2026568181535	0.2026568181535	-0.344024828610534	-0.229059189804	-9.45254323307062	4.48260717345733	0.000397270806740007	0.00974687130809464	-0.700662077848637	-0.392701215679432
TTC6	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.22108047751	-3.22108047751	-4.28513409191005	-4.26036322773	-12.909400638727	6.07909170827394	1.20224502477419e-05	0.000407908776183041	-1.26510524999417	-0.863001978805936
TTC6	BRD-K05104363-001-10-0::2.5::HTS002	2.5	PD-184352	MEK inhibitor	targeted cancer	MAP2K1, MAP3K1, MAP3K2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.07789335726495	-0.07789335726495	-0.358396263306763	-0.164030729397	-4.11452812494229	25.6643086029743	0.000353826452503289	0.00880065797128669	-0.420725366861793	-0.140280445221833
TTC6	BRD-K06222852-001-03-2::2.5::HTS002	2.5	posaconazole	sterol demethylase inhibitor	noncancer	CYP3A4	infectious disease	oropharyngeal candidiasis	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.617987587058	-0.617987587058	-0.041949377356738	0.00528280160376	10.8204571854469	3.04747001731957	0.00157338680505398	0.0327336847738706	0.408100617305738	0.743975802096786
TTC6	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.020339465795	-2.020339465795	-3.19162806118182	-3.102963726805	-8.89728186950062	8.10254865240607	1.85920070306375e-05	0.000609857097470081	-1.47419656484333	-0.868380625930305
TTC6	BRD-K10705233-001-02-2::2.5::HTS002	2.5	GW-405833	cannabinoid receptor agonist	noncancer	CNR2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.3321202553695	-0.3321202553695	0.190591575250624	0.239804537816	14.7140835354812	154.55092661281	3.37832821056669e-31	1.49293547843824e-28	0.452535402227332	0.592888259012917
TTC6	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.991198530141	-0.991198530141	-1.33832008666919	-1.3496917977	-4.92410074565881	34.5453305600409	2.07761778430471e-05	0.00067489200074605	-0.490300171132087	-0.203942941924287
TTC6	BRD-K12343256-001-08-9::2.5::HTS002	2.5	trametinib	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	oncology	melanoma	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.7800489376655	-0.7800489376655	-1.81449979957977	-1.56065418801	-8.16348708856195	9.59719674872779	1.27237061193617e-05	0.000429796565619648	-1.31840800830657	-0.750493715521985
TTC6	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.014816368405	-3.014816368405	-1.92058342882621	-2.01595157397	14.1746617661876	186.831539953383	1.92187162560089e-31	8.70851635609754e-29	0.941944300160595	1.24652157899699
TTC6	BRD-K13183738-317-10-2::2.5::HTS002	2.5	pentamidine	anti-pneumocystis agent	noncancer	TRDMT1	infectious disease	pneumonia	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.218571039785	-1.218571039785	-0.904161623427698	-0.814219930729	5.2611675625528	96.1288824684151	8.67544031873253e-07	3.57576624629543e-05	0.195788012823954	0.43303081989065
TTC6	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.266621334285	-2.266621334285	-2.60709280339619	-2.686193418095	-4.10003378052277	12.4437303796513	0.00136798885275835	0.0290325460761308	-0.520689582631005	-0.160253355591366
TTC6	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.978324775015	-1.978324775015	-1.28745620742787	-1.25961873039	10.6027007135493	6.24762732687299	3.17322570228647e-05	0.000992288140568072	0.532947978221038	0.848789156953224
TTC6	BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500	2.5	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.855370899605	-1.855370899605	-2.75013947759656	-2.77734094711	-15.6151776716014	7.07383640702939	9.6587312498879e-07	3.95821455077863e-05	-1.02997823173908	-0.759558924244042
TTC6	BRD-K18518344-001-15-9::2.5::HTS002	2.5	digitoxigenin	ATPase inhibitor	noncancer	ATP1A1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.83124493574	-2.83124493574	-4.14748657866225	-4.343421581	-10.1491000264949	172.99898194466	2.77999281206926e-19	4.29893996694079e-17	-1.57222100346871	-1.0602622823758
TTC6	BRD-K20605374-001-05-4::2.5::HTS002	2.5	NSC-697923	ubiquitin-conjugating enzyme inhibitor	noncancer	UBE2N	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.64143477019	-1.64143477019	-3.05351038169764	-3.177325410155	-13.5743312119445	86.0969908067843	4.17886552912216e-23	9.07448905766185e-21	-1.61886799437414	-1.20528322864114
TTC6	BRD-K21396683-001-04-8::2.5::HTS002	2.5	marimastat	matrix metalloprotease inhibitor	targeted cancer	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.8607846069295	-0.8607846069295	-1.8044977421731	-1.72083973318	-12.3480055043544	134.590057476126	6.81659058152093e-24	1.58287436917313e-21	-1.09486512411588	-0.792561146371322
TTC6	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.604658101135	-0.604658101135	-0.258636088811554	-0.291499790384	5.81584477693892	27.0320746053349	3.42659212609894e-06	0.000128529587643448	0.223952195116535	0.468091829530357
TTC6	BRD-K26531771-001-02-2::2.35203::HTS002	2.35203	EPZ-5676	histone lysine methyltransferase inhibitor	targeted cancer	DOT1L	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1113194933054	0.1113194933054	-0.506982830688962	-0.436225052339	-9.99403247300953	5.03222623244917	0.000165308918999539	0.00446621647551396	-0.777031060812834	-0.459573587175891
TTC6	BRD-K28360340-001-08-3::2.30697::HTS002	2.30697	TW-37	BCL inhibitor	targeted cancer	BCL2, BCL2L1, MCL1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.052306151845	-3.052306151845	-2.76588873337553	-2.71718912157	3.24235889636966	154.100679756696	0.00145318741411167	0.0306024961160662	0.111911362710518	0.460923474228414
TTC6	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.17991297171	-1.17991297171	-2.23484515650358	-2.28506663454	-9.32763673372176	62.9671236148248	1.77070199703189e-13	1.58394318999101e-11	-1.28094176855511	-0.828922601032057
TTC6	BRD-K33622447-066-01-9::2.5::HTS002	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.418789857845	-2.418789857845	-1.32440207935277	-1.23672379758	12.2802828878571	3.08405350601542	0.0010160034055515	0.0224216427006227	0.815099261738866	1.37367629524558
TTC6	BRD-K34157611-001-16-0::2.5::HTS002	2.5	cimetidine	histamine receptor antagonist	targeted cancer	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.5047145621055	0.5047145621055	0.160040111406841	0.154760250633	-9.75516620538116	3.16833383130555	0.00181449645771431	0.0369324986975736	-0.453812949041305	-0.235535952356013
TTC6	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.544636747007	0.544636747007	0.167109404975613	0.159843684784	-12.0951481482605	6.30753164341288	1.34261008898187e-05	0.000451813907617203	-0.453009460865827	-0.302045223196946
TTC6	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.513296929195	-0.513296929195	0.0322174396509802	0.056211415311	15.6027848681463	68.3394345505753	3.24217663261606e-24	7.74685033993275e-22	0.475753804123247	0.615274933568713
TTC6	BRD-K36739687-001-03-0::2.5::HTS002	2.5	stemregenin-1	aryl hydrocarbon receptor antagonist	noncancer	AHR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3038349816895	0.3038349816895	0.57772536096267	0.571651612309	7.079448102058	9.10390146378863	5.4685553305826e-05	0.00163750321831912	0.186523843857523	0.361256914688817
TTC6	BRD-K38548312-001-01-0::2.5::HTS002	2.5	VER-49009	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.01751247347	-2.01751247347	-2.74202436545298	-2.671842712285	-7.39518984870179	25.7900404624284	7.86487083606775e-08	3.7475987137029e-06	-0.925973363294797	-0.523050420671159
TTC6	BRD-K39484304-001-16-5::2.5::HTS002	2.5	triptolide	RNA polymerase inhibitor	targeted cancer	RELA	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-5.391128595555	-5.391128595555	-6.61293291162647	-6.671127343215	-11.0399082561029	3.74209560836703	0.000544289451714351	0.0129188276740294	-1.53761275075326	-0.905995881389692
TTC6	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.222483062685	-0.222483062685	-0.896164988490127	-0.852653660565	-9.14179422427924	8.16744226965606	1.44195910368371e-05	0.000482519364142741	-0.843012690256946	-0.504351161353308
TTC6	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3460825468515	0.3460825468515	-0.731907619589074	-0.623158972273	-9.21196634420953	6.3190900320809	6.81704497032503e-05	0.00200067154791838	-1.36086069273775	-0.795119640143394
TTC6	BRD-K45875383-001-01-2::2.5::HTS002	2.5	XBD173	benzodiazepine receptor ligand	noncancer	TSPO	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.14215505153	-1.14215505153	-0.284240892008034	-0.269064169965	19.5287557102027	177.074176749201	4.94670789989277e-46	8.34821226359147e-43	0.771218825745202	0.94460949329873
TTC6	BRD-K49669041-001-08-4::2.5::HTS002	2.5	BX-912	pyruvate dehydrogenase kinase inhibitor	targeted cancer	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.15802819225	-1.15802819225	-1.94499250500171	-1.738347180205	-7.44534354465802	15.1305065095663	1.95642193105726e-06	7.63090001931887e-05	-1.01208696488968	-0.561841660613747
TTC6	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.4700853024005	-0.4700853024005	-0.222436722493049	-0.176181988507	6.1068569786115	9.29106828766918	0.000155835270034396	0.00423267235980256	0.156348574078763	0.338948585736139
TTC6	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.4850104862095	0.4850104862095	0.224373917195435	0.2005091684065	-8.70916414370711	57.1203737468366	4.54630873576097e-12	3.5432938364615e-10	-0.320561021291665	-0.200712116736465
TTC6	BRD-K53561341-001-07-5::2.5::HTS002	2.5	aurora-a-inhibitor-i	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.2328952198605	-0.2328952198605	-0.621873299117502	-0.52264323687	-6.72214485800138	184.327408613663	2.17040244669424e-10	1.38446483927836e-08	-0.503141283873845	-0.27481487464016
TTC6	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.537362157695	-1.537362157695	-2.75223948076508	-2.66953815971	-14.5598320395331	187.275786256674	1.30139919905302e-32	6.51699974144471e-30	-1.37948109074869	-1.05027355539146
TTC6	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.229426036235	-1.229426036235	-0.609166962276284	-0.573831164789	6.84853707701494	6.81845922047365	0.000272604671970126	0.00695229494748753	0.404938186789328	0.835579961128105
TTC6	BRD-K55044200-001-15-3::2.5::HTS002	2.5	amoxicillin	penicillin binding protein inhibitor	noncancer	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.4768385283245	0.4768385283245	0.0934152366509799	0.127274405853	-10.0107320331537	2.90964792133359	0.00241407115510077	0.0471311219349238	-0.507484392907297	-0.259362190439743
TTC6	BRD-K55696337-003-24-4::2.5::MTS006	2.5	topotecan	topoisomerase inhibitor	chemo	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.58872551233	-1.58872551233	-3.16752304319507	-3.19197499768	-12.2956468270326	5.3673651027819	3.90065657520617e-05	0.0012013482764168	-1.90218725112233	-1.25540781060781
TTC6	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.592878877299	-0.592878877299	-0.201442676202124	-0.0713354708951	6.82542084924229	10.6623716543585	3.3398750023259e-05	0.00104105885598241	0.264720869759136	0.518151532434616
TTC6	BRD-K62391742-001-03-0::2.5::HTS002	2.5	venetoclax	BCL inhibitor	targeted cancer	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.125320206037	0.125320206037	0.361181365774289	0.3408626748475	7.66443764733522	18.9484768213233	3.20499351159561e-07	1.40647636025138e-05	0.171439740729877	0.300282578744701
TTC6	BRD-K66788707-001-14-3::2.5::HTS002	2.5	fludarabine	ribonucleotide reductase inhibitor	chemo	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.312498324218	0.312498324218	-0.34137936493051	-0.3277516003215	-13.4902024058517	35.9888697381119	1.20745539307554e-15	1.33398302547674e-13	-0.752181600364871	-0.555573777932148
TTC6	BRD-K67844266-003-01-9::2.5::MTS010::PROS003_PR500	2.5	pevonedistat	nedd activating enzyme inhibitor	targeted cancer	NAE1, UBA3	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.370677883075	-1.370677883075	-0.938713113810361	-0.949123876335	4.62455135625614	122.18395964622	9.40495208371456e-06	0.000325594245703514	0.247059371226438	0.61687016730284
TTC6	BRD-K69694239-001-02-2::2.5::HTS002	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-4.952919822895	-4.952919822895	-5.69922378090557	-5.75788752099	-9.86807093248437	182.010171440828	1.14439176267134e-18	1.66741225086055e-16	-0.89552460262261	-0.597083313398538
TTC6	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.042382289065	-0.042382289065	-0.729915994556779	-0.60872932846	-7.37830501171635	187.463475120087	5.04446220781432e-12	3.8961244704095e-10	-0.871356038028479	-0.503711372955079
TTC6	BRD-K70914287-300-02-8::2.5::HTS002	2.5	BIBX-1382	EGFR inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.379843969266	-0.379843969266	-0.61190388649924	-0.443084865138	-4.53535158417463	187.484356023526	1.02416719062122e-05	0.000352171875178334	-0.332996766135371	-0.131123068331108
TTC6	BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500	2.5	SCH-900776	CHK inhibitor	targeted cancer	CDK2, CHEK1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.6251078549155	0.6251078549155	-0.694192976875121	-0.481859441946	-13.2325267988168	5.69457340368576	1.71604506643873e-05	0.000567414722376961	-1.56646841168646	-1.07213325189478
TTC6	BRD-K78567475-001-01-4::2.5::HTS002	2.5	dolastatin-10	tubulin polymerization inhibitor	targeted cancer	TUBB	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.735861414895	-2.735861414895	-3.98368653377804	-3.95467393468	-10.7827030786601	175.520530277657	4.01133713968676e-21	7.31698619414403e-19	-1.47621612027728	-1.01943411748879
TTC6	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.1715450590035	-0.1715450590035	0.124839475121236	0.135109067247	6.0663082970735	4.84284959048583	0.0019643377361552	0.0394762815426542	0.169556621745461	0.423212446504011
TTC6	BRD-K83988098-003-03-4::2.5::HTS002	2.5	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-3.20785861861	-3.20785861861	-4.38779873633128	-4.37968901574	-13.1496845977869	73.2390664588039	5.80148160138327e-21	1.04753643651464e-18	-1.3587647832603	-1.00111545218226
TTC6	BRD-K85920262-001-02-1::2.5::HTS002	2.5	WAY-600	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.2338701616	-1.2338701616	-1.70489010943025	-1.55120007366	-6.48029633363192	31.4835987990738	2.93465606001755e-07	1.29526750141578e-05	-0.619169623723303	-0.322870271937195
TTC6	BRD-K86972824-001-01-4::2.5::HTS002	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1239275223505	0.1239275223505	0.00693559621824238	-0.004832023318045	-3.86217459618688	195.210674572668	0.000152797406930121	0.00415437212101051	-0.176732983938481	-0.0572508683260341
TTC6	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.1716093052245	0.1716093052245	-0.49748436994972	-0.41754362105	-10.2559814741486	4.22708890294949	0.000382607992994918	0.00943876479403864	-0.846453294133962	-0.491734056214477
TTC6	BRD-K89714990-001-01-5::2.5::MTS006	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.368285936037	0.368285936037	0.134939969086161	0.163955716777	-5.86444114042239	7.07553363594497	0.000597229495677394	0.0140324052377812	-0.327231074663902	-0.139460859237777
TTC6	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.520359945625	-2.520359945625	-2.88843726920898	-2.8540109683	-3.38961904590699	170.544102829002	0.000869505078160132	0.0195489514210619	-0.582430074968189	-0.153724572199772
TTC6	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-2.373469810255	-2.373469810255	-3.11500362825148	-3.009227373135	-6.69651584679726	112.737010128815	8.7259357858154e-10	5.2270013723813e-08	-0.960923924710626	-0.522143711282343
TTC6	BRD-K90948141-001-01-4::2.5::HTS002	2.5	indiplon	benzodiazepine receptor agonist	noncancer	GABRA1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2710057880075	0.2710057880075	0.101262852919993	0.1180798290625	-6.04803137306714	10.4500628365398	0.000103234910611472	0.00291748881282253	-0.231914321156931	-0.107571549018083
TTC6	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-5.015744752625	-5.015744752625	-5.62287063524106	-5.62740406384	-6.03701829605485	124.91389377343	1.66190562330147e-08	8.66864371712293e-07	-0.806162146581828	-0.408089618650289
TTC6	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-1.774904678205	-1.774904678205	-0.0147684420106335	0.0202365059018	25.9588670690843	4.58746586460625	3.7274754650759e-06	0.00013891603007377	1.58101684201426	1.93925563037447
TTC6	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	-0.54867197628	-0.54867197628	-0.34284585763932	-0.279710660695	4.61712982385209	12.549969232034	0.000528230840288635	0.0125822613656616	0.109167234426344	0.302485002855016
TTC6	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.2539277976935	0.2539277976935	0.600715127215243	0.600417589144	9.66206824531036	186.000143736445	3.73414266506523e-18	5.20712467964063e-16	0.275980328124013	0.417594330919472
TTC6	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	MCF7, HCC1419	BREAST	carcinoma, carcinoma (ductal_carcinoma)	0.3173326044005	0.3173326044005	0.0663092666576125	0.0390021562258	-9.38695685548861	6.86020514750204	3.67996667510829e-05	0.00113878656873994	-0.314519603686366	-0.187527071799409
TUBD1	BRD-A50157456-065-20-6::2.5::HTS002	2.5	terbutaline	adrenergic receptor agonist	noncancer	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.4109178925465	-0.4109178925465	0.157360987717469	0.167154929659	14.4189354724483	3.92853811061989	0.000150834836482952	0.00410726460024833	0.45806416578099	0.678493594746948
TUBD1	BRD-A86248581-001-01-4::2.5::HTS002	2.5	tetrahydrouridine	cytidine deaminase inhibitor	targeted cancer	CDA	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.389700673119	-0.389700673119	0.04978177959044	0.0776480680764	12.9982409141649	23.3450081806545	3.54381471934888e-12	2.79243479773281e-10	0.369596393197808	0.509368512221072
TUBD1	BRD-K05445342-001-05-3::2.56563::HTS002	2.56563	WP1066	STAT inhibitor	targeted cancer	STAT3	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-6.01980583657	-6.01980583657	-5.15559126529005	-5.11032297983	13.9762349167759	55.4977864224361	7.97040471207579e-20	1.28925782162564e-17	0.740320288453998	0.988108854105896
TUBD1	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.811534331885	-1.811534331885	-1.32925560267202	-1.32870952416	7.08475952974581	70.201528471279	8.63644446963865e-10	5.17773568316974e-08	0.346518856459841	0.618038601966126
TUBD1	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-2.855291321535	-2.855291321535	-2.05791114909486	-2.351388502545	8.02034045315577	85.1250420694698	5.10845970066526e-12	3.94129250966121e-10	0.599711283275426	0.995049061604853
TUBD1	BRD-K13662825-001-07-5::2.5::HTS002	2.5	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-6.25504736165	-6.25504736165	-4.91177357811784	-4.867325233515	17.5334524288444	189.06033183872	1.69413711043737e-41	2.05142775560978e-38	1.19214953590151	1.49439803116281
TUBD1	BRD-K16180792-001-01-7::2.5::MTS006	2.5	bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	noncancer	PTPN1	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.2845894107745	0.2845894107745	-0.239257760947823	-0.0973395896878	-9.4583280356592	190.88614580382	1.18295161906807e-17	1.57772767618694e-15	-0.633091909289332	-0.414602434155313
TUBD1	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.55549794459	-1.55549794459	-3.00402589688185	-2.880185474935	-18.6785027226977	124.20187085654	7.07644516769232e-38	5.9948119223175e-35	-1.60201973383265	-1.29503617075105
TUBD1	BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500	2.5	odanacatib	cathepsin inhibitor	targeted cancer	CTSK	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.2385781660445	-0.2385781660445	-0.168240965657973	-0.149311762512	3.42052661246933	41.5773321122751	0.00141305500448218	0.0298647733020079	0.0288263465303946	0.111848054242659
TUBD1	BRD-K26619122-001-02-1::2.5::HTS002	2.5	thiocolchicoside	GABA receptor antagonist	noncancer	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.7709179255465	0.7709179255465	0.151932607243338	0.1631740037055	-17.5484044693791	3.54321976202197	0.000142714650330065	0.00390002400747068	-0.722104810598893	-0.51586582600743
TUBD1	BRD-K27182532-001-02-3::2.5::HTS002	2.5	metatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, BCR	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.79639644897	-1.79639644897	-0.963529213116205	-0.9486901264415	15.5449276517202	34.3695694187939	4.07215729103033e-17	5.14611674545543e-15	0.72402660461877	0.941707867088819
TUBD1	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.323708787524	-0.323708787524	-0.693723789059162	-0.621232482709	-7.60362539415465	188.82082884762	1.31518184862e-12	1.08524111143567e-10	-0.466007925471754	-0.274022077598571
TUBD1	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.460186836582	0.460186836582	-0.243644564373057	-0.026104548309	-10.1198289419941	4.77080506261544	0.000210397152038059	0.00553303204897731	-0.885229191300517	-0.522433610609597
TUBD1	BRD-K38852836-001-02-1::2.5::HTS002	2.5	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-5.37151299422	-5.37151299422	-4.84856860103592	-4.86851000212	6.28849272049788	84.9729379410361	1.33118152059189e-08	7.02909101076472e-07	0.357601380003678	0.688287406364489
TUBD1	BRD-K39160765-003-02-9::2.5::HTS002	2.5	4-chlorophenylguanidine	urokinase inhibitor	noncancer	PLAUR	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.1935633134775	-0.1935633134775	0.0570130657300287	0.0820318935995	8.00344691745002	101.299240996777	2.08379698501127e-12	1.68091126834957e-10	0.188470846842737	0.31268191157232
TUBD1	BRD-K41337261-001-03-0::2.5::HTS002	2.5	ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.7313919468235	-0.7313919468235	-0.491039007393926	-0.306530142238	4.56292692176064	192.794444803044	8.9647862085289e-06	0.000311513239832651	0.13645933935195	0.344246539507197
TUBD1	BRD-K41783120-001-02-8::2.5::MTS006	2.5	STA-5326	interleukin synthesis inhibitor	noncancer	IL12A	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.021609969459	-0.021609969459	-0.538187628735817	-0.407422571936	-6.92062967590235	22.8395996757894	4.87563459678018e-07	2.08206791690237e-05	-0.671048824555371	-0.362106493998262
TUBD1	BRD-K41876534-001-13-7::2.5::HTS002	2.5	tioxolone	carbonic anhydrase inhibitor	noncancer	CA2	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.405214228159	-0.405214228159	0.222545673249474	0.2844579825675	12.1743813433133	11.6369076537585	5.66150966110545e-08	2.74592827371593e-06	0.515021555253732	0.740498247563215
TUBD1	BRD-K45662124-050-01-5::2.5::HTS002	2.5	3'-fluorobenzylspiperone	dopamine receptor ligand	noncancer	DRD2	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.0731155190232	0.0731155190232	0.513600879613775	0.5308791065105	11.6603672425642	7.69809299754219	3.64882967750292e-06	0.000136293136275623	0.352774820659909	0.528195900521241
TUBD1	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.04778678518737	0.04778678518737	-0.460352608291784	-0.3435721987365	-7.27564478342405	4.44377316647229	0.00125108080238699	0.0269111699412687	-0.694646111527759	-0.321632675430548
TUBD1	BRD-K51350053-048-16-5::2.5::HTS002	2.5	toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	ESR1	oncology	breast cancer	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.19923324157	-1.19923324157	-0.496055986434721	-0.414253606169	9.10217218911695	11.0511843530323	1.81365462058876e-06	7.10248092775752e-05	0.533238854120667	0.873115656149891
TUBD1	BRD-K51471001-303-04-7::2.5::HTS002	2.5	demecarium	acetylcholinesterase inhibitor	noncancer	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.4245794120165	-0.4245794120165	0.286301598460158	0.276786886739	17.3794176199243	2.15497294548435	0.00234879193182444	0.0460327565797367	0.546476119490859	0.875285901462457
TUBD1	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.568355674994	-0.568355674994	-0.0966711564613034	-0.09755826700195	9.09755347863683	12.850852586788	5.82814195490732e-07	2.4633008027082e-05	0.35954272375786	0.583826313307533
TUBD1	BRD-K57927309-001-01-7::2.5::HTS002	2.5	BW-180C	opioid receptor agonist	noncancer	OPRD1, OPRM1	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.9878514401335	0.9878514401335	0.252972246437632	0.239961209955	-23.1012619416649	4.77244711521354	4.40414529311589e-06	0.000162364668726167	-0.817839285739646	-0.65191910165209
TUBD1	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.5418965522895	-0.5418965522895	0.153167965719008	0.17108607142	24.1150806531286	18.7443000704147	1.43315947145001e-15	1.56958424300669e-13	0.634681924317488	0.755447111699527
TUBD1	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.94007310778	-1.94007310778	-1.06865722613672	-0.4089077458395	7.52071368614917	155.753475000119	4.04830271454092e-12	3.17478475120688e-10	0.642538906106344	1.10029285718021
TUBD1	BRD-K68065987-300-09-1::2.5::MTS006	2.5	MK-2206	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.8223826743935	-0.8223826743935	-1.18034164544569	-1.01733335597	-4.96551449233423	6.04917904258868	0.00247983800041996	0.0482393536750781	-0.534007357624505	-0.181910584479884
TUBD1	BRD-K68552125-001-05-3::2.02651::HTS002	2.02651	12-O-tetradecanoylphorbol-13-acetate	PKC activator	targeted cancer	KCNT2, TRPV4	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	1.05978996155	1.05978996155	-0.019480382784591	-0.0198550434605	-21.7515939268405	182.117287741289	1.6118986392596e-52	5.15636751423688e-49	-1.17717038602715	-0.981370302642031
TUBD1	BRD-K68747584-001-02-0::2.5::HTS002	2.5	PF-03814735	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.363858076852	-0.363858076852	-1.27934119114134	-1.09893939309	-9.45154974435271	7.73656734863409	1.61616750882695e-05	0.000537041187595923	-1.14017493353297	-0.690791295045704
TUBD1	BRD-K69694239-001-02-2::2.5::HTS002	2.5	bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	PPARG, STAT3	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-6.203882805735	-6.203882805735	-5.68555205431716	-5.73883515181	5.64830303887447	9.59743228204727	0.000248003907738624	0.00640600106856253	0.312691449220514	0.723970053615169
TUBD1	BRD-K81016934-001-02-0::2.5::HTS002	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.195358099519	-0.195358099519	0.147395451542941	0.2067474126465	10.1755497236892	41.3266287079584	8.01673777171487e-13	6.74075868918743e-11	0.274743590995213	0.410763511128669
TUBD1	BRD-K85402309-001-06-6::2.5::HTS002	2.5	dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.651475613704	-0.651475613704	-0.159180711873438	-0.1901331802295	9.07765442068498	3.79603620792826	0.00103826475005018	0.0228513763470574	0.338479145267136	0.64611065839399
TUBD1	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.617212594476	-0.617212594476	-0.318599678604196	-0.18498925291	5.16705551156913	23.3650924694506	2.94572921493496e-05	0.000927372498395703	0.179164960320423	0.418060871423185
TUBD1	BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500	2.5	linsitinib	IGF-1 inhibitor	targeted cancer	IGF1R, INSR, INSRR	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.163364215608	0.163364215608	0.041587428675293	0.0562766217073	-4.10797036951826	39.2456803860761	0.00019645812379268	0.00519835471782239	-0.18172549346322	-0.0618280804021942
TUBD1	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-0.0254090530131	-0.0254090530131	0.112820544417938	0.0998567885779	5.40867244752211	190.559185253686	1.88844849505977e-07	8.55525845482278e-06	0.0878185860667005	0.188640608795375
TUBD1	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.1697283481085	0.1697283481085	-0.122201132024951	-0.0479466221371	-9.0107196351915	176.119834720785	3.34500360813338e-16	3.90698244320228e-14	-0.355867786655459	-0.227991173611443
TUBD1	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-6.63896858936	-6.63896858936	-5.60569366342376	-5.60058662575	10.6027138549104	188.056409859944	6.87805112831332e-21	1.23361156508809e-18	0.841031792301564	1.22551805957092
TUBD1	BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500	2.5	linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK	NA	NA	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	0.310398556827	0.310398556827	0.0920366641366471	0.162270559212	-6.55839655469067	17.968910197036	3.69751897976337e-06	0.000138015594812557	-0.288320793680543	-0.148402991700163
TUBD1	BRD-K99792991-001-34-9::2.5::HTS002	2.5	hexachlorophene	potassium channel activator	noncancer	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	FADU, VMCUB1	UPPER_AERODIGESTIVE_TRACT, URINARY_TRACT	carcinoma (squamous_cell_carcinoma), carcinoma (transitional_cell_carcinoma)	-1.111313705555	-1.111313705555	-0.613311913560166	-0.6000769492995	7.8530443282256	6.3143976560634	0.000174626776322515	0.00468782343968291	0.344684286240165	0.651319297749502
TXNRD1	BRD-A26032986-050-02-1::2.5::HTS002	2.5	zaldaride	calmodulin antagonist	noncancer	CALM1	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.661457476071	-0.661457476071	-0.161881293643822	-0.153177968043	12.7678167887112	7.38766068468651	2.66675601897395e-06	0.000101919249427722	0.408028875857537	0.591123488996818
TXNRD1	BRD-A44090213-001-25-6::2.5::HTS002	2.5	indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	noncancer	CXCR1, CXCR2, PTGS1, PTGS2	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-1.33558426834	-1.33558426834	-1.90886241861553	-1.821377260325	-5.72206376791508	10.6465727670349	0.000151559828400728	0.00412543389145283	-0.79468532398551	-0.351870976565553
TXNRD1	BRD-A57798112-001-03-7::2.5::HTS002	2.5	PD-318088	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.262142880835	-0.262142880835	-1.03373204986315	-0.797857785181	-8.36938410085528	15.5534931540316	3.77943870458428e-07	1.63976380185191e-05	-0.967484183976978	-0.575694154079319
TXNRD1	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.220914801871	0.220914801871	-0.238094582145335	-0.2322368233935	-8.18177140531605	7.93623418899465	3.88938129393965e-05	0.00119822797664049	-0.58856075593298	-0.32945801209969
TXNRD1	BRD-A98990573-003-01-3::2.5::HTS002	2.5	epinastine	histamine receptor antagonist	noncancer	ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7	ophthalmology	conjunctivitis	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.5996497589405	0.5996497589405	0.398463369234381	0.387038692764	-6.53599751899054	6.04648387461435	0.000593954024110872	0.0139784311006543	-0.276365338954087	-0.126007440458152
TXNRD1	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.2630879802435	0.2630879802435	-0.428932007504335	-0.399128631959	-9.53290849562685	3.73182312897405	0.000939982434846064	0.0209671752965121	-0.899412420155729	-0.48462755533994
TXNRD1	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.1359416525871	0.1359416525871	-0.258483126203513	-0.1509093731905	-5.88593930666153	7.11526673422706	0.000572193638256152	0.0135108174830674	-0.552362566074813	-0.236486991506413
TXNRD1	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.296010563413	-0.296010563413	-0.481347253713338	-0.4134526693685	-4.00884641813279	181.589982555697	8.89895552392464e-05	0.00254850913747627	-0.276557545626904	-0.0941158349737715
TXNRD1	BRD-K16803204-001-01-6::2.5::HTS002	2.5	filgotinib	JAK inhibitor	noncancer	JAK1, JAK2, JAK3, TYK2	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.07505883783335	-0.07505883783335	0.246998721475013	0.2325578097185	9.21044330956171	9.52330432980722	4.76004011068025e-06	0.000174276501004781	0.243615328998795	0.400499789617931
TXNRD1	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.313466915404	-0.313466915404	-0.976779146143541	-0.735958486111	-9.61227653567696	176.609056348243	7.3778914472089e-18	1.00272422066508e-15	-0.799496228363072	-0.527128233116009
TXNRD1	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.135472929264	0.135472929264	0.549879013384519	0.548346398175	10.574774625562	2.83434264239207	0.0023118045341535	0.0454241615328737	0.285465085349823	0.543347082891215
TXNRD1	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.1726498149595	0.1726498149595	-0.214623819204684	-0.0984348398408	-6.55214700670119	15.4515193284006	7.91512289544956e-06	0.000277922735101378	-0.512935998965258	-0.261611269363109
TXNRD1	BRD-K26603252-003-04-9::2.5::HTS002	2.5	PD-153035	EGFR inhibitor	targeted cancer	EGFR, KDR	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.332526759978	-0.332526759978	-1.0436509376943	-0.8676646214495	-9.53738749630893	183.526801720489	9.16673887930643e-18	1.2372153509212e-15	-0.858232562393982	-0.564015793038612
TXNRD1	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.7651601023725	-0.7651601023725	-0.528577569299344	-0.447815997104	5.23249741446019	182.246173480717	4.56684091209008e-07	1.95996484951413e-05	0.147372167207822	0.325792898938491
TXNRD1	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.582431267303	-0.582431267303	-1.34920852491897	-1.37381285511	-11.5902996873303	180.941339804372	1.37198424060332e-23	3.09532642425547e-21	-0.897315318553407	-0.636239196678539
TXNRD1	BRD-K33127281-001-05-6::2.5::MTS006	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.04924423477145	0.04924423477145	0.212645552042358	0.242460199933	6.24532157485997	5.12593743578919	0.00140859905851877	0.0297911612012306	0.0966391163373643	0.230163518204451
TXNRD1	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.57864929085	-0.57864929085	0.0489560290903782	0.1528278299165	13.3617376128033	20.7434038415206	1.17189924687706e-11	8.70915373383886e-10	0.529851530801816	0.72535910907894
TXNRD1	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.0619679907222	-0.0619679907222	0.0387861634427117	0.0420255810144	4.99824745164636	133.898677702786	1.77691554115805e-06	6.96624347943778e-05	0.0608850726047336	0.14062323572509
TXNRD1	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.0809562785625	-0.0809562785625	0.134247803157136	0.1319992768505	6.9300133963406	187.000404142848	6.60295120804496e-11	4.46295783497026e-09	0.153943050857422	0.276465112581851
TXNRD1	BRD-K37237504-001-02-7::2.5::HTS002	2.5	CEP-33779	JAK inhibitor	targeted cancer	JAK2	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.06203413551475	-0.06203413551475	0.19260179852756	0.159444358103	6.13152385396111	10.4696517883293	9.1360993975542e-05	0.00260910199570739	0.162663167209497	0.346608700875123
TXNRD1	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.3873651402775	-0.3873651402775	-0.17580335282099	-0.120119113317	5.81866790109346	65.9495420081951	1.90570161751658e-07	8.62977227933048e-06	0.138967376386277	0.284156198526744
TXNRD1	BRD-K42805893-001-04-9::2.5::HTS002	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.0257013690716	-0.0257013690716	-0.636195552983903	-0.4291875223905	-9.57121513040461	189.97376165349	5.84747211902741e-18	8.03901765105212e-16	-0.736310815589929	-0.484677552234677
TXNRD1	BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.315645261982	-0.315645261982	-0.724905208913587	-0.623158972273	-4.46376514569029	188.655684703854	1.38335774590821e-05	0.000464650810723649	-0.590119294456861	-0.228400599406313
TXNRD1	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.306891507192	-0.306891507192	-1.4033742886338	-1.171371713075	-14.2907461757749	58.7672464988318	8.81662093049499e-21	1.56688022173471e-18	-1.25002541558205	-0.942940147301553
TXNRD1	BRD-K50168500-001-07-9::2.5::HTS002	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.233994588748	-0.233994588748	-0.473273454387772	-0.3595601778475	-4.21961951553515	84.1528057193326	6.14632242617697e-05	0.00182178832703649	-0.352042502305003	-0.126515228974541
TXNRD1	BRD-K53972329-001-07-0::2.5::MTS010::PROS003_PR500	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.6448640355735	-0.6448640355735	-0.00672905674439762	-0.0140997876931	25.2363093317809	21.4525639492188	1.94158707632466e-17	2.52664490881353e-15	0.58561653355221	0.690653424105995
TXNRD1	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.3303013818665	0.3303013818665	-0.127567969174148	-0.007473093877485	-9.90684004771878	14.7871503519647	6.43080720874287e-08	3.1022022917908e-06	-0.556503259895056	-0.359235442186239
TXNRD1	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.60269740097	-0.60269740097	-0.233047265729488	-0.09048394609	6.60447918696348	170.316693042773	4.88332533213233e-10	3.00412811455393e-08	0.259166659472866	0.480133611008158
TXNRD1	BRD-K58262659-001-09-7::2.5::HTS002	2.5	doxifluridine	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.548327679247	0.548327679247	0.23126436628423	0.271076937361	-7.87151345096983	41.3394797684638	9.43111805662438e-10	5.63053510294776e-08	-0.398389820463669	-0.23573680546187
TXNRD1	BRD-K63068307-001-08-9::2.5::HTS002	2.5	ZSTK-474	PI3K inhibitor	targeted cancer	PIK3CB, PIK3CD, PIK3CG	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-1.88399736292	-1.88399736292	-1.47575931772445	-1.34809352963	6.29695716956653	189.517646073815	2.06538854185211e-09	1.18710823487965e-07	0.280354979727778	0.536121110663329
TXNRD1	BRD-K66956375-001-11-3::2.5::HTS002	2.5	oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	noncancer	CNR1, GPR119, GPR55, PPARA	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.108799659662	0.108799659662	0.333753343363897	0.335539254934	9.36134609002792	69.0496704233569	6.54802604226558e-14	6.12050533629629e-12	0.177015646102833	0.272891721300962
TXNRD1	BRD-K70301465-001-02-6::2.5::HTS002	2.5	ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.1094514448811	0.1094514448811	-0.539796538503669	-0.407441526883	-7.56819266928706	6.25303964440126	0.000226689026563488	0.00590568036639429	-0.85711775689127	-0.441378209878268
TXNRD1	BRD-K71164191-001-01-0::2.5::HTS002	2.5	KD-023	ACAT inhibitor	noncancer	ACACA, ACACB	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-1.21828467678	-1.21828467678	-0.944613767676698	-0.959659141772	5.06156548380368	182.583977975801	1.0097677769532e-06	4.11527890980421e-05	0.166991630595999	0.380350187610606
TXNRD1	BRD-K73303757-001-21-6::2.5::HTS002	2.5	4-methylgenistein	protein tyrosine kinase inhibitor	targeted cancer	CYP19A1, ESRRA, ESRRB, ESRRG, FASN	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.016755233793965	0.016755233793965	0.243625877526237	0.276258886308	5.81978634149508	33.0538904849536	1.63071890346751e-06	6.44139977628617e-05	0.147564775520091	0.306176511944453
TXNRD1	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.577322353528	-0.577322353528	-1.1153985617232	-0.918129706972	-6.31211064057533	74.1028590010361	1.82036389546348e-08	9.4400380680085e-07	-0.707926767326008	-0.368225649064397
TXNRD1	BRD-K76908866-001-07-6::2.5::HTS002	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.259367318768	-0.259367318768	-0.700275358816066	-0.649995619328	-6.80398485856035	188.543885902102	1.31231284246476e-10	8.59091934064229e-09	-0.568737041150993	-0.313079038945138
TXNRD1	BRD-K80343549-001-02-6::2.5::HTS002	2.5	TAK-285	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.3995431743575	-0.3995431743575	-0.948981136174943	-0.8151847008705	-8.35589708914356	74.5682350591866	2.60785280110535e-12	2.08248317067105e-10	-0.680440105983659	-0.418435817651228
TXNRD1	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.4587371924985	0.4587371924985	0.28073182725538	0.273644438403	-5.2279905644166	81.4091214938128	1.29836351337552e-06	5.21313138737847e-05	-0.245746088228746	-0.110264642257493
TXNRD1	BRD-K81916719-001-13-9::2.5::HTS002	2.5	triclabendazole	microtubule inhibitor	noncancer	DNMT1	infectious disease	tapeworm	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-1.58265207441	-1.58265207441	-2.34017642772854	-2.3242666172	-7.31584050108166	4.99610916715744	0.000750229362181982	0.0171882318511066	-1.02375959390501	-0.491289112732065
TXNRD1	BRD-K82244583-001-01-3::2.5::HTS002	2.5	MEK162	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.6849557920825	-0.6849557920825	-1.69809700710055	-1.42296021894	-8.9499364028898	5.30336521871955	0.00021328506000931	0.00559456292090752	-1.29919748466196	-0.72708494537414
TXNRD1	BRD-K84868168-001-01-0::2.5::MTS006	2.5	erdafitinib	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.347184267663	-0.347184267663	0.0934545780938812	0.154218588669	11.4451491065214	187.110357402899	2.47314118023273e-23	5.46459665998043e-21	0.364688888417997	0.516588803095765
TXNRD1	BRD-K84937637-001-09-9::2.5::HTS002	2.5	sirolimus	mTOR inhibitor	noncancer	FGF2, FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-1.570948893055	-1.570948893055	-1.34621180175452	-1.32265051102	4.33894915808366	109.531961799639	3.20058197150562e-05	0.00100040474459797	0.122086123563294	0.327388059037674
TXNRD1	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.5015388422985	-0.5015388422985	-2.07710280054532	-1.887176140495	-15.2329596299984	151.160698122024	2.42568156204512e-32	1.18968856638803e-29	-1.77992154311534	-1.37120637337831
TXNRD1	BRD-K89714990-001-01-5::2.5::MTS006	2.5	tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	noncancer	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	-0.206009624036	-0.206009624036	0.140953535160223	0.165320273303	8.72546903494766	7.02146855692555	5.1224413919284e-05	0.00154089507521491	0.252993511752518	0.440932806639928
TXNRD1	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	GI1, NCIH1793	CENTRAL_NERVOUS_SYSTEM, LUNG	glioma (gliosarcoma), carcinoma (non_small_cell_carcinoma)	0.3743425097895	0.3743425097895	0.599427269331863	0.600417589144	5.33362690421253	12.794702768407	0.000143322485471579	0.00391513701104233	0.133765963638017	0.316403555446709
UBE2L3	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.3313238663015	0.3313238663015	0.175462776740319	0.21394626854	-5.75432281667874	186.159805824688	3.52406511964471e-08	1.75490091316991e-06	-0.209295882256807	-0.102426296865554
UBE2L3	BRD-A03932035-004-04-3::2.5::HTS002	2.5	methscopolamine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.35034379648	0.35034379648	0.239417206775837	0.224710721764	-3.90598369113914	127.589766166772	0.000151339538537414	0.00411996087326121	-0.167120870412433	-0.0547323089958932
UBE2L3	BRD-A23072235-050-18-5::2.5::HTS002	2.5	pheniramine	histamine receptor antagonist	noncancer	HRH1	allergy	allergic rhinitis, urticaria	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.6182131689905	-0.6182131689905	-1.72145330020378	-1.478667912985	-8.91586149940898	4.13545787539479	0.000749806614387927	0.0171822198070298	-1.44240192111977	-0.764078341306781
UBE2L3	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.834836835143	-0.834836835143	-1.2393350871023	-1.05465528871	-3.95548669109937	17.4074326131912	0.000980940404188223	0.0217643867380184	-0.619869383090802	-0.18912712082779
UBE2L3	BRD-A59303141-001-10-4::2.5::HTS002	2.5	quinethazone	thiazide diuretic	noncancer	CA1, CA2, SLC12A1, SLC12A2, SLC12A3	cardiology	hypertension	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.52631930346	0.52631930346	0.361748654746106	0.3935946417985	-4.86345496243536	29.3496065270023	3.60447875950318e-05	0.00111703922505141	-0.233741784272945	-0.0953995131548426
UBE2L3	BRD-A65248799-001-01-7::2.5::HTS002	2.5	EMD-53998	phosphodiesterase inhibitor	noncancer	TNNC1	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.7932051725205	-0.7932051725205	-0.52769306996589	-0.5103777767265	7.48588240827853	17.6596037834387	7.02086107994335e-07	2.93729091236225e-05	0.190892717604962	0.340131487504259
UBE2L3	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.0121554815442	-0.0121554815442	0.249847027325993	0.2649123832205	7.12221346931129	16.3230990419716	2.15912680846537e-06	8.37579664198102e-05	0.184143520636643	0.339861497103743
UBE2L3	BRD-A70858459-001-01-7::2.5::MTS010::PROS003_PR500	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.1671059707485	-0.1671059707485	-0.0134793850469409	-0.0140777407944	8.18753604147257	188.324840194762	3.94015759156526e-14	3.77172861296378e-12	0.116613002337312	0.190640169065806
UBE2L3	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.7165305798335	-0.7165305798335	-0.22822673602213	-0.218507717473	9.21998061418725	12.9118508532775	4.83019741280289e-07	2.06513341569645e-05	0.373808062648974	0.602799624973766
UBE2L3	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.6044037229535	0.6044037229535	0.411049709292375	0.462027349437	-5.96688353611914	177.169969994932	1.28542979148428e-08	6.79755444803935e-07	-0.257302530269016	-0.129405497053234
UBE2L3	BRD-A93093700-001-02-9::2.5::HTS002	2.5	temazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.133191893284	0.133191893284	0.298134973979935	0.2970613680105	5.65214451198543	13.3392385956972	7.16749277182101e-05	0.00209442748706215	0.102060958081551	0.227825203310318
UBE2L3	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.2286900251405	0.2286900251405	-0.386005199285795	-0.278845004201	-8.75510702112615	8.61743510293675	1.41693436665058e-05	0.00047509097693824	-0.774602404915571	-0.454788043937019
UBE2L3	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-1.7885401759	-1.7885401759	-1.21506164893351	-1.22574357102	7.42740132648153	57.0741942171336	6.12524056159095e-10	3.72219076928049e-08	0.418870133140216	0.728086920792763
UBE2L3	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-3.468061820785	-3.468061820785	-3.02473088684571	-2.91986435367	4.6209176248207	190.97212326062	7.01623438781944e-06	0.000248518013569154	0.254092713106097	0.632569154772485
UBE2L3	BRD-K07972848-001-02-0::2.5::HTS002	2.5	GSK2126458	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-3.05275358024	-3.05275358024	-3.87537226326536	-3.827765844565	-8.77562240489563	45.4052720218542	2.44102859180892e-11	1.73930590775869e-09	-1.01137236102857	-0.633865005022157
UBE2L3	BRD-K10845183-304-01-6::2.5::HTS002	2.5	tiludronate	bone resorption inhibitor, osteoclast inhibitor	noncancer	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.19484283911	-0.19484283911	0.221452927804885	0.2180493051285	11.4810879970556	138.542736704059	7.41016055749403e-22	1.43469945991611e-19	0.344602685828537	0.487988848001233
UBE2L3	BRD-K11073688-001-01-6::2.5::HTS002	2.5	CPI-1189	tumor necrosis factor release inhibitor	noncancer	TNF	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.690432234582	-0.690432234582	-0.255924261210826	-0.239432802339	8.74912635523604	35.392705856287	2.25053021743696e-10	1.43387006829086e-08	0.333726671879198	0.53528927486315
UBE2L3	BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500	0.625	dinaciclib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK5, CDK9	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-2.272091044685	-2.272091044685	-2.60703269668849	-2.686193418095	-4.63673826008871	139.529824207802	8.05423509021651e-06	0.000282483415586813	-0.477761249636588	-0.1921220543704
UBE2L3	BRD-K14560436-001-01-4::2.5::HTS002	2.5	TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-3.304206527095	-3.304206527095	-3.74053805938715	-3.62828968956	-3.7406217942012	178.969991442929	0.000246990678051754	0.0063833673020806	-0.666511543420945	-0.206151521163345
UBE2L3	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.1171054685645	0.1171054685645	-0.0718798286131777	0.0407112965926	-4.5510909369556	179.000499400192	9.82565051546297e-06	0.000339063250576182	-0.270927344023489	-0.107043250331866
UBE2L3	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.0937949212337	0.0937949212337	0.261005356035024	0.263001454047	6.01047626509132	129.589359295243	1.75727602567732e-08	9.13276462918026e-07	0.112170587501953	0.222250282100695
UBE2L3	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.3520735126095	-0.3520735126095	-0.185669195012706	-0.102291191228	3.61264661973703	15.9621280080774	0.00234368380314068	0.0459410468120852	0.0687392352823096	0.264069399911278
UBE2L3	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-1.818822167375	-1.818822167375	-2.87322959049135	-2.63264407289	-6.5503867760193	6.67873455891252	0.000388864109768404	0.00956886977985674	-1.43878126189441	-0.67003358433828
UBE2L3	BRD-K17894950-001-14-3::2.5::MTS010::PROS002_PR500	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.153382148672	0.153382148672	0.0180681202011539	0.01698904715675	-5.44338555306146	179.959432835855	1.69369996786438e-07	7.72195321021921e-06	-0.184365527126103	-0.0862625298155892
UBE2L3	BRD-K18163608-001-05-6::2.48005::HTS002	2.48005	HA14-1	BCL inhibitor	targeted cancer	BCL2	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.2573609647625	-0.2573609647625	-0.0406935245911175	0.0501858788395	4.24349101439041	66.705198374168	6.94968175558433e-05	0.00203402750374523	0.1147454247879	0.318589455554865
UBE2L3	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-1.09717794216	-1.09717794216	-0.363342833908449	-0.151227527586	7.90363922562317	7.17668824825779	8.62280644035884e-05	0.00247869833899634	0.515376077265056	0.952294139238047
UBE2L3	BRD-K20722021-001-02-1::2.5::HTS002	2.5	CEP-32496	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.0324012125936	-0.0324012125936	-0.306264207967949	-0.19710233478	-4.79035671390716	114.660951639887	5.0235043679864e-06	0.000182922641468936	-0.387108620729593	-0.160617370019105
UBE2L3	BRD-K23190681-001-01-1::2.5::HTS002	2.5	AV-412	protein tyrosine kinase inhibitor	targeted cancer	EGFR, ERBB2	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.14673463648225	-0.14673463648225	-0.862711372295439	-0.55802362728	-6.52917121384874	12.1209076981544	2.68187144123018e-05	0.00085244375519416	-0.954637223289047	-0.477316248337331
UBE2L3	BRD-K26712974-001-01-5::2.5::HTS002	2.5	VX-765	caspase inhibitor	noncancer	CASP1	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.952868356575	-0.952868356575	-0.52658067297804	-0.447815997104	7.29979618650645	5.78436391957391	0.000398147344325715	0.00976591006660404	0.282093627104897	0.570481740089022
UBE2L3	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.012692634850095	-0.012692634850095	-0.184064603306409	-0.06456986921455	-3.95547935462981	182.740398440309	0.000109162744766087	0.00306802280657889	-0.25685392972094	-0.0858900071916885
UBE2L3	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.6026014089165	0.6026014089165	-0.102331859859472	-0.09070553113985	-13.1373738599298	4.50848567810279	9.14570712506073e-05	0.00261122816501336	-0.847515164047146	-0.562351373504797
UBE2L3	BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500	2.30099	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.896646936835	0.896646936835	-0.805546047084904	-0.4002530483955	-14.4929763298326	68.5259093713902	1.48856133760032e-22	3.10050401289153e-20	-1.93652727020555	-1.46785869763426
UBE2L3	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.5932919984715	-0.5932919984715	-1.37632386613924	-1.00119520354	-5.94434892153919	6.00643635237864	0.0010088903599901	0.0222991092055603	-1.10527277297325	-0.460790962362235
UBE2L3	BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500	2.5	osimertinib	EGFR inhibitor	targeted cancer	EGFR	oncology	non-small cell lung cancer (NSCLC)	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.0577830990041	-0.0577830990041	-0.296189576447988	-0.160539632789	-4.00697780462964	102.501828370478	0.000116761831078462	0.0032589460207339	-0.356413203328943	-0.120399751558833
UBE2L3	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.778337381081	-0.778337381081	-1.59522436627083	-1.48697544025	-9.78810114304395	169.622775687602	3.2403091938612e-18	4.55404740466281e-16	-0.981635412123293	-0.65213855825636
UBE2L3	BRD-K49371609-003-03-8::2.5::HTS002	2.5	PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-4.58918214835	-4.58918214835	-5.34921586792989	-5.36758305195	-7.69496856372425	5.24723262839156	0.000474884596623104	0.011447704500015	-1.01037435336339	-0.509693085796396
UBE2L3	BRD-K50853363-001-02-3::2.5::HTS002	2.5	dienogest	progesterone receptor agonist	noncancer	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.472570372331	-0.472570372331	-0.27504583784316	-0.206947214108	4.08590583280424	183.490692262605	6.55507252291002e-05	0.00193066117735713	0.102145115827134	0.292903953148545
UBE2L3	BRD-K53972329-001-07-0::2.5::HTS002	2.5	ruxolitinib	JAK inhibitor	targeted cancer	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.249152628925	0.249152628925	0.558977363711819	0.4808891597695	4.86811088722695	6.36828957088883	0.00237218712684789	0.0464148707969856	0.156251425301957	0.463398044271681
UBE2L3	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.1491559270535	0.1491559270535	0.470756226600969	0.4617368983695	8.62774253929004	3.74025224538472	0.00133281641247616	0.0284098666205474	0.21521087132205	0.427989727772887
UBE2L3	BRD-K56032964-001-02-1::2.5::HTS002	2.5	AP26113	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, EGFR	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.12658198177895	-0.12658198177895	-0.550389881010461	-0.449925278333	-5.90184548926042	11.8437706487197	7.6272370386746e-05	0.00221419218104035	-0.58049631469392	-0.267119483769101
UBE2L3	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.016969610980245	0.016969610980245	-0.207828524246933	-0.0810605722641	-4.17712012652663	21.9651832877523	0.000392578395964596	0.00965140342150676	-0.336417057600796	-0.11317921285356
UBE2L3	BRD-K61688984-001-02-9::2.5::HTS002	2.5	RGFP966	HDAC inhibitor	targeted cancer	HDAC3	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.386920555389	0.386920555389	0.142090205572857	0.1478975736545	-6.5604689950833	35.5781062473755	1.31694269764668e-07	6.11744714876277e-06	-0.320548029948358	-0.169112669683928
UBE2L3	BRD-K62008436-001-22-1::2.5::HTS002	2.5	paclitaxel	tubulin polymerization inhibitor	chemo	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-5.40035532005	-5.40035532005	-3.97644671952268	-4.06345371982	9.59932194126744	3.8805276841098	0.000761942719203777	0.0174193515801841	1.00701746666058	1.84079973439406
UBE2L3	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-3.33383323579	-3.33383323579	-2.93685911653356	-2.87845710522	3.99808005865082	13.2661669999308	0.00146068829687137	0.0307441679249871	0.182905217978167	0.611043020534718
UBE2L3	BRD-K67844266-003-01-9::2.5::HTS002	2.5	pevonedistat	nedd activating enzyme inhibitor	targeted cancer	NAE1, UBA3	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-2.91123573408	-2.91123573408	-2.60824801732695	-2.60596765275	3.272029172201	190.121126929738	0.00126812326879085	0.0272094896462783	0.120333669955428	0.48564176355067
UBE2L3	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.021449955539125	-0.021449955539125	-0.263180519233672	-0.236194067289	-4.97937351925327	10.5311634225376	0.000474072690648143	0.011429417965571	-0.349163668859069	-0.134297458530024
UBE2L3	BRD-K69280563-001-01-8::2.5::HTS002	2.5	vinorelbine	tubulin polymerization inhibitor	chemo	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-3.73580271007	-3.73580271007	-3.36174641185209	-3.520745955955	3.57273235623725	21.0950209813443	0.00178609605146093	0.0364305463088665	0.156385541320557	0.591727055115264
UBE2L3	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-3.88481965286	-3.88481965286	-4.36211002893368	-4.09603677997	-3.98177706792476	127.94666279501	0.000114038225231079	0.00319040579239682	-0.714471989907963	-0.240108762239405
UBE2L3	BRD-K72327355-001-14-7::2.5::HTS002	2.5	baicalein	lipoxygenase inhibitor	targeted cancer	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.06053870000295	-0.06053870000295	0.103639081992463	0.130322249466	4.33643055009482	147.610053600909	2.66847276619282e-05	0.000849192426882467	0.0893599176018707	0.238995646388956
UBE2L3	BRD-K74671368-001-01-8::2.5::MTS006	2.5	idronoxil	XIAP inhibitor	targeted cancer	ENOX2, SPHK1	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.07818127707925	0.07818127707925	-0.254903508651322	-0.195737211392	-8.25308238427602	53.3374408093764	4.22152315498038e-11	2.92152029797801e-09	-0.414022402970972	-0.252147168490172
UBE2L3	BRD-K76011241-001-01-8::2.5::HTS002	2.5	oseltamivir-phosphate	neuraminidase inhibitor	noncancer	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.176454107617	0.176454107617	0.326841738461882	0.306165315644	5.85154391935695	38.1098004733576	9.00980122758211e-07	3.70645237486842e-05	0.0983646017592898	0.202410659930474
UBE2L3	BRD-K76210423-001-01-6::2.5::MTS010::PROS001_PR500	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.08493684449825	-0.08493684449825	0.108035139508643	0.094360121778	7.68237947297694	8.13252590189977	5.34216666732668e-05	0.00160294167666451	0.13521186908493	0.250732098928857
UBE2L3	BRD-K76239644-001-01-8::2.5::HTS002	2.5	BMS-690514	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, FLT3, KDR	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.1361119124715	-0.1361119124715	-1.1200185663416	-0.918129706972	-12.0861231312279	188.086320733634	2.93752569781733e-25	7.65002363654302e-23	-1.1444966261241	-0.823316681616093
UBE2L3	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.3726703528645	-0.3726703528645	-0.210831149842244	-0.185900015084	5.36675257831743	103.124380856029	4.95803059341421e-07	2.11598912595753e-05	0.10203296397001	0.221645442074501
UBE2L3	BRD-K77677632-003-02-6::2.5::HTS002	2.5	SB-200646	serotonin receptor antagonist	noncancer	HTR2B, HTR2C	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.1055938773443	0.1055938773443	-0.618607091149599	-0.496261939988	-8.04606168722155	5.70614336990072	0.000253606422190345	0.00652837026923306	-0.947218639242336	-0.501183297745462
UBE2L3	BRD-K78318619-001-02-7::2.5::HTS002	2.5	PF-4981517	cytochrome P450 inhibitor	noncancer	CYP3A4	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-1.81583139688	-1.81583139688	-0.574600436211493	-0.46824260427	16.4955062798101	186.861427874558	2.6029076378972e-38	2.30528343439202e-35	1.0927889170634	1.38967300427362
UBE2L3	BRD-K81332461-001-01-4::2.5::HTS002	2.5	maxacalcitol	vitamin D receptor agonist	noncancer	VDR	endocrinology	hyperparathyroidism	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.06459494698585	0.06459494698585	-0.14282777395099	-0.1171657345245	-5.51690682733911	20.8535718027968	1.83195601409926e-05	0.000602118234236896	-0.285644753432074	-0.129200688441605
UBE2L3	BRD-K82135108-001-04-3::0.15625::MTS010::PROS001_PR500	0.15625	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-2.25410288039	-2.25410288039	-0.962588945553921	-0.893367929172	12.2532188399047	3.37187427978294	0.000650892629744868	0.0151257905714613	0.97606528068266	1.6069625889895
UBE2L3	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.9058953843565	-0.9058953843565	-0.486318518244217	-0.397290410403	8.88711249516464	192.141887623945	4.52161092957704e-16	5.2074817244778e-14	0.326456849569172	0.512696882655394
UBE2L3	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.128424225289	0.128424225289	-0.121761726463041	-0.0479466221371	-6.26798381939672	7.73988157072163	0.000276455173986592	0.00703041777235076	-0.342771110821431	-0.157600792682651
UBE2L3	BRD-K88568253-011-19-9::2.5::HTS002	2.5	iproniazid	monoamine oxidase inhibitor	noncancer	MAOA, MAOB	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.208354311974	0.208354311974	0.476376625754019	0.497154810155	8.73526068169957	165.979739671015	2.53452281189022e-15	2.71475132308655e-13	0.207443422133289	0.328601205426749
UBE2L3	BRD-K89162000-001-06-4::2.5::HTS002	2.5	tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFD, PDGFRB	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.3823829498965	0.3823829498965	0.051942581869497	0.117993019303	-6.43387337962356	5.04719042189074	0.00130118927053525	0.0278298169009629	-0.462093687991423	-0.198787048062583
UBE2L3	BRD-K90027355-001-13-3::2.43634::HTS002	2.43634	spironolactone	mineralocorticoid receptor antagonist	noncancer	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-1.25325793437	-1.25325793437	-2.90283615570051	-2.8540109683	-13.7604007260644	21.5826702907425	3.69328546748941e-12	2.9059404587428e-10	-1.89847033646135	-1.40068610619968
UBE2L3	BRD-K90574421-001-03-5::2.5::HTS002	2.5	ipsapirone	serotonin receptor agonist	noncancer	HTR1A	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.3209340405185	-0.3209340405185	-0.035136024218881	-0.0431604898369	11.6728022395372	165.655259666591	2.34711978535293e-23	5.20223202145716e-21	0.237456911619968	0.33413912097927
UBE2L3	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.7812422264665	-0.7812422264665	-0.266523464958923	-0.201241346164	11.0209915990666	178.281737373541	7.15147172050898e-22	1.39089635425133e-19	0.422555985470146	0.606881537545009
UBE2L3	BRD-K93918653-001-08-9::2.5::HTS002	2.5	quizartinib	FLT3 inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET	NA	NA	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	0.03684675880734	0.03684675880734	-0.300957117479446	-0.183745665678	-4.72477616893294	7.83659201498142	0.00157936214059308	0.0328433667135012	-0.503274901187886	-0.172332851385686
UBE2L3	BRD-K97472745-001-01-8::2.5::HTS002	2.5	gestrinone	progesterone receptor antagonist	noncancer	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	DU145, KALS1	PROSTATE, CENTRAL_NERVOUS_SYSTEM	carcinoma, glioma	-0.5432102347735	-0.5432102347735	-0.156747269348832	-0.109259098298	8.56179143349271	10.8094606850461	3.8374116080035e-06	0.00014261636770102	0.286900607370157	0.486025323479178
VAT1L	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.489318960682	0.489318960682	0.169640418765072	0.1532922606755	-9.97100389421789	6.28439253131053	4.40388788020279e-05	0.0013432202724861	-0.397275953052167	-0.242081130781689
VAT1L	BRD-A55913614-316-09-6::2.5::HTS002	2.5	primaquine	antimalarial agent, DNA inhibitor	noncancer	KRT7, NQO2	infectious disease	malaria	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.317118578194	0.317118578194	0.0954191176755572	0.121843056182	-5.88153255204781	15.7653384936044	2.46292755893992e-05	0.000789879995181854	-0.301704296482814	-0.141694624554072
VAT1L	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3422890394275	0.3422890394275	-0.227481187652889	-0.09818472346655	-7.29054686996425	4.09599839222767	0.00171580423987236	0.0352889940435278	-0.78476376316363	-0.354776690997148
VAT1L	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2524965771575	-0.2524965771575	-0.697642812762345	-0.633794699256	-8.49143507250174	154.267631845235	1.59691522171045e-14	1.59119127175258e-12	-0.548705761595768	-0.341586709613922
VAT1L	BRD-A67516570-001-02-8::2.5::HTS002	2.5	lafutidine	histamine receptor antagonist	noncancer	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0668665470632	-0.0668665470632	0.15555109813038	0.174462972063	7.97389288306234	192.353402062566	1.33721722804943e-13	1.21391118708431e-11	0.167401773084049	0.277433517303112
VAT1L	BRD-A78391468-001-02-8::2.5::HTS002	2.5	prednisolone-hemisuccinate	glucocorticoid receptor agonist	noncancer	NR3C1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.362426415762	0.362426415762	-0.23958417808103	-0.2322368233935	-12.0950689485633	27.8406261575502	1.34115128179527e-12	1.10344573157734e-10	-0.703992725071978	-0.500028462614082
VAT1L	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.4974446006185	0.4974446006185	0.206982113977371	0.236646785158	-6.93998208717312	174.23470022582	7.41882373188226e-11	4.993935526478e-09	-0.373067586827055	-0.207857386455204
VAT1L	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.6643006681245	0.6643006681245	0.257948141896211	0.303778240807	-10.2938765980714	65.7400163022812	2.43853648251303e-15	2.61460391190945e-13	-0.485173063816094	-0.327531988640483
VAT1L	BRD-K00317371-001-06-1::2.40436::HTS002	2.40436	RITA	MDM inhibitor	targeted cancer	MDM2	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2812218473765	0.2812218473765	-2.21566787991751	-1.66399627555	-14.7111529558178	6.74992162483709	2.23205577101733e-06	8.64307644708896e-05	-2.90126594529994	-2.09251350928809
VAT1L	BRD-K00494077-066-01-9::2.5::HTS002	2.5	trovafloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.09139233954505	-0.09139233954505	-0.524923370121363	-0.32459433605	-5.75949114204474	46.4060241308001	6.45644287922349e-07	2.71227547209152e-05	-0.585010855705447	-0.282051205447178
VAT1L	BRD-K04111260-001-10-0::2.5::HTS002	2.5	raclopride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR1A	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.578488107408	-0.578488107408	-0.377463631745599	-0.261056095384	3.39705714061323	117.936854018798	0.000929232641097759	0.0207524750165512	0.0838391054709801	0.318209845853821
VAT1L	BRD-K08109215-001-06-4::0.625::HTS002	0.625	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	1.298526864665	1.298526864665	0.307053202368112	0.333968556929	-12.9426041761601	9.51532916521411	2.34864274709035e-07	1.05024463037998e-05	-1.16334702615002	-0.819600298443758
VAT1L	BRD-K10784860-003-02-3::2.5::HTS002	2.5	temocapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.571605187144	0.571605187144	0.333471414833548	0.3338165124735	-6.4835810933249	6.05686477545799	0.000615994846123614	0.0144022645767239	-0.32780163020114	-0.148465914419763
VAT1L	BRD-K13167095-001-02-9::2.5::HTS002	2.5	AR-42	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.82674278143	-2.82674278143	-3.25679557000938	-3.28129580755	-3.70886898956831	167.201483418687	0.000282968871174019	0.00718165536282614	-0.658972511988125	-0.201133065170633
VAT1L	BRD-K13390322-001-06-3::2.5::HTS002	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1099127272119	0.1099127272119	-0.336510698744623	-0.191679875324	-5.27136491541677	44.5907930751273	3.79114830117712e-06	0.000141019268351786	-0.617037820590372	-0.275809031322674
VAT1L	BRD-K21361524-001-01-1::0.625::MTS006	0.625	selinexor	exportin antagonist	targeted cancer	XPO1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.22398634676	-2.22398634676	-2.75298472442604	-2.60110257698	-5.84716377569739	32.8365405853364	1.54018609162537e-06	6.11482586000315e-05	-0.713097694756431	-0.344899060575642
VAT1L	BRD-K21547160-001-01-4::2.5::HTS002	2.5	sufentanil	opioid receptor modulator	noncancer	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5367638829495	0.5367638829495	0.296589856535618	0.330939410236	-7.14890960504692	4.02829372157144	0.00197204571955859	0.0396126135920593	-0.333193375539255	-0.147154677288509
VAT1L	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5415350418195	0.5415350418195	0.37152643368328	0.3847237758685	-5.70211358324717	138.973384288662	6.82775839185065e-08	3.28187178373392e-06	-0.228958292908574	-0.111058923363866
VAT1L	BRD-K25690923-001-02-4::2.5::HTS002	2.5	4-iodo-6-phenylpyrimidine	macrophage migration inhibiting factor inhibitor	targeted cancer	MIF	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5270144832385	0.5270144832385	0.236657079303459	0.237522768994	-9.75147093193882	19.8183096742972	5.26530855935255e-09	2.90328870135702e-07	-0.352505063671001	-0.228209744199081
VAT1L	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.142462283875	-5.142462283875	-4.67615625057872	-4.90330008871	4.55616791267773	19.8917388582551	0.000194334699843409	0.00515234560647426	0.252741289875797	0.679870776716768
VAT1L	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3151197866515	0.3151197866515	0.0396459345330709	0.143970790547	-6.41163779412443	140.227398233874	2.05022420305038e-09	1.17870843137228e-07	-0.360416096536002	-0.190531607700856
VAT1L	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.2017233973465	0.2017233973465	0.413669684742218	0.43502168689	7.93083986056117	19.925398034109	1.3679603737095e-07	6.33247470705796e-06	0.156186953376152	0.267705621415283
VAT1L	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.06665343773265	0.06665343773265	-0.180459953621094	-0.13613940777	-6.2021540445539	14.7018508283977	1.85259873512038e-05	0.000608066520419141	-0.332187315357057	-0.16203946735043
VAT1L	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.2723953771905	-0.2723953771905	-1.37968404018407	-1.00119520354	-10.9217941466768	190.004284130771	7.28906313035416e-22	1.41508841636384e-19	-1.30727025469693	-0.907307071290213
VAT1L	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.0474476394670716	-0.0474476394670716	-0.516286795860871	-0.465030888818	-6.94648441061541	4.05264405371122	0.00214927509609925	0.0426636094167525	-0.655273686748208	-0.28240462603939
VAT1L	BRD-K49522529-001-02-9::2.53325::HTS002	2.53325	alfacalcidol	vitamin D receptor agonist	noncancer	CYP27B1, VDR	endocrinology	vitamin D deficiency	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1374735956275	0.1374735956275	-0.28908262500499	-0.277245593931	-12.2054788642263	187.619955391624	1.3408619686632e-25	3.6013233694438e-23	-0.495497602937576	-0.357614838327405
VAT1L	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.20075141284	-3.20075141284	-3.66558086432527	-3.70951336465	-6.15746375336563	99.240718052887	1.57891866005304e-08	8.25586868725316e-07	-0.614614304362183	-0.315044598608349
VAT1L	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.555823758654	0.555823758654	0.377104605734001	0.393436647762	-6.80396856027035	24.8666617039869	4.05015000633492e-07	1.75118943051797e-05	-0.23283155589013	-0.124606749949868
VAT1L	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5884455763135	0.5884455763135	0.46627367915954	0.458736917071	-4.41944020436645	58.8982148795101	4.3121917714384e-05	0.00131844186901658	-0.177489817546889	-0.0668539767610308
VAT1L	BRD-K56291712-001-01-0::2.5::HTS002	2.5	voxtalisib	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.430277305595	-0.430277305595	-0.706556512718517	-0.5410189846345	-3.70574275122407	34.3038785321609	0.000739299473331775	0.0169686567594481	-0.427742434483515	-0.124815979763518
VAT1L	BRD-K57136142-001-02-4::2.5::HTS002	2.5	CCT129202	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.439224700094	-0.439224700094	-0.751005934317857	-0.661176661425	-5.52056855326205	8.74764349904839	0.00040937172467358	0.0100182955443667	-0.440103514786674	-0.18345895366104
VAT1L	BRD-K62200014-003-10-5::2.5::HTS002	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.172951536028	0.172951536028	-0.082559877182211	0.0371962455536	-4.73002682380246	174.003535467888	4.62283740906943e-06	0.000169891652786084	-0.362128275237096	-0.148894551183326
VAT1L	BRD-K62814476-001-03-3::2.5::HTS002	2.5	BMS-265246	CDK inhibitor	targeted cancer	CDK1, CDK2	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.259788196305	-2.259788196305	-2.53967771351677	-2.46335728498	-3.25341768484373	182.389027272755	0.00135876098935864	0.0288624507064925	-0.449630300434084	-0.110148733989464
VAT1L	BRD-K63923597-001-10-0::2.5::HTS002	2.5	barasertib-HQPA	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.206081279096	-0.206081279096	-1.17869434868965	-1.00704468422	-12.809039251956	124.570637027993	1.74904584035384e-24	4.29898217794953e-22	-1.12289653623325	-0.822329602954052
VAT1L	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.3808511177565	0.3808511177565	0.253963294995881	0.248858708206	-6.22953667305927	190.679799497796	2.92606914273624e-09	1.657788721368e-07	-0.167064821501873	-0.0867108240193647
VAT1L	BRD-K72951360-001-01-4::2.5::HTS002	2.5	valrubicin	DNA inhibitor, topoisomerase inhibitor	chemo	TOP2A	oncology	bladder cancer	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.476421583415	-2.476421583415	-3.29568958411064	-3.181546610205	-7.22599408467532	44.6841891353012	4.9022847166462e-09	2.71078890875661e-07	-1.04766735753936	-0.590868643851926
VAT1L	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.6807876816505	-0.6807876816505	-1.47875016344852	-1.368540965995	-9.12438507475607	191.758683549747	9.9978444960277e-17	1.21751591647109e-14	-0.970457499124931	-0.625467464471108
VAT1L	BRD-K75352575-001-01-3::2.5::HTS002	2.5	KPT-276	exportin antagonist	targeted cancer	XPO1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.16484006634	-2.16484006634	-2.93309857800628	-2.86819814614	-7.39878805170868	60.6043284016185	4.9419107952195e-10	3.0349421169874e-08	-0.975918292938829	-0.560598730393727
VAT1L	BRD-K77638923-001-02-0::2.5::HTS002	2.5	CUDC-907	PI3K inhibitor	targeted cancer	HDAC2, PIK3R1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.620847838805	-5.620847838805	-5.89381985133714	-5.8647928098	-3.7698398312961	128.127336071498	0.000248250645688531	0.00641129203997796	-0.416245113226287	-0.129698911837984
VAT1L	BRD-K78177893-001-02-4::2.5::HTS002	2.5	A-674563	AKT inhibitor	targeted cancer	AKT1, PKIA, PRKACA	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-2.36182679083	-2.36182679083	-2.67706205419949	-2.66704888005	-3.72787204550465	146.627945404544	0.000275140718229748	0.00700532543540313	-0.48235246577109	-0.14811806096788
VAT1L	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.440597287231	0.440597287231	0.186120246745994	0.18484230673	-7.27514100091952	157.525473532428	1.53403163360355e-11	1.1236755502345e-09	-0.323565360578424	-0.185388720391587
VAT1L	BRD-K91370081-001-25-1::2.5::HTS002	2.5	anisomycin	DNA synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-5.616899334355	-5.616899334355	-3.99527078371024	-3.812026280445	14.1686079386928	187.326447480798	1.89999849175473e-31	8.64596128958174e-29	1.3958476785003	1.84740942278922
VAT1L	BRD-K99113996-001-02-0::2.5::HTS002	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.974576020125	-3.974576020125	-3.15772871764399	-3.187890366305	10.1679919977841	13.5904732126459	9.9514877988681e-08	4.69076848129228e-06	0.644057138994112	0.989637465967899
VAV2	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.1741585950005	-0.1741585950005	0.477048580535722	0.483115092089	15.380260214049	25.9164033819852	1.52173839117052e-14	1.51910883857097e-12	0.564161463916568	0.738252887155876
VAV2	BRD-A07986123-001-02-8::2.5::HTS002	2.5	galeterone	androgen receptor modulator	targeted cancer	AR, CYP17A1	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-3.67800258716	-3.67800258716	-2.0778723137452	-2.05580997476	19.8121336521261	14.9214757159595	3.97537781703901e-12	3.11873628165503e-10	1.4279044591475	1.7723560876821
VAV2	BRD-A20644369-001-08-6::2.5::HTS002	2.5	canrenone	mineralocorticoid receptor antagonist	noncancer	NR3C2	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.9820383307775	0.9820383307775	0.504205022696222	0.518391273844	-15.8015840357405	187.076878130216	2.76339967227241e-36	2.05651627902248e-33	-0.537487711750332	-0.418178904412224
VAV2	BRD-A50998626-001-02-1::2.5::HTS002	2.5	palomid-529	AKT inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.441158750099	0.441158750099	0.0403340895416446	0.0209581438432	-10.2137274124159	5.08647371560995	0.000139867902713566	0.00382955387336431	-0.501190192129645	-0.300459128985066
VAV2	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.626795492135	0.626795492135	0.243121227603054	0.260666777641	-11.9989616920667	189.003822949782	5.01048337175967e-25	1.29228867699865e-22	-0.446749211095895	-0.320599317967996
VAV2	BRD-A69815203-001-07-6::2.5::HTS002	2.5	cyclosporin-a	calcineurin inhibitor	noncancer	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.618245276597	-0.618245276597	-0.0670105999788323	0.011278782305325	10.3871652048368	5.98398528764756	4.74277293259531e-05	0.00143697169899664	0.421295646536506	0.681173706699829
VAV2	BRD-A74391928-051-01-3::2.5::HTS002	2.5	ibutilide	potassium channel blocker	noncancer	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.6042413787985	0.6042413787985	0.161670029861217	0.15975952739	-10.8871929698432	97.3832290822659	1.56989784068995e-18	2.26125426275025e-16	-0.523247604828975	-0.36189509304559
VAV2	BRD-A81129465-001-03-8::2.5::HTS002	2.5	fenoprofen	prostaglandin inhibitor	noncancer	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.9392053322455	0.9392053322455	0.0200264092011355	0.05909936864605	-15.0194137086204	13.6375064574001	7.15715104542045e-10	4.32595890133649e-08	-1.05076663319008	-0.787591212898651
VAV2	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.5167491217925	-0.5167491217925	-0.0449712371028394	-0.0219502433982	11.9874074177943	5.72165054335962	2.86479400170302e-05	0.000904283407350525	0.374329807735461	0.56922596164386
VAV2	BRD-A90547603-001-02-5::2.5::HTS002	2.5	eptifibatide	platelet aggregation inhibitor	noncancer	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.2140925732505	0.2140925732505	0.0426468725458291	0.04269931862485	-6.29982354606292	40.698752310249	1.66929149072591e-07	7.62201908640378e-06	-0.226418584099918	-0.116472817309424
VAV2	BRD-A95696066-003-13-8::2.5::HTS002	2.5	nisoxetine	norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.5359497975285	0.5359497975285	0.336380976771843	0.334888037039	-9.30060117768834	183.239365939954	4.23161886748183e-17	5.34448226428116e-15	-0.241904604218446	-0.157233037294868
VAV2	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.0454051159567	-0.0454051159567	0.265302605979954	0.320326091732	7.95554747459619	88.3344067383367	5.59031451369678e-12	4.29569537704081e-10	0.233097258186475	0.388318185686833
VAV2	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.02710180391715	-0.02710180391715	0.159379319177708	0.166606190016	7.40634960670135	185.197207329283	4.44156577842809e-12	3.46796485145616e-10	0.136807472307163	0.236154773882552
VAV2	BRD-K03549949-001-01-0::2.5::HTS002	2.5	XL388	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-2.586416859235	-2.586416859235	-1.31556257781064	-1.133529637875	11.9758045099322	3.16495676427059	0.00096582190973377	0.0214578256547454	0.942880430949815	1.59882813189891
VAV2	BRD-K12068470-001-02-5::2.36422::HTS002	2.36422	LY2608204	glucokinase activator	noncancer	GCK	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-5.574812910295	-5.574812910295	-4.25697952662832	-4.34713599697	8.97808868046693	17.7361049918818	5.16500476590208e-08	2.51650444753587e-06	1.00912391511198	1.62654285222139
VAV2	BRD-K13183738-317-10-2::2.5::HTS002	2.5	pentamidine	anti-pneumocystis agent	noncancer	TRDMT1	infectious disease	pneumonia	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-1.225391067445	-1.225391067445	-0.904075293963647	-0.814219930729	5.18991935604311	44.2114116947497	5.07986861123431e-06	0.000184849432865406	0.196558162173186	0.446073384789519
VAV2	BRD-K14385366-001-04-4::2.59386::HTS002	2.59386	FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	noncancer	EGLN2	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.159850379442	0.159850379442	0.403332615042403	0.440216058218	7.09502484357836	18.4965627854843	1.10858390096859e-06	4.4923743412875e-05	0.17152271225581	0.315441758944995
VAV2	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-1.980960435305	-1.980960435305	-1.2874286088908	-1.25961873039	10.9167714527766	7.3329531853202	8.50797949736255e-06	0.000296891360744093	0.544681270171384	0.842382382657015
VAV2	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.407627358506	-0.407627358506	-0.567811296307746	-0.549657042838	-4.44738635572234	67.5683485088336	3.32315587603503e-05	0.00103660118724307	-0.232064144284564	-0.0883037313189274
VAV2	BRD-K16551357-001-03-2::2.5::HTS002	2.5	evacetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.190973381898	0.190973381898	0.0584855290602532	0.0357605741878	-3.73669368812947	20.3201117751714	0.00127297117930604	0.027308041226052	-0.206372950975628	-0.0586027546998653
VAV2	BRD-K18424115-003-01-3::2.5::HTS002	2.5	TG-100572	src inhibitor, VEGFR inhibitor	targeted cancer	KDR, SRC	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.7861534108345	-0.7861534108345	-1.20782016820299	-1.11267387683	-6.31063545487092	62.1968325310771	3.26489635232298e-08	1.63343130321436e-06	-0.555226489183607	-0.288107025553375
VAV2	BRD-K19540840-001-09-4::2.5::HTS002	2.5	saracatinib	src inhibitor	targeted cancer	ABL1, LCK, SRC, YES1	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-2.07682371759	-2.07682371759	-2.45416505576598	-2.36107459971	-3.75360887477969	24.3549272496855	0.000961446882529842	0.021371701813497	-0.584660243571057	-0.170022432780908
VAV2	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.2185444964345	0.2185444964345	0.415186124523335	0.442474468431	6.72687878048827	20.9787005886206	1.18342874103134e-06	4.78030717369972e-05	0.135846131706835	0.257437124470835
VAV2	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.139659668804	0.139659668804	-0.240452279450575	-0.0866927101235	-4.96063535424785	7.17489884686598	0.0015228035027873	0.0318451509365694	-0.560411306203205	-0.199812590305945
VAV2	BRD-K25279140-001-01-5::2.5::HTS002	2.5	MK-8745	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.735489905282	-0.735489905282	-1.58194333819099	-1.48579667397	-10.0497426155965	73.0253156467368	2.05432654646221e-15	2.22486990589539e-13	-1.01431538430558	-0.678591481512409
VAV2	BRD-K34332569-001-01-3::2.5::HTS002	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.579510447573	-0.579510447573	-1.00084317392134	-0.918687700318	-4.54813736869367	66.4241928654494	2.35761880211468e-05	0.000757466766959132	-0.606269460072153	-0.236395992624523
VAV2	BRD-K36627727-001-05-4::2.5::HTS002	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.242175482263	-0.242175482263	0.141016748960885	0.154182848854	12.0268664763521	11.9294414509564	5.01234368686426e-08	2.4460168717257e-06	0.313726741680399	0.45265772076737
VAV2	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-3.52152580269	-3.52152580269	-2.98535748094398	-3.07991378512	5.51072449218066	125.819820099722	1.93455492678879e-07	8.74564908044113e-06	0.343620848129865	0.728715795362178
VAV2	BRD-K41312087-001-02-7::2.5::HTS002	2.5	GW-441756	growth factor receptor inhibitor	targeted cancer	NTRK1	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.507968150907	-0.507968150907	-0.00247686818851637	0.0338208037479	10.694569688173	3.28795147787427	0.00114940307476222	0.025002579073451	0.362254070967832	0.648728494469136
VAV2	BRD-K44227013-001-06-4::2.5::HTS002	2.5	ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.7592286575565	-0.7592286575565	-1.75007201992071	-1.65992199057	-8.80364719945996	3.28600326921376	0.00214635367428844	0.0426226106417647	-1.33201864251819	-0.649668082210225
VAV2	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-1.08463000051	-1.08463000051	-1.3951004748751	-1.171371713075	-4.07064271465563	77.8479541384173	0.000111687783266247	0.00313159744893662	-0.462318301028403	-0.158622647701799
VAV2	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.5896982230695	0.5896982230695	0.400579441065373	0.450986520291	-5.97505905348635	58.0450814645741	1.49474109608267e-07	6.88072088449963e-06	-0.252474827402491	-0.125762736605764
VAV2	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-2.010569582295	-2.010569582295	-1.09811989748412	-0.990481977481	14.8886872322216	37.9827206432198	1.93899310182633e-17	2.52480226319159e-15	0.788383312523915	1.03651605709784
VAV2	BRD-K53523901-001-04-4::2.5::HTS002	2.5	arctigenin	MEK inhibitor	targeted cancer	CHUK, MAP2K1	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-1.13632533012	-1.13632533012	-0.426673561690666	-0.429548063404	12.1564117819645	2.55462719678756	0.00250209197069128	0.0486104849516217	0.504133250439155	0.915170286419513
VAV2	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-1.61647180721	-1.61647180721	-2.75141110747173	-2.66953815971	-9.30734211635954	3.43738469642002	0.00148015218993271	0.031076917735799	-1.49651460773604	-0.773363992787418
VAV2	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.3476369043535	0.3476369043535	0.113169410068996	0.147357951686	-7.40565702051914	15.6463415111074	1.70367353074726e-06	6.70732263356961e-05	-0.301708461646826	-0.167226526922181
VAV2	BRD-K56483981-342-06-4::2.5::HTS002	2.5	chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	noncancer	MIF	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.04241650016365	0.04241650016365	0.266243062870679	0.2788714906115	5.81669402882782	4.76994196339641	0.00247835626162401	0.0482192827884543	0.123458177379534	0.324194948034523
VAV2	BRD-K68633617-003-02-9::2.5::HTS002	2.5	ACDPP	glutamate receptor antagonist	noncancer	GRM5	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.730184180362	-0.730184180362	0.249483699239351	0.327184190562	18.9624767439562	64.9129249497533	3.62747403429653e-28	1.24795005184068e-25	0.87648612533627	1.08284963386643
VAV2	BRD-K68870568-066-01-5::2.5::HTS002	2.5	flumatinib	Bcr-Abl kinase inhibitor	targeted cancer	ABL1, PDGFRB	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.391611014387	0.391611014387	0.156638436674222	0.180263859869	-6.21885779463437	28.2684912580172	9.76711457074215e-07	3.99422991572714e-05	-0.312336243459994	-0.157608911965563
VAV2	BRD-K74141488-003-11-2::2.5::HTS002	2.5	naftifine	fungal squalene epoxidase inhibitor	noncancer	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-0.06922432372905	-0.06922432372905	0.366410780132192	0.337020873613	15.735985525373	14.2968927927217	1.9927334953182e-10	1.27721464508988e-08	0.376374287748275	0.49489591997421
VAV2	BRD-K74501079-001-18-1::2.5::HTS002	2.5	azithromycin	bacterial 50S ribosomal subunit inhibitor	noncancer	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	0.433460297825	0.433460297825	-0.7942655542557	-0.6289149698795	-12.4129757598757	3.32915625042793	0.000666544765138937	0.0154476506236444	-1.52559698371926	-0.929854720442136
VAV2	BRD-K77685957-300-09-1::2.5::HTS002	2.5	dequalinium	PKC inhibitor	targeted cancer	KCNN1, KCNN3	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-1.332245679385	-1.332245679385	-1.10704728477839	-1.10749370834	4.55385778974592	154.42871465634	1.06212227845389e-05	0.000364113253069007	0.127508264744637	0.32288852446858
VAV2	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	MKN45, HCC1419	STOMACH, BREAST	carcinoma (diffuse_adenocarcinoma), carcinoma (ductal_carcinoma)	-1.710456864985	-1.710456864985	-0.600599183955937	-0.5106967244835	14.9659960069169	7.88720886472298	4.52129465085602e-07	1.94158397359912e-05	0.938420971470737	1.28129439058739
VMP1	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	PATU8988T, 786O, PANC1, U2OS, MCF7, TE11, OVCAR8, DAOY, KYSE410, SCABER, SBC5, FADU, ES2, VMCUB1	PANCREAS, KIDNEY, BONE, BREAST, OESOPHAGUS, OVARY, CENTRAL_NERVOUS_SYSTEM, URINARY_TRACT, LUNG, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma (clear_cell_renal_cell_carcinoma), osteosarcoma, carcinoma, carcinoma (squamous_cell_carcinoma), primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (transitional_cell_carcinoma), carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.94911643067071	-1.98052007106	-1.28361362555038	-1.2742797829	4.65404012328351	21.254391289462	0.00013237683489208	0.00364915686759931	0.368345738019345	0.962659872221315
VMP1	BRD-K13756951-001-01-4::2.5::HTS002	2.5	bitopertin	glycine transporter inhibitor, GlyT-1 inhibitor	noncancer	SLC6A5, SLC6A9	NA	NA	PATU8988T, MKN45, 786O, PANC1, U2OS, MCF7, TE11, OVCAR8, NCIH1299, DAOY, KYSE410, SCABER, SBC5, FADU, ES2, VMCUB1	PANCREAS, STOMACH, KIDNEY, BONE, BREAST, OESOPHAGUS, OVARY, LUNG, CENTRAL_NERVOUS_SYSTEM, URINARY_TRACT, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma (diffuse_adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma), osteosarcoma, carcinoma, carcinoma (squamous_cell_carcinoma), carcinoma (non_small_cell_carcinoma), primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (transitional_cell_carcinoma), carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.0260818760499312	-0.08163691997495	-0.354846775219583	-0.33176355789	-3.71806843693153	20.8859504510699	0.001281580999872	0.0274597594843114	-0.512712948151613	-0.144816850187691
VMP1	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	PATU8988T, MKN45, 786O, PANC1, U2OS, MCF7, TE11, OVCAR8, DAOY, KYSE410, SCABER, SBC5, FADU, ES2, VMCUB1	PANCREAS, STOMACH, KIDNEY, BONE, BREAST, OESOPHAGUS, OVARY, CENTRAL_NERVOUS_SYSTEM, URINARY_TRACT, LUNG, UPPER_AERODIGESTIVE_TRACT	carcinoma (ductal_carcinoma), carcinoma (diffuse_adenocarcinoma), carcinoma (clear_cell_renal_cell_carcinoma), osteosarcoma, carcinoma, carcinoma (squamous_cell_carcinoma), primitive_neuroectodermal_tumour-medulloblastoma, carcinoma (transitional_cell_carcinoma), carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-3.89984504765933	-3.82193437116	-2.98843540781255	-2.874319746815	3.56313457005277	19.0397595270271	0.00206994418365141	0.0413119533418217	0.376113348955119	1.44670593073844
WIPF2	BRD-A06352508-001-03-7::2.5::HTS002	2.5	SB-218078	CHK inhibitor	noncancer	CHEK1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.6495033609585	-0.6495033609585	-0.950381602388914	-0.8814928301585	-4.75719082289561	100.486256626533	6.58315959285004e-06	0.000234528964503294	-0.426351133589642	-0.175405349271187
WIPF2	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.3396017706245	0.3396017706245	-0.00754927983955362	0.000253415549772	-9.46133469769914	8.24798582868772	1.04099782310386e-05	0.000357500436513422	-0.431321153647184	-0.262980947280924
WIPF2	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.09434622265915	0.09434622265915	0.404948987856648	0.4132826179685	5.97074909228125	69.5799943508009	8.97124422641539e-08	4.24927691448262e-06	0.206839665997748	0.414365864397248
WIPF2	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.7434799211805	-0.7434799211805	-0.995353990142405	-0.927705434	-3.63843280308937	20.1317910529322	0.00162177827909143	0.0335839726356896	-0.39621635054249	-0.107531787381319
WIPF2	BRD-A68083442-001-01-6::2.5::HTS002	2.5	pranidipine	calcium channel blocker	noncancer	CACNA1C	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4803030334295	0.4803030334295	0.244663253484165	0.260666777641	-5.85630895461639	7.37267931165242	0.000516851277763245	0.0123413789562966	-0.329818616340277	-0.141460943550394
WIPF2	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.138790800828	-0.138790800828	-1.13512144661967	-1.042052398785	-17.7999826081834	193.568056895235	1.27648698032161e-42	1.6581101697294e-39	-1.1067272765476	-0.885934015035743
WIPF2	BRD-A93695607-322-02-5::2.4707::HTS002	2.4707	nicotine	acetylcholine receptor agonist	noncancer	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.351841341008	0.351841341008	0.122040514505898	0.1466714970605	-6.51053733275929	138.422236541116	1.27773679248498e-09	7.52649041469962e-08	-0.299591337710493	-0.16001031529371
WIPF2	BRD-K02898090-001-02-7::2.5::HTS002	2.5	kifunensine	mannosidase inhibitor	noncancer	MAN1B1, MAN2A1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.276023001286	0.276023001286	-0.365897224904578	-0.264963110089	-10.2632821827238	123.48758281959	3.02060484153992e-18	4.25084185871575e-16	-0.765719988067512	-0.518120464313644
WIPF2	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.8287246836615	0.8287246836615	0.25090064791003	0.2240846909	-16.6114999955575	5.52624607057389	6.27608481430952e-06	0.000224490484340145	-0.664739264905078	-0.490908806597862
WIPF2	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.5641783469765	0.5641783469765	0.274445785334565	0.25640594941	-8.49325734691362	6.91969494100885	6.63129983042977e-05	0.0019504320863952	-0.370587727189894	-0.208877396093976
WIPF2	BRD-K10670311-001-15-5::0.625::HTS002	0.625	sulfasalazine	cyclooxygenase inhibitor	noncancer	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.2619146111395	-0.2619146111395	0.283969128835814	0.3338993038355	11.4111759009535	4.35393004020571	0.000208368373094594	0.00548169694820071	0.417216734804876	0.674550745145752
WIPF2	BRD-K10961822-001-05-1::2.5::HTS002	2.5	latanoprost	prostanoid receptor agonist	noncancer	PTGFR	ophthalmology	ocular hypertension, glaucoma	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.9788987081115	0.9788987081115	0.420700796213428	0.3989310314435	-13.6762143378078	7.42424770642481	1.56384650967874e-06	6.20354726213092e-05	-0.653603776670565	-0.462792047125578
WIPF2	BRD-K12502280-001-08-0::2.5::HTS002	2.5	TG-101348	FLT3 inhibitor, JAK inhibitor	targeted cancer	BRD4, JAK1, JAK2, JAK3, TYK2	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.412640431755	0.412640431755	-0.401330810249838	-0.2460199545545	-8.55482480514716	3.59717271117196	0.00162157510207511	0.0335830099577406	-1.09022958250617	-0.537712901503507
WIPF2	BRD-K12885236-001-02-7::2.5::HTS002	2.5	dapivirine	non-nucleoside reverse transcriptase inhibitor	noncancer	CYP3A4, CYP3A5	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.208793731965	-2.208793731965	-1.33099110219436	-1.23321321289	11.9520368755516	2.99179150056002	0.00127637066630134	0.0273700098586993	0.643708574520378	1.1118966850209
WIPF2	BRD-K13060017-001-01-3::2.5::MTS006	2.5	UNC0631	histone lysine methyltransferase inhibitor	targeted cancer	EHMT2	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.198470453527	-0.198470453527	-0.514160847595151	-0.419130200084	-4.79823750292473	67.5361672203098	9.21029106827371e-06	0.000319371052317107	-0.446994590888386	-0.184386197247917
WIPF2	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.01972179330215	-0.01972179330215	-0.48428649594856	-0.4134526693685	-7.84547032214828	6.02909946679764	0.000221319491207372	0.00577984467296027	-0.6092877347098	-0.319841670583019
WIPF2	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.02497325632848	0.02497325632848	0.261711219264821	0.263001454047	7.04443947864223	7.83089828861899	0.000119503035771144	0.00332938595525719	0.15894930124892	0.314526624623762
WIPF2	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.87885122091	-1.87885122091	-0.927299589018185	-0.8524847758	14.8103086024132	189.929613603412	1.70681249741779e-33	9.379985019463e-31	0.82481781969549	1.07828544408814
WIPF2	BRD-K18787491-001-08-6::2.5::HTS002	2.5	U-0126	MEK inhibitor	targeted cancer	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.2485563476165	0.2485563476165	-0.0631317994207372	-0.0626502991923	-9.22299456894393	94.6007688878175	7.83419529542153e-15	7.99950092173607e-13	-0.378782720831583	-0.244593573242892
WIPF2	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.336533681417	0.336533681417	-0.380309835370899	-0.173057746988	-7.37128759916659	5.46040015241438	0.000490603206426551	0.0117842087448388	-0.960619037441135	-0.473067996134662
WIPF2	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.700824114359	0.700824114359	0.543896461161292	0.547894384564	-5.90930255757502	67.5679359047577	1.24543917424418e-07	5.80164600688069e-06	-0.209925534908752	-0.103929771486665
WIPF2	BRD-K22385716-001-02-5::2.5::HTS002	2.5	LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.5532046247985	-0.5532046247985	-0.259186393371303	-0.291499790384	4.84012501824978	20.0960674218777	9.811138171568e-05	0.00278518070619072	0.167343118540775	0.420693344313618
WIPF2	BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500	2.5	GDC-0980	mTOR inhibitor, PI3K inhibitor	targeted cancer	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.11270826501	-1.11270826501	-0.771338410924414	-0.7406610501725	5.50287288580456	191.005296846078	1.19107002584171e-07	5.56288619674499e-06	0.21900850637586	0.463731201795312
WIPF2	BRD-K28307902-001-21-7::2.5::HTS002	2.5	flutamide	androgen receptor antagonist	targeted cancer	AHR, AR	oncology	prostate cancer	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.4199628376505	0.4199628376505	0.241176183526205	0.2782830589715	-7.0526725483987	183.834355556784	3.44720015897636e-11	2.40662854356106e-09	-0.228801388253638	-0.128771919994953
WIPF2	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.249117494035	0.249117494035	-0.406527752982715	-0.2809944464045	-10.5193734284074	117.246975114844	1.25274453312204e-18	1.821570441245e-16	-0.779078689672238	-0.532211804363193
WIPF2	BRD-K32107296-001-16-9::2.5::HTS002	2.5	temozolomide	DNA alkylating agent	chemo	MGMT	oncology	glioblastoma, astrocytoma	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.0080219572312	0.0080219572312	0.228019894663832	0.232952381397	6.425687354513	9.34507741014817	0.000102805412336178	0.00290650062268838	0.142981642030209	0.297014232835056
WIPF2	BRD-K33379087-001-07-5::2.5::HTS002	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-4.01769840931	-4.01769840931	-2.2006549705084	-2.23277244437	15.8375733881442	40.474934377265	6.02241291665992e-19	8.9887029109666e-17	1.58525035836539	2.04883651923781
WIPF2	BRD-K36467523-001-02-8::2.5::HTS002	2.5	bindarit	NFkB pathway inhibitor	noncancer	CCL2, CCL7, CCL8	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.179448762257	-0.179448762257	-0.0183503236442729	-0.01606038970165	4.63812816505092	7.56804049986486	0.00193408542355901	0.0389633043280363	0.0802000668951825	0.241996810330272
WIPF2	BRD-K36627727-001-05-4::2.5::HTS002	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.04100177166785	-0.04100177166785	0.138921189475518	0.154182848854	5.29887988991407	7.38977131551971	0.000944455540973067	0.021046393391684	0.100482937498631	0.259362984788106
WIPF2	BRD-K37237504-001-02-7::2.5::HTS002	2.5	CEP-33779	JAK inhibitor	targeted cancer	JAK2	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.6476217445735	0.6476217445735	0.184628136953535	0.151776458835	-11.7551605041708	17.3669245461039	1.07351488615688e-09	6.36122123403698e-08	-0.545958135681721	-0.380029079558209
WIPF2	BRD-K37720887-001-07-8::2.5::HTS002	2.5	SB-525334	TGF beta receptor inhibitor	noncancer	TGFBR1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.1987630059675	0.1987630059675	0.0276765260748119	0.0896615671228	-4.10456851672381	160.942028828959	6.42362887364269e-05	0.00189681368232797	-0.253400585520217	-0.0887723742651589
WIPF2	BRD-K42205652-001-02-7::2.5::HTS002	2.5	MNS-(3,4-Methylenedioxy-nitrostyrene)	src inhibitor, syk inhibitor	noncancer	SRC, SYK	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.388750960916	0.388750960916	0.238832577430606	0.255658141899	-3.99732058621518	180.966309671437	9.31770656749405e-05	0.00265459887133382	-0.22392117570403	-0.0759155912667581
WIPF2	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-4.600330096635	-4.600330096635	-5.28775570962862	-5.31222064742	-7.51321531725287	17.0074370560208	8.46476669902244e-07	3.49632873739599e-05	-0.880457876215548	-0.494393349771686
WIPF2	BRD-K51143828-003-03-1::2.5::HTS002	2.5	lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.3468535818935	0.3468535818935	-0.0238729834531166	0.03172783000245	-13.2756217066004	179.646618884612	1.80390505164155e-28	6.45457705865246e-26	-0.42583048748414	-0.315622643209093
WIPF2	BRD-K54314721-001-10-2::2.5::HTS002	2.5	zolmitriptan	serotonin receptor agonist	noncancer	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.514310800985	-0.514310800985	-0.73894595406576	-0.696454065727	-3.87793227080884	74.0580728283903	0.000226137517542456	0.00589489515900719	-0.340054776223072	-0.109215529938447
WIPF2	BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.333410383769	0.333410383769	-0.214592836981311	-0.1382371077965	-10.0897331431011	3.38338686873071	0.00121622596899541	0.0262589398316529	-0.710282318509993	-0.385724122990629
WIPF2	BRD-K62398570-300-01-2::2.5::HTS002	2.5	lerisetron	serotonin receptor antagonist	noncancer	HTR3A	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.668669093353	0.668669093353	0.496573582010011	0.5032243317015	-7.07651426802662	17.073179726469	1.81410774010428e-06	7.10295757816605e-05	-0.223387893566595	-0.120803129119382
WIPF2	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.236575202973	-0.236575202973	-1.08677954427297	-0.4202572111255	-7.45043601798779	187.648354564666	3.30219952564583e-12	2.61357873756332e-10	-1.07531690408681	-0.62509177851313
WIPF2	BRD-K66808046-065-03-7::2.5::MTS006	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.0759165966294	0.0759165966294	0.25715632663072	0.250852150231	6.42510493466974	4.29682500397748	0.00235175745637345	0.0460740241194759	0.105009836188938	0.257469623813702
WIPF2	BRD-K69608737-001-10-2::2.5::HTS002	2.5	tacrolimus	calcineurin inhibitor	noncancer	FKBP1A	transplant	organ rejection	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.626686115993	0.626686115993	0.301281474969954	0.3216320959495	-10.3863337348932	11.811630978731	2.72941573274569e-07	1.2106642065059e-05	-0.393787950893078	-0.257021331153015
WIPF2	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.044258298574	0.044258298574	0.313171697947139	0.309773585289	7.9344612097985	4.45943862384087	0.000857892460228167	0.0193263856535887	0.178517382099602	0.359309416646675
WIPF2	BRD-K71467466-001-02-3::2.5::HTS002	2.5	KPT-185	exportin antagonist	targeted cancer	XPO1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.73968309024	-3.73968309024	-4.36363778222442	-4.09603677997	-5.1928738978694	119.594247890829	8.60451098381782e-07	3.549944628779e-05	-0.861863329910215	-0.386046054058627
WIPF2	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.10952265531525	-0.10952265531525	-0.664931384315811	-0.50591048476	-7.22542579014899	7.91681436145808	9.50258261330431e-05	0.00270340741085967	-0.732992879908939	-0.377824578092184
WIPF2	BRD-K72703948-001-10-1::2.5::HTS002	2.5	ZM-447439	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.60797033768	-1.60797033768	-1.36962536402353	-1.20810086616	3.2565985912843	48.1454511674421	0.00206886904716924	0.0412943410328494	0.0912014815276876	0.385488465785254
WIPF2	BRD-K72726508-001-02-1::2.5::HTS002	2.5	arcyriaflavin-a	CDK inhibitor	targeted cancer	CCND1, CDK4	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.22652086493	-0.22652086493	-0.496502554729169	-0.4023952462985	-5.52240216726588	193.698930506668	1.06638719679254e-07	5.01003291322552e-06	-0.36640373583902	-0.173559643759317
WIPF2	BRD-K75478907-001-02-3::2.5::HTS002	2.5	GS-39783	GABA receptor modulator	noncancer	GABBR1	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.09208662989395	-0.09208662989395	0.484914620295549	0.491150994227	21.4025546831945	20.2604158965123	2.19898294731618e-15	2.36837093525291e-13	0.520811111368017	0.633191389010982
WIPF2	BRD-K77625799-001-07-7::2.5::HTS002	2.5	vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.465078214582	0.465078214582	0.104138027922581	0.160912505802	-6.23859847896443	17.5394177253289	7.80560852288157e-06	0.000274429814555114	-0.48272027458817	-0.239160098730668
WIPF2	BRD-K77677632-003-02-6::2.5::HTS002	2.5	SB-200646	serotonin receptor antagonist	noncancer	HTR2B, HTR2C	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.621439012185	-1.621439012185	-0.600427797575606	-0.486816676167	10.9466133160136	4.69381003044725	0.00016132547439304	0.00437071515626165	0.776466686150622	1.26555574306817
WIPF2	BRD-K78318619-001-02-7::2.5::HTS002	2.5	PF-4981517	cytochrome P450 inhibitor	noncancer	CYP3A4	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.09397140411	-1.09397140411	-0.582320863941653	-0.46824260427	6.12644772072654	26.7789753821338	1.5704165743419e-06	6.22615268150437e-05	0.340225625352899	0.683075454983795
WIPF2	BRD-K78809024-001-05-7::2.5::HTS002	2.5	SB-590885	RAF inhibitor	targeted cancer	BRAF	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.5803023994665	0.5803023994665	0.0883613823669492	0.1598746623085	-10.7528009803125	177.906930708599	4.27716541459257e-21	7.79524307945758e-19	-0.582223584334501	-0.4016584498646
WIPF2	BRD-K81528515-001-13-8::2.5::HTS002	2.5	nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	targeted cancer	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.7472670561675	0.7472670561675	0.184389119831715	0.2214201178065	-7.77958753294963	3.78017655994828	0.00184997077401907	0.0375298046402966	-0.768454582804199	-0.357301289867371
WIPF2	BRD-K81916719-001-13-9::2.5::HTS002	2.5	triclabendazole	microtubule inhibitor	noncancer	DNMT1	infectious disease	tapeworm	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-3.368447798075	-3.368447798075	-2.32147699606712	-2.31061831786	11.2905706524186	10.0168166921636	5.0938408656791e-07	2.17135604395413e-05	0.840403247652371	1.25353835636338
WIPF2	BRD-K82850175-001-01-1::2.5::HTS002	2.5	navarixin	CC chemokine receptor antagonist	targeted cancer	CXCR1, CXCR2	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.228837864225	0.228837864225	-0.894400999736011	-0.794282488065	-19.2108981686563	154.141490679259	9.47859144071069e-43	1.24634173306508e-39	-1.23874251260113	-1.00773521532089
WIPF2	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.01476166951245	-0.01476166951245	0.191884284173127	0.205191667076	5.91539762090381	157.997107027142	1.98398393888945e-08	1.02217618663037e-06	0.137648927819773	0.275642979551381
WIPF2	BRD-K82967180-001-01-6::2.5::MTS006	2.5	LY3023414	PI3K inhibitor, mTOR inhibitor	targeted cancer	MTOR	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.9410644643	-2.9410644643	-3.38156950962188	-3.49521149321	-7.0746896475483	168.680897167448	3.82190338403805e-11	2.65525034164503e-09	-0.563423945524414	-0.317586145119355
WIPF2	BRD-K83003151-057-02-4::2.34747::HTS002	2.34747	alogliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.494292866127	0.494292866127	0.243819792289288	0.320568591806	-6.16307780302869	157.993862946013	5.70408235880785e-09	3.13233478831906e-07	-0.330742631788085	-0.170203515887339
WIPF2	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-0.39764253714	-0.39764253714	-0.148492887198947	-0.137644446714	5.39278870211542	6.66942155414376	0.0011908868030914	0.0257845820405876	0.138795421568731	0.359503878313375
WIPF2	BRD-K87990216-001-10-2::2.5::HTS002	2.5	piretanide	glucocorticoid receptor agonist	noncancer	SLC12A1, SLC12A2	cardiology	hypertension, edema	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.164904748575	0.164904748575	0.00383999645223662	0.041364371782	-4.80087097653577	86.8957747436861	6.52261715601838e-06	0.000232687418846915	-0.227748287439855	-0.0943812168056722
WIPF2	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.14638583293	-1.14638583293	-2.06985732874048	-1.887176140495	-8.76007436000628	110.743800165329	2.55298452906747e-14	2.49057178484525e-12	-1.13237007278827	-0.714572918832682
WIPF2	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-1.84637084182	-1.84637084182	-1.24432135947054	-1.23927241763	8.64049451163771	180.960109192929	2.89338101515666e-15	3.07912343394991e-13	0.464564302918701	0.739534661780216
WIPF2	BRD-K97764662-001-17-3::2.5::HTS002	2.5	PD-173074	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	0.04427585871605	0.04427585871605	-0.243955886997614	-0.195507988981	-6.49173689069478	143.969844991226	1.28332046489433e-09	7.55432001978404e-08	-0.375991416585264	-0.200472074842064
WIPF2	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIH1693, NCIH2170	LUNG	carcinoma (adenocarcinoma), carcinoma (squamous_cell_carcinoma)	-2.80170679437	-2.80170679437	-3.14546650499972	-3.23564927932	-5.38868805927692	25.0716837589322	1.35551761406083e-05	0.000456014337943878	-0.47512447749655	-0.212394943762883
WNK1	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1385629033075	0.1385629033075	0.404416256764499	0.4132826179685	5.13996282967725	80.2763111182479	1.89313752394991e-06	7.39752547621988e-05	0.162927107240038	0.368779599673961
WNK1	BRD-A70858459-001-01-7::2.5::MTS010::PROS003_PR500	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0772026635487667	0.0730319569113	-0.0165607643936975	-0.0162841171901	-4.5020727887878	50.9170662435551	3.94022737165858e-05	0.00121215012536273	-0.135576474867845	-0.0519503810170829
WNK1	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	GI1, JHH1	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma)	-0.0839195400822	-0.0839195400822	0.418783678539967	0.4743784763675	10.0803053965052	2.92899104018812	0.00230184834563471	0.0452667246014411	0.341796080239131	0.663610357005203
WNK1	BRD-A93695607-322-02-5::2.4707::HTS002	2.4707	nicotine	acetylcholine receptor agonist	noncancer	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.139281077638	-0.139281077638	0.127621451081421	0.1533689039075	6.46401914356001	10.5905329288643	5.54541093428455e-05	0.00165835409534571	0.175592228093403	0.358212829345439
WNK1	BRD-A97739905-001-26-5::2.5::HTS002	2.5	ketoprofen	cyclooxygenase inhibitor	noncancer	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	GI1, JHH1	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma)	0.8610588564485	0.8610588564485	0.0236916907744428	0.005378846282065	-13.9795158819267	3.16584702604415	0.000595370942004308	0.0140010158688656	-1.0224675906286	-0.652266740719513
WNK1	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.91852242865	-3.90807584655	-3.16769546703802	-3.01978205902	6.96789225709765	189.772898946247	5.14942997084607e-11	3.52385752305705e-09	0.53827506685601	0.963378856367953
WNK1	BRD-K08109215-001-06-4::2.5::MTS010::PROS002_PR500	2.5	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.827230555393667	-0.792299885453	-0.162487572849519	-0.0332836606576	9.53525991253207	8.1348921943096	1.07884369541154e-05	0.000369491036103962	0.504444583689847	0.825041381398448
WNK1	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.258137756989	0.274601701865	-0.432458931035503	-0.399338202708	-10.8470786134767	14.3310256644615	2.68258629025614e-08	1.3569885225497e-06	-0.826852661315735	-0.554340714733271
WNK1	BRD-K11630072-001-13-2::0.625::HTS002	0.625	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.0777496253327	0.0777496253327	-0.277409846176119	-0.1988130745045	-6.20846378043063	13.4749704168698	2.70621327017245e-05	0.000858907128658064	-0.478303494998138	-0.2320154480195
WNK1	BRD-K19034817-001-01-4::2.5::HTS002	2.5	pacritinib	FLT3 inhibitor, JAK inhibitor	targeted cancer	FLT3, JAK1, JAK2, JAK3	NA	NA	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.20954753603667	-1.22036188496	-0.93657277309903	-0.888380886649	5.02264868069926	60.3921050248896	4.8108859078624e-06	0.000175897708247397	0.164275558421706	0.381673967453567
WNK1	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.563347945509	-0.563347945509	-0.975375412981936	-0.82417204092	-3.92150249702643	37.8809501656132	0.000357451171968384	0.00888359835770082	-0.624750038634684	-0.199304896311187
WNK1	BRD-K33588785-001-01-9::2.5::HTS002	2.5	obidoxime	cholinesterase reactivator	noncancer	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.511765197182	0.511765197182	0.169739470201815	0.177010520924	-13.6601010670243	183.148519303748	9.47901073829216e-30	3.7483891006041e-27	-0.391426327223701	-0.292625126736669
WNK1	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.17790024196	-3.12971631347	-2.73916481552583	-2.707630255965	4.1414624351483	18.0295205043898	0.000611129241472102	0.014302546319663	0.216195496755847	0.661275356112498
WNK1	BRD-K43905307-001-01-2::2.5::HTS002	2.5	L-798,106	prostanoid receptor antagonist	noncancer	PTGER3	NA	NA	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.588770263026333	-0.608391878788	-0.893879076257767	-0.8616766323795	-4.3531400487918	26.0744164477115	0.0001842767273241	0.0049166994510951	-0.449159552957348	-0.16105807350552
WNK1	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.5816443999235	0.5816443999235	0.40067148475847	0.450986520291	-5.22928326075445	14.3759874038835	0.000117004445228561	0.00326401740744401	-0.255017110907858	-0.106928719422202
WNK1	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.510709866530667	0.494148553245	0.25379438091123	0.250129064666	-6.05861862090509	7.74763782254903	0.0003441059275894	0.00858178721832772	-0.35525870554737	-0.158572265691503
WNK1	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.91366199938667	-1.90344831207	-1.32026748605121	-1.43413063966	7.22135378116502	8.16251447764508	8.18449943820306e-05	0.00236284426197552	0.40455977083512	0.782229255835784
WNK1	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.644875498715333	-0.620761129824	-1.08477581942844	-0.407089027549	-3.60352155421987	85.7952941450713	0.000525662097889529	0.0125308232430836	-0.682585885138479	-0.197214756287731
WNK1	BRD-K66175015-001-09-0::2.5::HTS002	2.5	afatinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-1.720305613875	-1.720305613875	-0.900430625349723	-0.737713790302	8.61189991264102	160.437708679117	6.38052808823587e-15	6.56205472468093e-13	0.631863196792519	1.00788678025803
WNK1	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.149379211077	0.149379211077	-0.0809934036087606	0.0411624842104	-5.1083910278208	65.0478701463772	3.0606412673228e-06	0.000115836867770445	-0.320436092723967	-0.140309136647554
WNK1	BRD-K74305673-001-06-2::2.5::HTS002	2.5	IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	targeted cancer	IKBKB	NA	NA	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-3.21569663706	-3.21569663706	-2.62461797061698	-2.476182958975	5.79152471225123	5.98490319741318	0.00117050758358524	0.025392076911158	0.341195900580465	0.840961432305584
WNK1	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	JHH1, KYSE30	LIVER, OESOPHAGUS	carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.165387001389	-0.165387001389	0.193790933943716	0.205191667076	9.80275202529123	64.1971951498314	2.22609446769611e-14	2.18860826223321e-12	0.285984411250558	0.432371459414873
WNK1	BRD-K89391146-001-08-0::2.5::HTS002	2.5	RG108	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3B	NA	NA	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	0.606071047726333	0.607550807118	0.376709014528471	0.39293992116	-5.51666201472719	5.06481734421828	0.00257305223597502	0.0498129990682224	-0.33582706797735	-0.122896998418376
WNK1	BRD-K96259238-001-01-4::2.5::HTS002	2.5	Y-320	interleukin inhibitor	noncancer	IL17A	NA	NA	GI1, JHH1, KYSE30	CENTRAL_NERVOUS_SYSTEM, LIVER, OESOPHAGUS	glioma (gliosarcoma), carcinoma (hepatocellular_carcinoma), carcinoma (squamous_cell_carcinoma)	-0.460879574076333	-0.476317978184	-0.0823269681633215	0.0909389038677	5.9875756444885	17.7338125765642	1.23058797829434e-05	0.000416799448166637	0.245582917601708	0.511522294224315
WWOX	BRD-A14886633-001-01-6::2.5::HTS002	2.5	norgestrel	progesterone receptor agonist	noncancer	PGR	endocrinology	contraceptive	MDAMB175VII, A375, SKMES1	BREAST, SKIN, LUNG	carcinoma (ductal_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.117614385288333	0.101354689635	-0.138296988899905	-0.0808038606924	-4.43019215756583	16.8559988913246	0.000373674084274926	0.00925458664300446	-0.377864862564603	-0.133957885811875
WWOX	BRD-A60786380-412-01-5::2.5::HTS002	2.5	sodium-stibogluconate	tyrosine phosphatase inhibitor	noncancer	PTPN6, TOP1	infectious disease	leishmaniasis	MDAMB175VII, NCIH1299, A375, SKMES1	BREAST, LUNG, SKIN	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.18037346734145	-0.2524965771575	-0.703980366044463	-0.641280431288	-5.49958823703506	6.02109867514523	0.00149812638430319	0.0314118499140401	-0.756375676605729	-0.290838120800297
WWOX	BRD-K03294269-001-08-0::2.5::HTS002	2.5	NU6027	CDK inhibitor	targeted cancer	CCNA2, CDK2	NA	NA	MDAMB175VII, NCIH1299, A375, SKMES1	BREAST, LUNG, SKIN	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.24263442263425	0.2390451005025	-0.0548562630427237	0.05458945851175	-4.14799687653851	9.07479121569772	0.00244761912531457	0.047690523591777	-0.459527010054375	-0.135454361299572
WWOX	BRD-K06222852-001-03-2::2.5::HTS002	2.5	posaconazole	sterol demethylase inhibitor	noncancer	CYP3A4	infectious disease	oropharyngeal candidiasis	MDAMB175VII, NCIH1299, A375, SKMES1	BREAST, LUNG, SKIN	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.19628170632575	0.173874724423	-0.0532060658815106	-0.00757889325578	-4.84968452418334	10.646611572737	0.000561164146339756	0.0132778932353954	-0.363175757030149	-0.135799787384372
WWOX	BRD-K13390322-001-06-3::2.5::HTS002	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	MDAMB175VII, SKMES1	BREAST, LUNG	carcinoma (ductal_carcinoma), carcinoma (squamous_cell_carcinoma)	0.1099127272119	0.1099127272119	-0.336510698744623	-0.191679875324	-5.27136491541677	44.5907930751273	3.79114830117712e-06	0.000141019268351786	-0.617037820590372	-0.275809031322674
WWOX	BRD-K25412176-001-01-9::2.5::HTS002	2.5	GSK2110183	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MDAMB175VII, A375, SKMES1	BREAST, SKIN, LUNG	carcinoma (ductal_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.0361479034391667	0.022586303374	-0.409477433107672	-0.317592260671	-5.0682589539997	6.19580958399592	0.0020854465712699	0.0415787607603448	-0.659131944845055	-0.232118728248623
WWOX	BRD-K25433859-003-25-4::2.5::HTS002	2.5	maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2	neurology/psychiatry	depression, dysthymic disorder	MDAMB175VII, A375, SKMES1	BREAST, SKIN, LUNG	carcinoma (ductal_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.503559456283	0.491881751573	0.167066643352752	0.17825104478	-8.31608537068018	5.99211335224142	0.000165133905935833	0.0044637387974929	-0.435533524587534	-0.237452101272963
WWOX	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	MDAMB175VII, A375, SKMES1	BREAST, SKIN, LUNG	carcinoma (ductal_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.0619564219969	0.0620861748259	-0.328093190698563	-0.240168973437	-5.4196764195224	6.21570441263261	0.00145751338650344	0.0306833696705527	-0.564680987351415	-0.21541823803951
WWOX	BRD-K57136142-001-02-4::2.5::HTS002	2.5	CCT129202	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	MDAMB175VII, NCIH1299, A375, SKMES1	BREAST, LUNG, SKIN	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.421299417155	-0.439224700094	-0.75476411594058	-0.661222059711	-4.77252109554945	9.55661410926919	0.000855877317302712	0.0192870707118256	-0.490133452651147	-0.176795944920013
WWOX	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	MDAMB175VII, NCIH1299, A375	BREAST, LUNG, SKIN	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), malignant_melanoma	-1.62171685792667	-1.59216157968	-1.02986437989627	-1.09295412345	5.03143921825092	6.44362535431494	0.00193004473473482	0.0388965263705669	0.308756150708883	0.874948805351917
WWOX	BRD-K62200014-003-10-5::2.5::HTS002	2.5	anagrelide	phosphodiesterase inhibitor	targeted cancer	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	MDAMB175VII, NCIH1299, A375, SKMES1	BREAST, LUNG, SKIN	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.2344836238785	0.2046799519665	-0.0869113207329145	0.02952507046325	-4.57821532558004	17.6721508174744	0.000243546264823732	0.00630499183396615	-0.469077981903512	-0.173711907319317
WWOX	BRD-K80431395-001-07-3::2.48737::HTS002	2.48737	triciribine	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MDAMB175VII, NCIH1299, A375, SKMES1	BREAST, LUNG, SKIN	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.59308765739875	-0.588467507273	-0.944428363697483	-0.790275734137	-4.60228351152175	30.4361193041507	6.94141672546114e-05	0.00203216350956339	-0.507155216756381	-0.195526195841085
WWOX	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	MDAMB175VII, NCIH1299, A375, SKMES1	BREAST, LUNG, SKIN	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	-0.18187594303715	-0.202745666604	-0.497087754019363	-0.425698071815	-5.07508214942342	16.7882825527626	9.72793071179977e-05	0.0027644890765438	-0.446377813811313	-0.184045808153112
WWOX	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	MDAMB175VII, NCIH1299, A375, SKMES1	BREAST, LUNG, SKIN	carcinoma (ductal_carcinoma), carcinoma (non_small_cell_carcinoma), malignant_melanoma, carcinoma (squamous_cell_carcinoma)	0.137889318474175	0.14176351701	-0.0258378020783202	0.00994256527881	-4.94068581735791	37.2408048116975	1.6700178123e-05	0.00055373336586084	-0.230857530725622	-0.0965967103793683
YAP1	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	1.137069929955	1.137069929955	0.460959886977986	0.473952429855	-16.5127509076759	45.9661557058095	5.95889413177328e-21	1.07505372084919e-18	-0.758529137086467	-0.593690948867561
YAP1	BRD-A20644369-001-08-6::2.5::HTS002	2.5	canrenone	mineralocorticoid receptor antagonist	noncancer	NR3C2	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	1.0150694624235	1.0150694624235	0.503855486911608	0.518391273844	-12.710008830068	5.05165784831192	4.9986195722434e-05	0.00150724413941947	-0.614289101774125	-0.408138849249658
YAP1	BRD-A28467416-002-01-0::2.5::HTS002	2.5	PKI-179	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.759313058825	-2.759313058825	-3.72869426362439	-3.729909299115	-12.8447065518193	112.636841087754	8.34474441277257e-24	1.92314056477971e-21	-1.1189047467149	-0.819857662883892
YAP1	BRD-K00494077-066-01-9::2.5::HTS002	2.5	trovafloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.8073191188945	-0.8073191188945	-0.516787838537846	-0.3150311767995	4.13413311357128	175.58350278127	5.51140303621847e-05	0.00164887423415643	0.151836450621246	0.429226110092062
YAP1	BRD-K05638300-001-01-2::2.5::HTS002	2.5	sevoflurane	membrane integrity inhibitor	noncancer	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.0767290098438	0.0767290098438	-0.58230891437585	-0.439418069219	-11.7070559375874	187.949635648554	3.95374576807777e-24	9.38430096042459e-22	-0.770087345162549	-0.54798850327675
YAP1	BRD-K06234293-001-04-2::2.5::HTS002	2.5	LY364947	TGF beta receptor inhibitor, p38 MAPK inhibitor	targeted cancer	TGFBR1	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	1.08206629857	1.08206629857	0.782746395861681	0.806042544038	-9.30815183067027	186.466343317814	3.61931338944952e-17	4.59552025738937e-15	-0.362757702013843	-0.235882103402795
YAP1	BRD-K07265709-003-05-6::2.61449::HTS002	2.61449	dexrazoxane	chelating agent, topoisomerase inhibitor	noncancer	TOP2A, TOP2B	cardiology	cardiomyopathy	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.159852591475	-1.159852591475	-1.95214420794896	-1.885064313955	-7.35805435906926	81.2547537624741	1.34225917823371e-10	8.77088620157477e-09	-1.00652445521827	-0.57805877772966
YAP1	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-3.550810893685	-3.550810893685	-3.02386440440697	-2.91986435367	5.2233450850641	68.6711603774139	1.78686390021853e-06	7.00268335838248e-05	0.325673305332142	0.728219673223927
YAP1	BRD-K13514097-001-05-3::2.5::HTS002	2.5	everolimus	mTOR inhibitor	targeted cancer	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.2382645940685	-0.2382645940685	-0.751761714612461	-0.7206768922275	-9.02711593291184	164.319239415941	4.54691667102789e-16	5.23381365834982e-14	-0.625814629819354	-0.401179611268568
YAP1	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.68112515866	-1.68112515866	-1.29056824529546	-1.25961873039	7.69163703499523	190.413300896217	7.58652188605564e-13	6.39406861705238e-11	0.290399587028382	0.490714239700697
YAP1	BRD-K14991967-001-02-6::2.5::HTS002	2.5	GSK650394	serum/glucocorticoid regulated kinase inhibitor	targeted cancer	SGK1, SGK2	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.8380579259515	-0.8380579259515	-0.563350875919709	-0.546522000374	8.0617768158557	192.043035149766	7.87217500529448e-14	7.29773095462699e-12	0.207497244562877	0.341916855500705
YAP1	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.06673393740865	0.06673393740865	-1.11463351627815	-0.898661589303	-8.39925055450054	3.93078892689322	0.00118639039521462	0.0257002089161062	-1.57460543163702	-0.788129475736589
YAP1	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.150824253379	-0.150824253379	0.0892842127904134	0.105022107206	7.54633930841118	83.0337618034745	5.15844840711461e-11	3.52890229380296e-09	0.176824376907076	0.303392555431751
YAP1	BRD-K17075857-001-18-4::2.5::HTS002	2.5	chloroxine	opioid receptor antagonist	noncancer	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.532249097415	-1.532249097415	-0.66572540222998	-0.654840996033	15.2348434649502	33.7446053802525	1.09045078301224e-16	1.32341577504094e-14	0.750901957416715	0.982145432953325
YAP1	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.192036274867	0.192036274867	0.324616485510209	0.343759219436	3.82526991752811	16.8093693046624	0.0013786755800549	0.0292044038740449	0.0593927902786898	0.205767631007728
YAP1	BRD-K19295594-015-14-3::2.2874::HTS002	2.2874	gossypol	BCL inhibitor, MCL1 inhibitor	targeted cancer	BCL2	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.63461376947	-2.63461376947	-2.99254594129802	-2.880185474935	-4.35453135219034	40.2844721163438	8.91401110455747e-05	0.0025524797408533	-0.524023250390503	-0.191841093265539
YAP1	BRD-K21283037-001-21-5::2.5::HTS002	2.5	riluzole	glutamate inhibitor	noncancer	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.1543367033095	-0.1543367033095	0.0475996753500349	0.027710059388	5.80165869401397	9.11611261849592	0.000246542806859289	0.00637332930302068	0.123350848552252	0.280521908766818
YAP1	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.886469152616	-0.886469152616	-0.2297074750378	-0.0566869180409	10.7102975682362	182.068536762111	4.53584041263348e-21	8.25264974362752e-19	0.53577131895711	0.77775203619929
YAP1	BRD-K26011976-001-01-0::2.5::HTS002	2.5	licochalcone-a	topoisomerase inhibitor	targeted cancer	PTPN1	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.001836554836505	0.001836554836505	-0.136675998050914	-0.1059972226705	-3.71475248286263	183.472524942837	0.000269818172032195	0.00689271263331209	-0.212079293496541	-0.0649458122782972
YAP1	BRD-K33127281-001-05-6::2.5::HTS002	2.5	adapalene	retinoid receptor agonist	noncancer	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.1337591432525	0.1337591432525	-0.167154737048267	-0.163237656736	-6.55846353691822	6.32313238021514	0.000485138067125761	0.0116594703732897	-0.411806336948742	-0.190021423652793
YAP1	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.2200299886825	0.2200299886825	-0.278867774256568	-0.153671266635	-7.00333496072211	4.50947220850423	0.00138348455081538	0.029294690801394	-0.688175363792155	-0.309620162085981
YAP1	BRD-K38904395-001-02-3::2.5::HTS002	2.5	SAR131675	VEGFR inhibitor	targeted cancer	FLT4	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.793154055092	-0.793154055092	-0.529920746683556	-0.519013652075	4.58489491625425	8.01216939110082	0.00178344481733846	0.0363903221872938	0.130873316755222	0.395593300061665
YAP1	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.595719126652	0.595719126652	0.252497163270408	0.2832758926905	-7.85918092587895	4.43356503289407	0.000915867310740125	0.0204945630448549	-0.459937239958395	-0.226506686804788
YAP1	BRD-K48826825-001-01-8::2.5::HTS002	2.5	S26948	PPAR receptor agonist	noncancer	PPARG	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.145583228461	0.145583228461	0.373512103795933	0.3764822376655	6.1674342657232	66.9664005366179	4.53480433186131e-08	2.22462823905585e-06	0.154162035569206	0.30169571510066
YAP1	BRD-K49049886-001-08-7::2.5::MTS006	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.02311017095036	0.02311017095036	-0.956207383481348	-0.580280097075	-10.9416470220802	46.8052041061743	1.71220111853498e-14	1.70052990516443e-12	-1.15939549520766	-0.799239613655759
YAP1	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.1165779960285	-0.1165779960285	0.0298388252311372	0.0483026079462	5.41091406039199	40.7733321894239	3.01063994521064e-06	0.000114166215289641	0.0917597529665749	0.201073889552699
YAP1	BRD-K49669041-001-08-4::2.5::HTS002	2.5	BX-912	pyruvate dehydrogenase kinase inhibitor	targeted cancer	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.8943650241915	-0.8943650241915	-1.94771068199201	-1.738347180205	-8.06435892946609	3.8070945522175	0.00157847707984601	0.0328300256231263	-1.4233609156367	-0.683330399964316
YAP1	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.159988703504	-0.159988703504	-1.26050248915906	-0.921278111753	-12.8303672474557	190.017335313316	1.51262166052968e-27	4.83157508017384e-25	-1.26970560578364	-0.931321965526486
YAP1	BRD-K50071428-001-03-3::2.5::HTS002	2.5	abiraterone	androgen biosynthesis inhibitor	targeted cancer	CYP11B1, CYP17A1	oncology	prostate cancer	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.605983402408	0.605983402408	0.521430543762015	0.521292609125	-3.30541829119789	194.584810545802	0.00112909405475774	0.0245907529379304	-0.13500266483653	-0.0341030524554403
YAP1	BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500	2.5	canertinib	EGFR inhibitor	targeted cancer	AKT1, EGFR, ERBB2, ERBB4	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.521140297602	0.521140297602	-0.116611633085618	0.03876057814515	-12.5248958107559	123.448049407141	9.87074735940434e-24	2.25302173673458e-21	-0.738538823255149	-0.536965038120087
YAP1	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-4.191854519045	-4.191854519045	-3.65503721425926	-3.66301517797	5.80024994080445	6.67300901952207	0.000788881122606067	0.0179719496308499	0.31577680324677	0.75785780632472
YAP1	BRD-K53581288-001-02-9::2.5::HTS002	2.5	baricitinib	JAK inhibitor	noncancer	JAK1, JAK2	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.825555463122	-0.825555463122	-0.287282836688874	-0.3736278329815	7.93006050955243	176.865492915847	2.38766143721224e-13	2.11203090456567e-11	0.404318597881464	0.672226654984789
YAP1	BRD-K56405753-001-02-4::2.5::HTS002	2.5	MK-2461	FGFR inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.07001414118	-2.07001414118	-0.735302248211995	-0.6455499330205	15.5091147061054	7.17613168377852	8.81587255724125e-07	3.62806672296651e-05	1.13222086592556	1.53720292001045
YAP1	BRD-K63932022-001-01-5::2.5::HTS002	2.5	2'-MeCCPA	adenosine receptor agonist	noncancer	ADORA1	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.282664173481	-0.282664173481	0.201785788053852	0.269128450915	9.22309882804379	180.996074173073	7.47655879262716e-17	9.26267843621379e-15	0.380808440334421	0.588091482735284
YAP1	BRD-K64881305-001-03-7::2.5::HTS002	2.5	ispinesib	kinesin inhibitor	targeted cancer	KIF11	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.4750068025	-2.4750068025	-2.12455038776854	-1.97310817512	3.66161485205251	79.2386494949652	0.000450567057363119	0.0109291067041172	0.159957575428935	0.540955254033984
YAP1	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.215939945885	-1.215939945885	-2.49928663155278	-2.41136656484	-14.0252442838667	35.5803795633188	4.58763940838554e-16	5.27785382050383e-14	-1.46899863662012	-1.09769473471544
YAP1	BRD-K67772619-001-05-1::2.5::HTS002	2.5	rheochrysidin	protein tyrosine kinase inhibitor	targeted cancer	PTPN1	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.8918330603845	-0.8918330603845	0.0302826814218916	0.07894128154425	23.4425526717078	191.585600894481	3.48794382698226e-58	1.73852909882158e-54	0.84453021472047	0.999701268892313
YAP1	BRD-K67844266-003-01-9::2.5::HTS002	2.5	pevonedistat	nedd activating enzyme inhibitor	targeted cancer	NAE1, UBA3	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-3.191067958025	-3.191067958025	-2.60531783697151	-2.60596765275	5.74854015922929	29.0182566405091	3.17467871432939e-06	0.000119730021848232	0.37735620896593	0.794144033141058
YAP1	BRD-K71847383-001-12-5::2.5::HTS002	2.5	cytarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.08541242191845	0.08541242191845	0.332084111981386	0.318284588664	9.02357212782646	184.701518202564	2.35349791021918e-16	2.7930390564749e-14	0.192740017003906	0.300603363121966
YAP1	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.509982595385	-0.509982595385	-0.204298242219538	-0.177852990832	5.44986299089763	9.31134663631259	0.000360484735512888	0.00895276163125629	0.179443122070324	0.4319255842606
YAP1	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.3363247220735	-0.3363247220735	-1.06329545281133	-0.7851415156885	-7.45131454720738	72.7611728356932	1.52960357874554e-10	9.91047174815456e-09	-0.921423761850089	-0.532517699625576
YAP1	BRD-K82122102-323-01-1::2.5::HTS002	2.5	amfenac	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	neurology/psychiatry	pain relief	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.3843642593475	0.3843642593475	0.118956836831808	0.120954188254	-7.33853141304509	188.119349734922	6.29275178115318e-12	4.81341611885361e-10	-0.33675101149569	-0.194063833535695
YAP1	BRD-K82135108-001-04-3::2.5::HTS002	2.5	elesclomol	oxidative stress inducer	targeted cancer	HSPA1A	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-4.7419251958	-4.7419251958	-3.04397729317718	-2.99006854464	11.776416661417	2.91241336573621	0.00151191589040389	0.0316421658895005	1.23119006603913	2.16470573920651
YAP1	BRD-K86930074-001-05-0::2.5::HTS002	2.5	cediranib	KIT inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.60244635578	-2.60244635578	-3.02213256265227	-2.830173101285	-4.66616930800437	192.424778361705	5.73716418635041e-06	0.000206801322384174	-0.597085687601728	-0.242286726142808
YAP1	BRD-K87124298-001-03-4::2.5::HTS002	2.5	OSI-027	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.676503382635	-1.676503382635	-1.95701628410323	-1.89031364576	-4.57616041504438	193.999862014232	8.43996248673646e-06	0.000294856692497001	-0.401410431346613	-0.159615371589846
YAP1	BRD-K92093830-003-30-8::2.5::HTS002	2.5	doxorubicin	topoisomerase inhibitor	chemo	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-5.07734449776	-5.07734449776	-5.62221878608619	-5.62740406384	-5.04934587446319	27.5662006475413	2.52487466835637e-05	0.000808174824961398	-0.766074466642896	-0.323674110009483
YAP1	BRD-K97714174-001-01-3::2.5::HTS002	2.5	P22077	ubiquitin specific protease inhibitor	noncancer	USP7	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.4604011536	0.4604011536	0.254956747836113	0.3142607574065	-5.21683686745074	29.761679902701	1.29112793325125e-05	0.000435583439014336	-0.285898212353559	-0.124990599174215
YAP1	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.28013381124	-0.28013381124	-0.723327783786019	-0.596555071115	-7.45713992464107	190.636894277867	3.02817831540483e-12	2.40380159319408e-10	-0.560423083174845	-0.325964861917193
YAP1	BRD-M80207679-001-01-5::2.5::HTS002	2.5	nemonapride	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.131740314521	0.131740314521	0.375017932244839	0.391465254449	6.76540499186429	72.0402564533025	2.97762657862957e-09	1.68610760098044e-07	0.171595222043492	0.314960013404187
YAP1	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	SW1271, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.07353716766075	0.07353716766075	-0.0780170997661632	-0.07508781022425	-5.31122992297043	193.111852816639	2.9802629171749e-07	1.31242402049554e-05	-0.20783392283828	-0.0952746120155461
ZCWPW2	BRD-A01643550-001-04-9::2.5::HTS002	2.5	prednisolone-acetate	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7910335484025	0.7910335484025	0.465205732150409	0.473952429855	-6.96829406646525	9.41776472142673	5.22558032981866e-05	0.00156993749160317	-0.430892221337907	-0.220763411166274
ZCWPW2	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.069853026426	0.069853026426	0.151266024879882	0.1647699361925	3.54417786453056	182.70704572329	0.000500121885610669	0.0119913439558171	0.0360906313149847	0.126735365592779
ZCWPW2	BRD-A08545410-311-03-4::2.5::HTS002	2.5	doxycycline	metalloproteinase inhibitor	noncancer	MMP8	dental	periodontitis	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.04040777548	-1.04040777548	-0.489827750298145	-0.488941484078	15.5948170964833	107.097256409927	2.53745779796158e-29	9.81680130648568e-27	0.48059207056691	0.620567979796799
ZCWPW2	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.79368382803	-1.79368382803	-1.20621558515855	-1.08580167806	8.63194690493637	193.232726466872	2.21802374986005e-15	2.38647998134415e-13	0.453237410355781	0.721699075387127
ZCWPW2	BRD-A13561534-003-02-0::2.5::HTS002	2.5	ornithine	NFkB pathway modulator	noncancer	ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.92686403753	0.92686403753	0.62244858709006	0.6438914807695	-9.23313656069809	7.20094094319041	3.02476430153817e-05	0.000950718152198817	-0.381937987679135	-0.226892913200746
ZCWPW2	BRD-A14240607-003-26-1::2.5::HTS002	2.5	octopamine	trace amine associated receptor agonist	noncancer	F10, TAAR1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7962588116985	0.7962588116985	0.689415265203164	0.666876685048	-4.06051144042338	187.959143856276	7.18080874138837e-05	0.00209680593560358	-0.158749957295252	-0.0549371356954195
ZCWPW2	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.249849590868	0.249849590868	-0.00661436130042342	0.000253415549772	-7.3365291083046	12.6780217627075	6.58116820772033e-06	0.000234528964503294	-0.332179655619519	-0.180748248717328
ZCWPW2	BRD-A27376179-001-01-3::2.5::HTS002	2.5	lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	targeted cancer	FLT3, NTRK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.34042783741	-3.34042783741	-2.90703441751993	-2.875482162025	4.37435346693211	129.647600854672	2.47956464147243e-05	0.000794858824472248	0.237378408482192	0.629408431297952
ZCWPW2	BRD-A68631409-001-05-4::2.5::HTS002	2.5	evodiamine	ATPase inhibitor, TRPV agonist	targeted cancer	TRPV1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.152781087285	-3.152781087285	-2.36887749498975	-2.292575025235	6.45197589545006	4.64411927635444	0.00174898307628119	0.0357996173962632	0.464244737255978	1.10356244733452
ZCWPW2	BRD-A80017228-001-25-7::2.5::HTS002	2.5	bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	noncancer	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.6098860452795	0.6098860452795	0.410988110165117	0.462027349437	-6.03016866476636	153.569261192228	1.1726777553152e-08	6.22588185828468e-07	-0.264058504477138	-0.13373736575163
ZCWPW2	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.5754991009945	-0.5754991009945	0.159032009431474	0.185523876977	16.9253175846282	125.819976232709	3.17593784054545e-34	1.8803745343267e-31	0.648645830476157	0.820416390375791
ZCWPW2	BRD-K02241333-001-02-7::2.5::HTS002	2.5	CHIR-124	CHK inhibitor	noncancer	CHEK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.657512585485	-5.657512585485	-2.99437606336216	-2.85234115214	23.7837712154736	125.907012725437	2.09707046136261e-48	4.63363932900399e-45	2.44154396741726	2.88472907682843
ZCWPW2	BRD-K04196797-001-24-4::2.5::HTS002	2.5	oxcarbazepine	sodium channel blocker	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.6486815978975	0.6486815978975	0.236070748534979	0.231867156581	-12.3716158601649	5.75147653322235	2.31728520492119e-05	0.000745961881474246	-0.495081270249193	-0.33014042847585
ZCWPW2	BRD-K06854232-001-19-9::2.5::HTS002	2.5	AM-580	retinoid receptor agonist	targeted cancer	RARA	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.339070787973	-0.339070787973	0.124733625883642	0.154475017862	12.9257905901172	8.05707560503249	1.13933118281261e-06	4.61174151238986e-05	0.381162076956699	0.546446750756586
ZCWPW2	BRD-K08109215-001-06-4::0.625::HTS002	0.625	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.14712200323	-0.14712200323	0.324366362462662	0.349176591288	7.27384109006744	143.640636463711	2.080837887543e-11	1.49358306630678e-09	0.343364600954021	0.599612130431304
ZCWPW2	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-4.352615654095	-4.352615654095	-1.22151422449004	-0.903447368813	29.7175163446423	17.0925518087049	3.71643846089239e-16	4.3172928936835e-14	2.90889837876902	3.3533044804409
ZCWPW2	BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500	0.625	pelitinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	1.22791306775	1.22791306775	0.00208124336200781	0.1859491052615	-17.8466452798425	18.524193956077	4.01526754875743e-13	3.47151383000255e-11	-1.36984562390648	-1.0818180248695
ZCWPW2	BRD-K09549677-300-03-4::2.5::HTS002	2.5	mibefradil	T-type calcium channel blocker	noncancer	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.3345936209365	0.3345936209365	0.210263076105271	0.2370962732805	-3.61239553004309	18.6301268939311	0.0019033854703717	0.0384460187050509	-0.196464655877903	-0.0521964337845547
ZCWPW2	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-2.03451250065	-2.03451250065	-1.32679175550334	-1.32870952416	10.7975502376057	161.122646495221	8.61142012317585e-21	1.53168221043996e-18	0.578283551763564	0.837157938529752
ZCWPW2	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.278358915365	-5.278358915365	-3.66150351976354	-3.56303502077	11.2042598764156	2.92885674814959	0.00169987268942915	0.0349915495248425	1.15122968016259	2.08248111104033
ZCWPW2	BRD-K15409150-001-05-8::2.5::HTS002	2.5	penfluridol	T-type calcium channel blocker	noncancer	CACNA1G	neurology/psychiatry	schizophrenia	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.959701585595	-3.959701585595	-2.8403748571974	-2.63540745447	9.99862509984235	9.27929041383068	2.84186183553009e-06	0.000108225551767471	0.86723975874622	1.37141369804898
ZCWPW2	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.10086790378345	0.10086790378345	-0.0717080025308386	0.0407112965926	-4.08318341119326	126.678037868321	7.81783229656619e-05	0.00226675889920283	-0.256212835795603	-0.0889389768329738
ZCWPW2	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.562762158271	-0.562762158271	-0.0373045701051451	0.10879840342	8.48128502289504	117.451569465783	7.6893630339209e-14	7.13134352962887e-12	0.402763985413908	0.648151190917802
ZCWPW2	BRD-K17705806-003-04-4::2.5::HTS002	2.5	JTC-801	opioid receptor antagonist	noncancer	OPRL1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.490137983133	-0.490137983133	-0.941917623100048	-0.8887322701185	-6.58691893947456	53.975093363344	1.93190833720495e-08	9.97309124216704e-07	-0.589290549648116	-0.31426873028598
ZCWPW2	BRD-K18574842-236-17-7::2.5::HTS002	2.5	nafcillin	bacterial cell wall synthesis inhibitor	noncancer	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7473709444165	0.7473709444165	0.303167916629533	0.3131581681635	-14.3463941895313	98.4007898473993	7.40722716133641e-26	2.01725996221356e-23	-0.505644360554578	-0.382761695019356
ZCWPW2	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.007812916450212	-0.007812916450212	-0.343811710186325	-0.216806871006	-5.92769732051293	181.055790365493	1.52101773715899e-08	7.97451591456822e-07	-0.447842731647975	-0.22415485582425
ZCWPW2	BRD-K22134346-001-24-9::2.42474::HTS002	2.42474	simvastatin	HMGCR inhibitor	noncancer	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.4162182990985	0.4162182990985	-0.217121957503545	-0.0984348398408	-12.1384915108201	156.479508525164	2.58547677302254e-24	6.23332566125025e-22	-0.736400766987078	-0.530279746217012
ZCWPW2	BRD-K25244359-066-03-4::2.68145::HTS002	2.68145	apatinib	RET tyrosine kinase inhibitor	targeted cancer	CSK, KDR, KIT, RET	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.5018479362295	-0.5018479362295	0.143413493677826	0.202676632561	16.664585352372	78.605020264969	1.61430899968876e-27	5.13343076549396e-25	0.568184138348987	0.722338721465665
ZCWPW2	BRD-K28578425-001-07-0::2.5::HTS002	2.5	cilostamide	phosphodiesterase inhibitor	targeted cancer	PDE3A, PDE3B	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.05718038723475	0.05718038723475	-0.0883064770758308	-0.0710584788856	-4.24453707272825	177.564340372181	3.52440375283248e-05	0.0010945977857424	-0.213128120377091	-0.0778456082440706
ZCWPW2	BRD-K29656036-001-02-5::2.5::HTS002	2.5	MK-8245	stearoyl-CoA desaturase inhibitor	noncancer	SCD	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.48636214273	-3.48636214273	-1.64502215379068	-1.528752793545	16.2057430304825	3.50208814722542	0.000203090350800466	0.00535533363640664	1.50737194110782	2.17530803677082
ZCWPW2	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.024774867716895	-0.024774867716895	-0.183936068914209	-0.06456986921455	-3.42271070553308	39.1384809540952	0.00146601028094983	0.0308319612899318	-0.253208735095642	-0.0651136672989863
ZCWPW2	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.0630591410846	-0.0630591410846	0.244370194596383	0.255954419506	11.4835981204496	144.999702230365	4.09471215981945e-22	8.11104956101611e-20	0.254517203571574	0.360341467790392
ZCWPW2	BRD-K32501161-300-06-2::2.5::HTS002	2.5	vanoxerine	dopamine uptake inhibitor	noncancer	SLC6A3	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.405762695615	-3.405762695615	-2.56722118981888	-2.525806741025	8.21896483204265	16.4723640387128	3.16579215005146e-07	1.3901271578127e-05	0.622760725352416	1.05432228623983
ZCWPW2	BRD-K34022604-001-06-6::2.5::HTS002	2.5	clofarabine	ribonucleotide reductase inhibitor	chemo	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.0458771487	-5.0458771487	-3.64589054229061	-3.59749422562	10.6767771023783	5.14827900464242	0.000104680225433531	0.00295521707546672	1.06581959835221	1.73415361446657
ZCWPW2	BRD-K35687421-001-02-5::2.5::HTS002	2.5	gimeracil	dihydropyrimidine dehydrogenase inhibitor	targeted cancer	DPYD	oncology	gastric adenocarcinoma	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.115707645382	-0.115707645382	0.417028743395429	0.43502168689	21.9585939542176	102.336143414694	1.6385251284977e-40	1.82908048055095e-37	0.484616803119783	0.580855974435075
ZCWPW2	BRD-K36234266-001-09-8::2.5::HTS002	2.5	carmustine	DNA alkylating agent, DNA inhibitor	chemo	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.391381048361	0.391381048361	0.129222937977099	0.121836586496	-7.79572200119136	38.6172759466519	1.89921006831134e-09	1.09688977292132e-07	-0.330199647338024	-0.194116573429777
ZCWPW2	BRD-K36363294-001-04-2::2.5::HTS002	2.5	I-BET151	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.209615904335	-1.209615904335	0.12924385915319	0.175731719762	17.0193270357609	4.68520971451617	2.15631756739816e-05	0.000698339963588517	1.13248401052623	1.54523551645015
ZCWPW2	BRD-K37249724-001-25-7::2.5::HTS002	2.5	astemizole	histamine receptor antagonist	noncancer	HRH1, KCNH1, KCNH2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.1937746806275	0.1937746806275	0.0611703014207595	0.100436576625	-3.61870276458607	187.921972798553	0.000380528809647903	0.00939828984132582	-0.204891171557783	-0.0603175868556984
ZCWPW2	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.592261125765	-3.592261125765	-2.6076287090415	-2.424137198535	10.1880728708246	43.9565140002942	3.79189065974046e-13	3.28634101581687e-11	0.789850565420739	1.17941426802626
ZCWPW2	BRD-K38868394-001-01-3::2.5::HTS002	2.5	MK-0773	androgen receptor modulator	noncancer	AR	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.5272317790335	-0.5272317790335	-0.140187037050162	-0.03734266076635	7.82263602523526	24.3215551799364	4.26962356337413e-08	2.09791447026299e-06	0.284999527716743	0.489089956249933
ZCWPW2	BRD-K39171998-001-01-1::2.5::HTS002	2.5	STF-118804	NAMPT inhibitor	targeted cancer	NAMPT	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.84306514094	-5.84306514094	-4.65384728401106	-4.65401991694	11.8118990518423	61.5675036625642	1.81119051869779e-17	2.36990630452979e-15	0.987933978585202	1.39050173527268
ZCWPW2	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.034618135815	-5.034618135815	-3.01638115643831	-2.87565347972	15.2610745512968	3.85720811365602	0.000136423859363363	0.00375058868054005	1.64563608447295	2.39083787428043
ZCWPW2	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.274474435688	0.274474435688	-0.213136368948703	-0.158274399371	-9.54226351914088	12.7391874576044	3.65051824621075e-07	1.58543449886951e-05	-0.598236092227899	-0.376985517045507
ZCWPW2	BRD-K42938903-332-01-1::2.5::HTS002	2.5	acetophenazine	dopamine receptor antagonist	noncancer	DRD1, DRD2	neurology/psychiatry	psychosis	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.6353123639325	0.6353123639325	0.471812984099487	0.492327571576	-5.59280839596033	146.607217835981	1.06208411268481e-07	4.99091045357646e-06	-0.221273593109859	-0.105725166556168
ZCWPW2	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-4.572373565285	-4.572373565285	-3.74482060748522	-3.638458649165	7.93153858285827	153.685702318812	4.15985983453553e-13	3.58928582317297e-11	0.621433117897052	1.03367279770251
ZCWPW2	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.06603668832	-3.06603668832	-2.23122566550389	-2.12735654465	10.428714576269	6.16065790818348	3.83881027646095e-05	0.00118400973916189	0.640169061756993	1.02945298387523
ZCWPW2	BRD-K52662033-003-21-2::2.5::HTS002	2.5	lidocaine	histamine receptor agonist	noncancer	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7573653503995	0.7573653503995	0.375037512485329	0.393436647762	-13.3694140611568	9.22833896494126	2.3812604923583e-07	1.06283461071775e-05	-0.446776024469336	-0.317879651359006
ZCWPW2	BRD-K53097745-001-01-5::2.5::HTS002	2.5	pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	targeted cancer	PTGS2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.2444013238885	-0.2444013238885	0.232133617302861	0.2141011890955	16.2535291420211	81.149341516027	3.04299738817181e-27	9.30388854792406e-25	0.418201234349443	0.534868648033279
ZCWPW2	BRD-K53523901-001-04-4::2.5::HTS002	2.5	arctigenin	MEK inhibitor	targeted cancer	CHUK, MAP2K1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.9310450711915	-0.9310450711915	-0.428800818259873	-0.429548063404	9.81128011609699	3.86708411384021	0.000713916553410352	0.016451244057186	0.358169198663395	0.646319307199858
ZCWPW2	BRD-K54847683-001-04-0::2.5::HTS002	2.5	equol	estrogen receptor agonist	noncancer	ESR1, ESR2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.2140206426765	-0.2140206426765	0.119112876175134	0.150496276102	10.1632655015838	10.787029118194	7.39472715858079e-07	3.08167310358052e-05	0.260815031416938	0.40545200628633
ZCWPW2	BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500	2.5	alpelisib	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.3681963058635	0.3681963058635	-0.127989023885226	-0.007473093877485	-10.2065554656913	9.15170306011553	2.65251402406284e-06	0.000101465407507293	-0.60588143031921	-0.386489229178242
ZCWPW2	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.04910063126	-1.04910063126	-1.33236393005949	-1.45938861893	-4.84522152456142	191.05715896832	2.6087057233867e-06	9.9947855912563e-05	-0.398577948788525	-0.167948648810454
ZCWPW2	BRD-K59866480-001-07-3::2.5::MTS006	2.5	cyclovalone	breast cancer resistance protein inhibitor	noncancer	ABCG2	gastroenterology	bile stimulation	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.03580325248235	0.03580325248235	-0.208025735152714	-0.0810605722641	-5.04953237334293	188.672060481281	1.03966334390317e-06	4.22827333653555e-05	-0.339081619491974	-0.148576355778155
ZCWPW2	BRD-K61192372-001-08-9::2.5::HTS002	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.516966175579	-0.516966175579	-0.203805784627939	-0.243848377549	9.34739968088099	10.7306712509709	1.7423976396775e-06	6.84092954230517e-05	0.239195656210157	0.387125125691965
ZCWPW2	BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.4323714347625	0.4323714347625	-0.498308001151974	0.00402399396559	-10.4774429319402	188.006709232387	1.59258532319054e-20	2.77059431602359e-18	-1.10590503144279	-0.755453840386158
ZCWPW2	BRD-K64888243-001-03-7::2.5::HTS002	2.5	AZ960	JAK inhibitor	targeted cancer	JAK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.02542677765	-3.02542677765	-2.48003677164038	-2.38802069166	5.68367335129545	18.7003773581795	1.8771716626374e-05	0.000615092990798671	0.344331027210522	0.74644898480871
ZCWPW2	BRD-K65781196-001-03-0::2.5::HTS002	2.5	avanafil	phosphodiesterase inhibitor	noncancer	PDE5A	urology	erectile dysfunction	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.306622124191	0.306622124191	0.520177797172758	0.5001680411375	7.99788215772324	150.029693053086	3.15863076176714e-13	2.75645835724262e-11	0.160796066722515	0.266315279241001
ZCWPW2	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.299599606656	0.299599606656	-0.0825914929234308	0.0411624842104	-7.17666696692973	7.57585233687856	0.00012370276641699	0.0034356732180105	-0.506203739027564	-0.258178460131297
ZCWPW2	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.49705251631	-1.49705251631	-0.780026367429946	-0.642853768929	9.73553135384276	20.4194652291975	4.05700769042965e-09	2.26264481207936e-07	0.563596097441185	0.870456200318924
ZCWPW2	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.8894545495365	-0.8894545495365	-0.523029796960183	-0.364234530081	6.66649243604005	65.1969240697374	6.6298580649839e-09	3.60744059205366e-07	0.256658054403356	0.476191450749279
ZCWPW2	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.8590488914	-3.8590488914	-2.50797977057536	-2.24664413304	8.75417524360783	3.51901704850311	0.00164398733596666	0.0339880545703096	0.898452078380518	1.80368616326877
ZCWPW2	BRD-K76037122-001-02-5::2.5::HTS002	2.5	guanidine	HSP inhibitor	noncancer	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.08236089830095	0.08236089830095	0.214496456527129	0.217996960587	4.13293600513709	12.0246482362913	0.00138234245867782	0.0292733995480643	0.0624917962394067	0.201779320212951
ZCWPW2	BRD-K81548480-001-01-2::2.5::HTS002	2.5	AC-264613	PAR agonist	noncancer	F2RL1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.3254443179745	0.3254443179745	-0.376669620555005	-0.2564995934565	-14.4643465873751	193.99958388509	1.19510444927635e-32	6.02695391785766e-30	-0.797849790502707	-0.606378086556302
ZCWPW2	BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500	2.5	neratinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, KDR	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.2608545739595	0.2608545739595	-0.327794099216086	-0.193950713334	-10.832846017958	71.8121863496842	9.31163882040345e-17	1.13588744265125e-14	-0.696976818586276	-0.480320527764896
ZCWPW2	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-5.59460480684	-5.59460480684	-4.8339473700577	-4.95161811894	8.18966894987735	152.642542487723	9.73494869509147e-14	8.92803516846495e-12	0.577160945357834	0.944153928206765
ZCWPW2	BRD-K86887724-001-10-6::2.58731::HTS002	2.58731	dofetilide	potassium channel blocker	noncancer	KCNH1, KCNH2, KCNJ12, KCNK2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.0818043345879	-0.0818043345879	0.113411070926575	0.0998567885779	7.42702502244734	124.865845439101	1.52096433561826e-11	1.1148658176769e-09	0.143194633873992	0.247236177154957
ZCWPW2	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.157760051922	0.157760051922	-0.122073809725094	-0.0479466221371	-8.61556421843166	170.307068969777	4.57756838948667e-15	4.79055495776508e-13	-0.343949172524387	-0.215718550769801
ZCWPW2	BRD-K91601245-001-12-0::2.5::HTS002	2.5	mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	targeted cancer	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.7323439264095	-0.7323439264095	-0.267040907287568	-0.201241346164	7.46904021064528	4.8934570369128	0.000745798515793736	0.0170976842540973	0.30410761293846	0.626498425305404
ZCWPW2	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.72660717278	-3.72660717278	-1.80708016688349	-1.68862958657	15.869906832908	3.03579152940021	0.000508901023980432	0.0121800388128087	1.53715243380363	2.3019015779894
ZCWPW2	BRD-K92428232-001-10-6::2.5::HTS002	2.5	GSK461364	PLK inhibitor	targeted cancer	PLK1	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-3.991668507425	-3.991668507425	-2.68531224087157	-2.35101835033	7.58471868152343	3.60066551074183	0.0024446220975934	0.0476451222656267	0.806494275250938	1.80621825785592
ZCWPW2	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.532796017447	-0.532796017447	-0.0889336643289606	-0.0408206395104	15.0213426823001	192.653807330464	2.86697202469997e-34	1.71163021471287e-31	0.385581697192	0.502143009044079
ZCWPW2	BRD-K92723993-001-06-7::2.5::HTS002	2.5	imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	targeted cancer	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.883320284796	-0.883320284796	-0.35738698724703	-0.28708101882	8.47077508492825	76.3367492632495	1.33700762004139e-12	1.10130478937683e-10	0.402283193495674	0.649583401602265
ZCWPW2	BRD-K94176593-001-09-4::2.5::HTS002	2.5	TWS-119	glycogen synthase kinase inhibitor	noncancer	GSK3B, JUN, MYC	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.6430257904935	-0.6430257904935	-0.292458291137632	-0.211299722741	7.84382463748608	23.8182165057705	4.70879258340372e-08	2.30523253907797e-06	0.25828750492241	0.442847493789326
ZCWPW2	BRD-K94353609-001-21-6::2.5::HTS002	2.5	fluocinolone-acetonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.7052893264125	0.7052893264125	0.294848534197782	0.274833859863	-11.5627721839673	194.004525913717	7.32365980349874e-24	1.69145763149147e-21	-0.480449862454973	-0.340431721974463
ZCWPW2	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-2.81932307911	-2.81932307911	-1.39256353393589	-1.36288222555	18.4876258353229	181.254567923181	1.4189940307427e-43	1.98778804977158e-40	1.27448504232301	1.57903404802522
ZCWPW2	BRD-K96006502-001-02-6::2.5::HTS002	2.5	deflazacort	glucocorticoid receptor agonist	noncancer	NR3C1	rheumatology	joint inflammation	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.06517191056135	-0.06517191056135	-0.970108268363088	-0.879578497328	-9.5154174198054	27.2866902098661	3.67401229187354e-10	2.29643447216379e-08	-1.09997390193047	-0.709898813673009
ZCWPW2	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.0793545747386	0.0793545747386	0.312702037863887	0.3392697962385	7.06023380491992	159.073450565762	4.87091237453302e-11	3.34393907213737e-09	0.168072185160893	0.29862274108968
ZCWPW2	BRD-K97752965-001-16-4::2.5::HTS002	2.5	nicorandil	nitric oxide donor, potassium channel activator	noncancer	KCNJ11	cardiology	angina pectoris	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.525267266716	0.525267266716	0.246744382421208	0.245556311183	-9.42972296913283	22.9563432326172	2.32894350115859e-09	1.33073882074065e-07	-0.339630630773473	-0.217415137816112
ZCWPW2	BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500	2.5	AZD8931	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB3	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.3377395552215	0.3377395552215	-0.228393407266589	-0.0281474951666	-9.22041670195334	95.8488473566077	7.12972640881124e-15	7.29755077112752e-13	-0.688013318004734	-0.444252606971443
ZCWPW2	BRD-K99023089-001-03-7::2.5::HTS002	2.5	AZD5363	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-1.90424557582	-1.90424557582	-0.706321377874187	-0.590290062749	12.8611827648096	2.75732637194044	0.00152719237551237	0.0319244723155359	0.886183472155505	1.50966492373612
ZCWPW2	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	0.063258311678689	0.063258311678689	-0.619468494345976	-0.542183140466	-7.79598614000126	3.54005196360751	0.00237640289645342	0.0464676632053612	-0.938851901030466	-0.426601711018865
ZCWPW2	BRD-M92675308-003-07-1::2.5::HTS002	2.5	efonidipine-monoethanolate	L-type calcium channel blocker, T-type calcium channel blocker	noncancer	CACNA1C, CACNA1G	NA	NA	KALS1, HGC27	CENTRAL_NERVOUS_SYSTEM, STOMACH	glioma, carcinoma (undifferentiated_adenocarcinoma)	-0.244801260475	-0.244801260475	-0.0747352603008461	-0.0657751951103	4.77667231319084	7.66947185266914	0.00157003504457639	0.0326829876718156	0.0873443174309035	0.252787682917404
ZFPM2	BRD-A10523515-001-07-9::2.5::HTS002	2.5	GSK429286A	rho associated kinase inhibitor	noncancer	ROCK1	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.3701945139865	0.3701945139865	-0.0114032924799684	0.0633629143304	-11.6913429827586	134.199563861325	3.27175744384782e-22	6.56584738934888e-20	-0.446151874020487	-0.317043738912449
ZFPM2	BRD-A11990600-001-03-4::2.5::HTS002	2.5	lorazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.257830601252	-0.257830601252	-0.493703375931007	-0.379151386241	-4.14998013669545	188.180119308901	5.03247420121889e-05	0.00151638572061443	-0.347992477007734	-0.12375307235028
ZFPM2	BRD-A25004090-001-08-4::2.5::HTS002	2.5	erastin	ion channel antagonist	targeted cancer	VDAC2	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-1.37651422426	-1.37651422426	-0.76190338722684	-0.407935159141	6.11587336865854	165.596050252439	6.68483752398948e-09	3.63551012859462e-07	0.416195444781339	0.813026229284981
ZFPM2	BRD-A25569250-001-03-3::2.5::HTS002	2.5	KI-16425	lysophosphatidic acid receptor antagonist	targeted cancer	LPAR1, LPAR3	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.06451662255555	0.06451662255555	-0.0535115128144698	0.002007296385155	-3.34623362961136	147.309989414923	0.00103954209320382	0.0228751557797003	-0.187732490990871	-0.0483237797491687
ZFPM2	BRD-A45498368-001-07-1::2.5::HTS002	2.5	WYE-125132	mTOR inhibitor	targeted cancer	MTOR	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-2.91330482314	-2.91330482314	-2.3359107750304	-2.38754178221	7.3338300142247	11.3880320608172	1.21715835703417e-05	0.0004124814849905	0.404827663595753	0.749960432623451
ZFPM2	BRD-A56085258-001-01-8::2.5::HTS002	2.5	LGX818	RAF inhibitor	targeted cancer	BRAF	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.5216260356825	0.5216260356825	-0.226608200581915	-0.093015492892	-8.22385499346058	3.97391411572299	0.00122573681196443	0.0264296725524672	-1.0014999432237	-0.494968529305126
ZFPM2	BRD-A74765037-001-01-1::2.5::HTS002	2.5	estradiol-benzoate	contraceptive agent	noncancer	ESR1	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.0666616359709	-0.0666616359709	0.0307732923707322	0.0157796912763	3.42780248019076	127.033682616943	0.000820639844479158	0.0186182827593282	0.0411873326972167	0.153682523986048
ZFPM2	BRD-A91452556-001-04-0::2.5::HTS002	2.5	estradiol-cypionate	estrogen receptor agonist	noncancer	ESR1	endocrinology	hypoestrogenism, menopause	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.872504293374	0.872504293374	0.590330119209442	0.60273481392	-8.67937385572215	4.42523739330619	0.000608761582819213	0.0142549176536719	-0.369118856812717	-0.195229491516399
ZFPM2	BRD-K04833372-001-06-2::2.5::HTS002	2.5	GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	targeted cancer	IGF1R, INSR	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.399294369044	-0.399294369044	-0.646726435305836	-0.593822379071	-3.93406437742485	28.7769511860906	0.00048329086448385	0.0116242001676534	-0.37610963216469	-0.118754500358982
ZFPM2	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-2.15903919473	-2.15903919473	-3.08243391545934	-3.12584681211	-9.61595640953586	157.028486501314	1.6840346467044e-17	2.21162660412689e-15	-1.1130666158728	-0.73372282558588
ZFPM2	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.718826133445	-0.718826133445	-1.50136116136226	-1.38879124785	-9.39019866803485	8.26596613452397	1.08636708998191e-05	0.000371711321884949	-0.973635586840402	-0.591434468994113
ZFPM2	BRD-K11630072-001-13-2::2.5::MTS010::PROS004_PR500	2.5	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.4727171346835	0.4727171346835	-0.246323530501539	-0.182730639513	-11.4467599419082	6.64801002176328	1.28115690336305e-05	0.000432491853742163	-0.869186354411325	-0.568894975958752
ZFPM2	BRD-K13606314-001-01-3::2.5::HTS002	2.5	P5091	ubiquitin specific protease inhibitor	targeted cancer	USP7	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.04483410581359	-0.04483410581359	-0.4840193436878	-0.4134526693685	-7.60379286759773	7.0374997207112	0.000122508972363197	0.00340649008012866	-0.575615483168246	-0.302754992580173
ZFPM2	BRD-K13949769-001-01-7::2.5::HTS002	2.5	tenovin-6	SIRT inhibitor	targeted cancer	SIRT1, SIRT2, SIRT3	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.4672558713875	-0.4672558713875	-1.27406866404989	-1.229883421555	-9.25820112483977	6.49193970347957	5.63025640086263e-05	0.00168138111208093	-1.01619444078546	-0.597431144539317
ZFPM2	BRD-K15519488-050-01-3::2.5::HTS002	2.5	CS-110266	dopamine receptor agonist	noncancer	SLC6A3	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.399912221672	0.399912221672	-0.121711662188581	-0.154725041554	-9.80498835211886	117.57464448621	6.00805102212836e-17	7.50594482496788e-15	-0.626978013650818	-0.416269754070343
ZFPM2	BRD-K19669037-001-01-1::1.25::HTS002	1.25	GGTI-298	GGTase inhibitor	targeted cancer	CDKN1A	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.2962079568635	0.2962079568635	-0.200536840285087	-0.14719250083	-9.31771463267078	44.7510699764457	4.78619650607064e-12	3.71566897212173e-10	-0.604136904271175	-0.389352690026
ZFPM2	BRD-K21528677-001-02-8::2.43672::HTS002	2.43672	desonide	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.398618353467	-0.398618353467	0.091518091146477	0.124628316908	9.77912289759171	5.24119934206298	0.00014595819969868	0.00398307550079176	0.363060193009814	0.61721269621714
ZFPM2	BRD-K23925186-001-02-8::2.50779::HTS002	2.50779	oridonin	BCL inhibitor	targeted cancer	BCL2	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.4881467311245	0.4881467311245	-0.244101358637177	-0.0866927101235	-12.0758882847695	190.211081749794	2.7197452187209e-25	7.10012512768856e-23	-0.851855830870318	-0.612640348653036
ZFPM2	BRD-K25244359-066-03-4::2.68145::HTS002	2.68145	apatinib	RET tyrosine kinase inhibitor	targeted cancer	CSK, KDR, KIT, RET	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.501231834026	0.501231834026	0.132910040586145	0.183294433483	-8.44948118298467	12.7427966889302	1.40789154574243e-06	5.62026424115159e-05	-0.46268812870932	-0.273955458170389
ZFPM2	BRD-K26026438-001-01-0::2.5::MTS006	2.5	tucatinib	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.496293980117	-0.496293980117	-0.237775790308758	-0.109165735913	6.41159848930421	73.9293654922129	1.20684424233088e-08	6.39618495584906e-07	0.178176771678486	0.338859607937999
ZFPM2	BRD-K33610132-001-02-9::2.5::HTS002	2.5	rociletinib	EGFR inhibitor	targeted cancer	EGFR	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.5264430459985	0.5264430459985	0.194431696733329	0.241806057711	-8.16752330766913	176.203825452249	5.86572814177486e-14	5.50677024484653e-12	-0.412235248612999	-0.251787449917342
ZFPM2	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.262201491527	0.262201491527	-0.241571419398659	-0.026104548309	-8.71017442726281	21.1805048347345	1.912256767929e-08	9.88548192989519e-07	-0.623989762028632	-0.383556059822686
ZFPM2	BRD-K38548312-001-01-0::2.5::HTS002	2.5	VER-49009	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-1.764576923775	-1.764576923775	-2.74471516917314	-2.671842712285	-11.1048745585897	187.687875462865	2.39359723939176e-22	4.86601160413593e-20	-1.15425124145248	-0.806025249343798
ZFPM2	BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500	0.15625	temsirolimus	mTOR inhibitor	targeted cancer	MTOR	oncology	renal cell carcinoma (RCC)	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.3008185087745	0.3008185087745	-0.213415142208878	-0.158274399371	-9.1209236177516	6.0269550805306	9.5159055878992e-05	0.00270674788155122	-0.652040038383262	-0.376427263583494
ZFPM2	BRD-K44067360-001-30-3::2.5::HTS002	2.5	flufenamic-acid	chloride channel blocker	noncancer	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.1720557914575	0.1720557914575	0.07141631811973	0.08403527726685	-3.35763233653661	81.1298340889698	0.00119891866066211	0.0259322875790744	-0.160275581742797	-0.0410033649327433
ZFPM2	BRD-K44827188-001-06-0::2.5::MTS010::PROS003_PR500	2.5	vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	targeted cancer	SMO	oncology	basal cell carcinoma (BCC)	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.5473639488775	0.5473639488775	0.0316601392450488	0.0567242940999	-16.9592891051228	3.41046034235416	0.000205456700702085	0.00541107510503529	-0.606210115338507	-0.425197503926395
ZFPM2	BRD-K44844162-001-01-6::2.5::HTS002	2.5	taselisib	PI3K inhibitor	targeted cancer	PIK3CA	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-3.089817761445	-3.089817761445	-1.31137151198419	-1.04970341453	14.1433361778941	3.67105747048801	0.000246212572572261	0.00636556024931727	1.41663336404333	2.14025913487828
ZFPM2	BRD-K45462423-001-03-7::2.5::HTS002	2.5	VU0361737	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.4339087521055	0.4339087521055	0.0780960571395579	0.1040664300715	-7.98058974387872	8.61044507442198	2.92056118240921e-05	0.00092012488264675	-0.457370304581556	-0.254255085350328
ZFPM2	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.1726860368145	0.1726860368145	-0.229167312432473	-0.187297921894	-8.46766872473973	3.8391364857565	0.00127475635642786	0.0273436003919964	-0.535822343505915	-0.267884354988031
ZFPM2	BRD-K51575138-001-13-2::2.5::HTS002	2.5	TPCA-1	IKK inhibitor	targeted cancer	IKBKB	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.2636197774885	-0.2636197774885	-0.0998127636520818	-0.09755826700195	3.68558976649977	193.896945499702	0.000296043181000414	0.00748238666752804	0.0761487682822214	0.251465259390615
ZFPM2	BRD-K53665955-001-03-0::2.5::HTS002	2.5	MK-5108	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-3.05304370627	-3.05304370627	-2.73636846978524	-2.65080783221	3.79186276366896	190.95021280779	0.000200478866892788	0.00529559219401829	0.151945934718579	0.481404538250947
ZFPM2	BRD-K53734668-003-02-0::2.65747::HTS002	2.65747	PRT062607	syk inhibitor	targeted cancer	FGR, MAP3K9, SYK	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.954123089513	-0.954123089513	-0.0550000350151882	-0.0448082329464	21.2582456962028	184.482175666873	1.7260236077575e-51	4.93249218436077e-48	0.815678462701744	0.982567646293879
ZFPM2	BRD-K56751279-300-01-4::0.15625::HTS002	0.15625	Y-39983	rho associated kinase inhibitor	noncancer	ROCK1, ROCK2	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	1.12661871149	1.12661871149	0.776734554491709	0.797329257919	-9.28501784674732	3.59026961363453	0.00123105925742484	0.0265284234450643	-0.459389354180006	-0.240378959816577
ZFPM2	BRD-K56981171-001-01-0::2.5::MTS006	2.5	brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	targeted cancer	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.5738520314975	0.5738520314975	-0.0773323262856903	-0.00736994010253	-13.741831513722	3.59400039217251	0.000309352396421758	0.00778846349966861	-0.788825816672708	-0.513542898893672
ZFPM2	BRD-K62627508-001-01-5::2.5::HTS002	2.5	idasanutlin	MDM inhibitor	targeted cancer	MDM2, TP53	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.2287511100355	-0.2287511100355	-1.11008819820881	-0.7188580200695	-6.77186336799866	5.2521784607394	0.000877156426311964	0.0197085710970769	-1.21111615433311	-0.551558022013511
ZFPM2	BRD-K67566344-001-07-5::2.5::HTS002	2.5	ku-0063794	mTOR inhibitor	targeted cancer	MTOR	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-1.99186600424	-1.99186600424	-1.75529777967192	-1.67073793274	3.71699704726044	192.922650220173	0.000264074398012053	0.00675968012080799	0.111038885375873	0.36209756376028
ZFPM2	BRD-K68488863-001-04-9::0.15625::HTS002	0.15625	ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	targeted cancer	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.7133075122735	0.7133075122735	0.510778879942768	0.514244743777	-7.17826306729242	9.24115532771905	4.53984287783754e-05	0.00138036598689749	-0.266100496256454	-0.13895676840501
ZFPM2	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.492326289109	0.492326289109	0.121089623124619	0.135505899737	-13.4634955588251	131.544745125031	1.63551480088695e-26	4.76922791509251e-24	-0.42578166338579	-0.316691668582971
ZFPM2	BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500	2.5	golvatinib	VEGFR inhibitor	targeted cancer	KDR, MET	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.4407409796885	0.4407409796885	-0.0840929968918617	0.0411624842104	-12.2406400719246	183.229266517315	1.45765557624403e-25	3.91011091365214e-23	-0.60942882282687	-0.440239130333853
ZFPM2	BRD-K70159787-001-01-1::2.5::HTS002	2.5	SMI-4a	Pim kinase inhibitor	targeted cancer	PIM1	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.947011566794	-0.947011566794	-0.629626319361312	-0.60780165798	5.60805587301088	60.3906332505485	5.39894499571619e-07	2.29365804159932e-05	0.204194405432569	0.430576089432808
ZFPM2	BRD-K79612754-001-19-1::2.62081::HTS002	2.62081	inosine	neurotrophic agent	noncancer	PARP1, PNP	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.7577634651445	-0.7577634651445	-1.40529727540899	-1.36932187497	-9.58332923025265	129.391236311746	9.14514082794751e-17	1.1174851131774e-14	-0.781216458120262	-0.513851162408727
ZFPM2	BRD-K81330143-001-04-8::2.38257::HTS002	2.38257	tideglusib	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.2820739954865	0.2820739954865	-0.276469611629489	-0.2593232641565	-8.31778832895378	3.71972740261058	0.00155514342722996	0.0324328437885345	-0.750656290862895	-0.366430923369083
ZFPM2	BRD-K81916719-001-13-9::2.5::HTS002	2.5	triclabendazole	microtubule inhibitor	noncancer	DNMT1	infectious disease	tapeworm	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-1.87079452237	-1.87079452237	-2.33715922932058	-2.3242666172	-5.98159309377337	184.415354741742	1.12420467912017e-08	5.97593414362962e-07	-0.620185955715795	-0.312543458185363
ZFPM2	BRD-K86930074-001-05-0::2.5::HTS002	2.5	cediranib	KIT inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-2.570074010455	-2.570074010455	-3.02246629817108	-2.830173101285	-4.17542589497519	9.59823518707714	0.00207865597753051	0.0414562798094819	-0.695179826861243	-0.209604748570921
ZFPM2	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.316732842935	0.316732842935	-0.498988240806823	-0.41754362105	-11.565272528338	3.1594575114776	0.00108548454025589	0.023732614100633	-1.03391044149154	-0.59753172599211
ZFPM2	BRD-K88677950-001-03-9::2.5::HTS002	2.5	PD-198306	MAP kinase inhibitor, MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.162779647634	-0.162779647634	-0.670606505128583	-0.5546333344115	-8.39409186010803	6.27995004088128	0.000121991602618493	0.00339433447080631	-0.654275428481124	-0.361378286508041
ZFPM2	BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500	2.5	bexarotene	retinoid receptor agonist	targeted cancer	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	-0.2184412725675	-0.2184412725675	0.027195397840498	0.0455215007673	11.2906488431528	183.388325599642	8.77690894828821e-23	1.85700505229779e-20	0.202712897527096	0.2885604432889
ZFPM2	BRD-K95523387-001-09-6::2.5::HTS002	2.5	OLDA	TRPV agonist	noncancer	GPR119	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.4784795777845	0.4784795777845	0.274136287514816	0.3623330707505	-3.63787738921864	16.1970884275469	0.00217672779538368	0.0431019855558748	-0.323302885636239	-0.0853836949031287
ZFPM2	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.171677756709	0.171677756709	-0.350468606136558	-0.28220904824	-9.95881377363689	4.27382560643545	0.000407606373554	0.00997851130068021	-0.664111450078898	-0.380181275612218
ZFPM2	BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500	2.5	brequinar	dihydroorotate dehydrogenase inhibitor	targeted cancer	DHODH	NA	NA	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.7018892972975	0.7018892972975	-0.0842762120526063	-0.0625986180944	-14.0361479482867	10.7819525846472	2.87203421390061e-08	1.44701509410227e-06	-0.909747678445963	-0.66258334025425
ZFPM2	BRD-K99383816-001-03-5::2.5::HTS002	2.5	ftorafur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	colorectal cancer	TE5, DMS273	OESOPHAGUS, LUNG	carcinoma (squamous_cell_carcinoma), carcinoma (small_cell_carcinoma)	0.1845194897425	0.1845194897425	0.0265716265684066	0.0625789324056	-4.43330467561066	14.1501043254084	0.000553386987528915	0.0131144272058917	-0.234285419332058	-0.0816103070161288
ZFYVE19	BRD-A14395271-074-17-8::2.5::HTS002	2.5	mesoridazine	dopamine receptor antagonist	noncancer	DRD2, HTR2A	neurology/psychiatry	schizophrenia	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.133743247266	0.133743247266	-0.00540492022123591	0.000253415549772	-4.32074916995222	40.4968012522309	9.82161020916485e-05	0.0027874151145658	-0.204211307215334	-0.0740850277591377
ZFYVE19	BRD-A19585813-003-03-3::2.5::HTS002	2.5	methylphenidate	dopamine-norepinephrine reuptake inhibitor	noncancer	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD), narcolepsy	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.6223317706305	0.6223317706305	0.253908627574055	0.248593111525	-12.7248240953061	187.3486554004	3.88564966108897e-27	1.17961388981804e-24	-0.425539135622237	-0.311307150490653
ZFYVE19	BRD-A24514565-001-09-7::2.5::HTS002	2.5	warfarin	vitamin K antagonist	noncancer	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.0307143284116	0.0307143284116	-0.124766719043992	-0.09418085429645	-4.23605735357865	98.2506392233477	5.13199858359766e-05	0.00154355336012336	-0.228316992615085	-0.0826451022960987
ZFYVE19	BRD-A58193911-003-18-7::2.5::HTS002	2.5	oxyphencyclimine	cholinergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.098793381835	-1.098793381835	-2.31441393351515	-2.14599876689	-10.6408474466368	129.316343548287	2.22049035330182e-19	3.46293276799548e-17	-1.44164383990552	-0.989597263454773
ZFYVE19	BRD-A60197193-001-14-6::2.5::HTS002	2.5	amisulpride	dopamine receptor antagonist	noncancer	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.417857254569	0.417857254569	0.0716727417178359	0.128125201883	-11.729935933964	143.208831040857	1.08624760468053e-22	2.28473368855322e-20	-0.40452172068601	-0.287847305016318
ZFYVE19	BRD-A60594020-034-01-1::2.5::HTS002	2.5	8-hydroxy-PIPAT	dopamine receptor ligand	noncancer	DRD2, DRD3	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.02844112064035	0.02844112064035	-0.224142380006217	-0.09818472346655	-4.47693998799764	178.666158100847	1.3463055210138e-05	0.000452986367367924	-0.363916405341207	-0.141250595951926
ZFYVE19	BRD-A83937277-001-10-5::2.5::HTS002	2.5	mephenytoin	hydantoin antiepileptic	noncancer	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.267815400118	-0.267815400118	-0.0667621383285523	-0.09044120254575	4.93084295093772	18.6284608882465	9.80153873841675e-05	0.00278282421018164	0.115595644319368	0.286510879259527
ZFYVE19	BRD-A84174393-236-07-1::2.5::HTS002	2.5	meloxicam	cyclooxygenase inhibitor	noncancer	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.3008377246695	-0.3008377246695	0.215341091205517	0.255620963174	11.1787469157491	21.8980338141747	1.61914964859699e-10	1.04684984927344e-08	0.420391834380806	0.611965797369229
ZFYVE19	BRD-A92630576-050-24-1::2.5::HTS002	2.5	trimebutine	opioid receptor agonist	noncancer	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.1774557431955	-0.1774557431955	-0.848549139739766	-0.797149374107	-8.09671851208129	3.69592459311572	0.0017570683750128	0.0359410868245961	-0.908880618623609	-0.433306174464924
ZFYVE19	BRD-K03273112-001-01-8::2.5::HTS002	2.5	1-azakenpaullone	glycogen synthase kinase inhibitor	noncancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.1816145050415	0.1816145050415	-0.724399284930296	-0.657905942127	-12.2328438837572	96.7946564235631	2.35035409390323e-21	4.38042645732334e-19	-1.05301433784132	-0.759013242102269
ZFYVE19	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.403870489426	-0.403870489426	-1.69484494430575	-1.35955217781	-8.72586316491012	6.49045264047242	8.07373738321472e-05	0.00233432626414006	-1.64646143963315	-0.935487470126348
ZFYVE19	BRD-K06543683-066-02-1::2.5::HTS002	2.5	bisindolylmaleimide-ix	PKC inhibitor	noncancer	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.380420432515	-2.380420432515	-3.71901886774721	-3.60790168659	-10.4906385856224	10.8996497541751	4.94684999144894e-07	2.11163794426859e-05	-1.61975845179974	-1.05743841866469
ZFYVE19	BRD-K06753942-001-14-5::2.5::HTS002	2.5	nobiletin	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.290903586921	0.290903586921	-0.0783545469259678	-0.0747677969197	-6.71907271075492	43.7889768839944	3.02086333104091e-08	1.5180741310168e-06	-0.480031183696459	-0.258485083997477
ZFYVE19	BRD-K07310275-001-02-5::2.5::HTS002	2.5	PF-04691502	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-4.71448720771	-4.71448720771	-3.91488816182917	-3.92269312667	8.23837154715355	171.730008638406	4.2853549594574e-14	4.08392993821941e-12	0.608018964442967	0.991179127318697
ZFYVE19	BRD-K07972848-001-02-0::2.5::HTS002	2.5	GSK2126458	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-5.280111545755	-5.280111545755	-3.84853662512663	-3.81318527776	16.4740947863717	165.783103568182	9.6888953311597e-37	7.46982463105082e-34	1.26000444901909	1.60314539223765
ZFYVE19	BRD-K08109215-001-06-4::2.5::MTS010::PROS002_PR500	2.5	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.6654397092515	-0.6654397092515	-0.167978265487455	-0.03477254501165	9.55492001061023	77.1025052915504	1.01413383001427e-14	1.02286253954414e-12	0.393792206424834	0.601130681103256
ZFYVE19	BRD-K11196887-001-22-0::2.49495::HTS002	2.49495	norfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.6990495214745	-0.6990495214745	-0.418961670698967	-0.37916191768	5.47942935351347	188.259080990728	1.35605887435697e-07	6.28145110183821e-06	0.179253641161993	0.380922060389074
ZFYVE19	BRD-K11630072-001-13-2::0.625::HTS002	0.625	carmofur	thymidylate synthase inhibitor	targeted cancer	TYMS	oncology	breast cancer, colorectal cancer	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.07508218811895	0.07508218811895	-0.277376081148097	-0.1988130745045	-7.11629650591823	152.920882002924	4.0200730421938e-11	2.78390382895107e-09	-0.450306358426719	-0.254610180107375
ZFYVE19	BRD-K11853856-001-01-7::2.5::HTS002	2.5	PJ-34	PARP inhibitor	targeted cancer	EEF2, PARP1, PARP15, PARP3	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.1262809524115	0.1262809524115	-0.258380352797389	-0.1509093731905	-6.93732230839474	88.2001557247424	6.39481754070107e-10	3.88160534885562e-08	-0.494849256952087	-0.274473353465692
ZFYVE19	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-3.08746846226	-3.08746846226	-1.91980640108444	-2.01595157397	11.5310557315948	5.50366376204289	4.61248478240829e-05	0.00140029687202831	0.914363202840103	1.42096091951101
ZFYVE19	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.5387933948145	-0.5387933948145	-1.65545261475056	-1.461946185705	-10.5781805469993	7.02423616507331	1.43966819526909e-05	0.000482051633582915	-1.36610038776865	-0.867218052103459
ZFYVE19	BRD-K13249881-001-02-3::2.5::HTS002	2.5	piperazine	benzodiazepine receptor agonist	noncancer	GABRB3	infectious disease	gastrointestinal roundworms	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.331573664619	0.331573664619	0.0333816661605462	0.0696303010169	-7.35734620925256	132.559472783677	1.75669310813323e-11	1.27414645405444e-09	-0.37836088013738	-0.218023116779527
ZFYVE19	BRD-K13810148-311-03-2::2.5::HTS002	2.5	givinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-4.22651669785	-4.22651669785	-3.51075295821202	-3.32713088666	4.81296291658754	10.4554235701789	0.000625624702817837	0.0146019293183321	0.386350303813054	1.0451771754629
ZFYVE19	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.407041229449	0.407041229449	-0.0476767988508135	0.0935597000564	-6.24032654733518	9.48816587062477	0.000120769377678728	0.0033629180133174	-0.618272359323932	-0.291163697275695
ZFYVE19	BRD-K17203476-001-01-9::2.5::HTS002	2.5	LY2874455	FGFR antagonist	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, KDR	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.67081686005	-1.67081686005	-2.87489257147253	-2.63264407289	-8.41870191319173	19.1375438182662	7.37314046818958e-08	3.52976954077866e-06	-1.50328265524028	-0.90486876760477
ZFYVE19	BRD-K21025364-001-05-6::2.43629::HTS002	2.43629	NVP-TAE226	protein tyrosine kinase inhibitor	targeted cancer	PTK2	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.460305623095	-2.460305623095	-3.0966227725037	-2.8622910827	-6.21713334668357	186.316018850219	3.24473816922307e-09	1.82962769553121e-07	-0.838228952208665	-0.43440534660873
ZFYVE19	BRD-K21670884-001-01-9::2.5::HTS002	2.5	cariporide	sodium/hydrogen exchanger inhibitor	noncancer	SLC9A1	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.426621669555	-1.426621669555	-1.86924501347919	-1.673362994515	-4.64180343535099	123.689887525342	8.67251096346644e-06	0.000301846476500292	-0.631364043308847	-0.253882644539527
ZFYVE19	BRD-K21937671-001-09-2::2.53426::HTS002	2.53426	loxistatin-acid	cysteine peptidase inhibitor	noncancer	CTSB	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.1883808665325	0.1883808665325	0.415525041713245	0.442474468431	7.34937166401829	11.1878414232651	1.31810477329317e-05	0.000444055451045507	0.159258268896038	0.295030081465452
ZFYVE19	BRD-K22127577-001-03-7::2.57578::HTS002	2.57578	crenolanib	PDGFR tyrosine kinase receptor inhibitor	targeted cancer	CSF1R, FLT3, KIT, PDGFRA, PDGFRB	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.11862858905	-1.11862858905	-2.88841481827803	-2.75215171608	-14.757645680107	13.3945617247406	1.13999263813975e-09	6.74767970560216e-08	-2.02809121829828	-1.51148124015779
ZFYVE19	BRD-K23363278-001-02-1::2.5::HTS002	2.5	CYT-997	tubulin polymerization inhibitor	chemo	TUBB	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.27840651558	-2.27840651558	-3.27752074713212	-3.04327234152	-6.95732104797845	6.87806890043681	0.000238145514770101	0.00617337808843264	-1.33991300903896	-0.658315454065275
ZFYVE19	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.63462044361	0.63462044361	0.370576582644601	0.3847237758685	-9.04379612603379	193.881926458835	1.57899359306034e-16	1.89593343309261e-14	-0.321626663310432	-0.206461058620366
ZFYVE19	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.035936970425	-2.035936970425	-2.81330083982744	-2.6496200301	-7.49094185595033	186.999771634333	2.63258554994101e-12	2.09988622379348e-10	-0.982081763508145	-0.572645975296732
ZFYVE19	BRD-K25340465-001-11-1::2.57636::HTS002	2.57636	OSI-930	KIT inhibitor, VEGFR inhibitor	targeted cancer	KDR, KIT	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.1017647626868	-0.1017647626868	-0.842913050225368	-0.742464669951	-12.3966906319767	174.528304262021	1.01743237444503e-25	2.75334928513167e-23	-0.859144861469576	-0.623151713607561
ZFYVE19	BRD-K25630527-001-03-8::2.5::HTS002	2.5	LY2784544	JAK inhibitor	noncancer	JAK2, JAK3	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.490405194493	-0.490405194493	-1.0845488156241	-0.892196306228	-6.51320464169974	5.82046435447261	0.000705462285640437	0.0162791802561401	-0.819033965735337	-0.369253276526862
ZFYVE19	BRD-K29542628-001-03-9::2.5::HTS002	2.5	1-naphthyl-PP1	src inhibitor	targeted cancer	SRC	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.05701973042	-2.05701973042	-1.33291472974641	-1.36979496737	8.3693871530344	5.64058532562717	0.00021828070685811	0.00571231814654357	0.509089085925186	0.939120915421996
ZFYVE19	BRD-K30480208-001-18-5::2.5::HTS002	2.5	torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	noncancer	SLC12A1	cardiology	edema, congestive heart failure, hypertension	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.3195989400115	-0.3195989400115	0.0331564907905677	0.1423741600205	5.38874752863686	5.50163320244212	0.00221084247787325	0.0437007892133261	0.188993097924278	0.516517763679858
ZFYVE19	BRD-K31866293-001-01-6::2.5::HTS002	2.5	TAK-632	RAF inhibitor	targeted cancer	BRAF	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.95316340263	-1.95316340263	-2.31232752563032	-2.045349051995	-3.47209630648595	164.539013362022	0.000659811466994688	0.0153154570412522	-0.563410966604427	-0.15491727939621
ZFYVE19	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.425942915621	-0.425942915621	-0.938018333707294	-0.797793160199	-7.31626562012646	158.278487364836	1.20253926142447e-11	8.92448190311098e-10	-0.650312931370533	-0.373837904802056
ZFYVE19	BRD-K34533029-001-08-5::2.5::HTS002	2.5	tyrphostin-AG-494	EGFR inhibitor	targeted cancer	EGFR	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.543865855553	0.543865855553	0.167117352310191	0.159843684784	-11.8832246659268	5.76536030565892	2.85070433830799e-05	0.000900366357390529	-0.455097756889222	-0.298399249596396
ZFYVE19	BRD-K35240538-001-26-2::2.5::HTS002	2.5	methylprednisolone	glucocorticoid receptor agonist	noncancer	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.03691370248456	0.03691370248456	0.430502249638636	0.4313451016155	6.09351477738232	7.61285298142334	0.000355385461377888	0.00883738375120796	0.243311720693991	0.543865373614162
ZFYVE19	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.56631003903	-1.56631003903	-2.59790785572307	-2.52528636523	-7.26879894312564	3.69807351581518	0.00256164334979367	0.0496190201100703	-1.43865234699761	-0.624543286388535
ZFYVE19	BRD-K40797222-001-01-8::2.5::HTS002	2.5	SC-12267	dihydroorotate dehydrogenase inhibitor	noncancer	IL17A	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.04206556238695	0.04206556238695	0.188653975900603	0.185775968658	5.40232596238801	9.01043053055116	0.000429983024342371	0.0104784345223736	0.0852171586418836	0.207959668385422
ZFYVE19	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.239659831515	-2.239659831515	-2.75154565107302	-2.75783530181	-5.91477104022018	186.001691511856	1.56446792491719e-08	8.18430182766844e-07	-0.682619113572697	-0.341152525543336
ZFYVE19	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.085797861995	-1.085797861995	-1.39508805081675	-1.171371713075	-4.07361981402469	87.1670525430392	0.000101704239266587	0.00287878604038144	-0.46019556476536	-0.158384812878139
ZFYVE19	BRD-K49027941-001-01-1::2.5::HTS002	2.5	PSB-1115	adenosine receptor antagonist	noncancer	ADORA1, ADORA2B, ADORA3	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.0760844779795	-0.0760844779795	0.118560231360088	0.179780985377	3.67159188401641	104.938800869299	0.000381086909657446	0.00940773741764232	0.0895275998206542	0.299761818858521
ZFYVE19	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.7849495845955	-0.7849495845955	-1.59514879823066	-1.48697544025	-9.33031363322823	73.9020686699121	4.01299623131822e-14	3.83802529791255e-12	-0.983225843046763	-0.637172584223559
ZFYVE19	BRD-K51350053-048-16-5::2.5::HTS002	2.5	toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	ESR1	oncology	breast cancer	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.178075560683	0.178075560683	-0.510328616509882	-0.436805913717	-9.41365589881702	20.2859012725962	7.59647910989921e-09	4.10318994744352e-07	-0.840809327060911	-0.535999027324853
ZFYVE19	BRD-K52313696-001-12-3::2.5::MTS010::PROS004_PR500	2.5	tacedinaline	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.48183198622	-0.48183198622	-0.00619019163212182	0.011267309880105	14.8700437134083	18.0357124509171	1.44606801713684e-11	1.06178250101035e-09	0.408450027259281	0.542833561916476
ZFYVE19	BRD-K56957086-001-06-3::2.5::HTS002	2.5	dacinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-6.18069736463	-6.18069736463	-5.58034438553176	-5.599173214095	5.53944485391943	5.14959082563737	0.00239688784401252	0.046825501296086	0.324175564984865	0.876530393211623
ZFYVE19	BRD-K58049875-001-04-7::2.5::HTS002	2.5	thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	noncancer	FOXM1	obstetrics/gynecology	mastitis	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.338010856483	-0.338010856483	-0.810008842589011	-0.698370160758	-6.9083930595684	31.4420670962136	8.84502385467744e-08	4.19227137936568e-06	-0.611263074552592	-0.33273289765943
ZFYVE19	BRD-K58122457-001-02-2::2.5::HTS002	2.5	hesperadin	Aurora kinase inhibitor	targeted cancer	AURKB	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.017605800715	-2.017605800715	-2.71237826018628	-2.71475551237	-6.19474908005773	10.9755549722234	6.83173552186291e-05	0.00200443400775545	-0.941691178678778	-0.447853740263785
ZFYVE19	BRD-K60230970-001-17-5::2.40205::HTS002	2.40205	MG-132	proteasome inhibitor	targeted cancer	PSMB1	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-5.72067159067	-5.72067159067	-6.16708244499263	-6.116258820345	-6.06755560102875	52.4968590720252	1.45877940280333e-07	6.72528996823908e-06	-0.5940134825116	-0.29880822613367
ZFYVE19	BRD-K61314889-001-04-4::2.5::HTS002	2.5	endo-IWR-1	PARP inhibitor	targeted cancer	TNKS, TNKS2	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.22420233097	-2.22420233097	-1.4345888597361	-1.402650367965	10.8594307136644	14.8526772194812	1.84678731589953e-08	9.56780465625889e-07	0.634497013952456	0.944729928515352
ZFYVE19	BRD-K62965247-001-04-9::2.5::HTS002	2.5	tipifarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, FNTB	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.04682594133	-1.04682594133	-1.47416068965011	-1.40587252118	-6.0037200117661	7.83604373089757	0.000349310697194129	0.00870247732406375	-0.592071978609707	-0.262597518030512
ZFYVE19	BRD-K63736853-001-04-8::2.5::HTS002	2.5	acipimox	cholesterol inhibitor	noncancer	HCAR2	endocrinology	hyperlipidemia	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.158806856423	0.158806856423	-0.174455328057666	-0.07625513394025	-6.78051579647152	187.193980602017	1.51930873757007e-10	9.84972542089099e-09	-0.430221211813554	-0.236303157147778
ZFYVE19	BRD-K64925568-001-01-8::2.5::HTS002	2.5	AMG-232	MDM inhibitor	targeted cancer	MDM2	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.209131705675	-0.209131705675	-1.08707149637188	-0.4202572111255	-7.66743541151669	184.472746061393	9.73255385406497e-13	8.11976852856322e-11	-1.10384239426294	-0.652037187130828
ZFYVE19	BRD-K66527818-001-02-6::2.5::HTS002	2.5	VU0364770	glutamate receptor positive allosteric modulator	noncancer	GRM4	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.02885467757245	-0.02885467757245	-1.15561686335426	-1.028958953375	-14.2075390365098	8.43897116383454	3.47108796785005e-07	1.51271820467941e-05	-1.30800253097809	-0.945521840585526
ZFYVE19	BRD-K69932463-001-10-6::2.5::HTS002	2.5	AZD8055	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-3.50659855664	-3.50659855664	-2.73333814630887	-2.73243511548	11.193850604041	24.2206377323599	4.64638123074322e-11	3.20349215473987e-09	0.630756984551331	0.915763836110924
ZFYVE19	BRD-K72703948-001-10-1::2.5::HTS002	2.5	ZM-447439	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.5953476646165	-0.5953476646165	-1.38011886322626	-1.23720066309	-11.5182340599626	192.667639648258	1.07697016645186e-23	2.44519002971887e-21	-0.919153425250974	-0.650388971968546
ZFYVE19	BRD-K78177893-001-02-4::2.5::HTS002	2.5	A-674563	AKT inhibitor	targeted cancer	AKT1, PKIA, PRKACA	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.008887564255	-2.008887564255	-2.68096193515612	-2.66704888005	-7.98955045048279	157.262320031156	2.70629393778787e-13	2.37817660267378e-11	-0.838223495888839	-0.505925245913392
ZFYVE19	BRD-K81074237-001-02-3::2.5::HTS002	2.5	azilsartan	angiotensin receptor antagonist	noncancer	AGTR1, AGTR2	cardiology	hypertension	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.651001181461	0.651001181461	0.27869728768964	0.273644438403	-8.99260157078536	6.58473671659979	6.18174966136783e-05	0.00183076996431022	-0.471467592436159	-0.273140195106562
ZFYVE19	BRD-K81225797-001-02-3::2.5::HTS002	2.5	SCH-58261	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-0.267895842643	-0.267895842643	0.0367921693736199	0.129465498685	5.09883803174131	6.7807439716469	0.00154299226846783	0.0322012704059714	0.162455154392095	0.446920869641145
ZFYVE19	BRD-K84466663-001-05-4::2.5::HTS002	2.5	nelarabine	DNA synthesis inhibitor, T cell inhibitor	chemo	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.935004148444	0.935004148444	0.604943401739	0.593873040614	-12.3306038995545	20.0778274918326	7.98082830123263e-11	5.35374944906069e-09	-0.385883122382212	-0.274238371027789
ZFYVE19	BRD-K86930074-001-05-0::2.5::HTS002	2.5	cediranib	KIT inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-2.27310613052	-2.27310613052	-3.0255278227065	-2.830173101285	-7.02781770025344	10.5157625239484	2.76996502553355e-05	0.000877192426060256	-0.989397227196209	-0.515446157176781
ZFYVE19	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-6.59809670792	-6.59809670792	-6.21035496424508	-6.171939349	6.01378529906949	32.800562070695	9.4818355441225e-07	3.88795165551221e-05	0.2565350697952	0.518948417554641
ZFYVE19	BRD-K89299012-001-06-0::2.5::HTS002	2.5	DCEBIO	potassium channel activator	noncancer	KCNN2, KCNN3, KCNN4	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.240063849055	-1.240063849055	-2.05146994773352	-1.8672769967	-9.05688168418509	175.103012994253	2.593568250328e-16	3.06606116671015e-14	-0.988221329833835	-0.634590867523208
ZFYVE19	BRD-K89704198-001-12-3::2.5::HTS002	2.5	vincamine	adrenergic receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.0262123521416	0.0262123521416	-0.195735487269536	-0.1128406004625	-4.9882454534537	192.473309777808	1.35708951294126e-06	5.43162723098388e-05	-0.309706614750347	-0.134189064071924
ZFYVE19	BRD-K95926480-003-03-6::2.5::HTS002	2.5	SRT1720	SIRT activator	noncancer	SIRT1	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	0.2465876075335	0.2465876075335	0.600793631922836	0.600417589144	9.67090180392221	152.688447889951	1.48940244569526e-17	1.96807729212959e-15	0.281846963406056	0.426565085372616
ZFYVE19	BRD-K98795921-001-01-7::2.5::HTS002	2.5	SB-2343	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-4.89729741336	-4.89729741336	-3.12386247799982	-3.215000704775	29.8973968948081	61.8440778986691	1.78478271766385e-38	1.6140535657982e-35	1.6548552564879	1.89201461423246
ZFYVE19	BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500	2.5	AZD2014	mTOR inhibitor	targeted cancer	MTOR	NA	NA	SKOV3, HCC1419	OVARY, BREAST	carcinoma (adenocarcinoma), carcinoma (ductal_carcinoma)	-1.796810654085	-1.796810654085	-0.599680526625086	-0.5106967244835	16.3875094564914	8.7130750320001	7.55761309040435e-08	3.61162911048668e-06	1.03104316617396	1.36321708874586
ZMPSTE24	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-3.50282055194	-3.50282055194	-4.28218393406262	-4.26036322773	-8.82332343886639	4.37237275472634	0.000601507477222168	0.0141158979618471	-1.01658504916268	-0.542141715082553
ZMPSTE24	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.1782643879345	-0.1782643879345	-1.03527803020696	-1.0089298839585	-15.1953389862485	37.5310240737324	1.284670677951e-17	1.70807805046253e-15	-0.971235880694656	-0.742791403850268
ZMPSTE24	BRD-K06749501-001-02-1::2.5::HTS002	2.5	GSK1838705A	insulin growth factor receptor inhibitor	targeted cancer	ALK, IGF1R, INSR, RPS6KA1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.531992233695	-1.531992233695	-0.219333015449018	-0.0999889784018	18.3092245592117	4.9042526491502	1.05281265971292e-05	0.000361268467088712	1.12727676250496	1.49804167398701
ZMPSTE24	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.593158599051	0.593158599051	-0.0496673589535087	0.0935597000564	-7.99661818243653	5.03572173664921	0.000477748215796804	0.0115089690169173	-0.849027785827617	-0.4366241301814
ZMPSTE24	BRD-K18779551-003-07-8::2.5::HTS002	2.5	bifemelane	acetylcholine release enhancer	noncancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.465157089513	-0.465157089513	0.024313376570593	0.0610865008582	11.0222368098644	4.36617368250591	0.000237496645324954	0.00615730234617781	0.370148223375509	0.608792708791677
ZMPSTE24	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.7258949897155	-0.7258949897155	-0.336370445178394	-0.200723129444	6.84201678508633	168.177910546651	1.3883092652496e-10	9.06074715321808e-09	0.27713258323831	0.501916505835901
ZMPSTE24	BRD-K20290250-001-02-1::2.46049::HTS002	2.46049	BIX-02188	MEK inhibitor	targeted cancer	MAP2K5	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.39756155312	-1.39756155312	-0.359787998275786	-0.151227527586	14.109093500486	168.786427200912	2.32013224007966e-30	9.58134148138792e-28	0.892570184171614	1.18297692551681
ZMPSTE24	BRD-K28352084-001-02-3::2.5::HTS002	2.5	CH5132799	PI3K inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.580825797695	-1.580825797695	-1.96589485883921	-1.89093805071	-5.17823615163593	124.312768325888	8.75207094309019e-07	3.6045784265211e-05	-0.532250576230951	-0.237887546057471
ZMPSTE24	BRD-K28392481-001-05-1::2.5::HTS002	2.5	AZD4547	FGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.08048930942035	-0.08048930942035	0.377101212879686	0.422629133595	10.4102474104845	41.9287076428452	3.40107283815038e-13	2.9583950500322e-11	0.368879702595698	0.546301342004375
ZMPSTE24	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-4.227674652785	-4.227674652785	-3.10834104206913	-3.10613635441	9.49731824300566	17.7027623067512	2.28162169549964e-08	1.16682819464267e-06	0.871425090067902	1.36724213136384
ZMPSTE24	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.48811367368	-1.48811367368	-3.00664975454618	-3.11792642927	-15.0397496875867	44.9479751156974	3.71585029740201e-19	5.67974779535696e-17	-1.72190292143154	-1.31516924030082
ZMPSTE24	BRD-K40331046-305-01-5::2.5::HTS002	2.5	CR8-(R)	CDK inhibitor	targeted cancer	CCNA2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-5.67433557643	-5.67433557643	-5.26139162236791	-5.161930725595	3.89750923545851	35.096948787339	0.000418165677784593	0.0102160072442601	0.197873771411718	0.628014136712471
ZMPSTE24	BRD-K40496271-396-01-1::2.34401::HTS002	2.34401	eltrombopag	thrombopoietin receptor agonist	noncancer	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.936812244023	-0.936812244023	-0.506974077488557	-0.419049148621	7.48838812150478	10.6818495722732	1.44011151539521e-05	0.000482051633582915	0.303039625828199	0.556636707240686
ZMPSTE24	BRD-K45293975-001-02-0::2.5::HTS002	2.5	7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	targeted cancer	CHEK1, MARK3, PDPK1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-5.10238041868	-5.10238041868	-3.73843498274552	-3.638458649165	13.2841190795273	165.912253613851	6.79800044666371e-28	2.24155175035844e-25	1.16122768684984	1.56666318501913
ZMPSTE24	BRD-K47114202-001-14-6::2.57945::HTS002	2.57945	chlorogenic-acid	antioxidant	noncancer	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.6031441452495	-0.6031441452495	-1.05678549526358	-0.967874485397	-5.42791498829292	7.12725316337571	0.000921843228173057	0.0206024752086656	-0.650553240897591	-0.256729459130571
ZMPSTE24	BRD-K49111258-003-29-7::2.5::HTS002	2.5	prazosin	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.1368575445545	-0.1368575445545	0.0300468206006346	0.0483026079462	6.19184175926555	43.7738099013224	1.79708322838092e-07	8.15686258482959e-06	0.112571138010842	0.221237592299427
ZMPSTE24	BRD-K50010139-001-02-3::2.5::MTS006	2.5	poziotinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.0646283166364	-0.0646283166364	-1.26150102724145	-0.921278111753	-9.36672975598902	3.29193699613731	0.00174832338627849	0.0357963701812841	-1.5838635880421	-0.809881833167988
ZMPSTE24	BRD-K52751261-001-06-1::2.5::HTS002	2.5	TAK-715	p38 MAPK inhibitor	noncancer	MAPK14	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.187586541021	-0.187586541021	0.141328449181378	0.155273340434	9.42779277455974	3.58998400698735	0.00116791890105277	0.0253436154848374	0.227527956722923	0.430302023681834
ZMPSTE24	BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500	2.49998	niraparib	PARP inhibitor	targeted cancer	PARP1	oncology	primary peritoneal cancer (PPC)	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.04864728494	-1.04864728494	-0.187124805867443	-0.0644082695915	14.5206684138176	6.20346612535881	5.05916912425125e-06	0.000184158739679288	0.71749176579223	1.00555319235288
ZMPSTE24	BRD-K71480163-001-01-4::2.5::HTS002	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.0308530461682	0.0308530461682	-0.666401286949146	-0.50591048476	-8.27548609700799	4.64684050650893	0.000594391760291522	0.0139841264096072	-0.918885552494294	-0.475623113740397
ZMPSTE24	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.1586098860385	0.1586098860385	-0.534004293667774	-0.376499820922	-9.97439891907944	5.04327868979703	0.000164821527479166	0.00445641896847259	-0.870653556716459	-0.51457480269609
ZMPSTE24	BRD-K72533376-001-01-2::2.5::MTS006	2.5	etoposide-phosphate	topoisomerase inhibitor	chemo	TOP2A	oncology	testicular carcinoma, small cell lung cancer	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.1102902273925	0.1102902273925	-0.199667631977329	-0.124222212564	-8.85727931902492	190.086612112594	5.78266452434742e-16	6.58201117811396e-14	-0.378985695708989	-0.24093002303067
ZMPSTE24	BRD-K74141488-003-11-2::2.5::HTS002	2.5	naftifine	fungal squalene epoxidase inhibitor	noncancer	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.636738964606	0.636738964606	0.359170131021063	0.330392231243	-11.5658915334549	194.931694358191	6.78619903041637e-24	1.57923914439751e-21	-0.324899692110275	-0.230237975059598
ZMPSTE24	BRD-K86525559-001-07-8::2.5217::HTS002	2.5217	AZD7762	CHK inhibitor	targeted cancer	CHEK1, CHEK2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-4.31881220521	-4.31881220521	-4.84759221071684	-5.01992364798	-4.79538028119854	9.68084039689372	0.000798292040814185	0.0181612498477511	-0.775576212188496	-0.281983798825194
ZMPSTE24	BRD-K87112191-001-04-5::2.5::HTS002	2.5	PP242	mTOR inhibitor	targeted cancer	MTOR, PASK	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.839998960335	-2.839998960335	-2.22654738588162	-2.16824610201	6.98350009088318	5.3039232075715	0.000726460557452938	0.0167043841667558	0.39148081419187	0.835422334714896
ZMPSTE24	BRD-K88506063-001-01-8::2.5::HTS002	2.5	KD025	rho associated kinase inhibitor	targeted cancer	ROCK2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-1.678359783035	-1.678359783035	-1.00785342332155	-0.931623279463	8.87484459704424	5.90581881617537	0.000124389541548435	0.00345161652648038	0.484921913976775	0.856090805450126
ZMPSTE24	BRD-K91543828-001-02-0::2.5::MTS006	2.5	pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	chemo	ADA	hematologic malignancy	hairy cell leukemia	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.1270728862715	-0.1270728862715	0.170600813280138	0.182655209923	10.5762040595453	4.11438985774701	0.000389835995910762	0.00959058300821369	0.220378384196518	0.374969014906759
ZMPSTE24	BRD-K92000912-001-12-6::2.5::HTS002	2.5	AM-251	cannabinoid receptor antagonist	targeted cancer	CNR1, GPR18, GPR55	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.5059473480545	-0.5059473480545	-0.122626805191035	-0.0809111569398	8.5039447209886	6.76970504195403	7.44932461551528e-05	0.00216753501971053	0.275994185726775	0.490646900000156
ZMPSTE24	BRD-K95142244-001-01-5::2.5::MTS006	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-2.429552391475	-2.429552391475	-1.3966449023928	-1.36288222555	10.4615480433986	6.26653890090838	3.36893481002589e-05	0.00104904900319343	0.793783954629028	1.27203102353538
ZMPSTE24	BRD-K95292280-001-01-3::2.5::HTS002	2.5	SB-657510	urotensin receptor antagonist	noncancer	UTS2R	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.7278279929375	-0.7278279929375	-0.0264676228516112	0.0202365059018	12.7344939195158	44.0726499748818	2.28162063395368e-16	2.71374843981497e-14	0.590367883891805	0.812352856279973
ZMPSTE24	BRD-K97714174-001-01-3::2.5::HTS002	2.5	P22077	ubiquitin specific protease inhibitor	noncancer	USP7	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	0.4765546062215	0.4765546062215	0.254790217396716	0.3142607574065	-6.19442618407017	193.01789102312	3.45627815109927e-09	1.94430614133059e-07	-0.292375073309237	-0.151153704340331
ZMPSTE24	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	COLO668, ES2	LUNG, OVARY	carcinoma (small_cell_carcinoma), carcinoma (clear_cell_carcinoma)	-0.134512132808	-0.134512132808	-0.0212710107502085	0.015242959648	4.02169414200831	190.995545764801	8.31520101131938e-05	0.00239734828834419	0.0577013832654076	0.168780860850175
ZMYND8	BRD-A28970875-300-04-9::0.625::HTS002	0.625	puromycin	protein synthesis inhibitor	noncancer	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.653292741155	-1.653292741155	-1.23062810937876	-1.016750192265	4.18319163696525	20.2945750356985	0.000446223785320958	0.0108311095904933	0.212097350374018	0.633231913178453
ZMYND8	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.248470907067	0.248470907067	0.0882397100542656	0.1234730068455	-6.09255029774196	190.977936157906	6.00549370337541e-09	3.28271221614575e-07	-0.212106054509494	-0.108356339515975
ZMYND8	BRD-A47706533-001-02-6::2.5::HTS002	2.5	buthionine-sulfoximine	glutathione transferase inhibitor	targeted cancer	GCLM	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.04555771592265	-0.04555771592265	0.210519324770825	0.242459349924	7.6280875477802	60.7389621687484	1.97019609836403e-10	1.26390350064731e-08	0.188943280400234	0.323210800986716
ZMYND8	BRD-A48300215-001-04-8::2.5::HTS002	2.5	ajmaline	sodium channel blocker	noncancer	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.236618816081	0.236618816081	0.0792577120466243	0.10011510474205	-3.27246688997868	163.347773088968	0.00130101087023003	0.0278287783239053	-0.252312152656389	-0.0624100554123619
ZMYND8	BRD-A81513827-001-03-6::2.5::HTS002	2.5	saxagliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.687977818137	-0.687977818137	-1.19376674778247	-1.043529721605	-6.50535658573835	12.3041633500889	2.58595423543961e-05	0.000825383447993351	-0.674727486335356	-0.336850372955592
ZMYND8	BRD-K04701033-001-03-9::2.5::MTS006	2.5	VE-822	ATR kinase inhibitor	targeted cancer	ATM, ATR, MTOR, PIK3CG	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.138136929115	-3.138136929115	-4.28600261074141	-4.26036322773	-16.2649803117113	25.7592637647149	4.59721167021541e-15	4.7993949345621e-13	-1.29299622125737	-1.00273514199546
ZMYND8	BRD-K07736136-001-04-6::2.51018::HTS002	2.51018	VX-702	p38 MAPK inhibitor	noncancer	MAPK11, MAPK12, MAPK14	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.1033518227415	0.1033518227415	0.258617380473009	0.2294815220965	5.5207421492142	73.8930614696737	4.77891672628499e-07	2.04484017374313e-05	0.0992258427359539	0.211305272727064
ZMYND8	BRD-K08109215-001-06-4::2.5::MTS010::PROS002_PR500	2.5	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.255067213135	-1.255067213135	-0.161426848777638	-0.03477254501165	22.2758234491252	179.676511040356	1.40877493063754e-53	5.03235536847687e-50	0.996762636042106	1.19051809267262
ZMYND8	BRD-K08893438-001-04-9::2.51845::HTS002	2.51845	CCG-50014	G protein signaling inhibitor	noncancer	RGS4, RGS8	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.760712279545	-1.760712279545	-1.48888348296585	-1.38645123972	3.56192871690623	20.6741066099426	0.00187694269463252	0.0379799141614325	0.112970476947309	0.43068711621099
ZMYND8	BRD-K13087974-001-02-5::2.5::HTS002	2.5	CGP-52411	EGFR inhibitor	targeted cancer	EGFR	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.040388475395	-3.040388475395	-1.92030993035573	-2.01595157397	13.4329802813292	37.9779471185007	5.2643425010747e-16	6.02403237540224e-14	0.951275817575154	1.28888127250339
ZMYND8	BRD-K14796088-003-26-8::2.5::HTS002	2.5	berberine	LDL receptor activator	targeted cancer	LDLR	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.93965847138	-1.93965847138	-1.28786109018844	-1.25961873039	12.8668481019907	190.682575998194	1.113269843382e-27	3.60432042692178e-25	0.55187709031479	0.751717672068321
ZMYND8	BRD-K15424032-001-03-6::2.5::HTS002	2.5	SB-228357	serotonin receptor antagonist	noncancer	HTR2A, HTR2B, HTR2C	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.208871617945	0.208871617945	-0.0728508989769925	0.0407112965926	-5.4847973490128	7.50620210692348	0.000726932485367722	0.0167098576422542	-0.401538809098193	-0.161906224745792
ZMYND8	BRD-K15766189-001-09-8::2.5::HTS002	2.5	cefdinir	bacterial cell wall synthesis inhibitor	noncancer	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.09619264047525	-0.09619264047525	0.262953946411526	0.263001454047	13.3304129162027	194.226797874069	3.27229801050736e-29	1.25240778623934e-26	0.306010351294558	0.412282822478994
ZMYND8	BRD-K16189898-003-03-3::2.5::HTS002	2.5	CHIR-99021	glycogen synthase kinase inhibitor	noncancer	CDK1, GSK3A, GSK3B, MAPK1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.400996585816	-0.400996585816	-0.0390346831795301	0.10879840342	6.02082201633931	186.326218667297	9.04624390910034e-09	4.85081914133992e-07	0.243361768931776	0.480562036341164
ZMYND8	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.231123738324	0.231123738324	-0.191744166376597	-0.123671466435	-10.58550051196	191.117259855962	6.67491498328798e-21	1.19818078178654e-18	-0.501663196893791	-0.344072612507403
ZMYND8	BRD-K17075857-001-18-4::2.5::HTS002	2.5	chloroxine	opioid receptor antagonist	noncancer	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.869414049141	-0.869414049141	-0.672523710417405	-0.654840996033	3.73271115875409	193.523198008721	0.000248970417094191	0.00642755727841254	0.0928569937189337	0.300923683728256
ZMYND8	BRD-K17894950-001-14-3::2.5::HTS002	2.5	indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CDK1, CDK5, GSK3A	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.414879630871	-0.414879630871	-0.0948727509313261	-0.04443726691935	7.76605845101333	188.409234028505	5.0417745767309e-13	4.30860647231323e-11	0.238722821247001	0.401290938632347
ZMYND8	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.508764061386	0.508764061386	0.321247040972773	0.339932692016	-5.143089315315	10.0329479652118	0.000431263226589575	0.0105036609195133	-0.268718808435723	-0.106315232390732
ZMYND8	BRD-K21528677-001-02-8::2.43672::HTS002	2.43672	desonide	glucocorticoid receptor agonist	noncancer	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.176983477263	-0.176983477263	0.089244912929	0.124628316908	5.39004945884736	5.76123372440074	0.00191058998011423	0.0385552057101877	0.144144524060941	0.388312256323059
ZMYND8	BRD-K24187789-001-01-7::2.5::HTS002	2.5	VU0238429	acetylcholine receptor allosteric modulator	noncancer	CHRM5	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-2.235033481665	-2.235033481665	-2.81117146537567	-2.6496200301	-5.30992895874137	81.0187521296964	9.38929909453483e-07	3.85443226514567e-05	-0.792022198623874	-0.360253768797474
ZMYND8	BRD-K26619122-001-02-1::2.5::HTS002	2.5	thiocolchicoside	GABA receptor antagonist	noncancer	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.306823971137	0.306823971137	0.156766919268437	0.1631740037055	-5.94251890034122	133.854452938793	2.29668955775925e-08	1.17397370909845e-06	-0.200000459333876	-0.100113644403249
ZMYND8	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.2112074739635	-0.2112074739635	-0.031007723573477	-0.0206189181826	5.99232858782714	6.86791254569936	0.000587396362512318	0.0138377747835681	0.108813205801819	0.251586294978227
ZMYND8	BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.3433392286935	0.3433392286935	-0.407530111862061	-0.2809944464045	-11.9663541724709	96.3175703559596	9.22878120275482e-21	1.6347069805002e-18	-0.875418649936283	-0.626320031174839
ZMYND8	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.118303874265	-0.118303874265	-0.880639221604253	-0.7074523288895	-8.4196694051642	188.13550011083	9.46569596398239e-15	9.57872120049283e-13	-0.940943723737488	-0.583726970941017
ZMYND8	BRD-K37561857-001-15-5::2.5::HTS002	2.5	zardaverine	phosphodiesterase inhibitor	noncancer	PDE4D	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.853989614665	-3.853989614665	-2.6048443634149	-2.424137198535	10.1675621753011	4.53113080908365	0.000273611933930937	0.00697300501634765	0.923247080815314	1.57504342168488
ZMYND8	BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500	0.625	ganetespib	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.346821708155	-1.346821708155	-1.72562315052731	-1.77978641517	-3.88955499761353	23.7697414637741	0.000705777514385664	0.0162829482110619	-0.579906382144119	-0.177696502600496
ZMYND8	BRD-K45446451-001-05-0::2.5::HTS002	2.5	JZL-184	monoacylglucerol lipase inhibitor	targeted cancer	MGLL	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.598073158185	-0.598073158185	-0.0436894778026046	-0.06430876639615	10.81964515355	3.231165129295	0.00120193564537624	0.0259896756394112	0.397724614939449	0.711042745825342
ZMYND8	BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.639715669672	-0.639715669672	-0.258212079219824	-0.219779888934	9.96101262556564	53.7969198687132	8.18338315937909e-14	7.57639883009313e-12	0.304710717316732	0.45829646358762
ZMYND8	BRD-K51313569-003-03-3::2.5::HTS002	2.5	palbociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.27538704815	-1.27538704815	-0.75254997470224	-0.730954040019	7.24746245793057	21.6441493983748	3.22334603041876e-07	1.41395114890222e-05	0.373083659025976	0.672590487869544
ZMYND8	BRD-K58529924-001-01-5::2.5::MTS006	2.5	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.857869134046	-0.857869134046	-1.18699640758702	-1.12103485225	-4.90732538805565	10.8614708825198	0.000483785219223442	0.011632174360662	-0.476974220900653	-0.181280326181394
ZMYND8	BRD-K59325863-001-02-8::2.5::HTS002	2.5	delanzomib	proteasome inhibitor	targeted cancer	CMA1, CTSG, CYP3A4, ELANE	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-4.30362256113	-4.30362256113	-5.59854552122921	-5.54901350857	-12.3019277378321	4.75078126302871	8.77090060563254e-05	0.00251620714215582	-1.56983262505761	-1.02001329514081
ZMYND8	BRD-K61097567-001-08-5::2.5::HTS002	2.5	SB-218795	tachykinin antagonist	noncancer	TACR3	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.20105334782	-1.20105334782	-0.362689321474732	-0.394478559639	11.404464416	2.69173620179748	0.0023516586101229	0.0460740241194759	0.588504203580905	1.08822384910963
ZMYND8	BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500	2.5	capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	chemo	TYMS	oncology	breast cancer, colorectal cancer	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.06117547534905	-0.06117547534905	-0.143047028278827	-0.139438991422	-4.2853869494852	188.542726318152	2.9061298710206e-05	0.000916116942382667	-0.119558218867999	-0.0441848869915549
ZMYND8	BRD-K62814476-001-03-3::2.5::HTS002	2.5	BMS-265246	CDK inhibitor	targeted cancer	CDK1, CDK2	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.741901314785	-3.741901314785	-2.52407652279593	-2.448908605325	9.91847628997588	3.62504099939095	0.000935094493638368	0.0208746867750253	0.862556239446388	1.57309334453175
ZMYND8	BRD-K64785675-001-04-0::2.5::HTS002	2.5	TG100-115	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.358391393389	0.358391393389	0.143435123063024	0.15713254048	-7.64618007981593	37.0452431233765	3.94298676414158e-09	2.20134516845976e-07	-0.271916061481836	-0.157996479170117
ZMYND8	BRD-K65814004-003-02-9::2.5::HTS002	2.5	diphenyleneiodonium	nitric oxide synthase inhibitor	targeted cancer	NOS2, NOS3	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-3.649380397985	-3.649380397985	-2.93337240755903	-2.87845710522	7.76648424708075	35.8315828736052	3.43759120331139e-09	1.93480957199193e-07	0.529003356886579	0.903012623965366
ZMYND8	BRD-K67298865-001-09-0::0.625::HTS002	0.625	SB-431542	TGF beta receptor inhibitor	targeted cancer	ACVR1C, TGFBR1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.388520804612	0.388520804612	0.142653189204887	0.0968721731692	-6.86288268021549	7.08476189307003	0.000226520639679372	0.00590219840026937	-0.330376921672692	-0.161358309141535
ZMYND8	BRD-K68346641-001-01-4::2.5::HTS002	2.5	amsacrine	topoisomerase inhibitor	chemo	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-2.579948921305	-2.579948921305	-3.14019668243693	-3.04544241525	-4.7479613395872	21.9400324186125	9.78077686040339e-05	0.00277729746119952	-0.804998468520441	-0.315497053743411
ZMYND8	BRD-K68567222-001-01-2::2.5::HTS002	2.5	BVT-948	tyrosine phosphatase inhibitor	noncancer	PTPN1, PTPN11, PTPN2	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.0086288366703795	-0.0086288366703795	0.341037609302901	0.377734553397	11.0658116506156	81.0883547601551	7.04476221448634e-18	9.60494173453335e-16	0.286795770451078	0.412537121495483
ZMYND8	BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.020958262015	0.020958262015	-0.730589830206567	-0.60872932846	-6.55736822524843	8.46374578314425	0.000137721909274624	0.00377803648955855	-1.01334252363246	-0.489753660810678
ZMYND8	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.575776122178	0.575776122178	0.307547170713234	0.289065772439	-10.1938929180081	51.4470491359156	6.03420932699437e-14	5.65750678410051e-12	-0.321042778863495	-0.215415124066037
ZMYND8	BRD-K70821460-300-02-4::2.5::HTS002	2.5	4-methylhistamine	histamine receptor agonist	noncancer	HRH4	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.199186222087	-0.199186222087	0.48422591262697	0.473971299308	20.128740369382	12.1863228760152	1.01128127388998e-10	6.69178462956362e-09	0.609562206703313	0.757262062724627
ZMYND8	BRD-K72093121-001-16-3::2.5::HTS002	2.5	vidarabine	antiviral	noncancer	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.023498783625825	0.023498783625825	0.223420093637483	0.235603358555	6.04523174275494	5.16163566377733	0.00159654301435014	0.0331639336812028	0.115704330278155	0.284138289745161
ZMYND8	BRD-K78431006-001-10-2::2.5::HTS002	2.5	crizotinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-1.549344806705	-1.549344806705	-1.17104585679511	-1.07734518699	4.87545150582684	11.5045515576222	0.000430788285271374	0.0104944785626197	0.208428170779676	0.548169729040103
ZMYND8	BRD-K80060353-303-03-9::2.4619::HTS002	2.4619	IEM1754	glutamate receptor antagonist	noncancer	GRIA1	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.338025207771	0.338025207771	-0.126428322327525	-0.118001057117	-14.5901342336858	23.5787220255557	2.68087359166909e-13	2.35873955676865e-11	-0.530216607310113	-0.398690452886937
ZMYND8	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.0567323755047	0.0567323755047	-0.104525319764339	-0.0756772814281	-4.4392906676648	10.6945214016226	0.00106654827434559	0.0233614946440692	-0.241488223379695	-0.0810271671583833
ZMYND8	BRD-K83003151-057-02-4::2.34747::HTS002	2.34747	alogliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.576280047859	0.576280047859	0.2427819798623	0.320568591806	-7.9807607877697	104.833214365057	1.94488241244946e-12	1.57299887765238e-10	-0.416357001312431	-0.250639134680968
ZMYND8	BRD-K85872723-001-15-9::2.5::HTS002	2.5	kynurenic-acid	glutamate receptor antagonist	noncancer	GPR35, GRIN1, GRIN2A, GRIN2B	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.661797953024	-0.661797953024	-0.145574042824538	-0.137644446714	11.1536114709495	6.40651018300326	1.96653488070468e-05	0.000641921191663957	0.404692523580287	0.627755296818637
ZMYND8	BRD-K89299012-001-06-0::2.5::HTS002	2.5	DCEBIO	potassium channel activator	noncancer	KCNN2, KCNN3, KCNN4	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-2.792548274805	-2.792548274805	-2.03402630250038	-1.82556226868	7.04487089906035	9.65237316165051	4.22204526897408e-05	0.00129253926646757	0.517441713228872	0.999602231380377
ZMYND8	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.3306993789305	-0.3306993789305	-0.0910279300130694	-0.0408206395104	6.30666197270665	6.44060940394414	0.000561213997263304	0.0132778932353954	0.148202200826096	0.331140697008766
ZMYND8	BRD-K93441486-067-12-8::2.5::HTS002	2.5	diphemanil	acetylcholine receptor antagonist	noncancer	CHRM3	neurology/psychiatry	spasms	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.2157830923215	0.2157830923215	0.132561567752537	0.147275600233	-3.2582396859199	156.239366714252	0.00137549379709395	0.0291514100699445	-0.133673451074767	-0.032769598063159
ZMYND8	BRD-K95773607-004-03-8::2.5::HTS002	2.5	darifenacin	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	-0.543561368615	-0.543561368615	-0.342899938143712	-0.279710660695	4.76474742785734	25.2201218240785	6.71518984139355e-05	0.00197212924570573	0.113964887062712	0.287357973879865
ZMYND8	BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500	2.49999	motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT	NA	NA	MCF7, KYSE410	BREAST, OESOPHAGUS	carcinoma, carcinoma (squamous_cell_carcinoma)	0.2966315991645	0.2966315991645	0.0665283249140781	0.0390021562258	-10.6991934447123	155.782172318294	2.24881265395919e-20	3.85897331713707e-18	-0.272585457005727	-0.187621091495117
ZNF217	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.156140134483	-0.156140134483	0.256680141759129	0.256070233499	11.710465351863	4.98854556084076	8.09932036399028e-05	0.00234140711396503	0.322138857692141	0.503501694792117
ZNF217	BRD-A13964793-001-02-6::2.5::HTS002	2.5	TC1	beta-secretase inhibitor	noncancer	BACE1	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.1728523744395	-0.1728523744395	0.17668479467062	0.161263687573	12.0137725641228	13.347253312584	1.5526781741695e-08	8.12659243935471e-07	0.286847709144227	0.412226629076013
ZNF217	BRD-A14344385-001-03-2::2.5::HTS002	2.5	IDRA-21	glutamate receptor positive allosteric modulator	noncancer	GRIA1, GRIA2, GRIA3, GRIA4	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.2363601259755	0.2363601259755	0.141020514659954	0.114657353	-3.56028469274574	129.947207758329	0.000518258585778261	0.0123708480266476	-0.148318166415885	-0.0423610562152073
ZNF217	BRD-A43671941-003-11-9::2.5::HTS002	2.5	oxprenolol	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	angina pectoris, hypertension, cardiac arrythmia	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.817878102025	-1.817878102025	-0.392244162790434	-0.38193178245	24.4071941733404	2.21174018598751	0.000983839697943844	0.0218219371438069	1.19601947290518	1.65524840556395
ZNF217	BRD-A49765801-001-04-1::2.5::HTS002	2.5	fludroxycortide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.32202920898	-0.32202920898	-0.0787428567428919	-0.05385103964535	4.76425336982348	7.50463271475679	0.00169284081316221	0.034870243022032	0.124163578972121	0.362409125502095
ZNF217	BRD-A81541225-001-06-8::2.5::HTS002	2.5	oligomycin-a	ATP synthase inhibitor, ATPase inhibitor	noncancer	ATP5A1	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-2.064970920345	-2.064970920345	-1.11526391961434	-1.02154011458	12.2544028538897	4.27806296125327	0.00017126967955923	0.00461098595028892	0.739939600146482	1.15947440131484
ZNF217	BRD-K03765900-001-01-9::2.5::MTS006	2.5	XL-647	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, EPHB4, ERBB2, FLT4, KDR	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.595361678524	-0.595361678524	-1.17282562957997	-0.823393929272	-6.7003876852422	161.387971454853	3.29605829175082e-10	2.06622075932337e-08	-0.747657046985838	-0.407270855126105
ZNF217	BRD-K05445342-001-05-3::2.56563::HTS002	2.56563	WP1066	STAT inhibitor	targeted cancer	STAT3	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-5.82046235895	-5.82046235895	-5.15767863154785	-5.11032297983	11.347942984104	190.943767969064	3.82310733405842e-23	8.34422374543183e-21	0.547580631452347	0.777986823351944
ZNF217	BRD-K07310275-001-02-5::2.5::HTS002	2.5	PF-04691502	mTOR inhibitor, PI3K inhibitor	targeted cancer	MTOR, PIK3CA	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-5.862155986	-5.862155986	-3.90199300701692	-3.92269312667	17.953659152395	16.1383675413358	4.32472524691009e-12	3.38413303192768e-10	1.72887496121977	2.19145099674639
ZNF217	BRD-K08248804-001-01-8::2.5::HTS002	2.5	LCL-161	XIAP inhibitor	targeted cancer	BIRC2, XIAP	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.514150904948	-0.514150904948	-1.26464304189618	-0.9430769633885	-5.96305353523317	5.42389113707875	0.00142972141242913	0.0301753580112774	-1.06655884553854	-0.434425428357826
ZNF217	BRD-K08303368-001-10-0::2.5::HTS002	2.5	chlorpyrifos	acetylcholinesterase inhibitor	noncancer	ACHE	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.05243412924735	0.05243412924735	0.293296680561292	0.280025726935	9.47810079141784	77.4820220405786	1.36086416954181e-14	1.35914565048335e-12	0.190264756199387	0.291460346428496
ZNF217	BRD-K09132007-001-07-5::2.5::HTS002	2.5	D-4476	TGF beta receptor inhibitor	noncancer	CSNK1A1, CSNK1D, TGFB1	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.149501154423	0.149501154423	0.278833903774285	0.26768413301	4.79151144328536	188.15339735813	3.34911790111528e-06	0.000125910031683588	0.0760868070022002	0.18257869170037
ZNF217	BRD-K14560436-001-01-4::2.5::HTS002	2.5	TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	targeted cancer	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-2.77538467426	-2.77538467426	-3.74644668344117	-3.62828968956	-7.51584503233681	24.7901497024158	7.59447327814847e-08	3.62843482664352e-06	-1.2372727165917	-0.704851301770633
ZNF217	BRD-K15179879-001-03-2::0.00976562::HTS002	0.00976562	carfilzomib	proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.227388750989	-0.227388750989	-1.11152110687712	-0.898661589303	-7.06060844379912	7.16098009599674	0.000180237018601919	0.00482513364475778	-1.1788875621401	-0.589377149636138
ZNF217	BRD-K15916496-001-27-9::2.5::HTS002	2.5	clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	noncancer	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.197920349024	0.197920349024	0.333537967999861	0.346280454324	4.42447778500203	8.55912215912424	0.00187676869206364	0.0379799141614325	0.0657304503161536	0.205504787635569
ZNF217	BRD-K18910433-001-36-6::2.58082::HTS002	2.58082	estradiol	estrogen receptor agonist	noncancer	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.0315838447932	-0.0315838447932	0.310898945553057	0.326005969483	11.4162494876627	166.758895544464	1.13367939329802e-22	2.38216049692324e-20	0.28325484844456	0.401710732247953
ZNF217	BRD-K19761926-001-03-6::2.44857::HTS002	2.44857	eplerenone	cytochrome P450 inhibitor	noncancer	NR3C2	cardiology	congestive heart failure, hypertension	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.200156557239	0.200156557239	-0.879670866084221	-0.799528598077	-12.0855926849696	9.75047907419997	3.46887138790617e-07	1.51205966178268e-05	-1.27960062065461	-0.880054225991829
ZNF217	BRD-K26756394-001-02-2::2.5::HTS002	2.5	VE-821	ATR kinase inhibitor	targeted cancer	ATR	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.386444454744	-0.386444454744	-0.112355738201755	-0.0474319307103	5.91741080508568	11.4561209665212	8.52753865458262e-05	0.00245328702321884	0.172634266095407	0.375543166989083
ZNF217	BRD-K28907958-001-04-3::2.5::HTS002	2.5	CD-437	retinoid receptor agonist	targeted cancer	RARG	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-5.176690195135	-5.176690195135	-4.19320493431239	-4.10711798107	10.4993214791717	158.041188417662	6.77994123954047e-20	1.10757471488527e-17	0.798476159112236	1.16849436253298
ZNF217	BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500	2.5	abemaciclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.3851445993605	-0.3851445993605	-0.693073674648194	-0.621232482709	-6.34833574485982	188.027478725744	1.59119143652859e-09	9.26483209453234e-08	-0.403613936335538	-0.212244214239849
ZNF217	BRD-K33818169-003-04-6::2.5::HTS002	2.5	GW-3965	LXR agonist	noncancer	NR1H2, NR1H3	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.546399182248	0.546399182248	0.037236774162274	0.143970790547	-9.13760263043354	5.17318246357178	0.000219619101576067	0.00574033444167034	-0.650969176876702	-0.36735563929475
ZNF217	BRD-K34851558-001-02-3::2.5::HTS002	2.5	parthenolide-(-)	NFkB pathway inhibitor	targeted cancer	HDAC1	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.4941660590585	-0.4941660590585	0.032018159753725	0.056211415311	15.4347603821189	130.609425104777	3.1092555995553e-31	1.3854545600771e-28	0.458742490344879	0.593625947279571
ZNF217	BRD-K37270826-001-27-6::2.65941::HTS002	2.65941	mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	noncancer	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.169367001804	0.169367001804	-0.181513426073108	-0.13613940777	-8.48726932700811	10.1348353696676	6.40149478571935e-06	0.000228632890506323	-0.44283022834638	-0.258930627407835
ZNF217	BRD-K38332599-001-01-3::2.5::HTS002	2.5	uprosertib	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-3.95148696088	-3.95148696088	-2.98085526986346	-3.07991378512	10.2947037002394	190.005501990069	4.92582141034733e-20	8.20953636903836e-18	0.784652758036279	1.15661062399681
ZNF217	BRD-K38527262-300-01-0::2.5::MTS006	2.5	atiprimod	JAK inhibitor, STAT inhibitor	targeted cancer	JAK2, STAT3	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.07016253247845	0.07016253247845	-1.38327103400259	-1.00119520354	-9.87623087216024	3.57642967227905	0.00101123677900104	0.0223463622648225	-1.88183940290414	-1.02502773005795
ZNF217	BRD-K40718343-001-02-6::2.5::HTS002	2.5	AEE788	EGFR inhibitor, VEGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.03850439117925	-0.03850439117925	-0.396160752392672	-0.1963749895675	-4.6907025254292	10.822621619096	0.000689540926829023	0.0159443971632687	-0.525813115492848	-0.189499606933997
ZNF217	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-3.358296426435	-3.358296426435	-2.73958162331986	-2.72063669108	6.36136804140193	21.2585470615458	2.48185157415739e-06	9.536263285005e-05	0.416598579174861	0.820831027055418
ZNF217	BRD-K42973005-001-04-0::2.5::HTS002	2.5	CHIR-98014	glycogen synthase kinase inhibitor	noncancer	GSK3A, GSK3B	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.661712679368	0.661712679368	0.365317617060962	0.394038132066	-6.13194740256468	15.0249766044235	1.90509726163304e-05	0.00062395719894338	-0.39940632834449	-0.193383796269585
ZNF217	BRD-K47832606-001-30-1::2.5::HTS002	2.5	floxuridine	DNA synthesis inhibitor	chemo	TYMS	oncology	colorectal cancer	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.75257443324	-1.75257443324	-2.24534891555851	-2.140330076935	-5.87561482220821	4.89627384712822	0.00217541090730448	0.0430798895270869	-0.709744323497748	-0.275804641139276
ZNF217	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.0855507494302	0.0855507494302	0.349230973141421	0.3889604534415	7.55132147573821	36.3393549391889	5.93035497344678e-09	3.24826744468151e-07	0.192885339105216	0.334475108317227
ZNF217	BRD-K48443249-001-01-0::2.5::HTS002	2.5	CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.604561039245	0.604561039245	-0.372284029000305	-0.243490121847	-14.7430313177343	45.9396180360383	4.91118001945065e-19	7.41273452386505e-17	-1.11022041292817	-0.84346972356244
ZNF217	BRD-K49027941-001-01-1::2.5::HTS002	2.5	PSB-1115	adenosine receptor antagonist	noncancer	ADORA1, ADORA2B, ADORA3	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.284976393195	-1.284976393195	0.13148955665651	0.179780985377	28.0084633899257	178.080675677551	3.71853851447482e-67	4.42772578482707e-63	1.3166668952424	1.51626500446062
ZNF217	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.484641451695	-1.484641451695	-1.83317581919197	-1.58248812639	-3.67845375011961	189.217814572646	0.000305752179886977	0.00770596883384243	-0.535436833926616	-0.161631901067327
ZNF217	BRD-K50140147-001-10-1::2.5::HTS002	2.5	NVP-TAE684	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, INSR	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-3.068331626335	-3.068331626335	-1.79243423512481	-1.63753619039	14.5303185988433	79.72449528966	4.08713971949448e-24	9.67059327858463e-22	1.10114200518131	1.45065277723907
ZNF217	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.499678070175	-0.499678070175	-0.22212685057918	-0.176181988507	8.17594841341679	160.627368313483	8.35180799772357e-14	7.71566662217283e-12	0.210510676349125	0.344591762842515
ZNF217	BRD-K51791723-003-01-7::2.5::MTS010::PROS004_PR500	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-2.6409468423	-2.6409468423	-2.22962135611866	-2.42069348361	5.21372312972953	37.9723966648103	6.81033798406757e-06	0.000241864611398048	0.251611444717033	0.571039527645655
ZNF217	BRD-K54606188-001-13-1::2.5::HTS002	2.5	JQ1-(+)	bromodomain inhibitor	targeted cancer	BRD4, BRDT	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.182189797955	-1.182189797955	-0.609653933804943	-0.573831164789	7.97024257958291	190.819806419183	1.40835787704293e-13	1.27579009056946e-11	0.430844815491262	0.714226912808851
ZNF217	BRD-K56483981-342-06-4::2.5::HTS002	2.5	chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	noncancer	MIF	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.1201050637295	0.1201050637295	0.265425288517354	0.2788714906115	5.11025654920253	189.653398474734	7.81580246569515e-07	3.24956959586804e-05	0.0892268381145077	0.2014136114612
ZNF217	BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500	0.15625	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-2.602539621355	-2.602539621355	-2.00182343720024	-2.19151625043	6.83685641751344	140.509026030143	2.27878548157314e-10	1.44971746357996e-08	0.427009061131578	0.774423307177942
ZNF217	BRD-K68507560-003-24-6::2.5::HTS002	2.5	dicycloverine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.08661366192725	0.08661366192725	0.232892257169094	0.2203060574785	4.61656451871267	158.537771611436	8.01410212454365e-06	0.000281213898862363	0.0836982652637258	0.208858925219963
ZNF217	BRD-K69776681-001-03-8::2.5::HTS002	2.5	volasertib	PLK inhibitor	targeted cancer	PLK1	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.90648389874	-1.90648389874	-2.58911727306751	-2.40345273405	-5.37797450023353	31.7251348129338	6.78452990316353e-06	0.000240987986346559	-0.941271883576077	-0.423994865078951
ZNF217	BRD-K70159787-001-01-1::2.5::HTS002	2.5	SMI-4a	Pim kinase inhibitor	targeted cancer	PIM1	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.850796279505	-1.850796279505	-0.619960172701301	-0.60780165798	17.7240371152268	5.4513220243832	4.98173398582001e-06	0.000181617632836676	1.05667845004956	1.40499376355784
ZNF217	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.171897707177	-0.171897707177	-0.793902334017726	-0.646845557406	-6.85847243756366	4.30146522233295	0.00180702601322043	0.036808211128567	-0.866995062445427	-0.377014191236025
ZNF217	BRD-K70246307-001-04-1::2.5::HTS002	2.5	riboflavin	vitamin B2	noncancer	BLVRB, RFK	gastroenterology	jaundice	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.5421904485075	0.5421904485075	0.307902574667419	0.289065772439	-6.76583308478389	4.08510036621105	0.00230674678697253	0.0453330948198272	-0.329646110981425	-0.138929636698736
ZNF217	BRD-K73237276-001-01-0::2.5::HTS002	2.5	tacalcitol	vitamin D receptor agonist	noncancer	VDR	dermatology	psoriasis, chapped lips	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.242777911147	-0.242777911147	0.0352999339210894	0.08123837122275	8.35078595676728	56.360480720453	1.95854356854026e-11	1.41052649362119e-09	0.211380141251496	0.344775548884682
ZNF217	BRD-K76719364-001-02-5::2.5::MTS006	2.5	GS-9973	syk inhibitor	noncancer	SYK	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.0988402158904	0.0988402158904	-0.215768433284704	-0.189464823924	-10.6174620135021	149.572606191413	5.61338575527122e-20	9.27610914064399e-18	-0.373158550420413	-0.256058747929795
ZNF217	BRD-K79239947-001-06-8::2.5::HTS002	2.5	PF-573228	focal adhesion kinase inhibitor	targeted cancer	CDK1, CDK2, CDK7, GSK3B, IKBKB	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.5493397092235	-0.5493397092235	-0.230517268885491	-0.1689116395825	6.21467319096981	24.2249814928459	1.93349933277209e-06	7.54561140738728e-05	0.212993233730507	0.424651646945512
ZNF217	BRD-K83508485-001-02-7::2.5::HTS002	2.5	FK-888	tachykinin antagonist	noncancer	TACR1, TACR2	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.0426575053431	0.0426575053431	0.310185892877409	0.330760339171	8.29069097029119	7.47864298968814	4.98966532582348e-05	0.00150475584581176	0.192204344521289	0.342852430547329
ZNF217	BRD-K84091759-001-07-1::2.5::HTS002	2.5	candesartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension, congestive heart failure	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.113551293334	0.113551293334	0.336474387722444	0.3438554060475	7.08894200081791	48.442657256817	5.12393606331478e-09	2.82897499359658e-07	0.159710398156809	0.286135790620079
ZNF217	BRD-K85090592-008-22-7::2.5::HTS002	2.5	pilocarpine	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.6350941954715	0.6350941954715	0.470581978914733	0.471563787015	-4.60446497509705	161.725632542782	8.32728220294646e-06	0.000291202164672102	-0.235067432054537	-0.0939570010589974
ZNF217	BRD-K85554912-001-06-3::2.5::HTS002	2.5	ivermectin	benzodiazepine receptor agonist	noncancer	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.429608674527	-0.429608674527	0.0401525456504371	0.0524875741405	16.1487060265224	19.3651383992746	1.07542822584487e-12	8.93393241151572e-11	0.408953359852652	0.530569080502223
ZNF217	BRD-K89014967-001-04-3::2.5::HTS002	2.5	AS-703026	MEK inhibitor	targeted cancer	MAP2K1, MAP2K2	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.805988183887	-0.805988183887	-2.07368202142635	-1.887176140495	-9.44786988765298	5.48441545654493	0.000134530290616421	0.00370328058791766	-1.60364389375658	-0.93174378132213
ZNF217	BRD-K92241597-001-06-0::2.5::MTS006	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-1.19872581432	-1.19872581432	-1.59961967593791	-1.38505413113	-4.42494016135429	7.86426792119192	0.00230623281824147	0.0453271502705983	-0.610444168899126	-0.191343554336688
ZNF217	BRD-K92657060-001-05-7::2.5::HTS002	2.5	zaleplon	benzodiazepine receptor agonist	noncancer	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.327729707299	-0.327729707299	-0.0910587038123596	-0.0408206395104	5.92724849400462	4.92535323072924	0.00205201808175185	0.0410076441439433	0.133559760536299	0.339782246436982
ZNF217	BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.5560982271045	0.5560982271045	-0.301752788856878	-0.214794605924	-11.5852218377172	58.4076356395338	9.06874749964903e-17	1.10941528701614e-14	-1.00605018506909	-0.709651846853662
ZNF217	BRD-K96344439-002-02-7::2.5::MTS006	2.5	tofogliflozin	sodium/glucose cotransporter inhibitor	noncancer	GCK	endocrinology	diabetes mellitus, diabetes mellitus	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.572961243084	0.572961243084	0.133787973282029	0.243893587025	-8.56544473539253	3.59707764558726	0.00161481163178629	0.0334914807653498	-0.588043754532691	-0.29030278507125
ZNF217	BRD-K97440753-066-18-1::2.5::HTS002	2.5	dihydroergocristine	adrenergic receptor antagonist, prolactin inhibitor	noncancer	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7	NA	NA	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.4889280310295	0.4889280310295	0.2153462453942	0.229709741117	-8.94646438679173	72.7435060109278	2.41497500061542e-13	2.13531013575454e-11	-0.334531014288595	-0.212632556982004
ZNF217	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	0.026292835863965	0.026292835863965	0.249291153780724	0.266502193274	6.51152875889883	10.9969224659448	4.36415547753384e-05	0.0013331885395444	0.147619283969248	0.298377351864271
ZNF217	BRD-M80207679-001-01-5::2.5::HTS002	2.5	nemonapride	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	MCF7, NCIH841	BREAST, LUNG	carcinoma, carcinoma (small_cell_carcinoma)	-0.634112799288	-0.634112799288	0.383623023411233	0.391465254449	27.0703418787669	19.8432448189315	3.86279333213075e-17	4.89018684041495e-15	0.939272263901916	1.09619938149655
ZNF562	BRD-A00077618-236-07-6::2.5::HTS002	2.5	8-bromo-cGMP	PKA activator	noncancer	PRKG1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.206121624901	-0.206121624901	0.181210856860132	0.215520353965	13.999302072334	133.677234173137	5.59428052333397e-28	1.87346335982132e-25	0.332608824147398	0.442056139374865
ZNF562	BRD-A08840375-001-01-3::2.5::HTS002	2.5	CID-5458317	MAP kinase phosphatase inhibitor	noncancer	MAPK3	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.9975768431025	-0.9975768431025	-1.21442287366295	-1.12011346307	-3.1436692740685	181.627062089132	0.00194914264519929	0.0392187189262973	-0.352948556939113	-0.0807435041817929
ZNF562	BRD-A12417644-001-07-6::2.3139::HTS002	2.3139	usniacin-(+)	MAP kinase activator	targeted cancer	PTPN1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.03528690506115	-0.03528690506115	0.173336924250763	0.1617912757505	7.2431191404647	187.363705390864	1.10512915605742e-11	8.22434815585525e-10	0.151803902546287	0.265443756077538
ZNF562	BRD-A12994259-001-02-1::2.5::HTS002	2.5	pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	targeted cancer	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.136909234437	-0.136909234437	0.256476640171341	0.256070233499	10.8055695944636	4.31684348276413	0.000275179146876601	0.00700532543540313	0.295166746186882	0.491605003029799
ZNF562	BRD-A70858459-001-01-7::2.5::HTS002	2.5	estramustine	DNA alkylating agent	chemo	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.445569423314	0.445569423314	0.0964988532259036	0.09357088918285	-12.0505154001056	187.844772591045	3.81199713104226e-25	9.89130185350068e-23	-0.406213534855925	-0.291927605320267
ZNF562	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.2824721873635	0.2824721873635	0.142642975521873	0.135666555282	-5.06073881648208	75.9780844574197	2.82812876295963e-06	0.000107817504382137	-0.194859775648715	-0.0847986480345388
ZNF562	BRD-K04394237-001-03-7::2.49369::HTS002	2.49369	drospirenone	mineralocorticoid receptor antagonist	noncancer	AR, NR3C2, PGR	endocrinology	contraceptive	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.744130376194	-0.744130376194	-0.287604956064427	-0.201937004263	7.5816122636744	14.3834604163249	2.15295399412622e-06	8.35640124243171e-05	0.327699744610735	0.58535109564841
ZNF562	BRD-K05524748-003-04-4::2.5::HTS002	2.5	dronedarone	adrenergic receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.3614781260425	-0.3614781260425	-1.14199822552017	-1.07388474495	-10.6275822590175	42.4369539661608	1.5531569757843e-13	1.39904490111823e-11	-0.928688604396532	-0.632351594558814
ZNF562	BRD-K05804044-001-06-0::2.5::HTS002	2.5	AZ-628	RAF inhibitor	targeted cancer	BRAF, RAF1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.0991319915994	-0.0991319915994	-0.68711908745024	-0.506361258966	-7.33729040616365	10.1895187544139	2.24749925872672e-05	0.000725348996572262	-0.766093911876265	-0.409880279825414
ZNF562	BRD-K06814349-304-01-9::2.5::HTS002	2.5	fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	chemo	CDH5	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-5.084339233825	-5.084339233825	-3.15937543204466	-3.022544850085	18.1380897131913	189.664072467868	2.68210500638172e-43	3.68495438405633e-40	1.71562045223975	2.13430715132093
ZNF562	BRD-K06858286-001-01-3::2.5::HTS002	2.5	cabazitaxel	microtubule inhibitor	chemo	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-2.008160923645	-2.008160923645	-3.08403051092056	-3.12584681211	-9.41405235453703	9.41496799583343	4.277870377739e-06	0.000157945164546154	-1.33266995015971	-0.8190692243914
ZNF562	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.5008041184175	0.5008041184175	0.19795541248189	0.204355413473	-9.29808408968158	10.9498823931046	1.5755207677061e-06	6.24407896859618e-05	-0.374577237870239	-0.231120174000982
ZNF562	BRD-K11636097-001-03-1::2.5::HTS002	2.5	JNJ-7706621	CDK inhibitor	targeted cancer	AURKA, AURKB, CDK1, CDK2	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.937659674241	-0.937659674241	-1.33891167623714	-1.3496917977	-5.30537311606619	13.2696325743214	0.000133016406468399	0.00366443102595957	-0.564306533693187	-0.238197470299099
ZNF562	BRD-K13169950-001-14-4::2.5::HTS002	2.5	NSC-3852	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.134356710305	-1.134356710305	-1.64883524457844	-1.461946185705	-5.78175539457363	59.0587576828325	2.96054655343549e-07	1.30535071436181e-05	-0.692529605143395	-0.336427463403484
ZNF562	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.3739463886385	0.3739463886385	0.239500478606746	0.274310189966	-4.59105587794681	19.5345118744908	0.000186932261629884	0.00497609376180295	-0.195625363439031	-0.0732664566244767
ZNF562	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.227888615725	0.227888615725	-0.191710467182857	-0.123671466435	-7.79463259448123	4.91166468836948	0.000603530106632118	0.0141494207202314	-0.55873003478107	-0.280468131034644
ZNF562	BRD-K17075857-001-18-4::2.5::HTS002	2.5	chloroxine	opioid receptor antagonist	noncancer	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.058252394131065	-0.058252394131065	-0.680843317135456	-0.656068942946	-8.60639651897249	4.35185088853219	0.000682116894121145	0.015784650377898	-0.817195310948296	-0.427986535060486
ZNF562	BRD-K17702546-001-03-2::2.5::HTS002	2.5	PD-168393	EGFR inhibitor	targeted cancer	EGFR, ERBB2, SRC	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.517988477275	-1.517988477275	-0.964297057419489	-0.729695465511	6.39862511771612	6.81909513862236	0.000409713148918993	0.0100255062786458	0.347968106546268	0.759414733164754
ZNF562	BRD-K17849083-001-32-9::2.43397::HTS002	2.43397	tranilast	angiogenesis inhibitor	noncancer	HPGDS, HRH1	pulmonary	asthma	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.66116302377	-1.66116302377	-2.36424935839239	-2.30540806626	-7.6963309960467	123.173290974296	3.89999863422597e-12	3.06408653693189e-10	-0.883912346361261	-0.522260322883528
ZNF562	BRD-K18961567-001-01-1::2.5::MTS010::PROS002_PR500	2.5	LY2801653	MET inhibitor	targeted cancer	MET	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.112882566647	-0.112882566647	-0.416708383750326	-0.32717924466	-5.17695126885089	179.928716515646	5.99241105822293e-07	2.53123269550229e-05	-0.419631441596437	-0.188020192610216
ZNF562	BRD-K19318328-001-01-3::2.5::HTS002	2.5	FR-139317	endothelin receptor antagonist	noncancer	EDNRA	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.500105966355	-1.500105966355	-0.810346626355253	-0.7654167490095	9.08008619147721	8.99661886204375	7.96102498915208e-06	0.000279442929069763	0.517907069713743	0.861611610285751
ZNF562	BRD-K19333160-001-01-3::2.5::HTS002	2.5	RKI-1447	rho associated kinase inhibitor	targeted cancer	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.0223121553718	-0.0223121553718	-0.34366145900579	-0.216806871006	-5.62099249317069	156.221406876465	8.5185019184552e-08	4.04108454555242e-06	-0.434274242351302	-0.208424364916678
ZNF562	BRD-K21565985-001-22-5::2.5::HTS002	2.5	xylazine	adrenergic receptor agonist	noncancer	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.401919900544	0.401919900544	0.547059468714889	0.548346398175	5.66264836583694	159.811296518229	6.7567954859802e-08	3.25140821669208e-06	0.0945203313396702	0.195758805002109
ZNF562	BRD-K21728777-001-02-3::2.5::HTS002	2.5	AMG900	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.902243495174	-0.902243495174	-1.55003900642389	-1.404443241845	-7.43640294027715	75.8910993401665	1.31969281934966e-10	8.628689514289e-09	-0.82129693764153	-0.474294084858245
ZNF562	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.59627462738	-1.59627462738	-2.06463320542025	-1.99815705335	-5.32166996338849	168.955797192356	3.23158635588901e-07	1.417275776696e-05	-0.642098894378555	-0.294618261701946
ZNF562	BRD-K23952234-236-01-8::2.5::HTS002	2.5	BMS-986020	lysophosphatidic acid receptor antagonist	noncancer	LPAR1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.6095606183295	0.6095606183295	0.370832295147463	0.3847237758685	-6.7397486856909	9.06651227258194	8.17243870012591e-05	0.00235968020228922	-0.318766571082656	-0.158690075281417
ZNF562	BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.0951297871381	0.0951297871381	-0.053701055287835	-0.030411088067	-7.4809570986539	27.8150336172186	3.95170832322155e-08	1.95468657560063e-06	-0.189595348453711	-0.108066336398159
ZNF562	BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500	2.5	axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.214634374103	0.214634374103	-0.18648297574208	-0.06456986921455	-7.06799232970375	5.36288857839994	0.00065387776934231	0.0151885735802935	-0.544081366269234	-0.258153333420927
ZNF562	BRD-K32405725-001-02-8::2.5::HTS002	2.5	etomoxir	carnitine palmitoyltransferase inhibitor	noncancer	CPT1A	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.598726926733	0.598726926733	0.237547657814758	0.2536769304835	-11.419670119292	9.60220238570848	6.67872417307793e-07	2.80071272410804e-05	-0.432048183656087	-0.290310354180397
ZNF562	BRD-K32821942-001-21-3::2.5::HTS002	2.5	azathioprine	dehydrogenase inhibitor	noncancer	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.4445531436595	-0.4445531436595	-0.640088992376784	-0.577859685861	-3.99797891674737	15.8433141021797	0.00105478435247927	0.0231416598917525	-0.299301004680181	-0.0917706927543873
ZNF562	BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500	2.5	tivantinib	tyrosine kinase inhibitor	targeted cancer	MET	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.12019421941085	-0.12019421941085	-0.880619530508983	-0.7074523288895	-8.11910373182015	92.4024156910613	1.98336992200448e-12	1.6023132002009e-10	-0.946428929871681	-0.574421692324586
ZNF562	BRD-K33588785-001-01-9::2.5::HTS002	2.5	obidoxime	cholinesterase reactivator	noncancer	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.2655237469745	-0.2655237469745	0.177752758285902	0.1909860451805	11.4487720584741	2.82651724938034	0.00187654140684304	0.0379799141614325	0.315666826807216	0.570886183713589
ZNF562	BRD-K36021395-300-02-4::2.5::HTS002	2.5	ABT-702	adenosine kinase inhibitor	noncancer	ADK	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.0941756564803	-0.0941756564803	-0.275611757208249	-0.153671266635	-3.2949649676054	63.2347369000388	0.00161592032964404	0.0335047487987111	-0.291466034621965	-0.0714061668339327
ZNF562	BRD-K36055864-001-19-2::2.5::HTS002	2.5	cycloheximide	protein synthesis inhibitor	targeted cancer	RPL3	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-2.44598921112	-2.44598921112	-1.96347382718948	-2.01098817996	5.70652310740944	6.93007819333265	0.000756973383158092	0.0173223177742546	0.282164770479876	0.682865997381173
ZNF562	BRD-K36269323-300-02-6::2.5::HTS002	2.5	asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	noncancer	NOS2, NOS3	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.69907204368	-1.69907204368	-1.02087146538304	-1.006604825335	7.07949429115634	5.05364721772345	0.000832622936655046	0.0188522334027403	0.432728477725687	0.923672678868236
ZNF562	BRD-K36529613-001-02-6::2.5::HTS002	2.5	PU-H71	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-3.06555248805	-3.06555248805	-3.48434185598628	-3.372344193665	-4.13172360403445	164.351172802129	5.72172300612812e-05	0.00170608120503678	-0.61892399290076	-0.218654742971794
ZNF562	BRD-K37312348-001-15-0::2.5::HTS002	2.5	kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	targeted cancer	CCNB1, CDK1, CDK5, GSK3B	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.92820894312	-0.92820894312	-0.08621806668014	-0.0710979031402	13.1913732668322	2.53182236701517	0.0021205437891802	0.0421913020266751	0.615863365747848	1.06811838713187
ZNF562	BRD-K37798499-001-27-2::2.5::HTS002	2.5	etoposide	topoisomerase inhibitor	chemo	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.37350009757	-1.37350009757	-1.94245092806503	-1.74375486562	-5.13662072373496	6.6124770835444	0.0015989741158373	0.0332058837834755	-0.834009199902845	-0.303892461087209
ZNF562	BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500	0.625	NVP-AUY922	HSP inhibitor	targeted cancer	HSP90AA1, HSP90AB1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.803085482172	-0.803085482172	-1.2901080044278	-1.33795379646	-6.10714289228927	178.960034111132	6.15455586194701e-09	3.35819705533411e-07	-0.644386721401178	-0.329658323110417
ZNF562	BRD-K42436189-001-01-2::2.5::HTS002	2.5	AZ20	ATR kinase inhibitor	targeted cancer	ATR, MTOR	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.963054467295	-1.963054467295	-2.75450399721441	-2.75783530181	-8.9376966419771	140.186091739763	2.06408728630393e-15	2.23318406858271e-13	-0.966519258940283	-0.61637980089853
ZNF562	BRD-K47150025-001-05-3::2.5::HTS002	2.5	KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.371946517786	-0.371946517786	-0.677889018111147	-0.588520646364	-5.03166136766374	14.5197645196688	0.000164293714007373	0.00444479052468275	-0.435916379286655	-0.175968621363639
ZNF562	BRD-K47557313-001-02-7::2.5::HTS002	2.5	LY2109761	TGF beta receptor inhibitor	targeted cancer	TGFBR1, TGFBR2	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.5900595163535	0.5900595163535	0.253195175890144	0.273399788387	-8.12214361011231	19.1620344565069	1.25753881630356e-07	5.8503806589869e-06	-0.423622453940189	-0.250106226986522
ZNF562	BRD-K47869605-001-32-0::0.625::HTS002	0.625	podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	noncancer	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-2.481357586315	-2.481357586315	-3.27754576877615	-3.15922322391	-7.11107844732769	52.8530808014545	3.03035264920697e-09	1.71279655314315e-07	-1.02077505821311	-0.571601306709203
ZNF562	BRD-K49962337-001-02-9::2.55951::HTS002	2.55951	baicalin	beta glucuronidase inhibitor	noncancer	PREP	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.507825767532	0.507825767532	0.401515126271516	0.450986520291	-3.31171071981183	43.9496265267271	0.00186040784957984	0.0377022838495271	-0.17100891160098	-0.0416123709199884
ZNF562	BRD-K50866992-003-10-3::2.5::HTS002	2.5	tropisetron	serotonin receptor antagonist	noncancer	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.6430101997495	0.6430101997495	0.196849631866107	0.2395368500345	-10.9747887118331	7.17185008214173	9.66936198993072e-06	0.000334100384642892	-0.541825190103025	-0.350495945663762
ZNF562	BRD-K54247840-004-01-3::2.5::HTS002	2.5	halofuginone	collagenase inhibitor	noncancer	COL1A1, MMP2	rheumatology	scleroderma	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-4.196191482665	-4.196191482665	-5.73061988829862	-5.5836707127	-12.8540745715772	86.1167127165646	9.8122257984743e-22	1.88107740890984e-19	-1.77172932695975	-1.29712748430749
ZNF562	BRD-K60341624-001-02-2::2.5::HTS002	2.5	GSK1292263	glucose dependent insulinotropic receptor agonist	noncancer	GRPR	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.200038647435	-1.200038647435	-1.01145775105426	-0.954160275858	4.7753089550593	38.5424023233025	2.597858900965e-05	0.000828689537706397	0.108672828104067	0.268488964657421
ZNF562	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.315502327475	-1.315502327475	-1.53816739380413	-1.43484346641	-3.35882194508045	25.4881737555848	0.00246731392148521	0.048013158296532	-0.359064775442361	-0.0862653572159003
ZNF562	BRD-K61734568-003-02-1::2.5::HTS002	2.5	2,3-DCPE	Bcl-XL downregulator	targeted cancer	BCL2L1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.6745485241	0.6745485241	-0.367841783029819	-0.146091240972	-15.0349225095955	182.70046489206	8.92183502626127e-34	5.09922127824947e-31	-1.17918322636919	-0.905597387890444
ZNF562	BRD-K62398570-300-01-2::2.5::HTS002	2.5	lerisetron	serotonin receptor antagonist	noncancer	HTR3A	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.6491487162085	0.6491487162085	0.496781245596655	0.5032243317015	-7.16188929825349	187.068055712408	1.76962228434316e-11	1.28178903204118e-09	-0.19433674897219	-0.1103981922515
ZNF562	BRD-K64538373-001-01-4::2.5::HTS002	2.5	Ro-4987655	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.51148586376	-1.51148586376	-1.8425476826521	-1.7566794361	-3.41530731474346	91.708121444336	0.000950863446349196	0.0211715781833136	-0.523590681369945	-0.13853295641426
ZNF562	BRD-K67261995-001-11-7::2.5::HTS002	2.5	iodipamide	radiopaque medium	noncancer	ALB	radiology	contrast agent	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.0093251079257	0.0093251079257	-0.792790848729161	-0.692855994301	-12.2755003783762	50.5824487997918	8.68447131148143e-17	1.06666707834871e-14	-0.933323462837018	-0.670908450472704
ZNF562	BRD-K67844266-003-01-9::2.5::HTS002	2.5	pevonedistat	nedd activating enzyme inhibitor	targeted cancer	NAE1, UBA3	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.72448739356	-1.72448739356	-2.62067470152088	-2.65202852716	-9.65075056427854	189.998813462513	3.47426515648655e-18	4.86575371507138e-16	-1.07936008610803	-0.713014529813724
ZNF562	BRD-K68174511-001-06-6::2.5::HTS002	2.5	torin-2	mTOR inhibitor	targeted cancer	MTOR	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-3.337224655485	-3.337224655485	-3.86468662813782	-3.711772040445	-6.28434152769978	9.06253957257208	0.000139419085204637	0.00381957633165885	-0.717131467182654	-0.337792478122979
ZNF562	BRD-K68507560-003-24-6::2.5::HTS002	2.5	dicycloverine	acetylcholine receptor antagonist	noncancer	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.930843804725	-0.930843804725	0.244454273835597	0.2203060574785	38.544437553014	134.908501393263	1.06893660562077e-74	7.63680379153646e-70	1.11499385990417	1.23560229721702
ZNF562	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-2.683712769185	-2.683712769185	-3.68168630212801	-3.50719189578	-8.64342159281152	90.9653318551292	1.76205323280576e-13	1.5775234224479e-11	-1.2273227534553	-0.768624312430726
ZNF562	BRD-K71480163-001-01-4::2.5::MTS006	2.5	GDC-0068	AKT inhibitor	targeted cancer	AKT1, AKT2, AKT3, PRKG1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.9146505872765	-0.9146505872765	-0.522765964104267	-0.364234530081	6.57022292376642	16.4056130575744	5.69011746291096e-06	0.000205381809651102	0.265695283191866	0.518073963152601
ZNF562	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.61393458381	-0.61393458381	-1.19621706391954	-1.12346956245	-6.70069478357145	8.70749353493487	0.000103256885123842	0.00291772510635569	-0.779872510762261	-0.384692449456819
ZNF562	BRD-K72815923-034-01-2::2.5::HTS002	2.5	xanomeline	acetylcholine receptor agonist	noncancer	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.8024282086	-1.8024282086	-2.52974295240393	-2.26266997363	-6.38602782351102	45.0513290162103	8.29169252884582e-08	3.93784659431641e-06	-0.956696930413223	-0.497932557194634
ZNF562	BRD-K75295174-001-05-0::2.5::HTS002	2.5	alisertib	Aurora kinase inhibitor	targeted cancer	AURKA	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.96854422657	-1.96854422657	-1.46560979054118	-1.346974687905	5.39626559758428	47.511613337832	2.11924111897437e-06	8.23378899288712e-05	0.315492575698236	0.690376296359409
ZNF562	BRD-K77554836-001-11-6::2.57309::HTS002	2.57309	triamcinolone	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.0216928716218	0.0216928716218	-0.209865524596572	-0.20601445055	-5.00205509186349	190.934815926389	1.28149780666536e-06	5.15120298958702e-05	-0.322869091670983	-0.140247700765762
ZNF562	BRD-K83003151-057-02-4::2.34747::HTS002	2.34747	alogliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.1554340968525	-0.1554340968525	0.252044184225737	0.333164165462	7.33157660424525	4.45974941251346	0.00119430327316492	0.0258481092834661	0.259243220782088	0.555713341374386
ZNF562	BRD-K83988098-001-02-0::0.039::MTS010::PROS005_PR500	0.039	alvespimycin	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-0.60015148449	-0.60015148449	-0.978976738356803	-0.942675371448	-3.54641051434046	35.7592617693689	0.00111204766913672	0.0242638771127358	-0.59551558248761	-0.162134925245995
ZNF562	BRD-K95142244-001-01-5::2.5::HTS002	2.5	talazoparib	PARP inhibitor	targeted cancer	PARP2	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-1.22061663299	-1.22061663299	-2.25493115742993	-2.18755983006	-9.25072857879103	5.5228599420235	0.000144408295209012	0.00394425413084317	-1.31373415626067	-0.754894892619188
ZNF562	BRD-K95435023-001-08-5::2.5::HTS002	2.5	PHA-665752	c-Met inhibitor	targeted cancer	MET	NA	NA	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	-2.40358779276	-2.40358779276	-1.23816426608999	-1.23927241763	16.7087015087076	173.347840493536	5.83176677655203e-38	5.01994022665979e-35	1.02775591440409	1.30309113893593
ZNF562	BRD-K99107520-001-24-1::2.5::HTS002	2.5	felbamate	glutamate receptor antagonist	noncancer	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	EFO21, RMGI	OVARY	carcinoma (serous_carcinoma), carcinoma (clear_cell_carcinoma)	0.438931898671	0.438931898671	0.245015101316403	0.250792854427	-5.76463778233732	13.1158097422033	6.32473900281955e-05	0.00186975860101422	-0.266524318399642	-0.121309276309553
ZNF586	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.2330801241395	0.2330801241395	0.149565742612033	0.1611474271015	-3.33617672112342	28.9438595305281	0.00234142247713782	0.0459093164488585	-0.134716849126715	-0.0323119139282201
ZNF586	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.310991516881	0.310991516881	-0.182313851098607	-0.1596607583295	-9.11003506750554	7.19169730880696	3.33563542121273e-05	0.00104003986644327	-0.620660335960645	-0.365950399998569
ZNF586	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.674232153666	-0.674232153666	-1.6315358062891	-1.545847432105	-8.92254926223242	5.53754744111253	0.000171901687678592	0.00462567693891588	-1.22524100363878	-0.689366301607411
ZNF586	BRD-A20239487-001-24-9::2.5::HTS002	2.5	atenolol-(+/-)	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.616307388263	0.616307388263	0.19461262246389	0.207866793196	-15.1467310462815	16.2545602035942	5.22069403778202e-11	3.56238819619161e-09	-0.480639266215117	-0.362750265383103
ZNF586	BRD-A27883417-300-01-6::2.5::HTS002	2.5	alexidine	phosphatidylglycerophosphatase inhibitor	targeted cancer	PTPMT1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.5134868837045	-0.5134868837045	-0.231180071792889	-0.2422575452235	6.18666812105119	32.712102084501	5.78017673616089e-07	2.4435098613109e-05	0.189437821866794	0.375175801956429
ZNF586	BRD-A28329383-001-02-1::2.5::HTS002	2.5	MTPG	glutamate receptor antagonist	noncancer	GRM2, GRM3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.3727590918325	0.3727590918325	0.0190153213821629	0.0389518722109	-9.65780306855997	37.8986983000442	9.15555890632058e-12	6.89737006971101e-10	-0.427899319555793	-0.279588221344882
ZNF586	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.2552180427405	0.2552180427405	-0.452350602476512	-0.3315553181695	-8.13302342129865	10.803449208515	6.2636908281599e-06	0.000224121968532334	-0.899479062620544	-0.51565822781348
ZNF586	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.702529764981	0.702529764981	0.138150381108851	0.135666555282	-21.3183919706576	157.591065179994	2.72064422412726e-48	5.71679368542129e-45	-0.61666867341394	-0.512090094330358
ZNF586	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.273317883122	0.273317883122	-0.0532441900338813	-0.0230394948173	-9.90537877576565	33.4747738707756	1.75977908596055e-11	1.27509023568235e-09	-0.393600169936838	-0.259523976374924
ZNF586	BRD-A91452556-001-04-0::2.5::HTS002	2.5	estradiol-cypionate	estrogen receptor agonist	noncancer	ESR1	endocrinology	hypoestrogenism, menopause	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7603131101175	0.7603131101175	0.59151732749787	0.60273481392	-7.10956793733329	188.683332754924	2.33410849160994e-11	1.66644616555052e-09	-0.215629758186559	-0.1219618070527
ZNF586	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-3.068995121165	-3.068995121165	-3.72456152227446	-3.62613694573	-4.97337587414864	6.98775854315918	0.00162128059408165	0.0335801554357292	-0.967370481713718	-0.343762320505205
ZNF586	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.672091678384	0.672091678384	0.152096053737071	0.1638819685105	-19.6582846297449	48.3095883610749	1.07978884483028e-24	2.71950720709317e-22	-0.573171587446672	-0.466819661847187
ZNF586	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-2.25691771672	-2.25691771672	-3.03741302406105	-2.93942386342	-7.97072553770843	140.93467509816	4.85348222715385e-13	4.1559807921041e-11	-0.97407767733705	-0.586912937345047
ZNF586	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-2.495633797245	-2.495633797245	-2.06165758163955	-2.351388502545	3.85227680732202	11.8280248133205	0.00236042797862666	0.046214320656899	0.188126805878961	0.679825625331943
ZNF586	BRD-K14175878-001-01-6::2.5::HTS002	2.5	MK-0812	CC chemokine receptor antagonist	noncancer	CCR2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.5356511904315	0.5356511904315	0.327844509524078	0.3144400388815	-6.66197749755229	9.11640630568862	8.70790594646823e-05	0.00249980816180095	-0.278232911040271	-0.137380450774573
ZNF586	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.493138206298	-0.493138206298	-0.184199771120118	-0.102291191228	6.07030628402322	6.74779198439717	0.000582459066717831	0.0137305179620068	0.187676842487418	0.430200027868347
ZNF586	BRD-K18910433-001-36-6::2.58082::HTS002	2.58082	estradiol	estrogen receptor agonist	noncancer	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.414173617467	0.414173617467	0.305833519845555	0.322506570142	-3.62518855337234	175.785560393375	0.000377955370280685	0.00934981493038885	-0.167320399133328	-0.0493597961095623
ZNF586	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-5.601385709225	-5.601385709225	-5.24668991900168	-5.41033082	4.46109499854106	26.2099426664694	0.000137212994363701	0.0037674511746064	0.191327040759105	0.518064539687544
ZNF586	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-1.327976173415	-1.327976173415	-2.06756542896085	-1.99815705335	-8.33909125461168	143.638135495613	5.55591737106075e-14	5.23426028229485e-12	-0.914894315126109	-0.564284195965594
ZNF586	BRD-K24696047-001-02-3::2.5::HTS002	2.5	NVP-AEW541	IGF-1 inhibitor	targeted cancer	IGF1R, INSR	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.770158192953	0.770158192953	0.158307887339413	0.182728129692	-17.3542328198931	23.154872052458	9.07932082072812e-15	9.21383405391021e-13	-0.684757044098179	-0.538943567128995
ZNF586	BRD-K25224017-001-25-0::2.5::HTS002	2.5	pirenperone	serotonin receptor antagonist	noncancer	HTR2A, HTR7	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.07119575101035	-0.07119575101035	-2.57651493102377	-2.47770840728	-19.4570643981402	3.89085076711138	5.06297251419517e-05	0.00152450384376923	-2.8668083103993	-2.14383004962754
ZNF586	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-6.100611857945	-6.100611857945	-4.66612327074552	-4.90330008871	15.7521471259839	180.117413153895	1.03691694546885e-35	6.98872239010673e-33	1.25479469627058	1.61418247812838
ZNF586	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.148876515952	0.148876515952	-0.310135157254234	-0.26288025127	-11.1812966035498	92.3065307974303	7.43457564847707e-19	1.09968610363178e-16	-0.540540363600037	-0.377482982812431
ZNF586	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.3641693234005	-0.3641693234005	-0.938693454933748	-0.797793160199	-7.70527632547068	37.7493643612816	2.91453375517086e-09	1.6516898604231e-07	-0.725500799244968	-0.423547463821528
ZNF586	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.655447238788	-0.655447238788	-0.0327621453134341	-0.03550064325705	12.96975202765	17.4652785145012	2.13289033864649e-10	1.36134679390043e-08	0.521596830596902	0.723773356352229
ZNF586	BRD-K36788280-001-01-2::2.5::HTS002	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4742160534055	0.4742160534055	-1.08213989081138	-1.010750177675	-17.9491901208066	7.66083742128252	1.55141918647186e-07	7.1278482919041e-06	-1.75785859976864	-1.35485328866513
ZNF586	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4754664269035	0.4754664269035	-0.24380456008323	-0.026104548309	-13.6686128357417	137.369389706033	2.16513895284365e-27	6.77448272443834e-25	-0.823325058816449	-0.61521691515701
ZNF586	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-1.376637532085	-1.376637532085	-3.05508994589577	-2.95683473862	-12.3823245720317	3.57447379175713	0.000460432514260627	0.0111390765154639	-2.07315135619675	-1.28375347142479
ZNF586	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-1.603717490405	-1.603717490405	-0.686024200195408	-0.55798899715	13.776528875223	49.0164783277755	1.76901183706966e-18	2.53104498015557e-16	0.78383097654258	1.0515556038766
ZNF586	BRD-K43471985-001-03-0::2.69009::HTS002	2.69009	OTX015	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4502311682355	0.4502311682355	-0.820000231463584	-0.721568534239	-11.689241093895	5.94968154031261	2.50824415715855e-05	0.000803211507484888	-1.5366753305329	-1.00378746886527
ZNF586	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.5796315248635	0.5796315248635	0.150113036189104	0.139916370482	-13.6517092925713	2.51064502918645	0.00202262877656684	0.0404769377266848	-0.541646039496237	-0.317390937852555
ZNF586	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.2298520782105	0.2298520782105	-0.270270824764164	-0.2054130743915	-8.89051370801817	10.5256305386526	3.23040173624929e-06	0.000121724467955094	-0.624620331000267	-0.375625474949061
ZNF586	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.3561874601045	-0.3561874601045	-1.60004893679627	-1.48697544025	-14.1764471950036	53.0402806193593	1.11201394711668e-19	1.77863311396695e-17	-1.41984534011975	-1.0678776132638
ZNF586	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.000921624061542	-0.000921624061542	-0.227349431166755	-0.187297921894	-6.78786799238255	190.343698549324	1.40607954458412e-10	9.15998853225438e-09	-0.292226090463125	-0.160629523747302
ZNF586	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-2.58490429018	-2.58490429018	-4.61102342157848	-4.62878838486	-17.9184007104899	12.2050047948396	3.90776988549333e-10	2.42978941626893e-08	-2.27202971890644	-1.78020854389052
ZNF586	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7607714495385	0.7607714495385	0.252547162037404	0.250850268444	-12.6427194938718	4.68094592613697	8.51191965111603e-05	0.00244945116394206	-0.613713863645149	-0.402734711357044
ZNF586	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.836938156552	-0.836938156552	-1.1104092317851	-1.00700802709	-4.57738485704858	75.9073065056866	1.80615332511275e-05	0.000594001896605938	-0.392463824018759	-0.154478326447437
ZNF586	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4887808304365	0.4887808304365	-0.775596545425266	-0.6098527820225	-11.9952543594015	2.77510071699709	0.00179278877561021	0.0365496647472426	-1.61574415681982	-0.913010594903716
ZNF586	BRD-K56981171-001-01-0::2.5::MTS006	2.5	brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	targeted cancer	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.245600643759	0.245600643759	-0.073895138979528	-0.00736994010253	-9.69693785152234	190.948206018377	2.48067000710584e-18	3.51175377776081e-16	-0.384484791316828	-0.254506774160228
ZNF586	BRD-K58529924-001-01-5::2.64858::MTS010::PROS001_PR500	2.64858	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.815010641956	0.815010641956	-0.126446608950122	-0.0782443732808	-14.3627957369575	2.43853603096737	0.002042411248234	0.040830888949048	-1.1800498705187	-0.702864631293547
ZNF586	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.343705806496	-0.343705806496	-1.33971179281745	-1.45938861893	-16.4333786390468	88.4216558241761	1.29260817997407e-28	4.68770589857299e-26	-1.11644506938941	-0.875566903253483
ZNF586	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.6883166767505	-0.6883166767505	-1.54502188179019	-1.43484346641	-10.7443572704364	4.99316858627648	0.000122031320273836	0.00339433447080631	-1.06175584972568	-0.651654560353697
ZNF586	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7342591783135	0.7342591783135	-0.2406416908372	-0.1756829862115	-14.3052671568619	8.75698130486072	2.2569961589238e-07	1.01158454568377e-05	-1.12972102968991	-0.820080708611494
ZNF586	BRD-K62965247-001-04-9::2.5::HTS002	2.5	tipifarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, FNTB	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.774919814399	-0.774919814399	-1.4770078742253	-1.40587252118	-12.1850364021178	183.84648858365	2.0298487239247e-25	5.35782570381844e-23	-0.815767297921957	-0.588408821730649
ZNF586	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.435790297551	-0.435790297551	-0.213584255575745	-0.1907303952045	4.2324319835638	121.925475282939	4.50427414648246e-05	0.00137032870623341	0.11827483918367	0.326137244766841
ZNF586	BRD-K66808046-065-03-7::2.5::HTS002	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.3472872615145	0.3472872615145	-0.46333115305582	-0.3317635225235	-8.89800408192247	25.9963231175994	2.27685204205786e-09	1.30236301393707e-07	-0.997880801674897	-0.623356027465744
ZNF586	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.1356853459595	0.1356853459595	-0.275429124988974	-0.224936831672	-12.8442667810432	173.710875221413	5.61728949755727e-27	1.68856667702939e-24	-0.474288382205209	-0.34794055969174
ZNF586	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.575945079264	-0.575945079264	-1.19663224976157	-1.12346956245	-7.92071162511724	26.9102690375721	1.66826187408064e-08	8.68920566598124e-07	-0.781498934480709	-0.459875406514437
ZNF586	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.1439750335985	0.1439750335985	-0.214799834510719	-0.195517916983	-13.5760810788193	70.2342717291201	2.55248455054033e-21	4.72020242651216e-19	-0.411478733668675	-0.306071002549762
ZNF586	BRD-K74671368-001-01-8::2.5::MTS006	2.5	idronoxil	XIAP inhibitor	targeted cancer	ENOX2, SPHK1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.0145559052907	-0.0145559052907	-0.253932438678862	-0.195737211392	-6.28616515974368	189.864953707315	2.1809271052242e-09	1.24949458844052e-07	-0.31449054946663	-0.164262517309693
ZNF586	BRD-K75478907-001-02-3::2.5::HTS002	2.5	GS-39783	GABA receptor modulator	noncancer	GABBR1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.8519708019005	0.8519708019005	0.474817749367266	0.475315506582	-14.9058668484461	78.2062994082519	1.45839274417765e-24	3.62196823252435e-22	-0.427524014547112	-0.326782090519355
ZNF586	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.764599669687	-0.764599669687	-2.33972000336628	-2.24109191203	-13.0265825205823	3.94181004205801	0.000218815497185018	0.00572351802491673	-1.91280014078369	-1.23744052657488
ZNF586	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.332480066815	0.332480066815	0.0136662413743319	0.0495734767378	-9.32798287180384	7.26943471007979	2.65900710011651e-05	0.000846683008113016	-0.399029178298012	-0.238598472583325
ZNF586	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.993874354388	-0.993874354388	-2.51992498568417	-2.254263331985	-9.92945207889272	3.69077784686294	0.000855307313737462	0.0192843636909359	-1.96723660432324	-1.08486465826909
ZNF586	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.5063939413715	-0.5063939413715	-1.29168133355983	-1.24885809452	-12.8648212747601	188.083764669231	1.39738929125384e-27	4.47016491649468e-25	-0.905701243179515	-0.664873541197151
ZNF586	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.5630083434675	-0.5630083434675	-0.0979672169180723	-0.0599890522741	10.7295231279824	3.75219989832718	0.000595728203066079	0.0140018345088575	0.341503921615808	0.588578331483048
ZNF586	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.05585838322755	-0.05585838322755	-0.384930409884869	-0.347155123363	-7.68144800576544	88.9882964484269	1.94842902036347e-11	1.40371375968229e-09	-0.414194036464246	-0.243950016850393
ZNF586	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	1.96833510959	1.96833510959	-0.87530967102487	-0.774088070041	-32.0256957208521	153.57105920707	7.26027484734001e-70	1.29673953979628e-65	-3.01905738103913	-2.66823218019061
ZNF586	BRD-K84564571-001-02-4::2.5::HTS002	2.5	telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4166957067675	0.4166957067675	-0.190813294311457	-0.150870587106	-11.9712256481756	7.75231059259001	2.83881597527736e-06	0.000108167215851595	-0.7251868185341	-0.489831183623813
ZNF586	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.4070182346315	-0.4070182346315	-3.1354874988309	-3.009227373135	-20.9455042895148	8.16718252685762	2.17813217158082e-08	1.11576694599127e-06	-3.02779427571971	-2.42914425267908
ZNF586	BRD-K90574421-001-03-5::2.5::HTS002	2.5	ipsapirone	serotonin receptor agonist	noncancer	HTR1A	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.4184682851415	-0.4184682851415	-0.033960912837881	-0.0431604898369	14.9379099979931	58.3803947931755	1.32283300980376e-21	2.49359257834855e-19	0.332989565090773	0.436025179516465
ZNF586	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7956042498315	0.7956042498315	0.0858908167096112	0.09873309755385	-25.676176684431	15.9792722268249	2.03049534475314e-14	2.00273371719096e-12	-0.768315767700651	-0.651111098543126
ZNF587B	BRD-A03216249-003-24-3::2.5::HTS002	2.5	mepivacaine	potassium channel blocker, sodium channel blocker	noncancer	SCN10A	neurology/psychiatry	local anesthetic	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.2330801241395	0.2330801241395	0.149565742612033	0.1611474271015	-3.33617672112342	28.9438595305281	0.00234142247713782	0.0459093164488585	-0.134716849126715	-0.0323119139282201
ZNF587B	BRD-A11132253-001-08-2::2.5::HTS002	2.5	nadide	electron acceptor	noncancer	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.310991516881	0.310991516881	-0.182313851098607	-0.1596607583295	-9.11003506750554	7.19169730880696	3.33563542121273e-05	0.00104003986644327	-0.620660335960645	-0.365950399998569
ZNF587B	BRD-A13133631-001-04-0::2.5::HTS002	2.5	fluorometholone	glucocorticoid receptor agonist	noncancer	NR3C1	ophthalmology	eye inflammation	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.674232153666	-0.674232153666	-1.6315358062891	-1.545847432105	-8.92254926223242	5.53754744111253	0.000171901687678592	0.00462567693891588	-1.22524100363878	-0.689366301607411
ZNF587B	BRD-A20239487-001-24-9::2.5::HTS002	2.5	atenolol-(+/-)	adrenergic receptor antagonist	noncancer	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.616307388263	0.616307388263	0.19461262246389	0.207866793196	-15.1467310462815	16.2545602035942	5.22069403778202e-11	3.56238819619161e-09	-0.480639266215117	-0.362750265383103
ZNF587B	BRD-A27883417-300-01-6::2.5::HTS002	2.5	alexidine	phosphatidylglycerophosphatase inhibitor	targeted cancer	PTPMT1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.5134868837045	-0.5134868837045	-0.231180071792889	-0.2422575452235	6.18666812105119	32.712102084501	5.78017673616089e-07	2.4435098613109e-05	0.189437821866794	0.375175801956429
ZNF587B	BRD-A28329383-001-02-1::2.5::HTS002	2.5	MTPG	glutamate receptor antagonist	noncancer	GRM2, GRM3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.3727590918325	0.3727590918325	0.0190153213821629	0.0389518722109	-9.65780306855997	37.8986983000442	9.15555890632058e-12	6.89737006971101e-10	-0.427899319555793	-0.279588221344882
ZNF587B	BRD-A49358627-001-14-6::2.5::HTS002	2.5	ciprofibrate	PPAR receptor agonist	noncancer	PPARA	endocrinology	hyperlipidemia	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.2552180427405	0.2552180427405	-0.452350602476512	-0.3315553181695	-8.13302342129865	10.803449208515	6.2636908281599e-06	0.000224121968532334	-0.899479062620544	-0.51565822781348
ZNF587B	BRD-A71033472-003-23-9::2.5::HTS002	2.5	fendiline	calcium channel blocker	noncancer	HTR2B	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.702529764981	0.702529764981	0.138150381108851	0.135666555282	-21.3183919706576	157.591065179994	2.72064422412726e-48	5.71679368542129e-45	-0.61666867341394	-0.512090094330358
ZNF587B	BRD-A90272038-001-01-7::2.5::HTS002	2.5	CGP-37849	glutamate receptor antagonist	noncancer	GRIN2A, GRIN2B, GRIN2C, GRIN2D	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.273317883122	0.273317883122	-0.0532441900338813	-0.0230394948173	-9.90537877576565	33.4747738707756	1.75977908596055e-11	1.27509023568235e-09	-0.393600169936838	-0.259523976374924
ZNF587B	BRD-A91452556-001-04-0::2.5::HTS002	2.5	estradiol-cypionate	estrogen receptor agonist	noncancer	ESR1	endocrinology	hypoestrogenism, menopause	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7603131101175	0.7603131101175	0.59151732749787	0.60273481392	-7.10956793733329	188.683332754924	2.33410849160994e-11	1.66644616555052e-09	-0.215629758186559	-0.1219618070527
ZNF587B	BRD-K00152668-001-01-5::2.5::HTS002	2.5	adarotene	retinoid receptor agonist	targeted cancer	RARB, RARG	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-3.068995121165	-3.068995121165	-3.72456152227446	-3.62613694573	-4.97337587414864	6.98775854315918	0.00162128059408165	0.0335801554357292	-0.967370481713718	-0.343762320505205
ZNF587B	BRD-K01109406-001-03-7::2.5::HTS002	2.5	nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor	noncancer	HPD	metabolism	tyrosinemia	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.672091678384	0.672091678384	0.152096053737071	0.1638819685105	-19.6582846297449	48.3095883610749	1.07978884483028e-24	2.71950720709317e-22	-0.573171587446672	-0.466819661847187
ZNF587B	BRD-K07881437-001-04-6::2.40744::HTS002	2.40744	danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	targeted cancer	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-2.25691771672	-2.25691771672	-3.03741302406105	-2.93942386342	-7.97072553770843	140.93467509816	4.85348222715385e-13	4.1559807921041e-11	-0.97407767733705	-0.586912937345047
ZNF587B	BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500	2.5	AT-7519	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-2.495633797245	-2.495633797245	-2.06165758163955	-2.351388502545	3.85227680732202	11.8280248133205	0.00236042797862666	0.046214320656899	0.188126805878961	0.679825625331943
ZNF587B	BRD-K14175878-001-01-6::2.5::HTS002	2.5	MK-0812	CC chemokine receptor antagonist	noncancer	CCR2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.5356511904315	0.5356511904315	0.327844509524078	0.3144400388815	-6.66197749755229	9.11640630568862	8.70790594646823e-05	0.00249980816180095	-0.278232911040271	-0.137380450774573
ZNF587B	BRD-K16730910-001-07-3::2.5::HTS002	2.5	regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.493138206298	-0.493138206298	-0.184199771120118	-0.102291191228	6.07030628402322	6.74779198439717	0.000582459066717831	0.0137305179620068	0.187676842487418	0.430200027868347
ZNF587B	BRD-K18910433-001-36-6::2.58082::HTS002	2.58082	estradiol	estrogen receptor agonist	noncancer	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.414173617467	0.414173617467	0.305833519845555	0.322506570142	-3.62518855337234	175.785560393375	0.000377955370280685	0.00934981493038885	-0.167320399133328	-0.0493597961095623
ZNF587B	BRD-K22064724-001-01-8::2.5::MTS006	2.5	napabucasin	STAT inhibitor	targeted cancer	STAT3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-5.601385709225	-5.601385709225	-5.24668991900168	-5.41033082	4.46109499854106	26.2099426664694	0.000137212994363701	0.0037674511746064	0.191327040759105	0.518064539687544
ZNF587B	BRD-K23677682-003-01-2::2.5::HTS002	2.5	voreloxin	topoisomerase inhibitor	chemo	TOP2A	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-1.327976173415	-1.327976173415	-2.06756542896085	-1.99815705335	-8.33909125461168	143.638135495613	5.55591737106075e-14	5.23426028229485e-12	-0.914894315126109	-0.564284195965594
ZNF587B	BRD-K24696047-001-02-3::2.5::HTS002	2.5	NVP-AEW541	IGF-1 inhibitor	targeted cancer	IGF1R, INSR	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.770158192953	0.770158192953	0.158307887339413	0.182728129692	-17.3542328198931	23.154872052458	9.07932082072812e-15	9.21383405391021e-13	-0.684757044098179	-0.538943567128995
ZNF587B	BRD-K25224017-001-25-0::2.5::HTS002	2.5	pirenperone	serotonin receptor antagonist	noncancer	HTR2A, HTR7	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.07119575101035	-0.07119575101035	-2.57651493102377	-2.47770840728	-19.4570643981402	3.89085076711138	5.06297251419517e-05	0.00152450384376923	-2.8668083103993	-2.14383004962754
ZNF587B	BRD-K28061410-001-06-6::2.5::MTS006	2.5	beta-lapachone	topoisomerase inhibitor	chemo	TOP1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-6.100611857945	-6.100611857945	-4.66612327074552	-4.90330008871	15.7521471259839	180.117413153895	1.03691694546885e-35	6.98872239010673e-33	1.25479469627058	1.61418247812838
ZNF587B	BRD-K31476763-001-01-5::2.5::HTS002	2.5	AZD9668	elastase inhibitor	noncancer	ELANE	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.148876515952	0.148876515952	-0.310135157254234	-0.26288025127	-11.1812966035498	92.3065307974303	7.43457564847707e-19	1.09968610363178e-16	-0.540540363600037	-0.377482982812431
ZNF587B	BRD-K31928526-001-02-1::2.5::HTS002	2.5	barasertib	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.3641693234005	-0.3641693234005	-0.938693454933748	-0.797793160199	-7.70527632547068	37.7493643612816	2.91453375517086e-09	1.6516898604231e-07	-0.725500799244968	-0.423547463821528
ZNF587B	BRD-K35245662-001-01-2::2.5::HTS002	2.5	ciclesonide	glucocorticoid receptor agonist	noncancer	NR3C1, SERPINA6	allergy	allergic rhinitis	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.655447238788	-0.655447238788	-0.0327621453134341	-0.03550064325705	12.96975202765	17.4652785145012	2.13289033864649e-10	1.36134679390043e-08	0.521596830596902	0.723773356352229
ZNF587B	BRD-K36788280-001-01-2::2.5::HTS002	2.5	ribociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4742160534055	0.4742160534055	-1.08213989081138	-1.010750177675	-17.9491901208066	7.66083742128252	1.55141918647186e-07	7.1278482919041e-06	-1.75785859976864	-1.35485328866513
ZNF587B	BRD-K37618799-001-03-0::2.5::MTS006	2.5	MRS-1220	adenosine receptor antagonist	noncancer	ADORA2B, ADORA3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4754664269035	0.4754664269035	-0.24380456008323	-0.026104548309	-13.6686128357417	137.369389706033	2.16513895284365e-27	6.77448272443834e-25	-0.823325058816449	-0.61521691515701
ZNF587B	BRD-K39974922-001-04-3::2.5::HTS002	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-1.376637532085	-1.376637532085	-3.05508994589577	-2.95683473862	-12.3823245720317	3.57447379175713	0.000460432514260627	0.0111390765154639	-2.07315135619675	-1.28375347142479
ZNF587B	BRD-K40438880-305-06-6::2.5::HTS002	2.5	spermidine	glutamate receptor modulator	noncancer	KCNJ4, TXNRD1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-1.603717490405	-1.603717490405	-0.686024200195408	-0.55798899715	13.776528875223	49.0164783277755	1.76901183706966e-18	2.53104498015557e-16	0.78383097654258	1.0515556038766
ZNF587B	BRD-K43471985-001-03-0::2.69009::HTS002	2.69009	OTX015	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4502311682355	0.4502311682355	-0.820000231463584	-0.721568534239	-11.689241093895	5.94968154031261	2.50824415715855e-05	0.000803211507484888	-1.5366753305329	-1.00378746886527
ZNF587B	BRD-K46862739-001-14-3::2.5::MTS006	2.5	metyrapone	cytochrome P450 inhibitor	noncancer	CYP11B1	nephrology	adrenal diagnostic agent	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.5796315248635	0.5796315248635	0.150113036189104	0.139916370482	-13.6517092925713	2.51064502918645	0.00202262877656684	0.0404769377266848	-0.541646039496237	-0.317390937852555
ZNF587B	BRD-K49075727-001-08-5::2.5::HTS002	2.5	nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.2298520782105	0.2298520782105	-0.270270824764164	-0.2054130743915	-8.89051370801817	10.5256305386526	3.23040173624929e-06	0.000121724467955094	-0.624620331000267	-0.375625474949061
ZNF587B	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.3561874601045	-0.3561874601045	-1.60004893679627	-1.48697544025	-14.1764471950036	53.0402806193593	1.11201394711668e-19	1.77863311396695e-17	-1.41984534011975	-1.0678776132638
ZNF587B	BRD-K51324732-001-01-0::2.5::HTS002	2.5	meglitinide	potassium channel blocker	noncancer	CCR2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.000921624061542	-0.000921624061542	-0.227349431166755	-0.187297921894	-6.78786799238255	190.343698549324	1.40607954458412e-10	9.15998853225438e-09	-0.292226090463125	-0.160629523747302
ZNF587B	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-2.58490429018	-2.58490429018	-4.61102342157848	-4.62878838486	-17.9184007104899	12.2050047948396	3.90776988549333e-10	2.42978941626893e-08	-2.27202971890644	-1.78020854389052
ZNF587B	BRD-K52020312-001-26-8::2.5::HTS002	2.5	metronidazole	DNA inhibitor	noncancer	CYP2C9, CYP3A4	dermatology	rosacea	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7607714495385	0.7607714495385	0.252547162037404	0.250850268444	-12.6427194938718	4.68094592613697	8.51191965111603e-05	0.00244945116394206	-0.613713863645149	-0.402734711357044
ZNF587B	BRD-K52911425-001-09-8::2.5::HTS002	2.5	GDC-0941	PI3K inhibitor	targeted cancer	PIK3CA, PIK3CB, PIK3CD, PIK3CG	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.836938156552	-0.836938156552	-1.1104092317851	-1.00700802709	-4.57738485704858	75.9073065056866	1.80615332511275e-05	0.000594001896605938	-0.392463824018759	-0.154478326447437
ZNF587B	BRD-K53414658-001-08-2::2.5::HTS002	2.5	tivozanib	VEGFR inhibitor	targeted cancer	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4887808304365	0.4887808304365	-0.775596545425266	-0.6098527820225	-11.9952543594015	2.77510071699709	0.00179278877561021	0.0365496647472426	-1.61574415681982	-0.913010594903716
ZNF587B	BRD-K56981171-001-01-0::2.5::MTS006	2.5	brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	targeted cancer	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.245600643759	0.245600643759	-0.073895138979528	-0.00736994010253	-9.69693785152234	190.948206018377	2.48067000710584e-18	3.51175377776081e-16	-0.384484791316828	-0.254506774160228
ZNF587B	BRD-K58529924-001-01-5::2.64858::MTS010::PROS001_PR500	2.64858	ONC201	AKT inhibitor, MAP kinase inhibitor	targeted cancer	TNFSF10	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.815010641956	0.815010641956	-0.126446608950122	-0.0782443732808	-14.3627957369575	2.43853603096737	0.002042411248234	0.040830888949048	-1.1800498705187	-0.702864631293547
ZNF587B	BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500	2.5	MLN0128	mTOR inhibitor	targeted cancer	MTOR, PIK3CA, PIK3CD, PIK3CG	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.343705806496	-0.343705806496	-1.33971179281745	-1.45938861893	-16.4333786390468	88.4216558241761	1.29260817997407e-28	4.68770589857299e-26	-1.11644506938941	-0.875566903253483
ZNF587B	BRD-K60997853-001-02-3::2.5::HTS002	2.5	PHA-848125	CDK inhibitor, growth factor receptor inhibitor	targeted cancer	CDK2, CDK4, CDK7, NTRK1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.6883166767505	-0.6883166767505	-1.54502188179019	-1.43484346641	-10.7443572704364	4.99316858627648	0.000122031320273836	0.00339433447080631	-1.06175584972568	-0.651654560353697
ZNF587B	BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500	2.5	AVN-944	inosine monophosphate dehydrogenase inhibitor	targeted cancer	IMPDH1, IMPDH2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7342591783135	0.7342591783135	-0.2406416908372	-0.1756829862115	-14.3052671568619	8.75698130486072	2.2569961589238e-07	1.01158454568377e-05	-1.12972102968991	-0.820080708611494
ZNF587B	BRD-K62965247-001-04-9::2.5::HTS002	2.5	tipifarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, FNTB	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.774919814399	-0.774919814399	-1.4770078742253	-1.40587252118	-12.1850364021178	183.84648858365	2.0298487239247e-25	5.35782570381844e-23	-0.815767297921957	-0.588408821730649
ZNF587B	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.435790297551	-0.435790297551	-0.213584255575745	-0.1907303952045	4.2324319835638	121.925475282939	4.50427414648246e-05	0.00137032870623341	0.11827483918367	0.326137244766841
ZNF587B	BRD-K66808046-065-03-7::2.5::HTS002	2.5	oxyquinoline	chelating agent	noncancer	METAP2	dermatology	cosmetic	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.3472872615145	0.3472872615145	-0.46333115305582	-0.3317635225235	-8.89800408192247	25.9963231175994	2.27685204205786e-09	1.30236301393707e-07	-0.997880801674897	-0.623356027465744
ZNF587B	BRD-K68408772-001-05-4::2.5::MTS006	2.5	carboxyamidotriazole	calcium channel blocker	targeted cancer	CXCL8	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.1356853459595	0.1356853459595	-0.275429124988974	-0.224936831672	-12.8442667810432	173.710875221413	5.61728949755727e-27	1.68856667702939e-24	-0.474288382205209	-0.34794055969174
ZNF587B	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.575945079264	-0.575945079264	-1.19663224976157	-1.12346956245	-7.92071162511724	26.9102690375721	1.66826187408064e-08	8.68920566598124e-07	-0.781498934480709	-0.459875406514437
ZNF587B	BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500	2.5	cinacalcet	calcium channel activator	targeted cancer	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.1439750335985	0.1439750335985	-0.214799834510719	-0.195517916983	-13.5760810788193	70.2342717291201	2.55248455054033e-21	4.72020242651216e-19	-0.411478733668675	-0.306071002549762
ZNF587B	BRD-K74671368-001-01-8::2.5::MTS006	2.5	idronoxil	XIAP inhibitor	targeted cancer	ENOX2, SPHK1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.0145559052907	-0.0145559052907	-0.253932438678862	-0.195737211392	-6.28616515974368	189.864953707315	2.1809271052242e-09	1.24949458844052e-07	-0.31449054946663	-0.164262517309693
ZNF587B	BRD-K75478907-001-02-3::2.5::HTS002	2.5	GS-39783	GABA receptor modulator	noncancer	GABBR1	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.8519708019005	0.8519708019005	0.474817749367266	0.475315506582	-14.9058668484461	78.2062994082519	1.45839274417765e-24	3.62196823252435e-22	-0.427524014547112	-0.326782090519355
ZNF587B	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.764599669687	-0.764599669687	-2.33972000336628	-2.24109191203	-13.0265825205823	3.94181004205801	0.000218815497185018	0.00572351802491673	-1.91280014078369	-1.23744052657488
ZNF587B	BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500	2.5	INC-280	c-Met inhibitor	targeted cancer	MET	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.332480066815	0.332480066815	0.0136662413743319	0.0495734767378	-9.32798287180384	7.26943471007979	2.65900710011651e-05	0.000846683008113016	-0.399029178298012	-0.238598472583325
ZNF587B	BRD-K81418486-001-47-5::2.5::HTS002	2.5	vorinostat	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.993874354388	-0.993874354388	-2.51992498568417	-2.254263331985	-9.92945207889272	3.69077784686294	0.000855307313737462	0.0192843636909359	-1.96723660432324	-1.08486465826909
ZNF587B	BRD-K82091397-001-03-0::2.5::HTS002	2.5	SB-239063	p38 MAPK inhibitor	noncancer	MAPK11, MAPK14, PTGS2	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.5063939413715	-0.5063939413715	-1.29168133355983	-1.24885809452	-12.8648212747601	188.083764669231	1.39738929125384e-27	4.47016491649468e-25	-0.905701243179515	-0.664873541197151
ZNF587B	BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500	2.5	batimastat	matrix metalloprotease inhibitor	targeted cancer	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.5630083434675	-0.5630083434675	-0.0979672169180723	-0.0599890522741	10.7295231279824	3.75219989832718	0.000595728203066079	0.0140018345088575	0.341503921615808	0.588578331483048
ZNF587B	BRD-K82928847-001-04-7::2.5::HTS002	2.5	ACY-1215	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.05585838322755	-0.05585838322755	-0.384930409884869	-0.347155123363	-7.68144800576544	88.9882964484269	1.94842902036347e-11	1.40371375968229e-09	-0.414194036464246	-0.243950016850393
ZNF587B	BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500	0.15625	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	1.96833510959	1.96833510959	-0.87530967102487	-0.774088070041	-32.0256957208521	153.57105920707	7.26027484734001e-70	1.29673953979628e-65	-3.01905738103913	-2.66823218019061
ZNF587B	BRD-K84564571-001-02-4::2.5::HTS002	2.5	telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	KDR	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.4166957067675	0.4166957067675	-0.190813294311457	-0.150870587106	-11.9712256481756	7.75231059259001	2.83881597527736e-06	0.000108167215851595	-0.7251868185341	-0.489831183623813
ZNF587B	BRD-K90382497-001-10-7::2.5::HTS002	2.5	GW-843682X	PLK inhibitor	targeted cancer	PLK1, PLK3	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.4070182346315	-0.4070182346315	-3.1354874988309	-3.009227373135	-20.9455042895148	8.16718252685762	2.17813217158082e-08	1.11576694599127e-06	-3.02779427571971	-2.42914425267908
ZNF587B	BRD-K90574421-001-03-5::2.5::HTS002	2.5	ipsapirone	serotonin receptor agonist	noncancer	HTR1A	NA	NA	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	-0.4184682851415	-0.4184682851415	-0.033960912837881	-0.0431604898369	14.9379099979931	58.3803947931755	1.32283300980376e-21	2.49359257834855e-19	0.332989565090773	0.436025179516465
ZNF587B	BRD-K92073408-001-15-7::2.5::MTS005	2.5	norethindrone	progesterone receptor agonist	noncancer	PGR	obstetrics/gynecology	endometriosis	NCIN87, HPAC	STOMACH, PANCREAS	carcinoma, carcinoma (ductal_carcinoma)	0.7956042498315	0.7956042498315	0.0858908167096112	0.09873309755385	-25.676176684431	15.9792722268249	2.03049534475314e-14	2.00273371719096e-12	-0.768315767700651	-0.651111098543126
ZNF675	BRD-A27887842-001-04-0::2.5::HTS002	2.5	prednisolone	glucocorticoid receptor agonist	noncancer	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	1.384281247005	1.384281247005	0.389407602021156	0.4040524647295	-18.1130189423994	20.6231223403512	3.87148356283975e-14	3.70976563157085e-12	-1.10922551661662	-0.880521773351065
ZNF675	BRD-A29485665-001-12-8::2.5::HTS002	2.5	bicalutamide	androgen receptor antagonist	targeted cancer	AR	oncology	prostate cancer	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.3101319049505	0.3101319049505	0.0875974079929791	0.1234730068455	-7.44491278665524	17.0989443648953	9.24125505362937e-07	3.79802292308596e-05	-0.285570812982171	-0.159498180932871
ZNF675	BRD-A42699921-001-03-6::2.60159::HTS002	2.60159	teriflunomide	dihydroorotate dehydrogenase inhibitor	noncancer	DHODH	neurology/psychiatry	multiple sclerosis	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.5381722550205	-0.5381722550205	-0.997503808636227	-0.927705434	-6.19131767316181	9.63068673131777	0.000120513853987873	0.00335667495924196	-0.625499634799157	-0.293163472432297
ZNF675	BRD-A85667082-001-12-7::2.5::HTS002	2.5	fulvestrant	estrogen receptor antagonist	targeted cancer	ESR1, ESR2, GPER1	oncology	breast cancer	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.0398597048894	-0.0398597048894	0.153303245836767	0.185523876977	3.83224783391441	11.5871101026241	0.00253758615742385	0.0492242106556698	0.0829051422000829	0.303420759252251
ZNF675	BRD-A99888680-001-03-8::2.37972::HTS002	2.37972	paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	noncancer	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.955241023061	0.955241023061	0.25493321593832	0.303778240807	-18.6172345160091	177.085735080489	1.48532424674152e-43	2.06719519792119e-40	-0.77454132866896	-0.6260742855764
ZNF675	BRD-K06426971-001-02-7::2.5::HTS002	2.5	ryuvidine	histone lysine methyltransferase inhibitor	noncancer	CDK2, CDK4	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.5362352072665	-0.5362352072665	-1.6934292788743	-1.35955217781	-8.09123755260375	8.18337887922714	3.53280273572559e-05	0.00109704734503815	-1.48571260609366	-0.828675537121941
ZNF675	BRD-K08109215-001-06-4::0.625::HTS002	0.625	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.10070402180705	-0.10070402180705	0.323810458493525	0.349176591288	6.66485136340743	166.563122086711	3.70840355643842e-10	2.31388188019764e-08	0.298761840365813	0.550267120235338
ZNF675	BRD-K08109215-001-06-4::2.5::MTS010::PROS002_PR500	2.5	I-BET-762	bromodomain inhibitor	targeted cancer	BRD2, BRD3, BRD4	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.634159247843	0.634159247843	-0.182418253899616	-0.0490787543204	-15.082974585917	30.9897567226328	8.02808759450857e-16	8.99452162071839e-14	-0.926996245555673	-0.706158757929559
ZNF675	BRD-K13112821-001-17-4::2.5::HTS002	2.5	artemisinin	DNA synthesis inhibitor	noncancer	CYP2B6	infectious disease	malaria	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.01360048768641	-0.01360048768641	-0.423783359454368	-0.390164965854	-11.0446965196456	28.0550456780434	1.00218367852054e-11	7.49727838162755e-10	-0.486250807016904	-0.334114936519013
ZNF675	BRD-K14003026-003-09-0::2.4604::HTS002	2.4604	ritodrine	adrenergic receptor agonist	noncancer	ADRB2	obstetrics/gynecology	premature labor	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.6798030725275	0.6798030725275	0.236363486977115	0.274310189966	-16.7026559075787	117.282437215132	8.60256912991573e-33	4.43358304524542e-30	-0.49601725763185	-0.390861913468919
ZNF675	BRD-K15108141-001-06-6::2.5::HTS002	2.5	gemcitabine	ribonucleotide reductase inhibitor	chemo	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-4.82395501389	-4.82395501389	-3.66631202665745	-3.56303502077	11.3980527570015	37.0113109692511	1.14789844153677e-13	1.0464820292477e-11	0.951854915431545	1.36343105903355
ZNF675	BRD-K21152241-001-07-3::2.5::MTS006	2.5	enoximone	phosphodiesterase inhibitor	noncancer	PDE3A	cardiology	congestive heart failure	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.009712928341415	0.009712928341415	0.100399478968585	0.137732029225	3.97132692710093	150.08147204893	0.000110566049647453	0.00310339324972355	0.0455663046529206	0.13580679660142
ZNF675	BRD-K21782625-001-02-4::2.5::HTS002	2.5	AMG458	MET inhibitor	targeted cancer	MET	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.420159832717	-0.420159832717	0.0323333657935586	0.0127189864736	10.5284660402203	184.211588890379	1.35902227726317e-20	2.37390289864333e-18	0.367700657516066	0.537285739505051
ZNF675	BRD-K24844714-001-24-5::2.5::HTS002	2.5	5-fluorouracil	thymidylate synthase inhibitor	chemo	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.8584495315085	-0.8584495315085	-1.05167801453985	-0.97521082715	-3.73942186844916	175.263771878614	0.000249570302284716	0.00644071683544622	-0.295210596682742	-0.0912463693799594
ZNF675	BRD-K27316855-001-13-3::2.43597::HTS002	2.43597	calcitriol	vitamin D receptor agonist	noncancer	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.3078353493385	0.3078353493385	-0.0402359594767282	-0.004671498458915	-6.79580692655872	6.91980367776944	0.000267553487906214	0.00683893518299952	-0.469469031688693	-0.226673585941764
ZNF675	BRD-K34332569-001-01-3::2.5::MTS006	2.5	imidapril	angiotensin converting enzyme inhibitor	noncancer	ACE	cardiology	hypertension, congestive heart failure	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.200014093708	0.200014093708	0.036042895542919	0.0389416186426	-8.05037399618302	100.071166051792	1.76400159011799e-12	1.43210870003181e-10	-0.2043806691028	-0.123561727227362
ZNF675	BRD-K36627727-001-05-4::2.5::HTS002	2.5	tamibarotene	retinoid receptor agonist	targeted cancer	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.3673276902515	0.3673276902515	0.134667757580525	0.147730167163	-8.47160617524398	170.395376870755	1.09237589794046e-14	1.09919170812056e-12	-0.286872433255523	-0.178447432086426
ZNF675	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-4.38037579366	-4.38037579366	-2.56715303873258	-2.46753908401	17.7388520483783	84.63486381127	2.99102005353197e-30	1.22574060622075e-27	1.60997413706494	2.0164713727899
ZNF675	BRD-K43389698-001-09-9::2.40172::HTS002	2.40172	BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	noncancer	CDK2, CDK7, CDK9	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-5.883218313645	-5.883218313645	-5.4423639102834	-5.470053491025	5.45375144146398	137.985412496002	2.21130749371595e-07	9.92352018049927e-06	0.281018775029325	0.600690031693866
ZNF675	BRD-K45551181-001-02-1::2.49051::HTS002	2.49051	MPI-0479605	mitotic kinase inhibitor	targeted cancer	TTK	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-1.39877309858	-1.39877309858	-2.31507206661742	-2.31598955621	-9.20505426513726	13.4865517263408	3.48291912128095e-07	1.51694893790901e-05	-1.13056260447738	-0.70203533159746
ZNF675	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.6780651235505	0.6780651235505	0.342092245742382	0.381901791063	-9.89131830380586	61.6409595718653	2.41759507629836e-14	2.3681934876963e-12	-0.403878693431925	-0.268067062184311
ZNF675	BRD-K49071277-001-04-7::2.5::HTS002	2.5	securinine	GABA receptor antagonist, TP53 activator	noncancer	GABRA1	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.5218655369265	0.5218655369265	0.288988366704029	0.288445970299	-7.08684344177467	4.4251605915082	0.00141839512640003	0.029968770607866	-0.320757335080248	-0.144997005364695
ZNF675	BRD-K50000283-001-04-4::2.5::HTS002	2.5	PHA-767491	CDC inhibitor	targeted cancer	CDK1, RPS6KB1	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.2044467367595	0.2044467367595	-0.462019203521274	-0.3435721987365	-9.30094023531109	3.95968842312399	0.000780040974332036	0.0177970408758368	-0.866215549538314	-0.466716331023235
ZNF675	BRD-K51544265-001-04-2::2.5::HTS002	2.5	cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	targeted cancer	KDR, MET	oncology	medullary thyroid cancer (MTC)	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.3805012872915	0.3805012872915	-0.329379857979259	-0.2394985033815	-12.9364324885156	13.6683165996215	4.70931421204916e-09	2.61217030474711e-07	-0.82784389643603	-0.591918394105489
ZNF675	BRD-K55675242-001-03-0::2.5::HTS002	2.5	torcetrapib	cholesteryl ester transfer protein inhibitor	noncancer	CETP	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.2660889019985	0.2660889019985	0.469563032979081	0.4617368983695	7.59627822904249	126.320172486324	5.95178052383383e-12	4.56237184511009e-10	0.150466669126662	0.2564815928345
ZNF675	BRD-K57169635-001-04-5::2.5::HTS002	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-1.881480744815	-1.881480744815	-1.28924425450424	-1.034969229585	7.36293863714505	193.717824319072	5.02157315106728e-12	3.88404457558679e-10	0.43359609707579	0.750876883545725
ZNF675	BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500	2.5	dacomitinib	EGFR inhibitor	targeted cancer	EGFR, ERBB2, ERBB4	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.593848887858	-0.593848887858	-0.386510502351908	-0.1848985030465	3.2721811913344	179.669530680864	0.0012797542363974	0.0274349446025411	0.0823050935702703	0.332371677441914
ZNF675	BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500	2.5	AT13387	HSP antagonist	targeted cancer	HSP90AA1	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-2.422355030855	-2.422355030855	-1.02412901701089	-1.108311362665	12.0142888385566	3.20767731662798	0.000894627398084504	0.020065361616163	1.04105505405463	1.75539697363358
ZNF675	BRD-K58466253-003-14-0::2.5::HTS002	2.5	palmatine-chloride	dopamine synthesis inhibitor	noncancer	CYP3A4	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.395215229163	0.395215229163	-0.0604363132481706	-0.0643126933566	-10.0703661097174	4.98051771033401	0.000169003265864064	0.00455569122995586	-0.572099046812417	-0.339204038009924
ZNF675	BRD-K58550667-001-08-7::2.5::HTS002	2.5	FK-866	niacinamide phosphoribosyltransferase inhibitor	targeted cancer	NAMPT	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-5.706736067505	-5.706736067505	-4.6370248305022	-4.72849824175	9.22709194772843	6.79146869482765	4.37076575522626e-05	0.00133444708483175	0.793861042010017	1.34556143199559
ZNF675	BRD-K61536336-001-01-7::2.5::HTS002	2.5	SB-366791	TRPV antagonist	noncancer	TRPV1	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.820663068721	0.820663068721	-0.261832207666674	-0.132231172134	-19.9700908725352	100.052530441191	1.1029575105053e-36	8.44270643818182e-34	-1.19003740042063	-0.974953152354714
ZNF675	BRD-K62814476-001-03-3::2.5::HTS002	2.5	BMS-265246	CDK inhibitor	targeted cancer	CDK1, CDK2	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-3.66633732248	-3.66633732248	-2.52487193324125	-2.448908605325	10.9186007219596	8.35737400463326	3.11521569511252e-06	0.000117694529299801	0.902171008550925	1.38075976992658
ZNF675	BRD-K66715657-050-01-0::2.5::HTS002	2.5	UH-232-(+)	dopamine receptor antagonist	noncancer	DRD2, DRD3, DRD4, HTR1A	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.166979225722	0.166979225722	-0.00384841586687828	0.0059117559481	-4.98766429743958	18.782547406863	8.44375122249611e-05	0.00243244725237415	-0.242569987821615	-0.0990852953561413
ZNF675	BRD-K67977190-066-02-3::2.5::HTS002	2.5	eprosartan	angiotensin receptor antagonist	noncancer	AGTR1	cardiology	hypertension	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.307133172841	0.307133172841	0.422722314600064	0.410651476159	3.68654763461958	182.2587439654	0.00029972893912527	0.00756751134335964	0.0537250481245644	0.177453235393564
ZNF675	BRD-K68997413-001-05-1::2.5::HTS002	2.5	PF-3845	FAAH inhibitor	noncancer	FAAH	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.468381049806	0.468381049806	0.121344359712949	0.135505899737	-12.5877363963605	134.159235540057	1.77853934567014e-24	4.36147093155761e-22	-0.401563624896058	-0.292509755290044
ZNF675	BRD-K76037122-001-02-5::2.5::HTS002	2.5	guanidine	HSP inhibitor	noncancer	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.0951869513761	0.0951869513761	0.214363544060029	0.217996960587	4.05075067474243	36.4684900902843	0.0002556695606774	0.00657200782806745	0.0595349150963237	0.178818270271534
ZNF675	BRD-K76210423-001-01-6::2.5::MTS010::PROS001_PR500	2.5	resiquimod	toll-like receptor agonist	targeted cancer	TLR7, TLR8	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.179411385188	-0.179411385188	0.109040187813853	0.094360121778	13.9826241503554	155.62513519389	2.69951799207285e-29	1.04249548058195e-26	0.247702031906769	0.329201114096938
ZNF675	BRD-K78789465-001-01-6::2.5::HTS002	2.5	pentagastrin	CCK receptor agonist	noncancer	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-0.03430381245895	-0.03430381245895	0.14821877587533	0.184916881491	3.45291425707361	47.5893676849371	0.00117428949188471	0.0254638094401213	0.076215840851295	0.288829335817266
ZNF675	BRD-K79684402-300-02-8::2.5::HTS002	2.5	Ro-10-5824	dopamine receptor agonist	noncancer	DRD4	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.6745112807285	0.6745112807285	0.0153101253458016	0.0259313359155	-19.4568266203499	6.65727714353818	4.0784564542491e-07	1.76271726836612e-05	-0.740158805004401	-0.578243505760996
ZNF675	BRD-K83029223-001-01-3::2.5::MTS006	2.5	litronesib	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-2.813740041965	-2.813740041965	-2.41582042411982	-2.23881824047	3.56856666576255	30.0217944311875	0.00122948295106161	0.0265051148076929	0.170199187410638	0.625640048279731
ZNF675	BRD-K86797399-001-05-1::2.54945::HTS002	2.54945	SB-939	HDAC inhibitor	targeted cancer	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-6.107988389125	-6.107988389125	-5.45767259846132	-5.51001928833	6.17793055108482	5.27294031335398	0.0013365853677926	0.0284760442637793	0.383884222302934	0.916747359024434
ZNF675	BRD-K86972824-001-01-4::2.5::HTS002	2.5	oltipraz	nuclear factor erythroid derived, like (NRF2) activator	targeted cancer	ANG	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.125442803796	0.125442803796	0.00692013416267606	-0.004832023318045	-3.62863010232165	38.9146492073027	0.000817934489862024	0.0185647655700135	-0.184594860375004	-0.0524504788916441
ZNF675	BRD-K87349682-347-03-8::2.36217::HTS002	2.36217	norepinephrine	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-1.28994429221	-1.28994429221	-0.482338736815683	-0.397290410403	15.0749327053861	16.4998684028939	4.48849246062724e-11	3.10027102995093e-09	0.694315392343384	0.920895718445249
ZNF675	BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500	0.625	alvocidib	CDK inhibitor	targeted cancer	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-2.183396142205	-2.183396142205	-1.64257440010177	-1.710789940465	7.51623407610458	6.54344358645448	0.000189180250081514	0.00503187066514282	0.368241598712735	0.713401885493732
ZNF675	BRD-K90497590-001-04-2::2.5::HTS002	2.5	AR-12	phosphoinositide dependent kinase inhibitor	targeted cancer	PDPK1	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-1.636392685835	-1.636392685835	-1.00621606977203	-0.9517219897545	11.4976896313041	68.7306515152854	1.1458585689994e-17	1.53016025691634e-15	0.520828052106309	0.739525180019637
ZNF675	BRD-K92241597-001-06-0::2.5::HTS002	2.5	tosedostat	peptidase inhibitor	targeted cancer	ANPEP, LAP3, NPEPPS	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-2.15969453488	-2.15969453488	-1.82348762906045	-1.68862958657	3.99548913715344	79.8493721976143	0.000142875245854754	0.00390391491188214	0.168744945942023	0.503668865697075
ZNF675	BRD-K96188950-001-16-9::2.5::HTS002	2.5	caffeic-acid-phenethyl-ester	HIV integrase inhibitor	targeted cancer	RELA	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	0.6205894289785	0.6205894289785	0.307004828871888	0.328628776305	-7.01557273193164	4.40711821493805	0.00150240905361058	0.0314862452382225	-0.433294017051287	-0.193875183161937
ZNF675	BRD-K98203492-003-04-1::2.5::HTS002	2.5	GSK-J4	histone lysine demethylase inhibitor	targeted cancer	KDM6A, KDM6B	NA	NA	H4, PLCPRF5	CENTRAL_NERVOUS_SYSTEM, LIVER	glioma, carcinoma (hepatocellular_carcinoma)	-3.76135772624	-3.76135772624	-3.06301737695371	-3.05318317183	7.24683783568555	109.82509980575	6.27560298800115e-11	4.25377518284408e-09	0.507364478050973	0.889316220521605
ZZEF1	BRD-A26032986-050-02-1::2.5::HTS002	2.5	zaldaride	calmodulin antagonist	noncancer	CALM1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.0749491334342	0.0749491334342	-0.169592357617699	-0.166433097848	-6.00436439716939	5.95063637819846	0.000990337560002846	0.0219456223012665	-0.344398317478453	-0.144684664625344
ZZEF1	BRD-A48300215-001-04-8::2.5::HTS002	2.5	ajmaline	sodium channel blocker	noncancer	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.228190717129	0.228190717129	0.0793592554074918	0.10011510474205	-3.11873431462572	165.219019470564	0.0021433404250825	0.0425864475727735	-0.243054541263938	-0.0546083821790789
ZZEF1	BRD-A93093700-001-02-9::2.5::HTS002	2.5	temazepam	benzodiazepine receptor agonist	noncancer	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.446811483768	0.446811483768	0.294688604853737	0.2827443589055	-5.84428907984704	90.3138026052499	7.96586631693769e-08	3.79235042612825e-06	-0.203832221313985	-0.100413536514541
ZZEF1	BRD-K05444225-001-01-7::2.5::HTS002	2.5	E7449	PARP inhibitor	targeted cancer	PARP1, PARP2, TNKS, TNKS2	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.3651859277745	-0.3651859277745	-1.23020371540293	-1.264129385735	-8.61187784524184	4.31829028000673	0.000705249194476019	0.0162783650354283	-1.13597448650829	-0.594061088748569
ZZEF1	BRD-K06294530-001-01-5::2.5::HTS002	2.5	UK-383367	Procollagen C-Endopeptidase Inhibitors	noncancer	BMP1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.300628124435	-1.300628124435	-1.02370727003685	-0.9876270936225	5.28425347529335	193.977523285769	3.37667153881756e-07	1.47637420286256e-05	0.173564266755558	0.380277442040733
ZZEF1	BRD-K07612980-001-05-3::2.58642::HTS002	2.58642	sparfloxacin	bacterial DNA gyrase inhibitor	noncancer	TOP2A	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.05236623277275	0.05236623277275	0.202700786933157	0.216719294223	5.17015491491011	57.9472482757095	3.02964926844211e-06	0.000114805816487965	0.0921287279777386	0.208540380343075
ZZEF1	BRD-K09090949-001-01-9::2.5::HTS002	2.5	CP-945,598	cannabinoid receptor antagonist	noncancer	CNR1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.101974102335	-1.101974102335	-0.687821984301847	-0.6179289044455	7.30126121884845	148.885582925734	1.5920611993082e-11	1.16339885709692e-09	0.302065292584001	0.526238943482305
ZZEF1	BRD-K11663430-001-02-3::2.5::HTS002	2.5	pyroxamide	HDAC inhibitor	targeted cancer	HDAC1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.987880213573	-0.987880213573	-0.634610018804734	-0.605158922275	4.55374070136373	8.33082680363264	0.0016809993748569	0.0346663056878384	0.175604015546343	0.53093637399019
ZZEF1	BRD-K12867552-001-04-7::2.5::HTS002	2.5	PCI-24781	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC6	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-5.12525421723	-5.12525421723	-4.12662663805435	-4.11179699224	8.31654237463183	178.761394525373	2.23865817717192e-14	2.19995125380596e-12	0.761676326875105	1.23557883147619
ZZEF1	BRD-K16195444-003-26-0::2.5::HTS002	2.5	oxymetazoline	adrenergic receptor agonist	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.187805695451	0.187805695451	0.085775094149688	0.0959513505756	-3.34205916294045	192.938814917809	0.000998660412895597	0.0221071976487813	-0.162244553144138	-0.0418166494584855
ZZEF1	BRD-K17472821-001-01-2::2.5::MTS006	2.5	GSK2830371	protein phosphatase inhibitor	targeted cancer	PPM1D	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.527481870491	0.527481870491	0.210697151498284	0.222894017996	-12.0838672975008	4.2264744021108	0.000195172608034671	0.00517136233248399	-0.388057974778531	-0.245511463206902
ZZEF1	BRD-K19085898-001-01-8::2.5::HTS002	2.5	darapladib	phospholipase inhibitor	noncancer	PLA2G7	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.5271117594305	0.5271117594305	0.321051852695704	0.339932692016	-5.87088219963279	14.4324843854384	3.59613777115616e-05	0.00111477670285526	-0.281127892301492	-0.130991921168101
ZZEF1	BRD-K24576554-001-04-8::2.5::HTS002	2.5	AT-9283	Aurora kinase inhibitor, JAK inhibitor	targeted cancer	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.157256482669	-0.157256482669	-0.980358130317396	-0.82417204092	-7.86196136666642	38.984692396619	1.45198773871164e-09	8.48890016503891e-08	-1.03486828614625	-0.611335009150539
ZZEF1	BRD-K24601397-001-01-1::2.5::HTS002	2.5	phlorizin	sodium/glucose cotransporter inhibitor	noncancer	SLC5A1, SLC5A11, SLC5A2, SLC5A3	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.17925302647	0.17925302647	0.386650874167142	0.399212772621	7.98380094648409	66.7078673424782	2.64583803125747e-11	1.88148579761573e-09	0.15554270173883	0.259252993655453
ZZEF1	BRD-K26657438-001-15-2::2.5::HTS002	2.5	imiquimod	interferon inducer, toll-like receptor agonist	targeted cancer	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.2555822547805	0.2555822547805	-0.0359735717516046	-0.0304287468122	-10.1192667645489	9.14911803592423	2.85893357104728e-06	0.000108798361745205	-0.356571416613417	-0.226540236450792
ZZEF1	BRD-K32744045-001-31-2::2.5::MTS006	2.5	disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	noncancer	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-3.98121411916	-3.98121411916	-3.11092178064112	-3.10613635441	8.40190909002903	190.603408839397	9.9749437280297e-15	1.00655353779891e-12	0.665976710629165	1.0746079664086
ZZEF1	BRD-K37379014-001-01-2::2.5::HTS002	2.5	filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.66056484846	-1.66056484846	-2.59687774851619	-2.52528636523	-9.47382041059646	182.964066930655	1.40831908968506e-17	1.86668906724249e-15	-1.13130909409764	-0.741316706014732
ZZEF1	BRD-K37590257-001-02-8::2.5::HTS002	2.5	GSK256066	phosphodiesterase inhibitor	noncancer	PDE4A	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.11808600743	-1.11808600743	-0.0710750492322223	-0.072384668123	16.7365947082712	162.985118308438	3.13880363845476e-37	2.52908513167809e-34	0.923481945018247	1.17053997137731
ZZEF1	BRD-K39381259-001-01-0::2.5::HTS002	2.5	DMH1	ALK tyrosine kinase receptor inhibitor	targeted cancer	ACVR1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.3532451212145	0.3532451212145	0.0866707802452996	0.1179670530315	-9.55843745195695	189.179719766157	6.53455704823557e-18	8.92635486036509e-16	-0.321587518271176	-0.211561163667225
ZZEF1	BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500	2.5	lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	FLT4, KDR	oncology	thyroid cancer	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.01254455933263	-0.01254455933263	-0.206853548918664	-0.158031671069	-5.64755656222161	168.413281221497	6.79045414892089e-08	3.26687148660845e-06	-0.262231301892437	-0.126386677279632
ZZEF1	BRD-K40109029-001-02-9::2.5::HTS002	2.5	SB-505124	ALK tyrosine kinase receptor inhibitor	noncancer	TGFBR1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.500593601387	0.500593601387	0.25350913694344	0.2832758926905	-7.58383508810271	135.301301570069	4.82603004856374e-12	3.7436054805596e-10	-0.311517194145059	-0.18265173474206
ZZEF1	BRD-K45401373-001-20-9::2.50156::HTS002	2.50156	betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	targeted cancer	GPBAR1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.5240575917705	-0.5240575917705	-0.694685504725798	-0.636668754802	-3.30684898326851	131.642464627623	0.0012164493063959	0.0262611163769667	-0.272697090913437	-0.0685587349971594
ZZEF1	BRD-K45724504-001-01-6::1.36461::HTS002	1.36461	anguidine	protein synthesis inhibitor	targeted cancer	SLC5A1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-4.979572894935	-4.979572894935	-5.28372121177436	-5.31222064742	-3.78879941184914	187.948894783265	0.00020369539597747	0.00536864615401565	-0.462505365927098	-0.145791267751625
ZZEF1	BRD-K46386702-001-02-1::2.5::HTS002	2.5	ARRY-334543	EGFR inhibitor	targeted cancer	ERBB2	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.06342187528	-1.06342187528	-1.39532609322861	-1.171371713075	-4.56665285242745	187.01302328568	8.97033503650268e-06	0.000311655525699235	-0.475282196317732	-0.18852623957949
ZZEF1	BRD-K48195008-001-19-9::0.15625::HTS002	0.15625	ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	noncancer	ESR1, ESR2, NR1I2	endocrinology	contraceptive	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.4781653431905	0.4781653431905	0.344500676831056	0.381901791063	-3.6959653210438	21.4712943368204	0.00130260282584311	0.0278516554471618	-0.208773553620427	-0.0585557790984606
ZZEF1	BRD-K49049886-001-08-7::2.5::HTS002	2.5	CGS-15943	adenosine receptor antagonist	noncancer	ADORA1, ADORA2A, ADORA2B, ADORA3	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.450512710122	0.450512710122	-0.0727610690581631	0.318163539168	-5.90321134722384	65.1347329132459	1.41155162501559e-07	6.52158758866062e-06	-0.700297582015578	-0.346249976344748
ZZEF1	BRD-K49350383-001-13-7::2.5::HTS002	2.5	thioguanine	purine antagonist	targeted cancer	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.815564116861	-0.815564116861	-1.59479891786191	-1.48697544025	-9.41382192525056	174.651171354449	2.80380021677614e-17	3.60057337724034e-15	-0.942604037573396	-0.615865564428429
ZZEF1	BRD-K49865102-001-08-4::2.5::HTS002	2.5	PD-0325901	MEK inhibitor	targeted cancer	MAP2K1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.6871072547415	-0.6871072547415	-1.8414834670769	-1.58248812639	-11.9292780435583	118.945365993171	4.6739045257763e-22	9.19883639214977e-20	-1.34598805766724	-0.962764367003566
ZZEF1	BRD-K50018155-003-02-1::2.5::HTS002	2.5	RS-67506	serotonin receptor partial agonist	noncancer	HTR4	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.12783410043	0.12783410043	0.301808620734464	0.3592817861405	4.27899135806857	40.302141989755	0.000112510748588022	0.00315384727100734	0.0918211581843318	0.256127882424597
ZZEF1	BRD-K50853363-001-02-3::2.5::HTS002	2.5	dienogest	progesterone receptor agonist	noncancer	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.964556317747	-0.964556317747	-0.26981194480682	-0.206947214108	11.9823023826372	9.31520122277854	5.71523604374356e-07	2.42035334127547e-05	0.56425594846298	0.82523279741738
ZZEF1	BRD-K51313569-003-03-3::2.5::HTS002	2.5	palbociclib	CDK inhibitor	targeted cancer	CDK4, CDK6	oncology	breast cancer	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.0511348916872	-0.0511348916872	-0.767300000683719	-0.762324031266	-9.86917530812349	19.4509293009461	5.1796796702497e-09	2.85680793629683e-07	-0.867809216812485	-0.564521001180554
ZZEF1	BRD-K51318897-001-15-3::2.5::HTS002	2.5	fenbendazole	tubulin polymerization inhibitor	noncancer	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.968115211065	-1.968115211065	-2.76407834112124	-2.716477305745	-7.2340433590731	37.5455885775081	1.27372561269496e-08	6.73898634518141e-07	-1.01879615948618	-0.573130100626299
ZZEF1	BRD-K51791723-003-01-7::2.5::HTS002	2.5	P276-00	CDK inhibitor	targeted cancer	CDK1, CDK4, CDK9	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-2.14352259621	-2.14352259621	-4.6156452194211	-4.62878838486	-25.94217529498	190.114716397776	2.27886796735713e-64	2.44213746287843e-60	-2.66009115817727	-2.28415408824493
ZZEF1	BRD-K51967704-001-03-6::2.5::HTS002	2.5	BIIB021	HSP inhibitor	targeted cancer	HSP90AA1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-2.98648019445	-2.98648019445	-3.66786034537197	-3.70951336465	-8.56055661694189	30.8910634477457	1.17587598859896e-09	6.94832518069683e-08	-0.843739060343478	-0.519021241500458
ZZEF1	BRD-K53523901-001-04-4::2.5::HTS002	2.5	arctigenin	MEK inhibitor	targeted cancer	CHUK, MAP2K1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.239047343187	-0.239047343187	-0.435971779171837	-0.434167377237	-5.43632071378799	192.838625808326	1.63198461352772e-07	7.47000444932706e-06	-0.26837024906473	-0.125478622904944
ZZEF1	BRD-K55187425-236-05-2::2.5::HTS002	2.5	rigosertib	cell cycle inhibitor, PLK inhibitor	targeted cancer	PLK1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-2.06931412276	-2.06931412276	-2.93117161862019	-2.897999861155	-6.74456592312631	4.70273278200543	0.00137979870263213	0.0292253064666906	-1.19668515559982	-0.527029836120567
ZZEF1	BRD-K56032964-001-02-1::2.5::HTS002	2.5	AP26113	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK, EGFR	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2717907401535	-0.2717907401535	-0.548802900044619	-0.449925278333	-4.08733651307242	23.6632314289843	0.000432233062985825	0.0105236942129602	-0.416994734402911	-0.137029585379327
ZZEF1	BRD-K56277358-001-07-5::2.5::HTS002	2.5	MGCD-265	VEGFR inhibitor	targeted cancer	AXL, MET	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.1379657249345	0.1379657249345	-0.240926660685919	-0.10314419939105	-6.47183065410456	59.327204963864	2.06189017094676e-08	1.05951296679177e-06	-0.496026852296097	-0.26175791894474
ZZEF1	BRD-K57136142-001-02-4::2.5::HTS002	2.5	CCT129202	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.5636961789525	-0.5636961789525	-0.749674688554665	-0.661176661425	-3.67951778174441	31.3675789741082	0.000871564874721687	0.0195890968995621	-0.289015271682603	-0.0829417475217267
ZZEF1	BRD-K61397605-001-03-4::2.5::HTS002	2.5	romidepsin	HDAC inhibitor	targeted cancer	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-8.977127239545	-8.977127239545	-7.19445966296144	-7.241239224365	11.4011692710348	2.89760716666826	0.00169764143032243	0.0349523333448199	1.27496870730184	2.29036644586529
ZZEF1	BRD-K62965247-001-04-9::2.5::HTS002	2.5	tipifarnib	farnesyltransferase inhibitor	targeted cancer	FNTA, FNTB	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.0217261912	-1.0217261912	-1.4744235142588	-1.40587252118	-7.57781474907053	87.8188362004559	3.37971361653708e-11	2.36259177990469e-09	-0.571421084334465	-0.333973561783136
ZZEF1	BRD-K63126190-003-01-6::2.5::HTS002	2.5	epinephrine	adrenergic receptor agonist, neurotransmitter	noncancer	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.166677173838	-0.166677173838	-0.441129224100197	-0.3976462300305	-4.01528150284776	161.414549090054	9.07480315272762e-05	0.00259263327768723	-0.409431276229284	-0.13947282429511
ZZEF1	BRD-K64866502-001-03-9::2.5::HTS002	2.5	CYC116	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, KDR	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.6071178354315	-0.6071178354315	-0.211659227060233	-0.1907303952045	6.86991302211049	19.7731258962214	1.19812633124214e-06	4.83603047926172e-05	0.275294147655292	0.515623069087241
ZZEF1	BRD-K65678996-001-05-5::2.5::HTS002	2.5	nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	noncancer	CHRM1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.143994277693	-0.143994277693	-0.607733080640813	-0.456560974373	-7.37001111743731	173.456301544739	6.67374856064879e-12	5.09756897810155e-10	-0.587930935429989	-0.339546670465637
ZZEF1	BRD-K68336408-001-10-9::2.5::HTS002	2.5	tyrphostin-AG-1478	EGFR inhibitor	targeted cancer	EGFR, MAPK14	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.89827728197	-1.89827728197	-2.64938635566829	-2.59421184968	-7.27855421924404	75.9803033356788	2.61571935275514e-10	1.65620240223532e-08	-0.956640226647884	-0.545577920748703
ZZEF1	BRD-K68408467-065-01-8::2.5::HTS002	2.5	proflavine-hemisulfate	topical anesthetic	noncancer	F2	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.227460556583	0.227460556583	-0.266179441066468	-0.236194067289	-9.40183985532696	5.89537211812974	9.11764207177948e-05	0.00260452500013651	-0.6226688956428	-0.364611099656136
ZZEF1	BRD-K68532323-003-02-8::2.5::HTS002	2.5	SB-743921	kinesin-like spindle protein inhibitor	targeted cancer	KIF11	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-2.86618699366	-2.86618699366	-3.6797755772644	-3.50719189578	-5.6677254381116	6.04195228350075	0.001267337153894	0.0271953448995742	-1.16424664566873	-0.462930521540065
ZZEF1	BRD-K70159787-001-01-1::2.5::HTS002	2.5	SMI-4a	Pim kinase inhibitor	targeted cancer	PIM1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.8565729041875	-0.8565729041875	-0.630593577784911	-0.60780165798	4.0675075383806	95.7820016816531	9.75713818421671e-05	0.00277168677254471	0.115695954366826	0.336262698438353
ZZEF1	BRD-K70163715-300-05-7::2.41798::HTS002	2.41798	vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	targeted cancer	EGFR, FLT1, FLT4, KDR, PDGFRB	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.30834218211	-1.30834218211	-0.78200239187183	-0.642853768929	8.02783963492135	190.996357898309	9.88763036367727e-14	9.06030751695846e-12	0.397016659310887	0.655662921165452
ZZEF1	BRD-K71512533-066-02-8::2.5::HTS002	2.5	SNS-314	Aurora kinase inhibitor	targeted cancer	AURKA, AURKB, AURKC	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.568552981676	-0.568552981676	-1.19671303771335	-1.12346956245	-7.12777995638438	7.83082247152983	0.00011022004841025	0.00309489751810828	-0.832151343163168	-0.424168768911541
ZZEF1	BRD-K76064317-001-07-3::2.5::HTS002	2.5	tyrphostin-AG-1296	FLT3 inhibitor	targeted cancer	FLT3	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-1.69986145952	-1.69986145952	-2.32977040985742	-2.24109191203	-7.31840533352594	187.609583501533	7.12681443379215e-12	5.42430046441845e-10	-0.799702037934325	-0.46011586274052
ZZEF1	BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500	2.5	CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	targeted cancer	ERBB2	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.2516247685255	-0.2516247685255	0.00520924749291734	0.03806515271055	7.26560803848372	5.46779519703675	0.000524368151631626	0.0125013683616301	0.168255050871721	0.345412981165114
ZZEF1	BRD-K77008974-001-03-2::2.5::HTS002	2.5	WYE-354	mTOR inhibitor	targeted cancer	MTOR	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.731572146581	-0.731572146581	-0.958853276884582	-0.892479910689	-3.71878157918241	14.7115515258206	0.00212069713726733	0.0421913020266751	-0.357771949166461	-0.0967903114407036
ZZEF1	BRD-K78055238-001-01-8::2.5::HTS002	2.5	LY2090314	glycogen synthase kinase inhibitor	targeted cancer	GSK3B	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.450826368771	-0.450826368771	-1.06211502346394	-0.7851415156885	-5.35550743224704	8.48042723229903	0.000560700245108163	0.0132707854030097	-0.871927654330106	-0.350649655055765
ZZEF1	BRD-K79584249-001-01-3::2.5::HTS002	2.5	CGM097	MDM inhibitor	targeted cancer	MDM2	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.4238307242545	0.4238307242545	-0.469802732704702	-0.217946401079	-8.52761170590139	8.07953756490845	2.58923827173996e-05	0.000826185573237685	-1.13487294228559	-0.652393971632814
ZZEF1	BRD-K80480517-001-02-4::2.5::HTS002	2.5	repsox	TGF beta receptor inhibitor	noncancer	TGFBR1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.6606230680155	-0.6606230680155	-0.894024573543528	-0.828383638665	-3.65551090051237	15.8299432518716	0.00216673721915784	0.042943834052606	-0.368874069883747	-0.0979289411723089
ZZEF1	BRD-K82846253-001-15-4::2.5::HTS002	2.5	repaglinide	insulin secretagogue	noncancer	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.0729564935836	0.0729564935836	0.348847572742008	0.388891879995	9.35814433735778	184.964013393472	2.76072705633101e-17	3.54951331287564e-15	0.217728061352001	0.334054096964816
ZZEF1	BRD-K82928892-001-02-5::0.614878::HTS002	0.614878	doxercalciferol	vitamin D receptor agonist	noncancer	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.561455947011	0.561455947011	0.184590390293083	0.18484230673	-10.130093370894	46.1097259192752	2.6215652981582e-13	2.31035143416509e-11	-0.451745647309366	-0.301985466126467
ZZEF1	BRD-K83003151-057-02-4::2.34747::HTS002	2.34747	alogliptin	dipeptidyl peptidase inhibitor	noncancer	DPP4	endocrinology	diabetes mellitus	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.811438548177	0.811438548177	0.239805289984857	0.320568591806	-11.7295588768721	9.59647676446319	5.2749249500063e-07	2.2423034304044e-05	-0.680842421435758	-0.462424094948527
ZZEF1	BRD-K84466663-001-05-4::2.5::HTS002	2.5	nelarabine	DNA synthesis inhibitor, T cell inhibitor	chemo	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.9327974392625	0.9327974392625	0.60496675315891	0.593873040614	-11.7659965154969	12.6598032702226	3.48529026988244e-08	1.73761055653323e-06	-0.388188910303154	-0.267472461904027
ZZEF1	BRD-K84810405-003-01-1::2.5::HTS002	2.5	almorexant	orexin receptor antagonist	noncancer	HCRTR1, HCRTR2	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.10270241484795	0.10270241484795	0.259583905167962	0.266189025128	5.54928315754825	162.284243692714	1.1453914017432e-07	5.36005663196984e-06	0.101055852428208	0.212707128211815
ZZEF1	BRD-K85849709-001-01-5::2.5::HTS002	2.5	AZD2858	glycogen synthase kinase inhibitor	noncancer	GSK3B	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.6477074373295	-0.6477074373295	-1.75083775113056	-1.58142257926	-11.2897304295924	189.964088180072	6.01346218160868e-23	1.29014948540741e-20	-1.29586815484917	-0.910392472752952
ZZEF1	BRD-K86930074-001-05-0::2.5::HTS002	2.5	cediranib	KIT inhibitor, VEGFR inhibitor	targeted cancer	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-2.3781967445	-2.3781967445	-3.02444441431495	-2.830173101285	-6.42988387169476	21.1693080674718	2.17283290232102e-06	8.42440490451449e-05	-0.855161461627	-0.437333878002896
ZZEF1	BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500	2.5	AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	targeted cancer	BTK, YES1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.5865104712085	-0.5865104712085	-0.114156038202429	-0.0422450278637	11.8980474747328	7.79295636415626	2.8451005972364e-06	0.000108329643969636	0.380380588679241	0.564328277332901
ZZEF1	BRD-K88510285-001-11-1::2.5::HTS002	2.5	bortezomib	NFkB pathway inhibitor, proteasome inhibitor	targeted cancer	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-6.61861139787	-6.61861139787	-6.21013787757894	-6.171939349	6.89751759265256	188.551689798407	7.7742533965589e-11	5.22171092519922e-09	0.291653926817749	0.525293113764367
ZZEF1	BRD-K89391146-001-08-0::2.5::HTS002	2.5	RG108	DNA methyltransferase inhibitor	targeted cancer	DNMT1, DNMT3B	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.5818802757105	0.5818802757105	0.378170822829679	0.397149460871	-8.02606052345973	189.915494006584	1.02133481541234e-13	9.3427942660056e-12	-0.253774336094474	-0.153644569667169
ZZEF1	BRD-K91825936-001-01-2::2.5::HTS002	2.5	ZK811752	CC chemokine receptor antagonist	targeted cancer	CCR1	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.8789898347115	-0.8789898347115	-1.0246342176612	-0.948156981669	-3.42454997779931	64.0417968577119	0.0010791696450904	0.0236138183626931	-0.230605749419987	-0.0606830164794135
ZZEF1	BRD-K93754473-048-20-2::2.5::HTS002	2.5	tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	targeted cancer	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.1765029720735	0.1765029720735	0.308312759154602	0.317996860903	4.92941536684068	64.5069819694969	6.06758266320893e-06	0.000217832315682229	0.0783997070962327	0.185219867065971
ZZEF1	BRD-K95581532-001-01-5::2.5::HTS002	2.5	RN-1734	TRPV antagonist	noncancer	TRPV4	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-2.079199614585	-2.079199614585	-2.42095007240713	-2.37248540058	-4.08663850661017	186.073848584492	6.50182025347768e-05	0.00191682067827733	-0.506728003275322	-0.176772912368935
ZZEF1	BRD-K96253961-046-03-1::2.5::HTS002	2.5	metaraminol	adrenergic receptor agonist	noncancer	ADRA1A	cardiology	hypotension	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-4.97944661646	-4.97944661646	-4.62529396294601	-4.61970061714	3.84515288536986	188.656831155387	0.00016463335410724	0.00445245453027769	0.172467297708578	0.535838009319403
ZZEF1	BRD-K96344439-002-02-7::2.5::MTS006	2.5	tofogliflozin	sodium/glucose cotransporter inhibitor	noncancer	GCK	endocrinology	diabetes mellitus, diabetes mellitus	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.4084605517245	0.4084605517245	0.135510493610401	0.243893587025	-7.1631344457762	43.7895951096574	6.77037779210129e-09	3.68004768170172e-07	-0.349755730924867	-0.196144385303331
ZZEF1	BRD-K97810537-001-13-6::2.5::HTS002	2.5	beclomethasone-dipropionate	glucocorticoid receptor agonist	noncancer	GPR97, NR3C1	allergy	allergic rhinitis	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	-0.375187027319	-0.375187027319	0.0799297155047013	0.06870536578965	10.7899411889963	73.2322785524724	8.67860952932934e-17	1.06655831525896e-14	0.3710571656196	0.539176320027803
ZZEF1	BRD-K99879819-001-02-1::2.5::MTS006	2.5	lorlatinib	ALK tyrosine kinase receptor inhibitor	targeted cancer	ALK	NA	NA	KYSE70, SKOV3	OESOPHAGUS, OVARY	carcinoma (squamous_cell_carcinoma), carcinoma (adenocarcinoma)	0.3848455626435	0.3848455626435	-0.0267093112261404	0.013127326234	-13.4714933002921	32.7742866206996	6.49575350007766e-15	6.67415317314546e-13	-0.473725695431418	-0.349384052307863